[
  {
    "model": "pages.page",
    "pk": 1,
    "fields": {
      "name": "ORZID CDSS PLACEHOLDER",
      "term": null,
      "displaytext": "CDSS PLACEHOLDER",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"This menu or quick order is currently under construction...\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 2,
    "fields": {
      "name": "ORZID GMENU ABX GENRL ALT AM LIST",
      "term": "This is the list that the CDSS user will see if the user indicates a need for an alternative drug. It will have all formulary drugs.  Greg Filice Created 24-Jan-03",
      "displaytext": "List of antimicrobials",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 500mg iv bid\", \"Text\": \"Acyclovir IV\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po tid\", \"Text\": \"Acyclovir PO\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amikacin 250mg iv qday\", \"Text\": \"Amikacin IV\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500mg po tid\", \"Text\": \"Amoxicillin PO\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid\", \"Text\": \"Amoxicillin-clavulanate PO\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydration BEFORE&AFTER\", \"Text\": \"Amphotericin B Liposomal (Ambisome)\", \"Mnemonic\": \"14\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2gm iv q6h (alt 2)\", \"Text\": \"Ampicillin IV\", \"Mnemonic\": \"16\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3gm iv q6h\", \"Text\": \"Ampicillin-sulbactam IV\", \"Mnemonic\": \"18\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone susp 750mg po bid\", \"Text\": \"Atovaquone PO\", \"Mnemonic\": \"20\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg once then 250mg q24h for 4 days\", \"Text\": \"Azithromycin IV\", \"Mnemonic\": \"22\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg po once then 250mg qday for 4 days\", \"Text\": \"Azithromycin PO\", \"Mnemonic\": \"24\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2gm iv q8h\", \"Text\": \"Aztreonam IV\", \"Mnemonic\": \"26\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine Penicillin 1.2mu IM once (alt)\", \"Text\": \"Benzathine Penicillin IM\", \"Mnemonic\": \"28\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 500 mg PO Q12H ($) [R]\", \"Text\": \"Cefadroxil PO\", \"Mnemonic\": \"30\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin IV\", \"Mnemonic\": \"32\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h ($) [R]\", \"Text\": \"Cefdinir PO\", \"Mnemonic\": \"34\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2gm iv q8h\", \"Text\": \"Cefepime IV\", \"Mnemonic\": \"38\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefotetan IV\", \"Mnemonic\": \"40\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefoxitin IV\", \"Mnemonic\": \"42\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 200mg po q12h\", \"Text\": \"Cefpodoxime PO\", \"Mnemonic\": \"44\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2gm iv q8h\", \"Text\": \"Ceftazidime IV\", \"Mnemonic\": \"46\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg im once (ALT)\", \"Text\": \"Ceftriaxone IM\", \"Mnemonic\": \"48\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2gm iv qday\", \"Text\": \"Ceftriaxone IV\", \"Mnemonic\": \"50\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefuroxime 500mg po bid\", \"Text\": \"Cefuroxime PO\", \"Mnemonic\": \"52\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500mg po q6h\", \"Text\": \"Cephalexin PO\", \"Mnemonic\": \"54\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400mg iv q12h (ALT)\", \"Text\": \"Ciprofloxacin IV\", \"Mnemonic\": \"56\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg po q12h\", \"Text\": \"Ciprofloxacin PO\", \"Mnemonic\": \"58\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500mg po bid\", \"Text\": \"Clarithromycin PO\", \"Mnemonic\": \"60\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600mg iv q8h (ALT)\", \"Text\": \"Clindamycin IV\", \"Mnemonic\": \"62\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po q6h\", \"Text\": \"Clindamycin PO\", \"Mnemonic\": \"64\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 2% cream vaginal applicator full qhs\", \"Text\": \"Clindamycin Vaginal\", \"Mnemonic\": \"66\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical to affected area qid\", \"Text\": \"Clotrimazole Topical\", \"Mnemonic\": \"68\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream vaginal applicator ful qhs\", \"Text\": \"Clotrimazole Vaginal\", \"Mnemonic\": \"70\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg iv q12h (ALT)\", \"Text\": \"Doxycycline IV\", \"Mnemonic\": \"74\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid\", \"Text\": \"Doxycycline PO\", \"Mnemonic\": \"76\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1gm iv q24h (ALT)\", \"Text\": \"Ertapenem IV\", \"Mnemonic\": \"78\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500mg iv q6h (ALT)\", \"Text\": \"Erythromycin IV\", \"Mnemonic\": \"80\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"erythromycin 0.5% ointment oph to affected eye qid\", \"Text\": \"Erythromycin OPTH\", \"Mnemonic\": \"82\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500mg po fqid\", \"Text\": \"Erythromycin PO\", \"Mnemonic\": \"84\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg iv q24h (ALT)\", \"Text\": \"Fluconazole IV\", \"Mnemonic\": \"86\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po qday\", \"Text\": \"Fluconazole PO\", \"Mnemonic\": \"88\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"ALTERNATIVE ANTIMICROBIALS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Ganciclovir 500mg iv q12h\", \"Text\": \"Ganciclovir IV\", \"Mnemonic\": \"90\"}, {\"Row\": 5, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg iv q24h\", \"Text\": \"Gentamicin IV\", \"Mnemonic\": \"92\"}, {\"Row\": 6, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po qday\", \"Text\": \"Itraconazole PO\", \"Mnemonic\": \"94\"}, {\"Row\": 7, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Levofloxacin IV\", \"Text\": \"Levofloxacin IV\", \"Mnemonic\": \"96\"}, {\"Row\": 8, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Levofloxacin PO\", \"Text\": \"Levofloxacin PO\", \"Mnemonic\": \"98\"}, {\"Row\": 9, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem IV\", \"Mnemonic\": \"100\"}, {\"Row\": 10, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg iv q6h (ALT)\", \"Text\": \"Metronidazole IV\", \"Mnemonic\": \"102\"}, {\"Row\": 11, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po tid\", \"Text\": \"Metronidazole PO\", \"Mnemonic\": \"104\"}, {\"Row\": 12, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% gel vaginal 1 applicatorful qhs\", \"Text\": \"Metronidazole Vaginal\", \"Mnemonic\": \"106\"}, {\"Row\": 13, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid (ALT)\", \"Text\": \"Minocycline PO\", \"Mnemonic\": \"108\"}, {\"Row\": 14, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Moxifloxacin oph 1 drop tid\", \"Text\": \"Moxifloxacin Ophthalmic\", \"Mnemonic\": \"110\"}, {\"Row\": 15, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Nafcillin 2gm iv q4h\", \"Text\": \"Nafcillin IV\", \"Mnemonic\": \"112\"}, {\"Row\": 16, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Neomycin 1000mg po tid (ALT)\", \"Text\": \"Neomycin PO\", \"Mnemonic\": \"114\"}, {\"Row\": 17, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100mg po Q12H\", \"Text\": \"Nitrofurantoin PO\", \"Mnemonic\": \"116\"}, {\"Row\": 19, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Penicillin 500mg po qid (ALT)\", \"Text\": \"Penicillin PO\", \"Mnemonic\": \"118\"}, {\"Row\": 20, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Penicillin 4MU iv q4h\", \"Text\": \"Penicillin IV\", \"Mnemonic\": \"120\"}, {\"Row\": 21, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Piperacillin/tazobactam 3.375 GM IV Q6H (ALT)\", \"Text\": \"Piperacillin/Tazobactam IV\", \"Mnemonic\": \"122\"}, {\"Row\": 22, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75 mg po qday\", \"Text\": \"Pyrimethamine PO\", \"Mnemonic\": \"124\"}, {\"Row\": 23, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Rifampin 300mg iv q12h (ALT)\", \"Text\": \"Rifampin IV\", \"Mnemonic\": \"126\"}, {\"Row\": 24, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Rifampin 300mg po bid (ALT)\", \"Text\": \"Rifampin PO\", \"Mnemonic\": \"128\"}, {\"Row\": 25, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Sulfacetamide soln oph 1 drop qid\", \"Text\": \"Sulfacetamide OPTH\", \"Mnemonic\": \"130\"}, {\"Row\": 26, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Sulfadiazine 1000mg po qid (ALT)\", \"Text\": \"Sulfadiazine PO\", \"Mnemonic\": \"132\"}, {\"Row\": 27, \"Column\": 2, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Terbinafine PO\", \"Mnemonic\": \"134\"}, {\"Row\": 28, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% vaginal 1 applicatorful qhs\", \"Text\": \"Terconazole 0.4% Vaginal\", \"Mnemonic\": \"136\"}, {\"Row\": 29, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Tobramycin 5 mg/kg iv q24h (ALT)\", \"Text\": \"Tobramycin IV\", \"Mnemonic\": \"140\"}, {\"Row\": 30, \"Column\": 2, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Trimethoprim PO\", \"Mnemonic\": \"142\"}, {\"Row\": 31, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1ds tablet bid\", \"Text\": \"Trimethoprim-sulfamethoxazole PO\", \"Mnemonic\": \"144\"}, {\"Row\": 32, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 5 mg/kg iv q12h\", \"Text\": \"Trimethoprim-sulfamethoxazole IV\", \"Mnemonic\": \"146\"}, {\"Row\": 33, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po bid (ALT)\", \"Text\": \"Valacyclovir PO\", \"Mnemonic\": \"148\"}, {\"Row\": 34, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Vancomycin soln 125mg po q6h\", \"Text\": \"Vancomycin PO\", \"Mnemonic\": \"150\"}, {\"Row\": 35, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Vancomycin 1000mg iv q12h\", \"Text\": \"Vancomycin IV\", \"Mnemonic\": \"152\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"Oseltamivir (see Influenza Menu)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 3,
    "fields": {
      "name": "ORZID GMENU ABX GENRL ALTERNATIVE DRUG",
      "term": "This page gives the user the opportunity to select an alternative drug.  Created by Greg Filice 31-Dec-02",
      "displaytext": "Need an alternative antimicrobial? (inpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Patient allergic to recommended drugs\", \"Text\": \"Allergic to recommended drug(s)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Decreased renal clearance\", \"Text\": \"Decreased renal clearance\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Liver secretory\", \"Text\": \"Liver secretory or metabolic impairment\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Drug interaction\", \"Text\": \"Drug interaction\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Multiple infections requiring antimicrobials\", \"Text\": \"Patient has multiple infections requiring antimicrobials\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Isolate not susceptible to recommended drug\", \"Text\": \"Adjust therapy based on antimicrobial susceptibility\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Other adverse drug affect order set\", \"Text\": \"Other adverse drug effect\", \"Mnemonic\": \"14\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Other reason\", \"Text\": \"Other reason\", \"Mnemonic\": \"16\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Please Click Here to contact the CDSS team\", \"Mnemonic\": \"18\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 144, \"DisplayText\": \"Drug allergies\", \"Text\": \"Information about drug allergies\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEED AN ALERNATIVE ANTIMICROBIAL?\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If you cannot use the recommended antimicrobials or you believe another one\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"would be better for your patient, you can order another drug. Please indicate\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"the reason you need an alternative drug below.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Note: Alternative antimicrobial selections will be reviewed and we may contact\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"prescribers to learn more about situations that need alternatives, improve the\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"CDSS, and in some cases offer suggestions.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Clarification/Comments:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 4,
    "fields": {
      "name": "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED",
      "term": null,
      "displaytext": "Help, legend, allergy info, consults, alternative antimicrobials and more (ER) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help and Additional Information Menu\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INPT CONSULTS MENU\", \"Text\": \"Inpatient Consult Menu - place consults to specialty service\", \"Mnemonic\": \"4\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"OUTPT CONSULT MENU\", \"Text\": \"Outpatient Consult Menu - place consults to specialty service\", \"Mnemonic\": \"6\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antibiogram\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 3, \"DisplayText\": \"Need an alternative antimicrobial? (inpatient)\", \"Text\": \"Inpatient Alternative Antimicrobials to CDSS Recommendations - select here\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 940, \"DisplayText\": \"Need an alternative antimicrobial? (outpatient)\", \"Text\": \"Outpatient Alternative Antimicrobials to CDSS Recommendations - select here\", \"Mnemonic\": \"12\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact Information\", \"Mnemonic\": \"14\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Antimicrobial Information\", \"Mnemonic\": \"16\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Important Drug Properties\", \"Mnemonic\": \"18\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 124, \"DisplayText\": \"Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)\", \"Text\": \"Antimicrobial Cost Information\", \"Mnemonic\": \"20\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"GENERAL INFORMATION\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"LEGEND ________________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"[DI] = Important interactions between antimicrobial and other drugs\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"[H] = Hepatic excretion of antimicrobial\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"[M] = Minimal risk posed by antimicrobial\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"[O] = Other important antimicrobial property\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"[R] = Renal excretion of antimicrobial\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"($) = <10 dollars per day\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"($$) = 10-50 dollars per day\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"($$$) = 51-100 dollars per day\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"($$$$) = 101-400 dollars per day\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"($$$$$) = >400 dollars per day\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam Reaction Assessment\", \"Mnemonic\": \"9\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 5,
    "fields": {
      "name": "ORZID GMENU ER/UC ABX LYME DISEASE",
      "term": null,
      "displaytext": "Lyme Disease ER/UC ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 40, \"DisplayText\": \"Lyme Disease Prophylaxis ER/UC\", \"Text\": \"Lyme Disease Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 932, \"DisplayText\": \"Erythema migrans associated with Lyme disease (Outpatient)\", \"Text\": \"Erythema migrans associated with Lyme disease\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 38, \"DisplayText\": \"Lyme Acute Neurological Disease ER/UC\", \"Text\": \"Acute neurological disease associated with Lyme disease\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 928, \"DisplayText\": \"Arthritis associated with Lyme disease (Outpatient)\", \"Text\": \"Arthritis associated with Lyme disease\", \"Mnemonic\": \"10\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 39, \"DisplayText\": \"Lyme Caridac Disease ER/UC\", \"Text\": \"Cardiac disease associated with Lyme disease\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Lyme disease results from the transmission of Borrelia burgdorferi from an\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Ixodes spp. tick bite. Patients who display signs of illness or fever within 30\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"days of removing an attached tick should be evaluated for tick-borne illness.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"(deer tick) but who do not display signs or symptoms of infection should not\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"be treated with antimicrobials.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Prophylactic antimicrobial treatment may be beneficial in certain patients who\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"have been bitten while in endemic areas.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Except for erythema migrans, Lyme disease is a complicated, difficult disease to\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"diagnose and treat. Infectious Diseases consultation is strongly encouraged.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Wormser GP Clin Infect Dis (2006), 43: 1089\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 6,
    "fields": {
      "name": "ORZID GMENU ER/UC ACUTE SINUSITIS",
      "term": null,
      "displaytext": "ED Acute Sinusitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 727, \"DisplayText\": \"Acute sinusitis--mild to moderate disease (Outpatient)\", \"Text\": \"[CLICK HERE] for treatment of mild to moderate bacterial sinusitis - Opt CDSS\", \"Mnemonic\": \"4\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 62, \"DisplayText\": \"ED Severe Sinusitis\", \"Text\": \"[CLICK HERE] for treatment of severe bacterial sinusitis\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"treated with decongestants, analgesics, and nasal saline. Diagnosis of acute\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sinusitis is based on the presence of at least 2 major or 1 major and at least 2\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"minor symptoms.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Major Symptoms\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"1. Purulent anterior nasal discharge\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"2. Purulent or discolored posterior nasal discharge\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"3. Nasal congestion or fullness\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"4. Facial pain or pressure\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"5. Hyposmia or anosmia\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"6. Fever\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Minor Symptoms\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"1. Headache\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"2. Ear pain, pressure or fullness\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"3. Halitosis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"4. Dental pain\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"5. Cough\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"6. Fatigue\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If patient meets criteria above for acute sinusitis, treat with antimicrobials\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"according to the following criteria for mild to moderate or severe bacterial\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"sinusitis.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mild to moderate bacterial sinusitis\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1. Symptoms persisting beyond 10 days\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"2. Double-sickening - Symptoms typical of viral upper respiratory infection\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"initially improving for 5-6 days then worsening with new development of fever,\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"headache or increased nasal discharge.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Severe bacterial sinusitis\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"pain lasting for at least 3-4 consecutive days at the beginning of illness.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 7,
    "fields": {
      "name": "ORZID GMENU ER/UC APPENDICITIS W/O PERFORATION",
      "term": null,
      "displaytext": "ED Appendicitis Without Perforation  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 8, \"DisplayText\": \"ED Appendicitis with Perforation\", \"Text\": \"Link to appendicitis with perforation menu\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFAZ 2GM METRO 500MG IV ONCE SURGERY ER/UC\", \"Text\": \"Cefazolin 2 gm IV once STAT ($) [R] <AND> metronidazole 500 mg IV once STAT\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"GENT 5MG/KG METRO 500MG IV ONCE SURGERY ER/UC\", \"Text\": \"Gentamicin 5 mg/kg IV once STAT ($) [R,O] <AND> metronidazole 500 mg IV once\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV once STAT ($$) [R,DI]\", \"Text\": \"Ertapenem 1 gm IV once STAT ($$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPENDICITIS WITHOUT PERFORATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with an acutely inflamed appendix and no gangrene or perforation are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"considered to have uncomplicated appendicitis. Patients with gangrene,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"perforation, peritonitis, or abscess have complicated appendicitis. Treatment\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with antibiotics is an option for patients who are unfit for surgery or refuse\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"surgery. Treatment with antibiotics should not be used routinely as an\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"alternative to surgery.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Select for treatment of complicated appendicitis\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Surgical prophylaxis for uncomplicated appendicitis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"($) [DI] infusion beginning 60 minutes before incision < OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"STAT ($) [DI] infusion beginning 60 minutes before incision\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment of patients who are unfit for surgery or refuse surgery\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Initial treatment\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Step down treatment after completion of initial intravenous treatment\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Appendicitis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Salminen et al, JAMA, 2015, 313(23):2340-2348\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Sanford keyword: Appendicitis\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-Date article: Management of acute appendicitis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 8,
    "fields": {
      "name": "ORZID GMENU ER/UC APPENDICITIS WITH PERFORATION",
      "term": null,
      "displaytext": "ED Appendicitis with Perforation  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV once STAT ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV once STAT ($$) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPRO 400MG METRO 500MG IV ONCE STAT\", \"Text\": \"Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1GM IV once ER/UC\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [R,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPENDICITIS WITH PERFORATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treat until normalization of temperature, WBC and GI tract functioning\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"STAT ($) [DI]\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"once STAT ($) [DI]\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Step down treatment after initial intravenous antibiotic treatment in patients\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"who can tolerate oral therapy. Base selection on culture results.\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Appendicitis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Solomkin JS Clin Infect Dis 2003, 37: 997\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-to-date\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 9,
    "fields": {
      "name": "ORZID GMENU ER/UC ASPIRATION PNEUMONIA",
      "term": null,
      "displaytext": "ED Aspiration Pneumonia  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 25, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community acquired pneumonia (CAP) < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 46, \"DisplayText\": \"ED Nosocomial Pneumonia\", \"Text\": \"Nosocomial pneumonia\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ASPIRATION PNEUMONIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Aspiration of oropharyngeal or gastric contents induces inflammation and is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"often accompanied by fever and/or an infiltrate. Bacterial pneumonia occurs in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"a minority of patients who aspirate, typically about 3 days later. The patient\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"usually improves for the first 2 days and then worsens as bacterial pneumonia\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"develops with increased fever, new or progressive infiltrates, leukocytosis, and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"newly purulent sputum.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobials have no role for treatment of aspiration and their use entails\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"risk of side effects and selection of resistant organisms.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobials used for community-acquired pneumonia are appropriate for cases\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"that develop after an episode of aspiration. For more information, consult\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pulmonary or Infectious Diseases.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment for patients with pneumonitis but without lung abscess or putrid\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"sputum\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Therapy directed towards anaerobic pathogens is usually unnecessary. If\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"pneumonia is confirmed, treat as\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treament for patients with LUNG ABSCESS\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Refer to Lung and Mediastinum section of the inpatient or outpatient\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Antimicrobial CDSS\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Luna CM Crit Care Med 2003, 31: 676\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Lung Abscess\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell LA Clin Infect Dis 2003,37:1405\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Roig J J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 10,
    "fields": {
      "name": "ORZID GMENU ER/UC BACT MENING W/O GRM STAIN RES",
      "term": null,
      "displaytext": "ED Bacterial Meningitis Without Gram Stain Results  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 10 mg IV once STAT ($)\", \"Text\": \"Dexamethasone 10 mg IV once STAT ($)\", \"Mnemonic\": \"4\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M] <AND> vancomycin 15mg/kg IV once STAT\", \"Mnemonic\": \"6\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEROPENEM 2GM IV ONCE VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Meropenem 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg once STAT ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Ampicillin 2 gm IV once STAT ($$) [R] <AND> ceftriaxone 2 gm IV once STAT\", \"Mnemonic\": \"12\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MOXI 400MG VANCO 15MG/KG TMP/SMX IV STAT\", \"Text\": \"Moxifloxacin 400mg IV once STAT ($$) [R,DI] <AND> vancomycin 15mg/kg once\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS (WITHOUT GRAM STAIN RESULTS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Intravenous dexamethasone therapy improves outcomes for meningitis with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae and is recommended for empirical treatment of all\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"community acquired cases that might be associated with S. pneumoniae.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Dexamethasone must be given before (1 to 20 minutes) with antimicrobials.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If meningococcal meningitis is identified, antimicrobial prophylaxis should be\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"considered for close contacts. Contact Infectious Diseases/Epidemiology for\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"advice and assistance.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Step 1 of Treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(Discontinue if isolated pathogen is not S. pneumoniae)\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Step 2 of Treatment, Select One of the Following:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment for Adults < 50 Years Without Alcoholism, Debilitating Disease, or\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Any Other Condition Associated with Impaired Cellular Immunity.\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treatment for Adults >= 50 Years or With Alcoholism, Debilitating Disease, or\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Impaired Cellular Immunity. Listeria Monocytogenes is One Important Pathogen.\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"($) [M] vancomycin 15mg/kg once STAT ($) [R]\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"STAT ($) [R] <AND> trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV once\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"STAT ($$$) [R,DI]\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Age > 50 years\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Age 1 mo to 50 years\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 11,
    "fields": {
      "name": "ORZID GMENU ER/UC BEBTELOVIMAB EUA",
      "term": null,
      "displaytext": "Bebtelovimab (EUA) Orders",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3001, \"DisplayText\": \"LINK EUA PROVIDER TO FILL OUT\", \"Text\": \"[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Provider Fact Sheet\", \"Text\": \"[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Bebtelovimab (EUA)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"for treating patients that meet specific criteria. bebtelovimab is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"not FDA approved drug.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"-Bebtelovimab EUA does NOT include post-exposure prophylaxis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Bebtelovimab Emergency Use Authorization (EUA)\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Inclusion Criteria\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"ALL of the following criteria must be met for a patient to receive:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"1) Patient has tested positive for COVID-19 and is diagnosed with mild to\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Note: patient may be hospitalized for some other reason.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"3) Patient does NOT require oxygen therapy for COVID-19.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For patients on chronic oxygen therapy: patient does NOT require an\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"increase in baseline oxygen flow rate due to COVID-19.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"4) Administration will begin within 7 days of symptom onset.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to bebtelovimab or components.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"6) Patient has at least one risk factor for progression to severe disease\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"including hospitalization or death.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"See link below for complete list:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"7) Counseling is provided and documented in the electronic health record per EUA\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"The provider has communicated with the patient/caregiver regarding\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"information contained in the \\\"Fact Sheet for Patients\\\". The patient/\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"caregiver has been given the Fact sheet, informed that the drug is an\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"unapproved drug that is authorized for use under an EUA, given information\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"on alternatives and their risks and benefits, and the patient/caregiver\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"has the right to refuse or accept. (See top of page for Fact Sheet)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Exclusion Criteria\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"If patient agreeable and meets criteria, please contact Minneapolis VA Emergency\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Department charge nurse at 31-6736 to arrange for treatment if available. Click\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"sharing personal items, clean and disinfect \\\"high touch\\\" surfaces, and\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"frequent handwashing) according to CDC guidelines.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"order set below to complete order form and place IV order for administration.\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Note: order does not contain medication order. ED provider will order.\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelivomab ED Info\", \"Text\": \"INV-Bebtelovimab 175 mg IV Push ONCE\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"moderate illness.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 12,
    "fields": {
      "name": "ORZID GMENU ER/UC BITE WNDS EIKENELLA CORRODENS",
      "term": null,
      "displaytext": "Bite Wounds Eikenella Corrodens ER/UC",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100mg PO BID ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Text\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"16a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Text\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"20\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH EIKENELLA CORRODENS\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 13,
    "fields": {
      "name": "ORZID GMENU ER/UC BITE WNDS METH RES S. AUREUS",
      "term": null,
      "displaytext": "Bite Wound Methicillin-Resistant Staphylococcus Aureus ER/UC ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 10 days\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]  < OR >\", \"Mnemonic\": \"10a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 14 days\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 14,
    "fields": {
      "name": "ORZID GMENU ER/UC BITE WNDS METH SUSC S. AUREUS",
      "term": null,
      "displaytext": "Bite Wounds Methicillin-Susceptible Staphylococcus Aureus ER/UC ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV once STAT ($$) [DI]\", \"Text\": \"Nafcillin 2 gm IV once STAT ($$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV once STAT ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"14a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV once STAT ($$) [DI]\", \"Text\": \"Nafcillin 2 gm IV once STAT ($$) [DI]\", \"Mnemonic\": \"20\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV once STAT ($) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treat for 14-21 days.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID x10days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"16a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 15,
    "fields": {
      "name": "ORZID GMENU ER/UC BITE WNDS P. MULTOCIDA",
      "term": null,
      "displaytext": "Bite Wounds Pasteurella Multocida ER/UC ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100mg PO BID ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Text\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"16a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Text\": \"Doxycycline 100mg IV once STAT ($$) [DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH PASTEURELLA MULTOCIDA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 16,
    "fields": {
      "name": "ORZID GMENU ER/UC BITE WNDS STREPTOCOCCI",
      "term": null,
      "displaytext": "Bite Wound Streptococci ER/UC  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV once STAT ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID for 10 days ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO QID for 10 days ($) [H,O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID for 10 days ($) [H,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV once STAT ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid for 14 days\", \"Text\": \"Clindamycin 300 mg PO QID for 14 days ($) [H,O]\", \"Mnemonic\": \"18a\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection but no arthritis - 10 days joint involved - 14-21 days\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH STREPTOCOCCI\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID x10days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 17,
    "fields": {
      "name": "ORZID GMENU ER/UC BITE WOUNDS",
      "term": null,
      "displaytext": "Bite Wounds ER/UC  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Mnemonic\": \"4\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV once STAT ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400mg IV once STAT ($$) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]\", \"Mnemonic\": \"16a\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 15, \"DisplayText\": \"Bite Wounds Pasteurella Multocida ER/UC\", \"Text\": \"Pasteurella multocida\", \"Mnemonic\": \"18\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 12, \"DisplayText\": \"Bite Wounds Eikenella Corrodens ER/UC\", \"Text\": \"Eikenella corrodens\", \"Mnemonic\": \"20\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 14, \"DisplayText\": \"Bite Wounds Methicillin-Susceptible Staphylococcus Aureus ER/UC\", \"Text\": \"Methicillin-susceptible Staphylococcus aureus\", \"Mnemonic\": \"22\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 13, \"DisplayText\": \"Bite Wound Methicillin-Resistant Staphylococcus Aureus ER/UC\", \"Text\": \"Methicillin-resistant Staphylococcus aureus\", \"Mnemonic\": \"24\"}, {\"Row\": 74, \"Column\": 1, \"Item\": 16, \"DisplayText\": \"Bite Wound Streptococci ER/UC\", \"Text\": \"Streptococci\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bite wounds are prone to infection because of the pathogenic oral flora carried\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into tissues  by teeth.  Common pathogens include Eikenella corrodens, usually\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"from human bites, and Pasteurella multocida, often from dog or cat bites,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"streptococci and staphylococci.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Clean wounds with soap and water as soon as possible, add local antiseptic\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and debride non-viable tissue.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult orthopedic surgery for all bite wounds involving the hand.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antibiotic Prophylaxis Indications:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Severe injury less than 8 hours, Crush injury, Bone or joint penetration,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Wound of the face or hands or genitals, Immunocompromised host, Asplenia,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Advanced liver disease\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"*Routine use of prophylactic antibiotics for non-immunocompromised patients\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"with superficial wounds with no puncture that do not involve the face/\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"genitals/hands is not recommended.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Antimicrobial Treatment:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empiric treatment for suspected or established infection following bite wound.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"In these cases, therapy should be directed against pathogen identified\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"by Gram stain and culture whenever possible.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Rabies Prophylaxis:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Consider rabies post-exposure prophylaxis for all animal bite cases.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Contact infectious diseases for assistance.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Consider tetanus immunization status:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"If immunization is up to date, nothing more needs to be done to prevent tetanus.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"If immunization is lacking, and:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"wound IS NOT tetanus prone, bring immunization up to date with Td\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"wound IS tetanus prone, bring immunization up to date with Td  < AND >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Select below for Tetanus vaccination information page:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treat deep wounds for the first 3-5 days after a bite to prevent infection.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"For wounds that later develop evidence of infection but without arthritis, treat\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"with antimicrobials for 7-14.  For wounds that develop infection of a joint,\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"treat 14 to 21 days.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Prophylaxis:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Duration 3 to 5 days:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative for patients with penicillin allergy:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Empiric treatment for suspected or estabished infection:\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Duration 7 to 14 days:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Alternative for patients with penicillin allergy:\", \"Header\": 1}, {\"Row\": 65, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Pathogen directed bite wound therapy:\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Abrahamian FM New Engl Journ Med 1999, 340:85\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 18,
    "fields": {
      "name": "ORZID GMENU ER/UC BRONCHITIS",
      "term": null,
      "displaytext": "ED Bronchitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 95, \"DisplayText\": \"Bronchitis not benefited\", \"Text\": \"Bronchitis-antibiotics not a benefit in otherwise healthy patient\", \"Mnemonic\": \"4\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Doxcycline 100 mg PO BID for 5 days ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once on day one then 250 mg PO qday for 4 days ($) [M]\", \"Mnemonic\": \"10a\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO BID for 5 days ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZITHROMYCIN 500 MG IV ONCE\", \"Text\": \"Azithromycin 500 mg IV once STAT ($) [M< OR >\", \"Mnemonic\": \"14\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV once STAT ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 3002, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BRONCHITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute bronchitis should not be treated with antimicrobials except in specific\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"circumstances. If pneumonia is suspected, order a chest x-ray. If an\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infiltrate is not present, the patient does not have bacterial pneumonia and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"need not be treated for it.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Acute bronchitis in an otherwise HEALTHY PATIENT\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobials provide no benefit. If bronchitis persists beyond 2 weeks,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"additional diagnostic workup is needed to find a cause. If a patient has\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"persistent cough with inspiratory whoop, consider a diagnosis of pertussis.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For symptomatic treatment dextromethorphan and benzonatate combined with\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"guaifenesin has shown some benefit. Benzonatate and guaifenesin\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"alone did not show benefit. Also, allergy medicines and codeine\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"do not appear to help the symptoms.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Refer to the outpatient or inpatient Antimicrobial CDSS for treatment of\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Pertussis recommendations\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Acute bronchitis in patients with COPD\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Symptoms of COPD exacerbation include dyspnea with increased sputum purulence\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"and volume, together with increased cough and wheeze. Co-morbidities are\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"common in COPD patients, thus exacerbations must be differentiated clinically\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"from other events such as acute coronary syndrome, worsening heart failure,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"pulmonary embolism and pneumonia.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Cornerstones of therapy include oxygen, bronchodilators, and in some cases\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"corticosteroids. Recommend antibiotics for moderately or severely ill patient\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"with COPD exacerbation who have increased sputum purulence and volume.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Treatment for MILD DISEASE:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"No antibiotics recommended\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment for MODERATE DISEASE\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treat for 5 to 7 days.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Treatment for SEVERE DISEASE\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"NOTE: Fluoroquinolones are not listed as a choice because the risk of serious\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"side effects outweigh the benefits.\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Access: http://www.goldcopd.org\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Wenzel WP et al NEJM 2006, 355: 2125\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Mandell chapter: Bronchitis\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Sanford keyword: Bronchitis\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Murphy TF Chest 2000, 118: 204\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Masterton RG Int J Antimicrob Agents 2001, 18: 503\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 19,
    "fields": {
      "name": "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING NON-SEVERE CAP",
      "term": null,
      "displaytext": "CAP treated in an INPATIENT setting  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN INPATIENT SETTING\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Inpatient, non-severe CAP (NOTE: DURATION of therapy)\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2GM IV STAT ($) [M] <AND> Azithromycin 500mg PO STAT ($) [M]\", \"Text\": \"Ceftriaxone 2GM IV STAT ($) [M] <AND> Azithromycin 500mg PO STAT ($) [M]\", \"Mnemonic\": \"14\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Be sure of the diagnosis.  Careful reviews have shown that over half of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"people treated for community-acquired pneumonia do not in fact have\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pneumonia.  Pneumonia is likely in persons with 3 or more signs or symptoms\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"including a) new infiltrate (or, no prior film for comparison) b) new\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"crackles, egophony, or dullness c) pleuritic pain, d) fever and/or chills\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"e) leukocytosis f) cough g) purulent sputum and h) new or worsened dyspnea\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"or tachypnea, and no likely alternative explanation for the presentation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Common alternative explanations include heart failure, thromboembolic\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"disease, COPD exacerbation, viral pneumonitis, aspiration pneumonitis, or\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"tumor. Most of the latter conditions do NOT benefit from antimicrobials.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Recommendation for duration of antibiotic therapy for CAP:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Patients with CAP should be treated for a minimum of 5 days, should be\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"afebrile for 48-72 hours, and should have no more than 1 CAP-\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"associated sign of clinical instability before discontinuation\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"of therapy.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Criteria for clinical stability:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Temperature less than/equal to 100 degrees F\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Heart rate less than/equal to 100 beats/minute\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Respiratory rate less than/equal to 24 breaths/minute\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Systolic blood pressure greater than/equal to 90 mm Hg\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Ability to maintain oral intake\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Normal mental status\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Arterial oxygen saturation greater than/equal to 90% --OR--\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"PO2 greater than/equal to 60 mm Hg on room air\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Preferred: (no prior respiratory isolation of MRSA or P. aeruginosa)\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 65, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Sanford website\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 3003, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO STAT ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for MRSA:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Obtain cultures BUT withhold MRSA coverage unless cultures or nasal carriage\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"positive for MRSA. (See below for prior respiratory isolation of MRSA)\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Obtain cultures BUT withhold anti-pseudomonal coverage unless cultures\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"are positive for P. aeruginosa. (See below for prior respiratory isolation\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin 4.5GM IV STAT ($$) [R] <AND> Azithromycin 500mg PO STAT\", \"Mnemonic\": \"20\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2GM IV STAT ($$) [R] <AND> Azithromycin 500mg PO STAT ($) [M]\", \"Mnemonic\": \"22\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of MRSA within last 12months: ADD MRSA COVERAGE\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of P.aeruginosa within last 12months: SELECT BELOW\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Select regimen below for P.aeruginosa, obtain cultures to allow deescalation\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"of P. aeruginosa)\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO STAT ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO STAT ($) [R,DI]\", \"Mnemonic\": \"24\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Alternative for P. aeruginosa:\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"ADD MRSA coverage to above regimen, otain cultures/nasal PCR to allow\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"for deescalation\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 20,
    "fields": {
      "name": "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING SEVERE CAP",
      "term": null,
      "displaytext": "CAP treated in an INPATIENT setting -  SEVERE CAP",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 37, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment on INTENSIVE CARE UNIT (ICU)\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Alternative Standard Regimen:\", \"Header\": 1}, {\"Row\": 87, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Preferred Standard Regimen: (no MRSA or P. aeruginosa coverage)\", \"Header\": 1}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Recommendation for duration of antibiotic therapy for CAP:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Patients with CAP should be treated for a minimum of 5 days, should be\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"afebrile for 48-72 hours, and should have no more than 1 CAP-\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"associated sign of clinical instability before discontinuation\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"of therapy.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Criteria for clinical stability:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Temperature less than/equal to 100 degrees F\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Heart rate less than/equal to 100 beats/minute\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Respiratory rate less than/equal to 24 breaths/minute\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Systolic blood pressure greater than/equal to 90 mm Hg\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Ability to maintain oral intake\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Normal mental status\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Arterial oxygen saturation greater than/equal to 90% --OR--\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"PO2 greater than/equal to 60 mm Hg on room air\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"Liu C Clin Inf Dis. 2011, 52:285\"}, {\"Row\": 96, \"Column\": 1, \"Text\": \"Mandell LA Clin Infect Dis 2007, 44:S27\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 98, \"Column\": 1, \"Text\": \"Sanford website\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEVERE Community-Acquired Pneumonia (CAP) Treated in Intensive Care Unit (ICU)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Criteria for Defining SEVERE Community-acquired Pneumonia\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Validated definition includes either one major or three or more minor criteria\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"MAJOR CRITERIA:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Septic shock with need for vasopressors\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Respiratory failure requiring mechanical ventilation\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"MINOR CRITERIA:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Respiratory rate greater than or equal to 30 breaths/minute\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"PaO2/FiO2 ratio less than or equal to 250\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Multilobar infiltrates\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Confusion/disorientation\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Uremia (blood urea nitrogen level greater than 20 mg/dl)\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Leukopenia* (WBC less than 4,000 cells/microliter)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"*Due to infection alone (i.e., not chemotherapy induced)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Thrombocytopenia (platelet count less than 100,000 microliters)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Hypothermia (core temperature less than 36 degrees C)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Hypotension requiring aggressive fluid resuscitation\"}, {\"Row\": 71, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO STAT ($) [R,DI]\", \"Mnemonic\": \"34\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV STAT ($) [R,DI]\", \"Mnemonic\": \"32\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 89, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV STAT ($) [R,DI]\", \"Mnemonic\": \"50\"}, {\"Row\": 91, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO STAT ($) [R,DI]\", \"Mnemonic\": \"54\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 82, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV STAT ($$) [R] <AND> Azithromycin\", \"Mnemonic\": \"38\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Prior respiratory isolation of MRSA in the last 12 months: ADD MRSA coverage\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"36\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Prior respiratory isolation of P. aeurginosa in the last 12 months:\", \"Header\": 1}, {\"Row\": 80, \"Column\": 1, \"Text\": \"SELECT REGIMEN BELOW:\", \"Header\": 1}, {\"Row\": 68, \"Column\": 1, \"Item\": 3004, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"confirmation of need for continued therapy. SEE MRSA Section below\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR-\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"COVER for P. aeruginosa. Obtain cultures to allow deescalation or\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"confirmation of need for continued therapy. SEE P. aeruginosa section below\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR-\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of P. aeruginosa in the last 12 months:\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Text\": \"ADD MRSA coverage to Standard Regimen above or Antipseudomonal regimen below:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of MRSA within last 12 months:\", \"Header\": 1}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 GM IV STAT ($$) [R] <AND> Azithromycin 500 mg IV STAT ($) [M]\", \"Mnemonic\": \"40\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 GM IV STAT ($) [R] <AND> Azithromycin 500 mg IV STAT ($) [M]\", \"Mnemonic\": \"30\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"500 mg IV STAT ($) [M]\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Stepdown empiric treatment for CAP (Intravenous to Oral conversion)\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"(Specific therapy should be guided by culture results.)\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 342, \"DisplayText\": \"Stepdown empiric treatment for CAP with oral antibiotics\", \"Text\": \"[Link] Stepdown empiric treatment for CAP with oral antibiotics\", \"Mnemonic\": \"3\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Recommend blood and lower respiratory tract specimen cultures for all patients\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"with Severe CAP.\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sputum Culture and Gram Stain\", \"Text\": \"Lab Order: Sputum Culture & Gram Stain\", \"Mnemonic\": \"4\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Blood Culture x2\", \"Text\": \"Lab order: Blood culture x2\", \"Mnemonic\": \"5\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of MRSA within last 12 months:\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"confirmation of need for continued therapy. SEE MRSA Section below\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 21,
    "fields": {
      "name": "ORZID GMENU ER/UC CAP OUTPATIENT TREATED SETTING",
      "term": null,
      "displaytext": "CAP treated in an outpatient setting (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Mnemonic\": \"16a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]\", \"Text\": \"Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]\", \"Mnemonic\": \"30a\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"30b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN OUTPATIENT SETTING\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Preferred outpatient treatment for PREVIOUSLY HEALTHY PATIENT:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"conditions, or use of immunosuppressing drugs)\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Outpatient and UNcomplicated:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred outpatient treatment for PATIENTS WITH COMORBIDITIES:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(WITH chronic obstructive pulmonary disease, diabetes, renal failure,\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"conditions, or use of immunosuppressing drugs)\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sanford: Community Acquired Pneumonia\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Outpatient and comorbidity:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Azithromycin 500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO TID for 5 days ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO TID for 5 days ($) [R]\", \"Mnemonic\": \"17a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"17b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA for above order\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"19b\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300mg PO BID for 5 to 7 days ($) [R] <AND> Azithromycin\", \"Text\": \"Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Azithromycin\", \"Mnemonic\": \"20a\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NON-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amox-clav 875/125mg po bid x5days <AND> Azithromycin 500 then 250\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>\", \"Mnemonic\": \"19a\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amox-clav 875/125 mg po bid <AND> Doxycycline 100mg po bid x5days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>\", \"Mnemonic\": \"22a\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"22b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300mg po bid <AND> Doxycycline 100mg po bid x5 days\", \"Text\": \"Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Doxycycline\", \"Mnemonic\": \"24a\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"100 mg PO BID for 5 days ($) [DI]\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA for above\", \"Text\": \"Non-VA for above\", \"Mnemonic\": \"24b\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"ER/UC MAY ADMINISTER AN INITIAL INTRAVENOUS DOSE STAT THEN DISPENSE RX FOR HOME\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 GM STAT ($) [M]\", \"Mnemonic\": \"18\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"ORDER OUTPATIENT PRESCRIPTIONS BELOW:\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"ER/UC MAY ADMINISTER AN INITIAL INTRAVENOUS DOSE STAT THEN DISPENSE RX FOR HOME\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Item\": 3005, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"ORDER OUTPATIENT PRESCRIPTION BELOW:\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV STAT ($) [R,DI]\", \"Mnemonic\": \"28\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 22,
    "fields": {
      "name": "ORZID GMENU ER/UC CELLULITIS",
      "term": null,
      "displaytext": "ED Cellulitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 41, \"DisplayText\": \"ED Approach to Cellulitis\", \"Text\": \"More about cellulitis...\", \"Mnemonic\": \"4\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV once STAT ($$) [DI]\", \"Text\": \"Nafcillin 2 gm IV once STAT ($$) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV once STAT ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R] <AND> vancomycin IV\", \"Mnemonic\": \"22\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15MG/KG CIPRO 400MG METRO 500MG IV ONCE STAT\", \"Text\": \"Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> Vancomycin 15 mg/kg IV\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL CELLULITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cellulitis refers to inflammation of the skin and subcutaneous tissue and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"often associated with bacterial pathogens. The most common pathogens are group\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"A streptococci and Staphylococcus aureus. Group B streptococci are associated\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with cellulitis in elderly people, in those with diabetes mellitus, and on\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and legs of patients with athlete's foot (tinea pedis).\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Mild cases can be treated with oral antimicrobials. Moderate to severe cases\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"should be treated initially with intravenous antimicrobials. Switch to oral\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"drugs after clinical improvement.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consider MRSA coverage for cellulitis associated with penetrating trauma, a\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"history of MRSA infection, injection drug use, or infections not responding\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"to first line beta-lactams.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"if not improved in this time.\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mild: Cellulitis without systemic signs of infection\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Empirical treatment for MILD cellulitis\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative for Penicillin Allergy or MRSA suspected\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"MRSA Suspected Mild Cellulitis\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Moderate: Cellulitis with systemic signs of infection\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Empirical treatment for MODERATE cellulitis\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or MRSA suspected\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Severe: Cellulitis in patients with signs of deeper infections\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"(e.g. bullae, skin sloughing, hypotension, or evidence of organ dysfunction).\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Patients may also qualify as severe if they are neutropenic, have a\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"hematologic malignancy or congenital immunodeficiency, or are receiving\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"immunosuppressant therapy. Consider whether surgical drainage is necessary.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Empirical treatment for SEVERE infection\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"15mg/kg once STAT ($) [R]\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or MRSA suspected:\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"once STAT ($) [R] <AND> Metronidazole 500 mg IV once STAT ($) [DI,H]\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO bid ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 23,
    "fields": {
      "name": "ORZID GMENU ER/UC CHOLANGITIS",
      "term": null,
      "displaytext": "ED Cholangitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV once STAT ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h once STAT [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1GM IV once ER/UC\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [DI,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 500 mg IV once\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHOLANGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are due to common bile duct obstruction. Obstruction (if present)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"must be relieved with an endoscopical, transcutaneous, or surgical procedure.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"The most common pathogens isolated are E. coli, Klebsiela, Enterococcus and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Enterobacter. Anaerobes such as Bacteriodes and Clostridia can be present as\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"part of a mixed infection.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"once STAT ($) [DI]\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Step down treatment for completion of antimicrobial course after initial\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"intravenous treatment in patients who can tolerate oral therapy. Base selection\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"on culture results.\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Cholangitis, Cholecystitis)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Gallbladder Infections\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date article: Acute cholangitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 24,
    "fields": {
      "name": "ORZID GMENU ER/UC CHOLECYSTITIS",
      "term": null,
      "displaytext": "ED Cholecystitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV STAT ($) [DI]\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV once STAT ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV once STAT ($$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1GM IV once ER/UC\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once\", \"Mnemonic\": \"18\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R] <AND> vancomycin 15\", \"Mnemonic\": \"20\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once\", \"Mnemonic\": \"22\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHOLECYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Adequate biliary drainage is the definitive treatment. Antimicrobials should be\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"prescribed only if signs of infection like leukocytosis or fever are present or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"if the patient is elderly. Surgery and Gastroenterology involvement are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"essential.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Most cases are associated with E. coli, Enterococcus, Klebsiella, and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Enterobacter. Anaerobic coverage is not indicated unless a biliary-enteric\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"anastomosis is present. For community-acquired acute cholecystitis, enterococcal\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"coverage is not required because Enterococcus has not been shown to be\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"pathogenic in these patients.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If needed, antimicrobial therapy should be continued only until adequate\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"drainage is established, then stopped.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Community-acquired acute cholecystitis\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment of mild to moderate infection and biliary-enteric anastomosis present\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"once STAT ($) [DI]\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treatment of severe infection, advanced age or immunocompromised patient\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Health care-associated infection\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"mg/kg IV once STAT ($) [R]\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"STAT ($) [R]\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Step down treatment for completion of antimicrobial course after initial\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"intravenous treatment in patients who can tolerate oral therapy. Base selection\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"on culture results.\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimimicrobial CDSS\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Cholangitis, Cholecystitis)\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Sanford keyword: Gallbladder Infections, Acute Cholecystitis\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of acute calculous cholecystitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 25,
    "fields": {
      "name": "ORZID GMENU ER/UC COM-ACQ PNEUMONIA",
      "term": null,
      "displaytext": "Community-acquired pneumonia (CAP)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Text\": \"Empirical regimens listed here cover the usual pathogens associated with CAP,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"including \\\"atypical\\\" pathogens.  Specific therapy should be guided by culture\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"results.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Diagnosis\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"a patient with pneumonia.  Pre-estimated risk can then be used to determine how\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"aggressively to treat the patient's pneumonia and whether the patient can be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treated safely outside of the hospital.\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 3006, \"DisplayText\": \"CAP Pneumonia Severity Index (PSI) Calculator\", \"Mnemonic\": \"08\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"If a patient has taken an antimicrobial in the previous 3 months, it is prudent\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"to avoid giving the same or a similar drug for the current episode of pneumonia.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \">> Setting-specific treatment regimens <<\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY-ACQUIRED PNEUMONIA (CAP)\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 21, \"DisplayText\": \"CAP treated in an outpatient setting (Outpatient)\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"CAP Pneumonia Severity Index (PSI) or PORT Score\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"The CAP pneumonia severity index is useful for estimation of mortality risk f\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"The Community-Acquired Pneumonia Severity Index (PSI) is a guide and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"should be used to augment clinical judgment. If social circumstances\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"or cognitive dysfunction would interfere with success of outpatient\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"treatment, the patient should be hospitalized.\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 19, \"DisplayText\": \"CAP treated in an INPATIENT setting\", \"Text\": \"CAP treated in an Inpatient setting - NON-SEVERE CAP\", \"Mnemonic\": \"12\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 20, \"DisplayText\": \"CAP treated in an INPATIENT setting -  SEVERE CAP\", \"Text\": \"CAP treated in an Inpatient setting - SEVERE CAP (ICU)\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Note: Healthcare-associated pneumonia (HCAP) no longer used in 2019\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"and/or P. aeruginosa are use to guide whether to start appropriate\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"coverage empirically.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Fine MJ, et al. N Engl J Med (1997) 336: 243-250\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 26,
    "fields": {
      "name": "ORZID GMENU ER/UC COMP CYSTITIS",
      "term": null,
      "displaytext": "ED Complicated Cystitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 50, \"DisplayText\": \"ED Pyelonephritis\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 296, \"DisplayText\": \"Urine Culture\", \"Text\": \"Urine culture\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 725, \"DisplayText\": \"Acute bacterial prostatitis (Outpatient)\", \"Text\": \"Acute prostatitis\", \"Mnemonic\": \"8\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30mL/min, for 7 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"18a\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"20a\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300mg PO BID ($) [R] for 7 days\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"22a\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID ($) [R] for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"22b\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"24\"}, {\"Row\": 68, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"26a\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"26b\"}, {\"Row\": 73, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"28\"}, {\"Row\": 80, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Mnemonic\": \"30\"}, {\"Row\": 82, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV STAT ($$) [R]\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"32\"}, {\"Row\": 76, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"30\"}, {\"Row\": 77, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV once STAT ($$) [R,DI]\", \"Text\": \"Ertapenem 1 gm IV once STAT ($$) [R,O]\", \"Mnemonic\": \"32\"}, {\"Row\": 89, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"38a\"}, {\"Row\": 90, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"38b\"}, {\"Row\": 92, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"40\"}, {\"Row\": 95, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"42\"}, {\"Row\": 96, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"44a\"}, {\"Row\": 98, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"46\"}, {\"Row\": 107, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"48a\"}, {\"Row\": 108, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"48b\"}, {\"Row\": 110, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Mnemonic\": \"50\"}, {\"Row\": 112, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV STAT ($$) [R]\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"52\"}, {\"Row\": 116, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 7 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R] for 7 days\", \"Mnemonic\": \"54a\"}, {\"Row\": 117, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"54b\"}, {\"Row\": 119, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 1-2 gm IV STAT ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"56\"}, {\"Row\": 122, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"58\"}, {\"Row\": 123, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"60a\"}, {\"Row\": 124, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"60b\"}, {\"Row\": 126, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days\", \"Mnemonic\": \"62a\"}, {\"Row\": 128, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"64\"}, {\"Row\": 130, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Mnemonic\": \"66\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMPLICATED CYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Complicated cystitis is defined as symptomatic bladder inflammation and symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"due to a bacterial infection in people with certain conditions (see below).\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Symptoms usually include dysuria, lower abdominal pain, and urgency. Complicated\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cystitis is commonly associated with Enterobacteriaceae, but more resistant\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"pathogens occur, including the Gram-positive pathogens staphylococci and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"enterococci.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Signs and symptoms that may indicate infection has extended beyond the bladder\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"include fever/other signs of systemic infection, flank pain, costovertebral\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"tenderness, and pelvic or perianal pain in men. Pyelonephritis should be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"considered in these patients:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Urine culture should be obtained before antimicrobials are given to guide\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"treatment of complicated cystitis:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Prostatitis should be considered in men with recurrence of urinary tract\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"infection:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"When patients who require paraenteral therapy are afebrile, clinically stable,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"and can take oral medication, convert to oral therapy based on the\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"identification and susceptibility of the isolate.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Complicating conditions\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Cystitis is considered complicated when one or more of the following is present:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"o Pregnant women\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"o Immunocompromise\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"o Persistent infection, relapse, recurrence, or treatment failure\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"o In some cases, men and patients admitted to health care settings may be\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"considered complicated\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Treat for 7 days. If patient is febrile, may extend duration up to 14 days total\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Mild to moderate disease\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Primary alternatives:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Secondary alternative:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Severe disease or if patient cannot take oral therapy\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"High risk of Pseudomonas or Gram-negative MDR bacteria:\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Treatment for specific pathogens\", \"Header\": 1}, {\"Row\": 87, \"Column\": 1, \"Text\": \"Enterobacteria including E. coli, klebsiella, and proteus\", \"Header\": 1}, {\"Row\": 88, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 100, \"Column\": 1, \"Text\": \"Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 101, \"Column\": 1, \"Text\": \"S. aureus is an uncommon urinary tract pathogen and presence in the urine may be\"}, {\"Row\": 102, \"Column\": 1, \"Text\": \"due to hematogenous seeding from another site. Blood cultures are indicated to\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"rule out bacteremia in patients who have S. aureus isolated from the urine.\"}, {\"Row\": 104, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 106, \"Column\": 1, \"Text\": \"Pseudomonas\", \"Header\": 1}, {\"Row\": 109, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 111, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 114, \"Column\": 1, \"Text\": \"Enterococcus\", \"Header\": 1}, {\"Row\": 115, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 118, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 121, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 125, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 127, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 129, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 131, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 134, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 135, \"Column\": 1, \"Text\": \"Drekonja et al., JAMA, 2021, 326(4)324-331\"}, {\"Row\": 136, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 137, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 138, \"Column\": 1, \"Text\": \"Sanford keyword: Cystitis\"}, {\"Row\": 139, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 140, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 141, \"Column\": 1, \"Text\": \"Tamma et al., Clinical Infectious Diseases, 2021, 72(7)1109-16\"}, {\"Row\": 142, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute complicated urinary tract infection (including\"}, {\"Row\": 143, \"Column\": 1, \"Text\": \"pyelonephritis) in adults\"}, {\"Row\": 144, \"Column\": 1, \"Text\": \"Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary\"}, {\"Row\": 145, \"Column\": 1, \"Text\": \"tract, gastrointestinal tract, and central nervous system\"}, {\"Row\": 146, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}, {\"Row\": 147, \"Column\": 1, \"Text\": \"Walker et al., Clinical Infectious Diseases, 2016, 63(7)960-5\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 27,
    "fields": {
      "name": "ORZID GMENU ER/UC COVID-19 MPLS PHARMACOLOGIC GUIDELINES",
      "term": null,
      "displaytext": "Outpatient COVID-19 Pharmacologic Treatment Guidelines ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3007, \"DisplayText\": \"Minneapolis COVID-19 SharePoint Site\", \"Text\": \"Minneapolis VAHCS COVID-19 SharePoint Site\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Minneapolis On-Call Schedule - Infectious Disease\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Monocolonal Antibody Allocation SOP\", \"Text\": \"Minneapolis VAHCS COVID Monocolonal Antibody and Antiviral Allocation SOP\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 685, \"DisplayText\": \"Nirmatrelvir-ritonavir (Paxlovid) for Treatment of COVID-19\", \"Text\": \"Paxlovid (EUA)\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 684, \"DisplayText\": \"Molnupiravir for treatment of COVID-19\", \"Text\": \"Molnupiravir (EUA)\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OUTPATIENT COVID-19 ANTIMICROBIAL TREATMENT GUIDELINES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional Informati\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"***COVID-19 therapy is a rapidly evolving field, including the widespread\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dissemination of therapies with little or no evidence for benefit. Therapies an\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"dosages not specifically listed here or on the NIH clinical guidelines should b\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"discussed with the infectious diseases service. ***\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"OUTPATIENT TREATMENT OF COVID-19\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"If you have any questions on the selection of therapy, please contact Infectious\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Disease.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"DECIDE ON APPROPRIATE TREATMENT PLAN BY REFERRING TO ALLOCATION SOP BELOW\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"ORAL COVID-19 ANTIVIRALS (Paxlovid or Molnupiravir):\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Outpatient Pharmacy - Mon-Fri 0800-2130 and Weekend/Holidays 0900-1700: 31-3144\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Inpatient Pharmacy - Off-Tours: 31-3128\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"*Please be ready to spend time on the phone with the pharmacist to complete EUA\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"documentation, address medication questions and determine the best method of\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"delivery.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Please contact Pharmacy to determine supply and availability.\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Medication Interaction Check\", \"Text\": \"Interaction checker for COVID-19 medications website link\", \"Mnemonic\": \"14\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 28,
    "fields": {
      "name": "ORZID GMENU ER/UC CUTANEOUS ABSCESS",
      "term": null,
      "displaytext": "ED Cutaneous Abscess  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"[CLICK HERE] for list of MRSA risk factors\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO bid for 7 days ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CUTANEOUS ABSCESS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Incise and drain and cover the site with a dry dressing.  For small abscesses,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"systemic antimicrobial therapy is rarely necessary.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"If the patient is neutropenic, has multiple lesions, or has fever or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"leukocytosis, antimicrobial treatment may be necessary.  Contact Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases for assistance.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antimicrobial\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration: Treat for 5 to 7 days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mild to Moderate Cases:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Moderate or high suspicion of MRSA\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Low suspicion of MRSA\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"For SEVERE cases empiric coverage with MRSA agent\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For Perirectal/Anorectal Abscess\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Refer to the inpatient or outpatient Soft Tissue Section of the Antimicrobial\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword:  Skin infections\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"CDSS\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 29,
    "fields": {
      "name": "ORZID GMENU ER/UC DIVERTICULITIS",
      "term": null,
      "displaytext": "ED Diverticulitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 to 10 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]  <AND>\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AN Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po qday for 7days\", \"Text\": \"Moxifloxacin 400 mg PO QDAY for 7 to 10 days ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po qday for 7days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO\", \"Mnemonic\": \"12a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-Tazobactam 3.375g IV once STAT ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once\", \"Mnemonic\": \"16\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV once STAT ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV once STAT ($$) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPRO 400MG METRO 500MG IV ONCE STAT\", \"Text\": \"Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV\", \"Mnemonic\": \"20\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1GM IV once ER/UC\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"24\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 500 mg IV once\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIVERTICULITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diverticulitis involves inflammation of an intestinal diverticulum, usually in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the colon, causing pain and disturbed bowel function.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Mild disease\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"metronidazole 1000 mg PO BID ($) [DI] for 7 to 10 days\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"BID ($) [DI] for 7 to 10 days\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Moderate disease\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If symptoms fail to respond within 48 to 72 hours, consult General Surgery.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"STAT ($) [DI]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Alternative for beta lactam allergy\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"once STAT ($) [DI]\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Severe, life-threatening disease\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Consult General Surgery.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Mandell chapter: Diverticulitis and Typhlitis\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Sanford keyword: Diverticulitis\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Up-to-Date article: Acute colonic diverticulitis: Medical management\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 30,
    "fields": {
      "name": "ORZID GMENU ER/UC EMERGENCY DEPARTMENT MAIN MENU",
      "term": null,
      "displaytext": "ED Emergency Department Main Menu ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 738, \"DisplayText\": \"Acute Respiratory Infection (ARI) Symptomatic Therapy\", \"Text\": \"[click here]\", \"Mnemonic\": \"20\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 66, \"DisplayText\": \"ED Suspected Bacteremia, Blood Cultures Not Yet Positive\", \"Text\": \"[click here]\", \"Mnemonic\": \"22\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 18, \"DisplayText\": \"ED Bronchitis\", \"Text\": \"[click here]\", \"Mnemonic\": \"24\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 802, \"DisplayText\": \"Conjunctivitis (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"26\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 8, \"DisplayText\": \"ED Appendicitis with Perforation\", \"Text\": \"Appenditicitis with perforation\", \"Mnemonic\": \"28\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 7, \"DisplayText\": \"ED Appendicitis Without Perforation\", \"Text\": \"Appendicitis without perforation\", \"Mnemonic\": \"30\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 23, \"DisplayText\": \"ED Cholangitis\", \"Text\": \"Cholangitis\", \"Mnemonic\": \"32\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 24, \"DisplayText\": \"ED Cholecystitis\", \"Text\": \"Cholecystitis\", \"Mnemonic\": \"34\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 29, \"DisplayText\": \"ED Diverticulitis\", \"Text\": \"Diverticulitis\", \"Mnemonic\": \"36\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 63, \"DisplayText\": \"ED Spontaneous Bacterial Peritonitis\", \"Text\": \"Spontaneous Bacterial Peritonitis\", \"Mnemonic\": \"38\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 734, \"DisplayText\": \"ANTIVIRAL TREATMENT OUTPATIENT\", \"Text\": \"Antiviral treatment for influenza\", \"Mnemonic\": \"40\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 5, \"DisplayText\": \"Lyme Disease ER/UC\", \"Text\": \"[click here]\", \"Mnemonic\": \"42\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 10, \"DisplayText\": \"ED Bacterial Meningitis Without Gram Stain Results\", \"Text\": \"[click here]\", \"Mnemonic\": \"44\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 37, \"DisplayText\": \"ED Neutropenic Fever\", \"Text\": \"[click here]\", \"Mnemonic\": \"46\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMERGENCY DEPARTMENT ANTIMICROBIAL CDSS MENU\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"This menu contains links to treatment recommendations\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"for the most common infections treated in the Emergency Dept.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"For infections not included in this menu, refer to full Outpatient or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Inpatient Antimicrobial CDSS for recommendations.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Acute Respiratory Infection (ARI) Symptomatic Therapy\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Bacteremia\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Bronchitis\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Conjunctivitis\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Gastrointestinal\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For infections not listed, see GI\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"section of the CDSS.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Influenza\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"For chemoprophylaxis see Lung and\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mediastiunum section of the CDSS, use\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"ED order set for vaccination.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Lyme Disease\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Meningitis, Bacterial\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"For pathogen specific, nosocomial and\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"trauma associated treatement see CNS\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"section of the CDSS.\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Neutropenic Fever\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"For infections in other\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"immunocompromised conditions, see\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Immunocompromised Patients section of\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"the CDSS.\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 48, \"DisplayText\": \"ED Pharyngitis\", \"Text\": \"[click here]\", \"Mnemonic\": \"52\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 9, \"DisplayText\": \"ED Aspiration Pneumonia\", \"Text\": \"Aspiration\", \"Mnemonic\": \"54\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 25, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community Acquired Pneumonia (CAP) (Updated Feb2020)\", \"Mnemonic\": \"56\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 46, \"DisplayText\": \"ED Nosocomial Pneumonia\", \"Text\": \"Nosocomial\", \"Mnemonic\": \"58\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 704, \"DisplayText\": \"Rabies Post-exposure Prophylaxis\", \"Text\": \"[click here]\", \"Mnemonic\": \"60\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 51, \"DisplayText\": \"ED Sepis and Septic Shock\", \"Text\": \"[click here]\", \"Mnemonic\": \"62\"}, {\"Row\": 27, \"Column\": 2, \"Item\": 6, \"DisplayText\": \"ED Acute Sinusitis\", \"Text\": \"[click here]\", \"Mnemonic\": \"66\"}, {\"Row\": 33, \"Column\": 2, \"Item\": 17, \"DisplayText\": \"Bite Wounds ER/UC\", \"Text\": \"Bite wounds\", \"Mnemonic\": \"68\"}, {\"Row\": 34, \"Column\": 2, \"Item\": 22, \"DisplayText\": \"ED Cellulitis\", \"Text\": \"Cellulitis\", \"Mnemonic\": \"70\"}, {\"Row\": 35, \"Column\": 2, \"Item\": 28, \"DisplayText\": \"ED Cutaneous Abscess\", \"Text\": \"Cutaneous abcesses\", \"Mnemonic\": \"72\"}, {\"Row\": 36, \"Column\": 2, \"Item\": 35, \"DisplayText\": \"ED Foot Ulcer With DM\", \"Text\": \"Diabetic foot ulcer\", \"Mnemonic\": \"74\"}, {\"Row\": 37, \"Column\": 2, \"Item\": 36, \"DisplayText\": \"ED Furuncles and Carbuncles\", \"Text\": \"Furuncles and cabuncles\", \"Mnemonic\": \"76\"}, {\"Row\": 44, \"Column\": 2, \"Item\": 64, \"DisplayText\": \"ED Suppurative Odontogenic Infections\", \"Text\": \"[click here]\", \"Mnemonic\": \"78\"}, {\"Row\": 51, \"Column\": 2, \"Item\": 26, \"DisplayText\": \"ED Complicated Cystitis\", \"Text\": \"Cystitis, complicated\", \"Mnemonic\": \"80\"}, {\"Row\": 52, \"Column\": 2, \"Item\": 1052, \"DisplayText\": \"Uncomplicated Cystitis (Outpatient)\", \"Text\": \"Cystitis, uncomplicated\", \"Mnemonic\": \"82\"}, {\"Row\": 54, \"Column\": 2, \"Item\": 50, \"DisplayText\": \"ED Pyelonephritis\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"84\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"Pharyngitis\", \"Header\": 1}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Pneumonia\", \"Header\": 1}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Rabies Post-Exposure Prophylaxis\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Sepsis and Septic Shock\", \"Header\": 1}, {\"Row\": 23, \"Column\": 2, \"Text\": \"Sinusitis, Acute\", \"Header\": 1}, {\"Row\": 24, \"Column\": 2, \"Text\": \"For chronic, fungal and nosocomial\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"sinusitis, see Head and Neck section\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"of CDSS\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \"Skin and Soft Tissue Infections\", \"Header\": 1}, {\"Row\": 30, \"Column\": 2, \"Text\": \"For infections not listed, see Skin\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"and Soft Tissue Infection sections of\"}, {\"Row\": 32, \"Column\": 2, \"Text\": \"CDSS. See above for rabies exposure.\"}, {\"Row\": 40, \"Column\": 2, \"Text\": \"Tooth Abcess and Other Suppurative\", \"Header\": 1}, {\"Row\": 41, \"Column\": 2, \"Text\": \"Odontogenic Infections\", \"Header\": 1}, {\"Row\": 42, \"Column\": 2, \"Text\": \"For other oral infections see Head\"}, {\"Row\": 43, \"Column\": 2, \"Text\": \"and Neck section of CDSS\"}, {\"Row\": 46, \"Column\": 2, \"Text\": \"Urogenital\", \"Header\": 1}, {\"Row\": 47, \"Column\": 2, \"Text\": \"For urogenital infections not\"}, {\"Row\": 48, \"Column\": 2, \"Text\": \"listed, see Genitourinary section of\"}, {\"Row\": 49, \"Column\": 2, \"Text\": \"CDSS\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"CDSS-MicroGuide Web and Mobile App\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Item\": 207, \"DisplayText\": \"MicroGuide Mobile App Instructions\", \"Text\": \"[click here]\", \"Mnemonic\": \"8\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"[CLICK HERE]\", \"Mnemonic\": \"50\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"Help Page\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Text version\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Beta-lactam Allergy Assessment *Updated\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": 3008, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"PDF version *Preferred\", \"Mnemonic\": \"4\"}, {\"Row\": 55, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually transmitted infections\", \"Mnemonic\": \"85\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 INFORMATION\", \"Text\": \"Minneapolis VAHCS SharePoint Site\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"COVID-19\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Item\": 27, \"DisplayText\": \"Outpatient COVID-19 Pharmacologic Treatment Guidelines\", \"Text\": \"Outpatient COVID-19 Antimicrobial Treatment Guidelines\", \"Mnemonic\": \"12\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Test CEFTRIAXONE 2GM IV ONCE ER/UC clinic infusion order\", \"Mnemonic\": \"999\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 126, \"DisplayText\": \"Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines\", \"Text\": \"Inpatient COVID-19 Antimicrobial Treatment Guidelines\", \"Mnemonic\": \"14\"}, {\"Row\": 50, \"Column\": 2, \"Item\": 636, \"DisplayText\": \"Balanitis and Balanoposthitis\", \"Text\": \"Balanitis and balanoposthitis\", \"Mnemonic\": \"79\"}, {\"Row\": 53, \"Column\": 2, \"Item\": 33, \"DisplayText\": \"Epididymitis\", \"Text\": \"Epididymitis\", \"Mnemonic\": \"83\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 44, \"DisplayText\": \"Necrotizing Infections\", \"Text\": \"Necrotizing infections\", \"Mnemonic\": \"77\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 31,
    "fields": {
      "name": "ORZID GMENU ER/UC EMP INTRAV W/ VANCO",
      "term": null,
      "displaytext": "ED Neutropenic Fever IV Treatment with Vancomycin",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Vancomycin 15 mg/kg IV once STAT  ($) [R] <AND> cefepime 2 gm IV once STAT\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin 15\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZ 4.5GM GENT 5MG/KG VANCO 15MG/KG ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) <AND> vancomycin 15 mg/kg IV once STAT ($)\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT ($)\", \"Mnemonic\": \"12\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRICAL INTRAVENOUS REGIMENS WITH VANCOMYCIN\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Discontinue vancomycin after 3 days unless culture results indicate that\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"continued therapy is needed.  Gentamicin is optional.  Contact Hematology-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Oncology or Infectious Diseases for advice.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"($$) [R]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"mg/kg IV once STAT ($) [R] < OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"5 mg/kg IV once STAT ($) [R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"[R] < OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 32,
    "fields": {
      "name": "ORZID GMENU ER/UC EMP INTRAV W/O VANCO",
      "term": null,
      "displaytext": "ED Neutropenic Fever IV Therapy Without Vancomycin  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV STAT ($$) [R]\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] < OR >\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM GENT 5MG/KG IV STAT\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin 5\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) <AND> vancomycin 15 mg/kg IV once STAT ($\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT ($)\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRICAL INTRAVENOUS REGIMENS WITHOUT VANCOMYCIN\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Gentamicin is optional.  Contact Hematology-Oncology or Infectious Diseases for\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"advice.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"mg/kg IV once STAT ($) [R]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Vancomycin must be added to aztreonam for coverage of Gram-positive organisms.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"[R] < OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Hughes WT  Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-to-Date\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 33,
    "fields": {
      "name": "ORZID GMENU ER/UC EPIDIDYMITIS",
      "term": null,
      "displaytext": "Epididymitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h\", \"Mnemonic\": \"6a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) for 10 days\", \"Mnemonic\": \"10\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"16a\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]\", \"Text\": \"Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"18a\"}, {\"Row\": 71, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 74, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"20\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po q24h ($)[R,DI]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"22a\"}, {\"Row\": 76, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po q24h ($0.19/day)[R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"22b\"}, {\"Row\": 78, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV once STAT ($)\", \"Text\": \"Levofloxacin 500 mg IV once STAT ($)\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Epididymitis is inflammation of the epididymis and when testicles are involved\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"is referred to as epididymo-orchitis. Acute epididymitis is the most common\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cause of scrotal pain in adults. Other features include scrotal erythema and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"unilateral. It is primarily caused by infection but can also result from trauma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and autoimmune diseases. Testicular torsion should be ruled out before\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"treatment. Most cases in men aged 35 and older, those with recent urinary tract\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"with enteric Gram-negative rods. Most cases in men under age 35 are associated\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"the patient has been in the hospital for more than 48 hours or received a course\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of antibiotics. There is increasing resistance in urinary pathogens to\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"ciprofloxacin.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"should be performed in all cases of suspected epididymitis before starting\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"treatment to guide therapy:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Patients with bacterial epididymitis treated with antibiotics should improve\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"within two or three days. If no improvement is noted, other causes of scrotal\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"pain and referral to a urologist should be considered.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Management should include bed rest, analgesics, and scrotal elevation. Older men\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"should have their residual urinary volume checked. If the residual volume is\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"elevated, the patient should be seen by a urologist as epididymitis is unlikely\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"to respond if the prostate is blocking the vas deferens.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Empirical treatment in men who practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"for 10 days ($) [R, DI]\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Empirical treatment in men who do not practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Age >/= 35 years or\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"biopsy, vasectomy):\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Age < 35 years\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Patient weighing less than 300 lbs\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Patients weighing 300 lbs or greater\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 82, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"Mandell Chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Sanford keyword: Epididymo-orchitis\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"Up-To-Date article: Evaluation of acute scrotal pain in adults\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 34,
    "fields": {
      "name": "ORZID GMENU ER/UC FOOT ULCER W/ INFECT SURR TISSUES",
      "term": null,
      "displaytext": "ED Foot Ulcer With Infected Surrounding Tissues  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 309, \"DisplayText\": \"Approach to foot ulcers with infection\", \"Text\": \"Approach to foot ulcers with infection\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO BID for 7 days ($) [DI]\", \"Mnemonic\": \"14a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 2GM IV VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV STAT ($) [M] < AND > Vancomycin 15mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AMPICIL/SULBACT 3GM VANCO 15MG/KG STAT\", \"Text\": \"Ampicillin-sulbactam 3 gm IV STAT ($) [R] <AND> Vancomycin 15 mg/kg IV\", \"Mnemonic\": \"24\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R] <AND> vancomycin 15mg/kg\", \"Mnemonic\": \"28\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTAZ 2GM VANCO 15MG/KG METRO 500MG IV STAT\", \"Text\": \"Ceftazidime 2 gm IV STAT ($$) R <AND> vancomycin 15 mg/kg IV q12h ($)\", \"Mnemonic\": \"30\"}, {\"Row\": 73, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV STAT ($$$$) [R] <AND> metronidazole 500 mg IV STAT ($) [DI]\", \"Mnemonic\": \"32\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antibiotics may be stopped 24-48 hours following curative amputation.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Otherwise, continue antibiotics until signs of infection have resolved.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Mild: ulcer with superficial inflammation\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration: treat until resolution of symptoms usually 1-2 weeks\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Oral therapy, no MRSA coverage:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Oral therapy, MRSA coverage:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Moderate: Ulcer with inflammation, extension into fascia\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Duration: treat to resolution of symptoms usually 1-3 weeks\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"For patients started on parenteral therapy, a switch to an oral regimen\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"is reasonable following clinical improvement.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Oral therapy with MRSA coverage:\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Intravenous regimens with MRSA coverage: (MRSA coverage until ruled out)\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"STAT ($) [R,DI]\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"________________________________________________________________________\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Severe: Extensive local inflammation plus systemic toxicity\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Intravenous regimens for SEVERE (limb-threatening) infections\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Duration: treat to resolution of symptoms usually 2-4 weeks\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"A switch to an oral regimen is reasonable following clinical improvement.\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"IV STAT ($) [R]\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"[R] <AND> metronidazole 500 mg IV STAT ($) [DI]\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV STAT ($) [R]\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"therapy, de-escalate/modify regimen based on culture and susceptibility data.\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"therapy, de-escalate/modify regimen based on culture and susceptibility data.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND>\", \"Mnemonic\": \"18a\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 14 days ($) [R,DI]\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clav 875/125 bid x14days +Trimeth-sulfa bid 14days\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875 mg po BID ($) [R] <AND> Doxycycline\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND> Doxycycline\", \"Mnemonic\": \"20a\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"100 mg PO BID for 14 days ($) [DI]\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125mg bid x14days + Doxycycline 100mg bid x14days\", \"Text\": \"Non-VA order for above\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 35,
    "fields": {
      "name": "ORZID GMENU ER/UC FOOT ULCER WITH DM",
      "term": null,
      "displaytext": "ED Foot Ulcer With DM ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 383, \"DisplayText\": \"Foot ulcers WITHOUT infection of surrounding tissues\", \"Text\": \"Foot ulcers WITHOUT infection of surrounding tissues\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 34, \"DisplayText\": \"ED Foot Ulcer With Infected Surrounding Tissues\", \"Text\": \"Foot ulcers WITH infection of surrounding tissues\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCER IN PATIENT WITH DIABETES MELLITUS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Foot ulcers in patients with diabetes mellitus are colonized with bacteria.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Antimicrobials should not be used to treat colonization.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Cases with infection of surrounding tissues signified by erythema, warmth, local\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"tenderness, or purulent discharge should be treated with antimicrobials. Pain\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"may not be present in patients with neuropathy. In patients with substantial\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"vascular disease, erythema and warmth may not be present and instead the tissues\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"will be dusky, mottled, or cool. Capillary refill may be impaired. Patiets\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"with diabetes and ulcers are at risk for gangrenous infections. If there is any\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"suggestion of gangrene, consult surgery immediately.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 36,
    "fields": {
      "name": "ORZID GMENU ER/UC FURUNCLES, CARBUNCLES, CUT ABSCESS",
      "term": null,
      "displaytext": "ED Furuncles and Carbuncles ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 716, \"DisplayText\": \"\", \"Text\": \"Select here for Staphylococcus aureus Decolonization\", \"Mnemonic\": \"4\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg po BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg po BID ($) [DI]\", \"Mnemonic\": \"16a\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"18a\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FURUNCLES AND CARBUNCLES\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Localized purulent infections include furuncles, carbuncles and cutaneous\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"inflamed nodule that usually develops as a complication of folliculitis. A\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"carbuncle is a more extensive lesion that extends further into the subcutaneous\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"tissue.  Contact a wound care nurse for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Incision and drainage is the mainstay of therapy for carbuncles, cutaneous\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"abscesses, and large furuncles.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"The decision to administer antibiotics directed against S. aureus as an adjunct\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"to incision and drainage should be made based on the presence of systemic\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"inflammatory response syndrome (SIRS) or in patients with markedly impaired\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"host defenses.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For recurrent skin abscesses in addition to culture and antibiotic therapy\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"recommended consider a decolonization regimen.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mild infection: Purulent infection without systemic signs of infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Recommend incision and drainage. No antibiotic indicated.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Moderate Infection: Purulent infection with signs of systemic infection.\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Recommend incision and drainage. Culture material and use results to guide\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"therapy.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treat for 5 days and extend/modify treatment if not improved in this time.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Alternatives\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Severe Infections:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Patients who have failed incision and drainage along with oral antibiotics\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"or those with SIRS or for infections in those with neutropenia or diminished\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"neutrophil function.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Recommend incision and drainage. Culture material and use results to guide\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"therapy.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Treat for 5 days. Reevaluate patient and extend or modify treatment if not\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"improved in this time.\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Sanford keyword: Furuncle, carbuncle\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO bid ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 37,
    "fields": {
      "name": "ORZID GMENU ER/UC IMMUNOCOM NEUT FEVER",
      "term": null,
      "displaytext": "ED Neutropenic Fever  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 941, \"DisplayText\": \"Neutropenic fever--Patient IS a candidate for oral therapy (Outpatient)\", \"Text\": \"If patient IS a candidate for oral therapy\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 45, \"DisplayText\": \"ED Neutropenic Fever, Not a Candidate for Oral Therapy\", \"Text\": \"If patient is NOT a candidate for oral therapy\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 502, \"DisplayText\": \"Scoring tool to identify low risk febrile neutropenic patients\", \"Text\": \"Link to a scoring tool that identifies low risk patients for oral therapy\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The risk of severe, rapidly progressive infections increases when the absolute\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"neutrophil count (ANC, segmented neutrophils plus bands) is less than 500\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cells/microliter. The risk increases dramatically when the ANC is <100\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cells/microliter. Because of these risks, patients with fever and neutropenia\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"to this degree should receive empirical antimicrobial therapy immediately.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical therapy should also be given to patients with fever and ANC 500-1000\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"cells/microliter when the concentration is expected to be <500 cells/microliter\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"within the next 48 hours. For this purpose, fever is defined as a single\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"temperature greater than 38.3 degrees Celsius.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Initial therapy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Since infection can be rapidly progressive and severe, broad-spectrum\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"antimicrobials are given urgently to patients with neutropenic fever as defined\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"above. Vancomycin should only be given when there are clear indications for its\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"use.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Candidates for empirical treatment with oral antimicrobials include those who\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"are febrile but who have no evidence of focal infection or signs or symptoms of\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"severe disease, like hypotension. Outpatient antimicrobials for neutropenic\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"fever must be ordered only in consultation with Hematology-Oncology or\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Modification to therapy\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Refer to the Systemic Infections section of the Antimicrobial CDSS\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sipsas NV Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 38,
    "fields": {
      "name": "ORZID GMENU ER/UC LYME ACUTE NEURO DISEASE",
      "term": null,
      "displaytext": "Lyme Acute Neurological Disease ER/UC",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"extensive neurological disease with intravenous antimicrobials.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment of isolated facial paresthesia (Bell palsy)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment of neurological disease other than Bell palsy\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treat for 14 to 28 days.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Halperin et. al., Neurology (2007) 69.91-102\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 39,
    "fields": {
      "name": "ORZID GMENU ER/UC LYME CARDIAC DISEASE",
      "term": null,
      "displaytext": "Lyme Caridac Disease ER/UC  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days. Cardiology consult recommended.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment of first degree or second degree heart block\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment of third degree heart block or other manifestation\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 40,
    "fields": {
      "name": "ORZID GMENU ER/UC LYME DISEASE PROPHYLAXIS",
      "term": null,
      "displaytext": "Lyme Disease Prophylaxis ER/UC ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 3009, \"DisplayText\": \"IXODES IDENTIFACTION LINK\", \"Text\": \"Ixodes scapularis identification\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TICKBORNE RISK MAP\", \"Text\": \"Tickborne Disease Risk in Minnesota\", \"Mnemonic\": \"6\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline PO 200 mg STAT ($) (DI)\", \"Text\": \"Doxycycline PO 200mg once STAT ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LYME DISEASE PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients who have been bitten while in endemic areas of New England, Mid-\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"tick infection rate with Borrelia burgdorferi is equal to or greater than 20%\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"may be treated with prophylactic antibiotics for prevention of Lyme disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Using a wait and see method by monitoring for signs and symptoms of Lyme disease\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"is also an acceptable approach in patients who have been bitten by an Ixodes\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"scapularis tick.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"All following criteria must be met to be considered for prophylactic treatment:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"2. Attached tick is reliably identified as an adult or nymphal Ixodes\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"scalpularis. Follow link below for identification guide:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"3. Tick is attached for greater than or equal to 36 hours based on degree of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"tick engorgement with blood or likely time of exposure to tick infested area.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"4. Prophylaxis must be started within 72 hours after time tick was removed.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"5. Patient was exposed to tick bite in endemic areas where rate of Ixodes\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"counties where there is high risk of tickborne disease are shown in the\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"following link:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Providers can call the Minnesota Department of Health (651-201-5414) or the\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services (608-266-1865) for specific rates of B.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"burdorferi infection of ixodes ticks in area where a patient was exposed.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"bite in New England or Mid-Atlantic States.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Prophylactic treatment if all above criteria are met\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Wormser GP Clin Infect Dis (2006), 43: 1089\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Lyme Disease Basics (2017)\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"https://www.dhs.wisconsin.gov/publications/p01295.pdf\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 41,
    "fields": {
      "name": "ORZID GMENU ER/UC MORE ABOUT CELLULITIS",
      "term": null,
      "displaytext": "ED Approach to Cellulitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 35, \"DisplayText\": \"ED Foot Ulcer With DM\", \"Text\": \"Foot ulcer in patient with diabetes mellitus\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"THE APPROACH TO CELLULITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In addition to antimicrobial therapy, several non-pharmacological treatments\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"improve the outcome of cellulitis. Elevation and immobilization of the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"affected limb reduces swelling. Heat reduces discomfort.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prevent tinea pedis infection by keeping feet clean and dry. In patients with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"peripheral edema, good skin hygiene and support stockings reduce the incidence\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"of recurrent infection.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"In many cases of cellulitis, the affected area is usually not well-\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"differentiated from unaffected areas of the skin. Erysipelas is a special case\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with typically a well-defined border and raised, orange-peel appearance.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"For treatment of erysipelas refer to the Soft Tissue Section of the inpatient or\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"outpatient Antimicrobial CDSS.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Use broad-spectrum therapy for cellulitis arising in feet of patients with\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"advanced diabetes.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Schwartz MN New Eng J Med 2004, 350: 904\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Cellulitis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 42,
    "fields": {
      "name": "ORZID GMENU ER/UC NECROT INFECT DIRECT THERAPY",
      "term": null,
      "displaytext": "Necrotizing Infections, Direct Therapy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICI 4MU IV CLINDA 900MG IV ONCE STAT\", \"Text\": \"Penicillin 4 million units IV STAT ($) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900 MG IV ONCE\", \"Text\": \"Clindamycin 900 mg IV STAT ($$) [H,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin 4 million units IV STAT ($) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900 MG IV ONCE\", \"Text\": \"Clindamycin 900 mg IV STAT ($$) [H,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZ 3.375GM CLINDA 900MG VANCO 15MG/KG ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"14\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 2GM IV CLINDA 900MG IV VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV STAT ($) [M] <AND> clindamycin 900 mg IV STAT\", \"Mnemonic\": \"16\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Meropenem 1 gm IV STAT ($$) [R] <AND> vancomycin 15 mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPROFLOXACIN 400MG CLINDA 900MG VANCOMYCIN 15MG/KG IV ONCE STAT\", \"Text\": \"Ciprofloxacin 400 mg IV STAT ($) [R,DI] <AND> clindamycin 900 mg IV\", \"Mnemonic\": \"20\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"GENT 2MG/KG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Gentamicin 5 mg/kg IV STAT ($) [R,O] <AND> clindamycin 900 mg IV STAT\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NECROTIZING INFECTIONS--PATHOGEN-DIRECTED THERAPY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Clostridial infections\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"IV STAT ($$) [H,O]\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"_______________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Group A Streptococcal infections (S. pyogenes)\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"_______________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"IV STAT ($$) [H,O]\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"______________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Polymicrobial infections\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"______________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"These are more common in injection drug users, or in patients who have had\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"recent abdominal surgery or trauma, vulvo-vaginal infection, or genital or\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"rectal abscess.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"IV STAT ($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R]\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R] < OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"STAT ($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"_________________________________________________________________________\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Gas gangrene\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 43,
    "fields": {
      "name": "ORZID GMENU ER/UC NECROT INFECT EMP THERAPY",
      "term": null,
      "displaytext": "Necrotizing Infections, Empiric Therapy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZ 3.375GM CLINDA 900MG VANCO 15MG/KG ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 2GM IV CLINDA 900MG IV VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV STAT ($) [M] <AND> clindamycin 900 mg IV STAT ($$)\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Meropenem 1gm IV STAT ($$) <AND> vancomycin 15 mg/kg IV STAT ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPROFLOXACIN 400MG CLINDA 900MG VANCOMYCIN 15MG/KG IV ONCE STAT\", \"Text\": \"Ciprofloxacin 400 mg IV STAT ($) [R,DI] <AND> clindamycin 900 mg IV\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"GENT 2MG/KG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Gentamicin 5 mg/kg IV STAT ($) [R,O] <AND> clindamycin 900 mg IV STAT\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRICAL THERAPY FOR NECROTIZING INFECTIONS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Preferred treatment:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"IV STAT ($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R]\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15 mg/kg IV STAT ($) [R]\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"STAT ($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15mg/kg IV STAT ($) [R]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Gas gangrene\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 44,
    "fields": {
      "name": "ORZID GMENU ER/UC NECROTIZING INFECTIONS",
      "term": null,
      "displaytext": "Necrotizing Infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 43, \"DisplayText\": \"Necrotizing Infections, Empiric Therapy\", \"Text\": \"Empirical therapy of necrotizing infections\", \"Mnemonic\": \"4\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 42, \"DisplayText\": \"Necrotizing Infections, Direct Therapy\", \"Text\": \"Pathogen-directed therapy of necrotizing infections\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NECROTIZING INFECTIONS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Call Surgery immediately and consult Infectious Diseases in all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Necrotizing infections involve tissues skin and/or deeper structures, including\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"fascia and muscle.These infections destroy tissue, often rapidly, and are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"often fatal if not treated promptly and appropriately.Necrotizing infections\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"usually result from trauma, surgery, and/or ischemia.These infections can be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"monomicrobial (e.g., with streptococci or clostridia) or polymicrobial (usually\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with a mixture of aerobes and anaerobes).Fournier gangrene is usually\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"associated with mixed infection.Myonecrosis is most commonly associated with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Clostridium species.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Necrotizing infections differ from cellulitis in several ways.Necrotic\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"infections typically have one or more of the following: (1) severe, constant\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"pain, (2) bullae, (3) bruising or necrosis of overlying skin, (4) gas in tissues\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"which can be felt or seen on images, (5) edema that extends beyond areas of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"erythema, (6) local anesthesia, and (7) signs of systemic toxicity, such as\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"fever, leukocytosis, delirium, or renal failure.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Necrotizing infections must be treated with both antimicrobial therapy and\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"surgical procedures (excision and/or drainage).Call surgery to see the patient\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"immediately in all cases.Obtain tissue and blood cultures and begin empirical\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"antimicrobials.For several necrotic diseases and/or pathogens, a combination\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"of two antimicrobials is recommended including a bactericidal antimicrobial\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"active at the cell wall or membrane (e.g., beta-lactam or glycopeptide) and an\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"antimicrobial that rapidly inhibits protein synthesis and thus inhibits toxin\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"production, typically clindamycin.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Repeat debridement should be performed daily until no further debridement is\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"necessary. Antibiotic therapy should be tailored as soon as culture results\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"become available.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Administer antibiotics until further debridement is no longer necessary, the\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"patient has improved clinically, and fever has been absent for 48-72 hours.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Empirical antimicrobials\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Pathogen-directed treatment regimens\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford keyword: Gas gangrene\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 45,
    "fields": {
      "name": "ORZID GMENU ER/UC NEUT FEVER CAND NOT ORAL THERA",
      "term": null,
      "displaytext": "ED Neutropenic Fever, Not a Candidate for Oral Therapy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 32, \"DisplayText\": \"ED Neutropenic Fever IV Therapy Without Vancomycin\", \"Text\": \"Empirical intravenous regimens WITHOUT vancomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 31, \"DisplayText\": \"ED Neutropenic Fever IV Treatment with Vancomycin\", \"Text\": \"Empirical intravenous regimens WITH vancomycin\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Vancomycin is not recommended as a standard part of the initial antibiotic\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sipsas NV Cancer 2005, 103: 1103\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"regimen.  Consider adding Vancomycin for specific clinical indications:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \">>  Hemodynamic instability\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \">>  Pneumonia,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \">>  Skin or soft-tissue infection,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \">>  Suspected catheter-related infection,\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 46,
    "fields": {
      "name": "ORZID GMENU ER/UC NOSO PNEUMONIA NEW",
      "term": null,
      "displaytext": "ED Nosocomial Pneumonia  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 209, \"DisplayText\": \"More about Nosocomial pneumonia...\", \"Text\": \"More about Nosocomial pneumonia...\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 49, \"DisplayText\": \"ED Hospital Acquired Pneumonia\", \"Text\": \"HOSPITAL ACQUIRED PNEUMONIA (HAP)\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 248, \"DisplayText\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Text\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Local facility antibiogram and patient risk factors for multi-drug\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"resistant pathogens guide antimicrobial therapy.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"VENTILATOR ASSOCIATED PNEUMONIA (VAP) - Refer to Lung and Mediastinum section of\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"the inpatient or outpatient Antimicrobial CDSS for recommendations\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Empirical therapy must be re-evaluated at 72 hours.\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Duration of Therapy:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for 7 days is generally sufficient if the initial empiric therapy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"covered the pathogen and the patient is clinically responding.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Narrow therapy to treat specific pathogen(s) based on results of\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"culture and susceptibility tests.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Pathogen-specific treatment\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Certain respiratory pathogens that are usually treated in unique ways are listed\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"here. Other respiratory pathogens are treated with drugs effective for\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"pneumonia and active against identified organisms.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Recommended duration of therapy for more resistant pathogens\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"(e.g. MRSA, Pseudomonas, Acinetobacter) require longer treatment.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Refer to pathogen-specific treatment regimen below for recommendation.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Pathogen-specific nosocomial pneumonia treatment regimens\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Refer to Lung and Mediastinum section of the inpatient or outpatient\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Antimicrobial CDSS for recommendations.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Luna CM. Crit Care Med 2003. 31:676\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 47,
    "fields": {
      "name": "ORZID GMENU ER/UC OTITIS EXTERNA",
      "term": null,
      "displaytext": "ED Otitis Externa  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 36, \"DisplayText\": \"ED Furuncles and Carbuncles\", \"Text\": \"Furuncles and carbuncles\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s) QID ($)\", \"Text\": \"Neomycin-polymixin-hydrocortisone ear drops 4 drops in affected ear(s) QID\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID ($) [M]\", \"Text\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OTITIS EXTERNA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute Localized Disease\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Often due to furunculosis and usually associated with Staphylococcus aureus.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treat mild cases with moist local heat. For cases with cellulitis or deep\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"invasion, incision and drainage as well as systemic antibiotics may be needed.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Refer to the Furuncules and Carbuncles page for antibiotic recommendations.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"__________________________________________________________________\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Acute diffuse and chronic otitis externa\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Most commonly associated with Pseudomonas aerogenosa and Staphylococcus\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"aureus/epidermidis. Irrigate to remove cerumen, desquamated skin and purulent\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"material which can improve effectiveness of topical antibiotics. Avoid products\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"that contain neomycin if the tympanic membrane is perforated.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treat for 7 to 10 days\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Preferred treatment if tympanic membrane is intact\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"($) [M]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative if tympanic membrane is perforated or allergy to preferred treatmen\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"__________________________________________________________________\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Complicated Cases\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"For cases resistant to topical therapy alone, diabetic patients,\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"immunocompromised patients, cases where infection has spread beyond ear canal\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"and in those where topical therapy cannot be delivered effectively. Culture\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"secretions to guide therapy.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"In addition to topical therapy above <ADD>\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Rosenfeld et al., Otolaryngology-Head and Neck Surgery (2014) 150.S1-S24\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Sanford keyword: Otitis Externa\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 48,
    "fields": {
      "name": "ORZID GMENU ER/UC PHARYNGITIS",
      "term": null,
      "displaytext": "ED Pharyngitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 854, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Treatment of Gonorrheal Infections - Opt CDSS, change parental orders to STAT\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HIV, Rapid\", \"Text\": \"HIV Rapid Test\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 937, \"DisplayText\": \"More About Pharyngitis\", \"Text\": \"More About Pharyngitis/Tonsillitis and Modified Centor score - Opt CDSS\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Strep A PCR\", \"Text\": \"Rapid Strep A throat PCR testing lab order\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin V 500 mg PO BID ($) for 10 days [R]\", \"Text\": \"Penicillin V 500 mg PO BID for 10 days ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin V 500 mg PO BID ($) for 10 days [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine penicillin 1.2 million units IM once STAT ($$$) [M]\", \"Text\": \"Benzathine penicillin 1.2 million units IM once STAT ($$$) [M]\", \"Mnemonic\": \"14\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"16\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($)\", \"Mnemonic\": \"20a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PHARYNGITIS AND TONSILLITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are viral, primarily due to adenovirus. Aside from streptococcal and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pharyngitis, use link below for recommendations.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consider HIV screening for patients with pharyngitis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Streptococcal Pharyngitis and Tonsillitis\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Diagnosis of group A streptococcal (GAS) infection is made through detection by\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"rapid PCR and should be reserved for patients who have a moderate to high risk\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of GAS infection according to the Modified Centor Score. Use link below for\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Modified Centor score criteria and for more details.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antimicrobials are not indicated\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"GAS Pharyngitis and Tonsillitis Treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Primary alternative:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Secondary alternative, after assessment of beta-lactam reaction above:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Choby, Am Fam Physician. 2009 79(5) 383-390\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Pharyngitis\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcal Pharyngitis\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Stanford et al, Clinical Infectious Diseases. 2012, cis629\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Up-To-Date article:  Evaluation of acute pharyngitis in adults\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-To-Date article:  Treatment and prevention of streptococcal pharyngitis\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID x10days ($) [R]\", \"Mnemonic\": \"18a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"18\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 49,
    "fields": {
      "name": "ORZID GMENU ER/UC PNEUMONIA HAP NEW",
      "term": null,
      "displaytext": "ED Hospital Acquired Pneumonia ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 248, \"DisplayText\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Text\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI]] <AND> vancomycin 15 mg/kg IV\", \"Mnemonic\": \"10\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM GENT 5MG/KG VANCO 15MG/KG IV STAT\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin 5\", \"Mnemonic\": \"12\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM GENT 5MG/KG VANCO 15MG/KG STAT\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R] <AND> gentamicin 5 mg/kg IV once STAT ($)\", \"Mnemonic\": \"14\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LEVOFLOXACIN 750MG GENT 5MG/KG VANCO 15MG/KG\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> gentamicin 5 mg/kg IV once\", \"Mnemonic\": \"16\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRIC TREATMENT: Hospital Acquired Pneumonia (HAP)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Development of pneumonia 48 hours or more after hospital admission.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Local facility antibiogram and patient risk factors for multi-drug\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"resistant pathogens guide antimicrobial therapy.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Risk Factors for Multi-Drug Resistant (MDR) Pathogen(s):\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Prior intravenous antibiotic use within 90 days\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment for 7 days is generally sufficient if the initial empiric therapy\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"covered the pathogen and the patient is clinically responding.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Narrow therapy to treat specific pathogen(s) based on results of\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"culture and susceptibility tests. Can discontinue MRSA coverage if no\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"MRSA isolated from respiratory cultures, if obtained, or if nasal\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"swab or throat cultures show no growth of MRSA, or if NAAT negative for\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"MRSA.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Empiric Treatment:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"No Risk of MDR Pathogen(s):\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"15 mg/kg IV once STAT ($) [R] < OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"once STAT ($) [R]\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Risk of MDR Pathogen(s):\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"mg/kg IV once STAT ($) [R] <AND> vancomycin 15mg/kg once STAT ($) [R] <OR>\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15mg/kg once STAT ($) [R]\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy:\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"STAT ($) [R] <AND> vancomycin 15mg/kg IV once STAT ($) [R]\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"<AND> vancomycin 15mg/kg IV once STAT ($) [R]\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1.\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Boyce JM. Antimicrob Agents Chemother 2013. 57:1163\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Chastre J. JAMA 2003. 290:2588.\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371.\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Luna CM. Crit Care Med 2003. 31:676.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Roig J. J Antimicrob Chemother 2003. 51:1119.\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 50,
    "fields": {
      "name": "ORZID GMENU ER/UC PYELONEPHRITIS",
      "term": null,
      "displaytext": "ED Pyelonephritis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once ($) [M] < THEN > one of the oral regimens below\", \"Mnemonic\": \"8\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R] for 14 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID for 14 days ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"16a\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV STAT ($$) [R]\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"22\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1GM IV once ER/UC\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [R,O]\", \"Mnemonic\": \"24\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"< ADD > Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Mnemonic\": \"26\"}, {\"Row\": 76, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"28a\"}, {\"Row\": 77, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"28b\"}, {\"Row\": 79, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"30\"}, {\"Row\": 82, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"32\"}, {\"Row\": 83, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"34a\"}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"36\"}, {\"Row\": 95, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 14 days\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"38a\"}, {\"Row\": 96, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"38b\"}, {\"Row\": 98, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 MG IV ONCE\", \"Text\": \"Ciprofloxacin 400 mg IV once STAT ($) [R,DI]\", \"Mnemonic\": \"40\"}, {\"Row\": 101, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Mnemonic\": \"42\"}, {\"Row\": 103, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV STAT ($$) [R]\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"44\"}, {\"Row\": 107, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 1-2 gm IV STAT ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"46\"}, {\"Row\": 109, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO tid for 14 days ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO q8h ($) [R] for 14 days\", \"Mnemonic\": \"48a\"}, {\"Row\": 110, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO tid for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"48b\"}, {\"Row\": 113, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"50\"}, {\"Row\": 114, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV once STAT ($) [R]\", \"Mnemonic\": \"52\"}, {\"Row\": 116, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days\", \"Mnemonic\": \"54a\"}, {\"Row\": 117, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days (Non-VA)_\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"54b\"}, {\"Row\": 119, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV once STAT ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV once STAT ($$$$) [DI,O]\", \"Mnemonic\": \"56\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PYELONEPHRITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Features of pyelonephritis include fever/other signs of systemic infection,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"flank pain, costovertebral tenderness, and pelvic or perianal pain in men. Most\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cases are caused by Escherichia coli. Resistant organisms, such as Enterococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and Pseudomonas, are more likely if the patient is elderly, has been in the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"hospital for more than 48 hours, or received a course of antibiotics.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Obtain a urine culture, urine Gram-stain, and blood culture immediately to guide\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antimicrobial therapy:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Drugs active against enterococci (ampicillin, piperacillin) or staphylococci\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"needn't be used if Gram-negative bacilli predominate on the smear. Broad\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"spectrum antimicrobials are needed if patient is at risk of having a multi-drug\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"resistant (MDR) organism.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Judge severity of infection based on clinical signs and symptoms, including\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"blood pressure, pulse, mental status, white blood count, and degree of fever.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Oral regimens are preferred over IV if severity is mild or moderate and patient\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"can tolerate oral antibiotics. In patients with severe or persistent disease,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"new renal failure, or suspected urinary obstruction, obtain a renal ultrasound\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"to rule out obstruction or other complicating condition. Consult urology if\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"abnormalities are found.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"When patients who require paraenteral therapy are afebrile, clinically stable,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"and can take oral medication, convert to oral therapy based on the\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"identification and susceptibility of the isolate.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treat for 7 to 14 days. In patients with a mild infection and a quick clinical\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"response, 7 days of treatment may be adequate. A longer duration may be required\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"in severe infection, resistant organisms, presence of obstruction, underlying\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"renal disease, immunosuppression, neurologic or structural abnormality, and men\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"in some cases. A 7-day course of ciprofloxacin has been shown to be as effective\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"as a 14-day course.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Oral treatment after single dose of ceftriaxone IV above:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"History of Pseudomonas or ESBL isolate\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"History of MRSA, add to intravenous therapy above\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Treatment for specific pathogens\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Enterobacteria including E. coli, klebsiella, and proteus\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Alternative or isolate resistant to preferred antimicrobials:\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 88, \"Column\": 1, \"Text\": \"S. aureus is an uncommon urinary tract pathogen and presence in the urine may be\"}, {\"Row\": 89, \"Column\": 1, \"Text\": \"due to hematogenous seeding from another site. Blood cultures are indicated to\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"rule out bacteremia in patients who have S. aureus isolated from the urine.\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Pseudomonas\", \"Header\": 1}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 100, \"Column\": 1, \"Text\": \"Isolate resistant to preferred antimicrobials:\"}, {\"Row\": 102, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 105, \"Column\": 1, \"Text\": \"Enterococcus\", \"Header\": 1}, {\"Row\": 106, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 108, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 112, \"Column\": 1, \"Text\": \"Resistant isolate or alternative to preferred antimicrobials:\"}, {\"Row\": 115, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 118, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 120, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 123, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 124, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 125, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 126, \"Column\": 1, \"Text\": \"Sanford keyword: Pyelonephritis, Acute\"}, {\"Row\": 127, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute complicated cystitis and pyelonephritis\"}, {\"Row\": 128, \"Column\": 1, \"Text\": \"Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary\"}, {\"Row\": 129, \"Column\": 1, \"Text\": \"tract, gastrointestinal tract, and central nervous system\"}, {\"Row\": 130, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 51,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS AND SHOCK",
      "term": null,
      "displaytext": "ED Sepis and Septic Shock",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 3010, \"DisplayText\": \"SOFA Online Calculator\", \"Text\": \"SOFA Online Calculator\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"ED sepsis order set\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS AND SEPTIC SHOCK\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Per the Sepsis-3 task force, sepsis is defined as life-threatening\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"organ dysfunction caused by dysregulated host response to infection.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"The Sequential Organ Failure Assessment (SOFA) score can be used to help\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"identify organ dysfunction. An acute increase of 2 or more points in a patient\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"with sepsis is associated with in-hospital mortality greater than 10%. Neither\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the SOFA nor the abbreviated qSOFA is sufficiently sensitive to be used as the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"sole method of identifying sepsis related organ dysfunction.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Septic shock is a subset of sepsis in which profound circulatory, cellular and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"metabolic abnormalities occur. Septic shock is associated with in-hospital\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"mortality greater than 40%.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Early intervention is crucial to prevention of death from sepsis. Antimicrobials\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"active against likely pathogens and supportive treatment to maintain vascular\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"perfusion should be initiated immediately.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Reassess antimicrobial therapy daily to narrow therapeutic spectrum when culture\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"and susceptibility data are available.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment of Sepsis or Septic Shock\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell Chapter: Sepsis, Severe Sepsis and Septic Shock\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Rhodes et al., Intensive Care Medicine (2017), 45.3: 304-377\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Singer et al., JAMA (2016), 315(8) 801-810\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 52,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS EMPIRIC THERAPY SITE UNK",
      "term": null,
      "displaytext": "ER/UC Sepsis, Site Unknown or Suspected Intraabdominal Infection",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR 2GM VANCO 15MG/KG METRO 1GM IV ONCE STAT\", \"Text\": \"Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 1 gm IV once STAT\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV STAT ($) [R,O]\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV once STAT\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Abdominal CT\", \"Text\": \"Please Click Here To Order an Abdominal CT\", \"Mnemonic\": \"12\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"IV once STAT ($) [R]\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For Severe Penicillin Allergy:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg once STAT\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Consider abdominal CT\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH UNKNOWN INFECTIOUS SITE\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"1\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 53,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS PNEUMONIA",
      "term": null,
      "displaytext": "ER/UC Sepsis, Suspected Pneumonia ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM VANC 15MG/KG AZITHRO 500MG IV ONCE STAT\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV once STAT( $$) [R] <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM VANCO 15MG/KG AZITH500MG IV ONCE STAT\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> vancomycin 15 mg/kg IV once\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV STAT ($) [R,O]\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV once STAT\", \"Mnemonic\": \"14\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Nosocomial pneumonia preferred treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"IV once STAT ($) [R]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Community acquired pneumonia preferred treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"IV q12H ($) [R] <AND> Azithromycin 500 mg IV once STAT ($) [M]\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"($) [R] <AND> Azithromycin 500 mg IV once STAT ($) [M]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For severe penicillin allergy in nosocomial and community acquired pneumonia\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"STAT ($) [R]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg once STAT\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"1\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED PNEUMONIA\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 54,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS PROTOCOL ANTIMICROBIALS",
      "term": null,
      "displaytext": "ER/UC Sepsis Protocol Antmicrobials  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Item\": 52, \"DisplayText\": \"ER/UC Sepsis, Site Unknown or Suspected Intraabdominal Infection\", \"Text\": \"Unknown Infectious Site (see below for Intraabdominal Infection)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 53, \"DisplayText\": \"ER/UC Sepsis, Suspected Pneumonia\", \"Text\": \"Suspected Pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 59, \"DisplayText\": \"ER/UC Sepsis, Suspected Meningitis, CNS Infection\", \"Text\": \"Suspected Meningitis, CNS Infection\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 56, \"DisplayText\": \"ER/UC Sepsis, Suspected Native Valve Endocarditis\", \"Text\": \"Suspected Native Valve Endocarditis\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 57, \"DisplayText\": \"ER/UC Sepsis, Suspected Prosthetic Valve Endocarditis\", \"Text\": \"Suspected Prosthetic Valve Endocarditis\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 44, \"DisplayText\": \"Necrotizing Infections\", \"Text\": \"Suspected Necrotizing Infection\", \"Mnemonic\": \"12\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 60, \"DisplayText\": \"ER/UC Sepsis, Suspected Skin Soft Tissue Infection\", \"Text\": \"Suspected Skin Soft Tissue Infection\", \"Mnemonic\": \"14\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 61, \"DisplayText\": \"ER/UC Sepsis, Suspected Urosepsis\", \"Text\": \"Suspected Urinary Tract Infection (AKA Urosepsis)\", \"Mnemonic\": \"16\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 58, \"DisplayText\": \"Sepsis Suspected Intraabdominal Infection ER/UC\", \"Text\": \"Suspected Intraabdominal Infection\", \"Mnemonic\": \"18\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 55, \"DisplayText\": \"ER/UC Sepsis, Suspected Severe Clostridium Difficile Infection\", \"Text\": \"Suspected Severe Clostridium Difficile Infection\", \"Mnemonic\": \"20\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 45, \"DisplayText\": \"ED Neutropenic Fever, Not a Candidate for Oral Therapy\", \"Text\": \"Suspected Neutropenic Fever\", \"Mnemonic\": \"22\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"INITIAL EMPIRIC ANTIBIOTIC GUIDELINES FOR SEPSIS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 55,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS SUSP C. DIFFICILE",
      "term": null,
      "displaytext": "ER/UC Sepsis, Suspected Severe Clostridium Difficile Infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125MG PO once STAT\", \"Text\": \"Vancomycin 125MG PO once STAT\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"METRO 500MG IV VANCOMYCIN 500MG PR ENEMA ONCE STAT\", \"Text\": \"Metronidazole 500MG IV once STAT AND Vancomycin Enema 500MG PR once STAT\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site: Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given: 1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If No ileus:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"If ileus:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED SEVERE CLOSTRIDIUM DIFFICILE INFECTION\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 56,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS SUSP NATIVE VALVE ENDOCARD",
      "term": null,
      "displaytext": "ER/UC Sepsis, Suspected Native Valve Endocarditis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZ 4.5GM GENT 2MG/KG VANCO 15MG/KG ONCE STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"GENT 5MG/KG IV CLINDA 900MG IV VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site: Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given: 1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV once STAT AND\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG once STAT AND\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG once STAT AND\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED NATIVE VALVE ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 57,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS SUSP PROS VALVE ENDOCARD",
      "term": null,
      "displaytext": "ER/UC Sepsis, Suspected Prosthetic Valve Endocarditis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZ4.5 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTR2 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site: Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given: 1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV once STAT AND\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG once STAT AND\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Rifampin 300MG IV once STAT\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"If Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Aztreonam 2GM IV once STAT AND\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG once STAT AND\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Rifampin 300MG IV once STAT\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"1\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED PROSTHETIC VALVE ENDOCARDITIS\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 58,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS SUSPECTED INTRAABDOMINAL INFECTION",
      "term": null,
      "displaytext": "Sepsis Suspected Intraabdominal Infection ER/UC  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM METRO 1GM IV ONCE STAT\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R] <AND>  metronidazole 1 gm IV once STAT\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPRO 400MG METRO 1GMMG IV ONCE STAT\", \"Text\": \"Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 1 gm IV once\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV STAT ($) [R,O]\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV once STAT\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Abdominal CT\", \"Text\": \"Please Click Here To Order an Abdominal CT\", \"Mnemonic\": \"12\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"For severe penicillin allergy\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"STAT ($) [DI]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg once STAT\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Consider Abdominal CT\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED INTRAABDOMINAL INFECTION\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"1\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 59,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS SUSPECTED MENINGITIS",
      "term": null,
      "displaytext": "ER/UC Sepsis, Suspected Meningitis, CNS Infection",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TRIM/SULFAM 5MG/KG VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"8\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site: Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given: 1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Penicillin Allergy and Listeria is NOT a concern:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Ceftriaxone 2GM IV once STAT AND Vancomycin 15 mg/kg IV once STAT\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"(Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"No Penicillin Allergy and Listeria IS a concern (Patient with age > 50\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"yrs, alcoholism, or impaired cellular immunity:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Ceftriaxone 2GM IV once STAT AND\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Ampicillin 2GM IV once STAT\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Definite, Severe Penicillin Allergy (Whether or not Listeria is a concern):\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Trimethoprim/Sulfamethoxazole 5mg/kg (TMP component) IV once STAT AND\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED MENINGITIS, CNS INFECTION\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 60,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS SUSPECTED SKIN SOFT TISSUE",
      "term": null,
      "displaytext": "ER/UC Sepsis, Suspected Skin Soft Tissue Infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 44, \"DisplayText\": \"Necrotizing Infections\", \"Text\": \"Necrotizing infections recommendations\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT\", \"Text\": \"Please Click Here to Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPROFLOXACIN 400MG VANCOMYCIN 15MG/KG IV ONCE STAT\", \"Text\": \"Please Click Here to Order This Set\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED SKIN SOFT TISSUE INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site: Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given: 1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Aggressive surgical debridement is recommended.\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For necrotizing infections refer to those recommendations for treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV once STAT <AND>\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Penicillin Allergy= Type 1 allergy (e.g. anaphylaxis, hives, angioedema,\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"hypotension, etc.)\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Ciprofloxacin 400 MG IV once STAT <AND>\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 61,
    "fields": {
      "name": "ORZID GMENU ER/UC SEPSIS SUSPECTED URO SEPSIS",
      "term": null,
      "displaytext": "ER/UC Sepsis, Suspected Urosepsis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO STAT\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPROFLOXACIN 400MG VANCOMYCIN 15MG/KG IV ONCE STAT\", \"Text\": \"Please Click Here to Order This Set\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV STAT ($) [R,O]\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV STAT\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED URINARY TRACT INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Pencillin Allergy:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV STAT AND\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV STAT (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Ciprofloxacin 400 mg IV STAT AND\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV STAT (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 62,
    "fields": {
      "name": "ORZID GMENU ER/UC SEVERE SINUSITIS",
      "term": null,
      "displaytext": "ED Severe Sinusitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"4a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID  ($) [DI] for 10 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3gm IV once STAT ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"16\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV STAT ($$) [R]\", \"Text\": \"Cefepime 2 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"22\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1GM IV once ER/UC\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [R,O]\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEVERE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Community-acquired bacterial sinusitis is most often due to Streptococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For patients who present with severe symptoms (high fever (>/= 102 degrees\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"consecutive days or facial pain lasting for at least 3-4 consecutive days at the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"to determine the extent of infection. If the CT shows extension of sinusitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"infection into surrounding structures (i.e. the cranium or orbit) consult ENT\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"immediately. Closely monitor all patients who present with severe signs and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"symptoms to ensure that signs and symptoms improve within 72 hours.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Outpatient Treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Treatment of hospitalized patient\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treatment failure\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"If symptoms worsen or no improvement is seen after 3-5 days of treatment,\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"broaden coverage, switch to different antimicrobial class and treat 10 days. If\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"symptoms continue to worsen or there is no improvement after 3-5 more days of\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"treatment, obtain CT to investigate non-infectious or suppurative causes. ENT\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"consultation is recommended. If sinuses are aspirated, specimens should be\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"cultured.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Preferred\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Chronic\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Up-To-Date article: Microbiology and antibiotic management of chronic\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"rhinosinusitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 63,
    "fields": {
      "name": "ORZID GMENU ER/UC SPON BACT PERITONITIS",
      "term": null,
      "displaytext": "ED Spontaneous Bacterial Peritonitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV STAT ($) [DI]\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO QDAY ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg po qday ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO QDAY ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg po qday ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV STAT ($) [DI]\", \"Text\": \"Levofloxacin 750 mg IV once STAT ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SPONTANEOUS BACTERIAL PERITONITIS (SBP)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"SBP is infection of the peritoneal cavity in the absence of apparent trauma or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"other obvious cause. SBP occurs primarily in people with end-stage liver disease\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"are isolated.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Long-term SBP prophylaxis is indicated for patients who experience a first\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"episode of SBP. Short-term SBP prophylaxis is indicated for patients with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"variceal bleeding, or for patients who have low-protein refractory ascites (<1\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with low-protein refractory ascites. Consult Gastroenterology for more\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"SBP\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Prophylaxis in a patient with a previous SBP episode\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Prophylaxis in a patient with cirrhosis and variceal hemorrhage\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Treat initially with an intravenous antimicrobial then step down to an oral\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"antimicrobial when the patient can tolerate oral treatment.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treat for a total of 7 days (intravenous and oral)\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Preffered initial treatment\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Initial treatment, alternative for beta-lactam allergy\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Step down treatment\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Refer to Intpatient Antimicrobial CDSS\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Prophylaxis for hospitalized patients with refractory low-protein ascites\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"(less than 1 gm/dL peritoneal fluid)\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Refer to Intpatient Antimicrobial CDSS\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Mandell chapter: Peritonitis and Intraperitoneal Abscesses\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"prophylaxis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 64,
    "fields": {
      "name": "ORZID GMENU ER/UC SUPP ODONTOGENIC INFECT",
      "term": null,
      "displaytext": "ED Suppurative Odontogenic Infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h for 7 to 14 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 450 mg PO TID for 7 days ($) [H,O]\", \"Text\": \"Clindamycin 450 mg PO q8h for 7 to 14 days ($) [H,O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 450 mg PO TID for 7 days ($) [H,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3gm IV once STAT ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once STAT\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5 GM IV once STAT ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"18\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1GM IV once ER/UC\", \"Text\": \"Meropenem 1 gm IV once STAT ($$) [R,O]\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TOOTH ABSCESS AND OTHER SUPPURATIVE ODONTOGENIC INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Surgical drainage, scaling and antimicrobial treatment are essential and tooth\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"extraction is required in most cases. All patients should be referred to the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"dental service for assessment and direction of treatment. Empirical coverage for\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"likely pathogens (streptococci, Peptostreptococcus, Finegoldia, Bacteriodes and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"other oral anaerobes is required. Immunocompromised patients need additional\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"coverage for Pseudomonas aeruginosa.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult Dental Service\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease in immunocompetent patients or step-down\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"therapy after initial intravenous therapy. Adjust duration for a total of 7-14\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"days of antimicrobial therapy.\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treatment of severe disease in immunocompetent patients\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Treatment in immunocompromised patients\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Oral Cavity, Neck, and Head\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Ogle, Dent Clin N Am. 2017, 61(2)235-252\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Reynolds et al. Lung. 2009, 187(5)271-279\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-to-date article: Complications, diagnosis and treatment of odontogenic\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 65,
    "fields": {
      "name": "ORZID GMENU ER/UC SURG GENTAMICIN SPECIFIC DOSING",
      "term": null,
      "displaytext": "ED Surgery Gentamicin Specific Dosing",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 240 mg IV beginning 60 minutes before incision\", \"Text\": \"Gentamicin 240 mg IV beginning 60 minutes before incision\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 300 mg IV beginning 60 minutes before incision\", \"Text\": \"Gentamicin 300 mg IV beginning 60 minutes before incision\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 400 mg beginning 60 minutes before incision\", \"Text\": \"Gentamicin 400 mg beginning 60 minutes before incision\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 500 mg IV ONCEinning 60 minutes before incision\", \"Text\": \"Gentamin 500 mg beginning 60 minutes before incision\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 600 mg IV beginning 60 minutes before incision\", \"Text\": \"Gentamicin 600 mg IV beginning 60 minutes before incision\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Recommended Gentamicin Doses based on patient weight:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Weight equal/less 50kg:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Weight greater 50 kg and less 75 kg\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Weight equal 75 kg and less than 100kg:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Weight equal to 100 kg and less than 120kg:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Weight equal/greater 120 kg:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 66,
    "fields": {
      "name": "ORZID GMENU ER/UC SUSP BACT, BLD CX NOT YET POS",
      "term": null,
      "displaytext": "ED Suspected Bacteremia, Blood Cultures Not Yet Positive  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 4, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (ER)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 87, \"DisplayText\": \"Bacteremia\", \"Text\": \"Link to Bacteremia order menus in the Inpatient Antimicrobial CDSS\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once STAT ($$) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 2GM VANCO 15MG/KG IV ONCE STAT\", \"Text\": \"Ceftriaxone 2 gm IV once STAT ($) [M] < AND > Vancomycin 15mg/kg IV once\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV once STAT ($$) <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15MG/KG GENT 5MG/KG IV ONCE STAT\", \"Text\": \"vancomycin 15 mg/kg IV once STAT ($) [R] <AND> gentamicin 5 mg/kg once STAT\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SUSPECTED BACTEREMIA, BLOOD CULTURES NOT YET POSITIVE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If blood cultures are positive, refer to the Bacteremia order menus in the\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"inpatient Antimicrobial CDSS (link below).\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"***ALERT*** Leaving ED Antimicrobial CDSS! When ordering antimicrobials from the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inpatient Antimicrobial CDSS, STAT priority must be manually selected.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Choice of antimicrobials\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Select antimicrobials active against any suspected site of infection that may be\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"present. Return to main menu and refer to the source infection's page within\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"the Antimicrobial CDSS.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients with an intravascular catheter, refer to the intravascular-\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"associated infection page in the Systemic Infections section of the Inpatient\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Antimicrobial CDSS\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Empirical therapy for mild to moderate infection, focal infection not found\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empirical therapy for severe infection\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"STAT ($) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Empirical therapy for immunosuppressed patients\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"IV once STAT ($) [R]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For patients with penicillin allergy\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"($) [R,O]\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter Treatment Guidelines 2010, 8: 94\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococci\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococci\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococci\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 67,
    "fields": {
      "name": "ORZID2 GMENU ABSCESSES",
      "term": null,
      "displaytext": "Abscesses:  Cutaneous abscess, Furuncle, Carbuncle, Pyomyositis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 351, \"DisplayText\": \"Cutaneous abscess\", \"Text\": \"Cutaneous abscess\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Perianal/Anorectal Abscess\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 394, \"DisplayText\": \"Furuncles and carbuncles\", \"Text\": \"Furuncles and carbuncles\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 543, \"DisplayText\": \"Pyomyositis\", \"Text\": \"Pyomyositis\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ABSCESSES: CUTANEOUS ABSCESS, FURUNCLE, CARBUNCLE, AND PYOMYOSITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"This section describes management of skin and soft tissue infections.  For\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"information on abscesses in other areas, please return to the main CDSS menu and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"choose the appropriate organ system.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword:  Skin infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 68,
    "fields": {
      "name": "ORZID2 GMENU ABX ABOUT THE CDSS",
      "term": null,
      "displaytext": "About the CDSS  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 32, \"Column\": 1, \"Item\": 69, \"DisplayText\": \"Antimicrobial restriction policy\", \"Text\": \"More information on antimicrobial restriction policy\", \"Mnemonic\": \"4\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 179, \"DisplayText\": \"How to use the CDSS\", \"Text\": \"How to use the CDSS\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ABOUT THE ANTIMICROBIAL COMPUTERIZED DECISION SUPPORT SYSTEM (CDSS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The Antimicrobial CDSS is a tool within the Computerized Patient Record System\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"that offers antimicrobial prescribing advice to clinicians at the point of order\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"entry. The system is structured as an order menu decision tree that contains\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"quick orders pre-programmed with appropriate antimicrobial regimens for specific\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious diseases.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Goals\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Improve patient outcomes, reduce rates of microbial resistance, prevent adverse\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"patient outcomes, optimize costs and improve providers' lives. In addition to\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"these goals, the program fulfills antimicrobial stewardship quality standards\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"implemented by the Joint Commission.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Rationale\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"*Improved patient outcomes\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"In a 2013 study, Minneapolis Veterans Affairs Medical Center (MVAMC)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"antimicrobial courses ordered through the Antimicrobial CDSS were significantly\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"more likely to be appropriate from start to completion, (44%) compared to non-\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"CDSS courses (33%, P = 0.013). This is consistent with other studies that have\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"shown significant improvement in appropriate use of antimicrobials when CDSS\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"programs are utilized.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"*Restricted formulary\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"The Minneapolis VAHCS has a restricted antimicrobial formulary. A restricted\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"formulary reduces cost of health care and is an integral part of antimicrobial\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"stewardship. The Antimicrobial CDSS provides a method of formulary restriction\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"that doesn't require a call back from pharmacy or a prior authorization for the\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"antimicrobial to be approved.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"*Increased efficiency\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Along with being able to order restricted antimicrobials without a prior\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"authorization or call back from pharmacy, the Antimicrobial CDSS provides quick\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"orders pre-programmed with appropriate antimicrobial regimens for specific\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"infectious diseases. Using the system saves time and increases the efficiency of\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"the ordering provider.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Features\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"The CDSS has been developed locally with input from a broad, representative\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"group of clinicians. Recommendations have been based on local susceptibility\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"patterns, clinical evidence, local preferences, and national guidelines. The\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"CDSS provides a way for clinicians to select alternative drugs when the\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"recommended drugs are contraindicated.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Detailed instructions can be found in the link below.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Dellit et al. Clinical Infectious Diseases 2007, 44:159-7\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Filice et al. Infection Control and Hospital Epidemiology. 2013, 34.6\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Rawson et al. Clinical Microbiology and Infection. 2017, 1e9\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 69,
    "fields": {
      "name": "ORZID2 GMENU ABX ABX RESTRICTION POLICY",
      "term": null,
      "displaytext": "Antimicrobial restriction policy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIMICROBIAL RESTRICTION POLICY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Medication orders placed using the CDSS system will NOT require Infectious\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Disease approval. Because prescribing advice within the system has been\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"developed with input from a broad, representative group of clinicians and the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"recommendations that have emerged are based on site-specific susceptibility\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"patterns, clinical evidence, local preferences, and national guidelines,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"INFECTIOUS DISEASE APPROVAL FOR RESTRICTED ANTIMICROBIALS WILL NOT BE NEEDED at\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"participating VA sites. Clinicians are still encouraged to seek advice from\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Infectious Diseases whenever it would be helpful.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Restricted antimicrobials ordered outside the CDSS system will continue to need\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"ID approval.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 70,
    "fields": {
      "name": "ORZID2 GMENU ABX ACKNOWLEDGEMENTS",
      "term": null,
      "displaytext": "Acknowledgements",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"ACKNOWLEDGEMENT\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"This project was funded as a VISN 23 Strategic Planning Project for FY2005-2007.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"It addresses the VISN's efforts to build a culture of continuous quality\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"improvement, evidence-based practice and optimal resource utilization.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"This project has been guided by our project collaborators as well as the efforts\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"of the guideline review committee members. We would like to thank these\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"individuals for their time and thoughtful input.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 71,
    "fields": {
      "name": "ORZID2 GMENU ABX ACNE",
      "term": null,
      "displaytext": "Acne",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% lotion topically q12h ($) [M]\", \"Text\": \"Clindamycin 1% lotion topically q12h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Text\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Text\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DOXY 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H\", \"Text\": \"Doxycycline 100 mg PO q12h  ($) [DI] for 12 weeks <AND> erythromycin 2% gel\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MINO 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI] for 12 weeks <AND> erythromycin 2% gel\", \"Mnemonic\": \"16\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 250, \"DisplayText\": \"Relcalcitrant Acne and Rosacea\", \"Text\": \"Recalcitrant acne\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACNE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acne is an inflammatory skin condition caused by excess sebum production, gland\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"obstruction and infection with Cutibacterum acnes. Early disease manifests with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"black heads and white heads and little inflammation. Small papules and pustules\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"are present in mild disease. Severe disease occurs when comedones, papules,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"pustules and less often cysts are present.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"The goal of treatment is prevention and reeducation of new comedones and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"creating an environment that is inhibitory for C. acnes. General skin care\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"treatment measures include utilizing gentle skin cleansers, avoiding aggressive\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"scrubbing, using non-comedogenic skin products, and avoiding picking of lesions.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Diet's role in therapy remains uncertain.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Non-Antimicrobial therapy includes benzoyl peroxide topical/wash, salicylic acid\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"topical, and tretinoin topical. These agents can be used as monotherapy in early\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"disease and in addition to antimicrobial treatment in mild to severe disease.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Early Disease:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mild Disease:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Severe Disease:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"topically q12h\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"topically q12h\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Sanford keyword: Acne Vulgaris\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Up-to-Date Article: Pathogenesis, clinical manifestations, and diagnosis of acne\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-to-Date Article: Acne vulgaris: Overview of management\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Zaenglein et al., N Engl J Med, 2018, 379(14)1343-1352\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Zaenglein et al., J Am Acad Dermatol, 2016, 74(5)945-73.e33\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 72,
    "fields": {
      "name": "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS",
      "term": null,
      "displaytext": "Acute Bacterial Prostatitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO ($) [DI]\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"6\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po q12h\", \"Text\": \"Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"8\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days\", \"Mnemonic\": \"10\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) for 14 days\", \"Mnemonic\": \"12\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE BACTERIAL PROSTATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute bacterial prostatitis typically presents with fever, dysuria, chills,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"malaise, myalgia, pelvic or perianal pain. On exam, the prostate gland is tense,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"boggy, and extremely tender. The urinalysis reveals pyuria, and the urine\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"culture is positive. Men with dysuria and fever but without pyuria and/or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bacteriuria should be seen by a urologist. If there is any suspicion of abscess,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"especially in men older than 40 years, the patient should be seen by a urologist\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and transurethral prostate resection for drainage should be considered.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Most cases in men aged 35 and older, those with recent urinary tract\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with enteric Gram-negative rods. Most cases in men under age 35 and those who\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"are at high risk of sexually transmitted infections are associated with N.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"gonorrhoeae and C. trachomatis. Resistant organisms are more likely if the\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"patient has been in the hospital for more than 48 hours or received a course of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"antibiotics. There is increasing resistance in urinary pathogens to\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"ciprofloxacin.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"A urine Gram stain and culture should be performed in all patients to guide\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"antimicrobial therapy:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"There is limited data on duration of antimicrobial treatment for prostatitis. 14\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"days minimum is required. 4 to 6 weeks may be necessary to completely eradicate\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"bacteria in the prostate to ensure patient does not progress to chronic\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"bacterial prostatitis.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"_____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Hydration, bed rest and analgesics are recommended along with antimicrobials\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Age < 35 years and those at high risk of sexually transmitted infections\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Patient weighing less than 300 lbs:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"14 days\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Patients weighing 300 lbs or greater:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"14 days\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Age >/= 35 years\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Mandell chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Sanford keyword: Prostatitis\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute Bacterial Prostatitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 73,
    "fields": {
      "name": "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE",
      "term": null,
      "displaytext": "Additional assistance... ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 26, \"Column\": 1, \"Item\": 3011, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"[CLICK HERE] to open Infectious Diseases on call schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"WHOM TO CONTACT FOR ADDITIONAL ASSISTANCE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"CDSS Team\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Contact for issues regarding\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"navigation or content of the CDSS\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Erik Stensgard, PharmD, BCPS\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobial CDSS Program Manager\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"(612) 271-4121 -OR- Microsoft TEAMS\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Email: Erik Stensgard@va.gov\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Bobbie Masoud, PharmD, BCPS\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Clinical Pharmacist CDSS\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(612) 719-6778 -OR- Microsoft TEAMS\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Email: Bobbie.Masoud@va.gov\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Infectious Diseases\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Contact for issues regarding\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"antimicrobial treatment\"}, {\"Row\": 23, \"Column\": 2, \"Item\": null, \"DisplayText\": \"PHARMACIST PHONE/PAGER NUMBERS\", \"Text\": \"[CLICK HERE] to open list of\", \"Mnemonic\": \"12\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Antimicrobial Stewardship\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Text\": \"Contact for issues regarding\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"antimicrobial stewardship\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"Muthu Narayan, DO\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"Antimicrobial Stewardship Physician\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"Pager: 612-818-3936\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"Eric Geurkink, PharmD, MBA, BCPS\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"Antimicrobial Stewardship Pharmacist\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"Pager: 612-818-0841\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 2, \"Text\": \"Pharmacy Staff\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Contact for pharmacy related\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \"antimicrobial issues\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"pharmacists' phone/pager numbers\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 2, \"Text\": \"Microbiology\", \"Header\": 1}, {\"Row\": 28, \"Column\": 2, \"Text\": \"Contact for microbiology issues\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"Phone extension: 31-2408\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"E-mail Antimicrobial CDSS Staff\", \"Text\": \"CDSS Team Email: VISN23AntimicrobialCDSS@va.gov\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 74,
    "fields": {
      "name": "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY",
      "term": null,
      "displaytext": "Adjust existing antimicrobial therapy",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"ADJUSTING EXISTING ANTIMICROBIAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"To change the DOSE of a CURRENTLY ACTIVE antimicrobial\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Right click on the active order and change the dose as needed.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"To change from the CURRENT ANTIMICROBIAL MEDICATION\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"We encourage clinicians to consult the CDSS when considering alternative\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobial therapy due to an adverse drug reaction, a culture result, or a\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"need to switch from intravenous to oral therapy. Many of the CDSS advice menus\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"contain more than one antimicrobial recommendation. If a suitable alternative\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"is not listed on the advice menu, clinicians have the additional resource of an\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"expanded menu of alternative medications that can be accessed by selecting the\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Need an alternative antimicrobial? link at the top of each advice menu. To\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"order an alternative medication using this link prescribers will need to\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"indicate the rationale behind the choice.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Note: Restricted antimicrobials ordered outside of the CDSS system will still\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"require Infectious Diseases approval.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 75,
    "fields": {
      "name": "ORZID2 GMENU ABX AEROMONAS",
      "term": null,
      "displaytext": "Diarrhea with Aeromonas  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 3 days($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH AEROMONAS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8(94)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford keyword: Aeromonas sp.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-to-Date article: Aeromonas infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 76,
    "fields": {
      "name": "ORZID2 GMENU ABX AMOXICILLIN CHALLENGE ALLERGY",
      "term": null,
      "displaytext": "Amoxicillin Challenge ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Amoxicillin Oral Challenge for Low Risk Patients\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Amoxicillin challenge protocol:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"To be given ONLY after patient has been evaluated with thorough beta lactam\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"history and found to be low risk, AND has given consent for amoxicillin\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Place order for medications:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Amoxicillin 500mg PO once + Epinephrine 0.5mg/0.5ml IM once prn\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"challenge.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Khan DA, et al. J Allergy Clin Immunol.,2022,150(6):1333-1393\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Drug allergy: A 2022 practice parameter update\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Inpatient orders:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Clinic orders:\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Amoxicillin 500mg PO once + Epinephrine 0.5MG/0.5ML IM once prn\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 77,
    "fields": {
      "name": "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"Select individual antimicrobial listed below for current status on shortages.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Currently NO antimicrobial shortages.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 78,
    "fields": {
      "name": "ORZID2 GMENU ABX ANTIVIRAL TREATMENT",
      "term": null,
      "displaytext": "ANTIVIRAL TREATMENT",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oseltamivir 75 MG PO q12h for 5 days\", \"Text\": \"Oseltamivir 75 mg po bid for 5 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Antiviral Therapy Recommendations:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Who to Treat:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"The decision to treat should be based on clinical symptoms and/or presence of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"a high risk condition, and should NOT be delayed until laboratory test\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"results are available.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"It is important to use antiviral drugs early to treat influenza in people who\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"are very sick with influenza (for example hospitalized people) and people who\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"are sick with influenza and have a greater chance of getting severe\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"complications. If a patient is not in a high-risk group or is not hospitalized,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"healthcare providers should use clinical judgment to guide treatment decisions.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"People who have a greater chance of serious influenza complications include:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"*Persons who have chronic pulmonary (including asthma) or cardiovascular\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"*Persons who are immunocompromised due to any cause (including immunosuppresion\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"caused by medications or by HIV infection)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*Persons younger than 19 years of age who are receiving long-term aspirin-\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"or salicylate-containing medications and who might be at risk for experiencing\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Reye syndrome after influenza virus infection\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"*Residents of nursing homes and other long-term care facilities\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*Persons who are extremely obese (BMI greater than or equal to 40)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Antiviral Treatment:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"If indicated, antivirals should be started as soon as possible.  Maximal\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"benefit occurs when started within 48 hours of symptom onset.  However,\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"antivirals should not be withheld if symptoms began more than 48 hours prior\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"and the patient meets criteria for treatment and remains severely ill.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treatment Dosing:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Zanamivir is not recommended for patients with chronic respiratory disease such\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"as asthma or chronic obstructive pulmonary disease. These patients may have\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"bronchospasm with zanamivir. If zanamivir must be used, and patients are using\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"an inhaled bronchodilator, zanamivir should be taken just after the\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"bronchodilator.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Requires Infectious Disease Approval\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Zanamivir 2 inhalations (2 x 5 mg) BID for 5 days ($) [O]\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Alternative for patients unable to tolerate or absorb oral oseltamivir:\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Requires Infectious Disease Approval\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Peramivir 600 mg IV q24h for 5 to 10 days ($$$$$) [R]\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"*Adults aged 65 years or older\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(except isolated hypertension), renal, hepatic, hematologic, metabolic\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"disorders (including diabetes mellitus), neurologic and\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"neuro-developmental disorders\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"patients wt <80kg ($$$) [DI]\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Hospitalized, high risk:\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Acute, uncomplicated:\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Peramivir 600mg IV Once ($$$$$) [R]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Extending the duration of treatment for oseltamivir or peramivir may be\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"needed for those patients with prolonged illness or who are immunosuppressed.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"*Pregnant women and women up to 2 weeks after the end of pregnancy\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"*Non-Hispanic Black persons, Hispanic or Latino persons, and American Indian\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"or Alaska Native persons\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Centers for Disease Control (CDC) (Accessed 9/20/22)\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"https://www.cdc.gov/flu/professionals/antivirals/summary-clinician\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"UpToDate Seasonal influenza in adults: Treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 79,
    "fields": {
      "name": "ORZID2 GMENU ABX APPRO TO BACTEREMIA",
      "term": null,
      "displaytext": "Approach to bacteremia",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Sepsis, severe sepsis, and septic shock\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 280, \"DisplayText\": \"Suspected bacteremia, blood cultures not yet positive\", \"Text\": \"Suspected bacteremia, blood cultures not yet positive\", \"Mnemonic\": \"6\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 462, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs\", \"Text\": \"Interim report of Gram-positive cocci in pairs\", \"Mnemonic\": \"8\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 463, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and clusters\", \"Text\": \"Interim report of Gram-positive cocci in pairs and clusters\", \"Mnemonic\": \"10\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 464, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and chains\", \"Text\": \"Interim report of Gram-positive cocci in pairs and chains\", \"Mnemonic\": \"12\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 460, \"DisplayText\": \"Interim report of Gram-negative bacilli\", \"Text\": \"Interim report of Gram-negative bacilli\", \"Mnemonic\": \"14\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 461, \"DisplayText\": \"Interim report of Gram-negative cocci\", \"Text\": \"Interim report of Gram-negative cocci\", \"Mnemonic\": \"16\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 465, \"DisplayText\": \"Interim report of Gram-positive rods\", \"Text\": \"Interim report of Gram-positive bacilli\", \"Mnemonic\": \"18\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 466, \"DisplayText\": \"Interim report of yeast\", \"Text\": \"Interim report of yeast\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO BACTEREMIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bacteremia usually results from a focal infection somewhere in the body. If a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"focal infection is not obvious, a careful search should be made beginning with a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"detailed history and physical examination.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If a focal infection seems to be the source of the bacteremia, select\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobials active against pathogens likely to be present in the focal\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infection. Return to the main menu and select the relevant diagnosis or\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"syndrome.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"For infections with signs and/or symptoms of severe sepsis, like hypotension or\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"end organ dysfunction\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sequence of evaluation\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Obtain blood cultures before starting antibiotics when signs or symptoms suggest\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"bacteremia. Obtain 2 or 3 blood culture sets from different venipuncture sites\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"within a 24 hour period. When suspicion is strong and the patient's signs and\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"symptoms have not responded, obtain 2 blood culture sets the next day. For more\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"information about blood cultures, see recommendations on the Q-drive\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Q:\\\\MICROBIOL INFO FOR CLINICIANS\\\\BLOOD CULTURE Recommendations.doc\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Empirical treatment of suspected bacteremia if local infection is not apparent\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"and blood cultures are not yet positive\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Cultures usually become positive after 1 or more days. Usually interim results\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"are reported first, followed by final identification and sensitivities after\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"another day or two. Adjust antimicrobials as appropriate as this sequence\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"unfolds.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Preliminary results of a positive culture are available\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"When a focal infection is not apparent, the type of bacteria growing in blood\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"culture might suggest a focal infection and direct the search for a diagnosis.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"When a focal infection is apparent, it may suggest the identity of the bacteria\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"growing in blood cultures before the laboratory completes its identification.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Preliminary positive results should lead to changes in antimicrobial therapy to\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"target suspected pathogens, narrow the spectrum, reduce toxicity, and reduce\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"costs.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mandell Chapter Sepsis, Severe Sepsis and Septic Shock\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 80,
    "fields": {
      "name": "ORZID2 GMENU ABX APPRO TO ENDOCARDITIS",
      "term": null,
      "displaytext": "Approach to Endocarditis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 146, \"DisplayText\": \"Modified Duke Diagnostic Criteria\", \"Text\": \"Diagnosis with Duke Criteria\", \"Mnemonic\": \"4\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Penicillin Desensitization protocol\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infectious Diseases and Cardiology consults are essential for proved cases and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"encouraged for suspected cases. See diagnosis page for more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Attempt to identify the pathogen before starting antimicrobials. At least three\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"sets of blood cultures should be obtained from different venipuncture sites.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"These cultures should be drawn at different times with the first and last\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"culture separated by at least one hour.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For a patient who is not clinically stable, or if the progression of the illness\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"is rapid, draw 3 sets of blood cultures and then initiate empirical\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"antimicrobial therapy and/or surgical intervention.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Ascertain whether any antimicrobials were taken during the previous 2 weeks to\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"help interpret culture results.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Penicillin susceptibility data are used to determine appropriate antimicrobial\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"therapy for streptococcal endocarditis. Because bacteria in cardiac vegetations\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"are not actively dividing, and are protected from host defense mechanisms,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"bactericidal antimicrobial regimens are necessary to treat bacterial\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"endocarditis. The minimum inhibitory concentration (MIC) cut-off levels used to\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"select therapy for endocarditis differ from those used to select therapy for\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"other infectious diseases (see below).\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Penicillin allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Beta-lactam antibiotics are more effective than vancomycin for treating\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"susceptible gram-positive pathogens. For patients with penicillin allergy that\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"is known or suspected to be class I (anaphylaxis, angioedema, or hives),\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"penicillin desensitization or therapy with a cephalosporin is usually the best\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"approach.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"When gentamicin is used for synergy against gram positive bacteria, serum\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"concentrations should be 3-4 mcg/ml peak and < 1 mcg/ml trough. Once daily\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"gentamicin dosing can be used for streptococcal cases but not for staphylococcal\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"or enterococcal cases.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 81,
    "fields": {
      "name": "ORZID2 GMENU ABX APPROACH TO ACUTE MENINGITIS",
      "term": null,
      "displaytext": "Approach to Acute Meningitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 322, \"DisplayText\": \"Bacterial meningitis without Gram stain results\", \"Text\": \"Community acquired meningitis\", \"Mnemonic\": \"4\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 314, \"DisplayText\": \"Bacterial meningitis associated with trauma or nosocomial infection\", \"Text\": \"Meningitis associated with trauma or nosocomial infection\", \"Mnemonic\": \"6\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 318, \"DisplayText\": \"Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia\", \"Text\": \"Gram-positive diplococci suggesting Streptococcus pneumoniae\", \"Mnemonic\": \"8\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 317, \"DisplayText\": \"Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis\", \"Text\": \"Gram-negative diplococci suggesting Neisseria meningitidis\", \"Mnemonic\": \"10\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 313, \"DisplayText\": \"Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes\", \"Text\": \"Gram-positive bacilli/coccobacilli suggesting Listeria monocytogenes\", \"Mnemonic\": \"12\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 316, \"DisplayText\": \"Bacterial meningitis with Gram negative bacilli\", \"Text\": \"Gram negative bacilli\", \"Mnemonic\": \"14\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 321, \"DisplayText\": \"Bacterial meningitis with S. pneumoniae\", \"Text\": \"S. pneumoniae\", \"Mnemonic\": \"16\"}, {\"Row\": 74, \"Column\": 1, \"Item\": 320, \"DisplayText\": \"Bacterial meningitis with N. meningitidis\", \"Text\": \"N. meningitidis\", \"Mnemonic\": \"18\"}, {\"Row\": 75, \"Column\": 1, \"Item\": 319, \"DisplayText\": \"Bacterial meningitis with L. monocytogenes\", \"Text\": \"L. monocytogenes\", \"Mnemonic\": \"20\"}, {\"Row\": 76, \"Column\": 1, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"E. Coli, Pseudomonas, or another organism\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO ACUTE MENINGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Meningitis is an inflammation of the meninges and tissues surrounding the brain\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"and spinal cord. It is characterized by an abnormal amount of white blood cells\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"in the cerebrospinal fluid (CSF) and symptoms include headache, fever, mental\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"status changes, nuchal rigidity, and nausea.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Acute Meningitis\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"The sudden onset of meningeal symptoms within hours to days caused by several\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"infectious etiologies, including bacterial, viral, fungal and protozoa, as well\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"as non-infectious etiologies. Bacterial meningitis is the most common type of\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"meningitis, accounting for up to 90% of cases where a CSF culture was obtained\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"prior to starting antimicrobials. Non-bacterial meningitis is commonly referred\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"to as aseptic meningitis (refer to \\\"Negative CSF culture\\\" below for\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"recommendations).\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Patients with acute bacterial meningitis often have severe symptoms and present\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"soon after onset of infection. The relationship between predisposing factors and\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"common bacterial pathogen are listed below.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Predisposing Factors and Common Bacterial Pathogens\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"*Age 2-50 years - S. pneumoniae, N. meningitidis\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*Age > 50 years - S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"gram-negative bacilli\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"*Immunocompromised state - S. pneumoniae, N. meningitidis, L. monocytogenes,\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"aerobic gram-negative bacilli (including Pseudomonas aeruginosa)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"*Basilar skull fracture - S. pneumoniae: H. influenzae, group A and\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"beta-hemolytic streptococci\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*Head trauma: after neurosurgery - Staphylococcus aureus, coagulase-negative\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"staphylococci (especially Staphylococcus epidermidis), aerobic gram-negative\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"bacilli (including P. aeruginosa)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Initial Management of Suspected Acute Bacterial Meningitis\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"to obtain CSF for establishing diagnosis and determining infectious\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"organism/susceptibility. Computed tomography (CT) should be performed prior to\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"LP in some patients (see list below). If CT must be obtained prior to LP or\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"there is another delay in performing LP, empiric antimicrobials should not be\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"delayed and initiated immediately after obtaining blood cultures only.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Relative LP contraindications (no absolute contraindications exist):\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Anticoagulation therapy or bleeding disorder, spinal epidural abscess, raised\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"intracranial pressure.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Computed tomography scan should be performed prior to lumbar puncture in cases\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"with the following: Immunocompromise, history of CNS disease, new onset seizure,\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"papilledema, abnormal level of consciousness, focal neurologic deficit.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"LP and CSF Analysis\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"LP opening pressure is often elevated in bacterial meningitis. CSF findings\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"characteristic of bacterial meningitis include CSF glucose <40mg/dL, CSF to\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"serum glucose ratio </=0.4, CSF protein concentration >/=200 mg/dL and CSF WBC\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \">1000 microL.\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Empiric Treatment After Blood Cultures are Drawn, and CSF is Obtained, or if LP\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Must be Delayed\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Empiric Treatment Based on CSF Gram-Stain Results\", \"Header\": 1}, {\"Row\": 65, \"Column\": 1, \"Text\": \"When gram stain results are available, adjust antimicrobials to optimize therapy\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Treatment Based on CSF Isolated Organism\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"When infectious organism is identified, adjust antimicrobials to optimize therap\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Negative CSF Culture\", \"Header\": 1}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Patients who have a negative CSF culture but have symptoms and CSF findings\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"consistent with bacterial meningitis should be treated based on likely pathogen.\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Patients with negative CSF culture, symptoms of acute meningitis but have labs\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"inconsistent with bacterial meningitis should be considered to have aseptic\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"meningitis. Aseptic meningitis is caused by a variety of non-bacterial\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"infectious etiologies and non-infectious etiologies. Consult Infectious Disease\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"for more information.\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 89, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 92, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 96, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 82,
    "fields": {
      "name": "ORZID2 GMENU ABX APPROACH TO UTI",
      "term": null,
      "displaytext": "Approach to Urinary Tract Infection (UTI)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 85, \"DisplayText\": \"Asymptomatic Bacteriuria\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 100, \"DisplayText\": \"Candida urinary tract infection\", \"Text\": \"Candida urinary tract infections\", \"Mnemonic\": \"8\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 291, \"DisplayText\": \"Uncomplicated Cystitis\", \"Text\": \"Uncomplicated cystitis\", \"Mnemonic\": \"10\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 123, \"DisplayText\": \"Complicated Cystitis\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"12\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 247, \"DisplayText\": \"Pyelonephritis\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"14\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 628, \"DisplayText\": \"Urosepsis\", \"Text\": \"Bacteremia or sepsis with urinary tract source (aka urosepsis)\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO URINARY TRACT INFECTION (UTI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Urinary tract infections (UTI) occur in patients with symptoms of infection in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the lower urinary tract (cystitis) and/or the upper urinary tract\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(pyelonephritis). Cystitis refers to infection of the urinary bladder, but\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inflammation often extends into the urethra. Typical signs and symptoms include\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dysuria, increased urinary frequency, urgency, and/or suprapubic tenderness.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Uncomplicated cystitis occurs in people with structurally and neurogenically\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"normal urinary tract. Most cases of uncomplicated cystitis occur in\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pre-menopausal, non-pregnant, sexually active young women and is associated with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"saprophyticus. Complicated cystitis occurs in the conditions listed below and is\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"associated with Enterobacteriaceae, but more resistant pathogens occur,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"including the Gram-positive pathogens staphylococci and enterococci. Features of\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"pyelonephritis include fever/other signs of systemic infection, flank pain,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"costovertebral tenderness, and pelvic or perianal pain in men. In rare and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"severe cases, urinary tract infections can also present with bacteremia, sepsis,\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"multiple organ system dysfunction, shock and/or acute renal failure.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"When a patient presents with symptoms of cystitis, like dysuria, increased\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"frequency, and suprapubic pain, perform a urine culture. Antimicrobial therapy\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"is not indicated for pyuria in the absence of symptoms. Patients with signs and\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"symptoms of pyelonephritis should have a urinary culture and susceptibility\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"obtained and a urine Gram-stain performed prior to starting empirical\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"antimicrobials to guide therapy. Patients presenting with bacteremia, sepsis,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"multiorgan dysfunction, shock and/or acute renal failure should be treated\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"accordingly with urinary tract as the foci of infection.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Asymptomatic bacteriuria occurs in patients who have bacteria in the urine but\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"do not have symptoms of a urinary tract infection. Asymptomatic bacteriuria is\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"further discussed elsewhere:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"treatment:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Candida urinary tract infections are discussed elsewhere:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Complicating conditions\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Cystitis is considered complicated when one or more of the following is present:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"o Pregnant women\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"o Immunocompromise\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"o Persistent infection, relapse, recurrence, or treatment failure\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"o In some cases, men and patients admitted to health care settings may be\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"considered complicated\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary Tract Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 83,
    "fields": {
      "name": "ORZID2 GMENU ABX ASPIRATION PNEUMONIA",
      "term": null,
      "displaytext": "Aspiration pneumonia  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 122, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community acquired pneumonia (CAP)  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Nosocomial pneumonia\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 201, \"DisplayText\": \"Lung abscess\", \"Text\": \"Lung abscess\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ASPIRATION PNEUMONIA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Aspiration of oropharyngeal or gastric contents induces inflammation and is\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"often accompanied by fever and/or an infiltrate.  Bacterial pneumonia occurs in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"a minority of patients who aspirate, typically about 3 days later.  The patient\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"usually improves for the first 2 days and then worsens as bacterial pneumonia\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"develops with increased fever, new or progressive infiltrates, leukocytosis, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"newly purulent sputum.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobials have no role for treatment of aspiration and their use entails\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"risk of side effects and selection of resistant organisms.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antimicrobials used for community-acquired pneumonia are appropriate for cases\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"that develop after an episode of aspiration.  For more information, consult\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Pulmonary or Infectious Diseases.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment for patients with pneumonitis but without lung abscess or putrid\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"sputum\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Therapy directed towards anaerobic pathogens is usually unnecessary.  If\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"pneumonia is confirmed, treat as\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treament for patients with LUNG ABSCESS\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Luna CM  Crit Care Med 2003, 31: 676\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell chapter: Lung Abscess\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell LA Clin Infect Dis 2003,37:1405\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 84,
    "fields": {
      "name": "ORZID2 GMENU ABX ASSOC COLITIS",
      "term": null,
      "displaytext": "Antibiotic Associated Colitis (C. Difficile Colitis)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 193, \"DisplayText\": \"Initial Episode of Antibiotic Associated Colitis...\", \"Text\": \"Initial Episode\", \"Mnemonic\": \"4\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 159, \"DisplayText\": \"\", \"Text\": \"First Recurrence\", \"Mnemonic\": \"6\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 267, \"DisplayText\": \"ORZID2 GMENU SECOND RECURRENCE ABX ASSOC COLITIS\", \"Text\": \"Second Recurrence\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Discontinue implicated antibiotic and avoid high risk antibiotic if antibiotic\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"therapy is still needed. Discontinue laxatives. Reassess need for tube feeds. C.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"difficile PCR testing should be completed to confirm diagnosis of C. difficile\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infection.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antibiotic risk (rank order):\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"High: clindamycin, fluoroquinolones, 2nd/3rd/4th generation cephalosporins,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medium: carbapenems, penicillins, 1st generation cephalosporins, macrolides,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"vancomycin, metronidazole\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Low: tetracyclines, aminoglycosides, trimethoprim/sulfamethoxazole, rifampin\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Very low: sulfonamides, nitrofurantoin, fosfomycin, methenamine\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Avoid antiperistaltic agents (narcotics, loperamide, etc.). Increasing evidence\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"suggests that antacid therapy, especially with PPIs and H2 blockers, increases\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"the risk for C. difficile disease and recurrences. Avoid antacid therapy\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"without clear indication, especially in patients at risk for primary recurrent C\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"difficile disease.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"The preferred route of antimicrobial therapy for C. difficile infection is by\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"mouth. Intravenous metronidazole should be used only when oral therapy cannot\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"be used to deliver drug to the colon. Intravenous vancomycin does not get into\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"colonic contents and is not effective.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"C. difficile infection usually responds to antimicrobial therapy, especially if\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"other antimicrobial therapy has been stopped. Relapse is usually due to failure\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"of normal colonic flora to re-establish itself, rather than antimicrobial\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"treatment failure. If symptoms do not respond to appropriate antimicrobial\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"therapy, re-consider the diagnosis. Relapse occurs in 6% to 25% of people after\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"their first episode of C. difficile infection.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Third Recurrence: Consult Gastroenterology and/or Infectious Disease\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Clinical\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"CDI: Patient with clinical symptom onset (e.g., 3 or more unformed stools in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"24 hours after discontinuation of laxatives) and laboratory confirmation of CDI.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"CDI Recurrence: Typically defined as a repeated symptomatic, laboratory\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"case of CDI within 12 weeks after a prior episode.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If diarrhea has improved or resolved prior to starting C. difficile\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"treatment, consider re-assessing the diagnosis before initiating therapy.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"The Infectious Disease service is always available to discuss CDI testing\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"and results.\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 97, \"DisplayText\": \"Clostridioides difficile Infection (CDI) 2-step testing\", \"Text\": \"<Click here> Information on C. difficile lab testing\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 85,
    "fields": {
      "name": "ORZID2 GMENU ABX ASYMP BACTERIURIA",
      "term": null,
      "displaytext": "Asymptomatic Bacteriuria ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl >30 mL/min, for 5 days\", \"Mnemonic\": \"4\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"6\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Text\": \"Cefadroxil 1000 mg q12h ($) [R] for 5 days\", \"Mnemonic\": \"8\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 610, \"DisplayText\": \"Urological procedures\", \"Text\": \"Antimicrobial prophylaxis for urological procedures\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ASYMPTOMATIC BACTERIURIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Asymptomatic bacteriuria is common in women and elderly people, especially in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"those with chronic medical problems (e.g., diabetes, spinal cord injury,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"institutionalized patients, catheterized patients). Most patients have no\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"adverse outcomes and receive no benefit from treatment of asymptomatic\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bacteriuria.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Patients who have no symptoms of cystitis (i.e., no dysuria, pain, urgency)\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"should not be treated. The presence of pyuria (>7 wbc/hpf) or positive leukocyte\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"esterase, urine nitrate, or urine bacteria is not a sufficient indication for\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antibiotic treatment. Screening and treatment of asymptomatic bacteriuria is\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"indicated for pregnant women and patients who will have urological procedures\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"and may be indicated in patients < 1-month post-renal transplant. If an\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"indwelling catheter is in place and can be removed safely, it should be done as\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"the bacteriuria may clear.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Bacteriuria in pregnant women is associated with pyelonephritis, premature\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"delivery, and lower birth weight. Screening for bacteriuria is recommended at\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"least once early in pregnancy. If bacteriuria is not found upon initial testing,\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"further screening cultures are not needed. If bacteriuria (>10,000 CFU/mL) is\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"present, the patient should be treated. Testing should be repeated throughout\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"the pregnancy to detect recurrences.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Pregnant women, empirical treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Patients having urological procedures\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Renal transplant recipients < 1 month after transplant\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Screening and treatment of asymptomatic bacteriuria may be indicated. Consult\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"nephrology for recommendations.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary Tract Infections\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Nicolle et al., Clinical Infectious Diseases, 2019, 2.68(10)e83-e110\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Bacteriuria, Asymptomatic\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Up-To-Date article: Urinary tract infections and asymptomatic bacteriuria in\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"pregnancy\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-To-Date article: Approach to the adult with asymptomatic bacteriuria\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-To-Date article: Kidney transplantation in adults: Urinary tract infection in\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"kidney transplant recipients\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"US Preventive Services Task Force, JAMA, 2019, 322(12)1188-1194\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 86,
    "fields": {
      "name": "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD",
      "term": null,
      "displaytext": "Azithromycin for Prevention of Exacerbations COPD",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 3012, \"DisplayText\": \"RESOURCE QTC PROLONGATION FOR DRUGS\", \"Text\": \"Please Click Here for Resource for Drugs that Cause QTc Prolongation\", \"Mnemonic\": \"4\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COPD Exacerbation Orders...\", \"Text\": \"Inpatient COPD Exacerbation Orders\", \"Mnemonic\": \"6\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 250 mg po daily\", \"Text\": \"Azithromycin 250 mg po daily long-term for COPD ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Azithromycin for Prevention of Exacerbations in Advanced COPD\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Daily azithromycin prevents chronic obstructive pulmonary disease (COPD)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"exacerbations in people with advanced COPD (Albert et al, see below).\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Of note, in the study there was no benefit in the most severely ill\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"subgroup that was on the most pulmonary medications.  People\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"with frequent exacerbations have more doctor visits and hospitalizations than\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"people with fewer or no exacerbations.  Frequent exacerbations are associated\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with rapid decline in lung function and quality of life and increased risk of\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"death.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"To receive daily azithromycin, patients must meet the following criteria and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"receive approval from pulmonary service.  The evidence that benefits of daily\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"azithromycin outweigh risks is limited to people who meet the following\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"criteria.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Eligibility Criteria:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"*Age >40 years\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"*Clinical diagnosis of COPD (>= 10 pack-years cigarette smoking, a ratio of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"postbronchodilator forced expiratory volume in 1 second [FEV1] to forced\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"vital capacity of <70%, and a postbronchodilator FEV1 of <80% of the\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"predicted value), *AND*\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"*Were either using continuous supplemental oxygen or had received systemic\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"glucocorticoids within the previous year, *OR*\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*Had gone to an emergency room or had been hospitalized for an acute\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"exacerbation of COPD.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Exclusion criteria:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"*Asthma\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"*People with hearing impairments\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"*Congestive heart failure\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*Resting heart rate > 100 beats per minute\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"*Use of medications that are associated with torsades de pointes (with the\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"exception of amiodarone)\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"*Prolonged QTc interval (>450 msec)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"*Use of medications that prolong the QTc interval\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"If, after trying all of the standard treatments, patients are still having\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"acute exacerbations of COPD, long-term antibiotic treatment with Azithromycin\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"may be considered.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Note: Guidelines for COPD can be found on the CPRS Tools Menu.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Select below for Inpatient COPD order sets for comprehensive management:\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"If the patient meets the criteria and is willing to have audiometric testing\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"and an electrocardiogram, please place a Pulmonary Consult for long-term\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Azithromycin therapy for the prevention of exacerbations of COPD.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Pulmonary is the only approved provider for ordering long-term\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Azithromycin therapy for COPD.\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Albert, RK, et al, Azithromycin for Prevention of Exacerbations of COPD.  New\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"England Journal of Medicine 2011, 365:689-698\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Ray, WA, et al, Azithromycin and the Risk of Cardiovascular Death.  New\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"England Journal of Medicine 2012, 366:1881-1890\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 87,
    "fields": {
      "name": "ORZID2 GMENU ABX BACTEREMIA",
      "term": null,
      "displaytext": "Bacteremia",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Item\": 79, \"DisplayText\": \"Approach to bacteremia\", \"Text\": \"Approach to bacteremia...\", \"Mnemonic\": \"4\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 280, \"DisplayText\": \"Suspected bacteremia, blood cultures not yet positive\", \"Text\": \"Suspected bacteremia, blood cultures not yet positive...\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 461, \"DisplayText\": \"Interim report of Gram-negative cocci\", \"Text\": \"Interim report:  Gram negative cocci\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 460, \"DisplayText\": \"Interim report of Gram-negative bacilli\", \"Text\": \"Interim report:  Gram negative bacilli\", \"Mnemonic\": \"10\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 462, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs\", \"Text\": \"Interim report:  Gram positive cocci in pairs\", \"Mnemonic\": \"12\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 464, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and chains\", \"Text\": \"Interim report:  Gram positive cocci in pairs and chains\", \"Mnemonic\": \"14\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 463, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and clusters\", \"Text\": \"Interim report:  Gram positve cocci in pair and clusters\", \"Mnemonic\": \"16\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 465, \"DisplayText\": \"Interim report of Gram-positive rods\", \"Text\": \"Interim report:  Gram positive bacilli\", \"Mnemonic\": \"18\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 466, \"DisplayText\": \"Interim report of yeast\", \"Text\": \"Interim report:  Yeast\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Bacteremia\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Bacteremia, PRELIMINARY results\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Last reviewed July 2017\", \"Header\": 1}, {\"Row\": 10, \"Column\": 2, \"Item\": 326, \"DisplayText\": \"Bacteremia associated with Staphylococcus aureus\", \"Text\": \"with Staphylococcus aureus\", \"Mnemonic\": \"24\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 324, \"DisplayText\": \"Bacteremia associated with Coagulase-negative Staphylococci (CNS)\", \"Text\": \"with Coagulase-negative Staphylococci (CNS)\", \"Mnemonic\": \"26\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 323, \"DisplayText\": \"Bacteremia associated with Candida spp.\", \"Text\": \"with Candida spp.\", \"Mnemonic\": \"28\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 325, \"DisplayText\": \"Bacteremia associated with Listeria monocytogenes\", \"Text\": \"with Listeria monocytogenes\", \"Mnemonic\": \"30\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Bacteremia, FINAL results (specific pathogens)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"_____________________________________\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 88,
    "fields": {
      "name": "ORZID2 GMENU ABX BALANITIS",
      "term": null,
      "displaytext": "Balanitis and Balanoposthitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical bid\", \"Text\": \"Clotrimazole 1% cream topically q12h ($) [M] for 7 days\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin Cream to affected area BID ($) [M]\", \"Text\": \"Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150 mg PO once ($) [R,DI]\", \"Text\": \"Fluconazole 150 mg PO once ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% cream topically q12h ($)[DI]\", \"Text\": \"Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days\", \"Mnemonic\": \"12\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500MG PO q12h\", \"Text\": \"Metronidazole 500 mg PO q12h ($) [DI] for 7 days\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BALANITIS AND BALANOPOSTHITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Balanitis is inflammation of the glans penis and is often associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"erythema and pruritis. When the foreskin is also involved, the condition is\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"known as balanoposthitis (also referred to as balanitis in this discussion).\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"There are a variety of causes of balanitis, but most are due to poor hygiene of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"the foreskin in uncircumcised men resulting in candida infection. Other, less\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"common causes, include bacterial infection (typically sexually transmitted or\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"anaerobic bacteria), dermatologic conditions, malignancy as well as others. Men\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with Candidal balanitis often have a white curd-like exudate compared to a thick\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"foul-smelling purulent exudate in menu with anaerobic bacterial balanitis.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"treatment:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Candidal balanitis empirical treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mild to moderate cases\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Severe cases\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Bacterial balanitis empirical treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mild cases\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Moderate to severe cases\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"___________________________________________________________________________\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Edwards et al., International Journal of STD & AIDS, 2014, 25(9)615-526\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: Balanitis\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-to-Date article: Balanitis in Adults\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 89,
    "fields": {
      "name": "ORZID2 GMENU ABX BARICITINIB EUA COVID-19",
      "term": null,
      "displaytext": "Barcitinib Emergency Use Authorization for COVID-19 ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with eGFR >/= 60 ml/min/1.73 m2:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib EUA 4 mg po qday for 14 days or until discharge (COVID-19) ($$$) [R]\", \"Text\": \"Baricitinib 4 mg PO qday for 14 days or until discharge (COVID-19) ($$$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Patients with eGFR 30-59 ml/min/1.73 m2:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Patients with eGFR 15-29 ml/min/1.73 m2:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Patients with an eGFR < 15ml/min/1.73 m2 or those on dialysis:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Baricitinib is NOT recommended\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"02\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib EUA 2 mg po qday for 14 days or until discharge (COVID-19) ($$) [R]\", \"Text\": \"Baricitinib 2 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib EUA 1 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]\", \"Text\": \"Baricitinib 1 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Barcitinib Oral\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib 4 mg NG qday for 14 days + Administration Instructions\", \"Text\": \"Baricitinib 4 mg NG qday for 14 days or until discharge (COVID-19) ($$$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib 2 mg q day for 14 days + Administration Instructions\", \"Text\": \"Baricitinib 2 mg NG qday for 14 days or until discharge (COVID-19) ($$) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib 1mg NG qday x 14 days + Administration Instructions\", \"Text\": \"Baricitinib 1 mg NG qday for 14 days or until discharge (COVID-19) ($$) [R]\", \"Mnemonic\": \"24\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib 4mg G Tube qday x 14 days or until discharge ($$) [R]\", \"Text\": \"Baricitinib 4 mg G Tube qday for 14 days or until discharge (COVID-19)\", \"Mnemonic\": \"14\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"($$$) [R]\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib EUA 2mg G Tube qday x 14 days or until hospital discharge ($$) [R]\", \"Text\": \"Baricitinib 2 mg G Tube qday for 14 days or until discharge (COVID-19)\", \"Mnemonic\": \"20\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Baricitinib 1mg G Tube qday x 14 days + Administration Instructions\", \"Text\": \"Baricitinib 1 mg G Tube qday for 14 days or until discharge (COVID-19)\", \"Mnemonic\": \"26\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"($$) [R]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"($$) [R]\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 90,
    "fields": {
      "name": "ORZID2 GMENU ABX BEBTELOVIMAB EUA",
      "term": null,
      "displaytext": "Bebtelovimab (EUA) Orders",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3013, \"DisplayText\": \"LINK EUA PROVIDER TO FILL OUT\", \"Text\": \"[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Provider Fact Sheet\", \"Text\": \"[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors\", \"Mnemonic\": \"10\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab 175 mg IV push once\", \"Text\": \"INV-Bebtelovimab 175 mg IV Push ONCE\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Bebtelovimab (EUA)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"for treating patients that meet specific criteria. bebtelovimab is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"not FDA approved drug.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"-Bebtelovimab EUA does NOT include post-exposure prophylaxis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Bebtelovimab Emergency Use Authorization (EUA)\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Inclusion Criteria\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"ALL of the following criteria must be met for a patient to receive:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"1) Patient has tested positive for COVID-19 and is diagnosed with mild to\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Note: patient may be hospitalized for some other reason.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"3) Patient does NOT require oxygen therapy for COVID-19.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For patients on chronic oxygen therapy: patient does NOT require an\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"increase in baseline oxygen flow rate due to COVID-19.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"4) Administration will begin within 7 days of symptom onset.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to bebtelovimab or components.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"6) Patient has at least one risk factor for progression to severe disease\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"including hospitalization or death.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"See link below for complete list:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"7) Counseling is provided and documented in the electronic health record per EUA\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"The provider has communicated with the patient/caregiver regarding\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"information contained in the \\\"Fact Sheet for Patients\\\". The patient/\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"caregiver has been given the Fact sheet, informed that the drug is an\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"unapproved drug that is authorized for use under an EUA, given information\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"on alternatives and their risks and benefits, and the patient/caregiver\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"has the right to refuse or accept. (See top of page for Fact Sheet)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Exclusion Criteria\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"If patient received tixagevimab plus cilgavimab previously, discuss with ID.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"If above requirements are met, place medication order:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Monitor patient during infusion and 1 hour after infusion completed.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"sharing personal items, clean and disinfect \\\"high touch\\\" surfaces, and\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"frequent handwashing) according to CDC guidelines.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"moderate illness.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 91,
    "fields": {
      "name": "ORZID2 GMENU ABX BELL'S PALSY",
      "term": null,
      "displaytext": "Bell's Palsy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Lyme Disease\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PREDNISONE 60MG Q24H 7D VALACYCLOVIR 1000MG PO Q8H\", \"Text\": \"Prednisone 60 mg q24h PO for 7 days <AND> valacyclovir 1000 mg PO q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PREDNISONE 60MG Q24H 7D ACYCLOVIR 400MG PO 5X/DAY\", \"Text\": \"Prednisone 60 mg q24h PO for 7 days <AND> acyclovir 400 mg PO 5X/day ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BELL'S PALSY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Herpes simplex and varicella-zoster are possible causes of Bell's palsy. Others\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"include Borrelia burgdorferi or trauma. Some cases are idiopathic. Risk factors\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Bell's Palsy include pregnancy, diabetes, obesity, hypertension, and upper\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"respiratory infections. Neurology consult is encouraged.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If Lyme disease is suspected, refer to the Lyme disease treatment page:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment with prednisone and an antiviral within 72 hours of symptoms onset\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"improves the chances of a complete recovery.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"for 10 days\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Baugh et al., Otolaryngology-Head and Neck Surgery, 2013, 149(3S)S1-S27\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Eviston et al., J Neurol Neurosurg Psychiatry, 2015, 56.1356-1361\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Jalali et al., Laryngoscope, 2021, 131.1615-1625\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Antivirals against Herpes Viruses\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes Simplex, Bell's Palsy\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Schwartz et al., Otolaryngology-Head and Neck Surgery, 2014, 150(5)709-711\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-To-Date article: Bell's palsy: Treatment and prognosis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 92,
    "fields": {
      "name": "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT",
      "term": null,
      "displaytext": "Beta-lactam Allergy Assessment ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Item\": 3014, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of Beta-lactam Reaction [CLICK HERE]\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 184, \"DisplayText\": \"Important Beta-lactam Allergy Facts and Reaction History\", \"Text\": \"Important Beta-Lactam Allergy Facts and Obtaining a Detailed Reaction History\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ASSESSMENT OF BETA-LACTAM REACTION AND ALTERNATIVE TREATMENT\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"This guide is intended to aid clinicians in assessment of beta-lactam\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"reactions and selection of appropriate alternative therapy. It is not a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"substitute for clinical judgment and should not be used as a sole resource when\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"selecting antimicrobial therapy.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Reaction Assessment and Selection of an Alternative Beta-lactam\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"- If the same or a different beta-lactam was subsequently tolerated without\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"reaction, that beta-lactam may be used.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"- If reaction was intolerance (e.g. headache, GI symptoms), family history of\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"reaction, or if the patient denies allergy, any beta-lactam may be used.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"- See below for treatment based on type of reaction (severe vs non-severe).\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"- If reaction is unknown and patient denies any severe reactions (see below for\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"list of severe reactions), reaction is considered non-severe.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"- If patient is in a suitable care setting, observation during the first 15\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"minutes to 1 hour after first dose of therapy may be performed to monitor for\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"signs/symptoms of an allergic reaction.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"SEVERE REACTION TO BETA-LACTAM:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"If the patient experienced a known severe reaction (use link below for severe\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"reaction list), AVOID ALL Beta-Lactam Antibiotics. If beta-lactam therapy is\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"ideal, contact Infectious Diseases for desensitization or alternative.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Severe Reaction Examples:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"- Anaphylaxis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"- Reaction needed medical intervention\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"- Mucosal, cardiovascular or respiratory system involvement\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"- Hemolytic anemia\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"- Immune hepatitis\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"- Interstitial nephritis\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"- Acute interstitial nephritis (AIN)\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"- Skin desquamation\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"- Drug reaction with eosinophilia and systemic symptoms (DRESS)\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"- Stevens-Johnson syndrome (SJS)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"- Generalized exanthematous pustulosis\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"- Toxic epidermal necrolysis (TEN)\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"NON-SEVERE REACTION TO BETA-LACTAM:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Select an alternative non-cross-reactive beta-lactam for therapy based on\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"beta-lactam class patient had a reaction to. Refer to PDF document above for\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"detailed cross-reactivity chart.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"PENICILLIN CLASS REACTION\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"(e.g. Amoxicillin, ampicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin,\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"penicillin, piperacillin, ticarcillin)\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Use: Cefazolin, cefdinir, cefuroxime, ceftazidime, ceftriaxone, cefepime,\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"ertapenem, imipenem, or meropenem\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"1ST GENERATION CEPHALOSPORIN CLASS REACTION\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"(e.g. Cefadroxil, cefatrizine, cefazolin, ceftezole, cephalexin, cephalothin,\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"cephapirin)\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Use: Dicloxacillin, nafcillin, cefazolin (unless reaction was to cefazolin)\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"cefdinir, ceftazidime, ceftriaxone, cefuroxime, cefepime, ertapenem, imipenem,\", \"Header\": 1}, {\"Row\": 65, \"Column\": 1, \"Text\": \"or meropenem\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"2ND GENERATION CEPHALOSPORIN CLASS REACTION\", \"Header\": 1}, {\"Row\": 68, \"Column\": 1, \"Text\": \"(e.g. Cefaclor, cefamandole, cefonicid, cefotetan, cefoxitin, cefprozil,\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"cefuroxime)\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, piperacillin,\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"cefadroxil cefazolin, cefdinir, ceftazidime, ceftriaxone, cephalexin, cefepime,\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"ertapenem imipenem, or meropenem\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"3RD-5TH GENERATION CEPHALOSPORIN CLASS REACTION\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Text\": \"(e.g. Cefdinir, cefditoren, cefepime, cefiderocol,cefixime, cefpirome,\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"cefoperazone, cefotaxime, cefpodoxime, ceftaroline, ceftazidime, ceftibuten,\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"ceftizoxime, ceftolozane, ceftriaxone)\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, penicillin,\", \"Header\": 1}, {\"Row\": 79, \"Column\": 1, \"Text\": \"piperacillin, cefadroxil, cefazolin, cephalexin, ertapenem, imipenem, or\", \"Header\": 1}, {\"Row\": 80, \"Column\": 1, \"Text\": \"meropenem\", \"Header\": 1}, {\"Row\": 82, \"Column\": 1, \"Text\": \"CARBAPENEM CLASS REACTION\", \"Header\": 1}, {\"Row\": 83, \"Column\": 1, \"Text\": \"(e.g. Ertapenem, imipenem and meropenem)\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, penicillin,\", \"Header\": 1}, {\"Row\": 85, \"Column\": 1, \"Text\": \"piperacillin, cefadroxil, cefazolin, cephalexin, cefdinir, ceftazidime,\", \"Header\": 1}, {\"Row\": 86, \"Column\": 1, \"Text\": \"ceftriaxone, or cefepime\", \"Header\": 1}, {\"Row\": 87, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 89, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 90, \"Column\": 1, \"Text\": \"Blumenthal et. al., Addressing Inpatient Beta-Lactam Allergies: A Multihospital\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Implementation. J Allergy Clin Immunol Pract. 2017, 5(3)616-625\"}, {\"Row\": 92, \"Column\": 1, \"Text\": \"Is it Really a Penicillin Allergy? Centers for Disease Control and Prevention,\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"2017\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Chaudhry et al., Cephalosporins: A Focus on Side Chains and Beta-Lactam Cross-\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"Reactivity. Pharmacy, 2019, 7(3)103\"}, {\"Row\": 96, \"Column\": 1, \"Text\": \"Collins, et al. Impact of an Antibiotic Side-Chain-Based Cross-reactivity Chart\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Combined With Enhanced Allergy Assessment Processes for Surgical Prophylaxis\"}, {\"Row\": 98, \"Column\": 1, \"Text\": \"Antimicrobials in Patients With Beta-Lactam Allergies. Clinical Infectious\"}, {\"Row\": 99, \"Column\": 1, \"Text\": \"Diseases, 2020\"}, {\"Row\": 100, \"Column\": 1, \"Text\": \"Patrick et al., Beta-lactam allergy Benefits of de-labeling can be achieved\"}, {\"Row\": 101, \"Column\": 1, \"Text\": \"safely. BC Medical Journal, 2019, 61(9)350\"}, {\"Row\": 102, \"Column\": 1, \"Text\": \"Sakoulas et al., Is a Reported Penicillin Allergy Sufficient Grounds to Forgo\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"the Multidimensional Antimicrobial Benefits of Beta-Lactam Antibiotics?\"}, {\"Row\": 104, \"Column\": 1, \"Text\": \"Clinical Infectious Diseases, 2019, 68(1)157\"}, {\"Row\": 105, \"Column\": 1, \"Text\": \"Shenoy et al., Evaluation and Management of Penicillin Allergy. JAMA. 2019,\"}, {\"Row\": 106, \"Column\": 1, \"Text\": \"321(2)188\"}, {\"Row\": 108, \"Column\": 1, \"Text\": \"Immunol. 2010, 105(4)259\"}, {\"Row\": 109, \"Column\": 1, \"Text\": \"Sanford keyword: Drug Allergy, Beta-lactams\"}, {\"Row\": 110, \"Column\": 1, \"Text\": \"Tribiano et al. The Three C's of Antibiotic Allergy - Classification, Cross-\"}, {\"Row\": 111, \"Column\": 1, \"Text\": \"Reactivity and Collaboration. J Allergy Clin Immunol Pract, 2017, 5(6)1532-\"}, {\"Row\": 112, \"Column\": 1, \"Text\": \"1542\"}, {\"Row\": 113, \"Column\": 1, \"Text\": \"Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of\"}, {\"Row\": 114, \"Column\": 1, \"Text\": \"cephalosporins and related antibiotics\"}, {\"Row\": 115, \"Column\": 1, \"Text\": \"Up-to-Date article: Drug allergy: Classification and clinical features\"}, {\"Row\": 116, \"Column\": 1, \"Text\": \"Zagursky et al., Cross-reactivity in b-Lactam Allergy. J Allergy Clin Immunol\"}, {\"Row\": 117, \"Column\": 1, \"Text\": \"Pract. 2018, 6(1)72\"}, {\"Row\": 107, \"Column\": 1, \"Text\": \"Solensky et al., Drug Allergy: An Updated Practice Parameter. Ann Allergy Asthma\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Streamlined Version (PDF form)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 93,
    "fields": {
      "name": "ORZID2 GMENU ABX BLANK PAGE",
      "term": null,
      "displaytext": "BLANK PAGE",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"RECOMMENDATIONS NOT AVAILABLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Recommendations for this condition are not available within CDSS. Please refer\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to facility guidelines or other clinical resources for recommendations.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 94,
    "fields": {
      "name": "ORZID2 GMENU ABX BRONCHITIS",
      "term": null,
      "displaytext": "Consider Antibiotic",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 235, \"DisplayText\": \"Pertussis\", \"Text\": \"Pertussis\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 95, \"DisplayText\": \"Bronchitis not benefited\", \"Text\": \"Bronchitis-antibiotics not a benefit in otherwise healthy patient\", \"Mnemonic\": \"6\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500mg PO once on day one then 250mg PO qday for 4 days ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R] < OR >\", \"Mnemonic\": \"14\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg IV once then 250 mg IV q24h x 4days\", \"Text\": \"Azithromycin 500 mg IV once on day 1, then 250 mg IV q24 for 4 days ($) [M< OR >\", \"Mnemonic\": \"16\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 3015, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"20\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BRONCHITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Acute bronchitis should not be treated with antimicrobials except in specific\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"circumstances. If pneumonia is suspected, order a chest x-ray.  If an\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infiltrate is not present, the patient does not have bacterial pneumonia and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"need not be treated for it.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Acute bronchitis in an otherwise HEALTHY PATIENT\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antimicrobials provide no benefit.  If bronchitis persists beyond 2 weeks,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"additional diagnostic workup is needed to find a cause.  If a patient has\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"persistent cough with inspiratory whoop, consider a diagnosis of pertussis.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Acute bronchitis in patients with COPD\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Symptoms of COPD exacerbation include dyspnea with increased sputum purulence\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"and volume, together with increased cough and wheeze. Co-morbidities are\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"common in COPD patients, thus exacerbations must be differentiated clinically\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"from other events such as acute coronary syndrome, worsening heart failure,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"pulmonary embolism and pneumonia.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Cornerstones of therapy include oxygen, bronchodilators, and in some cases\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"corticosteroids. Recommend antibiotics for moderately or severely ill patients\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"with COPD exacerbation who have increased sputum purulence and volume.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment for MILD DISEASE:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"No antibiotics recommended\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Treatment for MODERATE DISEASE\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Treat for 5 to 7 days.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treatment for SEVERE DISEASE\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"NOTE: Fluoroquinolones are not listed as a choice because the risk of serious\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"side effects outweigh the benefits.\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Access: http://www.goldcopd.org\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Wenzel WP et al NEJM 2006, 355: 2125\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Bronchitis\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Bronchitis\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Murphy TF Chest 2000, 118: 204\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Masterton RG Int J Antimicrob Agents 2001, 18: 503\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 95,
    "fields": {
      "name": "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT",
      "term": null,
      "displaytext": "Bronchitis not benefited ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BRONCHITIS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Acute bronchitis is a clinical syndrome with a brief, self-limited\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"pneumonia on chest radiograph. It is accompanied by dry or productive cough\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"lasting up to 3 weeks, is most prevalent in winter, and is primarily caused\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"by viruses.More than 1 in 20 people have acute bronchitis per year, with\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"highest rates during the winter months.  This discussion does not pertain to\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"acute exacerbations of chronic bronchitis, a clinical syndrome also\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"frequently associated with viral infection, but in which bacteria play a more\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"important role.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Narcotic cough suppressants, expectorants, antihistamines,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"decongestants, and beta 2-agonists have been used to treat patients with\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"acute bronchitis, but controlled trials have not clearly concluded that they\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"are beneficial.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Empirical antibacterial therapy has repeatedly been shown to provide no\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"benefit for most patients.  Acute bronchitis remains one of the five most\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"frequently cited rationales for excessive antibiotic use in outpatients.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Acute bronchitis and other acute respiratory syndromes (otitis media,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"sinusitis, pharyngitis, upper respiratory infections) account for\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"approximately 75% of ambulatory prescriptions in the United States.  Current\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"guidelines, endorsed by a number of national societies, including the\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Infectious Diseases Society of America, do not recommend the routine use of\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"antibiotics for uncomplicated acute bronchitis in otherwise normal persons.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"If pertussis is suspected, early therapy with macrolides or\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"tetracyclines is indicated to prevent transmission, although the clinical\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"findings early in pertussis infection are indistinguishable from viral causes\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"of bronchitis, and the incidence of disease is very low.  Treat for pertussis\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"only when a patient has likely been exposed to other cases.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Asthma attacks often have symptoms resembling bronchitis.  Asthma\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"attacks do not benefit from antimicrobial therapy.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 96,
    "fields": {
      "name": "ORZID2 GMENU ABX C DIFF TESTING 2 STEP",
      "term": null,
      "displaytext": "C Diff testing two-step  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"C diff 2-step testing helps differentiate between C diff infections vs.\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"colonization allowing providers to avoid unnecessary antibiotic use for\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Veterans. With improved C diff testing, Veterans benefit with reduced\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"incidence of health-care acquired C diff and appropriate antimicrobial use.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"New testing process will provide more accurate CDI test results. Our previous\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"method of testing for C diff infections was very sensitive, leading to an\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"over-diagnosis of C diff infections (CDI).\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"New 2-step C diff testing:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"1st step (PCR): high sensitivity for C diff\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"2nd step (reflex test): automatically completed if the PCR is positive-\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"detects toxin\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Ordering criteria for C diff lab panel:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"-Only acceptable specimen is unformed stool (i.e. stool that conforms to the\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"the shape of the container)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"-Symptomatic (patient has had 3 or more watery stools in 24 hours or\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"presents with ileus suspected to be due to C diff)\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"-No other explanation for diarrhea such as laxative use or recent initiation\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"of tube feedings\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"ii) Evaluate for other causes of diarrhea\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"i) No treatment or isolation needed for CDI\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"PCR Negative (Toxin testing will not be performed):\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"i) Initiate severity-based CDI therapy\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"ii) Stop acid suppressive medications and concomitant antimicrobials if\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"possible\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"iii) Place patient in enteric isolation\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Interpretation: CDI Not Present\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Interpretation: CDI Present\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"PCR Positive -and- Toxin Negative:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Interpretation: CDI MAY be Present\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"ii) Place patient in enteric isolation\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"iii) Treatment decision should be individualized, consider treatment for\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"severe, non-resolving, or otherwise unexplained diarrhea strongly\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"suggestive of CDI\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"-Testing should NOT be ordered for formed stool, asymptomatic patient, or\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"to perform \\\"test of cure\\\"\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"PCR Positive -and- Toxin Positive:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Place laboratory order for C diff panel:\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"[Click here] C diff treatment recommendations\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"[Click here] C diff treatment recommendations\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"C. difficile toxin (PRC)\", \"Text\": \"[Click here] C diff lab panel\", \"Mnemonic\": \"04\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"-Repeat orders within 7 days not accepted without Infectious Disease approval\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"***Interpretation of C diff lab panel:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"All positive C diff PCR tests are now tested for C diff toxin for confirmation.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"i) PCR positive, toxin negative may represent colonization or infection,\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"clinical judgement is needed\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Clostridioides difficile (C diff) 2-step lab testing\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 97,
    "fields": {
      "name": "ORZID2 GMENU ABX C DIFFICILE 2 STEP TESTING",
      "term": null,
      "displaytext": "Clostridioides difficile Infection (CDI) 2-step testing",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Text\": \"The Minneapolis VA Health Care System (MVAHCS) is using 2-step testing for\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"C. difficile infection (CDI), replacing our current testing method which is a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"single Polymerase Chain Reaction (PCR) test.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Benefits of 2-step testing are that it can be useful in differentiating patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with true infection vs. those that may simply be colonized.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"What will change:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"-All positive PCR tests for CDI (whether stand-alone CDI tests or the enteric\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pathogen panel testing for CDI and other pathogens) will reflex to a toxin test\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"(a test that detects C. difficile toxin responsible for disease).\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"-Patients with BOTH a positive PCR and toxin will be reported as\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"\\\"Toxigenic C. difficile detected. Repeat testing should not be performed.\\\"\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"-Patients with a positive PCR but a NEGATIVE toxin test will be reported as\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"\\\"C. difficile detected by PCR, toxin negative by EIA. Possible disease or\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"colonization. Interpretation requires clinical judgement.\\\"\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"What will not change:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"-C. difficile testing should be performed on patients with high suspicion of\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"of CDI, WITHOUT other potential causes of diarrhea (e.g., laxatives, tube\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"feedings, other medications)\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"-Negative PCR tests will be reported as negative\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"-Repeat testing within 7 days is strongly discouraged, unless there is a\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"significant change in stool pattern/disease severity\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"-Formed stool will not be tested\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Test Interpretation:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Negative PCR: \\\"Negative\\\"\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Positive PCR, Positive Toxin: \\\"Toxin producing C. difficile detected\\\"\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Positive PCR, negative toxin: \\\"C. difficile present, no toxin detected.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"This may represent colonization or disease. Interpretation requires clinical\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"judgement. Consider treatment for severe illness otherwise consistent with\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"CDI. Discussion with Infectious Disease may be helpful.\\\"\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Clostridioides difficile 2-step Testing\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 3016, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Minneapolis Clinical On-Call Schedule (Infectious Disease)\", \"Mnemonic\": \"02\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"-Patients with ongoing diarrhea (regardless of cause) should be placed in\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"contact plus precautions\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Infectious Disease Service is always available to discuss CDI testing/results.\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"**From 11pm to 7am, PCR test results will be reported WITHOUT the confirmatory\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"toxin test, which will be run the next morning. Postive PCR results will be\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"\\\"C. difficile detected by PCR, confirmatory toxin testing pending. Recommend\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"reported as:\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"deferring antibiotic treatment in clinically stable patients where the\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"diagnosis of C. difficile is not certain.\\\"\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Isolation for patients who are suspected of having CDI and who are receiving\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"treatment.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 98,
    "fields": {
      "name": "ORZID2 GMENU ABX C. AURIS CPO 4J/SCI SCREENING",
      "term": null,
      "displaytext": "C. auris and CPO 4J and SCI admission screening  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"C. AURIS CPO HIGH RISK ORDER SET\", \"Text\": \"[Click here] Place orders for laboratory and nursing for High Risk Category\", \"Mnemonic\": \"04\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"C. AURIS CPO MEDIUM RISK ORDER SET\", \"Text\": \"[Click here] Place orders for laboratory and nursing for Medium Risk Category\", \"Mnemonic\": \"06\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"C. auris and CPO Low Risk Nursing Text Order\", \"Text\": \"[Click here] Place nursing text order Low Risk Category (no labs required)\", \"Mnemonic\": \"08\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"All patients admitted or transferred to 4J or SCI will be assessed for risk\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"criteria below.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"** High Risk **\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"** Medium Risk **\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"** Low Risk **\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Does not meet High or Medium risk criteria above\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Candida auris and Carbapenamase-Producing Organisms (CPO) Screening\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients to assess for risk criteria:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Risk Categories: High, Medium or Low\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"1) Hospitalized overnight in an international hospital in the last 12 months\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"2) Exposure in domestic healthcare facility with a known outbreak Candida\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"auris or CPOs\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Does not meet High Risk criteria above\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< AND >\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Meets criteria for at least ONE of the following:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"1) Transferred from another healthcare facility,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"2) Resides in a State Veterans' Home,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"3) Overnight stay in a Military Healthcare facility,\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"4) Resides in a nursing home/long term care facility\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Reference:\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"MVAHCS CANDIDA AURIS AND CARBAPENAMASE-PRODUCING ORGANISMS SCREENING SOP\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Effective Date: December 7, 2022\"}, {\"Row\": 3, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Link to SOP\", \"Text\": \"[Click here] Link to above SOP document\", \"Mnemonic\": \"02\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 99,
    "fields": {
      "name": "ORZID2 GMENU ABX CAMPYLOBACTER",
      "term": null,
      "displaytext": "Diarrhea with Campylobacter ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h for 3 days ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 5 days ($)[R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CAMPYLOBACTER\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Fluoroquinolone resistance is increasing worldwide. Macrolide resistance is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"rare.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Campylobacter\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Campylobacter infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 100,
    "fields": {
      "name": "ORZID2 GMENU ABX CANDIDA UTI",
      "term": null,
      "displaytext": "Candida urinary tract infection",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 323, \"DisplayText\": \"Bacteremia associated with Candida spp.\", \"Text\": \"Fungemia Associated with Candida spp.\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 3 days before and 3 days\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg iv q24h\", \"Text\": \"Fluconazole 400 mg (6 mg/kg) IV q24h ($) [R,DI] for 3 days before and 3 days\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200 mg po q24h ($0.20) [R\", \"Text\": \"Fluconazole 200 mg (3 mg/kg) PO q24h ($) [R,DI] for 14 days\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200-400 mg IV q24h ($13/day) [R\", \"Text\": \"Fluconazole 200 mg (3 mg/kg) IV q24h ($) [R,DI] for 14 days\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 14 days\", \"Mnemonic\": \"14\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg iv q24h\", \"Text\": \"Fluconazole 400 mg (6 mg/kg) IV q24h ($) [R,DI] for 14 days\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA URINARY TRACT INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A positive urine culture for candida usually reflects colonization. Treat\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cystitis only if the patient has symptoms of urinary tract infection (e.g.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"dysuria, frequency, urgency, and/or suprapubic tenderness) or if the patient\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"will undergo invasive urological manipulation\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Asymptomatic candiduria in a patient with a urinary catheter should not be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"treated without an additional indication. Removal of catheter is strongly\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"recommended. Contact Infectious Diseases for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Neutropenic patients with asymptomatic candiduria should be assessed for\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"candidemia because they are at risk of dissemination. Obtain blood cultures and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"assess potential sources of candidemia such as central venous catheters. Refer\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"to fungemia page for treatment recommendations.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Patient undergoing invasive urological manipulation:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"after procedure\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"after procedure\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Symptomatic candida cystitis:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Pyelonephritis:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Resistant candida:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Pappas et al., Clinical Infectious Diseases, 2016, 62(4)e1-e50\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary Tract Infections\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-To-Date article: Candida Infections of the Bladder and Kidneys\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-To Date article: Candidemia in adults: Epidemiology, microbiology, and\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"pathogenesis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Urinary Tract Infections\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for treatment options\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 101,
    "fields": {
      "name": "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS",
      "term": null,
      "displaytext": "Candida Vulvo-Vaginitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150 mg PO once ($) [R,DI]\", \"Text\": \"Fluconazole 150 mg PO once ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole vaginal cream 1% 1 applicatorful qhs\", \"Text\": \"Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 7 to 14 days\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% cream vaginal QHS\", \"Text\": \"Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 7 days\", \"Mnemonic\": \"8\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150 mg PO q72h for 7 days (3 doses) ($) [R,DI]\", \"Text\": \"Fluconazole 150 mg PO q72h for 7 days (3 doses) ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole vaginal cream 1% 1 applicatorful qhs\", \"Text\": \"Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 10-14 days\", \"Mnemonic\": \"12\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% cream vaginal QHS\", \"Text\": \"Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 10-14 days\", \"Mnemonic\": \"14\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg po qweek\", \"Text\": \"Fluconazole 150 mg PO every 7 days ($) [R,DI] for 6 months\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA VULVOVAGINITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Candida vulvovaginitis typically presents with valvular irritation, burning or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pruritus. Vaginal pH should be measured, and the specimen should be examined\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"under the microscope for clue cells (epithelial cell coated with bacteria) to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"exclude bacterial vaginosis. In candida vulvovaginitis, the vaginal pH is\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"typically normal (4-4.5) and vaginal discharge is typically thick and curdy with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"white plaques on vaginal mucosa. Diagnosis is confirmed by identifying fungus or\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"yeast with KOH prep.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Most non-C. albicans species respond to fluconazole treatment except C. krusei\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"and C. glabrata. C. krusei can be treated with topical agents as for complicated\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"candida vulvovaginitis below. C. glabrata treatment is complicated and azole\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"therapy is frequently unsuccessful. Consult Infectious Diseases in patients with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"C. glabrata vulvovaginitis.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Recurrent candida vulvovaginitis is treated as complicated candida\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"vulvovaginitis for induction treatment, followed by maintenance regimen for 6\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"months.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment of uncomplicated candida vulvovaginitis\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment of complicated candida vulvovaginitis (e.g. immunocompromised, severe\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"disease, pregnancy) or recurrent infection induction treatment\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Recurrent candida vulvovaginitis maintenance regimen following induction\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"treatment above\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treatment of C. glabrate vulvovaginitis\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Failure of azole therapy is common, alternative topical treatments below require\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"compounding by a pharmacist. Please call pharmacy to order.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Topical flucytosine cream (17%) qhs for 14 days\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Topical boric acid capsule 600 mg intravaginal qhs for 14 days\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and cervicitis\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Vulvovaginitis\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-to-Date article: Candida vulvovaginitis: Treatment\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-to-Date article: Candida vulvovaginitis: Clinical manifestations and\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"diagnosis\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 102,
    "fields": {
      "name": "ORZID2 GMENU ABX CARDIOVASCULAR",
      "term": null,
      "displaytext": "Cardiovascular  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 80, \"DisplayText\": \"Approach to Endocarditis\", \"Text\": \"Approach to Endocarditis\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 142, \"DisplayText\": \"Diagnosis of Endocarditis\", \"Text\": \"Diagnosis of Endocarditis\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 364, \"DisplayText\": \"Native Valve Endocarditis - Empirical Therapy\", \"Text\": \"Empirical Therapy\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 365, \"DisplayText\": \"Native Valve Endocarditis--Selected Pathogens\", \"Text\": \"Selected Pathogens\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 368, \"DisplayText\": \"Prosthetic Valve Endocarditis--Empicaral Therapy\", \"Text\": \"Empirical Therapy\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 369, \"DisplayText\": \"Prosthetic Valve Endocarditis--Selected Pathogens\", \"Text\": \"Selected Pathogens\", \"Mnemonic\": \"14\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 481, \"DisplayText\": \"Cardiac disease associated with Lyme disease\", \"Text\": \"Cardiac Lyme Disease\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 187, \"DisplayText\": \"Infections involves cardiovascular devices (excluding valves)\", \"Text\": \"Cardiovascular Device Infections (Excluding Valves)\", \"Mnemonic\": \"18\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 474, \"DisplayText\": \"Intravascular catheter-associated infection\", \"Text\": \"Catheter-Related Bloodstream Infections\", \"Mnemonic\": \"20\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 211, \"DisplayText\": \"Myocarditis\", \"Text\": \"Myocarditis\", \"Mnemonic\": \"22\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 234, \"DisplayText\": \"Pericarditis\", \"Text\": \"Pericarditis\", \"Mnemonic\": \"24\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 278, \"DisplayText\": \"Suppurative Thrombophlebitis--Empirical Therapy\", \"Text\": \"Suppurative Thrombophlebitis\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  CARDIOVASCULAR  ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Endocarditis\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Native Valve Endocarditis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Prosthetic Valve Endocarditis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Other\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Section last reviewed  9/2020\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 103,
    "fields": {
      "name": "ORZID2 GMENU ABX CDSS VERSION",
      "term": null,
      "displaytext": "CDSS VERSION ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"VERSION 1.0\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"3-5-2020\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"NEW TEXT\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"AUTOMATION\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"AUTOMATION\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 104,
    "fields": {
      "name": "ORZID2 GMENU ABX CELLULITIS",
      "term": null,
      "displaytext": "Cellulitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 492, \"DisplayText\": \"The approach to cellulitis\", \"Text\": \"More about cellulitis...\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15mg/kg IV\", \"Mnemonic\": \"26\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15mg/kg iv q12h Cipro 400mg iv q8h Metro 500 mg iv q12h\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> Vancomycin 15 mg/kg IV\", \"Mnemonic\": \"26\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"28\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BACTERIAL CELLULITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cellulitis refers to inflammation of the skin and subcutaneous tissue and is\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"often associated with bacterial pathogens.  The most common pathogens are group\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"A streptococci and Staphylococcus aureus.  Group B streptococci are associated\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"with cellulitis in elderly people, in those with diabetes mellitus, and on feet\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and legs of patients with athlete's foot (tinea pedis).\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Mild cases can be treated with oral antimicrobials.  Moderate to severe cases\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"should be treated initially with intravenous antimicrobials.  Switch to oral\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"drugs after clinical improvement.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consider MRSA coverage for cellulitis associated with penetrating trauma, a\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"history of MRSA infection, injection drug use, or infections not responding\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"to first line beta-lactams.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"if not improved in this time.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mild: Cellulitis without systemic signs of infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empirical treatment for MILD cellulitis\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative for Penicillin Allergy or MRSA suspected\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"MRSA Suspected Mild Cellulitis\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Moderate: Cellulitis with systemic signs of infection\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Empirical treatment for MODERATE cellulitis\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or MRSA suspected\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Severe: Cellulitis in patients with signs of deeper infections\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"(e.g. bullae, skin sloughing, hypotension, or evidence of organ dysfunction).\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Patients may also qualify as severe if they are neutropenic, have a\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"hematologic malignancy or congenital immunodeficiency, or are receiving\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"immunosuppressant therapy.  Consider whether surgical drainage is necessary.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Empirical treatment for SEVERE infection\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"q12h ($) [R]\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or MRSA suspected:\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"q12h ($) [R] <AND> Metronidazole 500 mg IV q8h ($) [DI,H]\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Mnemonic\": \"24\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 105,
    "fields": {
      "name": "ORZID2 GMENU ABX CERVICITIS ASSOC STD",
      "term": null,
      "displaytext": "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Urine NAAT\", \"Text\": \"Chlamydia & GC PCR/LCR test\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 544, \"DisplayText\": \"Recurrent or persistent urethritis\", \"Text\": \"Treatment of recurrent or persistent cervicitis\", \"Mnemonic\": \"6\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 106, \"DisplayText\": \"Chlamydia Urethritis\", \"Text\": \"Treatment for chlamydial or non-gonococcal cervicitis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"The main diagnostic signs that characterize cervicitis are 1)women who present\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with purulent or mucopurulent exudate in the endocervical canal or on an\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"endocervical swab specimen and 2)sustained endocervical bleeding induced by\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"gentle passage of cotton swab through the cervical os. One or both signs may be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"present.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Neisseria gonorrhoeae and Chlamydia trachomatis are the two most common sexually\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"transmitted cervicitis pathogens. Nucleic acid amplification tests for these\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"pathogens are more sensitive than culture and should be used for patients at\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"risk for sexually transmitted cervicitis.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For patients who have recently been treated for cervicitis\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"When diagnosed with sexually transmitted cervicitis, the patient's sexual\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"partner(s) during the previous 60 days should be evaluated for sexually\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"transmitted infection. If diagnostic tests for the cause of cervicitis are not\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"feasible, therapy for both N. gonorrhoeae and C. trachomatis should be given to\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"partners.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Initial treatment of patients and sex partners\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Patients and partners are often infected with both N. gonorrhoeae and C.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"trachomatis. Treat for both pathogens unless one is ruled out by lab test.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute cervicitis\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 568, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 167, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Treatment for gonorrhea cervicitis\", \"Mnemonic\": \"10\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 106,
    "fields": {
      "name": "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS",
      "term": null,
      "displaytext": "Chlamydia Urethritis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 7 days ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Text\": \"Azithromycin 1 gm PO ONCE ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"CHLAMYDIAL OR NON-GONOCOCCAL URETHRITIS OR CERVICITIS OR RECTAL\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for chlamydial or non-gonococcal urethritis or cervicitis\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and Cervicitis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Sanford keyword: Urethritis, cervicitis: chlamydial\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute cervicitis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-To-Date article: Urethritis in men\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 107,
    "fields": {
      "name": "ORZID2 GMENU ABX CHOLANGITIS",
      "term": null,
      "displaytext": "Cholangitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h for 7 to 10 days ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h for 7 to 10 days [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($)\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHOLANGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are due to common bile duct obstruction. Obstruction (if present)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"must be relieved with an endoscopical, transcutaneous, or surgical procedure.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"The most common pathogens isolated are E. coli, Klebsiela, Enterococcus and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Enterobacter. Anaerobes such as Bacteriodes and Clostridia can be present as\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"part of a mixed infection.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"[DI] for 7 to 10 days\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Step down treatment for completion of antimicrobial course after initial\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"intravenous treatment in patients who can tolerate oral therapy. Base selection\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"on culture results.\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Cholangitis, Cholecystitis)\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Gallbladder Infections\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date article: Acute cholangitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 108,
    "fields": {
      "name": "ORZID2 GMENU ABX CHOLECYSTITIS",
      "term": null,
      "displaytext": "Cholecystitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"12\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"20\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"24\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"26\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"28\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"30\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHOLECYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Adequate biliary drainage is the definitive treatment. Antimicrobials should be\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"prescribed only if signs of infection like leukocytosis or fever are present or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"if the patient is elderly. Surgery and Gastroenterology involvement are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"essential.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Most cases are associated with E. coli, Enterococcus, Klebsiella, and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Enterobacter. Anaerobic coverage is not indicated unless a biliary-enteric\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"anastomosis is present. For community-acquired acute cholecystitis, enterococcal\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"coverage is not required because Enterococcus has not been shown to be\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"pathogenic in these patients.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If needed, antimicrobial therapy should be continued only until adequate\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"drainage is established, then stopped.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Community-acquired acute cholecystitis\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment of mild to moderate infection without biliary-enteric anastomosis\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment of mild to moderate infection and biliary-enteric anastomosis present\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment of severe infection, advanced age or immunocompromised patient\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Health care-associated infection\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"IV q12h ($) [R]\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Step down treatment for completion of antimicrobial course after initial\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"intravenous treatment in patients who can tolerate oral therapy. Base selection\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"on culture results.\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Cholangitis, Cholecystitis)\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Sanford keyword: Gallbladder Infections, Acute Cholecystitis\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of acute calculous cholecystitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 109,
    "fields": {
      "name": "ORZID2 GMENU ABX CHOLERA",
      "term": null,
      "displaytext": "Diarrhea with Cholera (Vibrio cholera)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 300mg po once (Var)\", \"Text\": \"Doxycycline 300 mg PO one-time dose ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 1000 mg PO one-time dose ($) [R,DI]\", \"Text\": \"Ciprofloxacin 1000 mg PO one-time dose ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CHOLERA (VIBRIO CHOLERAE)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary Treatment\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Aggressive hydration and electrolyte replacement are essential\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Tetracycline intolerant patient\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients who are hospitalized or unable to take oral medications\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Vibrio cholerae\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-to-Date article: Cholera: Clinical features, diagnosis, treatment, and\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"prevention\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"**Duration: 3 days**\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 110,
    "fields": {
      "name": "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN",
      "term": null,
      "displaytext": "Chronic protatitis/Chronic pelvic pain syndrome  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ibuprofen 600 mg PO Q8h\", \"Text\": \"Ibuprofen 400 mg PO q8h for 2 to 3 weeks\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"This syndrome presents with intermittent perineal and/or low back pain,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"obstructive voiding symptoms, relatively normal examination, and negative urine\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cultures. Antimicrobial therapy is not indicated.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consult urology for non-antimicrobial therapy recommendations (e.g.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"alpha-adrenergic antagonists, anti-inflammatory medications) to reduce symptoms.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Anti-inflammatory treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-To-Date article: Chronic prostatitis/chronic pelvic pain syndrome\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 111,
    "fields": {
      "name": "ORZID2 GMENU ABX CHRONIC BACT PROSTATITIS",
      "term": null,
      "displaytext": "Chronic bacterial prostatitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 110, \"DisplayText\": \"Chronic protatitis/Chronic pelvic pain syndrome\", \"Text\": \"Chronic prostate pain syndrome\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] for 4 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 4 weeks\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHRONIC BACTERIAL PROSTATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Chronic bacterial prostatitis usually presents as recurrent urinary tract\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infections with the same bacterial etiology. Pain, tenderness, and fever may\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"accompany intermittent episodes of cystitis, but men are usually asymptomatic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"between episodes and the prostate examination may be normal. Non-steroidal anti-\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"inflammatory drugs (NSAIDs) often relieve pain. If the diagnosis is uncertain or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"if the patient's symptoms do not respond to therapy, consult urology. The\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"presence of hematuria may be a sign of carcinoma, especially in older men, and a\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"urology consult should be requested.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"A urine culture should be performed in all patients to guide antimicrobial\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"therapy.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Chronic prostate pain syndrome should be considered in patients who have\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"symptoms of prostatitis but have negative urine cultures. Chronic prostate pain\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"syndrome is discussed elsewhere:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"4 weeks minimum and up to 6 weeks of treatment is required. Durations longer\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"than 6 weeks may be needed in treatment of resistant organisms. Treatment with\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"trimethoprim/sulfamethoxazole requires a treatment duration of 1 to 3 months.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Rees et al., BJU Int, 2015,116.509-525\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mandell chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Prostatitis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Up-To-Date article: Chronic bacterial prostatitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 112,
    "fields": {
      "name": "ORZID2 GMENU ABX CHRONIC MENINGITIS",
      "term": null,
      "displaytext": "Chronic Meningitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHRONIC MENINGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Subacute meningeal symptoms, including headache, fever, and nausea for 4 weeks\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"or more. Chronic meningitis is caused by a long list of infectious and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"non-infectious etiologies. Treatment is based on etiology and empirical\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"treatment is not urgent unless tuberculosis is suspected. Consult Infectious\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Diseases for more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Chronic meningitis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Chronic meningitis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Up-to-Date Article: Approach to the patient with chronic meningitis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 113,
    "fields": {
      "name": "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS",
      "term": null,
      "displaytext": "CMV Colitis or Esophagistis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valgancicilovir 900MG PO q12h\", \"Text\": \"Valganciclovir 900 mg PO q12h ($$$) [R,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ganciclovir 5 mg/kg IV Q12H\", \"Text\": \"Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Foscarnet 90 mg/kg IV Q12H\", \"Text\": \"Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV COLITIS OR ESOPHAGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection in immunocompetent patients is rare and usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"minimal or no symptoms. Patients in whom the risk for CMV disease is increased\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"include solid organ and bone marrow transplant recipients, persons receiving\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and requires Infectious Diseases consultation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for 3-6 weeks. Patients may be converted to oral therapy after initial\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"intravenous therapy and after clinical improvement of severe disease.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease or following clinical improvement of\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"severe disease\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 114,
    "fields": {
      "name": "ORZID2 GMENU ABX CMV ENCEPHALITIS",
      "term": null,
      "displaytext": "CMV Encephalitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ganciclovir 5 mg/kg IV Q12H Foscarnet 90 mg/kg IV Q12H\", \"Text\": \"Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> foscarnet 90 mg/kg IV q12h\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valgancicilovir 900MG PO q12h\", \"Text\": \"Valganciclovir 900 mg PO q12h ($$$) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV ENCEPHALITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection in immunocompetent patients is rare and usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"minimal or no symptoms. Patients in whom the risk for CMV disease is increased\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"include solid organ and bone marrow transplant recipients, persons receiving\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and requires Infectious Diseases consultation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration is likely to be prolonged and is individualized based on response.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Patients may be converted to oral therapy after initial intravenous therapy and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"after clinical improvement of severe disease.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"($$$$) [R,O]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Oral treatment following clinical improvement\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 115,
    "fields": {
      "name": "ORZID2 GMENU ABX CMV MAIN PAGE",
      "term": null,
      "displaytext": "Cytomegalovirus (CMV) Main Page",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 113, \"DisplayText\": \"CMV Colitis or Esophagistis\", \"Text\": \"Colitis or esophagitis\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 114, \"DisplayText\": \"CMV Encephalitis\", \"Text\": \"Encephalitis\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 117, \"DisplayText\": \"CMV Polyradiculopathy\", \"Text\": \"Polyradiculopathy\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 118, \"DisplayText\": \"CMV Retinitis\", \"Text\": \"Retinitis\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 116, \"DisplayText\": \"CMV Pneumonia\", \"Text\": \"Pneumonia\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CYTOMEGALOVIRUS (CMV)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antiviral toxicity information\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"The major toxicities of both ganciclovir and valganciclovir are neutropenia.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Nephrotoxicity is the major toxicity associated with foscarnet, which may be\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"reduced by concomitant saline administration (generally 0.5-1L).\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Immunocompetent patient\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Infection is rare and usually associated with minimal or no symptoms.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Mononucleosis can be associated with CMV, but is more commonly associated with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Epstein Barr virus. Antiviral treatment is not usually necessary as most\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"patients recover without intervention.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Immunocompromised patient\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Patients in whom the risk for CMV disease is increased include solid organ and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"bone marrow transplant recipients, persons receiving prolonged immunosuppressive\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"chemotherapy, and persons with advanced HIV disease indicated by a CD4 count of\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"less than 50 cells/microliter.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"CMV treatment recommendations\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 116,
    "fields": {
      "name": "ORZID2 GMENU ABX CMV PNEUMONIA",
      "term": null,
      "displaytext": "CMV Pneumonia",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ganciclovir 5 mg/kg and IV IG 0.5 gm/kg IV qother day\", \"Text\": \"Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> intravenous immune globulin\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900 mg po q24h\", \"Text\": \"Valganciclovir 900 mg PO Q24h ($$$) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV PNEUMONIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"CMV pneumonia occurs almost exclusively in bone marrow transplant recipients,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually within the first 120 days after transplantation. In these patients, CMV\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pneumonia is severe and requires aggressive treatment. Treatment is complex and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"requires Infectious Diseases consultation.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Induction therapy is indicated for 3 to 6 weeks, followed by maintenance\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"therapy. Duration of maintenance therapy is not well established.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"0.5 grams/kg IV every other day\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Maintenance therapy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 117,
    "fields": {
      "name": "ORZID2 GMENU ABX CMV POLYRADICULOPATHY",
      "term": null,
      "displaytext": "CMV Polyradiculopathy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valgancicilovir 900MG PO q12h\", \"Text\": \"Valganciclovir 900 mg PO q12h ($$$) [R,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ganciclovir 5 mg/kg IV Q12H\", \"Text\": \"Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Foscarnet 90 mg/kg IV Q12H\", \"Text\": \"Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV POLYRADICULOPATHY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection in immunocompetent patients is rare and usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"minimal or no symptoms. Patients in whom the risk for CMV disease is increased\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"include solid organ and bone marrow transplant recipients, persons receiving\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and requires Infectious Diseases consultation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration is likely to be prolonged and is individualized based on response.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Patients may be converted to oral therapy after initial intravenous therapy and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"after clinical improvement of severe disease.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease or following clinical improvement of\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"severe disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 118,
    "fields": {
      "name": "ORZID2 GMENU ABX CMV RETINITIS",
      "term": null,
      "displaytext": "CMV Retinitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ganciclovir 5 mg/kg IV Q12H\", \"Text\": \"Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Foscarnet 90 mg/kg IV Q12H\", \"Text\": \"Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ganciclovir 4mg intravitreous injection\", \"Text\": \"Ganciclovir 4mg/0.1mL intravitreal injection STAT ($$$$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Foscarnet 2.4 mg intravitreous injection\", \"Text\": \"Foscarnet 2.4mg/0.1 mL intravitreal injection STAT ($$$$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ganciclovir 5 mg/kg IV Q12H Foscarnet 90 mg/kg IV Q12H\", \"Text\": \"Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> foscarnet 90 mg/kg IV q12h\", \"Mnemonic\": \"12\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valgancicilovir 900MG PO q12h\", \"Text\": \"Valganciclovir 900 mg PO q12h($$$) [R,O]\", \"Mnemonic\": \"14\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900 mg po q24h\", \"Text\": \"Valganciclovir 900 mg PO q24h ($$$) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV RETINITIS AND ACUTE RETINAL NECROSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection in immunocompetent patients is rare and usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"minimal or no symptoms. Patients in whom the risk for CMV disease is increased\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"include solid organ and bone marrow transplant recipients, persons receiving\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and requires Infectious Diseases consultation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For sight threatening lesions (lesions within 1500 microns of the fovea)\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"intravitreal infections of ganciclovir or foscarnet are recommended in addition\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"to systemic treatment. Contact Infectious Diseases for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treat retinitis for 14 to 21 days. Patients may be converted to oral therapy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"after initial intravenous therapy and after clinical improvement of severe\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"disease. Treat acute retinal necrosis with IV therapy for at least 7 days and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"until disease stabilizes then oral therapy for a minimum of 6 weeks. Maintenance\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"therapy after completion of treatment is indicated when CD4 count <100.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Discontinue maintenance therapy when CD4 count is >100 for 6 months.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment acute retinal necrosis or severe disease\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Intravitreal antiviral in addition to systemic antiviral may provide added\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"therapeutic efficacy.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Optional add-on therapy for acute retinal necrosis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"For cases not responsive to Intravenous therapy with foscarnet and ganciclovir\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"used alone\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"($$$$) [R,O]\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"In cases not responsive to first-line therapy, second-line therapies may be\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"effective. Their use is highly specialized and must be done by someone\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"experienced with HIV/AIDS medicine.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Treatment of mild to moderate retinitis or after clinical improvement of severe\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"retinitis/acute retinal necrosis\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Maintenance therapy\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 119,
    "fields": {
      "name": "ORZID2 GMENU ABX CNS",
      "term": null,
      "displaytext": "Central Nervous System",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 81, \"DisplayText\": \"Approach to Acute Meningitis\", \"Text\": \"Approach to acute meningitis\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 322, \"DisplayText\": \"Bacterial meningitis without Gram stain results\", \"Text\": \"Community acquired\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 314, \"DisplayText\": \"Bacterial meningitis associated with trauma or nosocomial infection\", \"Text\": \"Associated with trauma or nosocomial infection\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 318, \"DisplayText\": \"Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia\", \"Text\": \"Gram-positive diplococci suggesting Streptococcus pneumoniae\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 317, \"DisplayText\": \"Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis\", \"Text\": \"Gram-negative diplococci suggesting Neisseria meningitidis\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 313, \"DisplayText\": \"Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes\", \"Text\": \"Gram-positive bacilli/coccobacilli suggesting Listeria monocytogenes\", \"Mnemonic\": \"14\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 316, \"DisplayText\": \"Bacterial meningitis with Gram negative bacilli\", \"Text\": \"Gram negative bacilli\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 321, \"DisplayText\": \"Bacterial meningitis with S. pneumoniae\", \"Text\": \"S. pneumoniae\", \"Mnemonic\": \"18\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 320, \"DisplayText\": \"Bacterial meningitis with N. meningitidis\", \"Text\": \"N. meningitidis\", \"Mnemonic\": \"20\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 319, \"DisplayText\": \"Bacterial meningitis with L. monocytogenes\", \"Text\": \"L. monocytogenes\", \"Mnemonic\": \"22\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"E. Coli, Pseudomonas, or another organism\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ CENTRAL NERVOUS SYSTEM ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute Meningitis\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Empiric Treatment Prior to Gram Stain Results\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empiric Treatment Based on Gram Stain Results\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment Based on Isolated Pathogen\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Last reviewed 11/2021\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 311, \"DisplayText\": \"Approach to Brain Abscess\", \"Text\": \"Approach to brain abscess\", \"Mnemonic\": \"26\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 335, \"DisplayText\": \"Brain abscess resulting from contiguous or hematogenous spread of infection\", \"Text\": \"Contiguous or hematogenous spread of infection\", \"Mnemonic\": \"28\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 337, \"DisplayText\": \"Post-surgical or post-traumatic brain abscess\", \"Text\": \"Post-surgical or post-traumatic\", \"Mnemonic\": \"30\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 336, \"DisplayText\": \"Brain Abscess with Nocardia spp.\", \"Text\": \"Nocardia spp.\", \"Mnemonic\": \"32\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 338, \"DisplayText\": \"Brain Abscess with Pseudomonas spp.\", \"Text\": \"Pseudomonas spp.\", \"Mnemonic\": \"34\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 339, \"DisplayText\": \"Brain Abscess with Toxoplasma gondii\", \"Text\": \"Toxoplasma gondii\", \"Mnemonic\": \"36\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 91, \"DisplayText\": \"Bell's Palsy\", \"Text\": \"Bell's Palsy\", \"Mnemonic\": \"38\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 112, \"DisplayText\": \"Chronic Meningitis\", \"Text\": \"Chronic Meningitis\", \"Mnemonic\": \"40\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 350, \"DisplayText\": \"Cranial epidural abscess\", \"Text\": \"Cranial epidural abscess\", \"Mnemonic\": \"42\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 595, \"DisplayText\": \"Neurosurgery\", \"Text\": \"Neurosurgery prophylaxis\", \"Mnemonic\": \"44\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 180, \"DisplayText\": \"HSV Encephalitis\", \"Text\": \"Herpes simplex encephalitis\", \"Mnemonic\": \"46\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"48\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 569, \"DisplayText\": \"Spinal epidural abscess\", \"Text\": \"Spinal epidural abscess\", \"Mnemonic\": \"50\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 574, \"DisplayText\": \"Subdural Empyema\", \"Text\": \"Subdural empyema\", \"Mnemonic\": \"52\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 575, \"DisplayText\": \"Suppurative intracranial thrombophlebitis\", \"Text\": \"Suppurative intracranial thrombophilia\", \"Mnemonic\": \"54\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Brain abscess\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"Empiric Treatment\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Treatment based on Isolated Pathogen\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Other\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 120,
    "fields": {
      "name": "ORZID2 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR",
      "term": null,
      "displaytext": "Colonized respiratory tract in patient with a ventilator  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 21, \"Column\": 1, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Nosocomial Pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COLONIZED RESPIRATORY TRACT IN A PATIENT ON A VENTILATOR\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The respiratory tracts of persons who are intubated, have a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"tracheostomy, or have other abnormalities of the larynx or trachea are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"usually colonized with bacteria and often fungi. The bacteria can be of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"relatively low virulence (e.g. coagulase negative staphylococci, streptococci,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"candida) or of potentially greater virulence (Staphylococcus aureus,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"enterobacteriaceae, pseudomonas). Candida and enterococci are common\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"respiratory tract colonizers and they almost never cause pneumonia. There is\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"no benefit from treatment of patients with systemic antimicrobials simply\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"because the respiratory tract is colonized with a potential pathogen and there\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"is no evidence of an infiltrate. Systemic antimicrobial therapy will select for\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"resistant organisms and may lead to other adverse effects.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"See below for ventilator-associated pneumonia treatment recommendations in\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"patients with a new or progressive infiltrate and at least one of the following:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"fever greater than 100.4F, leukocytosis, leukopenia or purulent bronchial\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"secretions.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Kalil et al. Clin Infect Dis, 2016, 63(5): e61-e111.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 121,
    "fields": {
      "name": "ORZID2 GMENU ABX COLONIZED WOUNDS",
      "term": null,
      "displaytext": "Colonized wounds",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 16, \"Column\": 1, \"Item\": 353, \"DisplayText\": \"Decubitus ulcers\", \"Text\": \"Decubitus ulcers\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 384, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus\", \"Text\": \"Diabetic foot ulcers\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COLONIZED WOUNDS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Open wounds are usually colonized with bacteria and often fungi. This is true of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"ulcers (see below), post-operative wounds, traumatic wounds, and others. Then\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"bacteria can be of relatively low virulence (eg, coagulase negative\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"staphylococci, diphtheroids) or of potentially greater virulence (Staphylococcus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"aureus, enterobacteriaceae, pseudomonas). Candida is commonly present on wounds\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"that are moist or covered. There is no need to treat patients with systemic\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials simply because a wound culture is positive for a potential\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"pathogen. Topical antimicrobials are not effective in nearly all circumstances\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"and can select for resistant organisms or lead to other adverse effects.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Systemic antimicrobial therapy may be indicated if there are signs of infection.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Lipsky et al, Clin Infect Dis, 2012, 54(12): e132-e173\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-to-Date article: Clinical assessment of chronic wounds\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 122,
    "fields": {
      "name": "ORZID2 GMENU ABX COM-ACQ PNEUMONIA",
      "term": null,
      "displaytext": "Community-acquired pneumonia (CAP)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 3017, \"DisplayText\": \"CAP Pneumonia Severity Index (PSI) Calculator\", \"Text\": \"CAP Pneumonia Severity Index (PSI) Calculator\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 341, \"DisplayText\": \"CAP NON-SEVERE treated in an Inpatient Ward setting\", \"Text\": \"CAP NON-SEVERE treated in an Inpatient Ward setting\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 340, \"DisplayText\": \"CAP SEVERE treated in an ICU setting\", \"Text\": \"CAP SEVERE treated in an ICU setting\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 342, \"DisplayText\": \"Stepdown empiric treatment for CAP with oral antibiotics\", \"Text\": \"Stepdown empiric treatment for CAP with oral antibiotics\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY-ACQUIRED PNEUMONIA (CAP)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Empirical regimens listed here cover the usual pathogens associated with CAP,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"including atypical pathogens.  Specific therapy should be guided by culture\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"results.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Diagnosis\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"CAP Pneumonia Severity Index (PSI) or PORT Score\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"The CAP pneumonia severity index is useful for estimation of mortality risk for\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"a patient with pneumonia.  Pre-estimated risk can then be used to determine how\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"aggressively to treat the patient's pneumonia and whether the patient can be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treated safely outside of the hospital.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"The Community-Acquired Pneumonia Severity Index (PSI) is a guide and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"should be used to augment clinical judgment. If social circumstances\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"or cognitive dysfunction would interfere with success of outpatient\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"treatment, the patient should be hospitalized.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If a patient has taken an antimicrobial in the previous 3 months, it is prudent\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"to avoid giving the same or a similar drug for the current episode of pneumonia.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Empiric treatment for CAP treated in an Inpatient setting:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Stepdown empiric treatment for CAP (Intravenous to Oral conversion)\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Note: These regimens may also be used to convert patients to oral medications\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"prior to discharge.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Fine MJ, et al. N Engl J Med (1997) 336:243-250\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 123,
    "fields": {
      "name": "ORZID2 GMENU ABX COMP CYSTITIS",
      "term": null,
      "displaytext": "Complicated Cystitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 247, \"DisplayText\": \"Pyelonephritis\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 72, \"DisplayText\": \"Acute Bacterial Prostatitis\", \"Text\": \"Acute prostatitis\", \"Mnemonic\": \"8\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"10\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30mL/min, for 7 days\", \"Mnemonic\": \"12\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"14\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOD 3 DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"16\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"18\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"20\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"22\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 7 days\", \"Mnemonic\": \"24\"}, {\"Row\": 74, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"30\"}, {\"Row\": 77, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R] for 7 days\", \"Mnemonic\": \"32\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"26\"}, {\"Row\": 71, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,O]\", \"Mnemonic\": \"28\"}, {\"Row\": 84, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"34\"}, {\"Row\": 86, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 7 days\", \"Mnemonic\": \"36\"}, {\"Row\": 89, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"38\"}, {\"Row\": 90, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"40\"}, {\"Row\": 100, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"42\"}, {\"Row\": 102, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"44\"}, {\"Row\": 105, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R] for 7 days\", \"Mnemonic\": \"46\"}, {\"Row\": 109, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R] for 7 days\", \"Mnemonic\": \"48\"}, {\"Row\": 111, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 1-2 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin 1 gm IV q6h ($$) [R] for 7 days\", \"Mnemonic\": \"50\"}, {\"Row\": 114, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"52\"}, {\"Row\": 115, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOD 3 DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"54\"}, {\"Row\": 117, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days\", \"Mnemonic\": \"56\"}, {\"Row\": 120, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 7 days\", \"Mnemonic\": \"58\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMPLICATED CYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Complicated cystitis is defined as symptomatic bladder inflammation and symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"due to a bacterial infection in people with certain conditions (see below).\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Symptoms usually include dysuria, lower abdominal pain, and urgency. Complicated\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cystitis is commonly associated with Enterobacteriaceae, but more resistant\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"pathogens occur, including the Gram-positive pathogens staphylococci and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"enterococci.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Signs and symptoms that may indicate infection has extended beyond the bladder\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"include fever/other signs of systemic infection, flank pain, costovertebral\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"tenderness, and pelvic or perianal pain in men. Pyelonephritis should be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"considered in these patients:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Urine culture should be obtained before antimicrobials are given to guide\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"treatment of complicated cystitis.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Prostatitis should be considered in men with recurrence of urinary tract\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"infection:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"When patients who require paraenteral therapy are afebrile, clinically stable,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"and can take oral medication, convert to oral therapy based on the\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"identification and susceptibility of the isolate.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Complicating conditions\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Cystitis is considered complicated when one or more of the following is present:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"o Pregnant women\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"o Immunocompromise\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"o Persistent infection, relapse, recurrence, or treatment failure\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"o In some cases, men and patients admitted to health care settings may be\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"considered complicated\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Treat for 7 days. If patient is febrile, may extend duration up to 14 days total\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Mild to moderate disease\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Primary alternatives:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Secondary alternative:\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Severe disease or if patient cannot take oral therapy\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"High risk of Pseudomonas or Gram-negative MDR bacteria:\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Treatment for specific pathogens\", \"Header\": 1}, {\"Row\": 82, \"Column\": 1, \"Text\": \"Enterobacteria including E. coli, klebsiella, and proteus\", \"Header\": 1}, {\"Row\": 83, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 88, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 94, \"Column\": 1, \"Text\": \"S. aureus is an uncommon urinary tract pathogen and presence in the urine may be\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"due to hematogenous seeding from another site. Blood cultures are indicated to\"}, {\"Row\": 96, \"Column\": 1, \"Text\": \"rule out bacteremia in patients who have S. aureus isolated from the urine.\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 99, \"Column\": 1, \"Text\": \"Pseudomonas\", \"Header\": 1}, {\"Row\": 101, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 104, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 107, \"Column\": 1, \"Text\": \"Enterococcus\", \"Header\": 1}, {\"Row\": 108, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 110, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 113, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 116, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 118, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 119, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 121, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 124, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 125, \"Column\": 1, \"Text\": \"Drekonja et al., JAMA, 2021, 326(4)324-331\"}, {\"Row\": 126, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 127, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 128, \"Column\": 1, \"Text\": \"Sanford keyword: Cystitis\"}, {\"Row\": 129, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 130, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 131, \"Column\": 1, \"Text\": \"Tamma et al., Clinical Infectious Diseases, 2021, 72(7)1109-16\"}, {\"Row\": 132, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute complicated urinary tract infection (including\"}, {\"Row\": 133, \"Column\": 1, \"Text\": \"pyelonephritis) in adults\"}, {\"Row\": 134, \"Column\": 1, \"Text\": \"Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary\"}, {\"Row\": 135, \"Column\": 1, \"Text\": \"tract, gastrointestinal tract, and central nervous system\"}, {\"Row\": 136, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}, {\"Row\": 137, \"Column\": 1, \"Text\": \"Walker et al., Clinical Infectious Diseases, 2016, 63(7)960-5\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 296, \"DisplayText\": \"Urine Culture\", \"Text\": \"Urine culture\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 124,
    "fields": {
      "name": "ORZID2 GMENU ABX COST INFORMATION",
      "term": null,
      "displaytext": "Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIMICROBIAL COST INFORMATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cost is represented as dollar ($) signs in parenthesis following the antibiotic.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"The number of $ signs represent the cost ranges below:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"$ = Less than 10 dollars per day\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"$$ = 10-50 dollars per day\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"$$$ = 51-100 dollars per day\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"$$$$ = 101-400 dollars per day\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"$$$$ = Greater than 400 dollars per day\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"The displayed cost of an antibiotic is an estimate based on usual daily doses\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for an 80kg patient. Costs may change frequently due to VA contract negotiations\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"as well as supply and demand effects. Antibiotic cost and formulary are reviewed\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"by members of the Antimicrobial Subcommittee annually.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 125,
    "fields": {
      "name": "ORZID2 GMENU ABX COVID-19 MAIN MENU",
      "term": null,
      "displaytext": "COVID-19  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Item\": 126, \"DisplayText\": \"Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines\", \"Text\": \"Antimicrobial Inpatient Treatment\", \"Mnemonic\": \"04\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 129, \"DisplayText\": \"TEsting\", \"Text\": \"Inpatient Vaccinations\", \"Mnemonic\": \"06\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3018, \"DisplayText\": \"COVID-19 INFORMATION\", \"Text\": \"SharePoint Site and More Info\", \"Mnemonic\": \"08\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COVID-19:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 126,
    "fields": {
      "name": "ORZID2 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINE",
      "term": null,
      "displaytext": "Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Select here for help, legend, consults, alternative antimicrobials and more (Ip)\", \"Mnemonic\": \"2\"}, {\"Row\": 2, \"Column\": 1, \"Item\": 3019, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"[Link] Minneapolis On-Call Schedule-Infectious Disease\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis COVID-19 SharePoint Site\", \"Text\": \"Minneapolis VAHCS COVID-19 SharePoint Site\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis VAHCS COVID-19 Pharmacologic Inpatient Treatment Guidelines\", \"Text\": \"Minneapolis VAHCS COVID Pharmacologic Inpatient Treatment Guidelines\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 4 days\", \"Text\": \"Remdesivir 200mg IV once on day 1, then 100mg IV daily for 4 additional days\", \"Mnemonic\": \"9\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 6 MG PO q24h for up to 10 days\", \"Text\": \"Dexamethasone 6 MG PO q24h for up to 10 days\", \"Mnemonic\": \"12\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 89, \"DisplayText\": \"Barcitinib Emergency Use Authorization for COVID-19\", \"Text\": \"Baricitinib PO/NG/GT\", \"Mnemonic\": \"14\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 285, \"DisplayText\": \"Tocilizumab for treatment of COVID-19\", \"Text\": \"Tocilizumab IV\", \"Mnemonic\": \"16\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PAXLOVID INPT AND OPT ORDERS\", \"Text\": \"Paxlovid (Nirmatrelvir 300 mg and ritonavir 100 mg) PO BID for 5 days\", \"Mnemonic\": \"18\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"INPATIENT COVID-19 ANTIMICROBIAL TREATMENT GUIDELINES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional info.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"***COVID-19 therapy is a rapidly evolving field, including the widespread\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"dissemination of therapies with little or no evidence for benefit. Therapies and\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"dosages not specifically listed here or on the NIH clinical guidelines should be\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"discussed with the infectious diseases service. ***\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"HOSPITALIZED DUE TO COVID-19\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to COVID-19 Pharmacological Inpatient Treatment Guidelines to determine\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"whether monotherapy or combination therapy with remdesivir and dexamethasone is\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"appropriate. For patients on dexamethasone with rapidly increasing oxygen needs\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"and systemic inflammation, add a second immunomodulatory drug (see\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Immunomodulatory Treatment below)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Immunomodulatory Treatment\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"MVAHCS recommends baricitinib over tocilizumab in patients on high flow nasal\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"cannula oxygen or non-invasive ventilated patients that can take PO or NG. For\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"patients who cannot take PO or NG, or for those who are mechanically ventilated,\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"we recommend tocilizumab.  These treatments are to be added on to dexamethasone,\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"with or without remdesivir.  Consult Infectious Diseases for more details.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"HOSPITALIZED FOR REASONS OTHER THAN COVID-19\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Treatment is recommended for patients with confirmed mild to moderate COVID-19\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"and are at high risk of progressing to severe COVID-19.\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Medication Interaction Check\", \"Text\": \"Interaction checker for COVID-19 medications website link\", \"Mnemonic\": \"17\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Remdesivir Labs\", \"Text\": \"Lab orders for monitoring remdesivir treatment (CMP, CBC with diff, INR)\", \"Mnemonic\": \"10\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 6 MG IV q24h for up to 10 days\", \"Text\": \"Dexamethasone 6 MG IV q24h for up to 10 days\", \"Mnemonic\": \"13\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Dexamethasone (PO/IV):\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Remdesivir (IV):\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"**Place medication orders for inpatient and outpatient (included in order set)\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Preferred treatment, within 5 days of symptom onset:\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Alternative, within 7 days of symptom onset:\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 2 days\", \"Text\": \"Remdesivir 200mg IV once on day 1, then 100mg IV daily for 2 additional days\", \"Mnemonic\": \"21\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Remdesivir labs x3 days\", \"Text\": \"Lab orders for monitoring remdesivir treatment (CMP, CBC with diff, INR)\", \"Mnemonic\": \"22\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"< AND >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< AND >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 127,
    "fields": {
      "name": "ORZID2 GMENU ABX COVID-19 VACCINE CLC",
      "term": null,
      "displaytext": "CLC COVID VACCINE (PFIZER-BIONTECH)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 vaccine with 15 minute monitoring\", \"Text\": \"First and Second Dose [CLICK HERE] to order COVID-19 Vaccine Series (Pfizer)\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine 3rd Dose with 15 minute monitoring CLC\", \"Text\": \"Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine Booster Dose with 15 minute monitoring CLC\", \"Text\": \"Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine appropriatenness nursing text order\", \"Text\": \"<ADD> *For SCI/4J Pts Only* nursing text order for vaccine appropriateness\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 vaccine with 30 minute monitoring\", \"Text\": \"First and Second Dose [CLICK HERE] to order COVID-19 Vaccine Series (Pfizer)\", \"Mnemonic\": \"12\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine 3rd Dose with 30 minute monitoring CLC\", \"Text\": \"Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)\", \"Mnemonic\": \"14\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine Booster Dose with 30 minute monitoring CLC\", \"Text\": \"Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine appropriatenness nursing text order\", \"Text\": \"<ADD> *For SCI/4J Pts Only* nursing text order for vaccine appropriateness\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY LIVING CENTER AND SPINAL CORD INJURY COVID-19 VACCINE ORDERS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with NO history of anaphylaxis (to oral medication, food, insect,\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"etc.), and NO history of immediate allergic reaction to non-COVID vaccine or\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"injectable medication\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Patients with history of anaphylaxis (to oral medication, food, insect, etc.),\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"OR history of immediate allergic reaction to non-COVID vaccine or injectable\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"medication\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Professional Resources. Atlanta, GA: U.S. Department of Health and Human Service\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"https://www.cdc.gov/vaccines/covid-19/index.html\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 128,
    "fields": {
      "name": "ORZID2 GMENU ABX COVID-19 VACCINE JANSSEN INPT",
      "term": null,
      "displaytext": "COVID VACCINE (JANSSEN)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 3020, \"DisplayText\": \"COVID-19 Vaccine Janssen EUA\", \"Text\": \"[CLICK HERE] for link to COVID-19 vaccine EUA\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine Booster Dose Eligibility Criteria\", \"Text\": \"[CLICK HERE] for a comprehensive list of eligibility criteria\", \"Mnemonic\": \"6\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Janssen Vaccine single dose with 15 minute monitoring\", \"Text\": \"Initial Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)\", \"Mnemonic\": \"8\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Janssen Vaccine booster dose with 15 minute monitoring\", \"Text\": \"Booster Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)\", \"Mnemonic\": \"10\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Janssen Vaccine single dose with 30 minute monitoring\", \"Text\": \"Initial Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)\", \"Mnemonic\": \"12\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Janssen Vaccine booster dose with 30 minute monitoring\", \"Text\": \"Booster Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"JANSSEN (JOHNSON & JOHNSON) COVID-19 VACCINE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Generally, mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) are preferred\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"over Janssen (Johnson & Johnson) vaccine. Janssen may be preferred in those who\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"have a contraindication to mRNA vaccines or are at risk of not showing up for a\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"second dose. By placing this order, the patient will be administered the vaccine\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dose the same day or the next business day when vaccine doses are available.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Prerequisites\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"All Orders:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Placing this order implies that you have already discussed the following with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"the patient: The patient meets the below criteria and understands that\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"this vaccine is an unapproved vaccine under an Emergency Use Authorization\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"(EUA). The patient has been offered a copy of the EUA Fact Sheet:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Booster Dose Additional Prerequisites:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"o If first dose was Janssen (Johnson & Johnson) - patients are eligibile 2 month\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"after receiving the 1st dose\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"o If first dose was Pfizer (BioNTech) or Moderna - patients are eligible\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"5 months after the second dose.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Absolute:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"1. Already received a 3rd dose of COVID-19 mRNA vaccine or Janssen booster dose\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"2. Active infection with COVID-19\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"3. Received monoclonal antibody or convalescent plasma for COVID-19 treatment in\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"the last 90 days\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"4. History of anaphylaxis requiring treatment with epinephrine to any Janssen\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"COVID-19 vaccine ingredient\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"5. History of any allergic reaction to previous COVID-19 vaccine or ingredient\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"(including PEG) OR polysorbate\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Relative:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Active infection where vaccine side effects may confuse diagnostic or\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"treatment course\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Please Note:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Booster doses may NOT be given at CBOCs, other satellite clinics or another\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"VA/hospital.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"If a booster dose is indicated, it should be administered 5 months after the\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"2nd dose of an mRNA vaccine (Pfizer (BioNTech) or Moderna) or 2 months after the\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Janssen (Johnson & Johnson) vaccine.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Order COVID-19 Vaccine (Janssen) Dose:\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Patients with NO history of anaphylaxis (to oral medication, food, insect,\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"etc.), and NO history of immediate allergic reaction to non-COVID vaccine or\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"injectable medication\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Patients with history of anaphylaxis (to oral medication, food, insect, etc.),\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"OR history of immediate allergic reaction to non-COVID vaccine or injectable\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Medication\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Risks and Benefits:\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Benefits:\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"May prevent contracting a symptomatic COVID-19 infection\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Risks:\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Common Side Effects:\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"1. Injection site reactions: pain, redness of the skin and swelling\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"2. General side effects: headache, feeling very tired, muscle aches, nausea, and\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"fever\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Uncommon Anaphylactoid Reactions:\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"1. Dyspnea\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"2. Tachycardia\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"3. Severe rash\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"4. Angioedema\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"5. Syncope or pre-syncope\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Rare but Serious Adverse Events\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"1. Thrombosis with Thrombocytopenia\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"2. Guillian-Barre' Syndrome\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"_________________________________________________________________________\", \"Header\": 1}, {\"Row\": 84, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"Professional Resources. Atlanta, GA: U.S. Department of Health and Human Service\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"https://www.cdc.gov/vaccines/covid-19/index.html\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 129,
    "fields": {
      "name": "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS",
      "term": null,
      "displaytext": "TEsting",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3021, \"DisplayText\": \"COVID-19 INFORMATION\", \"Text\": \"CDC COVID-19 Vaccine Interim Clinical Considerations\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Vaccine Once Dose\", \"Text\": \"Monovalent COVID-19 vaccine once dose\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 bivalent vaccine (Pfizer-BioNTech) booster dose\", \"Text\": \"Bivalent COVID-19 vaccine booster dose\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INPATIENT COVID-19 VACCINE RECOMMENDATIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For up to date COVID-19 vaccine recommendations, refer to the CDC:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Monovalent Primary Vaccine Series\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Give 2 doses of monovalent COVID-19 vaccine separated by at least 3 weeks to\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"those who have not received a previous COVID-19 vaccine dose. 3 doses are\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"required for immunocompromised individuals, use link above to refer to CDC\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"for list of immunocompromising conditions and specific recommendations.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Bivalent Booster\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Give 1 bivalent COVID-19 vaccine dose after completing any monovalent COVID-19\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"primary series and at least 2 months after last non-bivalent COVID-19 vaccine\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"dose, regardless of the number of COVID-19 booster vaccines received.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Professional Resources. Atlanta, GA, US Department of Health and Human Services\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"https://www.cdc.gov/vaccines/covid-19/index.html\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 130,
    "fields": {
      "name": "ORZID2 GMENU ABX CRYPTOSPORIDIA",
      "term": null,
      "displaytext": "Diarrhea with Cryptosporidium parvum ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitazoxanide 500mg po q12h\", \"Text\": \"Nitazoxanide 500 mg PO q12h for 3 days ($$$) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CRYPTOSPORIDIUM PARVUM\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibiotic therapy is usually used only for persons with severe disease or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"immunocompromised persons.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients without HIV/AIDS\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients with HIV/AIDS\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for patients with HIV/AIDS.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Cryptosporidiosis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of cryptosporidiosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 131,
    "fields": {
      "name": "ORZID2 GMENU ABX CYCLOSPORA",
      "term": null,
      "displaytext": "Cyclospora cayetanensis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 7 to 10 days ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CYCLOSPORA CAYETANENSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for patients with allergy to sulfonamides.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients without HIV/AIDS\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients with HIV/AIDS\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for patients with HIV/AIDS.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword: Cyclosporiasis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-to-Date article: Cyclospora infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 132,
    "fields": {
      "name": "ORZID2 GMENU ABX DELAYED STANDARD ABX CV SURG",
      "term": null,
      "displaytext": "Standard (Non PCN allergic) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE OPEN HEART\", \"Text\": \"Vancomycin 1500mg PRE-OPERATIVE dose **AND** 1000mg INTRAOPERATIVE dose\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFUROXIME 1500MG PRE-OPERATIVE & INTRA-OPERATIVE OPEN HEART\", \"Text\": \"Cefuroxime 1.5gm PRE-OPERATIVE dose **AND** 1.5gm INTRAOPERATIVE dose\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 133,
    "fields": {
      "name": "ORZID2 GMENU ABX DERM HIGH RISK SITE PROPHYLAXIS",
      "term": "HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS",
      "displaytext": "HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 2gm po once (Var)\", \"Text\": \"Cephalexin 2 GM PO ONCE - 1 hour prior to procedure ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TMP/SMX 1 DS TAB PO ONCE PENVK 500MG PO ONCE\", \"Text\": \"Trimethoprim/Sulfamethoxazole 1 DS tablet PO 60 minutes before incision ($)\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 1gm iv once\", \"Text\": \"Cefazolin 1 gm IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 mg/kg IV 120 minutes before incision ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibiotic prophylaxis is recommended for prevention of infection for the listed\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"high risk conditions:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"2. Groin or Lower Extremities\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"3. Skin flaps and grafts\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"4. Wedge excision of lip or ear\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Contaminated, dirty or infected wound may warrant antibiotic prophylaxis if\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"patient is not currently on an antimicrobial for treatment of infection at the\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"surgical site. Surgical prophylaxis is covered by antimicrobials for treatment\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"of infection at time of surgery. No additional antimicrobials are necessary.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"MRSA risk factor\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"[R,DI] < AND > penicillin VK 500 mg PO 60 minutes before incision ($) [R]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Unable to take oral medications\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"MRSA risk factors and unable to take oral medications\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Rosengren et al, Curr Derm Rep (2012) 1, 55-63\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"infection in adults\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Up-to-Date article: Skin surgery: Prevention and treatment of complications\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Wright et al, J Am Acad Dermatol (2008) 59, 464-73\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"1. Extensive inflammatory skin disease (e.g. high tension)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 134,
    "fields": {
      "name": "ORZID2 GMENU ABX DERM IE JI PROPHYLAXIS",
      "term": "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS",
      "displaytext": "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF PROSTHETIC JOINT INFECTION BEFORE INFECTED SKIN, SKIN STRUCTURES\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OR MUSKULOSKELETAL TISSUE PROCEDURES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"There is a lack of evidence supporting antimicrobial prophylaxis to prevent\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"prosthetic joint infections in patients undergoing procedures on infected skin,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"skin structures or musculoskeletal tissue procedures.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For more information contact Infectious Diseases.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Up-To-Date Article: Prevention of prosthetic joint and other types of orthopedic\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"hardware infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 135,
    "fields": {
      "name": "ORZID2 GMENU ABX DERM POST-OP INFECTIONS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"[CLICK HERE] for list of MRSA risk factors\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500 mg PO QID, three doses post-operatively ($) [R]\", \"Text\": \"Cephalexin 500 mg PO QID, three doses post-operatively ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 1 gm IV q8h, two doses post-operatively ($) [R]\", \"Text\": \"Cefazolin 1 gm IV q8h, two doses post-operatively ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE\", \"Text\": \"Vancomycin 15 mg/kg IV q12h, one dose post-operatively ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEPHALEX 500MG Q6H X3 METRON 500MG Q8H X2\", \"Text\": \"Cephalexin 500 mg PO QID, three doses post-operatively ($) [R] <AND>\", \"Mnemonic\": \"16\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPRO 500MG BID PO X1 METRON 500MG TID PO X2\", \"Text\": \"Ciprofloxacin 500 mg PO BID, one dose post-operatively ($) [R,DI] <AND>\", \"Mnemonic\": \"18\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TMP/SMX 1DS BID PO X1 METRON 500MG PO TID X2\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)\", \"Mnemonic\": \"20\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500 mg IV q8h x 2 doses post-op\", \"Text\": \"Metronidazole 500 mg IV q8h, two doses post-operatively ($) [DI]\", \"Mnemonic\": \"22\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPRO 400MG Q12H IV X1 METRON 500MG Q8H IV X2\", \"Text\": \"Ciprofloxacin 400 mg IV q12h, one dose post-operatively ($) [R,DI] <AND>\", \"Mnemonic\": \"24\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE\", \"Text\": \"Vancomycin 15 mg/kg IV q12h, one dose post-operatively ($) [R]\", \"Mnemonic\": \"26\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO BID, one dose post-operatively ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO BID, one dose post-operatively ($) [R]\", \"Mnemonic\": \"28\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TMP/SMX 1DS TAB PO BID X1 PENVK 500MG PO TID X2\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)\", \"Mnemonic\": \"30\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q6h, 3 doses post-operatively ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q6h, 3 doses post-operatively ($$) [R]\", \"Mnemonic\": \"32\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h, 2 doses post-operatively ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h, 2 doses post-operatively ($$) [H,O]\", \"Mnemonic\": \"34\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DERMATOLOGIC SURGERY POST-OPERATIVE ANTIBIOTIC PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"RECOMMENDATIONS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Conditions that may warrant dermatologic surgery post-operative antibiotic\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"prophylaxis:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"1. Large wound (>5cm)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"2. Long procedure where wound is open for a long time\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"3. Wound near cartilage or bone (e.g. some nose, scalp or ear sites)\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"If patient received pre-operative antibiotics, select the same antibiotic for\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"post-operative prophylaxis. Duration of antimicrobial prophylaxis should not\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"exceed 24 hours. Durations longer than 24 hours have not been shown effective in\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"preventing surgical site infections.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"MRSA risk factors\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Operations involving trunk or extremity away from axilla or perineum\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Penicillin allergy or MRSA risk factors\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"[R,DI]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Severe infections or patients unable to take oral medications\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Penicillin allergy or MRSA risk factors and severe infection or patient unable\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"to take oral medications\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Operations involving the axilla or perineum\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"metronidazole 500 mg PO TID, two doses post-operatively ($) [DI]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Penicillin allergy\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"metronidazole 500 mg PO TID, two doses post-operatively ($) [DI]\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"MRSA risk factors\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"[R,DI] <AND> metronidazole 500 mg PO q8h, two doses post-operatively ($) [DI]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Severe infections or unable to take oral medications\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Note: ceftriaxone does not require redosing due to it's long half-live\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Penicillin allergy and severe infections or unable to take oral medications\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"metronidazole 500 mg IV q8h, two doses post-operatively ($) [DI]\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"MRSA risk factors and severe infections or unable to take oral medications\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"< ADD > to one of the above IV regimens for operations involving axilla or\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"perineum\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Continuation of pre-operative antibiotics that are not listed above\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Note: azithromycin and ceftriaxone do not require redosing due to their long\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"half-lives\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"[R,DI] < AND > Penicillin VK 500 mg PO TID, 2 doses post-operatively ($) [R]\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"Rosengren et al, Curr Derm Rep (2012) 1, 55-63\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"infection in adults\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"endocarditis\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"Up-to-Date article: Skin surgery: Prevention and treatment of complications\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Wilson et al, Circulation (2007) 116, 1736-1754\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Wright et al, J Am Acad Dermatol (2008) 59, 464-73\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 136,
    "fields": {
      "name": "ORZID2 GMENU ABX DERM PROPHYLAXIS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"ANTIMICROBIAL PROPHYLAXIS AND DERMATOLOGIC SURGERY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Antibiotics are used to prevent infections in patients undergoing surgery in\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"certain well-defined circumstances. They are used to prevent surgical site\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infection or to prevent endocarditis in circumstances where the risk of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"endocarditis is high. For many low-risk surgeries, the risks associated with\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antibiotic use, which can be severe or cause death, outweigh the benefits. The\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"following recommendations are consistent with guidelines published by the\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"American Heart Association and Infectious Disease Society of America.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"In general, antibiotics are used to prevent post-operative wound infection\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"in clean-contaminated surgery. Most dermatological surgery involves clean\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"sites, and the risks of antibiotics outweigh potential benefits. Antibiotics\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"are used to prevent endocarditis and hematogenous joint infection in procedures\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"involving infected skin structures. Antibitic prophylaxis is also\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"recommended to prevent surgical site infections in procedures involving high\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"risk surgical sites and conditions.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"When they are used, prophylactic oral antimicrobial agents should be\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"administered 30-60 minutes before the first tissue manipulation or incision.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Intravenous antimicrobials should be administered 60 minutes (120 minutes for\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"vancomycin) prior to procedure.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Antimicrobials should not be used to prevent infections in patients with\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"vascular grafts or orthopedic prostheses because the risk of bacteremia or\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"infection of these devices is tiny and antibiotic risks outweigh any theoretical\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"benefit.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"A full course of antibiotics should be used to treat skin infections where\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"infection is already present at the time of surgery.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Suggested antibiotic prophylaxis regimens should be targeted against the typical\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"pathogens likely to be present. A risk-based approach for coverage of MRSA\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"should be taken in patients with specific risk factors for MRSA.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Rosengren et al, Curr Derm Rep (2012) 1, 55-63\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"infection in adults\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"endocarditis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-to-Date article: Skin surgery: Prevention and treatment of complications\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Wilson et al, Circulation (2007) 116, 1736-1754\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Wright et al, J Am Acad Dermatol (2008) 59, 464-73\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 137,
    "fields": {
      "name": "ORZID2 GMENU ABX DERM SURGICAL INFECTION",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"[CLICK HERE] for list of MRSA risk factors\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] <AND> metronidazole 500 mg PO q8h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 50O mg PO q12h ($) [R,DI] <AND> metronidazole 500 mg PO q8h ($\", \"Mnemonic\": \"16\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI] <AND> metronidazole\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI] <AND> metronidazole\", \"Mnemonic\": \"18\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"20\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($\", \"Mnemonic\": \"22\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DERMATOLOGIC SURGICAL SITE INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If an infection develops, obtain a gram stain and/or culture. Suture removal,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"incision and drainage is recommended. Antimicrobials may be beneficial in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"surgical site infections with significant systemic response (i.e induration\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"greater than 5cm from wound edge, fever, tachycardia and leukocytosis).\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"In general, most post-op infections develop greater than 48 hours after surgery.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Start on antibiotics as below until culture result is available and then switch\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antibiotics, if indicated.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"MRSA risk factors\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treat for 5-7 days\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Operations involving trunk or extremity away from axilla or perineum\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Penicillin allergy or MRSA risk factors\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Severe infections or unable to take oral medications\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Penicillin allergy or MRSA risk factors and severe infection or unable to take\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"oral medications\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Operations involving the axilla, gastrointestinal tract, or perineum, or female\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"genital tract\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Penicillin allergy\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"[DI]\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"MRSA risk factors\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"500 mg PO TID ($) [DI]\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Severe infections or unable to take oral medications\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Penicillin allergy and severe infections or unable to take oral medications\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"[DI]\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"MRSA risk factors and severe infections or unable to take oral medications\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"< ADD > to one of the above IV regimens for operations involving axilla or\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"perineum\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Up-to-Date article: Skin surgery: Prevention and treatment of complications\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Wright et al, J Am Acad Dermatol (2008) 59, 464-73\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 138,
    "fields": {
      "name": "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES",
      "term": null,
      "displaytext": "Dermatology Recommendations ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Item\": 136, \"DisplayText\": \"\", \"Text\": \"Antimicrobial Prophylaxis and Dermatologic Surgery\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 531, \"DisplayText\": \"Prevention of Bacterial Endocarditis\", \"Text\": \"[click here] for inpatients\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 993, \"DisplayText\": \"Prevention of bacterial endocarditis (Outpatient)\", \"Text\": \"[click here] for outpatients\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 533, \"DisplayText\": \"Prevention of prosthetic joint infection before dental procedures\", \"Text\": \"Oral mucosa or surgical site with high risk of hematogenous prosthetic joint\", \"Mnemonic\": \"8\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 134, \"DisplayText\": \"ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS\", \"Text\": \"Infected skin surgical site with high risk of hematogenous prosthetic joint\", \"Mnemonic\": \"10\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 133, \"DisplayText\": \"HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS\", \"Text\": \"Other high risk surgical sites and conditions\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 237, \"DisplayText\": \"Photodynamic therapy for HSV-1 prophylaxis\", \"Text\": \"[click here] for inpatients\", \"Mnemonic\": \"14\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 699, \"DisplayText\": \"Photodynamic therapy for HSV-1 prophylaxis\", \"Text\": \"[click here] for outpatients\", \"Mnemonic\": \"16\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 135, \"DisplayText\": \"\", \"Text\": \"Post-operative prophylaxis recommendations\", \"Mnemonic\": \"18\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 137, \"DisplayText\": \"\", \"Text\": \"Management of Post-Operative infections\", \"Mnemonic\": \"20\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"DERMATOLOGICAL GUIDELINES\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Background information on antibiotic prophylaxis in dermatologic surgery:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Specific antibiotic prophylaxis recommendations in dermatologic surgery:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Oral mucosa or infected skin surgical site with high risk of infective\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"endocarditis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"infection\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"infection\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"*Menu contains outpatient PO orders\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Photodynamic therapy and laser skin resurfacing HSV-1 prophylaxis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"*Menu contains outpatient PO orders\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Dermatologic surgical site infection recommendations:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*Menu contains outpatient PO orders\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 139,
    "fields": {
      "name": "ORZID2 GMENU ABX DERMATOLOGY MAIN",
      "term": null,
      "displaytext": "Dermatological Infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 183, \"DisplayText\": \"Impetigo\", \"Text\": \"Impetigo\", \"Mnemonic\": \"5\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 381, \"DisplayText\": \"Folliculitis\", \"Text\": \"Folliculitis\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 377, \"DisplayText\": \"Erysipelas\", \"Text\": \"Erysipelas\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 394, \"DisplayText\": \"Furuncles and carbuncles\", \"Text\": \"Furuncles and carbuncles\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 104, \"DisplayText\": \"Cellulitis\", \"Text\": \"Cellulitis\", \"Mnemonic\": \"12\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 496, \"DisplayText\": \"Necrotizing infections\", \"Text\": \"Necrotizing infections\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 372, \"DisplayText\": \"Ecthyma Gangrenosum\", \"Text\": \"Ecthyma gangrenosum\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 571, \"DisplayText\": \"Staphylococcal Scalded Skin Syndrom (Ritter's Disease)\", \"Text\": \"Scalded Skin Syndrome\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 443, \"DisplayText\": \"Hidradenitis Suppurativa\", \"Text\": \"Hidradenitis Suppurativa\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 624, \"DisplayText\": \"Toxic Shock Syndrome\", \"Text\": \"Toxic Shock Syndrome\", \"Mnemonic\": \"22\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 379, \"DisplayText\": \"Erythrasma\", \"Text\": \"Erythrasma\", \"Mnemonic\": \"24\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 378, \"DisplayText\": \"Erysipeloid\", \"Text\": \"Erysipeloid\", \"Mnemonic\": \"26\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 343, \"DisplayText\": \"Cat-Scratch Disease\", \"Text\": \"Cat-scratch disease\", \"Mnemonic\": \"28\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 477, \"DisplayText\": \"Leishmaniasis\", \"Text\": \"Leishmaniasis\", \"Mnemonic\": \"30\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 546, \"DisplayText\": \"Rocky Mountain Spotted Fever\", \"Text\": \"Rocky Mountain Spotted Fever\", \"Mnemonic\": \"32\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatology Post-Op Infection\", \"Mnemonic\": \"34\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  DERMATOLOGICAL INFECTIONS ++\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Section reviewed January 2018\", \"Header\": 1}, {\"Row\": 5, \"Column\": 2, \"Item\": 352, \"DisplayText\": \"Cutaneous Candidiasis\", \"Text\": \"Candidiasis\", \"Mnemonic\": \"40\"}, {\"Row\": 6, \"Column\": 2, \"Item\": 514, \"DisplayText\": \"Paronychia\", \"Text\": \"Paronychia\", \"Mnemonic\": \"42\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 328, \"DisplayText\": \"Bed Bugs (Hemiptera)\", \"Text\": \"Bed bugs (hemiptera)\", \"Mnemonic\": \"44\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 442, \"DisplayText\": \"Head Lice (Pediculosis Capitis)\", \"Text\": \"Head lice (Pediculosis Capitis)\", \"Mnemonic\": \"46\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 334, \"DisplayText\": \"Body Lice (Pediculosis Corporis)\", \"Text\": \"Body lice (Pediculosis corporis)\", \"Mnemonic\": \"48\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 542, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis)\", \"Text\": \"Pubic lice (Pediculosis pubis)\", \"Mnemonic\": \"50\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 547, \"DisplayText\": \"Scabies\", \"Text\": \"Scabies\", \"Mnemonic\": \"52\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"54\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 387, \"DisplayText\": \"Blastomyces dermatidis\", \"Text\": \"Blastomycosis\", \"Mnemonic\": \"56\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 570, \"DisplayText\": \"Sporotrichosis\", \"Text\": \"Sporotrichosis\", \"Mnemonic\": \"58\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually Transmitted Infections\", \"Mnemonic\": \"60\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 175, \"DisplayText\": \"Herpes Whitlow (digit/hand cellulitis)\", \"Text\": \"Herpes Whitlow (digit/hand cellulitis)\", \"Mnemonic\": \"62\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 225, \"DisplayText\": \"Orolabial Herpes\", \"Text\": \"Oral lesions: Mouth, Lips (Cold sores)\", \"Mnemonic\": \"64\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 620, \"DisplayText\": \"Tinea Capitis (Ringworm)\", \"Text\": \"Tinea capitis (ringworm)\", \"Mnemonic\": \"66\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 622, \"DisplayText\": \"Tinea Unguium (Onychomycosis)\", \"Text\": \"Tinea unguium (onychomycosis)\", \"Mnemonic\": \"68\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 621, \"DisplayText\": \"Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris\", \"Text\": \"Tinea pedis, Tinea corporis, Tinea cruris\", \"Mnemonic\": \"70\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 623, \"DisplayText\": \"Tinea Versicolor\", \"Text\": \"Tinea versicolor\", \"Mnemonic\": \"72\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 245, \"DisplayText\": \"Primary infection (Chickenpox)\", \"Text\": \"Varicella/Chickenpox (primary infection)\", \"Mnemonic\": \"74\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 249, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\")\", \"Text\": \"Zoster/Shingles (reactivation)\", \"Mnemonic\": \"76\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Herpes simplex virus infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 2, \"Text\": \"Tinea fungal infections\", \"Header\": 1}, {\"Row\": 28, \"Column\": 2, \"Text\": \"Varicella-Zoster virus infections\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": 71, \"DisplayText\": \"Acne\", \"Text\": \"Acne\", \"Mnemonic\": \"3\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 263, \"DisplayText\": \"Rosacea\", \"Text\": \"Rosacea\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 140,
    "fields": {
      "name": "ORZID2 GMENU ABX DEVICE-RELATED INFECTIONS",
      "term": null,
      "displaytext": "Device-related infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 474, \"DisplayText\": \"Intravascular catheter-associated infection\", \"Text\": \"Intravascular catheter-related infection\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 368, \"DisplayText\": \"Prosthetic Valve Endocarditis--Empicaral Therapy\", \"Text\": \"Prosthetic-valve endocarditis - Empirical therapy\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 369, \"DisplayText\": \"Prosthetic Valve Endocarditis--Selected Pathogens\", \"Text\": \"Prosthetic-valve endocarditis - Selected pathogens\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 187, \"DisplayText\": \"Infections involves cardiovascular devices (excluding valves)\", \"Text\": \"Infections involving cardiovascular devices (except valves)\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  DEVICE-RELATED INFECTIONS  ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If the desired syndrome is not listed below, return to the main menu and refer\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to the pertinent organ-system.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Last reviewed 11/17\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 141,
    "fields": {
      "name": "ORZID2 GMENU ABX DEXAMETHASONE FOR COVID",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 11, \"Column\": 1, \"Text\": \"Indications:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"COVID with hypoxia (<89% O2 at rest for more than an hour, not just a transient\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"episode or nocturnal hypoxia due to sleep apnea). May be discontinued early\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"if patient is no longer hypoxic.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Contraindications: Lack of hypoxia\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Dexamethasone (PO/IV):\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 6 MG PO q24h for up to 10 days\", \"Text\": \"Dexamethasone 6 MG PO q24h for up to 10 days\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 6 MG IV q24h for up to 10 days\", \"Text\": \"Dexamethasone 6 MG IV q24h for up to 10 days\", \"Mnemonic\": \"8\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-Dexamethasone (for up to 10 days) decreases mortality in patients with severe\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"or critical COVID-19 (RECOVERY trial).\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"-Dexamethasone may increase mortality in patients with mild/moderate COVID.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"-Dexamethasone is the preferred steroid, but a meta-analysis supports the use of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"other steroids (hydrocortisone, methylprednisolone, or hydrocortisone) if\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dexamethasone is not available.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DEXAMETHASONE (RECOVERY trial) for COVID-19\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"RECOVERY Collaborative Group, N Engl J Med. (2021) 384(8):693-704.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 142,
    "fields": {
      "name": "ORZID2 GMENU ABX DIAGNOSIS OF ENDOCARDITIS",
      "term": null,
      "displaytext": "Diagnosis of Endocarditis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 146, \"DisplayText\": \"Modified Duke Diagnostic Criteria\", \"Text\": \"Modified Duke Diagnostic Criteria\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIAGNOSIS OF ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis and management are complex. Cardiology, Infectious Disease, and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Surgery services should all be involved in diagnosis and management of infective\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"endocarditis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Endocarditis is the result of growth of microorganisms on endothelium of the\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"heart. The integrity of the endothelial surface must be compromised in order to\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"allow microorganisms to attach and proliferate. Often such lesions are caused by\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"abnormal blood flow or thrombi resulting from heart valvular disease, prosthetic\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"heart valves, or from foreign material or microorganisms introduced to the\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"bloodstream as byproducts of illicit intravenous drug use.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Endocarditis should be considered a possible diagnosis in a patient with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"persistent bacteremia without an identifiable focal infection, especially when\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"the patient has a structural heart abnormality, prosthesis, or has a recent\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"history of intravenous illicit drug use.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Diagnosis of endocarditis can be based on several combinations of signs and\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"symptoms. The Duke criteria help categorize cases as definite or possible\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"endocarditis based on major and minor criteria. The Duke criteria also indicate\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"when a diagnosis of endocarditis can be excluded.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Severity of Disease\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Endocarditis is categorized by time course and severity of symptoms of illness\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"into acute and subacute. These classifications help suggest which pathogens may\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"be more likely associated with symptoms.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Acute\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Acute endocarditis is a rapidly progressing illness that often causes fever. It\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"can be associated with spread of infection to other parts of the body and can\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"cause death within a matter of weeks. In patient with suspected acute\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"endocarditis, three sets of blood cultures should be obtained with the first and\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"last cultures separated by at least one hour. Empiric antimicrobial therapy\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"should then be initiated as soon as possible.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Subacute\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Subacute endocarditis follows an indolent course. Generally, patients have had\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"some symptoms for at least 2 weeks. Symptoms are more subtle and spread of\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"infection to other systems is uncommon. In patients with suspected subacute\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"endocarditis, every attempt should be made to identify a pathogen prior to\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"initiating antimicrobial therapy. These patients should be observed carefully\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"for signs of heart failure or embolic complications, and if signs are noted,\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"surgery should be consulted immediately.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 143,
    "fields": {
      "name": "ORZID2 GMENU ABX DIVERTICULITIS",
      "term": null,
      "displaytext": "Diverticulitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h for 7 to 10 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po q24h (Var)\", \"Text\": \"Moxifloxacin 400 mg PO q24h for 7 to 10 days ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-Tazobactam 3.375g IV q6h for 7 to 10 days ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h for 7 to 10 days ($$) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"18\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h for 10-14 days ($$) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"22\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIVERTICULITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diverticulitis involves inflammation of an intestinal diverticulum, usually in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the colon, causing pain and disturbed bowel function.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Mild disease or Step-down treatment for completion of antimicrobial course\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"after initial intravenous treatment in patients who can tolerate oral therapy.\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Base selection on culture results.\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"metronidazole 1000 mg PO q12h ($) [DI] for 7 to 10 days\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"q12h ($) [DI] for 7 to 10 days\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Moderate disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"If symptoms fail to respond within 48 to 72 hours, consult General Surgery.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"for 7 to 10 days\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative for beta lactam allergy\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"($) [DI] for 7 to 10 days\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Severe, life-threatening disease\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Consult General Surgery.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Diverticulitis and Typhlitis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford keyword: Diverticulitis\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-to-Date article: Acute colonic diverticulitis: Medical management\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 144,
    "fields": {
      "name": "ORZID2 GMENU ABX DRUG ALLERGIES",
      "term": null,
      "displaytext": "Drug allergies  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 53, \"Column\": 1, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Link to penicillin desensitization protocol\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DRUG ALLERGIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Importance of history\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"The nature and circumstances of a possible previous reaction including the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"timing should be considered. In many cases, previous reactions are clearly\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"not due to drug allergy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Types of reactions\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"*Immediate - within one hour of starting drug administration.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Type I reactions present with urticaria, hypotension, angioedema, bronchospasm,\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"or anaphylaxis and occur within an hour of exposure. These reactions are\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"immunoglobulin E (IgE) and mast cell and/or basophil mediated.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"*Delayed - After one hour of starting administration (usually after 6 days)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"1) Type II reactions manifest as hemolytic anemia, thrombocytopenia and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"neutropenia. They are caused by antibody (usually IgG)- mediated cell\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"destruction.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"2) Type III reactions can manifest as serum sickness, vasculitis or Arthus\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"reaction, and are caused by IgG:drug immune complex deposition and complement\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"activation.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"3) Type IV reactions typically manifest as contact dermatitis, morbilliform\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"reactions, severe exfoliative dermatoses (Stevens-Johnson syndrome/toxic\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"epidermal necrolysis) and other presentations. They are T-cell mediated.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Repeated exposures lead to reactions that are of the same type.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Beta-lactam allergies\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Approximately 10% of patients report a beta-lactam allergy. Up to 90% of these\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"patients can tolerate penicillin and have been designated penicillin allergic\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"unnecessarily. Patients allergic to cephalosporins will have a cross-reaction to\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"penicillins 3% to 5% of the time. Overall, patients with a history of penicillin\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"allergy can tolerate cephalosporins although there are rare reports to severe,\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"sometimes fatal anaphylactic reactions. Neither penicillin- or cephalosporin-\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"allergic patients will react to aztreonam. The degree of cross-reactivity of\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"penicillins and cephalosporins with carbapenems appears to be low.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Therapeutic implications\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"If a patient has had an immediate reaction to a drug in the past, an allergy\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"specialist should evaluate the patient before a drug of the same class is\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"administered to the patient. Patients with delayed onset reactions causing\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"fever, systemic symptoms or mucosal involvement should also be evaluated by an\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"allergy specialist before a drug of the same class is administered.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Desensitization\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"A patient with previous Type I reaction to a beta-lactam can be desensitized and\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"then receive therapeutic doses of the same class within a day. Severe\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"reactions during desensitization are uncommon. Pharmacy service must be\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"contacted for assistance and drug preparation. Infectious Disease consultation\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"strongly recommended.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"JAMA 2001, 285: 249\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Joint Task Force on Practice Parameters: Drug Allergy - An Updated Practice\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Parameter (2010)\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Kelkar PS NEJM 2001, 345: 804\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Mayo Clinic Proc 1999, 74: 290\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"cephalosporins and related antibiotics\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Up-to-Date article: Drug allergy: Classification and clinical features\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"related antibiotics. Clin Allergy 1988, 18:515\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 145,
    "fields": {
      "name": "ORZID2 GMENU ABX DRUG INFO PAGE",
      "term": null,
      "displaytext": "Click for drug information. ([R]=renal excretion, [H]=hepatic excretion, ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Item\": 3022, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Acyclovir PO\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Acyclovir IV\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Albendazole PO\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Amantadine PO\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Amikacin IV\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Amoxicillin PO\", \"Mnemonic\": \"12\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Amoxicillin-clavulanate PO\", \"Mnemonic\": \"14\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Amphotericin B IV\", \"Mnemonic\": \"16\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ampicillin IV\", \"Mnemonic\": \"18\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ampicillin-sulbactam IV\", \"Mnemonic\": \"20\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Atovaquone PO\", \"Mnemonic\": \"22\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Azithromycin PO\", \"Mnemonic\": \"24\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Azithromycin IV\", \"Mnemonic\": \"26\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Aztreonam IV\", \"Mnemonic\": \"28\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Benzathine penicillin IM\", \"Mnemonic\": \"30\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Caspofungin IV\", \"Mnemonic\": \"32\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cefazolin IV\", \"Mnemonic\": \"34\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cefepime IV\", \"Mnemonic\": \"36\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cefixime PO\", \"Mnemonic\": \"38\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cefotetan IV\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cefoxitin IV\", \"Mnemonic\": \"42\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cefpodoxime PO\", \"Mnemonic\": \"44\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ceftazidime IV\", \"Mnemonic\": \"46\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ceftriaxone IM\", \"Mnemonic\": \"48\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ceftriaxone IV\", \"Mnemonic\": \"50\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cefuroxime PO\", \"Mnemonic\": \"52\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Cephalexin PO\", \"Mnemonic\": \"54\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Chloramphenicol IV\", \"Mnemonic\": \"56\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ciprofloxacin PO\", \"Mnemonic\": \"58\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ciprofloxacin IV\", \"Mnemonic\": \"60\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Clarithromycin PO\", \"Mnemonic\": \"62\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Clindamycin PO\", \"Mnemonic\": \"64\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Clindamycin IV\", \"Mnemonic\": \"66\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Clindamycin Vaginal\", \"Mnemonic\": \"68\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Clotrimazole Topical\", \"Mnemonic\": \"70\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Clotrimazole Vaginal\", \"Mnemonic\": \"72\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Daptomycin IV\", \"Mnemonic\": \"74\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Dicloxacillin PO\", \"Mnemonic\": \"76\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Dolutegravir PO\", \"Mnemonic\": \"78\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Doxycycline PO\", \"Mnemonic\": \"80\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Doxycycline IV\", \"Mnemonic\": \"82\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Emtricitabine/Tenofovir PO\", \"Mnemonic\": \"84\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ertapenem IV\", \"Mnemonic\": \"86\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Erythromycin Ophthalmic\", \"Mnemonic\": \"88\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Erythromycin PO\", \"Mnemonic\": \"90\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Erythromycin IV\", \"Mnemonic\": \"92\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ethambutol PO\", \"Mnemonic\": \"94\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"++ IMPORTANT DRUG PROPERTIES PAGE ++\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Select below for drug info from online database\"}, {\"Row\": 5, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Fluconazole PO\", \"Mnemonic\": \"98\"}, {\"Row\": 6, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Fluconazole IV\", \"Mnemonic\": \"100\"}, {\"Row\": 7, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Flucytosine PO\", \"Mnemonic\": \"102\"}, {\"Row\": 8, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Foscarnet IV\", \"Mnemonic\": \"104\"}, {\"Row\": 9, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Fosfomycin PO\", \"Mnemonic\": \"106\"}, {\"Row\": 10, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Ganciclovir IV\", \"Mnemonic\": \"108\"}, {\"Row\": 11, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Gentamicin IV\", \"Mnemonic\": \"110\"}, {\"Row\": 12, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Griseofulvin PO\", \"Mnemonic\": \"112\"}, {\"Row\": 13, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Iodoquinol PO\", \"Mnemonic\": \"114\"}, {\"Row\": 14, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Itraconazole PO\", \"Mnemonic\": \"116\"}, {\"Row\": 15, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Itraconazole IV\", \"Mnemonic\": \"118\"}, {\"Row\": 16, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Levofloxacin PO\", \"Mnemonic\": \"120\"}, {\"Row\": 17, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Levofloxacin IV\", \"Mnemonic\": \"122\"}, {\"Row\": 18, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Linezolid PO\", \"Mnemonic\": \"124\"}, {\"Row\": 19, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Linezolid IV\", \"Mnemonic\": \"126\"}, {\"Row\": 20, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Meropenem IV\", \"Mnemonic\": \"128\"}, {\"Row\": 21, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Metronidazole PO\", \"Mnemonic\": \"130\"}, {\"Row\": 22, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Metronidazole IV\", \"Mnemonic\": \"132\"}, {\"Row\": 23, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Metronidazole Vaginal\", \"Mnemonic\": \"134\"}, {\"Row\": 24, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Micafungin IV\", \"Mnemonic\": \"136\"}, {\"Row\": 25, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Minocycline PO\", \"Mnemonic\": \"138\"}, {\"Row\": 26, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Moxifloxacin Ophthalmic\", \"Mnemonic\": \"140\"}, {\"Row\": 27, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Moxifloxacin PO\", \"Mnemonic\": \"142\"}, {\"Row\": 28, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Moxifloxacin IV\", \"Mnemonic\": \"144\"}, {\"Row\": 29, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Nafcillin IV\", \"Mnemonic\": \"146\"}, {\"Row\": 30, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Neomycin PO\", \"Mnemonic\": \"148\"}, {\"Row\": 31, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Nitazoxanide PO\", \"Mnemonic\": \"150\"}, {\"Row\": 32, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Nitrofurantoin PO\", \"Mnemonic\": \"152\"}, {\"Row\": 33, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Oseltamivir PO\", \"Mnemonic\": \"154\"}, {\"Row\": 34, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Paromomycin PO\", \"Mnemonic\": \"156\"}, {\"Row\": 35, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Penicillin PO\", \"Mnemonic\": \"158\"}, {\"Row\": 36, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Penicillin IV\", \"Mnemonic\": \"160\"}, {\"Row\": 37, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Piperacillin-tazobactam IV\", \"Mnemonic\": \"162\"}, {\"Row\": 38, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Pyrimethamine PO\", \"Mnemonic\": \"164\"}, {\"Row\": 39, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Quinupristin-dalfoprisin IV\", \"Mnemonic\": \"166\"}, {\"Row\": 40, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Rifabutin PO\", \"Mnemonic\": \"168\"}, {\"Row\": 41, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Rifampin IV\", \"Mnemonic\": \"170\"}, {\"Row\": 42, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Rifaximin PO\", \"Mnemonic\": \"172\"}, {\"Row\": 43, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Streptomycin IV\", \"Mnemonic\": \"174\"}, {\"Row\": 44, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Sulfacetamide Ophthalmic\", \"Mnemonic\": \"176\"}, {\"Row\": 45, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Sulfadiazine PO\", \"Mnemonic\": \"178\"}, {\"Row\": 46, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Terconazole 0.4% Vaginal\", \"Mnemonic\": \"180\"}, {\"Row\": 47, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Tetracycline PO\", \"Mnemonic\": \"182\"}, {\"Row\": 48, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Tobramycin IV\", \"Mnemonic\": \"184\"}, {\"Row\": 49, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Trimethoprim PO (does not contain sulfa)\", \"Mnemonic\": \"186\"}, {\"Row\": 50, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Trimethoprim-sulfamethoxazole PO\", \"Mnemonic\": \"188\"}, {\"Row\": 51, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Trimethoprim-sulfamethoxazole IV\", \"Mnemonic\": \"190\"}, {\"Row\": 52, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Valacyclovir PO\", \"Mnemonic\": \"192\"}, {\"Row\": 53, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Valganciclovir PO\", \"Mnemonic\": \"194\"}, {\"Row\": 54, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Vancomycin IV\", \"Mnemonic\": \"196\"}, {\"Row\": 55, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Voriconazole PO\", \"Mnemonic\": \"198\"}, {\"Row\": 56, \"Column\": 2, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Zanamivir INH\", \"Mnemonic\": \"200\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 146,
    "fields": {
      "name": "ORZID2 GMENU ABX DUKE CRITERIA",
      "term": null,
      "displaytext": "Modified Duke Diagnostic Criteria ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 147, \"DisplayText\": \"Duke Diagnostic Criteria Listing\", \"Text\": \"Modified Duke Criteria Diagnostic Listing\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MODIFIED DUKE DIAGNOSTIC CRITERIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The Modified Duke criteria are used to diagnose endocarditis on clinical\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"grounds. Endocarditis may also be diagnosed by pathology results.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Requirements for definite diagnosis of endocarditis\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Two major criteria\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"One major criterion and three minor criteria\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Five minor criteria\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Requirements for possible diagnosis of endocarditis\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"One major criterion and one minor criterion\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Three minor criteria\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Requirements for rejection of diagnosis of endocarditis\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Firm alternative diagnosis explaining evidence of endocarditis\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Resolution of endocarditis syndrome with antibiotic therapy for less than 4 days\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"No pathological evidence of endocarditis at surgery or autopsy, with antibiotic\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"therapy for less than 4 days\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Does not meet criteria for possible endocarditis as above.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 147,
    "fields": {
      "name": "ORZID2 GMENU ABX DUKE LISTING",
      "term": null,
      "displaytext": "Duke Diagnostic Criteria Listing  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MODIFIED DUKE CRITERIA DIAGNOSTIC LISTING\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Major criteria\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Blood culture positive\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"*Typical microorganisms consistent with IE from 2 separate blood cultures:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Viridans streptococci, Streptococcus bovis, HACEK group organisms (Haemophilus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"species, Aggregatibacter species, Cardiobacterium species, Eikenella corrodens,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and Kingella species), Staphylococcus aureus, or community-acquired enterococci\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"in the absence of a primary focus, or microorganisms consistent with IE from\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"persistently positive blood cultures defined as follows: at least 2 positive\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"cultures of blood samples drawn >12h apart or all 3 or a majority of >/= 4\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"separate cultures of blood (with first and last sample drawn at least 1 h apart)\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"*Single culture positive for Coxiella burnetii or anti-phase 1 IgG antibody\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"titer greater than or equal to 1:800\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Echocardiogram positive for endocarditis\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"*Echocardiographic evidence for endocarditis, defined as:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"An echo dense, intracardiac mass attached to valve or supporting structures, in\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"the path of regurgitant jets, or a mass present on implanted material in the\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"absence of an alternative anatomic explanation\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Paravalvular abscess\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"New partial dehiscence of prosthetic valve or new valvular regurgitation\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"(worsening or changing or preexisting murmur is not sufficient for a major\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"criterion)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Note: Echocardiography should be performed in all patients suspected of having\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"endocarditis. Transesophageal echocardiograph (TEE) is recommended for patients\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"with prosthetic valves. Transthoracic echocardiograph (TTE) is often adequate\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"for patients suspected of having native valve endocarditis, especially on the\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"aortic valve, but TEE may be needed for these patients as well. Contact\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"infectious diseases or cardiology for more information.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Minor criteria\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Predisposing heart condition or intravenous drug user\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Fever\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Temperature over 38 degrees Celsius (100.4 degrees Fahrenheit)\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Vascular phenomena\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Major arterial embolus, septic pulmonary infarcts, mycotic aneurysm,\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"intracranial hemorrhage, conjunctival hemorrhages, or Janeway's lesions\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Immunologic phenomena\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Glomerulonephritis, Osler's nodes, Roth's spots, or rheumatoid factor\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Microbiological evidence\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"A case with a positive blood culture, but with results that don't meet the major\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"criterion blood culture criteria listed above or serological evidence of active\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"infection with organism consistent with endocarditis. Microbiological evidence\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"is not intended to include all positive blood cultures. For example, a single\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"positive culture for coagulase-negative staphylococci or a culture yielding an\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"organism that is not a cause of endocarditis would not support a diagnosis of\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"endocarditis.\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 148,
    "fields": {
      "name": "ORZID2 GMENU ABX DURATION OF ABX THERAPY",
      "term": null,
      "displaytext": "Duration of antimicrobial therapy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"DURATION OF ANTIMICROBIAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In general, duration of therapy is based on multiple factors, including\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infection severity, rapidity of improvement, and pathogen susceptibility. For a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"few diseases guidelines are established based on available evidence and opinion.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"For many more diseases, guidelines have not been established.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For outpatient prescriptions, when a range is recommended by CDSS, the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"prescription order will default to the lowest dose and day supply. For inpatient\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"orders, durations are listed in the recommendations but are not included in the\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"quick order. The provider must select a duration, if desired, when completing an\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"inpatient quick order.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For all cases clinical judgment is important. More information is given within\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"specific diagnoses or syndromes sections.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 149,
    "fields": {
      "name": "ORZID2 GMENU ABX E COLI INFECT",
      "term": null,
      "displaytext": "Diarrhea with Enterohemorrhagic E. coli ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RIFAXAMIN 200MG PO Q8H FOR 3 DAYS\", \"Text\": \"Rifaximin 200 mg q8h for 3 days ($$) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 269, \"DisplayText\": \"Diarrhea with Shigella species (bacillary dysentery)\", \"Text\": \"Link to Shigella/Enteroinvasive E. coli menu\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH ESCHERICHIA COLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Enteroaggretive E. coli (EAEC), Enteropathogenic E. coli (EPEC), and\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Enterotoxigenic E. coli (ETEC)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"EAEC infection can cause watery diarrhea with mucus that is occasionally bloody.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"It is more common in patients with HIV and those who have traveled to developing\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"regions. EPEC infection is associated with severe acute watery diarrhea that is\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"occasionally bloody. ETEC infection causes acute watery diarrhea that is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"occasionally severe. It is most common in travelers to tropical regions who are\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"exposed to contaminated food and water.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antibiotic therapy is not required for mild to moderate disease caused by these\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"organisms because diarrhea often resolves on its own. Do not use antimotility\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"agents in patients with bloody stool.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Primary treatment\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Antimicrobial treatment of severe diarrhea\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Antimicrobial treatment in patients with AIDS\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Enterohemorrhagic E. coli (EHEC) and Shiga Toxin-producing E. coli (STEC)\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"EHEC and STEC disease often presents as bloody diarrhea. It is more common in\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"people who have consumed undercooked meats or poultry, fruits or unpasteurized\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"fruit juices, vegetables, leafy greens or seed sprouts. Exposure risks include\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"swimming in or drinking untreated fresh water and visiting a farm, petting zoo,\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"healthcare facility, prison or childcare facility.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treatment includes supportive measures such as volume repletion and\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"administering appropriate nutrition. Do not use antimotility or antimicrobial\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"agents as they can increase shiga-toxin release and increase the risk of\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"hemolytic uremia syndrome (HUS).\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Enteroinvasive E. coli (EIEC)\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"EIEC disease typically presents as watery diarrhea, sometimes progressing to\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"bloody diarrhea. Refer to Shigella/Enteroinvasive E. coli menu for\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"recommendations.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Brunette, Gary W. CDC Yellow Book 2018: Oxford University Press, 2017\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Enterohemorrhagic E. coli / Shiga toxin-producing E. coli\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Up-to-Date article: Pathogenic Escherichia coli\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment is complex, consult Infectious Diseases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 150,
    "fields": {
      "name": "ORZID2 GMENU ABX ELEMENTS OF CDSS ADVICE PAGE",
      "term": null,
      "displaytext": "Elements of a CDSS Advice Page ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"ELEMENTS OF A CDSS ADVICE MENU\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Advice menus are comprised of the following elements:\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"TYPICALLY present on an advice menu\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"1) Diagnosis or condition label-at the top of each advice menu.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"2) Treatment. Empirical treatment as well as treatment for selected pathogens\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"is presented with links to antimicrobial quick orders unless stated otherwise.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"In addition to the drug, dose, and route, each quick order text includes the\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"drug's approximate cost per day and coding for important drug properties of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"note. Drugs clustered together are considered equivalent.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"3) Help. At the top of each advice menu. There are links to a variety of\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"resources (susceptibilities, important drug properties, section-specific\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"consults, etc.).\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"4) References. At the bottom on each advice menu. These are key references for\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"the recommendations on the menu.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"DISCRETIONARY advice menu components\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"1) (Treatment) Alternative. Following the (preferred) Treatment section with\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"quick orders for common alternative antimicrobials. Antimicrobial listed under\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"each alternative header are equivalents among those listed. A broader selection\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"of medications can be accessed through the Need an alternative menu within the\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"help section. For some conditions we recommend alternative antimicrobials when\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"recommended drugs are not suitable for an individual patient. Unless otherwise\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"stated drugs clustered together under Alternatives are considered equivalent.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"If none of the recommended or alternative drugs is suitable you can find more\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"drugs by clicking on the Need an alternative link at the top of the menu.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"2) Consults. At the top of the menu, these are consultation requests pertinent\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"to the clinical problem addressed by the menu. Links to context-specific\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"consults can be found on advice menus, as appropriate. For example, the herpes\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"simplex encephalitis menu contains a link to a request for neurology consult.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"3) Resources. Pertinent to the clinical problem and addressed by the menu is\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"provided for example. For some menus, supplemental resources have been\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"identified (e.g., PORT score calculator for Community Acquired Pneumonia,\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"diagnostic tools, Epidemiology, etc.) the information is included on the advice\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"menu.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 151,
    "fields": {
      "name": "ORZID2 GMENU ABX EMPYEMA",
      "term": null,
      "displaytext": "Empyema",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg IV Q24H ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($)[H,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q6h ($)[H,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500 MG IV Q8H\", \"Text\": \"Metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 1000 mg PO q12h ($) [DI]\", \"Text\": \"Metronidazole 1000 mg PO q12h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"EMPYEMA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Empyema is usually a complication of pneumonia.  Blood cultures should be drawn\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"and whenever possible, diagnostic thoracentesis should be performed before\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials are begun to guide therapy.  Drainage is essential, and a chest\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"tube is often required.  Pulmonary or Infectious Diseases consultation is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"essential.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"The duration of antibiotic therapy for bacterial empyema is determined on\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"a patient-by-patient basis based on clinical and radiographic improvement.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Choose two antimicrobials, one from Group A and one from Group B.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \">>  Group A  <<\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \">>  Group B <<\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell Chapter:  Principles and Practice of Infectious Diseases\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Harrison's chapter: Infections due to mixed organisms\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 152,
    "fields": {
      "name": "ORZID2 GMENU ABX ENTAMOEBA HISTOLYTICA",
      "term": null,
      "displaytext": "Entoemeba histolytica ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Text\": \"Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTAMOEBA HISTOLYTICA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary treatment for gastroenteritis\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment for gastroenteritis or extraintestinal disease\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases. Paromomycin is nonformulary and must\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"be ordered by Infectious Diseases.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"25-35 mg/kg/day PO q8h for 7 days ($) [M]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Sanford keyword: Amoebiasis, Entamoeba histolytica\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-to-Date article: Intestinal Entamoeba histolytica amoebiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 153,
    "fields": {
      "name": "ORZID2 GMENU ABX ENTERIC FEVER",
      "term": null,
      "displaytext": "Enteric Fever",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 7-10 days ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h for 7-10 days ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1 gm PO once then 500 mg PO q24h for 5 days ($) [M]\", \"Text\": \"Azithromycin 1 gm PO once then 500 mg PO q24h for 5 to 7 days ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h for 7 to 14 days ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTERIC FEVER (INCLUDING TYPHOID AND PARATYPHOID FEVER)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Enteric fever is a systemic febrile illness caused by Salmonella enterica\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"serotypes Typhi and Paratyphi A, B, or C. It is characterized by dramatic fever\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and abdominal pain. Enteric fever typically occurs in patients who have traveled\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to impoverished areas where the organisms are endemic, but can also be acquired\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"within the United States. Treatment is based on location of acquisition due to\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"increasing rates of fluoroquinolone resistance in Asia.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobial treatment for infection NOT acquired in Asia\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Antimicrobial treatment for infection acquired in Asia\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Typhoid Fever, Enteric Fever\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of enteric (typhoid and\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"paratyphoid) fever\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 154,
    "fields": {
      "name": "ORZID2 GMENU ABX EPIDIDYMITIS",
      "term": null,
      "displaytext": "Epididymitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h\", \"Mnemonic\": \"6\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"8\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) for 10 days\", \"Mnemonic\": \"10\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 10 days\", \"Mnemonic\": \"12\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"14\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO ($) [DI]\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"16\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po q12h\", \"Text\": \"Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"18\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"20\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"22\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) for 10 days\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Epididymitis is inflammation of the epididymis and when testicles are involved\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"is referred to as epididymo-orchitis. Acute epididymitis is the most common\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cause of scrotal pain in adults. Other features include scrotal erythema and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"unilateral. It is primarily caused by infection but can also result from trauma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and autoimmune diseases. Testicular torsion should be ruled out before\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"treatment. Most cases in men aged 35 and older, those with recent urinary tract\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"with enteric Gram-negative rods. Most cases in men under age 35 are associated\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"the patient has been in the hospital for more than 48 hours or received a course\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of antibiotics. There is increasing resistance in urinary pathogens to\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"ciprofloxacin.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"should be performed in all cases of suspected epididymitis before starting\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"treatment to guide therapy:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Patients with bacterial epididymitis treated with antibiotics should improve\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"within two or three days. If no improvement is noted, other causes of scrotal\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"pain and referral to a urologist should be considered.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Management should include bed rest, analgesics, and scrotal elevation. Older men\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"should have their residual urinary volume checked. If the residual volume is\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"elevated, the patient should be seen by a urologist as epididymitis is unlikely\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"to respond if the prostate is blocking the vas deferens.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Empirical treatment in men who practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"for 10 days ($) [R, DI]\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Empirical treatment in men who do not practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Age >/= 35 years or\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"biopsy, vasectomy):\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Age < 35 years\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Patient weighing less than 300 lbs\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Patients weighing 300 lbs or greater\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Mandell Chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Sanford keyword: Epididymo-orchitis\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Up-To-Date article: Evaluation of acute scrotal pain in adults\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 155,
    "fields": {
      "name": "ORZID2 GMENU ABX EPIGLOTTITIS",
      "term": null,
      "displaytext": "Epiglottitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> vancomycin 15 mg/kg IV q 12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EPIGLOTTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Maintaining the airway is the key to management. Call ENT service and ask them\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to see the patient immediately. Blood cultures and epiglottal cultures (in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"intubated patients) should be used to direct antimicrobial therapy. Empirical\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"therapy should be initiated prior to results of cultures as infection is life\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"threatening and cover for likely pathogens (Moraxella catarrhalis, penicillin\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"resistant S. pneumonia, beta-hemolytic streptococci and possibly Staph. aureus)\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Epiglottitis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Rafei et al., Pediatric Clinics 2006, 53.2, 215-242\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Epiglottitis, Supraglottis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-date article: Epiglottis (supraglottis): Management\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 156,
    "fields": {
      "name": "ORZID2 GMENU ABX ESBL KPC ETC",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Gram-Negative Bacilli Drug Resistance\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In some Gram-negative bacilli, potent bacterial enzymes have emerged that\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"inactive many newer broad-spectrum beta lactam drugs. These include extended-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"spectrum beta-lactamases (ESBLs), serine carbapenemases, metallo-beta-\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"lactamases, AmpC beta-lactamases and oxacillinases. These enzymes are most\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"common in strains of Acinetobacter, Citrobacter, Enterobacter, Escherichia coli,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Klebsiella, Proteus, Pseudomonas aeruginosa, Salmonella, and Serratia\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"marcescens. The enzymes can be latent under many circumstances. However, in\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"patients receiving beta lactam antibiotics, the enzymes can be expressed and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"contribute to treatment failure. Because of this, and since the enzymes continue\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"to evolve, they are difficult to detect in clinical microbiology laboratories.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Bacteria carrying these enzymes are often also resistant to many other commonly\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"used antimicrobials, including trimethoprim-sulfamethoxazole, quinolones, and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"others, through different mechanisms. Enterobacteriaceae, Pseudomonas and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Acinetobacter are increasingly resistant to all antimicrobials.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Clinicians must be aware that these enzymes may not be detected in all strains\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"that carry them. If a Gram-negative infection is not responding to therapy with\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"a beta lactam drug, consider adding or switching to a drug that is not a beta\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"lactam and appears active in the susceptibility report.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If a patient is suspected of having a Gram-negative infection and is likely to\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"be colonized with bacteria carrying these enzymes, empirical therapy with\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"alternative drugs that are not inactivated by them should be considered.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Risk factors for colonization or infection with resistant gram-negative bacilli\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1. Travel to Asia\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"2. Central venous catheters and other indwelling tube and drains\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"3. Recent surgical procedures\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"4. Recent antibiotic therapy\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"5. Long-term care facility residence\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"6. Multiple, severe chronic illnesses\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"7. Ventilator assistance\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"8. Hemodialysis\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"9. Long hospital or ICU stay.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"AmpC beta-lactamases alternative antimicrobials\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Inactivate many cephalosporins, most penicillins, and beta-lactam inhibitor\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"combinations. Alternatives include aminoglycosides, carbapenems, cefepime and\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"colistin.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"ESBLs alternative antimicrobials\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Inactivate most cephalosporins, monobactams, and penicillins. Alternatives\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"include aminoglycosides, carbapenems and colistin.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Serine carbapenemases, metallo-beta-lactamases and oxacillinases alternative\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"antimicrobials\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Confer resistance to all beta-lactams. Most strains are also resistant to most\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"other antibiotic classes. Alternatives include aminoglycosides and colistin.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Infectious Diseases consultation is recommended.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Additional alternative antimicrobials\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Trimethoprim-sulfamethoxazole and quinolones are non-beta-lactam alternative\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"antimicrobials, especially useful for IV to PO conversion. Gram negative bacilli\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"co-resistance to these antimicrobials is common however. Tigecycline (restricted\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"to ID) and ceftazidime-avibactam (non-formulary) are also potential options for\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"susceptible isolates. Infectious Diseases consultation is required for their\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"use.\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Mandell chapter: Molecular Mechanisms of Antibiotic Resistance in Bacteria\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Up-to-Date article: Extended-spectrum beta-lactamases\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Up-to-Date article: Overview of carbapenemase-producing gram-negative bacilli\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Rodr\\ufffdguez-Bano et al. Clinical microbiology reviews, 2018, 31(2): e00079-17\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Sanford guide keyword: Gram Negative Bacilli, Drug Resistance, Overview\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Last Reviewed 9/18\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 157,
    "fields": {
      "name": "ORZID2 GMENU ABX ESOPHAGITIS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 388, \"DisplayText\": \"Candida albicans\", \"Text\": \"Candidiasis\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 113, \"DisplayText\": \"CMV Colitis or Esophagistis\", \"Text\": \"CMV Esophagitis\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 174, \"DisplayText\": \"\", \"Text\": \"Herpes Simplex Esophagitis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ESOPHAGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Esophagitis is usually associated with non-infectious diseases like\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"gastroesophageal reflux disease, mucositis and pill-induced esophagitis.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Esophageal infection occurs primarily in immunosuppressed individuals (e.g.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"chemotherapy, transplantation, HIV) and rarely in healthy individuals. The\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"majority of infectious esophagitis is caused by Candida albicans,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"cytomegalovirus (CMV) and herpes simplex virus. Aphthous ulceration of the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"esophagus is common in HIV infection. HIV screening is recommneded.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell chapter: Esophagitis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sanford Keyword: Candidiasis\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford Keyword: Cytomegalovirus, Gastrointestinal Disease\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-To-Date article: Herpes simplex virus infection of the esophagus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 158,
    "fields": {
      "name": "ORZID2 GMENU ABX EXCLUSIONS",
      "term": null,
      "displaytext": "Exclusions",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 11, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact VISN23 Antimicrobial CDSS Program Staff\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DISEASES AND SYNDROMES NOT COVERED\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Our system provides advice for the treatment of most infectious diseases likely\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to be encountered in our patient population. Diseases that do not require\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobial therapy are not included. For more information on a syndrome not\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"described in our system, please contact infectious diseases. If you feel that a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"syndrome should be included in our system please contact us.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Erik Stensgard, PharmD: (612) 271-4121\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Bobbie Masoud, PharmD:  (612) 719-6778\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 159,
    "fields": {
      "name": "ORZID2 GMENU ABX FIRST RECURRENCE ABX ASSOC",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin taper and pulse dosing\", \"Text\": \"Vancomycin Extended-Pulse Taper Regimen ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 286, \"DisplayText\": \"Severe disease - Ileus/Toxic megacolon\", \"Text\": \"Select for Fulminant CDI\", \"Mnemonic\": \"12\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Discontinue implicated antibiotic and avoid high-risk antibiotic if\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"antibiotic therapy is still needed. Discontinue antacid therapy if possible.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Severe/life-threatening disease (shock, ileus, megacolon)\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases consults are essential.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Treatment and\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"prevention\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg po q12h for 10 days ($$) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"CDI Recurrence: Typically defined as a repeated symptomatic, laboratory\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"confirmed case of CDI within 12 weeks after a prior episode.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"First Recurrence CDI: *The REGIMEN should be different from initial treatment.*\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125mg PO q6h for 10 days for C.difficile infection. ($) [M]\", \"Text\": \"Vancomycin 125 mg PO q6h for 10 days ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin Extended-Pulse Regimen ($$) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Fulminant CDI:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"125 mg po q12h for 7 days, then 125mg po qday for 7 days, then\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"125mg every other day for 6 weeks)\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FIRST RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 160,
    "fields": {
      "name": "ORZID2 GMENU ABX FUNGUS",
      "term": null,
      "displaytext": "Fungi  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 386, \"DisplayText\": \"Aspergillus spp.\", \"Text\": \"Aspergillus and other moulds\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 387, \"DisplayText\": \"Blastomyces dermatidis\", \"Text\": \"Blastomyces dermatitidis\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 388, \"DisplayText\": \"Candida albicans\", \"Text\": \"Candida albicans\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 389, \"DisplayText\": \"Candida glabrata\", \"Text\": \"Candida glabrata\", \"Mnemonic\": \"10\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 390, \"DisplayText\": \"Candida krusei\", \"Text\": \"Candida krusei\", \"Mnemonic\": \"12\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 391, \"DisplayText\": \"Coccidioidomyces\", \"Text\": \"Coccidioidomyces\", \"Mnemonic\": \"14\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 392, \"DisplayText\": \"Cryptococcus Neoformans\", \"Text\": \"Cryptococcus neoformans\", \"Mnemonic\": \"16\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 393, \"DisplayText\": \"Histoplasma capsulatum\", \"Text\": \"Histoplasma capsulatum\", \"Mnemonic\": \"18\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis (considered a fungus)\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ FUNGI ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome, site of infection, penetration of drug(s)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into site, and whether organism is pathogen, colonizer, or contaminant. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome section for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Last reviewed 8/18\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 161,
    "fields": {
      "name": "ORZID2 GMENU ABX GASTROINTESTINAL",
      "term": null,
      "displaytext": "Gastrointestinal and Intraabdominal  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 200, \"DisplayText\": \"\", \"Text\": \"Hepatic abscess\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 266, \"DisplayText\": \"Secondary Peritonitis\", \"Text\": \"Intraabdominal abscess\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 266, \"DisplayText\": \"Secondary Peritonitis\", \"Text\": \"Intraperitoneal abscess\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Perirectal/Anorectal abscess\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 307, \"DisplayText\": \"Appendicitis without perforation\", \"Text\": \"Appendicitis without perforation\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 308, \"DisplayText\": \"Appendicitis with perforation\", \"Text\": \"Appendicitis with perforation\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 108, \"DisplayText\": \"Cholecystitis\", \"Text\": \"[click here]\", \"Mnemonic\": \"16\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 107, \"DisplayText\": \"Cholangitis\", \"Text\": \"[click here]\", \"Mnemonic\": \"18\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Mild to moderate disease\", \"Mnemonic\": \"20\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 286, \"DisplayText\": \"Severe disease - Ileus/Toxic megacolon\", \"Text\": \"Severe/life-threatening disease\", \"Mnemonic\": \"22\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 457, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis\", \"Text\": \"[click here]\", \"Mnemonic\": \"24\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 143, \"DisplayText\": \"Diverticulitis\", \"Text\": \"[click here]\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GASTROINTESTINAL ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Abscess\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Appendicitis\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Cholecystitis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Cholangitis\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Clostridium difficile disease\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"(shock, ileus and megacolon)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Diarrhea, infectious\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Diverticulitis\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"SECTION LAST REVIEWED MAY 2018\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 153, \"DisplayText\": \"Enteric Fever\", \"Text\": \"[click here]\", \"Mnemonic\": \"28\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 441, \"DisplayText\": \"Helicobacter pylori infection\", \"Text\": \"[click here]\", \"Mnemonic\": \"32\"}, {\"Row\": 16, \"Column\": 2, \"Item\": 170, \"DisplayText\": \"Hepatitis A\", \"Text\": \"Hepatitis A\", \"Mnemonic\": \"34\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 171, \"DisplayText\": \"Hepatitis B\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"36\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 172, \"DisplayText\": \"Hepatitis C\", \"Text\": \"Hepatitis C\", \"Mnemonic\": \"38\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 290, \"DisplayText\": \"Neutropenic Enterocolitis (Typhlitis)\", \"Text\": \"[click here]\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 226, \"DisplayText\": \"Pancreatitis\", \"Text\": \"[click here]\", \"Mnemonic\": \"42\"}, {\"Row\": 28, \"Column\": 2, \"Item\": 275, \"DisplayText\": \"Acute spontaneous bacterial peritonitis (SBP)\", \"Text\": \"Acute Spontaneous Bacterial Peritonitis (SBP)\", \"Mnemonic\": \"44\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 232, \"DisplayText\": \"Peritonitis associated with peritoneal dialysis\", \"Text\": \"Peritonitis associated with\", \"Mnemonic\": \"46\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 266, \"DisplayText\": \"Secondary Peritonitis\", \"Text\": \"Secondary peritonitis\", \"Mnemonic\": \"48\"}, {\"Row\": 34, \"Column\": 2, \"Item\": 388, \"DisplayText\": \"Candida albicans\", \"Text\": \"[click here]\", \"Mnemonic\": \"50\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Helicobacter pylori infection\", \"Header\": 1}, {\"Row\": 15, \"Column\": 2, \"Text\": \"Hepatitis\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Neutropenic enterocolitis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 2, \"Text\": \"(Typhlitis)\", \"Header\": 1}, {\"Row\": 24, \"Column\": 2, \"Text\": \"Pancreatitis\", \"Header\": 1}, {\"Row\": 27, \"Column\": 2, \"Text\": \"Peritonitis\", \"Header\": 1}, {\"Row\": 30, \"Column\": 2, \"Text\": \"peritoneal dialysis\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"Thrush\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"[click here]\", \"Mnemonic\": \"15\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Asplenia (Fever Tx/Vaccines/Abx Prophylaxis)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"Esophagitis\", \"Header\": 1}, {\"Row\": 9, \"Column\": 2, \"Item\": 388, \"DisplayText\": \"Candida albicans\", \"Text\": \"Candidal\", \"Mnemonic\": \"29\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 157, \"DisplayText\": \"\", \"Text\": \"Other\", \"Mnemonic\": \"30\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Enteric Fever\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 162,
    "fields": {
      "name": "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT",
      "term": null,
      "displaytext": "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help and Additional Information Menu\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INPT CONSULTS MENU\", \"Text\": \"Consult Menu - place consults to specialty service\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antibiogram\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 3, \"DisplayText\": \"Need an alternative antimicrobial? (inpatient)\", \"Text\": \"Alternative Antimicrobials to CDSS Recommendations - select here\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact Information\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Antimicrobial Information\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Important Drug Properties\", \"Mnemonic\": \"14\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 124, \"DisplayText\": \"Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)\", \"Text\": \"Antimicrobial Cost Information\", \"Mnemonic\": \"16\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"GENERAL INFORMATION\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"LEGEND ________________________________________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"[DI] = Important interactions between antimicrobial and other drugs\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"[H] = Hepatic excretion of antimicrobial\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"[M] = Minimal risk posed by antimicrobial\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"[O] = Other important antimicrobial property\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"[R] = Renal excretion of antimicrobial\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"($) = <10 dollars per day\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"($$) = 10-50 dollars per day\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"($$$) = 51-100 dollars per day\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"($$$$) = 101-400 dollars per day\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"($$$$$) = >400 dollars per day\"}, {\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INFECTIOUS DISEASE (INPT)\", \"Text\": \"Infectious Diseases Consult\", \"Mnemonic\": \"3\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam Reaction Assessment\", \"Mnemonic\": \"9\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 163,
    "fields": {
      "name": "ORZID2 GMENU ABX GENITAL HERPES",
      "term": null,
      "displaytext": "Genital herpes  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO q8h\", \"Text\": \"Acyclovir 400 mg PO q8h for 7-10 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1GM PO q12h\", \"Text\": \"Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO q8h\", \"Text\": \"Acyclovir 400 mg PO q8h for 5 days ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800MG PO TID\", \"Text\": \"Acyclovir 800 mg PO q8h for 2 days ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO q12h ($) [R]\", \"Text\": \"Valacyclovir 500 mg PO q12h for 3 days ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO q8h\", \"Text\": \"Acyclovir 400 mg PO q8h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1GM PO q12h\", \"Text\": \"Valacyclovir 1 gm PO q12h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 5 mg/kg IV Q8H\", \"Text\": \"Acyclovir 5 mg/kg IV q8h ($$) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO BID\", \"Text\": \"Acyclovir 400 mg PO q12h ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO Q24h ($) [R]\", \"Text\": \"Valacyclovir 500 mg PO Q24h ($) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 78, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VALACYCLOVIR 1000 MG PO Q24h\", \"Text\": \"Valacyclovir 1000 mg PO Q24h ($) [R]\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GENITAL HERPES\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment of the initial episode decreases the duration of pain, lesions, and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"viral shedding by 1 to 2 days. Treatment of the initial episode does not\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"decrease likelihood of recurrent episodes.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Episodic therapy for relapses\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treatment of recurrent episodes must be started within 24 hours of symptom\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"onset. Treatment decreases the duration of pain and lesions, and viral shedding\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"by 1 to 2 days. Consider suppressive treatment for patients with more than 6\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"episodes per year.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Immunocompromised patients in whom genital herpes simplex disease is often\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"severe include: patients with HIV infection, organ transplants, malnourishment,\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"eczema or severe burns, and in patients receiving immunosuppressive\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"chemotherapy.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Treat mild to moderate disease for 10 days. In severe disease, treat with\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"intravenous acyclovir for 2 to 7 days based on clinical response, then treat\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"with an oral antiviral for a total duration of 10 days.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease or after clinical improvement of severe\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"disease\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Infectious Diseases consult encouraged.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Chronic suppressive therapy\", \"Header\": 1}, {\"Row\": 65, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Suppressive therapy is indicated in patients with more than 6 episodes per year.\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Suppressive therapy is optional, and some patients may find episodic treatment\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"more convenient. The frequency of recurrences usually decreases after 1 to 5\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"years, and suppressive therapy should be stopped every few years to see if it is\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"still needed.\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"For a patient with more than 9 episodes per year\", \"Header\": 1}, {\"Row\": 81, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"Center for Disease Control. MMWR 55(RR 11) 1-94\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes simplex\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 568, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 164,
    "fields": {
      "name": "ORZID2 GMENU ABX GENITOURINARY",
      "term": null,
      "displaytext": "Genitourinary",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 82, \"DisplayText\": \"Approach to Urinary Tract Infection (UTI)\", \"Text\": \"Approach to Urinary Tract Infection (UTI)\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 85, \"DisplayText\": \"Asymptomatic Bacteriuria\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 628, \"DisplayText\": \"Urosepsis\", \"Text\": \"Bacteremia/sepsis urinary tract source, Urosepsis\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 100, \"DisplayText\": \"Candida urinary tract infection\", \"Text\": \"Candida Urinary Tract Infection\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 123, \"DisplayText\": \"Complicated Cystitis\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"12\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 247, \"DisplayText\": \"Pyelonephritis\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"14\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 291, \"DisplayText\": \"Uncomplicated Cystitis\", \"Text\": \"Uncomplicated cystitis\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 72, \"DisplayText\": \"Acute Bacterial Prostatitis\", \"Text\": \"Acute bacterial prostatitis\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 88, \"DisplayText\": \"Balanitis and Balanoposthitis\", \"Text\": \"Balanitis and Balanoposthitis\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 111, \"DisplayText\": \"Chronic bacterial prostatitis\", \"Text\": \"Chronic bacterial prostatitis\", \"Mnemonic\": \"22\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 110, \"DisplayText\": \"Chronic protatitis/Chronic pelvic pain syndrome\", \"Text\": \"Chronic prostatitis/Chronic pelvic pain syndrome\", \"Mnemonic\": \"24\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 154, \"DisplayText\": \"Epididymitis\", \"Text\": \"Epididymitis and Epididymo-Orchitis\", \"Mnemonic\": \"26\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Urethritis\", \"Mnemonic\": \"28\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 297, \"DisplayText\": \"Bacterial Vaginosis\", \"Text\": \"Bacterial vaginosis\", \"Mnemonic\": \"30\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 101, \"DisplayText\": \"Candida Vulvo-Vaginitis\", \"Text\": \"Candida vulvovaginitis\", \"Mnemonic\": \"32\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Cervicitis\", \"Mnemonic\": \"34\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Pelvic Inflammatory Disease (PID)\", \"Mnemonic\": \"36\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Trichomonas vaginitis\", \"Mnemonic\": \"38\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GENITOURINARY ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Urinary tract infections\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Male specific infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Female specific Infections\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Last updated July 2022\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Cervicitis\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Epididymitis\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Genital Herpes\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Gonorrhea infection with/without Chlamydia\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Pelvic Inflammatory Disease (PID)\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Syphilis\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Trichomonas Vaginitis\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Urethritis\", \"Mnemonic\": \"18\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 496, \"DisplayText\": \"Necrotizing infections\", \"Text\": \"Necrotizing infection\", \"Mnemonic\": \"20\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 606, \"DisplayText\": \"Surgical Site Infection\", \"Text\": \"Surgical site infection\", \"Mnemonic\": \"22\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Sexually Transmitted Infections (STI)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Chlamydia (See Cervicitis or Urethritis)\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Necrotizing Infection (including Fournier gangrene)\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Surgical Site Infection\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 165,
    "fields": {
      "name": "ORZID2 GMENU ABX GI EUS-FNA ENDO PROCED",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg po qday for 4 days starting 60min before proce\", \"Text\": \"Levofloxacin 500 mg PO q24h for 4 days, beginning 60 minutes before\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h for 4 days\", \"Text\": \"Levofloxacin 500 mg PO q24h for 4 days, beginning 60 minutes before\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Antibiotic Prophylaxis for GI Endoscopic Ultrasound FNA Procedures\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The purpose of antibiotic prophylaxis during GI endoscopy is to reduce the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"risk of iatrogenic infectious complications.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Cystic lesions along GI tract including mediastinum:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Antibiotic prophylaxis is recommended before a FNA for cystic lesions along\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"the GI tract to prevent cyst infection.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Recommendation:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"INPATIENT:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"endoscopic procedure ($) [R,DI]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"OUTPATIENT:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"endoscopic procedure ($) [R,DI]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Solid Lesions along the upper or lower GI tract:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Antibiotic prophylaxis is not recommended before a diagnostic EUS or EUS-FNA\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"of solid lesions along the upper or lower GI tract.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Endoscopy 2008, 67:791-795\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 166,
    "fields": {
      "name": "ORZID2 GMENU ABX GIARDIA",
      "term": null,
      "displaytext": "Diarrhea with Giardia lamblia  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitazoxanide 500mg po q12h\", \"Text\": \"Nitazoxanide 500 mg PO q12h for 3 days ($$$)[M]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 250 mg PO q8h for 5 days($0.24/Day) [DI]\", \"Text\": \"Metronidazole 250 mg PO q8h for 5 to 7 days ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH GIARDIA DUODENALIS (ALSO KNOWN AS G. LAMBLIA AND G.INTESTINALIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Illness with Giardia is typically subacute but varies widely in its time course.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment is necessary when the patient has symptomatic disease. Diarrhea,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"abdominal pain, bloating, belching, flatus, nausea, and vomiting are present\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"acutely and after several days give way to flatus, loose stools, belching, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"weight loss.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Asymptomatic carriage of Giardia is common in household contacts of people who\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"are infected with Giardia. Treatment of asymptomatic patients can be considered\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"if they have contact with immunocompromised or pregnant people or live or work\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"in settings where there is risk of spreading infection to others (e.g., food\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"handlers, daycare, nursing home).\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Minetti et al, BMJ, 2016, 355.i5369\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Giardia duodenalis (G. intestinalis, G. lamblia)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date article: Giardiasis: Treatment and prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 167,
    "fields": {
      "name": "ORZID2 GMENU ABX GONOCOCCAL",
      "term": null,
      "displaytext": "Neisseria gonorrhoeae STI",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Uncomplicated gonococcal infections of the pharynx, cervix, urethra, or rectum:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"chlamydia.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients weighing less than 300lbs:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Patients weighing 300lbs or greater:\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"No reliable alternative treatments are available for pharyngeal gonorrhea.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"For persons with a history of a beta-lactam allergy, a thorough assessment\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"of the reaction is recommended. For persons with an anaphylactic or other\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"severe reaction to ceftriaxone, consult Infectious Disease for alternative\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"treatment recommendation.\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po bid x7days (\", \"Text\": \"Ceftriaxone 1 GM IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"-If chlamydial infection has not been excluded, recommend to treat for\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO bidx7days ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"-A test-of-cure is unnecessary for uncomplicated urogenital or rectal\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"gonorrhea for patients treated with the recommended or alternative regimen.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"For persons with a history of a beta-lactam allergy, a thorough assessment\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"of the reaction is recommended.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 240 MG IM Once ($) [R] <AND> Azithromycin 2000 mg PO Once ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Alternative treatment for beta-lactam allergy for pharynx:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Alternative treatment for beta-lactam allergy for cervix, urethra, or rectum:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"-A test-of-cure is recommended for patients with pharyngeal gonorrhea.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Obtain nucleic acid amplification test (NAAT) 7 to 14 days after initial\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treatment, regardless of regimen used for pharyngeal gonorrhea.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred treatment for patients and no chlamydial co-infection:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred treatment with chlamydial co-infection or chlamydial infection has\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"not been excluded:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Patient weighing less than 300lbs:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Patients weighing 300lbs or greater:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500 MG IM x1 dose ($) [M]\", \"Mnemonic\": \"08\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM x1 dose ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 106, \"DisplayText\": \"Chlamydia Urethritis\", \"Text\": \"[Click here] Chlamydial infection and no co-infection\", \"Mnemonic\": \"06\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Chlamydial infection and no co-infection:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Urine NAAT\", \"Text\": \"[Click here] Place order for gonorrhea/chlamydia lab NAAT test\", \"Mnemonic\": \"04\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Lab test:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-When diagnosed with sexually transmitted disease, the patient's sexual\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"partner(s) during the previous 60 days should be evaluated for sexually\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"transmitted infection.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Gonococcal Infections:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 168,
    "fields": {
      "name": "ORZID2 GMENU ABX HEAD AND NECK",
      "term": null,
      "displaytext": "Head and Neck",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 488, \"DisplayText\": \"Malignant Otitis Externa\", \"Text\": \"Malignant Otitis Externa\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 489, \"DisplayText\": \"Mastoiditis\", \"Text\": \"Mastoiditis\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 511, \"DisplayText\": \"Otitis Externa\", \"Text\": \"Otitis Externa\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 512, \"DisplayText\": \"Otitis Media\", \"Text\": \"Otitis Media\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 348, \"DisplayText\": \"Conjunctivitis\", \"Text\": \"Conjunctivitis\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 376, \"DisplayText\": \"Endophthalmitis\", \"Text\": \"Endophthalmitis\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 476, \"DisplayText\": \"Keratitis\", \"Text\": \"Keratitis\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 524, \"DisplayText\": \"Periocular Infections\", \"Text\": \"Periocular Infections\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 535, \"DisplayText\": \"Prophylaxis for ophthalmic surgery\", \"Text\": \"Prophylaxis for Ophthalmic Surgery\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 545, \"DisplayText\": \"Retinitis\", \"Text\": \"Retinitis\", \"Mnemonic\": \"22\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 629, \"DisplayText\": \"Uveitis\", \"Text\": \"Uveitis\", \"Mnemonic\": \"24\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 91, \"DisplayText\": \"Bell's Palsy\", \"Text\": \"Bell's Palsy\", \"Mnemonic\": \"26\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 528, \"DisplayText\": \"Preseptal Cellulitis\", \"Text\": \"Pre-septal Cellulitis\", \"Mnemonic\": \"28\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 527, \"DisplayText\": \"Postseptal Cellulitis\", \"Text\": \"Post-septal Cellulitis (Orbital Cellulitis)\", \"Mnemonic\": \"30\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  HEAD AND NECK++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Ear/Otologic\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Eye/Ophthalmologic\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Facial\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Section last reviewed June 2021\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 300, \"DisplayText\": \"Acute Sinusitis--Mild to Moderate Disease\", \"Text\": \"Acute Sinusitis\", \"Mnemonic\": \"34\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 344, \"DisplayText\": \"Chronic Sinusitis\", \"Text\": \"Chronic Sinusitis\", \"Mnemonic\": \"36\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 385, \"DisplayText\": \"Fungal Sinusitis\", \"Text\": \"Fungal Sinusitis\", \"Mnemonic\": \"38\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 212, \"DisplayText\": \"Nasal Packing (to prevent infection)\", \"Text\": \"Nasal Packing (to prevent infection)\", \"Mnemonic\": \"40\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 503, \"DisplayText\": \"Nosocomial Sinusitis\", \"Text\": \"Nosocomial Sinusitis\", \"Mnemonic\": \"42\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 354, \"DisplayText\": \"Deep Oropharyngeal Infections\", \"Text\": \"Deep Oropharyngeal Infections\", \"Mnemonic\": \"44\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 576, \"DisplayText\": \"Suppurative odontogenic infections\", \"Text\": \"Dental Infections\", \"Mnemonic\": \"46\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 155, \"DisplayText\": \"Epiglottitis\", \"Text\": \"Epiglottitis\", \"Mnemonic\": \"48\"}, {\"Row\": 16, \"Column\": 2, \"Item\": 157, \"DisplayText\": \"\", \"Text\": \"Esophagitis\", \"Mnemonic\": \"50\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 198, \"DisplayText\": \"Laryngitis and Croup\", \"Text\": \"Laryngitis\", \"Mnemonic\": \"52\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 228, \"DisplayText\": \"Parotitis\", \"Text\": \"Parotitis\", \"Mnemonic\": \"54\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 525, \"DisplayText\": \"Periodental disease\", \"Text\": \"Periodontal Disease\", \"Mnemonic\": \"56\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 235, \"DisplayText\": \"Pertussis\", \"Text\": \"Pertussis\", \"Mnemonic\": \"58\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 236, \"DisplayText\": \"Pharyngitis\", \"Text\": \"Pharyngitis\", \"Mnemonic\": \"60\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 388, \"DisplayText\": \"Candida albicans\", \"Text\": \"Thrush\", \"Mnemonic\": \"62\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 236, \"DisplayText\": \"Pharyngitis\", \"Text\": \"Tonsillitis\", \"Mnemonic\": \"64\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Nasal/Sinus\", \"Header\": 1}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Throat/Oropharyngeal\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 169,
    "fields": {
      "name": "ORZID2 GMENU ABX HELP PAGE",
      "term": null,
      "displaytext": "Help page (instructions, microbiology, drug properties, etc.)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": 178, \"DisplayText\": \"How to find an alternative antimicrobial\", \"Text\": \"[Click Here]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 3023, \"DisplayText\": \"Antimicrobial Formulary Hyperlink\", \"Text\": \"Formulary\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Important drug properties\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 988, \"DisplayText\": \"List of Antimicrobials with Pregnancy Risk Category\", \"Text\": \"Pregnancy and lactation risk\", \"Mnemonic\": \"12\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Susceptibilities (Antibiogram)\", \"Mnemonic\": \"14\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RESOURCE QTC PROLONGATION FOR DRUGS\", \"Text\": \"QTc prolongation drug resource\", \"Mnemonic\": \"16\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 1057, \"DisplayText\": \"\", \"Text\": \"Warfarin interactions\", \"Mnemonic\": \"18\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Additional assistance\", \"Mnemonic\": \"20\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Clinical on call schedule (ID)\", \"Mnemonic\": \"22\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 349, \"DisplayText\": \"\", \"Text\": \"Comments or suggestions\", \"Mnemonic\": \"24\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 158, \"DisplayText\": \"Exclusions\", \"Text\": \"[Click Here]\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CDSS HELP AND ADDITIONAL INFORMATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Allergies\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Penicillin desensitization\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Alternative antimicrobials\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"When to use and how to find\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antimicrobial information\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Contact Information\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Excluded diseases and syndromes\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 177, \"DisplayText\": \"Home IV at the Minneapolis VAMC\", \"Text\": \"[Click Here]\", \"Mnemonic\": \"28\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 179, \"DisplayText\": \"How to use the CDSS\", \"Text\": \"[Click Here]\", \"Mnemonic\": \"30\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 188, \"DisplayText\": \"Infection Control\", \"Text\": \"[Click Here]\", \"Mnemonic\": \"32\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 69, \"DisplayText\": \"Antimicrobial restriction policy\", \"Text\": \"[Click Here]\", \"Mnemonic\": \"34\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 68, \"DisplayText\": \"About the CDSS\", \"Text\": \"About the CDSS\", \"Mnemonic\": \"36\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 70, \"DisplayText\": \"Acknowledgements\", \"Text\": \"Acknowledgements\", \"Mnemonic\": \"38\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 213, \"DisplayText\": \"New Updates\", \"Text\": \"New updates information\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Lexicomp Online\", \"Text\": \"Lexicomp online\", \"Mnemonic\": \"42\"}, {\"Row\": 26, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Mandell Online\", \"Text\": \"Mandell's online\", \"Mnemonic\": \"44\"}, {\"Row\": 27, \"Column\": 2, \"Item\": null, \"DisplayText\": \"UP TO DATE WEB SITE\", \"Text\": \"Up-to-date online\", \"Mnemonic\": \"46\"}, {\"Row\": 28, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Sanford Guide Web Site\", \"Text\": \"Sanford Guide online\", \"Mnemonic\": \"48\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Home IV Treatment Information\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"How to use the CDSS\", \"Header\": 1}, {\"Row\": 9, \"Column\": 2, \"Text\": \"Navigation, adjusting regimens, menu\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"elements\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"Infection Control\", \"Header\": 1}, {\"Row\": 14, \"Column\": 2, \"Text\": \"Contact info, links, precautions\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Restriction policy information\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Other/additional resources\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Item\": 124, \"DisplayText\": \"Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)\", \"Text\": \"Cost Information\", \"Mnemonic\": \"7\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam reaction assessment\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 144, \"DisplayText\": \"Drug allergies\", \"Text\": \"History, types, implications,\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 170,
    "fields": {
      "name": "ORZID2 GMENU ABX HEPATITIS A",
      "term": null,
      "displaytext": "Hepatitis A  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HEPATITIS A\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Disease Management\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Most acute disease is self-limited, and the virus does not cause chronic\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease. No specific antiviral therapy is available.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Patients who appear to be developing fulminant hepatitis, including those with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"mental status changes should receive supportive treatment. Fulminant hepatitis\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"is suggested by increased prothrombin time, cholestasis, ascites, decreased\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"liver size, or decreasing serum albumin. Supportive treatment includes\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"maintenance of fluid and electrolyte balance, monitoring and possible correction\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"of coagulation defects, treatment of hepatic encephalopathy, and good nutrition\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with a low-protein diet.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Prevention for persons with continuing high risk of disease\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Vaccine should be offered to persons at high risk of hepatitis A infection: men\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"who have sex with men, travelers to endemic areas likely to be exposed, illegal\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"drug users, persons at occupational risk of disease, persons with chronic liver\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"disease or clotting factor disorders.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Prevention for persons with a specific, defined exposure\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Post-exposure prophylaxis should be offered to persons with substantial exposure\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"to hepatitis A. Specifically, persons exposed to acute hepatitis through\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"household or sexual contact, persons who attend or work in a day care center\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"with a recent case, or employee or patron of a restaurant with a food handler\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"with hepatitis. Post exposure prophylaxis must be given within 2 weeks of\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"exposure. Vaccine can be given at the same time as immune-globulin.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Immune globulin 0.02 ml/kg IM x 1 <AND>\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Acute viral hepatitis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Hepatitis A, Acute, Treatment\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-to-date article: Hepatitis A virus infections: Treatment and prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 171,
    "fields": {
      "name": "ORZID2 GMENU ABX HEPATITIS B",
      "term": null,
      "displaytext": "Hepatitis B  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B Vaccine Information Page\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 900, \"DisplayText\": \"Hepatitis B Evaluation Anti-CD20 Antibody\", \"Text\": \"Hepatitis B Evaluation\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HEPATITIS B\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute disease management\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Most acute hepatitis B disease is mild and self-limited. Patients who appear to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"be developing fulminant hepatitis, including those with mental status changes\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"should receive supportive treatment. Fulminant hepatitis is suggested by\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"increased prothrombin time, cholestasis, ascites, decreased liver size, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"decreasing serum albumin. Supportive treatment includes maintenance of fluid\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and electrolyte balance, monitoring and possible correction of coagulation\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"defects, treatment of hepatic encephalopathy, and good nutrition with a low-\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"protein diet. Antiviral therapy is not indicated. Gastroenterology consult\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"encouraged.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Chronic disease management\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Antiviral therapy for chronic hepatitis B is a complicated, highly specialized\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"task. Consult with gastroenterology and infectious diseases.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Vaccinate persons at high risk of disease including men who have sex with men,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"illegal drug users, and health care workers with substantial exposure to blood\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"or body fluids.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Select below for Hepatitis B evaluation for patients receiving Anti-CD20\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Antibody Treatment\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Acute viral hepatitis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Chronic viral hepatitis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-to-date article: Hepatitis B virus: Overview of management\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 172,
    "fields": {
      "name": "ORZID2 GMENU ABX HEPATITIS C",
      "term": null,
      "displaytext": "Hepatitis C  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HEPATITIS C\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment of acute disease\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Most acute disease is asymptomatic or mild. Patients with acute hepatitis C\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be referred to the Hepatitis C clinic. Treatment may be indicated for\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"disease that persists beyond 2 months\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Chronic disease treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antiviral therapy for chronic hepatitis C is a complicated, highly specialized\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"task\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Acute viral hepatitis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Chronic viral hepatitis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-to-date article: Overview of the management of chronic hepatitis C virus\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 173,
    "fields": {
      "name": "ORZID2 GMENU ABX HERPES KERATITIS",
      "term": null,
      "displaytext": "HERPES KERATITIS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO q8h\", \"Text\": \"Acyclovir 400 mg PO q8h for 7-10 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO q12h ($) [R]\", \"Text\": \"Valacyclovir 500 mg PO q12h for 7-10 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800MG PO 5x/d\", \"Text\": \"Acyclovir 800 mg PO 5x/day for 14-21 days ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO q8h ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO q8h for 14-21 days ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO BID\", \"Text\": \"Acyclovir 400 mg PO Q12h for 12 months ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO Q24h ($) [R]\", \"Text\": \"Valacyclovir 500 mg PO Q24h for 12 months ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES KERATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Ocular herpes infection can be caused by either HSV-1 or HSV-2. The majority of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cases are caused by HSV-1. The recurrence rate of ocular herpes is 40% over a 5\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"year period, less than that of oral or genital herpes. Ocular herpes is a\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"major cause of blindness and typically presents as infection of the epithelium\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"of the cornea but can also rarely involve the stroma and endothelium.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Ophthalmology consultation is recommended.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Involvement of the stroma or endothelium requires treatment with topical\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"steroid and close monitoring. For these cases, start oral antiviral and consult\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"ophthalmology for management.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Antiviral prophylaxis is recommended for patients with multiple recurrences,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"recurrent episodes with ulceration, recurrent inflammation with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"scar/vascularization approaching visual axis, patients who have had keratoplasty\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"for HSV-related scarring/astigmatism, and patients who have had HSV keratitis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"while on immunosuppressive therapy. Post-surgical prophylaxis is not discussed\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"here. Please consult ophthalmology for more information.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment of acute infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Without epithelial ulceration\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Ulceration of epithelium (Geographic ulcer)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Infection prophylaxis for prevention of recurrence\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Reassess need for prophylaxis every 12 months\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Baratz, Arch Ophthalmology, (2012) 130.1: 108-110\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Guess et al, The Ocular Surface, (2007) 5.3:240-250\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Wilhelmus, Cochrane Database of Systematic Reviews, (2015), 1:CD002898\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Miserocchi et al, Efficacy of Valacyclovir vs Acyclovir for the Prevention of\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Recurrent Herpes Simplex\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Virus Eye Disease: A Pilot Study, American Journal of Ophthalmology, 2007\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"144:547-551\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"White et al, Ocular Microbiology and Immunology Group and American Academy of\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Ophthalmology, (2014)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 174,
    "fields": {
      "name": "ORZID2 GMENU ABX HERPES SIMPLEX ESOPHAGITIS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO 5x/days\", \"Text\": \"Acyclovir 400 mg PO 5x/day (Cost $) [R] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1GM PO q12h\", \"Text\": \"Valacyclovir 1 gm PO q12h (Cost $) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO 5x/days\", \"Text\": \"Acyclovir 400 mg PO 5x/day (Cost $) [R] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1GM PO q12h\", \"Text\": \"Valacyclovir 1 gm PO q12h (Cost $) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 5 mg/kg IV Q8H\", \"Text\": \"Acyclovir 5 mg/kg IV q8h (Cost $) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES SIMPLEX ESOPHAGITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"HSV infection of the esophagus usually occurs in patients who are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"immunocompromised, typically solid organ and bone marrow transplant\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"recipients.  In healthy patients HSV esophagitis occurs occasionally,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"usually in men under the age of 40.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Patients usually present with odynophagia and dysphagia.  Fever\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"epigastric pain, nausea, vomiting, and heartburn are less frequent.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Some patients may have coexistent herpes labialis or oropharyngeal\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"ulcers.  Diagnosis is usually established with an upper endoscopy.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Suggestive findings may also be seen during a barium swallow.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Spontaneous resolution usually occurs in immunocompetent patients after\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"one to two weeks. Patients may respond more quickly if treated with a\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"short course of oral acyclovir.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treat for 7-10 days\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treat for 14-21 days\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Treat for 7-14 days\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"John Hopkin's Guides keyword: Herpes simplex virus\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes simplex\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date article: Herpes simplex virus infection of the esophagitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 175,
    "fields": {
      "name": "ORZID2 GMENU ABX HERPES WHITLOW",
      "term": null,
      "displaytext": "Herpes Whitlow (digit/hand cellulitis)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO q8h\", \"Text\": \"Acyclovir 400 mg PO q8h for 10 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1GM PO q12h\", \"Text\": \"Valacyclovir 1 gm PO q12h for 10 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES WHITLOW (DIGIT OR HAND CELLULITIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Alternative for easier compliance schedule\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Whitlow, herpetic\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 176,
    "fields": {
      "name": "ORZID2 GMENU ABX HIV-AIDS",
      "term": null,
      "displaytext": "HIV-AIDS  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INFECTIOUS DISEASE (INPT)\", \"Text\": \"ID consult\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRTC\", \"Text\": \"MRTC consult\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HIV\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"HIV infection and AIDS are associated with several host defense defects. Cell-\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"mediated immune defects render a patient more susceptible to opportunistic\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infections with pathogens like Pneumocystis jirovecii (formerly Pneumocystis\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"carinii), Toxoplasma gondii, cytomegalovirus, mycobacterium-avium intracellulare\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"complex, and Candida spp.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Contact ID or HIV (MRTC) service for assistance.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Rich RR, et al, eds. Clinical Immunology\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Roitt l, et al, eds. Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 177,
    "fields": {
      "name": "ORZID2 GMENU ABX HOME IV AT MPLS",
      "term": null,
      "displaytext": "Home IV at the Minneapolis VAMC",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HOME IV INFUSION COORDINATION\", \"Text\": \"Home IV consult (or page 7253)\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HOME IV AT THE MINNEAPOLIS VA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Minneapolis VA provides home IV therapy contracts with commercial providers. To\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"order home IV antimicrobials:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Step 1\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"An Infectious Disease staff physician must approve outpatient IV antimicrobials\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"in each case. Call x4185, or call the operator on off-tours to contact the ID\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"staff member on-call. If the ID service has been consulted, you must request\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Home IV approval and recommendations from the ID staff on-call.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Step 2\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Order a Home IV consult (click on quick order below). Note: Allow 24 hours for\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"home IV service assessment, teaching, etc to occur.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 178,
    "fields": {
      "name": "ORZID2 GMENU ABX HOW TO FIND ALT ABX",
      "term": null,
      "displaytext": "How to find an alternative antimicrobial",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"HOW TO FIND AN ALTERNATIVE ANTIMICROBIAL WITHIN THE CDSS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The CDSS has been developed locally with input from a broad, representative\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"group of clinicians. All antimicrobial recommendations within the Antimicrobial\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"CDSS are reviewed by a clinical pharmacist and an Infectious Diseases Medical\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Specialist. Recommendations provided are based on local susceptibility patterns,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"clinical evidence, local preferences, and national guidelines. In rare cases,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"the recommended antimicrobials and listed alternatives may not be preferred for\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the patient you are treating (e.g. isolate resistance, allergies, etc.). In\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"these cases, a broader set of alternative antimicrobials may be ordered through\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"the Antimicrobial CDSS. Like other antimicrobial orders in the CDSS,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antimicrobials ordered through the Alternative Antimicrobials menu do on require\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"a prior authorization or ID approval.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"To access the Alternative Antimicrobials menu, navigate to the menu containing\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"antimicrobial recommendations for the infectious disease you are treating.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"The Alternative Antimicrobial menu contains antimicrobial regimens that have\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"been deemed appropriate for use as alternatives to recommended antimicrobials by\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"the Antimicrobial P&T Subcommittee. If the list does not contain the preferred\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"antimicrobial, contact or consult Infectious Diseases.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"The regimens provided in the Alternative Antimicrobial menu are not tailored for\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"a specific infectious disease. The dose, frequency, and duration must be changed\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"based on the infectious disease you are treating as well as for patient specific\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"factors. The usage of alternative antimicrobials are monitored by the\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Antimicrobial CDSS team for appropriateness and to identify infectious diseases\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"for addition to the system.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"At the top of the menu, select:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"2 Help legend, allergy info, consults, alternative antimicrobials and more\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Then select- Alternative Antimicrobials to CDSS Recommendations\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Select the reason an alternative antimicrobial is required then the Alternative\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Antimicrobial menu will display.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 179,
    "fields": {
      "name": "ORZID2 GMENU ABX HOW TO USE CDSS",
      "term": null,
      "displaytext": "How to use the CDSS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 47, \"Column\": 1, \"Item\": 148, \"DisplayText\": \"Duration of antimicrobial therapy\", \"Text\": \"More information on duration of antimicrobial therapy\", \"Mnemonic\": \"4\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 150, \"DisplayText\": \"Elements of a CDSS Advice Page\", \"Text\": \"[Click Here]\", \"Mnemonic\": \"6\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 74, \"DisplayText\": \"Adjust existing antimicrobial therapy\", \"Text\": \"Adjusting existing antimicrobial therapy\", \"Mnemonic\": \"8\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 178, \"DisplayText\": \"How to find an alternative antimicrobial\", \"Text\": \"How to find an alternative antimicrobial within the CDSS\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HOW TO USE THE CDSS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The CDSS has been designed to offer antimicrobial prescribing advice quickly and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"efficiently. Since inpatient and outpatient drugs are ordered differently, the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"CDSS has both and inpatient and outpatient versions for prescribing.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"The Antimicrobial CDSS is located within CPRS. When CPRS is open, click on the\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Orders tab at the bottom left hand side of the CPRS window.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For inpatients\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"On the left-hand side of the \\\"Orders\\\" tab, click on the \\\"Medicine Inpt Orders.\\\"\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"now be open.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"For outpatients\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"On the left-hand side of the \\\"Orders\\\" tab, click on the \\\"Medicine Outpt Orders.\\\"\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"now be open.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Navigating Within the CDSS\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*Using the decision tree\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"The main menu of the Antimicrobial CDSS contains links to categories of\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"infectious diseases based on syndrome/organ system (e.g. cardiovascular,\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"genitourinary, etc.), organisms (e.g. gram-positive bacteria, gram-negative\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"bacteria, viruses, etc.) and other special cases. To navigate to specific\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"infectious disease, select the category the infectious disease is associated\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"with. Within the category menu, select the specific infectious disease sub-menu\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"for recommendations, quick orders and pertinent resources (e.g., section-\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"specific consults, important drug properties, CDSS system help resources, etc.).\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"*Using the Index\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"The Index is in the main menu at the top of the left-hand column under the\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"header Index of Antimicrobial CDSS content. The Index contains an alphabetized\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"list of Antimicrobial CDSS content. Find the infectious disease, organism or\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"other topic you are looking for by scrolling down the list. When you locate the\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"term you are looking for, click on it to be linked to the menu containing\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"specific recommendations, quick orders and pertinent resources.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Quick Orders\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Quick orders are preprogrammed with the usually recommended antimicrobial dose,\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"frequency and solution for the specific infectious disease.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Quick orders are not tailored to specific patient factors such as renal\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"insufficiency, comorbidities, contraindications, weight, allergies, etc. The\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"provider must assess every patient closely for these factors and modify\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"recommended antimicrobials if needed. To assist the provider, additional drug\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"information is provided within specific infectious diseases recommendation menus\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"and a link to more in depth information is provided at the top of these menus.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Alternatives to preferred antimicrobials quick orders are often provided in\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"recommendations, a broader selection of alternative antimicrobials is provided\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"in the Alternative Antimicrobial menu (see What if a Preferred Antimicrobial is\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"not Provided in the Recommendations?).\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Elements of a CDSS Advice Page\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"If you need to modify existing therapy\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"If you need an alternative antimicrobial\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"option.  In the right-hand column of the window that pops up, select \\\" 77\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobials (CDSS).\\\". The main menu of the Inpatient Antimicrobial CDSS will\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"option.In the right-hand column of the window that pops up, select \\\" 55\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Antimicrobial (CDSS).\\\". The main menu of the Outpatient Antimicrobial CDSS will\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 180,
    "fields": {
      "name": "ORZID2 GMENU ABX HSV ENCEPHALITIS",
      "term": null,
      "displaytext": "HSV Encephalitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 10 mg/kg IV q8h ($$) [R,DI]\", \"Text\": \"Acyclovir 10 mg/kg IV q8h ($$) [R,DI] for 14 to 21 days\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES SIMPLEX ENCEPHALITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Herpes simplex virus (HSV) type 1 is the leading cause of sporadic fatal\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"encephalitis worldwide and should be suspected in patients who have symptoms\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"unexplained by other causes. Typical symptoms include acute alteration of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"consciousness for more than 24 hours, fever, new onset seizures and/or focal\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"neurologic deficits. Patients taking natalizumab are at increased risk of HSV\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"encephalitis. Early diagnosis and treatment are essential to achieve resolution\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"of infection and symptoms. If diagnosis is not certain and there is little\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"likelihood of herniation, obtain cerebrospinal fluid (CSF) sample for HSV\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"polymerase chain reaction (PCR). MRI without contrast nearly always show\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"abnormal signs in patients with HSV encephalitis. Neurology and Infectious\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"disease consultations are strongly encouraged.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment, Initiate Immediately When HSV Encephalitis is Suspected\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Rabinstein, Neurol Clin, 2017, 695-705\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Encephalitis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-Date Article: Herpes simplex virus type 1 encephalitis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"*If BMI > 35, use IBW to dose\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 181,
    "fields": {
      "name": "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO",
      "term": null,
      "displaytext": "Ciprofloxacin PO",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"________________________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Ciprofloxacin PO\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Usual dose:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"250-500 mg q12h\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Dose adjustments for renal or hepatic insufficiency:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Creatinine clearance (ml/min) Dose adjustment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< 30250 mg q12h\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Hemodialysis  250-500 mg q24h\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Drug Interactions:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Hypoglycemia that can lead to coma especially in diabetics taking\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"oral hypoglycemic medicine or insulin.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Calcium, dairy products, iron, zinc, magnesium, aluminum  inhibit the absorption\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"of oral ciprofloxacin.  Give ciprofloxacin 2 hours before or 6 hours after these\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"drugs.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Increases effects of caffeine and theophylline by inhibiting  metabolism.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Monitor the patient for signs of agitation or anxiety.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Increases the effect of warfarin.  Monitor international normalized ratio (INR)\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"ratio (INR) frequently in patients taking warfarin.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Adverse Drug Reactions:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"FDA Drug Safety Communication\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"The U.S. Food and Drug Administration advised that the serious\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"side effects associated with fluoroquinolone antibacterial drugs\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"generally outweigh the benefits for patients with acute sinusitis, acute\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"bronchitis, and uncomplicated urinary tract infections who have other\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"treatment options. For patients with these conditions, fluoroquinolones should\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"be reserved for those who do not have alternative treatment options.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"An FDA safety review has shown that fluoroquinolones when used systemically\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"are associated with disabling and potentially permanent serious side effects\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"that can occur together. These side effects can involve the tendons,\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"muscles, joints, nerves, and central nervous system.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"FDA identified cases of hypoglycemic coma, resulting in death in some\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"instances. Most pateints had risk factors for hypoglycemia such as older age,\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"diabetes, renal insufficiency, and concomitant use of hypoglycemic drugs,\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"especally sulfonylureas.  FDA also identified reports of additional mental\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"health side effects, and requires that all fluoroquinolones include six\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"psychiatric adverse reactions (disturbance in attention, memory impairment,\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"delirium, nervousness, agitation and disorientation).\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Other adverse reactions:\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Nausea/vomiting, diarrhea, dizziness, confusion, CNS\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"stimulation, rare seizures, rare QT interval prolongation, and\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"tendinitis/tendon rupture. Six psychiatric adverse reactions\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"including disturbance in attention, memory impairment, delirium,\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"nervousness, agitation and disorientation.\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Hypoglycemia that can lead to coma, occuring more frequently in\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"the elderly and those with diabetes.\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Pregnancy Risk Factor Category: C\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 182,
    "fields": {
      "name": "ORZID2 GMENU ABX IMMUNOCOMPROMISED PATIENT",
      "term": null,
      "displaytext": "Infections in Immunocompromised Patients",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 446, \"DisplayText\": \"Basic concepts\", \"Text\": \"Basic concepts\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 447, \"DisplayText\": \"Complement deficiency\", \"Text\": \"Complement deficiency\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Spleen absent or dysfunctional\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 451, \"DisplayText\": \"Malnutrition\", \"Text\": \"Malnutrition\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 448, \"DisplayText\": \"Diabetes Mellitus\", \"Text\": \"Diabetes Mellitus\", \"Mnemonic\": \"12\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 452, \"DisplayText\": \"Neurological dysfunction\", \"Text\": \"Neurological dysfunction\", \"Mnemonic\": \"14\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 456, \"DisplayText\": \"Tobacco smoke\", \"Text\": \"Tobacco smoke\", \"Mnemonic\": \"16\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 455, \"DisplayText\": \"Stress\", \"Text\": \"Stress\", \"Mnemonic\": \"18\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 449, \"DisplayText\": \"Hypochlorhydria\", \"Text\": \"Hypochlorhydria\", \"Mnemonic\": \"20\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 445, \"DisplayText\": \"Altered microbial flora\", \"Text\": \"Altered microbial flora\", \"Mnemonic\": \"22\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 450, \"DisplayText\": \"Malignancy\", \"Text\": \"Malignancy\", \"Mnemonic\": \"24\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 454, \"DisplayText\": \"Neutropenia\", \"Text\": \"Neutropenia\", \"Mnemonic\": \"26\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 453, \"DisplayText\": \"Neutropenic fever\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"28\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 498, \"DisplayText\": \"Neutropenic fever--Patient is a candidate for oral therapy\", \"Text\": \"Oral therapy for neutropenic fever\", \"Mnemonic\": \"30\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 497, \"DisplayText\": \"Neutropenic fever--Patient is NOT a candidate for oral therapy\", \"Text\": \"Empirical intravenous therapy for neutropenic fever\", \"Mnemonic\": \"32\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 499, \"DisplayText\": \"Modification to Neutropenic fever therapy\", \"Text\": \"Modification to neutropenic fever therapy\", \"Mnemonic\": \"34\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"36\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ INFECTIONS IN IMMUNOCOMPROMISED PATIENTS ++\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Innate defects\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"HIV\", \"Mnemonic\": \"40\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 345, \"DisplayText\": \"Cell-mediated immunity (CMI) defects\", \"Text\": \"Cell-mediated immunity (CMI) defects\", \"Mnemonic\": \"42\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 444, \"DisplayText\": \"Immunoglobulin (Humoral immune system) deficiency\", \"Text\": \"Immunoglobulin (humoral immune system) deficiency\", \"Mnemonic\": \"44\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 626, \"DisplayText\": \"Transplantation\", \"Text\": \"Transplantation\", \"Mnemonic\": \"46\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Immune defects\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 183,
    "fields": {
      "name": "ORZID2 GMENU ABX IMPETIGO",
      "term": null,
      "displaytext": "Impetigo  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topical to affected area q8h\", \"Text\": \"Mupirocin ointment to affected area q8h for 5 days ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100MG PO q12h ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100MG PO q12h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"16\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Impetigo and Ecthyma\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Impetigo is a superficial skin infection that rarely causes systemic\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"symptoms. Ecthyma is a skin infection characterized by crusted sores\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"beneath which ulcers form. It is a deep form of impetigo, as the same\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"bacteria causing the infection are involved. Ecthyma causes deeper\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"erosions of the skin into the dermis.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Gram stain and culture of the pus or exudates from skin lesions of\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"impetigo and ecthyma are recommended to help identify whether\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Staphylococcus aureus and/or beta-hemolytic Streptococcus is the cause.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Bullous and non-bullous impetigo can be treated with oral or topical\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"antimicrobials, but oral therapy is recommended for patients with\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"numerous lesions or in outbreaks affecting several people to help\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"decrease transmission of infection. Treatment for ecthyma should be an\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"oral antimicrobial.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment for impetigo with few lesions\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment for ecthyma and for impetigo with numerous lesions or\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"whose symptoms have not responded to topical treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treat orally for 7 days\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"IF MRSA confirmed or suspected:\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014 59: 147\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 184,
    "fields": {
      "name": "ORZID2 GMENU ABX IMPORTANT BETA-LACTAM ALLERGY FACTS",
      "term": null,
      "displaytext": "Important Beta-lactam Allergy Facts and Reaction History  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Important Beta-lactam Allergy Facts\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"1. 10% of patients report an allergy to penicillin.\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"2. Less than 1% of patients are truly allergic to penicillin.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"3. 80% of patients who had an immediate allergic reaction (Type I,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Immunoglobulin E (IgE)-mediated) to penicillin lose sensitivity after 10\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"years.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"4. Cross-reactivity between penicillin and cephalosporins occurs in only 2% of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"patients and most patients do not have clinically significant reactions.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Obtaining a Detailed Reaction History\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"- Locate documented reaction information within the Computerized Patient Record\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"System (CPRS)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"> Reported reactions can be found in the Cover Sheet under Allergies/Adverse\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Reactions. Double click on the specific reaction for more information,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"including signs/symptoms and date of reaction.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"> A reaction report can also be found here: Reports tab -> Clinical Reports -\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Allergies.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"- Determine beta-lactam medication history. A list of all locally prescribed\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"medications can be found here: Reports tab -> Clinical Reports -> Pharmacy ->\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"All Medications.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"- Interview the patient or family for details about the reaction. Questions to\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"ask during the interview:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"> What medication were you taking when the reaction occurred? DO NOT accept\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Penicillin or Cephalosporin as an allergy, ensure specific offending\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"medication is identified.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"> How long after taking the medication did the reaction occur? Immediate\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"reactions typically occur within 1 hour and up to 72 hours after\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"administration. Delayed reactions occur after 72 hours.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"> How long ago did the reaction occur? Did it occur over 10 years ago?\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"> What kind of reaction occurred? Did the reaction require medical attention?\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Blumenthal et. al., Addressing Inpatient Beta-Lactam Allergies: A Multihospital\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Implementation. J Allergy Clin Immunol Pract. 2017, 5(3)616-625\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Is it Really a Penicillin Allergy? Centers for Disease Control and Prevention,\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"2017\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Chaudhry et al., Cephalosporins: A Focus on Side Chains and Beta-Lactam Cross-\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Reactivity. Pharmacy, 2019, 7(3)103\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Collins, et al. Impact of an Antibiotic Side-Chain-Based Cross-reactivity Chart\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Combined With Enhanced Allergy Assessment Processes for Surgical Prophylaxis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Antimicrobials in Patients With Beta-Lactam Allergies. Clinical Infectious\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Diseases, 2020\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Patrick et al., Beta-lactam allergy Benefits of de-labeling can be achieved\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"safely. BC Medical Journal, 2019, 61(9)350\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Sakoulas et al., Is a Reported Penicillin Allergy Sufficient Grounds to Forgo\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"the Multidimensional Antimicrobial Benefits of Beta-Lactam Antibiotics?\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Clinical Infectious Diseases, 2019, 68(1)157\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Shenoy et al., Evaluation and Management of Penicillin Allergy. JAMA. 2019,\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"321(2)188\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Immunol. 2010, 105(4)259\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Drug Allergy, Beta-lactams\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Tribiano et al. The Three C's of Antibiotic Allergy - Classification, Cross-\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Reactivity and Collaboration. J Allergy Clin Immunol Pract, 2017, 5(6)1532-\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"1542\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"cephalosporins and related antibiotics\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Up-to-Date article: Drug allergy: Classification and clinical features\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Zagursky et al., Cross-reactivity in b-Lactam Allergy. J Allergy Clin Immunol\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Pract. 2018, 6(1)72\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Solensky et al., Drug Allergy: An Updated Practice Parameter. Ann Allergy Asthma\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 185,
    "fields": {
      "name": "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES",
      "term": null,
      "displaytext": "Important drug properties",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 18, \"Column\": 1, \"Item\": 3024, \"DisplayText\": \"UP TO DATE WEB SITE\", \"Text\": \"Up-to-Date online (Lexicomp)\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sanford Guide Web Site\", \"Text\": \"Sanford online\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Alphabet: A-B (acyclovir-benzathine penicllin)\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Alphabet: C(caspofungin-clindamycin)\", \"Mnemonic\": \"10\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Alphabet D-E-F(daptomycin-fosfomycin)\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Alphabet: G-H-I-J-K-L  (ganciclovir-linezolid)\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Alphabet M-N-O(metronidazole-oseltamivir)\", \"Mnemonic\": \"16\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Alphabet: P-Q-R-S(paromomycin-sulfadiazine)\", \"Mnemonic\": \"18\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Alphabet: T-U-V-W-X-Y-Z(terconazole-zanamivir)\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"IMPORTANT DRUG PROPERTIES CODING\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Next to each drug quick order in CDSS, there are letters alerting the user to\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"important properties associated with that drug:\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"[DI]= clinically important drug interactions\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"[H] = may require dose adjustment in patients with hepatic dysfunction\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"[R] = may require dose adjustment in patients with renal dysfunction\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"[O] = other important information\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"[M] = minimal\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"The Important Drug Properties menu contains valuable information on common or\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"severe adverse effects, drug interactions and dose adjustments for hepatic and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"renal failure. This list is not comprehensive. Refer to Up-to-date, found in\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Clinical Online Resources under the Tools menu in CPRS, or click on the ling\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"below for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Infectious Diseases and Pharmacy Services can help with dose adjustments.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Important Drug Properties Menu Select by Alphabet of Generic Name\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Links to Sanford and Up-to-Date (Lexicomp) for drug information\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 186,
    "fields": {
      "name": "ORZID2 GMENU ABX INDEX INPATIENT",
      "term": null,
      "displaytext": "Inpatient Antimicrobial CDSS Index",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": 119, \"DisplayText\": \"Central Nervous System\", \"Text\": \"Abscess, brain\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 350, \"DisplayText\": \"Cranial epidural abscess\", \"Text\": \"Abscess, cranial epidural\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 351, \"DisplayText\": \"Cutaneous abscess\", \"Text\": \"Abscess, cutaneous\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 200, \"DisplayText\": \"\", \"Text\": \"Abscess, liver\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 201, \"DisplayText\": \"Lung abscess\", \"Text\": \"Abscess, lung\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Abscess, perianal/anorectal\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 67, \"DisplayText\": \"Abscesses:  Cutaneous abscess, Furuncle, Carbuncle, Pyomyositis\", \"Text\": \"Abscess, skin and soft tissue\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 569, \"DisplayText\": \"Spinal epidural abscess\", \"Text\": \"Abscess, spinal epidural\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 411, \"DisplayText\": \"Acinetobacter baumanni\", \"Text\": \"Acinetobacter baumannii, general\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 217, \"DisplayText\": \"Nosocomial pneumonia with Acinetobacter baumannii\", \"Text\": \"Acinetobacter baumannii, nosocomial pneumonia\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"Acquired immunodeficiency syndrome (AIDS)\", \"Mnemonic\": \"22\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 421, \"DisplayText\": \"Actinomyces spp.\", \"Text\": \"Actinomyces infections, general\", \"Mnemonic\": \"24\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Adenovirus diarrhea/gastroenteritis\", \"Mnemonic\": \"26\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 459, \"DisplayText\": \"Large uniform rods in an aerobic bottle\", \"Text\": \"Aerobic bottle, large uniform bacilli\", \"Mnemonic\": \"28\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 467, \"DisplayText\": \"Small pleomorphic rods in aerobic bottle\", \"Text\": \"Aerobic bottle, small pleomorphic bacilli\", \"Mnemonic\": \"30\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 75, \"DisplayText\": \"Diarrhea with Aeromonas\", \"Text\": \"Aeromonas diarrhea/gastroenteritis\", \"Mnemonic\": \"32\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Aggregatibacter native valve endocarditis\", \"Mnemonic\": \"34\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Aggregatibacter prosthetic valve endocarditis\", \"Mnemonic\": \"36\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 144, \"DisplayText\": \"Drug allergies\", \"Text\": \"Allergy information\", \"Mnemonic\": \"38\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 445, \"DisplayText\": \"Altered microbial flora\", \"Text\": \"Altered microbial flora\", \"Mnemonic\": \"40\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 199, \"DisplayText\": \"\", \"Text\": \"Amebic liver abscess\", \"Mnemonic\": \"42\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 458, \"DisplayText\": \"Large uniform rods in an anaerobic bottle\", \"Text\": \"Anaerobic bottle, large uniform bacilli\", \"Mnemonic\": \"44\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 468, \"DisplayText\": \"Small pleomorphic rods in an anaerobic bottle\", \"Text\": \"Anaerobic bottle, small pleomorphic bacilli\", \"Mnemonic\": \"46\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 422, \"DisplayText\": \"Anaerobic Gram-positive cocci (including Peptostreptococcus)\", \"Text\": \"Anaerobic gram-positive cocci\", \"Mnemonic\": \"48\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 301, \"DisplayText\": \"Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)\", \"Text\": \"Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)\", \"Mnemonic\": \"50\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Anorectal abscess\", \"Mnemonic\": \"52\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 529, \"DisplayText\": \"Prevention of bacterial infection in a patient with malignancy\", \"Text\": \"Antibacterial prophylaxis in malignancy\", \"Mnemonic\": \"54\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antibiogram\", \"Mnemonic\": \"56\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 530, \"DisplayText\": \"Prevention of fungal infections in a patient with malignancy\", \"Text\": \"Antifungal prophylaxis in malignancy\", \"Mnemonic\": \"58\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 1057, \"DisplayText\": \"\", \"Text\": \"Antimicrobial interactions with warfarin\", \"Mnemonic\": \"60\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Antimicrobial shortages updates\", \"Mnemonic\": \"62\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antimicrobial susceptibilities\", \"Mnemonic\": \"64\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 304, \"DisplayText\": \"\", \"Text\": \"Antiviral prophylaxis in malignancy\", \"Mnemonic\": \"66\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 308, \"DisplayText\": \"Appendicitis with perforation\", \"Text\": \"Appendicitis with perforation\", \"Mnemonic\": \"68\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 307, \"DisplayText\": \"Appendicitis without perforation\", \"Text\": \"Appendicitis without perforation\", \"Mnemonic\": \"70\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 480, \"DisplayText\": \"Arthritis associated with Lyme disease\", \"Text\": \"Arthritis associated with Lyme disease\", \"Mnemonic\": \"72\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 386, \"DisplayText\": \"Aspergillus spp.\", \"Text\": \"Aspergillus infections, general\", \"Mnemonic\": \"74\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 83, \"DisplayText\": \"Aspiration pneumonia\", \"Text\": \"Aspiration pneumonia\", \"Mnemonic\": \"76\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Asplenia [CLICK HERE], includes:\", \"Mnemonic\": \"78\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Astrovirus diarrhea/gastroenteritis\", \"Mnemonic\": \"80\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 223, \"DisplayText\": \"Bacteruria, Candiduria, and Pyuria\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"82\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 223, \"DisplayText\": \"Bacteruria, Candiduria, and Pyuria\", \"Text\": \"Asymptomatic candiduria\", \"Mnemonic\": \"84\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 223, \"DisplayText\": \"Bacteruria, Candiduria, and Pyuria\", \"Text\": \"Asymptomatic pyuria\", \"Mnemonic\": \"86\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 312, \"DisplayText\": \"Babesia species\", \"Text\": \"Babesia infections, general\", \"Mnemonic\": \"88\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 269, \"DisplayText\": \"Diarrhea with Shigella species (bacillary dysentery)\", \"Text\": \"Bacillary dysentery\", \"Mnemonic\": \"90\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 459, \"DisplayText\": \"Large uniform rods in an aerobic bottle\", \"Text\": \"Bacilli, large uniform, aerobic bottle\", \"Mnemonic\": \"92\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 458, \"DisplayText\": \"Large uniform rods in an anaerobic bottle\", \"Text\": \"Bacilli, large uniform, anaerobic bottle\", \"Mnemonic\": \"94\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 467, \"DisplayText\": \"Small pleomorphic rods in aerobic bottle\", \"Text\": \"Bacilli, small pleomorphic, aerobic bottle\", \"Mnemonic\": \"96\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 468, \"DisplayText\": \"Small pleomorphic rods in an anaerobic bottle\", \"Text\": \"Bacilli, small pleomorphic, anaerobic bottle\", \"Mnemonic\": \"98\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 423, \"DisplayText\": \"Bacillus species\", \"Text\": \"Bacillus infections, general\", \"Mnemonic\": \"100\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 87, \"DisplayText\": \"Bacteremia\", \"Text\": \"Bacteremia\", \"Mnemonic\": \"102\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 399, \"DisplayText\": \"Gram-negative Bacteria\", \"Text\": \"Bacteria, Gram-Negative section\", \"Mnemonic\": \"104\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 400, \"DisplayText\": \"Gram-positive bacteria\", \"Text\": \"Bacteria, Gram-Positive section\", \"Mnemonic\": \"106\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 223, \"DisplayText\": \"Bacteruria, Candiduria, and Pyuria\", \"Text\": \"Bacteriuria\", \"Mnemonic\": \"108\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 401, \"DisplayText\": \"Bacteroides spp. (including Prevotella, Porphyromonas)\", \"Text\": \"Bacteroides infections, general\", \"Mnemonic\": \"110\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 328, \"DisplayText\": \"Bed Bugs (Hemiptera)\", \"Text\": \"Bed bugs\", \"Mnemonic\": \"112\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 91, \"DisplayText\": \"Bell's Palsy\", \"Text\": \"Bell's palsy\", \"Mnemonic\": \"114\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 333, \"DisplayText\": \"Bite wounds\", \"Text\": \"Bite wounds\", \"Mnemonic\": \"116\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 387, \"DisplayText\": \"Blastomyces dermatidis\", \"Text\": \"Blastomycosis infections, general\", \"Mnemonic\": \"118\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 334, \"DisplayText\": \"Body Lice (Pediculosis Corporis)\", \"Text\": \"Body lice\", \"Mnemonic\": \"120\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 270, \"DisplayText\": \"Soft tissue, muscle, bone and joint infections\", \"Text\": \"Bone and Joint section\", \"Mnemonic\": \"122\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"Bone marrow transplant immunizations\", \"Mnemonic\": \"124\"}, {\"Row\": 74, \"Column\": 1, \"Item\": 536, \"DisplayText\": \"Enterococci infections in bone or joint prostheses\", \"Text\": \"Bone prosthesis infection\", \"Mnemonic\": \"126\"}, {\"Row\": 75, \"Column\": 1, \"Item\": 412, \"DisplayText\": \"Bordetella species\", \"Text\": \"Bordetella infections, general\", \"Mnemonic\": \"128\"}, {\"Row\": 76, \"Column\": 1, \"Item\": 335, \"DisplayText\": \"Brain abscess resulting from contiguous or hematogenous spread of infection\", \"Text\": \"Brain abscess from contiguous or hematogenous spread\", \"Mnemonic\": \"130\"}, {\"Row\": 77, \"Column\": 1, \"Item\": 336, \"DisplayText\": \"Brain Abscess with Nocardia spp.\", \"Text\": \"Brain abscess with Nocardia spp.\", \"Mnemonic\": \"132\"}, {\"Row\": 78, \"Column\": 1, \"Item\": 338, \"DisplayText\": \"Brain Abscess with Pseudomonas spp.\", \"Text\": \"Brain abscess with Pseudomonas spp.\", \"Mnemonic\": \"134\"}, {\"Row\": 79, \"Column\": 1, \"Item\": 339, \"DisplayText\": \"Brain Abscess with Toxoplasma gondii\", \"Text\": \"Brain abscess with Toxoplasma gondii\", \"Mnemonic\": \"136\"}, {\"Row\": 80, \"Column\": 1, \"Item\": 337, \"DisplayText\": \"Post-surgical or post-traumatic brain abscess\", \"Text\": \"Brain abscess, post-surgical or post-traumatic\", \"Mnemonic\": \"138\"}, {\"Row\": 81, \"Column\": 1, \"Item\": 94, \"DisplayText\": \"Consider Antibiotic\", \"Text\": \"Bronchitis\", \"Mnemonic\": \"140\"}, {\"Row\": 82, \"Column\": 1, \"Item\": 95, \"DisplayText\": \"Bronchitis not benefited\", \"Text\": \"Bronchitis in otherwise healthy patient\", \"Mnemonic\": \"142\"}, {\"Row\": 83, \"Column\": 1, \"Item\": 413, \"DisplayText\": \"Brucella spp.\", \"Text\": \"Brucella infections, general\", \"Mnemonic\": \"144\"}, {\"Row\": 84, \"Column\": 1, \"Item\": 413, \"DisplayText\": \"Brucella spp.\", \"Text\": \"Brucella spp.\", \"Mnemonic\": \"146\"}, {\"Row\": 85, \"Column\": 1, \"Item\": 566, \"DisplayText\": \"Septic bursitis\", \"Text\": \"Bursitis, septic\", \"Mnemonic\": \"148\"}, {\"Row\": 88, \"Column\": 1, \"Item\": 99, \"DisplayText\": \"Diarrhea with Campylobacter\", \"Text\": \"Campylobacter diarrhea/gastroenteritis\", \"Mnemonic\": \"150\"}, {\"Row\": 89, \"Column\": 1, \"Item\": 402, \"DisplayText\": \"Campylobacter spp.\", \"Text\": \"Campylobacter, general\", \"Mnemonic\": \"152\"}, {\"Row\": 90, \"Column\": 1, \"Item\": 450, \"DisplayText\": \"Malignancy\", \"Text\": \"Cancer [CLICK HERE], includes:\", \"Mnemonic\": \"154\"}, {\"Row\": 92, \"Column\": 1, \"Item\": 388, \"DisplayText\": \"Candida albicans\", \"Text\": \"Candida albicans infections, general\", \"Mnemonic\": \"156\"}, {\"Row\": 93, \"Column\": 1, \"Item\": 389, \"DisplayText\": \"Candida glabrata\", \"Text\": \"Candida glabrata infections, general\", \"Mnemonic\": \"158\"}, {\"Row\": 94, \"Column\": 1, \"Item\": 469, \"DisplayText\": \"Intravascular catheter-associated Candida Spp. infection\", \"Text\": \"Candida intravascular catheter-associated infection\", \"Mnemonic\": \"160\"}, {\"Row\": 95, \"Column\": 1, \"Item\": 390, \"DisplayText\": \"Candida krusei\", \"Text\": \"Candida krusei infections, general\", \"Mnemonic\": \"162\"}, {\"Row\": 96, \"Column\": 1, \"Item\": 545, \"DisplayText\": \"Retinitis\", \"Text\": \"Candida retinitis\", \"Mnemonic\": \"164\"}, {\"Row\": 97, \"Column\": 1, \"Item\": 100, \"DisplayText\": \"Candida urinary tract infection\", \"Text\": \"Candida urinary tract infection\", \"Mnemonic\": \"166\"}, {\"Row\": 98, \"Column\": 1, \"Item\": 101, \"DisplayText\": \"Candida Vulvo-Vaginitis\", \"Text\": \"Candida vulvo-vaginitis\", \"Mnemonic\": \"168\"}, {\"Row\": 99, \"Column\": 1, \"Item\": 323, \"DisplayText\": \"Bacteremia associated with Candida spp.\", \"Text\": \"Candidemia\", \"Mnemonic\": \"170\"}, {\"Row\": 100, \"Column\": 1, \"Item\": 352, \"DisplayText\": \"Cutaneous Candidiasis\", \"Text\": \"Candidiasis\", \"Mnemonic\": \"172\"}, {\"Row\": 101, \"Column\": 1, \"Item\": 223, \"DisplayText\": \"Bacteruria, Candiduria, and Pyuria\", \"Text\": \"Candiduria\", \"Mnemonic\": \"174\"}, {\"Row\": 102, \"Column\": 1, \"Item\": 394, \"DisplayText\": \"Furuncles and carbuncles\", \"Text\": \"Carbuncles\", \"Mnemonic\": \"176\"}, {\"Row\": 103, \"Column\": 1, \"Item\": 481, \"DisplayText\": \"Cardiac disease associated with Lyme disease\", \"Text\": \"Cardiac disease associated with Lyme disease\", \"Mnemonic\": \"178\"}, {\"Row\": 104, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Cardiobacterium native valve endocarditis\", \"Mnemonic\": \"180\"}, {\"Row\": 105, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Cardiobacterium prosthetic valve endocarditis\", \"Mnemonic\": \"182\"}, {\"Row\": 106, \"Column\": 1, \"Item\": 187, \"DisplayText\": \"Infections involves cardiovascular devices (excluding valves)\", \"Text\": \"Cardiovascular device infections (excluding valves)\", \"Mnemonic\": \"184\"}, {\"Row\": 108, \"Column\": 1, \"Item\": 474, \"DisplayText\": \"Intravascular catheter-associated infection\", \"Text\": \"Catheter-associated infection, intravascular\", \"Mnemonic\": \"186\"}, {\"Row\": 109, \"Column\": 1, \"Item\": 343, \"DisplayText\": \"Cat-Scratch Disease\", \"Text\": \"Cat-scratch disease\", \"Mnemonic\": \"188\"}, {\"Row\": 110, \"Column\": 1, \"Item\": 345, \"DisplayText\": \"Cell-mediated immunity (CMI) defects\", \"Text\": \"Cell-mediated immunity (CMI) defects\", \"Mnemonic\": \"190\"}, {\"Row\": 111, \"Column\": 1, \"Item\": 104, \"DisplayText\": \"Cellulitis\", \"Text\": \"Cellulitis\", \"Mnemonic\": \"192\"}, {\"Row\": 112, \"Column\": 1, \"Item\": 175, \"DisplayText\": \"Herpes Whitlow (digit/hand cellulitis)\", \"Text\": \"Cellulitis, herpes whitlow\", \"Mnemonic\": \"194\"}, {\"Row\": 113, \"Column\": 1, \"Item\": 527, \"DisplayText\": \"Postseptal Cellulitis\", \"Text\": \"Cellulitis, postseptal (orbital)\", \"Mnemonic\": \"196\"}, {\"Row\": 114, \"Column\": 1, \"Item\": 528, \"DisplayText\": \"Preseptal Cellulitis\", \"Text\": \"Cellulitis, preseptal\", \"Mnemonic\": \"198\"}, {\"Row\": 115, \"Column\": 1, \"Item\": 119, \"DisplayText\": \"Central Nervous System\", \"Text\": \"Central Nervous System section\", \"Mnemonic\": \"200\"}, {\"Row\": 116, \"Column\": 1, \"Item\": 105, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Cervicitis associated with sexually transmitted diseases\", \"Mnemonic\": \"202\"}, {\"Row\": 117, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Chickenpox vaccination\", \"Mnemonic\": \"204\"}, {\"Row\": 118, \"Column\": 1, \"Item\": 245, \"DisplayText\": \"Primary infection (Chickenpox)\", \"Text\": \"Chickenpox, primary infection\", \"Mnemonic\": \"206\"}, {\"Row\": 119, \"Column\": 1, \"Item\": 249, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\")\", \"Text\": \"Chickenpox, reactivation of primary infection\", \"Mnemonic\": \"208\"}, {\"Row\": 120, \"Column\": 1, \"Item\": 293, \"DisplayText\": \"Urethritis associated with sexually transmitted diseases\", \"Text\": \"Chlamydia urethritis\", \"Mnemonic\": \"210\"}, {\"Row\": 121, \"Column\": 1, \"Item\": 107, \"DisplayText\": \"Cholangitis\", \"Text\": \"Cholangitis\", \"Mnemonic\": \"212\"}, {\"Row\": 122, \"Column\": 1, \"Item\": 108, \"DisplayText\": \"Cholecystitis\", \"Text\": \"Cholecystitis\", \"Mnemonic\": \"214\"}, {\"Row\": 123, \"Column\": 1, \"Item\": 414, \"DisplayText\": \"Citrobacter spp.\", \"Text\": \"Citrobacter infections, general\", \"Mnemonic\": \"216\"}, {\"Row\": 124, \"Column\": 1, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Clostridium difficile suspected, sepsis\", \"Mnemonic\": \"218\"}, {\"Row\": 125, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Clostridium difficile, mild to moderate disease\", \"Mnemonic\": \"220\"}, {\"Row\": 126, \"Column\": 1, \"Item\": 286, \"DisplayText\": \"Severe disease - Ileus/Toxic megacolon\", \"Text\": \"Clostridium difficile, severe/life-threatening disease\", \"Mnemonic\": \"222\"}, {\"Row\": 127, \"Column\": 1, \"Item\": 424, \"DisplayText\": \"Clostridium spp.\", \"Text\": \"Clostridium infections, general\", \"Mnemonic\": \"224\"}, {\"Row\": 128, \"Column\": 1, \"Item\": 243, \"DisplayText\": \"Blood culture positive for coagulase negative staphylococci\", \"Text\": \"Coagulase negative staphylococci, single blood culture positive\", \"Mnemonic\": \"226\"}, {\"Row\": 129, \"Column\": 1, \"Item\": 324, \"DisplayText\": \"Bacteremia associated with Coagulase-negative Staphylococci (CNS)\", \"Text\": \"Coagulase-negative Staphylococci (CNS) bacteremia\", \"Mnemonic\": \"228\"}, {\"Row\": 130, \"Column\": 1, \"Item\": 432, \"DisplayText\": \"Treatment for Coagulase negative Staphylococci\", \"Text\": \"Coagulase-negative staphylococci, general\", \"Mnemonic\": \"230\"}, {\"Row\": 131, \"Column\": 1, \"Item\": 470, \"DisplayText\": \"Intravascular catheter-associated coagulase-negative staphylococcus infection\", \"Text\": \"Coagulase-negative staphylococci, intravascular catheter-associated infectio\", \"Mnemonic\": \"232\"}, {\"Row\": 132, \"Column\": 1, \"Item\": 391, \"DisplayText\": \"Coccidioidomyces\", \"Text\": \"Coccidioides infections, general\", \"Mnemonic\": \"234\"}, {\"Row\": 133, \"Column\": 1, \"Item\": 113, \"DisplayText\": \"CMV Colitis or Esophagistis\", \"Text\": \"Colitis, cytomegalovirus (CMV)\", \"Mnemonic\": \"236\"}, {\"Row\": 134, \"Column\": 1, \"Item\": 120, \"DisplayText\": \"Colonized respiratory tract in patient with a ventilator\", \"Text\": \"Colonized respiratory tract patient on a ventilator\", \"Mnemonic\": \"238\"}, {\"Row\": 135, \"Column\": 1, \"Item\": 121, \"DisplayText\": \"Colonized wounds\", \"Text\": \"Colonized wound\", \"Mnemonic\": \"240\"}, {\"Row\": 136, \"Column\": 1, \"Item\": 346, \"DisplayText\": \"Community acquired diarrhea\", \"Text\": \"Community-acquired diarrhea\", \"Mnemonic\": \"242\"}, {\"Row\": 137, \"Column\": 1, \"Item\": 122, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community-acquired pneumonia (CAP)\", \"Mnemonic\": \"244\"}, {\"Row\": 138, \"Column\": 1, \"Item\": 122, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community-acquired pneumonia (CAP), inpatient treatment setting\", \"Mnemonic\": \"246\"}, {\"Row\": 139, \"Column\": 1, \"Item\": 447, \"DisplayText\": \"Complement deficiency\", \"Text\": \"Complement deficiency\", \"Mnemonic\": \"248\"}, {\"Row\": 140, \"Column\": 1, \"Item\": 123, \"DisplayText\": \"Complicated Cystitis\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"250\"}, {\"Row\": 141, \"Column\": 1, \"Item\": 224, \"DisplayText\": \"Antibiotics not required\", \"Text\": \"Conditions not benefitted by antimicrobials\", \"Mnemonic\": \"252\"}, {\"Row\": 142, \"Column\": 1, \"Item\": 348, \"DisplayText\": \"Conjunctivitis\", \"Text\": \"Conjunctivitis\", \"Mnemonic\": \"254\"}, {\"Row\": 143, \"Column\": 1, \"Item\": 349, \"DisplayText\": \"\", \"Text\": \"Contact CDSS staff\", \"Mnemonic\": \"256\"}, {\"Row\": 144, \"Column\": 1, \"Item\": 335, \"DisplayText\": \"Brain abscess resulting from contiguous or hematogenous spread of infection\", \"Text\": \"Contiguous or hematogenous spread brain abscess\", \"Mnemonic\": \"258\"}, {\"Row\": 145, \"Column\": 1, \"Item\": 94, \"DisplayText\": \"Consider Antibiotic\", \"Text\": \"COPD exacerbation\", \"Mnemonic\": \"260\"}, {\"Row\": 146, \"Column\": 1, \"Item\": 86, \"DisplayText\": \"Azithromycin for Prevention of Exacerbations COPD\", \"Text\": \"COPD, prevention of exacerbations\", \"Mnemonic\": \"262\"}, {\"Row\": 147, \"Column\": 1, \"Item\": 425, \"DisplayText\": \"Corynebacterium spp.\", \"Text\": \"Corynebacterium spp.\", \"Mnemonic\": \"264\"}, {\"Row\": 148, \"Column\": 1, \"Item\": 542, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis)\", \"Text\": \"Crabs\", \"Mnemonic\": \"266\"}, {\"Row\": 149, \"Column\": 1, \"Item\": 350, \"DisplayText\": \"Cranial epidural abscess\", \"Text\": \"Cranial epidural abscess\", \"Mnemonic\": \"268\"}, {\"Row\": 150, \"Column\": 1, \"Item\": 392, \"DisplayText\": \"Cryptococcus Neoformans\", \"Text\": \"Cryptococcus neoformans\", \"Mnemonic\": \"270\"}, {\"Row\": 151, \"Column\": 1, \"Item\": 130, \"DisplayText\": \"Diarrhea with Cryptosporidium parvum\", \"Text\": \"Cryptosporidium parvum diarrhea/gastroenteritis\", \"Mnemonic\": \"272\"}, {\"Row\": 152, \"Column\": 1, \"Item\": 131, \"DisplayText\": \"Cyclospora cayetanensis\", \"Text\": \"Cyclospora cayetanensis diarrhea/gastroenteritis\", \"Mnemonic\": \"274\"}, {\"Row\": 153, \"Column\": 1, \"Item\": 123, \"DisplayText\": \"Complicated Cystitis\", \"Text\": \"Cystitis, complicated\", \"Mnemonic\": \"276\"}, {\"Row\": 154, \"Column\": 1, \"Item\": 291, \"DisplayText\": \"Uncomplicated Cystitis\", \"Text\": \"Cystitis, uncomplicated\", \"Mnemonic\": \"278\"}, {\"Row\": 155, \"Column\": 1, \"Item\": 115, \"DisplayText\": \"Cytomegalovirus (CMV) Main Page\", \"Text\": \"Cytomegalovirus (CMV) [CLICK HERE], includes:\", \"Mnemonic\": \"280\"}, {\"Row\": 160, \"Column\": 1, \"Item\": 276, \"DisplayText\": \"\", \"Text\": \"Decolonization of Staphylococcus aureus\", \"Mnemonic\": \"282\"}, {\"Row\": 161, \"Column\": 1, \"Item\": 353, \"DisplayText\": \"Decubitus ulcers\", \"Text\": \"Decubitus ulcers\", \"Mnemonic\": \"284\"}, {\"Row\": 162, \"Column\": 1, \"Item\": 354, \"DisplayText\": \"Deep Oropharyngeal Infections\", \"Text\": \"Deep oropharyngeal infections\", \"Mnemonic\": \"286\"}, {\"Row\": 163, \"Column\": 1, \"Item\": 576, \"DisplayText\": \"Suppurative odontogenic infections\", \"Text\": \"Dental infections\", \"Mnemonic\": \"288\"}, {\"Row\": 164, \"Column\": 1, \"Item\": 277, \"DisplayText\": \"Stasis dermatitis\", \"Text\": \"Dermatitis, stasis\", \"Mnemonic\": \"290\"}, {\"Row\": 165, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatological surgery guidelines\", \"Mnemonic\": \"292\"}, {\"Row\": 166, \"Column\": 1, \"Item\": 139, \"DisplayText\": \"Dermatological Infections\", \"Text\": \"Dermatological Infections section\", \"Mnemonic\": \"294\"}, {\"Row\": 167, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatology post-op infection\", \"Mnemonic\": \"296\"}, {\"Row\": 168, \"Column\": 1, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Desensitization protocol, penicillin\", \"Mnemonic\": \"298\"}, {\"Row\": 169, \"Column\": 1, \"Item\": 140, \"DisplayText\": \"Device-related infections\", \"Text\": \"Device-related infections\", \"Mnemonic\": \"300\"}, {\"Row\": 170, \"Column\": 1, \"Item\": 448, \"DisplayText\": \"Diabetes Mellitus\", \"Text\": \"Diabetes Mellitus\", \"Mnemonic\": \"302\"}, {\"Row\": 171, \"Column\": 1, \"Item\": 384, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus\", \"Text\": \"Diabetic foot ulcer\", \"Mnemonic\": \"304\"}, {\"Row\": 172, \"Column\": 1, \"Item\": 457, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis\", \"Text\": \"Diarrhea, infectious/gastroenteritis\", \"Mnemonic\": \"306\"}, {\"Row\": 173, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Diphtheria vaccination\", \"Mnemonic\": \"308\"}, {\"Row\": 174, \"Column\": 1, \"Item\": 158, \"DisplayText\": \"Exclusions\", \"Text\": \"Diseases and Syndromes not covered\", \"Mnemonic\": \"310\"}, {\"Row\": 175, \"Column\": 1, \"Item\": 630, \"DisplayText\": \"Diskitis and Vertebral Osteomyelitis\", \"Text\": \"Diskitis and vertebral osteomyelitis\", \"Mnemonic\": \"312\"}, {\"Row\": 176, \"Column\": 1, \"Item\": 357, \"DisplayText\": \"Disseminated Mycobacterium avium disease treatment\", \"Text\": \"Disseminated Mycobacterium avium\", \"Mnemonic\": \"314\"}, {\"Row\": 177, \"Column\": 1, \"Item\": 143, \"DisplayText\": \"Diverticulitis\", \"Text\": \"Diverticulitis\", \"Mnemonic\": \"316\"}, {\"Row\": 178, \"Column\": 1, \"Item\": 144, \"DisplayText\": \"Drug allergies\", \"Text\": \"Drug allergy information\", \"Mnemonic\": \"318\"}, {\"Row\": 179, \"Column\": 1, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Drug Information\", \"Mnemonic\": \"320\"}, {\"Row\": 180, \"Column\": 1, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Drug properties, important\", \"Mnemonic\": \"322\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"INPATIENT ANTIMICROIBAL CDSS INDEX\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"A through F\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"A______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"antimicrobial prophylaxis, management of fever,\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"patient initiated antibiotics, vaccines\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"B______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 87, \"Column\": 1, \"Text\": \"C______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 91, \"Column\": 1, \"Text\": \"antimicrobial prophylaxis, neutropenic fever\"}, {\"Row\": 156, \"Column\": 1, \"Text\": \"colitis, esophagitis, encephalitis, polyradiculopathy\"}, {\"Row\": 157, \"Column\": 1, \"Text\": \"retinitis, and pneumonia\"}, {\"Row\": 159, \"Column\": 1, \"Text\": \"D______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 183, \"Column\": 1, \"Item\": 168, \"DisplayText\": \"Head and Neck\", \"Text\": \"Ear, nose, throat (ENT)/Head and Neck section\", \"Mnemonic\": \"324\"}, {\"Row\": 184, \"Column\": 1, \"Item\": 372, \"DisplayText\": \"Ecthyma Gangrenosum\", \"Text\": \"Ecthyma gangrenosum\", \"Mnemonic\": \"326\"}, {\"Row\": 185, \"Column\": 1, \"Item\": 373, \"DisplayText\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)\", \"Text\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)\", \"Mnemonic\": \"328\"}, {\"Row\": 186, \"Column\": 1, \"Item\": 329, \"DisplayText\": \"Bite wounds with Eikenella corrodens\", \"Text\": \"Eikenella corrodens, bite wound\", \"Mnemonic\": \"330\"}, {\"Row\": 187, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Eikenella native valve endocarditis\", \"Mnemonic\": \"332\"}, {\"Row\": 188, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Eikenella prosthetic valve endocarditis\", \"Mnemonic\": \"334\"}, {\"Row\": 189, \"Column\": 1, \"Item\": 151, \"DisplayText\": \"Empyema\", \"Text\": \"Empyema\", \"Mnemonic\": \"336\"}, {\"Row\": 190, \"Column\": 1, \"Item\": 574, \"DisplayText\": \"Subdural Empyema\", \"Text\": \"Empyema, subdural\", \"Mnemonic\": \"338\"}, {\"Row\": 191, \"Column\": 1, \"Item\": 180, \"DisplayText\": \"HSV Encephalitis\", \"Text\": \"Encephalitis\", \"Mnemonic\": \"340\"}, {\"Row\": 192, \"Column\": 1, \"Item\": 114, \"DisplayText\": \"CMV Encephalitis\", \"Text\": \"Encephalitis, Cytomegalovirus (CMV)\", \"Mnemonic\": \"342\"}, {\"Row\": 193, \"Column\": 1, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Endocarditis with sepsis\", \"Mnemonic\": \"344\"}, {\"Row\": 194, \"Column\": 1, \"Item\": 80, \"DisplayText\": \"Approach to Endocarditis\", \"Text\": \"Endocarditis, approach to\", \"Mnemonic\": \"346\"}, {\"Row\": 195, \"Column\": 1, \"Item\": 142, \"DisplayText\": \"Diagnosis of Endocarditis\", \"Text\": \"Endocarditis, diagnosis of\", \"Mnemonic\": \"348\"}, {\"Row\": 196, \"Column\": 1, \"Item\": 365, \"DisplayText\": \"Native Valve Endocarditis--Selected Pathogens\", \"Text\": \"Endocarditis, native valve [CLICK HERE], includes:\", \"Mnemonic\": \"350\"}, {\"Row\": 200, \"Column\": 1, \"Item\": 364, \"DisplayText\": \"Native Valve Endocarditis - Empirical Therapy\", \"Text\": \"Endocarditis, native valve empirical therapy\", \"Mnemonic\": \"352\"}, {\"Row\": 201, \"Column\": 1, \"Item\": 369, \"DisplayText\": \"Prosthetic Valve Endocarditis--Selected Pathogens\", \"Text\": \"Endocarditis, prosthetic valve [CLICK HERE], includes:\", \"Mnemonic\": \"354\"}, {\"Row\": 205, \"Column\": 1, \"Item\": 368, \"DisplayText\": \"Prosthetic Valve Endocarditis--Empicaral Therapy\", \"Text\": \"Endocarditis, prosthetic valve empirical therapy\", \"Mnemonic\": \"356\"}, {\"Row\": 206, \"Column\": 1, \"Item\": 376, \"DisplayText\": \"Endophthalmitis\", \"Text\": \"Endophthalmitis\", \"Mnemonic\": \"358\"}, {\"Row\": 207, \"Column\": 1, \"Item\": 152, \"DisplayText\": \"Entoemeba histolytica\", \"Text\": \"Entamoeba histolytica diarrhea/gastroenteritis\", \"Mnemonic\": \"360\"}, {\"Row\": 208, \"Column\": 1, \"Item\": 153, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Enteric fever\", \"Mnemonic\": \"362\"}, {\"Row\": 209, \"Column\": 1, \"Item\": 403, \"DisplayText\": \"Enterobacter spp.\", \"Text\": \"Enterobacter species, general\", \"Mnemonic\": \"364\"}, {\"Row\": 210, \"Column\": 1, \"Item\": 218, \"DisplayText\": \"Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae\", \"Text\": \"Enterobacteriaceae (ESBL+) nosocomial pneumonia\", \"Mnemonic\": \"366\"}, {\"Row\": 211, \"Column\": 1, \"Item\": 426, \"DisplayText\": \"Enterococci\", \"Text\": \"Enterococcal infections, general\", \"Mnemonic\": \"368\"}, {\"Row\": 212, \"Column\": 1, \"Item\": 471, \"DisplayText\": \"INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION\", \"Text\": \"Enterococcal intravascular catheter-associated infection\", \"Mnemonic\": \"370\"}, {\"Row\": 213, \"Column\": 1, \"Item\": 559, \"DisplayText\": \"Septic arthritis (Native joint) with Enterococci\", \"Text\": \"Enterococcal native joint infection\", \"Mnemonic\": \"372\"}, {\"Row\": 214, \"Column\": 1, \"Item\": 360, \"DisplayText\": \"Endocarditis with Enterococci\", \"Text\": \"Enterococcal native valve endocarditis\", \"Mnemonic\": \"374\"}, {\"Row\": 215, \"Column\": 1, \"Item\": 536, \"DisplayText\": \"Enterococci infections in bone or joint prostheses\", \"Text\": \"Enterococcal prosthetic bone/joint infection\", \"Mnemonic\": \"376\"}, {\"Row\": 216, \"Column\": 1, \"Item\": 360, \"DisplayText\": \"Endocarditis with Enterococci\", \"Text\": \"Enterococcal prosthetic valve endocarditis\", \"Mnemonic\": \"378\"}, {\"Row\": 217, \"Column\": 1, \"Item\": 247, \"DisplayText\": \"Pyelonephritis\", \"Text\": \"Enterococcal pyelonephritis\", \"Mnemonic\": \"380\"}, {\"Row\": 218, \"Column\": 1, \"Item\": 154, \"DisplayText\": \"Epididymitis\", \"Text\": \"Epididymitis\", \"Mnemonic\": \"382\"}, {\"Row\": 219, \"Column\": 1, \"Item\": 350, \"DisplayText\": \"Cranial epidural abscess\", \"Text\": \"Epidural abscess, cranial\", \"Mnemonic\": \"384\"}, {\"Row\": 220, \"Column\": 1, \"Item\": 569, \"DisplayText\": \"Spinal epidural abscess\", \"Text\": \"Epidural abscess, spinal\", \"Mnemonic\": \"386\"}, {\"Row\": 221, \"Column\": 1, \"Item\": 155, \"DisplayText\": \"Epiglottitis\", \"Text\": \"Epiglottitis\", \"Mnemonic\": \"388\"}, {\"Row\": 222, \"Column\": 1, \"Item\": 377, \"DisplayText\": \"Erysipelas\", \"Text\": \"Erysipelas\", \"Mnemonic\": \"390\"}, {\"Row\": 223, \"Column\": 1, \"Item\": 378, \"DisplayText\": \"Erysipeloid\", \"Text\": \"Erysipeloid\", \"Mnemonic\": \"392\"}, {\"Row\": 224, \"Column\": 1, \"Item\": 483, \"DisplayText\": \"Erythema migrans associated with Lyme disease\", \"Text\": \"Erythema migrans, Lyme disease\", \"Mnemonic\": \"394\"}, {\"Row\": 225, \"Column\": 1, \"Item\": 379, \"DisplayText\": \"Erythrasma\", \"Text\": \"Erythrasma\", \"Mnemonic\": \"396\"}, {\"Row\": 226, \"Column\": 1, \"Item\": 149, \"DisplayText\": \"Diarrhea with Enterohemorrhagic E. coli\", \"Text\": \"Escherichia coli diarrhea/gastroenteritis\", \"Mnemonic\": \"398\"}, {\"Row\": 227, \"Column\": 1, \"Item\": 415, \"DisplayText\": \"Escherichia coli\", \"Text\": \"Escherichia coli infections, general\", \"Mnemonic\": \"400\"}, {\"Row\": 228, \"Column\": 1, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"Escherichia coli meningitis\", \"Mnemonic\": \"402\"}, {\"Row\": 229, \"Column\": 1, \"Item\": 157, \"DisplayText\": \"\", \"Text\": \"Esophagitis\", \"Mnemonic\": \"404\"}, {\"Row\": 230, \"Column\": 1, \"Item\": 94, \"DisplayText\": \"Consider Antibiotic\", \"Text\": \"Exacerbation of COPD\", \"Mnemonic\": \"406\"}, {\"Row\": 231, \"Column\": 1, \"Item\": 86, \"DisplayText\": \"Azithromycin for Prevention of Exacerbations COPD\", \"Text\": \"Exacerbations of COPD, prevention of\", \"Mnemonic\": \"408\"}, {\"Row\": 234, \"Column\": 1, \"Item\": 189, \"DisplayText\": \"Influenza Seasonal 2022-2023\", \"Text\": \"Flu\", \"Mnemonic\": \"410\"}, {\"Row\": 235, \"Column\": 1, \"Item\": 381, \"DisplayText\": \"Folliculitis\", \"Text\": \"Folliculitis\", \"Mnemonic\": \"412\"}, {\"Row\": 236, \"Column\": 1, \"Item\": 384, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus\", \"Text\": \"Foot ulcer in patient with diabetes\", \"Mnemonic\": \"414\"}, {\"Row\": 237, \"Column\": 1, \"Item\": 361, \"DisplayText\": \"Endocarditis with Fungi\", \"Text\": \"Fungal native valve endocarditis\", \"Mnemonic\": \"416\"}, {\"Row\": 238, \"Column\": 1, \"Item\": 361, \"DisplayText\": \"Endocarditis with Fungi\", \"Text\": \"Fungal prosthetic valve endocarditis\", \"Mnemonic\": \"418\"}, {\"Row\": 239, \"Column\": 1, \"Item\": 385, \"DisplayText\": \"Fungal Sinusitis\", \"Text\": \"Fungal sinusitis\", \"Mnemonic\": \"420\"}, {\"Row\": 240, \"Column\": 1, \"Item\": 323, \"DisplayText\": \"Bacteremia associated with Candida spp.\", \"Text\": \"Fungemia associated with Candida spp.\", \"Mnemonic\": \"422\"}, {\"Row\": 241, \"Column\": 1, \"Item\": 160, \"DisplayText\": \"Fungi\", \"Text\": \"Fungi section\", \"Mnemonic\": \"424\"}, {\"Row\": 242, \"Column\": 1, \"Item\": 394, \"DisplayText\": \"Furuncles and carbuncles\", \"Text\": \"Furuncles\", \"Mnemonic\": \"426\"}, {\"Row\": 182, \"Column\": 1, \"Text\": \"E______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 197, \"Column\": 1, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 198, \"Column\": 1, \"Text\": \"gram-negative bacilli, streptococci, staphylococci,\"}, {\"Row\": 199, \"Column\": 1, \"Text\": \"and HACEK bacteria\"}, {\"Row\": 202, \"Column\": 1, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 203, \"Column\": 1, \"Text\": \"gram-negative bacilli, Streptococcus bovis,\"}, {\"Row\": 204, \"Column\": 1, \"Text\": \"staphylococci, HACEK bacteria, and Viridans group streptococci\"}, {\"Row\": 233, \"Column\": 1, \"Text\": \"F______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 1, \"Column\": 2, \"Item\": 349, \"DisplayText\": \"\", \"Text\": \"Contact CDSS staff\", \"Mnemonic\": \"420\"}, {\"Row\": 2, \"Column\": 2, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help\", \"Mnemonic\": \"422\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 457, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis\", \"Text\": \"Gastroenteritis/infectious diarrhea\", \"Mnemonic\": \"424\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 161, \"DisplayText\": \"Gastrointestinal and Intraabdominal\", \"Text\": \"Gastrointestinal and Intraabdominal section\", \"Mnemonic\": \"426\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 163, \"DisplayText\": \"Genital herpes\", \"Text\": \"Genital herpes\", \"Mnemonic\": \"428\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 164, \"DisplayText\": \"Genitourinary\", \"Text\": \"Genitourinary section\", \"Mnemonic\": \"430\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 166, \"DisplayText\": \"Diarrhea with Giardia lamblia\", \"Text\": \"Giardia lamblia diarrhea\", \"Mnemonic\": \"432\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 166, \"DisplayText\": \"Diarrhea with Giardia lamblia\", \"Text\": \"Giardia lamblia infections, general\", \"Mnemonic\": \"434\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 293, \"DisplayText\": \"Urethritis associated with sexually transmitted diseases\", \"Text\": \"Gonococcal urethritis\", \"Mnemonic\": \"436\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 460, \"DisplayText\": \"Interim report of Gram-negative bacilli\", \"Text\": \"Gram-negative bacilli bacteremia\", \"Mnemonic\": \"438\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 397, \"DisplayText\": \"Interim results:  Gram-negative Bacilli\", \"Text\": \"Gram-negative bacilli interim culture results\", \"Mnemonic\": \"440\"}, {\"Row\": 16, \"Column\": 2, \"Item\": 472, \"DisplayText\": \"Intravascular catheter-associated Gram-negative Bacilli infection\", \"Text\": \"Gram-negative bacilli intravascular catheter-associated infection\", \"Mnemonic\": \"442\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 316, \"DisplayText\": \"Bacterial meningitis with Gram negative bacilli\", \"Text\": \"Gram-negative bacilli meningitis\", \"Mnemonic\": \"444\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 362, \"DisplayText\": \"Endocarditis with Gram Negative Bacilli\", \"Text\": \"Gram-negative bacilli, non-HACEK, native valve endocarditis\", \"Mnemonic\": \"446\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 362, \"DisplayText\": \"Endocarditis with Gram Negative Bacilli\", \"Text\": \"Gram-negative bacilli, non-HACEK, prosthetic valve endocarditis\", \"Mnemonic\": \"448\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 505, \"DisplayText\": \"Osteomyelitis with Gram Negative Bacilli (other than Pseudomonas)\", \"Text\": \"Gram-negative bacilli, non-pseudomonas, osteomyelitis\", \"Mnemonic\": \"450\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 537, \"DisplayText\": \"Gram Negative Bacilli infections in bone or joint prostheses\", \"Text\": \"Gram-negative bacilli, non-pseudomonas, prosthetic bone/joint infection\", \"Mnemonic\": \"452\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 560, \"DisplayText\": \"Septic arthritis (Native joint) with Gram negative bacilli\", \"Text\": \"Gram-negative bacilli, non-pseudomonas, native joint infection\", \"Mnemonic\": \"454\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 399, \"DisplayText\": \"Gram-negative Bacteria\", \"Text\": \"Gram-Negative Bacteria section\", \"Mnemonic\": \"456\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 461, \"DisplayText\": \"Interim report of Gram-negative cocci\", \"Text\": \"Gram-negative cocci bacteremia\", \"Mnemonic\": \"458\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 398, \"DisplayText\": \"Interim results:  Gram-negative cocci\", \"Text\": \"Gram-negative cocci interim culture results\", \"Mnemonic\": \"460\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 317, \"DisplayText\": \"Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis\", \"Text\": \"Gram-negative diplococci meningitis\", \"Mnemonic\": \"462\"}, {\"Row\": 27, \"Column\": 2, \"Item\": 465, \"DisplayText\": \"Interim report of Gram-positive rods\", \"Text\": \"Gram-positive bacilli bacteremia\", \"Mnemonic\": \"464\"}, {\"Row\": 28, \"Column\": 2, \"Item\": 313, \"DisplayText\": \"Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes\", \"Text\": \"Gram-positive bacilli meningitis\", \"Mnemonic\": \"466\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 465, \"DisplayText\": \"Interim report of Gram-positive rods\", \"Text\": \"Gram-positive bacilli, interim culture results\", \"Mnemonic\": \"468\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 400, \"DisplayText\": \"Gram-positive bacteria\", \"Text\": \"Gram-positive bacteria, section\", \"Mnemonic\": \"470\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 464, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and chains\", \"Text\": \"Gram-positive cocci in pairs and chains bacteremia\", \"Mnemonic\": \"472\"}, {\"Row\": 32, \"Column\": 2, \"Item\": 463, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and clusters\", \"Text\": \"Gram-positive cocci in pairs and clusters bacteremia\", \"Mnemonic\": \"474\"}, {\"Row\": 33, \"Column\": 2, \"Item\": 462, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs\", \"Text\": \"Gram-positive cocci in pairs bacteremia\", \"Mnemonic\": \"476\"}, {\"Row\": 34, \"Column\": 2, \"Item\": 462, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs\", \"Text\": \"Gram-positive cocci in pairs interim culture results\", \"Mnemonic\": \"478\"}, {\"Row\": 35, \"Column\": 2, \"Item\": 422, \"DisplayText\": \"Anaerobic Gram-positive cocci (including Peptostreptococcus)\", \"Text\": \"Gram-positive cocci, anaerobic\", \"Mnemonic\": \"480\"}, {\"Row\": 36, \"Column\": 2, \"Item\": 313, \"DisplayText\": \"Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes\", \"Text\": \"Gram-positive coccobacilli meningitis\", \"Mnemonic\": \"482\"}, {\"Row\": 37, \"Column\": 2, \"Item\": 318, \"DisplayText\": \"Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia\", \"Text\": \"Gram-positive diplococci meningitis\", \"Mnemonic\": \"484\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 435, \"DisplayText\": \"Group A Streptococci (S. pyogenes)\", \"Text\": \"Group A streptococci\", \"Mnemonic\": \"486\"}, {\"Row\": 39, \"Column\": 2, \"Item\": 440, \"DisplayText\": \"Group B Streptococci (S. agalactiae)\", \"Text\": \"Group B Streptococci\", \"Mnemonic\": \"488\"}, {\"Row\": 40, \"Column\": 2, \"Item\": 434, \"DisplayText\": \"Group D (S. bovis)\", \"Text\": \"Group D Streptococci\", \"Mnemonic\": \"490\"}, {\"Row\": 41, \"Column\": 2, \"Item\": 438, \"DisplayText\": \"Streptococci Groups C, F, G\", \"Text\": \"Groups C, F, G Streptococci\", \"Mnemonic\": \"492\"}, {\"Row\": 44, \"Column\": 2, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"HACEK bacteria native valve endocarditis\", \"Mnemonic\": \"494\"}, {\"Row\": 45, \"Column\": 2, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"HACEK bacteria prosthetic valve endocarditis\", \"Mnemonic\": \"496\"}, {\"Row\": 46, \"Column\": 2, \"Item\": 416, \"DisplayText\": \"Haemophilus spp.\", \"Text\": \"Haemophilus infections, general\", \"Mnemonic\": \"498\"}, {\"Row\": 47, \"Column\": 2, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae B vaccination\", \"Mnemonic\": \"500\"}, {\"Row\": 48, \"Column\": 2, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Haemophilus native valve endocarditis\", \"Mnemonic\": \"502\"}, {\"Row\": 49, \"Column\": 2, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Haemophilus prosthetic valve endocarditis\", \"Mnemonic\": \"504\"}, {\"Row\": 50, \"Column\": 2, \"Item\": 168, \"DisplayText\": \"Head and Neck\", \"Text\": \"Head and Neck/ENT section\", \"Mnemonic\": \"506\"}, {\"Row\": 51, \"Column\": 2, \"Item\": 442, \"DisplayText\": \"Head Lice (Pediculosis Capitis)\", \"Text\": \"Head lice\", \"Mnemonic\": \"508\"}, {\"Row\": 52, \"Column\": 2, \"Item\": 441, \"DisplayText\": \"Helicobacter pylori infection\", \"Text\": \"Helicobacter pylori\", \"Mnemonic\": \"510\"}, {\"Row\": 53, \"Column\": 2, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help\", \"Mnemonic\": \"512\"}, {\"Row\": 54, \"Column\": 2, \"Item\": 328, \"DisplayText\": \"Bed Bugs (Hemiptera)\", \"Text\": \"Hemiptera\", \"Mnemonic\": \"514\"}, {\"Row\": 55, \"Column\": 2, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Hemodialysis immunizations\", \"Mnemonic\": \"516\"}, {\"Row\": 56, \"Column\": 2, \"Item\": 200, \"DisplayText\": \"\", \"Text\": \"Hepatic abscess\", \"Mnemonic\": \"518\"}, {\"Row\": 57, \"Column\": 2, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Hepatic disease immunizations\", \"Mnemonic\": \"520\"}, {\"Row\": 58, \"Column\": 2, \"Item\": 170, \"DisplayText\": \"Hepatitis A\", \"Text\": \"Hepatitis A\", \"Mnemonic\": \"522\"}, {\"Row\": 59, \"Column\": 2, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A vaccination\", \"Mnemonic\": \"524\"}, {\"Row\": 60, \"Column\": 2, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A/Hepatitis B vaccination\", \"Mnemonic\": \"526\"}, {\"Row\": 61, \"Column\": 2, \"Item\": 171, \"DisplayText\": \"Hepatitis B\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"528\"}, {\"Row\": 62, \"Column\": 2, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B vaccination\", \"Mnemonic\": \"530\"}, {\"Row\": 63, \"Column\": 2, \"Item\": 172, \"DisplayText\": \"Hepatitis C\", \"Text\": \"Hepatitis C\", \"Mnemonic\": \"532\"}, {\"Row\": 64, \"Column\": 2, \"Item\": 174, \"DisplayText\": \"\", \"Text\": \"Herpes esophagitis\", \"Mnemonic\": \"534\"}, {\"Row\": 65, \"Column\": 2, \"Item\": 173, \"DisplayText\": \"HERPES KERATITIS\", \"Text\": \"Herpes keratitis\", \"Mnemonic\": \"536\"}, {\"Row\": 66, \"Column\": 2, \"Item\": 545, \"DisplayText\": \"Retinitis\", \"Text\": \"Herpes retinitis\", \"Mnemonic\": \"538\"}, {\"Row\": 67, \"Column\": 2, \"Item\": 175, \"DisplayText\": \"Herpes Whitlow (digit/hand cellulitis)\", \"Text\": \"Herpes whitlow (digit or hand cellulitis)\", \"Mnemonic\": \"540\"}, {\"Row\": 68, \"Column\": 2, \"Item\": 163, \"DisplayText\": \"Genital herpes\", \"Text\": \"Herpes, genital\", \"Mnemonic\": \"542\"}, {\"Row\": 69, \"Column\": 2, \"Item\": 225, \"DisplayText\": \"Orolabial Herpes\", \"Text\": \"Herpes, orolabial\", \"Mnemonic\": \"544\"}, {\"Row\": 70, \"Column\": 2, \"Item\": 443, \"DisplayText\": \"Hidradenitis Suppurativa\", \"Text\": \"Hidradenitis suppurativa\", \"Mnemonic\": \"546\"}, {\"Row\": 71, \"Column\": 2, \"Item\": 393, \"DisplayText\": \"Histoplasma capsulatum\", \"Text\": \"Histoplasma capsulatum\", \"Mnemonic\": \"548\"}, {\"Row\": 72, \"Column\": 2, \"Item\": 673, \"DisplayText\": \"Immunization of patients with HIV\", \"Text\": \"HIV patient immunization\", \"Mnemonic\": \"550\"}, {\"Row\": 73, \"Column\": 2, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"HIV infection, general\", \"Mnemonic\": \"552\"}, {\"Row\": 74, \"Column\": 2, \"Item\": 177, \"DisplayText\": \"Home IV at the Minneapolis VAMC\", \"Text\": \"Home IV therapy at MVAMC\", \"Mnemonic\": \"554\"}, {\"Row\": 75, \"Column\": 2, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Hospital-acquired pneumonia (HAP)\", \"Mnemonic\": \"556\"}, {\"Row\": 76, \"Column\": 2, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"HSCT immunizations\", \"Mnemonic\": \"558\"}, {\"Row\": 77, \"Column\": 2, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papilloma virus vaccination\", \"Mnemonic\": \"560\"}, {\"Row\": 78, \"Column\": 2, \"Item\": 449, \"DisplayText\": \"Hypochlorhydria\", \"Text\": \"Hypochlorhydria\", \"Mnemonic\": \"562\"}, {\"Row\": 81, \"Column\": 2, \"Item\": 676, \"DisplayText\": \"Immunization of Immunocompromised Patients\", \"Text\": \"Immunization of immunocompromised patients (except HIV)\", \"Mnemonic\": \"564\"}, {\"Row\": 82, \"Column\": 2, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Immunization of patients at high-risk of rabies exposure\", \"Mnemonic\": \"566\"}, {\"Row\": 83, \"Column\": 2, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Immunization of patients in kidney failure/HD\", \"Mnemonic\": \"568\"}, {\"Row\": 84, \"Column\": 2, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Immunization of patients with asplenia\", \"Mnemonic\": \"570\"}, {\"Row\": 85, \"Column\": 2, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"Immunization of patients with bone marrow transplant\", \"Mnemonic\": \"572\"}, {\"Row\": 86, \"Column\": 2, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Immunization of patients with chronic liver disease\", \"Mnemonic\": \"574\"}, {\"Row\": 87, \"Column\": 2, \"Item\": 673, \"DisplayText\": \"Immunization of patients with HIV\", \"Text\": \"Immunization of patients with HIV\", \"Mnemonic\": \"576\"}, {\"Row\": 88, \"Column\": 2, \"Item\": 989, \"DisplayText\": \"\", \"Text\": \"Immunization of patients with pregnancy\", \"Mnemonic\": \"578\"}, {\"Row\": 89, \"Column\": 2, \"Item\": 710, \"DisplayText\": \"CDC Recommended Adult Immunizations\", \"Text\": \"Immunization, adult [CLICK HERE], includes:\", \"Mnemonic\": \"580\"}, {\"Row\": 94, \"Column\": 2, \"Item\": 446, \"DisplayText\": \"Basic concepts\", \"Text\": \"Immunocompromised patients basic concepts\", \"Mnemonic\": \"582\"}, {\"Row\": 95, \"Column\": 2, \"Item\": 182, \"DisplayText\": \"Infections in Immunocompromised Patients\", \"Text\": \"Immunocompromised Patients section\", \"Mnemonic\": \"584\"}, {\"Row\": 96, \"Column\": 2, \"Item\": 444, \"DisplayText\": \"Immunoglobulin (Humoral immune system) deficiency\", \"Text\": \"Immunoglobulin (Humoral immune system) deficiency\", \"Mnemonic\": \"586\"}, {\"Row\": 97, \"Column\": 2, \"Item\": 183, \"DisplayText\": \"Impetigo\", \"Text\": \"Impetigo\", \"Mnemonic\": \"588\"}, {\"Row\": 98, \"Column\": 2, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Important drug properties\", \"Mnemonic\": \"590\"}, {\"Row\": 99, \"Column\": 2, \"Item\": 188, \"DisplayText\": \"Infection Control\", \"Text\": \"Infection control department information\", \"Mnemonic\": \"592\"}, {\"Row\": 100, \"Column\": 2, \"Item\": 244, \"DisplayText\": \"Prevention of Infection\", \"Text\": \"Infection Prevention section\", \"Mnemonic\": \"594\"}, {\"Row\": 101, \"Column\": 2, \"Item\": 457, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis\", \"Text\": \"Infectious diarrhea/gastroenteritis\", \"Mnemonic\": \"596\"}, {\"Row\": 102, \"Column\": 2, \"Item\": 189, \"DisplayText\": \"Influenza Seasonal 2022-2023\", \"Text\": \"Influenza\", \"Mnemonic\": \"598\"}, {\"Row\": 103, \"Column\": 2, \"Item\": 474, \"DisplayText\": \"Intravascular catheter-associated infection\", \"Text\": \"Intravascular catheter-associated infection\", \"Mnemonic\": \"600\"}, {\"Row\": 104, \"Column\": 2, \"Item\": 177, \"DisplayText\": \"Home IV at the Minneapolis VAMC\", \"Text\": \"Intravenous therapy at home, MVAMC\", \"Mnemonic\": \"602\"}, {\"Row\": 105, \"Column\": 2, \"Item\": 195, \"DisplayText\": \"Diarrhea with Isospora belli\", \"Text\": \"Isospora diarrhea/gastroenteritis\", \"Mnemonic\": \"604\"}, {\"Row\": 108, \"Column\": 2, \"Item\": 270, \"DisplayText\": \"Soft tissue, muscle, bone and joint infections\", \"Text\": \"Joint and Bone section\", \"Mnemonic\": \"606\"}, {\"Row\": 109, \"Column\": 2, \"Item\": 565, \"DisplayText\": \"Septic arthritis (Native joint)\", \"Text\": \"Joint infection, native [CLICK HERE], includes:\", \"Mnemonic\": \"608\"}, {\"Row\": 113, \"Column\": 2, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Joint infection, prosthetic [CLICK HERE], includes:\", \"Mnemonic\": \"610\"}, {\"Row\": 119, \"Column\": 2, \"Item\": 476, \"DisplayText\": \"Keratitis\", \"Text\": \"Keratitis\", \"Mnemonic\": \"612\"}, {\"Row\": 120, \"Column\": 2, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Kidney failure immunizations\", \"Mnemonic\": \"614\"}, {\"Row\": 121, \"Column\": 2, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Kingella native valve endocarditis\", \"Mnemonic\": \"616\"}, {\"Row\": 122, \"Column\": 2, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"Kingella prosthetic valve endocarditis\", \"Mnemonic\": \"618\"}, {\"Row\": 123, \"Column\": 2, \"Item\": 417, \"DisplayText\": \"Klebsiella spp.\", \"Text\": \"Klebsiella infections, general\", \"Mnemonic\": \"620\"}, {\"Row\": 126, \"Column\": 2, \"Item\": 459, \"DisplayText\": \"Large uniform rods in an aerobic bottle\", \"Text\": \"Large uniform bacilli, aerobic bottle\", \"Mnemonic\": \"622\"}, {\"Row\": 127, \"Column\": 2, \"Item\": 458, \"DisplayText\": \"Large uniform rods in an anaerobic bottle\", \"Text\": \"Large uniform bacilli, anaerobic bottle\", \"Mnemonic\": \"624\"}, {\"Row\": 128, \"Column\": 2, \"Item\": 198, \"DisplayText\": \"Laryngitis and Croup\", \"Text\": \"Laryngitis\", \"Mnemonic\": \"626\"}, {\"Row\": 129, \"Column\": 2, \"Item\": 418, \"DisplayText\": \"Legionella spp.\", \"Text\": \"Legionella infections, general\", \"Mnemonic\": \"628\"}, {\"Row\": 130, \"Column\": 2, \"Item\": 219, \"DisplayText\": \"Nosocomial pneumonia with Legionella pneumophila\", \"Text\": \"Legionella pneumophila nosocomial pneumonia\", \"Mnemonic\": \"630\"}, {\"Row\": 131, \"Column\": 2, \"Item\": 477, \"DisplayText\": \"Leishmaniasis\", \"Text\": \"Leishmaniasis\", \"Mnemonic\": \"632\"}, {\"Row\": 132, \"Column\": 2, \"Item\": 478, \"DisplayText\": \"Leukocytosis\", \"Text\": \"Leukocytosis\", \"Mnemonic\": \"634\"}, {\"Row\": 133, \"Column\": 2, \"Item\": 334, \"DisplayText\": \"Body Lice (Pediculosis Corporis)\", \"Text\": \"Lice, body\", \"Mnemonic\": \"636\"}, {\"Row\": 134, \"Column\": 2, \"Item\": 442, \"DisplayText\": \"Head Lice (Pediculosis Capitis)\", \"Text\": \"Lice, head\", \"Mnemonic\": \"638\"}, {\"Row\": 135, \"Column\": 2, \"Item\": 542, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis)\", \"Text\": \"Lice, pubic\", \"Mnemonic\": \"640\"}, {\"Row\": 136, \"Column\": 2, \"Item\": 427, \"DisplayText\": \"Listeria spp.\", \"Text\": \"Listeria infections, general\", \"Mnemonic\": \"642\"}, {\"Row\": 137, \"Column\": 2, \"Item\": 325, \"DisplayText\": \"Bacteremia associated with Listeria monocytogenes\", \"Text\": \"Listeria monocytogenes bacteremia\", \"Mnemonic\": \"644\"}, {\"Row\": 138, \"Column\": 2, \"Item\": 319, \"DisplayText\": \"Bacterial meningitis with L. monocytogenes\", \"Text\": \"Listeria monocytogenes meningitis\", \"Mnemonic\": \"646\"}, {\"Row\": 139, \"Column\": 2, \"Item\": 200, \"DisplayText\": \"\", \"Text\": \"Liver abscess\", \"Mnemonic\": \"648\"}, {\"Row\": 140, \"Column\": 2, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Liver disease immunizations\", \"Mnemonic\": \"650\"}, {\"Row\": 141, \"Column\": 2, \"Item\": 275, \"DisplayText\": \"Acute spontaneous bacterial peritonitis (SBP)\", \"Text\": \"Liver disease, prevention of spontaneous bacterial peritonitis\", \"Mnemonic\": \"652\"}, {\"Row\": 142, \"Column\": 2, \"Item\": 201, \"DisplayText\": \"Lung abscess\", \"Text\": \"Lung abscess\", \"Mnemonic\": \"654\"}, {\"Row\": 143, \"Column\": 2, \"Item\": 202, \"DisplayText\": \"Lung and Mediastinum\", \"Text\": \"Lungs and Mediastinum section\", \"Mnemonic\": \"656\"}, {\"Row\": 144, \"Column\": 2, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Lyme disease [CLICK HERE], includes:\", \"Mnemonic\": \"658\"}, {\"Row\": 149, \"Column\": 2, \"Item\": 450, \"DisplayText\": \"Malignancy\", \"Text\": \"Malignancy [CLICK HERE], includes:\", \"Mnemonic\": \"660\"}, {\"Row\": 151, \"Column\": 2, \"Item\": 488, \"DisplayText\": \"Malignant Otitis Externa\", \"Text\": \"Malignant otitis externa\", \"Mnemonic\": \"662\"}, {\"Row\": 152, \"Column\": 2, \"Item\": 451, \"DisplayText\": \"Malnutrition\", \"Text\": \"Malnutrition\", \"Mnemonic\": \"664\"}, {\"Row\": 153, \"Column\": 2, \"Item\": 489, \"DisplayText\": \"Mastoiditis\", \"Text\": \"Mastoiditis\", \"Mnemonic\": \"666\"}, {\"Row\": 154, \"Column\": 2, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles vaccination\", \"Mnemonic\": \"668\"}, {\"Row\": 155, \"Column\": 2, \"Item\": 205, \"DisplayText\": \"Mediastinitis\", \"Text\": \"Mediastinitis\", \"Mnemonic\": \"670\"}, {\"Row\": 156, \"Column\": 2, \"Item\": 202, \"DisplayText\": \"Lung and Mediastinum\", \"Text\": \"Mediastinum and Lung section\", \"Mnemonic\": \"672\"}, {\"Row\": 157, \"Column\": 2, \"Item\": 314, \"DisplayText\": \"Bacterial meningitis associated with trauma or nosocomial infection\", \"Text\": \"Meningitis associated with trauma or nosocomial infection\", \"Mnemonic\": \"674\"}, {\"Row\": 158, \"Column\": 2, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"Meningitis with E. coli, Pseudomonas or other organism\", \"Mnemonic\": \"676\"}, {\"Row\": 159, \"Column\": 2, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"Meningitis with Escherichia coli\", \"Mnemonic\": \"678\"}, {\"Row\": 160, \"Column\": 2, \"Item\": 316, \"DisplayText\": \"Bacterial meningitis with Gram negative bacilli\", \"Text\": \"Meningitis with gram-negative bacilli\", \"Mnemonic\": \"680\"}, {\"Row\": 161, \"Column\": 2, \"Item\": 317, \"DisplayText\": \"Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis\", \"Text\": \"Meningitis with gram-negative diplococci\", \"Mnemonic\": \"682\"}, {\"Row\": 162, \"Column\": 2, \"Item\": 313, \"DisplayText\": \"Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes\", \"Text\": \"Meningitis with gram-positive bacilli/coccobacilli\", \"Mnemonic\": \"684\"}, {\"Row\": 163, \"Column\": 2, \"Item\": 318, \"DisplayText\": \"Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia\", \"Text\": \"Meningitis with gram-positive diplococci\", \"Mnemonic\": \"686\"}, {\"Row\": 164, \"Column\": 2, \"Item\": 319, \"DisplayText\": \"Bacterial meningitis with L. monocytogenes\", \"Text\": \"Meningitis with Listeria monocytogenes\", \"Mnemonic\": \"688\"}, {\"Row\": 165, \"Column\": 2, \"Item\": 320, \"DisplayText\": \"Bacterial meningitis with N. meningitidis\", \"Text\": \"Meningitis with Neisseria meningitidis\", \"Mnemonic\": \"690\"}, {\"Row\": 166, \"Column\": 2, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"Meningitis with pseudomonas\", \"Mnemonic\": \"692\"}, {\"Row\": 167, \"Column\": 2, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Meningitis with sepsis\", \"Mnemonic\": \"694\"}, {\"Row\": 168, \"Column\": 2, \"Item\": 321, \"DisplayText\": \"Bacterial meningitis with S. pneumoniae\", \"Text\": \"Meningitis with Streptococcus pneumoniae\", \"Mnemonic\": \"696\"}, {\"Row\": 169, \"Column\": 2, \"Item\": 322, \"DisplayText\": \"Bacterial meningitis without Gram stain results\", \"Text\": \"Meningitis without gram stain results\", \"Mnemonic\": \"698\"}, {\"Row\": 170, \"Column\": 2, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"Meningitis, other organism\", \"Mnemonic\": \"700\"}, {\"Row\": 171, \"Column\": 2, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal conjugate (MENACWY) vaccination\", \"Mnemonic\": \"702\"}, {\"Row\": 172, \"Column\": 2, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MENB) vaccination\", \"Mnemonic\": \"704\"}, {\"Row\": 173, \"Column\": 2, \"Item\": 331, \"DisplayText\": \"Bite wounds with Staphylococcus aureus\", \"Text\": \"Methicillin-resistant Staphylococcus aureus bite wounds\", \"Mnemonic\": \"706\"}, {\"Row\": 174, \"Column\": 2, \"Item\": 208, \"DisplayText\": \"Microsporidia\", \"Text\": \"Microsporidia diarrhea/gastroenteritis\", \"Mnemonic\": \"708\"}, {\"Row\": 175, \"Column\": 2, \"Item\": 404, \"DisplayText\": \"Moraxella catarrhalis\", \"Text\": \"Moraxella catarrhalis infections, general\", \"Mnemonic\": \"710\"}, {\"Row\": 176, \"Column\": 2, \"Item\": 331, \"DisplayText\": \"Bite wounds with Staphylococcus aureus\", \"Text\": \"MRSA bite wounds\", \"Mnemonic\": \"712\"}, {\"Row\": 177, \"Column\": 2, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"MRSA risk factors\", \"Mnemonic\": \"714\"}, {\"Row\": 178, \"Column\": 2, \"Item\": 331, \"DisplayText\": \"Bite wounds with Staphylococcus aureus\", \"Text\": \"MSSA bite wounds\", \"Mnemonic\": \"716\"}, {\"Row\": 179, \"Column\": 2, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Mumps vaccination\", \"Mnemonic\": \"718\"}, {\"Row\": 180, \"Column\": 2, \"Item\": 270, \"DisplayText\": \"Soft tissue, muscle, bone and joint infections\", \"Text\": \"Muscle and Soft Tissue section\", \"Mnemonic\": \"720\"}, {\"Row\": 181, \"Column\": 2, \"Item\": 484, \"DisplayText\": \"Mycobacterium avium intracellulare complex (a.k.a MAI or MAC)\", \"Text\": \"Mycobacterium avium intracellular complex (MAI or MAC)\", \"Mnemonic\": \"722\"}, {\"Row\": 182, \"Column\": 2, \"Item\": 485, \"DisplayText\": \"Mycobacterium avium pneumonia\", \"Text\": \"Mycobacterium avium pneumonia\", \"Mnemonic\": \"724\"}, {\"Row\": 183, \"Column\": 2, \"Item\": 534, \"DisplayText\": \"Prophylaxis against Mycobacterium avium disease...\", \"Text\": \"Mycobacterium avium prophylaxis\", \"Mnemonic\": \"726\"}, {\"Row\": 184, \"Column\": 2, \"Item\": 357, \"DisplayText\": \"Disseminated Mycobacterium avium disease treatment\", \"Text\": \"Mycobacterium avium, disseminated\", \"Mnemonic\": \"728\"}, {\"Row\": 185, \"Column\": 2, \"Item\": 487, \"DisplayText\": \"Mycobacterium tuberculosis\", \"Text\": \"Mycobacterium tuberculosis\", \"Mnemonic\": \"730\"}, {\"Row\": 186, \"Column\": 2, \"Item\": 486, \"DisplayText\": \"Mycoplasma pneumoniae\", \"Text\": \"Mycoplasma pneumonia infections, general\", \"Mnemonic\": \"732\"}, {\"Row\": 187, \"Column\": 2, \"Item\": 211, \"DisplayText\": \"Myocarditis\", \"Text\": \"Myocarditis\", \"Mnemonic\": \"734\"}, {\"Row\": 4, \"Column\": 2, \"Text\": \"G through Pn\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Text\": \"G______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 2, \"Text\": \"H______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 80, \"Column\": 2, \"Text\": \"I______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 90, \"Column\": 2, \"Text\": \"diphtheria, Haemophilus influenza B, Hepatitis A and B,\"}, {\"Row\": 91, \"Column\": 2, \"Text\": \"human papilloma virus, influenza, measles, mumps,\"}, {\"Row\": 92, \"Column\": 2, \"Text\": \"meningococcal, pneumococcal, pertussis, rubella,\"}, {\"Row\": 93, \"Column\": 2, \"Text\": \"tetanus, varicella, zoster\"}, {\"Row\": 107, \"Column\": 2, \"Text\": \"J______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 110, \"Column\": 2, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 111, \"Column\": 2, \"Text\": \"Neisseria gonorrhoeae, Pseudomonas aeruginosa,\"}, {\"Row\": 112, \"Column\": 2, \"Text\": \"Staphylococcus aureus, streptococcus\"}, {\"Row\": 114, \"Column\": 2, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 115, \"Column\": 2, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aureus,\"}, {\"Row\": 116, \"Column\": 2, \"Text\": \"and streptococcus\"}, {\"Row\": 118, \"Column\": 2, \"Text\": \"K______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 125, \"Column\": 2, \"Text\": \"L______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 145, \"Column\": 2, \"Text\": \"arthritis, carditis, erythema migrans,\"}, {\"Row\": 146, \"Column\": 2, \"Text\": \"neurological complications, prophylaxis\"}, {\"Row\": 148, \"Column\": 2, \"Text\": \"M______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 150, \"Column\": 2, \"Text\": \"antimicrobial prophylaxis, neutropenic fever\"}, {\"Row\": 190, \"Column\": 2, \"Item\": 212, \"DisplayText\": \"Nasal Packing (to prevent infection)\", \"Text\": \"Nasal packing\", \"Mnemonic\": \"744\"}, {\"Row\": 191, \"Column\": 2, \"Item\": 565, \"DisplayText\": \"Septic arthritis (Native joint)\", \"Text\": \"Native joint infection [CLICK HERE], includes:\", \"Mnemonic\": \"746\"}, {\"Row\": 195, \"Column\": 2, \"Item\": 365, \"DisplayText\": \"Native Valve Endocarditis--Selected Pathogens\", \"Text\": \"Native valve endocarditis [CLICK HERE], includes:\", \"Mnemonic\": \"748\"}, {\"Row\": 199, \"Column\": 2, \"Item\": 364, \"DisplayText\": \"Native Valve Endocarditis - Empirical Therapy\", \"Text\": \"Native valve endocarditis empirical therapy\", \"Mnemonic\": \"750\"}, {\"Row\": 200, \"Column\": 2, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Native valve endocarditis with sepsis\", \"Mnemonic\": \"752\"}, {\"Row\": 201, \"Column\": 2, \"Item\": 496, \"DisplayText\": \"Necrotizing infections\", \"Text\": \"Necrotizing infections\", \"Mnemonic\": \"754\"}, {\"Row\": 202, \"Column\": 2, \"Item\": 405, \"DisplayText\": \"Neisseria gonorrhoeae\", \"Text\": \"Neisseria gonorrhoeae infections, general\", \"Mnemonic\": \"756\"}, {\"Row\": 203, \"Column\": 2, \"Item\": 561, \"DisplayText\": \"Septic arthritis (Native joint) with N. gonorrhoeae\", \"Text\": \"Neisseria gonorrhoeae native joint infection\", \"Mnemonic\": \"758\"}, {\"Row\": 204, \"Column\": 2, \"Item\": 406, \"DisplayText\": \"Neisseria meningitidis\", \"Text\": \"Neisseria meningitidis infections, general\", \"Mnemonic\": \"760\"}, {\"Row\": 205, \"Column\": 2, \"Item\": 320, \"DisplayText\": \"Bacterial meningitis with N. meningitidis\", \"Text\": \"Neisseria meningitidis meningitis\", \"Mnemonic\": \"762\"}, {\"Row\": 206, \"Column\": 2, \"Item\": 479, \"DisplayText\": \"Acute neurological disease associated with Lyme disease\", \"Text\": \"Neurological disease associated with Lyme disease\", \"Mnemonic\": \"764\"}, {\"Row\": 207, \"Column\": 2, \"Item\": 452, \"DisplayText\": \"Neurological dysfunction\", \"Text\": \"Neurological dysfunction\", \"Mnemonic\": \"766\"}, {\"Row\": 208, \"Column\": 2, \"Item\": 454, \"DisplayText\": \"Neutropenia\", \"Text\": \"Neutropenia\", \"Mnemonic\": \"768\"}, {\"Row\": 209, \"Column\": 2, \"Item\": 290, \"DisplayText\": \"Neutropenic Enterocolitis (Typhlitis)\", \"Text\": \"Neutropenic enterocolitis\", \"Mnemonic\": \"770\"}, {\"Row\": 210, \"Column\": 2, \"Item\": 453, \"DisplayText\": \"Neutropenic fever\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"772\"}, {\"Row\": 211, \"Column\": 2, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Neutropenic fever with sepsis\", \"Mnemonic\": \"774\"}, {\"Row\": 212, \"Column\": 2, \"Item\": 336, \"DisplayText\": \"Brain Abscess with Nocardia spp.\", \"Text\": \"Nocardia spp. brain abscess\", \"Mnemonic\": \"776\"}, {\"Row\": 213, \"Column\": 2, \"Item\": 307, \"DisplayText\": \"Appendicitis without perforation\", \"Text\": \"Non-perforated appendicitis\", \"Mnemonic\": \"778\"}, {\"Row\": 214, \"Column\": 2, \"Item\": 222, \"DisplayText\": \"Not Benefited by Abx Pharyngitis\", \"Text\": \"Non-streptococcal pharyngitis\", \"Mnemonic\": \"780\"}, {\"Row\": 215, \"Column\": 2, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Nosocomial pneumonia\", \"Mnemonic\": \"782\"}, {\"Row\": 216, \"Column\": 2, \"Item\": 503, \"DisplayText\": \"Nosocomial Sinusitis\", \"Text\": \"Nosocomial sinusitis\", \"Mnemonic\": \"784\"}, {\"Row\": 219, \"Column\": 2, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"Occupational post-exposure prophylaxis\", \"Mnemonic\": \"786\"}, {\"Row\": 220, \"Column\": 2, \"Item\": 622, \"DisplayText\": \"Tinea Unguium (Onychomycosis)\", \"Text\": \"Onychomycosis\", \"Mnemonic\": \"788\"}, {\"Row\": 221, \"Column\": 2, \"Item\": 527, \"DisplayText\": \"Postseptal Cellulitis\", \"Text\": \"Orbital cellulitis\", \"Mnemonic\": \"790\"}, {\"Row\": 222, \"Column\": 2, \"Item\": 225, \"DisplayText\": \"Orolabial Herpes\", \"Text\": \"Orolabial herpes\", \"Mnemonic\": \"792\"}, {\"Row\": 223, \"Column\": 2, \"Item\": 354, \"DisplayText\": \"Deep Oropharyngeal Infections\", \"Text\": \"Oropharyngeal infections, deep\", \"Mnemonic\": \"794\"}, {\"Row\": 224, \"Column\": 2, \"Item\": 508, \"DisplayText\": \"Osteomyelitis\", \"Text\": \"Osteomyelitis [CLICK HERE], includes:\", \"Mnemonic\": \"796\"}, {\"Row\": 227, \"Column\": 2, \"Item\": 510, \"DisplayText\": \"Other pathogens\", \"Text\": \"Other Pathogens section\", \"Mnemonic\": \"798\"}, {\"Row\": 228, \"Column\": 2, \"Item\": 511, \"DisplayText\": \"Otitis Externa\", \"Text\": \"Otitis externa\", \"Mnemonic\": \"800\"}, {\"Row\": 229, \"Column\": 2, \"Item\": 488, \"DisplayText\": \"Malignant Otitis Externa\", \"Text\": \"Otitis externa, malignant\", \"Mnemonic\": \"802\"}, {\"Row\": 230, \"Column\": 2, \"Item\": 512, \"DisplayText\": \"Otitis Media\", \"Text\": \"Otitis media\", \"Mnemonic\": \"804\"}, {\"Row\": 233, \"Column\": 2, \"Item\": 226, \"DisplayText\": \"Pancreatitis\", \"Text\": \"Pancreatitis\", \"Mnemonic\": \"806\"}, {\"Row\": 234, \"Column\": 2, \"Item\": 227, \"DisplayText\": \"Parainfluenza\", \"Text\": \"Parainfluenza\", \"Mnemonic\": \"808\"}, {\"Row\": 235, \"Column\": 2, \"Item\": 513, \"DisplayText\": \"Parasites\", \"Text\": \"Parasites\", \"Mnemonic\": \"810\"}, {\"Row\": 236, \"Column\": 2, \"Item\": 153, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Paratyphoid fever\", \"Mnemonic\": \"812\"}, {\"Row\": 237, \"Column\": 2, \"Item\": 514, \"DisplayText\": \"Paronychia\", \"Text\": \"Paronychia\", \"Mnemonic\": \"814\"}, {\"Row\": 238, \"Column\": 2, \"Item\": 228, \"DisplayText\": \"Parotitis\", \"Text\": \"Parotitis\", \"Mnemonic\": \"816\"}, {\"Row\": 239, \"Column\": 2, \"Item\": 330, \"DisplayText\": \"Bite wounds with Pasteurella multocida\", \"Text\": \"Pasteurella multocida bite wounds\", \"Mnemonic\": \"818\"}, {\"Row\": 240, \"Column\": 2, \"Item\": 407, \"DisplayText\": \"Pasteurella multocida\", \"Text\": \"Pasteurella multocida infections, general\", \"Mnemonic\": \"820\"}, {\"Row\": 241, \"Column\": 2, \"Item\": 334, \"DisplayText\": \"Body Lice (Pediculosis Corporis)\", \"Text\": \"Pediculosis corporis\", \"Mnemonic\": \"822\"}, {\"Row\": 242, \"Column\": 2, \"Item\": 238, \"DisplayText\": \"Pelvic Inflammatory Disease\", \"Text\": \"Pelvic inflammatory disease (PID)\", \"Mnemonic\": \"824\"}, {\"Row\": 243, \"Column\": 2, \"Item\": 110, \"DisplayText\": \"Chronic protatitis/Chronic pelvic pain syndrome\", \"Text\": \"Pelvic pain syndrome/prostatitis, chronic\", \"Mnemonic\": \"826\"}, {\"Row\": 244, \"Column\": 2, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Penicillin desensitization protocol\", \"Mnemonic\": \"828\"}, {\"Row\": 245, \"Column\": 2, \"Item\": 422, \"DisplayText\": \"Anaerobic Gram-positive cocci (including Peptostreptococcus)\", \"Text\": \"Peptostreptococcus infections, general\", \"Mnemonic\": \"830\"}, {\"Row\": 246, \"Column\": 2, \"Item\": 308, \"DisplayText\": \"Appendicitis with perforation\", \"Text\": \"Perforated appendicitis\", \"Mnemonic\": \"832\"}, {\"Row\": 247, \"Column\": 2, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Perianal abscess\", \"Mnemonic\": \"834\"}, {\"Row\": 248, \"Column\": 2, \"Item\": 234, \"DisplayText\": \"Pericarditis\", \"Text\": \"Pericarditis\", \"Mnemonic\": \"836\"}, {\"Row\": 249, \"Column\": 2, \"Item\": 524, \"DisplayText\": \"Periocular Infections\", \"Text\": \"Periocular infections\", \"Mnemonic\": \"838\"}, {\"Row\": 250, \"Column\": 2, \"Item\": 525, \"DisplayText\": \"Periodental disease\", \"Text\": \"Periodontal disease\", \"Mnemonic\": \"840\"}, {\"Row\": 251, \"Column\": 2, \"Item\": 232, \"DisplayText\": \"Peritonitis associated with peritoneal dialysis\", \"Text\": \"Peritoneal dialysis peritonitis\", \"Mnemonic\": \"842\"}, {\"Row\": 252, \"Column\": 2, \"Item\": 275, \"DisplayText\": \"Acute spontaneous bacterial peritonitis (SBP)\", \"Text\": \"Peritonitis, acute spontaneous bacterial\", \"Mnemonic\": \"844\"}, {\"Row\": 253, \"Column\": 2, \"Item\": 232, \"DisplayText\": \"Peritonitis associated with peritoneal dialysis\", \"Text\": \"Peritonitis, peritoneal dialysis associated\", \"Mnemonic\": \"846\"}, {\"Row\": 254, \"Column\": 2, \"Item\": 266, \"DisplayText\": \"Secondary Peritonitis\", \"Text\": \"Peritonitis, secondary\", \"Mnemonic\": \"848\"}, {\"Row\": 255, \"Column\": 2, \"Item\": 544, \"DisplayText\": \"Recurrent or persistent urethritis\", \"Text\": \"Persistent or recurrent urethritis\", \"Mnemonic\": \"850\"}, {\"Row\": 256, \"Column\": 2, \"Item\": 235, \"DisplayText\": \"Pertussis\", \"Text\": \"Pertussis\", \"Mnemonic\": \"852\"}, {\"Row\": 257, \"Column\": 2, \"Item\": 532, \"DisplayText\": \"Prevention of Pertussis\", \"Text\": \"Pertussis post-exposure prophylaxis\", \"Mnemonic\": \"854\"}, {\"Row\": 258, \"Column\": 2, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Pertussis vaccination\", \"Mnemonic\": \"856\"}, {\"Row\": 259, \"Column\": 2, \"Item\": 222, \"DisplayText\": \"Not Benefited by Abx Pharyngitis\", \"Text\": \"Pharyngitis, non-streptococcal\", \"Mnemonic\": \"858\"}, {\"Row\": 260, \"Column\": 2, \"Item\": 236, \"DisplayText\": \"Pharyngitis\", \"Text\": \"Pharyngitis, streptococcal\", \"Mnemonic\": \"860\"}, {\"Row\": 261, \"Column\": 2, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal vaccination\", \"Mnemonic\": \"862\"}, {\"Row\": 262, \"Column\": 2, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"864\"}, {\"Row\": 263, \"Column\": 2, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis prophylaxis\", \"Mnemonic\": \"866\"}, {\"Row\": 264, \"Column\": 2, \"Item\": 240, \"DisplayText\": \"Pneumonia\", \"Text\": \"Pneumonia\", \"Mnemonic\": \"868\"}, {\"Row\": 265, \"Column\": 2, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Pneumonia with sepsis\", \"Mnemonic\": \"870\"}, {\"Row\": 266, \"Column\": 2, \"Item\": 83, \"DisplayText\": \"Aspiration pneumonia\", \"Text\": \"Pneumonia, aspiration\", \"Mnemonic\": \"872\"}, {\"Row\": 267, \"Column\": 2, \"Item\": 122, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Pneumonia, community-acquired (CAP)\", \"Mnemonic\": \"876\"}, {\"Row\": 268, \"Column\": 2, \"Item\": 116, \"DisplayText\": \"CMV Pneumonia\", \"Text\": \"Pneumonia, Cytomegalovirus (CMV)\", \"Mnemonic\": \"878\"}, {\"Row\": 269, \"Column\": 2, \"Item\": 485, \"DisplayText\": \"Mycobacterium avium pneumonia\", \"Text\": \"Pneumonia, Mycobacterium avium\", \"Mnemonic\": \"880\"}, {\"Row\": 270, \"Column\": 2, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Pneumonia, nosocomial [CLICK HERE], includes:\", \"Mnemonic\": \"882\"}, {\"Row\": 189, \"Column\": 2, \"Text\": \"N______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 192, \"Column\": 2, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 193, \"Column\": 2, \"Text\": \"Neisseria gonorrhoeae, Pseudomonas aeruginosa,\"}, {\"Row\": 194, \"Column\": 2, \"Text\": \"Staphylococcus aureus, streptococcus\"}, {\"Row\": 196, \"Column\": 2, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 197, \"Column\": 2, \"Text\": \"gram-negative bacilli, streptococci, staphylococci,\"}, {\"Row\": 198, \"Column\": 2, \"Text\": \"and HACEK bacteria\"}, {\"Row\": 218, \"Column\": 2, \"Text\": \"O______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 225, \"Column\": 2, \"Text\": \"empirical therapy, gram-negative bacilli, Pseudomonas aeruginosa,\"}, {\"Row\": 226, \"Column\": 2, \"Text\": \"Staphylococcus aureus, and streptococci\"}, {\"Row\": 232, \"Column\": 2, \"Text\": \"Pa-Pn__________________________________________________________________________\", \"Header\": 1}, {\"Row\": 271, \"Column\": 2, \"Text\": \"72 hour re-evaluation, Acinetobacter baumannii,\"}, {\"Row\": 272, \"Column\": 2, \"Text\": \"empirical therapy, Enterobacteriaceae, HAP, Legionella pneumophila,\"}, {\"Row\": 273, \"Column\": 2, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aeruginosa, and VAP\"}, {\"Row\": 1, \"Column\": 3, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Drug Information\", \"Mnemonic\": \"884\"}, {\"Row\": 7, \"Column\": 3, \"Item\": 117, \"DisplayText\": \"CMV Polyradiculopathy\", \"Text\": \"Polyradiculopathy, Cytomegalovirus (CMV)\", \"Mnemonic\": \"886\"}, {\"Row\": 8, \"Column\": 3, \"Item\": 401, \"DisplayText\": \"Bacteroides spp. (including Prevotella, Porphyromonas)\", \"Text\": \"Porphyromonas infections, general\", \"Mnemonic\": \"888\"}, {\"Row\": 9, \"Column\": 3, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"Post-exposure prophylaxis, occupational\", \"Mnemonic\": \"890\"}, {\"Row\": 10, \"Column\": 3, \"Item\": 532, \"DisplayText\": \"Prevention of Pertussis\", \"Text\": \"Post-exposure prophylaxis, pertussis\", \"Mnemonic\": \"892\"}, {\"Row\": 13, \"Column\": 3, \"Item\": 526, \"DisplayText\": \"Antimicrobial Prophylaxis Post-op\", \"Text\": \"Post-operative antimicrobial prophylaxis\", \"Mnemonic\": \"896\"}, {\"Row\": 14, \"Column\": 3, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Post-operative dermatology infection\", \"Mnemonic\": \"898\"}, {\"Row\": 15, \"Column\": 3, \"Item\": 606, \"DisplayText\": \"Surgical Site Infection\", \"Text\": \"Post-operative wound infection\", \"Mnemonic\": \"900\"}, {\"Row\": 16, \"Column\": 3, \"Item\": 527, \"DisplayText\": \"Postseptal Cellulitis\", \"Text\": \"Postseptal cellulitis\", \"Mnemonic\": \"902\"}, {\"Row\": 17, \"Column\": 3, \"Item\": 337, \"DisplayText\": \"Post-surgical or post-traumatic brain abscess\", \"Text\": \"Post-surgical or post-traumatic brain abscess\", \"Mnemonic\": \"904\"}, {\"Row\": 18, \"Column\": 3, \"Item\": 989, \"DisplayText\": \"\", \"Text\": \"Pregnancy immunizations\", \"Mnemonic\": \"906\"}, {\"Row\": 19, \"Column\": 3, \"Item\": 988, \"DisplayText\": \"List of Antimicrobials with Pregnancy Risk Category\", \"Text\": \"Pregnancy risk factors for antimicrobials\", \"Mnemonic\": \"908\"}, {\"Row\": 20, \"Column\": 3, \"Item\": 490, \"DisplayText\": \"Pre-Op Antimicrobials...\", \"Text\": \"Pre-operative antimicrobial prophylaxis\", \"Mnemonic\": \"910\"}, {\"Row\": 21, \"Column\": 3, \"Item\": 528, \"DisplayText\": \"Preseptal Cellulitis\", \"Text\": \"Preseptal cellulitis\", \"Mnemonic\": \"912\"}, {\"Row\": 22, \"Column\": 3, \"Item\": 86, \"DisplayText\": \"Azithromycin for Prevention of Exacerbations COPD\", \"Text\": \"Prevention of COPD exacerbations\", \"Mnemonic\": \"914\"}, {\"Row\": 23, \"Column\": 3, \"Item\": 244, \"DisplayText\": \"Prevention of Infection\", \"Text\": \"Prevention of Infection section\", \"Mnemonic\": \"916\"}, {\"Row\": 24, \"Column\": 3, \"Item\": 401, \"DisplayText\": \"Bacteroides spp. (including Prevotella, Porphyromonas)\", \"Text\": \"Prevotella infections, general\", \"Mnemonic\": \"918\"}, {\"Row\": 25, \"Column\": 3, \"Item\": 529, \"DisplayText\": \"Prevention of bacterial infection in a patient with malignancy\", \"Text\": \"Prophylactic antibiotics in malignancy\", \"Mnemonic\": \"920\"}, {\"Row\": 26, \"Column\": 3, \"Item\": 530, \"DisplayText\": \"Prevention of fungal infections in a patient with malignancy\", \"Text\": \"Prophylactic antifungals in malignancy\", \"Mnemonic\": \"922\"}, {\"Row\": 27, \"Column\": 3, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Prophylactic antimicrobials for asplenia\", \"Mnemonic\": \"924\"}, {\"Row\": 28, \"Column\": 3, \"Item\": 482, \"DisplayText\": \"Lyme Disease Prophylaxis\", \"Text\": \"Prophylactic antimicrobials for Lyme disease\", \"Mnemonic\": \"926\"}, {\"Row\": 29, \"Column\": 3, \"Item\": 534, \"DisplayText\": \"Prophylaxis against Mycobacterium avium disease...\", \"Text\": \"Prophylactic antimicrobials for Mycobacterium avium\", \"Mnemonic\": \"928\"}, {\"Row\": 30, \"Column\": 3, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"Prophylactic antimicrobials for occupational post-exposure\", \"Mnemonic\": \"930\"}, {\"Row\": 31, \"Column\": 3, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Prophylactic antimicrobials for Pneumocystis\", \"Mnemonic\": \"932\"}, {\"Row\": 32, \"Column\": 3, \"Item\": 532, \"DisplayText\": \"Prevention of Pertussis\", \"Text\": \"Prophylactic antimicrobials for post-exposure pertussis\", \"Mnemonic\": \"934\"}, {\"Row\": 33, \"Column\": 3, \"Item\": 275, \"DisplayText\": \"Acute spontaneous bacterial peritonitis (SBP)\", \"Text\": \"Prophylactic antimicrobials for spontaneous bacterial peritonitis\", \"Mnemonic\": \"936\"}, {\"Row\": 34, \"Column\": 3, \"Item\": 526, \"DisplayText\": \"Antimicrobial Prophylaxis Post-op\", \"Text\": \"Prophylactic antimicrobials, post-operative\", \"Mnemonic\": \"938\"}, {\"Row\": 35, \"Column\": 3, \"Item\": 490, \"DisplayText\": \"Pre-Op Antimicrobials...\", \"Text\": \"Prophylactic antimicrobials, pre-operative\", \"Mnemonic\": \"940\"}, {\"Row\": 36, \"Column\": 3, \"Item\": 304, \"DisplayText\": \"\", \"Text\": \"Prophylactic antivirals in malignancy\", \"Mnemonic\": \"942\"}, {\"Row\": 39, \"Column\": 3, \"Item\": 428, \"DisplayText\": \"Propionibacterium spp.\", \"Text\": \"Propionibacterium infections, general\", \"Mnemonic\": \"946\"}, {\"Row\": 40, \"Column\": 3, \"Item\": 72, \"DisplayText\": \"Acute Bacterial Prostatitis\", \"Text\": \"Prostatitis, acute\", \"Mnemonic\": \"948\"}, {\"Row\": 41, \"Column\": 3, \"Item\": 111, \"DisplayText\": \"Chronic bacterial prostatitis\", \"Text\": \"Prostatitis, chronic\", \"Mnemonic\": \"950\"}, {\"Row\": 42, \"Column\": 3, \"Item\": 110, \"DisplayText\": \"Chronic protatitis/Chronic pelvic pain syndrome\", \"Text\": \"Prostatitis/pelvic pain syndrome, chronic\", \"Mnemonic\": \"952\"}, {\"Row\": 43, \"Column\": 3, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Prosthetic bone/joint infection [CLICK HERE], includes:\", \"Mnemonic\": \"954\"}, {\"Row\": 47, \"Column\": 3, \"Item\": 369, \"DisplayText\": \"Prosthetic Valve Endocarditis--Selected Pathogens\", \"Text\": \"Prosthetic valve endocarditis [CLICK HERE], includes:\", \"Mnemonic\": \"956\"}, {\"Row\": 51, \"Column\": 3, \"Item\": 368, \"DisplayText\": \"Prosthetic Valve Endocarditis--Empicaral Therapy\", \"Text\": \"Prosthetic valve endocarditis empirical therapy\", \"Mnemonic\": \"958\"}, {\"Row\": 52, \"Column\": 3, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Prosthetic valve endocarditis with sepsis\", \"Mnemonic\": \"960\"}, {\"Row\": 53, \"Column\": 3, \"Item\": 419, \"DisplayText\": \"Proteus spp.\", \"Text\": \"Proteus infections, general\", \"Mnemonic\": \"962\"}, {\"Row\": 54, \"Column\": 3, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Protocol for Penicillin Desensitization\", \"Mnemonic\": \"964\"}, {\"Row\": 55, \"Column\": 3, \"Item\": 562, \"DisplayText\": \"Septic arthritis (Native joint) with Pseudomonas aeruginosa\", \"Text\": \"Pseudomonas aeruginosa native joint infection\", \"Mnemonic\": \"966\"}, {\"Row\": 56, \"Column\": 3, \"Item\": 220, \"DisplayText\": \"Nosocomial pneumonia with Pseudomonas aeruginosa\", \"Text\": \"Pseudomonas aeruginosa nosocomial pneumonia\", \"Mnemonic\": \"968\"}, {\"Row\": 57, \"Column\": 3, \"Item\": 506, \"DisplayText\": \"Osteomyelitis with Pseudomonas aeruginosa\", \"Text\": \"Pseudomonas aeruginosa osteomyelitis\", \"Mnemonic\": \"970\"}, {\"Row\": 58, \"Column\": 3, \"Item\": 538, \"DisplayText\": \"Pseudomonas aeruginosa infections in bone or joint prostheses\", \"Text\": \"Pseudomonas aeruginosa prosthetic bone/joint infection\", \"Mnemonic\": \"972\"}, {\"Row\": 59, \"Column\": 3, \"Item\": 247, \"DisplayText\": \"Pyelonephritis\", \"Text\": \"Pseudomonas aeruginosa pyelonephritis\", \"Mnemonic\": \"974\"}, {\"Row\": 60, \"Column\": 3, \"Item\": 408, \"DisplayText\": \"Pseudomonas spp.\", \"Text\": \"Pseudomonas infections, general\", \"Mnemonic\": \"976\"}, {\"Row\": 61, \"Column\": 3, \"Item\": 315, \"DisplayText\": \"Bacterial meningitis with E. Coli, Pseudomonas, or other organism\", \"Text\": \"Pseudomonas meningitis\", \"Mnemonic\": \"978\"}, {\"Row\": 62, \"Column\": 3, \"Item\": 338, \"DisplayText\": \"Brain Abscess with Pseudomonas spp.\", \"Text\": \"Pseudomonas spp. brain abscess\", \"Mnemonic\": \"980\"}, {\"Row\": 63, \"Column\": 3, \"Item\": 542, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis)\", \"Text\": \"Pubic lice\", \"Mnemonic\": \"982\"}, {\"Row\": 64, \"Column\": 3, \"Item\": 247, \"DisplayText\": \"Pyelonephritis\", \"Text\": \"Pyelonephritis [CLICK HERE], includes:\", \"Mnemonic\": \"984\"}, {\"Row\": 66, \"Column\": 3, \"Item\": 200, \"DisplayText\": \"\", \"Text\": \"Pyogenic liver abscess\", \"Mnemonic\": \"986\"}, {\"Row\": 67, \"Column\": 3, \"Item\": 543, \"DisplayText\": \"Pyomyositis\", \"Text\": \"Pyomyositis\", \"Mnemonic\": \"988\"}, {\"Row\": 68, \"Column\": 3, \"Item\": 223, \"DisplayText\": \"Bacteruria, Candiduria, and Pyuria\", \"Text\": \"Pyuria\", \"Mnemonic\": \"990\"}, {\"Row\": 75, \"Column\": 3, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Rabies vaccination\", \"Mnemonic\": \"994\"}, {\"Row\": 76, \"Column\": 3, \"Item\": 544, \"DisplayText\": \"Recurrent or persistent urethritis\", \"Text\": \"Recurrent or persistent urethritis\", \"Mnemonic\": \"996\"}, {\"Row\": 77, \"Column\": 3, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Renal failure immunizations\", \"Mnemonic\": \"998\"}, {\"Row\": 78, \"Column\": 3, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"Resistant bacteria, more about\", \"Mnemonic\": \"1000\"}, {\"Row\": 79, \"Column\": 3, \"Item\": 264, \"DisplayText\": \"RSV\", \"Text\": \"Respiratory syncytial virus (RSV)\", \"Mnemonic\": \"1004\"}, {\"Row\": 80, \"Column\": 3, \"Item\": 69, \"DisplayText\": \"Antimicrobial restriction policy\", \"Text\": \"Restrictions on antimicrobials\", \"Mnemonic\": \"1006\"}, {\"Row\": 81, \"Column\": 3, \"Item\": 545, \"DisplayText\": \"Retinitis\", \"Text\": \"Retinitis [CLICK HERE], includes:\", \"Mnemonic\": \"1008\"}, {\"Row\": 83, \"Column\": 3, \"Item\": 620, \"DisplayText\": \"Tinea Capitis (Ringworm)\", \"Text\": \"Ringworm\", \"Mnemonic\": \"1010\"}, {\"Row\": 84, \"Column\": 3, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"Risk factors for MRSA\", \"Mnemonic\": \"1012\"}, {\"Row\": 85, \"Column\": 3, \"Item\": 546, \"DisplayText\": \"Rocky Mountain Spotted Fever\", \"Text\": \"Rocky mountain spotted fever\", \"Mnemonic\": \"1014\"}, {\"Row\": 86, \"Column\": 3, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Rubella vaccination\", \"Mnemonic\": \"1016\"}, {\"Row\": 89, \"Column\": 3, \"Item\": 265, \"DisplayText\": \"Diarrhea with Salmonella\", \"Text\": \"Salmonella diarrhea/gastroenteritis\", \"Mnemonic\": \"1018\"}, {\"Row\": 90, \"Column\": 3, \"Item\": 409, \"DisplayText\": \"Salmonella spp.\", \"Text\": \"Salmonella infections, general\", \"Mnemonic\": \"1020\"}, {\"Row\": 91, \"Column\": 3, \"Item\": 547, \"DisplayText\": \"Scabies\", \"Text\": \"Scabies\", \"Mnemonic\": \"1022\"}, {\"Row\": 92, \"Column\": 3, \"Item\": 571, \"DisplayText\": \"Staphylococcal Scalded Skin Syndrom (Ritter's Disease)\", \"Text\": \"Scalded skin syndrome\", \"Mnemonic\": \"1024\"}, {\"Row\": 93, \"Column\": 3, \"Item\": 189, \"DisplayText\": \"Influenza Seasonal 2022-2023\", \"Text\": \"Seasonal influenza\", \"Mnemonic\": \"1026\"}, {\"Row\": 94, \"Column\": 3, \"Item\": 266, \"DisplayText\": \"Secondary Peritonitis\", \"Text\": \"Secondary peritonitis\", \"Mnemonic\": \"1028\"}, {\"Row\": 95, \"Column\": 3, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Sepsis and septic shock\", \"Mnemonic\": \"1030\"}, {\"Row\": 96, \"Column\": 3, \"Item\": 565, \"DisplayText\": \"Septic arthritis (Native joint)\", \"Text\": \"Septic arthritis, native joint [CLICK HERE], includes:\", \"Mnemonic\": \"1032\"}, {\"Row\": 100, \"Column\": 3, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Septic arthritis, prosthetic joint [CLICK HERE], includes:\", \"Mnemonic\": \"1034\"}, {\"Row\": 104, \"Column\": 3, \"Item\": 566, \"DisplayText\": \"Septic bursitis\", \"Text\": \"Septic bursitis\", \"Mnemonic\": \"1036\"}, {\"Row\": 105, \"Column\": 3, \"Item\": 420, \"DisplayText\": \"Serratia spp.\", \"Text\": \"Serratia infections, general\", \"Mnemonic\": \"1038\"}, {\"Row\": 106, \"Column\": 3, \"Item\": 297, \"DisplayText\": \"Bacterial Vaginosis\", \"Text\": \"Sexually transmitted infection, bacterial vaginitis\", \"Mnemonic\": \"1040\"}, {\"Row\": 107, \"Column\": 3, \"Item\": 105, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Sexually transmitted infection, cervicitis\", \"Mnemonic\": \"1042\"}, {\"Row\": 108, \"Column\": 3, \"Item\": 105, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Sexually transmitted infection, chlamydia cervicitis\", \"Mnemonic\": \"1044\"}, {\"Row\": 109, \"Column\": 3, \"Item\": 293, \"DisplayText\": \"Urethritis associated with sexually transmitted diseases\", \"Text\": \"Sexually transmitted infection, chlamydia urethritis\", \"Mnemonic\": \"1046\"}, {\"Row\": 110, \"Column\": 3, \"Item\": 163, \"DisplayText\": \"Genital herpes\", \"Text\": \"Sexually transmitted infection, genital warts\", \"Mnemonic\": \"1048\"}, {\"Row\": 111, \"Column\": 3, \"Item\": 105, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Sexually transmitted infection, gonorrhea cervicitis\", \"Mnemonic\": \"1050\"}, {\"Row\": 112, \"Column\": 3, \"Item\": 293, \"DisplayText\": \"Urethritis associated with sexually transmitted diseases\", \"Text\": \"Sexually transmitted infection, gonorrhea urethritis\", \"Mnemonic\": \"1052\"}, {\"Row\": 113, \"Column\": 3, \"Item\": 238, \"DisplayText\": \"Pelvic Inflammatory Disease\", \"Text\": \"Sexually transmitted infection, pelvic inflammatory disease\", \"Mnemonic\": \"1054\"}, {\"Row\": 114, \"Column\": 3, \"Item\": 542, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis)\", \"Text\": \"Sexually transmitted infection, pubic lice (crabs)\", \"Mnemonic\": \"1056\"}, {\"Row\": 115, \"Column\": 3, \"Item\": 281, \"DisplayText\": \"Syphilis\", \"Text\": \"Sexually transmitted infection, syphilis\", \"Mnemonic\": \"1058\"}, {\"Row\": 116, \"Column\": 3, \"Item\": 288, \"DisplayText\": \"Trichomonas Vaginitis\", \"Text\": \"Sexually transmitted infection, trichomoniasis\", \"Mnemonic\": \"1060\"}, {\"Row\": 117, \"Column\": 3, \"Item\": 293, \"DisplayText\": \"Urethritis associated with sexually transmitted diseases\", \"Text\": \"Sexually transmitted infection, urethritis\", \"Mnemonic\": \"1062\"}, {\"Row\": 118, \"Column\": 3, \"Item\": 269, \"DisplayText\": \"Diarrhea with Shigella species (bacillary dysentery)\", \"Text\": \"Shigella diarrhea/gastroenteritis\", \"Mnemonic\": \"1064\"}, {\"Row\": 119, \"Column\": 3, \"Item\": 410, \"DisplayText\": \"Shigella spp. (bacillary dysentery)\", \"Text\": \"Shigella infections, general\", \"Mnemonic\": \"1066\"}, {\"Row\": 120, \"Column\": 3, \"Item\": 249, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\")\", \"Text\": \"Shingles\", \"Mnemonic\": \"1068\"}, {\"Row\": 121, \"Column\": 3, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Shingles vaccination\", \"Mnemonic\": \"1070\"}, {\"Row\": 122, \"Column\": 3, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Shortages of antimicrobials updates\", \"Mnemonic\": \"1072\"}, {\"Row\": 123, \"Column\": 3, \"Item\": 300, \"DisplayText\": \"Acute Sinusitis--Mild to Moderate Disease\", \"Text\": \"Sinusitis, acute\", \"Mnemonic\": \"1074\"}, {\"Row\": 124, \"Column\": 3, \"Item\": 344, \"DisplayText\": \"Chronic Sinusitis\", \"Text\": \"Sinusitis, chronic\", \"Mnemonic\": \"1076\"}, {\"Row\": 125, \"Column\": 3, \"Item\": 385, \"DisplayText\": \"Fungal Sinusitis\", \"Text\": \"Sinusitis, fungal\", \"Mnemonic\": \"1078\"}, {\"Row\": 126, \"Column\": 3, \"Item\": 503, \"DisplayText\": \"Nosocomial Sinusitis\", \"Text\": \"Sinusitis, nosocomial\", \"Mnemonic\": \"1080\"}, {\"Row\": 127, \"Column\": 3, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Skin and soft tissue infection with sepsis\", \"Mnemonic\": \"1082\"}, {\"Row\": 128, \"Column\": 3, \"Item\": 139, \"DisplayText\": \"Dermatological Infections\", \"Text\": \"Skin Infections section\", \"Mnemonic\": \"1084\"}, {\"Row\": 129, \"Column\": 3, \"Item\": 467, \"DisplayText\": \"Small pleomorphic rods in aerobic bottle\", \"Text\": \"Small pleomorphic bacilli, aerobic bottle\", \"Mnemonic\": \"1086\"}, {\"Row\": 130, \"Column\": 3, \"Item\": 468, \"DisplayText\": \"Small pleomorphic rods in an anaerobic bottle\", \"Text\": \"Small pleomorphic bacilli, anaerobic bottle\", \"Mnemonic\": \"1088\"}, {\"Row\": 131, \"Column\": 3, \"Item\": 270, \"DisplayText\": \"Soft tissue, muscle, bone and joint infections\", \"Text\": \"Soft Tissue and Muscle section\", \"Mnemonic\": \"1090\"}, {\"Row\": 132, \"Column\": 3, \"Item\": 475, \"DisplayText\": \"Introduction to Specific Pathogen section\", \"Text\": \"Specific pathogen introduction\", \"Mnemonic\": \"1092\"}, {\"Row\": 133, \"Column\": 3, \"Item\": 569, \"DisplayText\": \"Spinal epidural abscess\", \"Text\": \"Spinal epidural abscess\", \"Mnemonic\": \"1094\"}, {\"Row\": 134, \"Column\": 3, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Spleen absent or dysfunctional [CLICK HERE], includes:\", \"Mnemonic\": \"1096\"}, {\"Row\": 137, \"Column\": 3, \"Item\": 275, \"DisplayText\": \"Acute spontaneous bacterial peritonitis (SBP)\", \"Text\": \"Spontaneous bacterial peritonitis prevention\", \"Mnemonic\": \"1098\"}, {\"Row\": 138, \"Column\": 3, \"Item\": 570, \"DisplayText\": \"Sporotrichosis\", \"Text\": \"Sporotrichosis infections, general\", \"Mnemonic\": \"1100\"}, {\"Row\": 139, \"Column\": 3, \"Item\": 437, \"DisplayText\": \"Staphylococci\", \"Text\": \"Staphylococcal infections, general\", \"Mnemonic\": \"1102\"}, {\"Row\": 140, \"Column\": 3, \"Item\": 366, \"DisplayText\": \"Native Valve Endocarditis with Staphylococci\", \"Text\": \"Staphylococcal native valve endocarditis\", \"Mnemonic\": \"1104\"}, {\"Row\": 141, \"Column\": 3, \"Item\": 370, \"DisplayText\": \"Prosthetic Valve Endocarditis with Staphylococci\", \"Text\": \"Staphylococcal prosthetic valve endocarditis\", \"Mnemonic\": \"1106\"}, {\"Row\": 142, \"Column\": 3, \"Item\": 624, \"DisplayText\": \"Toxic Shock Syndrome\", \"Text\": \"Staphylococcal toxic shock syndrome\", \"Mnemonic\": \"1108\"}, {\"Row\": 143, \"Column\": 3, \"Item\": 432, \"DisplayText\": \"Treatment for Coagulase negative Staphylococci\", \"Text\": \"Staphylococci, coagulase-negative\", \"Mnemonic\": \"1110\"}, {\"Row\": 144, \"Column\": 3, \"Item\": 433, \"DisplayText\": \"Treatment for Staphyloccus aureus\", \"Text\": \"Staphylococcus aureus infections, general\", \"Mnemonic\": \"1112\"}, {\"Row\": 145, \"Column\": 3, \"Item\": 221, \"DisplayText\": \"STAPHYLOCOCCUS AUREUS PNEUMONIA\", \"Text\": \"Staphylococcus aureus nosocomial pneumonia\", \"Mnemonic\": \"1114\"}, {\"Row\": 146, \"Column\": 3, \"Item\": 509, \"DisplayText\": \"Osteomyelitis with Staphylococcus aureus\", \"Text\": \"Staphylococcus aureus osteomyelitis\", \"Mnemonic\": \"1116\"}, {\"Row\": 147, \"Column\": 3, \"Item\": 326, \"DisplayText\": \"Bacteremia associated with Staphylococcus aureus\", \"Text\": \"Staphylococcus aureus bacteremia\", \"Mnemonic\": \"1118\"}, {\"Row\": 148, \"Column\": 3, \"Item\": 276, \"DisplayText\": \"\", \"Text\": \"Staphylococcus aureus decolonization\", \"Mnemonic\": \"1120\"}, {\"Row\": 149, \"Column\": 3, \"Item\": 473, \"DisplayText\": \"Intravascular catheter-associated Staphyloccus aureus infection\", \"Text\": \"Staphylococcus aureus intravascular catheter-associated infection\", \"Mnemonic\": \"1122\"}, {\"Row\": 150, \"Column\": 3, \"Item\": 540, \"DisplayText\": \"Staphylococcus aureus infections in bone or joint prostheses\", \"Text\": \"Staphylococcus aureus prosthetic bone/joint infection\", \"Mnemonic\": \"1124\"}, {\"Row\": 151, \"Column\": 3, \"Item\": 563, \"DisplayText\": \"Septic arthritis (Native joint) with Staphylococcus aureus\", \"Text\": \"Staphylococcus aureus, native joint infection\", \"Mnemonic\": \"1126\"}, {\"Row\": 152, \"Column\": 3, \"Item\": 327, \"DisplayText\": \"Bacteremia associated with Staphylococcus lugdunensis\", \"Text\": \"Staphylococcus lugdunensis bacteremia\", \"Mnemonic\": \"1128\"}, {\"Row\": 153, \"Column\": 3, \"Item\": 436, \"DisplayText\": \"Staphylococcis Lugdunensis\", \"Text\": \"Staphylococcus lugdunensis infections, general\", \"Mnemonic\": \"1130\"}, {\"Row\": 154, \"Column\": 3, \"Item\": 277, \"DisplayText\": \"Stasis dermatitis\", \"Text\": \"Stasis dermatitis\", \"Mnemonic\": \"1132\"}, {\"Row\": 155, \"Column\": 3, \"Item\": 332, \"DisplayText\": \"Bite wounds with Streptococci\", \"Text\": \"Streptococcal bite wounds\", \"Mnemonic\": \"1134\"}, {\"Row\": 156, \"Column\": 3, \"Item\": 360, \"DisplayText\": \"Endocarditis with Enterococci\", \"Text\": \"Streptococcal native valve endocarditis (highly resistant isolate)\", \"Mnemonic\": \"1136\"}, {\"Row\": 157, \"Column\": 3, \"Item\": 367, \"DisplayText\": \"Native Valve Endocarditis with Streptococci\", \"Text\": \"Streptococcal native valve endocarditis (sensitive isolate)\", \"Mnemonic\": \"1138\"}, {\"Row\": 158, \"Column\": 3, \"Item\": 507, \"DisplayText\": \"Osteomyelitis with Streptococci\", \"Text\": \"Streptococcal osteomyelitis\", \"Mnemonic\": \"1140\"}, {\"Row\": 159, \"Column\": 3, \"Item\": 236, \"DisplayText\": \"Pharyngitis\", \"Text\": \"Streptococcal pharyngitis\", \"Mnemonic\": \"1142\"}, {\"Row\": 160, \"Column\": 3, \"Item\": 539, \"DisplayText\": \"Streptococcal infections in bone or joint prostheses\", \"Text\": \"Streptococcal prosthetic bone/joint infection\", \"Mnemonic\": \"1144\"}, {\"Row\": 161, \"Column\": 3, \"Item\": 371, \"DisplayText\": \"Pros. Valve Endocard with Viridans Group Streptococcus and Streptococcus bovis\", \"Text\": \"Streptococcal prosthetic valve endocarditis\", \"Mnemonic\": \"1146\"}, {\"Row\": 162, \"Column\": 3, \"Item\": 624, \"DisplayText\": \"Toxic Shock Syndrome\", \"Text\": \"Streptococcal toxic shock syndrome\", \"Mnemonic\": \"1148\"}, {\"Row\": 163, \"Column\": 3, \"Item\": 438, \"DisplayText\": \"Streptococci Groups C, F, G\", \"Text\": \"Streptococci Groups C, F, G infections, general\", \"Mnemonic\": \"1150\"}, {\"Row\": 164, \"Column\": 3, \"Item\": 439, \"DisplayText\": \"Viridans streptococci (including S. mutans, S. mitis, S. sanguis)\", \"Text\": \"Streptococci viridans infections, general [CLICK HERE], includes:\", \"Mnemonic\": \"1152\"}, {\"Row\": 166, \"Column\": 3, \"Item\": 440, \"DisplayText\": \"Group B Streptococci (S. agalactiae)\", \"Text\": \"Streptococcus agalactiae (Group B)\", \"Mnemonic\": \"1154\"}, {\"Row\": 167, \"Column\": 3, \"Item\": 429, \"DisplayText\": \"Streptococcus anginosus (formerly S. milleri)\", \"Text\": \"Streptococcus anginosus (formerly S. milleri)\", \"Mnemonic\": \"1156\"}, {\"Row\": 168, \"Column\": 3, \"Item\": 434, \"DisplayText\": \"Group D (S. bovis)\", \"Text\": \"Streptococcus bovis (Group D)\", \"Mnemonic\": \"1158\"}, {\"Row\": 169, \"Column\": 3, \"Item\": 564, \"DisplayText\": \"Septic arthritis (Native joint) with Streptococci\", \"Text\": \"Streptococcus native joint infection\", \"Mnemonic\": \"1160\"}, {\"Row\": 170, \"Column\": 3, \"Item\": 430, \"DisplayText\": \"Streptococcus pneumoniae\", \"Text\": \"Streptococcus pneumoniae infections, general\", \"Mnemonic\": \"1162\"}, {\"Row\": 171, \"Column\": 3, \"Item\": 321, \"DisplayText\": \"Bacterial meningitis with S. pneumoniae\", \"Text\": \"Streptococcus pneumoniae meningitis\", \"Mnemonic\": \"1164\"}, {\"Row\": 172, \"Column\": 3, \"Item\": 435, \"DisplayText\": \"Group A Streptococci (S. pyogenes)\", \"Text\": \"Streptococcus pyogenes (Group A) infections, general\", \"Mnemonic\": \"1166\"}, {\"Row\": 173, \"Column\": 3, \"Item\": 455, \"DisplayText\": \"Stress\", \"Text\": \"Stress\", \"Mnemonic\": \"1168\"}, {\"Row\": 174, \"Column\": 3, \"Item\": 574, \"DisplayText\": \"Subdural Empyema\", \"Text\": \"Subdural empyema\", \"Mnemonic\": \"1170\"}, {\"Row\": 175, \"Column\": 3, \"Item\": 575, \"DisplayText\": \"Suppurative intracranial thrombophlebitis\", \"Text\": \"Suppurative intracranial thrombophlebitis\", \"Mnemonic\": \"1172\"}, {\"Row\": 176, \"Column\": 3, \"Item\": 576, \"DisplayText\": \"Suppurative odontogenic infections\", \"Text\": \"Suppurative odontic infections\", \"Mnemonic\": \"1174\"}, {\"Row\": 177, \"Column\": 3, \"Item\": 278, \"DisplayText\": \"Suppurative Thrombophlebitis--Empirical Therapy\", \"Text\": \"Suppurative thrombophlebitis\", \"Mnemonic\": \"1176\"}, {\"Row\": 178, \"Column\": 3, \"Item\": 606, \"DisplayText\": \"Surgical Site Infection\", \"Text\": \"Surgical site infection\", \"Mnemonic\": \"1178\"}, {\"Row\": 179, \"Column\": 3, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Susceptibilities, antimicrobial\", \"Mnemonic\": \"1180\"}, {\"Row\": 180, \"Column\": 3, \"Item\": 280, \"DisplayText\": \"Suspected bacteremia, blood cultures not yet positive\", \"Text\": \"Suspected bacteremia, blood cultures not yet positive\", \"Mnemonic\": \"1182\"}, {\"Row\": 181, \"Column\": 3, \"Item\": 281, \"DisplayText\": \"Syphilis\", \"Text\": \"Syphilis\", \"Mnemonic\": \"1184\"}, {\"Row\": 182, \"Column\": 3, \"Item\": 282, \"DisplayText\": \"Systemic Infectious Diseases\", \"Text\": \"Systemic Infections section\", \"Mnemonic\": \"1186\"}, {\"Row\": 4, \"Column\": 3, \"Text\": \"Po through Z\", \"Header\": 1}, {\"Row\": 6, \"Column\": 3, \"Text\": \"Po-Py__________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 3, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 45, \"Column\": 3, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aureus,\"}, {\"Row\": 46, \"Column\": 3, \"Text\": \"and streptococcus\"}, {\"Row\": 48, \"Column\": 3, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 49, \"Column\": 3, \"Text\": \"gram-negative bacilli, Streptococcus bovis,\"}, {\"Row\": 50, \"Column\": 3, \"Text\": \"staphylococci, HACEK bacteria, and Viridans group streptococci\"}, {\"Row\": 65, \"Column\": 3, \"Text\": \"empiric therapy, enterococcus, pseudomonas\"}, {\"Row\": 70, \"Column\": 3, \"Text\": \"Q______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 72, \"Column\": 3, \"Text\": \"R______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 82, \"Column\": 3, \"Text\": \"candida, Cytomegalovirus, herpes, zoster, and others\"}, {\"Row\": 88, \"Column\": 3, \"Text\": \"S______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 97, \"Column\": 3, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 98, \"Column\": 3, \"Text\": \"Neisseria gonorrhoeae, Pseudomonas aeruginosa,\"}, {\"Row\": 99, \"Column\": 3, \"Text\": \"Staphylococcus aureus, streptococcus\"}, {\"Row\": 101, \"Column\": 3, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 102, \"Column\": 3, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aureus,\"}, {\"Row\": 103, \"Column\": 3, \"Text\": \"and streptococcus\"}, {\"Row\": 135, \"Column\": 3, \"Text\": \"antimicrobial prophylaxis, management of fever,\"}, {\"Row\": 136, \"Column\": 3, \"Text\": \"patient initiated antibiotics, vaccines\"}, {\"Row\": 165, \"Column\": 3, \"Text\": \"S. mutans, S. mitis, S. sanguis\"}, {\"Row\": 185, \"Column\": 3, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus vaccination\", \"Mnemonic\": \"1188\"}, {\"Row\": 186, \"Column\": 3, \"Item\": 388, \"DisplayText\": \"Candida albicans\", \"Text\": \"Thrush\", \"Mnemonic\": \"1190\"}, {\"Row\": 188, \"Column\": 3, \"Item\": 620, \"DisplayText\": \"Tinea Capitis (Ringworm)\", \"Text\": \"Tinea capitis\", \"Mnemonic\": \"1192\"}, {\"Row\": 189, \"Column\": 3, \"Item\": 621, \"DisplayText\": \"Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris\", \"Text\": \"Tinea corporis\", \"Mnemonic\": \"1194\"}, {\"Row\": 190, \"Column\": 3, \"Item\": 621, \"DisplayText\": \"Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris\", \"Text\": \"Tinea cruris\", \"Mnemonic\": \"1196\"}, {\"Row\": 191, \"Column\": 3, \"Item\": 621, \"DisplayText\": \"Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris\", \"Text\": \"Tinea pedis\", \"Mnemonic\": \"1198\"}, {\"Row\": 192, \"Column\": 3, \"Item\": 622, \"DisplayText\": \"Tinea Unguium (Onychomycosis)\", \"Text\": \"Tinea unguium\", \"Mnemonic\": \"1200\"}, {\"Row\": 193, \"Column\": 3, \"Item\": 623, \"DisplayText\": \"Tinea Versicolor\", \"Text\": \"Tinea versicolor\", \"Mnemonic\": \"1202\"}, {\"Row\": 194, \"Column\": 3, \"Item\": 456, \"DisplayText\": \"Tobacco smoke\", \"Text\": \"Tobacco smoke\", \"Mnemonic\": \"1204\"}, {\"Row\": 195, \"Column\": 3, \"Item\": 236, \"DisplayText\": \"Pharyngitis\", \"Text\": \"Tonsillitis\", \"Mnemonic\": \"1206\"}, {\"Row\": 196, \"Column\": 3, \"Item\": 576, \"DisplayText\": \"Suppurative odontogenic infections\", \"Text\": \"Tooth abscess and other suppurative odontic infections\", \"Mnemonic\": \"1208\"}, {\"Row\": 197, \"Column\": 3, \"Item\": 624, \"DisplayText\": \"Toxic Shock Syndrome\", \"Text\": \"Toxic shock syndrome\", \"Mnemonic\": \"1210\"}, {\"Row\": 198, \"Column\": 3, \"Item\": 339, \"DisplayText\": \"Brain Abscess with Toxoplasma gondii\", \"Text\": \"Toxoplasma gondii brain abscess\", \"Mnemonic\": \"1212\"}, {\"Row\": 199, \"Column\": 3, \"Item\": 625, \"DisplayText\": \"Toxoplasma spp.\", \"Text\": \"Toxoplasma infections, general\", \"Mnemonic\": \"1214\"}, {\"Row\": 200, \"Column\": 3, \"Item\": 626, \"DisplayText\": \"Transplantation\", \"Text\": \"Transplantation\", \"Mnemonic\": \"1216\"}, {\"Row\": 201, \"Column\": 3, \"Item\": 314, \"DisplayText\": \"Bacterial meningitis associated with trauma or nosocomial infection\", \"Text\": \"Trauma or nosocomial infection associated meningitis\", \"Mnemonic\": \"1218\"}, {\"Row\": 202, \"Column\": 3, \"Item\": 627, \"DisplayText\": \"Traveler's Diarrhea\", \"Text\": \"Traveler's diarrhea\", \"Mnemonic\": \"1220\"}, {\"Row\": 203, \"Column\": 3, \"Item\": 288, \"DisplayText\": \"Trichomonas Vaginitis\", \"Text\": \"Trichomonas vaginitis\", \"Mnemonic\": \"1222\"}, {\"Row\": 204, \"Column\": 3, \"Item\": 289, \"DisplayText\": \"Tuberculosis\", \"Text\": \"Tuberculosis\", \"Mnemonic\": \"1224\"}, {\"Row\": 205, \"Column\": 3, \"Item\": 290, \"DisplayText\": \"Neutropenic Enterocolitis (Typhlitis)\", \"Text\": \"Typhlitis\", \"Mnemonic\": \"1226\"}, {\"Row\": 206, \"Column\": 3, \"Item\": 153, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Typhoid fever\", \"Mnemonic\": \"1228\"}, {\"Row\": 209, \"Column\": 3, \"Item\": 353, \"DisplayText\": \"Decubitus ulcers\", \"Text\": \"Ulcer, decubitus\", \"Mnemonic\": \"1230\"}, {\"Row\": 210, \"Column\": 3, \"Item\": 384, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus\", \"Text\": \"Ulcer, diabetic foot\", \"Mnemonic\": \"1232\"}, {\"Row\": 211, \"Column\": 3, \"Item\": 291, \"DisplayText\": \"Uncomplicated Cystitis\", \"Text\": \"Uncomplicated cystitis\", \"Mnemonic\": \"1234\"}, {\"Row\": 212, \"Column\": 3, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Updates on antimicrobial shortages\", \"Mnemonic\": \"1236\"}, {\"Row\": 213, \"Column\": 3, \"Item\": 292, \"DisplayText\": \"Upper respiratory infections (URI)\", \"Text\": \"Upper respiratory infections (URI)\", \"Mnemonic\": \"1238\"}, {\"Row\": 214, \"Column\": 3, \"Item\": 293, \"DisplayText\": \"Urethritis associated with sexually transmitted diseases\", \"Text\": \"Urethritis associated with STIs [CLICK HERE], includes:\", \"Mnemonic\": \"1240\"}, {\"Row\": 216, \"Column\": 3, \"Item\": 544, \"DisplayText\": \"Recurrent or persistent urethritis\", \"Text\": \"Urethritis, recurrent or persistent\", \"Mnemonic\": \"1242\"}, {\"Row\": 217, \"Column\": 3, \"Item\": 82, \"DisplayText\": \"Approach to Urinary Tract Infection (UTI)\", \"Text\": \"Urinary tract infection (UTI), bacterial\", \"Mnemonic\": \"1244\"}, {\"Row\": 218, \"Column\": 3, \"Item\": 100, \"DisplayText\": \"Candida urinary tract infection\", \"Text\": \"Urinary tract infection (UTI), candida\", \"Mnemonic\": \"1246\"}, {\"Row\": 219, \"Column\": 3, \"Item\": 628, \"DisplayText\": \"Urosepsis\", \"Text\": \"Urinary tract infection with sepsis\", \"Mnemonic\": \"1248\"}, {\"Row\": 220, \"Column\": 3, \"Item\": 628, \"DisplayText\": \"Urosepsis\", \"Text\": \"Urosepsis\", \"Mnemonic\": \"1250\"}, {\"Row\": 221, \"Column\": 3, \"Item\": 629, \"DisplayText\": \"Uveitis\", \"Text\": \"Uveitis\", \"Mnemonic\": \"1252\"}, {\"Row\": 225, \"Column\": 3, \"Item\": 101, \"DisplayText\": \"Candida Vulvo-Vaginitis\", \"Text\": \"Vaginitis, Candida\", \"Mnemonic\": \"1254\"}, {\"Row\": 226, \"Column\": 3, \"Item\": 288, \"DisplayText\": \"Trichomonas Vaginitis\", \"Text\": \"Vaginitis, Trichomonas\", \"Mnemonic\": \"1256\"}, {\"Row\": 227, \"Column\": 3, \"Item\": 297, \"DisplayText\": \"Bacterial Vaginosis\", \"Text\": \"Vaginosis, bacterial\", \"Mnemonic\": \"1258\"}, {\"Row\": 228, \"Column\": 3, \"Item\": 245, \"DisplayText\": \"Primary infection (Chickenpox)\", \"Text\": \"Varicella\", \"Mnemonic\": \"1260\"}, {\"Row\": 229, \"Column\": 3, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella vaccination\", \"Mnemonic\": \"1262\"}, {\"Row\": 230, \"Column\": 3, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Ventilator-associated pneumonia (VAP)\", \"Mnemonic\": \"1264\"}, {\"Row\": 231, \"Column\": 3, \"Item\": 630, \"DisplayText\": \"Diskitis and Vertebral Osteomyelitis\", \"Text\": \"Vertebral osteomyelitis and diskitis\", \"Mnemonic\": \"1266\"}, {\"Row\": 232, \"Column\": 3, \"Item\": 109, \"DisplayText\": \"Diarrhea with Cholera (Vibrio cholera)\", \"Text\": \"Vibrio cholerae diarrhea/gastroenteritis\", \"Mnemonic\": \"1268\"}, {\"Row\": 233, \"Column\": 3, \"Item\": 215, \"DisplayText\": \"Vibrio non-cholera\", \"Text\": \"Vibrio non-cholerae, diarrhea/gastroenteritis\", \"Mnemonic\": \"1270\"}, {\"Row\": 234, \"Column\": 3, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Viral diarrhea/gastroenteritis\", \"Mnemonic\": \"1272\"}, {\"Row\": 235, \"Column\": 3, \"Item\": 439, \"DisplayText\": \"Viridans streptococci (including S. mutans, S. mitis, S. sanguis)\", \"Text\": \"Viridans streptococci\", \"Mnemonic\": \"1274\"}, {\"Row\": 236, \"Column\": 3, \"Item\": 299, \"DisplayText\": \"Viruses\", \"Text\": \"Viruses section\", \"Mnemonic\": \"1276\"}, {\"Row\": 237, \"Column\": 3, \"Item\": 101, \"DisplayText\": \"Candida Vulvo-Vaginitis\", \"Text\": \"Vulvo-vaginitis, candida\", \"Mnemonic\": \"1278\"}, {\"Row\": 240, \"Column\": 3, \"Item\": 1057, \"DisplayText\": \"\", \"Text\": \"Warfarin interactions with antimicrobials\", \"Mnemonic\": \"1280\"}, {\"Row\": 241, \"Column\": 3, \"Item\": 606, \"DisplayText\": \"Surgical Site Infection\", \"Text\": \"Wound infection, post-op\", \"Mnemonic\": \"1282\"}, {\"Row\": 242, \"Column\": 3, \"Item\": 333, \"DisplayText\": \"Bite wounds\", \"Text\": \"Wound, bite\", \"Mnemonic\": \"1284\"}, {\"Row\": 243, \"Column\": 3, \"Item\": 121, \"DisplayText\": \"Colonized wounds\", \"Text\": \"Wound, colonized\", \"Mnemonic\": \"1286\"}, {\"Row\": 248, \"Column\": 3, \"Item\": 466, \"DisplayText\": \"Interim report of yeast\", \"Text\": \"Yeast bacteremia\", \"Mnemonic\": \"1288\"}, {\"Row\": 249, \"Column\": 3, \"Item\": 631, \"DisplayText\": \"Diarrhea with Yersinia enterocolitica\", \"Text\": \"Yersinia enterocolitica diarrhea/gastroenteritis\", \"Mnemonic\": \"1290\"}, {\"Row\": 252, \"Column\": 3, \"Item\": 249, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\")\", \"Text\": \"Zoster\", \"Mnemonic\": \"1292\"}, {\"Row\": 253, \"Column\": 3, \"Item\": 545, \"DisplayText\": \"Retinitis\", \"Text\": \"Zoster retinitis\", \"Mnemonic\": \"1294\"}, {\"Row\": 254, \"Column\": 3, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Zoster vaccination\", \"Mnemonic\": \"1296\"}, {\"Row\": 184, \"Column\": 3, \"Text\": \"T______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 208, \"Column\": 3, \"Text\": \"U______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 215, \"Column\": 3, \"Text\": \"chlamydia and gonococcal\"}, {\"Row\": 223, \"Column\": 3, \"Text\": \"V______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 224, \"Column\": 3, \"Text\": \"Vaccination: see immunization, specific organism or condition\"}, {\"Row\": 239, \"Column\": 3, \"Text\": \"W______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 245, \"Column\": 3, \"Text\": \"X______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 247, \"Column\": 3, \"Text\": \"Y______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 251, \"Column\": 3, \"Text\": \"Z______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 73, \"Column\": 3, \"Text\": \"Rabies post-exposure prophylaxis - see Emergency\"}, {\"Row\": 74, \"Column\": 3, \"Text\": \"Department CDSS or contact ID for more information\"}, {\"Row\": 37, \"Column\": 3, \"Text\": \"Prophylaxis for post-exposure, Rabies - see Emergency\"}, {\"Row\": 38, \"Column\": 3, \"Text\": \"Department CDSS or contact ID for more information\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"Post-exposure prophylaxis, Rabies - see Emergency\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"Department CDSS or contact ID for more information\"}, {\"Row\": 107, \"Column\": 1, \"Item\": 102, \"DisplayText\": \"Cardiovascular\", \"Text\": \"Cardiovascular Section\", \"Mnemonic\": \"185\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Bite, tick\", \"Mnemonic\": \"115\"}, {\"Row\": 187, \"Column\": 3, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Tick Bite\", \"Mnemonic\": \"1191\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 187,
    "fields": {
      "name": "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES",
      "term": null,
      "displaytext": "Infections involves cardiovascular devices (excluding valves)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15MG/KG IV Q12H RIFAMPIN 300 MG PO Q8H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> rifampin 300 mg PO/NG q8h ($)\", \"Mnemonic\": \"6\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 1 mg/kg IV Q8H\", \"Text\": \"< ADD > gentamicin 1 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INFECTIONS INVOLVING CARDIOVASCULAR DEVICES (EXCLUDING VALVES)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most infections are associated with Staphylococcus aureus and coagulase-negative\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"staphylococci.  Many of these staphylococci are resistant to methicillin, so\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"initial empiric therapy with vancomycin is required. Consultation with\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Infectious Diseases is encouraged for patients with severe allergies to\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"vancomycin or for those who have vancomycin-resistant infections.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"At least 3 blood cultures should be drawn prior to the initiation of empirical\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antimicrobial. Modify antimicrobial regimen and narrow coverage based on results\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"of culture and susceptibility tests Infectious Disease and Cardiothoracic\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"surgery consultations are encouraged.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Device removal is necessary for cure in most cases.  However, it may be\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"difficult depending on the nature of the device and specific clinical\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"circumstances.  Device removal should be discussed with Cardiology, Infectious\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Disease, or Cardiothoracic surgery consultants.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"If the device removal is not possible add rifampin.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Duration of therapy should be determined in concert with Cardiology, Infectious\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Disease, or Cardiothoracic surgery consultants.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Empiric treatment in cases where device removal is planned\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Empiric treatment in cases where surgery cannot be performed\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"[DI,O]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For hemodynamically unstable patients, add gentamicin to one of the above\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"treatment regimens\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2010, 121.458-477\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Kusumoto et al., Heart Rhythm 2017, 14.15\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: Pacemaker/Defibrillator Infections\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of Nonvalvular Cardiovascular Devices\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-To-Date article: Infections involving cardiac implantable electronic devices:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Treatment and prevention\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 188,
    "fields": {
      "name": "ORZID2 GMENU ABX INFECTION CTRL",
      "term": null,
      "displaytext": "Infection Control  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 22, \"Column\": 1, \"Item\": 3025, \"DisplayText\": \"Minneapolis SharePoint Infection Control website\", \"Text\": \"[Click here] Minneapolis VAMC Infection Prevention & Control SharePoint site\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC website for the Infectious Diseases\", \"Text\": \"[Click here] CDC website\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INFECTIOUS DISEASE (INPT)\", \"Text\": \"[Click here] Consult Infectious Diseases (inpatient)\", \"Mnemonic\": \"8\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis VAMC Isolation Precautions\", \"Text\": \"[Click here] Minneapolis VAMC Isolation Precautions\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INFECTION CONTROL\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Minneapolis VAMC infection control policies and practices are designed to\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"prevent infection and infectious diseases among patients, employees, visitors,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"families and friends. This section briefly summarizes key infection control\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"practices.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"____________________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For more information\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"____________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \">> Infection Prevention is available via phone (612-467-6888) during\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"duty hours Monday to Friday. (Internal extension 31-6888)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \">> During nights, weekends, and holidays, contact the on-call person for\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \">> Minneapolis VAMC Infection Prevention and Control SharePoint site\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \">> CDC web site (www.cdc.gov)\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"____________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Standard and special precautions\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"____________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Consult Infectious Diseases (outpatient)\", \"Text\": \"[Click here] Consult Infectious Diseases (outpatient)\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \">> Place consults for ID\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"[Click here] Minneapolis Clinical On-Call Schedule\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 189,
    "fields": {
      "name": "ORZID2 GMENU ABX INFLUENZA 2022-2023",
      "term": null,
      "displaytext": "Influenza Seasonal 2022-2023",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 78, \"DisplayText\": \"ANTIVIRAL TREATMENT\", \"Text\": \"Antiviral Treatment Recommendations\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 190, \"DisplayText\": \"Early treatment as alternative to chemoprophylaxis:\", \"Text\": \"Chemoprophylaxis Recommendations\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nasopharyngeal Testing Menu\", \"Text\": \"Lab Influenza Testing Menu\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Seasonal Influenza\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Last reviewed September 2022\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza vaccination recommendations\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 190,
    "fields": {
      "name": "ORZID2 GMENU ABX INFLUENZA CHEMOPROPHYLAXIS",
      "term": null,
      "displaytext": "Early treatment as alternative to chemoprophylaxis: ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Early treatment as alternative to chemoprophylaxis:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"In most cases, if a person is suspected of having been exposed to influenza,\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"early treatment should signs or symptoms develop is preferred rather than\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"chemoprophylaxis.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"The provider should explain the early signs and symptoms of influenza to the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"patient and advise the patient to immediately contact a health care provider\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"for evaluation and possible early treatment if these symptoms or signs\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"develop. Influenza-like symptoms or signs include fever, cough, sore throat,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"runny or stuffy nose, body aches, headache, chills, fatigue, vomiting, and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"diarrhea. Influenza can present without fever.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Health care providers should use clinical judgment regarding situations where\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"early recognition of illness and treatment might be an appropriate\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"alternative to chemoprophylaxis.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Early treatment alternative or chemoprophylaxis may be considered:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"*Persons who are part of a high-risk group and are household or close\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"contacts of someone with influenza-like illness\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Chemoprophylaxis recommended:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Chemoprophylaxis considered:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"*Atypical situations (such as case clusters). Contact state health department\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"for consultation.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Zanamivir is not recommended for patients with chronic respiratory disease such\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"as asthma or chronic obstructive pulmonary disease. These patients may have\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"bronchospasm with zanamivir. If zanamivir must be used, and patients are using\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"an inhaled bronchodilator, zanamivir should be taken just after the\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"bronchodilator.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Requires Infectious Disease Approval\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Zanamivir 2 inhalations (2 x 5 mg)daily ($) [O]\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Centers for Disease Control (CDC) (Accessed 9/8/22)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*For control of outbreaks in institutional settings (long-term care\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"facilities and hospitals)\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Antiviral Prophylaxis Recommendations:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oseltamivir 75 mg po q daily  ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"(See information above for length of prophylaxis)\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"(See information above for length of prophylaxis)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Chemoprophylaxis duration: 7 days after last known exposure\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Chemoprophylaxis duration: minimum of 2 weeks and continuing up to 1 week\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"after the last known case identified.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Note: Antiviral chemoprophylaxis is recommended for all residents, including\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"those who have received influenza vaccination.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Preferred treatment:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative treatment:\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"UpToDate Seasonal influenza in adults: Role of antiviral prophylaxis for\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 191,
    "fields": {
      "name": "ORZID2 GMENU ABX INFLUENZA EGG ALLERGY ACIP",
      "term": null,
      "displaytext": "Information on Influenza Vaccinations for patients with egg allergies ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Influenza Vaccine for Patients with Egg Allergies\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Previously the ACIP had recommended that persons with serious egg allergies\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"receive the egg-free influenza vaccine- i.e FluBlok. In 2016-2017 the ACIP\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"changed the recommendation for persons with egg-allergies to state that\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"all persons should receive any formulation of age-appropriate flu vaccine\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"regardless of egg allergy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"This change was based on data from large studies of greater than 4000 egg\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"allergic patients with 500 of them having severe egg allergy who received\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"the influenza vaccine with no anaphylactic reactions. Egg-allergic patients\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"should be monitored just like everyone else for 15 minutes after influenza\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"vaccine receipt.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Grohskopf LA, MMWR Recommendations and Reports 2021, 70(5):1-28\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-to-date online: Influenza vaccination in individuals with egg allergy\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 192,
    "fields": {
      "name": "ORZID2 GMENU ABX INFLUENZA VACCINATION",
      "term": null,
      "displaytext": "INFLUENZA VACCINATION RECOMMENDATIONS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Annual influenza vaccination is recommended for all persons aged 6\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"months and older without a specific contraindication.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"B viruses.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Minneapolis VAHCS Influenza Commitee 2022-2023\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Grohskopf LA, MMWR Recommendations and Reports 2022, 71(1):1-28\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Adults aged >/= 65 years: Adjuvanted vaccine (Flu-Ad) quadrivalent once\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Adults aged <65 years: standard quadrivalent vaccine once\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Adjuvanted influenza vaccines - an ingredient is added to help create a\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"stronger immune response.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Quadrivalent influenza vaccine - made up of the four flu strains most likely\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"to cause the flu during the upcoming season (H1N1, H3N2, and two group\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Eggs and latex allergies are NOT considered contraindications to receiving\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"the vaccine, the only contraindication to the flu vaccination is severe\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"allergic reaction (i.e. Anaphylactic reactions).\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 3026, \"DisplayText\": \"Influenza Inpatient\", \"Text\": \"[Click here] Inpatient Influenza Vaccine Guidelines\", \"Mnemonic\": \"4\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Adjuvanted influenza vaccine for OVER 65 years old only\", \"Text\": \"*For Inpts Age >/= 65 Use Only* Adjuvanted influenza vaccine (Flu-Ad) once\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Standard influenza vaccine\", \"Text\": \"*For Inpts Age <65 Use Only* Standard quadrivalent influenza vaccine once\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Outpatient Vaccination:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Administer via standing order protocol - no patient specific order needed\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Inpatient Vaccination:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Influenza 2022-2023 Vaccination Recommendations:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Influenza orders are part of admission order set. For those who require an order\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"due to admission order being discontinued/expired or if patient was admitted\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"prior to influenza season, use orders below:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Recommend observing all patients for 15 minutes after receipt of any\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"influenza vaccine. A previous severe allergic reaction to influenza vaccine,\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"regardless of the component suspected of being responsible for the reaction,\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"is a contraindication to future receipt of ANY influenza vaccine.\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MVAHCS Vaccination Recommendations Inpatient and Outpatient:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 193,
    "fields": {
      "name": "ORZID2 GMENU ABX INI EPI ABX ASSOC COLITIS",
      "term": null,
      "displaytext": "Initial Episode of Antibiotic Associated Colitis... ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125mg PO q6h for 10 days for C.difficile infection. ($) [M]\", \"Text\": \"Vancomycin 125mg PO q6h for 10 days ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 286, \"DisplayText\": \"Severe disease - Ileus/Toxic megacolon\", \"Text\": \"Select for Fulminant CDI\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Discontinue implicated antibiotic and avoid high-risk antibiotic if antibiotic\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy is still needed. Discontinue antacid therapy if possible.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Severe/life-threatening disease (shock, ileus, megacolon)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases consults are essential.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Clinical\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg PO bid for 10 days ($$) [M]\", \"Text\": \"Fidaxomicin 200 mg PO q12h for 10 days ($$) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Patient at increased risk of CDI recurrence:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"(e.g., age >65 years old, concomitant antibiotic use during CDI treatment,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"and/or immunosuppression)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Patient not meeting criteria above for increased risk of CDI recurrence:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Patient with clinical symptom onset (e.g. 3 or more unformed stools in 24 hours\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"after discontinuation of laxatives) and laboratory confirmation of CDI.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Initial Episode Non-Severe\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Fulminant CDI\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INITIAL EPISODE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": 97, \"DisplayText\": \"Clostridioides difficile Infection (CDI) 2-step testing\", \"Text\": \"<Click here> Information on C. difficile lab testing\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 194,
    "fields": {
      "name": "ORZID2 GMENU ABX INPT MAIN",
      "term": null,
      "displaytext": "Inpatient Antimicrobial Computer Decision Support System (CDSS) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 18, \"Column\": 1, \"Item\": 186, \"DisplayText\": \"Inpatient Antimicrobial CDSS Index\", \"Text\": \"[CLICK HERE]\", \"Mnemonic\": \"7\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 119, \"DisplayText\": \"Central Nervous System\", \"Text\": \"Central Nervous System\", \"Mnemonic\": \"11\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 168, \"DisplayText\": \"Head and Neck\", \"Text\": \"Head and Neck\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 202, \"DisplayText\": \"Lung and Mediastinum\", \"Text\": \"Lungs & Mediastinum\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 189, \"DisplayText\": \"Influenza Seasonal 2022-2023\", \"Text\": \"[b] Influenza Seasonal 2022-2023\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 240, \"DisplayText\": \"Pneumonia\", \"Text\": \"[c] Pneumonia\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 102, \"DisplayText\": \"Cardiovascular\", \"Text\": \"Cardiovascular\", \"Mnemonic\": \"20\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 161, \"DisplayText\": \"Gastrointestinal and Intraabdominal\", \"Text\": \"GI & Intraabdominal\", \"Mnemonic\": \"22\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"[a] C. difficile Colitis Mild/Moderate\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 164, \"DisplayText\": \"Genitourinary\", \"Text\": \"Urogenital\", \"Mnemonic\": \"26\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"[a] Sexually Transmitted Infections (STI)\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 270, \"DisplayText\": \"Soft tissue, muscle, bone and joint infections\", \"Text\": \"Soft Tissue, Muscle, Bone and Joint Infection\", \"Mnemonic\": \"30\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 139, \"DisplayText\": \"Dermatological Infections\", \"Text\": \"Skin\", \"Mnemonic\": \"32\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 282, \"DisplayText\": \"Systemic Infectious Diseases\", \"Text\": \"Systemic Infections\", \"Mnemonic\": \"34\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 87, \"DisplayText\": \"Bacteremia\", \"Text\": \"[a] Bacteremia\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"[b] Sepsis and Septic Shock\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 453, \"DisplayText\": \"Neutropenic fever\", \"Text\": \"[c] Neutropenic Fever\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 475, \"DisplayText\": \"Introduction to Specific Pathogen section\", \"Text\": \"Introduction to Specific Pathogen\", \"Mnemonic\": \"42\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 399, \"DisplayText\": \"Gram-negative Bacteria\", \"Text\": \"Gram-negative Bacteria\", \"Mnemonic\": \"44\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 400, \"DisplayText\": \"Gram-positive bacteria\", \"Text\": \"Gram-positive Bacteria\", \"Mnemonic\": \"46\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 299, \"DisplayText\": \"Viruses\", \"Text\": \"Viruses\", \"Mnemonic\": \"48\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 160, \"DisplayText\": \"Fungi\", \"Text\": \"Fungi\", \"Mnemonic\": \"50\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 513, \"DisplayText\": \"Parasites\", \"Text\": \"Parasites\", \"Mnemonic\": \"52\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 510, \"DisplayText\": \"Other pathogens\", \"Text\": \"Other Pathogens\", \"Mnemonic\": \"54\"}, {\"Row\": 107, \"Column\": 1, \"Item\": 283, \"DisplayText\": \"CDSS INPATIENT TESTING MENU\", \"Text\": \"Inpatient Testing Menu\", \"Mnemonic\": \"56\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"*******************************************************\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"*ANTIMICROBIAL DECISION SUPPORT*\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"*>>>>>>>>INPATIENT<<<<<<<<<  *\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"*******************************************************\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Welcome.  Please click on the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"diagnosis or syndrome you wish to treat.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Index of Antimicrobial CDSS content\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Syndromes and diseases, by body systems\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Specific organisms\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Medicine is an inexact and rapidly\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"changing discipline.  The developers of\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"this system have made every effort to\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"provide current, accurate information.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"However, in view of the possibility of\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"human error or changes in medical\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"service, readers are encouraged to\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"confirm the information contained\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"herein with other sources.  In\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"particular, readers are encouraged to\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"check the product information for\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"antimicrobials to be certain that\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"information in this system is accurate\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"and current, especially for new or\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"infrequently used drugs.\"}, {\"Row\": 2, \"Column\": 2, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact CDSS & ASP Staff\", \"Mnemonic\": \"58\"}, {\"Row\": 3, \"Column\": 2, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help page...\", \"Mnemonic\": \"60\"}, {\"Row\": 4, \"Column\": 2, \"Item\": 3027, \"DisplayText\": \"CDSS FAQ\", \"Text\": \"Frequently Asked questions (FAQ)\", \"Mnemonic\": \"62\"}, {\"Row\": 5, \"Column\": 2, \"Item\": 349, \"DisplayText\": \"\", \"Text\": \"Comments or Suggestions about this CDSS\", \"Mnemonic\": \"64\"}, {\"Row\": 9, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Antimicrobial Formulary Hyperlink\", \"Text\": \"Antimicrobial Formulary (Restricted)\", \"Mnemonic\": \"68\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 69, \"DisplayText\": \"Antimicrobial restriction policy\", \"Text\": \"Restrictions on Antimicrobials\", \"Mnemonic\": \"70\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 74, \"DisplayText\": \"Adjust existing antimicrobial therapy\", \"Text\": \"Adjust Existing Antimicrobial Therapy\", \"Mnemonic\": \"72\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 178, \"DisplayText\": \"How to find an alternative antimicrobial\", \"Text\": \"How to Find Alternative Antimicrobials\", \"Mnemonic\": \"74\"}, {\"Row\": 13, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Clinical On-Call Schedule (Infectious Disease)\", \"Mnemonic\": \"76\"}, {\"Row\": 14, \"Column\": 2, \"Item\": null, \"DisplayText\": \"UP TO DATE WEB SITE\", \"Text\": \"Up-to-date Online (Clinical Resource)\", \"Mnemonic\": \"78\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 188, \"DisplayText\": \"Infection Control\", \"Text\": \"Infection Control/Prevention Information\", \"Mnemonic\": \"80\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatological Guidelines\", \"Mnemonic\": \"82\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 140, \"DisplayText\": \"Device-related infections\", \"Text\": \"Device-related Infections\", \"Mnemonic\": \"84\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 244, \"DisplayText\": \"Prevention of Infection\", \"Text\": \"Prevention of Infection\", \"Mnemonic\": \"86\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"HIV-AIDS\", \"Mnemonic\": \"88\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 182, \"DisplayText\": \"Infections in Immunocompromised Patients\", \"Text\": \"Immunocompromised Patients\", \"Mnemonic\": \"90\"}, {\"Row\": 32, \"Column\": 2, \"Item\": 490, \"DisplayText\": \"Pre-Op Antimicrobials...\", \"Text\": \"Antimicrobial Prophylaxis Pre-op\", \"Mnemonic\": \"92\"}, {\"Row\": 33, \"Column\": 2, \"Item\": 526, \"DisplayText\": \"Antimicrobial Prophylaxis Post-op\", \"Text\": \"Antimicrobial Prophylaxis Post-op\", \"Mnemonic\": \"94\"}, {\"Row\": 34, \"Column\": 2, \"Item\": 606, \"DisplayText\": \"Surgical Site Infection\", \"Text\": \"Surgical Site Infections\", \"Mnemonic\": \"96\"}, {\"Row\": 42, \"Column\": 2, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Important Drug (Abx) Properties\", \"Mnemonic\": \"99\"}, {\"Row\": 43, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Lexicomp Online\", \"Text\": \"Lexicomp Online Drug Information\", \"Mnemonic\": \"100\"}, {\"Row\": 44, \"Column\": 2, \"Item\": null, \"DisplayText\": \"RESOURCE QTC PROLONGATION FOR DRUGS\", \"Text\": \"QT Prolongation Drug Resource\", \"Mnemonic\": \"102\"}, {\"Row\": 45, \"Column\": 2, \"Item\": 1057, \"DisplayText\": \"\", \"Text\": \"DDI Warfarin and Antimicrobials\", \"Mnemonic\": \"104\"}, {\"Row\": 46, \"Column\": 2, \"Item\": 988, \"DisplayText\": \"List of Antimicrobials with Pregnancy Risk Category\", \"Text\": \"Pregnancy Risk Factors for Antibiotics\", \"Mnemonic\": \"106\"}, {\"Row\": 47, \"Column\": 2, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Shortages of Antimicrobials\", \"Mnemonic\": \"108\"}, {\"Row\": 50, \"Column\": 2, \"Item\": 224, \"DisplayText\": \"Antibiotics not required\", \"Text\": \"Conditions NOT benefitted by antibiotics\", \"Mnemonic\": \"110\"}, {\"Row\": 51, \"Column\": 2, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"ESBLs, Amp-C beta-lactamases and Carbapenemases\", \"Mnemonic\": \"112\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"HELP\", \"Header\": 1}, {\"Row\": 21, \"Column\": 2, \"Text\": \"General\", \"Header\": 1}, {\"Row\": 31, \"Column\": 2, \"Text\": \"Surgical: Antimicrobial Prophylaxis and Site Infections\", \"Header\": 1}, {\"Row\": 41, \"Column\": 2, \"Text\": \"Drug Information Links\", \"Header\": 1}, {\"Row\": 49, \"Column\": 2, \"Text\": \"Miscellaneous/Emerging Topics\", \"Header\": 1}, {\"Row\": 106, \"Column\": 1, \"Item\": 103, \"DisplayText\": \"CDSS VERSION\", \"Mnemonic\": \"999\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 286, \"DisplayText\": \"Severe disease - Ileus/Toxic megacolon\", \"Text\": \"[b] C. difficile Fulminant (severe/complicated)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"CDSS-MicroGuide Web and Mobile App\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Item\": 207, \"DisplayText\": \"MicroGuide Mobile App Instructions\", \"Text\": \"[CLICK HERE]\", \"Mnemonic\": \"4\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"TESTING MENU ONLY- DO NOT USE TO PLACE ORDERS\", \"Header\": 1}, {\"Row\": 104, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pan Culture\", \"Mnemonic\": \"140\"}, {\"Row\": 105, \"Column\": 1, \"Item\": null, \"DisplayText\": \"L/E Bypass Preop Set\", \"Mnemonic\": \"150\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 82, \"DisplayText\": \"Approach to Urinary Tract Infection (UTI)\", \"Text\": \"[b] Urinary Tract Infections\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"Testing Menu:Restricted to ID/ED\", \"Header\": 1}, {\"Row\": 102, \"Column\": 1, \"Item\": 129, \"DisplayText\": \"TEsting\", \"Text\": \"COVID-19 Vaccine Inpt Testing Menu\", \"Mnemonic\": \"55\"}, {\"Row\": 103, \"Column\": 1, \"Item\": 127, \"DisplayText\": \"CLC COVID VACCINE (PFIZER-BIONTECH)\", \"Text\": \"CLC COVID-19 VACCINES\", \"Mnemonic\": \"999\"}, {\"Row\": 101, \"Column\": 1, \"Item\": 285, \"DisplayText\": \"Tocilizumab for treatment of COVID-19\", \"Text\": \"Tocilizumab COVID-19 Treatment\", \"Mnemonic\": \"xx\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Call Ext 31-3144 to expedite URGENT Outpatient prescriptions\", \"Header\": 1}, {\"Row\": 52, \"Column\": 2, \"Item\": 298, \"DisplayText\": \"Information on Vancomycin IV New Starts and MRSA Nares Testing\", \"Text\": \"MRSA Nares Screening-Vanco New Start\", \"Mnemonic\": \"116\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"(List starts at top and goes down body systems)\"}, {\"Row\": 109, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TST\", \"Text\": \"TEST\", \"Mnemonic\": \"190\"}, {\"Row\": 110, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tocilizumab 8 mg/kg IV x1 dose 2 for COVID-19\", \"Text\": \"TESTING DOSE 2 TOCI\", \"Mnemonic\": \"220\"}, {\"Row\": 89, \"Column\": 1, \"Item\": 271, \"DisplayText\": \"Sotrovimab (EUA) Orders\", \"Text\": \"Sotrovimab (EUA) Menu/orders\", \"Mnemonic\": \"200\"}, {\"Row\": 83, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Paxlovid (nirmatrelvir-ritonavir) 150 mg - 100 mg PO BID for 5 days\", \"Text\": \"Inpatient Paxlovid Renally Dosed UD Order\", \"Mnemonic\": \"118\"}, {\"Row\": 84, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Molnupiravir 800 mg PO BID for 5 days Inpt\", \"Text\": \"Inpatient Molnupiravir UD Order\", \"Mnemonic\": \"120\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"**FOR INPATIENT PHARMACY USE ONLY**\", \"Header\": 1}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LINK EUA PROVIDER TO FILL OUT\", \"Text\": \"Emergency Use Authorization (EUA) SharePoint Site\", \"Mnemonic\": \"121\"}, {\"Row\": 100, \"Column\": 1, \"Item\": 126, \"DisplayText\": \"Minneapolis VAHCS COVID-19 Antimicrobial Inpatient Treatment Guidelines\", \"Text\": \"COVID-19 Inpt Treatment Guidelines Edits\", \"Mnemonic\": \"999\"}, {\"Row\": 112, \"Column\": 1, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Mnemonic\": \"500\"}, {\"Row\": 99, \"Column\": 1, \"Item\": 197, \"DisplayText\": \"Epididymitis\", \"Text\": \"Lab menu test - epididymitis\", \"Mnemonic\": \"test\"}, {\"Row\": 97, \"Column\": 1, \"Item\": 287, \"DisplayText\": \"TPOXX Monkeypox Treatment\", \"Text\": \"*FOR ID USE ONLY* Monkeypox Treatment with TPOXX\", \"Mnemonic\": \"Inpt\"}, {\"Row\": 98, \"Column\": 1, \"Item\": 721, \"DisplayText\": \"TPOXX Monkeypox Treatment\", \"Text\": \"*FOR ID USE ONLY* Monkeypox Treatment with TPOXX\", \"Mnemonic\": \"Opt\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vaccine Nursing Text Order\", \"Text\": \"TEST\", \"Mnemonic\": \"TEST\"}, {\"Row\": 95, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Return To Clinic\", \"Text\": \"GO RTC\", \"Mnemonic\": \"TEST\"}, {\"Row\": 96, \"Column\": 1, \"Item\": null, \"DisplayText\": \"3D ID Injection\", \"Text\": \"QUICK ORDER RTC\", \"Mnemonic\": \"TEST\"}, {\"Row\": 94, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Return to clinic for vaccine administration\", \"Text\": \"CDSS RTC VACCCINE\", \"Mnemonic\": \"TEST\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Vaccine Order Testing\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A vaccine order set test\", \"Mnemonic\": \"Test\"}, {\"Row\": 79, \"Column\": 1, \"Item\": 129, \"DisplayText\": \"TEsting\", \"Text\": \"Bivalent COVID-19 Vaccine Testing\", \"Mnemonic\": \"Test\"}, {\"Row\": 80, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nursing Vaccine Administration Text Order\", \"Text\": \"Monkeypox nursing text order\", \"Mnemonic\": \"Test\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Important Antimicrobial Information\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"*  *  *  *  *  *  *  *  *  *  *  *  *  *\"}, {\"Row\": 36, \"Column\": 2, \"Text\": \"Monkeypox\", \"Header\": 1}, {\"Row\": 37, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Monkeypox SharePoint Link\", \"Mnemonic\": \"98a\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 287, \"DisplayText\": \"TPOXX Monkeypox Treatment\", \"Text\": \"*ID Providers Only*Monkeypox Treatment\", \"Mnemonic\": \"98b\"}, {\"Row\": 39, \"Column\": 2, \"Text\": \"Monkeypox vaccine - see Outpatient CDSS\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Amoxicillin Challenge Testing\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Item\": 76, \"DisplayText\": \"Amoxicillin Challenge\", \"Mnemonic\": \"200\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antibiogram (Susceptibilities)\", \"Mnemonic\": \"66\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact CDSS & ASP Staff\", \"Mnemonic\": \"411\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Beta-lactam Reaction Assessment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 2, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"81a\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Text Version\", \"Mnemonic\": \"81b\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"Immunization Information and Vaccine Orders\", \"Header\": 1}, {\"Row\": 29, \"Column\": 2, \"Item\": 251, \"DisplayText\": \"CDC Recommended Adult Immunizations\", \"Text\": \"Recommended Adult Immunizations\", \"Mnemonic\": \"91\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 125, \"DisplayText\": \"COVID-19\", \"Text\": \"[a] COVID-19\"}, {\"Row\": 92, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"VANCO NOW MRSA SCREEN ORDER SET\", \"Mnemonic\": \"TEST\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 97, \"DisplayText\": \"Clostridioides difficile Infection (CDI) 2-step testing\", \"Text\": \"Information C diff 2-step lab testing\", \"Mnemonic\": \"2\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"[d] Lyme disease\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"C diff 2-step testing\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Item\": 612, \"DisplayText\": \"Urological procedures antimicrobial prophylaxis\", \"Text\": \"TEST Urology Preop\", \"Mnemonic\": \"200\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"TESTING MENU- Do NOT use\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Item\": 611, \"DisplayText\": \"Urology Postop\", \"Text\": \"Test Urology Postop\", \"Mnemonic\": \"220\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"UROLOGY:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 195,
    "fields": {
      "name": "ORZID2 GMENU ABX ISOSPORA",
      "term": null,
      "displaytext": "Diarrhea with Isospora belli",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 tablet DS PO Q12H for 7 to 10 days ($)\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75 mg PO q24h for 21-28 days ($$) [DI,O] <AND> leucovorin 25\", \"Text\": \"Pyrimethamine 75 mg PO q24h ($$) [DI,O] <AND> leucovorin 25 mg q24h ($) for\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 tablet DS q6h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 tablet DS q6h for 10 days ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75 mg PO q24h for 21-28 days ($$) [DI,O] <AND> leucovorin 25\", \"Text\": \"Pyrimethamine 75 mg PO q24h ($$) [DI,O] <AND> leucovorin 25 mg PO q24h ($)\", \"Mnemonic\": \"10\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 tablet DS PO q72h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 tablet DS PO QOD ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> leucovorin 10 mg q24h ($)\", \"Text\": \"Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> leucovorin PO mg PO q24h ($)\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CYSTOISOSPORA BELLI (FORMALLY ISOSPORA BELLI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"C. belli is associated with diarrhea in persons with HIV/AIDS and only rarely in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"immunocompetent persons.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons without HIV/AIDS\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"[R,DI]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for trimethoprim or sulfamethoxazole allergy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"for 21-28 days\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons with HIV/AIDS\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Infectious Diseases involvement is essential. Initial treatment of acute\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"infection is followed by secondary prophylaxis until CD4 count is >200 for >6\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"months in response to ART without evidence of active C. belli.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Initial treatment\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for trimethoprim or sulfamethoxazole allergy\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"for 21 to 28 days\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Secondary prophylaxis\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative for trimethoprim or sulfamethoxazole allergy\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Cystoisospora belli\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-to-Date article: Management of Cystoisospora (Isospora) infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 196,
    "fields": {
      "name": "ORZID2 GMENU ABX LAB MENU",
      "term": null,
      "displaytext": "Antimicrobial CDSS Lab Menu ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": 296, \"DisplayText\": \"Urine Culture\", \"Text\": \"Urine culture\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ANTIMICROBIAL CDSS LAB MENU\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Urogenital lab orders\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Urine analysis\", \"Text\": \"Urinalysis\", \"Mnemonic\": \"4\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Blood culture\", \"Text\": \"Blood culture\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Rectal Swab\", \"Text\": \"Rectal swab\", \"Mnemonic\": \"7\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Throat Swab\", \"Text\": \"Throat swab\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Urine NAAT\", \"Text\": \"Urine NAAT\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Gonorrhea and chlamydia lab orders\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 197,
    "fields": {
      "name": "ORZID2 GMENU ABX LAB MENU TESTING",
      "term": null,
      "displaytext": "Epididymitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h\", \"Mnemonic\": \"6\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"8\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) for 10 days\", \"Mnemonic\": \"10\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 10 days\", \"Mnemonic\": \"12\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"14\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM Once ($) [M] <AND> Doxycycline 100mg PO ($) [DI]\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"16\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1gm IM Once < AND > Doxycycline 100 mg po q12h\", \"Text\": \"Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"18\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"20\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"22\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) for 10 days\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Epididymitis is inflammation of the epididymis and when testicles are involved\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"is referred to as epididymo-orchitis. Acute epididymitis is the most common\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cause of scrotal pain in adults. Other features include scrotal erythema and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"unilateral. It is primarily caused by infection but can also result from trauma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and autoimmune diseases. Testicular torsion should be ruled out before\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"treatment. Most cases in men aged 35 and older, those with recent urinary tract\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"with enteric Gram-negative rods. Most cases in men under age 35 are associated\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"the patient has been in the hospital for more than 48 hours or received a course\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of antibiotics. There is increasing resistance in urinary pathogens to\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"ciprofloxacin.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"should be performed in all cases of suspected epididymitis before starting\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"treatment to guide therapy:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Patients with bacterial epididymitis treated with antibiotics should improve\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"within two or three days. If no improvement is noted, other causes of scrotal\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"pain and referral to a urologist should be considered.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Management should include bed rest, analgesics, and scrotal elevation. Older men\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"should have their residual urinary volume checked. If the residual volume is\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"elevated, the patient should be seen by a urologist as epididymitis is unlikely\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"to respond if the prostate is blocking the vas deferens.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Empirical treatment in men who practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"for 10 days ($) [R, DI]\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Empirical treatment in men who do not practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Age >/= 35 years or\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"biopsy, vasectomy):\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Age < 35 years\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Patient weighing less than 300 lbs\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Patients weighing 300 lbs or greater\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Mandell Chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Sanford keyword: Epididymo-orchitis\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Up-To-Date article: Evaluation of acute scrotal pain in adults\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 198,
    "fields": {
      "name": "ORZID2 GMENU ABX LARYNGITIS AND CROUP",
      "term": null,
      "displaytext": "Laryngitis and Croup  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LARYNGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cases are almost always viral (e.g. rhinovirus, influenza, adenovirus,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"coronavirus). Treatment is based on symptomatic therapy alone.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Mandell chapter: Acute laryngitis\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Up-To-Date article: Hoarseness in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 199,
    "fields": {
      "name": "ORZID2 GMENU ABX LIVER AMEBIC ABSCESS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Text\": \"Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"AMEBIC LIVER ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Serological testing for amoebiasis should be obtained in all patients with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"suspected amebic liver abscess. Multiple sets of anaerobic and aerobic blood\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cultures should also be obtained prior to starting antibiotics to exclude\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pyogenic liver abscess, which is a much more common cause of liver abscess.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Serologic testing can be negative in a small number of patients with acute\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"presentation (symptoms <2 weeks). Repeat serology is usually positive. If repeat\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"serological testing is negative for amoebiasis or patient does not respond to\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"treatment of amebic liver abscess, patient should have further diagnostic\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"testing completed to exclude pyogenic liver abscess.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Drainage of amebic liver abscess should be considered in patients with large\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"lesions at risk of rupture.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Due to complicated treatment and follow up, Infectious Diseases consultation\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"is recommended in all patients with liver abscess.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment of patients with confirmed or suspected amebic liver abscess (obtain\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"blood cultures prior to starting in suspected cases)\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Paromomycin is nonformulary and must be ordered by Infectious Diseases.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"25-35 mg/kg/day PO q8h for 7 days ($) [M]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Amoebiasis, Entamoeba histolytica\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date article: Extraintestinal Entamoeba histolytica amoebiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 200,
    "fields": {
      "name": "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 199, \"DisplayText\": \"\", \"Text\": \"Link to Amebic Liver Abscess menu\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($)\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LIVER ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Liver abscess should be suspected in all patients with fever, leukocytosis, and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"a space-occupying liver lesion. Liver abscesses fall broadly into two\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"categories: pyogenic and amebic. In the United States, pyogenic liver abscess is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"much more common. Amebic liver abscess occurs almost exclusively in travelers\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and immigrants. If amebic liver abscess is suspected, select the link below.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Due to complicated treatment and follow up, Infectious Diseases consultation is\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"recommended in patients with pyogenic liver abscess.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment of pyogenic liver abscess\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"A typical course for pyogenic liver abscess is 4 to 6 weeks.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Initial treatment\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for patients with mild to moderate disease and beta lactam allergy\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"[DI]\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative for patients with severe disease and beta lactam allergy\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Step down treatment for completion of antimicrobial course after initial\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"intravenous treatment in patients who can tolerate oral therapy. Base selection\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"on culture results.\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Sanford keyword: Hepatic Abscess\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-to-Date article: Pyogenic liver abscess\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 201,
    "fields": {
      "name": "ORZID2 GMENU ABX LUNG ABSCESS",
      "term": null,
      "displaytext": "Lung abscess ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] < AND > metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($) [H,O]  < OR >\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"LUNG ABSCESS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pulmonary and/or Infectious Diseases consultations are strongly encouraged for\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"all cases.  Obtain samples for gram stain and culture from fine needle\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"aspiration whenever possible.  Sputum culture is less helpful because it will be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"contaminated with upper respiratory flora.  Classically, lung abscess is a\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"complication of mixed anaerobic and aerobic pulmonary infection. The initial\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infection may or may not be clinically apparent.  Malaise, weight loss, fever,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"chills, and malodorous sputum typically develop over a period of weeks.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Cavitation and/or abscess can occur in cases of pneumonia from a single\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pathogen, commonly Staphylococcus aureus or Pseudomonas aeruginosa.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antimicrobial treatment should be directed against the specific pathogen.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treat for 6 to 8 weeks and adjust treatment based on clinical response.  Oral\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"medications should be used in patients who can take them.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred intravenous treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Preferred oral treatment\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternatives for patient with severe penicillin allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"If Staphloccus aureus MRSA suspected:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Bartlett JG Anaerobe 2012, 18:235\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword lung abscess\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell Chapter:  Principles and Practice of Infectious Diseases\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Harrison's chapter: Infections due to mixed organisms\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 202,
    "fields": {
      "name": "ORZID2 GMENU ABX LUNG AND MEDIASTINUM",
      "term": null,
      "displaytext": "Lung and Mediastinum  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 94, \"DisplayText\": \"Consider Antibiotic\", \"Text\": \"Bronchitis\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 151, \"DisplayText\": \"Empyema\", \"Text\": \"Empyema\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 94, \"DisplayText\": \"Consider Antibiotic\", \"Text\": \"Exacerbation of chronic obstructive pulmonary disease (COPD)\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 189, \"DisplayText\": \"Influenza Seasonal 2022-2023\", \"Text\": \"Influenza Seasonal\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 201, \"DisplayText\": \"Lung abscess\", \"Text\": \"Lung abscess\", \"Mnemonic\": \"12\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 205, \"DisplayText\": \"Mediastinitis\", \"Text\": \"Mediastinitis\", \"Mnemonic\": \"14\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 235, \"DisplayText\": \"Pertussis\", \"Text\": \"Pertussis\", \"Mnemonic\": \"16\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 289, \"DisplayText\": \"Tuberculosis\", \"Text\": \"Tuberculosis\", \"Mnemonic\": \"18\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 86, \"DisplayText\": \"Azithromycin for Prevention of Exacerbations COPD\", \"Text\": \"Azithromycin for prevention of COPD exacerbations\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  LUNGS AND MEDIASTINUM  ++\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 83, \"DisplayText\": \"Aspiration pneumonia\", \"Text\": \"Aspiration pneumonia\", \"Mnemonic\": \"24\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 122, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community-acquired pneumonia (CAP)\", \"Mnemonic\": \"26\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Nosocomial pneumonia (including HAP and VAP)\", \"Mnemonic\": \"28\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Pneumonia\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 203,
    "fields": {
      "name": "ORZID2 GMENU ABX LYME DISEASE",
      "term": null,
      "displaytext": "Lyme disease ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 482, \"DisplayText\": \"Lyme Disease Prophylaxis\", \"Text\": \"Lyme Disease Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 483, \"DisplayText\": \"Erythema migrans associated with Lyme disease\", \"Text\": \"Erythema migrans associated with Lyme disease\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 479, \"DisplayText\": \"Acute neurological disease associated with Lyme disease\", \"Text\": \"Acute neurological disease associated with Lyme disease\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 480, \"DisplayText\": \"Arthritis associated with Lyme disease\", \"Text\": \"Arthritis associated with Lyme disease\", \"Mnemonic\": \"10\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 481, \"DisplayText\": \"Cardiac disease associated with Lyme disease\", \"Text\": \"Cardiac disease associated with Lyme disease\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Lyme disease results from the transmission of Borrelia burgdorferi from an\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Ixodes spp. tick bite. Patients who display signs of illness or fever within 30\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"days of removing an attached tick should be evaluated for tick-borne illness.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"(deer tick) but who do not display signs or symptoms of infection should not\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"be treated with antimicrobials.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Prophylactic antimicrobial treatment may be beneficial in certain patients who\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"have been bitten while in endemic areas.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Except for erythema migrans, Lyme disease is a complicated, difficult disease to\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"diagnose and treat. Infectious Diseases consultation is strongly encouraged.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Wormser GP Clin Infect Dis (2006), 43: 1089\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 204,
    "fields": {
      "name": "ORZID2 GMENU ABX MANAGEMENT OF FEBRILE EPISODE ASPLENIA",
      "term": null,
      "displaytext": "Management of an Episode of Fever in an Asplenic Patient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]\", \"Text\": \"Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 321, \"DisplayText\": \"Bacterial meningitis with S. pneumoniae\", \"Text\": \"Bacterial meningitis with S. pneumoniae\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Fever in an Asplenic Patient\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Patients with impaired splenic function are at risk for severe and\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"and overwhelming infection with encapsulated bacteria. Streptococcus\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"pneumoniae is the most common cause of fulminant sepsis in patients with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"impaired splenic function, followed by Haemophilus influenzae and Neisseria\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"meningitidis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If fever develops in an asplenic patient, immediate administration of an\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobial agent is indicated, because fever can be the initial\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"manifestation of a fulminant infection and prompt administration of an\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antimicrobial agent may prevent the development of clinical sepsis.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Administration of antibiotics should not be delayed in order to perform\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"diagnostic studies, including lumbar punture.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Recommended Empiric Therapy:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative for penicillin/beta lactam allergy:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae meningitis suspected:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Rubin LG, N Engl J Med 2014, 371:349-356\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-date online\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 205,
    "fields": {
      "name": "ORZID2 GMENU ABX MEDIASTINITIS",
      "term": null,
      "displaytext": "Mediastinitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2 gm Iv q8h ($$)[R] <AND> Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R] <AND> Vancomycin 15 mg/kg IV q12h ($)[R]\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600mg IV q8h ($$) [H,O]  < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4MU Q4H and Metronidazole 500 MG IV Q8H\", \"Text\": \"Penicillin G 4 million units IV q4h ($) [R] <AND> metronidazole 500 mg\", \"Mnemonic\": \"10\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI] < AND > metronidazole 500 mg IV q8h\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV\", \"Mnemonic\": \"14\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 423, \"DisplayText\": \"Bacillus species\", \"Text\": \"Anthrax section\", \"Mnemonic\": \"16\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"MEDIASTINITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Mediastinitis occurs after cardiothoracic procedures or less commonly after\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"esophageal perforation.  Rarely, infectious diseases of the head, neck or thorax\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"spread into the mediastinum.  Surgical drainage and antimicrobial therapy are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"both essential.  Specific management depends on the source of infection.  Obtain\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"aerobic and anaerobic cultures in all cases.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Inhalational anthrax (due to Bacillus anthracis) typically presents as\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"mediastinitis with cough productive of hemorrhagic secretions.  This disease\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"should be considered in a patient without typical risk factors for mediastinitis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"or in the setting of suspected or confirmed bioterrorism.  If anthrax is\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"suspected, page the Infectious Diseases service.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment AFTER CARDIOTHORACIC SURGERY\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treat for 2 to 3 weeks:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment associated WITH MOUTH/THROAT INFECTION\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mixed aerobic/anaerobic infection is often present.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"IV q8h ($) [DI]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Treatment AFTER ESOPHAGEAL PERFORATION OR RUPTURE\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mixed aerobic/anaerobic infection is often present.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"q8h ($) [DI]\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Treatment if B. anthracis is suspected\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Intravenous antimicrobials should be used initially for treatment.  Contact\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"infectious diseases immediately.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Mandell chapter:  Principles and Practice of Infectious Diseases.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 206,
    "fields": {
      "name": "ORZID2 GMENU ABX MEDS DELAYED PRE-OP ANTIBIOTICS CV SURGERY2",
      "term": null,
      "displaytext": "CV Surgery Delayed Order Antibiotics ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": 132, \"DisplayText\": \"Standard (Non PCN allergic)\", \"Text\": \"Standard (Non PCN allergic)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 355, \"DisplayText\": \"Severly PCN allergic\", \"Text\": \"Severly PCN allergic\", \"Mnemonic\": \"4\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Delayed Antibiotic Orders CV Surgery\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Minneapolis VA facility specific recommendations for open-heart surgery\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 207,
    "fields": {
      "name": "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS",
      "term": null,
      "displaytext": "MicroGuide Mobile App Instructions",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Text\": \"DIRECTIONS TO INSTALL MICROGUIDE ON MOBILE DEVICE\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Within the Apple or Google app store on your mobile device, search for the term\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"\\\"MicroGuide\\\" and download the app. When opening the app, you will be prompted to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"submit information about yourself and institution (this is for tracking usage of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"the system by CDSS personal). Select the Minneapolis VA Health Care System as\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"your institution. You will then be prompted to download the Minneapolis VA\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Health Care System CDSS specific guide content.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"When updates to the CDSS MicroGuide are made, you will be prompted to update\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"the content on your mobile device when opening the app.\"}, {\"Row\": 3, \"Column\": 1, \"Item\": 3028, \"DisplayText\": \"MicroGuide Web App Link\", \"Text\": \"[CLICK HERE]\", \"Mnemonic\": \"2\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"MicroGuide Web App Link\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 208,
    "fields": {
      "name": "ORZID2 GMENU ABX MICROSPORIDIA",
      "term": null,
      "displaytext": "Microsporidia",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albendazole 400mg po q12h\", \"Text\": \"Albendazole 400 mg PO q12h for 7 to 14 days ($$) [O]\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albendazole 400mg po q12h\", \"Text\": \"Albendazole 400 mg PO q12h ($$) [O]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH MICROSPORIDIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In patients without HIV/AIDs, antimicrobial treatment may not be necessary\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"because symptoms can resolve without antimicrobial therapy. In persons with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"AIDS, highly active anti-retroviral therapy (HAART) is beneficial because\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"recovery of host defenses helps to control microsporidial disease. Treatment\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"must include dietary supplementation for weight loss. Infectious Diseases\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"involvement is essential in patients with HIV/AIDS.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons without HIV/AIDS\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons with HIV/AIDS\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Continue treatment until CD4 count is >200 for >6 months after initiation of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"ART.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Microsporidiosis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date article: Microsporidiosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 209,
    "fields": {
      "name": "ORZID2 GMENU ABX MORE ABOUT NOSOCOMIAL PNEUMO",
      "term": null,
      "displaytext": "More about Nosocomial pneumonia...",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 248, \"DisplayText\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Text\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Mnemonic\": \"4\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MORE ABOUT NOSOCOMIAL PNEUMONIA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Types of nosocomial pneumonia\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hospital acquired pneumonia (HAP):\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Development of pneumonia 48 hours or more after hospital admission.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Ventilator-associated pneumonia (VAP):\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Pneumonia occurring 48 hours or more after endotracheal intubation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Criteria for diagnosis of pneumonia\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"1.  Presence of new or progressive infiltrate <AND>\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"2.  At least two of the following:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"> Fever greater than 38 C (100.4 F)\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"> Leukocytosis or leukopenia\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"> Purulent bronchial secretions\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"HAP OR VAP suspected:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Gram stain and culture of lower respiratory tract secretions and blood\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"cultures are important for guiding therapy. If a patient with no change in\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"antimicrobial therapy during the previous 72 hours has few bacteria on gram\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"stain of secretions, bacterial pneumonia is unlikely.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment for 7 days is generally sufficient if the initial empiric therapy\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"covered the pathogen and the patient is clinically responding.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Narrow therapy to treat specific pathogen(s) based on results of\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"culture and susceptibility tests.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Longer duration of therapy is recommended for more resistant organisms\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"(e.g. Pseudomonas aeruginosa, Acinetobacter baumanni, and\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Legonella pneumophila).\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Kalil AC Clin Infect Dis 2016, 63:1\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Luna CM  Crit Care Med 2003, 31: 676\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 210,
    "fields": {
      "name": "ORZID2 GMENU ABX MRSA RISK FACTORS",
      "term": "MRSA Risk Factors",
      "displaytext": "[CLICK HERE] for list of MRSA risk factors ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"MRSA RISK FACTORS\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Patients with one or more of the following risk factors are at increased risk of\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"MRSA infection:\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"1. Recent hospitalization\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"2. Residence in a long-term care facility\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"3. Recent surgery\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"4. Hemodialysis\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"5. History of MRSA colonization or infection within the last year\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"6. Recent antibiotic use\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"7. Human immunodeficiency virus (HIV) infection\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"8. Injection drug use\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"9. Contact with person colonized with MRSA\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"adults: Epidemiology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 211,
    "fields": {
      "name": "ORZID2 GMENU ABX MYOCARDITIS",
      "term": null,
      "displaytext": "Myocarditis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYOCARDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Myocarditis is most commonly associated with enterovirus or coxsackie virus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infection. Less common pathogens include pyogenic bacteria, rickettsia,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"toxoplasmosis, and fungi.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Empirical antimicrobial treatment is not indicated. Supportive care and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"treatment of CHF are essential. Consult Cardiology and/or Infectious Diseases\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"for more assistance.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Avoid non-steroidal anti-inflammatory drugs (NSAIDS) and corticosteroids in\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"these patients, as the use of NSAIDs in myocarditis has been associated with\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"worse outcomes.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell chapter: Myocarditis and Pericarditis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment and prognosis of myocarditis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 212,
    "fields": {
      "name": "ORZID2 GMENU ABX NASAL PACKING",
      "term": null,
      "displaytext": "Nasal Packing (to prevent infection) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF INFECTION IN PATIENTS WITH NASAL PACKING\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis to prevent infection and toxic shock syndrome in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients with nasal packing is not recommended. Antibiotics increase the risk of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"adverse events in patients with nasal packing with no proven effectiveness in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"preventing infection.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cohn, Annals of emergency medicine 2015, 1.65, 109-111\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Kucik et al, Am Fam Physician 2005, 71.2, 305-311\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Up-to-Date article: Approach to the adult with epistaxis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 213,
    "fields": {
      "name": "ORZID2 GMENU ABX NEW UPDATES",
      "term": null,
      "displaytext": "New Updates  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"NEW UPDATES INFORMATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Section titles that are labeled with *New Updates* have been recently updated\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"according to current literature and guidelines. All updates are reviewed by a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Minneapolis VAHCS Infectious Diseases staff physician and a clinical pharmacist.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If you have any questions or concerns please contact the VISN23 CDSS team:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"[Click here] Contact the CDSS Team\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 214,
    "fields": {
      "name": "ORZID2 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA",
      "term": null,
      "displaytext": "Nirmatrelvir-ritonavir (Paxlovid) for Treatment of COVID-19 Inpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3029, \"DisplayText\": \"Paxlovid EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Paxlovid\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Paxlovid EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Paxlovid\", \"Mnemonic\": \"8\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PAXLOVID INPT AND OPT ORDERS\", \"Text\": \"INV-Nirmatrelvir 300 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PAXLOVID (EUA)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Paxlovid (nirmatrelvir-ritonavir) is available via FDA Emergency Use\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Authorization (EUA) for treating patients that meet specific criteria. Paxlovid\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"is not an FDA approved drug.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Inclusion Criteria, ALL the following criteria must be met for a patient to\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"receive:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"1) Patient has tested positive for COVID-19\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19. Note: patient may be\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"hospitalized for some other reason.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"4) Administration will begin within 5 days of symptom onset.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to Paxlovid or components.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Contraindications, NONE of the following must be met for patient to receive:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"1) Severe renal impairment (eGFR <30 mL/min).\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"2) Severe hepatic impairment (Child-Pugh Class C).\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"3) History of clinically significant hypersensitivity reactions to the active\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"ingredients (nirmatrelvir or ritonavir) or any other components.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"4) Co-administration with drugs highly dependent on CYP3A for clearance and for\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"which elevated concentrations are associated with serious and/or\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"life-threatening reactions.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"5) Co-administration with potent CYP3A inducers where significantly reduced\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"nirmatrelvir or ritonavir plasma concentrations may be associated with the\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"potential for loss of virologic response and possible resistance.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Warnings and Precautions:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"1) The concomitant use of PAXLOVID and certain other drugs may result in\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"potentially significant drug interactions. Consult the full prescribing\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"information prior to and during treatment for potential drug interactions.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"2) Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"jaundice have occurred in patients receiving ritonavir.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"3) HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"resistance to HIV protease inhibitors in individuals with uncontrolled or\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"undiagnosed HIV-1 infection.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"If all above criteria above are met and there are no contraindications, place\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"medication order:\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"*Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min): 150 mg\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet), with\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"both tablets taken together twice daily for 5 days.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid sharing\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"personal items, clean and disinfect \\\"high touch\\\" surfaces, and frequent\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"handwashing) according to CDC guidelines.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"6) Patient must be able to take PO and swallow tablets whole\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"**Place medication orders for inpatient and outpatient (included in order set)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 215,
    "fields": {
      "name": "ORZID2 GMENU ABX NON-CHOLERA",
      "term": null,
      "displaytext": "Vibrio non-cholera ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 3-5 days ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg BID for 3-5 days ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h for 3-5 days ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg IV q12h ($$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h for 7 to 14 days ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NON-CHOLERA VIBRIO\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Non-cholera vibrio is associated with gastroenteritis, septicemia, and wound\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infections. Vibrio vulnificans infections are acquired from contact with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"seawater or seafood, especially raw oysters. V. vulnificans cases are more\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"severe than cases with other species. V. parahaemolyticus causes\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"gastroenteritis and milder wound infections.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobials do not shorten the course of disease in immunocompetent patients\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with mild gastroenteritis.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Primary treatment for gastroenteritis\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Antimicrobial treatment of minor wound infection, severe gastroenteritis or\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"immunocompromised patient with gastroenteritis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative for patient intolerant of fluoroquinolones\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"For patients who are hospitalized or unable to take oral medications\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Antimicrobial treatment of severe wound infection or septicemia\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for advice on duration of treatment.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"for 7 to 14 days\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"for 7 to 14 days\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sanford keyword: Vibrio parahaemolyticus\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Vibrio vulnificus: Cellulitis, Sepsis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date article: Vibrio parahaemolyticus infections\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-to-Date article: Vibrio vulnificus infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 216,
    "fields": {
      "name": "ORZID2 GMENU ABX NOSO PNEUMONIA NEW",
      "term": null,
      "displaytext": "Nosocomial pneumonia (including HAP, AND VAP) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 209, \"DisplayText\": \"More about Nosocomial pneumonia...\", \"Text\": \"More about Nosocomial pneumonia...\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 241, \"DisplayText\": \"PNEUMONIA HAP\", \"Text\": \"Hospital Acquired Pneumonia (HAP)\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 242, \"DisplayText\": \"PNEUMONIA VAP\", \"Text\": \"VENTILATOR ASSOCIATED PNEUMONIA (VAP)\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 248, \"DisplayText\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Text\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Mnemonic\": \"10\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 217, \"DisplayText\": \"Nosocomial pneumonia with Acinetobacter baumannii\", \"Text\": \"Acinetobacter baumannii\", \"Mnemonic\": \"12\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 218, \"DisplayText\": \"Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae\", \"Text\": \"Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 219, \"DisplayText\": \"Nosocomial pneumonia with Legionella pneumophila\", \"Text\": \"Legionella pneumophila\", \"Mnemonic\": \"16\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 220, \"DisplayText\": \"Nosocomial pneumonia with Pseudomonas aeruginosa\", \"Text\": \"Pseudomonas aeruginosa\", \"Mnemonic\": \"18\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 221, \"DisplayText\": \"STAPHYLOCOCCUS AUREUS PNEUMONIA\", \"Text\": \"Staphylococcus aureus\", \"Mnemonic\": \"20\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Local facility antibiogram and patient risk factors for multi-drug\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"resistant pathogens guide antimicrobial therapy.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Empirical therapy must be re-evaluated at 72 hours.\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Duration of Therapy:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment for 7 days is generally sufficient if the initial empiric therapy\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"covered the pathogen and the patient is clinically responding.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Narrow therapy to treat specific pathogen(s) based on results of\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"culture and susceptibility tests.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Pathogen-specific treatment\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Certain respiratory pathogens that are usually treated in unique ways are listed\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"here.  Other respiratory pathogens are treated with drugs effective for\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"pneumonia and active against identified organisms.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Recommended duration of therapy for more resistant pathogens\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"(e.g. MRSA, Pseudomonas, Acinetobacter) require longer treatment.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Refer to pathogen-specific treatment regimen below for recommendation.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Pathogen-specific nosocomial pneumonia treatment regimens\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Luna CM. Crit Care Med 2003. 31:676\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 217,
    "fields": {
      "name": "ORZID2 GMENU ABX NOSOCOMIAL A. BAUMANNII",
      "term": null,
      "displaytext": "Nosocomial pneumonia with Acinetobacter baumannii",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA WITH ACINETOBACTER BAUMANNII\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Infectious Diseases consultation is essential for cases with Acinetobacter which\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"are often resistant to most therapies.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Duration of therapy is unclear and should be guided by clinical response.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Luna CM  Crit Care Med 2003, 31: 676\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 218,
    "fields": {
      "name": "ORZID2 GMENU ABX NOSOCOMIAL ESBL ENTEROBACT",
      "term": null,
      "displaytext": "Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA WITH EXTENDED-SPECTRUM BETA-LACTAMASE PRODUCING (ESBL+)\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTEROBACTERIACEAE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The microbiology laboratory tests for ESBL production in all E. coli and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Klebsiella isolates. Proteus isolated from blood samples are also tested for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"ESBL production.  Other Enterobacteriaceae produce ESBL less commonly but\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"practical tests are not available for these. If ESBL is suspected regardless of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"testing, consult Infectious Diseases and/or the microbiology laboratory for more\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Craven DE Infect Dis Clin N Am 2004, 18: 939\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Luna CM  Crit Care Med 2003, 31: 676\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mandell LA Clin Infect Dis 2003,37: 1405\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Singh N Am J Resp Crit Care Med 2000, 162: 505\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Anonymous  Am J Respir Crit Care Med 2005, 171: 388\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 219,
    "fields": {
      "name": "ORZID2 GMENU ABX NOSOCOMIAL L. PNEUMOPHILA",
      "term": null,
      "displaytext": "Nosocomial pneumonia with Legionella pneumophila ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg IV q24h ($) [O]\", \"Text\": \"Azithromycin 500 mg IV q24h ($) [M]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h ($) [M]  < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA WITH LEGIONELLA PNEUMOPHILA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Intravenous therapy preferred initially until signs and symptoms improve.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treat for 7 to 10 days. Consider longer courses of therapy in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"immunocompromised patients with severe illness.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Recommend to start with parenteral therapy:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Switch to oral to complete therapy:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell LA Clin Infect Dis 2007, 44: S27\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Phin N Lancet Infectious Diseases 2014, 14:1011\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford: Pneumonia Legionella\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Stout JE, Yu VL: Legionellosis. N Engl J Med 337:682, 1997\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 220,
    "fields": {
      "name": "ORZID2 GMENU ABX NOSOCOMIAL P. AERUGINOSA",
      "term": null,
      "displaytext": "Nosocomial pneumonia with Pseudomonas aeruginosa ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTAZIDIME 2GM IV Q8H GENT 5MG IV QD\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R] <AND> gentamicin 5mg/kg IV q24h\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPROFL 400MG IV Q8H GENT 5MG IV QD\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> gentamicin 5mg/kg IV q24h\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > gentamicin 5\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R] <AND> Ciprofloxacin 400 mg\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R]  < OR >\", \"Mnemonic\": \"12\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA WITH PSEUDOMONAS AERUGINOSA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Single drug therapy is as effective as combination therapy once susceptibility\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"results are known.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Empiric Treatment:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"($) [R,O]  < OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"($) [R,O] < OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"mg/kg IV q24h ($) [R,O] < OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"IV q8h ($) [R,DI]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Narrow therapy to single active antibiotic once susceptibility results are\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"available:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Oral therapy (usually given after several days of intravenous therapy)\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"if isolate known sensitive to fluoroquinolone:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Craven DE Infect Dis Clin N Am 2004, 18: 939\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Garnacho-Montero J Crit Care Med. 2007, 35:1888\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Kalil AC Clin Infect Dis 2016 63:1\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Singh N Am J Resp Crit Care Med 2000, 162: 505\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 221,
    "fields": {
      "name": "ORZID2 GMENU ABX NOSOCOMIAL STAPHYLOCOCCUS PNEUMONIA",
      "term": null,
      "displaytext": "STAPHYLOCOCCUS AUREUS PNEUMONIA",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcilin 2 gm IV q4h ($$) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] < OR >\", \"Mnemonic\": \"14\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI] < OR >\", \"Mnemonic\": \"20\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] < OR >\", \"Mnemonic\": \"22\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"24\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA WITH STAPHYLOCOCCUS AUREUS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Known Methicillin-SUSCEPTIBLE Staphylococcus aureus pneumonia\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Duration of therapy 7-14 days.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Oral therapy (usually given after several days of intravenous therapy):\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"A patient who is substantially improved, without fever for at least 2 days\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"can be treated with an oral agent to which the isolate is susceptible.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Methicillin-RESISTANT or Susceptibilities Unknown Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"In patients with MRSA pneumonia complicated by empyema, antimicrobial therapy\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"should be used in conjunction with drainage procedures.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"NOTE: A prospective trial comparing Linezolid to Vancomycin for MRSA\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"pneumonia, including ventilator-associated pneumonia, showed higher clinical\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"cure rate (p=0.042) for linezolid (95/165, 57.6%) than for vancomycin\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(81/174, 46.6%) but no difference in mortality (15.7% for linezolid vs. 17%\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"for vancomycin).  Other factors to consider are the drug-drug interactions\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"associated with linezolid and cost.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Duration of therapy 7-14 days\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Oral therapy (usually given after several days of intravenous therapy:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"In cases when a patient has substantially improved and has not had a fever\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"for at least 2 days, it may be appropriate to treat with an oral agent to\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"which the isolate is susceptible to complete therapy.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Liu C, Clin Infect Dis. 2011:52:285\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Wunderink RG, Clin Infect Dis. 2012: 54:621\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Rybak MJ, Clin Infect 2009: Dis 49:325\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford Keyword:Staphlococcus aureus pneumonia\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"John Hopkins Antimicrobial Guide  www.johnhopkinsguides.com\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 222,
    "fields": {
      "name": "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS",
      "term": null,
      "displaytext": "Not Benefited by Abx Pharyngitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 39, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References:\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PHARYNGITIS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Acute pharyngitis is common, accounting for 2 percent of all\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"ambulatory visits in the United States.  The major treatable pathogen, group\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"A streptococcus (GAS), is the cause of pharyngitis in only approximately 10\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"percent of adults who seek medical care.  The vast majority of patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"receive presumptive antibiotic therapy for pharyngitis which in most cases is\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"unnecessary and results in adverse effects including death, increases costs,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and adds to pressure on antimicrobial resistance.  Typical causes of\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"pharyngitis include viruses in about \\ufffd, beta-hemolytic streptococci other\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"than group A in 18%, Mycoplasma pneumoniae in 10%, Chlamydophila pneumoniae\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"in 8%, Group A streptococci in 5%, and no microbe identified in 1/3.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Rheumatic fever is rare in the United States, especially in adults, so\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"that some authorities recommend no treatment even if GAS is a potential cause\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"of pharyngitis.Others feel it is important to detect GAS  since antibiotic\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"therapy can slightly shorten the acute illness, prevent acute rheumatic fever\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"and possibly prevent suppurative sequelae.  Other potential causes of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"pharyngitis that should be considered and diagnosed if likely include\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Epstein-Barr virus (EBV) mononucleosis, primary HIV infection, influenza,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"gonococcal pharyngitis, diphtheria, and suppurative pharyngeal infections.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"The Centor criteria are used to predict whether GAS pharyngitis is present.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"*  Tonsillar exudates\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"*  Tender anterior cervical adenopathy\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"*  Fever by history\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"*  Absence of cough\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"If three or four of these criteria are met, the positive predictive value is\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"40 to 60 percent.  If fewer than three criteria are present, the likelihood\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"GAS is causing pharyngitis is less than 20 percent.  If 3 or > Centor criteria\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"are met, obtain a throat culture for group A streptococcus.  Treat\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"empirically for GAS if the patient has severe symptoms or treat later for GAS\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"if the throat culture is positive.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Pharyngitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 223,
    "fields": {
      "name": "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA",
      "term": null,
      "displaytext": "Bacteruria, Candiduria, and Pyuria",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 25, \"Column\": 1, \"Item\": 85, \"DisplayText\": \"Asymptomatic Bacteriuria\", \"Text\": \"Treatment of Asymptomatic Bacteriuria\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 100, \"DisplayText\": \"Candida urinary tract infection\", \"Text\": \"Treatment of Candida Urinary Tract Infections\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIURIA, CANDIDURIA, AND PYURIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Asymptomatic bacteriuria (>= 100,000 bacteria per ml of urine) is common in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"middle aged and older people, especially those who have chronic medical\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"conditions. Pyuria is common in persons with bacteriuria and individuals with\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"indwelling catheters in place. By itself, the presence of pyuria is not\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"sufficient to diagnose bacteriuria, and the presence or absence of pyuria does\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"not differentiate symptomatic from asymptomatic urinary infection. Candiduria is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"less common than bacteriuria, but the implications of candiduria are similar to\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"those of bacteriuria.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Many studies, including randomized clinical trials have shown that\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treatment of asymptomatic bacteriuria and candiduria, with or without pyuria is\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of no benefit, except in certain well-defined circumstances. Antimicrobial\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"therapy is always accompanied by risk of harms, including drug reactions,\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Clostridium difficile colitis, anaphylaxis and death. Except in circumstances\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"specified below, it is best to not order urinalysis or urine culture in\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"asymptomatic persons. If bacteriuria, candiduria or pyuria is discovered in an\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"asymptomatic person for some reason, antimicrobial therapy should not be given\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"except as specified below.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Pregnant women or patients undergoing urological procedures with bacteriuria\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Patients undergoing urological procedures or neutropenic patients with\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"candiduria\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Pappas et al, Clin Infect Dis, 2016, 62.409\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Nicolle et al, Clin Infect Dis, 2005, 40:643\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 224,
    "fields": {
      "name": "ORZID2 GMENU ABX NOT REQUIRED MAIN",
      "term": null,
      "displaytext": "Antibiotics not required ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 16, \"Column\": 1, \"Item\": 292, \"DisplayText\": \"Upper respiratory infections (URI)\", \"Text\": \"Upper Respiratory Infections (URI)\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 120, \"DisplayText\": \"Colonized respiratory tract in patient with a ventilator\", \"Text\": \"Colonized Respiratory Tract in a Patient on a Ventilator\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 277, \"DisplayText\": \"Stasis dermatitis\", \"Text\": \"Stasis Dermatitis\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 121, \"DisplayText\": \"Colonized wounds\", \"Text\": \"Colonized Wounds\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 223, \"DisplayText\": \"Bacteruria, Candiduria, and Pyuria\", \"Text\": \"Asymptomatic Bacteriuria, cadiduria and pyuria\", \"Mnemonic\": \"12\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 243, \"DisplayText\": \"Blood culture positive for coagulase negative staphylococci\", \"Text\": \"Blood culture positive for coagulase negative staphylococci\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CONDITIONS NOT BENEFITTED BY ANTIMICROBIAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Several common conditions associated with inflammation or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"microorganisms do not benefit from antibiotic therapy in most or all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Yet, antimicrobials are frequently prescribed for these conditions leading to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"unnecessary toxicity and costs, rare deaths, and the relentless increase in\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"antimicrobial resistance. Please review these conditions and do not give\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobials for these conditions unless there are extraordinary\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"circumstances that make your situation different. If you have any questions,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"please contact the infectious disease physician on call.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Lungs and Mediastinum\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Skin and Soft Tissue\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Genitourinary\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Miscellaneous\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Last reviewed 9-2018\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Item\": 222, \"DisplayText\": \"Not Benefited by Abx Pharyngitis\", \"Text\": \"Pharyngitis, non-streptococcal\", \"Mnemonic\": \"3\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 95, \"DisplayText\": \"Bronchitis not benefited\", \"Text\": \"Bronchitis in an Otherwise Healthy Patient\", \"Mnemonic\": \"5\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 225,
    "fields": {
      "name": "ORZID2 GMENU ABX OROLABIAL HERPES",
      "term": null,
      "displaytext": "Orolabial Herpes",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO q8h\", \"Text\": \"Acyclovir 400 mg PO q8h for 5 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 2 gm q12h for 1 day ($) [R]\", \"Text\": \"Valacyclovir 2 gm q12h for 1 day ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO q8h\", \"Text\": \"Acyclovir 400 mg PO q8h for 7-14 days($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1GM PO q12h\", \"Text\": \"Valacyclovir 1 gm q12h for 7-14 days ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 5 mg/kg IV Q8H\", \"Text\": \"Acyclovir 5 mg/kg IV q8h for 7-14 days ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO BID\", \"Text\": \"Acyclovir 400 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO Q24h ($) [R]\", \"Text\": \"Valacyclovir 500 mg PO Q24h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OROLABIAL HERPES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antiviral therapy is not beneficial after formation of vesicles. However, when\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"started as soon as prodromal symptoms of burning or tingling occur, antivirals\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"reduce duration of pain and lesions.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Immunocompromised patients in whom herpes simplex infections can be more severe\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"include: patients with HIV infection, organ transplant recipients, patients\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"undergoing chemotherapy, malnourished patients, and those with compromised skin\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"integrity.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Chronic suppressive therapy\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Indicated for patients with greater than 6 recurrences or severe recurrences,\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"immunocompromised patients or as adjunct to prevent transmission. Suppressive\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"therapy is optional, and some patients may find episodic treatment more\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"convenient. Patients should be reassessed every few years to evaluate if chronic\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"suppressive therapy is still necessary.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes simplex\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of herpes simplex virus type 1 infection in\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"immunocompetent patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 226,
    "fields": {
      "name": "ORZID2 GMENU ABX PANCREATITIS",
      "term": null,
      "displaytext": "Pancreatitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI] < AND > metronidazole 500 mg IV q8h\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) [R,DI] < AND > metronidazole 500 mg IV q8h\", \"Mnemonic\": \"10\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h ($)\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R,DI] < AND > metronidazole 1 gm PO q12h\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PANCREATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobials are not indicated for uncomplicated pancreatitis.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"In cases of necrotizing pancreatitis without infection, antimicrobial\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prophylaxis does not improve patient outcomes. Antimicrobials increase the risk\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"of fungal superinfection and should not be used.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobials are indicated for cases with pancreatic abscess, infected\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"pancreatic pseudocyst, or infected necrotic pancreas (phlegmon). The diagnosis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"of infection can be difficult and may require aspiration. Consultation with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases is encouraged.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Uncomplicated pancreatitis\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"No antimicrobials are indicated.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Cases with necrosis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"In cases with necrosis, aspirate necrotic material (fine needle under CT or\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"ultrasound guidance) for smear and culture. Uninfected cases should not receive\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"antimicrobials.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Pancreatic abscess, infected pancreatic pseudocyst, or infected necrotic\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"pancreas (phlegmon)\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Total duration of antimicrobial therapy is typically 2 to 4 weeks\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy in patients with mild or moderate disease\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Step down treatment for completion of antimicrobial course after initial\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"intravenous treatment in patients who can tolerate oral therapy. Base selection\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"on culture results.\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Mandell chapter: Pancreatic Infection\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Sanford Guide keyword: Pancreatitis\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Up-to-Date article: Management of acute pancreatitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 227,
    "fields": {
      "name": "ORZID2 GMENU ABX PARAINFLUENZA",
      "term": null,
      "displaytext": "Parainfluenza",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PARAINFLUENZA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"No specific antimicrobial therapy is indicated. Contact Infectious Diseases for\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"more information on management of this disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Sanford keyword: Parainfluenza virus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 228,
    "fields": {
      "name": "ORZID2 GMENU ABX PAROTITIS",
      "term": null,
      "displaytext": "Parotitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 229, \"DisplayText\": \"More Information on Parotitis\", \"Text\": \"More information on Parotitis\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg PO q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg PO q8h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG Q12 METRON 500 MG Q8\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG Q12H METRO 500MG PO Q8H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> metronidazole 500 mg PO q8h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PAROTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection of salivary tissue is a relatively common disease. It is usually\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"caused by a stone in the parotid duct, dehydration, or a viral infection.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Sialolithiasis in elderly patients often leads to ductal obstruction and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"secondary infection. Other predisposing factors for ductal occlusion include\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dehydration, anticholinergic medications such as tricyclics and diphenhydramine,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"general disability and trauma. Once culture results are available adjust\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobial therapy based on specific etiologic organism.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For more information click on the link below\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Therapy duration varies based on clinical response to treatment and is typically\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"10-14 days.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Suppurative Parotitis or Chronic Bacterial Parotitis Exacerbation Empiric\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Immunocompetent Patient\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"If MRSA suspected or alternative to above:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Immunocompromised Patient\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Viral Parotitis\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Suspect mumps parotitis if there is fever, malaise, earache and bilateral tender\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"swelling of the parotid glands. For mumps parotitis treat with warm compresses\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"and analgesics and maintain good hydration to prevent secondary bacterial\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"infection. Other viral causes of parotitis include influenza and enteroviruses.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Wilson et al., Am Fam Physician. 2014, 89(11)882-888\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Mandell chapter:Principles and Practice of Infectious Diseases\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Sanford keyword: Parotitis\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Up-To-Datearticle: Suppurative parotitis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 229,
    "fields": {
      "name": "ORZID2 GMENU ABX PAROTITIS MORE INFORMATION",
      "term": null,
      "displaytext": "More Information on Parotitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MORE ABOUT PAROTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Suppurative Parotitis. Acute bacterial parotitis affects primarily elderly,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"malnourished, dehydrated or post-operative patients. Symptoms include fever,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"toxicity, and tender swelling along the mandible with purulent drainage from the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"parotid duct. Suppurative parotitis is usually unilateral whereas viral\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"parotitis is usually bilateral. Pain is intense and aggressive, analgesic\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy is required. Progression of infection may lead to massive swelling of\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the neck, respiratory obstruction, septicemia and osteomyelitis of adjacent\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"facial bones. Empiric antibiotics are required for coverage of Staphylococcus\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"aureus if bacterial, and surgical drainage is usually necessary.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Chronic Parotitis. Parotitis is recurrent with intermittent acute exacerbations.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Chronic, low-grade bacterial infection results in functional destruction of the\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"salivary gland. It may be confused with Sjogren's syndrome, a noninfectious\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"illness. Therapy includes systemic antibiotics. Parotidectomy may eventually be\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"required for patients with long-standing infection.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Viral Parotitis. Mumps parotitis is characterized by the rapid, painful swelling\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"of one or both parotid glands within 2 to 3 weeks after exposure to the mumps\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"virus. Mumps usually involves both parotid glands whereas bacterial parotitis is\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"unilateral. Other viral causes of parotitis include influenza and enteroviruses.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mumps parotitis usually resolves spontaneously in 5 to 10 days. Provide\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"symptomatic relief of pain and fever and maintain hydration to prevent secondary\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"bacterial infection.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Wilson et al., Am Fam Physician. 2014, 89(11)882-888\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter:  Principles and Practice of Infectious Diseases\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Parotitis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-To-Date  article: Suppurative parotitis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 230,
    "fields": {
      "name": "ORZID2 GMENU ABX PCV20 NOT CURRENTLY AVAILABLE",
      "term": null,
      "displaytext": "PCV20 Quick Orders Not Currently Available ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PCV20 MUST BE ADMINISTERED THROUGH CLINICAL REMINDER\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"PCV20 orders are currently not availble in CDSS. Please contact Erik Stensgard,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"PharmD, more information (email: erik.stensgard@va.gov).\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Use the Pneumococcal Conjugate Vaccine (PCV15/PCV20) Nursing Clinical\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Reminder on the Cover Sheet for administration of this vaccine.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 231,
    "fields": {
      "name": "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL",
      "term": null,
      "displaytext": "Penicillin Desensitization Protocol  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"PENICILLIN DESENSITIZATION PROTOCOL\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pharmacy Service must be involved. Contact satellite pharmacist at ext. 2040 or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"menu 648-6746. Infectious Diseases Consult strongly recommended.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"When penicillin is the drug of choice for an infectious disease in a patient\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with Type I penicillin allergy, one option is to desensitize the patient.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Severe reactions cannot be predicted accurately with skin testing in the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"clinical setting.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Penicillin Desensitization\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"> Perform in an ICU or similar setting.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"> Discontinue all beta-adrenergic antagonists.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"> Have IV line in place and EKG and spirometer ready.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"> Once desensitization has been accomplished, therapy with this drug must not\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"lapse or the risk of allergic reactions increases.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"> A history of Stevens Johnson syndrome, exfoliative dermatitis, or erythroderma\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"are nearly absolute contraindications to desensitization.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"ORAL ROUTE\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Oral route is preferred if oral preparation is available and GI tract is\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"functional. 1/3 of patients will develop transient reaction, usually mild.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"[Step, 15 minute intervals] concentration, volume\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"[1] 0.5mg/ml, 0.1ml\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"[2] 0.5mg/ml, 0.2ml\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"[3] 0.5mg/ml, 0.4ml\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"[4] 0.5mg/ml, 0.8ml\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"[5] 0.5mg/ml, 1.6ml\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"[6] 0.5mg/ml, 3.2ml\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"[7] 0.5mg/ml, 6.4ml\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"[8] 5mg/ml, 1.2ml\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"[9] 5mg/ml, 2.4ml\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"[10] 5mg/ml, 4.8ml\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"[11] 50mg/ml, 1ml\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"[12] 50mg/ml, 2ml\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"[13] 50mg/ml, 4ml\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"[14] 50mg/ml, 8ml\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"After step 14, observe 30 minutes. If no reaction, give 1 gm IV.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"PARENTERAL ROUTE\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"[Step, 15 minute intervals] concentration, volume\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"[1] 0.1mg/ml, 0.1ml\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"[2] 0.1mg/ml, 0.2ml\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"[3] 0.1mg/ml, 0.4ml\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"[4] 0.1mg/ml, 0.8ml\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"[5] 1mg/ml, 0.16ml\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"[6] 1mg/ml, 0.32ml\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"[7] 1mg/ml, 0.64ml\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"[8] 10mg/ml, 0.12ml\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"[9] 10mg/ml, 0.24ml\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"[10] 10mg/ml, 0.48ml\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"[11] 100mg/ml, 0.1ml\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"[12] 100mg/ml, 0.2ml\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"[13] 100mg/ml, 0.4ml\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"[14] 100mg/ml, 0.8ml\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"[15] 1000mg/ml, 0.16ml\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"[16] 1000mg/ml, 0.32ml\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"[17] 1000mg/ml, 0.64ml\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"After step 17, observe 30 minutes. If no reaction, give 1 gm IV.\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Sanford key term: allergy\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Allergy: Principles and Practice 1993, p1726\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Curr Clin Topics Inf Dis 1993, 13:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 232,
    "fields": {
      "name": "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL",
      "term": null,
      "displaytext": "Peritonitis associated with peritoneal dialysis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 82, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200 mg PO q48h ($) [R,DI]\", \"Text\": \"Fluconazole 200 mg PO every other day ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 84, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 100 mg q24h ($) [R,DI]\", \"Text\": \"Fluconazole 100 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 517, \"DisplayText\": \"Cefepime 1 gm q24h in 2000 mL 2.5% dextrose diasylate\", \"Text\": \"Cefepime 1 gm PD q24h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 516, \"DisplayText\": \"Cefazolin and gentamicin PD order menu\", \"Text\": \"Cefazolin 15 mg/kg ($) [R] <AND> gentamicin 0.6 mg/kg ($) [R,O] PD q24h\", \"Mnemonic\": \"10\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 518, \"DisplayText\": \"Cefepime and Vancomycin Treatment of Peritonitis Associated with PD\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>\", \"Mnemonic\": \"12\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 523, \"DisplayText\": \"Vancomycin and gentamicin PD order menu\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>\", \"Mnemonic\": \"14\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 515, \"DisplayText\": \"Cefazolin PD order menu\", \"Text\": \"Cefazolin 15 mg/kg PD q24h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 522, \"DisplayText\": \"Vancomycin PD order menu\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 517, \"DisplayText\": \"Cefepime 1 gm q24h in 2000 mL 2.5% dextrose diasylate\", \"Text\": \"Cefepime 1 gm PD q24h ($$) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 521, \"DisplayText\": \"Gentamicin PD order menu\", \"Text\": \"Gentamicin 0.6 mg/kg PD q24h ($) [R,O]\", \"Mnemonic\": \"22\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 515, \"DisplayText\": \"Cefazolin PD order menu\", \"Text\": \"Cefazolin 15 mg/kg PD q24h ($) [R]\", \"Mnemonic\": \"24\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 519, \"DisplayText\": \"Ceftazidime PD order menu\", \"Text\": \"Ceftazidime 1 gm PD q24h ($) [R]\", \"Mnemonic\": \"26\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 520, \"DisplayText\": \"Ceftriaxone PD order menu\", \"Text\": \"Ceftriaxone 1 gm PD q24h ($) [M]\", \"Mnemonic\": \"28\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 521, \"DisplayText\": \"Gentamicin PD order menu\", \"Text\": \"Gentamicin 0.6 mg/kg PD q24h ($) [R,O]\", \"Mnemonic\": \"30\"}, {\"Row\": 75, \"Column\": 1, \"Item\": 522, \"DisplayText\": \"Vancomycin PD order menu\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]\", \"Mnemonic\": \"32\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Peritonitis associated with peritoneal dialysis usually presents with abdominal\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pain, fever, nausea or vomiting, and cloudy effluent. The leukocyte\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"concentration is greater than 100 cells/microliter of dialysate, with more than\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"50% neutrophils.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Obtain Gram stain, culture, and cell count with differential of dialysate before\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials are given. Nephrology consultation is essential. If cultures\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"show Gram-negative or mixed bacterial infection, a gastrointestinal tract\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"infectious source is more likely. Gram-positive organisms like staphylococci\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"usually result from external contamination. Fungal peritonitis is rare and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"requires immediate catheter removal.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"**Antimicrobial recommendations are for empirical therapy only. Regimens should\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"be tailored according to patient response and microbiology results in\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"consultation with Nephrology and/or Infectious Diseases for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"To prevent catheter occlusion by turbid dialysate, add 1,000 units of heparin\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"per dialysis bag each day until one day after the dialysate is clear.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"If vancomycin is used, trough serum concentrations should be kept above 15\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"mcg/ml to ensure adequate intraperitoneal levels. Usually vancomycin must be\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"given every 3 to 7 days. Contact Nephrology and/or Pharmacy for more\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Antifungal prophylaxis:\", \"Header\": 1}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Antifungal prophylaxis may be used for the duration of antimicrobial therapy to\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"possibly reduce the risk of fungal peritonitis.\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Antimicrobial therapy\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Duration of therapy depends on the pathogen identified. Treat staphylococcal and\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"streptococcal infections for 2 weeks and all other gram-positive infections for\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"3 weeks. In patients who have Staphylococcus isolated and had a previous\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"staphylococcal infection, treat for 3 weeks\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"All antimicrobials below are administered via peritoneal dialysate bag over 6\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"hours with the option to include heparin 1000 units.\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Empirical treatment while waiting for results of gram stain\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"MRSA risk factors\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"cefepime 1 gm PD q24h ($) [R]\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Alternative for severe penicillin or cephalosporin allergy\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"gentamicin 0.6 mg/kg PD q24h ($) [R,O]\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Gram positive organism\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Gram negative organism\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Alternative for severe penicillin allergy\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Alternative treatments for narrowing coverage based on isolate susceptibilities\", \"Header\": 1}, {\"Row\": 68, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 88, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"De Vin et al, Peritoneal Dialysis International, 2009, Vol. 39, pp. 5-15\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Li et al, Peritoneal Dialysis International, 2016, Vol. 36, pp. 481-508\"}, {\"Row\": 92, \"Column\": 1, \"Text\": \"Mandell chapter: Peritonitis and Intraperitoneal Abscesses\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Sanford keyword: Peritonitis, Dialysis (CAPD) Associated\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Up-to-Date article: Microbiology and therapy of peritonitis in peritoneal\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"dialysis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Consult Nephrology in all cases.\", \"Header\": 1}, {\"Row\": 86, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 233,
    "fields": {
      "name": "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 531, \"DisplayText\": \"Prevention of Bacterial Endocarditis\", \"Text\": \"High risk of infective endocarditis\", \"Mnemonic\": \"4\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>\", \"Mnemonic\": \"8\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"12\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-Tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"20\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"24\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERIANAL/ANORECTAL ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary therapy: abscess drainage\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prompt surgical drainage is important. Antibiotics have a limited role in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"treatment of uncomplicated anorectal abscess. In general, the addition of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"antibiotics to routine incision and drainage of uncomplicated anorectal abscess\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"does not improve healing time or reduce recurrences. Antibiotics may be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"considered in patients with significant cellulitis, underlying\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"immunosuppression, concomitant systemic illness, or failure to improve with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"drainage alone.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antibiotic prophylaxis for prevention of infective endocarditis is recommended\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for procedures involving infected skin or skin structures in patients with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"underlying cardiac conditions. Click on link below for list of conditions and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"recommendations.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Although culture of abscess fluid in patients who undergo drainage is rarely\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"helpful, it may be considered in patients who will be treated with adjunctive\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"antibiotic treatment, recurrent infection or nonhealing wounds, substantial host\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"defense deficiency, and patients with MRSA risk factors.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Duration of adjunctive antimicrobial therapy\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"After adequate drainage, 5-14 days of antibiotic coverage is indicated for those\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"who receive adjunctive antimicrobial therapy, with duration in part based on\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"resolution of fever and leukocytosis, severity of infection, and additional\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"indicators of clinical response.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Adjunctive antibiotic treatment for drained perirectal abscess in patients with\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"significant cellulitis, underlying immunosuppression, concomitant systemic\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"illness, or failure to improve with drainage alone\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mild disease\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"metronidazole 1000 mg PO q12h ($) [DI]\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Moderate disease\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Severe, life-threatening disease\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Alternative for patients with penicillin allergy\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Rosengren et al, Curr Derm Rep (2012) 1, 55-63\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Steele et al, Dis Colon Rectum 54(12):1465-74, 2011\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Wilson et al, Circulation 116:1736, 2007\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"Up-to-date article: Perianal and perirectal abscess\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Up-to-date article: Cellulitis and skin abscess in adults: Treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 234,
    "fields": {
      "name": "ORZID2 GMENU ABX PERICARDITIS",
      "term": null,
      "displaytext": "Pericarditis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> piperacillin-tazobactam 4.5 gm\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERICARDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases arise from non-infectious causes or are associated with viruses.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Antimicrobial therapy is not indicated unless pericardial fluid is purulent. If\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"fluid is purulent, pericardial drainage is required in most cases. Modify\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antimicrobial regimen and narrow coverage based on results of culture and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"susceptibility tests.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Cardiology consultation is essential for management of therapy. Infectious\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Diseases consultation is recommended if an infectious origin is suspected.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration is based on patient specific factors such as resolution of fever and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"clinical signs of infection. Generally, duration is 2 to 4 weeks depending on\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"how adequacy  of drainage of pericardial fluid and susceptibility of infectious\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"organism.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"IV q6h ($$) [R]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Adler et al., European Heart Journal 2015, 36.2921-2964\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Myocarditis and Pericarditis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Pericarditis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-To-Date article: Purulent pericarditis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 235,
    "fields": {
      "name": "ORZID2 GMENU ABX PERTUSSIS",
      "term": null,
      "displaytext": "Pertussis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 356, \"DisplayText\": \"Diagnosis of Pertussis\", \"Text\": \"Diagnosis of pertussis\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 532, \"DisplayText\": \"Prevention of Pertussis\", \"Text\": \"Prevention of pertussis\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 then 250 mg QD for 4 days ($)[M]\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERTUSSIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pertussis is associated with persistent cough in adolescents and adults.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Immunity conferred by pertussis vaccine wanes after about 10 years. The first 1\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"to 2 weeks of disease resembles viral upper respiratory infection.  After this,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"the characteristic cough with whoop is present for 1 to 6 weeks, followed by a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"2 to 3 week period of gradual resolution.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative for macrolide intolerant or allergic patients\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Kline et al, Am Fam Physician (2013) 88.8, 507-514\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Langley et al, Pediatrics (2004), e96-e101\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Pertussis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Bordetella species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 236,
    "fields": {
      "name": "ORZID2 GMENU ABX PHARYNGITIS",
      "term": null,
      "displaytext": "Pharyngitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 167, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Treatment of Gonorrheal Infections\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HIV, Rapid\", \"Text\": \"HIV Rapid Test\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 493, \"DisplayText\": \"More about Pharyngitis...\", \"Text\": \"More About Pharyngitis/Tonsillitis and Modified Centor score\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Strep A PCR\", \"Text\": \"Rapid Strep A throat PCR testing lab order\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin V 500mg po q12h\", \"Text\": \"Penicillin V 500 mg PO q12h for 10 days ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine penicillin 1.2MU IM once\", \"Text\": \"Benzathine penicillin 1.2 million units IM x 1 ($$$) [M]\", \"Mnemonic\": \"14\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"16\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once on day one then 250mg PO q24h for 4 days ($)\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PHARYNGITIS AND TONSILLITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are viral, primarily due to adenovirus. Aside from streptococcal and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pharyngitis, use link below for recommendations.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consider HIV screening for patients with pharyngitis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Streptococcal Pharyngitis and Tonsillitis\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Diagnosis of group A streptococcal (GAS) infection is made through detection by\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"rapid PCR and should be reserved for patients who have a moderate to high risk\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of GAS infection according to the Modified Centor Score. Use link below for\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Modified Centor score criteria and for more details.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antimicrobials are not indicated\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"GAS Pharyngitis and Tonsillitis Treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Primary alternative:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Secondary alternative, after assessment of beta-lactam reaction above:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Choby, Am Fam Physician. 2009 79(5) 383-390\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Pharyngitis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcal Pharyngitis\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Stanford et al, Clinical Infectious Diseases. 2012, cis629\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-To-Date article:  Evaluation of acute pharyngitis in adults\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-To-Date article:  Treatment and prevention of streptococcal pharyngitis\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Text\": \"Cefadroxil 1000 mg PO q12h for 10 days ($) [R]\", \"Mnemonic\": \"18\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 237,
    "fields": {
      "name": "ORZID2 GMENU ABX PHOTODYNAMIC THERAPY HSV-1",
      "term": null,
      "displaytext": "Photodynamic therapy for HSV-1 prophylaxis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"PHOTODYNAMIC THERAPY AND LASER SKIN RESURFACING HSV-1 PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Recommended in patients with history of HSV-1 infection. Initiate prophylaxis\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"24-48 hours prior to surgery and continue for 3-7 days.\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400MG PO BID\", \"Text\": \"Acyclovir 400 mg PO BID for 5 days ($) [R]\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes Simplex Virus\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Up-To-Date article: Prevention of herpes simplex virus type 1 infection in\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"immunocompetent patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 238,
    "fields": {
      "name": "ORZID2 GMENU ABX PID",
      "term": null,
      "displaytext": "Pelvic Inflammatory Disease ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg q12h for 14\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg q12h for 14\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg PO q12h for 7\", \"Mnemonic\": \"6\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAX 500MG IM ONCE AZITHROMYCIN 1GM PO ONCE\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > azithromycin 1 gm PO once ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg IV q12h ($) [DI]\", \"Text\": \"Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg IV q12h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900 mg IV q8h ($$) [H,O] < AND > gentamicin 5 mg/kg q24h ($) [R,\", \"Text\": \"Clindamycin 900 mg IV q8h ($$) [H,O] < AND > gentamicin 5 mg/kg q24h ($) [R,\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PELVIC INFLAMMATORY DISEASE (PID)\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Pelvic inflammatory disease (PID) refers to bacterial infection of the upper\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"female reproductive tract. Likely bacterial pathogens include Neisseria\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"gonorrhoeae, Chlamydia trachomatis, anaerobes, enteric Gram-negative rods, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Streptococcus agalactiae. PID should be considered in sexually active women\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"with pelvic tenderness and signs of lower genital tract inflammation. Signs and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"symptoms may be mild or non-specific, and providers should have a low threshold\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"to initiate treatment. All women who are diagnosed with acute PID should be\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"tested for N. gonorrohoeae, C. trachomatis, and HIV. Male sex partners of\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"patients with PID should be examined and treated (see below) if they had sexual\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"contact within the 60 days before onset of the patient's symptoms.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Judge severity of infection based on clinical signs and symptoms, including\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"blood pressure, pulse, mental status, and degree of fever.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"days ($) [DI] < OPTIONAL > metronidazole 500 mg PO q12h ($) [DI]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For patients who cannot take ceftriaxone and doxycycline, call ID\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment of sex partner who is a veteran\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treat for both Chlamydia and Gonorrhea\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"days ($) [DI]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"O]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines: MMWR (2015) 64.3\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Mandell chapter: Neisseria gonorrheoeae (Gonorrhea)\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Pelvic inflammatory disease\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article: Pelvic inflammatory disease: Treatment\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Pelvic inflammatory disease\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Up-To-Date article: Pelvic inflammatory disease: Treatment\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 568, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 239,
    "fields": {
      "name": "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS",
      "term": null,
      "displaytext": "Pneumocyctis Jirovecii Prophylaxis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po q24h\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet q day ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 SS tablet PO q24h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 SS tablet q day ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dapsone 100 mg PO qd for PCP prophylaxis\", \"Text\": \"Dapsone 100mg PO q day ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PNEUMOCYSTIS JIROVECII PROPHYLAXIS (PCP Prophylaxis)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Indications for primary prophylaxis of P. jirovecii include:\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"1) HIV/AIDS patients with CD4 count <200 cells/microliter\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"2) Hematopoietic or organ transplantation patients during immunosuppression\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"3) Patients receiving Alemtuzumab, temozolomide or fludarabine\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"4) Patients receiving >/= 20mg equivalent of prednisone per day for over 1 month\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"5) Patients with acute lymphocytic leukemia, rheumatologic disease receiving\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"immunosuppressive therapy and certain primary immunodeficiencies (e.g. severe\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-IgM\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Dose and duration of prophylaxis varies with the indication. Please contact\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Infectious Diseases or Hematology/Oncology for more information.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Prophylaxis should be discontinued when host defenses are restored. In persons\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"with AIDS on highly active antiretroviral therapy, Prophylaxis should be\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"discontinued when the CD4 cell concentrations remain over 200 cells/microliter\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"for 3 to 6 months in patients, except that prophylaxis should be continued for\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"life in those who have had P. jirovecii disease.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2018)\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Sanford keyword: Pneumocystis pneumonia, Adult\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of Pneumocystis pneumonia in HIV-\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"uninfected patients\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Recommended FIRST-LINE prophylaxis:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"**Patient should be tested for glucose-6-phosphate dehydrogenase (G6-PD)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"deficiency before starting dapsone. Individuals deficient in G6-PD\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone 1500mg qday for PCP prophylaxis\", \"Text\": \"Atovaquone 1500mg q day for PCP prophylaxis ($$) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Atovaquone is alternative for patient for clinical reason:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"(e.g. patients with SLE, hematologic concerns, G6PD deficiency)\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Alternative to the above preferred regimens:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"G6-PD Screen\", \"Text\": \"[Click here] G6-PD Screen Lab Order\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"syndrome)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"show about a 2-fold increase in sensitivity toward dapsone-induced hemolytic\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"anemia.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"G6-PD lab test are resulted the same day or next day. May be add on lab.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"G6-PD lab result should be \\\"normal\\\" to start dapsone therapy.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative when trimethoprim/sulfa is poorly tolerated or contraindicated:\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Maertens J, et al. J Antimicrob Chemother. 2016, 71(9): 2397-404\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Martin SI, et al. Am J Transplant. 2013, 13 Suppl 4:272-9\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Alternative to the above regimens:\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pentamidine inhalation order set\", \"Text\": \"Pentamidine 300mg Inhalation QMONTH ($) [DI,O] <AND> Albuterol 0.083%\", \"Mnemonic\": \"14\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"inhalation QMONTH ($) [M] clinic orders (call 612-467-5193 for 3V LPN\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"appointment)\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Due to efficacy and complicated logistics for administration, alternative\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"when above recommendations not appropriate for patient.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 240,
    "fields": {
      "name": "ORZID2 GMENU ABX PNEUMONIA",
      "term": null,
      "displaytext": "Pneumonia ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 83, \"DisplayText\": \"Aspiration pneumonia\", \"Text\": \"Aspiration Pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 122, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community-acquired pneumonia (CAP)\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 216, \"DisplayText\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Text\": \"Nosocomial pneumonia (including HAP, AND VAP)\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ PNEUMONIA - INPATIENT ++\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Note: Healthcare-associated pneumonia (HCAP), no longer used in the 2019\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and/or P. aeruginosa are used to guide whether to start\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"appropriate coverage empirically. (See CAP above)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 241,
    "fields": {
      "name": "ORZID2 GMENU ABX PNEUMONIA HAP NEW",
      "term": null,
      "displaytext": "PNEUMONIA HAP",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"15 mg/kg IV q12h ($) [R]< OR >\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRIC TREATMENT: Hospital Acquired Pneumonia (HAP)\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]] <AND> vancomycin 15 mg/kg IV\", \"Mnemonic\": \"20\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"q12h ($) [R]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Chastre J. JAMA 2003. 290:2588.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Luna CM. Crit Care Med 2003. 31:676.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Roig J. J Antimicrob Chemother 2003. 51:1119.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Risk Factors for Multi-Drug Resistant (MDR) Pathogen(s):\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Prior intravenous antibiotic use within 90 days\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment for 7 days is generally sufficient if the initial empiric therapy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"covered the pathogen and the patient is clinically responding.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empiric Treatment:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Boyce JM. Antimicrob Agents Chemother 2013. 57:1163\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Narrow therapy to treat specific pathogen(s) based on results of\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"culture and susceptibility tests. Can discontinue MRSA coverage if no\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"MRSA isolated from respiratory cultures, if obtained, or if nasal\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"swab or throat cultures show no growth of MRSA, or if NAAT negative for\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"MRSA.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"resistant pathogens guide antimicrobial therapy.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Local facility antibiogram and patient risk factors for multi-drug\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Development of pneumonia 48 hours or more after hospital admission.\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 248, \"DisplayText\": \"Re-evaluate Nosocomial pneumonia at 72 hours\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Conditions that increase risk for Pseudomonas infections:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \">Bronchiectasis or Bronchomalacia\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \">Lung Cancer\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \">Pneumonectomy\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \">Bronchoesophageal fistula\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \">Cystic Fibrosis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \">Chronic pleural effusions with chest tubes\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \">Severe obstructive Lung Disease with FEV1%<31\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"22\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If no risk factors for pseudomonas:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"If risk factors for Pseudomonas *ADD* additional coverage to above regimens:\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 242,
    "fields": {
      "name": "ORZID2 GMENU ABX PNEUMONIA VAP",
      "term": null,
      "displaytext": "PNEUMONIA VAP",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV\", \"Mnemonic\": \"8\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin 5\", \"Mnemonic\": \"10\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime Gentamicin Vancomycin\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> gentamicin 5\", \"Mnemonic\": \"12\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) <AND> gentamicin 5 mg/kg IV\", \"Mnemonic\": \"14\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg Gentamicin 5 mg/kg Vancomycin 15 mg/kg\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h ($)\", \"Mnemonic\": \"16\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"EMPIRIC TREATMENT: Ventilator Associated Pneumonia (VAP)\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pneumonia occurring 48 hours or more after endotracheal intubation\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Local facility antibiogram and patient risk factors for multi-drug\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"resistant pathogens guide antimicrobial therapy.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Risk factors for Multi-Drug Resistant VAP:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prior intravenous antibiotic use within 90 days\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Septic shock at the time of VAP\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"ARDS preceding VAP\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"5 or more days of hospitalization prior to the occurrence of VAP\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Acute renal replacement therapy prior to VAP onset\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Local resistance pattern\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment for 7 days is generally sufficient if the initial empiric therapy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"covered the pathogen and the patient is clinically responding.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Narrow therapy to treat specific pathogen(s) based on results of\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"culture and susceptibility tests. Can discontinue MRSA coverage if no\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"MRSA isolated from respiratory cultures, if obtained, or if nasal\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"swab or throat cultures show no growth of MRSA, or if NAAT negative for\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"MRSA.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Empiric Treatment:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"No Risk of MDR Pathogen(s):\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"15mg/kg IV q12h ($) [R]  <OR>\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"q12h ($) [R]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative for Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"q12h ($) [R]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Risk of MDR Pathogens:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]  <OR>\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]  <OR>\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Boyce JM. Antimicrob Agents Chemother 2013. 57:1163\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Chastre J. JAMA 2003. 290:2588.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371.\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Luna CM. Crit Care Med 2003. 31:676.\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Roig J. J Antimicrob Chemother 2003. 51:1119.\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 243,
    "fields": {
      "name": "ORZID2 GMENU ABX POSITIVE BLOOD CULTURE COAG NEG STAPH",
      "term": null,
      "displaytext": "Blood culture positive for coagulase negative staphylococci  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 25, \"Column\": 1, \"Item\": 324, \"DisplayText\": \"Bacteremia associated with Coagulase-negative Staphylococci (CNS)\", \"Text\": \"Treatment of CNS Bacteremia\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 470, \"DisplayText\": \"Intravascular catheter-associated coagulase-negative staphylococcus infection\", \"Text\": \"Treatment of CNS Infected Intravascular Catheters\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BLOOD CULTURE POSITIVE FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"CNS are the most common contaminants isolated from blood cultures. When CNS\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"isolated from blood cultures represent true bacteremia, the blood is usually\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"obtained from a patient with plastic or metal in the body. The most common\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"source of coagulase negative staphylococcal bacteremia is an infected\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"intravascular catheter.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"When CNS are isolated from blood, the physician should carefully assess the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"patient to decide whether the isolation represents disease or colonization.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Colonization is more likely if a single bottle is positive or both bottles from\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"a single blood draw are positive. If multiple bottles are positive from separate\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"blood draws, it is more likely that the isolates reflect disease or colonization\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of an intravascular device. Isolates from contaminated bottles often take\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"several days to become positive. If the patient has risk factors for true\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"coagulase negative staphylococcal bacteremia, catheter-related blood stream\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"infection and/or the patient is severely ill, antimicrobials should be given\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"(see below). If there is a plastic or metal prosthesis in the body, the\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"physician should evaluate the site for possible infection. If the isolates are\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"likely to represent contamination and the patient does not seem ill with CNS,\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"antimicrobial therapy would not be helpful and should not be given.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus epidermis and Other Coagulase-Negative\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Staphylococci\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mermel et al, Clin Infect Dis, 2009, 49\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 244,
    "fields": {
      "name": "ORZID2 GMENU ABX PREVENTION OF INFECTION",
      "term": null,
      "displaytext": "Prevention of Infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 531, \"DisplayText\": \"Prevention of Bacterial Endocarditis\", \"Text\": \"Prevention of bacterial endocarditis\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 533, \"DisplayText\": \"Prevention of prosthetic joint infection before dental procedures\", \"Text\": \"Before dental procedures\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 529, \"DisplayText\": \"Prevention of bacterial infection in a patient with malignancy\", \"Text\": \"Antibacterial prophylaxis\", \"Mnemonic\": \"10\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 530, \"DisplayText\": \"Prevention of fungal infections in a patient with malignancy\", \"Text\": \"Antifungal prophylaxis\", \"Mnemonic\": \"12\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 304, \"DisplayText\": \"\", \"Text\": \"Antiviral prophylaxis\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 275, \"DisplayText\": \"Acute spontaneous bacterial peritonitis (SBP)\", \"Text\": \"Spontaneous bacterial peritonitis\", \"Mnemonic\": \"16\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis jirovecii prophylaxis\", \"Mnemonic\": \"18\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 276, \"DisplayText\": \"\", \"Text\": \"Click Here\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  PREVENTION OF INFECTION  ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Prevention of bacterial endocarditis\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Prevention of prosthetic joint infection\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Prevention of infection in patient with malignancy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Prevention of infection in patients with liver disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Prevention of Pneumocystis infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Prevention of recurrent Staphylococcus aureus skin infection\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Section reviewed January 2019\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 134, \"DisplayText\": \"ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS\", \"Text\": \"Before procedures involving infected skin, skin structures or musculoskeletal\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"tissue\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 245,
    "fields": {
      "name": "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX",
      "term": null,
      "displaytext": "Primary infection (Chickenpox) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800MG PO 5x/d\", \"Text\": \"Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO q8h ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO q8h for 5 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800MG PO 5x/d\", \"Text\": \"Acyclovir 800 mg PO 5x/day for 7 days ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO q8h ($) [R]\", \"Text\": \"Valacyclovir 1000 mg PO q8h for 7 days ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 10 mg/kg IV q8h ($$) [R,DI]\", \"Text\": \"Acyclovir 10 mg/kg IV q8h for 7 days ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PRIMARY INFECTION (CHICKENPOX)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Vaccinate all adults without evidence of immunity except for pregnant women.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Test antibody first in adults who have uncertain history of chickenpox or\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"vaccination.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Give Varicella vaccine x 2, 2nd dose 4-8 weeks after 1st dose\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Therapy must be started within 24 hrs onset of rash.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Therapy must be started within 24 hrs onset of rash.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Immunocompromised patients without prior immunity to varicella who are at risk\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"for disease include: patients with malignancy, current immunosuppressive\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"therapy, or HIV infection. Vaccination is not recommended while patients are\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"immunocompromised.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Contact Infectious Diseases for more information.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treatment for severe disease, or if mild to moderate disease doesn't improve on\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"above therapy\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Kim et al. Annals Intern Med. 2018, 168(3):210-220\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Varicella-Zoster Virus\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 246,
    "fields": {
      "name": "ORZID2 GMENU ABX PROCED FOR INFECTED SKIN, SKIN STRUCTURES",
      "term": null,
      "displaytext": "Drugs for procedures that involve infected skin, skin structures",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 1gm iv once\", \"Text\": \"Cefazolin 1 gm IV over 20 minutes, beginning 60 minutes before incision\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/Sulfa 1 DS table PO (Pre-Op)\", \"Text\": \"Trimethoprim/Sulfamethoxazole 1 DS table PO 1 hour before incision\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO 1 hour before incision (Pre-Op)\", \"Text\": \"Minocycline 100 mg PO 1 hour before incision ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15mg/kg IV over 60 minutes, beginning 120 minutes before incision\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIMICROBIALS FOR PATIENTS UNDERGOING PROCEDURES THAT INVOLVE INFECTED SKIN,\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"SKIN STRUCTURES, OR INFECTED MUSCULOSKELETAL TISSUE TO PREVENT ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Pathogen unknown or possibly MSSA or beta-hemolytic streptococcus\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Patients unable to take oral medications\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Suspected MRSA\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"($) [R,DI]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Rosengren et al, Curr Derm Rep (2012) 1, 55-63\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"infection in adults\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date article: Skin surgery: Prevention and treatment of complications\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Wilson et al., Circulation, 2021, 143(20)e963-e978\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Wright et al, J Am Acad Dermatol (2008) 59, 464-73\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 2 GM PO 1 hour before procedure ($) [R]\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 247,
    "fields": {
      "name": "ORZID2 GMENU ABX PYELONEPHRITIS",
      "term": null,
      "displaytext": "Pyelonephritis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"20\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 14 days\", \"Mnemonic\": \"22\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"24\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"26\"}, {\"Row\": 81, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"28\"}, {\"Row\": 83, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"30\"}, {\"Row\": 86, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"32\"}, {\"Row\": 89, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R] for 14 days\", \"Mnemonic\": \"34\"}, {\"Row\": 93, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q6h ($$) [R] for 14 days\", \"Mnemonic\": \"36\"}, {\"Row\": 95, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO q8h ($) [R] for 14 days\", \"Mnemonic\": \"38\"}, {\"Row\": 98, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"40\"}, {\"Row\": 99, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 14 days\", \"Mnemonic\": \"42\"}, {\"Row\": 101, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days\", \"Mnemonic\": \"44\"}, {\"Row\": 103, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O] for 14 days\", \"Mnemonic\": \"46\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PYELONEPHRITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Features of pyelonephritis include fever/other signs of systemic infection,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"flank pain, costovertebral tenderness, and pelvic or perianal pain in men. Most\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cases are caused by Escherichia coli. Resistant organisms, such as Enterococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and Pseudomonas, are more likely if the patient is elderly, has been in the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"hospital for more than 48 hours, or received a course of antibiotics.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Obtain a urine culture, urine Gram-stain, and blood culture immediately to guide\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antimicrobial therapy:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Drugs active against enterococci (ampicillin, piperacillin) or staphylococci\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"needn't be used if Gram-negative bacilli predominate on the smear. Broad\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"spectrum antimicrobials are needed if patient is at risk of having a multi-drug\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"resistant (MDR) organism.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Judge severity of infection based on clinical signs and symptoms, including\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"blood pressure, pulse, mental status, white blood count, and degree of fever.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Oral regimens are preferred over IV if severity is mild or moderate and patient\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"can tolerate oral antibiotics. In patients with severe or persistent disease,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"new renal failure, or suspected urinary obstruction, obtain a renal ultrasound\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"to rule out obstruction or other complicating condition. Consult urology if\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"abnormalities are found.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"When patients who require paraenteral therapy are afebrile, clinically stable,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"and can take oral medication, convert to oral therapy based on the\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"identification and susceptibility of the isolate.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treat for 7 to 14 days. In patients with a mild infection and a quick clinical\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"response, 7 days of treatment may be adequate. A longer duration may be required\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"in severe infection, resistant organisms, presence of obstruction, underlying\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"renal disease, immunosuppression, neurologic or structural abnormality, and men\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"in some cases. A 7-day course of ciprofloxacin has been shown to be as effective\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"as a 14-day course.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"History of Pseudomonas or ESBL isolate\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"History of MRSA, add to intravenous therapy above\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Treatment for specific pathogens\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Enterobacteria including E. coli, klebsiella, and proteus\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Alternative or isolate resistant to preferred antimicrobials:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"S. aureus is an uncommon urinary tract pathogen and presence in the urine may be\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"due to hematogenous seeding from another site. Blood cultures are indicated to\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"rule out bacteremia in patients who have S. aureus isolated from the urine.\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Pseudomonas\", \"Header\": 1}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Isolate resistant to preferred antimicrobials:\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"for 14 days\"}, {\"Row\": 88, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Enterococcus\", \"Header\": 1}, {\"Row\": 92, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Resistant isolate or alternative to preferred antimicrobials:\"}, {\"Row\": 100, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 102, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 104, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 107, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 108, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 109, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 110, \"Column\": 1, \"Text\": \"Sanford keyword: Pyelonephritis, Acute\"}, {\"Row\": 111, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute complicated cystitis and pyelonephritis\"}, {\"Row\": 112, \"Column\": 1, \"Text\": \"Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary\"}, {\"Row\": 113, \"Column\": 1, \"Text\": \"tract, gastrointestinal tract, and central nervous system\"}, {\"Row\": 114, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 248,
    "fields": {
      "name": "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO",
      "term": null,
      "displaytext": "Re-evaluate Nosocomial pneumonia at 72 hours  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RE-EVALUATE NOSOCOMIAL PNEUMONIA AT 72 HOURS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"_____________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Step 1.  Evaluate the patient\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_____________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Assess for favorable clinical response indicated by improvement in one or more\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"of the following: fever, mental status, appetite, ability to eat, oxygenation,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"blood pressure, pulse, leukopenia.  If the patient has improved, continue to\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"step 2.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"If the patient has not improved, consider the following\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"1. The patient has pneumonia with a pathogen resistant to empirical\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"antimicrobials (e.g., resistant bacteria, fungi, mycobacteria)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"2. The patient does not have bacterial pneumonia.  Consider alternative\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"diagnoses including pulmonary edema, atelectasis, pulmonary embolus, ARDS,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"pulmonary hemorrhage, underlying disease, and neoplasm.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"3. The patient has infectious disease outside the lungs.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"4. The patient has one or more complications of pneumonia (e.g., empyema, lung\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"abscess, mediastinitis, or pericarditis)\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"5. The patient has an adverse drug event\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Infectious Disease or Pulmonary consult is strongly encouraged for patients who\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"do not respond to initial therapy.  If bacterial pneumonia is still considered\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"likely, continue to step 2.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"____________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Step 2.  Evaluate microbiology results\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"____________________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Decide whether a likely pathogen has been identified from respiratory secretions\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"or blood.  The clinician must decide whether any organisms identified on smear\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"or culture of respiratory tract secretions reflect disease, colonization, or\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"contamination based on clinical and microbiological information.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"The quality of a respiratory secretion sample must be evaluated.  Sputum samples\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"with fewer than 25 polymorphonuclear leukocytes per high power field (hpf) are\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"unlikely to be from a site of bacterial infection unless the patient is\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"profoundly neutropenic.  Sputum samples with more than 10 epithelial cells/hpf\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"are likely to be contaminated with upper respiratory tract secretions.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"In cases of bacterial pneumonia, a gram stain of a high quality respiratory\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"tract secretion usually contains 3+ or 4+ of bacteria with morphology and\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"staining characteristics consistent with the pathogen.  Culture of the\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"respiratory tract secretion indicates the species and susceptibilities of the\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"bacteria seen on gram stain.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"_____________________________________________________\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Step 3.  Adjust or discontinue antimicrobial therapy\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"_____________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Decide whether to continue, modify, or discontinue antimicrobials.  If an\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"organism likely to be a respiratory pathogen is isolated from a patient thought\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"to have bacterial pneumonia, adjust therapy if necessary to treat this pathogen.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"If the patient does not have convincing evidence for bacterial pneumonia and/or\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"a likely pathogen has not been isolated from respiratory secretions then stop\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"antimicrobials for pneumonia.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290: 2588\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Luna CM  Crit Care Med 2003, 31: 676\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 249,
    "fields": {
      "name": "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER",
      "term": null,
      "displaytext": "Reactivation of primary infection (Zoster or \"Shingles\")  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO q8h ($) [R]\", \"Text\": \"Valacyclovir 1000 mg PO q8h for 7 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PREDNISONE TAPER HERPES ZOSTER TX\", \"Text\": \"Prednisone 60 mg daily for 7 days then 30 mg daily for 7 days, then 15 mg\", \"Mnemonic\": \"6\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO q8h ($) [R]\", \"Text\": \"Valacyclovir 1000 mg PO q8h for 7 days ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 10 mg/kg IV q8h ($$) [R,DI]\", \"Text\": \"Acyclovir 10 mg/kg IV q8h for 7-14 days ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 7.5 mg/kg iv q8h\", \"Text\": \"Acyclovir 7.5 mg/kg IV q8h for 7-14 days($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"REACTIVATION OF PRIMARY INFECTION (ZOSTER OR SHINGLES)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Zoster represents reactivation of varicella-zoster virus. After primary\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infection, virus remains latent in the sensory dorsal root ganglia.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Reactivation syndrome is characterized by painful, unilateral, vesicular,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"dermatomal rash.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Vaccinate all adults greater than or equal to 50 years of age with the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"recombinant zoster vaccine regardless of past episode or receipt of the live\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"zoster vaccine.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Give recombinant zoster vaccine x2, 2nd dose 2-6 months after the first\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment in persons <50 years\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment is not beneficial, none is recommended.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment in persons >=50 years\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment with antivirals can shorten duration of pain and rash in patients over\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"50 years old. Treatment must be started within 72 hours of onset.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"There is evidence that addition of corticosteroids to antiviral\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"therapy decreases pain and duration of rash and improves quality of life\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"modestly during the acute shingles episode. Corticosteroids do not decrease the\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"incidence of post-herpetic neuralgia. Some authorities recommend addition of\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"corticosteroid therapy to antiviral therapy for patients over age 50 years.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Corticosteroids are not recommended for patients at greater risk for steroid\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"toxicities (e.g., insulin-dependent diabetes mellitus, hypertension, peptic\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"ulcer disease) or for immunocompromised patients.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Optional Recommendation:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"daily for 7 days. ($)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Immunocompromised patients at increased risk for complications of VZV disease\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"include: patients with malignancy, current immunosuppressive therapy, or HIV\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"infection. Treatment with antivirals shortens duration of symptoms and reduces\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"incidence of complications. In immunocompromised patients, treatment is\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"recommended to be started at any point during an active infection.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Treatment for severe disease or progression from mild to moderate disease in\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"patients <=65 years\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Treatment for severe disease or progression from mild to moderate disease in\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"patients >65 years\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Kim et al. Annals Intern Med. 2018, 168(3):210-220\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Sanford keyword: Varicella-Zoster Virus\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 250,
    "fields": {
      "name": "ORZID2 GMENU ABX RECALCITRANT ACNE AND ROSACEA",
      "term": null,
      "displaytext": "Relcalcitrant Acne and Rosacea ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500 mg PO BID ($) [R] for 12 weeks\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks\", \"Text\": \"Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg three times weekly ($) [O] for 12 weeks\", \"Text\": \"Azithromycin 500 mg three times weekly ($) [O] for 12 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 50 mg PO BID ($) [DI]\", \"Text\": \"Doxycycline 50 mg PO BID ($) [DI] prolonged therapy\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DERMATOLOGY SERVICE ORDER MENU FOR RECALCITRANT ACNE AND ROSACEA\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Recalcitrant Acne and Rosacea Treatment:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Refractory Severe Rosacea Treatment:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"**For dermatology use only, requires dermatology consult prior to treatment**\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 251,
    "fields": {
      "name": "ORZID2 GMENU ABX RECOMMENDED IMMUNIZATIONS",
      "term": "CDC Recommended Adult Immunizations",
      "displaytext": "CDC Recommended Adult Immunizations  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3030, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"[Click Here] for vaccination history including link to Joint Legacy Viewer\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"[Click Here] for link to PDF of CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 129, \"DisplayText\": \"TEsting\", \"Text\": \"COVID-19 (Comirnaty, Spikevax, Janssen)\", \"Mnemonic\": \"8\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Flu (seasonal influenza)\", \"Mnemonic\": \"10\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Functional or Anatomical Asplenia\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RECOMMENDED IMMUNIZATION SCHEDULES AND INPATIENT VACCINE ORDERS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patient Vaccine History:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"(See Outpatient CDSS for complete list of vaccinations with clinic orders.)\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Inpatient Vaccine Information and Orders\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 252,
    "fields": {
      "name": "ORZID2 GMENU ABX REF JOURN (A-C)",
      "term": null,
      "displaytext": "Journal References (Author Lastname: A-C)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Anonymous.  Antibiotic prophylaxis for urological patients with total joint\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"replacement.  Advisory statement, American Urological Association And\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"American Academy Of Orthopaedic Surgeons.  J Urol 2003, 169: 1796\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Anonymous.  Antifungal drugs.  Med Letter Treatment Guidelines 2005, 3: 7\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Anonymous.  Antimicrobial prophylaxis in surgery.  Med Lett 2001, 43: 92\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Anonymous.  ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Am J Health-Syst Pharm 1999, 56: 1839\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Anonymous.  Choice of antibacterial drugs.  Med Letter Treatment Guidelines\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"2004, 2: 13\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Anonymous.  Guidelines for the management of adults with hospital-acquired,\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"ventilator-associated, and healthcare-associated pneumonia.  Am J Respir\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Crit Care Med 2005, 171: 388\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Anonymous.  Prevention of wound infection and sepsis in surgical patients.  Med\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Lett 2001, 43: 92\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Baddour et al. Infective endocarditis: diagnosis, antimicrobial therapy, and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"management of complications.  AHA scientific statement.  Circulation 2005,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"111: e394-e433.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Baddour LM, et al.  Nonvalvular cardiovascular device-related infections.  AHA\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Scientific Statement.  Circulation 2003, 108: 2015-31.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Bartlett JG.  Antibiotic-associated diarrhea.  NEJM 2002, 346:334\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Baum J.  Infections of the eye.  Clin Infect Dis 1995, 21: 479\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Beutner KR, et al.  Valacyclovir compared with acyclovir for improved therapy\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"for herpes zoster in immunocompetent adults.  Antimicrob Ag Chemother 1995,\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"39:1546.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Bisno AL, et al.  Practice guidelines for the diagnosis and management of group\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"A streptococcal pharyngitis.  Clin Infect Dis 2002, 35: 113\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Boivin G, et al.  Predicting influenza infections during epidemics with use of a\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"clinical case definition. Clin Infect Dis 2000, 31: 1166.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Bratzler, DW, et al.  Antimicrobial prophylaxis for surgery: an advisory\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"statement from the national surgical infection prevention project.  Clin\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Infect Dis 2004, 38: 1706\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Byl B, et al.  Antibiotic prophylaxis for infectious complications after\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"therapeutic endoscopic retrograde cholangiopancreatography: a randomized,\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"double-blind, placebo-controlled study.  Clin Infect Dis 1995, 20: 1236\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Calderone RR, et al.  Overview and classification of spinal infections.  Ortho\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Clin N Amer 1996, 27: 1\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Casburn-Jones AC, et al.  Management of infectious diarrhea.  Gut 2004, 53:296-\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"305\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Center for Disease Control.  MMWR 2002, 51: 73-6\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Center for Disease Control and Prevention. Sexually transmitted diseases\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002, 51(No. RR-6):1\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Chastre J et al.  Comparison of 8 vs 15 days of antibiotic therapy for\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"ventilator-associated pneumonia in adults.  JAMA 2003, 290: 2588\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"prophylactic administration of antibiotics and the risk of surgical-wound\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"infection. New England Journal of Medicine. 1992,326(5):281-286\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Cohen JI, et al.  Recent advances in varicella-zoster infection.  Ann Intern Med\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"1999,130:922.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Couch RB.  Prevention and treatment of influenza.  N Engl J Med 2000, 343: 1778.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Cox NJ, Subbaro K.Influenza.  Lancet 354:1277, 1999.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Craven DE et al.  Healthcare-associated pneumonia in adults: management\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"principles to improve outcomes. Infect Dis Clin N Am 2004, 18:939\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Cunha BA.  Osteomyelitis in elderly patients.  Clin Infect Dis 2002, 35: 287\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CDSS Journal References (Author Lastname: A-C)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 253,
    "fields": {
      "name": "ORZID2 GMENU ABX REF JOURN (D-J)",
      "term": null,
      "displaytext": "Journal References (Author Lastname: D-J)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Delzell JE et al  Urinary tract infections during pregnancy.  Am Fam Physician\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"2000, 61: 713\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Dennesen PJ et al.  Resolution of infectious parameters after antimicrobial\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"therapy in patients with ventilator-associated pneumonia.  Am J Respir Crit\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Care Med 2001, 163: 1371\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Dryden MS, et al.  Empirical treatment of severe community-acquired diarrhea\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with ciprofloxacin.  Clin Infect Dis 1996, 22: 1019\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Dupont HL, et al.  Persistent diarrhea in travelers.  Clin Infect Dis 1996,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"22:124\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Dupont HL, et al.  Rifaximin versus ciprofloxacin for the treatment of\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"traveler's diarrhea.  Clin Infect Dis 2001, 33: 1807\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Dworkin RH.  Prevention of postherpetic neuralgia.  Lancet 1999, 353:1636.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Frazee LA, et al.  Long-term prophylaxis of spontaneous bacterial peritonitis in\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"patients with cirrhosis.  Ann Pharmacother 2005, 39: 908\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Gerding D, et al.  Clostridium-difficile associated diarrhea and colitis.  Inf\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Cont Hosp Epi 1995, 16:459\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Gorecki P, Schein M, Rucinski JC, Wise L. Antibiotic administration in patients\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"undergoing common surgical procedures in a community teaching hospital: the\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"chaos continues. World Journal of Surgery. 1999,23(5):429-432, discussion\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"433.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Gould IM. A review of the role of antimicrobial policies in the control of\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"antibiotic resistance. Journal of Antimicrobial Chemotherapy. 1999,43:459-\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"465.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Guerrant RL, et al.  Practice guidelines for the management of infectious\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"diarrhea.  Clin Infect Dis 2001, 32: 331\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Hanssen AD, Osmon DR. The use of prophylactic antimicrobial agents during and\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"after hip arthroplasty. Clinical Orthopaedics & Related Research.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1999(369):124-138.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Harris A, et al.  Meta-analysis of antibiotic prophylaxis in endoscopic\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"retrograde cholangiopancreatography (ERCP).  Endoscopy 1999, 31: 718\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Hewlett EL, et al.  Pertussis - not just for kids.  NEJM 2005, 352: 1215\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Hooton et al.  Acute uncomplicated cystitis in an era of increasing antibiotic\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"resistance: a proposed approach to empiric therapy.  Clin Infect Dis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"2004:39:75\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Hughes WT, et al.  2002 guidelines for the use of antimicrobial agents in\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"neutropenic patients with cancer.  Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Interagency Task Force on Antimicrobial Resistance. A public health action plan\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"to combat antimicrobial resistance.  Part I:  Domestic issues. Centers for\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Disease Control and Prevention, Atlanta, Georgia. 2000.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Jaeckel et al.  Treatment of acute hepatitis C with interferon alfa-2b.  NEJM\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"2001, 345: 1452.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Jensen L et al.  Oral antivirals for the acute treatment of recurrent herpes\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"labialis.  Ann Pharmacother 2004, 38:705.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Johnson RT.  Acute encephalitis. Clin Infect Dis 1996, 23:219.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Joshi N, et al.  Infections in patients with diabetes mellitus.  New Eng J Med\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"1999, 341: 1906.\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CDSS Journal References (Author Lastname: D-J)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 254,
    "fields": {
      "name": "ORZID2 GMENU ABX REF JOURN (K-N)",
      "term": null,
      "displaytext": "Journal References (Author Lastname: K-N)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Lew DP, et al.  Osteomyelitis.  Lancet 2004, 364: 369\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Lipsky BA et al.  Diagnosis and treatment of diabetic foot infections.  Clin\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infect Dis 2004, 39: 885\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Little P et al.  Information leaflet and antibiotic prescribing strategies for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"acute lower respiratory tract infection.  JAMA 2005, 293: 3029\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Ljungman P, et al.  Treatment of interstitial pneumonitis due to cytomegalovirus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with ganciclovir and intravenous immune globulin: experience of European\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"bone marrow donor transplant group.  Clin Infect Dis 1992 14:831-5.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Luna CM, et al.  Resolution of ventilator-associated pneumonia: prospective\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"evaluation of the clinical pulmonary infection score as an early clinical\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"predictor of outcome.  Crit Care Med 2003, 31: 676\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Madigosky WS.  Does acyclovir help herpes simplex virus cold sores if treatment\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"is delayed?  J Fam Prac 2004, 53: 923.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Magnus G.  Perioperative antibiotic prophylaxis in urology.  Curr Opin Urol\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"2001, 11: 81\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Maki DG, Schuna AA. A study of antimicrobial misuse in a university hospital.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"American Journal of the Medical Sciences. 1978,275:271-282.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell LA, Bartlett JG, Dowell SF, et al, Update of practice guidelines for the\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"management of community-acquired pneumonia in immunocompetent adults., Clin\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Infect Dis 2003,37:1405\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mangram AJ, et al.  Guideline for Prevention of Surgical Site Infection, Infect\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Control Hosp Epidemiol 1999, 20: 247\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"of Surgical Site Infection, 1999. Infection Control and Hospital\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Epidemiology. 1999,20(4):250-278.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mathisen GE, et al.  Brain abscess.  Clin Infect Dis 1997, 25: 763.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"antimicrobial prophylaxis for major surgery:  a systematic review.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Australia & New Zealand Journal of Surgery. 1998,68:388-396.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"McGowan JE, Jr. Do intensive hospital antibiotic control programs prevent the\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"spread of antibiotic resistance? Infection Control & Hospital Epidemiology.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"1994,7:478-483.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Merrill et al Treating postoperative mediastinitis.  Ann Thorac Surg 2004, 78:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"608-12.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Morris A, Kellner JD, Low DE. The superbugs: evolution, dissemination and\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"fitness. [Review] 70. Current Opinion in Microbiology. 1998,1(5):524-529.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mulhern JG, et al.  Trough serum vancomycin levels predict the relapse of gram-\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"positive peritonitis in peritoneal dialysis patients.  Am J Kidney Dis\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"1995, 25: 611\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Murphy TF, et al.  The role of bacteria in exacerbations of COPD.  Chest 2000,\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"118:204\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Naber et al.Chronic prostatitis - an infectious disease?  JAC 2000, 46:157\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Nathens AB et al.  Management of the critically ill patient with severe acute\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"pancreatitis.  Crit Care Med 2004, 32: 2524-2536\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Nichols RL. Preventing surgical site infections: a surgeon's perspective.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Emerging Infectious Diseases. 2001,7(2):220-224.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Nicolle et al IDSA guidelines for the diagnosis and treatment of asymptomatic\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"bacteriuria in adults.  Clin Infect Dis 2005, 40: 643\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Novella M, et al.  Continuous versus inpatient prophylaxis of the first episode\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"of spontaneous bacterial peritonitis with norfloxacin.  Hepatol 1997, 25:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"532\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CDSS Journal References (Author Lastname: K-N)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 255,
    "fields": {
      "name": "ORZID2 GMENU ABX REF JOURN (P-R)",
      "term": null,
      "displaytext": "Journal References (Author Lastname: P-R)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Pappas PG, et al.  Guidelines for treatment of candidiasis.  Clin Infect Dis\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"2004, 38: 161\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Parish LC et al.  Controversies about the decubitus ulcer.  Dermatol Clin 2004,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"22: 87.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Parsi MA, et al.  Spontaneous bacterial peritonitis: recent data on incidence\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and treatment.  Clev Clin J Med 2004, 71: 569\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Payne TH. Computer decision support systems. Chest. 2000,118:47S-52S.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Peterson LR.  Penicillins for treatment of pneumococcal pneumonia: does in vitro\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"resistance really matter?  Clin Infect Dise 2006, 42: 224\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Pharmacy Benefits Management-Medical Advisory Panel. The Pharmacologic\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Management of Helicobacter pylori in Peptic Ulcer Disease and Dyspepsia.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"VHA PBM-SHG Publication No. 98-0009.  Hines, IL: Pharmacy Benefits\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Management Strategic Health Group, Veterans Health Administration,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Department of Veterans Affairs. February 1998.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Piraino B, et al.  Peritoneal dialysis-related infections recommendations: 2005\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"update.  Perit Dial Int 2005, 25: 107.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Ray S, et al.  Neuroretinitis.  Int Ophth Clin 2001, 41: 83.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology.  2nd ed.  London, UK: Mosby\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"International Limited 2001.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Roig J, et al.  Legionnaire's disease: a rational approach to therapy.  J\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Antimicrob Chemother 2003, 51: 1119-29\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Roitt I, Brostoff J, Male D, eds.  Immunology.  5th ed.  London, UK: Mosby\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"International Limited 1998.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Rolston KVI.  The infectious diseases society of America 2002 guidelines for the\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"use of antimicrobial agents in neutropenic patients with cancer and\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"neutropenia: salient features and comments.  Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Ronald A The etiology of urinary tract infection: traditional and emerging\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"pathogens.  Dis Mon 2003, 49: 71\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Runyon BA, et al.  Short course versus long course antibiotic treatment of\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"spontaneous bacterial peritonitis.  Gastroenterol 1991, 100: 1737\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CDSS Journal References (Author Lastname: P-R)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 256,
    "fields": {
      "name": "ORZID2 GMENU ABX REF JOURN (S-V)",
      "term": null,
      "displaytext": "Journal References (Author Lastname: S-V)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Saag MS, et al.  Practice guidelines for the management of cryptococcal disease.\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Clin Infect Dis 2000, 30: 710\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Sapico FL.  Microbiology and antimicrobial therapy of spinal infections.  Ortho\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Clin N Amer 1996, 27:9\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Scheid DC, et al.  Acute bacterial rhinosinusitis in adults.  Am Fam Phys 2004,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"70: 1697\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Scher KS. Studies on the duration of antibiotic administration for surgical\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"prophylaxis. The American Surgeon. 1997,63:59-63.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Schwartz MN.  Cellulitis.  New Eng J Med 2004, 350: 904\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"America and Infectious Diseases Society of American Joint Committee on the\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"prevention of antimicrobial resistance:  guidelines for the prevention of\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"antimicrobial resistance in hospitals. Infection Control & Hospital\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Epidemiology. 1997,18:275-291.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Singh N et al.  Short-course empiric antibiotic therapy for patients with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"pulmonary infiltrates in the intensive care unit.  Am J Resp Crit Care Med\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"2000, 162: 505\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sipsas NV, et al.  Perspectives for the management of febrile neutropenic\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"patients with cancer in the 21st century.  Cancer 2005, 103: 1103.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Snow V, et al.Principles of appropriate antibiotic use for acute sinusitis in\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"adults. Ann Intern Med 2001, 1234: 495\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Snow V, et al.  Principles of appropriate antibiotic use for acute pharyngitis\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"for adults.  Ann Intern Med 2001, 134: 506\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Soares-Weiser K, et al.  Antibiotic prophylaxis for cirrhotic patients with\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"gastrointestinal bleeding.  Cochrane Database of Systematic Reviews 3, 2005\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Solomkin JS, et al.  Guidelines for the selection of anti-infective agents for\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"complicated intra-abdominal infections.  Clin Infect Dis 2003, 37: 997\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"review of randomized controlled trials. British Journal of Surgery.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"1998,85(9):1232-1241.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Stevens DL, et al.  Practice guidelines for the diagnosis and management of skin\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"and soft-tissue infections.  Clin Infect Dis 2005, 41: 1373.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Strader DB, et al.  Diagnosis, management, and treatment of hepatitis C.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Hepatology 2004, 39:1147-71.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Stulberg DL, et al.  Common bacterial skin infections.  Am Fam Phys 2002, 66:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"119\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Such J et al.  Spontaneous bacterial peritonitis.  Clin Infect Dis 1998, 27: 669\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Tay BK et al.  Spinal infections.  J Amer Acad Ortho Surg 2002, 10: 188\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Thielman, NM.  Acute infectious diarrhea.  NEJM 2004, 350: 38\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Tunkel et al.  Practice guidelines for the management of bacterial meningitis.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Clin Infect Dis 2004, 39: 1267-84.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Van der Valk P et al.  Clinical predictors of bacterial involvement in\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"exacerbations of chronic obstructive pulmonary disease.  CID 2004, 39: 980\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Vincent MT, et al.  Pharyngitis.  Am Fam Phys 2004, 69: 1465\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CDSS Journal References (Author Lastname: S-V)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 257,
    "fields": {
      "name": "ORZID2 GMENU ABX REF JOURN (W-Z)",
      "term": null,
      "displaytext": "Journal References (Author Lastname: W-Z)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Weinstein L, et al.  Gas gangrene.  New Eng J Med 1973, 289: 1129\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Westphal JF.  Biliary tract infections.  Drugs 1999, 57: 81-91.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Wheat J, et al.  Practice guidelines for the management of patients with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Histoplasmosis.  Clin Infect Dis 2000, 30: 688\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Whitely RJ, et al.  Herpes simplex virus infections.  Lancet 2001, 357: 1513.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Whitely RJ, et al.  Herpes zoster: risk categories for persistent pain.  J\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Infect Dis 1999,179:9.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Wald A.  New therapies and prevention strategies for genital herpes.  Clin\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Infect Dis 1999, 28(Suppl 1):S4.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Wallace MR, et al.  Treatment of adult varicella with acyclovir.  Ann Int Med\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"1992, 117:358.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Warren et al.  Guidelines for antimicrobial treatment of uncomplicated acute\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"bacterial cystitis and acute pyelonephritis in women.  Clin Infect Dis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"1999, 29:745\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Woods RK, et al.  Current guidelines for antibiotic prophylaxis of surgical\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"wounds.  Am Fam Phys 1998, 57:2731\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Wormser GP, et al.  Duration of antibiotic therapy for early Lyme disease.  Ann\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Intern Med 2003, 138: 697.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Wormser GP, et al.  Practice guidelines for the treatment of Lyme disease.  Clin\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Infect Dis 2000, 31 (Supp 1): S1\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Zimmerli W, et al.  Prosthetic-joint infections.  New Eng J Med 2004, 351:1645\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CDSS Journal References (Author Lastname: W-Z)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 258,
    "fields": {
      "name": "ORZID2 GMENU ABX REFERENCES",
      "term": null,
      "displaytext": "References",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Item\": 259, \"DisplayText\": \"Book References\", \"Text\": \"Book references\", \"Mnemonic\": \"02\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 261, \"DisplayText\": \"Website References\", \"Text\": \"Website references\", \"Mnemonic\": \"04\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 260, \"DisplayText\": \"Journal References\", \"Text\": \"Journal references\", \"Mnemonic\": \"06\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 259,
    "fields": {
      "name": "ORZID2 GMENU ABX REFERENCES BOOK",
      "term": null,
      "displaytext": "Book References ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"CDSS Book References (common to most CDSS guidelines)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford Guide to\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Antimicrobial Therapy. 35th ed. Hyde Park, VT: Antimicrobial Therapy Inc,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"2005.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison's Principles of Internal\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Medicine. 16th ed. Mcgraw-Hill, 2005.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Diseases. 6th ed. Philadelphia, PA: Churchill-Livingston, 2005.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Johns Hopkins Point of Care Information Technology (POC-IT): ABX Guide.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"www.hopkins-abxguide.org\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 260,
    "fields": {
      "name": "ORZID2 GMENU ABX REFERENCES JOURNAL",
      "term": null,
      "displaytext": "Journal References ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"CDSS Journal References\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": 252, \"DisplayText\": \"Journal References (Author Lastname: A-C)\", \"Text\": \"Go to CDSS Journal References (Author Lastname: A-C)\", \"Mnemonic\": \"02\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 253, \"DisplayText\": \"Journal References (Author Lastname: D-J)\", \"Text\": \"Go to CDSS Journal References (Author Lastname: D-J)\", \"Mnemonic\": \"04\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 254, \"DisplayText\": \"Journal References (Author Lastname: K-N)\", \"Text\": \"Go to CDSS Journal References (Author Lastname: K-N)\", \"Mnemonic\": \"06\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 255, \"DisplayText\": \"Journal References (Author Lastname: P-R)\", \"Text\": \"Go to CDSS Journal References (Author Lastname: P-R)\", \"Mnemonic\": \"08\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 256, \"DisplayText\": \"Journal References (Author Lastname: S-V)\", \"Text\": \"Go to CDSS Journal References (Author Lastname: S-V)\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 257, \"DisplayText\": \"Journal References (Author Lastname: W-Z)\", \"Text\": \"Go to CDSS Journal References (Author Lastname: W-Z)\", \"Mnemonic\": \"12\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 261,
    "fields": {
      "name": "ORZID2 GMENU ABX REFERENCES WEBSITE",
      "term": null,
      "displaytext": "Website References ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 5, \"Column\": 1, \"Text\": \"Up-to-date (view up-to-date web site)www.uptodate.com\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CDSS Website References (common to most CDSS guidelines)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 262,
    "fields": {
      "name": "ORZID2 GMENU ABX REMDESIVER FOR TREATMENT OF COVID-19",
      "term": null,
      "displaytext": "Remdesivir for treatment of COVID-19 ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Select here for help, legend, consults, alternative antimicrobials and more (Ip)\", \"Mnemonic\": \"2\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 4 days\", \"Text\": \"Remdesivir 200mg IV once on day 1, then 100mg IV daily for 4 additional days\", \"Mnemonic\": \"12\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Note: Consult Infectious Disease for approval to extend therapy beyond 5 days\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"1. Requirement: PCR-confirmed COVID-19\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"(maximum 10 days total therapy)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Remdesivir is FDA approved for treatment of COVID-19 in hospitalized patients:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Monitoring required for Remdesivir:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"***If above requirements are met, place order for labs and Remdesivir***\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"1. Daily laboratory monitoring includes:\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"See below for full prescribing information including WARNINGS and PRECAUTIONS\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Relative contraindications:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"2. Consider discontinuing drug if ALT levels increase to greater than 10 times\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"upper limit of normal\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"3. Discontinue drug if ALT elevation is accompanied by signs or symptoms of\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"liver inflammation\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1. Hepatic impairment (pharmacokinetics and need for dose adjustment unclear)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"3. Pregnancy (maternal and fetal risks unknown)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Note: Consult Infectious Disease for COVID-19 negative patients, but\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"clinically very consistent with COVID-19\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Use not recommended unless potential benefit outweighs potential risk.\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3031, \"DisplayText\": \"Remdesivir PI\", \"Text\": \"[Link] Remdesivir Package Insert (FDA approved Oct 2020)\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Comprehensive Metabolic Profile, CBC with Diff, and INR\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Note: Discuss with Infectious Disease patients with these contraindications:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"2. Renal impairment: not recommended in patients with eGFR less than 30ml/min\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"-Remdesivir can shorten COVID symptom duration but does not affect mortality. It\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"appears most effective for patients needing supplemental oxygen but not\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"receiving mechanical ventilation. It has little benefit for patients not\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"requiring oxygen.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"considering an extension of therapy beyond 5 days.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Please Note:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"REMDESIVIR COVID-19 REGIMEN\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"-Remdesivir may be discontinued early in patients who are minimally symptomatic\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"and ready for discharge.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"-The default duration of therapy is 5 days and DOES NOT require Infectious\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Disease approval, extending therapy is of minimal benefit. Contact ID if\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Note: May be given to patients on dialysis at recommended dose.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Monitor Labs Daily: Comprehensive Metabolic Profile, CBC with Diff, and INR\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Place medication order:\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Remdesivir Labs\", \"Text\": \"[Click here] Place lab orders for Remdesivir daily x 5 days\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 263,
    "fields": {
      "name": "ORZID2 GMENU ABX ROSACEA",
      "term": null,
      "displaytext": "Rosacea",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% cream topically q24h ($) [DI]\", \"Text\": \"Metronidazole 0.75% cream topically q24h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 250, \"DisplayText\": \"Relcalcitrant Acne and Rosacea\", \"Text\": \"Recalcitrant Rosacea\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ROSACEA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Rosacea is an inflammatory skin condition resulting in erythema and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"telangiectasia of nose, cheeks, eyelids, and forehead. It typically occurs in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"mid-life and the etiology is unknown. Erythematous rosacea is the early stage of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"the disease and usually manifests with flushing reactions and persistently\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"erythematous skin. Late-stage disease is known as papulopustular rosace.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Symptoms include papular, pustular, cysts and nodules. Severe disease results in\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"tissue atrophy and rhinophyma (bulbus nose).\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"The goal of treatment is control of symptoms, not cure. General treatment\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"measures include avoiding triggers (e.g. spicy food, alcohol), skin care (e.g.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"moisturizing, gentle cleansing, avoiding topical irritants) and using sun\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"screen. Medical treatment includes topical agents as first line therapy and oral\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"treatment for refractory disease.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Papulopustular rosacea\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Acne Rosacea\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-to-Date Article: Rosacea: Pathogenesis, clinical features, and diagnosis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-Date Article: Management of rosacea\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"van Zuuren EJ et al., N Engl J Med, 2017, 377(18)1754-1764\"}, {\"Row\": 39, \"Column\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 264,
    "fields": {
      "name": "ORZID2 GMENU ABX RSV",
      "term": null,
      "displaytext": "RSV ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RESPIRATORY SYNCYTIAL VIRUS (RSV)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"No specific antimicrobial therapy is indicated. Contact Infectious Diseases for\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"more information on management of this disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Sanford keyword: Respiratory Syncytial Virus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 265,
    "fields": {
      "name": "ORZID2 GMENU ABX SALMONELLA SPECIES",
      "term": null,
      "displaytext": "Diarrhea with Salmonella ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 153, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Link to Enteric Fever Menu\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h for 7 days ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h for 7 days ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 14 days ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h for 14 days ($) [M]\", \"Mnemonic\": \"14\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h for 14 days ($) [M]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH SALMONELLA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For systemic febrile illness or typhoidal Salmonella, refer to Enteric Fever\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Menu:\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment is not recommended for mild or moderately severe disease in otherwise\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"healthy individuals <50 years old, because the disease is self-limiting and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials can prolong the carrier state and increase the risk of relapse.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"By contrast, treatment should be considered for severe disease, and if the\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"patient is > 50 years old, is immunocompromised, or has another debilitating\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"underlying disease.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Antimicrobial treatment of immunocompetent patients\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"If infection acquired in Asia or patient is intolerant to fluoroquinolones\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"For patients who are hospitalized or unable to take oral medications\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Antimicrobial treatment of immunocompromised patients\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"If infection acquired in Asia or patient is intolerant to fluoroquinolones\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For patients who are hospitalized or unable to take oral medications\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Salmonella: Non-typhi\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date article: Nontyphoidal Salmonella: Gastrointestinal infection and\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"carriage\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 266,
    "fields": {
      "name": "ORZID2 GMENU ABX SECOND PERITONITIS",
      "term": null,
      "displaytext": "Secondary Peritonitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SECONDARY PERITONITIS, INTRAABDOMINAL ABSCESS, INTRAPERITONEAL ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Secondary peritonitis occurs after spillage of colonic flora into the peritoneum\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"due to ruptured viscus, perforated appendicitis, gastrointestinal trauma, or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"diverticulitis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Intraperitoneal or intraabdominal abscess can complicate secondary or primary\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"peritonitis. Abscess location is generally related to primary disease site.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Primary therapy: abscess drainage\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"CT or US-guided percutaneous or surgical drainage should be considered in all\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"cases for diagnostic confirmation, microbiologic evaluation, and therapy.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"After adequate drainage, 4 days of antibiotic coverage is indicated, with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"duration in part based on resolution of fever, leukocytosis, ileus severity of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"infection, and additional indicators of clinical response. Inadequately drained\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"abscess with residual fluid may require prolonged therapy with follow-up imaging\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"to ensure resolution.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Treatment of severe disease (typically necessitating ICU admission)\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"< AND > vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Step down treatment after initial intravenous antibiotic treatment in patients\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"who can tolerate oral therapy. Base selection on culture results.\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Peritonitis and Intraperitoneal Abscesses\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Peritonitis, Secondary: rupture, perforation, abscess\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sawyer et al, N Engl J Med, 2015, 372:1996-2005\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial approach to intra-abdominal infections in\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 267,
    "fields": {
      "name": "ORZID2 GMENU ABX SECOND RECUR ABX ASSOC COLITIS",
      "term": null,
      "displaytext": "ORZID2 GMENU SECOND RECURRENCE ABX ASSOC COLITIS ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin taper and pulse dosing\", \"Text\": \"Vancomycin Extended Pulse-Taper Regimen ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 286, \"DisplayText\": \"Severe disease - Ileus/Toxic megacolon\", \"Text\": \"Select for Fulminant CDI\", \"Mnemonic\": \"12\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with more than one recurrence of C. difficile infection are complex and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"difficult.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Discontinue any antibiotics if possible and avoid high-risk antibiotic if\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antibiotic therapy is still needed. Discontinue antacid therapy if possible.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Second Recurrence:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Severe/life-threatening disease (shock, ileus, megacolon)\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases consults are essential.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Treatment and\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"prevention\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg po q12h for 10 days ($$) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin Extended-Pulse Regimen ($$) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"125 mg po q12h for 7 days, then 125mg po qday for 7 days, then\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"125mg every other day for 6 weeks)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"*Infectious Disease or Gastroenterology consultation is recommended*\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Fulminant CDI:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Third or more recurrence: Consult Gastroenterology or Infectious Disease\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SECOND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 268,
    "fields": {
      "name": "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION",
      "term": null,
      "displaytext": "Sexually Transmitted Infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"14\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A diagnosis of a sexually transmitted infection can suggest sexual activity\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Sexually Transmitted Infections (STI)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"consult to MRTC clinic for further discussion and evaluation for PrEP.\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 154, \"DisplayText\": \"Epididymitis\", \"Mnemonic\": \"28\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 238, \"DisplayText\": \"Pelvic Inflammatory Disease\", \"Text\": \"Pelvic Inflammatory Disease (PID)\", \"Mnemonic\": \"32\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 105, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Cervicitis\", \"Mnemonic\": \"26\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 163, \"DisplayText\": \"Genital herpes\", \"Mnemonic\": \"30\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 293, \"DisplayText\": \"Urethritis associated with sexually transmitted diseases\", \"Text\": \"Urethritis\", \"Mnemonic\": \"34\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sexually Transmitted Infections (STIs)\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Mnemonic\": \"38\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"42\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 693, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"40\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 288, \"DisplayText\": \"Trichomonas Vaginitis\", \"Text\": \"Trichomonas Vaginitis, Urethritis and Male Sex Partners\", \"Mnemonic\": \"36\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"that could result in HIV exposure. Recommendation is for the provider to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"HIV acquisition.  If the patient is interested, the provider should place a\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Pre-exposure prophylaxis (or PrEP) is a way for people who do not have\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"HIV but who are at high risk of getting HIV to prevent HIV infection by\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"taking a pill every day. When someone is exposed to HIV through sex or\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"injection drug use, these medicines can work to keep the virus from\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"establishing a permanent infection.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"When taken daily, PrEP is highly effective for preventing HIV. Studies\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"have shown that PrEP reduces the risk of getting HIV from sex by about\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"99% when taken daily. PrEP is much less effective if not taken consistently.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"As PrEP only protects against HIV, condoms are important for the protection\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"against other STIs. Condoms are also an important prevention strategy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"if PrEP is not taken consistently.\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 106, \"DisplayText\": \"Chlamydia Urethritis\", \"Text\": \"Chlamydia\", \"Mnemonic\": \"20\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 167, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Gonorrhea\", \"Mnemonic\": \"22\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 281, \"DisplayText\": \"Syphilis\", \"Text\": \"Syphilis\", \"Mnemonic\": \"24\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 269,
    "fields": {
      "name": "ORZID2 GMENU ABX SHIGELLA SPECIES",
      "term": null,
      "displaytext": "Diarrhea with Shigella species (bacillary dysentery)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h for 3 days ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h for 5 days ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH SHIGELLA (BACILLARY DYSENTERY) OR ENTEROINVASIVE E. COLI (EIEC)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Shigellosis is generally a self-limited infection lasting 5-7 days.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Antimicrobial resistance is common and continues to rise for all recommended\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobials. Treatment should be reserved for patients who are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"immunocompromised, or who develop severe illness (e.g., requiring\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"hospitalization, invasive, or with complications) or live or work in settings\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"where there is risk of spreading infection to others (e.g., food handlers,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"daycare, nursing home).\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"For patients who are hospitalized or unable to take oral medications\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"CDC advisory: https://emergency.cdc.gov/han/han00401.asp\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Shigella\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date article: Shigella infection: Treatment and prevention in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 270,
    "fields": {
      "name": "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE",
      "term": null,
      "displaytext": "Soft tissue, muscle, bone and joint infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 333, \"DisplayText\": \"Bite wounds\", \"Text\": \"Bite wounds\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 566, \"DisplayText\": \"Septic bursitis\", \"Text\": \"Septic bursitis\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 67, \"DisplayText\": \"Abscesses:  Cutaneous abscess, Furuncle, Carbuncle, Pyomyositis\", \"Text\": \"Abscesses\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 351, \"DisplayText\": \"Cutaneous abscess\", \"Text\": \"Cutaneous abscess\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Perirectal/Anorectal Abscess\", \"Mnemonic\": \"12\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 543, \"DisplayText\": \"Pyomyositis\", \"Text\": \"Pyomyositis\", \"Mnemonic\": \"14\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 353, \"DisplayText\": \"Decubitus ulcers\", \"Text\": \"Decubitus ulcers\", \"Mnemonic\": \"16\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 606, \"DisplayText\": \"Surgical Site Infection\", \"Text\": \"Surgical wound infections\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++SOFT TISSUE, MUSCLE, BONE AND JOINT INFECTIONS  ++\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Section reviewed Dec 2018\"}, {\"Row\": 5, \"Column\": 2, \"Item\": 384, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus\", \"Text\": \"Foot ulcer in patient with diabetes mellitus\", \"Mnemonic\": \"22\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 508, \"DisplayText\": \"Osteomyelitis\", \"Text\": \"Osteomyelitis\", \"Mnemonic\": \"24\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 630, \"DisplayText\": \"Diskitis and Vertebral Osteomyelitis\", \"Text\": \"Diskitis and vertebral osteomylitis\", \"Mnemonic\": \"26\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"28\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 565, \"DisplayText\": \"Septic arthritis (Native joint)\", \"Text\": \"Septic arthritis (Native joint)\", \"Mnemonic\": \"30\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Prosthetic joint\", \"Mnemonic\": \"32\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"Septic arthritis\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 271,
    "fields": {
      "name": "ORZID2 GMENU ABX SOTROVIMAB EUA",
      "term": null,
      "displaytext": "Sotrovimab (EUA) Orders  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Mnemonic\": \"02\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"If above requirements are met, place medication order:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"sharing personal items, clean and disinfect \\\"high touch\\\" surfaces, and\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"frequent handwashing) according to CDC guidelines.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Monitor patient during infusion and 1 hour after infusion completed.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Inclusion Criteria\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"ALL of the following criteria must be met for a patient to receive:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"3) Patient does NOT require oxygen therapy for COVID-19.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For patients on chronic oxygen therapy: patient does NOT require an\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"increase in baseline oxygen flow rate due to COVID-19.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"4) Administration will begin within 7 days of symptom onset.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to sotrovimab or components.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"The provider has communicated with the patient/caregiver regarding\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"information contained in the \\\"Fact Sheet for Patients\\\". The patient/\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"caregiver has been given the Fact sheet, informed that the drug is an\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"unapproved drug that is authorized for use under an EUA, given information\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"on alternatives and their risks and benefits, and the patient/caregiver\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"has the right to refuse or accept. (See top of page for Fact Sheet)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"7) Counseling is provided and documented in the electronic health record per EUA\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3032, \"DisplayText\": \"LINK EUA PROVIDER TO FILL OUT\", \"Text\": \"[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering\", \"Mnemonic\": \"04\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Inv-Sotrovimab 500 mg IVPB Once + Nursing Text Order\", \"Text\": \"INV-Sotrovimab 500mg IVPB ONCE\", \"Mnemonic\": \"14\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"including hospitalization or death.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"6) Patient has at least one risk factor for progression to severe disease\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"See link below for complete list:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Note: patient may be hospitalized for some other reason.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Sotrovimab (EUA)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Sotrovimab Emergency Use Authorization (EUA)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-Sotrovimab is available via FDA Emergency Use Authorization (EUA)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"for treating patients that meet specific criteria. Sotrovimab is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"not FDA approved drug.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"-Sotrovimab EUA does NOT include post-exposure prophylaxis.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sotrovimab EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Sotrovimab\", \"Mnemonic\": \"06\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sotrovimab EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Sotrovimab\", \"Mnemonic\": \"08\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sotrovimab EUA Provider Fact Sheet\", \"Text\": \"[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors\", \"Mnemonic\": \"12\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Exclusion Criteria\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 272,
    "fields": {
      "name": "ORZID2 GMENU ABX SPLENECTOMY CHART",
      "term": null,
      "displaytext": "Splenectomy Vaccines  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"02\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Functional or Anatomical Asplenia\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meningococcal B vaccine one dose\", \"Mnemonic\": \"08\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meningococcal Oligosaccharide conj (MenACWY) one dose\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Repeat every 5 years:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pneumococcal 20-valent conjugate vaccine one dose\", \"Mnemonic\": \"06\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"(Note: 2 dose series- order 2nd dose in 4 weeks in Outpatient CDSS)\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"(Note: 2 dose series- order 2nd dose in 8 weeks in Outpatient CDSS)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Note: Please select EACH of the recommended 4 vaccines to place orders\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Revaccination (booster): (Order in Outpatient CDSS)\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Meningococcal Oligosaccharide conj (MenACWY) one dose\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Repeat 1 year after completing the primary series and every 2 to 3 years\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"thereafter:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Meningococcal B vaccine one dose\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Haemophilus B vaccine one dose\", \"Mnemonic\": \"04\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 273,
    "fields": {
      "name": "ORZID2 GMENU ABX SPLENECTOMY DAILY ANTIBIOTICS",
      "term": null,
      "displaytext": "Asplenic Empiric Antibiotics",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500MG PO bid for daily prophylaxis asplenic patient ($) [R]\", \"Text\": \"Amoxicillin 500MG PO bid for daily prophylaxis asplenic patient ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 250MG PO bid for daily prophylaxis asplenic patient ($) [R]\", \"Text\": \"Cephalexin 250MG PO bid for daily prophylaxis asplenic patient ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 250MG PO qday for daily prophylaxis for asplenic patients ($) [DI]\", \"Text\": \"Azithromycin 250MG PO qday for daily prophylaxis for asplenic patients ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Daily Antibiotic Prophylaxis for Asplenia\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"The need for daily antibiotic prophylaxis and its duration is typically\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"determined individually based on patient age, immune status, history of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infection, potential for adverse drug reactions and other factors.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consider Prophylaxis:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"1) Approximately 1 year prophylaxis for all patients following splenectomy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"2) Lifelong prophylaxis for patients with history of sepsis or other severe\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infections caused by encapsulated organisms.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"3) Prophylaxis for as long as the patient is immunocompromised or for life\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"for patients with concurrent immunocompromising conditions (e.g. hematologic\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"malignancy, hypogammaglobulinemia, solid-organ transplant, advanced liver\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"disease, or HIV infection).\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Daily antibiotic prophylaxis is in addition to the emergency supply.\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative for penicillin and beta lactam allergy:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-Date online\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 274,
    "fields": {
      "name": "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY",
      "term": null,
      "displaytext": "Asplenia Recommendations Vaccines Empiric Abx INPATIENT",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 204, \"DisplayText\": \"Management of an Episode of Fever in an Asplenic Patient\", \"Text\": \"Management of an Episode of Fever in an Asplenic Patient\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 272, \"DisplayText\": \"Splenectomy Vaccines\", \"Text\": \"[click here] Place Order for specific vaccines for asplenia\", \"Mnemonic\": \"8\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 273, \"DisplayText\": \"Asplenic Empiric Antibiotics\", \"Text\": \"Daily Antibiotic Prophylaxis INPATIENT\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 1031, \"DisplayText\": \"Asplenic Empiric Antibiotics\", \"Text\": \"Self-medicate Empiric Antibiotics\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Asplenia Functional or Anatomical\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Following a splenectomy there is considerably increased risk of developing\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"septicemia from invasive encapsulated organisms, namely Streptococcus pneumonia,\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Haemophilus inluenza type b and meningococcus. Key measures to prevent\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"such infections include education, vaccination, prophylactic antimicrobial\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"therapy in selected patients, and early empirical therapy for febrile\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"epsisodes. It is critically important to educate patients regarding the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"lifelong risk of postsplenectomy sepsis, the importance of vaccinations,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and the need for urgent action in response to a febrile episode.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Management of an Episode of Fever in an Asplenic Patient\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Initiation of vaccine regimen:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Ideally splenectomy vaccinations should be given 10 to 12 weeks before\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"elective splenectomy.  Where this is not possible they can be given up to\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"two weeks before or at least two weeks post-splenectomy.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Use of Antibiotic Prophylaxis for Asplenia:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Use of antibiotic prophylaxis, in addition to vaccination, further reduces\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"the risk of infection and poor outcomes.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Daily Antibiotic Prophylaxis: (in addition to emergency supply)\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Emergency Supply Empiric Abx for Fever or Other Signs of Systemic Infection:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"**OUTPATIENT ORDERS**\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"MMWR Morb Mortal Wkly Rep 2022, 71(7):229\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Clin Infect Dis 2014, 58:e44-100\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"See CDSS immunization section to order, if needed.\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 3033, \"DisplayText\": \"Vaccinations for Adults without a Spleen\", \"Text\": \"[click here] Recommendations: Vaccinations for Adults without a Spleen\", \"Mnemonic\": \"6\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-to-Date: Prevention of infection in patients with impaired splenic function\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"ROUTINE VACCINATIONS SHOULD BE UP TO DATE.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Specific Asplenia Vaccines:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 275,
    "fields": {
      "name": "ORZID2 GMENU ABX SPON BACT PERITONITIS",
      "term": null,
      "displaytext": "Acute spontaneous bacterial peritonitis (SBP) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h for 5 days ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h for 5 days ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po q24h\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q24h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO qday for prophylaxis ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po q24h\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q24h until discharge from\", \"Mnemonic\": \"20\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO qday for prophylaxis ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q24h until discharge from hospital ($) [R,DI]\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SPONTANEOUS BACTERIAL PERITONITIS (SBP)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"SBP is infection of the peritoneal cavity in the absence of apparent trauma or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"other obvious cause. SBP occurs primarily in people with end-stage liver disease\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"are isolated.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Long-term SBP prophylaxis is indicated for patients who experience a first\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"episode of SBP. Short-term SBP prophylaxis is indicated for patients with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"variceal bleeding, or for patients who have low-protein refractory ascites (<1\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with low-protein refractory ascites. Consult Gastroenterology for more\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"SBP\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Prophylaxis in a patient with a previous SBP episode\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Prophylaxis in a patient with cirrhosis and variceal hemorrhage\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treat initially with an intravenous antimicrobial then step down to an oral\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"antimicrobial when the patient can tolerate oral treatment.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treat for a total of 7 days (intravenous and oral)\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Preffered initial treatment\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Initial treatment, alternative for beta-lactam allergy\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Step down treatment\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Prophylaxis for hospitalized patients with refractory low-protein ascites\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"(less than 1 gm/dL peritoneal fluid)\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"hospital ($) [R,DI]\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Mandell chapter: Peritonitis and Intraperitoneal Abscesses\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"prophylaxis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 276,
    "fields": {
      "name": "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topically q12h ($) [M] <AND> chlorhexidine 4% liquid\", \"Text\": \"Mupirocin 2% ointment topically q12h ($) [M] <AND> chlorhexidine 4% liquid\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid\", \"Text\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STAPHYLOCOCCUS AUREUS DECOLONIZATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"From 10% to 40% of adults are colonized with Staphylococcus aureus, and the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"anterior nares is the most common site of colonization. The great majority of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"people never have disease with S. aureus, but a tiny fraction of people develop\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"clinical infections with the S. aureus that has colonized their skin or anterior\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"nares. Steps to decolonize the skin and anterior nares can transiently diminish\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"or eradicate S. aureus colonization and can prevent post-operative wound\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infection in certain high-risk circumstances. For people who have other forms\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"of recurrent S. aureus disease, not associated with an operation, results with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"decolonization have been disappointing, and decolonization is not routinely\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"recommended. Colonization typically reappears in most patients within a few\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"days or weeks after decolonization has been attempted. Clinicians occasionlly\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"wish to attempt decolonization for patients with frequent, troublesome\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"recurrences. The procedure here is one of several that have been studied, but\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"none have been particularly effective over the long run.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Consultation with Infectious Diseases is recommended.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Inpatient Decolonization Order Set:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"topically q24h nursing text order ($) [M] for 5 days\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Outpatient Decolonization Order Set:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Order if patient is being discharged within 5 days\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"topically qday ($) [M] for 5 days\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Instructions\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"* Patient must wear clean clothes after bathing to prevent recontaminat\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"* Bedding and linens must be changed/cleaned daily until the end of the\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"decolonization protocol.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Bradley S Clin Infect Dis 2007, 44: 186\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Lonneke G NEJM 2010, 362: 9\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Schweizer et al, JAMA 2015, 313.212:162-2171\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"adults: Prevention and control\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 277,
    "fields": {
      "name": "ORZID2 GMENU ABX STASIS DERMATITIS",
      "term": null,
      "displaytext": "Stasis dermatitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 68, \"Column\": 1, \"Item\": 104, \"DisplayText\": \"Cellulitis\", \"Text\": \"Bacterial Cellulitis\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STASIS DERMATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Stasis dermatitis is a common condition that is often confused with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"bacterial cellulitis. Stasis dermatitis does not benefit from antimicrobial\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"therapy. It is important to distinguish between the two. The provider\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"should be mindful of the fact that bacterial cellulitis can occur on skin\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with underlying stasis dermatitis. (See link below for bacterial cellulitis)\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Common risk factors for venous stasis include advancing age, family\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"history of venous disease, increased body mass index, smoking, a history of\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"trauma, prior venous thrombosis and pregnancy. Chronic venous disease and\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"arterial vascular disease have some common risk factors (eg, smoking,\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"obesity) and pathophysiological processes. The most common symptoms reported\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"by patients with chronic venous disease are limb discomfort (tired, heavy\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"legs), pain, and limb swelling. Swelling is often worse with prolonged\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"standing and improves with leg elevation and walking. The skin of the\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"anterior surfaces of the lower legs often has brown or blue-grey\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"hyperpigmentation.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"People with venous stasis are prone to develop stasis dermatitis which\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"is one of the most common and earliest dermatologic signs of chronic venous\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"insufficiency. Stasis dermatitis is an inflammatory process that presents as\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"an eczematous rash characterized by itching, erythema, scaling, weeping,\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"erosions, and crusting. Longstanding cases may develop lipodermatosclerosis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"a fibrosing panniculitis of the subcutaneous tissue. Lipodermatosclerosis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"typically starts with a firm area of induration at the medial ankle. As the\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"process progresses, the entire leg lower leg can become involved with\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"extension up to the mid leg in more advanced cases. The skin overlying the\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"panniculitis is typically heavily pigmented and bound down to the\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"subcutaneous tissues. Brawny edema above the fibrotic area and on the foot\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"below is seen in advanced cases. Leukocytosis and fever are common in people\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"with stasis dermatitis.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Chronic venous disease is the most common cause of leg ulcers. They\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"are usually found low on the medial ankle over a perforating vein, or along\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"the course of the great or small saphenous veins. They occur more proximally\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"if precipitated by trauma. Venous ulcers are not found on the forefoot or\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"above the level of the knee. Venous ulcers can be multiple or single, and\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"can be exquisitely tender, shallow, exudative and have a granulation base.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"The ulcer borders are usually irregular but not undermined. They can extend\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"circumferentially around the leg if left untreated.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Arterial ulcers are typically painful, and punched out or stellate. The\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"surrounding skin is red and taut. Some arterial ulcers are pale - others have\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"a black or yellow eschar. They are often associated with trauma and commonly\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"occur on the foot over pressure points. There may be other signs of arterial\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"insufficiency on the lower limb including thin atrophic or hairless skin,\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"poor pedal pulses, diminished capillary refill, or hypertrophic deformed\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"nails.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Patients with stasis or lipodermatosclerosis are prone to bouts of\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"bacterial cellulitis, usually caused by Staphylococcus aureus or encapsulated\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"streptococci. Typically, stasis dermatitis develops slowly, over a week or\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"more. It is often bilateral. The onset of bacterial cellulitis is usually\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"abrupt, typically developing over 1 or 2 days. Bacterial cellulitis often\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"starts in one area and spreads to adjacent areas. Bacterial cellulitis is\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"unilateral. Both can present with fever and leukocytosis.\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"In a patient with stasis and cellulitis and the physician is uncertain\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"about whether bacterial cellulitis is present, the physician should consider\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"a trial of bed rest, leg elevation, and if there is fluid overload, diuresis\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"If the cellulitis improves in 24-48 hours, antibacterial therapy and the\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"attendant adverse reactions can be avoided. If it is clear that bacterial\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"cellulitis has occurred, antimicrobial therapy should be given.\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Stevens et al, Clin Infect Dis, 2014, 59(2): e10-52\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Up-to-Date article: Stasis dermatitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 278,
    "fields": {
      "name": "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY",
      "term": null,
      "displaytext": "Suppurative Thrombophlebitis--Empirical Therapy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 1 GM IV Q12H CEFTRIAX 2 GM IV Q24H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"6\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg IV q24h ($)\", \"Mnemonic\": \"8\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SUPPURATIVE THROMBOPHLEBITIS - EMPIRICAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Obtain blood cultures before starting empirical antimicrobials.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Peripheral vein suppurative thrombophlebitis may require surgical intervention\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"in addition to antimicrobial therapy. The usual treatment for jugular vein\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"suppurative thrombophlebitis (Lemierre's syndrome) and vena cava suppurative\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"thrombophlebitis is prolonged antimicrobial therapy, with or without\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"radiological or thrombolytic clot removal. Consult Infectious Diseases and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Vascular Surgery for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Modify antimicrobial regimen and narrow coverage based on results of culture and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"susceptibility tests.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"A minimum of 4 to 6 weeks of antimicrobial therapy is appropriate and may be\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"abbreviated in peripheral vein infections based on patient specific factors.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Antimicrobial therapy should be continued until there is definite clinical\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"response and oral antimicrobial therapy may be used after completion of initial\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"course of intravenous therapy.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empirical treatment for peripheral vein infections and central vein infections\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"associated with a venous catheter\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"[R,O]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Empirical treatment for jugular vein infection (also known as Lemierre's) or\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"suppurative pelvic vein infection\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Consultation with Surgery and Infectious Diseases is encouraged.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"For catheter-associated infection, add vancomycin to one of the above treatment\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"regimens\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Suppurative Thrombophlebitis\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Mermel et al., Clinical Infectious Diseases 2009, 49.1-45\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Up-To-date article: Suppurative (septic) thrombophlebitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 279,
    "fields": {
      "name": "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)",
      "term": null,
      "displaytext": "Antimicrobial susceptibilities (Antibiogram)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 18, \"Column\": 1, \"Item\": 3034, \"DisplayText\": \"Mpls VAMC Antibiotic Susceptibilities\", \"Text\": \"[Click here] to go directly to the Antibiotic Susceptibilities.\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MDH antibiogram\", \"Text\": \"Please Click Here For the MDH website\", \"Mnemonic\": \"6\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sanford Guide Web Site\", \"Text\": \"Click Here for link to Sanford Guide online access\", \"Mnemonic\": \"8\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mandell Online\", \"Text\": \"Click Here for link to Principles and Practice of Infectious Diseases online\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ANTIMICROBIAL SUSCEPTIBILITIES\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Antimicrobial selection should be based on likely susceptibilities of\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"anticipated or proven pathogens. Clinicians should be aware of local, regional,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"and national susceptibility patterns. Several sources for susceptibility\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patterns are listed below.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"LOCAL\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Minneapolis VAMC Network W-Drive\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"W:\\\\LABORATORY\\\\MICROBIOL INFO FOR CLINICIANS-Lab\\\\Antibiotic Susceptibilities\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Minneapolis VAMC Microbiology Laboratory\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Call (ext. 31-2408) or visit (room BB-127) the Microbiology Laboratory\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"REGIONAL\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Minnesota Department of Health\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"NATIONAL\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"_____________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford Guide\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Gilbert DN et al: The Sanford Guide to Antimicrobial Therapy, published\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"annually by Antimicrobial Therapy, Inc., Hyde Park, VT.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell, Douglas, and Bennett Textbook\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"access\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell et al: Principles and Practice of Infectious Diseases, Churchill\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Livingstone\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobial Susceptibilities Pathway:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"[ OR ]\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"and ask for the most recent summary.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"[ OR ]\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 280,
    "fields": {
      "name": "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS",
      "term": null,
      "displaytext": "Suspected bacteremia, blood cultures not yet positive  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 474, \"DisplayText\": \"Intravascular catheter-associated infection\", \"Text\": \"Intravascular Catheter-Associated Infection\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) <AND> vancomycin 15 mg/kg IV q12h\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]\", \"Text\": \"vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SUSPECTED BACTEREMIA, BLOOD CULTURES NOT YET POSITIVE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If blood cultures are positive, return to the previous menu and make a selection\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"based on the interim results.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Choice of antimicrobials\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Select antimicrobials active against any suspected site of infection that may be\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"present. Return to main menu and refer to the source infection's page within\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the Antimicrobial CDSS.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For patients with an intravascular catheter, refer to the intravascular-\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"associated infection page\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Empirical therapy for mild to moderate infection, focal infection not found\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Empirical therapy for severe infection\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empirical therapy for immunosuppressed patients\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For patients with penicillin allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Medical Letter Treatment Guidelines 2010, 8: 94\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococci\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococci\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococci\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 281,
    "fields": {
      "name": "ORZID2 GMENU ABX SYPHILIS",
      "term": null,
      "displaytext": "Syphilis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 568, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Mnemonic\": \"4\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Syphilis AB w/reflex to RPR w/titer\", \"Text\": \"Syphilis antibody test with reflex to rapid plasma reagin (RPR)\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine Penicillin 2.4 million units IM one time dose (Cost $$$) [M]\", \"Text\": \"Benzathine Penicillin 2.4 million units IM once ($$$) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam Reaction Assessment\", \"Mnemonic\": \"12\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 14 days\", \"Mnemonic\": \"14\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine Penicillin 2.4 million units IM qweek x3 ($$$)[M]\", \"Text\": \"Benzathine Penicillin 2.4 million units IM qweek ($$$) [M] x3 doses\", \"Mnemonic\": \"16\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam Reaction Assessment\", \"Mnemonic\": \"18\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 28 days\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SYPHILIS\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Syphilis is a sexually transmitted disease caused by the spirochete Treponema\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"pallidum that can manifest as a variety of signs or symptoms. Primary syphilis\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"typically consists of painless ulcers or chancre at the site of infection with\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"regional adenopathy. Secondary syphilis often includes a skin rash (disseminated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"and/or including the palms and soles), fever, malaise, mucocutaneous lesions and\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"lymphadenopathy. Tertiary syphilis includes those with cardiovascular or\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"gummatous disease.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Latent syphilis is a period of disease when a patient does not have symptoms but\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"is found to be infected through serologic testing. Early latent syphilis refers\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"to latent syphilis acquired within the preceding year and late latent syphilis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"refers to all other cases of latent syphilis. Neurosyphilis, Ocular syphilis or\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Otosyphilis, can occur at any stage of syphilis with early manifestations (e.g.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"meningitis, stroke, vision or hearing loss) occurring within the first months to\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"years of infection and late manifestations (e.g. dementia, tabes dorsalis)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"occurring after 10-30 years.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Diagnosis\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"A presumptive diagnosis is made through use of a nontreponemal or serologic test\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"(i.e. rapid plasma reagin [RPR]) and a treponemal test (i.e. fluorescent\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"treponemal antibody absorbed [FTA-ABS]). Direct methods through darkfield\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"microscopy and direct fluorescent antibody (DFA) must be used for definitive\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"diagnosis since T. pallidum cannot be cultured.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Management of sex partners\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Persons with sexual contact with a person with primary, secondary or early\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"latent syphilis within the last 90 days should be presumptively treated even if\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"serologic test is negative.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Primary, Secondary and Early Latent Syphilis\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Secondary treatment for patients who are not pregnant\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Tertiary and Late Latent Syphilis\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Secondary treatment for patients who are not pregnant\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Neurosyphilis, Ocular syphilis or Otosyphilis\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Consult Infectious Disease for treatment\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines MMWR (2021) 70.4\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Mandell Chapter: Syphilis (Treponema pallidum)\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Sanford keyword: Syphilis\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Up-To-Date article: Syphilis: Screening and diagnostic testing\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Up-To-Date article: Syphilis: Treatment and monitoring\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases. Evaluation and management are complex.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 282,
    "fields": {
      "name": "ORZID2 GMENU ABX SYSTEM INFECTIOUS DISEASES",
      "term": null,
      "displaytext": "Systemic Infectious Diseases",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 79, \"DisplayText\": \"Approach to bacteremia\", \"Text\": \"Approach to bacteremia\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 280, \"DisplayText\": \"Suspected bacteremia, blood cultures not yet positive\", \"Text\": \"Suspected bacteremia, blood cultures not yet positive\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 461, \"DisplayText\": \"Interim report of Gram-negative cocci\", \"Text\": \"Interim report of Gram-negative cocci\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 460, \"DisplayText\": \"Interim report of Gram-negative bacilli\", \"Text\": \"Interim report of Gram-negative bacilli\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 462, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs\", \"Text\": \"Interim report of Gram-positive cocci in pairs\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 464, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and chains\", \"Text\": \"Interim report of Gram-positive cocci in pairs and chains\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 463, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs and clusters\", \"Text\": \"Interim report of Gram-positive cocci in pairs and clusters\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 465, \"DisplayText\": \"Interim report of Gram-positive rods\", \"Text\": \"Interim report of Gram-positive bacilli\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 466, \"DisplayText\": \"Interim report of yeast\", \"Text\": \"Interim report of yeast\", \"Mnemonic\": \"20\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 326, \"DisplayText\": \"Bacteremia associated with Staphylococcus aureus\", \"Text\": \"Bacteremia associated with Staphylococcus aureus\", \"Mnemonic\": \"22\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 324, \"DisplayText\": \"Bacteremia associated with Coagulase-negative Staphylococci (CNS)\", \"Text\": \"Bacteremia associated with Coagulase-negative Staphylococci (CNS)\", \"Mnemonic\": \"24\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 327, \"DisplayText\": \"Bacteremia associated with Staphylococcus lugdunensis\", \"Text\": \"Bacteremia associated with Staphylococcus lugdunensis\", \"Mnemonic\": \"26\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 325, \"DisplayText\": \"Bacteremia associated with Listeria monocytogenes\", \"Text\": \"Bacteremia associated with Listeria monocytogenes\", \"Mnemonic\": \"28\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 323, \"DisplayText\": \"Bacteremia associated with Candida spp.\", \"Text\": \"Fungemia associated with Candida spp.\", \"Mnemonic\": \"30\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  SYSTEMIC INFECTIOUS DISEASES  ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bacteremia\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Bacteremia, preliminary results\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Bacteremia, final results (specific pathogens)\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Last reviewed July 2017\", \"Header\": 1}, {\"Row\": 10, \"Column\": 2, \"Item\": 474, \"DisplayText\": \"Intravascular catheter-associated infection\", \"Text\": \"Intravascular catheter-associated infection\", \"Mnemonic\": \"34\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Sepsis and septic shock\", \"Mnemonic\": \"36\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 478, \"DisplayText\": \"Leukocytosis\", \"Text\": \"Leukocytosis\", \"Mnemonic\": \"38\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 380, \"DisplayText\": \"Fever of unknown origin\", \"Text\": \"Fever of unknown origin\", \"Mnemonic\": \"40\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 453, \"DisplayText\": \"Neutropenic fever\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"42\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"44\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"Other systemic diseases\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 283,
    "fields": {
      "name": "ORZID2 GMENU ABX TESTING INPATIENT MENU",
      "term": null,
      "displaytext": "CDSS INPATIENT TESTING MENU ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TheraDoc Link\", \"Text\": \"CLICK HERE FOR THERADOC\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 294, \"DisplayText\": \"Urinary Catheter Decision Tree\", \"Text\": \"Urinary catheters\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3035, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Important Drug Properties A-B\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Important Drug Properties C\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Important Drug Properties D-E-F\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Important Drug Propertie G-L\", \"Mnemonic\": \"12\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Important Drug Properties M-N-O\", \"Mnemonic\": \"14\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Important Drug Properties P-Q-R-S\", \"Mnemonic\": \"16\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"Important Drug Properties T-U-V-W-X-Y-Z\", \"Mnemonic\": \"18\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"testing drug info\", \"Mnemonic\": \"20\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"MENINGOCOCCAL VACCINE INFO PAGE\", \"Mnemonic\": \"30\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Post SCT Vaccinations Blood 2016\", \"Text\": \"Test Post SCT Blood\", \"Mnemonic\": \"34\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC website for the Infectious Diseases\", \"Text\": \"Antimicrobial CDSS Website Link\", \"Mnemonic\": \"40\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 597, \"DisplayText\": \"Orthopedic surgery, ALBC for tx of periprosthetic hip/knee joint infections\", \"Text\": \"TEST ortho\", \"Mnemonic\": \"42\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"IDP SANFORD OR LEXI LINK\", \"Text\": \"SANFORD LINKS\", \"Mnemonic\": \"44\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CDSS TESTING ONLY BELOWS\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"THERADOC:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Item\": 241, \"DisplayText\": \"PNEUMONIA HAP\", \"Text\": \"Pneumonia HAP (new page Pseudomonas)\", \"Mnemonic\": \"RRx\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 284,
    "fields": {
      "name": "ORZID2 GMENU ABX TESTING MENU",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV\", \"Mnemonic\": \"8\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin 5\", \"Mnemonic\": \"10\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime Gentamicin Vancomycin\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> gentamicin 5\", \"Mnemonic\": \"12\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) <AND> gentamicin 5 mg/kg IV\", \"Mnemonic\": \"14\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg Gentamicin 5 mg/kg Vancomycin 15 mg/kg\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h ($)\", \"Mnemonic\": \"16\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"EMPIRIC TREATMENT: Ventilator Associated Pneumonia (VAP)\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pneumonia occurring 48 hours or more after endotracheal intubation\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Local facility antibiogram and patient risk factors for multi-drug\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"resistant pathogens guide antimicrobial therapy.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Risk factors for Multi-Drug Resistant VAP:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prior intravenous antibiotic use within 90 days\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Septic shock at the time of VAP\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"ARDS preceding VAP\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"5 or more days of hospitalization prior to the occurrence of VAP\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Acute renal replacement therapy prior to VAP onset\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Local resistance pattern\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment for 7 days is generally sufficient if the initial empiric therapy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"covered the pathogen and the patient is clinically responding.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Narrow therapy to treat specific pathogen(s) based on results of\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"culture and susceptibility tests. Can discontinue MRSA coverage if no\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"MRSA isolated from respiratory cultures, if obtained, or if nasal\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"swab or throat cultures show no growth of MRSA, or if NAAT negative for\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"MRSA.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Empiric Treatment:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"No Risk of MDR Pathogen(s):\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"15mg/kg IV q12h ($) [R]<OR>\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"q12h ($) [R]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative for Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"q12h ($) [R]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Risk of MDR Pathogens:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Kalil AC et al. Clin Infect Dis 2016. 63:1.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Boyce JM. Antimicrob Agents Chemother 2013. 57:1163\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Chastre J. JAMA 2003. 290:2588.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371.\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Luna CM. Crit Care Med 2003. 31:676.\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Roig J. J Antimicrob Chemother 2003. 51:1119.\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 285,
    "fields": {
      "name": "ORZID2 GMENU ABX TOCILIZUMAB FOR TREATMENT OF COVID-19",
      "term": null,
      "displaytext": "Tocilizumab for treatment of COVID-19",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tocilizumab 800 mg IV x1 dose 1 for COVID-19\", \"Text\": \"Tocilizumab 800 mg IV x 1 ($$$$) [DI,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tocilizumab 600 mg IV x1 dose 1 for COVID-19\", \"Text\": \"Tocilizumab 600 mg IV x 1 ($$$$) [DI,O]\", \"Mnemonic\": \"7\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tocilizumab 400 mg IV x1 dose 1 for COVID-19\", \"Text\": \"Tocilizumab 400 mg IV x 1 ($$$$) [DI,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tocilizumab 8 mg/kg x1 dose 1 for COVID-19\", \"Text\": \"Tocilizumab 8 mg/kg IV x 1 ($$$$) [DI,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TOCILIZUMAB (IL- 6 RECEPTOR BLOCKER) FOR TREATMENT OF COVID-19\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Inclusion Criteria:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"o Confirmed COVID-19 <AND>\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"o Hospitalized <AND>\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"o Clinical evidence of progressive COVID-19 (supplemental oxygen, high-flow\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"oxygen, or noninvasive or invasive ventilation) <AND>\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Exclusion Criteria:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"o Outpatient\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"o Current documented or suspected bacterial or fungal infection\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"o Active tuberculosis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"o ANC < 1000/mm3, platelet count < 50,000/mm3, ALT/AST> 10x ULN\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"**1ST DOSE**\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"If all the above inclusion criteria are met and no exclusion criteria, the 1st\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"dose of tocilizumab may be ordered below based on patient's weight.\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patient weight >/= 90 kg\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Patient weight >/= 65 kg and < 90 kg\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Patient weight >/= 40 kg and < 65 kg\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Patient weight < 40 kg\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"**2ND DOSE**\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"If the patient's condition has not improved in 12-24 hours after receiving the\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"1st dose, a second dose may be considered in select patients. Please page ID for\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Horby, Peter W., et al. Tocilizumab in patients admitted to hospital with\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"COVID-19 (RECOVERY): preliminary results of a randomized, controlled, open-\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"label, platform trial. Medrxiv (2021).\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"o Patient does not have a known hypersensitivity to tocilizumab\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"discussion of 2nd dose.\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"o GI perforation\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 286,
    "fields": {
      "name": "ORZID2 GMENU ABX TOXIC MEGACOLON",
      "term": null,
      "displaytext": "Severe disease - Ileus/Toxic megacolon  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole IV Vanco 500mg Caps Vanco Enema\", \"Text\": \"Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg PO q6h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG soln q6h ($)\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole IV Vanco 500mg Caps\", \"Text\": \"Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg PO q6h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG q6h ($$) [R]\", \"Text\": \"Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG q6h ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Discontinue any antibiotics if possible and avoid high risk antibiotic if\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antibiotic therapy is still needed. Discontinue antacid therapy if possible.\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"An enteral dose of 125mg of vancomycin results in colonic vancomycin\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"concentrations hundreds of times greater than needed to inhibit Clostridium\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"difficile. Only with toxic megacolon or ileus is a higher dose of vancomycin\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"(500mg) administered by enteral route.\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Antimicrobial therapy should be continued for 10 days but may be prolonged\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"considering clinical circumstances. In patients being treated with antibiotics\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"for predisposing infections, continue treatment for 7 days after completion of\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"those antibiotics. If patient is being treated for C. difficile recurrence,\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"pulse taper therapy is indicated after resolution of severe disease. Refer to\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"mild to moderate C. difficile treatment menu for recommendations.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment if ileus is present\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Deliver antimicrobials by intravenous, oral, and rectal routes.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"<AND> vancomycin enema 500 mg in 100 ml normal saline q6h ($) [M]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"**ONLY for Vancomycin NG administration**\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"[M] <AND> vancomycin enema 500 mg in 100 ml normal saline q6h ($) [M]\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treatment if ileus is not present\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases consults are essential.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"**ONLY for Vancomycin NG administration**\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"McDonald et al, Clin Inf Dis, 2018, (00)1-48\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Clinical\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Definition of fulminant CDI is supported by:\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Hypotension or shock, ileus, megacolon\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases consults are essential.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis,2021,73(5):e1029-e1044\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Note: There are no available data supporting the use of fidaxomicin for\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"treatment of fulminant CDI.\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 287,
    "fields": {
      "name": "ORZID2 GMENU ABX TPOXX MONKEYPOX TREATMENT",
      "term": null,
      "displaytext": "TPOXX Monkeypox Treatment",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TPOXX SharePoint Link\", \"Text\": \"[CLICK HERE] for link to required documents (Monkeypox Taskforce Teams group)\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INV-TECOVIRIMAT 600 MG ORALLY Q12H 14 DAYS\", \"Text\": \"INV-Tecovirimat 600 mg (3 capsules) orally q12h for 14 days\", \"Mnemonic\": \"6\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INV-TECOVIRIMAT 600 MG ORALLY Q8H 14 DAYS\", \"Text\": \"INV-Tecovirimat 600 mg (3 capsules) orally q8h for 14 days\", \"Mnemonic\": \"8\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INV-TECOVIRIMAT 200MG IV Q12H X14 DAYS\", \"Text\": \"INV-Tecovirimat 200 mg IV q12h over 6 hours for 14 days\", \"Mnemonic\": \"10\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INV-TECOVIRIMAT 300MG IV Q12H X14 DAYS\", \"Text\": \"INV-Tecovirimat 300 mg IV q12h over 6 hours for 14 days\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CDC MONKEYPOX TREATMENT WITH TPOXX\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Eligibility:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"o Consent: Must have documented consent by patient or legally authorized\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"representative in paper or i-Med consent\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"o Primary/empiric treatment: Confirmed diagnosis or suspected infection based\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"on exposure and/or symptoms while testing is pending.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"o Secondary Treatment: Complications from replication competent vaccinia\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infection from vaccination, secondary transmission, or other exposure. TPOXX may\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"be used after VIGIV treatment or in conjunction with VIGIV and/or with other\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"therapies based on clinical judgement.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"o Post-exposure prophylaxis (PEP): May be considered on a case-by-case basis in\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"consultation with the CDC. Eligibility for PEP use depends on high risk exposure\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"confirmed or probable case and alternative or complement to PEP vaccination\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"is needed based on clinical judgment (e.g. vaccine allergy, immunocompromise).\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"o Dosage and duration: Weight based dosing for 14 days. But it may be longer\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"based on clinical progress but not to exceed 90 days. Oral tecovirimat capsule\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"should be taken by mouth with a full glass of water within 30 minutes after\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"eating a full meal of moderate or high fat (ideally about 600 calories and 25\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"grams of fat).\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"o CDC Case Reports Forms:  To be completed and returned to CDC by treating\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"physicians per IND protocol.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Exclusions:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"o Patient or legally authorized representative unwilling to sign an informed\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"consent and refuse tecovirimat treatment\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"o  Known allergy to tecovirimat and/or excipients of tecovirimat\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"o  Upon negative test results for orthopoxvirus whose treatment was initiated\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"based on clinical manifestations prior to laboratory results.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"o For IV tecovirimat only: patients with severe renal impairment (creatinine\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"clearance <30 mL/min)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Oral Treatment:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Patients 40kg to < 120 kg\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"*Places medication orders for inpatient and outpatient (included in order set)\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Patients 120 kg and Above\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"*Places medication orders for inpatient and outpatient (included in order set)\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Intravenous Treatment:\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"o Very ill hospitalized patients who are unable to take oral therapy or for whom\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"there is a concern that oral drug absorption may be altered.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"o IV tecovirimat should not be administered in patients with severe renal\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"impairment (creatinine clearance <30 mL/min) and should be used with caution in\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"patients with moderate (creatinine clearance 30-49 mL/min) or mild (creatinine\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"clearance 50-80 mL/min) renal impairment.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"o IV tecovirimat should be switched to the oral formulation as soon as patients\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"can take oral medications and/or gastrointestinal disfunction impacting\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"absorption has resolved.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Patients 35 kg to < 120 kg\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Patients 120 kg and Above\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"*Places medication orders for 2 seperate INV-tecovirimat IV 100mg q12h orders\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"*Places medication orders for 2 seperate INV-tecovirimat IV 150 mg q12h orders\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"for a total of 400 mg over 24hrs via slow infusion.\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"for a total of 600 mg over 24hrs via slow infusion.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 288,
    "fields": {
      "name": "ORZID2 GMENU ABX TRICH VAGINITIS",
      "term": null,
      "displaytext": "Trichomonas Vaginitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 568, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500MG PO q12h\", \"Text\": \"Metronidazole 500 mg PO q12h for 7 days ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500MG PO q12h\", \"Text\": \"Metronidazole 500 mg PO q12h for 7 days ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 2 gm PO q24h for 7 days ($) [DI]\", \"Text\": \"Metronidazole 2 gm PO q24h for 7 days ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TRICHOMONAS VAGINITIS AND URETHRITIS\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Male sexual partners of women with trichomonas vaginitis will not have symptoms\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"but should be treated to prevent recurrent vaginitis in the female sexual\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"partner.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Diagnosis\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"The discharge is purulent, malodorous, and thin. The vaginal pH is greater\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"than 4.5. Nucleic Acid amplification test (NAAT) for trichomonas has improved\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"sensitivities and specifities compared to wet mount.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment of Initial Episode in Men and Woman\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pregnant women with trichomonas infection may be treated with metronidazole\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"during any trimester.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment of Veteran Male Sex Partners (Non-Veteran Sex Partners Should Be\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Referred to Non-VA Care)\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"1st failure\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"2nd failure\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"3rd failure\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Consult Infectious Disease\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"________________________________________________________________________\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Trichomoniasis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and cervicitis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines: MMWR (2021) 70.4\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-To-Date article: Trichomoniasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 289,
    "fields": {
      "name": "ORZID2 GMENU ABX TUBERCULOSIS",
      "term": null,
      "displaytext": "Tuberculosis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TUBERCULOSIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Evaluation and management are complex.  Consult pulmonary and/or infectious\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diseases.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Patients with suspected or proven pulmonary tuberculosis must be in respiratory\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"isolation.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Centers for Disease Control (CDC). Tuberculosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 290,
    "fields": {
      "name": "ORZID2 GMENU ABX TYPHLITIS",
      "term": null,
      "displaytext": "Neutropenic Enterocolitis (Typhlitis)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Clostridium difficile infection\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($35/day) [R] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC ENTEROCOLITIS (TYPHLITIS)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patients, especially in those with acute leukemia. Send stool for C. difficile\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"PCR testing to exclude of C. difficile infection.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Hematology-oncology, Infectious Diseases and general surgery consults\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"are essential.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Broad spectrum antimicrobials that include anaerobic coverage should be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"initiated promptly.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Continue antimicrobial therapy until normalization of body temperature, recovery\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"of neutropenia and thrombocytopenia, return of normal gastrointestinal function\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"and resolution of bacteremia if initially present.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< AND > Vancomycin 15 mg/kg ($)[R]\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Step down treatment after initial intravenous antibiotic treatment in patients\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"who can tolerate oral therapy. Base selection on culture results.\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Diverticulitis and typhlitis\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Nesher and Rolston, Clinical Infectious Diseases, 2013, 56(5):711-7\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Sanford keyword: Neutropenic Enterocolitis, Typhlitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Up-to-Date article: Neutropenic enterocolitis (typhlitis)\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Freifeld AG Clin Infect Dis 2011, 52: e56\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Neutropenic enterocolitis, also known as \\\"typhlitis\\\" or \\\"necrotizing\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"enterocolitis\\\", is a severe intraabdominal infection that occurs in neutropenic\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 291,
    "fields": {
      "name": "ORZID2 GMENU ABX UNCOMP CYSTITIS",
      "term": null,
      "displaytext": "Uncomplicated Cystitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 123, \"DisplayText\": \"Complicated Cystitis\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 85, \"DisplayText\": \"Asymptomatic Bacteriuria\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days\", \"Mnemonic\": \"8\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"10\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"12\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 5 days\", \"Mnemonic\": \"16\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 5 days\", \"Mnemonic\": \"18\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 3 days\", \"Mnemonic\": \"20\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3 GM PO ONCE\", \"Text\": \"Fosfomycin 3GM sachet PO ($$)[M] once\", \"Mnemonic\": \"22\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"24\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"26\"}, {\"Row\": 68, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 3 days\", \"Mnemonic\": \"28\"}, {\"Row\": 73, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]\", \"Mnemonic\": \"30\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]\", \"Mnemonic\": \"32\"}, {\"Row\": 77, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO QHS ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min\", \"Mnemonic\": \"34\"}, {\"Row\": 79, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O], CrCl =/>30 mL/min\", \"Mnemonic\": \"36\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"UNCOMPLICATED CYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Uncomplicated cystitis is defined as symptomatic bladder inflammation caused by\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"bacterial infections in people with structurally and neurogenically normal\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"urinary tract. Symptoms usually include dysuria, lower abdominal pain, and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"urgency. Most cases of uncomplicated cystitis occur in pre-menopausal,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"non-pregnant, sexually active young women and is commonly associated with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"saprophyticus.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cystitis is considered complicated when it occurs in pregnant women, people\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"with abnormalities of the urinary tract, immunocompromised individuals and those\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"who have persistent, recurrent, or relapsed infections, or treatment failure are\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"considered complicated. Diagnosis and treatment of complicated cystitis is\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"discussed elsewhere.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"The presence of pyuria (>7 wbc/hpf) or positive leukocyte esterase, urine\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"nitrate, or urine bacteria is not a sufficient indication for antibiotic\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"treatment. Asymptomatic bacteriuria occurs in patients who have bacteria in the\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"urine with no symptoms of cystitis, and with few exceptions, should not be\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"treated. Diagnosis and treatment of asymptomatic bacteriuria is further\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"discussed elsewhere:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"The prevalence of antimicrobial resistance among bacteria associated with\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"uncomplicated cystitis has increased. A urine culture should be considered in a\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"patient who has had substantial involvement with healthcare or exposure to\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"antimicrobials. If a patient fails to respond to therapy, a urine culture should\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"be done.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For women with recurrent uncomplicated cystitis (2 episodes in 6 months or 3 or\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"more episodes in 12 months), suppressive therapy is indicated after infection is\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"eradicated and non-antimicrobial prevention methods, such as increased fluid\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"intake and avoiding spermicide, are considered. Consider consulting Women's\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Clinic for treatment recommendations.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Men, empirical treatment\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Primary alternative:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Secondary alternative:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Women, empirical treatment\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Primary alternatives:\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Secondary alternative:\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Women, suppression\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 83, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Drekonja et al., JAMA, 2021, 326(4)324-331\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"Sanford keyword: UTI, Acute, Uncomplicated, Adult, Female\"}, {\"Row\": 88, \"Column\": 1, \"Text\": \"Sanford keyword: UTI, Adult, Male\"}, {\"Row\": 89, \"Column\": 1, \"Text\": \"Sanford keyword: Prevention of Recurrent UTI, Female\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute simple cystitis in men\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute simple cystitis in women\"}, {\"Row\": 92, \"Column\": 1, \"Text\": \"Up-To-Date article: Recurrent simple cystitis in women\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 292,
    "fields": {
      "name": "ORZID2 GMENU ABX UPPER RESPIRATORY INFECTIONS (URI)",
      "term": null,
      "displaytext": "Upper respiratory infections (URI)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 15, \"Column\": 1, \"Item\": 94, \"DisplayText\": \"Consider Antibiotic\", \"Text\": \"Bronchitis\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 300, \"DisplayText\": \"Acute Sinusitis--Mild to Moderate Disease\", \"Text\": \"Sinusitis\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 236, \"DisplayText\": \"Pharyngitis\", \"Text\": \"Pharyngitis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"UPPER RESPIRATORY INFECTION (URI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Upper respiratory infections include several common syndromes including\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the common cold, bronchitis (see below), pharyngitis (see below) and sinusitis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(see below). Most are caused by viruses and there is no benefit from\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antimicrobial therapy. If a patient presents with a URI, consider specific\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infections that do respond to antimicrobial therapy like herpes simplex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"stomatitis, pertussis or thrush. If no condition that benefits from\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobial therapy is present, antimicrobials will almost certainly not help\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"but will likely select for antimicrobial resistance and may lead to other\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"adverse effects.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Kogawa et al, General medicine, 2009, 10:7-15\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 293,
    "fields": {
      "name": "ORZID2 GMENU ABX URETHRITIS ASSOC STD",
      "term": null,
      "displaytext": "Urethritis associated with sexually transmitted diseases  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Urine NAAT\", \"Text\": \"Chlamydia & GC PCR/LCR test\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 544, \"DisplayText\": \"Recurrent or persistent urethritis\", \"Text\": \"Treatment of recurrent or persistent urethritis\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 167, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Treatment for gonococcal urethritis\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 106, \"DisplayText\": \"Chlamydia Urethritis\", \"Text\": \"Treatment for chlamydial or non-gonococcal urethritis\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"URETHRITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"The main differential in a person who presents with dysuria is between cystitis\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and urethritis. Bacterial urethritis is more likely in people with mild\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dysuria, onset over a few days, or recent sexual contact.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"The two most common sexually transmitted urethritis pathogens are Neisseria\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"gonorrhoeae and Chlamydia trachomatis. Nucleic acid amplification tests for\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"these pathogens are more sensitive than culture and should be used for patients\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"at risk for sexually transmitted urethritis.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients who have recently been treated for urethritis\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"When dysuria is from a sexually transmitted disease, the patient's sexual\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"partner(s) during the previous 60 days should be evaluated for sexually\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"transmitted infection.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"If diagnostic tests for the cause of urethritis are not feasible, therapy for\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"both N. gonorrhoeae and C. trachomatis should be given to partners.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Initial treatment of patients and sex partners\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Patients and partners are often infected with both N. gonorrhoeae and C.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"trachomatis. Treat for both pathogens unless one is ruled out by lab test.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-To-Date article: Urethritis in men\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 568, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 294,
    "fields": {
      "name": "ORZID2 GMENU ABX URINARY CATHETER",
      "term": null,
      "displaytext": "Urinary Catheter Decision Tree ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 28, \"Column\": 1, \"Text\": \"1) Urinary blockage due to clots\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"2) Urinary blockage due to urinary obstruction (not clots)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"3) Urinary retention due to neurological condition\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"4) Urinary incontinence\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"5) Prolonged surgical procedure\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"6) Monitoring of urinary output\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"7) Open sacral wound\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"8) Suprapubic catheter\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"9) Nephrostomy tubes present\"}, {\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"UROLOGY INPT\", \"Text\": \"Consult Urology (inpatient)\", \"Mnemonic\": \"02\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"HELP, additional information:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Urinary Catheters:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Bladder catheters are used for urinary drainage, or as a means to collect\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"urine for measurement. Many clinical situations are appropriate for the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"placement of catheters, BUT too frequently they are used without proper\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indication or continued longer than needed.  Unwarranted urinary catheters\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Daily evaluation of the ongoing need for the catheter is essential to reduce\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"complications including catheter-assosciated urinary tract infection.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternatives to indwelling urethral catheterization should be considered\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"and include intermittent catheterization, external sheath (ie,condom)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"catheters, suprapubic catheters, and in some cases, supportive management\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"with protective garments.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Hospital-acquired urinary tract infection is the most common type of\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"nosocomial infection.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"are placed in 21 to 50 percent of hospitalized patients.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Indications for Catheterization:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Management of immobilized patients (eg, stroke, pelvic fracture)\", \"Mnemonic\": \"06\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 295, \"DisplayText\": \"Management of patients with neurogenic bladder/spinal cord injury\", \"Mnemonic\": \"08\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"04 Description of types of catheters and insertion\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 295,
    "fields": {
      "name": "ORZID2 GMENU ABX URINARY CATHETER NEUROGENIC BLADDER",
      "term": null,
      "displaytext": "Management of patients with neurogenic bladder/spinal cord injury  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Text\": \"Management of patients with neurogenic bladder/spinal cord injury\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The goal of an SCI bladder program is to preserve renal function while\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"eliminating urine at regular and socially acceptable times, avoiding high\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"bladder pressures, retention, incontinence, and infection.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Clean intermittent catheterization, which is the removal of the catheter\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"immediately after bladder decompression with recatheterization on a scheduled\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Clean technique intermittent catheterization has a lower infection rate\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"compared with with the use of indwelling catheters.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"basis is  preferred. Clean intermittent catheterization is performed at regular\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"intervals, usually every 4 hours. A bladder volume of less than 500 mls\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"of urine is targeted in order to avoid bladder distention, pressure, and reflux\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"as well as to reduce the incidence of infections.\"}, {\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"UROLOGY INPT\", \"Text\": \"Urology Consult (Inpatient)\", \"Mnemonic\": \"02\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"HELP, additional information:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"08 Order for  Intermittent Catheterization Q4Hours\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Intermittent urinary incontinence is expected. Condom catheters (for men)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"and adult diapers are important short-term interventions. Recommend rule\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"out infection and adjust the frequency of intermittent catheterization\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"and fluid intake.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"10 Order for condom catheter for men\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"12 Order for adult diapers\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"available caregivers, a chronic indwelling catheter may be necessary.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"The indwelling catheter should be changed each month to minimize infections.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"13 Order for indwelling catheter\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"For admitted patients who normally use chronic indwelling catheter:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For patients unable to perform intermittent catheterization and without\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 296,
    "fields": {
      "name": "ORZID2 GMENU ABX URINE CULTURE MENU",
      "term": null,
      "displaytext": "Urine Culture",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"URINE CULTURE MAIN ORDER MENU\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"-Cloudy urine\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"-Malodorous urine\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"-Discolored urine\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"-When a urinary catheter is placed\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"-Automatic on admission\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fever or sepsis with no other identifiable cause\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dysuria, frequency, or urgency\", \"Mnemonic\": \"12\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Flank, suprapubic, or pelvic pain\", \"Mnemonic\": \"14\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CVA tenderness\", \"Mnemonic\": \"16\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Urine Culture is NOT indicated for the following conditions alone:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acute hematuria\", \"Mnemonic\": \"18\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pre-operative screening for urologic procedure\", \"Text\": \"PRE-OPERATIVE SCREENING for urologic procedure\", \"Mnemonic\": \"20\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pregnant and due for screening\", \"Mnemonic\": \"22\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Increased bladder spasticity or autonomic dysreflexia in patients with\", \"Mnemonic\": \"24\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Urine cultures should be ordered in patients with symptoms of a urinary tract\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"infection, during pregnancy at appropriate screening intervals, and prior\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"to an invasive urologic procedure.\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Select indication for urine culture your patient has to place lab order:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"-End of therapy re-testing\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Altered mental status with no other identifiable cause\", \"Mnemonic\": \"26\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"(note that UC not usually indicated, call ID with questions)\"}, {\"Row\": 3, \"Column\": 1, \"Item\": 3036, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Minneapolis Clinical On-Call Schedule (Infectious Disease)\", \"Mnemonic\": \"02\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"spinal cord injury or neurologic deficit\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"OR/IR Sterile Aspirate Collection Only\", \"Mnemonic\": \"28\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 297,
    "fields": {
      "name": "ORZID2 GMENU ABX VAGINITIS",
      "term": null,
      "displaytext": "Bacterial Vaginosis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500MG PO q12h\", \"Text\": \"Metronidazole 500 mg PO q12h ($) [DI] for 7 days\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Metronidazole vaginal gel 0.75%, contents of 1 applicator intravaginally qhs ($)\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300MG PO q12h\", \"Text\": \"Clindamycin 300 mg PO q12h ($) [H,O] for 7 days\", \"Mnemonic\": \"10\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clindamycin phosphate vaginal cream 2%, contents of 1 applicator\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL VAGINOSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Vaginitis usually presents with discharge, itching, irritation, odor, or pain.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Bacterial vaginosis is the most common form of vaginitis. Normal hydrogen\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"peroxide and lactic acid producing vaginal flora, including Lactobacillus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"species, is reduced and high concentrations of anaerobic bacterial pathogens are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"present. Pathogenic bacteria commonly include Gardnerella vaginalis, Mycoplasma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"hominis, Nobiluncus, Prevotella and other Gram-negative anaerobes.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Vaginal pH should be measured, and the specimen should be examined under the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"microscope for identification of clue cells (epithelial cell coated with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"bacteria). In bacterial vaginosis the vaginal pH is high (> 4.5), the discharge\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"is homogenous and gray-white, and the specimen has a positive amine or whiff\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"test characterized by a fishy odor before or after addition of 10% KOH.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Bacterial vaginosis nucleic acid amplification tests are available for common\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"pathogens to aide in identification of pathogen(s).\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Bacterial vaginosis may be transmitted sexually. Patients at risk of sexually\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"transmitted infections should be assessed for treatment.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"[DI] for 5 days\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"intravaginally qhs ($) [H,O] for 7 days\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and cervicitis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Bacterial Vaginosis\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacterial vaginosis: Clinical manifestations and diagnosis\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacterial Vaginosis: Treatment\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 298,
    "fields": {
      "name": "ORZID2 GMENU ABX VANCO + MRSA NARES INFORMATION",
      "term": null,
      "displaytext": "Information on Vancomycin IV New Starts and MRSA Nares Testing  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Text\": \"MRSA nares screening will be ordered on all new IV Vancomycin starts.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"MRSA nares may be a helpful tool in identifying patients with low risk of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"MRSA infection in whom empiric vancomycin may not be required.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"A negative MRSA nares does not definitively rule out the presence of MRSA\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"elsewhere and is one factor to consider in the de-escalation of vancomycin\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"(and other anti-MRSA antimicrobials).\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The Clinical Utility of\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial  Stewardship\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Implications. Clin Infect Dis. (2018) 67(1):1-7\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"doi: 10.1093/cid/ciy024. PMID: 29340593.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Jones BE, Ying J, Stevens V, et al. Empirical Anti-MRSA vs Standard Antibiotic\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"JAMA Intern Med. (2020) 180(4):552-560. doi:10.1001/jamainternmed.2019.7495\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Information on adding MRSA nares screening with new IV Vancomycin starts:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 299,
    "fields": {
      "name": "ORZID2 GMENU ABX VIRUSES",
      "term": null,
      "displaytext": "Viruses",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 115, \"DisplayText\": \"Cytomegalovirus (CMV) Main Page\", \"Text\": \"[click here]\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 457, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis\", \"Text\": \"[click here]\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 170, \"DisplayText\": \"Hepatitis A\", \"Text\": \"Hepatitis A\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 171, \"DisplayText\": \"Hepatitis B\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 172, \"DisplayText\": \"Hepatitis C\", \"Text\": \"Hepatitis C\", \"Mnemonic\": \"12\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 91, \"DisplayText\": \"Bell's Palsy\", \"Text\": \"Bell's palsy\", \"Mnemonic\": \"14\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 180, \"DisplayText\": \"HSV Encephalitis\", \"Text\": \"Encephalitis\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 268, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Genital herpes\", \"Mnemonic\": \"18\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 175, \"DisplayText\": \"Herpes Whitlow (digit/hand cellulitis)\", \"Text\": \"Herpes Whitlow (digit or hand\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 173, \"DisplayText\": \"HERPES KERATITIS\", \"Text\": \"Keratitis\", \"Mnemonic\": \"22\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 225, \"DisplayText\": \"Orolabial Herpes\", \"Text\": \"Oral lesions: Mouth,Lips (Cold sores)\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ VIRUSES ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cytomegalovirus (CMV)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Diarrhea, viral\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Hepatitis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Herpes Simplex\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"cellulitis)\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Last reviewed 8/2018\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"[click here]\", \"Mnemonic\": \"28\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 189, \"DisplayText\": \"Influenza Seasonal 2022-2023\", \"Text\": \"[click here]\", \"Mnemonic\": \"30\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 227, \"DisplayText\": \"Parainfluenza\", \"Text\": \"[click here]\", \"Mnemonic\": \"32\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 264, \"DisplayText\": \"RSV\", \"Text\": \"[click here]\", \"Mnemonic\": \"34\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 91, \"DisplayText\": \"Bell's Palsy\", \"Text\": \"Bell's palsy\", \"Mnemonic\": \"36\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 245, \"DisplayText\": \"Primary infection (Chickenpox)\", \"Text\": \"Varicella/Chickenpox (primary infection)\", \"Mnemonic\": \"38\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 249, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\")\", \"Text\": \"Zoster/Shingles (reactivation)\", \"Mnemonic\": \"40\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"Influenza, Seasonal\", \"Header\": 1}, {\"Row\": 11, \"Column\": 2, \"Text\": \"Parainfluenza\", \"Header\": 1}, {\"Row\": 14, \"Column\": 2, \"Text\": \"Respiratory Syncytial Virus (RSV)\", \"Header\": 1}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Varicella-zoster\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 300,
    "fields": {
      "name": "ORZID2 GMENU ACUTE SINUSITIS",
      "term": null,
      "displaytext": "Acute Sinusitis--Mild to Moderate Disease  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 491, \"DisplayText\": \"Mild to Moderate Sinusitis\", \"Text\": \"[CLICK HERE] for treatment of mild to moderate bacterial sinusitis\", \"Mnemonic\": \"4\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 567, \"DisplayText\": \"Severe Sinusitis\", \"Text\": \"[CLICK HERE] for treatment of severe bacterial sinusitis\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"treated with decongestants, analgesics, and nasal saline. Diagnosis of acute\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sinusitis is based on the presence of at least 2 major or 1 major and at least 2\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"minor symptoms.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Major Symptoms\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"1. Purulent anterior nasal discharge\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"2. Purulent or discolored posterior nasal discharge\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"3. Nasal congestion or fullness\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"4. Facial pain or pressure\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"5. Hyposmia or anosmia\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"6. Fever\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Minor Symptoms\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"1. Headache\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"2. Ear pain, pressure or fullness\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"3. Halitosis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"4. Dental pain\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"5. Cough\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"6. Fatigue\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If patient meets criteria above for acute sinusitis, treat with antimicrobials\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"according to the following criteria for mild to moderate or severe bacterial\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"sinusitis.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mild to moderate bacterial sinusitis\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1. Symptoms persisting beyond 10 days\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"2. Double-sickening - Symptoms typical of viral upper respiratory infection\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"initially improving for 5-6 days then worsening with new development of fever,\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"headache or increased nasal discharge.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Severe bacterial sinusitis\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"pain lasting for at least 3-4 consecutive days at the beginning of illness.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 301,
    "fields": {
      "name": "ORZID2 GMENU ANAPLASMA PHATOCYTOPHILUM",
      "term": null,
      "displaytext": "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h for 10 days ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Doxycycline 100 mg IV q12h for 10 days ($$) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANAPLASMA PHAGOCYTOPHILUM (HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"MMWR RR. 2016, 65 (2) 1-44\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Ehrlichia sp., Anaplasma sp.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-to-Date article: Human ehrlichiosis and anaplasmosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 302,
    "fields": {
      "name": "ORZID2 GMENU ANTIVIRAL IMMUNOSUPPRESSIVE MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 MG PO q12h ($) [R]\", \"Text\": \"Acyclovir 800 MG PO q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 MG PO q12h ($) [R]\", \"Text\": \"Acyclovir 800 MG PO q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Severly Immunosuppressive Chemo-immunotherapy\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Purine Analogues\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Chemotherapy with purine analogues such as fludarabine, cladribine, or\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pentostatin results in major cellular-immunodeficiency that may outlast the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"exposure by months and enhances the risk for viral infections.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Recommend antiviral prophylaxis for patients treated with purine analogues,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"if at least one of the following risk factors is present:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"a) Second-line chemotherapy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"b) Treatment with corticosteroids\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"c) CD4 cell count <50/ul\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"d) Age >65 years\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"e) Prolonged Mild or Moderate Neutropenia: Mild<1000 Neutrophils /\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"\\ufffdL (Grade III neutropenia) OR Moderate: <500 Neutrophils/\\ufffdL\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(Grade IV neutropenia)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Duration: Antiviral prophylaxis should be initiated in the first week of\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"therapy and continued until 2 months after completion of therapy.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alemtuzumab Therapy:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alemtuzumab is a potent reactivator of latent intracellular pathogens,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"including CMV. Chemotherapy with alemtuzumab results in major cellular-\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"immunodeficiency that may outlast the exposure by months and enhances the\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"risk for viral infections. The risk of viral disease increases with the\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"intensity and duration of functional T-cell suppression experienced with\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"recipients of alemtuzumab.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Duration: Initiate antiviral prophylaxis with alemtuzumab therapy and\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"continue therapy for at least 2 months after last dose or until CD4 counts\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"are greater than or equal to 200 cells/ul, whichever is later.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Taplitz RA Journal of Clinical Oncology 2018, 36:3043\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sandherr M Annals of Oncology 2006, 17:1051\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 303,
    "fields": {
      "name": "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 302, \"DisplayText\": \"\", \"Text\": \"Select for recommendations for antiviral prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 189, \"DisplayText\": \"Influenza Seasonal 2022-2023\", \"Text\": \"Seasonal Influenza Recommendations\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INFECTIOUS DISEASE (INPT)\", \"Text\": \"Consult Infectious Disease\", \"Mnemonic\": \"8\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 900, \"DisplayText\": \"Hepatitis B Evaluation Anti-CD20 Antibody\", \"Text\": \"Hepatitis B Evaluation Anti-CD20 Antibody\", \"Mnemonic\": \"10\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INFECTIOUS DISEASE (INPT)\", \"Text\": \"Consult Infectious Disease\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Prophylaxis for Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prophylaxis for Influenza and Other Respiratory Viruses\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Yearly influenza vaccination with inactivated vaccine is recommended for all\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"patients receiving chemotherapy for malignancy and all family and household\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"contacts and health care providers.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Optimal timing of vaccination for patients being treated for cancer is not\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"established, but serologic responses may be best between chemotherapy cycles\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"(greater than 7 days after the last treatment) or greater than 2 weeks\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"before chemotherapy starts.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Patients with active malignant disease are at higher risk for upper\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"respiratory infections due to influenza, parainfluenza or respiratory\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"syncytial virus (RSV). Although response to vaccination with the attenuated\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"influenza vaccine in patients on chemotherapy is variable, ranging\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"from 24-75%, immnunoprophylaxis with the influenza vaccine is recommended for\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"patients with active malignant disease or chemotherapy, lymphoproliferative\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"disease, or multiple myeloma. In areas and seasons where influenza is\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"endemic, chemoprophylaxis can be considered in addition to vaccination in\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"exposed patients with a high risk of influenza complications.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Prophylaxis for Cytomegalovirus (CMV)\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Prophylaxis and monitoring for CMV reactivation is not recommended unless the\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"patient has received an allogeneic HSCT. Usually the recommendations for\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"surveillance and prophylaxis of CMV infections from the institution\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"performing the HSCT will be followed.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Prophylaxis for Chronic Hepatitis B\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Reactivation of chronic hepatitis B in patients undergoing immunosuppressive\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"or antineoplastic treatment is a severe complication. Patients with positive\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"HBsAg, chronic hepatitis B infection, or a previous episode of HBV\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"reactivation who will receive immunosuppressive therapy should receive\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"prophylaxis.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Recommend routine testing for Hepatitis B prior to initiating Rituximab\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"(Anti-CD20 antibody) therapy in patients.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Taplitz RA Journal of Clinical Oncology 2018, 36:3043\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sandherr M Annals of Oncology 2006, 17: 1051\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 304,
    "fields": {
      "name": "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 306, \"DisplayText\": \"\", \"Text\": \"Solid Tumors, Acute Leukemia, or Lymphoma\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 302, \"DisplayText\": \"\", \"Text\": \"Purine analogues or Alemtuzumab\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 305, \"DisplayText\": \"\", \"Text\": \"Stem cell transplant recipients (autologous or allogeneic)\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 305, \"DisplayText\": \"\", \"Text\": \"Rituximab therapy\", \"Mnemonic\": \"10\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 303, \"DisplayText\": \"\", \"Text\": \"Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 303, \"DisplayText\": \"\", \"Text\": \"Influenza and Other Respiratory Viruses\", \"Mnemonic\": \"14\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 303, \"DisplayText\": \"\", \"Text\": \"Cytomegalovirus (CMV)\", \"Mnemonic\": \"16\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 303, \"DisplayText\": \"\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF VIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Viral infections reactivate in a small percentage of people with malignancy.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most viral infections in patients with hematologic malignancies or solid\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"tumors result from reactivation of asymptomatic latent infections,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"predominantly of herpes viruses, including herpes simplex virus (HSV),\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"varicella zoster virus (VZV) and cytomegalovirus (CMV). Exogenous\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"respiratory tract infections caused by influenza, parainfluenza\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"or respiratory syncytial virus (RSV) are less common.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"The main risk factor for clinically relevant reactivation is profound\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"disruption of cellular immune response, usually due to chemotherapy.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"The duration and severity of neutropenia are of lesser importance.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"The risk of viral disease increases with the intensity and duration\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of functional T-cell suppression. Patients receiving conventionally\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"dosed chemotherapy regimens for solid tumors experience no major\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"T-cell suppression and do not have a higher incidence of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"invasive viral infections.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"This section is organized mainly by type of malignancy.\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"There are separate sections for purine analogues (fludarabine,\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"cladribine, pentostatin), alemtuzumab and rituximab.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Select below for recommended antiviral prophylaxis:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"This section is organized by virus.\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Select below for recommended antiviral prophylaxis:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Taplitz RA Journal of Clinical Oncology, 2018, 36:3043\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sandherr M Annals of Oncology 2006, 17:1051\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 305,
    "fields": {
      "name": "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 303, \"DisplayText\": \"\", \"Text\": \"Select for Hepatitis B recommendations\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"**Stem cell transplant recipients (autologous or allogeneic)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Usually the standard prophylaxis and monitoring strategies recommended\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"by the institution performing the stem cell transplant will be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"followed.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consult Hematology-Oncology or Infectious Disease for recommendations.\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Rituximab Therapy\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Recommend routine testing for Hepatitis B prior to initiating treatment\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with Rituximab.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Vega, J et al, J Clin Oncol 26: 2008 (May 20 suppl, abstract 8558)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 306,
    "fields": {
      "name": "ORZID2 GMENU ANTIVIRAL TYPE OF MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 MG PO q12h ($) [R]\", \"Text\": \"Acyclovir 800 MG PO q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 171, \"DisplayText\": \"Hepatitis B\", \"Text\": \"Hepatitis B information page\", \"Mnemonic\": \"6\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 900, \"DisplayText\": \"Hepatitis B Evaluation Anti-CD20 Antibody\", \"Text\": \"Hepatitis B Evaluation Anti-CD20 Antibody\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"**Solid Tumors**\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"No Antiviral Prophylaxis Recommended\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Solid tumors do not significantly compromise the cellular immune system.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Therefore, patients are at low risk for opportunistic viral infections.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Documented invasive viral infections are very rare. Coincidental\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"mucocutaneous infections by herpes simplex are easily treated and do not\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"result in life-threatening invasive infections. Reactivation of\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) is rarely observed.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"**Acute Leukemia**\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Herpes simplex virus-seronegative patients\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"No Antiviral Prophylaxis Recommended\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"In patients with acute leukemia, treatment is highly aggressive and consists\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"of a combination of various cytotoxic agents administered in sequential\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"cycles as induction, consolidation and maintenance therapy. Persistent, i.e.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \">10 days and profound neutropenia (<500 neutrophils) regularly occurs and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"correlates with the risk of developing fever and infections. Almost all viral\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"infections during neutropenia constitute reactivations of herpes viruses.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"None of the available studies demonstrated an effect of antiviral prophylaxis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"on the initiation of antibiotic treatment, number of febrile days, duration\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"of antibiotic treatment, and onset of opportunistic infections. Therefore, no\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"recommendation for antiviral prophylaxis in patients with acute leukemia can\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"be given.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Herpes simplex virus-seropostive patients\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Patients undergoing leukemia induction therapy should receive prophylaxis.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"**Lymphoma**\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"No Antiviral Prophylaxis Recommended\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Rituximab is a monoclonal anti-CD-20 antibody used for treatment of\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"lymphomas. It leads to a profound depletion of circulating B-cells. B-cells\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"recover usually within 3-6 months after treatment. Prolonged administration\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"of rituximab (e.g., maintenance treatment >12 months) may result in a\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"significant decrease of levels of immunoglobulin M. Parvovirus B19 and JC-\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"papovavirus infections have been reported with maintenance rituximab therapy,\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"but drugs that would prevent these infections are not available. There is no\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"substantial increase in risk of reactivation of herpes viruses (including\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"HSV, VZV, and CMV).\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Recommend routine testing for Hepatitis B virus prior to initiating Rituximab\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"therapy in patients.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-to-Date\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 307,
    "fields": {
      "name": "ORZID2 GMENU APPENDICITIS W/O PERFORATION",
      "term": null,
      "displaytext": "Appendicitis without perforation  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 308, \"DisplayText\": \"Appendicitis with perforation\", \"Text\": \"Link to appendicitis with perforation menu\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"metronidazole 500 mg IV over 30 minutes <AND> Cefazolin 2gm IVPB over 30 mins\", \"Text\": \"Cefazolin 2 gm IV ($) [R] <AND> metronidazole 500 mg IV ($) [DI] both given\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFDINIR 300MG PO Q12H METRONIDAZOLE 500MG PO Q12H\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] <AND> metronidazole 1000 mg PO q12h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFDINIR 300MG PO Q12H METRONIDAZOLE 500MG PO Q12H\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] <AND> metronidazole 1000 mg PO q12h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPENDICITIS WITHOUT PERFORATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with an acutely inflamed appendix and no gangrene or perforation are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"considered to have uncomplicated appendicitis. Patients with gangrene,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"perforation, peritonitis, or abscess have complicated appendicitis. Treatment\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with antibiotics is an option for patients who are unfit for surgery or refuse\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"surgery. Treatment with antibiotics should not be used routinely as an\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"alternative to surgery.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Select for treatment of complicated appendicitis\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment of uncomplicated appendicitis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Administer prophylaxis regimen below prior to surgery. After surgery, treat for\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"3-5 days with one of the oral post-surgical treatment options below. For\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"patients who will not be undergoing surgery for source control, refer to the\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"recommendations below.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Surgical prophylaxis:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"over 30 minutes beginning 60 minutes before incision\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Post-post surgical treatment:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treat for 3-5 days after surgery\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Treatment of patients without surgical intervention\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treat fo 10 days total\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Initial treatment\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Step down treatment after completion of initial intravenous treatment\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"CODA Collaborative, N Engl J Med, 2020, 383:1907-1919\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Appendicitis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Salminen et al, JAMA, 2015, 313(23):2340-2348\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Appendicitis\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Up-to-Date article: Management of acute appendicitis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 308,
    "fields": {
      "name": "ORZID2 GMENU APPENDICITIS WITH PERFORATION",
      "term": null,
      "displaytext": "Appendicitis with perforation  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"10\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFDINIR 300MG PO Q12H METRONIDAZOLE 500MG PO Q12H\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] <AND> metronidazole 1000 mg PO q12h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPENDICITIS WITH PERFORATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treat until source control or clinical improvement\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Step down treatment after initial intravenous antibiotic treatment in patients\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"who can tolerate oral therapy. Base selection on culture results.\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR>\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Appendicitis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Appendicitis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-Date article: Management of acute appendicitis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 309,
    "fields": {
      "name": "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT",
      "term": null,
      "displaytext": "Approach to foot ulcers with infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO FOOT ULCER WITH INFECTION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Whenever possible, material should be obtained for Gram stain and culture.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Specimens from deep ulcer biopsy, aspiration, or bone biopsy are superior to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"wound swab or drainage.  Pathogen identification is especially important because\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"therapy is often given for weeks.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"While foot ulcers in patients with diabetes typically have many bacterial\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"species on the surface, disease is usually caused by only one or two.  When\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Staphylococcus aureus is present in a surface culture, it is usually a pathogen\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"in the deeper tissues.  Therapy can usually be directed against the predominant\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"or virulent organisms found on surface cultures and need not be active against\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"every isolate.  To reduce uncertainty it is better to obtain deeper cultures.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Bacteria that are most likely to be responsible for invasive infection include\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"S. aureus, streptococci, enteric gram-negative bacilli, Pseudomonas aeruginosa,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"and anaerobes typical of the human enteric flora.  When there is no evidence\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"that would direct therapy to any single organism, empirical therapy should be\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"directed against these organisms.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 310,
    "fields": {
      "name": "ORZID2 GMENU APPRO INTRAVAS CATH-ASSOC INFECT",
      "term": null,
      "displaytext": "Approach to Intravascular catheter-associated infection",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 278, \"DisplayText\": \"Suppurative Thrombophlebitis--Empirical Therapy\", \"Text\": \"Suppurative thrombophlebitis\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO INTRAVASCULAR CATHETER-ASSOCIATED INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The likelihood of colonization of an intravenous catheter increases with time,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"increasing noticeably after 3 days. Patients whose catheters become colonized\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"may or may not develop local or systemic signs or symptoms. All types of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"catheters are associated with risk of local and catheter-associated bacteremia.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Since central catheters are usually used for more days than peripheral\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"catheters, central catheters have a greater risk of catheter-associated\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"bacteremia.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"When catheter-related bacteremia is suspected, draw blood cultures from both the\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"catheter and a peripheral vein. Growth rate between the two cultures may be used\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"to determine if the source of bacteremia is likely catheter-associated. If the\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"catheter obtained culture's time to positivity is 2 hours or more before the\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"peripheral vein obtained culture's time to positivity, this suggests catheter-\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"associated infection. Sample any exudate at the catheter site for gram stain and\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"culture.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Suppurative thrombophlebitis presents with inflammation in and around a vein.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"There may be local thrombosis and/or bacteremia. Cases may be life-threatening\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"and can require surgical drainage.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For patients with catheter-associated bacteremia with virulent pathogens like\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Staphylococcus aureus, gram-negative bacilli, or candida, catheter removal is\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"almost always necessary. For mild or moderate cases with less virulent\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"organisms like coagulase-negative staphylococci, antimicrobial therapy is\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"successful without catheter removal about half of the time. The decision about\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"whether to remove the catheter depends on severity of illness, the need for the\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"catheter, and how difficult catheter replacement would be.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Antimicrobial lock therapy\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"For cases in which an infected catheter is not removed, the success rate is\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"improved when the infected catheter is filled with an antimicrobial solution\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"during periods when the catheter is not used. Consult Infectious Diseases or\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Pharmacy for information.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"In Staphylococcus aureus cases, document that bacteremia has cleared during\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"antimicrobial therapy. Infectious Disease consultation is required for all\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"cases of S. aureus bacteremia.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"For a patient whose blood cultures remain positive for more than 3 days or with\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"a catheter tunnel abscess or who has a prosthetic device, contact Infectious\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"diseases.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Gaur et al., Clinical infectious diseases 2003, 37.4\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Mandell chapter: Infections Caused by Percutaneous Intravascular Devices\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Mandell chapter Sepsis, Severe Sepsis and Septic Shock\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mermel et al., Clinical Infectious Diseases 49 (2009)\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-to-Date article: Prevention of Intravascular Catheter Associated Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 311,
    "fields": {
      "name": "ORZID2 GMENU APPROACH TO BRAIN ABSCESS",
      "term": null,
      "displaytext": "Approach to Brain Abscess",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 335, \"DisplayText\": \"Brain abscess resulting from contiguous or hematogenous spread of infection\", \"Text\": \"Brain abscess from contiguous or hematogenous spread of infection\", \"Mnemonic\": \"4\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 337, \"DisplayText\": \"Post-surgical or post-traumatic brain abscess\", \"Text\": \"Post-surgical or post-traumatic brain abscess\", \"Mnemonic\": \"6\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 336, \"DisplayText\": \"Brain Abscess with Nocardia spp.\", \"Text\": \"Nocardia spp.\", \"Mnemonic\": \"8\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 338, \"DisplayText\": \"Brain Abscess with Pseudomonas spp.\", \"Text\": \"Pseudomonas spp.\", \"Mnemonic\": \"10\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 339, \"DisplayText\": \"Brain Abscess with Toxoplasma gondii\", \"Text\": \"Toxoplasma gondii\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO BRAIN ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Brain abscess is a focal infection of the brain parenchyma. Symptoms often\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"include headache, fever, altered mental status, seizures, and focal neural\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"deficits. Pathogens vary based on primary site of infection and patient's immune\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"status. Bacteria cause most infections in immunocompetent patients whereas a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"wider array of pathogens, including fungi, cause infection in immunocompromised\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"patients.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Streptococci are the most isolated pathogen, often isolated from mixed\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"infections. Bacteroides are also commonly isolated in mixed cultures. Enteric\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"gram-negative bacilli are typically isolated in patients with otitic foci,\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"bacteremia, or post-neurosurgery. Staphylococcus aureus is commonly isolated in\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"a pure culture and in patients with endocarditis or cranial trauma. Brain\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"abscess caused by Listeria and Nocardia may occur in patients who are\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"immunocompromised.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Magnetic resonance imaging (MRI) should be obtained in all patients with\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"suspected brain abscess for diagnosis and determining number of lesions. Prior\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"to beginning antimicrobial therapy, when possible, computed topographic (CT) -\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"guided aspiration or surgery should be performed to obtain abscess material for\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"determination of infectious pathogen.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Solitary brain abscesses usually result from the spread of focal ear, sinus, or\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"dental infection (contiguous source). Cases with multiple abscesses often result\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"from hematogenous spread from infections such as endocarditis, abdominal\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"infection, or lung abscess.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Empiric Treatment After Obtaining Abscess Sample, When Possible\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treatment Based on Isolated Pathogen\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"When infectious organism is identified, adjust antimicrobials to optimize\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"therapy\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Brouwer et al. N Engl J Med, 2014, 371(5)447-56\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Brain Abscess\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford keyword: Brain Abscess\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-to-Date article: Pathogenesis, clinical manifestations, and diagnosis of\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"brain abscess\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 312,
    "fields": {
      "name": "ORZID2 GMENU BABESIA SPP.",
      "term": null,
      "displaytext": "Babesia species ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 500 mg PO once ($) on day 1, then 250 mg PO q24h ($) [M] for 6\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZITHRO 500MG IV Q24H ATOVA 750MG PO Q12H\", \"Text\": \"Azithromycin 500 IV q24h ($) [M] <AND> atovaquone 750 mg PO q12h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BABESIA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treat for 7-10 days. If patient has persistent relapsing disease, treat for 6\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"weeks including 2 weeks after babesia are no longer detected in blood smear.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"days <AND> atovaquone 750 mg PO q12h ($) [M] for 7 days\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"*Consult Infectious Diseases, requires NF consult for quinine.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Clindamycin 600 mg PO q8h <AND> quinine 650 mg PO q8h\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"*Consult Infectious diseases, requires NF consult for quinine.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Clindamycin 600mg IV q6h <AND> quinine 650 mg PO q8h\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Babesia Species\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Babesiosis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date article: Babesiosis: Treatment and prevention\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Vannier et al. N Engl J Med. 2012 (366)2397-407\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 313,
    "fields": {
      "name": "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO",
      "term": null,
      "displaytext": "Bacterial meningitis with Gram pos bacilli suggesting L. monocytogenes",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 2 mg/kg iv once then 1.7 mg/kg iv q8h\", \"Text\": \"Gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 3037, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimeth/sulfa 5-25 mg/kg iv q6h\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH GRAM-POSITIVE BACILLI/COCCOBACILLI SUGGESTING LISTERI\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"MONOCYTOGENES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OPTIONAL ADD ON TO ONE OF THE AGENTS ABOVE FOR SYNERGY >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 314,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING ASSOC TRAUMA",
      "term": null,
      "displaytext": "Bacterial meningitis associated with trauma or nosocomial infection",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2gm IV q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R] for 10-14\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 3038, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R] for\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS ASSOCIATED WITH TRAUMA OR NOSOCOMIAL INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult Neurosurgery and Infectious Diseases\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Removal of Infected Shunt, Drain, and Other Hardware is Required for Source\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Control\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment duration is typically 10-14 days depending on infection type,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"organism, severity, and source control.A shorter duration may be used in\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infections caused by P. acnes, coagulase-negative staphylococci, diptheroids,\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"and infections with minimal CSF abnormalities.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"days\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"10-14 days\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Tunkel et al., Clinical Infectious Diseases, 2017, 64(6)e34-e65\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 315,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS",
      "term": null,
      "displaytext": "Bacterial meningitis with E. Coli, Pseudomonas, or other organism  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH E. COLI, PSEUDOMONAS, OR ANOTHER ORGANISM\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment is complicated and non-standardized. Consult Infectious Diseases to\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"assist in treatment in all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 316,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING GNB",
      "term": null,
      "displaytext": "Bacterial meningitis with Gram negative bacilli  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM IV Q8H GENT 2MG/KG X1 1.7MG/KG IV Q8H\", \"Text\": \"Cefepime 2gm IV q8h ($$) [R] <AND> gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 3039, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH GRAM-NEGATIVE BACILLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"q8h ($) [R,O]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Gram-negative Bacilli\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 317,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING",
      "term": null,
      "displaytext": "Bacterial meningitidis with Gram negative diplococci suggesting N. meningitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 3040, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH GRAM-NEGATIVE DIPLOCOCCI SUGGESTING NEISSERIA\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"MENINGITIDIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"If meningococcal meningitis is identified, antimicrobial prophylaxis should be\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"considered for close contacts. Contact Infectious Diseases/Epidemiology for\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"advice and assistance.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 318,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO",
      "term": null,
      "displaytext": "Bacterial meningitis with Gram positive diplococci suggesting S. pneumonia  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 10 MG IV q6h\", \"Text\": \"Dexamethasone 10 mg IV q6h ($) for 4 days\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 3041, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH GRAM-POSITIVE DIPLOCOCCI SUGGESTING STREPTOCOCCUS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"PNEUMONIAE\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Intravenous dexamethasone therapy improves outcomes for meningitis with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae and is recommended for empirical treatment of all\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"community acquired cases that might be associated with S. pneumoniae.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Dexamethasone must be given before (1 to 20 minutes) with antimicrobials.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Step 1 of Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Step 2 of Treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empirical Antimicrobials\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 319,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING L. MONOCYTOGENES",
      "term": null,
      "displaytext": "Bacterial meningitis with L. monocytogenes ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] for 21 days\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 2 mg/kg iv once then 1.7 mg/kg iv q8h\", \"Text\": \"Gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV q8h ($) [R,O] for 7 days\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 3042, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimeth/sulfa 5-25 mg/kg iv q6h\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH L. MONOCYTOGENES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat for a total duration of 21 days. If gentamicin is added for synergy, treat\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for at least 1 week. May be extended for up to 3 weeks in those who are poor\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"responders and do not have signs of toxicity.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OPTIONAL ADD ON TO ONE OF THE AGENTS ABOVE FOR SYNERGY >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Listeria monocytogenes\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 320,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING N. MENINGITIDIS",
      "term": null,
      "displaytext": "Bacterial meningitis with N. meningitidis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 3043, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Penicillin MIC <0.1 mcg/mL: Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Penicillin MIC 0.1-1.0 mcg/mL: Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH N. MENINGITIDIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Meningococcal disease prophylaxis should be given to close contacts. Contact\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Infectious Diseases/Epidemiology for advice and assistance.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat for a total duration of 7 days.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Preferred treatment:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Neisseria meningitidis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 321,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING S. PNEUMONIAE",
      "term": null,
      "displaytext": "Bacterial meningitis with S. pneumoniae ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 10 MG IV q6h\", \"Text\": \"Dexamethasone 10 mg IV q6h ($) for 4 days\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 3044, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rifampin 600 mg PO Q24h ($) [DI,O]\", \"Text\": \"< ADD > Rifampin 600 mg PO q24h to above ($) [DI,O]\", \"Mnemonic\": \"20\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rifampin 600 mg IV q24h to above ($$$$) [DI,O]\", \"Text\": \"< ADD > Rifampin 600 mg IV q24h to above ($$$$) [DI,O]\", \"Mnemonic\": \"22\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"24\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]\", \"Text\": \"Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS WITH S. PNEUMONIAE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Intravenous dexamethasone therapy improves outcomes for meningitis with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae and is recommended for empirical treatment of all\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"community acquired cases that might be associated with S. pneumoniae.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Dexamethasone must be given before (1 to 20 minutes) with antimicrobials.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If Initiating Therapy, Give:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Antimicrobial Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Note: Antimicrobials depend on S. pneumoniae MIC results. In most cases results\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"will usually be known only after 2 or 3 days of therapy.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treat for a total duration of 10-14 days.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment if Penicillin MIC < or = 0.1 mcg/mL\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treatment if Penicillin MIC > or = 0.1 mcg/mL and Ceftriaxone MIC < or = 0.5\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"mcg/mL\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Treatment if Penicillin MIC > or = 0.1 mcg/mL and Ceftriaxone MIC > 0.5 mcg/mL\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Treat as listed below, and obtain another CSF specimen in 24 to 48 hours.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Ceftriaxone MIC < 2 mcg/mL\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Ceftriaxone MIC >/= 2 mcg/mL\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Streptococcus pneumoniae\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 322,
    "fields": {
      "name": "ORZID2 GMENU BACT MENING W/O GRM STAIN RES",
      "term": null,
      "displaytext": "Bacterial meningitis without Gram stain results  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dexamethasone 10 MG IV q6h\", \"Text\": \"Dexamethasone 10 mg IV q6h ($) for 4 days\", \"Mnemonic\": \"4\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 3045, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> ceftriaxone 2 gm IV q12h ($) [M] <AND>\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> ceftriaxone 2 gm IV q12h ($) [M] <AND>\", \"Mnemonic\": \"12\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15mg/kg q12h ($) [R]\", \"Text\": \"Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15mg/kg q12h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL MENINGITIS (WITHOUT GRAM STAIN RESULTS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Once a diagnosis of acute bacterial meningitis is considered likely,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"antimicrobials should be initiated as soon as possible. Two blood cultures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be drawn. Lumbar puncture (LP) should be performed in nearly all patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to obtain cerebrospinal fluid (CSF) for establishing diagnosis and determining\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infectious organism/susceptibility. Adjust antimicrobial regimen to optimize\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy and treatment duration based on pathogen once isolated.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Intravenous dexamethasone therapy improves outcomes for meningitis with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae and is recommended for empirical treatment of all\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"community acquired cases that might be associated with S. pneumoniae.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Dexamethasone must be given before (1 to 20 minutes) with antimicrobials.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If meningococcal meningitis is identified, antimicrobial prophylaxis should be\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"considered for close contacts. Contact Infectious Diseases/Epidemiology for\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"advice and assistance.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Step 1 of Treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(Discontinue if isolated pathogen is not S. pneumoniae)\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Step 2 of Treatment, Select One of the Following:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment for Adults < 50 Years Without Alcoholism, Debilitating Disease, or\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Any Other Condition Associated with Impaired Cellular Immunity.\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment for Adults >= 50 Years or With Alcoholism, Debilitating Disease, or\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Impaired Cellular Immunity. Listeria Monocytogenes is One Important Pathogen.\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"vancomycin 15mg/kg q12h ($) [R]\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"<AND> trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Mandell chapter: Acute meningitis\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Age > 50 years\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, Age 1 mo to 50 years\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Meningitis, bacterial, positive gram stain\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Tunkel et al., Clin Infect Dis, 2004, 39.1267-84\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Up-to-Date Article: Clinical features and diagnosis of acute bacterial\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"meningitis in adults\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Up-to-Date Article: Treatment of bacterial meningitis caused by specific\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"pathogens in adults\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 323,
    "fields": {
      "name": "ORZID2 GMENU BACTEREMIA CANDIDA SPP.",
      "term": null,
      "displaytext": "Bacteremia associated with Candida spp. ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Micafungin 100 mg IV q24h\", \"Text\": \"Micafungin 100 mg IV q24h ($$$) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FUNGEMIA ASSOCIATED WITH CANDIDA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases. Antifungal treatment is indicated for all cases of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"candidemia. Treat until 14 days after the last positive blood culture.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Most Candida can be treated with fluconazole. If the patient is critically ill,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"if the patient has recently taken an azole antifungal, or if Candida krusei or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"C. glabrata are present, micafungin should be used initially.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"If the patient has substantial renal disease, but is not dialysis-dependent,\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"consider micafungin. Call Infectious Diseases for advice.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment for Candida albicans, Candida parapsilosis and\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Candida tropicalis\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For patients who cannot take oral medication\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment for Candida glabrata and Candida krusei\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Andes et al, Clinical Infectious Diseases 2012, 54.8\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Pappas et al, Clinical Infectious Diseases 2016, 62.4e1-50\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 324,
    "fields": {
      "name": "ORZID2 GMENU BACTEREMIA COAG NEG STAPH",
      "term": null,
      "displaytext": "Bacteremia associated with Coagulase-negative Staphylococci (CNS)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 327, \"DisplayText\": \"Bacteremia associated with Staphylococcus lugdunensis\", \"Text\": \"Bacteremia associated with Staphylococcus lugdunensis\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEREMIA ASSOCIATED WITH COAGULASE-NEGATIVE STAPHYLOCOCCI (CNS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"warneri and S. xylosus.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"to Bacteremia Associated S. lugdunensis page for treatment.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"CNS are present in 50% of positive blood cultures, and 90% are contaminants. In\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"a patient without signs or symptoms of infection, a single positive blood\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"culture for CNS often represents contamination and not infection. CNS are more\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"likely to be pathogens in patients with a prosthetic device. Contact Infectious\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Diseases for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"For patients with catheter-related bacteremia or those with suspected\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"endocarditis, please return to the main menu and proceed to the appropriate\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"advice page.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Most isolates are methicillin-resistant. Use vancomycin empirically, but switch\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"to the more effective beta-lactam antimicrobials if the isolate is susceptible.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Empirical treatment of coagulase-negative staphylococci\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Treatment for methicillin-susceptible staphylococci\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For patients with non-severe penicillin allergy\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treatment for methicillin-resistant staphylococci or for patients with severe\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"penicillin allergy\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus, Coagulase-negative species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 325,
    "fields": {
      "name": "ORZID2 GMENU BACTEREMIA LISTERIA",
      "term": null,
      "displaytext": "Bacteremia associated with Listeria monocytogenes",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEREMIA ASSOCIATED WITH LISTERIA MONOCYTOGENES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment of listeria infection\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For immunocompromised patients and for patients with meningitis or endocarditis\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"($) [R,O]\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"For patients with penicillin allergy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell chapter: Listeria Monocytogenes\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Listeria monocytogenes\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 326,
    "fields": {
      "name": "ORZID2 GMENU BACTEREMIA S. AUREUS",
      "term": null,
      "displaytext": "Bacteremia associated with Staphylococcus aureus ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 102, \"DisplayText\": \"Cardiovascular\", \"Text\": \"CARDIOVASCULAR\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEREMIA ASSOCIATED WITH STAPHYLOCOCCUS AUREUS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases. Empirical therapy should cover\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"methicillin-resistant Staphylococcus aureus. If an isolate susceptible to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"beta-lactams is identified, use one of these drugs because they are more\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"effective.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If there is an easily removable or drainable focus (e.g. infected intravenous\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"catheter, minor abscess, urinary cystitis, or mild to moderate pneumonia), and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"this focus has been treated, give parenteral antimicrobials for 2 weeks.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Consider echocardiogram to assess for associated endocarditis, which would\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"require 4-6 weeks of therapy. Consult Cardiology or Infectious Diseases for more\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to cardiovascular section for suspected endocarditis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment for methicillin-susceptible staphylococci\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment for methicillin-resistant staphylococci\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Antimicrobial Therapy\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 327,
    "fields": {
      "name": "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS",
      "term": null,
      "displaytext": "Bacteremia associated with Staphylococcus lugdunensis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 102, \"DisplayText\": \"Cardiovascular\", \"Text\": \"CARDIOVASCULAR\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEREMIA ASSOCIATED WITH STAPHYLOCOCCUS LUGDUNENSIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Severity of S. lugdenensis infections vary from moderate to severe.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Approximately 25% of isolates are resistant to penicillin, but methicillin\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"resistance is uncommon. Since optimal duration of therapy has not been\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"established, treat until patient is clearly improved and has been free of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"symptoms or signs of S. lugdunensis infection for several days.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Refer to cardiovascular section for suspected endocarditis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment for methicillin-susceptible S. lugdunensis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment for methicillin-resistant S. lugdunensis\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Staphylococci\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-To-Date article: Staphylococcus lugdunensis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus lugdunensis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 328,
    "fields": {
      "name": "ORZID2 GMENU BED BUGS (HEMIPTERA)",
      "term": null,
      "displaytext": "Bed Bugs (Hemiptera)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Triamcinolone 0.1% cream topical bid prn\", \"Text\": \"Triamcinolone 0.1% cream apply to affected area BID PRN for itching ($)[M]\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Hydroxyzine pamoate 25mg po tid then 25mg po tid prn (Var)\", \"Text\": \"Hydroxyzine pamoate 25 mg PO TID until symptoms resolve, then take 25 mg PO\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BED BUGS (HEMIPTERA)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Antimicrobial treatment is not indicated.  Treat itching with topical\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"corticosteroids or systemic antihistamines.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"TID PRN for itching ($) [H]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 329,
    "fields": {
      "name": "ORZID2 GMENU BITE WNDS EIKENELLA CORRODENS",
      "term": null,
      "displaytext": "Bite wounds with Eikenella corrodens ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100MG PO Q12H\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH EIKENELLA CORRODENS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Bites\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 330,
    "fields": {
      "name": "ORZID2 GMENU BITE WNDS P. MULTOCIDA",
      "term": null,
      "displaytext": "Bite wounds with Pasteurella multocida  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100mg PO q12h ($) [DI] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Doxycycline 100mg IV q12h ($$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH PASTEURELLA MULTOCIDA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Sanford keyword: Bites\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 331,
    "fields": {
      "name": "ORZID2 GMENU BITE WNDS S. AUREUS",
      "term": null,
      "displaytext": "Bite wounds with Staphylococcus aureus  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [DI]  OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] < OR >\", \"Mnemonic\": \"14\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]  < OR >\", \"Mnemonic\": \"16\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI]  < OR >\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH STAPHYLOCOCCUS AUREUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"_________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Methicillin-SUSCEPTIBLE S. aureus\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Methicillin-RESISTANT S. aureus\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Bites\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 332,
    "fields": {
      "name": "ORZID2 GMENU BITE WNDS STREPTOCOCCI",
      "term": null,
      "displaytext": "Bite wounds with Streptococci  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 MU IV q4h ($) [R]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH STREPTOCOCCI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for penicillin allergic patients:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Sanford keyword: Bites\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 333,
    "fields": {
      "name": "ORZID2 GMENU BITE WOUNDS",
      "term": null,
      "displaytext": "Bite wounds  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Mnemonic\": \"4\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]  < OR >\", \"Mnemonic\": \"6\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po q24h (Var)\", \"Text\": \"Moxifloxacin 400mg po q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg IV q24h ($$) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 330, \"DisplayText\": \"Bite wounds with Pasteurella multocida\", \"Text\": \"Bite wounds with Pasteurella multocida\", \"Mnemonic\": \"20\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 329, \"DisplayText\": \"Bite wounds with Eikenella corrodens\", \"Text\": \"Bite wounds with Eikenella corrodens\", \"Mnemonic\": \"22\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 331, \"DisplayText\": \"Bite wounds with Staphylococcus aureus\", \"Text\": \"Bite wounds with Staphylococcus aureus\", \"Mnemonic\": \"24\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 332, \"DisplayText\": \"Bite wounds with Streptococci\", \"Text\": \"Bite wounds with Streptococci\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bite wounds are prone to infection because of the pathogenic oral flora carried\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into tissues  by teeth.  Common pathogens include Eikenella corrodens, usually\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"from human bites, and Pasteurella multocida, often from dog or cat bites,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"streptococci and staphylococci.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Clean wounds with soap and water as soon as possible, add local antiseptic\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and debride non-viable tissue.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult orthopedic surgery for all bite wounds involving the hand.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antibiotic Prophylaxis Indications:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Severe injury less than 8 hours, Crush injury, Bone or joint penetration,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Wound of the face or hands or genitals, Immunocompromised host, Asplenia,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Advanced liver disease\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"*Routine use of prophylactic antibiotics for non-immunocompromised patients\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"with superficial wounds with no puncture that do not involve the face/\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"genitals/hands is not recommended.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Antimicrobial Treatment:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empiric treatment for suspected or established infection following bite wound.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"In these cases, therapy should be directed against pathogen identified\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"by Gram stain and culture whenever possible.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Rabies Prophylaxis:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Consider rabies post-exposure prophylaxis for all animal bite cases.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Contact infectious diseases for assistance.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Consider tetanus immunization status:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"If immunization is up to date, nothing more needs to be done to prevent tetanus.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"If immunization is lacking, and:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"wound IS NOT tetanus prone, bring immunization up to date with Td\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"wound IS tetanus prone, bring immunization up to date with Td  < AND >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Select below for Tetanus vaccination information page:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treat deep wounds for the first 3-5 days after a bite to prevent infection.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"For wounds that later develop evidence of infection but without arthritis, treat\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"with antimicrobials for 7-14.  For wounds that develop infection of a joint,\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"treat 14 to 21 days.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Prophylaxis:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Duration 3 to 5 days:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative for patients with penicillin allergy:\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Empiric treatment for suspected or estabished infection:\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Duration 7 to 14 days:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Alternative for patients with penicillin allergy:\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Pathogen directed bite wound therapy:\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Abrahamian FM New Engl Journ Med 1999, 340:85\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 334,
    "fields": {
      "name": "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)",
      "term": null,
      "displaytext": "Body Lice (Pediculosis Corporis)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion to the affected area for 10 minutes\", \"Text\": \"Permethrin 1% lotion Apply to affected area for 10 minutes then comb out\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BODY LICE (PEDICULOSIS CORPORIS)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Lice are parasitic insects. Human lice survive by feeding on human blood.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Body lice proliferate in places where crowding of persons with poor hygiene is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"common, especially homeless persons.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Infested clothing and bed linen should be heat washed or discarded.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Itching is the most common symptom, but some patients present only with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"excoriations and inflammation on the neck and trunk.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"A repeat application may be used if live lice are seen 7-10 days after\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"nits ($) [M]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: lice\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 335,
    "fields": {
      "name": "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT",
      "term": null,
      "displaytext": "Brain abscess resulting from contiguous or hematogenous spread of infection ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAX 2GM IV Q12H METRO 500MG IV Q8H\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 3046, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"10\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM IV Q8H METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H\", \"Text\": \"Cefepime 2gm IV Q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BRAIN ABSCESS FROM CONTIGUOUS OR HEMATOGENOUS SPREAD OF INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Prior to beginning antimicrobial therapy, when possible, computed topographic\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(CT) - guided aspiration or surgery should be performed to obtain abscess\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"material for determination of infectious pathogen. Adjust antimicrobial regimen\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to optimize therapy and treatment duration to optimize therapy based on pathogen\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"once isolated.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Broad spectrum empiric antimicrobials are indicated initially for brain abscess.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Staphylococcus aureus is a common pathogen. Beta-lactam antibiotics are more\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"effective than vancomycin for susceptible Staphylococci. If Staphylococcus is\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"isolated, once methicillin- resistance is ruled out, switch to an\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"anti-staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"in post-surgical patients, and those who are known to be colonized with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pseudomonas.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Duration is typically 6-8 weeks, with the shorter duration for those with\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"cerebritis only or drained abscess, longer for undrained or encapsulated\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"abscesses, multiple or loculated abscesses, abscess in an immunocompromised\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"host.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Empiric Treatment for Solitary Brain Abscess from Contiguous Source\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Empiric Treatment for Solitary Brain Abscess from Unknown Source, From\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Hematogenous Spread, Multiple Brain Abscesses or History of MRSA Infection or\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Colonization\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is not likely:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is likely:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Brouwer et al. N Engl J Med, 2014, 371(5)447-56\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mandell chapter: Brain Abscess\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Brain Abscess\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Up-to-Date article: Pathogenesis, clinical manifestations, and diagnosis of\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"brain abscess\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 336,
    "fields": {
      "name": "ORZID2 GMENU BRN ABSC NOCARDIA SPP",
      "term": null,
      "displaytext": "Brain Abscess with Nocardia spp.  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TMP-SMZ 15-75MG/KG IV Q8H IMIPENEM 1GM IV Q8H\", \"Text\": \"Trimethoprim 15 mg/kg - sulfamethoxazole 75 mg/kg IV q8h ($$$) [R,DI] <AND>\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 15 mg/kg - sulfamethoxazole 75 mg/kg IV q8h ($$$) [R,DI] <AND>\", \"Text\": \"Trimethoprim 15 mg/kg - sulfamethoxazole 75 mg/kg IV q8h ($$$) [R,DI] <AND>\", \"Mnemonic\": \"6\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amikacin 7.5 mg/kg q12h ($$)\", \"Text\": \"< ADD > Amikacin 7.5 mg/kg q12h ($$)\", \"Mnemonic\": \"8\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LINEZOLID 600MG IV Q12H IMIPENEM 1GM IV Q8H\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O] < AND > imipenem 1 gm q8h ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 2 DS PO q12h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100mg q12h($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BRAIN ABSCESS WITH NOCARDIA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Magnetic resonance imaging (MRI) should be obtained in all patients with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"suspected brain abscess for diagnosis and determining number of lesions. Prior\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"to beginning antimicrobial therapy, when possible, computed topographic (CT) -\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"guided aspiration or surgery should be performed to obtain abscess material for\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"determination of infectious pathogen.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Nocardia brain abscesses typically occur in immunocompromised patients and is\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"often concomitant with disseminated or pulmonary infection. May occur with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"meningitis and/or ventriculitis.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat with IV therapy for total duration of 3-6 weeks in immunocompetent and 6\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"weeks in immunocompromised patients. Switch to oral antimicrobials after\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"completing IV therapy and treat for an additional 3 months or more (longer for\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"meningitis, immunocompromise or extensive disease).\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Initial IV Therapy\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"imipenem 1000 mg q8h ($$) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"If Nocardia isolate is susceptible to third generation cephalosporins\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"ceftriaxone 2 gm IV q12h ($) [M]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"If multiorgan or rapidly progressive disease, in addition to above therapy\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Oral Therapy, After Completing IV Therapy Above\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"For immunocompetent patients, treat with one of the below PO antimicrobials for\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"at least 3 months after initial IV treatment. For immunocompromised patients,\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Treat with 2 of the below antimicrobials for at least one year.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Brouwer et al. N Engl J Med, 2014, 371(5)447-56\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Brain Abscess\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Brain Abscess\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of Nocardiosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 337,
    "fields": {
      "name": "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC",
      "term": null,
      "displaytext": "Post-surgical or post-traumatic brain abscess ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2gm IV Q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 3047, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2gm IV Q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"POST-SURGICAL OR POST-TRAUMATIC BRAIN ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Prior to beginning antimicrobial therapy, when possible, computed topographic\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(CT) - guided aspiration or surgery should be performed to obtain abscess\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"material for determination of infectious pathogen. Adjust antimicrobial regimen\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to optimize therapy based on pathogen once isolated.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Broad spectrum empiric antimicrobials are indicated initially for brain abscess.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Staphylococcus aureus is a common pathogen. Beta-lactam antibiotics are more\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"effective than vancomycin for susceptible Staphylococci. If Staphylococcus is\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"isolated, once methicillin- resistance is ruled out, switch to an\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"anti-staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"in post-surgical patients, and those who are known to be colonized with\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Pseudomonas.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Post-Surgical Empiric Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Post Traumatic Empiric Treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred if pseudomonas is not suspected and paranasal sinuses are not\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"involved:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is suspected and paranasal sinuses are not involved:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"If paranasal sinuses are involved or alternative:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Brouwer et al. N Engl J Med, 2014, 371(5)447-56\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Mandell chapter: Brain Abscess\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford keyword: Brain Abscess, Post-traumatic or Post-surgical\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 338,
    "fields": {
      "name": "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.",
      "term": null,
      "displaytext": "Brain Abscess with Pseudomonas spp.  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Text\": \"Cefepime 2gm IV Q8h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 3048, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BRAIN ABSCESS WITH PSEUDOMONAS SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Prior to beginning antimicrobial therapy, when possible, computed topographic\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(CT) - guided aspiration or surgery should be performed to obtain abscess\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"material for determination of infectious pathogen. Adjust antimicrobial regimen\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to optimize therapy based on pathogen once isolated.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for a total duration of 6-8 weeks\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Brouwer et al. N Engl J Med, 2014, 371(5)447-56\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Brain abscess\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date Article: Pseudomonas aeruginosa infections of the eye, ear, urinary\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"tract, gastrointestinal tract and central nervous system\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 339,
    "fields": {
      "name": "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII",
      "term": null,
      "displaytext": "Brain Abscess with Toxoplasma gondii ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM200MGTHEN75MGQ24H SULFAD1.5GMQ6H LEUCO10MGQ24H\", \"Text\": \"Pyrimethamine 200 mg PO x 1 then 75 mg po daily ($$$$$) [DI,O] <AND>\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 200 mg PO x 1 ($$$$$) [DI,O] then 50 mg PO QD ($$$$$)\", \"Text\": \"Pyrimethamine 200 mg PO x 1 then 50 mg PO daily ($$$$$) [DI,O] <AND>\", \"Mnemonic\": \"6\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 75MG Q24H CLINDA 600MG PO Q6H LEUCO 10MG Q24H\", \"Text\": \"Pyrimethamine 75 mg PO q24h ($$$$$) [DI,O] <AND> clindamycin 600 mg PO q6h\", \"Mnemonic\": \"8\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 50MG Q24H CLINDA 600MG PO Q6H LEUCO 10MG Q24H\", \"Text\": \"Pyrimethamine 50 mg PO q24h ($$$$$) [DI,O] <AND> clindamycin 600 mg PO q6h\", \"Mnemonic\": \"10\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BRAIN ABSCESS WITH TOXOPLASMA GONDII\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Prior to beginning antimicrobial therapy, when possible, computed topographic\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(CT) - guided aspiration or surgery should be performed to obtain abscess\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"material for determination of infectious pathogen. Adjust antimicrobial regimen\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to optimize therapy based on pathogen once isolated.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Central nervous system toxoplasmosis occurs mostly in HIV-infected patients.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Continue treatment for a minimum of 6 weeks after resolution of signs/symptoms,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"followed by suppressive therapy until sustained immune reconstitution occurs.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Suppression can be discontinued if CD4 count >200 for 6 months.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Patient weight >/= 60 kg\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"sulfadiazine 1.5 gm PO q6h ($$) [DI,O] <AND> leucovorin 10 to 25 mg po daily ($)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Patient weight < 60 kg\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"sulfadiazine 1 gm po q6h ($$) [DI,O] <AND> leucovorin 10 to 25 mg po daily ($)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Patient weight >/= 60 kg\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"($) [H,O] <AND> leucovorin 10 to 25 mg po daily ($)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Patient weight < 60 kg\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"($) [H,O] <AND> leucovorin 10 to 25 mg po daily ($)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Brouwer et al. N Engl J Med, 2014, 371(5)447-56\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Brain Abscess\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford keyword: Brain Abscess, Toxoplasmosis\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date article: Toxoplasmosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 340,
    "fields": {
      "name": "ORZID2 GMENU CAP INPATIENT TREATED SETTING",
      "term": null,
      "displaytext": "CAP SEVERE treated in an ICU setting ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 342, \"DisplayText\": \"Stepdown empiric treatment for CAP with oral antibiotics\", \"Text\": \"[Link] Stepdown empiric treatment for CAP with oral antibiotics\", \"Mnemonic\": \"4\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sputum Culture and Gram Stain\", \"Text\": \"Lab Order: Sputum Culture & Gram Stain\", \"Mnemonic\": \"6\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Blood Culture x2\", \"Text\": \"Lab order: Blood culture x2\", \"Mnemonic\": \"8\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftriaxone 2 gm IV q24h($) [M] <AND> azithromycin 500 mg IV once\", \"Mnemonic\": \"10\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 3049, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"12\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg po q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg po q24h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV q12h (PNA) ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 78, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIPERACILLIN-TAZO 4.5 AND AZITH 500/250 BOTH IV\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV Q6H ($$) [R] <AND> Azithromycin 500 mg IV\", \"Mnemonic\": \"20\"}, {\"Row\": 81, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime and Azithromycin IV for pna pseudomonas\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> Azithromycin 500 mg IV x1 on day 1,\", \"Mnemonic\": \"22\"}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"24\"}, {\"Row\": 86, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"26\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg po q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg po q24h ($) [R,DI]\", \"Mnemonic\": \"28\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEVERE Community-Acquired Pneumonia (CAP) Treated in Intensive Care Unit (ICU)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Criteria for Defining SEVERE Community-acquired Pneumonia\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Validated definition includes either one major or three or more minor criteria\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"MAJOR CRITERIA:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Septic shock with need for vasopressors\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Respiratory failure requiring mechanical ventilation\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"MINOR CRITERIA:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Respiratory rate greater than or equal to 30 breaths/minute\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"PaO2/FiO2 ratio less than or equal to 250\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Multilobar infiltrates\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Confusion/disorientation\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Uremia (blood urea nitrogen level greater than 20 mg/dl)\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Leukopenia* (WBC less than 4,000 cells/microliter)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"*Due to infection alone (i.e., not chemotherapy induced)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Thrombocytopenia (platelet count less than 100,000 microliters)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Hypothermia (core temperature less than 36 degrees C)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Hypotension requiring aggressive fluid resuscitation\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Recommendation for duration of antibiotic therapy for CAP:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Patients with CAP should be treated for a minimum of 5 days, should be\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"afebrile for 48-72 hours, and should have no more than 1 CAP-\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"associated sign of clinical instability before discontinuation\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"of therapy.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Criteria for clinical stability:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Temperature less than/equal to 100 degrees F\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Heart rate less than/equal to 100 beats/minute\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Respiratory rate less than/equal to 24 breaths/minute\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Systolic blood pressure greater than/equal to 90 mm Hg\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Arterial oxygen saturation greater than/equal to 90% --OR--\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"PO2 greater than/equal to 60 mm Hg on room air\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Ability to maintain oral intake\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Normal mental status\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment on INTENSIVE CARE UNIT (ICU)\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Stepdown empiric treatment for CAP (Intravenous to Oral conversion)\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"(Specific therapy should be guided by culture results.)\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Recommend blood and lower respiratory tract specimen cultures for all patients\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"with Severe CAP.\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of MRSA within last 12 months:\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"confirmation of need for continued therapy. SEE MRSA Section below\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of P. aeruginosa in the last 12 months:\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"COVER for P. aeruginosa. Obtain cultures to allow deescalation or\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"confirmation of need for continued therapy. SEE P. aeruginosa section below\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Preferred Standard Regimen: (no MRSA or P. aeruginosa coverage)\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"on day 1, then 250 mg IV Q24H for 4 days ($) [M]\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Alternative Standard Regimen:\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Prior respiratory isolation of MRSA in the last 12 months: ADD MRSA coverage\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"ADD MRSA coverage to Standard Regimen above or Antipseudomonal regimen below:\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Prior respiratory isolation of P. aeruginosa in the last 12 months:\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Text\": \"SELECT REGIMEN BELOW:\", \"Header\": 1}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 79, \"Column\": 1, \"Text\": \"on day 1, then 250 mg IV Q24H for 4 days ($) [M]\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"then 250 mg IV Q24H for 4days ($) [M]\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 87, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45\"}, {\"Row\": 92, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Sanford website\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 341,
    "fields": {
      "name": "ORZID2 GMENU CAP INPATIENT TREATED SETTING NON-SEVERE CAP",
      "term": null,
      "displaytext": "CAP NON-SEVERE treated in an Inpatient Ward setting ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 342, \"DisplayText\": \"Stepdown empiric treatment for CAP with oral antibiotics\", \"Text\": \"[Link] Stepdown empiric treatment for CAP with oral antibiotics\", \"Mnemonic\": \"16\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftriaxone 2 gm IV q24h for 5 days ($) [M] <AND> azithromycin 500 mg PO x1\", \"Mnemonic\": \"18\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 3050, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"20\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO Q24H for 5 days ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO Q24H for 5 days ($) [R,DI]\", \"Mnemonic\": \"22\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazo 4.5 PO q6h and azith 500/250 iv\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> Azithromycin\", \"Mnemonic\": \"26\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV Q8H ($$) [R] <AND> Azithromycin PO 500/250\", \"Text\": \"Cefepime 2 gm IV Q8H ($$) [R] <AND> Azithromycin 500 mg PO x1 on\", \"Mnemonic\": \"28\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"30\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg po q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO Q24H ($) [R,DI]\", \"Mnemonic\": \"32\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NON-SEVERE COMMUNITY-ACQUIRED PNEUMONIA TREATED IN AN INPATIENT SETTING\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Be sure of the diagnosis.  Careful reviews have shown that over half of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"people treated for community-acquired pneumonia do not in fact have\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pneumonia.  Pneumonia is likely in persons with 3 or more signs or symptoms\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"including a) new infiltrate (or, no prior film for comparison) b) new\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"crackles, egophony, or dullness c) pleuritic pain, d) fever and/or chills\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"e) leukocytosis f) cough g) purulent sputum and h) new or worsened dyspnea\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"or tachypnea, and no likely alternative explanation for the presentation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Common alternative explanations include heart failure, thromboembolic\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"disease, COPD exacerbation, viral pneumonitis, aspiration pneumonitis, or\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"tumor. Most of the latter conditions do NOT benefit from antimicrobials.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Recommendation for duration of antibiotic therapy for CAP:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Patients with CAP should be treated for a minimum of 5 days, should be\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"afebrile for 48-72 hours, and should have no more than 1 CAP-\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"associated sign of clinical instability before discontinuation\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"of therapy.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Criteria for clinical stability:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Temperature less than/equal to 100 degrees F\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Heart rate less than/equal to 100 beats/minute\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Respiratory rate less than/equal to 24 breaths/minute\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Systolic blood pressure greater than/equal to 90 mm Hg\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Arterial oxygen saturation greater than/equal to 90% --OR--\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"PO2 greater than/equal to 60 mm Hg on room air\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Ability to maintain oral intake\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Normal mental status\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Inpatient, non-severe CAP (NOTE: DURATION of therapy)\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Stepdown empiric treatment for CAP (Intravenous to Oral conversion)\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Note: These regimens may also be used to convert patients to oral medications\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"prior to discharge.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for MRSA:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Obtain cultures BUT withhold MRSA coverage unless cultures or nasal carriage\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"positive for MRSA. (See below for prior respiratory isolation of MRSA)\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa:\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Obtain cultures BUT withhold anti-pseudomonal coverage unless cultures\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"are positive for P. aeruginosa. (See below for prior respiratory isolation\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"of P. aeruginosa)\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Preferred: (no prior respiratory isolation of MRSA or P. aeruginosa)\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"on day 1, then 250 mg PO Q24H for 4 days ($) [M]  < OR >\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of MRSA within last 12months: ADD MRSA COVERAGE\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"ADD MRSA coverage to Standard Regimen above or Antipseudomonal Regimen below:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Prior Respiratory Isolation of P.aeruginosa within last 12months: SELECT BELOW\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Select regimen below for P.aeruginosa, obtain cultures to allow deescalation\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"500mg PO x1 on day 1, then 250 mg PO Q24H for 4 days ($) [M]\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"day 1, then 250 mg PO Q24H for 4 days ($) [M]\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Alternative for P. aeruginosa:\", \"Header\": 1}, {\"Row\": 73, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"Sanford website\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Obtain cultures/nasal PCR to allow for deescalation.\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV q12h (PNA) ($) [R]\", \"Mnemonic\": \"24\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 342,
    "fields": {
      "name": "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING",
      "term": null,
      "displaytext": "Stepdown empiric treatment for CAP with oral antibiotics  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO Q12H for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO Q12H for 5 days ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO Q8H for 5 days ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO Q8H for 5 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R] <AND> Azithromycin\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO Q12H for 5 days ($) [R] <AND> Azithromycin\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO Q12H ($) [R] <AND> Azithromycin 500mg PO\", \"Text\": \"Cefdinir 300 mg PO Q12H for 5 days ($) [R] <AND> Azithromycin\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amox-clav 875 mg po q12h and doxy 100 mg po q12h both 5days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO Q12H for 5 days ($) [R] <AND> Doxycycline\", \"Mnemonic\": \"12\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg po bid and Doxycycline 100 mg po q12h 5 days\", \"Text\": \"Cefdinir 300 mg PO q12h for 5 days ($) [R] <AND> Doxycycline\", \"Mnemonic\": \"14\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 3051, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO Q24H for 5 days ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h for 5 days ($) [DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED WITH ORAL ANTIBIOTICS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"NOTE: These are INPATIENT orders.  To transfer these orders to outpatient for\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"discharge, highlight the order in the MEDS tab of CPRS, click on the\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"heading ACTION then click on Transfer to Outpatient.\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred oral treatment for PREVIOUSLY HEALTHY PATIENTS:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"conditions, or use of immunosuppressing drugs)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"No comorbidities:(Note: duration of therapy)\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred oral treatment for PATIENTS WITH COMORBIDITIES:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"(WITH chronic obstructive pulmonary disease, diabetes, renal failure, congestive\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"heart failure, malignancy, alcoholism, asplenia, immunosuppressing conditions\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"or use of immunosuppressing drugs)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Comorbidities:(Note: duration of therapy)\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"po once on day 1, then 250 mg PO QDAY for 4 days ($) [M]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"once on day 1, then 250 mg PO QDAY for 4 days ($) [M]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"100 mg PO Q12H for 5 days ($) [DI]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"100 mg PO Q12H for 5 days ($) [DI]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford: Community Acquired Pneumonia\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 343,
    "fields": {
      "name": "ORZID2 GMENU CAT-SCATCH DISEASE",
      "term": null,
      "displaytext": "Cat-Scratch Disease",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1on day 1, then 250 mg PO QDAY for 4 days ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CAT-SCRATCH DISEASE\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cat-scratch disease occurs when a cat infected with Bartonella henselae\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"scratches or bites a person or licks a person's open wound.  A local pustule\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"develops followed by lymphadenopathy, typically on the same side of the body as\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"the scratch or bite.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Infections associated with other pathogens such as Francisella tularemia,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Coxiella burnetiid and other slow-growing bacteria may present with similar\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"symptoms.  Consult Infectious Diseases for more information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"About 10% of cases of cat-scratch disease present atypically with symptoms\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"involving the eye, nervous system, or lungs.  Consult Infectious Diseases in\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"these cases.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Bartonella, including cat-scratch disease\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: cat-scratch disease\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 344,
    "fields": {
      "name": "ORZID2 GMENU CHRONIC SINUSITIS",
      "term": null,
      "displaytext": "Chronic Sinusitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 567, \"DisplayText\": \"Severe Sinusitis\", \"Text\": \"Severe Sinusitis\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHRONIC SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis of chronic sinusitis is based on presence of at least 2 of the 4\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cardinal signs/symptoms lasting >/= 12 weeks. In addition, diagnosis requires\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"objective evidence of mucosal inflammation using nasal endoscopy and/or CT\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"imaging. The initial therapy for chronic sinusitis is treatment with intranasal\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"corticosteroids and saline. For patients with severe nasal blockage by polyps,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"treat with a short course of oral glucocorticoids. Reassess patient after 1 to 3\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"months of intranasal therapy or after completion of glucocorticoid therapy. If\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"signs/symptoms have not improved, consult surgery, ENT and Infectious Diseases\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"as treatment is complex.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Acute exacerbations of chronic sinusitis can be caused by discontinuing medical\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"therapy, viral infections, allergens, noxious inhalants and bacterial or fungal\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"infections. Bacterial infections should be suspected when the patient has\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"increased signs/symptoms persisting for more than 10 days. Refer to Severe\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sinusitis recommendations for choice of antimicrobial therapy in these patients.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Repeated use of the same agent should be avoided to prevent promotion of drug\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"resistant bacteria or increased fungal colonization.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Cardinal Signs/Symptoms of Chronic Sinusitis\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"1. Anterior and/or posterior nasal mucopurulent drainage\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"2. Nasal obstruction/nasal blockage/congestion\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"3. Facial pain, pressure, and/or fullness\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"4. Reduction or loss of sense of smell\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Objective Evidence mucosal inflammation\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1. Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"2. Polyps in the nasal cavity or the middle meatus\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"3. Radiographic imaging demonstrating mucosal thickening or partial or complete\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"opacification of the paranasal sinuses\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Rudmik et al., JAMA. 2015, 314(9) 926-939\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Chronic\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-To-Date article: Chronic rhinosinusitis: Clinical manifestations,\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"pathophysiology, and diagnosis\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-To-Date article: Microbiology and antibiotic management of chronic\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"rhinosinusitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 345,
    "fields": {
      "name": "ORZID2 GMENU CMI DEFECTS",
      "term": null,
      "displaytext": "Cell-mediated immunity (CMI) defects ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CELL-MEDIATED IMMUNITY (CMI) DEFECTS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with reduced CMI include those with HIV/AIDS, hematologic malignancies,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cytotoxic chemotherapy, and congenital abnormalities.  Patients with cell-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"mediated immune defects are more susceptible to infections from ubiquitous\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"microorganisms that do not usually cause infection in healthy patients.  The\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"specific organisms that are more likely to be associated with disease vary\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"depending on the specific type of immune defect present, but include:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Pneumocystis jirovecii (formerly Pneumocystis carinii), Mycobacterium avium,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mycobacterium tuberculosis, Salmonella spp., Candida spp., Aspergillus spp.,\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Toxoplasma gondii, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"and Cryptosporidium parvum.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"These infectious diseases usually have a subacute or chronic presentation.  The\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"best approach in most circumstances is for the clinician to conduct a methodical\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"diagnostic workup to identify the specific pathogen and guide therapy.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Empirical antimicrobials are not indicated for patients with CMI defects who\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"present only with fever.  Contact Infectious Disease for more information.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 346,
    "fields": {
      "name": "ORZID2 GMENU COMM ACQ DIARRHEA",
      "term": null,
      "displaytext": "Community acquired diarrhea ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Clostridium difficile\", \"Mnemonic\": \"4\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 3-5 days ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h for 3 days ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY ACQUIRED DIARRHEA (NO RECENT TRAVEL)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Acute diarrhea (< 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Empirical antimicrobials should be given only in cases of severe acute disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"or high-risk conditions: fever, >/= 6 stools in 24 hours, volume depletion\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"requiring hospitalization, severe abdominal pain, immune compromise, cardiac\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"disease, >/= 70 years old.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"If in the preceding two months the patient has taken a PPI or has been\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"hospitalized for three or more days, consider Clostridium difficile infection.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Bloody diarrhea\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"therapy and antimotility agents are not recommended in most patients with bloody\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"diarrhea due to an increased risk of hemolytic uremic syndrome when using these\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"agents. Obtain a stool sample for enteric pathogen PCR testing and reserve\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"antimicrobial and antimotility agent treatment until results are known. Enteric\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"pathogen PCR testing results are reported within 2 hours between 7am and 11pm.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"For more information on when an antimicrobial is indicated or if the patient has\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"severe/life threatening diarrhea or is immunocompromised, contact Infectious\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Empiric antimicrobial treatment for non-bloody severe acute diarrhea\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Subacute or chronic (>/= 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Primary treatment is hydration and electrolyte replacement. Empiric\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"antimicrobial therapy is not indicated. Investigate for the cause of diarrhea.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases involvement is encouraged.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford guide keyword: Gastroenteritis, Diarrhea: Overview\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"settings\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 347,
    "fields": {
      "name": "ORZID2 GMENU COMM VIRAL GASTROENTERITIS",
      "term": null,
      "displaytext": "Viral Diarrhea  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"VIRAL GASTROENTERITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infectious diarrhea caused by viral pathogens such as Adenovirus, Astrovirus,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Norovirus, Rotavirus, and Sapovirus is usually self-limited. Treatment includes\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"supportive measures such as oral rehydration and unrestricted nutrition.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antiviral therapy is not recommended and for most viruses is unavailable.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antimotility agents may be used for one or two days in patients with mild to\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"moderate volume depletion. Antiemetic agents may be used for one or two days in\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"patients with vomiting.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford guide keyword: Gastroenteritis, Diarrhea: Overview\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute viral gastroenteritis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 348,
    "fields": {
      "name": "ORZID2 GMENU CONJUNCTIVITIS",
      "term": null,
      "displaytext": "Conjunctivitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)\", \"Mnemonic\": \"4\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ofloxacin 0.3% ophthalmic solution 2 drops in affected eye q2h while awake for 2\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CONJUNCTIVITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Conjunctivitis is associated with viral or bacterial pathogens. Viral\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"conjunctivitis presents with watery discharge. Bacterial infections are more\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"likely to present with thick exudate and conjunctival injection. Allergic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"conjunctivitis typically presents with stringy mucus. If there is pus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"(hypopion), corneal involvement, possible bacterial conjunctivitis, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"keratitis, consult ophthalmology.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Viral conjunctivitis is most commonly caused by adenovirus. It is self-limited\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"and antivirals provide no benefit. Symptomatic treatment with ophthalmic\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antihistamine/decongestants and warm or cool compresses may relieve symptoms.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Bacterial conjunctivitis is most commonly associated with Staphylococcus aureus,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae, Haemophilus spp., Moraxella catarrhalis,\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Corynebacterium diphtheriae, Neisseria spp. or enteric gram-negative rods. It is\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"generally self-limited, but topical antimicrobials reduce duration of symptoms\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"and limit person-to-person spread of infection. If symptoms do not improve after\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"2 days of antimicrobial therapy, the patient should be seen by an\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"ophthalmologist.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment for acute bacterial conjunctivitis\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"q3h for 7 days ($) [M]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment for severe cases of bacterial conjunctivitis involving suppuration or\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"contact lens wearers\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Consult ophthalmology and begin topical antimicrobials.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"days then 2 drops QID for 5 days ($) [M]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Azari eta al, JAMA (2013) 1721-1730\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Microbial conjunctivitis\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date Article: Conjunctivitis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Conjunctivitis, Bacterial\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 349,
    "fields": {
      "name": "ORZID2 GMENU CONTACT CDSS STAFF",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": 158, \"DisplayText\": \"Exclusions\", \"Text\": \"Exclusions- recommendations for additions to CDSS\", \"Mnemonic\": \"4\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"The CDSS Project Team can be contacted in Outlook using the\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"group Email: VISN23AntimicrobialCDSS@va.gov\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact CDSS Team\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 350,
    "fields": {
      "name": "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS",
      "term": null,
      "displaytext": "Cranial epidural abscess ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM IV Q8H METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H\", \"Text\": \"Cefepime 2gm IV Q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 3052, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CRANIAL EPIDURAL ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment involves source control by drainage procedure and antimicrobial\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"therapy.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Beta-lactam antibiotics are more effective than vancomycin against susceptible\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Staphylococci. If Staphylococcus is isolated, once methicillin-resistance is\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"ruled out, switch to an anti-staphylococcal beta-lactam antibiotic. Pseudomonas\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"is a potential pathogen in post-surgical patients or patients with known\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Pseudomonas colonization.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treat for 6 weeks after surgical drainage. In patients with associated\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"osteomyelitis, patients in whom surgical drainage did not occur, and patients in\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"whom the response to therapy has been slow, treat for 6 to 8 weeks.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is not suspected:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is suspected:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Treatment if methicillin-sensitive S. aureus is isolated\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Intracranial Thrombophlebitis\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Pradilla et al, Lancet Neurol, 2009, 8(3)292-300\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-To-Date Article: Intracranial Epidural Abscess\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 351,
    "fields": {
      "name": "ORZID2 GMENU CUTANEOUS ABSCESS",
      "term": null,
      "displaytext": "Cutaneous abscess  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"[CLICK HERE] for list of MRSA risk factors\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Perianal/Anorectal Abscess\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CUTANEOUS ABSCESS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Incise and drain then cover the site with a dry dressing. For small abscesses,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"systemic antimicrobial therapy is rarely necessary.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"If the patient is neutropenic, has multiple lesions, or has fever or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"leukocytosis, antimicrobial treatment may be necessary.  Contact Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases for assistance.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antimicrobial\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mild to Moderate Cases:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Moderate or high suspicion of MRSA\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Low suspicion of MRSA\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"For SEVERE cases empiric coverage with MRSA agent\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For Perirectal/Anorectal Abscess Select Below\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword:  Skin infections\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 352,
    "fields": {
      "name": "ORZID2 GMENU CUTANEOUS CANDIDIASIS",
      "term": null,
      "displaytext": "Cutaneous Candidiasis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical bid\", \"Text\": \"Clotrimazole 1% cream apply to affected area BID ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin Cream to affected area BID ($) [M]\", \"Text\": \"Nystatin Cream to affected area BID ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CUTANEOUS CANDIDIASIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cutaneous candidiasis is a superficial fungal infection of the epidermis.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Presents with red, erythematous patches, often in areas where skin contacts\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"skin, including axillae, groin, and abdominal folds.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Keep affected areas dry and clean.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treat for 4 weeks.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sanford: Cutaneous Candidiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 353,
    "fields": {
      "name": "ORZID2 GMENU DECUBITUS ULCERS",
      "term": null,
      "displaytext": "Decubitus ulcers",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 233, \"DisplayText\": \"\", \"Text\": \"Perianal/Anorectal Abscess\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 104, \"DisplayText\": \"Cellulitis\", \"Text\": \"Cellulitis\", \"Mnemonic\": \"16\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 508, \"DisplayText\": \"Osteomyelitis\", \"Text\": \"Osteomyelitis\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DECUBITUS ULCERS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Relieve pressure and friction, provide good nutrition, and debride the ulcer.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Decubitus ulcers are colonized with bacteria.  Antimicrobial therapy is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"unnecessary unless the patient has infection of surrounding tissues signified by\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"erythema, warmth, local tenderness, or purulent discharge.  Rectal or groin\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"decubitus ulcers with surrounding infection need broad spectrum antimicrobials.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Ulcers located in other sites are usually treated with antimicrobials for\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"staphylococci and streptococci.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of therapy usually 7-14 days, but adjust to clinical response\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For deep abscesses away from the rectal area, obtain material for Gram stain an\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"culture to guide therapy.\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"For severe cases\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For deep PERIRECTAL ABSCESSES that need a systemic antimicrobial SELECT BELOW:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"If there are signs and/or symptoms of cellulitis or osteomyelitis, refer to the\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"advice page for the appropriate syndrome.  Contact the ET nurse, Infectious\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Diseases, Dietician, or Vascular surgery for more information.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Parish LC Dermatol Clin 2004, 22: 87\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 354,
    "fields": {
      "name": "ORZID2 GMENU DEEP OROPHAR INFECT",
      "term": null,
      "displaytext": "Deep Oropharyngeal Infections  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h for 7 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"MRSA risk factors\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"< ADD > vancomycin 15 mg/kg IV q12 hours ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R] < AND > vancomycin 15 mg/kg IV q 12 hours ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DEEP OROPHARYNGEAL INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Deep oropharyngeal infections may threaten life and must be treated immediately.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Assess the risk of airway compromise and monitor the airway if it is threatened.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"These infections are more common in people with diabetes mellitus and are caused\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"by mixed organisms including streptococcus sp., Staphylococcus aureus and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"anaerobes . Perform CT scan to diagnose abscess. ENT and Infectious Diseases\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"consults are essential.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"If the patient's condition worsens or does not improve during the first 48 hours\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"of antimicrobial therapy, surgical drainage is indicated. If surgical drainage\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"is done, antimicrobials are usually continued for 48 hours after the procedure.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"If surgical drainage is not done, 2 weeks of antimicrobial therapy until\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"clinical improvement is observed (e.g. resolution of fever and leukocytosis) is\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"appropriate.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative: Assessment of Beta-lactam Reaction\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Risk factors for MRSA or gram-positive cocci in clusters on gram stain, in\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"addition to one of the above antimicrobial regimens\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Immunocompromised patient or severe infection\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Immunocompromised patients require additional coverage for Staphylococcus aureus\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"and Pseudomonas aeruginosa.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"< AND > vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Step-down treatment after initial intravenous therapy. Adjust duration based on\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"criteria above.\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Oral Cavity, Neck, and Head\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Ogle, Dent Clin N Am. 2017, 61(2)235-252\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Reynolds et al. Lung. 2009, 187(5)271-279\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-to-Date article: Submandibular space infections (Ludwig's angina)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 355,
    "fields": {
      "name": "ORZID2 GMENU DELAYED PCN ALLERGIC CV SURG",
      "term": null,
      "displaytext": "Severly PCN allergic  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE OPEN HEART\", \"Text\": \"Vancomycin 1500mg PREOPERATIVE dose **AND** 1000mg INTRAOPERATIVE dose\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750mg IV once Pre-Op Delayed Order\", \"Text\": \"Levofloxacin 750mg IV once Pre-op Delayed Order\", \"Mnemonic\": \"4\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Severly PCN Allergic Pre-op Antibiotic Delayed Order\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 356,
    "fields": {
      "name": "ORZID2 GMENU DIAGNOSIS PERTUSSIS",
      "term": null,
      "displaytext": "Diagnosis of Pertussis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Td/Tdap Immunization Menu\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MICRO ORDER\", \"Text\": \"Obtain nasopharyngeal sample for PCR\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MICRO ORDER\", \"Text\": \"Obtain nasopharyngeal sample for PCR\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Igg antibodies for Bordetella pertussis\", \"Text\": \"Obtain serum sample for IgG antibodies to Bordetella pertussis\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Igg antibodies for Bordetella pertussis\", \"Text\": \"Obtain serum sample for IgG antibodies to Bordetella pertussis\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIAGNOSIS OF PERTUSSIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Laboratory testing is recommended to confirm a clinical diagnosis of pertussis.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Nasopharyngeal samples should be obtained with calcium alginate swabs.  The\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"appropriate diagnostic strategy depends upon the duration of coughing symptoms.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For previously unvaccinated individuals, the three-dose serious of Td/Tdap\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"should be administered. A Tdap booster should be administered every 10 years\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"after completion of the series.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \">>  During the first 2 weeks of coughing\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \">>  Between 2 and 4 weeks of coughing\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \">>  More than 4 weeks of coughing\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date article: Pertussis infection in adolescents and adults: Clinic\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Pertussis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Bordetella species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 357,
    "fields": {
      "name": "ORZID2 GMENU DISSEMINATED M. AVIUM",
      "term": null,
      "displaytext": "Disseminated Mycobacterium avium disease treatment  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clarithromycin 500 mg PO q12h ($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 250 mg PO q24h ($) [M] <AND> ethambutol 15 mg/kg PO q24h [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clarithromycin 500 mg PO q12h($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 250 mg PO q24h ($) M <AND> ethambutol 15 mg/kg PO q24h [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DISSEMINATED MYCOBACTERIUM AVIUM DISEASE TREATMENT\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Many of these patients have HIV/AIDS. Management is complex. Consult\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Rifabutin is optional for disseminated disease. Rifabutin can improve cure\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"rates, but may decrease blood concentrations of many drugs. Consult Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases or Pharmacy for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment is continued for 12 months and until CD4 count is >100 cells per\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"microliter for at least 6 months.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Two-drug treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"($$) [R]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Three-drug treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"($$) [R] <AND> rifabutin 300 mg PO q24h ($$) [R,DI]\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"<AND> rifabutin 300 mg q24h ($$) [R,DI]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Mycobacterium avium complex\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Mycobacterium avium-intracellulare\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 358,
    "fields": {
      "name": "ORZID2 GMENU DRUG PT UNDERGO DENTAL PROC",
      "term": null,
      "displaytext": "Drugs for patients undergoing dental, oral, or esophageal procedures  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 2gm po once (Var)\", \"Text\": \"Amoxicillin 2 gm PO 1 hour before procedure ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2gm iv once\", \"Text\": \"Ampicillin 2 gm IV over 20 minutes, beginning 60 minutes before incision ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 1gm iv once\", \"Text\": \"Cefazolin 1 gm IV over 20 minutes, beginning 60 minutes before incision ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg po once (Var)\", \"Text\": \"Azithromycin 500mg PO 1 hour before procedure ($) [M]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIMICROBIALS FOR PATIENTS UNDERGOING DENTAL OR ORAL MUCOSA TO PREVENT\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"BACTERIAL ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Preferred\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Primary Alternative\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Secondary Alternative, after assessment of beta-lactam reaction above\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"endocarditis\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Wilson et al., Circulation, 2021, 143(20)e963-e978\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 2 GM PO 1 hour before procedure ($) [R]\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 359,
    "fields": {
      "name": "ORZID2 GMENU EC CX NEG",
      "term": null,
      "displaytext": "Endocarditis with Negative Culture",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOCARDITIS WITH CULTURE-NEGATIVE RESULTS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cultures are often negative in cases of infection with fastidious organisms like\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Abiotrophia (formerly nutritionally variant Streptococci), Bartonella, Coxiella,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Chlamydia, Legionella spp., or Trophyrema or when antimicrobials are given\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"before blood cultures are obtained. Consult Infectious Diseases and Cardiology.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 360,
    "fields": {
      "name": "ORZID2 GMENU EC ENTEROCOCCI",
      "term": null,
      "displaytext": "Endocarditis with Enterococci  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] < AND > ceftriaxone 2 gm IV q12h ($) for 6\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV\", \"Text\": \"Penicillin G 4 MU IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($)\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] < AND > ceftriaxone 2 gm IV q12h ($) for 6\", \"Mnemonic\": \"10\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] < AND > gentamicin 1 mg/kg IV q8h ($)\", \"Mnemonic\": \"12\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI] for 6 weeks\", \"Mnemonic\": \"14\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Daptomycin 10-12 mg/kg IV q24h ($$$$) [R,DI]\", \"Text\": \"Daptomycin 10-12 mg/kg IV q24h ($$$$) [R,DI] for 6 weeks\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOCARDITIS WITH ENTEROCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infectious diseases and cardiology should be consulted in all cases\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Native valve endocarditis (NVE):\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of therapy depends on duration of symptoms, susceptibility of the\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"enterococcus isolate to antimicrobials, and the effectiveness of the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials that can be used. For patients who have experienced symptoms for\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"less than 3 months and who can be treated with ampicillin or penicillin plus\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"gentamicin, treat for 4. Treat all other patients including any patient\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"receiving vancomycin for at least 6 weeks. Duration should be determined with\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"input from Infectious Diseases.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Prosthetic Valve endocarditis (PVE):\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat for at least 6 weeks, duration should be determined with input from\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Organism Susceptibility\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Isolate is susceptible to penicillin (MIC </= 16 mcg/mL) and high concentration\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"gentamicin (MIC </= 500 mcg/mL)\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"weeks\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"[R,O] for 4 to 6 weeks (NVE) for 6 weeks (PVE)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"for 4 to 6 weeks (NVE) for 6 weeks (PVE)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Isolate is resistant to gentamicin (MIC > 500 mcg/mL)\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"weeks\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Isolate is penicillin-resistant (MIC > 16 mcg/mL)\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"[R,O] for 6 weeks\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Isolate is penicillin resistant (MIC > 16 mcg/mL), gentamicin resistant (MIC >\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"500 mcg/mL) and vancomycin resistant\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Fernandez-Hidalgo, Clinical Infectious Diseases 2013, 56: 1261\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 361,
    "fields": {
      "name": "ORZID2 GMENU EC FUNGI",
      "term": null,
      "displaytext": "Endocarditis with Fungi  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOCARDITIS WITH FUNGI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases, Cardiology, and Cardiothoracic surgery.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 362,
    "fields": {
      "name": "ORZID2 GMENU EC GNB",
      "term": null,
      "displaytext": "Endocarditis with Gram Negative Bacilli ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 6 weeks\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Text\": \"Cefepime  2 gm IV q8h ($$) [R] for 6 weeks\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOCARDITIS WITH GRAM NEGATIVE BACILLI OTHER THAN HACEK ORGANISMS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa and various Enterobacteriaceae are uncommon endocarditis\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pathogens. Risk factors include cirrhosis, IV drug use and prosthetic valve.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Choice of agents should be based on in vitro susceptibilities.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Consult Infectious Diseases and Cardiothoracic surgery in all cases.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment for Enterobacteriaceae\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment for Pseudomonas\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Most cases of pseudomonas endocarditis occur in IV drug users.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Begin treatment with a beta-lactam agent, and when appropriate, Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases will initiate treatment with add-on aminoglycoside or fluroquinolone\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"agent for additional coverage.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 363,
    "fields": {
      "name": "ORZID2 GMENU EC HACEK",
      "term": null,
      "displaytext": "Endocarditis with \"HACEK\" bacteria",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 4 weeks (NVE) or 6 weeks (PVE)\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($) [R] for 4 weeks (NVE) or 6 weeks (PVE)\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOCARDITIS WITH HACEK BACTERIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"HACEK bacteria are the fastidious Gram-negative bacilli, including Haemophilus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"parainfluenzae, Haemophilus paraphrophilus, Haemophilus influenzae,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Aggregatibacter aphrophilus (Haemophilus aphrophilus), Actinobacillus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"kingae and Kingella denitrificans. It may take up three weeks for the\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"microbiology laboratory to isolate these organisms.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment options are limited for patients with allergies to beta-lactam\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antibiotics. Consult Infectious Diseases for advice.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Native valve endocarditis (NVE): 4 weeks\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Prosthetic valve endocarditis (PVE): 6 weeks\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Isolate is susceptible to ampicillin\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 364,
    "fields": {
      "name": "ORZID2 GMENU EC NV EMP THERA",
      "term": null,
      "displaytext": "Native Valve Endocarditis - Empirical Therapy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($)\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NATIVE VALVE ENDOCARDITIS--EMPIRICAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Empirical treatment in a non-intravenous drug user\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Wait for identification of pathogen before initiating antimicrobial therapy in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"most cases. If empiric antimicrobial treatment is necessary, due to hemodynamic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"instability or other severe disease, use:\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"[R,O]\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Empirical treatment in an intravenous drug user\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Staphylococcus aureus is the most likely pathogen, followed by streptococci and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"enterococci. However, gram negative pathogens are often associated with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"endocarditis in these patients. Culture results are key for appropriate therapy.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Consult Cardiology and Infectious Diseases for more information.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"[R,O]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 365,
    "fields": {
      "name": "ORZID2 GMENU EC NV SEL PATH",
      "term": null,
      "displaytext": "Native Valve Endocarditis--Selected Pathogens ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 359, \"DisplayText\": \"Endocarditis with Negative Culture\", \"Text\": \"Culture-negative endocarditis\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 360, \"DisplayText\": \"Endocarditis with Enterococci\", \"Text\": \"Enterococci\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 361, \"DisplayText\": \"Endocarditis with Fungi\", \"Text\": \"Fungi\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 362, \"DisplayText\": \"Endocarditis with Gram Negative Bacilli\", \"Text\": \"Gram negative bacilli (other than HACEK organisms)\", \"Mnemonic\": \"10\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"HACEK bacteria\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 366, \"DisplayText\": \"Native Valve Endocarditis with Staphylococci\", \"Text\": \"Staphylococci\", \"Mnemonic\": \"14\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 367, \"DisplayText\": \"Native Valve Endocarditis with Streptococci\", \"Text\": \"Streptococci\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NATIVE VALVE ENDOCARDITIS--SELECTED PATHOGENS\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 366,
    "fields": {
      "name": "ORZID2 GMENU EC NV STAPHYLOCOCCI",
      "term": null,
      "displaytext": "Native Valve Endocarditis with Staphylococci  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [DI] for 6 weeks\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]\", \"Text\": \"Daptomycin 8-12mg/kg q24h ($$$$) [R,DI] for 6 weeks\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NATIVE VALVE ENDOCARDITIS WITH STAPHYLOCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Endocarditis with Staphylococcus aureus and coagulase-negative staphylococci are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"treated similarly.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Retrospective studies show that patients with native valve staphylococcal\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"endocarditis treated with valve replacement and antimicrobials have a lower\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"mortality rate than those treated with antimicrobials alone. Consult\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"cardiothoracic surgery for all patients with staphylococcal endocarditis.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Most patients need 6 weeks of antimicrobial treatment. For vancomycin-resistant\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"strains Infectious Disease consultation is recommended.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment for methicillin-susceptible strains\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Primary alternative:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Secondary alternative, after assessment of beta-lactam reaction above:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment for methicillin-resistant strains\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"5\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treat for 6 weeks:\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 367,
    "fields": {
      "name": "ORZID2 GMENU EC NV STREPTOCOCCI",
      "term": null,
      "displaytext": "Native Valve Endocarditis with Streptococci",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 3 million units IV Q4H\", \"Text\": \"Penicillin G 3 million units IV q4h ($$) [R] for 4 weeks\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN 3MU IV Q4H GENT 3 MG/KG ONCE DAILY\", \"Text\": \"Penicillin G 3 million units IV q4h ($$) [R] for 2 weeks <AND> gentamicin\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 4 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) for 2 weeks <AND> gentamicin 3 mg/kg IV once\", \"Mnemonic\": \"12\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks\", \"Mnemonic\": \"14\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) for 4 weeks\", \"Mnemonic\": \"16\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] for 4 weeks <AND> gentamicin\", \"Mnemonic\": \"18\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) for 4 weeks <AND> gentamicin 3 mg/kg IV q24h\", \"Mnemonic\": \"20\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks\", \"Mnemonic\": \"22\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q24h\", \"Mnemonic\": \"24\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"26\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"28\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks\", \"Mnemonic\": \"30\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NATIVE VALVE ENDOCARDITIS WITH STREPTOCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Selection is based on susceptibility to penicillin.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment of highly susceptible viridians streptococci or Streptococcus\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"gallolyticus (bovis) (penicillin MIC less than or equal to 0.12 mcg/ml)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"The addition of gentamicin provides a synergistic effect and is reasonable to\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"add in patients with uncomplicated endocarditis, rapid response to therapy and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"no underlying renal disease\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"3 mg/kg IV q24h ($) [R,O] for 2 weeks\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Primary alternatives:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"daily ($) [R,O] for 2 weeks\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Secondary alternative, after assessment of beta-lactam reaction above:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment of relatively resistant viridians streptococci or S. gallolyticus\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"(bovis) (penicillin MIC greater than 0.12 and less than or equal to 0.5 mcg/ml)\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"For ceftriaxone susceptible isolates (MIC < 0.5 mcg/mL):\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"For ceftriaxone resistant isolates (MIC >/= 0.5 mcg/mL):\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"3 mg/kg IV q24h ($) [R,O] for first 2 weeks\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"($) [R,O] for first 2 weeks\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Treatment of highly resistant viridians streptococci or S. gallolyticus (bovis)\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"(penicillin MIC greater than or equal to 0.5 mcg/mL)\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"($) [R,O] for 4 weeks\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR>\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"for 4 weeks\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Treatment of Streptococci pneumonia, Streptococcus pyogenes, and Groups B, C, F\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"and G beta-hemolytic streptococci\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Treatment is non-standardized and must be tailored to each patient. Consult\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"21\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 368,
    "fields": {
      "name": "ORZID2 GMENU EC PV EMP THERAPY",
      "term": null,
      "displaytext": "Prosthetic Valve Endocarditis--Empicaral Therapy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco 15 MG/KG IV Q12H Rifamp 300MG PO Q8H Gent 1 MG/KG IV Q8H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROSTHETIC VALVE ENDOCARDITIS--EMPIRICAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Early surgical consultation is essential.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"If a patient is hemodynamically stable and the diagnosis is uncertain,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antimicrobial therapy can safely be withheld until the diagnosis is clear and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"blood culture results are available to guide therapy. In all cases, be sure\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"adequate numbers of blood cultures are obtained before antimicrobials are given.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"[R,O] <AND> rifampin 300 mg PO/NG q8h ($) [DI,O]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 369,
    "fields": {
      "name": "ORZID2 GMENU EC PV SEL PATH",
      "term": null,
      "displaytext": "Prosthetic Valve Endocarditis--Selected Pathogens",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 359, \"DisplayText\": \"Endocarditis with Negative Culture\", \"Text\": \"Culture-negative endocarditis\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 360, \"DisplayText\": \"Endocarditis with Enterococci\", \"Text\": \"Enterococci\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 361, \"DisplayText\": \"Endocarditis with Fungi\", \"Text\": \"Fungi\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 362, \"DisplayText\": \"Endocarditis with Gram Negative Bacilli\", \"Text\": \"Gram negative bacilli (other than HACEK organisms)\", \"Mnemonic\": \"10\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 363, \"DisplayText\": \"Endocarditis with \\\"HACEK\\\" bacteria\", \"Text\": \"HACEK bacteria\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 370, \"DisplayText\": \"Prosthetic Valve Endocarditis with Staphylococci\", \"Text\": \"Staphylococci\", \"Mnemonic\": \"14\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 371, \"DisplayText\": \"Pros. Valve Endocard with Viridans Group Streptococcus and Streptococcus bovis\", \"Text\": \"Streptococci\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROSTHETIC VALVE ENDOCARDITIS--SELECTED PATHOGEN\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 370,
    "fields": {
      "name": "ORZID2 GMENU EC PV STAPHYLOCOCCI",
      "term": null,
      "displaytext": "Prosthetic Valve Endocarditis with Staphylococci ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NAFCILLIN 2GM IV Q4H RIFAMPIN 300MG PO Q8H GENT 1MG/KG Q8H\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [DI] x 6 weeks <AND> rifampin 300 mg PO/NG q8h\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco 15 MG/KG IV Q12H Rifamp 300MG PO Q8H Gent 1 MG/KG IV Q8H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] x 6 weeks <AND> rifampin 300 mg PO/NG\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROSTHETIC VALVE ENDOCARDITIS WITH STAPHYLOCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Endocarditis with Staphylococcus aureus and coagulase-negative staphylococci are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"treated similarly. Surgery is required frequently in these patients.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment for methicillin-susceptible strains\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"($) [DI,O] for 6 weeks <AND> gentamicin 1 mg/kg IV q8h ($) [R,O] for initial 2\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"weeks\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment for methicillin-resistant strains\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"($) [DI,O] q8h for 6 weeks <AND> gentamicin 1 mg/kg IV q8h ($) [R,O] for initial\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"2 weeks\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 371,
    "fields": {
      "name": "ORZID2 GMENU EC PV VGS/S. BOVIS",
      "term": null,
      "displaytext": "Pros. Valve Endocard with Viridans Group Streptococcus and Streptococcus bovis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] for 6 weeks\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] for 6 weeks <AND> gentamicin\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) for 6 weeks\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) for 6 weeks <AND> gentamicin 3 mg/kg IV q24h\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks\", \"Mnemonic\": \"14\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q24h\", \"Mnemonic\": \"16\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAX 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) <AND> gentamicin 1 mg/kg IV QD  ($) R,O] both\", \"Mnemonic\": \"18\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"20\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks\", \"Mnemonic\": \"22\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"24\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction [CLICK HERE]\", \"Mnemonic\": \"26\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks\", \"Mnemonic\": \"28\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROSTHETIC VALVE ENDOCARDITIS WITH STREPTOCOCCUS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment of highly susceptible viridians streptococci or Streptococcus\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"gallolyticus (bovis) (penicillin MIC less than or equal to 0.12 mcg/ml)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Addition of gentamicin to penicillin or ceftriaxone is optional, as combination\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"therapy has not demonstrated superior outcomes. Contact Infectious Diseases for\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"3 mg/kg IV q24h  ($) [R,O] for 2 weeks\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"($) [R,O] for 2 weeks\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment of relatively resistant viridians streptococci or S. gallolyticus\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"(bovis) (penicillin MIC greater than 0.12 and less than or equal to 0.5 mcg/ml)\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"($) [R,O] both drugs for 6 weeks\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"drugs for 6 weeks\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment of highly resistant viridians streptococci or S. gallolyticus (bovis)\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"(penicillin MIC greater than or equal to 0.5 mcg/mL)\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"($) [R,O] for 6 weeks\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR>\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"for 6 weeks\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Treatment of Streptococci pneumonia, Streptococcus pyogenes, and Groups B, C, F\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"and G beta-hemolytic streptococci\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Treatment is non-standardized and must be tailored to each patient. Consult\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Baddour et al., Circulation 2015, 132:1-52\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and intravascular infections\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Sanford keyword: Endocarditis\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of management of infective endocarditis in adults\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Wang et al., JAMA 2018, 320.1:72-83\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 372,
    "fields": {
      "name": "ORZID2 GMENU ECTHYMA GANGRENOSUM",
      "term": null,
      "displaytext": "Ecthyma Gangrenosum",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > gentamicin\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPROFL 400MG IV Q8H GENT 5MG IV QD\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] < AND > gentamicin 5 mg/kg\", \"Mnemonic\": \"12\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ECTHYMA GANGRENOSUM\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Ecthyma gangrenosum lesions commonly begin as painless red macules which\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"rapidly evolve into areas of induration that develop into pustules and-or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"bullae. Ultimately, these become gangrenous ulcers. Ecthyma lesions\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"typically progress rapidly within 12 to 18 hours. They are often associated\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with Pseudomonas aeruginosa bacteremia, especially in neutropenic patients.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Recommend blood cultures and culture of skin exudates.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Infectious disease consult is suggested.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consider combination therapy in patients with severe infections.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for 7 days.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative for severe infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"5 mg/kg IV q24h ($) [R,O]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"IV q24h ($) [R,O]\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Pseudomonas aeruginosa\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 373,
    "fields": {
      "name": "ORZID2 GMENU EHRLICHIA CHAFFEENSIS",
      "term": null,
      "displaytext": "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EHRLICHIA CHAFFEENSIS (HUMAN MONOCYTOTROPIC EHRLICHIOSIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treat for at least 5 to 7 days, up to 10 days may be required for more severe or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"complicated cases\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"MMWR RR. 2016, 65 (2) 1-44\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword: Ehrlichiosis: Human monocytic ehrlichiosis (HME)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-to-Date article: Human ehrlichiosis and anaplasmosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 374,
    "fields": {
      "name": "ORZID2 GMENU EMP INTRAV W/ VANCO",
      "term": null,
      "displaytext": "Empirical intravenous regimens WITH vancomycin",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($6/day) [R] <AND> cefepime 2 gm IV q8h\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> vancomycin 15mg/kg\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> gentamicin 5\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Aztreonam 2 gm IV q8h ($50/day) <AND> vancomycin 15mg/kg IV q12h\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Aztreonam 2 gm IV q8h ($50/day) <AND> gentamicin 5 mg/kg IV q24h ($3/day)\", \"Mnemonic\": \"12\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRICAL INTRAVENOUS REGIMENS WITH VANCOMYCIN\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Discontinue vancomycin after 3 days unless culture results indicate that\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"continued therapy is needed.  Gentamicin is optional.  Contact Hematology-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Oncology or Infectious Diseases for advice.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"($35/DAY) [R]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"IV q12h ($6.00/day) [R] < OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"mg/kg IV q24h ($3/day) [R] <AND> vancomycin 15mg/kg q12h ($6.00/day) [R]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"($6/day) [R] < OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15mg/kg IV q12h ($6.00/day) [R]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 375,
    "fields": {
      "name": "ORZID2 GMENU EMP INTRAV W/O VANCO",
      "term": null,
      "displaytext": "Empirical intravenous regimens WITHOUT vancomycin",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q8h ($35/day) [R]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] < OR >\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> gentamicin 5\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Aztreonam 2 gm IV q8h ($50/day) <AND> vancomycin 15mg/kg IV q12h\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Aztreonam 2 gm IV q8h ($50/day) <AND> gentamicin 5 mg/kg IV q24h ($3/day)\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRICAL INTRAVENOUS REGIMENS WITHOUT VANCOMYCIN\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Gentamicin is optional.  Contact Hematology-Oncology or Infectious Diseases for\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"advice.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"mg/kg IV q24h ($3/day) [R]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Vancomycin must be added to aztreonam for coverage of Gram-positive organisms.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"($6/day) [R] < OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"[R] <AND> vancomycin 15mg/kg IV q12h ($6.00/day) [R]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Hughes WT  Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 376,
    "fields": {
      "name": "ORZID2 GMENU ENDOOPTHALMITIS",
      "term": null,
      "displaytext": "Endophthalmitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 1mg intravitreous inject Ceftazidime 2.25mg intrav inj\", \"Text\": \"Vancomycin 1 mg/0.1 mL intravitreal injection STAT ($) [R] < AND > ceftazidime\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 1mg intravitreous inj Amikacin 0.4mg intravitreous inj\", \"Text\": \"Vancomycin 1 mg/0.1 mL intravitreal injection STAT ($) [R] < AND > amikacin 0.4\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B 5mcg/0.1mL intravitreal injection STAT\", \"Text\": \"Amphotericin B 5mcg/0.1mL intravitreal injection STAT ($$$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 100 mcg/0.1 mL intravitreal injection STAT\", \"Text\": \"Voriconazole 100 mcg/0.1mL intravitreal injection STAT ($$$$) [R,H,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOPHTHALMITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Endophthalmitis is a medical emergency and presents with eye pain and visual\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"loss. It may be associated with gram positive or gram-negative bacteria,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"including Staphylococcus aureus and Pseudomonas aeruginosa, or with fungi.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consult ophthalmology immediately. The ophthalmologist will obtain an aqueous or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"vitreous fluid sample for gram stain and culture and begin intravitreal\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobials.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment with intravitreal antimicrobials\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"2.25 mg/0.1 mL intravitreal injection STAT ($$) [M]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"mg/0.1 mL intravitreal injection STAT ($$) [M]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Fungal endophthalmitis\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Fungal endophthalmitis is rarely diagnosed in temperate climates and treatment\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"is complicated. Ophthalmology and Infectious Diseases involvement is essential.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Endophthalmitis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Endophthalmitis, Hematogenous or Endogenous\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Tranos et al., Advances in therapy. 2016, 33(5)727-746\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacterial endophthalmitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 377,
    "fields": {
      "name": "ORZID2 GMENU ERYSIPELAS",
      "term": null,
      "displaytext": "Erysipelas",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 250 - 500 mg PO q6h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500MG PO q6h\", \"Text\": \"Erythromycin 500 mg po q6h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin 3 million units iv q6h\", \"Text\": \"Penicillin 3 million units IV q6h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($) [H,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ERYSIPELAS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"In contrast to cellulitis, erysipelas has sharply demarcated borders and a\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"characteristic raised, orange-peel appearance.  Most cases are associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"streptococcus.  In a minority of cases, especially those involving the face,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Staphylococcus aureus is also a potential pathogen.  In severe cases,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"methicillin-resistant Staphylococcus aureus (MRSA) coverage must be provided\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"until microbiology results are available.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treat for 5 to 10days, longer if patient is bacteremic.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Facial\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sudden onset of rapidly spreading red edematous tender plaque-like skin on the\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"face in an otherwise healthy host.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If erysipelas-like on the face treat as if MRSA is present:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Non-facial\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"MILD TO MODERATE disease\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"SEVERE disease\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or MRSA suspected\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Erysipelas\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 378,
    "fields": {
      "name": "ORZID2 GMENU ERYSIPELOID",
      "term": null,
      "displaytext": "Erysipeloid  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin V 500 mg PO QID ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500MG PO q6h\", \"Text\": \"Erythromycin 500 mg PO QID ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 GM IV q24h ($$) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ERYSIPELOID (ERYSIPELOTHRIX RHUSOPATHIAE INFECTION)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Erysipeloid is a localized cutaneous infection with Erysipelothrix rhusopathiae.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"It is a zoonotic infection of fisherman, fish handlers, and butchers acquired by\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"direct animal contact, most commonly with fish, but also with other animals\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(e.g., swine). It usually affects the hand or fingers and is characterized by\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"throbbing pain and a red rash with a purple center and an elevated border.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Localized infections can be treated with oral antimicrobials.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Severe, diffuse cutaneous infections or systemic infections with E.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"rhusopathiae occur rarely after ingestion of undercooked pork or contaminated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"seafood in immunosuppressed individuals.  These infections are treated\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"initially with intravenous antimicrobials.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment of localized infection (erysipeloid)\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treat for 7 days\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"___________________________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment of systemic or severe diffuse cutaneous infection with E.\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"rhusopathiae.\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"___________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment duration is at least 4 weeks. Infectious Disease Consult recommended.\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Erysipelothrix\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 379,
    "fields": {
      "name": "ORZID2 GMENU ERYTHRASMA",
      "term": null,
      "displaytext": "Erythrasma",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% topical solution apply twice daily\", \"Text\": \"Clindamycin 1% topical solution apply twice daily ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500mg po q12h\", \"Text\": \"Clarithromycin 500 mg PO q12h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ERYTHRASMA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Erythrasma presents as brownish-red, well circumscribed, irregularly shaped\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"patches in or near skin folds.  Patches in the groin often itch.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Most cases respond to topical therapy.  Systemic antibiotics are used for more\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"severe cases or those that do not respond to topical therapy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: erythrasma\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Holdiness MR Drugs 2002, 62:1131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 380,
    "fields": {
      "name": "ORZID2 GMENU FEVER OF UNK ORIGIN",
      "term": null,
      "displaytext": "Fever of unknown origin  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 453, \"DisplayText\": \"Neutropenic fever\", \"Text\": \"NEUTROPENIC FEVER\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FEVER OF UNKNOWN ORIGIN\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Fever of unknown origin (FUO) is the occurrence of several episodes of fever\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"greater than 101 degrees Fahrenheit over a time period of at least 3 weeks\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"despite 1 week of hospital evaluation. Cases with FUO are often classified in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"four categories: (1) classical, (2) neutropenic, (3) nosocomial, and (4) fever\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in persons with HIV/AIDS. Empirical antimicrobial therapy is rarely indicated\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"in patients with FUO.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Note that FUO in neutropenic patients refers to persistent fever that has\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"remained undiagnosed after extensive diagnostic work and empirical antimicrobial\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"therapy. New fever in patients with profound neutropenia is a different\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"syndrome and does require empirical antimicrobial therapy. Infectious Diseases\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"should be involved in any case where empirical treatment for fever of unknown\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"origin is being considered.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell Chapter: Fever of Unknown Origin\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 381,
    "fields": {
      "name": "ORZID2 GMENU FOLLICULITIS",
      "term": null,
      "displaytext": "Folliculitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topical to affected area q8h\", \"Text\": \"Mupirocin ointment to affected area q8h for 7 days ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream top to affected area q8h\", \"Text\": \"Clotrimazole cream q8h for 7 days ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"FOLLICULITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Folliculitis is an infection of the hair follicle with purulent exudate in the\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"epidermis. It is usually associated with Staphylococcus aureus.  In patients\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"exposed to swimming pools or hot tubs, folliculitis may be associated with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa. Candida albicans can cause folliculitis in patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"receiving antimicrobials and/or corticosteroids. For folliculitis in patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with severe acne, consult Dermatology.  For extensive folliculitis or in\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"patients with HIV, consult Infectious Diseases.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Usually self-limiting. For most cases, treat with daily saline compresses until\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"symptoms resolve.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For moderate to severe cases associated with Staphylococcus aureus:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For cases associated with Candida albicans\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Folliculitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 382,
    "fields": {
      "name": "ORZID2 GMENU FOOT ULCER W/ INFECT SURR TISSUES",
      "term": null,
      "displaytext": "Foot ulcers WITH infection of surrounding tissues",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 309, \"DisplayText\": \"Approach to foot ulcers with infection\", \"Text\": \"Approach to foot ulcers with infection\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125mg q12h and Trimeth-sulfa 1DS q12h\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] <AND> Trimethoprim-\", \"Mnemonic\": \"18\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"21\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($) [R] <AND> Vancomycin 15 mg/kg IV\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($) [R] <AND> Vancomycin 15 mg/kg IV\", \"Mnemonic\": \"22\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15mg/kg\", \"Mnemonic\": \"26\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) R <AND> vancomycin 15 mg/kg IV q12h ($)\", \"Mnemonic\": \"28\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"30\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antibiotics may be stopped 24-48 hours following curative amputation.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Otherwise, continue antibiotics until signs of infection have resolved.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Mild: ulcer with superficial inflammation\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Oral therapy, no MRSA coverage:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Oral therapy, MRSA coverage:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Moderate: Ulcer with inflammation, extension into fascia\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Duration: treat to resolution of symptoms usually 1-3 weeks\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For patients started on parenteral therapy, a switch to an oral regimen\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"is reasonable following clinical improvement.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Oral therapy with MRSA coverage: (MRSA coverage until ruled out)\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"sulfamethoxazole 1 DS tablet po q12h ($) [R,DI]\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Intravenous regimens with MRSA coverage: (MRSA coverage until ruled out)\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"q12h ($) [R,DI]\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Severe: Extensive local inflammation plus systemic toxicity\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Intravenous regimens for SEVERE (limb-threatening) infections\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Duration: treat to resolution of symptoms usually 2-4 weeks\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"A switch to an oral regimen is reasonable following clinical improvement.\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"IV q12h ($) [R]\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"[R] <AND> metronidazole 500 mg IV q8h ($) [DI]\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration: treat until resolution of symptoms usually 1-2 weeks\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"therapy, de-escalate/modify regimen based on culture and susceptibility data.\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 500 mg PO q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] <AND> Doxycycline 100 mg\", \"Mnemonic\": \"20\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"PO BID for 14 days ($) [DI]\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"therapy, de-escalate/modify regimen based on culture and susceptibility data.\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 383,
    "fields": {
      "name": "ORZID2 GMENU FOOT ULCER W/O INFECT SURR TISSUES",
      "term": null,
      "displaytext": "Foot ulcers WITHOUT infection of surrounding tissues",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCERS WITHOUT INFECTION OF SURROUNDING TISSUES\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Clinically uninfected wounds do not need antibiotic treatment.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Topical antimicrobials are not helpful, are associated with allergic reactions,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and select for resistant organisms.  In general, local treatment should consist\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"of dressings with frequent changes, soaks, and debridement.Patients with\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"edema or impaired venous return should keep the limb elevated.  Wound care and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"improved control of diabetes can improve outcomes of infection and prevent\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"future complications.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2004, 39: 885\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 384,
    "fields": {
      "name": "ORZID2 GMENU FOOT ULCER WITH DM",
      "term": null,
      "displaytext": "Foot ulcer in patient with diabetes mellitus  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 383, \"DisplayText\": \"Foot ulcers WITHOUT infection of surrounding tissues\", \"Text\": \"Foot ulcers WITHOUT infection of surrounding tissues\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 382, \"DisplayText\": \"Foot ulcers WITH infection of surrounding tissues\", \"Text\": \"Foot ulcers WITH infection of surrounding tissues\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCER IN PATIENT WITH DIABETES MELLITUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Foot ulcers in patients with diabetes mellitus are colonized with bacteria.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Antimicrobials should not be used to treat colonization.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Cases with infection of surrounding tissues signified by erythema, warmth, local\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"tenderness, or purulent discharge should be treated with antimicrobials. Pain\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"may not be present in patients with neuropathy.  In patients with substantial\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"vascular disease, erythema and warmth may not be present and instead the tissues\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"will be dusky, mottled, or cool.  Capillary refill may be impaired.  Patients\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"with diabetes and ulcers are at risk for gangrenous infections.  If there is any\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"suggestion of gangrene, consult surgery immediately.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 385,
    "fields": {
      "name": "ORZID2 GMENU FUNGAL SINUSITIS",
      "term": null,
      "displaytext": "Fungal Sinusitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FUNGAL SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Fungal sinusitis mainly affects immunocompromised patients, but occasionally it\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"occurs in immunocompetent hosts. Drainage is essential. Consult ENT and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Infectious Disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Sanford Keyword: Aspergillosis, Allergic Fungal Sinusitis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Up-to-Date article: Fungal rhinosinusitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 386,
    "fields": {
      "name": "ORZID2 GMENU FUNGI ASPERGILLUS SPP.",
      "term": null,
      "displaytext": "Aspergillus spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 6mg/kg iv q12h then 4mg/kg iv q12h for 2 doses\", \"Text\": \"Voriconazole 6 mg/kg IV q12h for 2 doses, then 4 mg/kg IV q12h ($$$$) [R,H,\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 200mg po bid (Var)\", \"Text\": \"Voriconazole 200 mg PO q12h ($$) [R,H,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ASPERGILLUS SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For localized disease (fungus ball), antifungal therapy is ineffective.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Consult Surgery and Pulmonary for cases of localized disease without systemic\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infection. Consult Infectious Diseases in all cases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat invasive disease with intravenous antifungals initially, then\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"switch to oral antifungals for a total duration of therapy of 6-12\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"weeks dependent on the degree and duration of immunosuppression, site of disease\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"and evidence of disease improvement.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred intravenous therapy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative intravenous therapy for patients intolerant to voriconazole\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Oral therapy after disease has stabilized\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mandell Chapter: Aspergillus Species\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Patterson et al. Clinical Infectious Diseases. 2016, 63(4): e1-60\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Aspergillosis, Invasive\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of invasive aspergillosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 387,
    "fields": {
      "name": "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS",
      "term": null,
      "displaytext": "Blastomyces dermatidis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200 mg PO tid for 3 days, then 200 mg po BID for 6-12 months\", \"Text\": \"Itraconazole 200 mg PO q8h for 3 days then q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po q12h\", \"Text\": \"Itraconazole 200 mg PO q12h ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400-800 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"14\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po q12h\", \"Text\": \"Itraconazole 200 mg PO q12h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg PO q24h ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BLASTOMYCES DERMATITIDIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Contact Infectious Diseases in all cases. Lifelong suppressive therapy may be\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"required in immunosuppressed patients if immunosuppression cannot be reversed.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Disease outside of the central nervous system\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat for 6-12 months. It is recommended that immunocompromised patients be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treated with at least 1-2 weeks of intravenous treatment and a total treatment\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"duration of 12 months.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Change to oral itraconazole after the patient's condition has stabilized.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Oral therapy after disease has stabilized\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Central nervous system infection\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treat with intravenous therapy for 4-6 weeks followed by oral azole for at least\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"12 months.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Initial intravenous treatment\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Oral therapy after disease has stabilized\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Stanley et al. Clinical Infectious Diseases. 2008, (46)1801-12\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Blastomycosis\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of blastomycosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 388,
    "fields": {
      "name": "ORZID2 GMENU FUNGI CANDIDA ALBICANS",
      "term": null,
      "displaytext": "Candida albicans",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin swish and swallow 500\", \"Text\": \"Nystatin swish and swallow q6h for 7-14 days ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazolel troche 10mg po 5x/day\", \"Text\": \"Clotrimazole troche 10 mg PO 5X/day for 7-14 days ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200 mg po q24h ($0.20) [R\", \"Text\": \"Fluconazole 200 mg PO q24h for 7-14 days ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400 mg PO q24h for 14-21 days ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg iv q24h\", \"Text\": \"Fluconazole 400 IV q24h for 14-21 days ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Text\": \"Liposomal amphotericin (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O]\", \"Mnemonic\": \"18\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Micafungin 100 mg IV q24h\", \"Text\": \"Micafungin 100-150 mg IV q24h ($$$) [H,DI]\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA ALBICANS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Avoid using fluconazole empirically to treat candidal infections in patients who\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"have received an imidazole in the previous year.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment of thrush or oropharyngeal candidiasis\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Oropharyngeal candidal disease may present in different patterns, like white\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"plaques in the oropharyngeal area, erythematous macules (often in patients with\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"dentures), or as pseudomembranes.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Thrush infection often recurs, especially in patients with AIDS. Consult MRTC\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"clinic or Infectious Diseases (MRTC may also be consulted in the MVAHCS) for\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"more information on treatment of recurrent infection.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mild disease.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Moderate to severe disease\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Esophageal candidiasis\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Esophageal infection requires systemic therapy.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative for patient who cannot swallow tablets\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Systemic candidal infection\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Fluconazole is preferred empirical therapy in most cases. Amphotericin B should\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"be used empirically in patients who have received an azole antifungal drug\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"recently, or in patients who are critically ill.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location, severity of infection,\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Recent azole antifungal treatment\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Candidemia or Disseminated\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 389,
    "fields": {
      "name": "ORZID2 GMENU FUNGI CANDIDA GLABRATA",
      "term": null,
      "displaytext": "Candida glabrata",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Micafungin 100 mg IV q24h\", \"Text\": \"Micafungin 100-150 mg IV q24h ($$$) [H,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 6mg/kg iv q12h then 4mg/kg iv q12h for 2 doses\", \"Text\": \"Voriconazole 6mg/kg IV q12h for 2 doses, then 4mg/kg IV q12h ($$$$) [R,H,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po q12h for 2 doses then 200mg po q12h\", \"Text\": \"Voriconazole 400 mg PO q12h for 2 doses, then 200 mg PO q12h ($$) [R,H,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA GLABRATA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"C. glabrata is often resistant to fluconazole and occasionally has some degree\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"of resistance to amphotericin. Higher doses of amphotericin are recommended due\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"to delayed killing effects against Candida glabrata.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"*150mg q24h for esophageal candidiasis, 100mg q24h for other indications\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative for susceptible isolates\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Candidemia or Disseminated\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 390,
    "fields": {
      "name": "ORZID2 GMENU FUNGI CANDIDA KRUSEI",
      "term": null,
      "displaytext": "Candida krusei  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Micafungin 100 mg IV q24h\", \"Text\": \"Micafungin 100-150 mg IV q24h ($$$) [H,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 6mg/kg iv q12h then 4mg/kg iv q12h for 2 doses\", \"Text\": \"Voriconazole 6mg/kg IV q12h for 2 doses, then 4mg/kg IV q12h ($$$$) [R,H,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po q12h for 2 doses then 200mg po q12h\", \"Text\": \"Voriconazole 400 mg PO q12h for 2 doses, then 200 mg PO q12h ($$) [R,H,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA KRUSEI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"C. krusei is resistant to fluconazole, and often has some degree of resistance\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to amphotericin. Higher doses of amphotericin are recommended for treatment of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"C. krusei due to decreased susceptibility.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"*150mg q24h for esophageal candidiasis, 100mg q24h for other indications\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Candidemia or Disseminated\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 391,
    "fields": {
      "name": "ORZID2 GMENU FUNGI COCCIDIOIDOMYCES",
      "term": null,
      "displaytext": "Coccidioidomyces",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po q12h\", \"Text\": \"Itraconazole 200 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg iv q24h\", \"Text\": \"Fluconazole 400-800 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COCCIDIOIDOMYCES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pulmonary and Infectious Diseases consultations are essential for diagnosis and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mild to moderate disease\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Observation alone is indicated for some cases. Consult Infectious Diseases for\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"more information. If antifungal treatment is indicated:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Severe disease (diffuse pneumonia, rapid progression or central nervous system\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"infection)\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Galgiani et al. Clinical Infectious Diseases. 2016, 63(6) e112-46\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell Chapter: Coccidioidomycosis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford guide keyword: Coccidioidomycosis\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 392,
    "fields": {
      "name": "ORZID2 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS",
      "term": null,
      "displaytext": "Cryptococcus Neoformans  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po q12h\", \"Text\": \"Itraconazole 200 mg PO q12h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CRYPTOCOCCUS NEOFORMANS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment of mild to moderate infection outside of the central nervous system\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"or step-down treatment once disease has stabilized\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment of central nervous system infection or severe infection outside\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"central nervous system\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases, recommended combination therapy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"with flucytosine requires ID approval\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Cryptococcosis (Cryptococcus neoformans and Cryptococcus\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"gattii)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Perfect et al. Clinical Infectious Diseases 2010, (50) 291-322\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Cryptococcus\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Amphotericin B Liposomal (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O] <AND>\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"flucytosine 25 mg/kg PO q6h ($$$$$) [R,O]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(Reminder: for Ampho B add NS 500 ml hydration BEFORE & AFTER.)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 393,
    "fields": {
      "name": "ORZID2 GMENU FUNGI HISTOPLASMA CAPSULATUM",
      "term": null,
      "displaytext": "Histoplasma capsulatum",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po q12h\", \"Text\": \"Itraconazole 200 mg PO q12h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400-800 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HISTOPLASMA CAPSULATUM\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Intravenous antifungals are indicated initially for severe or progressive\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"disease. After disease has stabilized, oral antifungals may be used to complete\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"the course. Contact Infectious Diseases and Pulmonary services for advice.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Contact HIV expert for advice on cases involving patients with HIV.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Preferred initial therapy for meningitis, severe pulmonary or disseminated\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"disease\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment after disease has stabilized\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Itraconazole is more effective than fluconazole, but fluconazole may be used in\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"patients who cannot tolerate itraconazole.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Histoplasma capsulatum (Histoplasmosis)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Histoplasmosis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date article: Diagnosis and treatment of pulmonary histoplasmosis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Wheat et al. Clinical Infectious Diseases. 2007 (45) 807-25\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 394,
    "fields": {
      "name": "ORZID2 GMENU FURUNCLES AND CARBUNCLES",
      "term": null,
      "displaytext": "Furuncles and carbuncles ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 276, \"DisplayText\": \"\", \"Text\": \"Select here for Staphylococcus aureus Decolonization\", \"Mnemonic\": \"4\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg po q12h ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FURUNCLES AND CARBUNCLES\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Localized purulent infections include furuncles, carbuncles and cutaneous\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is an\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"inflamed nodule that usually develops as a complication of folliculitis.  A\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"carbuncle is a more extensive lesion that extends further into the subcutaneous\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"tissue.  Contact a wound care nurse for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Incision and drainage is the mainstay of therapy for carbuncles, cutaneous\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"abscesses, and large furuncles.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"The decision to administer antibiotics directed against S. aureus as an adjunct\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"to incision and drainage should be made based on the presence of systemic\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"inflammatory response syndrome (SIRS) or in patients with markedly impaired\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"host defenses.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For recurrent skin abscesses in addition to culture and antibiotic therapy\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"recommended consider a decolonization regimen.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mild infection: Purulent infection without systemic signs of infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Recommend incision and drainage. No antibiotic indicated.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Moderate Infection: Purulent infection with signs of systemic infection.\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Recommend incision and drainage. Culture material and use results to guide\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"therapy.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treat for 5 days and extend/modify treatment if not improved in this time.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Preferred treatment:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Severe Infections:\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Patients who have failed incision and drainage along with oral antibiotics\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"or those with SIRS or for infections in those with neutropenia or diminished\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"neutrophil function.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Recommend incision and drainage. Culture material and use results to guide\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"therapy.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Treat for 5 days. Reevaluate patient and extend or modify treatment if not\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"improved in this time.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Sanford keyword: Furuncle, carbuncle\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"20\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 395,
    "fields": {
      "name": "ORZID2 GMENU GI ENDOSCOPIC PROCEDURES",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 587, \"DisplayText\": \"Endoscopic Retrograde Cholangiopancreatography (ERCP)\", \"Text\": \"Endoscopic Retrograde Cholangiopancreatography (ERCP)-Inpatient\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 165, \"DisplayText\": \"\", \"Text\": \"Endoscopic Ultrasound-FNA Gastrointestinal Tract\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 396, \"DisplayText\": \"\", \"Text\": \"Placement of Percutaneous Gastrostomy (PEG) Tube\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIBIOTIC PROPHYLAXIS FOR GI ENDOSCOPIC PROCEDURES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The purpose of antibiotic prophylaxis during GI endoscopy is to reduce the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"risk of iatrogenic infectious complications.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 396,
    "fields": {
      "name": "ORZID2 GMENU GI PEG TUBE PLACEMENT",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600mg iv once\", \"Text\": \"Clindamycin 600 mg IV over 30 minutes beginning 60 minutes\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Antibiotic Prophylaxis for Placement of Percutaneous Gastrostomy (PEG) Tube\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibiotics are recommended for all patients prior to placement of PEG tube\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to reduce the risk of peristomal wound infection.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred Prophylaxis:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative for patient with severe penicillin allergy:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"before incision ($$) [H,O]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Endoscopy 2008, 67:791-795\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 397,
    "fields": {
      "name": "ORZID2 GMENU GN INT RS GNB",
      "term": null,
      "displaytext": "Interim results:  Gram-negative Bacilli ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM RESULTS: GRAM-NEGATIVE BACILLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pseudomonas, Bordetella, and Brucella spp. usually grow aerobically (but can\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"show up in an anaerobic bottle). Bacteroides, Fusobacterium, Porphyromonas, and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prevotella spp. usually grow anaerobically (but can show up in an aerobic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"bottle). Most other gram-negative bacilli are facultative, i.e. they can grow\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in aerobic or anaerobic culture conditions.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Some antimicrobial combinations are synergistic in vitro against some Gram-\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"negative bacilli. Combination therapy has not been shown to improve outcomes\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"in most circumstances. Single drug therapy is used in most cases. Contact\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Infectious Diseases for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Use susceptibility information to select an antimicrobial when a pathogen is\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"identified.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment before pathogen is identified\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment if Pseudomonas is suspected\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative for critically ill patients\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"IV q24h ($) [R,O]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford Keyword: Antibacterial Activity Spectra\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford Keyword: Pseudomonas aeruginosa\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-Date Article: Principles of antimicrobial therapy of Pseudomonas\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"aeruginosa infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 398,
    "fields": {
      "name": "ORZID2 GMENU GN INT RS GNC",
      "term": null,
      "displaytext": "Interim results:  Gram-negative cocci",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 3-4 million units IV q4 hr ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM RESULTS: GRAM-NEGATIVE COCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Gram-negative cocci may represent meningococci, gonococci, or Moraxella. This\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"page recommends empirical therapy before the final identification of the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pathogen,based on the clinical situation.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If meningococci are suspected\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"If gonoccoci are suspected\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"If Moraxella is suspected\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseria meningitidis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseia gonorrhoeae\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Moraxella catarrhalis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 399,
    "fields": {
      "name": "ORZID2 GMENU GRAM NEGATIVE BACTERIA",
      "term": null,
      "displaytext": "Gram-negative Bacteria",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 397, \"DisplayText\": \"Interim results:  Gram-negative Bacilli\", \"Text\": \"Gram-negative bacilli\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 398, \"DisplayText\": \"Interim results:  Gram-negative cocci\", \"Text\": \"Gram-negative cocci\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GRAM-NEGATIVE BACTERIA ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"site of infection, penetration of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"drug(s)into site, and whether\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"organism is pathogen, colonizer, or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"contaminant. See disease/syndrome\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"section for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Interim culture results\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"++ MULTIDRUG RESTANT ORGANISMS ++\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"ESBLS, Amp-C beta-lactamases, and\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Carbapenemases\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Consider whether patient is at risk\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"for or has evidence of infection with\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Gram-negative bacilli carrying\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"extended-spectrum beta-lactamases\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(ESBLs), AmpC beta-lactamases, or\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"carbapenemases.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"lactamases, and carbapenemases.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Last Reviewed December 2017\", \"Header\": 1}, {\"Row\": 16, \"Column\": 2, \"Item\": 411, \"DisplayText\": \"Acinetobacter baumanni\", \"Text\": \"Acinetobacter baumanni\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 414, \"DisplayText\": \"Citrobacter spp.\", \"Text\": \"Citrobacter spp.\", \"Mnemonic\": \"18\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 403, \"DisplayText\": \"Enterobacter spp.\", \"Text\": \"Enterobacter spp.\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 415, \"DisplayText\": \"Escherichia coli\", \"Text\": \"Escherichia coli\", \"Mnemonic\": \"22\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 417, \"DisplayText\": \"Klebsiella spp.\", \"Text\": \"Klebsiella spp.\", \"Mnemonic\": \"28\"}, {\"Row\": 28, \"Column\": 2, \"Item\": 419, \"DisplayText\": \"Proteus spp.\", \"Text\": \"Proteus spp.\", \"Mnemonic\": \"34\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 420, \"DisplayText\": \"Serratia spp.\", \"Text\": \"Serratia spp.\", \"Mnemonic\": \"40\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 412, \"DisplayText\": \"Bordetella species\", \"Text\": \"Bordetella spp.\", \"Mnemonic\": \"12\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 413, \"DisplayText\": \"Brucella spp.\", \"Text\": \"Brucella spp.\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 402, \"DisplayText\": \"Campylobacter spp.\", \"Text\": \"Campylobacter spp.\", \"Mnemonic\": \"16\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 416, \"DisplayText\": \"Haemophilus spp.\", \"Text\": \"Haemophilus spp.\", \"Mnemonic\": \"24\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 441, \"DisplayText\": \"Helicobacter pylori infection\", \"Text\": \"Helicobacter pylori\", \"Mnemonic\": \"26\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 418, \"DisplayText\": \"Legionella spp.\", \"Text\": \"Legionella spp.\", \"Mnemonic\": \"30\"}, {\"Row\": 27, \"Column\": 2, \"Item\": 407, \"DisplayText\": \"Pasteurella multocida\", \"Text\": \"Pasteurella multocida\", \"Mnemonic\": \"32\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 408, \"DisplayText\": \"Pseudomonas spp.\", \"Text\": \"Pseudomonas spp.\", \"Mnemonic\": \"36\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 409, \"DisplayText\": \"Salmonella spp.\", \"Text\": \"Salmonella spp.\", \"Mnemonic\": \"38\"}, {\"Row\": 32, \"Column\": 2, \"Item\": 269, \"DisplayText\": \"Diarrhea with Shigella species (bacillary dysentery)\", \"Text\": \"Shigella spp (bacillary dysentery)\", \"Mnemonic\": \"42\"}, {\"Row\": 39, \"Column\": 2, \"Item\": 406, \"DisplayText\": \"Neisseria meningitidis\", \"Text\": \"Neisseria meningitidis\", \"Mnemonic\": \"50\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 405, \"DisplayText\": \"Neisseria gonorrhoeae\", \"Text\": \"Neisseria gonorrhoeae\", \"Mnemonic\": \"48\"}, {\"Row\": 37, \"Column\": 2, \"Item\": 404, \"DisplayText\": \"Moraxella catarrhalis\", \"Text\": \"Moraxella catarrhalis\", \"Mnemonic\": \"46\"}, {\"Row\": 35, \"Column\": 2, \"Item\": 401, \"DisplayText\": \"Bacteroides spp. (including Prevotella, Porphyromonas)\", \"Text\": \"Bacteriodes, Porphyromonas,\", \"Mnemonic\": \"44\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Final culture results\", \"Header\": 1}, {\"Row\": 13, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 2, \"Text\": \">> Gram-negative bacilli <<\", \"Header\": 1}, {\"Row\": 34, \"Column\": 2, \"Text\": \">> Gram-negative cocci <<\", \"Header\": 1}, {\"Row\": 36, \"Column\": 2, \"Text\": \"Prevotella\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 400,
    "fields": {
      "name": "ORZID2 GMENU GRAM POS BACTERIA",
      "term": null,
      "displaytext": "Gram-positive bacteria",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 462, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs\", \"Text\": \"Gram-positive cocci\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 465, \"DisplayText\": \"Interim report of Gram-positive rods\", \"Text\": \"Gram-positive bacilli\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GRAM-POSTITIVE BACTERIA ++\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Always consider disease or syndrome,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"site of infection, penetration of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"drug(s) into site, and whether\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"organism is pathogen, colonizer, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"contaminant. See disease/syndrome\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"section for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Interim culture results\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Last Reviewed December 2017\", \"Header\": 1}, {\"Row\": 18, \"Column\": 2, \"Item\": 437, \"DisplayText\": \"Staphylococci\", \"Text\": \"Staphylococci\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 435, \"DisplayText\": \"Group A Streptococci (S. pyogenes)\", \"Text\": \"Group A (S. pyogenes)\", \"Mnemonic\": \"12\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 440, \"DisplayText\": \"Group B Streptococci (S. agalactiae)\", \"Text\": \"Group B (S. agalactiae)\", \"Mnemonic\": \"14\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 438, \"DisplayText\": \"Streptococci Groups C, F, G\", \"Text\": \"Groups C, F, G\", \"Mnemonic\": \"16\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 434, \"DisplayText\": \"Group D (S. bovis)\", \"Text\": \"Group D (S. bovis)\", \"Mnemonic\": \"18\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 439, \"DisplayText\": \"Viridans streptococci (including S. mutans, S. mitis, S. sanguis)\", \"Text\": \"Viridans streptococci (including S. mutans, S. mitis, S. sanguis)\", \"Mnemonic\": \"20\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 430, \"DisplayText\": \"Streptococcus pneumoniae\", \"Text\": \"Streptococcus pneumoniae\", \"Mnemonic\": \"22\"}, {\"Row\": 27, \"Column\": 2, \"Item\": 429, \"DisplayText\": \"Streptococcus anginosus (formerly S. milleri)\", \"Text\": \"Streptococcus anginosus (formerly S. milleri)\", \"Mnemonic\": \"24\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 422, \"DisplayText\": \"Anaerobic Gram-positive cocci (including Peptostreptococcus)\", \"Text\": \"Anaerobic Gram-positive cocci (including Peptostreptococcus)\", \"Mnemonic\": \"26\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 426, \"DisplayText\": \"Enterococci\", \"Text\": \"Enterococci\", \"Mnemonic\": \"28\"}, {\"Row\": 34, \"Column\": 2, \"Item\": 423, \"DisplayText\": \"Bacillus species\", \"Text\": \"Bacillus spp.\", \"Mnemonic\": \"30\"}, {\"Row\": 35, \"Column\": 2, \"Item\": 424, \"DisplayText\": \"Clostridium spp.\", \"Text\": \"Clostridium spp.\", \"Mnemonic\": \"32\"}, {\"Row\": 36, \"Column\": 2, \"Item\": 425, \"DisplayText\": \"Corynebacterium spp.\", \"Text\": \"Corynebacteriium spp.\", \"Mnemonic\": \"34\"}, {\"Row\": 37, \"Column\": 2, \"Item\": 428, \"DisplayText\": \"Propionibacterium spp.\", \"Text\": \"Cutibacterium (formerly Propionibacterium) spp.\", \"Mnemonic\": \"36\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 421, \"DisplayText\": \"Actinomyces spp.\", \"Text\": \"Actinomyces spp.\", \"Mnemonic\": \"38\"}, {\"Row\": 39, \"Column\": 2, \"Item\": 427, \"DisplayText\": \"Listeria spp.\", \"Text\": \"Listeria spp.\", \"Mnemonic\": \"40\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 2, \"Text\": \"Final culture results\", \"Header\": 1}, {\"Row\": 14, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 2, \"Text\": \">> Gram-positive cocci <<\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Streptococci\", \"Header\": 1}, {\"Row\": 33, \"Column\": 2, \"Text\": \">> Gram-positive bacilli <<\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 401,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.",
      "term": null,
      "displaytext": "Bacteroides spp. (including Prevotella, Porphyromonas) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 1000 mg PO q12h ($) [DI]\", \"Text\": \"Metronidazole 1000 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"METRONIDAZOLE 1000MG IV Q12H\", \"Text\": \"Metronidazole 1000 mg IV q12h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEROIDES SPP. (INCLUDING PREVOTELLA, PORPHYROMONAS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"These bacteria are strict anaerobes and will only grow in anaerobic media.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Bacteriodes sp., Overview\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-To-Date article: Anaerobic bacterial infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 402,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN CAMPYLOBACTER SPP.",
      "term": null,
      "displaytext": "Campylobacter spp. ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h ($) [O]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg IV q24h ($) [O]\", \"Text\": \"Azithromycin 500 mg IV q24h ($) [O]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CAMPYLOBACTER SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal Optimal therapy depends on both the disease or syndrome and the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pathogen. See diagnosis/syndrome section for more information. Drugs\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"recommended below are best for most cases. If susceptibility results or other\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"factors make these inappropriate for this case, click need an alternative\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For information on gastroenteritis (usually involving C. jejuni), refer to the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Gastrointestinal and Intraabdominal infection section.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment of extraintestinal infectious not involving the central nervous\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"system infections\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment of central nervous system infections\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Campylobacter jejuni, Campylobacter coli\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Campylobacter infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 403,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN ENTEROBACTER SPP.",
      "term": null,
      "displaytext": "Enterobacter spp.  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTEROBACTER SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"q24h ($) [R,O]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"($) [R,O]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Enterobacter sp.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 404,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS",
      "term": null,
      "displaytext": "Moraxella catarrhalis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MORAXELLA CATARRHALIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Moraxella catarrhalis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-To-Date article: Moracella catarrhalis infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 405,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE",
      "term": null,
      "displaytext": "Neisseria gonorrhoeae ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEISSERIA GONORRHOEAE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See diagnosis/syndrome section for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preferred treatment for disseminated gonococcal infection:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Up-To-Date article: Disseminated gonococcal infection\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseria gonorrhoeae\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treat for at least 7 days. Need susceptibility testing of the bloodstream\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"isolate to guide potential switch to an oral medication.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"For persons with a history of a beta-lactam allergy, a thorough assessment\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"of the reaction is recommended.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"-Consult Infectious Disease to determine best alternative to cephalosporin.\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"04\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"All gonorrhea patients should be tested for HIV, syphilis, and Chlamydia\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"trachomatis. Sexual partners should be evaluated.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 406,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS",
      "term": null,
      "displaytext": "Neisseria meningitidis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 3 million units IV Q4H\", \"Text\": \"Penicillin 2-4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 1 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chloramphenicol 12.5 mg/kg IV q6h ($$) [O]\", \"Text\": \"Chloramphenicol 12.5 mg/kg IV q6h ($$) [O]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEISSERIA MENINGITIDIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Central nervous system infections require higher doses of antimicrobials.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment for infections outside of the central nervous system\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment for central nervous system infections\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"For patients intolerant to cephalosporins\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Call pharmacy, chloramphenicol is not regularly stocked and will need to be\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"special ordered.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseria meningitidis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment and prevention of meningococcal infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 407,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN P. MULTICIDA",
      "term": null,
      "displaytext": "Pasteurella multocida ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PASTEURELLA MULTOCIDA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Pasteurella multocida\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-To-Date article: Pasteurella infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 408,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN PSEUDOMONAS SPP.",
      "term": null,
      "displaytext": "Pseudomonas spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > tobramycin 5 mg/kg IV\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > tobramycin 5 mg/kg IV\", \"Mnemonic\": \"12\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2 gm IV q8h ($$) [R] < AND > tobramycin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R] < AND > tobramycin 5 mg/kg IV q24h ($) [R,O\", \"Mnemonic\": \"14\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R] < AND > tobramycin 5 mg/kg IV q24h ($)\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] < AND > tobramycin 5 mg/kg IV q24h ($)\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PSEUDOMONAS SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"In severe cases, addition of an aminoglycoside to a beta\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"lactam may be beneficial. Aminoglycoside monotherapy is effective only in\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"treatment of UTI. Refer to genitourinary section for treatment of UTI due to\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pseudomonas. Consult Infectious Diseases for more information.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Oral treatment for mild infections\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"For patients with Beta-lactam allergy\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for severe infections\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"q24h ($) [R,O]\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"For patients with Beta-lactam allergy\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"[R,O]\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-To-Date article: Principles of antimicrobial therapy of Pseudomonas\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"aeruginosa infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 409,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN SALMONELLA SPP.",
      "term": null,
      "displaytext": "Salmonella spp. ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SALMONELLA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For gastroenteritis antimicrobials are not usually indicated. Please refer to\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the Gastrointestinal and Intra-abdominal infections section for more\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"salmonella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"For localized or systemic extraintestinal infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Salmonella sp.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 410,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FIN SHIGELLA SPP.",
      "term": null,
      "displaytext": "Shigella spp. (bacillary dysentery)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h ($) [O]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SHIGELLA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infections section for more information. antibiotic resistance is increasing,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"especially among men who have sex with men. Drug selection should be based on\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antimicrobial susceptibility tests.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred treatment for systemic infections\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"MMWR (2015) 64.318\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Shigella Sp.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-To-Date article: Shigella infection: Treatment and prevention in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 411,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL A. BAUMANNI",
      "term": null,
      "displaytext": "Acinetobacter baumanni",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases.\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2 gm IV q8h ($$) [R] <AND> amikacin 7.5 mg/kg IV q12h ($$) [R,O]\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R] <AND> amikacin 7.5 mg/kg IV q12h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACINETOBACTER BAUMANNII\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Isolation of Acinetobacter baumannii from a culture often represents\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"contamination or colonization and not disease. For questions about whether a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patient should be treated, contact Infectious Diseases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Many isolates are resistant to multiple antimicrobials. If susceptibilities are\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"not known, start therapy with imipenem or amikacin.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"If susceptibities are known, use appropriate antimicrobial.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Acinetobacter carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sulbactam is active against some strains of ESBLs\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Acinetobacter baumannii\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-To-Date article: Acinetobacter infection: Treatment and prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 412,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL BORDETELLA SPP.",
      "term": null,
      "displaytext": "Bordetella species ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg IV once then 250 mg IV q24h x 4days\", \"Text\": \"Azithromycin 500 mg IV once ($) [O] on day 1, then 250 mg IV q24h ($) [O]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BORDETELLA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Bordetella pertussis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 413,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.",
      "term": null,
      "displaytext": "Brucella spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI] < AND > rifampin 600 mg PO\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] < AND > rifampin 600 mg PO q24h ($)\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BRUCELLA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for non-localizing disease only. Consult Infectious Diseases for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"specifc clinical syndrome since regimens vary (e.g. arthritis, neurobrucellosis,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"endocarditis, etc.)\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat with both drugs for 45 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"[DI,O]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford keyword: Brucellosis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"brucellosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 414,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL CITROBACTER SPP.",
      "term": null,
      "displaytext": "Citrobacter spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CITROBACTER SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Citrobacter sp.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 415,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL ESCHERICHIA COLI",
      "term": null,
      "displaytext": "Escherichia coli",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3 GM PO ONCE\", \"Text\": \"Fosfomycin 3 gm sachet PO ($$) [M] once\", \"Mnemonic\": \"12\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"14\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Mnemonic\": \"18\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Mnemonic\": \"20\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Mnemonic\": \"22\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOD 3 DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"24\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Mnemonic\": \"26\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOD 3 DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"28\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ESCHERICHIA COLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infections section.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"E. coli carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Mild to moderate infections including cystitis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"E. coli carrying ESBL:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"E. coli carrying carbapenemase:\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sanford keyword: Escherichia coli\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 416,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL HAEMOPHILUS SPP.",
      "term": null,
      "displaytext": "Haemophilus spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg IV once then 250 mg IV q24h x 4days\", \"Text\": \"Azithromycin 500 mg IV once ($) [O] on day 1, then 250 mg IV q24h ($) [O]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HAEMOPHILUS SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Haemophilus influenzae\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-To-Date article:\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 417,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL KLEBSIELLA SPP.",
      "term": null,
      "displaytext": "Klebsiella spp. ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Text\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3 GM PO ONCE\", \"Text\": \"Fosfomycin 3 gm sachet PO ($$) [M] once\", \"Mnemonic\": \"14\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"16\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Mnemonic\": \"18\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"KLEBSIELLA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"klebsiella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mild to moderate infections including cystitis\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Sanford keyword: Klebsiella sp.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 418,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL LEGIONELLA SPP.",
      "term": null,
      "displaytext": "Legionella spp. ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h ($) [O]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg IV q24h ($) [O]\", \"Text\": \"Azithromycin 500 mg IV q24h ($) [O]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LEGIONELLA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consider treating for up to 21 days in immunosuppressed patients who are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"severely ill upon presentation.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treat for 10 days\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative for patients intolerant to macrolides\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat for 10 days\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Legionella sp.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment and prevention of Legionella infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 419,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL PROTEUS SPP.",
      "term": null,
      "displaytext": "Proteus spp. ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Text\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"14\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROTEUS SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"proteus carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mild to moderate infections including cystitis\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Allergy to penicillin\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Proteus sp.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 420,
    "fields": {
      "name": "ORZID2 GMENU GRAM-NEG FINAL SERRATIA SPP.",
      "term": null,
      "displaytext": "Serratia spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Text\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SERRATIA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Serratia marcescens\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-To-Date article: Infections due to Serratia species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 421,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI ACTINOMYCES SPP.",
      "term": null,
      "displaytext": "Actinomyces spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACTINOMYCES SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Actinomycosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 422,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI",
      "term": null,
      "displaytext": "Anaerobic Gram-positive cocci (including Peptostreptococcus) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 3 million units IV Q4H\", \"Text\": \"Penicillin G 3 million units IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANAEROBIC GRAM-POSITIVE COCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Anaerobic Gram-positive cocci, including peptostreptococci, are often involved\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"in mixed aerobic/anaerobic infections. Beta-lactams (like ampicillin and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"penicillin) and clindamycin are the drugs of choice against anaerobic gram-\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"positive cocci. Beta-lactam/beta-lactamase inhibitors are active against\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"peptostreptococci, so no additional anaerobic antimicrobials are needed\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"specifically to cover peptostreptococcus when drugs such as ampicillin-sulbactam\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"or piperacillin-tazobactam are used.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Anaerobic Cocci and Anaerobic Gram-Positive Nonsporulating\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Bacilli\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Peptostreptococcus sp.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 423,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.",
      "term": null,
      "displaytext": "Bacillus species",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> Meropenem 2 gm IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> Meropenem 2 gm IV q8h\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8\", \"Mnemonic\": \"12\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> clindamycin 900mg IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> clindamycin 900mg IV q8h\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACILLUS SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"B. cereus\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome sections for more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If isolate is clindamycin-susceptable\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"B. anthracis\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Start combination therapy and contact Infectious Diseases immediately.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"If meningitis has not been ruled out\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treat for 6 weeks\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"($$) [R,O] < AND > linezolid 600 mg IV q12h ($$$$) [DI]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"If meningitis has been ruled out\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If isolate is penicillin-susceptible\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Isolate is not penicillin susceptible or susceptibility unknown\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Hendricks et al., Emerg Infect Dis 2014, 20.2\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 424,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI CLOSTRIDIUM SPP.",
      "term": null,
      "displaytext": "Clostridium spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Clostridium difficile disease\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 3 million units IV Q4H\", \"Text\": \"Penicillin G 3 million units IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CLOSTRIDIUM SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For Clostridium difficile disease refer to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Mild to moderate infections may be treated with oral antimicrobials. For\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"neutropenic enterocolitis, gas gangrene, or other necrotizing infection,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"intravenous therapy is indicated. Combination therapy may be preferred. Refer\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to the appropriate section of the CDSS or contact Infectious Diseases for more\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"C. perfringens food poisoning is treated with supportive care. Diarrhea resolves\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"within 24 hours.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"For severe infection with Clostridium spp. other than perfringens, septicum or\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"sordellii, call Infectious Diseases.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred empirical treatment for mild to moderate infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergic patients\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred empirical therapy for severe infections\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergic patients\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford Table 2: Recommended antimicrobial agents\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 425,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI CORYNEBACTERIUM SPP.",
      "term": null,
      "displaytext": "Corynebacterium spp.  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Daptomycin 6 mg/kg iv q24h\", \"Text\": \"Daptomycin 4-6 mg/kg IV q24h ($$$$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500 mg PO q8h ($$) [DI]\", \"Text\": \"Erythromycin 500 mg PO q8h ($$) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500 mg IV q6h ($$) [DI]\", \"Text\": \"Erythromycin 500 mg IV q6h ($$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 500,000 units IV q4h ($$) [R]\", \"Text\": \"Penicillin G 500,000 units IV q4h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 250 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 250 mg PO q6h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CORYNEBACTERIUM SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Corynebacterium jeikeium\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome sections for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for patients intolerant of vancomycin\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Corynebacterium diphtheriae\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Diphtheria is usually severe and often fatal. Antitoxin is the most important\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"treatment. Contact Infectious Diseases immediately.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative for patients intolerant of erythromycin\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium diptheriae\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium jeikeium\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"diptheria\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 426,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI ENTEROCOCCI",
      "term": null,
      "displaytext": "Enterococci  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 431, \"DisplayText\": \"Treatment for Enterococcal infections\", \"Text\": \"Treatment for enterococcal infections\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTEROCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The important human pathogens are Enterococcus faecium and Enterococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"faecalis. The antimicrobial susceptibilities that are reported for enterococci\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"depend on the site of the sample. For all enterococci the microbiology\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"laboratory reports susceptibility for ampicillin and vancomycin. Additionally\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"the lab reports fluoroquinolone susceptibility for urinary isolates and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"susceptibility to gentamicin synergy for bloodstream isolates. For more\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"information on culture and susceptibilities, contact the microbiology laboratory\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Ampicillin is the drug of choice for enterococcal infections. Piperacillin is\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"also active against enterococcus. Cephalosporins are ineffective as single\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"agents for enterococcal infections. For patients who are allergic to penicillin\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"or infected with penicillin-resistant enterococcus, vancomycin is the preferred\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"drug. Nitrofurantoin is effective in urinary tract infections only. Linezolid\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"must be reserved for cases where no other drug can be used as it has many side\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"effects and drug interactions, is expensive, is bacteriostatic rather than\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"bactericidal, and its use promotes resistance.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Combination regimens include a primary anti-enterococcal agent (ampicillin or\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"vancomycin) plus gentamicin or streptomycin are synergistic in vitro and are\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"needed for severe infections like endocarditis or prosthetic joint infections.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"See relevant disease/syndrome sections for more information. Milder diseases\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"like cystitis or wound infection can usually be treated with a single drug. For\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"more information on treatment of enterococcal infections, contact Infectious\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Leuconostoc Species\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecalis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 427,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI LISTERIA SPP.",
      "term": null,
      "displaytext": "Listeria spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimeth/sulfa 5-25 mg/kg iv q6h\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LISTERIA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"For meningitis, please refer to the meningitis section for treatment advice.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy or intolerant of gentamicin\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword: Listeria monocytogenes\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment, prognosis, and prevention of Listeria\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"monocytogenes infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 428,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI PROPIONIBACT SPP.",
      "term": null,
      "displaytext": "Propionibacterium spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin 2 million units iv q4h\", \"Text\": \"Penicillin G 2 million units IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CUTIBACTERIUM (FORMERLY PROPIONIBACTERIUM) SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Isolation of Propionibacterium species from a culture often represents\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"contamination or colonization and not disease. For questions about whether a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patient should be treated, contact Infectious Diseases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"disease/syndrome sections for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Propionibacterium acnes\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-To-Date article: Invasive Cutibacterium (formerly Propionibacterium)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 429,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI S. ANGINOSUS",
      "term": null,
      "displaytext": "Streptococcus anginosus (formerly S. milleri) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 600 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCUS ANGINOSUS (FORMERLY S. MILLERI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Ceftriaxone or penicillin are preferred for central nervous system infection.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Cefazolin or penicillin are preferred for infection outside of the central\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"nervous system.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Central nervous system infections\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Contact Infectious Diseases for advice.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Infections outside of the central nervous system\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"If isolate is clindamycin-susceptable\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Streptococcus anginosus group\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus anginosus group\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-To-Date article: Infections due to the Streptococcus anginosus (Streptococcus\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"milleri) group\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 430,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI S. PNEUMONIAE",
      "term": null,
      "displaytext": "Streptococcus pneumoniae ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 119, \"DisplayText\": \"Central Nervous System\", \"Text\": \"Central Nervous System section\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin 2-4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCUS PNEUMONIAE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Refer to Central Nervous System section for treatment of meningitis\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preferred treatment for infections outside of the central nervous system\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy, or when beta-lactam resistance\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"is suspected or proved\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Streptococcus pneumoniae\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus pneumoniae\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-To-Date article: Invasive pneumococcal (Streptococcus pneumoniae) infections\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"and bacteremia\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 431,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FI TREAT ENTEROCOCCI",
      "term": null,
      "displaytext": "Treatment for Enterococcal infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"14\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]\", \"Text\": \"Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR ENTEROCOCCAL INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Isolation of enterococci in wounds often represents colonization rather than\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infection. When colonization is suspected, enterococci need not be treated.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment for urinary tract infections\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment for systemic infections\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for resistant organisms\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for patients unable to take vancomycin or vancomycin resistant\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"enterococci\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Linezolid has many drug interactions and adverse effects, is expensive, and\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"promotes bacterial resistance. It should only be used in cases where other\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"options are not feasible. Contact Infectious Diseases for assistance.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Enterococcus Species, Streptococcus\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"gallolyticus Group, and Leuconostoc Species\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecalis\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 432,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH",
      "term": null,
      "displaytext": "Treatment for Coagulase negative Staphylococci",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 436, \"DisplayText\": \"Staphylococcis Lugdunensis\", \"Text\": \"Treatment for Staphylococcus lugdunensis\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 3 million units IV Q4H\", \"Text\": \"Penicillin 2-4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"20\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"22\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Mnemonic\": \"26\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"28\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"warneri and S. xylosus\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to S. lugdunensis page for treatment.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Isolation of coagulase-negative staphylococci from a culture often represents\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"contamination or colonization and not disease. For questions about whether a\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"patient should be treated, contact Infectious Diseases.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If susceptibility results are known, use them to select one of the following\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"drugs.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Preferred treatment for urinary tract infection associated with S. saprophyticu\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Alternative for resistant organisms\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Staphylococci\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus sp., Coagulase-negative\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus epidermidis\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-To-Date article: Infection due to coagulase-negative staphylococci: Treatment\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"31\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"If not, use drug for resistant organisms empirically until final culture\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"and susceptibilities available.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 433,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN S. AUREUS",
      "term": null,
      "displaytext": "Treatment for Staphyloccus aureus ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Mnemonic\": \"18\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR STAPHYLOCOCCUS AUREUS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If susceptibility results are known, use them to select one of the following\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"drugs.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for resistant organisms\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus aureus\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus aureus\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"If susceptibility results are not known, empirically select one of the\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"following drugs until final culture and susceptibilities available.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 434,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN S. BOVIS",
      "term": null,
      "displaytext": "Group D (S. bovis) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GROUP D STREPTOCOCCI (S. BOVIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Bacteremia with Streptococcus bovis is associated with malignancy of the colon.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Resistance to penicillin is uncommon. Vancomycin should only be used in a\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"patient with beta-lactam allergy, or if beta-lactam resistance is strongly\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"suspected.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"infections due to group D streptococci (Streptococcus bovis/Streptococcus\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"equinus complex)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 435,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN S. PYOGENES",
      "term": null,
      "displaytext": "Group A Streptococci (S. pyogenes)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 250 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 250 mg PO q6h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> clindamycin 900 mg IV q8h ($$) [H,O]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> clindamycin 900 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"18\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> clindamycin 900 mg IV q8h ($$)\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> clindamycin 900 mg IV q8h ($$)\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GROUP A STREPTOCOCCI (S. PYOGENES)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Group A streptococcus (Streptococcus pyogenes) is the most virulent\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"streptococcal species. Important syndromes include pharyngitis, cellulitis,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"streptococcal toxic shock syndrome, necrotizing fasciitis, erysipelas, rheumatic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"fever, and post-streptococcal glomerulonephritis. Optimal therapy depends on\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"both the disease or syndrome and the pathogen. See diagnosis/syndrome section\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mild to moderate infections (non-necrotizing)\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Bacteremia, toxic shock syndrome and necrotizing infections\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"[H,O]\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Streptococcus pyogenes\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Strep\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-To-Date article: Group A streptococcal (Streptococcus pyogenes) bacteremia in\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"adults\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 436,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN STAPH LUGDUNENSIS",
      "term": null,
      "displaytext": "Staphylococcis Lugdunensis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR STAPHYLOCOCCUS LUGDUNENSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Severity of S. lugdunensis infections vary from moderate to severe.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Approximately 25% of isolates are resistant to penicillin, but methicillin\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"resistance is uncommon.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If susceptibility results are known, use them to select one of the following\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"drugs. If not, use vancomycin empirically until final culture and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"susceptibilities are available.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative for resistant organisms\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for patients unable to take vancomycin\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Staphylococci\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus lugdunensis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-To-Date article: Staphylococcus lugdunensis\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Mnemonic\": \"18\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 437,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN STAPHYLOCOCCI",
      "term": null,
      "displaytext": "Staphylococci",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 433, \"DisplayText\": \"Treatment for Staphyloccus aureus\", \"Text\": \"for Staphylococcus aureus\", \"Mnemonic\": \"4\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 432, \"DisplayText\": \"Treatment for Coagulase negative Staphylococci\", \"Text\": \"for coagulase-negative staphylococci\", \"Mnemonic\": \"6\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 276, \"DisplayText\": \"\", \"Text\": \"Click Here\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STAPHYLOCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Staphylococcus aureus is a virulent pathogen, and staphylococcal disease tends\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to relapse. Optimal therapy often involves intravenous therapy for defined\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"durations. See sections on specific syndromes (e.g., bacteremia or\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"endocarditis) for more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Coagulase-negative staphylococci, including Staphylococcus epidermidis and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"several less common species, are less virulent than S. aureus and are most\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"commonly pathogenic when they colonize plastic or metal devices in a patient\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"(e.g., intravenous catheters, prosthetic joints or heart valves). S.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"lugdunensis is an uncommon but virulent coagulase-negative staphylococcus\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"species. S. saprophyticus is associated with urinary tract infections in women.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Beta-lactam antimicrobials are the most active drugs against beta-lactam\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"susceptible staphylococci. Penicillin is superior for penicillin-susceptible\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"staphylococci, but most strains are resistant. Nafcillin and oxacillin are\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"nearly as active as penicillin. Cefazolin or ceftriaxone (also beta-lactams are\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"next best. Vancomycin, a glycopeptide, is less active than the beta-lactams.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Trimethoprim-sulfamethoxazole, minocycline, and clindamycin are less effective\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"than beta-lactams for treatment of methicillin-susceptible staphylococcal\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"infections, but may be useful in patients with severe penicillin allergy. For\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"methicillin-resistant staphylococcal infections, trimethoprim-sulfamethoxazole,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"minocycline, and clindamycin are useful alternatives to to vancomycin, as they\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"are inexpensive and available in both intravenous and oral formulations. They\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"are preferred over linezolid in most circumstances because linezolid is\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"expensive, toxic with long-term use, and needed for treatment of highly\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"resistant bacteria like vancomycin-resistant enterococci.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Combination regimens include a primary anti-staphylococcal agent (beta-lactam or\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"vancomycin) plus one or more supplemental drugs (e.g. gentamicin and/or\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"rifampin) often synergistic against staphylococci in vitro, but there is no\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"evidence that combination therapy improves outcomes in staphylococcal infections\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"in humans. Combination therapy has become the community standard for treatment\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"of prosthetic-valve staphylococcal endocarditis based on experimental models and\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"limited clinical data that combination therapy is superior (see endocarditis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"section for details).\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Decolonization\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Baddour, et al. Circulation 2015, 132.15\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and Intravascular Infections\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus aureus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 438,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN STREP C,F,G",
      "term": null,
      "displaytext": "Streptococci Groups C, F, G ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin 2-4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCI GROUPS C, F, G\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Preferred\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Groups C and G Streptococci, and Other Related Organisms\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Strep\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-To-Date article: Group C and group G streptococcal infection\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"12\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 439,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP",
      "term": null,
      "displaytext": "Viridans streptococci (including S. mutans, S. mitis, S. sanguis)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 102, \"DisplayText\": \"Cardiovascular\", \"Text\": \"Cardiovascular\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"VIRIDANS STREPTOCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Viridans streptococci are a heterogeneous group defined by their production of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"green pigment on blood agar. Clinically important members of this group include\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"S. mutans, S. mitis, and S. sanguis. S. anginosus (formerly S. milleri) and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Streptococcus bovis are described separately. Viridans streptococci are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"important, common pathogens in endocarditis and can also be contaminants in\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"cultures of blood and other specimens. Consult Infectious Diseases for more\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to Cardiovascular Section for diagnosis and treatment of endocarditis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred treatment is penicillin or cefazolin. Vancomycin should be used only\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"in patients with beta-lactam allergy, or if beta-lactam resistance is strongly\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"suspected. For serious disease, consider addition of gentamicin for synergy.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Contact Infectious Diseases for more information.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"q8h ($) [R,O]\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative for patient with penicillin allergy, or if beta-lactam resistance\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"is suspected\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Groups C and G Streptococci, and Other Related Organisms\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococci, viridans group\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 440,
    "fields": {
      "name": "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE",
      "term": null,
      "displaytext": "Group B Streptococci (S. agalactiae) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin 2-4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GROUP B STREPTOCOCCI (S. AGALACTIAE)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Group B streptococci (Streptococcus agalactiae) are associated most commonly\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"with bacteremia and meningitis in infants and bacteremia and urinary tract\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infections in elderly people and people with diabetes mellitus.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell Chapter: Streptococcus agalactiae (Group B Streptococcus)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus agalactiae, Group B Strep\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-To-Date article: Group B streptococcal infections in nonpregnant adults\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 441,
    "fields": {
      "name": "ORZID2 GMENU H. PYLORI INFECT",
      "term": null,
      "displaytext": "Helicobacter pylori infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"BIS SUBSAL METRO TCN OMEP H PYLORI\", \"Text\": \"Bismuth subsalicylate 524 mg PO PO q6h <AND> Tetracycline 500 mg q6h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HELICOBACTER PYLORI INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"H. pylori infection is associated with peptic ulcers, gastritis, gastric\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"adenocarcinoma, and gastric lymphoma. Antimicrobials should be given to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patients with confirmed H. pylori infection. Antisecretory therapy should be\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"given concurrently. Contact Gastroenterology for more information or\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"<AND> metronidazole 250mg PO q6h ($) [DI] <AND> omeprazole 20 mg PO q12h\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Take all for 14 days.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Helicobacter pylori and Other Gastric Helicobacter Species\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Gastric/Duodenal Ulcer, Helicobacter pylori\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment regimens for Helicobacter pylori\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Chey et al, Am J Gastroenterol, 2017,112:212-239\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"treatment failures to first line.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"First line treatment:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CLARITH AMOX METRO OMEPRO H PYLORI\", \"Text\": \"Clarithromycin 500 mg PO q12h ($)[R,DI] <AND> Amoxicillin 1000 mg PO q12h\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"($)[R] <AND> metronidazole 500 mg PO q12h ($) [DI] <AND> omeprazole 20 mg\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"PO q12h. Take all for 14 days.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Resistance to clarithromycin is increasing, do not use for patients with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"prior exposure to macrolides:\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 442,
    "fields": {
      "name": "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)",
      "term": null,
      "displaytext": "Head Lice (Pediculosis Capitis)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 3053, \"DisplayText\": \"Treating Head Lice URL\", \"Text\": \"https://www.cdc.gov/parasites/lice/head/index.html\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion to the affected area for 10 minutes\", \"Text\": \"Permethrin 1% lotion Apply to affected area for 10 minutes then comb out\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"HEAD LICE (PEDICULOSIS CAPITIS)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Lice are parasitic insects. Human lice survive by feeding on human blood.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"To make a diagnosis, use a nit comb, bright light, or lens to find a louse\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"living on the scalp.  Dead nits may remain for months after successful\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"treatment.  Dead nits are usually located more than 6 mm from the scalp.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Lice are often transmitted by infected clothing and bedclothes but not by\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"ordinary furniture that is not typically in contact with hair or scalp.  Refer\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to the following for advice on household cleaning for lice infestations:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Repeat if live lice are seen 7-10 days after treatment.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"nits ($) [M]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: lice\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 443,
    "fields": {
      "name": "ORZID2 GMENU HIDRADENITIS SUPPURATIVA",
      "term": null,
      "displaytext": "Hidradenitis Suppurativa ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]\", \"Text\": \"Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]\", \"Text\": \"Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% topical solution apply twice daily\", \"Text\": \"Clindamycin 1% solution topically to affected areas q12h prn for flares ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"12\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300MG PO q12h\", \"Text\": \"Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]\", \"Mnemonic\": \"14\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MOXI 400MG PO Q24H METRO 500MG PO Q8H RIFAMPIN 300MG PO Q12H\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($)[R,DI] for 12 weeks <AND> metronidazole 500\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HIDRADENITIS SUPPURATIVA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A chronic inflammatory condition that typically involves occlusion, rupture,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"abscess formation and infection of hair follicles as well as secondary infection\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"of apocrine glands/surrounding tissues. Lesions most often occur in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"intertriginous areas (axillae, inguinal and anogenital) in is associated with\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"smoking and obesity. There is a 40% genetic predisposition for hidradenitis\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"suppurativa (HS) and is often accompanied by pain, malodor, and drainage.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Cultures are negative 50% of the time and often are polymicrobial with S.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"epidermidis and S. aureus most isolated. The Hurley Staging System is often used\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"to determine severity of HS.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Therapy generally consists of treatment of comorbidities that can exacerbate HS,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"avoidance of triggers, pain management, wound care, and topical/oral\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"antimicrobials. Hormonal agents, steroids, retinoids, and surgery can also be\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"used to treat certain patients. Biologics may be considered in Stage II-III HS.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Consult Dermatology in all cases\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Hurley Staging System:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Stage I: recurrent nodules and abscesses with minimal scarring\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Stage II: limited number of sinuses and/or scarring within a body region\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Stage III: multiple or extensive sinuses and/or scarring\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Duration of Therapy:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment is typically for 12 weeks but may require longer durations in certain\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"cases. Metronidazole should only be used for a maximum of 6 weeks to avoid\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"neurologic toxicity.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Interventions for All Patients:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Smoking cessation, weight loss, avoidance of triggers, and pain management\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"should be part of all treatment plans. Consult Dermatology for use of hormonal\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"agents, steroids, retinoids, and surgery.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Optional Topical Treatment, May be Used in Addition to Oral Therapies Below:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"< ADD ON THERAPY FOR FLARES - MUST USE IN ADDITION TO ONE OF THE AGENTS ABOVE>\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Stage I-II Initial Treatment:\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Stage III Initial Treatment and Stage I-II Failure of Oral Doxycycline:\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Stage II-III Failure of Oral Clindamycin:\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"mg q8h ($) [DI] for 6 weeks <AND> rifampin 300 mg PO q12h ($) [DI,O] for 12\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"weeks\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Alikhan, Ali, et al. Journal of the American Academy of Dermatology 81.1 (2019):\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"76-90\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"John Hopkins ABX Guide Keyword: Hidradenitis Suppurativa\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Up-To-Date article: Hidradenitis suppurativa: Management\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Up-To-Date article: Hidradenitis suppurativa: Pathogenesis, clinical features,\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"and diagnosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 444,
    "fields": {
      "name": "ORZID2 GMENU IG HIS DEFICIENCY",
      "term": null,
      "displaytext": "Immunoglobulin (Humoral immune system) deficiency",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($5.71/day) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"IMMUNOGLOBULIN DEFICIENCY (HUMORAL IMMUNE SYSTEM)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibody deficiency typically leads to recurrent, severe respiratory tract\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infections associated with encapsulated bacteria, especially Streptococcus\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pneumoniae and Haemophilus influenzae, and to a lesser extent, Staphylococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"aureus. Recurrent otitis media, sinusitis, and pneumonia are common syndromes.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Gastrointestinal disease associated with Salmonella, Shigella, Campylobacter, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"rotavirus is also common in some patients.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred empirical treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative for severe penicillin allergy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Chloramphenicol is not currently available.  Contact Infectious Diseases for\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"advice.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 445,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA",
      "term": null,
      "displaytext": "Altered microbial flora  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ALTERED MICROBIAL FLORA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A rich, diverse microbial flora lives on or in skin, mucosal surfaces, and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"respiratory and gastrointestinal tracts of healthy people.  This flora prevents\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease by inhibiting the growth of potential pathogens.  Disruption of the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"normal flora, usually by antimicrobial therapy, reduces this barrier and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"increases the risk of infectious disease.  Patients exposed to broad-spectrum\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobials are at greater risk for colonization with resistant bacteria,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"fungal infections, and Clostridium difficile colitis.  During hospitalization,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"many patients become colonized with more resistant organisms like methicillin-\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"resistant Staphylococcus aureus and resistant Gram-negative bacilli.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 446,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS",
      "term": null,
      "displaytext": "Basic concepts  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BASIC CONCEPTS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Humans are protected by a broad array of host defenses that fall into two major\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"categories: innate and immune host defenses.  Innate defense operate\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"continuously without specific antigenic stimulation and immune defenses are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"primed by and respond to antigenic stimulation.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Each type of host defense protects against a specific set of organisms.  As a\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"result, infectious diseases more common because of host defense defects in an\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"individual patient are usually predictable from that patient's host defense\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"defects.  For example, antibody or complement deficiencies predispose patients\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"to disease with encapsulated organisms but not fungi.  Defects in cell-mediated\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"immunity predispose patients to infections with mycobacteria or cytomegalovirus\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"but not Escherichia coli or influenza virus.  Suspected cases of infectious\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"disease must be evaluated in the context of the patient's host defects.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Management, including possible antimicrobial therapy, should be initiated on the\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"basis of the most likely offending pathogens.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 447,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM COMP DEFICIENCY",
      "term": null,
      "displaytext": "Complement deficiency ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($5.71/day) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMPLEMENT DEFICIENCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Complement deficiency can be inherited or acquired.  Acquired defects are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually a consequence of other diseases like systemic lupus erythematosus.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Complement deficiency leads to increased rates of infections, usually of the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"upper respiratory tract, but also occasionally with bacteremia or meningitis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Pathogens are usually Streptococcus pneumoniae, Neisseria meningitidis, and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Neisseria gonorrhea.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Patients presenting with fever or other symptoms suggesting systemic bacterial\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"infection should be treated immediately with antimicrobials active against these\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"pathogens.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred empirical treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative for severe penicillin allergy\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Chloramphenicol is not currently available.  Contact Infectious Diseases for\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"advice.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 448,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS",
      "term": null,
      "displaytext": "Diabetes Mellitus  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIABETES MELLITUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Hyperglycemia increases the risk of infectious diseases in diabetic patients,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"and increased blood glucose slows infection resolution.  Diabetic patients are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"prone to a variety of infections including urinary tract infections,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cholecystitis, and bacteremia.  Peripheral neuropathy and arterial insufficiency\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"predispose to infections of skin, soft tissue, and bone infection in the lower\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"legs and feet.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Joshi N  New Eng J Med 1999, 341: 1906\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 449,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA",
      "term": null,
      "displaytext": "Hypochlorhydria ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HYPOCHLORHYDRIA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diminished gastric acid allows increased numbers of bacteria in the stomach and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"predisposes to infection with several potentially pathogenic bacterial species.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"These changes increase the risk of nosocomial pneumonia and possibly the risk of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"community-acquired respiratory infections.  However, interventions to\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"decontaminate the upper gastrointestinal tract do not prevent infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"disease.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 450,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM MALIGNANCY",
      "term": null,
      "displaytext": "Malignancy",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 453, \"DisplayText\": \"Neutropenic fever\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 529, \"DisplayText\": \"Prevention of bacterial infection in a patient with malignancy\", \"Text\": \"Prevention of bacterial infections in a patient with malignancy\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 530, \"DisplayText\": \"Prevention of fungal infections in a patient with malignancy\", \"Text\": \"Prevention of fungal infections in a patient with malignancy\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 304, \"DisplayText\": \"\", \"Text\": \"Prevention of viral infection in a patient with malignancy\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MALIGNANCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Malignancies affect host defenses in many ways.  Hematogenous malignancies can\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diminish the effectiveness of neutrophils and other cells involved in host\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"defense.  Tumors often disrupt mucous membranes or blood vessels and allow\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"contaminating organisms into hollow cavities or the bloodstream.  Chemotherapy\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"used to treat these malignancies often impairs mucus membranes and suppresses\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"neutrophil production and function.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Ordinarily, empirical antimicrobials are not indicated for patients with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"malignancy and fever unless they have neutropenia or a specific infectious\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"disease.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 451,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM MALNUTRITION",
      "term": null,
      "displaytext": "Malnutrition ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MALNUTRITION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Adequate nutrition is necessary for optimal host defense function.  A few days\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"of malnutrition can decrease host defenses, mainly cell-mediated immunity. The\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"degree of compromised immunity increases with the duration of malnutrition.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"However, nutritional replacement has not been shown to improve outcomes in\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"patients with mild-moderate malnutrition.  Enteral nutritional replacement is\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"far superior to and safer than intravenous hyperalimentation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Empirical antimicrobials are not indicated for malnourished patients with fever\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"but without evidence of a specific infectious disease.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 452,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM NEUROL DYSFUNCTION",
      "term": null,
      "displaytext": "Neurological dysfunction ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 83, \"DisplayText\": \"Aspiration pneumonia\", \"Text\": \"Aspiration pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUROLOGICAL DYSFUNCTION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Several types of neurological dysfunction predispose patients to infectious\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diseases.  Comatose patients are unable to keep weight off dependent tissues,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"predisposing them to decubitus ulcers and pressure necrosis.  Atelectasis is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"common in obtunded patients who cannot cough or breathe deeply.  When patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"require artificial ventilation, intubation compounds the risk of respiratory\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"infection.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Neurological dysfunction of the bladder can interfere with normal bladder\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"emptying and predisposes patients to bacteriuria.  The risk of bacteruria\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"increases if patients are catheterized.  Antimicrobial treatment is not\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"indicated for asymptomatic bacteriuria.  It provides no benefit and increases\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"risk of colonization with resistant organisms.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Neurological dysfunction predisposes patients to aspiration of oropharyngeal or\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"gastric contents.  Aspiration causes fever, inflammation, and/or pulmonary\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infiltrate, but does not require antimicrobial treatment. Bacterial pneumonia\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"occurs in a minority of patients who experience significant aspiration,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"typically about 3 days later.  Typically, the patient improves for the first 2\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"days and then worsens as bacterial pneumonia develops with increased fever, new\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"or progressive infiltrates, leukocytosis, and newly purulent sputum.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 453,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM NEUT FEVER",
      "term": null,
      "displaytext": "Neutropenic fever  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 498, \"DisplayText\": \"Neutropenic fever--Patient is a candidate for oral therapy\", \"Text\": \"If patient IS a candidate for oral therapy\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 497, \"DisplayText\": \"Neutropenic fever--Patient is NOT a candidate for oral therapy\", \"Text\": \"If patient is NOT a candidate for oral therapy\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 502, \"DisplayText\": \"Scoring tool to identify low risk febrile neutropenic patients\", \"Text\": \"Link to a scoring tool that identifies low risk patients for oral therapy\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 499, \"DisplayText\": \"Modification to Neutropenic fever therapy\", \"Text\": \"Modification to neutropenic fever therapy\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The risk of severe, rapidly progressive infections increases when the absolute\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"neutrophil count (ANC, segmented neutrophils plus bands) is less than 500\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cells/microliter.  The risk increases dramatically when the ANC is <100\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cells/microliter.  Because of these risks, patients with fever and neutropenia\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"to this degree should receive empirical antimicrobial therapy immediately.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical therapy should also be given to patients with fever and ANC 500-1000\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"cells/microliter when the concentration is expected to be <500 cells/microliter\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"within the next 48 hours.  For this purpose, fever is defined as a single\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"temperature greater than 38.3 degrees Celsius.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Initial therapy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Since infection can be rapidly progressive and severe, broad-spectrum\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"antimicrobials are given urgently to patients with neutropenic fever as defined\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"above.  Vancomycin should only be given when there are clear indications for its\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"use.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Candidates for empirical treatment with oral antimicrobials include those who\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"are febrile but who have no evidence of focal infection or signs or symptoms of\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"severe disease, like hypotension.  Outpatient antimicrobials for neutropenic\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"fever must be ordered only in consultation with Hematology-Oncology or\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Modifcation to therapy\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Hughes WT  Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 454,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM NEUTROPENIA",
      "term": null,
      "displaytext": "Neutropenia  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with neutropenia are at risk of infection from pyogenic organisms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"including Staphylococcus aureus, streptococci, Gram-negative bacilli,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa, candida, and certain filamentous fungi, most notably\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Aspergillus and the zygomycetes.  The risk is inversely related to the absolute\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"neutrophil count (ANC), the disease or condition associated with neutropenia,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"duration of neutropenia, and the presence of other host defense defects or\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"underlying diseases.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 455,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM STRESS",
      "term": null,
      "displaytext": "Stress ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STRESS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute psychological stress is associated with immune stimulation and increased\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cellular host defenses.  However, chronic stress decrease humoral and cell-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"mediated immunity.  Chronic stress has been correlated with increased risk of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"respiratory tract infection.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Critically ill patients are usually profoundly stressed.  The risk of infection\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"is subtle and the defects are non-specific.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 456,
    "fields": {
      "name": "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE",
      "term": null,
      "displaytext": "Tobacco smoke",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TOBACCO SMOKE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Active or passive exposure to tobacco smoke is associated with increased\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"susceptibility to respiratory infectious diseases and several systemic\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infectious diseases with bacterial and viral pathogens.  Compounds found in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"tobacco or tobacco smoke interfere with several host defense mechanisms in the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"respiratory tract and elsewhere in the body.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 457,
    "fields": {
      "name": "ORZID2 GMENU INFECT DIARRHEA/GASTRO",
      "term": null,
      "displaytext": "Infectious diarrhea/Gastroenteritis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 346, \"DisplayText\": \"Community acquired diarrhea\", \"Text\": \"Community acquired diarrhea (no recent travel)\", \"Mnemonic\": \"4\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 627, \"DisplayText\": \"Traveler's Diarrhea\", \"Text\": \"Traveler's diarrhea\", \"Mnemonic\": \"6\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 75, \"DisplayText\": \"Diarrhea with Aeromonas\", \"Text\": \"Aeromonas\", \"Mnemonic\": \"8\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Adenovirus\", \"Mnemonic\": \"10\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Astrovirus\", \"Mnemonic\": \"12\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 99, \"DisplayText\": \"Diarrhea with Campylobacter\", \"Text\": \"Campylobacter\", \"Mnemonic\": \"14\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 84, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"[CLICK HERE] for mild to moderate disease\", \"Mnemonic\": \"16\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 286, \"DisplayText\": \"Severe disease - Ileus/Toxic megacolon\", \"Text\": \"[CLICK HERE] for severe/life-threatening disease (shock, ileus and megacolon)\", \"Mnemonic\": \"18\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 195, \"DisplayText\": \"Diarrhea with Isospora belli\", \"Text\": \"Cystoisospora belli\", \"Mnemonic\": \"20\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 130, \"DisplayText\": \"Diarrhea with Cryptosporidium parvum\", \"Text\": \"Cryptosporidium parvum\", \"Mnemonic\": \"22\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 131, \"DisplayText\": \"Cyclospora cayetanensis\", \"Text\": \"Cyclospora cayetanensis\", \"Mnemonic\": \"24\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 152, \"DisplayText\": \"Entoemeba histolytica\", \"Text\": \"Entamoeba histolytica\", \"Mnemonic\": \"26\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 149, \"DisplayText\": \"Diarrhea with Enterohemorrhagic E. coli\", \"Text\": \"Escherichia coli [CLICK HERE], including varieties listed below:\", \"Mnemonic\": \"28\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 166, \"DisplayText\": \"Diarrhea with Giardia lamblia\", \"Text\": \"Giardia duodenalis\", \"Mnemonic\": \"30\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 208, \"DisplayText\": \"Microsporidia\", \"Text\": \"Microsporidia\", \"Mnemonic\": \"32\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Norovirus\", \"Mnemonic\": \"34\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Rotavirus\", \"Mnemonic\": \"36\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 347, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Sapovirus\", \"Mnemonic\": \"38\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 265, \"DisplayText\": \"Diarrhea with Salmonella\", \"Text\": \"Salmonella\", \"Mnemonic\": \"40\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 269, \"DisplayText\": \"Diarrhea with Shigella species (bacillary dysentery)\", \"Text\": \"Shigella\", \"Mnemonic\": \"42\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 109, \"DisplayText\": \"Diarrhea with Cholera (Vibrio cholera)\", \"Text\": \"Vibrio cholerae\", \"Mnemonic\": \"44\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 215, \"DisplayText\": \"Vibrio non-cholera\", \"Text\": \"Vibrio non-cholerae\", \"Mnemonic\": \"46\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 631, \"DisplayText\": \"Diarrhea with Yersinia enterocolitica\", \"Text\": \"Yersinia enterocolitica\", \"Mnemonic\": \"48\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INFECTIOUS DIARRHEA / GASTROENTERITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most episodes of acute diarrhea are self limited and do not need to be evaluated\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"or treated. In most mild to moderate cases, antimicrobial therapy does not\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"provide benefit and may prolong symptoms or shedding. Antimicrobial therapy is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"detrimental in cases involving enterohemorrhagic Escherichia coli.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"The decision for whether to test stool depends on illness severity and duration,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the likelihood of specific infectious agents and the severity of any underlying\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"diseases. Send stool sample for enteric pathogen PCR testing if the patient has\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"volume depletion warranting hospitalization, bloody stool, >/= 6 stools in 24\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"hours, temperature >38.4 C, or severe abdominal pain or signs of sepsis, or is\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \">/= 70 years old or substantially immunocompromised. Replace fluid losses and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"correct electrolyte imbalances. Patients with diarrhea who were potentially\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"exposed during a community outbreak of infectious diarrhea should be tested for\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"the suspected bacterial, viral, and parasitic agents regardless of symptom\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"severity.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Obtain blood cultures if patients have signs of septicemia, suspected enteric\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"fever (e.g., fever plus recent travel to an endemic area or contact with someone\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"who has enteric fever), other systemic symptoms, immune compromise, or other\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"high-risk conditions.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Bloody diarrhea\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"therapy and antimotility agents are not recommended in most patients with bloody\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"diarrhea due to an increased risk of hemolytic uremic syndrome when using these\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"agents. Obtain a stool sample for enteric pathogen PCR testing and reserve\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"antimicrobial and antimotility agent treatment until results are known. Enteric\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"pathogen PCR testing results are reported within 2 hours between 7am and 11pm.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"For more information on when an antimicrobial is indicated or if the patient has\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"severe/life threatening diarrhea or is immunocompromised, contact Infectious\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Empirical antimicrobial treatment of diarrhea\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Treatment of diarrhea caused by specific bacteria, parasites, and viruses\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Clostridium difficile:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Enteroaggretive E. coli (EAEC), Enterotoxigenic E. coli (ETEC),\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Enterohemorrhagic E. coli (EHEC), Shiga Toxin-producing E. coli (STEC),\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Enteropathogenic E. coli (EPEC), Enteroinvasive E. Coli (EIEC)\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Sanford guide keyword: Gastroenteritis, Diarrhea: Overview\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"settings\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 458,
    "fields": {
      "name": "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT",
      "term": null,
      "displaytext": "Large uniform rods in an anaerobic bottle  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h (Cost $$)[R]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h (Cost $) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin G 4 million units IV q4h (Cost $$) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LARGE UNIFORM BACILLI IN AN ANAEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Large uniform bacilli in an anaerobic bottle usually suggest clostridium, a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"potentially severe pathogen. Combination therapy is recommended for necrotizing\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infections as clindamycin has the theoretical benefit of inhibiting toxin\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"production.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical treatment of mild to moderate infection\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For patients with non-severe penicillin allergy\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients with severe penicillin allergy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Empirical treatment of severe or necrotizing infection\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"IV q8h (Cost $$) [H,O]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium perfingens\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Stevens et al., Clinical Infectious Diseases 2014 59.2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 459,
    "fields": {
      "name": "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT",
      "term": null,
      "displaytext": "Large uniform rods in an aerobic bottle ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> Meropenem 2 gm IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q8h (Cost $) [R,DI] <AND> Meropenem 2 gm IV q8h\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin 4 million units IV q4H (Cost $$) [R,DI] <AND> clindamycin 900mg\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> clindamycin 900mg IV q8h\", \"Text\": \"Ciprofloxacin 400 mg IV q8h (Cost $) [R,DI] <AND> clindamycin 900mg IV q8h\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LARGE UNIFORM BACILLI IN AN AEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Large uniform bacilli in an aerobic bottle usually suggest Bacillus species.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Bacillus subtilis is usually a contaminant, Bacillus cereus is uncommon but\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"usually pathogenic. If Bacillus anthracis is suspected or isolated contact\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Infectious Diseases immediately.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical treatment of suspected non-anthracis Bacillus spp. associated with\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"disease\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Empirical treatment of suspected Bacillus anthracis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Start combination therapy and contact Infectious Diseases immediately.\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If meningitis has not been ruled out\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat for 6 weeks\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"(Cost $$) [R,O] < AND > linezolid 600 mg IV q12h (Cost $$$$) [DI]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"If meningitis has been ruled out\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Isolate is penicillin-susceptible\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"IV q8h (Cost $$) [H,O]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Isolate is not penicillin susceptible or susceptibility unknown\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"(Cost $$) [H,O]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Hendricks et al., Emerg Infect Dis 2014, 20.2\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 460,
    "fields": {
      "name": "ORZID2 GMENU INT RPT GNB",
      "term": null,
      "displaytext": "Interim report of Gram-negative bacilli ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h (Cost $$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q8h (Cost $$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R]\", \"Text\": \"Aztreonam 2 gm IV q8h (Cost $$$$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Text\": \"Gentamicin 5 mg/kg IV q24h (Cost $) [R,O] <AND> piperacillin-tazobactam\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-NEGATIVE BACILLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most Gram-negative bacilli grow in aerobic or anaerobic bottles. Pseudomonas\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"nearly always grows in aerobic bottles. One drug is sufficient to treat Gram-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"negative bacillus bacteremia, unless the patient is critically ill.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Empirical treatment if pseudomonas is suspected\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients with non-severe penicillin allergy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For patients with severe penicillin allergy\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empirical treatment for critically ill patients or resistant organism likely\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"4.5 gm q6h (Cost $$) [R]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date article: Gram-negative bacillary bacteremia in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 461,
    "fields": {
      "name": "ORZID2 GMENU INT RPT GNC",
      "term": null,
      "displaytext": "Interim report of Gram-negative cocci",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h (Cost $$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h (Cost $) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg IV q24h ($) [O]\", \"Text\": \"Azithromycin 500mg IV q24h (Cost $) [O]\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 406, \"DisplayText\": \"Neisseria meningitidis\", \"Text\": \"NEISSERIA MENINGITIDIS\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 405, \"DisplayText\": \"Neisseria gonorrhoeae\", \"Text\": \"NEISSERIA GONORRHOEAE\", \"Mnemonic\": \"12\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 404, \"DisplayText\": \"Moraxella catarrhalis\", \"Text\": \"MORAXELLA CATARRHALIS\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-NEGATIVE COCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Gram-negative cocci may represent meningococci, gonococci, or moraxella. Based\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"on the clinical situation, select from following possibilities:\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Empirical treatment if meningococci are suspected\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empirical treatment if gonococci, moraxella are suspected or if unknown\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"suspected organism\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For suspected meningococci or gonococci and severe penicillin allergy\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For suspected moraxella and severe penicillin allergy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Refer to specific organism page when final culture results are available\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Warkowski et al, MMWR Recomm Rep 2015, 64.3\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Neisseria Meningitidis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseria Meningitidis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseria Gonorrhoeae\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 462,
    "fields": {
      "name": "ORZID2 GMENU INT RPT GPC IN PAIRS",
      "term": null,
      "displaytext": "Interim report of Gram-positive cocci in pairs",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin 2 million units iv q4h\", \"Text\": \"Penicillin G 2 million units IV q4h (Cost $) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h (Cost $$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A preliminary report of gram-positive cocci in pairs suggests staphylococci,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"streptococci, or enterococci. If the patient is severely ill, is likely\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"colonized with resistant organisms, or if staphylococci or enterococci are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"likely, treat with vancomycin until susceptibility results are known.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Cephalosporins are not active against enterococci or methicillin-resistant\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Staphylococcus aureus.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empirical treatment of suspected streptococci\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For patients with non-severe penicillin allergy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"For severe disease, resistance to beta lactams likely or patient with severe\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"penicillin allergy\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empirical treatment of suspected enterococci\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For severe disease, resistance to beta-lactams likely or patient with\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"penicillin allergy\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Empirical treatment of suspected staphylococci\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococci\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococci\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococci\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 463,
    "fields": {
      "name": "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS",
      "term": null,
      "displaytext": "Interim report of Gram-positive cocci in pairs and clusters  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS AND CLUSTERS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"This suggests staphylococci. Empirical therapy should cover methicillin-\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"resistant Staphylococcus aureus. If a susceptible isolate is identified, beta-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"lactam antimicrobials should be used as they are most effective at killing\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"staphylococci. When a final pathogen is identified, treatment depends on which\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"specific bacterium is identified.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Empirical treatment of suspected staphylococcus infection\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococci\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 464,
    "fields": {
      "name": "ORZID2 GMENU INT RPT GPC PRS/CHAINS",
      "term": null,
      "displaytext": "Interim report of Gram-positive cocci in pairs and chains ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin 2 million units iv q4h\", \"Text\": \"Penicillin G 2 million units IV q4h (Cost $) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h (Cost $) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h (Cost $$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS AND CHAINS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If chains are reported, streptococci are likely. If short chains are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"reported, enterococci are likely. Beta-lactam antimicrobials are more effective\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"than vancomycin in killing susceptible streptococci and enterococci, so\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"penicillin or ampicillin should be used if resistance is unlikely.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If the patient is severely ill or is likely to be colonized with resistant\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"organisms, treat with vancomycin until susceptibility results are known.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Empirical treatment of suspected streptococcus infection\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients with non-severe penicillin allergy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For patients with severe-penicillin allergy\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empirical treatment of suspected enterococcal infection\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For patients with severe disease, resistance to beta-lactams is likely or\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"patient with penicillin allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococci\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococci\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 465,
    "fields": {
      "name": "ORZID2 GMENU INT RPT GPR",
      "term": null,
      "displaytext": "Interim report of Gram-positive rods ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 459, \"DisplayText\": \"Large uniform rods in an aerobic bottle\", \"Text\": \"LARGE UNIFORM BACILLI in an AEROBIC bottle\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 458, \"DisplayText\": \"Large uniform rods in an anaerobic bottle\", \"Text\": \"LARGE UNIFORM BACILLI in an ANAEROBIC bottle\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 467, \"DisplayText\": \"Small pleomorphic rods in aerobic bottle\", \"Text\": \"SMALL PLEOMORPHIC BACILLI in AEROBIC bottle\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 468, \"DisplayText\": \"Small pleomorphic rods in an anaerobic bottle\", \"Text\": \"SMALL PLEOMORPHIC BACILLI in ANAEROBIC bottle\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-POSITIVE BACILLI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"There are three typical morphologies (1)large and regular, (2)medium sized and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"variable, and (3)small and pleomorphic.  The large, uniformly rod-shaped Gram-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"positive bacilli are usually Bacillus spp. (aerobic) or Clostridium species\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"(anaerobic).  Bacillus spp. include Bacillus subtilis (usually a contaminant),\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Bacillus cereus, and Bacillus anthracis.  Medium-sized Gram-positive bacilli are\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"usually Lactobacilli (anaerobic).  Small and pleomorphic bacilli are usually\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Listeria (aerobic), diphtheroids (aerobic), Propionibacteria (anaerobic), and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Corynebacteria (aerobic).\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 466,
    "fields": {
      "name": "ORZID2 GMENU INT RPT YEAST",
      "term": null,
      "displaytext": "Interim report of yeast  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 160, \"DisplayText\": \"Fungi\", \"Text\": \"Fungi\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Micafungin 100 mg IV q24h\", \"Text\": \"Micafungin 100 mg IV q24h ($$$) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF YEAST\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases. If the yeast appear to be or are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"known to be Candida species treat as follows. If other yeasts (e.g.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Cryptococcus, Histoplasma) are suspected, contact Infectious Diseases for\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"treatment advice.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Refer to specific organism for yeasts other than candida\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Most Candida can be treated with fluconazole. If the patient is critically ill\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"or neutropenic or has recently taken an azole antifungal, or if Candida krusei\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"or C. glabrata are suspected, micafungin should be used initially. Removal of\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"central venous catheter is associated with decreased mortality. Call Infectious\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Diseases for advice.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Empirical treatment for patients with mild to moderate illness who have no\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"prior azole antifungal therapy\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"For patients who cannot take oral medication\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Empirical treatment for critically ill patients, neutropenic patients, patients\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"who have recently taken azole antifungals, or if C. glabrata or C. krusei are\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"suspected\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Andes et al, Clinical Infectious Diseases 2012, 54.8\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Pappas et al, Clinical Infectious Diseases 2016, 62.4e1-50\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 467,
    "fields": {
      "name": "ORZID2 GMENU INT SM RODS AEROBIC BOT",
      "term": null,
      "displaytext": "Small pleomorphic rods in aerobic bottle",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h (Cost $$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]\", \"Text\": \"Ampicillin 2 gm IV q4h (Cost $$) [R] and gentamicin 1.7 mg/kg IV q8h (Cost\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h\", \"Text\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h (Cost $$$) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SMALL PLEOMORPHIC BACILLI IN AEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Small pleomorphic bacilli in aerobic bottle are usually diphtheroids. These are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually contaminants. Uncommonly such organisms prove to be Listeria\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"monocytogenes, which when present in a blood culture is likely a pathogen.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Listeria is more likely in patients with impaired cell-mediated immunity,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"pregnant women, elderly and patients on immunosuppressive therapy for\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"transplantation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empirical treatment if there is a strong suspicion of listeria\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For immunocompromised, meningitis or endocarditis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"$) [R,O]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For patients with penicillin allergy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empirical treatment if therapy is indicated and listeria is not suspected\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Listeria Monocytogenes\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Other Coryneform Bacteria and Rhodococci\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Listeria monocytogenes\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Propionibacterium acnes\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 468,
    "fields": {
      "name": "ORZID2 GMENU INT SM RODS ANAEROBIC BOT",
      "term": null,
      "displaytext": "Small pleomorphic rods in an anaerobic bottle ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h (Cost $$)[R]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h (Cost $) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SMALL PLEOMORPHIC BACILLI IN AN ANAEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Small pleomorphic bacilli in anaerobic bottle usually suggest propionibacteria.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"These are often contaminants.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment if therapy is indicated\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For penicillin allergy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"For severe penicillin allergy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell chapter: Other Coryneform Bacteria and Rhodococci\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Propionibacterium acnes\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 469,
    "fields": {
      "name": "ORZID2 GMENU INTRAVAS CATH CANDIDA SPP",
      "term": null,
      "displaytext": "Intravascular catheter-associated Candida Spp. infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 323, \"DisplayText\": \"Bacteremia associated with Candida spp.\", \"Text\": \"FUNGEMIA ASSOCIATED WITH CANDIDA SPP.\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRAVASCULAR CATHETER-ASSOCIATED CANDIDA SPP. INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Remove catheter and Consult Infectious Diseases\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Refer to candidemia page for antifungal choice and duration of treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 470,
    "fields": {
      "name": "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH",
      "term": null,
      "displaytext": "Intravascular catheter-associated coagulase-negative staphylococcus infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IVPB q8h ($) [R] <AND> cefazolin antibiotic lock therapy\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRAVASCULAR CATHETER-ASSOCIATED COAGULASE-NEGATIVE STAPHYLOCOCCUS INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Catheter removal is optional.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment if the catheter is removed\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treat for 7 days.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Methicillin-susceptible isolate\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For patients with non-severe penicillin allergy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Methicillin-resistant isolate or alternative for patients with severe\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"penicillin allergy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment if the catheter is retained\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treat concurrently with systemic therapy and antibiotic lock therapy for 10 to\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"14 days.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Methicillin susceptible isolate\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Methicillin resistant isolate or alternative for patients with\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"penicillin/cephalosporin allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Infections Caused by Percutaneous Intravascular Devices\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mermel et al., Clinical Infectious Diseases 49 (2009)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-to-date article: Treatment of Intravascular Catheter-Related Infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 471,
    "fields": {
      "name": "ORZID2 GMENU INTRAVAS CATH ENTEROCOCCUS",
      "term": null,
      "displaytext": "INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg IV q12h ($$$$) [DI,O]\", \"Text\": \"Linezolid 600 mg IV q12h ($$$$) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]\", \"Text\": \"Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> ampicillin antibiotic lock therapy\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] <AND> ampicillin antibiotic lock therapy\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Remove catheter and treat for 7-14 days for uncomplicated catheter-associated\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"bacteremia. Document that bacteremia clears on therapy. If there is evidence of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"deep-seated infection or endocarditis refer to pertinent sections.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment if the catheter is removed (preferred)\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treat for 7-14 days\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment for ampicillin-resistant isolates or alternative for patients with\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"penicillin allergy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment for ampicillin and vancomycin resistant isolate\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treat for 6 weeks\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treatment if catheter removal is not possible (less desirable)\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Use concurrent systemic AND antibiotic lock therapy, both for 14 days.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment for ampicillin resistant isolates or alternative for patients with\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"penicillin allergy\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Treatment for ampicillin and vancomycin resistant isolate\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"If catheter removal is not possible, discuss options with Infectious Diseases\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Infections Caused by Percutaneous Intravascular Devices\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mermel et al., Clinical Infectious Diseases 49 (2009)\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of intravascular catheter-related infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 472,
    "fields": {
      "name": "ORZID2 GMENU INTRAVAS CATH GNB",
      "term": null,
      "displaytext": "Intravascular catheter-associated Gram-negative Bacilli infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2 gm IV q8h ($$$$) [R]\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin antibiotic\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin antibiotic\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRAVASCULAR CATHETER-ASSOCIATED GRAM-NEGATIVE BACILLI INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Adjust initial antibiotics to narrow spectrum when cultures and susceptibility\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"data are available.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment if the catheter is removed (preferred)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 10 to 14 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for patients with non-severe penicillin allergy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative for patients with severe penicillin allergy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Critically ill patient or resistant organism likely\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"IV q24h ($) [R,O]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment if catheter removal is not possible (less desirable)\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Use concurrent systemic AND antibiotic lock therapy, both for 14 days.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"lock therapy\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Infections Caused by Percutaneous Intravascular Devices\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mermel et al., Clinical Infectious Diseases 49 (2009)\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of intravascular catheter-related infections\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-to-Date article gram-negative bacillary bacteremia in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 473,
    "fields": {
      "name": "ORZID2 GMENU INTRAVAS CATH S. AUREUS",
      "term": null,
      "displaytext": "Intravascular catheter-associated Staphyloccus aureus infection ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRAVASCULAR CATHETER-ASSOCIATED STAPHYLOCOCCUS AUREUS INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Remove catheter and treat for 2 weeks. Duration should be extended to 4 to 6\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"weeks in complicated cases. Document that bacteremia clears on therapy. If\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"there is evidence of deep-seated infection or endocarditis refer to pertinent\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sections.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consult infectious Diseases in all cases.\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment for methicillin-susceptible isolates\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Methicillin resistant isolate or alternative for patient with severe penicillin\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"allergy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell chapter: Infections Caused by Percutaneous Intravascular Devices\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mermel et al., Clinical Infectious Diseases 49 (2009)\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of intravascular catheter-related infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 474,
    "fields": {
      "name": "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT",
      "term": null,
      "displaytext": "Intravascular catheter-associated infection",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 310, \"DisplayText\": \"Approach to Intravascular catheter-associated infection\", \"Text\": \"Approach to intravascular catheter-associated infection and antimicrobial\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg IV\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 470, \"DisplayText\": \"Intravascular catheter-associated coagulase-negative staphylococcus infection\", \"Text\": \"Coagulase-negative staph. intravascular catheter-associated infection\", \"Mnemonic\": \"12\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 473, \"DisplayText\": \"Intravascular catheter-associated Staphyloccus aureus infection\", \"Text\": \"Staphyloccus aureus intravascular catheter-associated infection\", \"Mnemonic\": \"14\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 471, \"DisplayText\": \"INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION\", \"Text\": \"Enterococcus intravascular catheter-associated infection\", \"Mnemonic\": \"16\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 472, \"DisplayText\": \"Intravascular catheter-associated Gram-negative Bacilli infection\", \"Text\": \"Gram-negative Bacilli intravascular catheter-associated infection\", \"Mnemonic\": \"18\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 469, \"DisplayText\": \"Intravascular catheter-associated Candida Spp. infection\", \"Text\": \"Candida Spp. intravascular catheter-associated infection\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRAVASCULAR CATHETER-ASSOCIATED INFECTION\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"lock therapy\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"When catheter-related bacteremia is suspected, draw blood cultures from both the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"catheter and a peripheral vein. If patient is seriously ill (hypotension,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"hypoperfusion, signs and symptoms of organ failure) remove catheter and culture\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"tip. In patients who are moderately ill (e.g. hypotension, organ failure),\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"remove catheter and culture tip if patient has a prosthetic valve, pacemaker or\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"vascular graft. Start empirical antibiotics while awaiting culture results.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Narrow therapeutic spectrum based on sensitivities of cultured pathogens.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Empirical therapy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Empirical therapy for immunosuppressed patients\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"q12h ($) [R]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"For patients with penicillin allergy\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Pathogen-directed therapy\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell chapter: Infections Caused by Percutaneous Intravascular Devices\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mermel et al., Clinical Infectious Diseases 49 (2009)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-date article: Treatment of Intravascular Catheter-Related Infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 475,
    "fields": {
      "name": "ORZID2 GMENU INTRO SPEC PATHOGEN",
      "term": null,
      "displaytext": "Introduction to Specific Pathogen section  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 3054, \"DisplayText\": \"Mandell Online\", \"Text\": \"Mandell's Principles and Practice of Infectious Disease Online Access\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRODUCTION TO SPECIFIC PATHOGEN SECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"This section gives brief advice on antimicrobial treatment for specific\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pathogens. Colonization by pathogens in most non-sterile sites rarely requires\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobial therapy. If there is a question about whether an isolate should\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"be treated, contact Infectious Diseases.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If culture and susceptibility results are available, use them to select\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobial therapy. If culture and susceptibility results are not available,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"use clinical judgment to decide the appropriate spectrum of coverage. If you\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"need advice on a disease or syndrome, return to the main menu and proceed to\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"that disease or syndrome. In most cases, culture and susceptibility results\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"should be used when they become available to select antimicrobials. This\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"section gives the most common drugs to treat most microorganisms. Contact\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Infectious Diseases or consult a textbook such as Mandell's Principles and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Practice of Infectious Disease for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Microbiology results often become available in stages. Interim reports\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"typically indicate the morphology and staining properties of an organism before\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"final identification and susceptibility reports are available. Use an interim\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"report along with the patient's presenting syndrome to refine the empirical\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"therapy regimen pending final results. Use this section to adjust antimicrobial\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"therapy based on an interim report.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 476,
    "fields": {
      "name": "ORZID2 GMENU KERATITIS",
      "term": null,
      "displaytext": "Keratitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 173, \"DisplayText\": \"HERPES KERATITIS\", \"Text\": \"Herpes keratitis\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 0.5% opth 1 drop q1h\", \"Text\": \"Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) q1h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 50 mg/mL oph Gentamicin 15 mg/mL oph q1h\", \"Text\": \"Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops q1h <AND> gentamicin 15 mg/ml\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"KERATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Keratitis is an emergency requiring prompt treatment to prevent vision loss.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Contact Ophthalmology immediately.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Keratitis is associated with viral or bacterial infection, trauma, foreign\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bodies, or allergies. About half of cases of infectious keratitis are caused by\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"bacterial pathogens, most commonly Staphylococcus spp., Streptococcus spp., and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"gram-negative bacilli. Viruses are the second leading cause. Fungi and parasites\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"have also been associated with corneal infection. Obtain corneal scrapings for\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"gram stain and bacterial and viral cultures and start empirical therapy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"immediately.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Link to herpes keratitis page\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"If bacterial keratitis is likely, contact ophthalmology to obtain a corneal\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"scraping and give empirical antibacterial drops immediately. Modify therapy\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"based on Ophthalmology and/or Infectious Diseases recommendations. Ophthalmic\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"corticosteroids are contraindicated in patients with keratitis.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment should be continued until ulcer and other signs of infectious\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"keratitis have resolved. A minimum of two weeks and in rare cases, up to a month\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"of therapy may be required.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mild to moderate bacterial keratitis empirical treatment\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Severe (vision-threatening) bacterial keratitis empirical treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"ophthalmic drops: 1-2 drops q1h ($) [M] in affected eye(s)\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Suspected MRSA\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Patient may require vancomycin 50mg/mL eye drops q1h in addition to gentamicin\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"eye drops. Vancomycin eye drops must be specially compounded and managed by\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Ophthalmology.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Lin et al., Ophthalmology. 2019,126(1):1-55\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Microbial keratitis\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford keyword: Keratitis\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date article:  Complications of contact lenses\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 477,
    "fields": {
      "name": "ORZID2 GMENU LEISHMANIASIS",
      "term": null,
      "displaytext": "Leishmaniasis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LEISHMANIASIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis and treatment are complex.  Consult Infectious Diseases and/or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Dermatology in all cases.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 478,
    "fields": {
      "name": "ORZID2 GMENU LEUKOCYTOSIS",
      "term": null,
      "displaytext": "Leukocytosis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LEUKOCYTOSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The majority of leukocytosis cases are due to infection but a sizable minority\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"are associated with physiological stress, inflammation, medications (e.g\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"glucosteroids), and hematological conditions. In a review of 100 cases of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"extreme leukocytosis (more than 25000 leukocytes per microliter with more than\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"50% granulocytes) at the Minneapolis VA, only 48 were from infectious problems.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Infection should be considered as a possible stimulus for leukocytosis in a\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"patient with leukocytosis. Antimicrobials should be administered if the patient\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"has a syndrome or disease that calls for antimicrobials. Antimicrobials should\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"not be administered solely to treat a patient with leukocytosis and no other\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"sign or symptom of infection.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Wanahita et al., Clinical Infectious Diseases (2002), 34.1585-92\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Reding et al., The American Journal of Medicine (1998), 104.12-16\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 479,
    "fields": {
      "name": "ORZID2 GMENU LYME ACUTE NEURO DISEASE",
      "term": null,
      "displaytext": "Acute neurological disease associated with Lyme disease",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"extensive neurological disease with intravenous antimicrobials.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment of isolated facial paresthesia (Bell palsy)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment of neurological disease other than Bell palsy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treat for 14 to 28 days.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Halperin et. al., Neurology (2007) 69.91-102\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 480,
    "fields": {
      "name": "ORZID2 GMENU LYME ARTHRITIS",
      "term": null,
      "displaytext": "Arthritis associated with Lyme disease  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ARTHRITIS ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases respond to a 28 day course of oral antimicrobials. If symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"persist or recur, Consult Infectious Diseases or Rheumatology.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 481,
    "fields": {
      "name": "ORZID2 GMENU LYME CARDIAC DISEASE",
      "term": null,
      "displaytext": "Cardiac disease associated with Lyme disease  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days. Cardiology consult recommended.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment of first degree or second degree heart block\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment of third degree heart block or other manifestation\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 482,
    "fields": {
      "name": "ORZID2 GMENU LYME DISEASE PROPHYLAXIS",
      "term": null,
      "displaytext": "Lyme Disease Prophylaxis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 3055, \"DisplayText\": \"IXODES IDENTIFACTION LINK\", \"Text\": \"Ixodes scapularis identification\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TICKBORNE RISK MAP\", \"Text\": \"Tickborne Disease Risk in Minnesota\", \"Mnemonic\": \"6\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxyclycline PO 200mg once ($) [DI] (Var)\", \"Text\": \"Doxyclycline PO 200mg once ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LYME DISEASE PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients who have been bitten while in endemic areas of New England, Mid-\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"tick infection rate with Borrelia burgdorferi is equal to or greater than 20%\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"may be treated with prophylactic antibiotics for prevention of Lyme disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Using a wait and see method by monitoring for signs and symptoms of Lyme disease\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"is also an acceptable approach in patients who have been bitten by an Ixodes\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"scapularis tick.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"All following criteria must be met to be considered for prophylactic treatment:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"2. Attached tick is reliably identified as an adult or nymphal Ixodes\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"scalpularis. Follow link below for identification guide:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"3. Tick is attached for greater than or equal to 36 hours based on degree of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"tick engorgement with blood or likely time of exposure to tick infested area.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"4. Prophylaxis must be started within 72 hours after time tick was removed.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"5. Patient was exposed to tick bite in endemic areas where rate of Ixodes\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"counties where there is high risk of tickborne disease are shown in the\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"following link:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Providers can call the Minnesota Department of Health (651-201-5414) or the\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services (608-266-1865) for specific rates of B.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"burdorferi infection of ixodes ticks in area where a patient was exposed.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"bite in New England or Mid-Atlantic States.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Prophylactic treatment if all above criteria are met\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Wormser GP Clin Infect Dis (2006), 43: 1089\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Lyme Disease Basics (2017)\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"https://www.dhs.wisconsin.gov/publications/p01295.pdf\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 483,
    "fields": {
      "name": "ORZID2 GMENU LYME ERYTHEMA MIGRANS",
      "term": null,
      "displaytext": "Erythema migrans associated with Lyme disease ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ERYTHEMA MIGRANS ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Erythema migrans is the first manifestation of Lyme disease in 70-80% of cases.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"It is typically an erythematous circular rash, 5cm or larger in diameter, with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"induration and central clearing (although other patterns occur). It usually\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"develops at the site of the bite and/or in one or more distant locations. The\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"rash occurs 3 to 30 days after the bite. Rashes with onset less than 3 days\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"after a tick bite are not from Lyme disease.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treat for 14 days\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 484,
    "fields": {
      "name": "ORZID2 GMENU M. AVIUM INTRACELLULARE",
      "term": null,
      "displaytext": "Mycobacterium avium intracellulare complex (a.k.a MAI or MAC)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 485, \"DisplayText\": \"Mycobacterium avium pneumonia\", \"Text\": \"Treatment for pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 357, \"DisplayText\": \"Disseminated Mycobacterium avium disease treatment\", \"Text\": \"Treatment for disseminated disease\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 534, \"DisplayText\": \"Prophylaxis against Mycobacterium avium disease...\", \"Text\": \"Prophylaxis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOBACTERIUM AVIUM INTRACELLULARE (MAI OR MAC)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"MAI colonization in patients with chronic lung disease is common. These\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients should not be treated with antimicrobials.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Occasionally, MAI causes pulmonary disease in patients who are not\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"immunosuppressed. Diagnosis and management are complex. Consult Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases and/or Pulmonary.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"MAI causes systemic disease commonly in patients with HIV/AIDS. Most of these\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"cases do not involve the lungs. After treatment, long-term prophylaxis is\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"usually given. Consult Infectious Diseases in all cases.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 485,
    "fields": {
      "name": "ORZID2 GMENU M. AVIUM PNEUMONIA",
      "term": null,
      "displaytext": "Mycobacterium avium pneumonia  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clarithromycin 500 mg PO q12h ($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 250 mg PO q24h ($) M <AND> ethambutol 15 mg/kg PO q24h [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOBACTERIUM AVIUM PNEUMONIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis and treatment are complex. Regimens containing 3 or 4 drugs are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually recommended, but two drug regimens may be sufficient in some cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Consult Infectious Diseases and/or Pulmonary in all cases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment is continued until sputum cultures are consecutively negative for 12\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"months.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Three-drug regimens\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"($$) [R] <AND> rifabutin 300 mg PO q24h ($$) [R,DI]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"<AND> rifabutin 300 mg q24h ($$) [R,DI]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Four-drug regimens may be recommended for advanced (severe) or previously\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"treated disease-Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Mycobacterium avium Complex\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Mycobacterium avium-intracellulare\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of Mycobacterium avium complex lung infection in\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 486,
    "fields": {
      "name": "ORZID2 GMENU M. PNEUMONIAE",
      "term": null,
      "displaytext": "Mycoplasma pneumoniae ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 7 to 14 days ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 ($) on day 1, then 250 mg PO QD ($) for 4 days\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg PO q24h for 5 days ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOPLASMA PNEUMONIAE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Intolerance to doxycycline and azithromycin\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell Chapter: Mycoplasma pneumoniae and Atypical Pneumonia\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sanford keyword: Mycoplasma pneumoniae\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Up-to-Date article: Mycoplasma pneumoniae infection in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 487,
    "fields": {
      "name": "ORZID2 GMENU M. TUBERCULOSIS",
      "term": null,
      "displaytext": "Mycobacterium tuberculosis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOBACTERIUM TUBERCULOSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Management of tuberculosis is complex. Contact Infectious Diseases and/or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Pulmonary service for more information.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 488,
    "fields": {
      "name": "ORZID2 GMENU MALIGNANT OTITIS EXTERNA",
      "term": null,
      "displaytext": "Malignant Otitis Externa ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h for 6 weeks ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q8h for 6 weeks ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h for 6 weeks ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MALIGNANT OTITIS EXTERNA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Those who are elderly, diabetic, immunocompromised and debilitated are at\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"highest risk. Most cases are associated with Pseudomonas aeruginosa, but other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pathogens can be involved. Obtain culture to identify etiologic agent and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"susceptibilities. Obtain a CT scan to determine whether osteomyelitis is\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"present. ENT and Infectious Disease consultations are recommended.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for 6 weeks\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment of early infection or step-down treatment after initial intravenous\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"antimicrobial therapy. Adjust for a total duration of 6 weeks of antimicrobial\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"therapy.\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Evans, Journal of Laryngology and Otology. 2011, 125(12)1212-1217Mandell\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mahdyoun et al., Otol Neurotol. 2013, 34(4)620-629\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Otitis Externa\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date article: Malignant (necrotizing) external otitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 489,
    "fields": {
      "name": "ORZID2 GMENU MASTOIDITIS",
      "term": null,
      "displaytext": "Mastoiditis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q 12 hours ($) [R] < AND > cefepime 2 gm IV q12h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefuroxime 500mg PO q12h for 7 days ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h for 7 days ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)\", \"Mnemonic\": \"16\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MASTOIDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute Mastoiditis\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Acute mastoiditis most commonly occurs as a suppurative complication of acute\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"otitis media. Diagnosis is supported by CT or MRI imaging and culture of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"drainage. Antibiotics and drainage of middle ear are sufficient treatment in\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"most cases. Mastoidectomy is necessary if abscess has formed in the mastoid\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"bone. If complication of first episode of acute otitis media, etiologies\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"typically include Streptococcus pneumonia (most common), Streptococcus pyogenes,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"or Staphylococcus aureus. If secondary to chronic otitis media, etiologies\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"typically include Staphylococcus aureus or Pseudomonas aeruginosa. Patients\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"usually too ill for outpatient therapy. ENT consultation recommended. Obtain\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"cultures of auditory canal or middle ear fluid (preferred).\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q 12 hours ($) [R] for 7 days\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Step down treatment after initial intravenous antibiotic treatment in patients\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"who can tolerate oral therapy. Base selection on culture results. Adjust for a\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"total duration of 7 days of antimicrobial therapy.\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Chronic Mastoiditis\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Chronic mastoiditis is usually the result of chronic otitis media with\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"perforation of the tympanic membrane. There is often associated formation of a\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"cholesteatoma (keratoma). Diagnosis is supported by CT or MRI imaging and\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"culture of drainage. Long term treatment with topical antimicrobials is first\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"line therapy. Infection is often polymicrobial, including Staphylococcus aureus,\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa and anaerobes. Treatment should be managed in\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"collaboration with otolaryngology and includes topical antimicrobials, care of\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"external auditory canal, and is some cases mastoidectomy. If possible, withhold\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"therapy until a pathogen is identified by culture of drainage to direct therapy.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Specific drug choice dictated by culture results.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"weeks ($) [M]\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Loh et. al., The Journal of Laryngology & Otology. 2018, 132(2)96-104.\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Sanford keyword: Mastoiditis\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Up-to-Date article: Chronic otitis media, cholesteatoma, and mastoiditis in\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 490,
    "fields": {
      "name": "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS",
      "term": null,
      "displaytext": "Pre-Op Antimicrobials... ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Item\": 603, \"DisplayText\": \"Surgical prophylaxis general information\", \"Text\": \"Surgical prophylaxis general information\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Item\": 618, \"DisplayText\": \"Surgical wound classification and antimicrobial prophylaxis...\", \"Text\": \"Surgical wound classification and prophylaxis recommendations\", \"Mnemonic\": \"4\"}, {\"Row\": 4, \"Column\": 1, \"Item\": 609, \"DisplayText\": \"Timing and dosing (including re-dosing) of prophylatic antimicrobials\", \"Text\": \"Timing of prophylactic antibiotics\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 604, \"DisplayText\": \"Doses and Redosing of prophylactic antibiotics\", \"Text\": \"CHART: Doses and Redosing Interval for NORMAL renal function\", \"Mnemonic\": \"8\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 578, \"DisplayText\": \"Redosing Interval for renal fxn normal vs esrd\", \"Text\": \"CHART: Redosing Interval for Normal and ESRD renal function\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3056, \"DisplayText\": \"Surgical Prophylaxis Guidelines\", \"Text\": \"<Hyperlink> Surgical Antimicrobial Prophylaxis Guidelines 2013\", \"Mnemonic\": \"12\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"14\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 531, \"DisplayText\": \"Prevention of Bacterial Endocarditis\", \"Text\": \"Inpatient status\", \"Mnemonic\": \"16\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 993, \"DisplayText\": \"Prevention of bacterial endocarditis (Outpatient)\", \"Text\": \"Outpatient status\", \"Mnemonic\": \"18\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 595, \"DisplayText\": \"Neurosurgery\", \"Text\": \"Neurosurgery\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 592, \"DisplayText\": \"Head and neck surgery\", \"Text\": \"Head and neck surgery (See Thoracic for esophageal procedures)\", \"Mnemonic\": \"22\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 596, \"DisplayText\": \"Ophthalmic surgery\", \"Text\": \"Ophthalmology Surgery- Moxifloxacin Intracameral for Cataract Surgery\", \"Mnemonic\": \"24\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 206, \"DisplayText\": \"CV Surgery Delayed Order Antibiotics\", \"Text\": \"CV Surgery (open heart)\", \"Mnemonic\": \"26\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 580, \"DisplayText\": \"Cardiac surgery and implantation of pacemaker\", \"Text\": \"Cardiac Procedures\", \"Mnemonic\": \"28\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 584, \"DisplayText\": \"CIED Pre Op\", \"Text\": \"Cardiac Implantable Electronic Devices Surgery\", \"Mnemonic\": \"30\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 608, \"DisplayText\": \"Thoracic surgery\", \"Text\": \"Thoracic surgery (See CV surgery for heart)\", \"Mnemonic\": \"32\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 642, \"DisplayText\": \"\", \"Text\": \"Cardiovascular surgery decolonization\", \"Mnemonic\": \"34\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 589, \"DisplayText\": \"Gastroduodenal Surgery\", \"Text\": \"Gastroduodenal surgery\", \"Mnemonic\": \"36\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 395, \"DisplayText\": \"\", \"Text\": \"GI Endoscopic Procedures\", \"Mnemonic\": \"38\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 616, \"DisplayText\": \"Vascular surgery\", \"Text\": \"Vascular surgery\", \"Mnemonic\": \"40\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 307, \"DisplayText\": \"Appendicitis without perforation\", \"Text\": \"Appendectomy\", \"Mnemonic\": \"42\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 579, \"DisplayText\": \"Biliary Surgery\", \"Text\": \"Biliary surgery\", \"Mnemonic\": \"44\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 585, \"DisplayText\": \"Bowel/Colo-rectal Surgery\", \"Text\": \"Colon and rectal surgery\", \"Mnemonic\": \"46\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 593, \"DisplayText\": \"Hernia repair surgery with abdominal mesh\", \"Text\": \"Hernia repair surgery with abdominal mesh\", \"Mnemonic\": \"48\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 591, \"DisplayText\": \"Gynecological surgery\", \"Text\": \"Gynecological surgery\", \"Mnemonic\": \"50\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 610, \"DisplayText\": \"Urological procedures\", \"Text\": \"Urological Procedures\", \"Mnemonic\": \"52\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 598, \"DisplayText\": \"Orthopedic surgery, including joint arthroplasty\", \"Text\": \"Orthopedic surgery,including joint arthroplasty\", \"Mnemonic\": \"54\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 597, \"DisplayText\": \"Orthopedic surgery, ALBC for tx of periprosthetic hip/knee joint infections\", \"Text\": \"Orthopedic surgery ALBC Joint Infections\", \"Mnemonic\": \"56\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatologic surgery\", \"Mnemonic\": \"58\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 600, \"DisplayText\": \"\", \"Text\": \"Plastic surgery\", \"Mnemonic\": \"60\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 599, \"DisplayText\": \"Other Procedures\", \"Text\": \"Other procedures\", \"Mnemonic\": \"62\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"++  Surgical Prophylaxis  ++\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"For the complete guideline follow the link below:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Endocarditis Prophylaxis\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Patients receiving preop antibiotics to prevent an SSI generally\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"do NOT need additional antibiotics for endocarditis prophylaxis.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Antimicrobial Surgical Prophylaxis Specific Surgeries\", \"Header\": 1}, {\"Row\": 23, \"Column\": 2, \"Text\": \"__Oral Medications and Nasal Spray__\", \"Header\": 1}, {\"Row\": 24, \"Column\": 2, \"Text\": \"Do NOT use Delayed Orders\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"Go to Surgery Outpt Orders\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"then  56 Pre Op Clinic Medications\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 605, \"DisplayText\": \"Spinal Cord Stimulator Trial Procedure Antimicrobial Prophylaxis\", \"Text\": \"Pain Clinic-Spinal Cord Stim Trial\", \"Mnemonic\": \"64\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 601, \"DisplayText\": \"Podiatry Antimicrobial Surgical Prophylaxis Orders\", \"Mnemonic\": \"57\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 594, \"DisplayText\": \"Interventional Radiology\", \"Text\": \"Interventional Radiology\", \"Mnemonic\": \"39\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 491,
    "fields": {
      "name": "ORZID2 GMENU MILD TO MOD SINUSITIS",
      "term": null,
      "displaytext": "Mild to Moderate Sinusitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 5 days\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R,DI] for 7 days\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MILD TO MODERATE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Community-acquired bacterial sinusitis is most often due to Streptococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. Streptococci,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Staphylococcus aureus and anaerobes are isolated less frequently.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment for first 10 days of illness\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat with decongestants, analgesics, and nasal saline spray.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment of cases that have not improved in 10 days despite\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"treatment with decongestants, analgesics, and nasal saline.\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment Failure\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If symptoms worsen despite 72 hours or  fail to improve after 3-5 days of\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"initial empirical antimicrobial therapy, broaden coverage, switch to different\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"antimicrobial class and treat 7-10 days. If symptoms continue to worsen or there\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"is no improvement after 3-5 more days of treatment, obtain CT to investigate\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"non-infectious or suppurative causes. ENT consultation is recommended. If\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"sinuses are aspirated, specimens should be cultured.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"5\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 492,
    "fields": {
      "name": "ORZID2 GMENU MORE ABOUT CELLULITIS",
      "term": null,
      "displaytext": "The approach to cellulitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 377, \"DisplayText\": \"Erysipelas\", \"Text\": \"Erysipelas\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 384, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus\", \"Text\": \"Foot ulcer in patient with diabetes mellitus\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"THE APPROACH TO CELLULITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In addition to antimicrobial therapy, several non-pharmacological treatments\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"improve the outcome of cellulitis.Elevation and immobilization of the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"affected limb reduces swelling.  Heat reduces discomfort.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prevent tinea pedis infection by keeping feet clean and dry.  In patients with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"peripheral edema, good skin hygiene and support stockings reduce the incidence\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"of recurrent infection.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"In many cases of cellulitis, the affected area is usually not well-\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"differeniated from unaffected areas of the skin. Erysipelas is a special case\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with typically a well-defined border and raised, orange-peel appearance.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Use broad-spectrum therapy for cellulitis arising in feet of patients with\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"advanced diabetes.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Schwartz MN New Eng J Med 2004, 350: 904\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Cellulitis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 493,
    "fields": {
      "name": "ORZID2 GMENU MORE ABOUT PHARYNGITIS",
      "term": null,
      "displaytext": "More about Pharyngitis...",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MORE ABOUT PHARYNGITIS/ TONSILLITIS AND THE MODIFIED CENTOR SCORE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"As most cases are of viral origin, antimicrobials are not indicated in these\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cases. Warm saltwater gargle rinses and throat lozenges provide temporary relief\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"of throat pain. Five to 10% of cases are caused by group A Streptococcus.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment reduces symptoms by one day, prevents suppurative\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"complications and prevents acute rheumatic fever, an uncommon disease in US\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"adults.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Streptococcal pharyngitis or tonsillitis should be suspected when patients have\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"fever and exudate on the pharyngeal wall or tonsils without symptoms like cough,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"nasal congestion, or runny nose that suggest viral infection or common cold. If\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"streptococcal pharyngitis is suspected in adults, perform PCR testing for group\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"A streptococci and treat only if positive.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Neisseria gonorrhoeae is a rare cause of pharyngitis. N. gonorrhoeae should be\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"considered for patients with risk factors for sexually transmitted diseases. N.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"gonorrhoeae infections must be reported to the state health department and this\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"will be done by Infection Control if the culture is positive.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"The Modified Centor score\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Used to estimate the likelihood that a patient with sore throat has\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"streptococcal pharyngitis and whether rapid PCR testing should be performed.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"1) Absence of cough = 1 point\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"2) Swollen and tender anterior cervical nodes = 1 point\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"3) Temperature greater than 100.4 degrees Fahrenheit (38 degrees Centigrade) = 1\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"point\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"4) Tonsillar exudates or swelling = 1 point\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"5) Age: 3-14 years = 1 point\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"15-44 years = 0 points\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"45 years and older = -1 point\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Patients with a score of 0 or 1 are at very low risk. PCR testing and antibiotic\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"treatment are not indicated. Patients with a score of 2 to 4 are at moderate to\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"high risk. PCR testing should be obtained in these patients to determine if GAS\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"is present. In patients with a score of 4 or greater, consider empiric\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"antibiotic treatment.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Choby, Am Fam Physician. 2009 79(5) 383-390\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Mandell chapter: Pharyngitis\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcal Pharyngitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Stanford et al, Clinical Infectious Diseases. 2012, cis629\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-To-Date article:  Evaluation of acute pharyngitis in adults\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-To-Date article:  Treatment and prevention of streptococcal pharyngitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 494,
    "fields": {
      "name": "ORZID2 GMENU NECROT INFECT DIRECT THERAPY",
      "term": null,
      "displaytext": "Pathogen-directed therapy of necrotizing infections ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Text\": \"Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"14\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> clindamycin 900 mg IV q8h\", \"Mnemonic\": \"16\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> clindamycin 900 mg IV\", \"Mnemonic\": \"20\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O] <AND> clindamycin 900 mg IV q8h\", \"Mnemonic\": \"22\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"24\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"NECROTIZING INFECTIONS--PATHOGEN-DIRECTED THERAPY\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Clostridial infections\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"IV q8h ($$) [H,O]\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"_______________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Group A Streptococcal infections (S. pyogenes)\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_______________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"IV q8h ($$) [H,O]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"______________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Polymicrobial infections\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"______________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"These are more common in injection drug users, or in patients who have had\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"recent abdominal surgery or trauma, vulvo-vaginal infection, or genital or\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"rectal abscess.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"IV q8h ($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R] < OR >\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"q8h ($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]  < OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Gas gangrene\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 495,
    "fields": {
      "name": "ORZID2 GMENU NECROT INFECT EMP THERAPY",
      "term": null,
      "displaytext": "Empirical therapy for Necrotizing infections  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> clindamycin 900 mg IV q8h ($$)\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 1gm IV q8h ($$) <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> clindamycin 900 mg IV\", \"Mnemonic\": \"10\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O] <AND> clindamycin 900 mg IV q8h\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"EMPIRICAL THERAPY FOR NECROTIZING INFECTIONS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Preferred treatment:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"IV q8h ($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternatives for penicillin allergy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"q8h ($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Gas gangrene\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 496,
    "fields": {
      "name": "ORZID2 GMENU NECROTIZING INFECTIONS",
      "term": null,
      "displaytext": "Necrotizing infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 495, \"DisplayText\": \"Empirical therapy for Necrotizing infections\", \"Text\": \"Empirical therapy of necrotizing infections\", \"Mnemonic\": \"4\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 494, \"DisplayText\": \"Pathogen-directed therapy of necrotizing infections\", \"Text\": \"Pathogen-directed therapy of necrotizing infections\", \"Mnemonic\": \"6\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NECROTIZING INFECTIONS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Call Surgery immediately and consult Infectious Diseases in all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Necrotizing infections involve tissues skin and/or deeper structures, including\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"fascia and muscle.  These infections destroy tissue, often rapidly, and are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"often fatal if not treated promptly and appropriately.  Necrotizing infections\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"usually result from trauma, surgery, and/or ischemia.  These infections can be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"monomicrobial (e.g., with streptococci or clostridia) or polymicrobial (usually\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with a mixture of aerobes and anaerobes).  Fournier gangrene is usually\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"associated with mixed infection.  Myonecrosis is most commonly associated with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Clostridium species.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Necrotizing infections differ from cellulitis in several ways.  Necrotic\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"infections typically have one or more of the following: (1) severe, constant\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"pain, (2) bullae, (3) bruising or necrosis of overlying skin, (4) gas in tissues\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"which can be felt or seen on images, (5) edema that extends beyond areas of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"erythema, (6) local anesthesia, and (7) signs of systemic toxicity, such as\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"fever, leukocytosis, delirium, or renal failure.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Necrotizing infections must be treated with both antimicrobial therapy and\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"surgical procedures (excision and/or drainage).  Call surgery to see the patient\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"immediately in all cases.  Obtain tissue and blood cultures and begin empirical\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"antimicrobials.  For several necrotic diseases and/or pathogens, a combination\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"of two antimicrobials is recommended including a bactericidal antimicrobial\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"active at the cell wall or membrane (e.g., beta-lactam or glycopeptide) and an\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"antimicrobial that rapidly inhibits protein synthesis and thus inhibits toxin\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"production, typically clindamycin.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Repeat debridement should be performed daily until no further debridement is\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"necessary. Antibiotic therapy should be tailored as soon as culture results\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"become available.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Administer antibiotics until further debridement is no longer necessary, the\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"patient has improved clinically, and fever has been absent for 48-72 hours.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Empirical antimicrobials\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Pathogen-directed treatment regimens\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford keyword: Gas gangrene\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 497,
    "fields": {
      "name": "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA",
      "term": null,
      "displaytext": "Neutropenic fever--Patient is NOT a candidate for oral therapy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 375, \"DisplayText\": \"Empirical intravenous regimens WITHOUT vancomycin\", \"Text\": \"Empirical intravenous regimens WITHOUT vancomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 374, \"DisplayText\": \"Empirical intravenous regimens WITH vancomycin\", \"Text\": \"Empirical intravenous regimens WITH vancomycin\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Vancomycin is not recommended as a standard part of the initial antibiotic\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"regimen.  Consider adding Vancomycin for specific clinical indications:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \">>  Suspected catheter-related infection,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \">>  Skin or soft-tissue infection,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \">>  Pneumonia,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \">>  Hemodynamic instability\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 498,
    "fields": {
      "name": "ORZID2 GMENU NEUT FEVER CAND ORAL THERA",
      "term": null,
      "displaytext": "Neutropenic fever--Patient is a candidate for oral therapy",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 502, \"DisplayText\": \"Scoring tool to identify low risk febrile neutropenic patients\", \"Text\": \"Link to a scoring tool that identifies low risk patients for oral therapy\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> amoxicillin-clavulanate\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg PO q12h ($) [R,DI] <AND> Clindamycin 300mg po q6h ($) [H,O]\", \"Text\": \"Ciprofloxacin 500mg PO q12h ($) [R,DI] <AND> Clindamycin 300mg po q6h ($) [H,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER--PATIENT IS A CANDIDATE FOR ORAL THERAPY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Can the patient be treated with oral therapy?\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"875/125 mg PO q12h ($) [R]\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Freifeld AG Clinical Infectious Disease 2011, 52: 427-431\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Taplitz RA, J Clin Oncol 2018, 36: 1443-1453\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford: Neutropenia, Febrile, Low-Risk\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Related Infections. Version 1.2019. nccn.org\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 499,
    "fields": {
      "name": "ORZID2 GMENU NEUT FEVER MOD THERAPY",
      "term": null,
      "displaytext": "Modification to Neutropenic fever therapy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 500, \"DisplayText\": \"Patients who BECOME AFEBRILE in the first 3 to 5 days of treatment\", \"Text\": \"Patients who BECOME AFEBRILE in the first 3 to 5 days of treatment\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 501, \"DisplayText\": \"Patients whose FEVER PERSISTS throughout the first 3 to 5 days of treatment\", \"Text\": \"Patients whose FEVER PERSISTS throughout the first 3 to 5 days of treatment\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MODIFICATION TO NEUTROPENIC FEVER THERAPY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Determine efficacy of the initial regimen during the first 3 to 5 days.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Decisions about therapy should be made based on (1) whether an infectious\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease has been diagnosed (e.g., pneumonia or cellulitis), (2) whether the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"fever has resolved, and (3) the clinical course.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If a specific infectious disease and/or pathogen is identified, ensure that the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobial regimen is adequate to treat that pathogen or disease, and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"continue broad-spectrum antimicrobial therapy.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"(www.journals.uchicago.edu/doi/pdf/10.1086/339215)\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 500,
    "fields": {
      "name": "ORZID2 GMENU NEUT FEVER PT BECOME AFEBRILE",
      "term": null,
      "displaytext": "Patients who BECOME AFEBRILE in the first 3 to 5 days of treatment ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 502, \"DisplayText\": \"Scoring tool to identify low risk febrile neutropenic patients\", \"Text\": \"Scoring tool to identify low risk febrile neutropenic patients\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 500 mg PO q12h  ($0.18/day) [R,DI] <AND> amoxicillin-\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PATIENTS WITH NEUTROPENIC FEVER WHO BECOME AFEBRILE IN THE FIRST 3 TO 5 DAYS OF\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"TREATMENT\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \">>  Treatment if an INFECTIOUS CAUSE WAS IDENTIFIED and has resolved\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(The infectious disease associated with the fever has resolved, the pathogen has\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"been controlled or eradicated, and the patient seems well)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Stop antimicrobials after treatment for pathogen/disease is completed, often\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"after 7 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \">>  Treatment if infectious cause of fever WAS NOT identified\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"To determine a patients risk level refer to\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment for low risk patients\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Consider a change to oral therapy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"clavulanate 875/125 mg PO q12h  ($1.56/day) [R]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for high risk patients\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Continue same antimicrobials for 7 days\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 501,
    "fields": {
      "name": "ORZID2 GMENU NEUT FEVER PT FEVER PERSISTS",
      "term": null,
      "displaytext": "Patients whose FEVER PERSISTS throughout the first 3 to 5 days of treatment ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PATIENTS WITH NEUTROPENIC FEVER WHOSE FEVER PERSISTS THROUGHOUT THE FIRST 3 TO 5\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"DAYS OF TREATMENT\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"If no infectious disease has been diagnosed but the patient is clinically\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"stable, continue the current regimen.  If vancomycin was part of initial therapy\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"but culture results have not yielded a pathogen that must be treated with\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"vancomycin, discontinue it to minimize development of resistance.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Consider adding amphotericin B for empirical antifungal therapy.  Hematology-\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"oncology or Infectious Diseases may recommend another antifungal like\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"micafungin or voriconazole.  Contact Infectious Diseases for more information.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"If the patient is receiving prophylactic fluconazole, stop it when empirical\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"antifungals are started.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Rolston KVI  Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sipsas NV  Cancer 2005, 103: 1103\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal 3-5MG/KG IV q24h ($$$$)[R,O]+ NS Hydratio\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 502,
    "fields": {
      "name": "ORZID2 GMENU NEUT FEVER SCORING TOOL",
      "term": null,
      "displaytext": "Scoring tool to identify low risk febrile neutropenic patients  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"MASCC RISK INDEX FOR FEBRILE NEUTROPENIA\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SCORING TOOL TO IDENTIFY LOW RISK FEBRILE NEUTROPENIC PATIENTS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with minimal risk of severe or rapidly progressive infection can be\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"treated with oral antimicrobials safely.  Many can be treated as outpatients.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Use the scoring index to identify febrile neutropenic patients who at\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sufficiently low risk for severe infections and can be treated with outpatient\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"oral antimicrobials.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"SCORING INDEX\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"CharacteristicScore\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Severity of symptoms of illness (choose one only)\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"No symptoms or mild symptoms5\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Moderate symptoms  3\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"No hypotension  5\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"No chronic obstructive pulmonary disease4\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Solid tumor or no previous fungal infection4\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"No dehydration  3\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Outpatient status at onset of fever3\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Age less than 60 years2\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sum total __\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Interpretation\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"The highest possible score is 26. A risk index score of 21 or greater indicates\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"that the patient is likely to be at LOW RISK for complications and morbidity.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"This is a guide.  Always use clinical judgement.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Klastersky, J Clin Oncol 2000, 18: 3038\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 503,
    "fields": {
      "name": "ORZID2 GMENU NOSOCOMIAL SINUSITIS",
      "term": null,
      "displaytext": "Nosocomial Sinusitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NOSOCOMIAL SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Nasogastric tubes increase the risk of bacterial sinus infection associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Staphylococcus aureus, streptococcus, and gram-negative bacilli, including\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa. Aspirate sinuses for gram stain and culture to direct\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antimicrobial therapy. Adequate sinus drainage is vital to treatment.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical antimicrobial treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"MRSA suggestive on gram-stain\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Intubation Associated\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-To-Date article: Complications of the endotracheal tube following initial\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"placement: Prevention and management in adult intensive care unit patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 504,
    "fields": {
      "name": "ORZID2 GMENU OSTEOM EMPIRICAL THERAPY",
      "term": null,
      "displaytext": "Empirical therapy for Osteomyelitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po q24h ($0.19/day) [R\", \"Text\": \"Levofloxacin 500mg po q24h ($) [R] <AND> Rifampin 600 mg po\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRICAL THERAPY FOR OSTEOMYELITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Therapy should be modified when culture results and patient response to therapy\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"are known.  If cultures cannot be obtained, the oral regimens listed below can\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"be used for empirical therapy or to complete a treatment course after the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"patient's disease has improved. Consult Infectious Diseases for more\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Duration of treatment 4 to 6 weeks.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"ORAL treatment for MILD disease or for completion of treatment course\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"q24h ($) [DI,O]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"INTRAVENOUS treatment for MODERATE to SEVERE disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford: key term: Osteomyelitis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell Chapter: Osteomyelitis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Berbari EF Clin Infect Dis 2015, 61:e26\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Calhoun JH Infect Dis Clin North AM 2005, 19:765\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:393\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 505,
    "fields": {
      "name": "ORZID2 GMENU OSTEOM WITH GNB",
      "term": null,
      "displaytext": "Osteomyelitis with Gram Negative Bacilli (other than Pseudomonas)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]  < OR >\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]  < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Lew DP Lancet 2004, 364: 369\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Cunha BA Clin Infect Dis 2002, 35: 287\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 506,
    "fields": {
      "name": "ORZID2 GMENU OSTEOM WITH P. AERUGINOSA",
      "term": null,
      "displaytext": "Osteomyelitis with Pseudomonas aeruginosa  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH PSEUDOMONAS AERUGINOSA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Lew DP Lancet 2004, 364: 369\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Cunha BA Clin Infect Dis 2002, 35: 287\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI] <OR>\", \"Mnemonic\": \"6\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacilin-tazobactam 4.5 gm IV q6h ($$) [R]  <OR>\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 507,
    "fields": {
      "name": "ORZID2 GMENU OSTEOM WITH STREPTOCOCCI",
      "term": null,
      "displaytext": "Osteomyelitis with Streptococci",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($) [R]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]  < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH STREPTOCOCCI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Lew DP Lancet 2004, 364: 369\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Cunha BA Clin Infect Dis 2002, 35: 287\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Oral treatment:\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 508,
    "fields": {
      "name": "ORZID2 GMENU OSTEOMYELITIS",
      "term": null,
      "displaytext": "Osteomyelitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 504, \"DisplayText\": \"Empirical therapy for Osteomyelitis\", \"Text\": \"Empirical therapy for osteomyelitis\", \"Mnemonic\": \"4\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 509, \"DisplayText\": \"Osteomyelitis with Staphylococcus aureus\", \"Text\": \"Osteomyelitis with Staphylococcus aureus\", \"Mnemonic\": \"6\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 507, \"DisplayText\": \"Osteomyelitis with Streptococci\", \"Text\": \"Osteomyelitis with Streptococci\", \"Mnemonic\": \"8\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 505, \"DisplayText\": \"Osteomyelitis with Gram Negative Bacilli (other than Pseudomonas)\", \"Text\": \"Osteomyelitis with Gram negative bacilli (other than Pseudomonas)\", \"Mnemonic\": \"10\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 506, \"DisplayText\": \"Osteomyelitis with Pseudomonas aeruginosa\", \"Text\": \"Osteomyelitis with Pseudomonas aeruginosa\", \"Mnemonic\": \"12\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"14\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 205, \"DisplayText\": \"Mediastinitis\", \"Text\": \"Mediastinitis\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In acute osteomyelitis, symptoms have been present for several days to weeks.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Chronic osteomyelitis is characterized by a longer duration of symptoms,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"sometimes months or years, and often dead, necrotic bone is present.  There is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"considerable overlap between the syndromes of acute and chronic osteomyelitis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Symptom duration may be unreliable in a patient with neuropathy.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Obtain material for gram stain and culture before initiating antimicrobials.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Blood and bone cultures are ideal.  Sinus tracts are often colonized with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"multiple species and usually only one or two are pathogens in bone.  If\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Staphylococcus aureus is present, it is likely to be a pathogen in bone.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Empirical antimicrobial therapy is the same for acute and chronic osteomyelitis,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"but necrotic bone must often be removed for cure of chronic osteomyelitis.  If\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"complete debridement is not possible, long-term suppressive antimicrobials may\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"be needed.  Consult Infectious Diseases for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"The most important pathogens are S. aureus and streptococci.  Gram negative\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"bacilli are common pathogens in osteomyelitis associated with diabetic foot\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"infection.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Duration of treatment and route will vary with differences in location of\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"infection, infecting organism, and host comorbidities.  In general treat\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"for 4 to 6 weeks.  For difficult location (e.g. spine) or difficult bacteria\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"(e.g. staphylococcus, pseudomonas) give intravenous therapy for 4 to 6 weeks.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"For moderate cases, give intravenous therapy for 1 to 2 weeks followed\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"by oral therapy for the balance of 4 to 6 weeks.  For mild cases, start with\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"intravenous therapy for only a few days followed by oral therapy for the\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"balance of 4 to 6 weeks.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Empirical treatment regimens\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Pathogen-directed treatment regimens\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Recommend Orthopedic, Neurosurgery (for spine or skull osteomyelitis), Podiatry\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"(for foot infections), and Infectious Diseases consults.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Treat for 4 to 6 weeks.  Do not place a long-term intravascular access device\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"(e.g. a PICC line) until it is clear the patient will need long-term intravenous\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"therapy.  Consult Infectious Diseases or Orthopedic Surgery for more\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \">>  For patients with infections associated with prosthetic materials see\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \">>  For patients with sternal infection associated with chest surgery see\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Disease 2012, 54:393\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 509,
    "fields": {
      "name": "ORZID2 GMENU OSTEOMYELITIS WITH S. AUREUS",
      "term": null,
      "displaytext": "Osteomyelitis with Staphylococcus aureus",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($) [DI] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] < OR >\", \"Mnemonic\": \"14\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]  < OR >\", \"Mnemonic\": \"16\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH STAPHYLOCOCCUS AUREUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Methicillin-SUSCEPTIBLE S. aureus\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Methicillin-RESISTANT S. aureus\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Spellberg B Clin Infect Dis 2012, 54:393\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Berbari EF Clin Infect Dis 2015, 61:e26\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Calhoun JH Infect Dis Clin North Am 2005,19:765\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Oral treatment:\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 510,
    "fields": {
      "name": "ORZID2 GMENU OTHER PATHOGENS",
      "term": null,
      "displaytext": "Other pathogens ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 373, \"DisplayText\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)\", \"Text\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 301, \"DisplayText\": \"Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)\", \"Text\": \"Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 487, \"DisplayText\": \"Mycobacterium tuberculosis\", \"Text\": \"Mycobacterium tuberculosis\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 484, \"DisplayText\": \"Mycobacterium avium intracellulare complex (a.k.a MAI or MAC)\", \"Text\": \"Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC)\", \"Mnemonic\": \"12\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 486, \"DisplayText\": \"Mycoplasma pneumoniae\", \"Text\": \"Mycoplasma pneumonia\", \"Mnemonic\": \"14\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ OTHER PATHOGENS ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome, site of infection, penetration of drug(s)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into site, and whether organism is pathogen, colonizer, or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"contaminant. See disease/syndrome section for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Coxiella and Ehrlichia\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Lyme Disease\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mycobacteria\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mycoplasma\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Pneumocystis infection\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Last reviewed 8/2018\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 511,
    "fields": {
      "name": "ORZID2 GMENU OTITIS EXTERNA",
      "term": null,
      "displaytext": "Otitis Externa  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 394, \"DisplayText\": \"Furuncles and carbuncles\", \"Text\": \"Furuncles and Carbuncles\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 7 days ($)\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg po q12h (Var)\", \"Text\": \"< ADD > ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OTITIS EXTERNA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute Localized Disease\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Often due to furunculosis and usually associated with Staphylococcus aureus.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treat mild cases with moist local heat. For cases with cellulitis or deep\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"invasion, incision and drainage as well as systemic antibiotics may be needed.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Refer to the Furuncles and Carbuncles page for antibiotic recommendations.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Acute diffuse and chronic otitis externa\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Most commonly associated with Pseudomonas aeruginosa, Staphylococcus aureus and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Staphylococcus epidermidis. Irrigate to remove cerumen, desquamated skin and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"purulent material which can improve effectiveness of topical antibiotics. Avoid\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"products that contain neomycin if the tympanic membrane is perforated.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment if tympanic membrane is intact\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"for 7 days ($) [M]\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative if tympanic membrane is perforated or allergy to preferred treatmen\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Complicated Cases\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"For cases resistant to topical therapy alone, patients with poorly controlled\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"diabetes mellitus, immunocompromised patients, cases where infection has spread\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"beyond ear canal and in those where topical therapy cannot be delivered\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"effectively. Culture secretions to guide therapy.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"In addition to topical therapy above\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Rosenfeld et al., Otolaryngology-Head and Neck Surgery. 2014, 150(2)161-168\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sanford keyword: Otitis Externa\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-To-Date article: External otitis: Treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 512,
    "fields": {
      "name": "ORZID2 GMENU OTITIS MEDIA",
      "term": null,
      "displaytext": "Otitis Media ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO q8h for 10 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h for 10 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h for 10 days ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Text\": \"Cefpodoxime 200 mg PO BID for 10 days ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OTITIS MEDIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the most common bacteria to cause otitis media.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Patient has NOT received antibiotics in the prior month\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Patient has received antibiotics in the prior month\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternatives\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Harmes et al, American Family Physician. 2013, 88(7)435-440\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Otitis media\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date Online: Acute otitis media in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 513,
    "fields": {
      "name": "ORZID2 GMENU PARASITES",
      "term": null,
      "displaytext": "Parasites ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 312, \"DisplayText\": \"Babesia species\", \"Text\": \"Babesia spp.\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 457, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis\", \"Text\": \"Diarrhea, parasitic\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 239, \"DisplayText\": \"Pneumocyctis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 625, \"DisplayText\": \"Toxoplasma spp.\", \"Text\": \"Toxoplasma\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ PARASITES ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome, site of infection, penetration of drug(s)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into site, and whether organism is pathogen, colonizer, or contaminant. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome section for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Last reviewed 8/2018\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 514,
    "fields": {
      "name": "ORZID2 GMENU PARONYCHIA",
      "term": null,
      "displaytext": "Paronychia",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical qday\", \"Text\": \"Clotrimazole 1% apply to affected area once daily ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin Cream to affected area BID ($) [M]\", \"Text\": \"Nystatin Cream to affected area BID ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 175, \"DisplayText\": \"Herpes Whitlow (digit/hand cellulitis)\", \"Text\": \"Link to Herpes whitlow\", \"Mnemonic\": \"12\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PARONYCHIA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cutaneous infection of the hand, cuticle or fingers usually occurring near OR\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"around the nail.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment depends on etiology.  Candida spp. are commonly involved when the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patient has extensive exposure to water (e.g. dishwashers).  Staphylococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"aureus is more commonly after manicures or nail biting.  Herpes simplex\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"(whitlow) usually follows exposure to oral mucosa (e.g. wrestlers, dentists, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"anesthetists).\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment for paronychia associated with Candida\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat for 14 days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for paronychia associated with Staphylococcus\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treat for 10 days\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Treatment for paronychia associated with Herpes whitlow\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: paronychia\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 515,
    "fields": {
      "name": "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H",
      "term": null,
      "displaytext": "Cefazolin PD order menu  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 1 gm PD q24h\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 1 gm PD q24h with heparin\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFAZOLIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cefazolin 15 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 516,
    "fields": {
      "name": "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H AND GENT 0.6MG/KG Q24H",
      "term": null,
      "displaytext": "Cefazolin and gentamicin PD order menu  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefaz 1 gm PD q24h and gent PD 24h\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefaz 1 gm PD q24h and gent PD 24h with hep\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFAZOLIN AND GENTAMICIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cefazolin 15 mg/kg PD q24h and gentamicin 0.6 mg/kg PD q24h in 2000 mL\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"2.5% dextrose diaslyate solution (low mag)\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 517,
    "fields": {
      "name": "ORZID2 GMENU PD CEFEPIME 1 GM Q24H",
      "term": null,
      "displaytext": "Cefepime 1 gm q24h in 2000 mL 2.5% dextrose diasylate  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 1 gm PD q24h\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 1 gm PD q24h with heparin\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFIPIME\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cefepime 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 518,
    "fields": {
      "name": "ORZID2 GMENU PD CEFEPIME 1GM Q24H VANCO 15-30MG/KG Q5-7D",
      "term": null,
      "displaytext": "Cefepime and Vancomycin Treatment of Peritonitis Associated with PD",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime PD q24h and vanco q5-7d in low mag 1.5%\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime PD q24h and vanco q5-7d in low mag 1.5% with heparin\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFIPIME AND VANCOMYCIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cefepime 1 gm PD q24h and vancomycin 30 mg/kg PD loading dose followed by 15\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"mg/kg PD every 3 to 7 days in 2000 mL 2.5% dextrose diaslyate solution (low mag)\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 519,
    "fields": {
      "name": "ORZID2 GMENU PD CEFTAZIDIME 1GM Q24H",
      "term": null,
      "displaytext": "Ceftazidime PD order menu",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 1 gm PD q24h\", \"Text\": \"Low Mag 2.5%\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 1 gm PD q24h with heparin\", \"Text\": \"Low Mag 2.5% with heparin 1000 units daily\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFTAZIDIME\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Ceftazidime 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 520,
    "fields": {
      "name": "ORZID2 GMENU PD CEFTRIAXONE 1GM Q24H",
      "term": null,
      "displaytext": "Ceftriaxone PD order menu",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 gm PD q24h\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 gm PD q24h with heparin\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFTRIAXONE\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Ceftriaxone 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 521,
    "fields": {
      "name": "ORZID2 GMENU PD GENTAMICIN 0.6MG/KG Q24H",
      "term": null,
      "displaytext": "Gentamicin PD order menu ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 0.6 mg/kg PD q24h\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 0.6 mg/kg PD q24h with heparin\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"GENTAMICIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Gentamicin 0.6 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low ma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 522,
    "fields": {
      "name": "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D",
      "term": null,
      "displaytext": "Vancomycin PD order menu ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco 30mg/kg PD LD 15mg/kg q5-7d in in low mag 2.5%\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco 30mg/kg PD LD 15mg/kg q5-7d in low mag 2.5% with heparin\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"VANCOMYCIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Vancomycin 30 mg/kg PD loading dose followed by 15 mg/kg PD every 3 to 7 days\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"in 2000 mL 2.5% dextrose diaslyate solution (low mag)\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 523,
    "fields": {
      "name": "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D AND GENT 0.6MG/KG Q24H",
      "term": null,
      "displaytext": "Vancomycin and gentamicin PD order menu ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco PD q5-7d and gent PD q24h in low mag 2.5%\", \"Text\": \"[Click Here] to order WITHOUT heparin\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco PD q5-7d and gent PD q24h in low mag 2.5% with heparin\", \"Text\": \"[Click Here] to order WITH heparin\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"VANCOMYCIN AND GENTAMICIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Vancomycin 30 mg/kg PD loading dose followed by 15 mg/kg PD every 3 to 7 days\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"and gentamicin 0.6 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(low mag)\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 524,
    "fields": {
      "name": "ORZID2 GMENU PERIOCULAR INFECTIONS",
      "term": null,
      "displaytext": "Periocular Infections ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERIOCULAR INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Eyelid infections\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Patients with moderate or severe eyelid infections should be referred to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"ophthalmology.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Blepharitis\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Wash margins with baby shampoo daily and use warm compresses daily.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobials have no benefit.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Hordeolum (stye)\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For external disease (involving the gland of Zeis), daily hot pack massage\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"encourages drainage and relieves symptoms. For internal disease (involving\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Meibomian glands) ophthalmology consult is encouraged, as the infection seldom\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"drains without intervention.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Lacrimal infections\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Refer cases of lacrimal infection to ophthalmology, including infections of the\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"lacrimal gland (dacryoadenitis), lacrimal sac (dacrocystitis), or tear ducts\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(canaliculitis).\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Carlisle et al., American Family Physician. 2015, 92(2)106-112\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Periocular infections\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-To-Date article: Blepharitis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-To-Date article: Eyelid lesions\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Blepharitis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Hordeolum, Stye\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 525,
    "fields": {
      "name": "ORZID2 GMENU PERIODENTAL DISEASE",
      "term": null,
      "displaytext": "Periodental disease",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlorhexidine 0.12% oral rinse swish for 30 secs then spint 15ml 2x/daily\", \"Text\": \"Chlorhexidine 0.12% oral rinse swish for 30 seconds, then spit 15 ml twice\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERIODONTAL DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Periodontal disease, including gingivitis and periodontitis, may progress into\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"more severe disease or cause hematogenous spreading of bacteria if left\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"untreated. All patients with periodontal disease should be referred to the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"dental service for assessment and direction of treatment. In the presence of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"gingivitis, the most commonly isolated subgingival flora includes Prevotella\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"intermedia, Capnocytophaga spp, Finegoldia magna and Peptostreptococcus. In the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"presence of periodontitis, flora increases in complexity to most commonly\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"include Porphyromonas gingivalis, P. intermedia, Aggregatibacter\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"actinomycetemcomitans, Tanneralla forsythensis and Treponema denticola.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consult Dental Service\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Non-severe periodontitis or acute simple gingivitis treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"daily for 7 days ($) [M]\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Severe periodontitis or acute complicated gingivitis (ulceration, rapidly\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"advancing disease, severe pain, patients with immunocompromising conditions)\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"treatment\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Consult Dental Service\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandel Chapter: Infections of the Oral Cavity, Neck and Head\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-To-Date article: Complications, diagnosis, and treatment of odontogenic\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"infections\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of gingivitis and periodontitis in adults\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Vincent's Angina\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Slots et al., Periodontology. 2002, 28(1)106-176\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Tonetti et al., Journal of Periodontology, 2018, 89 S159-S172.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 526,
    "fields": {
      "name": "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS",
      "term": null,
      "displaytext": "Antimicrobial Prophylaxis Post-op ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": 583, \"DisplayText\": \"CIED Post Op\", \"Text\": \"CIED Surgery Post-op Prophylaxis\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 586, \"DisplayText\": \"CV POSTOPERATIVE PROPHYLAXIS\", \"Text\": \"CV Surgery (Open Heart) Postoperative Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 607, \"DisplayText\": \"THORACIC POSTOPERATIVE PROPHYLAXIS\", \"Text\": \"Thoracic Surgery Postoperative Prophylaxis\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 527,
    "fields": {
      "name": "ORZID2 GMENU POSTSEPTAL CELLULITIS",
      "term": null,
      "displaytext": "Postseptal Cellulitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h metronidazole 500 mg q8h vancomycin 15 mg/kg q12h\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125mg q12h and Trimeth-sulfa 2DS q12h\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND >\", \"Mnemonic\": \"10\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"12\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h and trimethoprim-sulfamethoxazole 2DS PO q12h\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] < AND > trimethoprim-sulfamethoxazole 2 DS PO\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"POSTSEPTAL CELLULITIS (ORBITAL CELLULITIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Postseptal cellulitis (orbital cellulitis) is often preceded by sinusitis and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"requires immediate consultation with otolaryngology and ophthalmology. Urgent\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"surgical drainage may be necessary. The most common pathogenic organisms in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"adults are streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"aureus. Broad-spectrum empirical antimicrobials should be used until a pathogen\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"can be identified from the drainage fluid.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Orbital cellulitis should be treated until all signs of infection have resolved.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Uncomplicated orbital cellulitis should be treated for minimum of 2 weeks and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"complicated orbital cellulitis (severe ethmoid sinusitis and bony destruction of\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"sinus) should be treated for at least 4 weeks.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Empiric treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Step-down treatment after initial intravenous therapy. Base selection on cultur\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"results.  Adjust duration based on criteria above.\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 7 days\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"q12h ($) [R,DI] for 7 days\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Carlisle et al., American Family Physician. 2015, 92(2)106-112\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Mandell chapter: Periocular infections\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date article: Orbital Cellulitis\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford keyword: Orbital cellulitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 528,
    "fields": {
      "name": "ORZID2 GMENU PRESEPTAL CELLULITIS",
      "term": null,
      "displaytext": "Preseptal Cellulitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h metronidazole 500 mg q8h vancomycin 15 mg/kg q12h\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125mg q12h and Trimeth-sulfa 2DS q12h\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND>\", \"Mnemonic\": \"10\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"12\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h and trimethoprim-sulfamethoxazole 2DS PO q12h\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] <AND> trimethoprim-sulfamethoxazole 2 DS PO\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PRESEPTAL CELLULITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Preseptal cellulitis involves soft tissues in front of the orbital septum and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the eyelids and is often preceded by sinusitis. Infection does not involve the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"orbital contents. The most common pathogenic organisms in adults are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus aureus.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat under the guidance of ophthalmology and/or otolaryngology. Intravenous\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials are indicated initially for treatment of moderate to severe\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"disease. Switch to oral antimicrobials when the patient's symptoms improve and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"the patient can tolerate oral medications.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Moderate to severe infection or failure of oral antibiotics\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Transition to oral antibiotics can be considered if significant improvement\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"within 24-48 hours.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R] for 5 days\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment of mild disease or step-down treatment after initial intravenous\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"therapy. Treat for a total duration of 5 days.\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 5 days\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"BID ($) [R,DI] for 5 days\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Carlisle et al., American Family Physician. 2015, 92(2)106-112\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Periocular infections\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Johns Hopkins website\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-date article: Preseptal cellulitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 529,
    "fields": {
      "name": "ORZID2 GMENU PREV INFECT BACT PROPHYL",
      "term": null,
      "displaytext": "Prevention of bacterial infection in a patient with malignancy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h  ($) [R,DI] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Text\": \"Cefpodoxime 100 mg PO q12h ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF BACTERIAL INFECTIONS IN A PATIENT WITH MALIGNANCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is often given to patients likely to have profound,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"prolonged neutropenia.  Profound neutropenia is less than 100 neutrophils and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"bands per microliter, and such neutropenia is considered prolonged when it is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"expected to last more than 7 days.  Most patients who should receive prophylaxis\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"have received stem cell transplants or are undergoing induction chemotherapy for\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"acute leukemia.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"If antibacterial prophylaxis is indicated\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of therapy: During period of expected neutropenia\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Taplitz RA Journal of Clinical Oncology, 2018, 36:3043\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell chapter:  Prophylaxis and Empirical Therapy for Infection in Cancer\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Related Infections. Version 1.2019. nccn.org\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 530,
    "fields": {
      "name": "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL",
      "term": null,
      "displaytext": "Prevention of fungal infections in a patient with malignancy ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po q24h\", \"Text\": \"Fluconazole 400 mg po q24h ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF FUNGAL INFECTIONS IN A PATIENT WITH MALIGNANCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antifungal chemoprophylaxis is often given to patients undergoing induction\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"chemotherapy for acute leukemia expected to have profound neutropenia (less than\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"100 neutrophils and bands per milliliter) for more than 10 days and for patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"receiving allogeneic stem cell transplantation.  For most other patients the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"expected benefits do not outweigh the risks of adverse effects and selection of\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"resistant fungi.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antifungal is usually given until the absolute neutrophil concentration\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"increases to more than 500 cells/microliter in patients undergoing induction\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"chemotherapy for leukemia.  Duration is 100 days for patients undergoing stem\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"cell transplantation.  Some physicians continue prevention after 100 days if\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"corticosteroids are part of the immunosuppressive regimen.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Recommend posaconazole prophylaxis for patients with Acute Myeloid Leukemia.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Contact Hematology Oncology or Infectious Disease for more information.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Patients who have had invasive fungal infection in the recent past and who are\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"about to become neutropenic may require chemoprophylaxis.  Contact Hematology-\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Oncology or Infectious Disease for more information.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"If antifungal prophylaxis is indicated:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Duration of therapy: during period of expected neutropenia\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"For patients being treated for AML:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Requires Infectious Disease approval:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Posaconazole 300mg Tablets twice daily on day 1, then 300mg once daily on\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"day 2 and thereafter. Continue for 7 days after the neutrophil count\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"rises above 500/mm3. ($$$$) [DI]\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Taplitz RA Journal of Clinical Oncology, 2018, 36:3043\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Prophylaxis and empirical therapy for infection in cancer\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"patients\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Related Infections. Version 1.2019. nccn.org\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 531,
    "fields": {
      "name": "ORZID2 GMENU PREV OF BACT ENDOCARDITIS",
      "term": null,
      "displaytext": "Prevention of Bacterial Endocarditis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 3057, \"DisplayText\": \"DENTAL ABX PPX SOP\", \"Text\": \"SOP for dental surgery antimicrobial prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 358, \"DisplayText\": \"Drugs for patients undergoing dental, oral, or esophageal procedures\", \"Text\": \"Patients undergoing dental or oral mucosa procedures\", \"Mnemonic\": \"6\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 592, \"DisplayText\": \"Head and neck surgery\", \"Text\": \"Patients undergoing procedures on the respiratory tract that involve incision or\", \"Mnemonic\": \"8\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 246, \"DisplayText\": \"Drugs for procedures that involve infected skin, skin structures\", \"Text\": \"Patients undergoing procedures for infected skin, skin structures, or infected\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF BACTERIAL ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bacteremia occurs several times a day during daily activities like eating and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"brushing teeth and rarely results in endocarditis, even in people with abnormal\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"valves.  While bacteremia might occur following dental or other procedures, most\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cases of endocarditis are from the millions more episodes of transient\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bacteremia a person experiences per year from ordinary daily activities.  There\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"is no evidence that antimicrobial prophylaxis prevents endocarditis after\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"procedures.  The best available evidence suggests that prophylactic\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antimicrobials confer more risks than benefits in most situations.  A decision\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"about whether to administer antimicrobial prophylaxis should be based on both\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"the risk of endocarditis conferred by the patient's cardiac defect and the risk\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"of bacteremia from a planned dental or surgical procedure.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Minneapolis VAHCS SOP antimicrobial prophylaxis for dental surgery:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Determine the need for prophylaxis through the 2-step process outlined\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"below.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Step 1.  Assess the risk of endocarditis for your patient\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Prophylaxis is recommended if a patient has any of the following conditions:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"o  Prosthetic cardiac valve or material including: Presence of cardiac\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"prosthetic valve, transcatheter implantation of prosthetic valves (e.g. TAVR\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"cardiac valve repair with devices (e.g. annuloplasty, rings, or clips), left\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"ventricular assist devices or implantable heart\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"o  A history of infective endocarditis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"o  Certain specific congenital heart conditions - refer to the full SOP\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"(link above) or consult Cardiology for more detailed recommendations\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"o  Cardiac transplant that develops a problem in the heart valve\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Step 2.  Assess the risk of bacteremia from the planned procedure\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Prophylaxis is indicated for these procedures:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"o  All dental procedures that involve manipulation of gingival tissue or the\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"periapical region of teeth or perforation of the oral mucosa.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"o  Procedures on the respiratory tract that involve incision or biopsy of the\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"respiratory mucosa, such as tonsillectomy and adenoidectomy. Prophylaxis is\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"recommended for bronchoscopy when procedure involves incision of the respira\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"tract mucosa.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"o  Procedures that involve incision through infected skin, skin structures, or\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"musculoskeletal tissue.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"o  Dermatologic procedures that breach the oral mucosa.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Prophylactic Antimicrobials select below:\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"biopsy of the respiratory mucosa\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"musculoskeletal tissues\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"endocarditis\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Wilson et al., Circulation, 2021, 143(20)e963-e978\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 532,
    "fields": {
      "name": "ORZID2 GMENU PREV OF PERTUSSIS",
      "term": null,
      "displaytext": "Prevention of Pertussis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500mg PO once on day one then 250mg PO qday for 4 days ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF PERTUSSIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Immunization\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Give a single dose of tetanus-diphtheria acellular pertussis vaccine (Tdap) in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"adults regardless of interval between most recent Td vaccine. One dose of Tdap\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"vaccine is given to pregnant women during each pregnancy.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Postexposure prophylaxis in adults\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Household contacts with symptomatic coughing should be treated as if they have\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"pertussis. Consult Infectious Diseases for all suspected cases of pertussis and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"exposure to pertussis.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"CDC recommends postexposure prophylaxis in household contacts within 21 days\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"after exposure to pertussis regardless of immunization history. Non-household\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"contacts who are at high risk of severe illness or who have close contact with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"high risk individuals should receive post exposure prophylaxis within 21 days of\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"exposure. Those at high risk of severe illness are infants less than one year of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"age, women in third trimester of pregnancy and those with preexisting health\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"conditions that may be exacerbated by pertussis (e.g. immunosuppressed and\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"asthmatic individuals). A single dose of Tdap should be administered in those\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"who are not up to date.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for macrolide intolerant or allergic patients\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"CDC:Pertussis https://www.cdc.gov/pertussis/outbreaks/pep.html\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Kim et al, Annals of internal medicine (2016) 184-194\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Pertussis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Bordetella species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 533,
    "fields": {
      "name": "ORZID2 GMENU PREV PROS JOINT DENTAL",
      "term": null,
      "displaytext": "Prevention of prosthetic joint infection before dental procedures  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF PROSTHETIC JOINT INFECTION BEFORE DENTAL PROCEDURES\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Dental procedures are not associated with an increased risk of prosthetic joint\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"infection. The routine use of antimicrobial prophylaxis before dental procedures\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"in patients with prosthetic joints is not recommended. Good dental health should\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"be maintained in patients with prosthetic joints and dental infections should be\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"treated promptly.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For more information contact Infectious Diseases.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-To-Date Article: Prevention of prosthetic joint and other types of orthopedic\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"hardware infection\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sollecito et al., J Am Dent Assoc, 2015, 146(1):11-16\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Rethman et al., J Am Acad Orthop Surg, 2013, 21:180-189\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 534,
    "fields": {
      "name": "ORZID2 GMENU PROPHYLAXIS M. AVIUM",
      "term": null,
      "displaytext": "Prophylaxis against Mycobacterium avium disease...  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1200mg po q week (Var)\", \"Text\": \"Azithromycin 1200 mg PO q week ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500mg po q12h\", \"Text\": \"Clarithromycin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROPHYLAXIS AGAINST MYCOBACTERIUM AVIUM DISEASE IN PERSONS WITH HIV/AIDS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infectious Diseases should be involved in all cases. Patients with CD4 count <\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"50 cells per microliter, after ruling out disseminated MC disease, should\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"receive prophylaxis until CD4 count is >100 for at least 3 months in response to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antiretroviral therapy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred prophylaxis\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Mandell chapter: Mycobacterium avium complex\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Mycobacterium avium-intracellulare\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 535,
    "fields": {
      "name": "ORZID2 GMENU PROPHYLAXIS OPTH SURG",
      "term": null,
      "displaytext": "Prophylaxis for ophthalmic surgery",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROPHYLAXIS FOR OPHTHALMIC SURGERY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"When indicated, ophthalmology will order antimicrobial prophylaxis before\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"procedures.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 536,
    "fields": {
      "name": "ORZID2 GMENU PROS B/J ENTEROCOCCI",
      "term": null,
      "displaytext": "Enterococci infections in bone or joint prostheses  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100mg PO q12h ($) [DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTEROCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"followed by oral antibiotics. For severe infections, add an aminoglycoside for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"synergy during the first weeks of therapy. Mild infections can be treated with\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"oral antibiotics only.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of Treatement\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"may follow treatment based on individual patient circumstances.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or resistant organism\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Optional Addition to Above IV Treatment < ADD >\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, Continuation of Therapy and Chronic\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Suppression\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Allergy to penicillin\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For resistant isolates only\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 537,
    "fields": {
      "name": "ORZID2 GMENU PROS B/J GNB",
      "term": null,
      "displaytext": "Gram Negative Bacilli infections in bone or joint prostheses ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Text\": \"Ertapenem 1 gm IV q24h ($$) [R,DI,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS) INFECTIONS IN BONE OR JOINT\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"PROSTHESES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"followed by oral antibiotics. Mild infections can be treated with oral\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antibiotics only.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of Treatement\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"may follow treatment based on individual patient circumstances.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for penicillin or cephalosporin allergy\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, Continuation of Therapy and Chronic\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Suppression\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative Oral Treatment for Intolerance to Above Oral Antibiotics\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"For treatment of mild infections and continuation of therapy\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"For Chronic Suppression\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 538,
    "fields": {
      "name": "ORZID2 GMENU PROS B/J P. AERUGINOSA",
      "term": null,
      "displaytext": "Pseudomonas aeruginosa infections in bone or joint prostheses",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2g IV q12h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q8h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Text\": \"Gentamicin 1 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PSEUDOMONAS AERUGINOSA INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"followed by oral antibiotics. Mild infections can be treated with oral\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antibiotics only.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Duration of Treatement\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"may follow treatment based on individual patient circumstances.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"For cephalosporin allergy\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Optional addition to above IV antibiotic < ADD >\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, For Continuation of Therapy\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Oral Treatment for Chronic Suppression\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 539,
    "fields": {
      "name": "ORZID2 GMENU PROS B/J STREPTOCOCCI",
      "term": null,
      "displaytext": "Streptococcal infections in bone or joint prostheses",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO q6h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"followed by oral antibiotics. Mild infections can be treated with oral\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antibiotics only.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases for specific management advice.\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of Treatement\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic suppression with oral\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"antimicrobials may follow treatment based on individual patient circumstances.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Allergy to penicillin or cephalosporin\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, Continuation of Therapy or Chronic\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Suppression\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Allergy to penicillin or cephalosporin\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 540,
    "fields": {
      "name": "ORZID2 GMENU PROS BONE/JOINT S. AUREUS",
      "term": null,
      "displaytext": "Staphylococcus aureus infections in bone or joint prostheses ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RIFAMPIN 600MG PO Q24H\", \"Text\": \"Rifampin 600 mg PO q24h ($) [DI,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100mg PO q12h ($) [DI]\", \"Mnemonic\": \"22\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RIFAMPIN 600MG PO Q24H\", \"Text\": \"Rifampin 600 mg PO q24h ($) [DI,O]\", \"Mnemonic\": \"24\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"STAPHYLOCOCCUS AUREUS INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment Following Debridement and Retention of Prosthesis\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 to 6 months of\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"an oral antibiotic combined with rifampin (3 months in total hip, elbow,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"shoulder and ankle arthroplasty and 6 months in total knee arthroplasty).\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment Following 2-stage Exchange or Resection Arthroplasty Without Planned\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Staged Reimplantation of Prosthesis\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat with intravenous antibiotic for 6 weeks for all joint types.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment Following 1-Stage Exchange of Prosthesis\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 months of an\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"oral antibiotic combined with rifampin for all joint types.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Rifampin Synergy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Rifampin is recommended for treatment with debridement and retention or one\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"stage exchange. When rifampin is combined with a beta-lactam or vancomycin in\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"vitro, bacterial killing is enhanced. Do not use rifampin alone, as bacterial\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"resistance develops rapidly. If patient does not tolerate rifampin it may be\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Chronic Suppression\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Chronic suppression with oral antimicrobials may follow treatment based on\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"individual patient circumstances.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Oxacillin-susceptible:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"MRSA or allergy to penicillin and cephalosporins:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Rifampin Synergy for Debridement and Retention or One Stage Exchange\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"In addition to IV treatment above < ADD >\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Oral Treatment for Continuation of Therapy or Chronic Suppression\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"MRSA or allergy to penicillin or cephalosporin\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Rifampin Synergy for Debridement and Retention or One Stage Exchange (Not For\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Chronic Suppression)\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"In addition to PO treatment above < ADD >\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"omitted from treatment regimen. Contact Infectious Diseases for more\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 541,
    "fields": {
      "name": "ORZID2 GMENU PROS JOINT BONE INFECT",
      "term": null,
      "displaytext": "Infections in bone or joint prostheses  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 540, \"DisplayText\": \"Staphylococcus aureus infections in bone or joint prostheses\", \"Text\": \"Staphylococcus aureus infections\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 539, \"DisplayText\": \"Streptococcal infections in bone or joint prostheses\", \"Text\": \"Streptococci infections\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 536, \"DisplayText\": \"Enterococci infections in bone or joint prostheses\", \"Text\": \"Enterococci infections\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 537, \"DisplayText\": \"Gram Negative Bacilli infections in bone or joint prostheses\", \"Text\": \"Gram negative bacilli (other than Pseudomonas) infections\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 538, \"DisplayText\": \"Pseudomonas aeruginosa infections in bone or joint prostheses\", \"Text\": \"Pseudomonas aeruginosa infections\", \"Mnemonic\": \"12\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($) [R]\", \"Text\": \"Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($)[R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Common important pathogens include coagulase-negative staphylococci,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Staphylococcus aureus, streptococci, enterococci, and gram negative bacilli.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Obtain material for gram stain and culture and base antimicrobial therapy on\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"results of Gram stain. Blood, joint fluid, and affected tissue and/or bone are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"ideal specimens to culture. Sinus tracts are often colonized and isolates from\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"drainage may not be pathogens. If Staphylococcus aureus is present,it is likely\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to be a pathogen in the bone.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Pathogen-directed Treatment Regimens\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Acute infections can often be cured with debridement with joint retention\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"followed by antimicrobials. Infections with duration of symptoms greater then 3\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"weeks or infection within 4 weeks of implantation require one or two stage\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"remimplantation. Cases that are inoperable can be managed with long-term\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"suppressive antimicrobial therapy or joint removal without replacement depending\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"on patient's condition. Consult Infectious Diseases (inpatient) for more\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Infectious Disease and Orthopedics consultations are essential.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Empirical Therapy Before a Pathogen is Identified is Not Recommended.\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"If patient has sepsis or is otherwise unstable, empiric treatment before culture\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"results are obtained may be justified.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 542,
    "fields": {
      "name": "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)",
      "term": null,
      "displaytext": "Pubic Lice (Pediculosis Pubis) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion to the affected area for 10 minutes\", \"Text\": \"Permethrin 1% lotion. Apply to affected area for 10 minutes then comb out\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PUBIC LICE (PEDICULOSIS PUBIS)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Lice are parasitic insects. Human lice survive by feeding on human blood.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"To make a diagnosis, use a nit comb, bright light, or lens to find a louse\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"living in pubic hair.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"The presence of nits on a hair shaft, especially when they are located more\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"than 6 mm from the skin, does NOT indicate active infestation.  Nits may remain\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"present for months after successful treatment.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Household contacts and persons who may have come into contact with personal\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"belongings of an infested individual should be examined for evidence of lice\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"and discarded or cleaned if contaminated.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"A repeat application may be used if live lice are seen 7-10 days after\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"nits ($) [M]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: lice\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 543,
    "fields": {
      "name": "ORZID2 GMENU PYOMYOSITIS",
      "term": null,
      "displaytext": "Pyomyositis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15mg/kg IV q 12 hours ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PYOMYOSITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pyomyositis is the presence of pus in a muscle group.  It occurs more often in\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"patients with HIV infection or diabetes, and is usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Staphylococcus aureus.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Early drainage of purulent material should be performed.  Cultures\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"of blood and abscess material should be obtained to guide therapy.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antibiotics should be administered intravenously initially, but once\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"the patient is clinically improved, oral antibiotics are appropriate\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"for whom bacteremia cleared promptly and there is no evidence of endocarditis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"or metastatic abscess.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of treatment: 2 to 3 weeks\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Initial empirical therapy:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"ADD for immunocompromised patient or following open trauma to muscles:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"IF proven MSSA:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Myositis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 544,
    "fields": {
      "name": "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS",
      "term": null,
      "displaytext": "Recurrent or persistent urethritis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 2 gm PO ONCE ($) [DI] Azithromycin 1 gm PO ONCE ($) [M]\", \"Text\": \"Metronidazole 2 gm PO ONCE ($) [DI] Azithromycin 1 gm PO ONCE ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERSISTENT OR RECURRENT URETHRITIS OR CERVICITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Retreat with initial treatment regimen if patient was non-compliant with initial\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"treatment regimen or re-exposed to an untreated sex partner. If infection is not\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"due to non-compliance with treatment regimen or re-exposure to an untreated sex\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"partner, infection is most commonly caused by M. genitalium and less commonly T.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"vaginalis.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment for persistent or recurrent urethritis and failure of initial\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"doxycycline treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Failure of above treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Consult Infectious Diseases (inpatient)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines: MMWR (2015) 64.3\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and Cervicitis\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Urethritis, Recurrent/Persistent\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute cervicitis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-To-Date article: Urethritis in men\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 545,
    "fields": {
      "name": "ORZID2 GMENU RETINITIS",
      "term": null,
      "displaytext": "Retinitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 118, \"DisplayText\": \"CMV Retinitis\", \"Text\": \"Link to Treatment of CMV Retinitis and ARN\", \"Mnemonic\": \"4\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800MG PO 5x/d\", \"Text\": \"Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 10 mg/kg IV q8h ($$) [R,DI]\", \"Text\": \"Acyclovir 10 mg/kg IV q8h for 7 days ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO q8h ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO q8h for 5 days ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg q8h ($) [R]\", \"Text\": \"Acyclovir 400 mg PO q8h for 7-10 days ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 5 mg/kg IV Q8H\", \"Text\": \"Acyclovir 5 mg/kg IV q8h ($$) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1GM PO q12h\", \"Text\": \"Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 10 mg/kg IV q8h ($$) [R,DI]\", \"Text\": \"Acyclovir 10 mg/kg IV q8h for 7 days ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Foscarnet 2.4 mg intravitreous injection\", \"Text\": \"< Optional add-on therapy > Foscarnet 2.4mg/0.1 mL intravitreal injection STAT\", \"Mnemonic\": \"20\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO q8h ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO q8h for 42 days ($) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RETINITIS AND ACUTE RETINAL NECROSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Retinitis is a subset of uveitis, is rare in immunocompetent people: in these\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"individuals it is usually caused by varicella-zoster virus (VZV) or herpes\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"simplex virus (HSV). Retinitis is more common in immunocompromised patients and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cytomegalovirus being the most common pathogen in these patients. Other\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"retinitis pathogens include Toxoplasma gondii, Bartonella henselae, Histoplasma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"capsulatum, and Treponema pallidum. In most cases, patients have other\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"neurological symptoms or signs.  Patients with candidemia may present with 1-3\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"mm white punctate retinal lesions called cotton-wool spots. These may only be\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"visible on fundus examination. Treatment of candidal retinitis  is systemic\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antifungal therapy. Consult Ophthalmology, Infectious Diseases, or Neurology for\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"help.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"VZV and HSV cause nearly all cases of acute retinal necrosis (ARN), with a small\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"number being caused by cytomegalovirus. ARN is a rapidly progressing retinitis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"that occurs primarily in immunocompetent people and can cause vision loss.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment with intravenous acyclovir or valacyclovir is essential to halt\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"progression of ARN.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Ophthalmology and Infectious Diseases consultation is essential\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment of Non-viral Retinitis or ARN\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Refer to specific pathogen treatment recommendations of the CDSS to treat\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"underlying infection\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment of Retinitis or ARN due to CMV:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Treatment of VZV Retinitis\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Treatment of HSV Retinitis\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Treatment of VZV and HSV Acute Retinal Necrosis\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Ophthalmologist involvement is essential for treatment including\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"corticosteroids, vitrectomy, or laser therapy. Intravitreal foscarnet in\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"addition to a systemic antiviral may provide added therapeutic efficacy.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Duration\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Treat with intravenous therapy for a minimum of 7 days until disease has\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"stabilized then treat with or therapy for a minimum of 6 weeks\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Treatment\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"($$$$) [R,O]\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"< THEN >\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Lau et al, Ophthalmology. 2007, 114(4)756-762\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious causes of uveitis\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Schoenbergeret al., Ophthalmology. 2017, 124(3)382-392\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Sanford keyword: Acute Retinal Necrosis\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes Simplex\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Sanford keyword: Retinitis\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Sanford keyword: Varicella-zoster Virus (Chickenpox)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 546,
    "fields": {
      "name": "ORZID2 GMENU ROCKY MTN SPOT FEVER",
      "term": null,
      "displaytext": "Rocky Mountain Spotted Fever",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Text\": \"Doxycycline 100 mg IV q12h ($$) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ROCKY MOUNTAIN SPOTTED FEVER\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Rocky Mountain Spotted Fever is a tick-borne, potentially life-threatening\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"rickettsial disease. The highest incidence in the United States is in the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Southeastern and South-central states. Clinical diagnosis include fever in an\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"endemic area, known or possible tick bite, with or without rash. Rash typically\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"spreads from the extremities to the trunk.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diagnosis is difficult, consult Infectious Diseases for assistance.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consider empirical therapy with doxycycline for a patient with an undiagnosed\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"febrile illness and relevant tick exposure.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treat for 7 days.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Rocky mountain spotted fever\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Masters EJ Arch Intern Med 2003, 163: 769\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 547,
    "fields": {
      "name": "ORZID2 GMENU SCABIES",
      "term": null,
      "displaytext": "Scabies",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 5% cream apply from head to feet\", \"Text\": \"Permethrin 5% cream apply from head to feet, leave on for 8-14 hours, then\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"SCABIES\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Scabies is an infestation of the skin by the mite Sarcoptes scabiei.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"It is transmitted by skin to skin contact. Outbreaks occur in nursing\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"homes, day care centers, and residential institutions.  Scabies is highly\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"contagious and meticulous infection control is needed.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment is a single application of permethrin cream.  Some experts recommend a\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"second application 7-10 days after the first application if the patient is still\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"symptomatic or if live mites are found at that time.  Contact Dermatology or\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Infectious Diseases for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat family members and other close contacts to prevent spread and recurrence.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Repeat application 7-10 days after the first application if patient is still\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"experiencing symptoms, or if lives mites are found.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"wash cream off with soap and water ($) [M]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Scabies\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 548,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS AND SHOCK",
      "term": null,
      "displaytext": "Sepsis and septic shock  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 3058, \"DisplayText\": \"SOFA Online Calculator\", \"Text\": \"SOFA Online Calculator\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sepsis ICU Orders\", \"Text\": \"ICU sepsis order set\", \"Mnemonic\": \"6\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Medicine Inpatient Time Zero Order\", \"Text\": \"Ward sepsis order set\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"ED sepsis order set\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS AND SEPTIC SHOCK\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Per the Sepsis-3 task force, sepsis is defined as life-threatening\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"organ dysfunction caused by dysregulated host response to infection.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"The Sequential Organ Failure Assessment (SOFA) score can be used to help\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"identify organ dysfunction. An acute increase of 2 or more points in a patient\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"with sepsis is associated with in-hospital mortality greater than 10%. Neither\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the SOFA nor the abbreviated qSOFA is sufficiently sensitive to be used as the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"sole method of identifying sepsis related organ dysfunction.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Septic shock is a subset of sepsis in which profound circulatory, cellular and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"metabolic abnormalities occur. Septic shock is associated with in-hospital\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"mortality greater than 40%.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Early intervention is crucial to prevention of death from sepsis. Antimicrobials\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"active against likely pathogens and supportive treatment to maintain vascular\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"perfusion should be initiated immediately.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Reassess antimicrobial therapy daily to narrow therapeutic spectrum when culture\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"and susceptibility data are available.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment of Sepsis or Septic Shock\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell Chapter: Sepsis, Severe Sepsis and Septic Shock\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Rhodes et al., Intensive Care Medicine (2017), 45.3: 304-377\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Singer et al., JAMA (2016), 315(8) 801-810\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 549,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS EMPIRIC THERAPY SITE UNK",
      "term": null,
      "displaytext": "Site Unknown Or Suspected Intraabdominal Infection ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R] SEPSIS\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"AZTREO 2GM Q8H METRO 1GM Q12H VANCO 15MG/KG\", \"Text\": \"Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 1 gm IV q12H ($) [DI] <AND>\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV x 1 dose\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Abdominal CT\", \"Text\": \"Please Click Here To Order an Abdominal CT\", \"Mnemonic\": \"12\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"For Severe Penicillin Allergy:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vancomycin 15 mg/kg IV q12H ($) [R]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Consider abdominal CT\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH UNKNOWN INFECTIOUS SITE\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 550,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS PNEUMONIA",
      "term": null,
      "displaytext": "Community-Acquired Pneumonia",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R] SEPSIS\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pip/Tazo, Vanco 15mg/kg, and Azithromycin\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H\", \"Mnemonic\": \"8\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"cefepime, Vanco 15mg/kg, and Azithromycin\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R] <AND>\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"LEVOFLOXACIN 750MG IV Q24H VANCO 15MG/KG\", \"Text\": \"Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV q12H ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV x 1 dose\", \"Mnemonic\": \"14\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Nosocomial pneumonia preferred treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Community acquired pneumonia preferred treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"($) [R] <AND> Azithromycin 500 mg IV once then 250mg IV q24H x 4 days ($) [M]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Azithromycin 500 mg IV once then 250mg IV q24H x 4 days ($) [M]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For severe penicillin allergy in nosocomial and community acquired pneumonia\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED PNEUMONIA\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 551,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS PROTOCOL ANTIMICROBIALS",
      "term": null,
      "displaytext": "Empirical Antimicrobials ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": 549, \"DisplayText\": \"Site Unknown Or Suspected Intraabdominal Infection\", \"Text\": \"Unknown Infectious Site (see below for Intraabdominal infection)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 550, \"DisplayText\": \"Community-Acquired Pneumonia\", \"Text\": \"Suspected Pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 556, \"DisplayText\": \"Suspected Meningitis, CNS Infection\", \"Text\": \"Suspected Meningitis, CNS Infection\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 553, \"DisplayText\": \"Suspected Native Valve Endocarditis\", \"Text\": \"Suspected Native Valve Endocarditis\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 554, \"DisplayText\": \"Suspected Prosthetic Valve Endocarditis\", \"Text\": \"Suspected Prosthetic Valve Endocarditis\", \"Mnemonic\": \"10\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 496, \"DisplayText\": \"Necrotizing infections\", \"Text\": \"Suspected Necrotizing Infection\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 557, \"DisplayText\": \"Sepsis Suspected Skin Soft Tissue\", \"Text\": \"Suspected Skin Soft Tissue Infection\", \"Mnemonic\": \"14\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 558, \"DisplayText\": \"Suspected Urosepsis\", \"Text\": \"Suspected Urinary Tract Infection (AKA urospesis)\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 555, \"DisplayText\": \"Suspected Intraabdominal Infection\", \"Text\": \"Suspected Intraabdominal Infection\", \"Mnemonic\": \"18\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 552, \"DisplayText\": \"Suspected Severe Clostridium Difficile Infection\", \"Text\": \"Suspected Severe Clostridium Difficile Infection\", \"Mnemonic\": \"20\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 497, \"DisplayText\": \"Neutropenic fever--Patient is NOT a candidate for oral therapy\", \"Text\": \"Suspected Neutropenic Fever\", \"Mnemonic\": \"22\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Initial Empiric Antibiotic Guidelines for Sepsis:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 552,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS SUSP C. DIFFICILE",
      "term": null,
      "displaytext": "Suspected Severe Clostridium Difficile Infection ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125MG PO QID (Var)\", \"Text\": \"Vancomycin 125MG PO QID\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500MG IV Q6H AND Vancomycin Enema 500MG PR Q6H\", \"Text\": \"Metronidazole 500MG IV Q6H AND Vancomycin Enema 500MG PR Q6H\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If No ileus:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"If ileus:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED SEVERE CLOSTRIDIUM DIFFICILE INFECTION\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 553,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS SUSP NATIVE VALVE ENDOCARD",
      "term": null,
      "displaytext": "Suspected Native Valve Endocarditis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6Please Click Here To Order This Set.\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"1Please Click Here To Order This Set.\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV Q6H AND\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG LOAD then 1.5 MG/KG IV Q8H AND\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Aztreonam 2GM IV Q8H AND\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG LOAD then 1.5 MG/KG IV Q8H AND\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED NATIVE VALVE ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 554,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS SUSP PROS VALVE ENDOCARD",
      "term": null,
      "displaytext": "Suspected Prosthetic Valve Endocarditis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV Q6H AND\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG LOAD THEN 1.5 MG/KG IV Q8H AND\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Rifampin 300MG IV Q8H\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"If Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Aztreonam 2GM IV Q8H AND\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Gentamicin 2 MG/KG LOAD THEN 1.5 MG/KG IV Q8H AND\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Rifampin 300MG IV Q8H\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED PROSTHETIC VALVE ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 555,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS SUSPECTED INTRAABDOMINAL INFECTION",
      "term": null,
      "displaytext": "Suspected Intraabdominal Infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin/Tazobactam 4.5GM IV Q6H\", \"Text\": \"Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] and metronidazole 1gm q12h SEPSIS\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND>  metronidazole 1 gm IV q12h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CIPRO 400MG IV Q12H METRO 1GM IV Q12H\", \"Text\": \"Ciprofloxacin 400 mg IV q12H ($) [R,DI] <AND> metronidazole 1 gm IV q12h\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV x 1 dose\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Abdominal CT\", \"Text\": \"Please Click Here To Order an Abdominal CT\", \"Mnemonic\": \"12\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"For severe penicillin allergy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"($) [DI]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Consider Abdominal CT\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED INTRAABDOMINAL INFECTION\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 556,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS SUSPECTED MENINGITIS",
      "term": null,
      "displaytext": "Suspected Meningitis, CNS Infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"4Please Click Here To Order This Set.\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Please Click Here To Order This Set.\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"8\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Penicillin Allergy and Listeria is NOT a concern:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Ceftriaxone 2GM IV Q12H AND Vancomycin 15mg/kg IV Q12H\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"(Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"No Penicillin Allergy and Listeria IS a concern (Patient with age > 50\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"yrs, alcoholism, or impaired cellular immunity:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Ceftriaxone 2GM IV Q12H AND\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Ampicillin 2GM IV Q4H\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Definite, Severe Penicillin Allergy (Whether or not Listeria is a concern):\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Trimethoprim/Sulfamethoxazole 5mg/kg (TMP component) IV Q6H AND\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED MENINGITIS, CNS INFECTION\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 557,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS SUSPECTED SKIN SOFT TISSUE",
      "term": null,
      "displaytext": "Sepsis Suspected Skin Soft Tissue",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 496, \"DisplayText\": \"Necrotizing infections\", \"Text\": \"Necrotizing infections recommendations\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8Please Click Here To Order This Set.\", \"Text\": \"Please Click Here to Order This Set.\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Please Click Here to Order This Set\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED SKIN SOFT TISSUE INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Aggressive surgical debridement is recommended.\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For necrotizing infections refer to those recommendations for treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV Q6H <AND>\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"If Penicillin Allergy= Type 1 allergy (e.g. anaphylaxis, hives, angioedema,\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"hypotension, etc.)\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Ciprofloxacin 400 MG IV Q12H <AND>\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 558,
    "fields": {
      "name": "ORZID2 GMENU SEPSIS SUSPECTED URO SEPSIS",
      "term": null,
      "displaytext": "Suspected Urosepsis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8Please Click Here To Order This Set.\", \"Text\": \"Please Click Here To Order This Set.\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Please Click Here to Order This Set\", \"Mnemonic\": \"6\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Site:  Unless the specific site or etiologic agent is known with a high\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"level of probability strong consideration should be given:  1) To\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"empiric broad spectrum antibiotics for empiric first dose therapy in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"first 24 hours following presentation (Empirical Therapy Site Unknown)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and 2) Strongly consider ID consult.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"No Pencillin Allergy:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Piperacillin/Tazobactam 4.5GM IV Q6H AND\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If Penicillin Allergy:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Ciprofloxacin 400 mg IV q12H AND\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Consider selecting alternative agents from separate drug class if\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"recently treated with any of the above antibiotics.\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS WITH SUSPECTED URINARY TRACT INFECTION\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"1\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If patient is at risk of multi-drug resistant gram-negative rods:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"*Pharmacy to follow\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"<ADD> Gentamicin 5 mg/kg IV x 1 dose\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 559,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC ARTH ENTEROCOCCI",
      "term": null,
      "displaytext": "Septic arthritis (Native joint) with Enterococci ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Vancomycin 15mg/kg IV q12h ($) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH ENTEROCOCCI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For severe enterococcal infections, add an aminoglycoside for synergy during the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"first 2-4 weeks of therapy.  Consult Infectious Diseases for specific management\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"advice.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of treatment for 2-4 weeks, depending on response\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment, MILD-MODERATE infections\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or resistant organism\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment, SEVERE infections\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy or resistant organism\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Stevens DL Clin Inf Dis 2014, 59:e10-52\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 560,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC ARTH GNB",
      "term": null,
      "displaytext": "Septic arthritis (Native joint) with Gram negative bacilli",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg IV q24h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO q24h ($) [R]\", \"Text\": \"Levofloxacin 500 mg po q24h ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH GRAM NEGATIVE BACILLI (OTHER THAN\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"PSEUDOMONAS)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Administer parenteral therapy initially for approximately 1-2 weeks\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"then can be converted to appropriate oral therapy.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 4 weeks\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Oral therapy to complete the course after intravenous therapy initially:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 561,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC ARTH N. GONORRHOEAE",
      "term": null,
      "displaytext": "Septic arthritis (Native joint) with N. gonorrhoeae ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h for 7 days ($) [DI] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH NEISSERIA GONORRHOEAE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat presumptively also for Chlamydia trachomatis infection (asymptomatic\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"urethritis) and test for HIV.  Infection control will report cases with N.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"gonorrhea isolated to the state department of health.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Susceptibility results are required to guide potential switch to an oral medicat\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"N. gonorrheae Treat for 1-2 weeks (Plus see below for Chlamydia treatment)\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative for severe penicillin allergy\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consult Infectious Disease for alternative\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_______________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Concomitant treatment for C. trachomatis\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred treatment:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative treatment:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"MMWR Recommendations and Reports CDC 2015, 64:1-137\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 562,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC ARTH P. AERUGINOSA",
      "term": null,
      "displaytext": "Septic arthritis (Native joint) with Pseudomonas aeruginosa  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI]  < OR >\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH PSEUDOMONAS AERUGINOSA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat for 4 weeks\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 563,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC ARTH S. AUREUS",
      "term": null,
      "displaytext": "Septic arthritis (Native joint) with Staphylococcus aureus",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [DI]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]  < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] < OR >\", \"Mnemonic\": \"14\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]  < OR >\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI]  < OR >\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH STAPHYLOCOCCUS AUREUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Administer parenteral therapy initially for approximately two weeks\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"then can be converted to appropriate oral therapy.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Methicillin-SUSCEPTIBLE Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treat for 4-6 weeks depending on response\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Oral therapy to complete the course after intravenous therapy initially:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Methicillin-RESISTANT Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treat for 4-6 weeks depending on response\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Oral therapy to complete the course after intravenous therapy initially:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Coakley G Rheumatology (Oxford) 2006, 45:1039\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 564,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC ARTH STREPTOCOCCI",
      "term": null,
      "displaytext": "Septic arthritis (Native joint) with Streptococci",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PENICILLIN G 4 MILLION UNITS IV Q4H\", \"Text\": \"Penicillin G 4 million units IV q4h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO q8h ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q6h ($) [H,O]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH STREPTOCOCCI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Duration: treat for 2-4 weeks\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy, or when beta-lactam resistance\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"is suspected or proved:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Oral step-down therapy to complete full course once sensitivities are known:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 565,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)",
      "term": null,
      "displaytext": "Septic arthritis (Native joint)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 541, \"DisplayText\": \"Infections in bone or joint prostheses\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 333, \"DisplayText\": \"Bite wounds\", \"Text\": \"Bite wounds\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 203, \"DisplayText\": \"Lyme disease\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15mg/kg IV q 12 hours ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Text\": \"Ampicillin 2 gm IV q4h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M] < AND > azithromycin 1 gm PO once ($) [O]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> Azithromycin 1 gm PO x1dose ($) [O]\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Text\": \"Ceftazidime 2 gm IV q8h ($$) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 563, \"DisplayText\": \"Septic arthritis (Native joint) with Staphylococcus aureus\", \"Text\": \"Staphylococcus aureus\", \"Mnemonic\": \"22\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 564, \"DisplayText\": \"Septic arthritis (Native joint) with Streptococci\", \"Text\": \"Streptococci\", \"Mnemonic\": \"24\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 559, \"DisplayText\": \"Septic arthritis (Native joint) with Enterococci\", \"Text\": \"Enterococci\", \"Mnemonic\": \"26\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 560, \"DisplayText\": \"Septic arthritis (Native joint) with Gram negative bacilli\", \"Text\": \"Gram negative bacilli (other than Pseudomonas)\", \"Mnemonic\": \"28\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 562, \"DisplayText\": \"Septic arthritis (Native joint) with Pseudomonas aeruginosa\", \"Text\": \"Pseudomonas aeruginosa\", \"Mnemonic\": \"30\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 561, \"DisplayText\": \"Septic arthritis (Native joint) with N. gonorrhoeae\", \"Text\": \"Neisseria gonorrhoeae\", \"Mnemonic\": \"32\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \">>  For arthritis associated with a PROSTHETIC JOINT see\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \">>  For arthritis associated with a BITE WOUND see\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \">>  For arthritis associated with TICK EXPOSURE in an endemic area, consider\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Septic arthritis native joint:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Aspirate the joint for gram stain and culture.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Use the Gram stain of aspirated fluid to select initial therapy.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Use culture results to guide definitive therapy.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"In addition to antimicrobial treatment, successful management of acute\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"septic arthritis requires removal of intra-articular pus.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"**Synovial fluid Gram stain with organisms:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Gram positive cocci in clusters:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Gram positive cocci in chains (streptococci):\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Gram negative diplococci (Neisseria) or STD risk and Gram stain negative:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"(one dose of azithromycin for possible concomitant C. trachomatis)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Gram negative rods:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"**Synovial fluid without organisms on Gram stain:\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"*No MRSA risk factors:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"*MRSA risk factors, high risk of Gram negative infection (elderly,\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"nursing home, hospitalized, cutaneous ulcers)\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Pathogen-specific septic arthritis treatment regimens\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Duration of therapy based on pathogen and clinical response. (See pathogen)\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"If the patient has an underlying rheumatoid arthritis, 6 to 12 weeks of\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"antimicrobials may be needed, depending on clinical response.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Consult Rheumatology for more information\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Sharff KA Curr Rheumatol Rep 2013 15:332\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Coakley G Lancet 2010, 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 566,
    "fields": {
      "name": "ORZID2 GMENU SEPTIC BURSITIS",
      "term": null,
      "displaytext": "Septic bursitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [DI]  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID  ($) [DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"SEPTIC BURSITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Aspiration for treatment and diagnostic confirmation should be performed in all\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"cases. Obtain synovial fluid for gram stain and culture to guide therapy. Most\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cases are associated with Staphylococcus aureus.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Intravenous therapy is recommended. Some clinicians treat mild cases in\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"otherwise healthy individuals with intravenous therapy for part of the course\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and then switch to oral therapy. Other clinicians treat mild cases with oral\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"therapy for the entire course. Drug selection should be based on microbiological\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"results. Close clinical follow-up is needed for all cases\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat for 2 to 3 weeks.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mild cases in otherwise healthy adults\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Bursitis\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Baumbach SF, Arch Orthop Trauma Surg 2014, 134:359\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 567,
    "fields": {
      "name": "ORZID2 GMENU SEVERE SINUSITIS",
      "term": null,
      "displaytext": "Severe Sinusitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID  ($) [DI] for 10 days\", \"Mnemonic\": \"10\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3gm IV q6h ($) [R] for 10 days\", \"Mnemonic\": \"12\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] for 10 days\", \"Mnemonic\": \"16\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R] for 10 days\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEVERE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Community-acquired bacterial sinusitis is most often due to Streptococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For patients who present with severe symptoms (high fever (>/= 102 degrees\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"consecutive days or facial pain lasting for at least 3-4 consecutive days at the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"to determine the extent of infection. If the CT shows extension of sinusitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"infection into surrounding structures (i.e. the cranium or orbit) consult ENT\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"immediately. Closely monitor all patients who present with severe signs and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"symptoms to ensure that signs and symptoms improve within 72 hours.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Outpatient Treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment of hospitalized patient\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treatment failure\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"If symptoms worsen or no improvement is seen after 3-5 days of treatment,\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"broaden coverage, switch to different antimicrobial class and treat 10 days. If\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"symptoms continue to worsen or there is no improvement after 3-5 more days of\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"treatment, obtain CT to investigate non-infectious or suppurative causes. ENT\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"consultation is recommended. If sinuses are aspirated, specimens should be\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"cultured.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Preferred\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"for 10 days\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Chronic\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-To-Date article: Microbiology and antibiotic management of chronic\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"rhinosinusitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 568,
    "fields": {
      "name": "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU",
      "term": null,
      "displaytext": "Sexually Transmitted Infections (STI) HIV Exposure  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 693, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Sexually Transmitted Infections (STI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A diagnosis of a sexually transmitted infection can suggest sexual activity\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"that could result in HIV exposure. Recommendation is for the provider to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"HIV acquisition.  If the patient is interested, the provider should place a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"consult to MRTC clinic for further discussion and evaluation for PrEP.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Pre-exposure prophylaxis (or PrEP) is a way for people who do not have\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"HIV but who are at high risk of getting HIV to prevent HIV infection by\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"taking a pill every day. When someone is exposed to HIV through sex or\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"injection drug use, these medicines can work to keep the virus from\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"establishing a permanent infection.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"have shown that PrEP reduces the risk of getting HIV from sex by about\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"99% when taken daily. PrEP is much less effective if not taken consistently.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"As PrEP only protects against HIV, condoms are important for the protection\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"against other STIs. Condoms are also an important prevention strategy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"if PrEP is not taken consistently.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 569,
    "fields": {
      "name": "ORZID2 GMENU SPINAL EPIDURAL ABSCESS",
      "term": null,
      "displaytext": "Spinal epidural abscess  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Cefepime 2gm IV Q8h ($$) [R]  < AND > vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 3059, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SPINAL EPIDURAL ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are associated with Staphylococcus aureus. Others are associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Gram-negative bacilli and streptococci. Beta-lactam antibiotics are more\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"effective than vancomycin against susceptible Staphylococci. If Staphylococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"is isolated, once methicillin-resistance is ruled out, switch to an anti-\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen in\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"post-surgical patients or patients with known Pseudomonas colonization.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat for 4 to 8 weeks. Shorter durations may be used in patients who have\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"undergone surgical drainage and who have responded well to therapy.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is not suspected:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is suspected:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment if methicillin-sensitive S. aureus is isolated\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Krishnamohan et al, Curr Infect Dis Rep, 2014, 16(11)1-6\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-To-Date Article: Spinal Epidural Abscess\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 570,
    "fields": {
      "name": "ORZID2 GMENU SPOROTRICHOSIS",
      "term": null,
      "displaytext": "Sporotrichosis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po q12h\", \"Text\": \"Itraconazole 200 mg PO q12h continue for 2-4 weeks after all lesions\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"SPOROTRICHOSIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Sporotrichosis occurs most often in people who have had significant outdoor\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"exposure to soil.  In immunocompetent people, disease is usually limited to the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"skin.  In people with decreased host defenses (eg, HIV/AIDS, alcoholism,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"diabetes mellitus, or chronic obstructive pulmonary disease) sporotrichosis\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"often disseminates to bones, joints, or lungs.  Consult Infectious Diseases or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Dermatology\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Cutaneous infection in a patient without HIV infection\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"resolved, usually for a total of 3-6 months ($) [DI]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Consult Dermatology or Infectious Diseases.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Extracutaneous infection or any infection in a patient with HIV/AIDS\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Consult Dermatology or Infectious Diseases.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Kaufman CA Clin Infect Dis 2000, 30: 684\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 571,
    "fields": {
      "name": "ORZID2 GMENU STAPH SCALDED SYNDROME",
      "term": null,
      "displaytext": "Staphylococcal Scalded Skin Syndrom (Ritter's Disease) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"STAPHYLOCOCCAL SCALDED SKIN SYNDROME (RITTER'S DISEASE)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Staphylococcal scalded skin syndrome (SSSS) presents with severe skin\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"blistering and exfoliation resulting from toxins produced by Staphylococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"aureus.  SSSS is usually found in children and rarely in older adults.  Obtain\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"a skin biopsy to differentiate between SSSS and toxic epidermal necrolysis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Initiate anti-staphylococcal therapy and obtain cultures and susceptibilities.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empiric therapy active against both MRSA and MSSA until results available.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If cultures reveal methicillin-susceptible Staphylococcus aureus (MSSA), change\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"to nafcillin or cefazolin for better antimicrobial activity.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment if MSSA is isolated\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Staph. Scalded skin syndrome\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: The acutely ill patient with fever and rash\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Patel GK Am J Clin Dermatol 2003, 4:165\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 572,
    "fields": {
      "name": "ORZID2 GMENU STAPH TOXIC SHOCK SYNDROME",
      "term": null,
      "displaytext": "CDC criteria for diagnosis of Staphylococcal Toxic Shock Syndrome  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CDC CRITERIA FOR DIAGNOSIS OF STAPHYLOCOCCAL TOXIC SHOCK SYNDROME\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"These criteria were developed for epidemiological purposes.  Treat cases when\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"fewer criteria are met if staphylococcal TSS seems likely.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Definite:  All 6 of the following criteria are met.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Probable:  Five of the 6 criteria are met.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Fever\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"T >38.9 degree Celsius (102.0 degree Fahrenheit)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Hypotension\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Systolic blood pressure 90 mmHg, orthostatic drop in diastolic 15 mmHg,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"orthostatic syncope or dizziness\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Rash\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Diffuse macular erythroderma\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Desquamation\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Occurs 1 to 2 weeks after onset of illness and usually involving palms and\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"soles\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Multisystem involvement (3 or more of the following organ systems)\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"GI\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Vomiting or diarrhea at onset of illness\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Muscular\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Severe myalgia or CPK elevation >2 times the normal upper limit\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mucous membranes\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Vaginal, oropharyngeal, or conjunctival hyperemia\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Renal\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"BUN or serum creatinine >2 times the normal upper limit, or pyuria (>5\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"WBC/hpf)\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Hepatic\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Bilirubin or transaminases >2 times the normal upper limit\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Hematologic\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Platelets <100,000/microLiter\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Central nervous system\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Disorientation or alterations in consciousness without focal neurologic\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"signs in the absence of fever and hypotension\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Negative results on the following tests, if obtained\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Blood, throat, or cerebrospinal fluid cultures for another pathogen (blood\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"cultures may be positive for S. aureus).\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Serologic tests for Rocky Mountain spotted fever, leptospirosis, or measles\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"MMWR 1990, 39(RR-13):1\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"DeVries AS PLoS One 2011, 6(8):e22997\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 573,
    "fields": {
      "name": "ORZID2 GMENU STREP TOXIC SHOCK SYNDROME",
      "term": null,
      "displaytext": "Criteria for diagnosis of Streptococcal Toxic Shock Syndrome ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CRITERIA FOR DIAGNOSIS OF STREPTOCOCCAL TOXIC SHOCK SYNDROME\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"These criteria were developed for epidemiological purposes.  Treat cases when\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"fewer criteria are met if streptococcal TSS seems likely.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"1.)  Isolation of Group A Streptococcus from a normally sterile site (eg, blood\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"cerebrospinal, pleural, or peritoneal fluid, tissue biopsy, or surgical wound)\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< AND >\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"2.)  Hypotension (systolic blood pressure 90 mm Hg in adults\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< AND >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"3.)  Two or more of the following:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Renal impairment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"(creatinine in adults, 2 mg/dL, in children, two-times upper limit of normal\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"for age, in patients with pre-existing renal disease two-fold elevation over\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"baseline)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Coagulopathy\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(eg, thrombocytopenia, disseminated intravascular coagulation)\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Liver involvement\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"(eg, two-times upper limit of normal for age of transaminases or bilirubin, in\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"patients with pre-existing liver disease two-fold elevation over baseline)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Adult respiratory distress syndrome\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Erythematous macular rash\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"may desquamate\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Soft tissue necrosis (eg, necrotizing fasciitis, myositis, or gangrene)\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Working Group on Severe Streptococcal Infections JAMA 1993, 269:390\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 574,
    "fields": {
      "name": "ORZID2 GMENU SUBDURAL EMPYEMA",
      "term": null,
      "displaytext": "Subdural Empyema",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAX 2GM IV Q12H METRO 500MG IV Q8H\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 3060, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"10\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"12\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SUBDURAL EMPYEMA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases (60-90%) result from extension of sinusitis or otitis media\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(contiguous sources). Surgical drainage is necessary. Obtain material for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"culture. For patients with severe penicillin allergy consult Infectious\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consult Neurosurgery, Neurology, and Infectious Disease\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for 4-6 weeks\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Empiric Treatment for Infection from Contiguous Source\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empiric Treatment for Unknown Source, History of MRSA Infection or Colonization\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Intracranial Thrombophlebitis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Subdural empyema\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 575,
    "fields": {
      "name": "ORZID2 GMENU SUPP INTRACRANIAL THROMBOPH",
      "term": null,
      "displaytext": "Suppurative intracranial thrombophlebitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Text\": \"Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 500 mg IV q8h\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFEPIME 2GM IV Q8H METRO 500MG IV Q8H VANCO 15MG/KG IV Q12H\", \"Text\": \"Cefepime 2gm IV Q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 3061, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\", \"Text\": \"Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV Q4H ($$) [R]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IV q8h ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SUPPURATIVE INTRACRANIAL THROMBOPHLEBITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Adjust therapy from empirical regimens listed below after consultation with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Infectious Disease or Neurosurgery services. Beta-lactam antibiotics are more\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"effective than vancomycin against susceptible Staphylococci. If Staphylococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"is isolated, once methicillin-resistance is ruled out, switch to an anti-\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen in\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"post-surgical patients or patients with known pseudomonas colonization.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consult Infectious Disease and Neurosurgery.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of Therapy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat for 3 to 6 weeks.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is not suspected:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred if Pseudomonas is suspected:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"<AND> vancomycin 15 mg/kg IV q12h ($) [R]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment if Methicillin-Sensitive S. Aureus is Isolated\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Kombogiorgas et al, British Journal of Neurosurgery, 2007, 21(6)603 - 609\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Intracranial Thrombophlebitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 576,
    "fields": {
      "name": "ORZID2 GMENU SUPP ODONTOGENIC INFECT",
      "term": null,
      "displaytext": "Suppurative odontogenic infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO q8h ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h for 5 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h for 5 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO q12h ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"10\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO q24h for 4 days ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($) [M]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DENTAL INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Surgical drainage, scaling and antimicrobial treatment are essential. All\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients should be referred to the dental service for assessment and direction\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"of treatment. Empirical coverage for likely pathogens (streptococci,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Peptostreptococcus, Finegoldia, Bacteriodes and other oral anaerobes) is\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"required.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Consult Dental Service\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Primary alternative:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Secondary alternative, after assessment of beta-lactam reaction above:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Lockhart et al. JADA. 2019, 150(11)906-921\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Oral Cavity, Neck, and Head\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Ogle, Dent Clin N Am. 2017, 61(2)235-252\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Reynolds et al. Lung. 2009, 187(5)271-279\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-to-date article: Complications, diagnosis and treatment of odontogenic\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 577,
    "fields": {
      "name": "ORZID2 GMENU SURG 48HRS AFTER PROC",
      "term": null,
      "displaytext": "Patients with signs of infection 48 HOURS OR MORE after procedure  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"WOUND NURSE INPT\", \"Text\": \"Wound care (ET) nurse consult\", \"Mnemonic\": \"4\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRSA Nares Screening + Vancomycin 15mg/kg IV now then q12h ($) [R]\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R]\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R] < OR >\", \"Mnemonic\": \"8\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> Clindamycin 600 mg IV\", \"Mnemonic\": \"10\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3 gm IV q6h ($) [R] <AND> Vancomycin 15 mg/kg IV\", \"Text\": \"Ampicillin-sulbactam 3 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"14\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]\", \"Text\": \"Piperacillin-tazobactam 3.375 gm IV q6h ($$) <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"16\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg\", \"Mnemonic\": \"18\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PATIENTS WITH SIGNS OF INFECTION MORE THAN 48 HOURS AFTER PROCEDURE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most post-operative infections appear at least 4 days after the operation.  If\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the wound appears normal to examination surgical site infection is unlikely.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Seek other source of fever.  Consider opening wounds that show induration or\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"erythema.  Obtain material for gram stain and culture whenever possible.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Determine whether the patient has signs of invasive or systemic infection like\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"erythema (diameter greater than 5 centimeters), temperature greater than 38.5\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"degrees Celsius (101.3 degrees Fahrenheit) or heart rate higher than 100 beats\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"per minute.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"If there are no signs of invasive or systemic infection systemic antimicrobials\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"are unnecessary.  Dressing changes alone are indicated.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"For wounds that require complicated care\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"If there are signs of invasive or systemic infection obtain blood cultures and\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"wound Gram stain and cultures.  Whenever possible select antimicrobial therapy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"based on the Gram stain.  When the Gram stain cannot provide guidance give\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"empirical therapy as indicated:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Empirical treatment of INFECTED WOUNDS AFTER CLEAN SURGERY or wounds on the\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"trunk, head, neck, arms or legs\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Vancomycin should be included in the initial regimen due to the prevalence of\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"methicillin-resistant Staphylococcus aureus.  However beta-lactam antibiotics\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"are more effective for susceptible bacteria than is vancomycin.  If methicillin-\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"susceptible S. aureus is identified switch to an anti-staphylococcal beta-lactam\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"antibiotic.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Preferred empirical treatment for INFECTED WOUNDS AFTER CLEAN-CONTAMINATED or\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"CONTAMINATED SURGERY\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"q8h ($$) [H]\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Alternative if methicillin-resistant Staphylococcus aureus is suspected\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"IV q12h ($) [R] < OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"IV q12h ($) [R] < OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"IV q8h ($) [DI] <AND> vancomycin 15mg/kg IV q12 ($) [R]\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 578,
    "fields": {
      "name": "ORZID2 GMENU SURG ANTIBIOTIC RENAL REDOSING",
      "term": null,
      "displaytext": "Redosing Interval for renal fxn normal vs esrd",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"Recommended Redosing Interval\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Based on Normal and ESRD renal function\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Recommended redosing interval 2 times the half-life\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"ANTIMICROBIAL\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Ampicillin\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Ampicillin sulbactam\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Aztreonam\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Cefazolin\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Cefuroxime\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Cefoxitin\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Cefotetan\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Ceftriaxone\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Ciprofloxacin\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Clindamycin\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Gentamicin\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Levofloxacin\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Metronidazole\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Piperacilln Tazobactam\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Vancomycin\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Am J Health-Syst Pharm. 2013, 70: 195-283\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford Guide Online\", \"Header\": 1}, {\"Row\": 10, \"Column\": 2, \"Text\": \"REDOSING INTERVAL**\", \"Header\": 1}, {\"Row\": 11, \"Column\": 2, \"Text\": \"NORMAL RENAL FXN\", \"Header\": 1}, {\"Row\": 13, \"Column\": 2, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 15, \"Column\": 2, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 17, \"Column\": 2, \"Text\": \"4 hours\", \"Header\": 1}, {\"Row\": 19, \"Column\": 2, \"Text\": \"4 hours\", \"Header\": 1}, {\"Row\": 21, \"Column\": 2, \"Text\": \"4 hours\", \"Header\": 1}, {\"Row\": 23, \"Column\": 2, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 25, \"Column\": 2, \"Text\": \"6 hours\", \"Header\": 1}, {\"Row\": 27, \"Column\": 2, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 31, \"Column\": 2, \"Text\": \"6 hours\", \"Header\": 1}, {\"Row\": 39, \"Column\": 2, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 45, \"Column\": 2, \"Text\": \"Doses based on Dosing Weight (DW)*\", \"Header\": 1}, {\"Row\": 46, \"Column\": 2, \"Text\": \"*Calculate Dosing Weight (DW)\", \"Header\": 1}, {\"Row\": 47, \"Column\": 2, \"Text\": \"DW = IBW + 0.4 (ABW - IBW)\", \"Header\": 1}, {\"Row\": 48, \"Column\": 2, \"Text\": \"IBW=Ideal Body Wt  ABW=Actual Body Wt\", \"Header\": 1}, {\"Row\": 49, \"Column\": 2, \"Text\": \"Male IBW (kg)=50+2.3 * (Ht-60inches)\", \"Header\": 1}, {\"Row\": 50, \"Column\": 2, \"Text\": \"Female IBW (kg)=45.5+2.3 * (Ht-60inches)\", \"Header\": 1}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Antimicrobial Surgical Prophylaxis\", \"Header\": 1}, {\"Row\": 10, \"Column\": 3, \"Text\": \"REDOSING INTERVAL**\", \"Header\": 1}, {\"Row\": 11, \"Column\": 3, \"Text\": \"END STAGE RENAL DISEASE\", \"Header\": 1}, {\"Row\": 13, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 15, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 17, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 19, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 21, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 23, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 25, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 27, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 31, \"Column\": 3, \"Text\": \"6 hours\", \"Header\": 1}, {\"Row\": 33, \"Column\": 3, \"Text\": \"Only give 3mg/kg preop ONCE*\", \"Header\": 1}, {\"Row\": 39, \"Column\": 3, \"Text\": \"6 hours\", \"Header\": 1}, {\"Row\": 41, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 44, \"Column\": 3, \"Text\": \"based on typical case length, for\", \"Header\": 1}, {\"Row\": 45, \"Column\": 3, \"Text\": \"unusually long procedures,\", \"Header\": 1}, {\"Row\": 46, \"Column\": 3, \"Text\": \"redosing may be needed.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 3, \"Text\": \"**For those marked N/A --\", \"Header\": 1}, {\"Row\": 6, \"Column\": 3, \"Text\": \"based on typical case length,\", \"Header\": 1}, {\"Row\": 7, \"Column\": 3, \"Text\": \"unusually long procedures,\", \"Header\": 1}, {\"Row\": 8, \"Column\": 3, \"Text\": \"redosing may be needed.\", \"Header\": 1}, {\"Row\": 43, \"Column\": 3, \"Text\": \"**For those marked N/A --\", \"Header\": 1}, {\"Row\": 33, \"Column\": 2, \"Text\": \"Single dose only preop\", \"Header\": 1}, {\"Row\": 29, \"Column\": 2, \"Text\": \"Do not redose\", \"Header\": 1}, {\"Row\": 29, \"Column\": 3, \"Text\": \"Do not redose\", \"Header\": 1}, {\"Row\": 41, \"Column\": 2, \"Text\": \"12 hours\", \"Header\": 1}, {\"Row\": 37, \"Column\": 2, \"Text\": \"12 hours\", \"Header\": 1}, {\"Row\": 37, \"Column\": 3, \"Text\": \"12 hours\", \"Header\": 1}, {\"Row\": 35, \"Column\": 2, \"Text\": \"Do not redose\", \"Header\": 1}, {\"Row\": 35, \"Column\": 3, \"Text\": \"Do not redose\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"John Hopkins Antibiotic Guide.Online.Oct2021.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 579,
    "fields": {
      "name": "ORZID2 GMENU SURG BILIARY",
      "term": null,
      "displaytext": "Biliary Surgery ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BILIARY SURGERY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Surgical prophylaxis is indicated for open procedures and high risk\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"laparoscopic procedures.  Additional doses should not be given after\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"incisions are closed. Surgical prophylaxis is not indicated in elective\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"low risk laparoscopic procedures.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"The risk of infectious complications after laparoscopic cholecystectomy is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"increased after emergent procedures, procedures lasting more than 120 minutes,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"intraoperative gall bladder rupture or bile spillage, conversion from\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"laparoscopic to open cholecystectomy, and insertion of a prosthetic device.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"The risk is increased in patients who have had an episode of colic or a\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"biliary procedure within 30 days before the procedure, patients with acute\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"cholecystitis or jaundice, patients with a nonfunctional gallbladder, patients\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"with immunosuppression, pregnancy, diabetes, age greater than 70 years, or\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"American Society of Anesthesiologists classification of 3 or greater.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"If one of these risk factors exists, prophylaxis is indicated for laparoscopic\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"cholecystectomy.  If there is a substantial likelihood that one of these risk\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"factors will develop during a procedure, the surgeon may elect to order\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"prophylaxis.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Open procedure or high-risk laparoscopic procedure:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred prophylaxis\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Alternative in patients with beta lactam allergy\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 580,
    "fields": {
      "name": "ORZID2 GMENU SURG CARDIAC SURG",
      "term": null,
      "displaytext": "Cardiac surgery and implantation of pacemaker ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Item\": 584, \"DisplayText\": \"CIED Pre Op\", \"Text\": \"Click here to go to CIED Surgery Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 206, \"DisplayText\": \"CV Surgery Delayed Order Antibiotics\", \"Text\": \"Click here to go to CV (open heart) Surgery Prophylaxis\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"8\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CARDIAC SURGERY\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is not indicated before cardiac catheterization\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with or without stent placement or for transesophageal echocardiogram.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For patients undergoing cardiac procedures the recommended regimen is a\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"single pre-incision dose of antibiotic with additional doses\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"while incisions are open for long procedures.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Prophylaxis should not be continued beyond 24 hours\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"even if drains or intravenous catheters remain in place.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Cefazolin is preferred for prophylaxis, as it is more active than vancomycin\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"against methicillin-susceptible staphylococci.  Vancomycin should\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"be used when methicillin-resistant Staphylococcus aureus infection is likely.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Consult Cardiothoracic Surgery or Infectious Diseases for more information.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Prophylaxis\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"in surrgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Letter 2012 Vol 10 pages 73-77\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Baddour LM, et al. Circulation 2010 Vol 121 pages 458-477\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy or IF MRSA likely:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"[Click here] Beta-lactam allergy assessment\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 3062, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"12\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 581,
    "fields": {
      "name": "ORZID2 GMENU SURG CEFAZOLIN WEIGHT BASED DOSING",
      "term": null,
      "displaytext": "Cefazolin Weight Based Dosing Preop  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 3GM IVPB ONCE\", \"Mnemonic\": \"06\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2GM IVPB ONCE\", \"Mnemonic\": \"04\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Weight <120 kg:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Weight >/= 120 kg:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Preop dose administer over 30 minutes, beginning 60 minutes before incision.\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"<Click here> Display last recorderd patient weight (limited 2 years)\", \"Text\": \"<Click here> Display last recorded patient weight (limited to 2 years)\", \"Mnemonic\": \"02\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Recommended Cefazolin Preop Dose based on patient weight:\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CEFAZOLIN:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 582,
    "fields": {
      "name": "ORZID2 GMENU SURG CEFAZOLIN WT BASED POSTOP DOSES X2",
      "term": null,
      "displaytext": "Cefazolin Weight Based Dosing q8h x2 doses postop",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 3GM IV q8hours X2 doses Postop\", \"Mnemonic\": \"06\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2GM IVPB q8hours X2 doses Postop\", \"Mnemonic\": \"04\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Weight <120 kg:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Weight >/= 120 kg:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"<Click here> Display last recorderd patient weight (limited 2 years)\", \"Text\": \"<Click here> Display last recorded patient weight (limited to 2 years)\", \"Mnemonic\": \"02\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Cefazolin Postop Dose based on patient weight:\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Text\": \"CEFAZOLIN:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Postoperative antimicrobial administration for preventing SSI is not\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"necessary for most procedures. The duration of antimicrobial prophylaxis\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"should be less than 24 hours.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 583,
    "fields": {
      "name": "ORZID2 GMENU SURG CIED POSTOP",
      "term": null,
      "displaytext": "CIED Post Op ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2GM IVPB q8hours X2 doses Postop\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 3GM IV q8hours X2 doses Postop\", \"Text\": \"Cefazolin 3 GM q8h for 2 doses post-op ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15 MG/KG iv q12h for 2 doses post-op ($) [R]\", \"Text\": \"Vancomycin 15mg/kg for 2 doses post-op ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefazolin 2 GM q8h x 2 doses post-op ($) [R] < AND >\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefazolin 3 GM q8h x 2 doses post-op ($) [R] < AND >\", \"Mnemonic\": \"12\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500MG PO bid for 3 days AFTER CIED PROCEDURE\", \"Text\": \"Cephalexin 500MG PO bid for 3 days AFTER CIED PROCEDURE\", \"Mnemonic\": \"14\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300MG po qid for 3 days AFTER CIED PROCEDURE\", \"Text\": \"Clindamycin 300MG po qid for 3 days AFTER CIED PROCEDURE\", \"Mnemonic\": \"16\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100MG PO bid for 3 days AFTER CIED PROCEDURE\", \"Text\": \"Doxycycline 100MG PO bid for 3 days AFTER CIED PROCEDURE\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Cardiac Implantable Electronic Device (CIED) Post-Op Prophylaxis Antibiotics\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Post-procedure CIED IV antibiotic prophylaxis:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Place post-op IV antimicrobial prophylaxis after admission.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If new CIED implant, then give same antibiotic(s) as preop for 2 doses post-op\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"If generator replacement only, then no additional doses recommended.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred POST-PROCEDURE prophylaxis:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For patients weight less than 120 kg:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For patients weight equal to or greater than 120kg:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative in patients with beta lactam allergy:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"MRSA Positive Patients Post-Procedure antibiotics:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients weight less than 120 kg:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV q12h x 2 doses post-op ($) [R]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For patients weight equal to or greater than 120 kg:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Vancomycin 15mg/kg IV q12h x 2 doses post-op ($) [R]\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"__________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Post-procedure CIED ORAL TAKE HOME MEDICATIONS:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Preferred POST-PROCEDURE prophylaxis:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"MRSA Positive Patients Post-Procedure antibiotics:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 584,
    "fields": {
      "name": "ORZID2 GMENU SURG CIED PREOP",
      "term": null,
      "displaytext": "CIED Pre Op  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topical to affected area tid for 5 days ($) [M]\", \"Text\": \"Mupirocin Ointment apply  topical to each nares bid for 5 days PRIOR TO\", \"Mnemonic\": \"10\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin weight based once + Vancomycin 15mg/kg once\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Cardiac Implantable Electronic Device (CIED) Pre-Op Prophylaxis Antibiotics\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pre-procedure IV prophylaxis antibiotic recommendations:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Preferred prophylaxis:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Alternative in patients with beta lactam allergy:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Recommended for MRSA Positive Patients: Decolonization AND Pre-op Antibiotics\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Decolonization for MRSA positive:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"PROCEDURE (ideally) ($) [M]\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Preferred prophylaxis for MRSA positive:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 585,
    "fields": {
      "name": "ORZID2 GMENU SURG COLON AND RECTAL SURG",
      "term": null,
      "displaytext": "Bowel/Colo-rectal Surgery",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin weight based dosing Preop + Metronidazole 500mg IV ONCE Preop\", \"Text\": \"Cefazolin 2gm IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Gentamicin 5 MG/KG  IV over 30 minutes ($) [R,O] beginning 60 minutes\", \"Mnemonic\": \"10\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg IV over 30min once and levofloxacin 500mg IV over 30 min once\", \"Text\": \"Clindamycin 900mg IV over 30 minutes ($)[H,O] beginning 60 minutes\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Bowel/Colo-rectal Surgery\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bowel preparation should be done for cases in which the colon should be cleansed\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"for surgical reasons.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Systemic antimicrobials should provide coverage for aerobes and anaerobes.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Systemic antimicrobials\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred prophylaxis\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"($) [R] <AND> metronidazole 500 mg IV over 30 minutes beginning 60\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"minutes before incision ($) [DI]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative in patient with beta lactam allergy\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"before incision <AND> metronidazole 500 mg IV ($) [DI] over 30 minutes\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"beginning 60 minutes before incision\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"before incision <AND> levofloxacin 500mg IV over 60 minutes ($)[R,DI]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"beginning 60 minutes before incision.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013, 70: 195-283\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter 2012, 10: 73-77\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Prophylaxis\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Outpatient Orders for Bowel Prep Medications\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Inpatient Orders for Bowel Prep Medications\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"General Surgery Bowel Prep Orders\", \"Text\": \"Outpatient orders for Bowel Prep (Golytely+Neomycin PO+Erythromycin PO)\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Reglan 10mg PO prior to Golytely\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Golytely Bowel Prep\", \"Mnemonic\": \"8\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Neomycin 1GM TID day before surgery.\", \"Text\": \"Neomycin 1000 mg PO TID day before surgery\", \"Mnemonic\": \"10\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 1GM TID day before surgery.\", \"Text\": \"Erythromycin 1000 mg PO TID day before surgery\", \"Mnemonic\": \"12\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 586,
    "fields": {
      "name": "ORZID2 GMENU SURG CV POSTOP",
      "term": null,
      "displaytext": "CV POSTOPERATIVE PROPHYLAXIS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 583, \"DisplayText\": \"CIED Post Op\", \"Text\": \"CIED Surgery Postoperative Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefuroxime 1.5 gm IV q8h x 1 dose post-op ($$) [R] <AND> vancomycin 15 mg/kg\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE\", \"Text\": \"Vancomycin 15 mg/kg (pharmacy to dose) IV q12h x 1 dose post-op ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CV SURGERY (OPEN HEART) MVAHCS POSTOPERATIVE PROPHYLAXIS RECOMMENDATIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Place post-op IV antimicrobial prophylaxis orders after admission to ward.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Duration of antimicrobial prophylaxis should not exceed 24 hours. Durations\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"longer than 24 hours have not been shown effective in preventing cardiothoracic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"surgical site infections. There is no benefit to continuing antimicrobial\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"prophylaxis until all indwelling drains and intravascular catheters are removed.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For CIED surgery postoperative antimicrobial prophylaxis click link below:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"CV Surgery (including CAB and TAVR) Postoperative Prophylaxis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"(pharmacy to dose) IV q12h x 1 dose post-op ($) [R]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative for patient with cephalosporin allergy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Levofloxacin has a duration of action of 24 hours. If patient received a pre-op\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"dose of levofloxacin, a post-op dose is not required.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Bratzler DW et al, Clinical Practice Guidelines for Antimicrobial Prophylaxis in\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Surgery, Am J Health-Syst Pharm (2013) 70:195-283\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 587,
    "fields": {
      "name": "ORZID2 GMENU SURG ERCP",
      "term": null,
      "displaytext": "Endoscopic Retrograde Cholangiopancreatography (ERCP)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 588, \"DisplayText\": \"Antimicrobial Prophylaxis After ERCP with Incomplete Drainage\", \"Text\": \"Antimicrobial prophylaxis after ERCP with incomplete drainage\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2gram IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Text\": \"Ampicillin 2 gm IV over 20 minutes ($) [R] < AND > gentamicin 5mg/kg\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400mg IV ONCE Preop\", \"Text\": \"Ciprofloxacin 400 mg IV over 60 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobials are not indicated in the absence of obstruction or intervention.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"If obstruction is present or intervention is likely antimicrobial prophylaxis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"is recommended.  Use of gentamicin is optional.  Contact Gastroenterology for\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"more information.  If drainage is incomplete, prophylactic antimicrobials after\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"ERCP may be indicated.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred prophylaxis\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"over 20 minutes ($) [R,O] both beginning 60 minutes before incision\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"($) [R,DI]\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< AND > gentamicin 5mg/kg ($) [R,O] over 20 minutes beginning 60\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"minutes before incision\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford website: Surgical Prophylaxis Gastroduodenal, Biliary\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Prophylaxis in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter 2012 vol 10 pages 73-77\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Endoscopy 2008 vol 67 pages 791-795\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 588,
    "fields": {
      "name": "ORZID2 GMENU SURG ERCP INCOMP DRAINAGE",
      "term": null,
      "displaytext": "Antimicrobial Prophylaxis After ERCP with Incomplete Drainage",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]\", \"Text\": \"Amoxicillin-clavulante 875/125 mg PO q12h ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIMICROBIAL PROPHYLAXIS AFTER ERCP WITH INCOMPLETE DRAINAGE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The risk of symptomatic infection is increased when drainage of the common bile\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"duct is incomplete or if dye is trapped in the biliary tract.  In such cases,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"give antimicrobials for 5 days.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Up to date website\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Endoscopy 2008, vol 67 pages 791-795\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 589,
    "fields": {
      "name": "ORZID2 GMENU SURG GASTRODUODENAL SURG",
      "term": null,
      "displaytext": "Gastroduodenal Surgery",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GASTRODUODENAL SURGERY\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Prophylaxis is indicated in procedures involving entry into lumen of\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"gastrointestinal tract.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"For procedures without entry into gastrointestinal tract, prophylaxis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"is indicated only in patients with unusual risk for infection.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \">>Patients with high gastric pH or acid-suppression therapy,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \">>Patients with decreased gastroduodenal motility due to obstruction,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"hemorrhage, gastric ulcer, malignancy, or diabetic gastroparesis, or\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \">>Obese patients\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Prophylaxis\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Medical Letter 2012 vol 10 pages 73-77\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg and Ciprofloxacin 400 mg IVPB Preop Gastroduodenal\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"($) [H,O] < AND > Ciprofloxacin 400 mg IV over 60 minutes beginning 120 minutes\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"before incision ($) [R,O]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"For a patient with a history of anaphylactic shock or severe allergy to\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"penicillin OR beta-lactam antibiotic please order:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 590,
    "fields": {
      "name": "ORZID2 GMENU SURG GENTAMICIN WEIGHT BASED DOSING",
      "term": null,
      "displaytext": "Gentamicin 5mg/kg Weight Based Dosing Preop",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 240 mg IV ONCE\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 300 mg IV ONCE\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 400 mg IV ONCE\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 500 mg IV ONCE\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 600 mg IV ONCE\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Weight >/= 120 kg:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"<Click here> Display last recorderd patient weight (limited 2 years)\", \"Text\": \"<Click here> Display last recorded patient weight\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Preop dose administer beginning 60 minutes before incision:\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Recommended Gentamicin Preop Dose based on patient weight:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Weight >/= 50 kg and < 75 kg:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Weight >/= 75 kg and < 100 kg:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Weight < 50 kg:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Weight >/= 100 kg and < 120 kg:\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Text\": \"GENTAMICIN:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 591,
    "fields": {
      "name": "ORZID2 GMENU SURG GYNECOL SURG",
      "term": null,
      "displaytext": "Gynecological surgery ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GYNECOLOGICAL SURGERY\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Prophylaxis is indicated for abdominal or vaginal hysterectomy with either open\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"or laparoscopic approach.  Antimicrobials are not indicated after incisions are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"closed.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred prophylaxis\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative in patients with beta lactam allergy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 3063, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"6\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 592,
    "fields": {
      "name": "ORZID2 GMENU SURG HEAD AND NECK SURG",
      "term": null,
      "displaytext": "Head and neck surgery ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-Sulbactam 3 GM IV once pre-op\", \"Text\": \"Ampicillin-sulbactam 3 gm IV over 30 minutes beginning 60 minutes before\", \"Mnemonic\": \"12\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin weight based dosing Preop + Metronidazole 500mg IV ONCE Preop\", \"Mnemonic\": \"14\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"HEAD AND NECK SURGERY\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Clean procedures include thyroidectomy and lymph node excisions.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Clean-contaminated procedures include all procedures involving an incision\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"through the oral or pharyngeal mucosa. Clean-contaminated procedures include\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"esophagectomy.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Clean procedures, no prosthesis:  No antimicrobial prophylaxis recommended.\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Clean, prosthesis inserted:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Post-op doses are not indicated.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Post-op doses are not indicated.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Clean-contaminated procedures** including cancer surgery:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"incision. ($) [R]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Prophylaxis recommendations includes q6h for 3 doses post-op.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Please place post-op antimicrobial prophylaxis order after admission.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Prophylaxis recommendations includes BOTH MEDICATIONS q8h for 2 doses post-op.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Please place post-op antimicrobial prophylaxis orders after admission.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q8h for 2 doses post-op. Please place\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order after admission.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"**Prophylaxis not indicated for tonsillectomy or functional endoscopic sinus\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"procedures.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Each over 30 minutes beginning 60 minutes before incision\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 3064, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 593,
    "fields": {
      "name": "ORZID2 GMENU SURG HERNIA REPAIR",
      "term": null,
      "displaytext": "Hernia repair surgery with abdominal mesh  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERNIA REPAIR SURGERY\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Surgical prophylaxis is recommended for hernioplasty and herniorrhaphy.  For\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"patients known to be colonized with MRSA, add a single dose of vancomycin\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to the preferred agent (cefazolin).\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Antimicrobials are not indicated after incisions are closed.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preferred prophylaxis\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"For patients colonized with MRSA *ADD* Vancomycin in addition to cefazolin:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative for patient with beta lactam allergy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DVT Prophylaxis\", \"Text\": \"DVT prophylaxis orders\", \"Mnemonic\": \"3\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 3065, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 594,
    "fields": {
      "name": "ORZID2 GMENU SURG INTERVENTIONAL RADIOLOGY",
      "term": null,
      "displaytext": "Interventional Radiology ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"NEUROSURGERY\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy or IF MRSA concern:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Letter 2012 Vol 10 pages 73-77\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophy\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 3066, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 595,
    "fields": {
      "name": "ORZID2 GMENU SURG NEUROSURGERY",
      "term": null,
      "displaytext": "Neurosurgery ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"NEUROSURGERY\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Risk factors for postoperative infections following neurologic procedures\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"include diabetes, procedure duration longer than two to four hours, placement\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"of a foreign body, repeat surgery, emergency surgery, cerebrospinal fluid\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(CSF) leak, postoperative intracranial pressure monitoring or presence of a\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"ventricular drain for more than five days postoperatively, and concurrent or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"prior infection of an incision or shunt.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"In spinal surgery, the infection rate after conventional lumbar discectomy is\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"low, but due to the severe consequences of postoperative infection at this site\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antimicrobial prophylaxis is recommended. Infection rates are higher after\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"prolonged spinal surgery or spinal procedures involving fusion or insertion of\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"foreign material, and antimicrobial prophylaxis is also recommended.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is warranted for patients undergoing clean craniotomy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"CSF shunt procedures, or intrathecal pump placement.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"For all other neurosurgical procedures, antimicrobial prophylaxis is not\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"indicated.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Cefazolin is preferred for most patients as it penetrates into the cerebrospinal\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"fluid and is more active than vancomycin against susceptible staphylococci.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Vancomycin should be used when the patient is colonized or has been recently\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"infected with methicillin-resistant Staphylococcus aureus.  Consult Neurosurgery\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"or Infectious Diseases for more information.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy or IF MRSA concern:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Letter 2012 Vol 10 pages 73-77\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophy\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 3067, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 596,
    "fields": {
      "name": "ORZID2 GMENU SURG OPHTHALMIC SURG",
      "term": null,
      "displaytext": "Ophthalmic surgery ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 0.5% Eye Drops Cataract Surgery (Dose: 0.5mg/0.1ml)\", \"Text\": \"Moxifloxacin 0.5% Eye Drops INTRACAMERAL for Cataract Surgery (0.5mg/0.1ml)\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OPHTHALMIC SURGERY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"When indicated, ophthalmology will order antimicrobial prophylaxis before\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"procedures.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Cataract Surgery\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Intracameral moxifloxacin is recommended for use to reduce the risk of\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"post-operative endophthalmitis after cataract surgery only in those patients\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"at highest risk of infection, including the following:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"* Patients with prior intravitreal injections\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"* Immunosuppressed patients\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"* Patients with significant ocular surface eyelid disease\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"* Complication occurs during surgery (i.e. capusle rupture, vitreous loss)\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"* Other possible high risk situations as they arise but not listed above\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Arshinoff S., J Cataract Refract Surg, (2016) 42:1730-1741\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 597,
    "fields": {
      "name": "ORZID2 GMENU SURG ORTHO ALBC HIP AND KNEE JOINT INFECTIONS",
      "term": null,
      "displaytext": "Orthopedic surgery, ALBC for tx of periprosthetic hip/knee joint infections ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefuroxime and vancomycin ALBC order set\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Aztreonam and vancomycin ALBC order set\", \"Mnemonic\": \"6\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 3068, \"DisplayText\": \"Orthopedic ALBC protocol\", \"Text\": \"Select here for full protocol\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MVAHCS Protocol for Antibiotic Loaded Bone Cement (ALBC) for\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Treatment of Periprosthetic Hip and Knee Joint Infections\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Patient Classification:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"No beta-lactam allergy: gram-positive and/or non-pseudomonas\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"gram-negative infection\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Patient Classification:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Beta-lactam allergy, any infecting organism OR No beta-lactam allergy,\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"but with documented pseudomonas infection\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"MVAHCS Protocol for Use of Antibiotic Loaded Cement (ALBC) for Treatment of\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Periprosthetic Hip and Knee Joint Infections at The Minneapolis VA\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Medical Center, July 2017\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 598,
    "fields": {
      "name": "ORZID2 GMENU SURG ORTHO SURG JOINT ARTHRO",
      "term": null,
      "displaytext": "Orthopedic surgery, including joint arthroplasty ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"14\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"22\"}, {\"Row\": 78, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"26\"}, {\"Row\": 84, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"28\"}, {\"Row\": 92, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"30\"}, {\"Row\": 98, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"34\"}, {\"Row\": 104, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"36\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ORTHOPAEDIC SURGERY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is not recommended for most clean procedures,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"including knee, hand or foot procedures, arthroscopy, or other procedures\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"without implantation of foreign materials.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prophylaxis is indicated for joint replacement, internal fixation, or hip\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"fracture repair.  Open fractures should be treated as infected.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Cefazolin is preferred for prophylaxis, as it is more active than vancomycin\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"against susceptible staphylococci, the most common surgical pathogens.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Vancomycin should be used when methicillin-resistant Staphylococcus aureus\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"infection, in patients who are colonized or were recently infected with\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"methicillin-resistant Staphylococcus aureus.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Prophylaxis beyond 24 hours is not supported by current data and guidelines.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Longer durations provide no additional benefit and are associated with\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"side effects, increased costs, and bacterial resistance.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Also, there is no evidence of benefit of antimicrobial administration until\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"all drains or catheters are removed.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Clean operations involving hand, knee, or foot and NOT involving implantation\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"of foreign materials: (Select below)\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Prophylaxis for Total Joint Replacement\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q8h for 2 doses post-op. Please place\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Known MRSA colonization:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Prophylaxis for Hip Fracture Repair:\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q8h for 2 doses post-op. Please place\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Known MRSA colonization:\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Prophylaxis for Implantation of Internal Fixation Devices (e.g. nails, screws,\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"plates, wires):\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q8h for 2 doses post-op. Please place\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"Known MRSA colonization:\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 89, \"Column\": 1, \"Text\": \"Prophylaxis for Orthopedic Spinal Procedures with and without instrumentation\", \"Header\": 1}, {\"Row\": 90, \"Column\": 1, \"Text\": \"(e.g. rods, plates):\", \"Header\": 1}, {\"Row\": 91, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q8h for 2 doses post-op. Please place\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\"}, {\"Row\": 99, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 100, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 101, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"Known MRSA colonization:\"}, {\"Row\": 105, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 106, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order from orthopedic standing post-op orders\"}, {\"Row\": 107, \"Column\": 1, \"Text\": \"AFTER patient is admitted.\"}, {\"Row\": 109, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 110, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 111, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013, vol 70 pages 195-283\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 599,
    "fields": {
      "name": "ORZID2 GMENU SURG OTHER PROCEDURES",
      "term": null,
      "displaytext": "Other Procedures",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OTHER PROCEDURES\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In view of the small number of wound infections that would be prevented by\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"systemic antimicrobial prophylaxis the risks outweigh benefits for patients who\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"will have cardiac catheterization, varicose vein surgery, most dermatologic and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"plastic surgery, arterial puncture, thoracentesis, paracentesis, repair of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"simple lacerations, outpatient treatment of burns, dental extractions, or root\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"canal therapy.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 600,
    "fields": {
      "name": "ORZID2 GMENU SURG PLASTIC SURGERY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Text\": \"Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PLASTIC SURGERY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is not recommended for most clean procedures in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients without additional postoperative infection risk factors.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Risk factors that increase the risk of postoperative infectious complications\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"for plastic surgery procedures include implants, skin irradiation before the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"procedure, and procedures below the waist.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is recommended for clean-contaminated procedures,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"breast cancer procedures, and clean procedures with risk factors. A single\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"preoperative dose is recommended.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Clean with risk factors or clean-contaminated:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred Prophylaxis:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"($) [R]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Letter 2012 Vol 10 pages 73-77\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 601,
    "fields": {
      "name": "ORZID2 GMENU SURG PODIATRY",
      "term": null,
      "displaytext": "Podiatry Antimicrobial Surgical Prophylaxis Orders  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"[Select here] No antimicrobial prophylaxis recommended for procedure/surgery\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"8\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"12\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Letter 2012 Vol 10 pages 73-77\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Podiatry Surgery\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Known MRSA colonization:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": 618, \"DisplayText\": \"Surgical wound classification and antimicrobial prophylaxis...\", \"Text\": \"[Select here] Surgical wound classification and prophlaxis recommendations\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR PODIATRY ABX\", \"Text\": \"[Select here] No antimicrobial prophylaxis, already on concurrent antimicrobials\", \"Mnemonic\": \"7\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select appropriate order below:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 602,
    "fields": {
      "name": "ORZID2 GMENU SURG POST-OP WND INFECT",
      "term": null,
      "displaytext": "Post-operative wound infection ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 617, \"DisplayText\": \"Patients with signs of infection WITHIN 48 HOURS of procedure\", \"Text\": \"Patients with signs of infection WITHIN 48 HOURS of procedure\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 577, \"DisplayText\": \"Patients with signs of infection 48 HOURS OR MORE after procedure\", \"Text\": \"Patients with signs of infection 48 HOURS OR MORE after procedure\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"POST-OPERATIVE WOUND INFECTION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Surgical site infections are categorized by the extent of tissues involved.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Superficial incisional infections involve only the subcutaneous space and occur\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"within 30 days of operation.  Deep incisional infections involve deep layers of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"soft tissue, such as fascia and muscle, and occur within 30 days of operation,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"or within 1 year of operation if prosthetic material was inserted.  Organ/space\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"infections involve anatomical areas other than the incisional wound that were\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"opened or manipulated during operation.  Organ/space infections should be\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"treated as infections of the relevant area of the anatomy.  Return to the main\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"page and choose the pertinent organ system for advice on management of these\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"infections.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Post-operative wound infections usually occur between 2 and 30 days after the\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"operation.  Infections within 48 hours of the surgery are uncommon, but are\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"serious when they do occur.  Symptoms commonly begin to appear no sooner than 5\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"days after the operation and may take up to 2 weeks to appear.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 603,
    "fields": {
      "name": "ORZID2 GMENU SURG PROPHYL GENRL INFO",
      "term": null,
      "displaytext": "Surgical prophylaxis general information",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SURGICAL PROPHYLAXIS COMMON PRINCIPLES\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Potential pathogens are introduced into normally sterile areas of the body\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"during most surgical procedures.  The purpose of antimicrobial prophylaxis is to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"reduce the intraoperative microbial burden so that local host defenses can\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"eliminate microorganisms and prevent disease.  Prophylaxis cannot be expected to\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"sterilize tissues.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobial agent for surgical prophylaxis should be:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"1. active against the pathogens most likely to contaminate the surgical site\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"2. given in an appropriate dosage and at a time that ensures adequate serum\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"and tissue concentrations during the period of potential contamination\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"3. safe, and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"4. administered for the shortest effective period to minimize adverse\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"effects, the development of resistance, and costs.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Medical Letter 2012 Vol 10 pages 73-77\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 604,
    "fields": {
      "name": "ORZID2 GMENU SURG PROPHYLAXIS DOSES AND REDOSING",
      "term": null,
      "displaytext": "Doses and Redosing of prophylactic antibiotics",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"Recommended Doses and Redosing Interval\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Existing renal or hepatic dysfunction:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"for single dose, no modification usually necessary.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"ANTIMICROBIAL\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Ampicillin\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Ampicillin sulbactam\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Aztreonam\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Cefazolin\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Cefuroxime\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Cefoxitin\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Cefotetan\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Ceftriaxone\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Ciprofloxacin\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Clindamycin\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Gentamicin\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Levofloxacin\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Metronidazole\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Piperacilln Tazobactam\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Vancomycin\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Am J Health-Syst Pharm. 2013, 70: 195-283\", \"Header\": 1}, {\"Row\": 33, \"Column\": 2, \"Item\": 590, \"DisplayText\": \"Gentamicin 5mg/kg Weight Based Dosing Preop\", \"Text\": \"Select for Gentamicin doses\", \"Mnemonic\": \"2\"}, {\"Row\": 42, \"Column\": 2, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Select for Vancomycin doses\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"RECOMMENDED DOSE\", \"Header\": 1}, {\"Row\": 11, \"Column\": 2, \"Text\": \"2  grams\", \"Header\": 1}, {\"Row\": 13, \"Column\": 2, \"Text\": \"3  grams\", \"Header\": 1}, {\"Row\": 15, \"Column\": 2, \"Text\": \"2  grams\", \"Header\": 1}, {\"Row\": 17, \"Column\": 2, \"Text\": \"2  grams\", \"Header\": 1}, {\"Row\": 18, \"Column\": 2, \"Text\": \"Recommend 3gm dose patients >=120kg\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"1.5grams\", \"Header\": 1}, {\"Row\": 22, \"Column\": 2, \"Text\": \"2  grams\", \"Header\": 1}, {\"Row\": 24, \"Column\": 2, \"Text\": \"2  grams\", \"Header\": 1}, {\"Row\": 26, \"Column\": 2, \"Text\": \"2  grams\", \"Header\": 1}, {\"Row\": 28, \"Column\": 2, \"Text\": \"400mg\", \"Header\": 1}, {\"Row\": 30, \"Column\": 2, \"Text\": \"900mg\", \"Header\": 1}, {\"Row\": 32, \"Column\": 2, \"Text\": \"5mg/kg based on dosing wt*\", \"Header\": 1}, {\"Row\": 35, \"Column\": 2, \"Text\": \"500mg\", \"Header\": 1}, {\"Row\": 37, \"Column\": 2, \"Text\": \"500mg\", \"Header\": 1}, {\"Row\": 39, \"Column\": 2, \"Text\": \"3.375 grams\", \"Header\": 1}, {\"Row\": 41, \"Column\": 2, \"Text\": \"15mg/kg based on dosing wt\", \"Header\": 1}, {\"Row\": 45, \"Column\": 2, \"Text\": \"Doses based on Dosing Weight (DW)*\", \"Header\": 1}, {\"Row\": 46, \"Column\": 2, \"Text\": \"*Calculate Dosing Weight (DW)\", \"Header\": 1}, {\"Row\": 47, \"Column\": 2, \"Text\": \"DW = IBW + 0.4 (ABW - IBW)\", \"Header\": 1}, {\"Row\": 48, \"Column\": 2, \"Text\": \"IBW=Ideal Body Wt  ABW=Actual Body Wt\", \"Header\": 1}, {\"Row\": 49, \"Column\": 2, \"Text\": \"Male IBW (kg)=50+2.3 * (Ht-60inches)\", \"Header\": 1}, {\"Row\": 50, \"Column\": 2, \"Text\": \"Female IBW (kg)=45.5+2.3 * (Ht-60inches)\", \"Header\": 1}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Antimicrobial Surgical Prophylaxis\", \"Header\": 1}, {\"Row\": 9, \"Column\": 3, \"Text\": \"REDOSING INTERVAL**\", \"Header\": 1}, {\"Row\": 10, \"Column\": 3, \"Text\": \"(from initiation of preop dose)\", \"Header\": 1}, {\"Row\": 11, \"Column\": 3, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 13, \"Column\": 3, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 15, \"Column\": 3, \"Text\": \"4 hours\", \"Header\": 1}, {\"Row\": 17, \"Column\": 3, \"Text\": \"4 hours\", \"Header\": 1}, {\"Row\": 20, \"Column\": 3, \"Text\": \"4 hours\", \"Header\": 1}, {\"Row\": 22, \"Column\": 3, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 24, \"Column\": 3, \"Text\": \"6 hours\", \"Header\": 1}, {\"Row\": 26, \"Column\": 3, \"Text\": \"N/A\", \"Header\": 1}, {\"Row\": 28, \"Column\": 3, \"Text\": \"Do not redose\", \"Header\": 1}, {\"Row\": 30, \"Column\": 3, \"Text\": \"6 hours\", \"Header\": 1}, {\"Row\": 35, \"Column\": 3, \"Text\": \"Do not redose\", \"Header\": 1}, {\"Row\": 37, \"Column\": 3, \"Text\": \"12 hours\", \"Header\": 1}, {\"Row\": 39, \"Column\": 3, \"Text\": \"2 hours\", \"Header\": 1}, {\"Row\": 41, \"Column\": 3, \"Text\": \"12 hours\", \"Header\": 1}, {\"Row\": 43, \"Column\": 3, \"Text\": \"**For those marked N/A--\", \"Header\": 1}, {\"Row\": 44, \"Column\": 3, \"Text\": \"based on typical case length, for\", \"Header\": 1}, {\"Row\": 45, \"Column\": 3, \"Text\": \"unusually long procedures,\", \"Header\": 1}, {\"Row\": 46, \"Column\": 3, \"Text\": \"redosing may be needed.\", \"Header\": 1}, {\"Row\": 32, \"Column\": 3, \"Text\": \"Do not redose\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"**For those marked N/A -\", \"Header\": 1}, {\"Row\": 5, \"Column\": 3, \"Text\": \"based on typical case length, for\", \"Header\": 1}, {\"Row\": 6, \"Column\": 3, \"Text\": \"unusually long procedures,\", \"Header\": 1}, {\"Row\": 7, \"Column\": 3, \"Text\": \"redosing may be needed.\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"John Hopkins Antibiotic Guide Online Oct2021\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 605,
    "fields": {
      "name": "ORZID2 GMENU SURG SPINAL CORD STIMULATOR TRIAL",
      "term": null,
      "displaytext": "Spinal Cord Stimulator Trial Procedure Antimicrobial Prophylaxis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 GM IVPB Once administer 60 minutes prior to procedure ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Preferred Prophylaxis:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for patient with beta lactam allergy:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Medical Letter 2012 vol 10 pages 73-77\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"For patients weight < 120 kg:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For patients weight >/= 120 kg:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pain Clinic Antimicrobial Prophylaxis Pre-procedure Orders\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Spinal Cord Stimulator Trial\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 3 GM IVPB Once administer 60 minutes prior to procedure  ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin Weight Based Dosing IVPB x1 Dose\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"10\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"ADD Vancomycin with Cefazolin (above) for MRSA positive nares + risk factors\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin Weight Based Dosing IVPB x1 Dose\", \"Mnemonic\": \"14\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"MRSA positive nares + risk factors:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 606,
    "fields": {
      "name": "ORZID2 GMENU SURG SURGICAL SITE INFECT",
      "term": null,
      "displaytext": "Surgical Site Infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 602, \"DisplayText\": \"Post-operative wound infection\", \"Text\": \"Post-operative wound infection\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 205, \"DisplayText\": \"Mediastinitis\", \"Text\": \"Mediastinitis\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatologic Infections\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  SURGICAL SITE INFECTION  ++\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"++SURGICAL PROPHYLAXIS FOR DERMATOLGY/POST-OP SKIN INFECTION++\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 607,
    "fields": {
      "name": "ORZID2 GMENU SURG THORACIC POSTOP",
      "term": null,
      "displaytext": "THORACIC POSTOPERATIVE PROPHYLAXIS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 583, \"DisplayText\": \"CIED Post Op\", \"Text\": \"CIED Surgery Postoperative Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 586, \"DisplayText\": \"CV POSTOPERATIVE PROPHYLAXIS\", \"Text\": \"CV Surgery Postoperative Prophylaxis\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2gm IVPB Metronidazole 500mg IV 2 doses post op\", \"Text\": \"Cefazolin 2 gm IV q8h x 2 doses post-op ($) [R] <AND> metronidazole 500 mg IV\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg IV q8h x2doses postop\", \"Text\": \"Clindamycin 900 mg IV q8h x 2 doses post-op ($$)\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE\", \"Text\": \"Vancomycin 15 mg/kg IV (pharmacy to dose) q12h x 1 dose post-op ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"THORACIC SURGERY POST-OPERATIVE ANTIMICROBIAL PROPHYLAXIS RECOMMENDATIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Place post-op IV antimicrobial prophylaxis orders after admission to ward.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Duration of antimicrobial prophylaxis should not exceed 24 hours. Durations\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"longer than 24 hours have not been shown effective in preventing cardiothoracic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"surgical site infections. There is no benefit to continuing antimicrobial\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"prophylaxis until all indwelling drains and intravascular catheters are removed.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For CIED surgery postoperative antimicrobial prophylaxis click link below:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"For CV surgery (Open Heart) postoperative prophylaxis click link below:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Esophageal Surgical Procedures Postoperative Prophylaxis\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"q8h x 2 doses post-op ($) [R]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative for patient with cephalosporin allergy\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative for patient colonized or recently infected with MRSA\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Non-Esophageal Thoracic Procedures Postoperative Prophylaxis\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Includes video-assisted thoracoscopic surgery (VATS) and non-cardiac procedures\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"including lobectomy, pneumonectomy, lung resection and thoracotomy.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"No postoperative antibiotic prophylaxis is recommended\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Bratzler DW et al, Clinical Practice Guidelines for Antimicrobial Prophylaxis in\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Surgery, Am J Health-Syst Pharm (2013) 70:195-283\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 608,
    "fields": {
      "name": "ORZID2 GMENU SURG THORACIC SURGERY",
      "term": null,
      "displaytext": "Thoracic surgery",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin weight based dosing Preop + Metronidazole 500mg IV ONCE Preop\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"THORACIC SURGERY (INCLUDES SECTION ON ESOPHAGEAL PROCEDURES)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Esophageal Surgical Procedures:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Prophylaxis:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prophylaxis recommendations includes BOTH MEDICATIONS q8h for 2 doses post-op.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Please place post-op antimicrobial prophylaxis orders after admission.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"($) [H,O]\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q8h for 2 doses post-op.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Please place post-op antimicrobial prophylaxis order after admission.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"___________________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Thoracic surgery (except for esophageal procedures):\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Includes video-assisted thoracoscopic surgery (VATS) and non-cardiac procedures,\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"including lobectomy, pneumonectomy, lung resection and thoracotomy.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"No post-operative doses are recommended.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Prophylaxis\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"($) [H,O]\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative for patient colonized or recently infected with MRSA\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Letter 2012 Vol 10 pages 73-77\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"beginning 60 minutes before incision\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 609,
    "fields": {
      "name": "ORZID2 GMENU SURG TIMING DOSING PROPHYL ABX",
      "term": null,
      "displaytext": "Timing and dosing (including re-dosing) of prophylatic antimicrobials ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 604, \"DisplayText\": \"Doses and Redosing of prophylactic antibiotics\", \"Text\": \"Doses and Redosing Recommendations for Common Antimicrobials\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TIMING AND DOSING (INCLUDING RE-DOSING) OF PROPHYLACTIC ANTIMICROBIALS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For optimal prevention, antimicrobial concentrations should be above the minimal\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"inhibitory concentration (MIC) of potential pathogens from initial incision\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"until closure.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"There is no advantage to giving post-operative doses. Despite a lack of\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"demonstrated benefit, post-operative doses are sometimes given in clinical\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"practice.  If post-operative doses are given, they should be discontinued by 24\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"hours after closure of the incision.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"When prophylaxis consists of a single dose as should be the case in the majority\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"of procedures, adjustment for renal or hepatic dysfunction is not necessary.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"The optimal time for administration of preoperative doses is 30 to\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"60 minutes before surgical incision for most antimicrobials.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Infusions of drugs like fluoroquinolones and vancomycin that require longer\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infusion times should begin 60 to 120 minutes before first incision.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"During procedures that last so long that concentrations might fall below the\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"MICs of potential pathogens, repeated doses of antimicrobials should be given.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Re-dosing may also be warranted if prolonged or excessive bleeding\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"occurs.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter 2012 Vol 10 pages 73-77\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 610,
    "fields": {
      "name": "ORZID2 GMENU SURG UROLOGICAL PROCED",
      "term": null,
      "displaytext": "Urological procedures ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 3069, \"DisplayText\": \"<Click here> AUA Surgery Abx Prophylaxis Guidelines\", \"Text\": \"<Hyperlink> AUA Surgical Prophylaxis Guidelines\", \"Mnemonic\": \"4\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 MG po Q12H ($) [R,O]-INPATIENT ORDER\", \"Mnemonic\": \"6\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 7DS 100 MG PO BID\", \"Text\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]-OUTPATIENT ORDER\", \"Mnemonic\": \"8\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg po q12h (Var)\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]-INPATIENT ORDER\", \"Mnemonic\": \"14\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]-OUTPATIENT ORDER**ADJUST QUANTITY**\", \"Mnemonic\": \"16\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 100, \"DisplayText\": \"Candida urinary tract infection\", \"Text\": \"Candida urinary tract infection- INPATIENT\", \"Mnemonic\": \"18\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 641, \"DisplayText\": \"Candida Urinary Tract Infections\", \"Text\": \"Candida urinary tract infection- OUTPATIENT\", \"Mnemonic\": \"20\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"22\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 998, \"DisplayText\": \"\", \"Text\": \"Link to prophylaxis for TRUSP procedure\", \"Mnemonic\": \"26\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 613, \"DisplayText\": \"\", \"Text\": \"Link to Urology Surgery Antimicrobial Prophylaxis (OPEN,ROBOTIC,LAP)\", \"Mnemonic\": \"28\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"30\"}, {\"Row\": 74, \"Column\": 1, \"Item\": 590, \"DisplayText\": \"Gentamicin 5mg/kg Weight Based Dosing Preop\", \"Text\": \"Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure\", \"Mnemonic\": \"32\"}, {\"Row\": 80, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"34\"}, {\"Row\": 82, \"Column\": 1, \"Item\": 590, \"DisplayText\": \"Gentamicin 5mg/kg Weight Based Dosing Preop\", \"Text\": \"Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure\", \"Mnemonic\": \"36\"}, {\"Row\": 88, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"38\"}, {\"Row\": 90, \"Column\": 1, \"Item\": 590, \"DisplayText\": \"Gentamicin 5mg/kg Weight Based Dosing Preop\", \"Text\": \"Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure\", \"Mnemonic\": \"40\"}, {\"Row\": 96, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"42\"}, {\"Row\": 98, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure\", \"Mnemonic\": \"44\"}, {\"Row\": 104, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"46\"}, {\"Row\": 106, \"Column\": 1, \"Item\": 590, \"DisplayText\": \"Gentamicin 5mg/kg Weight Based Dosing Preop\", \"Text\": \"Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure\", \"Mnemonic\": \"48\"}, {\"Row\": 112, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"50\"}, {\"Row\": 114, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision\", \"Mnemonic\": \"52\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"UROLOGICAL PROCEDURES\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Though uncommon, most post-operative infections after urological surgery occur\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"when 1) a procedure is done in a person with significant bacteriuria and the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"urinary mucosa is cut, 2) fecal flora enter tissues when the colon or rectal\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"mucosa is cut, or 3) skin flora enter tissues when the skin is cut.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is given to prevent symptomatic infection after\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"procedures with these characteristics.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Patient-related factors affecting host response to surgical infections\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"In situations when the risk benefit ratio supporting antimicrobial\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"prophylaxis is not clear, certain risk factors may tip the balance in favor\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"of prophylaxis. These risk factors include:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Advanced age: Anatomic anomalies of the urinary tract:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Smoking: Chronic corticosteroid use: Immunodeficiency:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Externalized catheters: Colonized endogenous - exogenous material:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Distant coexistent infection: Prolonged hospitalization\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"When surgical prophylaxis is recommended, a single dose of the appropriate\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"antibiotic should be administered prior to the urological procedure\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"UNLESS otherwise noted.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"The recommended antimicrobial prophylaxis is based on the incision site.  An\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"antimicrobial active against pathogens likely to be present at the site and\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"to cause post-operative wound infection is needed.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Recommendations are based on AUA guidelines\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Obtain urine culture for invasive or complex urological procedures:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For invasive or complex urological procedures, whenever possible,\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"please obtain an urine culture a few days before the procedure.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"If bacteriuria or fungiuria is present, select an antimicrobial that will be\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"be effective against organisms that have been isolated.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"If prosthetic material is to be placed, test of cure recommended.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment of bacteriuria before procedures in which urinary mucosa will be cut\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treat for 3 to 7 days.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"If known susceptibility to a fluoroquinolone:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Treatment of funguria before procedures in which urinary mucosa will be cut\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Prevention of Prosthetic Joint Infection Before Genitourinary Procedures\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Recommended prophylaxis TRUSP (transrectal ultrasound biopsy prostate)\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Recommended antimicrobial prophylaxis for Urology Surgery (Open,Robotic,Lap)\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Recommended antimicrobial prophylaxis for Lower Tract Instrumentation\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Procedure: Removal of external urinary catheter\", \"Header\": 1}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Prophylaxis indicated for patients with higher risk of developing urinary\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"retention, such as BPH, or neurogenic bladder.\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Also could be considered if risk factors.\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"($) [R,O]\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Procedure: Cystography, urodynamic study, or simple cystourethrosocpy\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Prophylaxis not usually indicated, could consider if risk factors.\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Alternative for patients with beta lactam allergy:\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"($) [R,O]\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Procedure: Cystourethroscopy with manipulation OR Ureteroscopy\", \"Header\": 1}, {\"Row\": 86, \"Column\": 1, \"Text\": \"Prophylaxis indicated for all procedures.\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 89, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy:\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"($) [R,O]\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Procedure: Prostate brachytherapy or cyrotherapy\", \"Header\": 1}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Prophylaxis indicated uncertain, assess individual case.\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy:\"}, {\"Row\": 99, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 101, \"Column\": 1, \"Text\": \"Procedure: Shock-wave lithotripsy\", \"Header\": 1}, {\"Row\": 102, \"Column\": 1, \"Text\": \"Prophylaxis indicated IF risk factors.\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 105, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy:\"}, {\"Row\": 107, \"Column\": 1, \"Text\": \"($) [R,O]\"}, {\"Row\": 109, \"Column\": 1, \"Text\": \"Procedure: Percutaneous renal surgery\", \"Header\": 1}, {\"Row\": 110, \"Column\": 1, \"Text\": \"Prophylaxis indicated for all procedures.\"}, {\"Row\": 111, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 113, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy:\"}, {\"Row\": 115, \"Column\": 1, \"Text\": \"($) [H,O] <AND> Gentamicin 5 mg/kg IV over 30 minutes beginning 60\"}, {\"Row\": 116, \"Column\": 1, \"Text\": \"minutes before incision ($) [R,O]\"}, {\"Row\": 118, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 119, \"Column\": 1, \"Text\": \"Lightner DJ, et al. Best Practice Statement on Urologic Procedures\"}, {\"Row\": 120, \"Column\": 1, \"Text\": \"and Antimicrobial Prophylaxis, The Journal of Urology (2019)\"}, {\"Row\": 122, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 123, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"24\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R]\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R] -INPATIENT ORDER\", \"Mnemonic\": \"10\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Cefadroxil 1000 mg PO BID ($) [R] -OUTPATIENT ORDER**ADJUST QUANTITY**\", \"Mnemonic\": \"12\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 611,
    "fields": {
      "name": "ORZID2 GMENU SURG UROLOGY POSTOP",
      "term": null,
      "displaytext": "Urology Postop  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 614, \"DisplayText\": \"Vancomycin 15mg/kg Dosing q12h x1 dose postop\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative for beta lactam allergy:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 582, \"DisplayText\": \"Cefazolin Weight Based Dosing q8h x2 doses postop\", \"Mnemonic\": \"6\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophy\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 3070, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Urological procedures postop antimicrobial prophylaxis:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"*Postoperative antimicrobial administration for preventing SSI is not\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"necessary for most procedures.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Lightner DJ, et al. Best Practice Statement on Urologic Procedures\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"and Antimicrobial Prophylaxis, J Urol (2020) 203:351\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500mg PO qid X5 days postop urology procedure ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sulfa/Trimeth 1 DS tablet PO q12h X5 days postop urology procedure ($) [R,DI]\", \"Mnemonic\": \"20\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 1 capsule q12h X5 days postop urology procedure ($) [R,O]\", \"Mnemonic\": \"22\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Prophylaxis may be recommended in limited cases due to the severity of\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"complications of postoperative infection (e.g., an infected device that is\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"not easily removable).\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"<Click here> AUA Surgery Abx Prophylaxis Guidelines\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"INPATIENT Postop Oral Medications:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"*Prophylactic antibiotics should be discontinued within 24 hours.\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500mg PO q6h X1 day postop urology ($) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sulfa/Trimeth DS 1 tablet po q12h X1 day postop urology procedure ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 1 capsule q12h X1 day postop urology procedure ($) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"OUTPATIENT POSTOP PRESCRIPTION ORDERS:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"INPATIENT Postop IV medications:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"MVAHCS Urology Section (July 2023)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 612,
    "fields": {
      "name": "ORZID2 GMENU SURG UROLOGY PREOP",
      "term": null,
      "displaytext": "Urological procedures antimicrobial prophylaxis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3071, \"DisplayText\": \"<Click here> AUA Surgery Abx Prophylaxis Guidelines\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended order\", \"Mnemonic\": \"6\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 998, \"DisplayText\": \"\", \"Text\": \"Link to outpatient menu\", \"Mnemonic\": \"42\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Lightner DJ, et al. Best Practice Statement on Urologic Procedures\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"and Antimicrobial Prophylaxis, The Journal of Urology (2019)\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"TRUSP Biopsy:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Implants:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Endoscopic procedures:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"If no prophylaxis recommended, enter order:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Urological Procedures\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Open/Robotic procedures:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"24\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Mnemonic\": \"14\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"**Additional single agents:\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 590, \"DisplayText\": \"Gentamicin 5mg/kg Weight Based Dosing Preop\", \"Mnemonic\": \"16\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin Weight Based IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Mnemonic\": \"34\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15mg/kg IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Mnemonic\": \"38\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative for cephalosporin allergy:\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2gram IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Mnemonic\": \"10\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400mg IV ONCE Preop\", \"Mnemonic\": \"18\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg IV ONCE Preop\", \"Mnemonic\": \"22\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Soak Solution for Penile Implant prior to implantation in OR\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penile Implant Soak (Gentamicin 50MG and Rifampin 500MG) prior to implantation\", \"Mnemonic\": \"40\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefoxitin 2 gram IV ONCE Preop\", \"Mnemonic\": \"30\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Cystectomy/large bowel/vaginal procedures:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"12\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for allergy to penicillin/cephalosporin:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Alternative for cephalosporin allergy:\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"36\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg po x1 give in clinic\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefoxitin 2 gram IV ONCE AND Metronidazole 500 mg IV ONCE Preop\", \"Mnemonic\": \"32\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Single-dose antimicrobial prophylaxis is appropriate in the majority of\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"uncomplicated urologic cases.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Select alternative from Endoscopic procedures above\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Mnemonic\": \"26\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 613,
    "fields": {
      "name": "ORZID2 GMENU SURG UROLOGY SURGERY (OPEN,ROBOTIC,LAP)",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophlaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure\", \"Mnemonic\": \"12\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin Weight Based IV ONCE AND Gentamicin 5mg/kg IV ONCE Preop\", \"Mnemonic\": \"14\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penile Implant Soak (Gentamicin 50MG and Rifampin 500MG) prior to implantation\", \"Text\": \"Penile Implant Soak (Gentamicin 50MG and Rifampin 500MG) prior to implantation\", \"Mnemonic\": \"18\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 585, \"DisplayText\": \"Bowel/Colo-rectal Surgery\", \"Text\": \"Link to Bowel Surgery\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Urology Surgery Open, Robotic or Laparoscopic\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Surgery through skin without opening urinary tract\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prophylaxis indicated IF risk factors.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Vaginal surgery includes urethral sling procedures\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Prophylaxis indicated for all surgeries.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"($$) [H,O]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Surgery involving implanted prosthesis including penile prosthesis\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Prophylaxis indicated for all surgeries.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy or history of MRSA:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< AND > gentamicin 5mg/kg ($) [R,O] over 30 minutes beginning 60\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"minutes before incision\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Soak Solution for Penile Implant prior to implantation in OR\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Urologic surgery with entry into bowel/intestines\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"(Note: updated order 7/2022 per OR pharmacist DM)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 614,
    "fields": {
      "name": "ORZID2 GMENU SURG VANCOMYCIN POST-OP SPECIFIC DOSING",
      "term": null,
      "displaytext": "Vancomycin 15mg/kg Dosing q12h x1 dose postop ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Text\": \"Recommended Vancomycin Dose based on patient weight:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 1000 mg IV q12h x1 dose Postop\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 1500 mg IV q12h x1 dose Postop\", \"Mnemonic\": \"12\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 2000 mg IV q12h x1 dose Postop\", \"Mnemonic\": \"14\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vancomycin:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Postoperative antimicrobial administration for preventing SSI is not\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"necessary for most procedures. The duration of antimicrobial prophylaxis\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"should be less than 24 hours.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Weight <70 kg:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Weight 70-100 kg:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Weight >100 kg:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Alternative for allergy to penicillin/cephalosporins and/or MRSA positive:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"<Click here> Display last recorderd patient weight (limited 2 years)\", \"Mnemonic\": \"8\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Vancomycin Postop dose:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 615,
    "fields": {
      "name": "ORZID2 GMENU SURG VANCOMYCIN WEIGHT BASED DOSING",
      "term": null,
      "displaytext": "Vancomycin Weight Based Dosing Preop ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 1000 mg IV ONCE\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 1500 mg IV ONCE\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 2000 mg IV ONCE\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Recommended Vancomycin Preop Dose based on patient weight:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Weight <70 kg:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Weight >100 kg:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Preop dose administer beginning 120 minutes before incision:\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"<Click here> Display last recorderd patient weight (limited 2 years)\", \"Text\": \"<Click here> Display patients last recorded weight\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Weight 70-100 kg:\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Text\": \"VANCOMYCIN:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 616,
    "fields": {
      "name": "ORZID2 GMENU SURG VASCULAR SURG",
      "term": null,
      "displaytext": "Vascular surgery",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NURSE GENERIC ORDER FOR ABX\", \"Text\": \"*No antimicrobial prophylaxis recommended\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 900mg iv once\", \"Text\": \"Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision\", \"Mnemonic\": \"8\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 615, \"DisplayText\": \"Vancomycin Weight Based Dosing Preop\", \"Text\": \"Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rifampin 600 mg & Sterile Water VIALS for Vascular Surgery for Vascular Surgery\", \"Text\": \"Rifampin Vascular Graft Soak (600mg)\", \"Mnemonic\": \"16\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"VASCULAR SURGERY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is not recommended for some procedures, including\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"brachiocephalic procedures (e.g., carotid endarterectomy, brachial artery\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"repair) without implantation of prosthetic material.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is recommended in vascular procedures that involve\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"implantation of prosthetic material and procedures for which there is greater\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"risk of infection, such as aneurysm repair, thromboendarterectomy and vein\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"bypass. Longer duration of antimicrobial prophylaxis therapy is warranted for\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"graft placement.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Prophylaxis for vascular procedures OTHER THAN graft placement* and procedures\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"involving the groin** (SEE BELOW FOR * AND **):\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"($$) [R]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"*Prophylaxis for graft placement procedures:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis orders.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Alternative for beta lactam allergy or MRSA concern:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q12h for 1 dose post-op. Please place\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"post-op antimicrobial prophylaxis order.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Rifampin vascular graft soak for INFECTED graft\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"**Prophylaxis for procedures that involve the abdominal aorta or groin incision\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"due to the potential for gastrointestinal flora:\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Alternative for beta lactam allergy or MRSA concern:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"<AND> gentamicin 5 mg/kg IV over 30 minutes ($) [R,O] beginning 60\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"minutes before incision\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial prophylaxis\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Medical Letter 2012 vol 10 pages 73-77\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 581, \"DisplayText\": \"Cefazolin Weight Based Dosing Preop\", \"Mnemonic\": \"18\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Prophylaxis recommendation includes q8h for 2 doses post-op. Please place\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 617,
    "fields": {
      "name": "ORZID2 GMENU SURG W/I 48HRS PROCEDURE",
      "term": null,
      "displaytext": "Patients with signs of infection WITHIN 48 HOURS of procedure",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 496, \"DisplayText\": \"Necrotizing infections\", \"Text\": \"Necrotizing infections\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PATIENTS WITH SIGNS OF INFECTION WITHIN 48 HOURS OF PROCEDURE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Fever within 48 hours of procedure is usually due to anesthesia or other non-\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infectious factors but Clostridium species and Streptococcus pyogenes can cause\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"early infections.  Examine the wound of any patient with systemic signs of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"infection, like fever, within 48 hours of surgery.  If there are signs of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infection consider opening the wound.  Obtain a STAT Gram stain and culture of\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"any drainage. If the Gram stain shows evidence of streptococci or clostridia\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"refer to the section on necrotizing infections.  If signs of wound infection are\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"absent seek an alternative source of the fever.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 618,
    "fields": {
      "name": "ORZID2 GMENU SURG WND CLASS PROPHYL REC",
      "term": null,
      "displaytext": "Surgical wound classification and antimicrobial prophylaxis...  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SURGICAL WOUND CLASSIFICATION AND ANTIMICROBIAL PROPHYLAXIS RECOMMENDATIONS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \">>  Clean  <<\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"A wound resulting from a procedure in which no inflammation or infection was\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"encountered and the respiratory, alimentary, genital, or uninfected urinary\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"tract was not entered.  Clean wounds are closed at the end of surgery and if\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"drainage is necessary wounds are closed with drains in place.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is usually not indicated.  Exceptions are procedures\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"in which prosthetic material will be inserted or for operations in which a\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"surgical site infection would be catastrophic.  These exceptions include most\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"cardiac operations, joint replacement, revascularization procedures in legs, and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"most neurosurgical operations.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \">>  Clean contaminated  <<\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Clean-contaminated wounds are those in which the respiratory, alimentary,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"genital, or urinary tracts are entered but there is no evidence of infection and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"there is no major break in technique.  These include operations on the biliary\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"tract, appendix, vagina, and oropharynx.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is indicated for most of these procedures.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \">>  Contaminated  <<\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Contaminated wounds include an open, fresh, accidental wound, or operations with\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"major breaks in sterile technique, gross spillage from the gastrointestinal\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"tract, or incisions in which acute, non-purulent inflammation is encountered.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Antimicrobials are therapeutic and not prophylactic.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \">>  Dirty-Infected  <<\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Dirty-infected wounds are old traumatic wounds with devitalized tissue and those\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"that involve existing infection or perforated viscera.  The organisms usually\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"have been present in the operative field since before the operation.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Antimicrobials are therapeutic and not prophylactic.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Bratzler DW, et al.  Clinical practice guidelines for antimicrobial\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Medical Letter 2012 Vol 10 pages 73-77\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 619,
    "fields": {
      "name": "ORZID2 GMENU TEST",
      "term": null,
      "displaytext": "TESTING",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"TEST1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 620,
    "fields": {
      "name": "ORZID2 GMENU TINEA CAPITIS (RINGWORM)",
      "term": null,
      "displaytext": "Tinea Capitis (Ringworm) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250mg po qday\", \"Text\": \"Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"TINEA CAPITIS (RINGWORM)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Tinea capitis is a common fungal infection of the scalp and hair. It is\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"characterized by itchy, red, raised, scaly patches often sharply defined. The\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"redder margins than centers create impression of ring. Tinea capitis primarily\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"affects prepubescent children, but can affect people of any age.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat for 4 weeks.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 621,
    "fields": {
      "name": "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)",
      "term": null,
      "displaytext": "Tinea Pedis (Athlete's Foot), Tinea Coporis, or Tinea Cruris ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical bid\", \"Text\": \"Clotrimazole 1% cream apply to affected area BID ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 1% cream topical bid\", \"Text\": \"Terbinafine 1% cream apply to affected area BID ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg po qweek\", \"Text\": \"Fluconazole 150mg q week x 2-6 weeks ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250mg po qday\", \"Text\": \"Terbinafine 250 mg PO QDAY x 2 weeks ($) [R,H,DI,O]\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Dermatophyte (tinea) Infections\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TINEA PEDIS (ATHLETE'S FOOT), TINEA CORPORIS, TINEA MANUUM, OR TINEA CRURIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Dermatophyte fungal infections are common worldwide. Dermatophytes\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"metabolize and subsist upon keratin in the skin, hair, and nails.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Most tinea infections can often be cured with topical therapy alone.  Systemic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"therapy is reserved for severe or refractory infection, recurrent infection, or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in immunocompromised patients.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treat for 4 weeks\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Systemic treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 622,
    "fields": {
      "name": "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)",
      "term": null,
      "displaytext": "Tinea Unguium (Onychomycosis)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250mg po qday\", \"Text\": \"Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TINEA UNGUIUM (ONYCHOMYCOSIS)\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treat fingernail infections for 6 weeks\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Gupta AK, et al. Br J Dermatol 2020 182(2): 287-299\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Up-to-date website: Onychomycosis Management\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treat toenail infections for 12 weeks\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative oral therapy:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Preferred Terbinafine first-line oral:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treat fingernail infections for 3 months\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Treat toenail infections for 6 months\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 300 mg PO q week for fungal nail infection ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Topical Treatment:\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Ciclopirox is a topical first-line treatment for both fingernails and toenails\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Complete resolution occurs in approximately 7 percent of patients treated\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"daily for 48 weeks.  Ciclopirox is a well-tolerated treatment. Potential side\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"effects include temporary nail changes and local skin irritation.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"See accompanying medication pamphlet for specific instructions.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Treatment is continued until nail clearance or up to 48 weeks.\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciclopirox 8% nail lacquer: Apply once daily to affected nail(s)\", \"Mnemonic\": \"8\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Remove with rubbing alcohol every 7 days. ($) [M]\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Onychomycosis is a fungal infection of the nail that presents with yellow,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"thick, or crumbling nails. Obtain a fungal stain of nail sample prior to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"initiating treatment. Using large nail clippers, remove as much of the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"unattached dystrophic nail as possible. Place the piece of clipped nail plate\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in formalin jar and send to pathology for fungal stain (PAS). Treatment should\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"only be initiated if stain is positive for fungal elements. Fungal culture is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"NOT recommended.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cure is unlikely if the entire nail is involved, or if a portion of the lunula\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"is involved. Sometimes after treatment the fungus is cured, but the nail\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"still does not appear normal because once nail dystrophy occurs, that\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"is not reversible.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Systemic therapy is most likely to achieve a cure, especially with more nail\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"involvement. If <25% involvement topical therapy may be considered. If\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \">50-75% involvement systemic therapy should be considered.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Terbinafine works about 70% of the time to cure the fungus, and reinfection\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"is common, so many patients will need to do more than one course\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"of treatment.  Fluconazole pulse dosing response rate is approximately 50%.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"May consider retreatment with oral therapy after one year.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Recommend Dermatology Consult for retreatment after failure of 2 courses of\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"terbinafine or fluconazole.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Oral Treatment:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Toenails take 12-18 months to grow out completely, so improvement should not\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"be expected to be observed for at least 6-9 months.  Continued improvement can\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"be experienced following treatment completion.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 623,
    "fields": {
      "name": "ORZID2 GMENU TINEA VERSICOLOR",
      "term": null,
      "displaytext": "Tinea Versicolor",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ketoconazole 2% cream topical qday\", \"Text\": \"Ketoconazole 2% cream to affected area QDAY for 14 days ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 1% cream topical qday\", \"Text\": \"Terbinafine 1% cream apply to affected area QDAY for 7 days ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Selenium sulfide lotion 2.5% to affected area for 10 minutes\", \"Text\": \"Selenium sulfide lotion 2.5% apply to affected area, leave on for 10\", \"Mnemonic\": \"8\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 300 MG PO weekly for 2 weeks ($) [R,DI]\", \"Text\": \"Fluconazole 300 MG PO weekly for 2 weeks ($) [R,DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"TINEA VERSICOLOR\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pityriasis or tinea versicolor is a common superficial fungal infection.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients often present with erythematous, hypo- or hyperpigmented patches,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually on the trunk or extremities.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Topical antifungals can be used for limited disease.  For disease that involves\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"nails or does not respond to topical therapy, use oral antifungals.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Oily skin products or exposure to hot environments often lead to recurrences.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Return of normal skin color often takes several weeks after the treatment\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"course is finished.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment limited disease:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"minutes, then rinse/shower thoroughly QDAY for 7 days ($) [M]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment extensive disease:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"AK Gupta AK, J Cutan Med Surg. 2014, 18:79\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 624,
    "fields": {
      "name": "ORZID2 GMENU TOXIC SHOCK SYNDROME",
      "term": null,
      "displaytext": "Toxic Shock Syndrome  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 573, \"DisplayText\": \"Criteria for diagnosis of Streptococcal Toxic Shock Syndrome\", \"Text\": \"Link to Diagnosis of Streptococcal toxic shock syndrome\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 572, \"DisplayText\": \"CDC criteria for diagnosis of Staphylococcal Toxic Shock Syndrome\", \"Text\": \"Link to Diagnosis of Staphylococcal toxic shock syndrome\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h\", \"Text\": \"Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg\", \"Mnemonic\": \"8\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco 15mg/kg and Clindamycin 900 mg q8h IV\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Clindamycin 900 mg IV\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vanco 15mg/kg and Clindamycin 900 mg q8h IV\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"12\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nafcillin 2 gm IV q4h ($$) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Text\": \"Nafcillin 2 gm IV q4h ($$) [H,O]) [R] <AND> Clindamycin 900 mg IV q8h ($$\", \"Mnemonic\": \"14\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 2 gm IVPB ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Text\": \"Cefazolin 2 gm IV q8h ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"TOXIC SHOCK SYNDROME\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Toxic shock syndrome (TSS) can be associated with either staphylococci or\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"streptococci.  Antimicrobial treatment and supportive care is urgent.  Click one\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"of the links below for diagnostic criteria.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment of Streptococcal Toxic Shock Syndrome\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"_________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"IV q8h ($$) [H,O]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"q8h ($$) [H,O]\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"_________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment of Staphylococcal Toxic Shock Syndrome\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Use vancomycin initially in case methicillin-resistant Staphylococcus aureus is\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"present.  If cultures reveal methicillin-susceptible Staphylococcus aureus\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"(MSSA), change to nafcillin or cefazolin for better antimicrobial activity.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Treatment if MSSA is isolated\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"MMWR 1990, 39(RR-13):1\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford: Staphylococcal toxic shock\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Lappin E, Lancet Infect Dis 2009, 9:281\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 625,
    "fields": {
      "name": "ORZID2 GMENU TOXOPLASMA SPP.",
      "term": null,
      "displaytext": "Toxoplasma spp. ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM200MGTHEN50MGQ24H SULFDIAZ1GMQ6H LEUCO10MGQ24H\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 50 mg PO q24h ($$) [DI,O] <AND>\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM200MGTHEN75MGQ24H SULFAD1.5GMQ6H LEUCO10MGQ24H\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 75 mg PO q24h ($$) [DI,O] <AND>\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM200MGTHEN50MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 50 mg PO q24h ($$) [DI,O] <AND>\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ORZ SET ABX PYRIM200MGTHEN75MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 75 mg PO q24h ($$) [DI,O] <AND>\", \"Mnemonic\": \"10\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim (5 mg/kg)/sulfamethoxazole (25 mg/kg) IV q12h\", \"Text\": \"Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg IV q12h ($$) [R,DI]\", \"Mnemonic\": \"12\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Text\": \"Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 50MG Q24H SULFADIAZ 0.5GM Q6H LEUCO 10MG Q24H\", \"Text\": \"Pyrimethamine 50 mg PO q24h ($$) [DI,O] <AND> sulfadiazine 0.5-1 gm PO q6h\", \"Mnemonic\": \"16\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 50MG Q24H CLINDA 600MG Q8H LEUCO 10MG Q24H\", \"Text\": \"Pyrimethamine 50 mg PO q24h ($$) [DI,O] <AND> clindamycin 600 mg PO q8h ($)\", \"Mnemonic\": \"18\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIME 25MG Q24H ATOVA 750MG Q12H LEUCO 10MG Q24H\", \"Text\": \"Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> atovaquone 750-1500 mg PO\", \"Mnemonic\": \"20\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po q24h\", \"Text\": \"Trimethoprim sulfamethoxazole 1DS tablet PO q24h ($) [R,DI]\", \"Mnemonic\": \"22\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone 750mg po q12h\", \"Text\": \"Atovaquone 750-1500 mg PO q12h ($) [M]\", \"Mnemonic\": \"24\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY\", \"Text\": \"Pyrimethamine 50 mg q12h for 2 days, then 50 mg PO q24h ($$) [DI,O] <AND>\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TOXOPLASMA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If patient is immunocompetent and not pregnant, treatment is usually not needed\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"as disease is usually self-limited. Patients who are immunocompromised, pregnant\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"or have severe disease should be treated. Consult Infectious Diseases in all\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Non-pregnant patients\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat immunocompetent patients for 2-4 weeks. Treat immunocompromised patients\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for 6 weeks or longer if radiologic disease is extensive or response is\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"incomplete at 6 weeks.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Patients weighing <60 kg\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"sulfadiazine 1 gm PO q6h ($$) [DI,O] <AND> leucovorin 10-25 mg PO q24h($) [M]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients weighing >60kg\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"sulfadiazine 1.5 gm PO q6h ($$) [DI,O] <AND> leucovorin 10-25 mg PO q24h($) [M]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Preferred alternative for sulfa allergy\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Patients weighing <60 kg\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"clindamycin 600 mg PO q6h ($) [H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Patients weighing >60 kg\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"clindamycin 600 mg PO q6h ($) [H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Secondary alternatives\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Chronic Maintenance therapy for immunocompromised patients\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Discontinue maintenance therapy if patient has remained asymptomatic and CD4 >\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"200 cells per microliter.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Maintenance therapy\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"($$) <AND> leucovorin 10-25 mg PO q24h ($) [M]\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Preferred alternative for sulfa allergy\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"[H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Secondary alternatives\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"q12h ($) [M] <AND> leucovorin 10-25 mg PO q24h ($) [M]\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Pregnant patients\", \"Header\": 1}, {\"Row\": 68, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Patient diagnosed <16-18 weeks of gestation\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"*Contact Infectious Diseases, non-formulary consult is required for spiramycin\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Spiramycin 1 gm po q8h until week 18 of gestation\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Patient diagnosed >16-18 weeks of gestation\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Text\": \"sulfadiazine 75mg/kg once, then 50mg/kg q12h ($$) [DI,O] <AND> leucovorin 10-25\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"mg PO q24h ($) [M] for 4 weeks or duration of pregnancy if ultrasound evidence\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"of fetal distress\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Mandell chapter: Toxoplasma gondii\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Sanford keyword: Toxoplasmosis\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"Up-to-Date article: Toxoplasmosis in immunocompetent hosts\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 626,
    "fields": {
      "name": "ORZID2 GMENU TRANSPLANTATION",
      "term": null,
      "displaytext": "Transplantation ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TRANSPLANTATION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Organ transplantation is associated with many host defense defects.  Early on,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"surgical wounds may become infected.  Preparation for transplantation and anti-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"rejection drugs can induce neutropenia.  Later, CMI defects predominate.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Patients become infected with exogenous pathogens and also endogenous pathogens\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"like cytomegalovirus that might have been present in latent or subclinical form.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Cell-mediated immune defects caused by anti-rejection drugs cause patients to be\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"especially susceptible to infections with organisms that infrequently cause\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"disease in healthy people.  They include: Pneumocystis jirovecii (formerly\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Pneumocystis carinii), mycobacteria, salmonella, candida, aspergillus,\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Toxoplasma gondii, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"and cryptosporidia.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"The approach to fever or other signs or symptoms suggesting the possibility of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"an infectious disease depends on the specific defects present in the patient,\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"the nature of the presenting signs and symptoms and a bedside assessment of the\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"severity of illness.  Empirical antimicrobials are usually not indicated for\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"fever alone unless the patient has a host defense defect that predisposes to\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"rapid progression of illness like severe neutropenia or splenectomy.  Contact\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Infectious Diseases for more information.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 627,
    "fields": {
      "name": "ORZID2 GMENU TRAVELERS DIARRHEA",
      "term": null,
      "displaytext": "Traveler's Diarrhea",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO one-time dose ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO one time dose ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO q24h ($) [M]\", \"Text\": \"Azithromycin 500 mg PO q24h for 3 days ($) [M]\", \"Mnemonic\": \"6\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 3 days ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RIFAXAMIN 200MG PO Q8H FOR 3 DAYS\", \"Text\": \"Rifaximin 200 mg q8h for 3 days ($$) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TRAVELER'S DIARRHEA\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Acute non-bloody diarrhea (< 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Most cases are mild and self-limited. Reserve antimicrobial therapy for\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"patients who have severe traveler's diarrhea: pus, or mucus in stool, fever, or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"diarrhea that is incapacitating.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Bloody diarrhea\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"therapy and antimotility agents are not recommended in most patients with bloody\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"diarrhea due to an increased risk of hemolytic uremic syndrome when using these\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"agents. Obtain a stool sample for enteric pathogen PCR testing and reserve\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"antimicrobial and antimotility agent treatment until results are known. Enteric\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"pathogen PCR testing results are reported within 2 hours between 7am and 11pm.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"For more information on when an antimicrobial is indicated or if the patient has\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"severe/life threatening diarrhea or is immunocompromised, contact Infectious\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Empiric antimicrobial treatment for non-bloody severe acute diarrhea\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Subacute diarrhea (>/= 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Primary treatment is hydration and electrolyte replacement. Empirical\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"antimicrobial therapy is not indicated. Attempt to make a diagnosis with, for\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"example, enteric pathogen PCR testing, Clostridium difficile testing in those\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"who used a PPI or were treated with antimicrobials in the last 8-12 weeks, and\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"endoscopy. If bloody diarrhea, fever, or abdominal pain/tenderness is present\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"the case should be evaluated by Gastroenterology and/or Infectious Diseases.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Sanford keyword: Travelers Diarrhea\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-to-Date article: Travelers' diarrhea: Clinical manifestations, diagnosis, and\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 628,
    "fields": {
      "name": "ORZID2 GMENU UROSEPSIS",
      "term": null,
      "displaytext": "Urosepsis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 548, \"DisplayText\": \"Sepsis and septic shock\", \"Text\": \"Sepsis and septic shock\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 87, \"DisplayText\": \"Bacteremia\", \"Text\": \"Bacteremia\", \"Mnemonic\": \"6\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M]\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Text\": \"Cefepime 2 gm IV q12h ($$) [R]\", \"Mnemonic\": \"12\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEREMIA OR SEPSIS WITH URINARY TRACT SOURCE (AKA UROSEPSIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients with signs and symptoms of sepsis, like multiple organ system\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"dysfunction, shock and/or acute renal failure, should be treated as outlined in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"the sepsis pathway. Early intervention is crucial to prevention of death from\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sepsis.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment for patients with signs and/or symptoms of sepsis\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Bacteremia with a urinary source\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Obtain blood cultures before starting antibiotics when signs or symptoms suggest\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"bacteremia. Obtain 2 or 3 blood culture sets from different venipuncture sites\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"within a 24-hour period. When suspicion is strong and the patient's signs and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"symptoms have not responded, obtain 2 blood culture sets the next day.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Bacteremia is discussed in more detail elsewhere:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"When patients who require paraenteral therapy are afebrile, clinically stable,\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"and can take oral medication, convert to oral therapy based on the\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"identification and susceptibility of the isolate.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Antimicrobial treatment duration is based on pathogen isolated from blood\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"cultures and patient response to therapy, typically 7-14 days.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Drekonja, Dimitri M., et al. JAMA 326.4 (2021): 324-331\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Gupta K. et. al. IDSA Clinical Practice Guidelines (2011) 52.1\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Sanford keyword: Cystitis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute complicated urinary tract infection (including\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"pyelonephritis) in adults\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article: Gram-negative bacillary bacteremia in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 629,
    "fields": {
      "name": "ORZID2 GMENU UVEITIS",
      "term": null,
      "displaytext": "Uveitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 545, \"DisplayText\": \"Retinitis\", \"Text\": \"VZV or HSV retinitis and ARN\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 118, \"DisplayText\": \"CMV Retinitis\", \"Text\": \"CMV retinitis and ARN\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"UVEITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are non-infectious. Most infectious cases are associated with a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pathogen causing systemic or central nervous system infection. Diagnosis of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"uveitis usually must be made presumptively due to the technical difficulty of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sampling the uvea. Cases have been associated with fungi, bacteria, viruses, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"protozoa like Toxoplasma gondii.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For treatment of posterior uveitis (retinitis) or acute retinal necrosis (ARN)\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"due to Varicella-zoster virus (VZV) or herpes simplex virus (HSV) or\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cytomegalovirus (CMV)\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment of uveitis involves treating the underlying infection and is usually\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"systemic. Refer to specific pathogen recommendations for treatment of underlyin\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"infection. Contact Ophthalmology and/or Infectious Diseases for assistance.\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious causes of uveitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 630,
    "fields": {
      "name": "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM",
      "term": null,
      "displaytext": "Diskitis and Vertebral Osteomyelitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H\", \"Text\": \"Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Ceftriaxone 2GM IV\", \"Mnemonic\": \"4\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 15 mg/kg IV Q12H CIPRO 400 MG IV Q12H\", \"Text\": \"Vancomycin 15mg/kg IV q12h ($) [R] <AND> Ciprofloxacin 400mg IV q12h ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DISKITIS AND VERTEBRAL OSTEOMYELITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"About half of cases of diskitis are culture negative, and many of those appear\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to be uninfected.  Infectious cases often result from a surgical procedure near\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"the disk or back trauma.  Vertebral osteomyelitis usually results from\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"hematogenous seeding or directly from nearby organs.  Patients usually present\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with subacute or chronic pain which is often attributed initially to other\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"conditions including osteoarthritis, trauma, and malignancy.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"When possible obtain diagnostic cultures before starting empiric therapy.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Obtain blood cultures and image guided aspirates or surgical bone biopsy.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Definitive therapy based on culture and susceptibility test results.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"The most common causes of vertebral osteomyelitis are staphylococci,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"streptococci, and gram-negative bacilli. Anaerobes are uncommon pathogens.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If cultures are negative but infection is suspected, direct empirical\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"therapy against the most common pathogens.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Surgical intervention and spinal stabilization may be required.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Surgery and Infectious Diseases consultations are essential.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Recommended duration of therapy:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treat for 6 to 8 weeks for low risk infections.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treat for at least 8 weeks of pathogen-directed IV/PO therapy for high risk\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"including MRSA infection, ESRD, or undrained abscess or device implantation.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Once culture and susceptibility testing is available switch to\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"pathogen directed therapy.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Empiric therapy:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Recommended:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"q24h ($) [M]\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Alternative for allergy to penicillin:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date online\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Park KH Clin Infect Dis 2016, 62:1262\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Berbari EF Clin Infect Dis 2015, 61:e26\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 631,
    "fields": {
      "name": "ORZID2 GMENU YERSINIA ENTEROCOLITICA",
      "term": null,
      "displaytext": "Diarrhea with Yersinia enterocolitica",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h for 5 days ($) [R,DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 5 days ($) [R,DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTRIAXONE 2G Q24H GENT 5MG/KG Q24H\", \"Text\": \"Ceftriaxone 2 gm IV q24h ($) [M] <AND> gentamicin 5 mg/kg IV q24h ($) [R,O]\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"YERSINIA ENTEROCOLITICA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobials are indicated only for patients with severe disease or immune\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"compromise.  For patients with extra-intestinal disease, consult Infectious\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Diseases or Gastroenterology for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Primary treatment of gastroenteritis\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobial treatment of severe gastroenteritis or immunocompromised patient\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative for fluoroquinolone intolerant patients\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Antimicrobial treatment of extra-intestinal infection\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"for 2-3 weeks\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Yersinia enterocolitica\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of Yersinia enterocolitica and\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Yersinia pseudotuberculosis infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 632,
    "fields": {
      "name": "ORZID2 GO DIAGNOSIS UTI 3",
      "term": null,
      "displaytext": "Diagnosis: Uncomplicated Cystitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1.0, \"Item\": null, \"DisplayText\": \"Comments:\", \"Text\": \"Uncomplicated Cystitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 633,
    "fields": {
      "name": "ORZID3 GMENU ABSCESSES",
      "term": null,
      "displaytext": "Abscesses (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 803, \"DisplayText\": \"Cutaneous abscess (Outpatient)\", \"Text\": \"Cutaneous abscess\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 698, \"DisplayText\": \"Perianal/Anorectal Abscess\", \"Text\": \"Perirectal abscess\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 849, \"DisplayText\": \"Furuncles and Carbuncles (Outpatient)\", \"Text\": \"Furuncles and carbuncles\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 1007, \"DisplayText\": \"Pyomyositis\", \"Text\": \"Pyomyositis\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ABSCESSES: CUTANEOUS ABSCESS, FURUNCLE, AND CARBUNCLE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"This section describes management of skin and soft tissue infections.  For\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"information on abscesses in other areas, please return to the main CDSS menu and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"choose the appropriate organ system.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 634,
    "fields": {
      "name": "ORZID3 GMENU ABX ACNE",
      "term": null,
      "displaytext": "Acne",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% lotion topically q12h ($) [M]\", \"Text\": \"Clindamycin 1% lotion topically q12h ($) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Text\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Text\": \"Erythromycin 2% gel topically q12h ($) [DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DOXY 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H\", \"Text\": \"Doxycycline 100 mg PO q12h  ($) [DI] for 12 weeks <AND> erythromycin 2% gel\", \"Mnemonic\": \"14\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MINO 100MG PO BID 12WKS ERYTHROMYCIN 2% GEL Q12H\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI] for 12 weeks <AND> erythromycin 2% gel\", \"Mnemonic\": \"16\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 709, \"DisplayText\": \"Acne and Rosacea Dermatology Orders\", \"Text\": \"Recalcitrant acne\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACNE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acne is an inflammatory skin condition caused by excess sebum production, gland\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"obstruction and infection with Cutibacterum acnes. Early disease manifests with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"black heads and white heads and little inflammation. Small papules and pustules\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"are present in mild disease. Severe disease occurs when comedones, papules,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"pustules and less often cysts are present.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"The goal of treatment is prevention and reeducation of new comedones and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"creating an environment that is inhibitory for C. acnes. General skin care\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"treatment measures include utilizing gentle skin cleansers, avoiding aggressive\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"scrubbing, using non-comedogenic skin products, and avoiding picking of lesions.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Diet's role in therapy remains uncertain.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Non-Antimicrobial therapy includes benzoyl peroxide topical/wash, salicylic acid\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"topical, and tretinoin topical. These agents can be used as monotherapy in early\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"disease and in addition to antimicrobial treatment in mild to severe disease.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Early Disease:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mild Disease:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Severe Disease:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"topically q12h\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"topically q12h\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Sanford keyword: Acne Vulgaris\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Up-to-Date Article: Pathogenesis, clinical manifestations, and diagnosis of acne\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-to-Date Article: Acne vulgaris: Overview of management\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Zaenglein et al., N Engl J Med, 2018, 379(14)1343-1352\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Zaenglein et al., J Am Acad Dermatol, 2016, 74(5)945-73.e33\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 635,
    "fields": {
      "name": "ORZID3 GMENU ABX APPROACH TO UTI",
      "term": null,
      "displaytext": "APPROACH TO URINARY TRACT INFECTION (UTI)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 740, \"DisplayText\": \"Asymptomatic bacteriuria (Outpatient)\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 641, \"DisplayText\": \"Candida Urinary Tract Infections\", \"Text\": \"Candida urinary tract infections\", \"Mnemonic\": \"8\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 1052, \"DisplayText\": \"Uncomplicated Cystitis (Outpatient)\", \"Text\": \"Uncomplicated cystitis\", \"Mnemonic\": \"10\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 801, \"DisplayText\": \"Complicated Cystitis (Outpatient)\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"12\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 1006, \"DisplayText\": \"Pyelonephritis (Outpatient)\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPROACH TO URINARY TRACT INFECTION (UTI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Urinary tract infections (UTI) occur in patients with symptoms of infection in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the lower urinary tract (cystitis) and/or the upper urinary tract\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(pyelonephritis). Cystitis refers to infection of the urinary bladder, but\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inflammation often extends into the urethra. Typical signs and symptoms include\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dysuria, increased urinary frequency, urgency, and/or suprapubic tenderness.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Uncomplicated cystitis occurs in people with structurally and neurogenically\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"normal urinary tract. Most cases of uncomplicated cystitis occur in\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pre-menopausal, non-pregnant, sexually active young women and is associated with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"saprophyticus. Complicated cystitis occurs in the conditions listed below and is\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"associated with Enterobacteriaceae, but more resistant pathogens occur,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"including the Gram-positive pathogens staphylococci and enterococci. Features of\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"pyelonephritis include fever/other signs of systemic infection, flank pain,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"costovertebral tenderness, and pelvic or perianal pain in men. In rare and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"severe cases, urinary tract infections can also present with bacteremia, sepsis,\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"multiple organ system dysfunction, shock and/or acute renal failure.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"When a patient presents with symptoms of cystitis, like dysuria, increased\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"frequency, and suprapubic pain, perform a urine culture. Antimicrobial therapy\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"is not indicated for pyuria in the absence of symptoms. Patients with signs and\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"symptoms of pyelonephritis should have a urinary culture and susceptibility\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"obtained and a urine Gram-stain performed prior to starting empirical\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"antimicrobials to guide therapy. Patients presenting with bacteremia, sepsis,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"multiorgan dysfunction, shock and/or acute renal failure should be treated\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"accordingly with urinary tract as the foci of infection.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Asymptomatic bacteriuria occurs in patients who have bacteria in the urine but\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"do not have symptoms of a urinary tract infection. Asymptomatic bacteriuria is\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"further discussed elsewhere:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"treatment:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Candida urinary tract infections are discussed elsewhere:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Complicating conditions\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Cystitis is considered complicated when one or more of the following is present:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"o Pregnant women\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"o Immunocompromise\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"o Persistent infection, relapse, recurrence, or treatment failure\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"o In some cases, men and patients admitted to health care settings may be\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"considered complicated\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"*Bacteremia or sepsis with urinary tract source (aka urosepsis) - refer to inpt\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary Tract Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 636,
    "fields": {
      "name": "ORZID3 GMENU ABX BALANITIS",
      "term": null,
      "displaytext": "Balanitis and Balanoposthitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clotrimazole 1% cream topically q12h ($) [M] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days\", \"Text\": \"Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin cream 100,000 units/g cream topically q12h ($) [M] for 7 days (non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg po once\", \"Text\": \"Fluconazole 150 mg PO once ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg po once Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days\", \"Text\": \"Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% cream topically q12h ($)[DI] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days\", \"Text\": \"Metronidazole 500 mg PO q12h ($) [DI] for 7 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BALANITIS AND BALANOPOSTHITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Balanitis is inflammation of the glans penis and is often associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"erythema and pruritis. When the foreskin is also involved, the condition is\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"known as balanoposthitis (also referred to as balanitis in this discussion).\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"There are a variety of causes of balanitis, but most are due to poor hygiene of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"the foreskin in uncircumcised men resulting in candida infection. Other, less\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"common causes, include bacterial infection (typically sexually transmitted or\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"anaerobic bacteria), dermatologic conditions, malignancy as well as others. Men\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with Candidal balanitis often have a white curd-like exudate compared to a thick\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"foul-smelling purulent exudate in menu with anaerobic bacterial balanitis.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"treatment:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Candidal balanitis empirical treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mild to moderate cases\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Severe cases\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Bacterial balanitis empirical treatment\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mild cases\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Moderate to severe cases\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"___________________________________________________________________________\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Edwards et al., International Journal of STD & AIDS, 2014, 25(9)615-526\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford keyword: Balanitis\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-to-Date article: Balanitis in Adults\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 637,
    "fields": {
      "name": "ORZID3 GMENU ABX BEBTELOVIMAB EUA",
      "term": null,
      "displaytext": "Bebtelovimab (EUA) Orders",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3072, \"DisplayText\": \"LINK EUA PROVIDER TO FILL OUT\", \"Text\": \"[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bebtelovimab EUA Provider Fact Sheet\", \"Text\": \"[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Bebtelovimab (EUA)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"for treating patients that meet specific criteria. bebtelovimab is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"not FDA approved drug.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"-Bebtelovimab EUA does NOT include post-exposure prophylaxis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Bebtelovimab Emergency Use Authorization (EUA)\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Inclusion Criteria\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"ALL of the following criteria must be met for a patient to receive:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"1) Patient has tested positive for COVID-19 and is diagnosed with mild to\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Note: patient may be hospitalized for some other reason.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"3) Patient does NOT require oxygen therapy for COVID-19.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For patients on chronic oxygen therapy: patient does NOT require an\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"increase in baseline oxygen flow rate due to COVID-19.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"4) Administration will begin within 7 days of symptom onset.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to bebtelovimab or components.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"6) Patient has at least one risk factor for progression to severe disease\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"including hospitalization or death.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"See link below for complete list:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"7) Counseling is provided and documented in the electronic health record per EUA\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"The provider has communicated with the patient/caregiver regarding\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"information contained in the \\\"Fact Sheet for Patients\\\". The patient/\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"caregiver has been given the Fact sheet, informed that the drug is an\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"unapproved drug that is authorized for use under an EUA, given information\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"on alternatives and their risks and benefits, and the patient/caregiver\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"has the right to refuse or accept. (See top of page for Fact Sheet)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Exclusion Criteria\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"If patient agreeable and meets criteria, please contact Minneapolis VA Emergency\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Department charge nurse at 31-6736 to arrange for treatment if available. Click\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"sharing personal items, clean and disinfect \\\"high touch\\\" surfaces, and\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"frequent handwashing) according to CDC guidelines.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"text order below to complete order form for ED administration.\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Note: order does not contain medication order. ED provider will order.\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Bebtelovimab Emergency Department Information\", \"Text\": \"ED text order for administration of INV-Bebtelovimab 175 mg IV Push ONCE\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"moderate illness.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 638,
    "fields": {
      "name": "ORZID3 GMENU ABX BONE MARROW POST TRANSPLANT VACCINATIONS",
      "term": null,
      "displaytext": "Bone Marrow Post-Transplant Vaccinations",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 639, \"DisplayText\": \"Seattle and Nashville Allogenic Bone Marrow Transplant Vaccinations\", \"Text\": \"Allogenic\", \"Mnemonic\": \"6\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 640, \"DisplayText\": \"Seattle and Nashville Autologous Bone Marrow Transplant Vaccinations\", \"Text\": \"Autologous\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BONE MARROW POST-TRANSPLANT VACCINATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Seasonal influenza vaccination should be administered yearly. Patient should be\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"administered COVID-19 vaccinations to be up-to-date per current CDC guidelines.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Influenza and COVID-19 vaccinations may be administered via nursing standing\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"orders.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Order sets are available below for other post-transplant vaccine regimens.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Choose vaccine regimen based on location where transplant was performed and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"type of transplantation.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mayo Clinic\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Seattle or Nashville\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"University of Minnesota (U of M)\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \">>Under construction\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \">>Under construction\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 639,
    "fields": {
      "name": "ORZID3 GMENU ABX BONE MARROW SEATTLE NASHVILLE ALLOGENIC",
      "term": null,
      "displaytext": "Seattle and Nashville Allogenic Bone Marrow Transplant Vaccinations",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DTaP, Hib, Hep B, HPV, Meningicoccal conj, PCV20, and polio vaccines\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"4\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE\", \"Text\": \"Pneumococcal 20 valent\", \"Mnemonic\": \"6\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DTAP HIB HEPB HPV PCV20 POLIO VACCINES\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"8\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DTaP, Hib, Hep B, and polio vaccines\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"10\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HPV PPSV23 MCCONJ ZOSTER VACCINES\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"12\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE ONE DOSE\", \"Text\": \"Zoster recombinant - 2 of 2\", \"Mnemonic\": \"14\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"MMR (If not on active myelosuppressive treatment)\", \"Mnemonic\": \"16\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE\", \"Text\": \"Pneumococcal 20 valent (only if GVHD negative)\", \"Mnemonic\": \"18\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE\", \"Text\": \"Pneumococcal 23 valent (only if GVHD negative)\", \"Mnemonic\": \"20\"}, {\"Row\": 76, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HAEMOPHILUS B VACCINE ONE DOSE\", \"Text\": \"Hib (if titers negative - check yearly until positive)\", \"Mnemonic\": \"22\"}, {\"Row\": 77, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE ONE DOSE\", \"Text\": \"Hepatitis B (if titers negative - check yearly until positive)\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEATTLE OR NASHVILLE ALLOGENIC POST-TRANSPLANT VACCINATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Select below vaccine order sets based on time from transplant. Only doses that\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"are due will be placed. Follow up vaccine doses in series will need to be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"ordered, using the below order sets, when they are due. Vaccinations that should\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"be ordered via nursing standing orders are listed as such.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Certain vaccinations are only indicated in those who are a certain age or have\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"other co-morbidities. These indications are noted within parentheses in the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"below order sets. If the patient does not meet these criteria, cancel the order\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"after selecting the order set.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"COVID-19 vaccination changes rapidly. Refer to CDC for most up to date\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"recommendations.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"3 months\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \">>Administer 1st COVID-19 vaccine via standing orders\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"4 months\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \">>Administer 2nd COVID-19 vaccine and influenza vaccine via standing orders\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"5 months\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \">>Administer 3rd COVID-19 vaccine via standing orders\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"6 months\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"DTaP - 1 of 3\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Hib - 1 of 3\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Hepatitis B - 1 of 3\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"HPV - 1 of 3 (for those under 45)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Meningococcal conj - 1 of 2 (For those with splenectomy, HIV, or those at risk)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Pneumococcal 20 valent\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Polio - 1 of 3\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"7 Months\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"8 months\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \">>Administer 4th COVID-19 vaccine via standing orders\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"DTap - 2 of 3\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Hib - 2 of 3\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Hepatitis B - 2 of 3\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"HPV - 2 of 3 (for those under 45)\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Pneumococcal 20 valent\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Polio - 2 of 3\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"10 months\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"DTaP - 3 of 3\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Hib - 3 of 3\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Hepatitis B - 3 of 3\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Polio - 3 of 3\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"12 months\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \">>OPTIONAL - administer 4th COVID-19 vaccine via standing orders\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"HPV - 3 of 3 (for those under 45)\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Pneumococcal 23 valent (if GVHD postive - give PCV20 instead of PPSV23)\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Meningococcal conj - 2 of 2 (For those with splenectomy, HIV, or those at risk)\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Zoster recombinant - 1 of 2\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"14 months\", \"Header\": 1}, {\"Row\": 68, \"Column\": 1, \"Text\": \"24 Months\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Annually\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Text\": \">> Administer seasonal influenza and COVID-19 via standing orders per CDC recs\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 640,
    "fields": {
      "name": "ORZID3 GMENU ABX BONE MARROW SEATTLE NASHVILLE AUTOLOGOUS",
      "term": null,
      "displaytext": "Seattle and Nashville Autologous Bone Marrow Transplant Vaccinations  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DTaP, Hib, Hep B, HPV, Meningicoccal conj, PCV20, and polio vaccines\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"4\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DTaP, Hib, Hep B, PCV23, and polio vaccines\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"6\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"DTaP, Hib, Hep B, and polio vaccines\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"8\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HPV, MENINGOCOCCAL CONJ, ZOSTER RECOMBINANT Vaccination\", \"Text\": \"[CLICK HERE] to order above vaccine orders\", \"Mnemonic\": \"10\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE ONE DOSE\", \"Text\": \"Zoster recombinant - 2 of 2\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEATTLE OR NASHVILLE AUTOLOGOUS POST-TRANSPLANT VACCINATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Select below vaccine order sets based on time from transplant. Only doses that\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"are due will be placed. Follow up vaccine doses in series will need to be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"ordered, using the below order sets, when they are due. Vaccinations that should\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"be ordered via nursing standing orders are listed as such.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Certain vaccinations are only indicated in those who are a certain age or have\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"other co-morbidities. These indications are noted within parentheses in the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"below order sets. If the patient does not meet these criteria, cancel the order\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"after selecting the order set.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"COVID-19 vaccination changes rapidly. Refer to CDC for most up to date\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"recommendations.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"3 months\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \">>Administer 1st COVID-19 vaccine and influenza vaccine via standing orders\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"4 months\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \">>Administer 2nd COVID-19 vaccine via standing orders\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"5 months\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \">>Administer 3rd COVID-19 vaccine via standing orders\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"6 months\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"DTaP - 1 of 3\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Hib - 1 of 3\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Hepatitis B - 1 of 3\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"HPV - 1 of 2 (for those under 45)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Meningococcal conj - 1 of 2 (For those with splenectomy, HIV, or those at risk)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Pneumococcal 20 valent\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Polio - 1 of 3\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"8 months\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \">>Administer 4th COVID-19 vaccine via standing orders\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"DTap - 2 of 3\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Hib - 2 of 3\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Hepatitis B - 2 of 3\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Pneumococcal 23 valent\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Polio - 2 of 3\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"10 months\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"DTaP - 3 of 3\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Hib - 3 of 3\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Hepatitis B - 3 of 3\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Polio - 3 of 3\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"12 months\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"HPV - 2 of 2 (for those under 45)\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Meningococcal conj - 2 of 2 (For those with splenectomy, HIV, or those at risk))\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Zoster recombinant - 1 of 2\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"14 months\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Annually\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Seasonal influenza and COVID-19 per CDC recommendations\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 641,
    "fields": {
      "name": "ORZID3 GMENU ABX CANDIDA UTI",
      "term": null,
      "displaytext": "Candida Urinary Tract Infections  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI]\", \"Text\": \"Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 3 days before and 3 days\", \"Mnemonic\": \"4a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FLUCONAZOLE 200MG QDAY 14 DAYS\", \"Text\": \"Fluconazole 200 mg (3 mg/kg) PO q24h ($) [R,DI] for 14 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FLUCONAZOLE 200MG QDAY 14 DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI]\", \"Text\": \"Fluconazole 400 mg (6 mg/kg) PO q24h ($) [R,DI] for 14 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA URINARY TRACT INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A positive urine culture for candida usually reflects colonization. Treat\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cystitis only if the patient has symptoms of urinary tract infection (e.g.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"dysuria, frequency, urgency, and/or suprapubic tenderness) or if the patient\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"will undergo invasive urological manipulation\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Asymptomatic candiduria in a patient with a urinary catheter should not be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"treated without an additional indication. Removal of catheter is strongly\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"recommended. Contact Infectious Diseases for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Neutropenic patients with asymptomatic candiduria should be assessed for\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"candidemia because they are at risk of dissemination. Obtain blood cultures and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"assess potential sources of candidemia such as central venous catheters. Refer\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"to fungemia page in the Inpatient Antimicrobialc CDSS for treatment\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"recommendations.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Patient undergoing invasive urological manipulation:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"after procedure\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Symptomatic candida cystitis:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Pyelonephritis:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Resistant candida:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for treatment options\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Pappas et al., Clinical Infectious Diseases, 2016, 62(4)e1-e50\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary Tract Infections\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-To-Date article: Candida Infections of the Bladder and Kidneys\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Up-To Date article: Candidemia in adults: Epidemiology, microbiology, and\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"pathogenesis\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Urinary Tract Infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 642,
    "fields": {
      "name": "ORZID3 GMENU ABX CARD SURGERY DECOLON",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CHLORHEXADINE MUPIROCIN DECOLINIZATION\", \"Text\": \"Chlorhexidine 4% liquid topically Q24h ($) [M] < AND > Mupirocin 2%\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CHLOHEX MUPIR ORDER SET\", \"Text\": \"Chlorhexidine 4% liquid topically Q24h ($) [M] nursing text order\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Cardiac Surgery MRSA/MSSA Decolonization Protocol Pre-Op\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Outpatient\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"ointment topically Q12h ($) [M]\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Inpatient\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If patient is discharged prior to surgery, place outpatient orders as well\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< AND > Mupirocin 2% ointment topically Q12h ($) [M]\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"adults: Prevention and control\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 643,
    "fields": {
      "name": "ORZID3 GMENU ABX CMV MAIN PAGE",
      "term": null,
      "displaytext": "Cytomegalovirus (CMV) Main Page (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 791, \"DisplayText\": \"CMV colitis or esophagitis (Outpatient)\", \"Text\": \"Colitis or esophagitis\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 792, \"DisplayText\": \"CMV encephalitis (Outpatient)\", \"Text\": \"Encephalitis\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 794, \"DisplayText\": \"CMV polyradiculopathy (Outpatient)\", \"Text\": \"Polyradiculopathy\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 795, \"DisplayText\": \"CMV retinitis (Outpatient)\", \"Text\": \"Retinitis\", \"Mnemonic\": \"10\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 793, \"DisplayText\": \"CMV pneumonia (Outpatient)\", \"Text\": \"Pneumonia\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CYTOMEGALOVIRUS (CMV)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antiviral toxicity information\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"The major toxicities of both ganciclovir and valganciclovir are neutropenia.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Nephrotoxicity is the major toxicity associated with foscarnet, which may be\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"reduced by concomitant saline administration (generally 0.5-1L).\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Immunocompetent patient\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Infection is rare and usually associated with minimal or no symptoms.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Mononucleosis can be associated with CMV, but is more commonly associated with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Epstein Barr virus. Antiviral treatment is not usually necessary as most\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"patients recover without intervention.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Immunocompromised patient\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Patients in whom the risk for CMV disease is increased include solid organ and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"bone marrow transplant recipients, persons receiving prolonged immunosuppressive\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"chemotherapy, and persons with advanced HIV disease indicated by a CD4 count of\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"less than 50 cells/microliter.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"CMV treatment recommendations\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 644,
    "fields": {
      "name": "ORZID3 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR OP",
      "term": null,
      "displaytext": "Colonized Respiratory Tract in a Patient on a Ventilator (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"COLONIZED RESPIRATORY TRACT IN A PATIENT ON A VENTILATOR\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The respiratory tracts of persons who are intubated, have a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"tracheostomy, or have other abnormalities of the larynx or trachea are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"usually colonized with bacteria and often fungi. The bacteria can be of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"relatively low virulence (e.g. coagulase negative staphylococci, streptococci,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"candida) or of potentially greater virulence (Staphylococcus aureus,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"enterobacteriaceae, pseudomonas). Candida and enterococci are common\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"respiratory tract colonizers and they almost never cause pneumonia. There is\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"no benefit from treatment of patients with systemic antimicrobials simply\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"because the respiratory tract is colonized with a potential pathogen and there\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"is no evidence of an infiltrate. Systemic antimicrobial therapy will select for\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"resistant organisms and may lead to other adverse effects.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for ventilator-associated pneumonia\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"treatment recommendations in patients with a new or progressive infiltrate and\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"at least one of the following: fever greater than 100.4F, leukocytosis,\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"leukopenia or purulent bronchial secretions.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Kalil et al. Clin Infect Dis, 2016, 63(5): e61-e111.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 645,
    "fields": {
      "name": "ORZID3 GMENU ABX COLONIZED WOUNDS OP",
      "term": null,
      "displaytext": "Colonized Wounds (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 16, \"Column\": 1, \"Item\": 805, \"DisplayText\": \"Decubitis ulcers (Outpatient)\", \"Text\": \"Decubitus ulcers\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 836, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus (Outpatient)\", \"Text\": \"Diabetic foot ulcers\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COLONIZED WOUNDS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Open wounds are usually colonized with bacteria and often fungi. This is true of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"ulcers (see below), post-operative wounds, traumatic wounds, and others. Then\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"bacteria can be of relatively low virulence (eg, coagulase negative\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"staphylococci, diphtheroids) or of potentially greater virulence (Staphylococcus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"aureus, enterobacteriaceae, pseudomonas). Candida is commonly present on wounds\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"that are moist or covered. There is no need to treat patients with systemic\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials simply because a wound culture is positive for a potential\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"pathogen. Topical antimicrobials are not effective in nearly all circumstances\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"and can select for resistant organisms or lead to other adverse effects.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Systemic antimicrobial therapy may be indicated if there are signs of infection.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Lipsky et al, Clin Infect Dis, 2012, 54(12): e132-e173\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-to-Date article: Clinical assessment of chronic wounds\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 646,
    "fields": {
      "name": "ORZID3 GMENU ABX COVID-19 MPLS ANTIMICROBIAL GUIDELINES OPT",
      "term": null,
      "displaytext": "Outpatient COVID-19 Antimicrobial Treatment Guidelines ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3073, \"DisplayText\": \"Minneapolis COVID-19 SharePoint Site\", \"Text\": \"Minneapolis VAHCS COVID-19 SharePoint Site\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Minneapolis On-Call Schedule - Infectious Disease\", \"Mnemonic\": \"8\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Monocolonal Antibody Allocation SOP\", \"Text\": \"Minneapolis VAHCS COVID Monocolonal Antibody and Antiviral Allocation SOP\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Paxlovid EUA\", \"Text\": \"Paxlovid (Nirmatrelvir 300 mg and ritonavir 100 mg) BID for 5 days\", \"Mnemonic\": \"10\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Molnupiravir EUA\", \"Text\": \"Molnupiravir 800 mg PO BID for 5 days\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OUTPATIENT COVID-19 ANTIMICROBIAL TREATMENT GUIDELINES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional info.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"***COVID-19 therapy is a rapidly evolving field, including the widespread\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dissemination of therapies with little or no evidence for benefit. Therapies an\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"dosages not specifically listed here or on the NIH clinical guidelines should b\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"discussed with the infectious diseases service. ***\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If you have any questions on the selection of therapy, please contact Infectious\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Disease.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"DECIDE ON APPROPRIATE TREATMENT PLAN BY REFERRING TO ALLOCATION SOP BELOW\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"ORAL COVID-19 ANTIVIRALS:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Please contact Pharmacy to determine supply and availability.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Outpatient Pharmacy - Mon-Fri 0800-2130 and Weekend/Holidays 0900-1700: 31-3144\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Inpatient Pharmacy - Off-Tours: 31-3128\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"documentation, address medication questions and determine the best method of\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"delivery.\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COVID-19 Medication Interaction Check\", \"Text\": \"Interaction checker for COVID-19 medications website link\", \"Mnemonic\": \"9\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"*Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min):\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Paxlovid EUA\", \"Text\": \"Paxlovid (Nirmatrelvir 150 mg and ritonavir 100 mg) PO BID for 5 days\", \"Mnemonic\": \"11\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"*Please be ready to spend time on the phone with the pharmacist to complete\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 647,
    "fields": {
      "name": "ORZID3 GMENU ABX DENTAL SOP ANTIBIOTIC CHOICE",
      "term": null,
      "displaytext": "Dental SOP - Antibiotic choice ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Dental SOP for Antibiotic Prophylaxis\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"a. See links below for recommendations\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"b. Amoxicillin is preferred over Penicillin as it is more effective against\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"gram negative anaerobes and is associated with lower incidence of GI\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"adverse effects.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"c. If a patient reports a Penicillin allergy, conduct an allergy assessment\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to determine if it is a true allergy. If not, consider prescribing\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Cephalexin.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"d. In the unusual case where a patient cannot take Penicillin or Cephalexin,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Doxycycline or Azithromycin would be first choice. Clindamycin is no longer\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"recommended by the ADA, due to the side effects--it increases the risk\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of developing Clostridioides difficile Infection (CDI), even after a\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"single dose. Clindamycin also gives suboptimal prophylactic coverage.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"e. If patient is taking an antibiotic with the same spectrum as the one\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"indicated for antibiotic prophylaxis, additional antibiotics do not need\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"to be prescribed.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"f. Consider intramuscular antibiotic therapy for patients with GI disorders.\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 1036, \"DisplayText\": \"Suppurative odontogenic infections (Outpatient)\", \"Text\": \"Dental Infections\", \"Mnemonic\": \"04\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 982, \"DisplayText\": \"Periodental disease (Outpatient)\", \"Text\": \"Periodontal Disease\", \"Mnemonic\": \"06\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 1036, \"DisplayText\": \"Suppurative odontogenic infections (Outpatient)\", \"Text\": \"Tooth Abscess and other Suppurative Odonotogenic Infections\", \"Mnemonic\": \"08\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibiotic choice considerations:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Select indication below for recommendations:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 648,
    "fields": {
      "name": "ORZID3 GMENU ABX DENTAL SOP BACKGROUND INFORMATION",
      "term": null,
      "displaytext": "[Click here] Background Information  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Text\": \"a. Compared to previous recommendations, there are currently few patient\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"subpopulations who would benefit from antibiotic prophylaxis prior to\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"designated dental procedures.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"b. Cumulative, low grade bacteremias (triggered by normal daily activities,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"such as tooth brushing, flossing and chewing) are a greater risk factor in\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"developing Infective Endocarditis (IE), more so than sporadic, high grade\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"bacteremias (caused by invasive dental procedures). Maintenance of oral\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"health to reduce bacteremia from daily activities is more important than\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antibiotic prophylaxis.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"c. Adverse events associated with inappropriate antibiotic use include\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antimicrobial resistance, C. difficile associated disease (CDI), allergic\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"reactions and disruptions in normal flora.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"d. Some conditions that may warrant antibiotic prophylaxis are:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"i. Heart conditions (risk of developing IE)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"1. Artificial heart valve\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"2. History of IE\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"3. Certain specific congenital heart conditions--highly recommend\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Cardiology consult\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"4. Cardiac transplant that develops a problem in the heart valve\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"ii. These conditions are NOT recommended for prophylaxis:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"1. Coronary artery stents, history of coronary artery bypass\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"graft (CABG).\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"e. Presence of prosthetic joints is no longer an indication to provide\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 649,
    "fields": {
      "name": "ORZID3 GMENU ABX DENTAL SOP MAIN",
      "term": null,
      "displaytext": "Antibiotic Propylaxis for Dental Procedures",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 6, \"Column\": 1, \"Text\": \"Purpose:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"To establish guidelines that can be used by dentists or dental specialists\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to determine if antibiotic prophylaxis is necessary for their patients prior\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"to undergoing dental procedures, while being cognizant of the VA Antimicrobial\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Stewardship Program (ASP).\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Responsibility and Authority:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"The dental team is responsible for management of their patients, including\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"the use of antibiotic prophylaxis where applicable.\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Guidance pertaining to making an informed decision about Antibiotic Prophylaxis\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"before dental procedures\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Procedure:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"[Click here] Procedure\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antibiotic choice considerations:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Minneapolis VA Health Care System, Service Line: Specialty Care, Dental SOP\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Reference:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Background information:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dental SOP Antibiotic Prophylaxis\", \"Text\": \"[Click here] Review Dental SOP for Antibiotic Prophylaxis Document\", \"Mnemonic\": \"04\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"(Revised: Feb 2023, to be reviewed annually)\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dental SOP Antibiotic Prophylaxis\", \"Text\": \"[Click here] Dental SOP Antibiotic Prophylaxis Document\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 647, \"DisplayText\": \"Dental SOP - Antibiotic choice\", \"Text\": \"[Click here] Antibiotic choice considerations\", \"Mnemonic\": \"10\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 648, \"DisplayText\": \"[Click here] Background Information\", \"Mnemonic\": \"06\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 650,
    "fields": {
      "name": "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS",
      "term": "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS",
      "displaytext": "ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF PROSTHETIC JOINT INFECTION BEFORE INFECTED SKIN, SKIN STRUCTURES\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OR MUSKULOSKELETAL TISSUE PROCEDURES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"There is a lack of evidence supporting antimicrobial prophylaxis to prevent\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"prosthetic joint infections in patients undergoing procedures on infected skin,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"skin structures or musculoskeletal tissue procedures.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For more information contact Infectious Diseases.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Up-To-Date Article: Prevention of prosthetic joint and other types of orthopedic\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"hardware infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 651,
    "fields": {
      "name": "ORZID3 GMENU ABX ENTERIC FEVER",
      "term": null,
      "displaytext": "Enteric Fever",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 7-10 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1 gm PO once then 500 mg PO QDAY for 5 days ($) [M]\", \"Text\": \"Azithromycin 1 gm PO once then 500 mg PO QDAY for 5 to 7 days ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1 gm PO once then 500 mg PO QDAY for 5 days ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTERIC FEVER (INCLUDING TYPHOID AND PARATYPHOID FEVER)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Enteric fever is a systemic febrile illness caused by Salmonella enterica\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"serotypes Typhi and Paratyphi A, B, or C. It is characterized by dramatic fever\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and abdominal pain. Enteric fever typically occurs in patients who have traveled\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"to impoverished areas where the organisms are endemic, but can also be acquired\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"within the United States. Treatment is based on location of acquisition due to\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"increasing rates of fluoroquinolone resistance in Asia.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobial treatment for infection NOT acquired in Asia\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antimicrobial treatment for infection acquired in Asia\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Typhoid Fever, Enteric Fever\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of enteric (typhoid and\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"paratyphoid) fever\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 652,
    "fields": {
      "name": "ORZID3 GMENU ABX ESOPHAGITIS",
      "term": null,
      "displaytext": "Esophagitis (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 843, \"DisplayText\": \"Candida albicans (Outpatient)\", \"Text\": \"Candidiasis\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 791, \"DisplayText\": \"CMV colitis or esophagitis (Outpatient)\", \"Text\": \"CMV Esophagitis\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 661, \"DisplayText\": \"Herpes Simplex Esophagitis (Outpatient)\", \"Text\": \"Herpes Simplex Esophagitis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ESOPHAGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Esophagitis is usually associated with non-infectious diseases like\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"gastroesophageal reflux disease, mucositis and pill-induced esophagitis.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Esophageal infection occurs primarily in immunosuppressed individuals (e.g.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"chemotherapy, transplantation, HIV) and rarely in healthy individuals. The\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"majority of infectious esophagitis is caused by Candida albicans,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"cytomegalovirus (CMV) and herpes simplex virus. Aphthous ulceration of the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"esophagus is common in HIV infection. HIV screening is recommneded.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mandell chapter: Esophagitis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sanford Keyword: Candidiasis\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford Keyword: Cytomegalovirus, Gastrointestinal Disease\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-To-Date article: Herpes simplex virus infection of the esophagus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 653,
    "fields": {
      "name": "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT",
      "term": null,
      "displaytext": "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help and Additional Information Menu\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"OUTPT CONSULT MENU\", \"Text\": \"Consult Menu - place consults to specialty service\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antibiogram\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 940, \"DisplayText\": \"Need an alternative antimicrobial? (outpatient)\", \"Text\": \"Alternative Antimicrobials to CDSS Recommendations - select here\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact Information\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Antimicrobial Information\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Important Drug Properties\", \"Mnemonic\": \"14\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 124, \"DisplayText\": \"Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)\", \"Text\": \"Antimicrobial Cost Information\", \"Mnemonic\": \"16\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"GENERAL INFORMATION\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"LEGEND ________________________________________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"[DI] = Important interactions between antimicrobial and other drugs\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"[H] = Hepatic excretion of antimicrobial\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"[M] = Minimal risk posed by antimicrobial\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"[O] = Other important antimicrobial property\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"[R] = Renal excretion of antimicrobial\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"($) = <10 dollars per day\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"($$) = 10-50 dollars per day\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"($$$) = 51-100 dollars per day\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"($$$$) = 101-400 dollars per day\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"($$$$$) = >400 dollars per day\"}, {\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Consult Infectious Diseases (outpatient)\", \"Text\": \"Infectious Diseases Consult\", \"Mnemonic\": \"3\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam Reaction Assessment\", \"Mnemonic\": \"9\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 654,
    "fields": {
      "name": "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Hepatitis A Vaccine Information Page ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"2 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient HepA orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"HEPATITIS A VACCINE INJ,SUSP\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Havrix\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Hepatitis A\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"(HepA)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*All adults who want to be\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"protected from hepatitis A\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"virus (HAV) infection.\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"*People who travel or work\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"anywhere EXCEPT the U.S.,\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"most, but not all of\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"Western Europe, New\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Zealand, Australia,\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"Canada, and Japan.\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"*People with chronic liver\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"disease, injecting and\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"non-injecting drug users,\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"people who have HIV\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"infection, men who have\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"sex with men, people who\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \"are homeless or live in\"}, {\"Row\": 22, \"Column\": 2, \"Text\": \"temporary housing (e.g., a\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"shelter), people who work\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"with HAV in lab settings.\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"*People who anticipate\"}, {\"Row\": 27, \"Column\": 2, \"Text\": \"close personal contact\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"with an international\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \"adoptee from\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"a country of high or\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"intermediate endemicity\"}, {\"Row\": 32, \"Column\": 2, \"Text\": \"during the first 60d\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"following the adoptee's\"}, {\"Row\": 34, \"Column\": 2, \"Text\": \"arrival in the U.S.\"}, {\"Row\": 36, \"Column\": 2, \"Text\": \"*Postexposure: adults with\"}, {\"Row\": 37, \"Column\": 2, \"Text\": \"recent (within 2wks)\"}, {\"Row\": 38, \"Column\": 2, \"Text\": \"exposure to HAV, give\"}, {\"Row\": 39, \"Column\": 2, \"Text\": \"HepA. Vaccine may be used\"}, {\"Row\": 40, \"Column\": 2, \"Text\": \"in conjunction with IG at\"}, {\"Row\": 41, \"Column\": 2, \"Text\": \"the provider's discretion\"}, {\"Row\": 42, \"Column\": 2, \"Text\": \"in adults older than age\"}, {\"Row\": 43, \"Column\": 2, \"Text\": \"40 or immunocompromised\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 2 doses, spaced 6-\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"12 months apart.\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"*If dose  2 is delayed, do\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"not repeat dose  1. Just\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"give dose  2.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"without fever.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 655,
    "fields": {
      "name": "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Hepatitis A and Hepatitis B Vaccine Information Page",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"3 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES\", \"Text\": \"4 dose series\", \"Mnemonic\": \"6\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient HepA/B orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Rapid schedule:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"HEPATITIS A/HEPATITIS B\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"VACCINE INJ,SUSP\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Twinrix\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Hepatitis A/B Recombinant\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"(HepA/HepB)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Murthy et al. Annals\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"internal medicine, 2022,\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"175(3)432-443\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*All adults who want to be\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"protected from hepatitis A\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"and hepatitis B virus\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"infection.\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"HepA Specific:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 2, \"Text\": \"*People who travel or work\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"anywhere EXCEPT the U.S.,\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"most, but not all of\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"Western Europe, New\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"Zealand, Australia,\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"Canada, and Japan.\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"*People with chronic liver\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"disease, injecting and\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"non-injecting drug users,\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"people who have HIV\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \"infection, men who have\"}, {\"Row\": 22, \"Column\": 2, \"Text\": \"sex with men, people who\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"are homeless or live in\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"temporary housing (e.g., a\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"shelter), people who work\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"with HAV in lab settings.\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"*People who anticipate\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \"close personal contact\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"with an international\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"adoptee from\"}, {\"Row\": 32, \"Column\": 2, \"Text\": \"a country of high or\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"intermediate endemicity\"}, {\"Row\": 34, \"Column\": 2, \"Text\": \"during the first 60d\"}, {\"Row\": 35, \"Column\": 2, \"Text\": \"following the adoptee's\"}, {\"Row\": 36, \"Column\": 2, \"Text\": \"arrival in the U.S.\"}, {\"Row\": 38, \"Column\": 2, \"Text\": \"*Postexposure: adults with\"}, {\"Row\": 39, \"Column\": 2, \"Text\": \"recent (within 2wks)\"}, {\"Row\": 40, \"Column\": 2, \"Text\": \"exposure to HAV, give\"}, {\"Row\": 41, \"Column\": 2, \"Text\": \"HepA. Vaccine may be used\"}, {\"Row\": 42, \"Column\": 2, \"Text\": \"in conjunction with IG at\"}, {\"Row\": 43, \"Column\": 2, \"Text\": \"the provider's discretion\"}, {\"Row\": 44, \"Column\": 2, \"Text\": \"in adults older than age\"}, {\"Row\": 45, \"Column\": 2, \"Text\": \"40 or immunocompromised\"}, {\"Row\": 47, \"Column\": 2, \"Text\": \"HepB Specific\", \"Header\": 1}, {\"Row\": 48, \"Column\": 2, \"Text\": \"*People age 19-59yrs\"}, {\"Row\": 50, \"Column\": 2, \"Text\": \"*People age 60yrs and older\"}, {\"Row\": 51, \"Column\": 2, \"Text\": \"who want to be protected\"}, {\"Row\": 52, \"Column\": 2, \"Text\": \"from hepatitis B virus\"}, {\"Row\": 53, \"Column\": 2, \"Text\": \"infection and those who are\"}, {\"Row\": 54, \"Column\": 2, \"Text\": \"at risk for hepatitis B\"}, {\"Row\": 55, \"Column\": 2, \"Text\": \"virus infection:\"}, {\"Row\": 56, \"Column\": 2, \"Text\": \"o Chronic liver disease\"}, {\"Row\": 57, \"Column\": 2, \"Text\": \"(e.g., persons with\"}, {\"Row\": 58, \"Column\": 2, \"Text\": \"hepatitis C, cirrhosis,\"}, {\"Row\": 59, \"Column\": 2, \"Text\": \"fatty liver disease,\"}, {\"Row\": 60, \"Column\": 2, \"Text\": \"alcoholic liver disease,\"}, {\"Row\": 61, \"Column\": 2, \"Text\": \"autoimmune hepatitis,\"}, {\"Row\": 62, \"Column\": 2, \"Text\": \"alanine aminotransferase\"}, {\"Row\": 63, \"Column\": 2, \"Text\": \"[ALT] or aspartate\"}, {\"Row\": 64, \"Column\": 2, \"Text\": \"aminotransferase [AST]\"}, {\"Row\": 65, \"Column\": 2, \"Text\": \"level greater than twice\"}, {\"Row\": 66, \"Column\": 2, \"Text\": \"upper limit of normal)\"}, {\"Row\": 67, \"Column\": 2, \"Text\": \"o HIV infection\"}, {\"Row\": 68, \"Column\": 2, \"Text\": \"o Sexual exposure risk\"}, {\"Row\": 69, \"Column\": 2, \"Text\": \"(e.g., sex partners of\"}, {\"Row\": 70, \"Column\": 2, \"Text\": \"hepatitis B surface\"}, {\"Row\": 71, \"Column\": 2, \"Text\": \"antigen [HBsAg]-positive\"}, {\"Row\": 72, \"Column\": 2, \"Text\": \"persons: sexually active\"}, {\"Row\": 73, \"Column\": 2, \"Text\": \"persons not in mutually\"}, {\"Row\": 74, \"Column\": 2, \"Text\": \"monogamous relationships:\"}, {\"Row\": 75, \"Column\": 2, \"Text\": \"persons seeking evaluation\"}, {\"Row\": 76, \"Column\": 2, \"Text\": \"or treatment for a\"}, {\"Row\": 77, \"Column\": 2, \"Text\": \"sexually transmitted\"}, {\"Row\": 78, \"Column\": 2, \"Text\": \"infection: men who have\"}, {\"Row\": 79, \"Column\": 2, \"Text\": \"sex with men)\"}, {\"Row\": 80, \"Column\": 2, \"Text\": \"o Current or recent\"}, {\"Row\": 81, \"Column\": 2, \"Text\": \"injection drug use\"}, {\"Row\": 82, \"Column\": 2, \"Text\": \"o Percutaneous or mucosal\"}, {\"Row\": 83, \"Column\": 2, \"Text\": \"risk for exposure to blood\"}, {\"Row\": 84, \"Column\": 2, \"Text\": \"(e.g., household contacts\"}, {\"Row\": 85, \"Column\": 2, \"Text\": \"of HBsAg-positive persons:\"}, {\"Row\": 86, \"Column\": 2, \"Text\": \"residents and staff of\"}, {\"Row\": 87, \"Column\": 2, \"Text\": \"facilities for\"}, {\"Row\": 88, \"Column\": 2, \"Text\": \"developmentally disabled\"}, {\"Row\": 89, \"Column\": 2, \"Text\": \"persons: health care and\"}, {\"Row\": 90, \"Column\": 2, \"Text\": \"public safety personnel\"}, {\"Row\": 91, \"Column\": 2, \"Text\": \"with reasonably\"}, {\"Row\": 92, \"Column\": 2, \"Text\": \"anticipated risk for\"}, {\"Row\": 93, \"Column\": 2, \"Text\": \"exposure to blood or\"}, {\"Row\": 94, \"Column\": 2, \"Text\": \"blood-contaminated body\"}, {\"Row\": 95, \"Column\": 2, \"Text\": \"fluids: hemodialysis,\"}, {\"Row\": 96, \"Column\": 2, \"Text\": \"peritoneal dialysis, home\"}, {\"Row\": 97, \"Column\": 2, \"Text\": \"dialysis, and predialysis\"}, {\"Row\": 98, \"Column\": 2, \"Text\": \"patients: patients with\"}, {\"Row\": 99, \"Column\": 2, \"Text\": \"diabetes)\"}, {\"Row\": 100, \"Column\": 2, \"Text\": \"o Incarcerated persons\"}, {\"Row\": 101, \"Column\": 2, \"Text\": \"o Travel in countries with\"}, {\"Row\": 102, \"Column\": 2, \"Text\": \"high or intermediate\"}, {\"Row\": 103, \"Column\": 2, \"Text\": \"endemic hepatitis B\"}, {\"Row\": 104, \"Column\": 2, \"Text\": \"patient is chronically\"}, {\"Row\": 105, \"Column\": 2, \"Text\": \"infected, assure\"}, {\"Row\": 106, \"Column\": 2, \"Text\": \"appropriate disease\"}, {\"Row\": 107, \"Column\": 2, \"Text\": \"management. For sex\"}, {\"Row\": 108, \"Column\": 2, \"Text\": \"partners and household\"}, {\"Row\": 109, \"Column\": 2, \"Text\": \"contacts of HBsAg-positive\"}, {\"Row\": 110, \"Column\": 2, \"Text\": \"people, provide serologic\"}, {\"Row\": 111, \"Column\": 2, \"Text\": \"screening and administer\"}, {\"Row\": 112, \"Column\": 2, \"Text\": \"initial dose of HepB\"}, {\"Row\": 113, \"Column\": 2, \"Text\": \"vaccine at same visit.\"}, {\"Row\": 115, \"Column\": 2, \"Text\": \"*Serologic testing is\"}, {\"Row\": 116, \"Column\": 2, \"Text\": \"recommended 1 to 2 months\"}, {\"Row\": 117, \"Column\": 2, \"Text\": \"after the final dose of\"}, {\"Row\": 118, \"Column\": 2, \"Text\": \"the primary vaccine series\"}, {\"Row\": 119, \"Column\": 2, \"Text\": \"and annually to determine\"}, {\"Row\": 120, \"Column\": 2, \"Text\": \"the need for booster\"}, {\"Row\": 121, \"Column\": 2, \"Text\": \"doses. Persons with anti-\"}, {\"Row\": 122, \"Column\": 2, \"Text\": \"HBs concentrations of <10\"}, {\"Row\": 123, \"Column\": 2, \"Text\": \"milliunits/mL should\"}, {\"Row\": 124, \"Column\": 2, \"Text\": \"receive a booster dose\"}, {\"Row\": 126, \"Column\": 2, \"Text\": \"NOTE: Provide serologic\"}, {\"Row\": 127, \"Column\": 2, \"Text\": \"screening for immigrants\"}, {\"Row\": 128, \"Column\": 2, \"Text\": \"from endemic areas. If\"}, {\"Row\": 129, \"Column\": 2, \"Text\": \"patient is chronically\"}, {\"Row\": 130, \"Column\": 2, \"Text\": \"infected, assure\"}, {\"Row\": 131, \"Column\": 2, \"Text\": \"appropriate disease\"}, {\"Row\": 132, \"Column\": 2, \"Text\": \"management. For sex\"}, {\"Row\": 133, \"Column\": 2, \"Text\": \"partners and household\"}, {\"Row\": 134, \"Column\": 2, \"Text\": \"contacts of HBsAg-positive\"}, {\"Row\": 135, \"Column\": 2, \"Text\": \"people, provide serologic\"}, {\"Row\": 136, \"Column\": 2, \"Text\": \"screening and administer\"}, {\"Row\": 137, \"Column\": 2, \"Text\": \"initial dose of HepB\"}, {\"Row\": 138, \"Column\": 2, \"Text\": \"vaccine at same visit.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Standard Schedule: Give 3\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"doses on a 0, 1, 6-month\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"schedule.\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"*Rapid Schedule: Give 4\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"doses on a 0, 1wk, 3wks,\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"and 1yr schedule. Must\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"receive all dose for long\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"term protection.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"without fever.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 656,
    "fields": {
      "name": "ORZID3 GMENU ABX HEPATITIS A",
      "term": null,
      "displaytext": "Hepatitis A (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"HEPATITIS A\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Disease Management\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Most acute disease is self-limited, and the virus does not cause chronic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"disease. No specific antiviral therapy is available.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Patients who appear to be developing fulminant hepatitis, including those with\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"mental status changes should receive supportive treatment. Fulminant hepatitis\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"is suggested by increased prothrombin time, cholestasis, ascites, decreased\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"liver size, or decreasing serum albumin. Supportive treatment includes\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"maintenance of fluid and electrolyte balance, monitoring and possible correction\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"of coagulation defects, treatment of hepatic encephalopathy, and good nutrition\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"with a low-protein diet.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Prevention for persons with continuing high risk of disease\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Vaccine should be offered to persons at high risk of hepatitis A infection: men\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"who have sex with men, travelers to endemic areas likely to be exposed, illegal\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"drug users, persons at occupational risk of disease, persons with chronic liver\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"disease or clotting factor disorders.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Prevention for persons with a specific, defined exposure\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Post-exposure prophylaxis should be offered to persons with substantial exposure\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"to hepatitis A. Specifically, persons exposed to acute hepatitis through\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"household or sexual contact, persons who attend or work in a day care center\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"with a recent case, or employee or patron of a restaurant with a food handler\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"with hepatitis. Post exposure prophylaxis must be given within 2 weeks of\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"exposure. Vaccine can be given at the same time as immune-globulin.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Immune globulin 0.02 ml/kg IM x 1 <AND>\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Acute viral hepatitis\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sanford keyword: Hepatitis A, Acute, Treatment\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-date article: Hepatitis A virus infections: Treatment and prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 657,
    "fields": {
      "name": "ORZID3 GMENU ABX HEPATITIS B",
      "term": null,
      "displaytext": "Hepatitis B (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 900, \"DisplayText\": \"Hepatitis B Evaluation Anti-CD20 Antibody\", \"Text\": \"Hepatitis B Evaluation\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HEPATITIS B\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute disease management\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Most acute hepatitis B disease is mild and self-limited. Patients who appear to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"be developing fulminant hepatitis, including those with mental status changes\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"should receive supportive treatment. Fulminant hepatitis is suggested by\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"increased prothrombin time, cholestasis, ascites, decreased liver size, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"decreasing serum albumin. Supportive treatment includes maintenance of fluid\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and electrolyte balance, monitoring and possible correction of coagulation\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"defects, treatment of hepatic encephalopathy, and good nutrition with a low-\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"protein diet. Antiviral therapy is not indicated. Gastroenterology consult\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"encouraged.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Chronic disease management\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Antiviral therapy for chronic hepatitis B is a complicated, highly specialized\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"task. Consult with gastroenterology and infectious diseases.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Vaccinate persons at high risk of disease including men who have sex with men,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"illegal drug users, and health care workers with substantial exposure to blood\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"or body fluids.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Give Hepatitis B vaccine 1 dose IM in deltoid at 0, then 1 or 2 months, and\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"again at 4 to 6 months.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Select below for Hepatitis B evaluation for patients receiving Anti-CD20\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Antibody Treatment\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Acute viral hepatitis\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Chronic viral hepatitis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-to-date article: Hepatitis B virus: Overview of management\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 658,
    "fields": {
      "name": "ORZID3 GMENU ABX HEPATITIS C",
      "term": null,
      "displaytext": "Hepatitis C (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HEPATITIS C\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment of acute disease\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Most acute disease is asymptomatic or mild. Patients with acute hepatitis C\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"should be referred to the Hepatitis C clinic. Treatment may be indicated for\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"disease that persists beyond 2 months\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Chronic disease treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antiviral therapy for chronic hepatitis C is a complicated, highly specialized\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"task\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Acute viral hepatitis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Chronic viral hepatitis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-to-date article: Overview of the management of chronic hepatitis C virus\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 659,
    "fields": {
      "name": "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Hepatitis B Vaccine Information Page ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"3 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"4 dose series\", \"Mnemonic\": \"6\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient HepB orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"*Hemodialysis pts only:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"HEPATITIS B INJ\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Engerix-B\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Hepatitis B\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"(HepB)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Murthy et al. Annals\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"internal medicine, 2022,\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"175(3)432-443\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*People age 19-59yrs\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"*People age 60yrs and older\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"who want to be protected\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"from hepatitis B virus\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"infection and those who are\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"at risk for hepatitis B\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"virus infection:\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"o Chronic liver disease\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"(e.g., persons with\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"hepatitis C, cirrhosis,\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"fatty liver disease,\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"alcoholic liver disease,\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"autoimmune hepatitis,\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"alanine aminotransferase\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"[ALT] or aspartate\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"aminotransferase [AST]\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \"level greater than twice\"}, {\"Row\": 22, \"Column\": 2, \"Text\": \"upper limit of normal)\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"o HIV infection\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"o Sexual exposure risk\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"(e.g., sex partners of\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"hepatitis B surface\"}, {\"Row\": 27, \"Column\": 2, \"Text\": \"antigen [HBsAg]-positive\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"persons: sexually active\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \"persons not in mutually\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"monogamous relationships:\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"persons seeking evaluation\"}, {\"Row\": 32, \"Column\": 2, \"Text\": \"or treatment for a\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"sexually transmitted\"}, {\"Row\": 34, \"Column\": 2, \"Text\": \"infection: men who have\"}, {\"Row\": 35, \"Column\": 2, \"Text\": \"sex with men)\"}, {\"Row\": 36, \"Column\": 2, \"Text\": \"o Current or recent\"}, {\"Row\": 37, \"Column\": 2, \"Text\": \"injection drug use\"}, {\"Row\": 38, \"Column\": 2, \"Text\": \"o Percutaneous or mucosal\"}, {\"Row\": 39, \"Column\": 2, \"Text\": \"risk for exposure to blood\"}, {\"Row\": 40, \"Column\": 2, \"Text\": \"(e.g., household contacts\"}, {\"Row\": 41, \"Column\": 2, \"Text\": \"of HBsAg-positive persons:\"}, {\"Row\": 42, \"Column\": 2, \"Text\": \"residents and staff of\"}, {\"Row\": 43, \"Column\": 2, \"Text\": \"facilities for\"}, {\"Row\": 44, \"Column\": 2, \"Text\": \"developmentally disabled\"}, {\"Row\": 45, \"Column\": 2, \"Text\": \"persons: health care and\"}, {\"Row\": 46, \"Column\": 2, \"Text\": \"public safety personnel\"}, {\"Row\": 47, \"Column\": 2, \"Text\": \"with reasonably\"}, {\"Row\": 48, \"Column\": 2, \"Text\": \"anticipated risk for\"}, {\"Row\": 49, \"Column\": 2, \"Text\": \"exposure to blood or\"}, {\"Row\": 50, \"Column\": 2, \"Text\": \"blood-contaminated body\"}, {\"Row\": 51, \"Column\": 2, \"Text\": \"fluids: hemodialysis,\"}, {\"Row\": 52, \"Column\": 2, \"Text\": \"peritoneal dialysis, home\"}, {\"Row\": 53, \"Column\": 2, \"Text\": \"dialysis, and predialysis\"}, {\"Row\": 54, \"Column\": 2, \"Text\": \"patients: patients with\"}, {\"Row\": 55, \"Column\": 2, \"Text\": \"diabetes)\"}, {\"Row\": 56, \"Column\": 2, \"Text\": \"o Incarcerated persons\"}, {\"Row\": 57, \"Column\": 2, \"Text\": \"o Travel in countries with\"}, {\"Row\": 58, \"Column\": 2, \"Text\": \"high or intermediate\"}, {\"Row\": 59, \"Column\": 2, \"Text\": \"endemic hepatitis B\"}, {\"Row\": 60, \"Column\": 2, \"Text\": \"patient is chronically\"}, {\"Row\": 61, \"Column\": 2, \"Text\": \"infected, assure\"}, {\"Row\": 62, \"Column\": 2, \"Text\": \"appropriate disease\"}, {\"Row\": 63, \"Column\": 2, \"Text\": \"management. For sex\"}, {\"Row\": 64, \"Column\": 2, \"Text\": \"partners and household\"}, {\"Row\": 65, \"Column\": 2, \"Text\": \"contacts of HBsAg-positive\"}, {\"Row\": 66, \"Column\": 2, \"Text\": \"people, provide serologic\"}, {\"Row\": 67, \"Column\": 2, \"Text\": \"screening and administer\"}, {\"Row\": 68, \"Column\": 2, \"Text\": \"initial dose of HepB\"}, {\"Row\": 69, \"Column\": 2, \"Text\": \"vaccine at same visit.\"}, {\"Row\": 71, \"Column\": 2, \"Text\": \"*Serologic testing is\"}, {\"Row\": 72, \"Column\": 2, \"Text\": \"recommended 1 to 2 months\"}, {\"Row\": 73, \"Column\": 2, \"Text\": \"after the final dose of\"}, {\"Row\": 74, \"Column\": 2, \"Text\": \"the primary vaccine series\"}, {\"Row\": 75, \"Column\": 2, \"Text\": \"and annually to determine\"}, {\"Row\": 76, \"Column\": 2, \"Text\": \"the need for booster\"}, {\"Row\": 77, \"Column\": 2, \"Text\": \"doses. Persons with anti-\"}, {\"Row\": 78, \"Column\": 2, \"Text\": \"HBs concentrations of <10\"}, {\"Row\": 79, \"Column\": 2, \"Text\": \"milliunits/mL should\"}, {\"Row\": 80, \"Column\": 2, \"Text\": \"receive a booster dose\"}, {\"Row\": 82, \"Column\": 2, \"Text\": \"NOTE: Provide serologic\"}, {\"Row\": 83, \"Column\": 2, \"Text\": \"screening for immigrants\"}, {\"Row\": 84, \"Column\": 2, \"Text\": \"from endemic areas. If\"}, {\"Row\": 85, \"Column\": 2, \"Text\": \"patient is chronically\"}, {\"Row\": 86, \"Column\": 2, \"Text\": \"infected, assure\"}, {\"Row\": 87, \"Column\": 2, \"Text\": \"appropriate disease\"}, {\"Row\": 88, \"Column\": 2, \"Text\": \"management. For sex\"}, {\"Row\": 89, \"Column\": 2, \"Text\": \"partners and household\"}, {\"Row\": 90, \"Column\": 2, \"Text\": \"contacts of HBsAg-positive\"}, {\"Row\": 91, \"Column\": 2, \"Text\": \"people, provide serologic\"}, {\"Row\": 92, \"Column\": 2, \"Text\": \"screening and administer\"}, {\"Row\": 93, \"Column\": 2, \"Text\": \"initial dose of HepB\"}, {\"Row\": 94, \"Column\": 2, \"Text\": \"vaccine at same visit.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 3 doses on a 0, 1, 6-\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"month schedule.\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"There must be at least\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"4wks between doses  1 and\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"2, and at least 8wks\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"between doses  2 and  3.\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"Overall, there must be at\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"least 16wks between doses\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"1 and  3.\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"[Alternative timing\"}, {\"Row\": 14, \"Column\": 3, \"Text\": \"Options for vaccination\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"include:\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"1) 0, 2, 4 months\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"2) 0, 1, 4 months\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"3) 0, 1, 2, 12 months]\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"*For adults on\"}, {\"Row\": 21, \"Column\": 3, \"Text\": \"hemodialysis or with other\"}, {\"Row\": 22, \"Column\": 3, \"Text\": \"conditions, give 2 doses\"}, {\"Row\": 23, \"Column\": 3, \"Text\": \"of 20 micrograms/mL\"}, {\"Row\": 24, \"Column\": 3, \"Text\": \"simultaneously at 0, 1, 2,\"}, {\"Row\": 25, \"Column\": 3, \"Text\": \"6 months\"}, {\"Row\": 27, \"Column\": 3, \"Text\": \"*Schedule for those who\"}, {\"Row\": 28, \"Column\": 3, \"Text\": \"have fallen behind: If the\"}, {\"Row\": 29, \"Column\": 3, \"Text\": \"series is delayed between\"}, {\"Row\": 30, \"Column\": 3, \"Text\": \"doses, DO NOT start the\"}, {\"Row\": 31, \"Column\": 3, \"Text\": \"series over. Continue from\"}, {\"Row\": 32, \"Column\": 3, \"Text\": \"where the schedule was\"}, {\"Row\": 33, \"Column\": 3, \"Text\": \"interrupted.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"without fever.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 660,
    "fields": {
      "name": "ORZID3 GMENU ABX HERPES KERATITIS",
      "term": null,
      "displaytext": "HERPES KERATITIS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO TID ($0.29/day) [R]\", \"Text\": \"Acyclovir 400 mg PO TID for 7-10 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO TID ($0.29/day) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO BID ($) [R] for 7 days\", \"Text\": \"Valacyclovir 500 mg PO BID for 7-10 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO BID ($) [R] for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 mg PO 5 times per day ($) [R] for 14 days\", \"Text\": \"Acyclovir 800 mg PO 5x/day for 14-21 days ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 mg PO 5 times per day ($) [R] for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO TID ($) [R] for 14 days\", \"Text\": \"Valacyclovir 1 gm PO TID for 14-21 days ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO TID ($) [R] for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO BID ($) [R] for 1 year\", \"Text\": \"Acyclovir 400 mg PO BID for 12 months ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO BID ($) [R] for 1 year Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO QDAY ($) [R] for 1 year\", \"Text\": \"Valacyclovir 500 mg PO QDay for 12 months ($) [R]\", \"Mnemonic\": \"14a\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO QDAY ($) [R] for 1 year Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES KERATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Ocular herpes infection can be caused by either HSV-1 or HSV-2. The majority of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cases are caused by HSV-1. The recurrence rate of ocular herpes is 40% over a 5\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"year period, less than that of oral or genital herpes. Ocular herpes is a\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"major cause of blindness and typically presents as infection of the epithelium\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"of the cornea but can also rarely involve the stroma and endothelium.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Ophthalmology consultation is recommended.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Involvement of the stroma or endothelium requires treatment with topical\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"steroid and close monitoring. For these cases, start oral antiviral and consult\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"ophthalmology for management.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Antiviral prophylaxis is recommended for patients with multiple recurrences,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"recurrent episodes with ulceration, recurrent inflammation with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"scar/vascularization approaching visual axis, patients who have had keratoplasty\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"for HSV-related scarring/astigmatism, and patients who have had HSV keratitis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"while on immunosuppressive therapy. Post-surgical prophylaxis is not discussed\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"here. Please consult ophthalmology for more information.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment of acute infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Without epithelial ulceration\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Ulceration of epithelium (Geographic ulcer)\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Infection prophylaxis for prevention of recurrence\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Reassess need for prophylaxis every 12 months\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Baratz, Arch Ophthalmology, (2012) 130.1: 108-110\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Guess et al, The Ocular Surface, (2007) 5.3:240-250\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Wilhelmus, Cochrane Database of Systematic Reviews, (2015), 1:CD002898\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Miserocchi et al, Efficacy of Valacyclovir vs Acyclovir for the Prevention of\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Recurrent Herpes Simplex\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Virus Eye Disease: A Pilot Study, American Journal of Ophthalmology, 2007\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"144:547-551\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"White et al, Ocular Microbiology and Immunology Group and American Academy of\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Ophthalmology, (2014)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 661,
    "fields": {
      "name": "ORZID3 GMENU ABX HERPES SIMPLEX ESOPHAGITIS",
      "term": null,
      "displaytext": "Herpes Simplex Esophagitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO 5x/day for 7 days ($) [R]\", \"Text\": \"Acyclovir 400 mg PO 5x/day for 7 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO 5x/day for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO 5x/day for 14 days ($) [R]\", \"Text\": \"Acyclovir 400 mg PO 5x/day for 14 days ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO 5x/day for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 14 days ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO BID for 14 days ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES SIMPLEX ESOPHAGITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"HSV infection of the esophagus usually occurs in patients who are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"immunocompromised, typically solid organ and bone marrow transplant\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"recipients. In healthy patients HSV esophagitis occurs occasionally,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"usually in men under the age of 40.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Patients usually present with odynophagia and dysphagia. Fever\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"epigastric pain, nausea, vomiting, and heartburn are less frequent.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Some patients may have coexistent herpes labialis or oropharyngeal\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"ulcers. Diagnosis is usually established with an upper endoscopy.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Suggestive findings may also be seen during a barium swallow.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Spontaneous resolution usually occurs in immunocompetent patients after\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"one to two weeks. Patients may respond more quickly if treated with a\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"short course of oral acyclovir.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treat for 7-10 days\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Treat for 14-21 days\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"John Hopkin's Guides keyword: Herpes simplex virus\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes simplex\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date article: Herpes simplex virus infection of the esophagitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 662,
    "fields": {
      "name": "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Haemophilus Influenza Type B Information Page ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HAEMOPHILUS B VACCINE ONE DOSE\", \"Text\": \"One dose\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HAEMOPHILUS B VACCINE 3 DOSE SERIES\", \"Text\": \"3 dose series\", \"Mnemonic\": \"4\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient Hib orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"HSCT Pts only:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"HAEMOPHILUS B VACCINE\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"INJ,LYPHL\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Hiberix\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Haemophilus influenzae\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"type b\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"(Hib)\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*Not routinely recommended\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"for healthy adults.\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"*Those adults at highest\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"risk of serious Hib\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"disease include people who\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"1) have anatomic or\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"functional asplenia,\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"2) are undergoing an\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"elective splenectomy, or\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"3) are recipients of\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"hematopoietic stem cell\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"transplant (HSCT).\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 1 dose to adults in\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"categories 1 or 2 (see 2nd\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"bullet in column to left)\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"if no history of previous\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"Hib vaccine.\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"*For HSCT patients,\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"regardless of Hib vacci-\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"nation history, give 3\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"doses, at least 4wks\"}, {\"Row\": 14, \"Column\": 3, \"Text\": \"apart, beginning 6-12\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"months after transplant.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"without fever.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 663,
    "fields": {
      "name": "ORZID3 GMENU ABX HIV-AIDS",
      "term": null,
      "displaytext": "HIV-AIDS (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Consult Infectious Diseases (outpatient)\", \"Text\": \"ID consult\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRTC\", \"Text\": \"MRTC consult\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HIV\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"HIV infection and AIDS are associated with several host defense defects. Cell-\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"mediated immune defects render a patient more susceptible to opportunistic\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infections with pathogens like Pneumocystis jirovecii (formerly Pneumocystis\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"carinii), Toxoplasma gondii, cytomegalovirus, mycobacterium-avium intracellulare\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"complex, and Candida spp.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Contact ID or HIV (MRTC) service for assistance.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Rich RR, et al, eds. Clinical Immunology\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Roitt l, et al, eds. Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 664,
    "fields": {
      "name": "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE",
      "term": null,
      "displaytext": "Human Papillomavirus Vaccine Information Page ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"3 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient HPV orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"PAPILLOMAVIRUS HUMAN\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"VACCINE INJ,SUSP\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Gardasil 9\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Human papillomavirus\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(HPV)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*For unvaccinated or\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"partially vaccinated\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"adults through age 26yrs:\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Complete a 3-dose series\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"of HPV.\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"*Unvaccinated adults age\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"27 through 45yrs may be\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"vaccinated based on\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"shared clinical decision-\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"making.\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"*Other guidance: Pregnancy\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"is neither a\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"contraindication nor a\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"precaution\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"to HPV vaccine.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 3 doses on a 0, 1-2,\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"6-month schedule.\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"*There must be at least\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"4wks between doses  1 and\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"2 and at least 12wks\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"between doses  2 and  3.\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"Overall, there must be at\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"least 5 months between\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"doses  1 and  3\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"*If the type of HPV\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"vaccine previously given\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"is not known or not\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"available, any available\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"HPV vaccine should be used\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"to complete the series.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"without fever.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 665,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION 65 YEARS OR GREATER",
      "term": null,
      "displaytext": "Immunization of Patients Age 65 Years or Greater ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3074, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"14\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis\", \"Mnemonic\": \"16\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series.\", \"Mnemonic\": \"18\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"20\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"22\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series for 19 to 23yrs, and for those w/additional risk\", \"Mnemonic\": \"24\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"Pneumococcal 20-valent: one dose.\", \"Mnemonic\": \"26\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"28\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series for those w/additional risk factor or another.\", \"Mnemonic\": \"30\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"32\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"34\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"36\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"38\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"40\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"42\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"44\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"46\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"48\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"50\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"52\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"54\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"56\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS AGE 65 YEARS OR GREATER\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients age 65 years or greater:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Human papillomavirus: not indicated.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Measles, mumps, and rubella: not indicated\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 666,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION AGE 19-26 YEARS",
      "term": null,
      "displaytext": "Immunization of Patients Age 19-26 Years",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3075, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series.\", \"Mnemonic\": \"18\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"20\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"22\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"24\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"26\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series for 19 to 23yrs, and for those w/additional risk\", \"Mnemonic\": \"28\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal: for those w/additional risk factor or another indication. Refer to\", \"Mnemonic\": \"30\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"32\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"34\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"36\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"38\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"40\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"42\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"44\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"46\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"48\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"50\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"52\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"54\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"56\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"58\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS AGE 19-26 YEARS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients age 19-26 years:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Herpes zoster: not indicated.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"specific immunization recommendations for patients with these indications or\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"refer to the Pneumococcal vaccine information menus below.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Varicella: not indicated.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 73, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 667,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION AGE 27-49 YEARS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3076, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series for age 27-45yrs based on shared clinical\", \"Mnemonic\": \"18\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"20\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"22\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"24\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"26\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose for those w/additional risk factor or another\", \"Mnemonic\": \"28\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal: for those w/additional risk factor or another indication. Refer to\", \"Mnemonic\": \"30\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"32\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series for those born 1980 or later.\", \"Mnemonic\": \"34\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"36\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"38\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"40\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"42\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"44\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"46\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"48\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"50\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"52\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"54\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"56\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"58\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"60\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS AGE 27-49 YEARS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients age 27-49 years:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Herpes zoster: not indicated.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"decision making.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"specific immunization recommendations for patients with these indications or\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"refer to the Pneumococcal vaccine information menus below.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 668,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION AGE 50-64 YEARS",
      "term": null,
      "displaytext": "Immunization of Patients Age 50-64 Years",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3077, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"18\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"20\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"22\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"24\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"26\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose for those w/additional risk factor or another\", \"Mnemonic\": \"28\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal: for those w/additional risk factor or another indication. Refer to\", \"Mnemonic\": \"30\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"32\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series for those w/additional risk factor or another.\", \"Mnemonic\": \"34\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"36\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"38\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"40\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"42\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"44\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"46\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"48\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"50\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"52\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"54\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"56\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"58\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"60\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS AGE 50-64 YEARS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients age 50-64 years:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Human papillomavirus: not indicated.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"nor another indication.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"specific immunization recommendations for patients with these indications or\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"refer to the Pneumococcal vaccine information menus below.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 73, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 669,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION HEART, LUNG DISEASE, ALCOHOLISM",
      "term": null,
      "displaytext": "Immunization of Patients with Heart/Lung Disease or Alcoholism  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3078, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"18\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs\", \"Mnemonic\": \"20\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"22\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"24\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"26\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"28\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"30\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"Pneumococcal 20-valent: one dose.\", \"Mnemonic\": \"32\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"34\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series.\", \"Mnemonic\": \"36\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"38\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"40\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"42\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"44\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"46\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"48\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"50\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"52\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"54\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"56\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"58\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"60\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"62\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS WITH HEART/LUNG DISEASE OR ALCOHOLISM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients with heart/lung disease or alcoholism:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"based on shared clinical decision making.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 670,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE",
      "term": null,
      "displaytext": "Immunization in Chronic Liver Disease",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3079, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series.\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series.\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis\", \"Mnemonic\": \"16\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"18\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs\", \"Mnemonic\": \"20\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"22\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"24\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"26\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"28\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"30\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"Pneumococcal 20-valent: one dose prior to age 65.\", \"Mnemonic\": \"32\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"34\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series.\", \"Mnemonic\": \"36\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"38\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"40\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"42\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"44\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"46\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"48\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"50\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"52\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"54\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"56\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"58\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"60\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"62\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS WITH CHRONIC LIVER DISEASE\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See specific immunization information pages located at the bottom of this page\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"for other indications, contraindications, and one-time dose orders to listed\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"vaccines.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients with chronic liver disease:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"based on shared clinical decision making.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 68, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 671,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION IN DIABETES",
      "term": null,
      "displaytext": "Immunization of Patients with Diabetes  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3080, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"18\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs\", \"Mnemonic\": \"20\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"22\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"24\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"26\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"28\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"30\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"Pneumococcal 20-valent: one dose.\", \"Mnemonic\": \"32\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"34\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series.\", \"Mnemonic\": \"36\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"38\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"40\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"42\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"44\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"46\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"48\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"50\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"52\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"54\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"56\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"58\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"60\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"62\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS WITH DIABETES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients with diabetes:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"based on shared clinical decision making.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 672,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION IN HEALTH CARE PERSONNEL",
      "term": null,
      "displaytext": "Immunization of Patients who are Health Care Personnel ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3081, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"18\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs\", \"Mnemonic\": \"20\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"22\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"24\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"26\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"28\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"30\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal: for those w/additional risk factor or another indication. Refer to\", \"Mnemonic\": \"32\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"34\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series.\", \"Mnemonic\": \"36\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"38\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"40\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"42\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"44\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"46\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"48\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"50\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"52\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"54\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"56\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"58\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"60\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"62\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS WHO ARE HEALTH CARE PERSONNEL\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients who are health care personnel:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"based on shared clinical decision making.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"specific immunization recommendations for patients with these indications or\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"refer to the Pneumococcal vaccine information menus below.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 673,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS",
      "term": null,
      "displaytext": "Immunization of patients with HIV ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3082, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series.\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series.\", \"Mnemonic\": \"12\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"18\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs\", \"Mnemonic\": \"20\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"22\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella *CONTRAINDICATED IF CD4<200 cells/mm3: 2 dose\", \"Mnemonic\": \"24\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES\", \"Text\": \"Meningococcal A, C, W and Y: 2 dose primary series, booster every 5yrs.\", \"Mnemonic\": \"26\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"28\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"Pneumococcal 20-valent: one dose.\", \"Mnemonic\": \"30\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"32\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: *CONTRAINDICATED IF CD4<200 cells/mm3: 2 dose series.\", \"Mnemonic\": \"34\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"36\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"38\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"40\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"42\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"44\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"46\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"48\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"50\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"52\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"54\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"56\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"58\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"60\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS WITH HIV\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See specific immunization information pages located at the bottom of this page\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"for other indications, contraindications, and one-time dose orders to listed\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"vaccines.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients with HIV:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"based on shared clinical decision making.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"series.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 674,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD",
      "term": null,
      "displaytext": "Immunization of patient with renal failure on hemodialysis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3083, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series.\", \"Mnemonic\": \"12\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"14\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs\", \"Mnemonic\": \"16\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"18\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"20\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"22\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"24\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"26\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"Pneumococcal 20-valent: one dose.\", \"Mnemonic\": \"28\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"30\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series.\", \"Mnemonic\": \"32\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"34\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"36\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"38\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"40\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"42\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"44\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"46\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"48\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"50\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"52\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"54\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"56\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"58\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PATIENTS WITH END STAGE RENAL DISEASE OR ON HEMODIALYSIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for patients with end stage renal disease or on\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"hemodialysis:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Hepatitis A/B: refer to hepatitis A vaccine series above and high dose hepatitis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"vaccine series below.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Hepatitis B: give high dose series below.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"based on shared clinical decision making.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 70, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 73, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 675,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION IN MEN WHO HAVE SEX WITH MEN",
      "term": null,
      "displaytext": "Immunization of Men who Have Sex with Men  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3084, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series\", \"Mnemonic\": \"12\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs.\", \"Mnemonic\": \"18\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs\", \"Mnemonic\": \"20\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"22\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, mumps, and rubella: one dose.\", \"Mnemonic\": \"24\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor\", \"Mnemonic\": \"26\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"28\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"30\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal: for those w/additional risk factor or another indication. Refer to\", \"Mnemonic\": \"32\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.\", \"Mnemonic\": \"34\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Varicella: 2 dose series.\", \"Mnemonic\": \"36\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"38\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"40\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"42\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"44\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"46\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"48\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"50\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"52\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"54\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"56\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"58\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"60\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"62\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF MEN WHO HAVE SEX WITH MEN\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See immunization information pages located at the bottom of this page for other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Specific vaccine orders for men who have sex with men:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"based on shared clinical decision making.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"or another indication.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"indication.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"specific immunization recommendations for patients with these indications or\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"refer to the Pneumococcal vaccine information menus below.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 676,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS",
      "term": null,
      "displaytext": "Immunization of Immunocompromised Patients ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3085, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: 2 dose series, for those who want protection, or w/additional risk\", \"Mnemonic\": \"10\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: 3 dose series, for those who want protection, or w/additional\", \"Mnemonic\": \"12\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster: 2 dose series in those age >/= 50yrs\", \"Mnemonic\": \"18\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Human papillomavirus: 3 dose series through age </= 26yrs\", \"Mnemonic\": \"20\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually\", \"Mnemonic\": \"22\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"24\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B: 2 dose series, for those w/additional risk factor or another\", \"Mnemonic\": \"26\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"Pneumococcal 20-valent: one dose.\", \"Mnemonic\": \"28\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs\", \"Mnemonic\": \"30\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"32\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"34\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"36\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"38\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"40\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"42\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"44\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"46\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"48\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"50\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"52\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"54\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"56\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF IMMUNOCOMPROMISED PATIENTS (EXCLUDING HIV and HSCT)\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See specific immunization information pages located at the bottom of this page\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"for other indications, contraindications, and one-time dose orders to listed\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"vaccines.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Specific vaccine orders for immunocompromised patients:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"factor or another indication.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"risk factor or another indication.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Measles, mumps, and rubella *CONTRAINDICATED*\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"indication\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Varicella: *CONTRAINDICATED*\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 677,
    "fields": {
      "name": "ORZID3 GMENU ABX IMMUNIZATIONS SPECIALTY CLINICS",
      "term": null,
      "displaytext": "Immunizations-Administered in Clinic ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A 2 Dose Series\", \"Mnemonic\": \"14\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B 3 Dose Series\", \"Mnemonic\": \"16\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B 4 Dose High Dose Series (for immunocompromised patients)\", \"Mnemonic\": \"18\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B (Twinrix) 3 Dose Series\", \"Mnemonic\": \"20\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES\", \"Text\": \"Hepatitis A/B (Twinrix) Accelerated 4 Dose Series\", \"Mnemonic\": \"22\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster (Shingrix) 2 dose series\", \"Mnemonic\": \"24\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B Vaccine 2 Dose Series\", \"Mnemonic\": \"34\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES\", \"Text\": \"Meningococcal Conjugate (MenACWY) Vaccine 2 dose series\", \"Mnemonic\": \"36\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 13-VALENT VACCINE ONE DOSE\", \"Text\": \"Pneumococcal 13-valent vaccine ONCE\", \"Mnemonic\": \"38\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE\", \"Text\": \"Pneumococcal 23-valent vaccine ONCE\", \"Mnemonic\": \"40\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TETANUS/DIPHTHERIA VACCINE ONE DOSE\", \"Text\": \"Tetanus Diptheria Vaccine booster\", \"Mnemonic\": \"50\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE\", \"Text\": \"Tetanus/Diphteria/Pertussis (TDAP) Vaccine booster\", \"Mnemonic\": \"52\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Vaccines - Administered in Clinic (select vaccine to place order)\", \"Header\": 1}, {\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Recommended Immunization Schedules and Outpatient Vaccine Orders\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": 710, \"DisplayText\": \"CDC Recommended Adult Immunizations\", \"Text\": \"[Click Here] Main CDSS Recommended Immunizations Page\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Patient Vaccine History:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Item\": 3086, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"[Click Here] for vaccination history including link to Joint Legacy Viewer\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Below are links to immunization information and outpatient vaccine orders:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"[Click Here] for links to PDFs of CDC Adult Immunization Schedules\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Please note:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"*A vaccine series does not need to be restarted, regardless of the time\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"that has elapsed between doses.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"*For the purpose of calculating intervals between doses, 4 weeks = 28 days.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Intervals of 4 months or greater are determined by calendar months.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"*Any vaccine can be given with another unless otherwise noted on the\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"specific vaccine page. (See link above for Main CDSS Immunization page)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"*Mild illness is not a contraindication to receiving any vaccine.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 678,
    "fields": {
      "name": "ORZID3 GMENU ABX INDEX OUTPATIENT",
      "term": "Outpatient Antimicrobial CDSS Index",
      "displaytext": "Outpatient Antimicrobial CDSS Index  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Abscess, brain\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Abscess, cranial epidural\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 803, \"DisplayText\": \"Cutaneous abscess (Outpatient)\", \"Text\": \"Abscess, cutaneous\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 853, \"DisplayText\": \"\", \"Text\": \"Abscess, liver\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 925, \"DisplayText\": \"Lung abscess (Outpatient)\", \"Text\": \"Abscess, lung\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 698, \"DisplayText\": \"Perianal/Anorectal Abscess\", \"Text\": \"Abscess, perianal/anorectal\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 633, \"DisplayText\": \"Abscesses (Outpatient)\", \"Text\": \"Abscess, skin and soft tissue\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Abscess, spinal epidural\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 857, \"DisplayText\": \"Acinetobacter baumanni (Outpatient)\", \"Text\": \"Acinetobacter baumannii, general\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Acinetobacter baumannii, nosocomial pneumonia\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"Acquired immunodeficiency syndrome (AIDS)\", \"Mnemonic\": \"22\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 877, \"DisplayText\": \"Actinomyces spp. (Outpatient)\", \"Text\": \"Actinomyces infections, general\", \"Mnemonic\": \"24\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Adenovirus diarrhea/gastroenteritis\", \"Mnemonic\": \"26\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 924, \"DisplayText\": \"Large uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"Aerobic bottle, large uniform bacilli\", \"Mnemonic\": \"28\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 1027, \"DisplayText\": \"Small uniform bacillin in an aerobic bottle (Outpatient)\", \"Text\": \"Aerobic bottle, small pleomorphic bacilli\", \"Mnemonic\": \"30\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 809, \"DisplayText\": \"Diarrhea with Aeromonas (Outpatient)\", \"Text\": \"Aeromonas diarrhea/gastroenteritis\", \"Mnemonic\": \"32\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Aggregatibacter native valve endocarditis\", \"Mnemonic\": \"34\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Aggregatibacter prosthetic valve endocarditis\", \"Mnemonic\": \"36\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 144, \"DisplayText\": \"Drug allergies\", \"Text\": \"Allergy information\", \"Mnemonic\": \"38\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 445, \"DisplayText\": \"Altered microbial flora\", \"Text\": \"Altered microbial flora\", \"Mnemonic\": \"40\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 680, \"DisplayText\": \"Amebic Liver Abscess\", \"Text\": \"Amebic liver abscess\", \"Mnemonic\": \"42\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 923, \"DisplayText\": \"Large uniform bacilli in an aerobic bottle (Outpatient)\", \"Text\": \"Anaerobic bottle, large uniform bacilli\", \"Mnemonic\": \"44\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 1028, \"DisplayText\": \"Small uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"Anaerobic bottle, small pleomorphic bacilli\", \"Mnemonic\": \"46\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 878, \"DisplayText\": \"Anaerobic Gram-positive cocci (Outpatient)\", \"Text\": \"Anaerobic gram-positive cocci\", \"Mnemonic\": \"48\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 962, \"DisplayText\": \"Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis) - Outpatient\", \"Text\": \"Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)\", \"Mnemonic\": \"50\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 698, \"DisplayText\": \"Perianal/Anorectal Abscess\", \"Text\": \"Anorectal abscess\", \"Mnemonic\": \"52\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 991, \"DisplayText\": \"Prevention of infection in a patient with malignancy (Outpatient)\", \"Text\": \"Antibacterial prophylaxis in malignancy\", \"Mnemonic\": \"54\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antibiogram\", \"Mnemonic\": \"56\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 992, \"DisplayText\": \"Prevention of fungal infection in a patient with malignancy\", \"Text\": \"Antifungal prophylaxis in malignancy\", \"Mnemonic\": \"58\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 1057, \"DisplayText\": \"\", \"Text\": \"Antimicrobial interactions with warfarin\", \"Mnemonic\": \"60\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Antimicrobial shortages updates\", \"Mnemonic\": \"62\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antimicrobial susceptibilities\", \"Mnemonic\": \"64\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 732, \"DisplayText\": \"\", \"Text\": \"Antiviral prophylaxis in malignancy\", \"Mnemonic\": \"66\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 736, \"DisplayText\": \"Appendicitis with perforation (Outpatient)\", \"Text\": \"Appendicitis with perforation\", \"Mnemonic\": \"68\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 737, \"DisplayText\": \"Appendicitis without perforation (Outpatient)\", \"Text\": \"Appendicitis without perforation\", \"Mnemonic\": \"70\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 928, \"DisplayText\": \"Arthritis associated with Lyme disease (Outpatient)\", \"Text\": \"Arthritis associated with Lyme disease\", \"Mnemonic\": \"72\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 841, \"DisplayText\": \"Aspergillus spp. (Outpatient)\", \"Text\": \"Aspergillus infections, general\", \"Mnemonic\": \"74\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 739, \"DisplayText\": \"Aspiration pneumonia (Outpatient)\", \"Text\": \"Aspiration pneumonia\", \"Mnemonic\": \"76\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"Asplenia [CLICK HERE], includes:\", \"Mnemonic\": \"78\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Astrovirus diarrhea/gastroenteritis\", \"Mnemonic\": \"80\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 687, \"DisplayText\": \"Bacteriuria, Candiduria and Pyuria (outpatient)\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"82\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 687, \"DisplayText\": \"Bacteriuria, Candiduria and Pyuria (outpatient)\", \"Text\": \"Asymptomatic candiduria\", \"Mnemonic\": \"84\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 687, \"DisplayText\": \"Bacteriuria, Candiduria and Pyuria (outpatient)\", \"Text\": \"Asymptomatic pyuria\", \"Mnemonic\": \"86\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 958, \"DisplayText\": \"Babesia spp. (Outpatient)\", \"Text\": \"Babesia infections, general\", \"Mnemonic\": \"88\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 819, \"DisplayText\": \"Diarrhea with Shigella (Outpatient)\", \"Text\": \"Bacillary dysentery\", \"Mnemonic\": \"90\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 924, \"DisplayText\": \"Large uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"Bacilli, large uniform, aerobic bottle\", \"Mnemonic\": \"92\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 923, \"DisplayText\": \"Large uniform bacilli in an aerobic bottle (Outpatient)\", \"Text\": \"Bacilli, large uniform, anaerobic bottle\", \"Mnemonic\": \"94\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 1027, \"DisplayText\": \"Small uniform bacillin in an aerobic bottle (Outpatient)\", \"Text\": \"Bacilli, small pleomorphic, aerobic bottle\", \"Mnemonic\": \"96\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 1028, \"DisplayText\": \"Small uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"Bacilli, small pleomorphic, anaerobic bottle\", \"Mnemonic\": \"98\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 879, \"DisplayText\": \"Bacilli species (Outpatient)\", \"Text\": \"Bacillus infections, general\", \"Mnemonic\": \"100\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Bacteremia\", \"Mnemonic\": \"102\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 855, \"DisplayText\": \"Gram negative bacteria (Outpatient)\", \"Text\": \"Bacteria, Gram-Negative section\", \"Mnemonic\": \"104\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 856, \"DisplayText\": \"\", \"Text\": \"Bacteria, Gram-Positive section\", \"Mnemonic\": \"106\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 687, \"DisplayText\": \"Bacteriuria, Candiduria and Pyuria (outpatient)\", \"Text\": \"Bacteriuria\", \"Mnemonic\": \"108\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 858, \"DisplayText\": \"Bacteroides spp. (Outpatient)\", \"Text\": \"Bacteroides infections, general\", \"Mnemonic\": \"110\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 744, \"DisplayText\": \"Bed Bugs (Hemiptera) - Outpatient\", \"Text\": \"Bed bugs\", \"Mnemonic\": \"112\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 745, \"DisplayText\": \"Bell's palsy (Outpatient)\", \"Text\": \"Bell's palsy\", \"Mnemonic\": \"114\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 751, \"DisplayText\": \"Bite wounds (Outpatient)\", \"Text\": \"Bite wounds\", \"Mnemonic\": \"116\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 842, \"DisplayText\": \"Blastomyces dermatitidis (Outpatient)\", \"Text\": \"Blastomycosis infections, general\", \"Mnemonic\": \"118\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 752, \"DisplayText\": \"Body Lice (Pediculosis Corporis) - Outpatient\", \"Text\": \"Body lice\", \"Mnemonic\": \"120\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 1029, \"DisplayText\": \"Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)\", \"Text\": \"Bone and Joint section\", \"Mnemonic\": \"122\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"Bone marrow transplant immunizations\", \"Mnemonic\": \"124\"}, {\"Row\": 74, \"Column\": 1, \"Item\": 999, \"DisplayText\": \"Enterococci infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Bone prosthesis infection\", \"Mnemonic\": \"126\"}, {\"Row\": 75, \"Column\": 1, \"Item\": 859, \"DisplayText\": \"Bordetella spp. (Outpatient)\", \"Text\": \"Bordetella infections, general\", \"Mnemonic\": \"128\"}, {\"Row\": 76, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Brain abscess from contiguous or hematogenous spread\", \"Mnemonic\": \"130\"}, {\"Row\": 77, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Brain abscess with Nocardia spp.\", \"Mnemonic\": \"132\"}, {\"Row\": 78, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Brain abscess with Pseudomonas spp.\", \"Mnemonic\": \"134\"}, {\"Row\": 79, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Brain abscess with Toxoplasma gondii\", \"Mnemonic\": \"136\"}, {\"Row\": 80, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Brain abscess, post-surgical or post-traumatic\", \"Mnemonic\": \"138\"}, {\"Row\": 81, \"Column\": 1, \"Item\": 777, \"DisplayText\": \"Bronchitis/COPD Exacerbation\", \"Text\": \"Bronchitis\", \"Mnemonic\": \"140\"}, {\"Row\": 82, \"Column\": 1, \"Item\": 95, \"DisplayText\": \"Bronchitis not benefited\", \"Text\": \"Bronchitis in otherwise healthy patient\", \"Mnemonic\": \"142\"}, {\"Row\": 83, \"Column\": 1, \"Item\": 860, \"DisplayText\": \"Brucella spp.\", \"Text\": \"Brucella infections, general\", \"Mnemonic\": \"144\"}, {\"Row\": 84, \"Column\": 1, \"Item\": 860, \"DisplayText\": \"Brucella spp.\", \"Text\": \"Brucella spp.\", \"Mnemonic\": \"146\"}, {\"Row\": 85, \"Column\": 1, \"Item\": 1024, \"DisplayText\": \"Septic bursitis (Outpatient)\", \"Text\": \"Bursitis, septic\", \"Mnemonic\": \"148\"}, {\"Row\": 88, \"Column\": 1, \"Item\": 812, \"DisplayText\": \"Diarrhea with Campylobacter (Outpatient)\", \"Text\": \"Campylobacter diarrhea/gastroenteritis\", \"Mnemonic\": \"150\"}, {\"Row\": 89, \"Column\": 1, \"Item\": 861, \"DisplayText\": \"Campylobacter spp. (Outpatient)\", \"Text\": \"Campylobacter, general\", \"Mnemonic\": \"152\"}, {\"Row\": 90, \"Column\": 1, \"Item\": 907, \"DisplayText\": \"Malignancy (Outpatient)\", \"Text\": \"Cancer [CLICK HERE], includes:\", \"Mnemonic\": \"154\"}, {\"Row\": 92, \"Column\": 1, \"Item\": 843, \"DisplayText\": \"Candida albicans (Outpatient)\", \"Text\": \"Candida albicans infections, general\", \"Mnemonic\": \"156\"}, {\"Row\": 93, \"Column\": 1, \"Item\": 844, \"DisplayText\": \"Candida glabrata (Outpatient)\", \"Text\": \"Candida glabrata infections, general\", \"Mnemonic\": \"158\"}, {\"Row\": 94, \"Column\": 1, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Candida intravascular catheter-associated infection\", \"Mnemonic\": \"160\"}, {\"Row\": 95, \"Column\": 1, \"Item\": 845, \"DisplayText\": \"Candida krusei (Outpatient)\", \"Text\": \"Candida krusei infections, general\", \"Mnemonic\": \"162\"}, {\"Row\": 96, \"Column\": 1, \"Item\": 1011, \"DisplayText\": \"Retinitis (Outpatient)\", \"Text\": \"Candida retinitis\", \"Mnemonic\": \"164\"}, {\"Row\": 97, \"Column\": 1, \"Item\": 641, \"DisplayText\": \"Candida Urinary Tract Infections\", \"Text\": \"Candida urinary tract infection\", \"Mnemonic\": \"166\"}, {\"Row\": 98, \"Column\": 1, \"Item\": 778, \"DisplayText\": \"Candida vulvo-vaginitis (Outpatient)\", \"Text\": \"Candida vulvo-vaginitis\", \"Mnemonic\": \"168\"}, {\"Row\": 99, \"Column\": 1, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Candidemia\", \"Mnemonic\": \"170\"}, {\"Row\": 100, \"Column\": 1, \"Item\": 804, \"DisplayText\": \"Cutaneous Candidiasis (Outpatient)\", \"Text\": \"Candidiasis\", \"Mnemonic\": \"172\"}, {\"Row\": 101, \"Column\": 1, \"Item\": 687, \"DisplayText\": \"Bacteriuria, Candiduria and Pyuria (outpatient)\", \"Text\": \"Candiduria\", \"Mnemonic\": \"174\"}, {\"Row\": 102, \"Column\": 1, \"Item\": 849, \"DisplayText\": \"Furuncles and Carbuncles (Outpatient)\", \"Text\": \"Carbuncles\", \"Mnemonic\": \"176\"}, {\"Row\": 103, \"Column\": 1, \"Item\": 929, \"DisplayText\": \"Cardiac disease associated with Lyme disease (Outpatient)\", \"Text\": \"Cardiac disease associated with Lyme disease\", \"Mnemonic\": \"178\"}, {\"Row\": 104, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Cardiobacterium native valve endocarditis\", \"Mnemonic\": \"180\"}, {\"Row\": 105, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Cardiobacterium prosthetic valve endocarditis\", \"Mnemonic\": \"182\"}, {\"Row\": 106, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Cardiovascular device infections (excluding valves)\", \"Mnemonic\": \"184\"}, {\"Row\": 108, \"Column\": 1, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Catheter-associated infection, intravascular\", \"Mnemonic\": \"186\"}, {\"Row\": 109, \"Column\": 1, \"Item\": 781, \"DisplayText\": \"Cat-Scratch Disease (Outpatient)\", \"Text\": \"Cat-scratch disease\", \"Mnemonic\": \"188\"}, {\"Row\": 110, \"Column\": 1, \"Item\": 345, \"DisplayText\": \"Cell-mediated immunity (CMI) defects\", \"Text\": \"Cell-mediated immunity (CMI) defects\", \"Mnemonic\": \"190\"}, {\"Row\": 111, \"Column\": 1, \"Item\": 783, \"DisplayText\": \"Cellulitis (Outpatient)\", \"Text\": \"Cellulitis\", \"Mnemonic\": \"192\"}, {\"Row\": 112, \"Column\": 1, \"Item\": 901, \"DisplayText\": \"Herpes whitlow (Digit or Hand Cellulitis) - Outpatient\", \"Text\": \"Cellulitis, herpes whitlow\", \"Mnemonic\": \"194\"}, {\"Row\": 113, \"Column\": 1, \"Item\": 987, \"DisplayText\": \"Postseptal cellulitis (Orbital cellulitis) - Outpatient\", \"Text\": \"Cellulitis, postseptal (orbital)\", \"Mnemonic\": \"196\"}, {\"Row\": 114, \"Column\": 1, \"Item\": 990, \"DisplayText\": \"Preseptal cellulitis (Outpatient)\", \"Text\": \"Cellulitis, preseptal\", \"Mnemonic\": \"198\"}, {\"Row\": 115, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Central Nervous System section\", \"Mnemonic\": \"200\"}, {\"Row\": 116, \"Column\": 1, \"Item\": 784, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Cervicitis associated with sexually transmitted diseases\", \"Mnemonic\": \"202\"}, {\"Row\": 117, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Chickenpox vaccination\", \"Mnemonic\": \"204\"}, {\"Row\": 118, \"Column\": 1, \"Item\": 996, \"DisplayText\": \"Primary infection (Chickenpox) - Outpatient\", \"Text\": \"Chickenpox, primary infection\", \"Mnemonic\": \"206\"}, {\"Row\": 119, \"Column\": 1, \"Item\": 1008, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\") - Outpatient\", \"Text\": \"Chickenpox, reactivation of primary infection\", \"Mnemonic\": \"208\"}, {\"Row\": 120, \"Column\": 1, \"Item\": 1053, \"DisplayText\": \"Urethritis associated with sexually transmitted disease (Outpatient)\", \"Text\": \"Chlamydia urethritis\", \"Mnemonic\": \"210\"}, {\"Row\": 121, \"Column\": 1, \"Item\": 786, \"DisplayText\": \"Cholangitis (Outpatient)\", \"Text\": \"Cholangitis\", \"Mnemonic\": \"212\"}, {\"Row\": 122, \"Column\": 1, \"Item\": 787, \"DisplayText\": \"Cholecystitis (Outpatient)\", \"Text\": \"Cholecystitis\", \"Mnemonic\": \"214\"}, {\"Row\": 123, \"Column\": 1, \"Item\": 862, \"DisplayText\": \"Citrobacter spp. (Outpatient)\", \"Text\": \"Citrobacter infections, general\", \"Mnemonic\": \"216\"}, {\"Row\": 124, \"Column\": 1, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Clostridium difficile suspected, sepsis\", \"Mnemonic\": \"218\"}, {\"Row\": 125, \"Column\": 1, \"Item\": 782, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Clostridium difficile, mild to moderate disease\", \"Mnemonic\": \"220\"}, {\"Row\": 126, \"Column\": 1, \"Item\": 905, \"DisplayText\": \"Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)\", \"Text\": \"Clostridium difficile, severe/life-threatening disease\", \"Mnemonic\": \"222\"}, {\"Row\": 127, \"Column\": 1, \"Item\": 880, \"DisplayText\": \"Clostridium spp. (Outpatient)\", \"Text\": \"Clostridium infections, general\", \"Mnemonic\": \"224\"}, {\"Row\": 128, \"Column\": 1, \"Item\": 701, \"DisplayText\": \"Blood Culture Positive for Coagulase-Negative Staphylococci (outpatient)\", \"Text\": \"Coagulase negative staphylococci, single blood culture positive\", \"Mnemonic\": \"226\"}, {\"Row\": 129, \"Column\": 1, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Coagulase-negative Staphylococci (CNS) bacteremia\", \"Mnemonic\": \"228\"}, {\"Row\": 130, \"Column\": 1, \"Item\": 881, \"DisplayText\": \"Treatment for Coagulase Negative Staphylococci (Outpatient)\", \"Text\": \"Coagulase-negative staphylococci, general\", \"Mnemonic\": \"230\"}, {\"Row\": 131, \"Column\": 1, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Coagulase-negative staphylococci, intravascular catheter-associated infectio\", \"Mnemonic\": \"232\"}, {\"Row\": 132, \"Column\": 1, \"Item\": 846, \"DisplayText\": \"Coccidioidomyces (Outpatient)\", \"Text\": \"Coccidioides infections, general\", \"Mnemonic\": \"234\"}, {\"Row\": 133, \"Column\": 1, \"Item\": 791, \"DisplayText\": \"CMV colitis or esophagitis (Outpatient)\", \"Text\": \"Colitis, cytomegalovirus (CMV)\", \"Mnemonic\": \"236\"}, {\"Row\": 134, \"Column\": 1, \"Item\": 644, \"DisplayText\": \"Colonized Respiratory Tract in a Patient on a Ventilator (outpatient)\", \"Text\": \"Colonized respiratory tract patient on a ventilator\", \"Mnemonic\": \"238\"}, {\"Row\": 135, \"Column\": 1, \"Item\": 645, \"DisplayText\": \"Colonized Wounds (outpatient)\", \"Text\": \"Colonized wound\", \"Mnemonic\": \"240\"}, {\"Row\": 136, \"Column\": 1, \"Item\": 797, \"DisplayText\": \"Community acquired diarrhea (no recent travel) - Outpatient\", \"Text\": \"Community-acquired diarrhea\", \"Mnemonic\": \"242\"}, {\"Row\": 137, \"Column\": 1, \"Item\": 798, \"DisplayText\": \"Community acquired pneumonia (Outpatient)\", \"Text\": \"Community-acquired pneumonia (CAP)\", \"Mnemonic\": \"244\"}, {\"Row\": 138, \"Column\": 1, \"Item\": 122, \"DisplayText\": \"Community-acquired pneumonia (CAP)\", \"Text\": \"Community-acquired pneumonia (CAP), inpatient treatment setting\", \"Mnemonic\": \"246\"}, {\"Row\": 139, \"Column\": 1, \"Item\": 906, \"DisplayText\": \"Complement Deficiency (Outpatient)\", \"Text\": \"Complement deficiency\", \"Mnemonic\": \"248\"}, {\"Row\": 140, \"Column\": 1, \"Item\": 801, \"DisplayText\": \"Complicated Cystitis (Outpatient)\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"250\"}, {\"Row\": 141, \"Column\": 1, \"Item\": 688, \"DisplayText\": \"Conditions Not Benefited by Antimicrobial Therapy (outpatient)\", \"Text\": \"Conditions not benefitted by antimicrobials\", \"Mnemonic\": \"252\"}, {\"Row\": 142, \"Column\": 1, \"Item\": 802, \"DisplayText\": \"Conjunctivitis (Outpatient)\", \"Text\": \"Conjunctivitis\", \"Mnemonic\": \"254\"}, {\"Row\": 143, \"Column\": 1, \"Item\": 349, \"DisplayText\": \"\", \"Text\": \"Contact CDSS staff\", \"Mnemonic\": \"256\"}, {\"Row\": 144, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Contiguous or hematogenous spread brain abscess\", \"Mnemonic\": \"258\"}, {\"Row\": 145, \"Column\": 1, \"Item\": 777, \"DisplayText\": \"Bronchitis/COPD Exacerbation\", \"Text\": \"COPD exacerbation\", \"Mnemonic\": \"260\"}, {\"Row\": 146, \"Column\": 1, \"Item\": 741, \"DisplayText\": \"\", \"Text\": \"COPD, prevention of exacerbations\", \"Mnemonic\": \"262\"}, {\"Row\": 147, \"Column\": 1, \"Item\": 882, \"DisplayText\": \"Corynebacterium spp. (Outpatient)\", \"Text\": \"Corynebacterium spp.\", \"Mnemonic\": \"264\"}, {\"Row\": 148, \"Column\": 1, \"Item\": 1005, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis) - Outpatient\", \"Text\": \"Crabs\", \"Mnemonic\": \"266\"}, {\"Row\": 149, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Cranial epidural abscess\", \"Mnemonic\": \"268\"}, {\"Row\": 150, \"Column\": 1, \"Item\": 847, \"DisplayText\": \"Cyptococcus Neoformans (outpatient)\", \"Text\": \"Cryptococcus neoformans\", \"Mnemonic\": \"270\"}, {\"Row\": 151, \"Column\": 1, \"Item\": 811, \"DisplayText\": \"Diarrhea with Crytosporidium parvum (Outpatient)\", \"Text\": \"Cryptosporidium parvum diarrhea/gastroenteritis\", \"Mnemonic\": \"272\"}, {\"Row\": 152, \"Column\": 1, \"Item\": 810, \"DisplayText\": \"Diarrhea with Cyclospora cayetanensis (Outpatient)\", \"Text\": \"Cyclospora cayetanensis diarrhea/gastroenteritis\", \"Mnemonic\": \"274\"}, {\"Row\": 153, \"Column\": 1, \"Item\": 801, \"DisplayText\": \"Complicated Cystitis (Outpatient)\", \"Text\": \"Cystitis, complicated\", \"Mnemonic\": \"276\"}, {\"Row\": 154, \"Column\": 1, \"Item\": 1052, \"DisplayText\": \"Uncomplicated Cystitis (Outpatient)\", \"Text\": \"Cystitis, uncomplicated\", \"Mnemonic\": \"278\"}, {\"Row\": 155, \"Column\": 1, \"Item\": 643, \"DisplayText\": \"Cytomegalovirus (CMV) Main Page (outpatient)\", \"Text\": \"Cytomegalovirus (CMV) [CLICK HERE], includes:\", \"Mnemonic\": \"280\"}, {\"Row\": 160, \"Column\": 1, \"Item\": 716, \"DisplayText\": \"\", \"Text\": \"Decolonization of Staphylococcus aureus\", \"Mnemonic\": \"282\"}, {\"Row\": 161, \"Column\": 1, \"Item\": 805, \"DisplayText\": \"Decubitis ulcers (Outpatient)\", \"Text\": \"Decubitus ulcers\", \"Mnemonic\": \"284\"}, {\"Row\": 162, \"Column\": 1, \"Item\": 806, \"DisplayText\": \"Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient\", \"Text\": \"Deep oropharyngeal infections\", \"Mnemonic\": \"286\"}, {\"Row\": 163, \"Column\": 1, \"Item\": 1036, \"DisplayText\": \"Suppurative odontogenic infections (Outpatient)\", \"Text\": \"Dental infections\", \"Mnemonic\": \"288\"}, {\"Row\": 164, \"Column\": 1, \"Item\": 718, \"DisplayText\": \"Stasis Dermatitis (outpatient)\", \"Text\": \"Dermatitis, stasis\", \"Mnemonic\": \"290\"}, {\"Row\": 165, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatological surgery guidelines\", \"Mnemonic\": \"292\"}, {\"Row\": 166, \"Column\": 1, \"Item\": 807, \"DisplayText\": \"Dermatology Infections (Outpatient)\", \"Text\": \"Dermatological Infections section\", \"Mnemonic\": \"294\"}, {\"Row\": 167, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatology post-op infection\", \"Mnemonic\": \"296\"}, {\"Row\": 168, \"Column\": 1, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Desensitization protocol, penicillin\", \"Mnemonic\": \"298\"}, {\"Row\": 169, \"Column\": 1, \"Item\": 808, \"DisplayText\": \"Device-related infections (Outpatient)\", \"Text\": \"Device-related infections\", \"Mnemonic\": \"300\"}, {\"Row\": 170, \"Column\": 1, \"Item\": 448, \"DisplayText\": \"Diabetes Mellitus\", \"Text\": \"Diabetes Mellitus\", \"Mnemonic\": \"302\"}, {\"Row\": 171, \"Column\": 1, \"Item\": 836, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus (Outpatient)\", \"Text\": \"Diabetic foot ulcer\", \"Mnemonic\": \"304\"}, {\"Row\": 172, \"Column\": 1, \"Item\": 911, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis (Outpatient)\", \"Text\": \"Diarrhea, infectious/gastroenteritis\", \"Mnemonic\": \"306\"}, {\"Row\": 173, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Diphtheria vaccination\", \"Mnemonic\": \"308\"}, {\"Row\": 174, \"Column\": 1, \"Item\": 158, \"DisplayText\": \"Exclusions\", \"Text\": \"Diseases and Syndromes not covered\", \"Mnemonic\": \"310\"}, {\"Row\": 175, \"Column\": 1, \"Item\": 823, \"DisplayText\": \"Diskitis and vertebral osteomyelitis (Outpatient)\", \"Text\": \"Diskitis and vertebral osteomyelitis\", \"Mnemonic\": \"312\"}, {\"Row\": 176, \"Column\": 1, \"Item\": 963, \"DisplayText\": \"Disseminated Mycobacterium avium disease (Outpatient)\", \"Text\": \"Disseminated Mycobacterium avium\", \"Mnemonic\": \"314\"}, {\"Row\": 177, \"Column\": 1, \"Item\": 824, \"DisplayText\": \"Diverticulitis (Outpatient)\", \"Text\": \"Diverticulitis\", \"Mnemonic\": \"316\"}, {\"Row\": 178, \"Column\": 1, \"Item\": 144, \"DisplayText\": \"Drug allergies\", \"Text\": \"Drug allergy information\", \"Mnemonic\": \"318\"}, {\"Row\": 179, \"Column\": 1, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Drug Information\", \"Mnemonic\": \"320\"}, {\"Row\": 180, \"Column\": 1, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Drug properties, important\", \"Mnemonic\": \"322\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"OUTPATIENT ANTIMICROIBAL CDSS INDEX\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"A______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"antimicrobial prophylaxis, management of fever,\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"patient initiated antibiotics, vaccines\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"B______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 87, \"Column\": 1, \"Text\": \"C______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 91, \"Column\": 1, \"Text\": \"antimicrobial prophylaxis, neutropenic fever\"}, {\"Row\": 156, \"Column\": 1, \"Text\": \"colitis, esophagitis, encephalitis, polyradiculopathy\"}, {\"Row\": 157, \"Column\": 1, \"Text\": \"retinitis, and pneumonia\"}, {\"Row\": 159, \"Column\": 1, \"Text\": \"D______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 183, \"Column\": 1, \"Item\": 898, \"DisplayText\": \"Head and Neck / ENT (Outpatient)\", \"Text\": \"Ear, nose, throat (ENT)/Head and Neck section\", \"Mnemonic\": \"324\"}, {\"Row\": 184, \"Column\": 1, \"Item\": 825, \"DisplayText\": \"Ecthyma Gangrenosum (Outpatient)\", \"Text\": \"Ecthyma gangrenosum\", \"Mnemonic\": \"326\"}, {\"Row\": 185, \"Column\": 1, \"Item\": 964, \"DisplayText\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) - Outpatient\", \"Text\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)\", \"Mnemonic\": \"328\"}, {\"Row\": 186, \"Column\": 1, \"Item\": 746, \"DisplayText\": \"Bite wounds with Eikenella corrodens (Outpatient)\", \"Text\": \"Eikenella corrodens, bite wound\", \"Mnemonic\": \"330\"}, {\"Row\": 187, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Eikenella native valve endocarditis\", \"Mnemonic\": \"332\"}, {\"Row\": 188, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Eikenella prosthetic valve endocarditis\", \"Mnemonic\": \"334\"}, {\"Row\": 189, \"Column\": 1, \"Item\": 826, \"DisplayText\": \"Empyema (Outpatient)\", \"Text\": \"Empyema\", \"Mnemonic\": \"336\"}, {\"Row\": 190, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Empyema, subdural\", \"Mnemonic\": \"338\"}, {\"Row\": 191, \"Column\": 1, \"Item\": 903, \"DisplayText\": \"HSV encephalitis (Outpatient)\", \"Text\": \"Encephalitis\", \"Mnemonic\": \"340\"}, {\"Row\": 192, \"Column\": 1, \"Item\": 792, \"DisplayText\": \"CMV encephalitis (Outpatient)\", \"Text\": \"Encephalitis, Cytomegalovirus (CMV)\", \"Mnemonic\": \"342\"}, {\"Row\": 193, \"Column\": 1, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Endocarditis with sepsis\", \"Mnemonic\": \"344\"}, {\"Row\": 194, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Endocarditis, approach to\", \"Mnemonic\": \"346\"}, {\"Row\": 195, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Endocarditis, diagnosis of\", \"Mnemonic\": \"348\"}, {\"Row\": 196, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Endocarditis, native valve [CLICK HERE], includes:\", \"Mnemonic\": \"350\"}, {\"Row\": 200, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Endocarditis, native valve empirical therapy\", \"Mnemonic\": \"352\"}, {\"Row\": 201, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Endocarditis, prosthetic valve [CLICK HERE], includes:\", \"Mnemonic\": \"354\"}, {\"Row\": 205, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Endocarditis, prosthetic valve empirical therapy\", \"Mnemonic\": \"356\"}, {\"Row\": 206, \"Column\": 1, \"Item\": 827, \"DisplayText\": \"Endophthalmitis (Outpatient)\", \"Text\": \"Endophthalmitis\", \"Mnemonic\": \"358\"}, {\"Row\": 207, \"Column\": 1, \"Item\": 813, \"DisplayText\": \"Diarrhea with Entamoeba histolytica (Outpatient)\", \"Text\": \"Entamoeba histolytica diarrhea/gastroenteritis\", \"Mnemonic\": \"360\"}, {\"Row\": 208, \"Column\": 1, \"Item\": 651, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Enteric fever\", \"Mnemonic\": \"362\"}, {\"Row\": 209, \"Column\": 1, \"Item\": 864, \"DisplayText\": \"Enterobacter spp. (Outpatient)\", \"Text\": \"Enterobacter species, general\", \"Mnemonic\": \"364\"}, {\"Row\": 210, \"Column\": 1, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Enterobacteriaceae (ESBL+) nosocomial pneumonia\", \"Mnemonic\": \"366\"}, {\"Row\": 211, \"Column\": 1, \"Item\": 883, \"DisplayText\": \"Enterococci (Outpatient)\", \"Text\": \"Enterococcal infections, general\", \"Mnemonic\": \"368\"}, {\"Row\": 212, \"Column\": 1, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Enterococcal intravascular catheter-associated infection\", \"Mnemonic\": \"370\"}, {\"Row\": 213, \"Column\": 1, \"Item\": 1017, \"DisplayText\": \"Septic arthritis (Native Joint) with Enterococci - Outpatient\", \"Text\": \"Enterococcal native joint infection\", \"Mnemonic\": \"372\"}, {\"Row\": 214, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Enterococcal native valve endocarditis\", \"Mnemonic\": \"374\"}, {\"Row\": 215, \"Column\": 1, \"Item\": 999, \"DisplayText\": \"Enterococci infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Enterococcal prosthetic bone/joint infection\", \"Mnemonic\": \"376\"}, {\"Row\": 216, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Enterococcal prosthetic valve endocarditis\", \"Mnemonic\": \"378\"}, {\"Row\": 217, \"Column\": 1, \"Item\": 1006, \"DisplayText\": \"Pyelonephritis (Outpatient)\", \"Text\": \"Enterococcal pyelonephritis\", \"Mnemonic\": \"380\"}, {\"Row\": 218, \"Column\": 1, \"Item\": 828, \"DisplayText\": \"Epididymitis (Outpatient)\", \"Text\": \"Epididymitis\", \"Mnemonic\": \"382\"}, {\"Row\": 219, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Epidural abscess, cranial\", \"Mnemonic\": \"384\"}, {\"Row\": 220, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Epidural abscess, spinal\", \"Mnemonic\": \"386\"}, {\"Row\": 221, \"Column\": 1, \"Item\": 829, \"DisplayText\": \"Epiglottitis (Outpatient)\", \"Text\": \"Epiglottitis\", \"Mnemonic\": \"388\"}, {\"Row\": 222, \"Column\": 1, \"Item\": 830, \"DisplayText\": \"Erysipelas (Outpatient)\", \"Text\": \"Erysipelas\", \"Mnemonic\": \"390\"}, {\"Row\": 223, \"Column\": 1, \"Item\": 831, \"DisplayText\": \"Erysipeloid (Erysipeloithrix Rhusopathiae Infection) - Outpatient\", \"Text\": \"Erysipeloid\", \"Mnemonic\": \"392\"}, {\"Row\": 224, \"Column\": 1, \"Item\": 932, \"DisplayText\": \"Erythema migrans associated with Lyme disease (Outpatient)\", \"Text\": \"Erythema migrans, Lyme disease\", \"Mnemonic\": \"394\"}, {\"Row\": 225, \"Column\": 1, \"Item\": 832, \"DisplayText\": \"Erythrasma (Outpatient)\", \"Text\": \"Erythrasma\", \"Mnemonic\": \"396\"}, {\"Row\": 226, \"Column\": 1, \"Item\": 814, \"DisplayText\": \"Diarrhea with enterohemorrhagic E. Coli (Outpatient)\", \"Text\": \"Escherichia coli diarrhea/gastroenteritis\", \"Mnemonic\": \"398\"}, {\"Row\": 227, \"Column\": 1, \"Item\": 863, \"DisplayText\": \"Escherichia coli (Outpatient)\", \"Text\": \"Escherichia coli infections, general\", \"Mnemonic\": \"400\"}, {\"Row\": 228, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Escherichia coli meningitis\", \"Mnemonic\": \"402\"}, {\"Row\": 229, \"Column\": 1, \"Item\": 652, \"DisplayText\": \"Esophagitis (outpatient)\", \"Text\": \"Esophagitis\", \"Mnemonic\": \"404\"}, {\"Row\": 230, \"Column\": 1, \"Item\": 777, \"DisplayText\": \"Bronchitis/COPD Exacerbation\", \"Text\": \"Exacerbation of COPD\", \"Mnemonic\": \"406\"}, {\"Row\": 231, \"Column\": 1, \"Item\": 741, \"DisplayText\": \"\", \"Text\": \"Exacerbations of COPD, prevention of\", \"Mnemonic\": \"408\"}, {\"Row\": 234, \"Column\": 1, \"Item\": 912, \"DisplayText\": \"Influenza Seasonal 2021-2022\", \"Text\": \"Flu\", \"Mnemonic\": \"410\"}, {\"Row\": 235, \"Column\": 1, \"Item\": 835, \"DisplayText\": \"Folliculitis (Outpatient)\", \"Text\": \"Folliculitis\", \"Mnemonic\": \"412\"}, {\"Row\": 236, \"Column\": 1, \"Item\": 836, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus (Outpatient)\", \"Text\": \"Foot ulcer in patient with diabetes\", \"Mnemonic\": \"414\"}, {\"Row\": 237, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Fungal native valve endocarditis\", \"Mnemonic\": \"416\"}, {\"Row\": 238, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Fungal prosthetic valve endocarditis\", \"Mnemonic\": \"418\"}, {\"Row\": 239, \"Column\": 1, \"Item\": 385, \"DisplayText\": \"Fungal Sinusitis\", \"Text\": \"Fungal sinusitis\", \"Mnemonic\": \"420\"}, {\"Row\": 240, \"Column\": 1, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Fungemia associated with Candida spp.\", \"Mnemonic\": \"422\"}, {\"Row\": 241, \"Column\": 1, \"Item\": 840, \"DisplayText\": \"Fungi (Outpatient)\", \"Text\": \"Fungi section\", \"Mnemonic\": \"424\"}, {\"Row\": 242, \"Column\": 1, \"Item\": 849, \"DisplayText\": \"Furuncles and Carbuncles (Outpatient)\", \"Text\": \"Furuncles\", \"Mnemonic\": \"426\"}, {\"Row\": 182, \"Column\": 1, \"Text\": \"E______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 197, \"Column\": 1, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 198, \"Column\": 1, \"Text\": \"gram-negative bacilli, streptococci, staphylococci,\"}, {\"Row\": 199, \"Column\": 1, \"Text\": \"and HACEK bacteria\"}, {\"Row\": 202, \"Column\": 1, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 203, \"Column\": 1, \"Text\": \"gram-negative bacilli, Streptococcus bovis,\"}, {\"Row\": 204, \"Column\": 1, \"Text\": \"staphylococci, HACEK bacteria, and Viridans group streptococci\"}, {\"Row\": 233, \"Column\": 1, \"Text\": \"F______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 1, \"Column\": 2, \"Item\": 349, \"DisplayText\": \"\", \"Text\": \"Contact CDSS staff\", \"Mnemonic\": \"428\"}, {\"Row\": 2, \"Column\": 2, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help\", \"Mnemonic\": \"430\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 911, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis (Outpatient)\", \"Text\": \"Gastroenteritis/infectious diarrhea\", \"Mnemonic\": \"432\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 850, \"DisplayText\": \"Gastrointestinal (Outpatient)\", \"Text\": \"Gastrointestinal and Intraabdominal section\", \"Mnemonic\": \"434\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 851, \"DisplayText\": \"Genital herpes (Outpatient)\", \"Text\": \"Genital herpes\", \"Mnemonic\": \"436\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 852, \"DisplayText\": \"Genitourinary (Outpatient)\", \"Text\": \"Genitourinary section\", \"Mnemonic\": \"438\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 815, \"DisplayText\": \"Diarrhea with Giardia lamblia (Outpatient)\", \"Text\": \"Giardia lamblia diarrhea\", \"Mnemonic\": \"440\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 815, \"DisplayText\": \"Diarrhea with Giardia lamblia (Outpatient)\", \"Text\": \"Giardia lamblia infections, general\", \"Mnemonic\": \"442\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 1053, \"DisplayText\": \"Urethritis associated with sexually transmitted disease (Outpatient)\", \"Text\": \"Gonococcal urethritis\", \"Mnemonic\": \"444\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Gram-negative bacilli bacteremia\", \"Mnemonic\": \"446\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 916, \"DisplayText\": \"Interim results:  Gram-negative bacilli (Outpatient)\", \"Text\": \"Gram-negative bacilli interim culture results\", \"Mnemonic\": \"448\"}, {\"Row\": 16, \"Column\": 2, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Gram-negative bacilli intravascular catheter-associated infection\", \"Mnemonic\": \"450\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Gram-negative bacilli meningitis\", \"Mnemonic\": \"452\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Gram-negative bacilli, non-HACEK, native valve endocarditis\", \"Mnemonic\": \"454\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Gram-negative bacilli, non-HACEK, prosthetic valve endocarditis\", \"Mnemonic\": \"456\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 948, \"DisplayText\": \"Osteomyelitis with Gram negative bacilli (other than Pseudomonas) - Outpatient\", \"Text\": \"Gram-negative bacilli, non-pseudomonas, osteomyelitis\", \"Mnemonic\": \"458\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 1000, \"DisplayText\": \"Gram neg bacilli (other than pseudomonas) infections in bone or joint prostheses\", \"Text\": \"Gram-negative bacilli, non-pseudomonas, prosthetic bone/joint infection\", \"Mnemonic\": \"460\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 1018, \"DisplayText\": \"Septic arthritis (Native Joint ) with Gram negative Bacilli - Outpatient\", \"Text\": \"Gram-negative bacilli, non-pseudomonas, native joint infection\", \"Mnemonic\": \"462\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 855, \"DisplayText\": \"Gram negative bacteria (Outpatient)\", \"Text\": \"Gram-Negative Bacteria section\", \"Mnemonic\": \"464\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Gram-negative cocci bacteremia\", \"Mnemonic\": \"466\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 917, \"DisplayText\": \"Iterim report of Gram-negative cocci (Outpatient)\", \"Text\": \"Gram-negative cocci interim culture results\", \"Mnemonic\": \"468\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Gram-negative diplococci meningitis\", \"Mnemonic\": \"470\"}, {\"Row\": 27, \"Column\": 2, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Gram-positive bacilli bacteremia\", \"Mnemonic\": \"472\"}, {\"Row\": 28, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Gram-positive bacilli meningitis\", \"Mnemonic\": \"474\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 918, \"DisplayText\": \"Interim report of Gram-positive Bacilli (Outpatient)\", \"Text\": \"Gram-positive bacilli, interim culture results\", \"Mnemonic\": \"476\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 856, \"DisplayText\": \"\", \"Text\": \"Gram-positive bacteria, section\", \"Mnemonic\": \"478\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Gram-positive cocci in pairs and chains bacteremia\", \"Mnemonic\": \"480\"}, {\"Row\": 32, \"Column\": 2, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Gram-positive cocci in pairs and clusters bacteremia\", \"Mnemonic\": \"482\"}, {\"Row\": 33, \"Column\": 2, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Gram-positive cocci in pairs bacteremia\", \"Mnemonic\": \"484\"}, {\"Row\": 34, \"Column\": 2, \"Item\": 919, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs (Outpatient)\", \"Text\": \"Gram-positive cocci in pairs interim culture results\", \"Mnemonic\": \"486\"}, {\"Row\": 35, \"Column\": 2, \"Item\": 878, \"DisplayText\": \"Anaerobic Gram-positive cocci (Outpatient)\", \"Text\": \"Gram-positive cocci, anaerobic\", \"Mnemonic\": \"488\"}, {\"Row\": 36, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Gram-positive coccobacilli meningitis\", \"Mnemonic\": \"490\"}, {\"Row\": 37, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Gram-positive diplococci meningitis\", \"Mnemonic\": \"492\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 891, \"DisplayText\": \"Group A (S. pyogenes) - Outpatient\", \"Text\": \"Group A streptococci\", \"Mnemonic\": \"494\"}, {\"Row\": 39, \"Column\": 2, \"Item\": 887, \"DisplayText\": \"Group B (S. agalactiae) - Outpatient\", \"Text\": \"Group B Streptococci\", \"Mnemonic\": \"496\"}, {\"Row\": 40, \"Column\": 2, \"Item\": 889, \"DisplayText\": \"Group D Streptococci (S. bovis) - Outpatient\", \"Text\": \"Group D Streptococci\", \"Mnemonic\": \"498\"}, {\"Row\": 41, \"Column\": 2, \"Item\": 884, \"DisplayText\": \"Streptococci Groups C, F, G (Outpatient)\", \"Text\": \"Groups C, F, G Streptococci\", \"Mnemonic\": \"500\"}, {\"Row\": 44, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"HACEK bacteria native valve endocarditis\", \"Mnemonic\": \"502\"}, {\"Row\": 45, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"HACEK bacteria prosthetic valve endocarditis\", \"Mnemonic\": \"504\"}, {\"Row\": 46, \"Column\": 2, \"Item\": 865, \"DisplayText\": \"Haemophilus spp. (Outpatient)\", \"Text\": \"Haemophilus infections, general\", \"Mnemonic\": \"506\"}, {\"Row\": 47, \"Column\": 2, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae B vaccination\", \"Mnemonic\": \"508\"}, {\"Row\": 48, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Haemophilus native valve endocarditis\", \"Mnemonic\": \"510\"}, {\"Row\": 49, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Haemophilus prosthetic valve endocarditis\", \"Mnemonic\": \"512\"}, {\"Row\": 50, \"Column\": 2, \"Item\": 898, \"DisplayText\": \"Head and Neck / ENT (Outpatient)\", \"Text\": \"Head and Neck/ENT section\", \"Mnemonic\": \"514\"}, {\"Row\": 51, \"Column\": 2, \"Item\": 899, \"DisplayText\": \"Head Lice (Pediculosis Capitis) - Outpatient\", \"Text\": \"Head lice\", \"Mnemonic\": \"516\"}, {\"Row\": 52, \"Column\": 2, \"Item\": 897, \"DisplayText\": \"Helicobacter pylori infection (Outpatient)\", \"Text\": \"Helicobacter pylori\", \"Mnemonic\": \"518\"}, {\"Row\": 53, \"Column\": 2, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help\", \"Mnemonic\": \"520\"}, {\"Row\": 54, \"Column\": 2, \"Item\": 744, \"DisplayText\": \"Bed Bugs (Hemiptera) - Outpatient\", \"Text\": \"Hemiptera\", \"Mnemonic\": \"522\"}, {\"Row\": 55, \"Column\": 2, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Hemodialysis immunizations\", \"Mnemonic\": \"524\"}, {\"Row\": 56, \"Column\": 2, \"Item\": 853, \"DisplayText\": \"\", \"Text\": \"Hepatic abscess\", \"Mnemonic\": \"526\"}, {\"Row\": 57, \"Column\": 2, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Hepatic disease immunizations\", \"Mnemonic\": \"528\"}, {\"Row\": 58, \"Column\": 2, \"Item\": 656, \"DisplayText\": \"Hepatitis A (outpatient)\", \"Text\": \"Hepatitis A\", \"Mnemonic\": \"530\"}, {\"Row\": 59, \"Column\": 2, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A vaccination\", \"Mnemonic\": \"532\"}, {\"Row\": 60, \"Column\": 2, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A/Hepatitis B vaccination\", \"Mnemonic\": \"534\"}, {\"Row\": 61, \"Column\": 2, \"Item\": 657, \"DisplayText\": \"Hepatitis B (outpatient)\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"536\"}, {\"Row\": 62, \"Column\": 2, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B vaccination\", \"Mnemonic\": \"538\"}, {\"Row\": 63, \"Column\": 2, \"Item\": 658, \"DisplayText\": \"Hepatitis C (outpatient)\", \"Text\": \"Hepatitis C\", \"Mnemonic\": \"540\"}, {\"Row\": 64, \"Column\": 2, \"Item\": 661, \"DisplayText\": \"Herpes Simplex Esophagitis (Outpatient)\", \"Text\": \"Herpes esophagitis\", \"Mnemonic\": \"542\"}, {\"Row\": 65, \"Column\": 2, \"Item\": 660, \"DisplayText\": \"HERPES KERATITIS\", \"Text\": \"Herpes keratitis\", \"Mnemonic\": \"544\"}, {\"Row\": 66, \"Column\": 2, \"Item\": 1011, \"DisplayText\": \"Retinitis (Outpatient)\", \"Text\": \"Herpes retinitis\", \"Mnemonic\": \"546\"}, {\"Row\": 67, \"Column\": 2, \"Item\": 901, \"DisplayText\": \"Herpes whitlow (Digit or Hand Cellulitis) - Outpatient\", \"Text\": \"Herpes whitlow (digit or hand cellulitis)\", \"Mnemonic\": \"548\"}, {\"Row\": 68, \"Column\": 2, \"Item\": 851, \"DisplayText\": \"Genital herpes (Outpatient)\", \"Text\": \"Herpes, genital\", \"Mnemonic\": \"550\"}, {\"Row\": 69, \"Column\": 2, \"Item\": 946, \"DisplayText\": \"Orolabial herpes (Outpatient)\", \"Text\": \"Herpes, orolabial\", \"Mnemonic\": \"552\"}, {\"Row\": 70, \"Column\": 2, \"Item\": 902, \"DisplayText\": \"Hidradenitis Suppurativa (Outpatient)\", \"Text\": \"Hidradenitis suppurativa\", \"Mnemonic\": \"554\"}, {\"Row\": 71, \"Column\": 2, \"Item\": 848, \"DisplayText\": \"Histoplasma capsulatum (Outpatient)\", \"Text\": \"Histoplasma capsulatum\", \"Mnemonic\": \"556\"}, {\"Row\": 72, \"Column\": 2, \"Item\": 673, \"DisplayText\": \"Immunization of patients with HIV\", \"Text\": \"HIV patient immunization\", \"Mnemonic\": \"558\"}, {\"Row\": 73, \"Column\": 2, \"Item\": 663, \"DisplayText\": \"HIV-AIDS (outpatient)\", \"Text\": \"HIV infection, general\", \"Mnemonic\": \"560\"}, {\"Row\": 74, \"Column\": 2, \"Item\": 177, \"DisplayText\": \"Home IV at the Minneapolis VAMC\", \"Text\": \"Home IV therapy at MVAMC\", \"Mnemonic\": \"562\"}, {\"Row\": 75, \"Column\": 2, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Hospital-acquired pneumonia (HAP)\", \"Mnemonic\": \"564\"}, {\"Row\": 76, \"Column\": 2, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"HSCT immunizations\", \"Mnemonic\": \"566\"}, {\"Row\": 77, \"Column\": 2, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papilloma virus vaccination\", \"Mnemonic\": \"568\"}, {\"Row\": 78, \"Column\": 2, \"Item\": 449, \"DisplayText\": \"Hypochlorhydria\", \"Text\": \"Hypochlorhydria\", \"Mnemonic\": \"570\"}, {\"Row\": 81, \"Column\": 2, \"Item\": 676, \"DisplayText\": \"Immunization of Immunocompromised Patients\", \"Text\": \"Immunization of immunocompromised patients (except HIV)\", \"Mnemonic\": \"572\"}, {\"Row\": 82, \"Column\": 2, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Immunization of patients at high-risk of rabies exposure\", \"Mnemonic\": \"574\"}, {\"Row\": 83, \"Column\": 2, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Immunization of patients in kidney failure/HD\", \"Mnemonic\": \"576\"}, {\"Row\": 84, \"Column\": 2, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"Immunization of patients with asplenia\", \"Mnemonic\": \"578\"}, {\"Row\": 85, \"Column\": 2, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"Immunization of patients with bone marrow transplant\", \"Mnemonic\": \"580\"}, {\"Row\": 86, \"Column\": 2, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Immunization of patients with chronic liver disease\", \"Mnemonic\": \"582\"}, {\"Row\": 87, \"Column\": 2, \"Item\": 673, \"DisplayText\": \"Immunization of patients with HIV\", \"Text\": \"Immunization of patients with HIV\", \"Mnemonic\": \"584\"}, {\"Row\": 88, \"Column\": 2, \"Item\": 989, \"DisplayText\": \"\", \"Text\": \"Immunization of patients with pregnancy\", \"Mnemonic\": \"586\"}, {\"Row\": 89, \"Column\": 2, \"Item\": 710, \"DisplayText\": \"CDC Recommended Adult Immunizations\", \"Text\": \"Immunization, adult [CLICK HERE], includes:\", \"Mnemonic\": \"588\"}, {\"Row\": 94, \"Column\": 2, \"Item\": 446, \"DisplayText\": \"Basic concepts\", \"Text\": \"Immunocompromised patients basic concepts\", \"Mnemonic\": \"590\"}, {\"Row\": 95, \"Column\": 2, \"Item\": 909, \"DisplayText\": \"Infections in Immunocompromised patients (Outpatient)\", \"Text\": \"Immunocompromised Patients section\", \"Mnemonic\": \"592\"}, {\"Row\": 96, \"Column\": 2, \"Item\": 904, \"DisplayText\": \"Immunoglobulin deficiency (Humoral immune system) - Outpatient\", \"Text\": \"Immunoglobulin (Humoral immune system) deficiency\", \"Mnemonic\": \"594\"}, {\"Row\": 97, \"Column\": 2, \"Item\": 910, \"DisplayText\": \"Impetigo (Outpatient)\", \"Text\": \"Impetigo\", \"Mnemonic\": \"596\"}, {\"Row\": 98, \"Column\": 2, \"Item\": 185, \"DisplayText\": \"Important drug properties\", \"Text\": \"Important drug properties\", \"Mnemonic\": \"598\"}, {\"Row\": 99, \"Column\": 2, \"Item\": 188, \"DisplayText\": \"Infection Control\", \"Text\": \"Infection control department information\", \"Mnemonic\": \"600\"}, {\"Row\": 100, \"Column\": 2, \"Item\": 994, \"DisplayText\": \"Prevention of Infection - Outpatient\", \"Text\": \"Infection Prevention section\", \"Mnemonic\": \"602\"}, {\"Row\": 101, \"Column\": 2, \"Item\": 911, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis (Outpatient)\", \"Text\": \"Infectious diarrhea/gastroenteritis\", \"Mnemonic\": \"604\"}, {\"Row\": 102, \"Column\": 2, \"Item\": 912, \"DisplayText\": \"Influenza Seasonal 2021-2022\", \"Text\": \"Influenza\", \"Mnemonic\": \"606\"}, {\"Row\": 103, \"Column\": 2, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Intravascular catheter-associated infection\", \"Mnemonic\": \"608\"}, {\"Row\": 104, \"Column\": 2, \"Item\": 177, \"DisplayText\": \"Home IV at the Minneapolis VAMC\", \"Text\": \"Intravenous therapy at home, MVAMC\", \"Mnemonic\": \"610\"}, {\"Row\": 105, \"Column\": 2, \"Item\": 816, \"DisplayText\": \"Diarrhea with Isospora belli (Outpatient)\", \"Text\": \"Isospora diarrhea/gastroenteritis\", \"Mnemonic\": \"612\"}, {\"Row\": 108, \"Column\": 2, \"Item\": 1029, \"DisplayText\": \"Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)\", \"Text\": \"Joint and Bone section\", \"Mnemonic\": \"614\"}, {\"Row\": 109, \"Column\": 2, \"Item\": 1023, \"DisplayText\": \"Septic arthritis (Native Joint) - Outpatient\", \"Text\": \"Joint infection, native [CLICK HERE], includes:\", \"Mnemonic\": \"616\"}, {\"Row\": 113, \"Column\": 2, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Joint infection, prosthetic [CLICK HERE], includes:\", \"Mnemonic\": \"618\"}, {\"Row\": 119, \"Column\": 2, \"Item\": 921, \"DisplayText\": \"Keratitis (Outpatient)\", \"Text\": \"Keratitis\", \"Mnemonic\": \"620\"}, {\"Row\": 120, \"Column\": 2, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Kidney failure immunizations\", \"Mnemonic\": \"622\"}, {\"Row\": 121, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Kingella native valve endocarditis\", \"Mnemonic\": \"624\"}, {\"Row\": 122, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Kingella prosthetic valve endocarditis\", \"Mnemonic\": \"626\"}, {\"Row\": 123, \"Column\": 2, \"Item\": 866, \"DisplayText\": \"Klebsiella spp. (Outpatient)\", \"Text\": \"Klebsiella infections, general\", \"Mnemonic\": \"628\"}, {\"Row\": 126, \"Column\": 2, \"Item\": 924, \"DisplayText\": \"Large uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"Large uniform bacilli, aerobic bottle\", \"Mnemonic\": \"630\"}, {\"Row\": 127, \"Column\": 2, \"Item\": 923, \"DisplayText\": \"Large uniform bacilli in an aerobic bottle (Outpatient)\", \"Text\": \"Large uniform bacilli, anaerobic bottle\", \"Mnemonic\": \"632\"}, {\"Row\": 128, \"Column\": 2, \"Item\": 198, \"DisplayText\": \"Laryngitis and Croup\", \"Text\": \"Laryngitis\", \"Mnemonic\": \"634\"}, {\"Row\": 129, \"Column\": 2, \"Item\": 867, \"DisplayText\": \"Legionella spp. (Outpatient)\", \"Text\": \"Legionella infections, general\", \"Mnemonic\": \"636\"}, {\"Row\": 130, \"Column\": 2, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Legionella pneumophila nosocomial pneumonia\", \"Mnemonic\": \"638\"}, {\"Row\": 131, \"Column\": 2, \"Item\": 922, \"DisplayText\": \"Leishmaniasis\", \"Text\": \"Leishmaniasis\", \"Mnemonic\": \"640\"}, {\"Row\": 132, \"Column\": 2, \"Item\": 478, \"DisplayText\": \"Leukocytosis\", \"Text\": \"Leukocytosis\", \"Mnemonic\": \"642\"}, {\"Row\": 133, \"Column\": 2, \"Item\": 752, \"DisplayText\": \"Body Lice (Pediculosis Corporis) - Outpatient\", \"Text\": \"Lice, body\", \"Mnemonic\": \"644\"}, {\"Row\": 134, \"Column\": 2, \"Item\": 899, \"DisplayText\": \"Head Lice (Pediculosis Capitis) - Outpatient\", \"Text\": \"Lice, head\", \"Mnemonic\": \"646\"}, {\"Row\": 135, \"Column\": 2, \"Item\": 1005, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis) - Outpatient\", \"Text\": \"Lice, pubic\", \"Mnemonic\": \"648\"}, {\"Row\": 136, \"Column\": 2, \"Item\": 885, \"DisplayText\": \"Listeria spp. (Outpatient)\", \"Text\": \"Listeria infections, general\", \"Mnemonic\": \"650\"}, {\"Row\": 137, \"Column\": 2, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Listeria monocytogenes bacteremia\", \"Mnemonic\": \"652\"}, {\"Row\": 138, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Listeria monocytogenes meningitis\", \"Mnemonic\": \"654\"}, {\"Row\": 139, \"Column\": 2, \"Item\": 853, \"DisplayText\": \"\", \"Text\": \"Liver abscess\", \"Mnemonic\": \"656\"}, {\"Row\": 140, \"Column\": 2, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Liver disease immunizations\", \"Mnemonic\": \"658\"}, {\"Row\": 141, \"Column\": 2, \"Item\": 729, \"DisplayText\": \"Spontaneous Bacterial Peritonitis (Outpatient)\", \"Text\": \"Liver disease, prevention of spontaneous bacterial peritonitis\", \"Mnemonic\": \"660\"}, {\"Row\": 142, \"Column\": 2, \"Item\": 925, \"DisplayText\": \"Lung abscess (Outpatient)\", \"Text\": \"Lung abscess\", \"Mnemonic\": \"662\"}, {\"Row\": 143, \"Column\": 2, \"Item\": 926, \"DisplayText\": \"Lungs and Mediastinum (Outpatient)\", \"Text\": \"Lungs and Mediastinum section\", \"Mnemonic\": \"664\"}, {\"Row\": 144, \"Column\": 2, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Lyme disease [CLICK HERE], includes:\", \"Mnemonic\": \"666\"}, {\"Row\": 149, \"Column\": 2, \"Item\": 907, \"DisplayText\": \"Malignancy (Outpatient)\", \"Text\": \"Malignancy [CLICK HERE], includes:\", \"Mnemonic\": \"668\"}, {\"Row\": 151, \"Column\": 2, \"Item\": 933, \"DisplayText\": \"Malignant otitis externa (Outpatient)\", \"Text\": \"Malignant otitis externa\", \"Mnemonic\": \"670\"}, {\"Row\": 152, \"Column\": 2, \"Item\": 451, \"DisplayText\": \"Malnutrition\", \"Text\": \"Malnutrition\", \"Mnemonic\": \"672\"}, {\"Row\": 153, \"Column\": 2, \"Item\": 934, \"DisplayText\": \"Mastoiditis (Outpatient)\", \"Text\": \"Mastoiditis\", \"Mnemonic\": \"674\"}, {\"Row\": 154, \"Column\": 2, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles vaccination\", \"Mnemonic\": \"676\"}, {\"Row\": 155, \"Column\": 2, \"Item\": 935, \"DisplayText\": \"Mediastinitis (Outpatient)\", \"Text\": \"Mediastinitis\", \"Mnemonic\": \"678\"}, {\"Row\": 156, \"Column\": 2, \"Item\": 926, \"DisplayText\": \"Lungs and Mediastinum (Outpatient)\", \"Text\": \"Mediastinum and Lung section\", \"Mnemonic\": \"680\"}, {\"Row\": 157, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis associated with trauma or nosocomial infection\", \"Mnemonic\": \"682\"}, {\"Row\": 158, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with E. coli, Pseudomonas or other organism\", \"Mnemonic\": \"684\"}, {\"Row\": 159, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with Escherichia coli\", \"Mnemonic\": \"686\"}, {\"Row\": 160, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with gram-negative bacilli\", \"Mnemonic\": \"688\"}, {\"Row\": 161, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with gram-negative diplococci\", \"Mnemonic\": \"690\"}, {\"Row\": 162, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with gram-positive bacilli/coccobacilli\", \"Mnemonic\": \"692\"}, {\"Row\": 163, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with gram-positive diplococci\", \"Mnemonic\": \"694\"}, {\"Row\": 164, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with Listeria monocytogenes\", \"Mnemonic\": \"696\"}, {\"Row\": 165, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with Neisseria meningitidis\", \"Mnemonic\": \"698\"}, {\"Row\": 166, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with pseudomonas\", \"Mnemonic\": \"700\"}, {\"Row\": 167, \"Column\": 2, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Meningitis with sepsis\", \"Mnemonic\": \"702\"}, {\"Row\": 168, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis with Streptococcus pneumoniae\", \"Mnemonic\": \"704\"}, {\"Row\": 169, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis without gram stain results\", \"Mnemonic\": \"706\"}, {\"Row\": 170, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Meningitis, other organism\", \"Mnemonic\": \"708\"}, {\"Row\": 171, \"Column\": 2, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal conjugate (MENACWY) vaccination\", \"Mnemonic\": \"710\"}, {\"Row\": 172, \"Column\": 2, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MENB) vaccination\", \"Mnemonic\": \"712\"}, {\"Row\": 173, \"Column\": 2, \"Item\": 747, \"DisplayText\": \"Bite wounds with Methicillin-resistant S. aureus (Outpatient)\", \"Text\": \"Methicillin-resistant Staphylococcus aureus bite wounds\", \"Mnemonic\": \"714\"}, {\"Row\": 174, \"Column\": 2, \"Item\": 817, \"DisplayText\": \"Diarrhea with Microsporidia (Outpatient)\", \"Text\": \"Microsporidia diarrhea/gastroenteritis\", \"Mnemonic\": \"716\"}, {\"Row\": 175, \"Column\": 2, \"Item\": 868, \"DisplayText\": \"Moraxella catarrhalis (Outpatient)\", \"Text\": \"Moraxella catarrhalis infections, general\", \"Mnemonic\": \"718\"}, {\"Row\": 176, \"Column\": 2, \"Item\": 747, \"DisplayText\": \"Bite wounds with Methicillin-resistant S. aureus (Outpatient)\", \"Text\": \"MRSA bite wounds\", \"Mnemonic\": \"720\"}, {\"Row\": 177, \"Column\": 2, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"MRSA risk factors\", \"Mnemonic\": \"722\"}, {\"Row\": 178, \"Column\": 2, \"Item\": 748, \"DisplayText\": \"Bite wounds with Methicillin-susceptible Staphylococcus aureus (Outpatient)\", \"Text\": \"MSSA bite wounds\", \"Mnemonic\": \"724\"}, {\"Row\": 179, \"Column\": 2, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Mumps vaccination\", \"Mnemonic\": \"726\"}, {\"Row\": 180, \"Column\": 2, \"Item\": 1029, \"DisplayText\": \"Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)\", \"Text\": \"Muscle and Soft Tissue section\", \"Mnemonic\": \"728\"}, {\"Row\": 181, \"Column\": 2, \"Item\": 965, \"DisplayText\": \"Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC) - Outpatient\", \"Text\": \"Mycobacterium avium intracellular complex (MAI or MAC)\", \"Mnemonic\": \"730\"}, {\"Row\": 182, \"Column\": 2, \"Item\": 966, \"DisplayText\": \"Mycobacterium avium pneumonia (Outpatient)\", \"Text\": \"Mycobacterium avium pneumonia\", \"Mnemonic\": \"732\"}, {\"Row\": 183, \"Column\": 2, \"Item\": 968, \"DisplayText\": \"Prophylaxis against Mycobacterium avium disease... (Outpatient)\", \"Text\": \"Mycobacterium avium prophylaxis\", \"Mnemonic\": \"734\"}, {\"Row\": 184, \"Column\": 2, \"Item\": 963, \"DisplayText\": \"Disseminated Mycobacterium avium disease (Outpatient)\", \"Text\": \"Mycobacterium avium, disseminated\", \"Mnemonic\": \"736\"}, {\"Row\": 185, \"Column\": 2, \"Item\": 969, \"DisplayText\": \"Mycobacterium tuberculosis (Outpatient)\", \"Text\": \"Mycobacterium tuberculosis\", \"Mnemonic\": \"738\"}, {\"Row\": 186, \"Column\": 2, \"Item\": 967, \"DisplayText\": \"Mycoplasma pneumonia (Outpatient)\", \"Text\": \"Mycoplasma pneumonia infections, general\", \"Mnemonic\": \"740\"}, {\"Row\": 187, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Myocarditis\", \"Mnemonic\": \"742\"}, {\"Row\": 4, \"Column\": 2, \"Text\": \"G through Pn\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Text\": \"G______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 2, \"Text\": \"H______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 80, \"Column\": 2, \"Text\": \"I______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 90, \"Column\": 2, \"Text\": \"diphtheria, Haemophilus influenza B, Hepatitis A and B,\"}, {\"Row\": 91, \"Column\": 2, \"Text\": \"human papilloma virus, influenza, measles, mumps,\"}, {\"Row\": 92, \"Column\": 2, \"Text\": \"meningococcal, pneumococcal, pertussis, rubella,\"}, {\"Row\": 93, \"Column\": 2, \"Text\": \"tetanus, varicella, zoster\"}, {\"Row\": 107, \"Column\": 2, \"Text\": \"J______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 110, \"Column\": 2, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 111, \"Column\": 2, \"Text\": \"Neisseria gonorrhoeae, Pseudomonas aeruginosa,\"}, {\"Row\": 112, \"Column\": 2, \"Text\": \"Staphylococcus aureus, streptococcus\"}, {\"Row\": 114, \"Column\": 2, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 115, \"Column\": 2, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aureus,\"}, {\"Row\": 116, \"Column\": 2, \"Text\": \"and streptococcus\"}, {\"Row\": 118, \"Column\": 2, \"Text\": \"K______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 125, \"Column\": 2, \"Text\": \"L______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 145, \"Column\": 2, \"Text\": \"arthritis, carditis, erythema migrans,\"}, {\"Row\": 146, \"Column\": 2, \"Text\": \"neurological complications, prophylaxis\"}, {\"Row\": 148, \"Column\": 2, \"Text\": \"M______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 150, \"Column\": 2, \"Text\": \"antimicrobial prophylaxis, neutropenic fever\"}, {\"Row\": 190, \"Column\": 2, \"Item\": 938, \"DisplayText\": \"Prevention of infection in patients with nasal packing (Outpatient)\", \"Text\": \"Nasal packing\", \"Mnemonic\": \"744\"}, {\"Row\": 191, \"Column\": 2, \"Item\": 1023, \"DisplayText\": \"Septic arthritis (Native Joint) - Outpatient\", \"Text\": \"Native joint infection [CLICK HERE], includes:\", \"Mnemonic\": \"746\"}, {\"Row\": 195, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Native valve endocarditis [CLICK HERE], includes:\", \"Mnemonic\": \"748\"}, {\"Row\": 199, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Native valve endocarditis empirical therapy\", \"Mnemonic\": \"750\"}, {\"Row\": 200, \"Column\": 2, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Native valve endocarditis with sepsis\", \"Mnemonic\": \"752\"}, {\"Row\": 201, \"Column\": 2, \"Item\": 939, \"DisplayText\": \"Necrotizing infections (Outpatient)\", \"Text\": \"Necrotizing infections\", \"Mnemonic\": \"754\"}, {\"Row\": 202, \"Column\": 2, \"Item\": 869, \"DisplayText\": \"Neisseria gonorrhoeae (Outpatient)\", \"Text\": \"Neisseria gonorrhoeae infections, general\", \"Mnemonic\": \"756\"}, {\"Row\": 203, \"Column\": 2, \"Item\": 1019, \"DisplayText\": \"Septic arthritis (Native Joint) with N. gonorrhoeae - Outpatient\", \"Text\": \"Neisseria gonorrhoeae native joint infection\", \"Mnemonic\": \"758\"}, {\"Row\": 204, \"Column\": 2, \"Item\": 870, \"DisplayText\": \"Neisseria meningitidis (Outpatient)\", \"Text\": \"Neisseria meningitidis infections, general\", \"Mnemonic\": \"760\"}, {\"Row\": 205, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Neisseria meningitidis meningitis\", \"Mnemonic\": \"762\"}, {\"Row\": 206, \"Column\": 2, \"Item\": 927, \"DisplayText\": \"Acute neurological disease associated with Lyme disease (Outpatient)\", \"Text\": \"Neurological disease associated with Lyme disease\", \"Mnemonic\": \"764\"}, {\"Row\": 207, \"Column\": 2, \"Item\": 908, \"DisplayText\": \"Neurologial Dysfunction (Outpatient)\", \"Text\": \"Neurological dysfunction\", \"Mnemonic\": \"766\"}, {\"Row\": 208, \"Column\": 2, \"Item\": 454, \"DisplayText\": \"Neutropenia\", \"Text\": \"Neutropenia\", \"Mnemonic\": \"768\"}, {\"Row\": 209, \"Column\": 2, \"Item\": 1051, \"DisplayText\": \"Neutropenic enterocolitis (Typhlitis) - Outpatient\", \"Text\": \"Neutropenic enterocolitis\", \"Mnemonic\": \"770\"}, {\"Row\": 210, \"Column\": 2, \"Item\": 943, \"DisplayText\": \"Neutropenic fever (Outpatient)\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"772\"}, {\"Row\": 211, \"Column\": 2, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Neutropenic fever with sepsis\", \"Mnemonic\": \"774\"}, {\"Row\": 212, \"Column\": 2, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Nocardia spp. brain abscess\", \"Mnemonic\": \"776\"}, {\"Row\": 213, \"Column\": 2, \"Item\": 737, \"DisplayText\": \"Appendicitis without perforation (Outpatient)\", \"Text\": \"Non-perforated appendicitis\", \"Mnemonic\": \"778\"}, {\"Row\": 214, \"Column\": 2, \"Item\": 222, \"DisplayText\": \"Not Benefited by Abx Pharyngitis\", \"Text\": \"Non-streptococcal pharyngitis\", \"Mnemonic\": \"780\"}, {\"Row\": 215, \"Column\": 2, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Nosocomial pneumonia\", \"Mnemonic\": \"782\"}, {\"Row\": 216, \"Column\": 2, \"Item\": 944, \"DisplayText\": \"Nosocomial sinusitis (Outpatient)\", \"Text\": \"Nosocomial sinusitis\", \"Mnemonic\": \"784\"}, {\"Row\": 219, \"Column\": 2, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"Occupational post-exposure prophylaxis\", \"Mnemonic\": \"786\"}, {\"Row\": 220, \"Column\": 2, \"Item\": 1042, \"DisplayText\": \"Tinea Unguium (Onychomycosis)\", \"Text\": \"Onychomycosis\", \"Mnemonic\": \"788\"}, {\"Row\": 221, \"Column\": 2, \"Item\": 987, \"DisplayText\": \"Postseptal cellulitis (Orbital cellulitis) - Outpatient\", \"Text\": \"Orbital cellulitis\", \"Mnemonic\": \"790\"}, {\"Row\": 222, \"Column\": 2, \"Item\": 946, \"DisplayText\": \"Orolabial herpes (Outpatient)\", \"Text\": \"Orolabial herpes\", \"Mnemonic\": \"792\"}, {\"Row\": 223, \"Column\": 2, \"Item\": 806, \"DisplayText\": \"Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient\", \"Text\": \"Oropharyngeal infections, deep\", \"Mnemonic\": \"794\"}, {\"Row\": 224, \"Column\": 2, \"Item\": 952, \"DisplayText\": \"Osteomyelitis (Outpatient)\", \"Text\": \"Osteomyelitis [CLICK HERE], includes:\", \"Mnemonic\": \"796\"}, {\"Row\": 227, \"Column\": 2, \"Item\": 953, \"DisplayText\": \"Other Pathogens (Outpatient)\", \"Text\": \"Other Pathogens section\", \"Mnemonic\": \"798\"}, {\"Row\": 228, \"Column\": 2, \"Item\": 954, \"DisplayText\": \"Otitis externa (Outpatient)\", \"Text\": \"Otitis externa\", \"Mnemonic\": \"800\"}, {\"Row\": 229, \"Column\": 2, \"Item\": 933, \"DisplayText\": \"Malignant otitis externa (Outpatient)\", \"Text\": \"Otitis externa, malignant\", \"Mnemonic\": \"802\"}, {\"Row\": 230, \"Column\": 2, \"Item\": 955, \"DisplayText\": \"Otitis media (Outpatient)\", \"Text\": \"Otitis media\", \"Mnemonic\": \"804\"}, {\"Row\": 233, \"Column\": 2, \"Item\": 957, \"DisplayText\": \"Pancreatitis (Outpatient)\", \"Text\": \"Pancreatitis\", \"Mnemonic\": \"806\"}, {\"Row\": 234, \"Column\": 2, \"Item\": 690, \"DisplayText\": \"Parainfluenza (outpatient)\", \"Text\": \"Parainfluenza\", \"Mnemonic\": \"808\"}, {\"Row\": 235, \"Column\": 2, \"Item\": 960, \"DisplayText\": \"Parasites (Outpatient)\", \"Text\": \"Parasites\", \"Mnemonic\": \"810\"}, {\"Row\": 236, \"Column\": 2, \"Item\": 651, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Paratyphoid fever\", \"Mnemonic\": \"812\"}, {\"Row\": 237, \"Column\": 2, \"Item\": 961, \"DisplayText\": \"Paronychia (Outpatient)\", \"Text\": \"Paronychia\", \"Mnemonic\": \"814\"}, {\"Row\": 238, \"Column\": 2, \"Item\": 691, \"DisplayText\": \"Parotitis (outpatient)\", \"Text\": \"Parotitis\", \"Mnemonic\": \"816\"}, {\"Row\": 239, \"Column\": 2, \"Item\": 749, \"DisplayText\": \"Bite wounds with Pasteurella multocida (Outpatient)\", \"Text\": \"Pasteurella multocida bite wounds\", \"Mnemonic\": \"818\"}, {\"Row\": 240, \"Column\": 2, \"Item\": 871, \"DisplayText\": \"Pasteurella multocida (Outpatient)\", \"Text\": \"Pasteurella multocida infections, general\", \"Mnemonic\": \"820\"}, {\"Row\": 241, \"Column\": 2, \"Item\": 752, \"DisplayText\": \"Body Lice (Pediculosis Corporis) - Outpatient\", \"Text\": \"Pediculosis corporis\", \"Mnemonic\": \"822\"}, {\"Row\": 242, \"Column\": 2, \"Item\": 978, \"DisplayText\": \"Pelvic inflammatory disorder (PID) - Outpatient\", \"Text\": \"Pelvic inflammatory disease (PID)\", \"Mnemonic\": \"824\"}, {\"Row\": 243, \"Column\": 2, \"Item\": 788, \"DisplayText\": \"Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)\", \"Text\": \"Pelvic pain syndrome/prostatitis, chronic\", \"Mnemonic\": \"826\"}, {\"Row\": 244, \"Column\": 2, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Penicillin desensitization protocol\", \"Mnemonic\": \"828\"}, {\"Row\": 245, \"Column\": 2, \"Item\": 878, \"DisplayText\": \"Anaerobic Gram-positive cocci (Outpatient)\", \"Text\": \"Peptostreptococcus infections, general\", \"Mnemonic\": \"830\"}, {\"Row\": 246, \"Column\": 2, \"Item\": 736, \"DisplayText\": \"Appendicitis with perforation (Outpatient)\", \"Text\": \"Perforated appendicitis\", \"Mnemonic\": \"832\"}, {\"Row\": 247, \"Column\": 2, \"Item\": 698, \"DisplayText\": \"Perianal/Anorectal Abscess\", \"Text\": \"Perianal abscess\", \"Mnemonic\": \"834\"}, {\"Row\": 248, \"Column\": 2, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Pericarditis\", \"Mnemonic\": \"836\"}, {\"Row\": 249, \"Column\": 2, \"Item\": 524, \"DisplayText\": \"Periocular Infections\", \"Text\": \"Periocular infections\", \"Mnemonic\": \"838\"}, {\"Row\": 250, \"Column\": 2, \"Item\": 982, \"DisplayText\": \"Periodental disease (Outpatient)\", \"Text\": \"Periodontal disease\", \"Mnemonic\": \"840\"}, {\"Row\": 251, \"Column\": 2, \"Item\": 980, \"DisplayText\": \"Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis...\", \"Text\": \"Peritoneal dialysis peritonitis\", \"Mnemonic\": \"842\"}, {\"Row\": 252, \"Column\": 2, \"Item\": 729, \"DisplayText\": \"Spontaneous Bacterial Peritonitis (Outpatient)\", \"Text\": \"Peritonitis, acute spontaneous bacterial\", \"Mnemonic\": \"844\"}, {\"Row\": 253, \"Column\": 2, \"Item\": 980, \"DisplayText\": \"Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis...\", \"Text\": \"Peritonitis, peritoneal dialysis associated\", \"Mnemonic\": \"846\"}, {\"Row\": 254, \"Column\": 2, \"Item\": 1015, \"DisplayText\": \"Secondary peritonitis (Outpatient)\", \"Text\": \"Peritonitis, secondary\", \"Mnemonic\": \"848\"}, {\"Row\": 255, \"Column\": 2, \"Item\": 1009, \"DisplayText\": \"Recurrent or persistent urethritis (Outpatient)\", \"Text\": \"Persistent or recurrent urethritis\", \"Mnemonic\": \"850\"}, {\"Row\": 256, \"Column\": 2, \"Item\": 983, \"DisplayText\": \"Pertussis (Outpatient)\", \"Text\": \"Pertussis\", \"Mnemonic\": \"852\"}, {\"Row\": 257, \"Column\": 2, \"Item\": 995, \"DisplayText\": \"Prevention of pertussis (Outpatient)\", \"Text\": \"Pertussis post-exposure prophylaxis\", \"Mnemonic\": \"854\"}, {\"Row\": 258, \"Column\": 2, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Pertussis vaccination\", \"Mnemonic\": \"856\"}, {\"Row\": 259, \"Column\": 2, \"Item\": 222, \"DisplayText\": \"Not Benefited by Abx Pharyngitis\", \"Text\": \"Pharyngitis, non-streptococcal\", \"Mnemonic\": \"858\"}, {\"Row\": 260, \"Column\": 2, \"Item\": 984, \"DisplayText\": \"Pharyngitis (Outpatient)\", \"Text\": \"Pharyngitis, streptococcal\", \"Mnemonic\": \"860\"}, {\"Row\": 261, \"Column\": 2, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal vaccination\", \"Mnemonic\": \"862\"}, {\"Row\": 262, \"Column\": 2, \"Item\": 985, \"DisplayText\": \"Pneumocyctis Jirovecii Disease (Outpatient)\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"864\"}, {\"Row\": 263, \"Column\": 2, \"Item\": 986, \"DisplayText\": \"Pneumocystis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis prophylaxis\", \"Mnemonic\": \"866\"}, {\"Row\": 264, \"Column\": 2, \"Item\": 799, \"DisplayText\": \"Pneumonia (Outpatient)\", \"Text\": \"Pneumonia\", \"Mnemonic\": \"868\"}, {\"Row\": 265, \"Column\": 2, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Pneumonia with sepsis\", \"Mnemonic\": \"870\"}, {\"Row\": 266, \"Column\": 2, \"Item\": 739, \"DisplayText\": \"Aspiration pneumonia (Outpatient)\", \"Text\": \"Pneumonia, aspiration\", \"Mnemonic\": \"872\"}, {\"Row\": 267, \"Column\": 2, \"Item\": 798, \"DisplayText\": \"Community acquired pneumonia (Outpatient)\", \"Text\": \"Pneumonia, community-acquired (CAP)\", \"Mnemonic\": \"876\"}, {\"Row\": 268, \"Column\": 2, \"Item\": 793, \"DisplayText\": \"CMV pneumonia (Outpatient)\", \"Text\": \"Pneumonia, Cytomegalovirus (CMV)\", \"Mnemonic\": \"878\"}, {\"Row\": 269, \"Column\": 2, \"Item\": 966, \"DisplayText\": \"Mycobacterium avium pneumonia (Outpatient)\", \"Text\": \"Pneumonia, Mycobacterium avium\", \"Mnemonic\": \"880\"}, {\"Row\": 270, \"Column\": 2, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Pneumonia, nosocomial [CLICK HERE], includes:\", \"Mnemonic\": \"882\"}, {\"Row\": 189, \"Column\": 2, \"Text\": \"N______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 192, \"Column\": 2, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 193, \"Column\": 2, \"Text\": \"Neisseria gonorrhoeae, Pseudomonas aeruginosa,\"}, {\"Row\": 194, \"Column\": 2, \"Text\": \"Staphylococcus aureus, streptococcus\"}, {\"Row\": 196, \"Column\": 2, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 197, \"Column\": 2, \"Text\": \"gram-negative bacilli, streptococci, staphylococci,\"}, {\"Row\": 198, \"Column\": 2, \"Text\": \"and HACEK bacteria\"}, {\"Row\": 218, \"Column\": 2, \"Text\": \"O______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 225, \"Column\": 2, \"Text\": \"empirical therapy, gram-negative bacilli, Pseudomonas aeruginosa,\"}, {\"Row\": 226, \"Column\": 2, \"Text\": \"Staphylococcus aureus, and streptococci\"}, {\"Row\": 232, \"Column\": 2, \"Text\": \"Pa-Pn__________________________________________________________________________\", \"Header\": 1}, {\"Row\": 271, \"Column\": 2, \"Text\": \"72 hour re-evaluation, Acinetobacter baumannii,\"}, {\"Row\": 272, \"Column\": 2, \"Text\": \"empirical therapy, Enterobacteriaceae, HAP, Legionella pneumophila,\"}, {\"Row\": 273, \"Column\": 2, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aeruginosa, and VAP\"}, {\"Row\": 1, \"Column\": 3, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Drug Information\", \"Mnemonic\": \"884\"}, {\"Row\": 7, \"Column\": 3, \"Item\": 794, \"DisplayText\": \"CMV polyradiculopathy (Outpatient)\", \"Text\": \"Polyradiculopathy, Cytomegalovirus (CMV)\", \"Mnemonic\": \"886\"}, {\"Row\": 8, \"Column\": 3, \"Item\": 858, \"DisplayText\": \"Bacteroides spp. (Outpatient)\", \"Text\": \"Porphyromonas infections, general\", \"Mnemonic\": \"888\"}, {\"Row\": 9, \"Column\": 3, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"Post-exposure prophylaxis, occupational\", \"Mnemonic\": \"890\"}, {\"Row\": 10, \"Column\": 3, \"Item\": 995, \"DisplayText\": \"Prevention of pertussis (Outpatient)\", \"Text\": \"Post-exposure prophylaxis, pertussis\", \"Mnemonic\": \"892\"}, {\"Row\": 13, \"Column\": 3, \"Item\": 526, \"DisplayText\": \"Antimicrobial Prophylaxis Post-op\", \"Text\": \"Post-operative antimicrobial prophylaxis\", \"Mnemonic\": \"896\"}, {\"Row\": 14, \"Column\": 3, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Post-operative dermatology infection\", \"Mnemonic\": \"898\"}, {\"Row\": 15, \"Column\": 3, \"Item\": 1037, \"DisplayText\": \"Surgical site infection\", \"Text\": \"Post-operative wound infection\", \"Mnemonic\": \"900\"}, {\"Row\": 16, \"Column\": 3, \"Item\": 987, \"DisplayText\": \"Postseptal cellulitis (Orbital cellulitis) - Outpatient\", \"Text\": \"Postseptal cellulitis\", \"Mnemonic\": \"902\"}, {\"Row\": 17, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Post-surgical or post-traumatic brain abscess\", \"Mnemonic\": \"904\"}, {\"Row\": 18, \"Column\": 3, \"Item\": 989, \"DisplayText\": \"\", \"Text\": \"Pregnancy immunizations\", \"Mnemonic\": \"906\"}, {\"Row\": 19, \"Column\": 3, \"Item\": 988, \"DisplayText\": \"List of Antimicrobials with Pregnancy Risk Category\", \"Text\": \"Pregnancy risk factors for antimicrobials\", \"Mnemonic\": \"908\"}, {\"Row\": 20, \"Column\": 3, \"Item\": 490, \"DisplayText\": \"Pre-Op Antimicrobials...\", \"Text\": \"Pre-operative antimicrobial prophylaxis\", \"Mnemonic\": \"910\"}, {\"Row\": 21, \"Column\": 3, \"Item\": 990, \"DisplayText\": \"Preseptal cellulitis (Outpatient)\", \"Text\": \"Preseptal cellulitis\", \"Mnemonic\": \"912\"}, {\"Row\": 22, \"Column\": 3, \"Item\": 741, \"DisplayText\": \"\", \"Text\": \"Prevention of COPD exacerbations\", \"Mnemonic\": \"914\"}, {\"Row\": 23, \"Column\": 3, \"Item\": 994, \"DisplayText\": \"Prevention of Infection - Outpatient\", \"Text\": \"Prevention of Infection section\", \"Mnemonic\": \"916\"}, {\"Row\": 24, \"Column\": 3, \"Item\": 858, \"DisplayText\": \"Bacteroides spp. (Outpatient)\", \"Text\": \"Prevotella infections, general\", \"Mnemonic\": \"918\"}, {\"Row\": 25, \"Column\": 3, \"Item\": 991, \"DisplayText\": \"Prevention of infection in a patient with malignancy (Outpatient)\", \"Text\": \"Prophylactic antibiotics in malignancy\", \"Mnemonic\": \"920\"}, {\"Row\": 26, \"Column\": 3, \"Item\": 992, \"DisplayText\": \"Prevention of fungal infection in a patient with malignancy\", \"Text\": \"Prophylactic antifungals in malignancy\", \"Mnemonic\": \"922\"}, {\"Row\": 27, \"Column\": 3, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"Prophylactic antimicrobials for asplenia\", \"Mnemonic\": \"924\"}, {\"Row\": 28, \"Column\": 3, \"Item\": 931, \"DisplayText\": \"Lyme Disease Prophylaxis\", \"Text\": \"Prophylactic antimicrobials for Lyme disease\", \"Mnemonic\": \"926\"}, {\"Row\": 29, \"Column\": 3, \"Item\": 968, \"DisplayText\": \"Prophylaxis against Mycobacterium avium disease... (Outpatient)\", \"Text\": \"Prophylactic antimicrobials for Mycobacterium avium\", \"Mnemonic\": \"928\"}, {\"Row\": 30, \"Column\": 3, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"Prophylactic antimicrobials for occupational post-exposure\", \"Mnemonic\": \"930\"}, {\"Row\": 31, \"Column\": 3, \"Item\": 986, \"DisplayText\": \"Pneumocystis Jirovecii Prophylaxis\", \"Text\": \"Prophylactic antimicrobials for Pneumocystis\", \"Mnemonic\": \"932\"}, {\"Row\": 32, \"Column\": 3, \"Item\": 995, \"DisplayText\": \"Prevention of pertussis (Outpatient)\", \"Text\": \"Prophylactic antimicrobials for post-exposure pertussis\", \"Mnemonic\": \"934\"}, {\"Row\": 33, \"Column\": 3, \"Item\": 729, \"DisplayText\": \"Spontaneous Bacterial Peritonitis (Outpatient)\", \"Text\": \"Prophylactic antimicrobials for spontaneous bacterial peritonitis\", \"Mnemonic\": \"936\"}, {\"Row\": 34, \"Column\": 3, \"Item\": 526, \"DisplayText\": \"Antimicrobial Prophylaxis Post-op\", \"Text\": \"Prophylactic antimicrobials, post-operative\", \"Mnemonic\": \"938\"}, {\"Row\": 35, \"Column\": 3, \"Item\": 490, \"DisplayText\": \"Pre-Op Antimicrobials...\", \"Text\": \"Prophylactic antimicrobials, pre-operative\", \"Mnemonic\": \"940\"}, {\"Row\": 36, \"Column\": 3, \"Item\": 732, \"DisplayText\": \"\", \"Text\": \"Prophylactic antivirals in malignancy\", \"Mnemonic\": \"942\"}, {\"Row\": 39, \"Column\": 3, \"Item\": 886, \"DisplayText\": \"Propionibacterium species (Outpatient)\", \"Text\": \"Propionibacterium infections, general\", \"Mnemonic\": \"946\"}, {\"Row\": 40, \"Column\": 3, \"Item\": 725, \"DisplayText\": \"Acute bacterial prostatitis (Outpatient)\", \"Text\": \"Prostatitis, acute\", \"Mnemonic\": \"948\"}, {\"Row\": 41, \"Column\": 3, \"Item\": 789, \"DisplayText\": \"Chronic bacterial prostatitis (Outpatient)\", \"Text\": \"Prostatitis, chronic\", \"Mnemonic\": \"950\"}, {\"Row\": 42, \"Column\": 3, \"Item\": 788, \"DisplayText\": \"Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)\", \"Text\": \"Prostatitis/pelvic pain syndrome, chronic\", \"Mnemonic\": \"952\"}, {\"Row\": 43, \"Column\": 3, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Prosthetic bone/joint infection [CLICK HERE], includes:\", \"Mnemonic\": \"954\"}, {\"Row\": 47, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Prosthetic valve endocarditis [CLICK HERE], includes:\", \"Mnemonic\": \"956\"}, {\"Row\": 51, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Prosthetic valve endocarditis empirical therapy\", \"Mnemonic\": \"958\"}, {\"Row\": 52, \"Column\": 3, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Prosthetic valve endocarditis with sepsis\", \"Mnemonic\": \"960\"}, {\"Row\": 53, \"Column\": 3, \"Item\": 872, \"DisplayText\": \"Proteus spp. (Outpatient)\", \"Text\": \"Proteus infections, general\", \"Mnemonic\": \"962\"}, {\"Row\": 54, \"Column\": 3, \"Item\": 231, \"DisplayText\": \"Penicillin Desensitization Protocol\", \"Text\": \"Protocol for Penicillin Desensitization\", \"Mnemonic\": \"964\"}, {\"Row\": 55, \"Column\": 3, \"Item\": 1020, \"DisplayText\": \"Septic arthritis (Native Joint) with P. aeruginosa - Outpatient\", \"Text\": \"Pseudomonas aeruginosa native joint infection\", \"Mnemonic\": \"966\"}, {\"Row\": 56, \"Column\": 3, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Pseudomonas aeruginosa nosocomial pneumonia\", \"Mnemonic\": \"968\"}, {\"Row\": 57, \"Column\": 3, \"Item\": 949, \"DisplayText\": \"Osteomyelitis with Pseudomonas aeruginosa (Outpatient)\", \"Text\": \"Pseudomonas aeruginosa osteomyelitis\", \"Mnemonic\": \"970\"}, {\"Row\": 58, \"Column\": 3, \"Item\": 1001, \"DisplayText\": \"Pseudomonas aeringunosa infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Pseudomonas aeruginosa prosthetic bone/joint infection\", \"Mnemonic\": \"972\"}, {\"Row\": 59, \"Column\": 3, \"Item\": 1006, \"DisplayText\": \"Pyelonephritis (Outpatient)\", \"Text\": \"Pseudomonas aeruginosa pyelonephritis\", \"Mnemonic\": \"974\"}, {\"Row\": 60, \"Column\": 3, \"Item\": 873, \"DisplayText\": \"Pseudomonas spp. (Outpatient)\", \"Text\": \"Pseudomonas infections, general\", \"Mnemonic\": \"976\"}, {\"Row\": 61, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Pseudomonas meningitis\", \"Mnemonic\": \"978\"}, {\"Row\": 62, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Pseudomonas spp. brain abscess\", \"Mnemonic\": \"980\"}, {\"Row\": 63, \"Column\": 3, \"Item\": 1005, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis) - Outpatient\", \"Text\": \"Pubic lice\", \"Mnemonic\": \"982\"}, {\"Row\": 64, \"Column\": 3, \"Item\": 1006, \"DisplayText\": \"Pyelonephritis (Outpatient)\", \"Text\": \"Pyelonephritis [CLICK HERE], includes:\", \"Mnemonic\": \"984\"}, {\"Row\": 66, \"Column\": 3, \"Item\": 853, \"DisplayText\": \"\", \"Text\": \"Pyogenic liver abscess\", \"Mnemonic\": \"986\"}, {\"Row\": 67, \"Column\": 3, \"Item\": 1007, \"DisplayText\": \"Pyomyositis\", \"Text\": \"Pyomyositis\", \"Mnemonic\": \"988\"}, {\"Row\": 68, \"Column\": 3, \"Item\": 687, \"DisplayText\": \"Bacteriuria, Candiduria and Pyuria (outpatient)\", \"Text\": \"Pyuria\", \"Mnemonic\": \"990\"}, {\"Row\": 75, \"Column\": 3, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Rabies vaccination\", \"Mnemonic\": \"994\"}, {\"Row\": 76, \"Column\": 3, \"Item\": 1009, \"DisplayText\": \"Recurrent or persistent urethritis (Outpatient)\", \"Text\": \"Recurrent or persistent urethritis\", \"Mnemonic\": \"996\"}, {\"Row\": 77, \"Column\": 3, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Renal failure immunizations\", \"Mnemonic\": \"998\"}, {\"Row\": 78, \"Column\": 3, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"Resistant bacteria, more about\", \"Mnemonic\": \"1000\"}, {\"Row\": 79, \"Column\": 3, \"Item\": 715, \"DisplayText\": \"Respiratory Syncytial Virus (RSV) (outpatient)\", \"Text\": \"Respiratory syncytial virus (RSV)\", \"Mnemonic\": \"1004\"}, {\"Row\": 80, \"Column\": 3, \"Item\": 69, \"DisplayText\": \"Antimicrobial restriction policy\", \"Text\": \"Restrictions on antimicrobials\", \"Mnemonic\": \"1006\"}, {\"Row\": 81, \"Column\": 3, \"Item\": 1011, \"DisplayText\": \"Retinitis (Outpatient)\", \"Text\": \"Retinitis [CLICK HERE], includes:\", \"Mnemonic\": \"1008\"}, {\"Row\": 83, \"Column\": 3, \"Item\": 1040, \"DisplayText\": \"Tinea Capitis (Ringworm) - Outpatient\", \"Text\": \"Ringworm\", \"Mnemonic\": \"1010\"}, {\"Row\": 84, \"Column\": 3, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"Risk factors for MRSA\", \"Mnemonic\": \"1012\"}, {\"Row\": 85, \"Column\": 3, \"Item\": 1012, \"DisplayText\": \"Rocky Mountain Spotted Fever (Outpatient)\", \"Text\": \"Rocky mountain spotted fever\", \"Mnemonic\": \"1014\"}, {\"Row\": 86, \"Column\": 3, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Rubella vaccination\", \"Mnemonic\": \"1016\"}, {\"Row\": 89, \"Column\": 3, \"Item\": 818, \"DisplayText\": \"Diarrhea with Salmonella (Outpatient)\", \"Text\": \"Salmonella diarrhea/gastroenteritis\", \"Mnemonic\": \"1018\"}, {\"Row\": 90, \"Column\": 3, \"Item\": 874, \"DisplayText\": \"Salmonella spp. (Outpatient)\", \"Text\": \"Salmonella infections, general\", \"Mnemonic\": \"1020\"}, {\"Row\": 91, \"Column\": 3, \"Item\": 1013, \"DisplayText\": \"Scabies (Outpatient)\", \"Text\": \"Scabies\", \"Mnemonic\": \"1022\"}, {\"Row\": 92, \"Column\": 3, \"Item\": 1035, \"DisplayText\": \"Staphylococcal Scalded Skin Syndrome (Ritter's Disease) - Outpatient\", \"Text\": \"Scalded skin syndrome\", \"Mnemonic\": \"1024\"}, {\"Row\": 93, \"Column\": 3, \"Item\": 912, \"DisplayText\": \"Influenza Seasonal 2021-2022\", \"Text\": \"Seasonal influenza\", \"Mnemonic\": \"1026\"}, {\"Row\": 94, \"Column\": 3, \"Item\": 1015, \"DisplayText\": \"Secondary peritonitis (Outpatient)\", \"Text\": \"Secondary peritonitis\", \"Mnemonic\": \"1028\"}, {\"Row\": 95, \"Column\": 3, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Sepsis and septic shock\", \"Mnemonic\": \"1030\"}, {\"Row\": 96, \"Column\": 3, \"Item\": 1023, \"DisplayText\": \"Septic arthritis (Native Joint) - Outpatient\", \"Text\": \"Septic arthritis, native joint [CLICK HERE], includes:\", \"Mnemonic\": \"1032\"}, {\"Row\": 100, \"Column\": 3, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Septic arthritis, prosthetic joint [CLICK HERE], includes:\", \"Mnemonic\": \"1034\"}, {\"Row\": 104, \"Column\": 3, \"Item\": 1024, \"DisplayText\": \"Septic bursitis (Outpatient)\", \"Text\": \"Septic bursitis\", \"Mnemonic\": \"1036\"}, {\"Row\": 105, \"Column\": 3, \"Item\": 875, \"DisplayText\": \"Serratia spp. (Outpatient)\", \"Text\": \"Serratia infections, general\", \"Mnemonic\": \"1038\"}, {\"Row\": 106, \"Column\": 3, \"Item\": 743, \"DisplayText\": \"Bacterial vaginosis (Outpatient)\", \"Text\": \"Sexually transmitted infection, bacterial vaginitis\", \"Mnemonic\": \"1040\"}, {\"Row\": 107, \"Column\": 3, \"Item\": 784, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Sexually transmitted infection, cervicitis\", \"Mnemonic\": \"1042\"}, {\"Row\": 108, \"Column\": 3, \"Item\": 784, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Sexually transmitted infection, chlamydia cervicitis\", \"Mnemonic\": \"1044\"}, {\"Row\": 109, \"Column\": 3, \"Item\": 1053, \"DisplayText\": \"Urethritis associated with sexually transmitted disease (Outpatient)\", \"Text\": \"Sexually transmitted infection, chlamydia urethritis\", \"Mnemonic\": \"1046\"}, {\"Row\": 110, \"Column\": 3, \"Item\": 851, \"DisplayText\": \"Genital herpes (Outpatient)\", \"Text\": \"Sexually transmitted infection, genital warts\", \"Mnemonic\": \"1048\"}, {\"Row\": 111, \"Column\": 3, \"Item\": 784, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Sexually transmitted infection, gonorrhea cervicitis\", \"Mnemonic\": \"1050\"}, {\"Row\": 112, \"Column\": 3, \"Item\": 1053, \"DisplayText\": \"Urethritis associated with sexually transmitted disease (Outpatient)\", \"Text\": \"Sexually transmitted infection, gonorrhea urethritis\", \"Mnemonic\": \"1052\"}, {\"Row\": 113, \"Column\": 3, \"Item\": 978, \"DisplayText\": \"Pelvic inflammatory disorder (PID) - Outpatient\", \"Text\": \"Sexually transmitted infection, pelvic inflammatory disease\", \"Mnemonic\": \"1054\"}, {\"Row\": 114, \"Column\": 3, \"Item\": 1005, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis) - Outpatient\", \"Text\": \"Sexually transmitted infection, pubic lice (crabs)\", \"Mnemonic\": \"1056\"}, {\"Row\": 115, \"Column\": 3, \"Item\": 719, \"DisplayText\": \"Syphilis\", \"Text\": \"Sexually transmitted infection, syphilis\", \"Mnemonic\": \"1058\"}, {\"Row\": 116, \"Column\": 3, \"Item\": 1049, \"DisplayText\": \"Trichomonas vaginitis (Outpatient)\", \"Text\": \"Sexually transmitted infection, trichomoniasis\", \"Mnemonic\": \"1060\"}, {\"Row\": 117, \"Column\": 3, \"Item\": 1053, \"DisplayText\": \"Urethritis associated with sexually transmitted disease (Outpatient)\", \"Text\": \"Sexually transmitted infection, urethritis\", \"Mnemonic\": \"1062\"}, {\"Row\": 118, \"Column\": 3, \"Item\": 819, \"DisplayText\": \"Diarrhea with Shigella (Outpatient)\", \"Text\": \"Shigella diarrhea/gastroenteritis\", \"Mnemonic\": \"1064\"}, {\"Row\": 119, \"Column\": 3, \"Item\": 876, \"DisplayText\": \"Shigella spp. (Outpatient)\", \"Text\": \"Shigella infections, general\", \"Mnemonic\": \"1066\"}, {\"Row\": 120, \"Column\": 3, \"Item\": 1008, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\") - Outpatient\", \"Text\": \"Shingles\", \"Mnemonic\": \"1068\"}, {\"Row\": 121, \"Column\": 3, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Shingles vaccination\", \"Mnemonic\": \"1070\"}, {\"Row\": 122, \"Column\": 3, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Shortages of antimicrobials updates\", \"Mnemonic\": \"1072\"}, {\"Row\": 123, \"Column\": 3, \"Item\": 726, \"DisplayText\": \"ACUTE SINUSITIS\", \"Text\": \"Sinusitis, acute\", \"Mnemonic\": \"1074\"}, {\"Row\": 124, \"Column\": 3, \"Item\": 790, \"DisplayText\": \"Chronic sinusitis (Outpatient)\", \"Text\": \"Sinusitis, chronic\", \"Mnemonic\": \"1076\"}, {\"Row\": 125, \"Column\": 3, \"Item\": 385, \"DisplayText\": \"Fungal Sinusitis\", \"Text\": \"Sinusitis, fungal\", \"Mnemonic\": \"1078\"}, {\"Row\": 126, \"Column\": 3, \"Item\": 944, \"DisplayText\": \"Nosocomial sinusitis (Outpatient)\", \"Text\": \"Sinusitis, nosocomial\", \"Mnemonic\": \"1080\"}, {\"Row\": 127, \"Column\": 3, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Skin and soft tissue infection with sepsis\", \"Mnemonic\": \"1082\"}, {\"Row\": 128, \"Column\": 3, \"Item\": 807, \"DisplayText\": \"Dermatology Infections (Outpatient)\", \"Text\": \"Skin Infections section\", \"Mnemonic\": \"1084\"}, {\"Row\": 129, \"Column\": 3, \"Item\": 1027, \"DisplayText\": \"Small uniform bacillin in an aerobic bottle (Outpatient)\", \"Text\": \"Small pleomorphic bacilli, aerobic bottle\", \"Mnemonic\": \"1086\"}, {\"Row\": 130, \"Column\": 3, \"Item\": 1028, \"DisplayText\": \"Small uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"Small pleomorphic bacilli, anaerobic bottle\", \"Mnemonic\": \"1088\"}, {\"Row\": 131, \"Column\": 3, \"Item\": 1029, \"DisplayText\": \"Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)\", \"Text\": \"Soft Tissue and Muscle section\", \"Mnemonic\": \"1090\"}, {\"Row\": 132, \"Column\": 3, \"Item\": 475, \"DisplayText\": \"Introduction to Specific Pathogen section\", \"Text\": \"Specific pathogen introduction\", \"Mnemonic\": \"1092\"}, {\"Row\": 133, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Spinal epidural abscess\", \"Mnemonic\": \"1094\"}, {\"Row\": 134, \"Column\": 3, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"Spleen absent or dysfunctional [CLICK HERE], includes:\", \"Mnemonic\": \"1096\"}, {\"Row\": 137, \"Column\": 3, \"Item\": 729, \"DisplayText\": \"Spontaneous Bacterial Peritonitis (Outpatient)\", \"Text\": \"Spontaneous bacterial peritonitis prevention\", \"Mnemonic\": \"1098\"}, {\"Row\": 138, \"Column\": 3, \"Item\": 1034, \"DisplayText\": \"Sporotrichosis (Outpatient)\", \"Text\": \"Sporotrichosis infections, general\", \"Mnemonic\": \"1100\"}, {\"Row\": 139, \"Column\": 3, \"Item\": 893, \"DisplayText\": \"Staphylococci (Outpatient)\", \"Text\": \"Staphylococcal infections, general\", \"Mnemonic\": \"1102\"}, {\"Row\": 140, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Staphylococcal native valve endocarditis\", \"Mnemonic\": \"1104\"}, {\"Row\": 141, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Staphylococcal prosthetic valve endocarditis\", \"Mnemonic\": \"1106\"}, {\"Row\": 142, \"Column\": 3, \"Item\": 1046, \"DisplayText\": \"Toxic Shock Syndrome (Outpatient)\", \"Text\": \"Staphylococcal toxic shock syndrome\", \"Mnemonic\": \"1108\"}, {\"Row\": 143, \"Column\": 3, \"Item\": 881, \"DisplayText\": \"Treatment for Coagulase Negative Staphylococci (Outpatient)\", \"Text\": \"Staphylococci, coagulase-negative\", \"Mnemonic\": \"1110\"}, {\"Row\": 144, \"Column\": 3, \"Item\": 895, \"DisplayText\": \"Treatment for Staphylococcus aureus (Outpatient)\", \"Text\": \"Staphylococcus aureus infections, general\", \"Mnemonic\": \"1112\"}, {\"Row\": 145, \"Column\": 3, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Staphylococcus aureus nosocomial pneumonia\", \"Mnemonic\": \"1114\"}, {\"Row\": 146, \"Column\": 3, \"Item\": 950, \"DisplayText\": \"Osteomyelitis with Staphylococcus aureus (Outpatient)\", \"Text\": \"Staphylococcus aureus osteomyelitis\", \"Mnemonic\": \"1116\"}, {\"Row\": 147, \"Column\": 3, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Staphylococcus aureus bacteremia\", \"Mnemonic\": \"1118\"}, {\"Row\": 148, \"Column\": 3, \"Item\": 716, \"DisplayText\": \"\", \"Text\": \"Staphylococcus aureus decolonization\", \"Mnemonic\": \"1120\"}, {\"Row\": 149, \"Column\": 3, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Staphylococcus aureus intravascular catheter-associated infection\", \"Mnemonic\": \"1122\"}, {\"Row\": 150, \"Column\": 3, \"Item\": 1002, \"DisplayText\": \"Staphylococcus aureus infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Staphylococcus aureus prosthetic bone/joint infection\", \"Mnemonic\": \"1124\"}, {\"Row\": 151, \"Column\": 3, \"Item\": 1021, \"DisplayText\": \"Septic arthristis (Native Joint) with S. aureus - Outpatient\", \"Text\": \"Staphylococcus aureus, native joint infection\", \"Mnemonic\": \"1126\"}, {\"Row\": 152, \"Column\": 3, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Staphylococcus lugdunensis bacteremia\", \"Mnemonic\": \"1128\"}, {\"Row\": 153, \"Column\": 3, \"Item\": 892, \"DisplayText\": \"Treatment for Staphylococcus lugdunensis\", \"Text\": \"Staphylococcus lugdunensis infections, general\", \"Mnemonic\": \"1130\"}, {\"Row\": 154, \"Column\": 3, \"Item\": 718, \"DisplayText\": \"Stasis Dermatitis (outpatient)\", \"Text\": \"Stasis dermatitis\", \"Mnemonic\": \"1132\"}, {\"Row\": 155, \"Column\": 3, \"Item\": 750, \"DisplayText\": \"Bite wounds with Streptococci (Outpatient)\", \"Text\": \"Streptococcal bite wounds\", \"Mnemonic\": \"1134\"}, {\"Row\": 156, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Streptococcal native valve endocarditis (highly resistant isolate)\", \"Mnemonic\": \"1136\"}, {\"Row\": 157, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Streptococcal native valve endocarditis (sensitive isolate)\", \"Mnemonic\": \"1138\"}, {\"Row\": 158, \"Column\": 3, \"Item\": 951, \"DisplayText\": \"Osteomyelitis with Streptococci (Outpatient)\", \"Text\": \"Streptococcal osteomyelitis\", \"Mnemonic\": \"1140\"}, {\"Row\": 159, \"Column\": 3, \"Item\": 984, \"DisplayText\": \"Pharyngitis (Outpatient)\", \"Text\": \"Streptococcal pharyngitis\", \"Mnemonic\": \"1142\"}, {\"Row\": 160, \"Column\": 3, \"Item\": 1003, \"DisplayText\": \"Streptococci infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Streptococcal prosthetic bone/joint infection\", \"Mnemonic\": \"1144\"}, {\"Row\": 161, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Streptococcal prosthetic valve endocarditis\", \"Mnemonic\": \"1146\"}, {\"Row\": 162, \"Column\": 3, \"Item\": 1046, \"DisplayText\": \"Toxic Shock Syndrome (Outpatient)\", \"Text\": \"Streptococcal toxic shock syndrome\", \"Mnemonic\": \"1148\"}, {\"Row\": 163, \"Column\": 3, \"Item\": 884, \"DisplayText\": \"Streptococci Groups C, F, G (Outpatient)\", \"Text\": \"Streptococci Groups C, F, G infections, general\", \"Mnemonic\": \"1150\"}, {\"Row\": 164, \"Column\": 3, \"Item\": 896, \"DisplayText\": \"Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient\", \"Text\": \"Streptococci viridans infections, general [CLICK HERE], includes:\", \"Mnemonic\": \"1152\"}, {\"Row\": 166, \"Column\": 3, \"Item\": 887, \"DisplayText\": \"Group B (S. agalactiae) - Outpatient\", \"Text\": \"Streptococcus agalactiae (Group B)\", \"Mnemonic\": \"1154\"}, {\"Row\": 167, \"Column\": 3, \"Item\": 888, \"DisplayText\": \"Streptococcus anginosus (formerly S. milleri) - Outpatient\", \"Text\": \"Streptococcus anginosus (formerly S. milleri)\", \"Mnemonic\": \"1156\"}, {\"Row\": 168, \"Column\": 3, \"Item\": 889, \"DisplayText\": \"Group D Streptococci (S. bovis) - Outpatient\", \"Text\": \"Streptococcus bovis (Group D)\", \"Mnemonic\": \"1158\"}, {\"Row\": 169, \"Column\": 3, \"Item\": 1022, \"DisplayText\": \"Septic arthritis (Native Joint) with Streptococci - Outpatient\", \"Text\": \"Streptococcus native joint infection\", \"Mnemonic\": \"1160\"}, {\"Row\": 170, \"Column\": 3, \"Item\": 890, \"DisplayText\": \"Streptococcus pneumoniae (Outpatient)\", \"Text\": \"Streptococcus pneumoniae infections, general\", \"Mnemonic\": \"1162\"}, {\"Row\": 171, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Streptococcus pneumoniae meningitis\", \"Mnemonic\": \"1164\"}, {\"Row\": 172, \"Column\": 3, \"Item\": 891, \"DisplayText\": \"Group A (S. pyogenes) - Outpatient\", \"Text\": \"Streptococcus pyogenes (Group A) infections, general\", \"Mnemonic\": \"1166\"}, {\"Row\": 173, \"Column\": 3, \"Item\": 455, \"DisplayText\": \"Stress\", \"Text\": \"Stress\", \"Mnemonic\": \"1168\"}, {\"Row\": 174, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Subdural empyema\", \"Mnemonic\": \"1170\"}, {\"Row\": 175, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Suppurative intracranial thrombophlebitis\", \"Mnemonic\": \"1172\"}, {\"Row\": 176, \"Column\": 3, \"Item\": 1036, \"DisplayText\": \"Suppurative odontogenic infections (Outpatient)\", \"Text\": \"Suppurative odontic infections\", \"Mnemonic\": \"1174\"}, {\"Row\": 177, \"Column\": 3, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Suppurative thrombophlebitis\", \"Mnemonic\": \"1176\"}, {\"Row\": 178, \"Column\": 3, \"Item\": 1037, \"DisplayText\": \"Surgical site infection\", \"Text\": \"Surgical site infection\", \"Mnemonic\": \"1178\"}, {\"Row\": 179, \"Column\": 3, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Susceptibilities, antimicrobial\", \"Mnemonic\": \"1180\"}, {\"Row\": 180, \"Column\": 3, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Suspected bacteremia, blood cultures not yet positive\", \"Mnemonic\": \"1182\"}, {\"Row\": 181, \"Column\": 3, \"Item\": 719, \"DisplayText\": \"Syphilis\", \"Text\": \"Syphilis\", \"Mnemonic\": \"1184\"}, {\"Row\": 182, \"Column\": 3, \"Item\": 1038, \"DisplayText\": \"Systemic Infectious Diseases (Outpatient)\", \"Text\": \"Systemic Infections section\", \"Mnemonic\": \"1186\"}, {\"Row\": 4, \"Column\": 3, \"Text\": \"Po through Z\", \"Header\": 1}, {\"Row\": 6, \"Column\": 3, \"Text\": \"Po-Py__________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 3, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 45, \"Column\": 3, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aureus,\"}, {\"Row\": 46, \"Column\": 3, \"Text\": \"and streptococcus\"}, {\"Row\": 48, \"Column\": 3, \"Text\": \"culture negative, enterococci, fungi,\"}, {\"Row\": 49, \"Column\": 3, \"Text\": \"gram-negative bacilli, Streptococcus bovis,\"}, {\"Row\": 50, \"Column\": 3, \"Text\": \"staphylococci, HACEK bacteria, and Viridans group streptococci\"}, {\"Row\": 65, \"Column\": 3, \"Text\": \"empiric therapy, enterococcus, pseudomonas\"}, {\"Row\": 70, \"Column\": 3, \"Text\": \"Q______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 72, \"Column\": 3, \"Text\": \"R______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 82, \"Column\": 3, \"Text\": \"candida, Cytomegalovirus, herpes, zoster, and others\"}, {\"Row\": 88, \"Column\": 3, \"Text\": \"S______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 97, \"Column\": 3, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 98, \"Column\": 3, \"Text\": \"Neisseria gonorrhoeae, Pseudomonas aeruginosa,\"}, {\"Row\": 99, \"Column\": 3, \"Text\": \"Staphylococcus aureus, streptococcus\"}, {\"Row\": 101, \"Column\": 3, \"Text\": \"empirical therapy, enterococci, gram-negative bacilli,\"}, {\"Row\": 102, \"Column\": 3, \"Text\": \"Pseudomonas aeruginosa, Staphylococcus aureus,\"}, {\"Row\": 103, \"Column\": 3, \"Text\": \"and streptococcus\"}, {\"Row\": 135, \"Column\": 3, \"Text\": \"antimicrobial prophylaxis, management of fever,\"}, {\"Row\": 136, \"Column\": 3, \"Text\": \"patient initiated antibiotics, vaccines\"}, {\"Row\": 165, \"Column\": 3, \"Text\": \"S. mutans, S. mitis, S. sanguis\"}, {\"Row\": 185, \"Column\": 3, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus vaccination\", \"Mnemonic\": \"1188\"}, {\"Row\": 186, \"Column\": 3, \"Item\": 843, \"DisplayText\": \"Candida albicans (Outpatient)\", \"Text\": \"Thrush\", \"Mnemonic\": \"1190\"}, {\"Row\": 188, \"Column\": 3, \"Item\": 1040, \"DisplayText\": \"Tinea Capitis (Ringworm) - Outpatient\", \"Text\": \"Tinea capitis\", \"Mnemonic\": \"1192\"}, {\"Row\": 189, \"Column\": 3, \"Item\": 1041, \"DisplayText\": \"Tinea Pedis (Athlete's Foot) - Outpatient\", \"Text\": \"Tinea corporis\", \"Mnemonic\": \"1194\"}, {\"Row\": 190, \"Column\": 3, \"Item\": 1041, \"DisplayText\": \"Tinea Pedis (Athlete's Foot) - Outpatient\", \"Text\": \"Tinea cruris\", \"Mnemonic\": \"1196\"}, {\"Row\": 191, \"Column\": 3, \"Item\": 1041, \"DisplayText\": \"Tinea Pedis (Athlete's Foot) - Outpatient\", \"Text\": \"Tinea pedis\", \"Mnemonic\": \"1198\"}, {\"Row\": 192, \"Column\": 3, \"Item\": 1042, \"DisplayText\": \"Tinea Unguium (Onychomycosis)\", \"Text\": \"Tinea unguium\", \"Mnemonic\": \"1200\"}, {\"Row\": 193, \"Column\": 3, \"Item\": 1043, \"DisplayText\": \"Tinea Versicolor (Outpatient)\", \"Text\": \"Tinea versicolor\", \"Mnemonic\": \"1202\"}, {\"Row\": 194, \"Column\": 3, \"Item\": 456, \"DisplayText\": \"Tobacco smoke\", \"Text\": \"Tobacco smoke\", \"Mnemonic\": \"1204\"}, {\"Row\": 195, \"Column\": 3, \"Item\": 984, \"DisplayText\": \"Pharyngitis (Outpatient)\", \"Text\": \"Tonsillitis\", \"Mnemonic\": \"1206\"}, {\"Row\": 196, \"Column\": 3, \"Item\": 1036, \"DisplayText\": \"Suppurative odontogenic infections (Outpatient)\", \"Text\": \"Tooth abscess and other suppurative odontic infections\", \"Mnemonic\": \"1208\"}, {\"Row\": 197, \"Column\": 3, \"Item\": 1046, \"DisplayText\": \"Toxic Shock Syndrome (Outpatient)\", \"Text\": \"Toxic shock syndrome\", \"Mnemonic\": \"1210\"}, {\"Row\": 198, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Toxoplasma gondii brain abscess\", \"Mnemonic\": \"1212\"}, {\"Row\": 199, \"Column\": 3, \"Item\": 959, \"DisplayText\": \"Toxoplasma spp. (Outpatient)\", \"Text\": \"Toxoplasma infections, general\", \"Mnemonic\": \"1214\"}, {\"Row\": 200, \"Column\": 3, \"Item\": 626, \"DisplayText\": \"Transplantation\", \"Text\": \"Transplantation\", \"Mnemonic\": \"1216\"}, {\"Row\": 201, \"Column\": 3, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Trauma or nosocomial infection associated meningitis\", \"Mnemonic\": \"1218\"}, {\"Row\": 202, \"Column\": 3, \"Item\": 1048, \"DisplayText\": \"Traveler's diarrhea\", \"Text\": \"Traveler's diarrhea\", \"Mnemonic\": \"1220\"}, {\"Row\": 203, \"Column\": 3, \"Item\": 1049, \"DisplayText\": \"Trichomonas vaginitis (Outpatient)\", \"Text\": \"Trichomonas vaginitis\", \"Mnemonic\": \"1222\"}, {\"Row\": 204, \"Column\": 3, \"Item\": 1050, \"DisplayText\": \"Tuberculosis (Outpatient)\", \"Text\": \"Tuberculosis\", \"Mnemonic\": \"1224\"}, {\"Row\": 205, \"Column\": 3, \"Item\": 1051, \"DisplayText\": \"Neutropenic enterocolitis (Typhlitis) - Outpatient\", \"Text\": \"Typhlitis\", \"Mnemonic\": \"1226\"}, {\"Row\": 206, \"Column\": 3, \"Item\": 651, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Typhoid fever\", \"Mnemonic\": \"1228\"}, {\"Row\": 209, \"Column\": 3, \"Item\": 805, \"DisplayText\": \"Decubitis ulcers (Outpatient)\", \"Text\": \"Ulcer, decubitus\", \"Mnemonic\": \"1230\"}, {\"Row\": 210, \"Column\": 3, \"Item\": 836, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus (Outpatient)\", \"Text\": \"Ulcer, diabetic foot\", \"Mnemonic\": \"1232\"}, {\"Row\": 211, \"Column\": 3, \"Item\": 1052, \"DisplayText\": \"Uncomplicated Cystitis (Outpatient)\", \"Text\": \"Uncomplicated cystitis\", \"Mnemonic\": \"1234\"}, {\"Row\": 212, \"Column\": 3, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Updates on antimicrobial shortages\", \"Mnemonic\": \"1236\"}, {\"Row\": 213, \"Column\": 3, \"Item\": 722, \"DisplayText\": \"Upper Respiratory Infections (outpatient)\", \"Text\": \"Upper respiratory infections (URI)\", \"Mnemonic\": \"1238\"}, {\"Row\": 214, \"Column\": 3, \"Item\": 1053, \"DisplayText\": \"Urethritis associated with sexually transmitted disease (Outpatient)\", \"Text\": \"Urethritis associated with STIs [CLICK HERE], includes:\", \"Mnemonic\": \"1240\"}, {\"Row\": 216, \"Column\": 3, \"Item\": 1009, \"DisplayText\": \"Recurrent or persistent urethritis (Outpatient)\", \"Text\": \"Urethritis, recurrent or persistent\", \"Mnemonic\": \"1242\"}, {\"Row\": 217, \"Column\": 3, \"Item\": 635, \"DisplayText\": \"APPROACH TO URINARY TRACT INFECTION (UTI)\", \"Text\": \"Urinary tract infection (UTI), bacterial\", \"Mnemonic\": \"1244\"}, {\"Row\": 218, \"Column\": 3, \"Item\": 641, \"DisplayText\": \"Candida Urinary Tract Infections\", \"Text\": \"Urinary tract infection (UTI), candida\", \"Mnemonic\": \"1246\"}, {\"Row\": 219, \"Column\": 3, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Urinary tract infection with sepsis\", \"Mnemonic\": \"1248\"}, {\"Row\": 220, \"Column\": 3, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Urosepsis\", \"Mnemonic\": \"1250\"}, {\"Row\": 221, \"Column\": 3, \"Item\": 629, \"DisplayText\": \"Uveitis\", \"Text\": \"Uveitis\", \"Mnemonic\": \"1252\"}, {\"Row\": 225, \"Column\": 3, \"Item\": 778, \"DisplayText\": \"Candida vulvo-vaginitis (Outpatient)\", \"Text\": \"Vaginitis, Candida\", \"Mnemonic\": \"1254\"}, {\"Row\": 226, \"Column\": 3, \"Item\": 1049, \"DisplayText\": \"Trichomonas vaginitis (Outpatient)\", \"Text\": \"Vaginitis, Trichomonas\", \"Mnemonic\": \"1256\"}, {\"Row\": 227, \"Column\": 3, \"Item\": 743, \"DisplayText\": \"Bacterial vaginosis (Outpatient)\", \"Text\": \"Vaginosis, bacterial\", \"Mnemonic\": \"1258\"}, {\"Row\": 228, \"Column\": 3, \"Item\": 996, \"DisplayText\": \"Primary infection (Chickenpox) - Outpatient\", \"Text\": \"Varicella\", \"Mnemonic\": \"1260\"}, {\"Row\": 229, \"Column\": 3, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella vaccination\", \"Mnemonic\": \"1262\"}, {\"Row\": 230, \"Column\": 3, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Ventilator-associated pneumonia (VAP)\", \"Mnemonic\": \"1264\"}, {\"Row\": 231, \"Column\": 3, \"Item\": 823, \"DisplayText\": \"Diskitis and vertebral osteomyelitis (Outpatient)\", \"Text\": \"Vertebral osteomyelitis and diskitis\", \"Mnemonic\": \"1266\"}, {\"Row\": 232, \"Column\": 3, \"Item\": 820, \"DisplayText\": \"Diarrhea with Vibrio cholera (Outpatient)\", \"Text\": \"Vibrio cholerae diarrhea/gastroenteritis\", \"Mnemonic\": \"1268\"}, {\"Row\": 233, \"Column\": 3, \"Item\": 821, \"DisplayText\": \"Diarrhea with non-cholera vibrio (Outpatient)\", \"Text\": \"Vibrio non-cholerae, diarrhea/gastroenteritis\", \"Mnemonic\": \"1270\"}, {\"Row\": 234, \"Column\": 3, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Viral diarrhea/gastroenteritis\", \"Mnemonic\": \"1272\"}, {\"Row\": 235, \"Column\": 3, \"Item\": 896, \"DisplayText\": \"Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient\", \"Text\": \"Viridans streptococci\", \"Mnemonic\": \"1274\"}, {\"Row\": 236, \"Column\": 3, \"Item\": 1056, \"DisplayText\": \"Viruses (Outpatient)\", \"Text\": \"Viruses section\", \"Mnemonic\": \"1276\"}, {\"Row\": 237, \"Column\": 3, \"Item\": 778, \"DisplayText\": \"Candida vulvo-vaginitis (Outpatient)\", \"Text\": \"Vulvo-vaginitis, candida\", \"Mnemonic\": \"1278\"}, {\"Row\": 240, \"Column\": 3, \"Item\": 1057, \"DisplayText\": \"\", \"Text\": \"Warfarin interactions with antimicrobials\", \"Mnemonic\": \"1280\"}, {\"Row\": 241, \"Column\": 3, \"Item\": 1037, \"DisplayText\": \"Surgical site infection\", \"Text\": \"Wound infection, post-op\", \"Mnemonic\": \"1282\"}, {\"Row\": 242, \"Column\": 3, \"Item\": 751, \"DisplayText\": \"Bite wounds (Outpatient)\", \"Text\": \"Wound, bite\", \"Mnemonic\": \"1284\"}, {\"Row\": 243, \"Column\": 3, \"Item\": 121, \"DisplayText\": \"Colonized wounds\", \"Text\": \"Wound, colonized\", \"Mnemonic\": \"1286\"}, {\"Row\": 248, \"Column\": 3, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Yeast bacteremia\", \"Mnemonic\": \"1288\"}, {\"Row\": 249, \"Column\": 3, \"Item\": 822, \"DisplayText\": \"Diarrhea with Yersinia enterocolitica (Outpatient)\", \"Text\": \"Yersinia enterocolitica diarrhea/gastroenteritis\", \"Mnemonic\": \"1290\"}, {\"Row\": 252, \"Column\": 3, \"Item\": 1008, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\") - Outpatient\", \"Text\": \"Zoster\", \"Mnemonic\": \"1292\"}, {\"Row\": 253, \"Column\": 3, \"Item\": 1011, \"DisplayText\": \"Retinitis (Outpatient)\", \"Text\": \"Zoster retinitis\", \"Mnemonic\": \"1294\"}, {\"Row\": 254, \"Column\": 3, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Zoster vaccination\", \"Mnemonic\": \"1296\"}, {\"Row\": 184, \"Column\": 3, \"Text\": \"T______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 208, \"Column\": 3, \"Text\": \"U______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 215, \"Column\": 3, \"Text\": \"chlamydia and gonococcal\"}, {\"Row\": 223, \"Column\": 3, \"Text\": \"V______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 224, \"Column\": 3, \"Text\": \"Vaccination: see immunization, specific organism or condition\"}, {\"Row\": 239, \"Column\": 3, \"Text\": \"W______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 245, \"Column\": 3, \"Text\": \"X______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 247, \"Column\": 3, \"Text\": \"Y______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 251, \"Column\": 3, \"Text\": \"Z______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"A through F\", \"Header\": 1}, {\"Row\": 11, \"Column\": 3, \"Text\": \"Post-exposure prophylaxis, Rabies - see Emergency\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"Department CDSS or contact ID for more information\"}, {\"Row\": 37, \"Column\": 3, \"Text\": \"Prophylaxis for post-exposure, Rabies - see Emergency\"}, {\"Row\": 38, \"Column\": 3, \"Text\": \"Department CDSS or contact ID for more information\"}, {\"Row\": 73, \"Column\": 3, \"Text\": \"Rabies post-exposure prophylaxis - see Emergency\"}, {\"Row\": 74, \"Column\": 3, \"Text\": \"Department CDSS or contact ID for more information\"}, {\"Row\": 107, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Cardiovascular Section\", \"Mnemonic\": \"185\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Bite, Tick\", \"Mnemonic\": \"117\"}, {\"Row\": 187, \"Column\": 3, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Tick bite\", \"Mnemonic\": \"1191\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 679,
    "fields": {
      "name": "ORZID3 GMENU ABX LARYNGITIS AND CROUP",
      "term": null,
      "displaytext": "Laryngitis and Croup  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LARYNGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cases are almost always viral (e.g. rhinovirus, influenza, adenovirus,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"coronavirus). Treatment is based on symptomatic therapy alone.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Mandell chapter: Acute laryngitis\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Up-To-Date article: Hoarseness in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 680,
    "fields": {
      "name": "ORZID3 GMENU ABX LIVER AMEBIC ABSCESS",
      "term": null,
      "displaytext": "Amebic Liver Abscess  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Text\": \"Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"AMEBIC LIVER ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Serological testing for amoebiasis should be obtained in all patients with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"suspected amebic liver abscess. Multiple sets of anaerobic and aerobic blood\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cultures should also be obtained prior to starting antibiotics to exclude\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pyogenic liver abscess, which is a much more common cause of liver abscess.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Serologic testing can be negative in a small number of patients with acute\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"presentation (symptoms <2 weeks). Repeat serology is usually positive. If repeat\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"serological testing is negative for amoebiasis or patient does not respond to\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"treatment of amebic liver abscess, patient should have further diagnostic\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"testing completed to exclude pyogenic liver abscess.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Drainage of amebic liver abscess should be considered in patients with large\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"lesions at risk of rupture.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Due to complicated treatment and follow up, Infectious Diseases consultation\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"is recommended in all patients with liver abscess.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment of patients with confirmed or suspected amebic liver abscess (obtain\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"blood cultures prior to starting in suspected cases)\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Paromomycin is nonformulary and must be ordered by Infectious Diseases.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"25-35 mg/kg/day PO TID for 7 days ($) [M]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Amoebiasis, Entamoeba histolytica\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date article: Extraintestinal Entamoeba histolytica amoebiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 681,
    "fields": {
      "name": "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Meningococcal Conjugate Vaccine Information Page ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES\", \"Text\": \"2 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient MenACWY orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"MENINGOCOCCAL\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"OLIGOSACCHARIDE\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"CONJ. VACC INJ,SUSP\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Menveo\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Meningococcal conjugate\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(MenACWY)\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*People with anatomic or\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"functional asplenia, HIV\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"infection, or persistent\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"complement component\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"deficiency, or complement\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"inhibitor use.\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"*People who travel to or\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"reside in countries in\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"which meningococcal\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"disease is hyperendemic or\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"epidemic (e.g., the\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"meningitis belt of Sub-\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Saharan Africa).\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"*Microbiologists routinely\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"exposed to isolates of N.\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \"meningitidis.\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"*For first year college\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"students living in a\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"residence hall, regardless\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"of age,\"}, {\"Row\": 27, \"Column\": 2, \"Text\": \">> if unvaccinated, give 1\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"dose.\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \">> if history of 1 dose\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"given when younger than\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"age 16, give dose  2.\"}, {\"Row\": 32, \"Column\": 2, \"Text\": \">> if most recent dose\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"given after 16th birthday\"}, {\"Row\": 34, \"Column\": 2, \"Text\": \"and more than 5 years\"}, {\"Row\": 35, \"Column\": 2, \"Text\": \"have elapsed, give 1 dose.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 2 initial doses of\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"MenACWY separated by 2m to\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"adults with risk factors\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"listed in 1st bullet in\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"column to left.\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"*Give 1 initial dose of\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"MenACWY to all other\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"adults with risk factors\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"(see 2nd-4th bullets in\"}, {\"Row\": 14, \"Column\": 3, \"Text\": \"column to left).\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"*Give booster doses of\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"MenACWY every 5yrs to\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"adults with continuing\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"risk (see the 1st-3rd\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"bullets in column to\"}, {\"Row\": 21, \"Column\": 3, \"Text\": \"left).\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"without fever.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 682,
    "fields": {
      "name": "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Meningococcal Serogroup B Vaccine Information Page  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"2 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient MenB orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"MENINGOCOCCAL B VACCINE\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"INJ,SUSP\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Bexsero\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Meningococcal serogroup B\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(MenB)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*People with anatomic or\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"functional asplenia or\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"persistent complement\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"component deficiency.\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"*Microbiologists routinely\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"exposed to isolates of N.\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"meningitidis.\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"*People identified as at\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"a serogroup B\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"meningococcal disease\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"outbreak.\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"*Young adults through age\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"23yrs may be vaccinated\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"routinely.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 2 doses spaced 1\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"month apart\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"*For people with continuing\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"risk (see 1st-3rd bullets\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"in column to left), give a\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"booster 1 year after\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"completing the primary\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"series, followed by a\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"booster every 2-3 years as\"}, {\"Row\": 14, \"Column\": 3, \"Text\": \"long as risk continues.\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"Booster doses must be same\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"brand as primary series.\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"*MenB vaccine may be given\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"concomitantly with MenACWY\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"vaccine\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"*Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"without fever.\"}, {\"Row\": 16, \"Column\": 4, \"Text\": \"*Pregnancy\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 683,
    "fields": {
      "name": "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Measles, Mumps, Rubella Vaccine Information Page ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"2 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"One dose\", \"Mnemonic\": \"4\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: Subcutaneous\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient MMR orders:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"MEASLES/MUMPS/RUBELLA\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"VIRUS VACCINE INJ\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"M-M-R II\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Measles, mumps, rubella\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(MMR)\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*People born in 1957 or\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"later (especially those\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"born outside the U.S.)\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"should receive at least 1\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"dose of MMR if they have\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"no laboratory evidence of\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"immunity to each of the 3\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"diseases or documentation\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"of a dose given on or\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"after the first birthday.\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"*People in high-risk\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"groups, such as healthcare\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"personnel (paid, unpaid,\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"or volunteer), students\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"entering college and other\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"post-high school\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \"educational institutions,\"}, {\"Row\": 22, \"Column\": 2, \"Text\": \"and international\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"travelers, should receive\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"a total of 2 doses.\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"*HIV infection with CD4\"}, {\"Row\": 27, \"Column\": 2, \"Text\": \"count >/=200 cells/mm3 for\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"at least 6 months and no\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \"evidence of immunity to\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"measles, mumps, or rubella\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"should receive a total of\"}, {\"Row\": 32, \"Column\": 2, \"Text\": \"2 doses. MMR\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"contraindicated for HIV\"}, {\"Row\": 34, \"Column\": 2, \"Text\": \"infection with CD4 count\"}, {\"Row\": 35, \"Column\": 2, \"Text\": \"<200 cells/mm3\"}, {\"Row\": 37, \"Column\": 2, \"Text\": \"*People born before 1957\"}, {\"Row\": 38, \"Column\": 2, \"Text\": \"are usually considered\"}, {\"Row\": 39, \"Column\": 2, \"Text\": \"immune, but evidence of\"}, {\"Row\": 40, \"Column\": 2, \"Text\": \"immunity (serology or\"}, {\"Row\": 41, \"Column\": 2, \"Text\": \"documented history of 2\"}, {\"Row\": 42, \"Column\": 2, \"Text\": \"doses of MMR) should be\"}, {\"Row\": 43, \"Column\": 2, \"Text\": \"considered for healthcare\"}, {\"Row\": 44, \"Column\": 2, \"Text\": \"personnel.\"}, {\"Row\": 46, \"Column\": 2, \"Text\": \"*Women of childbearing age\"}, {\"Row\": 47, \"Column\": 2, \"Text\": \"who do not have acceptable\"}, {\"Row\": 48, \"Column\": 2, \"Text\": \"evidence of rubella\"}, {\"Row\": 49, \"Column\": 2, \"Text\": \"immunity or vaccination.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 1 or 2 doses (see\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"criteria in 1st and 2nd\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"bullets in box to left).\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"*If dose  2 is\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"recommended, give it no\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"sooner than 4wks after\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"dose  1.\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"*If woman of childbearing-\"}, {\"Row\": 14, \"Column\": 3, \"Text\": \"age is found to be rubella\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"susceptible and is not\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"pregnant, give 1 dose of\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"MMR. If she is pregnant,\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"the dose should be given\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"postpartum. This includes\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"women who have already\"}, {\"Row\": 21, \"Column\": 3, \"Text\": \"received 1 or 2 doses of\"}, {\"Row\": 22, \"Column\": 3, \"Text\": \"rubella-containing\"}, {\"Row\": 23, \"Column\": 3, \"Text\": \"vaccine.\"}, {\"Row\": 25, \"Column\": 3, \"Text\": \"*If 2 or more of the\"}, {\"Row\": 26, \"Column\": 3, \"Text\": \"following live virus\"}, {\"Row\": 27, \"Column\": 3, \"Text\": \"vaccines are to be given -\"}, {\"Row\": 28, \"Column\": 3, \"Text\": \"MMR, LAIV, Var, ZVL,\"}, {\"Row\": 29, \"Column\": 3, \"Text\": \"and/or yellow fever - they\"}, {\"Row\": 30, \"Column\": 3, \"Text\": \"should be given on the\"}, {\"Row\": 31, \"Column\": 3, \"Text\": \"same day. If they are not\"}, {\"Row\": 32, \"Column\": 3, \"Text\": \"given on the same day,\"}, {\"Row\": 33, \"Column\": 3, \"Text\": \"space them by at least 28d\"}, {\"Row\": 34, \"Column\": 3, \"Text\": \"(30d for yellow fever).\"}, {\"Row\": 35, \"Column\": 3, \"Text\": \"May use as post-exposure\"}, {\"Row\": 36, \"Column\": 3, \"Text\": \"prophylaxis if given\"}, {\"Row\": 37, \"Column\": 3, \"Text\": \"within 3d of exposure.\"}, {\"Row\": 35, \"Column\": 4, \"Item\": 3087, \"DisplayText\": \"ACIP's Best Practices Guidance\", \"Text\": \"Best Practices Guidance\", \"Mnemonic\": \"8\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"*History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"*Pregnancy or possibility\"}, {\"Row\": 12, \"Column\": 4, \"Text\": \"of pregnancy within 4wks.\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"*Severe immunodeficiency\"}, {\"Row\": 15, \"Column\": 4, \"Text\": \"(e.g., hematologic and\"}, {\"Row\": 16, \"Column\": 4, \"Text\": \"solid tumors, receiving\"}, {\"Row\": 17, \"Column\": 4, \"Text\": \"chemotherapy, congenital\"}, {\"Row\": 18, \"Column\": 4, \"Text\": \"immunodeficiency, long-\"}, {\"Row\": 19, \"Column\": 4, \"Text\": \"term immunosuppressive\"}, {\"Row\": 20, \"Column\": 4, \"Text\": \"therapy, people with human\"}, {\"Row\": 21, \"Column\": 4, \"Text\": \"immunodeficiency virus\"}, {\"Row\": 22, \"Column\": 4, \"Text\": \"(HIV) infection who are\"}, {\"Row\": 23, \"Column\": 4, \"Text\": \"severely\"}, {\"Row\": 24, \"Column\": 4, \"Text\": \"immunocompromised (CD4\"}, {\"Row\": 25, \"Column\": 4, \"Text\": \"count <200 cells/mm3).)\"}, {\"Row\": 27, \"Column\": 4, \"Text\": \"Precautions\", \"Header\": 1}, {\"Row\": 28, \"Column\": 4, \"Text\": \"*Moderate or severe acute\"}, {\"Row\": 29, \"Column\": 4, \"Text\": \"illness with or without\"}, {\"Row\": 30, \"Column\": 4, \"Text\": \"fever.\"}, {\"Row\": 32, \"Column\": 4, \"Text\": \"*If blood, plasma, and/or\"}, {\"Row\": 33, \"Column\": 4, \"Text\": \"immune globulin were given\"}, {\"Row\": 34, \"Column\": 4, \"Text\": \"in past 11m, see ACIP's\"}, {\"Row\": 36, \"Column\": 4, \"Text\": \"regarding time to wait\"}, {\"Row\": 37, \"Column\": 4, \"Text\": \"before vaccinating.\"}, {\"Row\": 39, \"Column\": 4, \"Text\": \"*History of\"}, {\"Row\": 40, \"Column\": 4, \"Text\": \"thrombocytopenia or\"}, {\"Row\": 41, \"Column\": 4, \"Text\": \"thrombocytopenic purpura.\"}, {\"Row\": 43, \"Column\": 4, \"Text\": \"*Need for tuberculin skin\"}, {\"Row\": 44, \"Column\": 4, \"Text\": \"testing (TST) or\"}, {\"Row\": 45, \"Column\": 4, \"Text\": \"interferon-gamma release\"}, {\"Row\": 46, \"Column\": 4, \"Text\": \"assay (IGRA) testing.\"}, {\"Row\": 47, \"Column\": 4, \"Text\": \"note: If TST or IGRA and\"}, {\"Row\": 48, \"Column\": 4, \"Text\": \"MMR are both needed but\"}, {\"Row\": 49, \"Column\": 4, \"Text\": \"not given on same day,\"}, {\"Row\": 50, \"Column\": 4, \"Text\": \"delay TST or IGRA for at\"}, {\"Row\": 51, \"Column\": 4, \"Text\": \"least 4wks after MMR.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 684,
    "fields": {
      "name": "ORZID3 GMENU ABX MOLNUPIRAVIR EUA",
      "term": null,
      "displaytext": "Molnupiravir for treatment of COVID-19  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 3088, \"DisplayText\": \"Molnupiravir EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Molnupiravir\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Molnupiravir EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Molnupiravir\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MOLNUPIRAVIR (EUA)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Molnupiravir is available via FDA Emergency Use Authorization (EUA) for treating\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients that meet specific criteria. Molnupiravir is not an FDA approved drug.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Inclusion Criteria, ALL the following criteria must be met for a patient to\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"receive:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"1) Patient has tested positive for COVID-19.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19. Note: patient may be\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"hospitalized for some other reason.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"4) Administration will begin within 5 days of symptom onset.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to Molnupiravir or components.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Contraindications: None\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Warnings and Precautions:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"1) Embryo-Fetal Toxicity: Molnupiravir is not recommended for use during\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"pregnancy.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"2) Bone and Cartilage Toxicity: Molnupiravir is not authorized for use in\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"patients less than 18 years of age because it may affect bone and cartilage\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"growth.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"If above requirements are met, place medication order:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid sharing\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"personal items, clean and disinfect \\\"high touch\\\" surfaces, and frequent\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"handwashing) according to CDC guidelines.\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Molnupiravir EUA\", \"Text\": \"INV-Molnupiravir 800 mg PO BID for 5 days\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 685,
    "fields": {
      "name": "ORZID3 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA",
      "term": null,
      "displaytext": "Nirmatrelvir-ritonavir (Paxlovid) for Treatment of COVID-19  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3089, \"DisplayText\": \"Paxlovid EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Paxlovid\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Paxlovid EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Paxlovid\", \"Mnemonic\": \"8\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Paxlovid EUA\", \"Text\": \"INV-Nirmatrelvir 300 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PAXLOVID (EUA)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Paxlovid (nirmatrelvir-ritonavir) is available via FDA Emergency Use\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Authorization (EUA) for treating patients that meet specific criteria. Paxlovid\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"is not an FDA approved drug.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Inclusion Criteria, ALL the following criteria must be met for a patient to\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"receive:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"1) Patient has tested positive for COVID-19\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19. Note: patient may be\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"hospitalized for some other reason.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"4) Administration will begin within 5 days of symptom onset.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to Paxlovid or components.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Contraindications, NONE of the following must be met for patient to receive:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"1) Severe renal impairment (eGFR <30 mL/min).\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"2) Severe hepatic impairment (Child-Pugh Class C).\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"3) History of clinically significant hypersensitivity reactions to the active\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"ingredients (nirmatrelvir or ritonavir) or any other components.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"4) Co-administration with drugs highly dependent on CYP3A for clearance and for\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"which elevated concentrations are associated with serious and/or\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"life-threatening reactions.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"5) Co-administration with potent CYP3A inducers where significantly reduced\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"nirmatrelvir or ritonavir plasma concentrations may be associated with the\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"potential for loss of virologic response and possible resistance.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Warnings and Precautions:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"1) The concomitant use of PAXLOVID and certain other drugs may result in\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"potentially significant drug interactions. Consult the full prescribing\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"information prior to and during treatment for potential drug interactions.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"2) Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"jaundice have occurred in patients receiving ritonavir.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"3) HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"resistance to HIV protease inhibitors in individuals with uncontrolled or\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"undiagnosed HIV-1 infection.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"If all above criteria above are met and there are no contraindications, place\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"medication order:\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid sharing\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"personal items, clean and disinfect \\\"high touch\\\" surfaces, and frequent\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"handwashing) according to CDC guidelines.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"6) Patient must be able to take PO and swallow tablets whole\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Paxlovid EUA\", \"Text\": \"INV-Nirmatrelvir 150 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days\", \"Mnemonic\": \"12\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min):\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 686,
    "fields": {
      "name": "ORZID3 GMENU ABX NON-VA ORDER INFORMATION",
      "term": null,
      "displaytext": "Non-VA orders are available below each prescription order for CBOC use",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Non-VA orders are available below each prescription order for CBOC use\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 687,
    "fields": {
      "name": "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP",
      "term": null,
      "displaytext": "Bacteriuria, Candiduria and Pyuria (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 25, \"Column\": 1, \"Item\": 740, \"DisplayText\": \"Asymptomatic bacteriuria (Outpatient)\", \"Text\": \"Treatment of Asymptomatic Bacteriuria\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 641, \"DisplayText\": \"Candida Urinary Tract Infections\", \"Text\": \"Treatment of Candida Urinary Tract Infections\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIURIA, CANDIDURIA, AND PYURIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Asymptomatic bacteriuria (>= 100,000 bacteria per ml of urine) is common in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"middle aged and older people, especially those who have chronic medical\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"conditions. Pyuria is common in persons with bacteriuria and individuals with\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"indwelling catheters in place. By itself, the presence of pyuria is not\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"sufficient to diagnose bacteriuria, and the presence or absence of pyuria does\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"not differentiate symptomatic from asymptomatic urinary infection. Candiduria is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"less common than bacteriuria, but the implications of candiduria are similar to\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"those of bacteriuria.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Many studies, including randomized clinical trials have shown that\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treatment of asymptomatic bacteriuria and candiduria, with or without pyuria is\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of no benefit, except in certain well-defined circumstances. Antimicrobial\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"therapy is always accompanied by risk of harms, including drug reactions,\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Clostridium difficile colitis, anaphylaxis and death. Except in circumstances\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"specified below, it is best to not order urinalysis or urine culture in\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"asymptomatic persons. If bacteriuria, candiduria or pyuria is discovered in an\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"asymptomatic person for some reason, antimicrobial therapy should not be given\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"except as specified below.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Pregnant women or patients undergoing urological procedures with bacteriuria\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Patients undergoing urological procedures or neutropenic patients with\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"candiduria\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Pappas et al, Clin Infect Dis, 2016, 62.409\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Nicolle et al, Clin Infect Dis, 2005, 40:643\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 688,
    "fields": {
      "name": "ORZID3 GMENU ABX NOT REQUIRED MAIN OP",
      "term": null,
      "displaytext": "Conditions Not Benefited by Antimicrobial Therapy (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 16, \"Column\": 1, \"Item\": 722, \"DisplayText\": \"Upper Respiratory Infections (outpatient)\", \"Text\": \"Upper Respiratory Infections (URI)\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 644, \"DisplayText\": \"Colonized Respiratory Tract in a Patient on a Ventilator (outpatient)\", \"Text\": \"Colonized Respiratory Tract in a Patient on a Ventilator\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 718, \"DisplayText\": \"Stasis Dermatitis (outpatient)\", \"Text\": \"Stasis Dermatitis\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 645, \"DisplayText\": \"Colonized Wounds (outpatient)\", \"Text\": \"Colonized Wounds\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 687, \"DisplayText\": \"Bacteriuria, Candiduria and Pyuria (outpatient)\", \"Text\": \"Asymptomatic Bacteriuria, cadiduria and pyuria\", \"Mnemonic\": \"12\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 701, \"DisplayText\": \"Blood Culture Positive for Coagulase-Negative Staphylococci (outpatient)\", \"Text\": \"Blood culture positive for coagulase negative staphylococci\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CONDITIONS NOT BENEFITTED BY ANTIMICROBIAL THERAPY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Several common conditions associated with inflammation or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"microorganisms do not benefit from antibiotic therapy in most or all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Yet, antimicrobials are frequently prescribed for these conditions leading to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"unnecessary toxicity and costs, rare deaths, and the relentless increase in\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"antimicrobial resistance. Please review these conditions and do not give\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobials for these conditions unless there are extraordinary\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"circumstances that make your situation different. If you have any questions,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"please contact the infectious disease physician on call.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Lungs and Mediastinum\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Skin and Soft Tissue\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Genitourinary\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Miscellaneous\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"`Last reviewed 9-2018\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Item\": 95, \"DisplayText\": \"Bronchitis not benefited\", \"Text\": \"Bronchitis in and Otherwise Healthy Patient\", \"Mnemonic\": \"5\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 222, \"DisplayText\": \"Not Benefited by Abx Pharyngitis\", \"Text\": \"Pharyngitis, non-streptococcal\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 689,
    "fields": {
      "name": "ORZID3 GMENU ABX OUTPT MAIN",
      "term": null,
      "displaytext": "Outpatient Antimicrobial Computer Decision Support System (CDSS)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 23, \"Column\": 1, \"Item\": 796, \"DisplayText\": \"Central nervous system (Outpatient)\", \"Text\": \"Central Nervous System (CNS)\", \"Mnemonic\": \"11\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 898, \"DisplayText\": \"Head and Neck / ENT (Outpatient)\", \"Text\": \"Head and Neck\", \"Mnemonic\": \"12\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 926, \"DisplayText\": \"Lungs and Mediastinum (Outpatient)\", \"Text\": \"Lungs & Mediastinum\", \"Mnemonic\": \"14\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 912, \"DisplayText\": \"Influenza Seasonal 2021-2022\", \"Text\": \"[b] Influenza Seasonal 2022-2023\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 799, \"DisplayText\": \"Pneumonia (Outpatient)\", \"Text\": \"[c] Pneumonia\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 738, \"DisplayText\": \"Acute Respiratory Infection (ARI) Symptomatic Therapy\", \"Text\": \"[d] Acute Respiratory Infection (ARI) Symptomatic Therapy\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Cardiovascular\", \"Mnemonic\": \"22\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 850, \"DisplayText\": \"Gastrointestinal (Outpatient)\", \"Text\": \"GI & Intraabdominal\", \"Mnemonic\": \"24\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 782, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"[a] C. difficile colitis Mild/Moderate\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 852, \"DisplayText\": \"Genitourinary (Outpatient)\", \"Text\": \"Urogenital\", \"Mnemonic\": \"28\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"[a] Sexually Transmitted Infections (STI)\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 1029, \"DisplayText\": \"Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)\", \"Text\": \"Soft Tissue, Bone and Joint Infections\", \"Mnemonic\": \"32\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 807, \"DisplayText\": \"Dermatology Infections (Outpatient)\", \"Text\": \"Skin\", \"Mnemonic\": \"34\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 1038, \"DisplayText\": \"Systemic Infectious Diseases (Outpatient)\", \"Text\": \"Systemic Infections\", \"Mnemonic\": \"36\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"[a] Bacteremia\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"[b] Sepsis and Septic Shock\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 475, \"DisplayText\": \"Introduction to Specific Pathogen section\", \"Text\": \"Introduction to Specific Pathogen\", \"Mnemonic\": \"42\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 855, \"DisplayText\": \"Gram negative bacteria (Outpatient)\", \"Text\": \"Gram-negative Bacteria\", \"Mnemonic\": \"44\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 856, \"DisplayText\": \"\", \"Text\": \"Gram-positive Bacteria\", \"Mnemonic\": \"46\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 1056, \"DisplayText\": \"Viruses (Outpatient)\", \"Text\": \"Viruses\", \"Mnemonic\": \"48\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 840, \"DisplayText\": \"Fungi (Outpatient)\", \"Text\": \"Fungi\", \"Mnemonic\": \"50\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 960, \"DisplayText\": \"Parasites (Outpatient)\", \"Text\": \"Parasites\", \"Mnemonic\": \"52\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 953, \"DisplayText\": \"Other Pathogens (Outpatient)\", \"Text\": \"Other Pathogens\", \"Mnemonic\": \"54\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"*******************************************************\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"*ANTIMICROBIAL DECISION SUPPORT *\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"*  >>>>>>>>OUTPATIENT<<<<<<<<<*\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"*******************************************************\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Welcome.  Please click on the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"diagnosis or syndrome you wish to treat.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"*  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Syndromes and diseases, by body systems\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Specific organisms\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Medicine is an inexact and rapidly\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"changing discipline.  The developers of\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"this system have made every effort to\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"provide current, accurate information.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"However, in view of the possibility of\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"human error or changes in medical\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"service, readers are encouraged to\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"confirm the information contained\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"herein with other sources.  In\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"particular, readers are encouraged to\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"check the product information for\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"antimicrobials to be certain that\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"information in this system is accurate\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"and current, especially for new or\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"infrequently used drugs.\"}, {\"Row\": 2, \"Column\": 2, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact CDSS & ASP Staff\", \"Mnemonic\": \"58\"}, {\"Row\": 3, \"Column\": 2, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help page...\", \"Mnemonic\": \"60\"}, {\"Row\": 4, \"Column\": 2, \"Item\": 3090, \"DisplayText\": \"CDSS FAQ\", \"Text\": \"Frequently Asked Questions (FAQ)\", \"Mnemonic\": \"62\"}, {\"Row\": 5, \"Column\": 2, \"Item\": 349, \"DisplayText\": \"\", \"Text\": \"Comments or Suggestions about this CDSS\", \"Mnemonic\": \"64\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 279, \"DisplayText\": \"Antimicrobial susceptibilities (Antibiogram)\", \"Text\": \"Antibiogram (Susceptibilities)\", \"Mnemonic\": \"66\"}, {\"Row\": 9, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Antimicrobial Formulary Hyperlink\", \"Text\": \"Antimicrobial Formulary (Restricted)\", \"Mnemonic\": \"68\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 69, \"DisplayText\": \"Antimicrobial restriction policy\", \"Text\": \"Restrictions on Antimicrobials\", \"Mnemonic\": \"70\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 74, \"DisplayText\": \"Adjust existing antimicrobial therapy\", \"Text\": \"Adjust Existing Antimicrobial Therapy\", \"Mnemonic\": \"72\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 178, \"DisplayText\": \"How to find an alternative antimicrobial\", \"Text\": \"How to Find Alternative Antimicrobials\", \"Mnemonic\": \"74\"}, {\"Row\": 13, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Clinical On-Call Schedule (Infectious Disease)\", \"Mnemonic\": \"76\"}, {\"Row\": 14, \"Column\": 2, \"Item\": null, \"DisplayText\": \"UP TO DATE WEB SITE\", \"Text\": \"UpToDate Online (Clinical Resource)\", \"Mnemonic\": \"78\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 188, \"DisplayText\": \"Infection Control\", \"Text\": \"Infection Control/Prevention Information\", \"Mnemonic\": \"80\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatologic Guidelines\", \"Mnemonic\": \"82\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 808, \"DisplayText\": \"Device-related infections (Outpatient)\", \"Text\": \"Device-Related Infections\", \"Mnemonic\": \"84\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 994, \"DisplayText\": \"Prevention of Infection - Outpatient\", \"Text\": \"Prevention of Infection\", \"Mnemonic\": \"86\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"HIV-AIDS\", \"Mnemonic\": \"88\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 909, \"DisplayText\": \"Infections in Immunocompromised patients (Outpatient)\", \"Text\": \"Immunocompromised Patients\", \"Mnemonic\": \"90\"}, {\"Row\": 39, \"Column\": 2, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"OCCUPATIONAL Post-Exposure Prophylaxis Blood or Body Fluids\", \"Mnemonic\": \"100\"}, {\"Row\": 40, \"Column\": 2, \"Item\": 693, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE\", \"Text\": \"NON-OCCUPATIONAL Post-Exposure Prophylaxis Blood or Body Fluids\", \"Mnemonic\": \"101\"}, {\"Row\": 48, \"Column\": 2, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Text\": \"Important Drug (Abx) Properties\", \"Mnemonic\": \"103\"}, {\"Row\": 49, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Lexicomp Online\", \"Text\": \"Lexicomp Online Drug Information\", \"Mnemonic\": \"104\"}, {\"Row\": 50, \"Column\": 2, \"Item\": null, \"DisplayText\": \"RESOURCE QTC PROLONGATION FOR DRUGS\", \"Text\": \"QTc Prolongation Drug Resource\", \"Mnemonic\": \"106\"}, {\"Row\": 51, \"Column\": 2, \"Item\": 1057, \"DisplayText\": \"\", \"Text\": \"DDI Warfarin and Antimicrobials\", \"Mnemonic\": \"108\"}, {\"Row\": 52, \"Column\": 2, \"Item\": 988, \"DisplayText\": \"List of Antimicrobials with Pregnancy Risk Category\", \"Text\": \"Pregnancy Risk Factors for Antibiotics\", \"Mnemonic\": \"110\"}, {\"Row\": 53, \"Column\": 2, \"Item\": 77, \"DisplayText\": \"\", \"Text\": \"Shortages of Antimicrobials\", \"Mnemonic\": \"112\"}, {\"Row\": 56, \"Column\": 2, \"Item\": 688, \"DisplayText\": \"Conditions Not Benefited by Antimicrobial Therapy (outpatient)\", \"Text\": \"Conditions NOT benefitted by antibiotics\", \"Mnemonic\": \"114\"}, {\"Row\": 57, \"Column\": 2, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"ESBLs, Amp-C beta-lactamases, and Carbapenemases\", \"Mnemonic\": \"116\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"HELP\", \"Header\": 1}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Important Antimicrobial Information\", \"Header\": 1}, {\"Row\": 21, \"Column\": 2, \"Text\": \"General\", \"Header\": 1}, {\"Row\": 38, \"Column\": 2, \"Text\": \"Post-Exposure Prophylaxis (PEP)\", \"Header\": 1}, {\"Row\": 47, \"Column\": 2, \"Text\": \"Drug Information Links\", \"Header\": 1}, {\"Row\": 55, \"Column\": 2, \"Text\": \"Miscellaneous/Emerging Topics\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Item\": 635, \"DisplayText\": \"APPROACH TO URINARY TRACT INFECTION (UTI)\", \"Text\": \"[b] Urinary Tract Infections\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Call Ext 31-3144 to expedite URGENT medications only\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"(List starts at top and goes down body systems)\"}, {\"Row\": 83, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tick-Borne Encephalitis Vaccine Once\", \"Text\": \"Tick-Borne Encephalitis Vaccine Once\", \"Mnemonic\": \"test\"}, {\"Row\": 84, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tick-Borne Encephalitis Vaccine 3 Dose Series\", \"Text\": \"Tick-Borne Encephalitis Vaccine 3 Dose Series\", \"Mnemonic\": \"test\"}, {\"Row\": 80, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B Vaccine Update\", \"Mnemonic\": \"test\"}, {\"Row\": 81, \"Column\": 1, \"Item\": 634, \"DisplayText\": \"Acne\", \"Text\": \"Acne\", \"Mnemonic\": \"test\"}, {\"Row\": 82, \"Column\": 1, \"Item\": 714, \"DisplayText\": \"Rosacea\", \"Text\": \"Rosacea\", \"Mnemonic\": \"test\"}, {\"Row\": 89, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vaccine Nursing Text Order\", \"Text\": \"VACC 3 TEST\", \"Mnemonic\": \"TEST\"}, {\"Row\": 86, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vaccine Nursing Text Order\", \"Text\": \"VACC 1 TEST\", \"Mnemonic\": \"TEST\"}, {\"Row\": 87, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vaccine Nursing Text Order\", \"Text\": \"VACC 2 TEST\", \"Mnemonic\": \"TEST\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vaccine Nursing Text Order\", \"Text\": \"VACC 4 TEST\", \"Mnemonic\": \"TEST\"}, {\"Row\": 90, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vaccine Nursing Text Order\", \"Text\": \"VACC 3 TEST 2\", \"Mnemonic\": \"TEST\"}, {\"Row\": 79, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Remdesivir 200mg loading dose day 1, then 100mg q24h for additional 2 days\", \"Text\": \"Remedesivir 200mg load followed by 100mg q24h for 3 days\", \"Mnemonic\": \"test\"}, {\"Row\": 78, \"Column\": 1, \"Item\": 721, \"DisplayText\": \"TPOXX Monkeypox Treatment\", \"Text\": \"*FOR ID USE ONLY* Monkeypox Treatment with TPOXX\", \"Mnemonic\": \"Opt\"}, {\"Row\": 77, \"Column\": 1, \"Item\": 287, \"DisplayText\": \"TPOXX Monkeypox Treatment\", \"Text\": \"*FOR ID USE ONLY* Monkeypox Treatment with TPOXX\", \"Mnemonic\": \"Inpt\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Dr. Waisbren Testing\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HERNIA REPAIR ORDER SET\", \"Text\": \"HERNIA ORDER SET\", \"Mnemonic\": \"TEST\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Surgical Pathology\", \"Text\": \"Waisbren AP Order\", \"Mnemonic\": \"TEST\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"Bone Marrow Transplant Vaccinations\", \"Mnemonic\": \"TEST\"}, {\"Row\": 42, \"Column\": 2, \"Text\": \"Monkeypox\", \"Header\": 1}, {\"Row\": 43, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Monkeypox SharePoint Link\", \"Mnemonic\": \"102a\"}, {\"Row\": 44, \"Column\": 2, \"Item\": 721, \"DisplayText\": \"TPOXX Monkeypox Treatment\", \"Text\": \"*ID Providers Only*Monkeypox Treatment\", \"Mnemonic\": \"102b\"}, {\"Row\": 45, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Nursing Vaccine Administration Text Order\", \"Text\": \"Monkeypox vaccine nursing text order\", \"Mnemonic\": \"102c\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact CDSS & ASP Staff\", \"Mnemonic\": \"411\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 710, \"DisplayText\": \"CDC Recommended Adult Immunizations\", \"Text\": \"By Organism/Vaccine\", \"Mnemonic\": \"92a\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 711, \"DisplayText\": \"CDC Recommended Adult Immunizations by Age\", \"Text\": \"By Age\", \"Mnemonic\": \"92b\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 712, \"DisplayText\": \"CDC Recommended Adult Immunizations by Indication\", \"Text\": \"By Indication\", \"Mnemonic\": \"92c\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"Immunization Information and Vaccine Orders\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Item\": 646, \"DisplayText\": \"Outpatient COVID-19 Antimicrobial Treatment Guidelines\", \"Text\": \"[a] COVID-19\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 678, \"DisplayText\": \"Outpatient Antimicrobial CDSS Index\", \"Text\": \"[CLICK HERE]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Index of Antimicrobial CDSS contents\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"CDSS-MicroGuide Web and Mobile App\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Item\": 207, \"DisplayText\": \"MicroGuide Mobile App Instructions\", \"Text\": \"[CLICK HERE]\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Beta-lactam Allergy Assessment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 2, \"Item\": null, \"DisplayText\": \"[Click here] Beta-lactam allergy assessment\", \"Text\": \"PDF version *Preferred\", \"Mnemonic\": \"81a\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Text version\", \"Mnemonic\": \"81b\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"Surgical Prophylaxis & Infections\", \"Header\": 1}, {\"Row\": 34, \"Column\": 2, \"Item\": 490, \"DisplayText\": \"Pre-Op Antimicrobials...\", \"Text\": \"Pre-op Prophylaxis\", \"Mnemonic\": \"94\"}, {\"Row\": 35, \"Column\": 2, \"Item\": 526, \"DisplayText\": \"Antimicrobial Prophylaxis Post-op\", \"Text\": \"Post-op Prophylaxis\", \"Mnemonic\": \"96\"}, {\"Row\": 36, \"Column\": 2, \"Item\": 1037, \"DisplayText\": \"Surgical site infection\", \"Mnemonic\": \"98\"}, {\"Row\": 85, \"Column\": 1, \"Item\": 649, \"DisplayText\": \"Antibiotic Propylaxis for Dental Procedures\", \"Text\": \"Dental SOP Antibiotic Prophylaxis\", \"Mnemonic\": \"199\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 97, \"DisplayText\": \"Clostridioides difficile Infection (CDI) 2-step testing\", \"Text\": \"Information for C difficile 2-step lab testing\", \"Mnemonic\": \"2\"}, {\"Row\": 71, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin skin testing\", \"Text\": \"PCN SKIN TESTING\", \"Mnemonic\": \"TEST\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"[d] Lyme disease\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM ONCE ($) [M] Lidocaine 2.1 ML 1% IM ONCE\", \"Text\": \"Ceftriaxone 1gm Lidocaine 1% IM ONCE\", \"Mnemonic\": \"TEST\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"C diff 2-step testing\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 690,
    "fields": {
      "name": "ORZID3 GMENU ABX PARAINFLUENZA",
      "term": null,
      "displaytext": "Parainfluenza (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PARAINFLUENZA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"No specific antimicrobial therapy is indicated. Contact Infectious Diseases for\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"more information on management of this disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Sanford keyword: Parainfluenza virus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 691,
    "fields": {
      "name": "ORZID3 GMENU ABX PAROTITIS",
      "term": null,
      "displaytext": "Parotitis (outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 692, \"DisplayText\": \"More Information on Parotitis (outpatient)\", \"Text\": \"More information on Parotitis\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PAROTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection of salivary tissue is a relatively common disease. It is usually\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"caused by a stone in the parotid duct, dehydration, or a viral infection.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Sialolithiasis in elderly patients often leads to ductal obstruction and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"secondary infection. Other predisposing factors for ductal occlusion include\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dehydration, anticholinergic medications such as tricyclics and diphenhydramine,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"general disability and trauma. Once culture results are available adjust\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobial therapy based on specific etiologic organism.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For more information click on the link below\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Suppurative Parotitis or Chronic Bacterial Parotitis Exacerbation Empiric\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Viral Parotitis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Suspect mumps parotitis if there is fever, malaise, earache and bilateral tender\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"swelling of the parotid glands. For mumps parotitis treat with warm compresses\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"and analgesics and maintain good hydration to prevent secondary bacterial\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"infection. Other viral causes of parotitis include influenza and enteroviruses.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Wilson et al., Am Fam Physician. 2014, 89(11)882-888\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter:  Principles and Practice of Infectious Diseases\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Parotitis\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-To-Date  article: Suppurative parotitis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 692,
    "fields": {
      "name": "ORZID3 GMENU ABX PAROTITIS MORE INFORMATION",
      "term": null,
      "displaytext": "More Information on Parotitis (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MORE ABOUT PAROTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Suppurative Parotitis. Acute bacterial parotitis affects primarily elderly,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"malnourished, dehydrated or post-operative patients. Symptoms include fever,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"toxicity, and tender swelling along the mandible with purulent drainage from the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"parotid duct. Suppurative parotitis is usually unilateral whereas viral\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"parotitis is usually bilateral. Pain is intense and aggressive, analgesic\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy is required. Progression of infection may lead to massive swelling of\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the neck, respiratory obstruction, septicemia and osteomyelitis of adjacent\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"facial bones. Empiric antibiotics are required for coverage of Staphylococcus\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"aureus if bacterial, and surgical drainage is usually necessary.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Chronic Parotitis. Parotitis is recurrent with intermittent acute exacerbations.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Chronic, low-grade bacterial infection results in functional destruction of the\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"salivary gland. It may be confused with Sjogren's syndrome, a noninfectious\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"illness. Therapy includes systemic antibiotics. Parotidectomy may eventually be\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"required for patients with long-standing infection.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Viral Parotitis. Mumps parotitis is characterized by the rapid, painful swelling\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"of one or both parotid glands within 2 to 3 weeks after exposure to the mumps\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"virus. Mumps usually involves both parotid glands whereas bacterial parotitis is\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"unilateral. Other viral causes of parotitis include influenza and enteroviruses.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mumps parotitis usually resolves spontaneously in 5 to 10 days. Provide\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"symptomatic relief of pain and fever and maintain hydration to prevent secondary\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"bacterial infection.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Wilson et al., Am Fam Physician. 2014, 89(11)882-888\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter:  Principles and Practice of Infectious Diseases\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Parotitis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-To-Date  article: Suppurative parotitis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 693,
    "fields": {
      "name": "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE",
      "term": null,
      "displaytext": "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 3091, \"DisplayText\": \"POST EXPOSURE PROPHYLAXIS NON-OCCUPATIONAL HYPERLINK\", \"Text\": \"< SELECT HERE > Post-Exposure Prophylaxis Non-occup Protocol\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 696, \"DisplayText\": \"< SELECT HERE> FOR TABLE\", \"Text\": \"< SELECT HERE > FOR TABLE\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 695, \"DisplayText\": \"NON-OCCUPATIONAL nPEP Laboratory orders\", \"Text\": \"< SELECT HERE > INITIAL LABORATORY ORDERS\", \"Mnemonic\": \"8\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 694, \"DisplayText\": \"ANTIRETROVIRAL TREATMENT RECOMMENDATIONS for nPEP\", \"Text\": \"< SELECT HERE > ANTIRETROVIRAL RECOMMENDATIONS for nPEP\", \"Mnemonic\": \"10\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"< SELECT HERE> Order 4 week follow-up labs + RTC Order\", \"Text\": \"< SELECT HERE > ORDER FOLLOW-UP FOR BOTH LABS AND RTC ID PHARMACY\", \"Mnemonic\": \"12\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MRTC\", \"Text\": \"< SELECT HERE> Consult MRTC\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Non-occupational:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Post-Exposure Prophylaxis (nPEP) for Exposure to Blood or Body Fluids\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"for HIV (sexual, injection drug use, or other substantial non-occupational\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"HIV exposure)\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Please review and follow the Post-Exposure Prophylaxis (nPEP) Protocol:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Eligibility for nPEP requires ALL:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"1.  Less than 72 hours since exposure < AND >\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"2.  High-risk anatomic site of exposure < AND >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"3.  High-risk type of fluid < AND >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"4.  Known (or strongly suspected) HIV-positive source\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Estimated per-act risk for acquiring HIV from infected source, by exposure act:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"****** Complete/assess all four items below for nPEP: ******\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"For initial laboratory orders for assessment:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"For nPEP drug treatment recommendations:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"For Follow-up Laboratory Orders and Schedule Return to Clinic Appointment:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"IF risk factors for HIV persist place MRTC consult:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"If risk factors for HIV persist, place a consult to MRTC clinic for\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"consideration of PreP prior to the 28 days of nPEP ending.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"CDC Guidelines 2016\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"(vagina, rectum, eye, mouth or other mucous membrane, nonintact skin,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"percutaneous inoculation)\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"(blood, semen, vaginal secretions, rectal secretions, breast milk,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"any body fluid visibly contaminated with blood)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"When source HIV status is unknown, recommend erring on the side of providing\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"antivirals for nPEP given the safety and tolerability of these medications,\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"while including the patient in shared decision making.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"**ID on-call is availble if there are any questions.**\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 694,
    "fields": {
      "name": "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL DRUG TX",
      "term": null,
      "displaytext": "ANTIRETROVIRAL TREATMENT RECOMMENDATIONS for nPEP",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Emtricitabine 200MG/Tenofov AF 25mg PO qday + Dolutegravir 50mg PO qday [R,O]\", \"Text\": \"Emtricitabine 200MG/Tenofov AF 25MG Tab 1 po qday ($$)[R,DI] < AND >\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Dolutegravir 50MG Tab 1 po qday ($$) [DI] for 28 days\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Post-Exposure Prophylaxis (nPEP) for Exposure to Blood or Body Fluids\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Dolutegravir 50MG Tab 1 po qday ($$) [DI] for 28 days\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Non-Occupational:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"All persons offered nPEP should be prescribed a 28-day course of a 3-drug\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antiretroviral regimen.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"* These medications may be taken with or without food\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"* Side effects of these medications are infrequent but may include:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"nausea, vomiting, diarrha, rash, fever, headaches, insomnia, arthralgias,\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"fatigue, abdominal pain, hepatitis, renal dysfunction, rare lactic acidosis\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"* IMPORTANT- First dose should be given as soon as possible after exposure\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment recommendations:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Select appropriate treatment below based on patient renal function:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-to-Date Online\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"CDC Guidelines 2016\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Dolutegravir 50MG Tab 1 po qday ($$) [DI] for 28 days\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Creatinine clearance >/= 30 ml/min:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Note: Dolutegravir is now a recommended agent to be used for HIV treatment\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"and prevention in pregnancy (updated 2023).\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"ESRD dialysis:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Creatinine clearance < 30 ml/min not on dialysis*:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Emtricitabine 200MG+Tenofov AF 25MG + Dolutegravir\", \"Text\": \"Emtricitabine 200MG/Tenofov AF 25MG Tab 1 PO qday ($$) [R,DI] < AND >\", \"Mnemonic\": \"18\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Emtricitabine 200mg/Tenofovir 300mg po q72h nPEP crcl <30\", \"Text\": \"Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q3days ($$) [R,DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"*Optimal dosing is uncertain. Follow-up with ID in 1-2 weeks is recommended\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"to individualize dosing if needed.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 695,
    "fields": {
      "name": "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL LABORATORY ORDERS",
      "term": null,
      "displaytext": "NON-OCCUPATIONAL nPEP Laboratory orders ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 25, \"Column\": 1, \"Text\": \"C) Hepatitis B and Hepatitis C labs to assess status:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"GI Liver\", \"Text\": \"Consult Gastroenterology Liver Outpatient for Hep B or Hep C Positive patients\", \"Mnemonic\": \"18\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Labs: Comprehensive Metabolic AND CBC with Diff\", \"Mnemonic\": \"04\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"A) Baseline labs:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"D) For females of child-bearing years:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Urine Pregnancy Test\", \"Text\": \"Labs: Pregnancy Screen\", \"Mnemonic\": \"24\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"E) For all persons considered for or prescribed nPEP for sexual exposure:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Recommended laboratory assessments of exposed persons prior to providing nPEP:\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"CDC Guidelines 2016\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"STD LABS: Chlamydia, Gonorrhea, and Syphilis\", \"Text\": \"Labs: Chlamydia, Gonorrhea, and Syphilis\", \"Mnemonic\": \"26\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Labs: Hepatitis B Serology and Hepatitis C Antibody\", \"Mnemonic\": \"16\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Throat Chlamydia with Gonorrhea\", \"Text\": \"Lab: Throat  swab for Chlamydia with Gonorrhea (submit only ONE swab in media)\", \"Mnemonic\": \"28\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rectal Chlamydia with Gonorrhea\", \"Text\": \"Lab: Rectal  swab for Chlamydia with Gonorrhea (submit only ONE swab in media)\", \"Mnemonic\": \"30\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For women of reproductive capacity who have had genital exposure to semen\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"and a negative pregnancy test when evaluated for possible nPEP, current\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"contraception use should be assessed, and if a risk for pregnancy exists,\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"emergency contraception should be discussed with the patient.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"NEGATIVE HIV Ag/Ab Test:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"POSITIVE HIV Ag/Ab Test:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"___________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"_____________________________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"B) HIV Testing\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"**ADD Labs** below for relevant exposure:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"C.TRACHOMATIS/N.GONORRHEA DNA Vaginal (submit ONLY ONE SWAB in transport media)\", \"Text\": \"Lab: Vaginal swab for Chlamydia with Gonorrhea (submit only ONE swab in media)\", \"Mnemonic\": \"32\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Call Lab x2400 for APTIMA Unisex Swab Specimen Collection Kit\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Order HIV Ag/Ab to assess status for all persons:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HIV AG/AB\", \"Text\": \"Lab: HIV Ag/Ab\", \"Mnemonic\": \"06\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Note:  Negative result reported in approximately 1 hour\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Preliminary positive result sent out to Quest for confirmation\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"(may take 3-5 days for confirmation)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Next steps in assessment depends on if HIV Ag/Ab result is positive or negative:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"IF HIV Ag/Ab result is NEGATIVE, continue with assessment for nPEP.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"IF HIV Ag/Ab inhouse preliminary result is POSITIVE, this may indicate\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"pre-existing HIV infection (pending confirmation from send out lab).\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Please PAGE INPATIENT INFECTIOUS DISEASE on all such patients.\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 3092, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Mpls ON-CALL Schedule\", \"Mnemonic\": \"08\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 696,
    "fields": {
      "name": "ORZID3 GMENU ABX PEP NONOCCUP RISK TABLE BY EXPOSURE ACT",
      "term": null,
      "displaytext": "< SELECT HERE> FOR TABLE ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Text\": \"Parenteral\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"Parenteral\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Blood Transfusion\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"9,250\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Needle sharing during injection drug use\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"63\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Percutaneous (needlestick)\"}, {\"Row\": 12, \"Column\": 2}, {\"Row\": 5, \"Column\": 1, \"Text\": \"EXPOSURE TYPE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Rate for HIV acquisition\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Text\": \"per 10,000 exposures\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Sexual\", \"Header\": 1}, {\"Row\": 13, \"Column\": 2, \"Text\": \"Sexual\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Receptive anal intercourse\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"138\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"23\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Receptive penile-vaginal intercourse\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"8\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Insertive anal intercourse\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"11\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Insertive penile-vaginal intercourse\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"4\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"Low\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Receptive oral intercourse\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Insertive oral intercourse\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"Low\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"OTHER:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 2, \"Text\": \"OTHER:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Biting\"}, {\"Row\": 22, \"Column\": 2, \"Text\": \"Negligible\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"Negligible\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Spitting\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Throwing body fluids (including semen or saliva)\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"Negligible\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sharing sex toys\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"Negligible\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Estimated per-act risk for qcquiring HIV\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"from an infected source, by exposure act\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 697,
    "fields": {
      "name": "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE",
      "term": null,
      "displaytext": "POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 3093, \"DisplayText\": \"POST EXPOSURE PROPHYLAXIS OCCUPATIONAL\", \"Text\": \"Post-Exposure Prophylaxis Protocol\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Blood Borne Pathogen Labs...\", \"Text\": \"Blood Borne Pathogen Labs\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ED LABS FOR POST-EXPOSURE PROPHYLAXIS (PEP)\", \"Text\": \"Select to place order for labs [CBC, LFTs, Basic Metabolic(SMA-7)]\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"POST EXPOSURE PROPHYLAXIS OCCUPATIONAL HIV\", \"Text\": \"Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q day($$)[R,DI,O] < AND >\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Post-Exposure Prophylaxis (PEP) for Exposure to Blood or Body Fluids\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"A.  Please review and follow the Post-Exposure Prophylaxis Protocol:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"B.  Order the following laboratory tests for the source patient and employee:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"C.  Evaluate employee for post-exposure prophylaxis antiviral medications:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If the source patient is known or suspected of having HIV infection, you are\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"strongly encouraged to call the infectious diseases staff physician\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"on call for advice any time, day or night.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"If there has been a significant known or potential exposure to blood or\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"body fluids from a patient with HIV infection, the employee must be seen\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"in Occupational Health by the end of the next business day.  Post-exposure\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"prophylaxis (PEP) medications should be recommended to the employee.  If\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"acceptable to the employee, medications should be started within two hours of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"of exposure and should be taken for up to 28 days.  To get the medications\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"started, order a 5-day supply of antiviral medications here (see link below).\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Additional medications can only be ordered by Occupational Health personnel\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"after the employee is seen.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If the employee accepts PEP, employee baseline labs CBC, LFTs,\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Basic Metabolic(SMA-7) should be drawn:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Select below to order 5 day emergency supply of PEP antiviral medications:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Dolutegravir 50MG Tab 1 po qday ($$)[O]\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 698,
    "fields": {
      "name": "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS",
      "term": null,
      "displaytext": "Perianal/Anorectal Abscess  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 993, \"DisplayText\": \"Prevention of bacterial endocarditis (Outpatient)\", \"Text\": \"High risk of infective endocarditis\", \"Mnemonic\": \"4\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>\", \"Mnemonic\": \"10\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]\", \"Mnemonic\": \"14\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO BID\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO BID\", \"Mnemonic\": \"18\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERIANAL/ANORECTAL ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary therapy: abscess drainage\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prompt surgical drainage is important. Antibiotics have a limited role in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"treatment of uncomplicated anorectal abscess. In general, the addition of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"antibiotics to routine incision and drainage of uncomplicated anorectal abscess\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"does not improve healing time or reduce recurrences. Antibiotics may be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"considered in patients with significant cellulitis, underlying\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"immunosuppression, concomitant systemic illness, or failure to improve with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"drainage alone.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antibiotic prophylaxis for prevention of infective endocarditis is recommended\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for procedures involving infected skin or skin structures in patients with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"underlying cardiac conditions. Click on link below for list of conditions and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"recommendations.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Although culture of abscess fluid in patients who undergo drainage is rarely\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"helpful, it may be considered in patients who will be treated with adjunctive\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"antibiotic treatment, recurrent infection or nonhealing wounds, substantial host\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"defense deficiency, and patients with MRSA risk factors.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Duration of adjunctive antimicrobial therapy\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"After adequate drainage, 5-14 days of antibiotic coverage is indicated for those\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"who receive adjunctive antimicrobial therapy, with duration in part based on\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"resolution of fever and leukocytosis, severity of infection, and additional\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"indicators of clinical response.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Adjunctive antibiotic treatment for drained perirectal abscess in patients with\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"significant cellulitis, underlying immunosuppression, concomitant systemic\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"illness, or failure to improve with drainage alone\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mild disease\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"metronidazole 1000 mg PO BID ($) [DI] for 5 days\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"($) [DI] for 5 days\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Moderate to severe disease\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Rosengren et al, Curr Derm Rep (2012) 1, 55-63\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Sanford Keyword: Perirectal abscess\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Steele et al, Dis Colon Rectum 54(12):1465-74, 2011\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Wilson et al, Circulation 116:1736, 2007\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Up-to-date article: Perianal and perirectal abscess\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Up-to-date article: Cellulitis and skin abscess in adults: Treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 699,
    "fields": {
      "name": "ORZID3 GMENU ABX PHOTODYNAMIC THERAPY HSV-1",
      "term": null,
      "displaytext": "Photodynamic therapy for HSV-1 prophylaxis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"PHOTODYNAMIC THERAPY AND LASER SKIN RESURFACING HSV-1 PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Recommended in patients with history of HSV-1 infection. Initiate prophylaxis\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"24-48 hours prior to surgery and continue for 3-7 days.\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO BID for 5 days ($) [R]\", \"Text\": \"Acyclovir 400 mg PO BID for 5 days ($) [R]\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes Simplex Virus\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Up-To-Date article: Prevention of herpes simplex virus type 1 infection in\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"immunocompetent patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 700,
    "fields": {
      "name": "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Pneumococcal Vaccine Information Page",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE\", \"Text\": \"PPSV23 one dose\", \"Mnemonic\": \"2\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"IM (PCV20 and PPSV23)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Subcutaneous (PPSV23 only)\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Outpatient orders:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"*for those who received\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"prior dose of PCV13:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"CPRS names:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"PNEUMOCOCCAL 20-VALENT\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"CONJUGATE VACCINE INJ\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(PCV20)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"PNEUMOCOCCAL 23-VALENT\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"CONJUGATE VACCINE INJ\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"(PPSV23)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Stocked brand names:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Prevnar 20 (PCV20)\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Pneumovax 23 (PPSV23)\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Pneumococcal conjugate\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"(PCV20)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Pneumococcal\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"polysaccharide\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"(PPSV23)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Murthy et al. Annals\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"internal medicine, 2022,\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"175(3)432-443\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*People age 65yrs or older.\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"*People younger than age\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"65yrs with certain\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"underlying medical\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"conditions:\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"alcoholism, chronic\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"heart/liver/lung disease,\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"chronic renal failure,\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"cigarette smoking,\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"cochlear implant,\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"congenital or acquired\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"asplenia, CSF leak,\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"diabetes mellitus,\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"generalized malignancy,\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"HIV, Hodgkin disease,\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"immunodeficiency,\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \"iatrogenic\"}, {\"Row\": 22, \"Column\": 2, \"Text\": \"immunosuppression,\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"leukemia, lymphoma,\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"multiple myeloma,\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"nephrotic syndrome, solid\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"organ transplants, or\"}, {\"Row\": 27, \"Column\": 2, \"Text\": \"sickle cell disease or\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"other hemoglobinopathies.\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \"public health authorities\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"if increased risk exists\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"in their community.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*When recommended (see\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"column 2), give PCV20 if\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"unvaccinated or if\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"previous vaccination\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"history is unknown.\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"*If patient received PCV13\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"previously, give one dose\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"of PPSV23 at least 1 year\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"after PSV13. A minimum\"}, {\"Row\": 14, \"Column\": 3, \"Text\": \"of 8 weeks may be\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"considered in patients\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"with immunocompromising\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"conditions:\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"Chronic renal failure,\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"nephrotic syndrome,\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"immunodeficiency,\"}, {\"Row\": 21, \"Column\": 3, \"Text\": \"iatrogenic\"}, {\"Row\": 22, \"Column\": 3, \"Text\": \"immunosuppression,\"}, {\"Row\": 23, \"Column\": 3, \"Text\": \"generalized malignancy,\"}, {\"Row\": 24, \"Column\": 3, \"Text\": \"human immunodeficiency\"}, {\"Row\": 25, \"Column\": 3, \"Text\": \"virus, Hodgkin disease,\"}, {\"Row\": 26, \"Column\": 3, \"Text\": \"leukemia, lymphoma,\"}, {\"Row\": 27, \"Column\": 3, \"Text\": \"multiple myeloma, solid\"}, {\"Row\": 28, \"Column\": 3, \"Text\": \"organ transplants,\"}, {\"Row\": 29, \"Column\": 3, \"Text\": \"congenital or acquired\"}, {\"Row\": 30, \"Column\": 3, \"Text\": \"asplenia, sickle cell\"}, {\"Row\": 31, \"Column\": 3, \"Text\": \"disease, or other\"}, {\"Row\": 32, \"Column\": 3, \"Text\": \"hemoglobinopathies.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"History of severe allergic\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component including (for\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"PCV13) to any diphtheria\"}, {\"Row\": 12, \"Column\": 4, \"Text\": \"toxoid containing vaccine,\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"or to any of its\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"components, including\"}, {\"Row\": 15, \"Column\": 4, \"Text\": \"yeast.\"}, {\"Row\": 17, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 4, \"Text\": \"Moderate or severe acute\"}, {\"Row\": 19, \"Column\": 4, \"Text\": \"illness with or\"}, {\"Row\": 20, \"Column\": 4, \"Text\": \"without fever.\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 230, \"DisplayText\": \"PCV20 Quick Orders Not Currently Available\", \"Text\": \"PCV20 one dose\", \"Mnemonic\": \"1\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 701,
    "fields": {
      "name": "ORZID3 GMENU ABX POSITIVE BLOOD CULTURE OP COAG NEG STAPH",
      "term": null,
      "displaytext": "Blood Culture Positive for Coagulase-Negative Staphylococci (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"BLOOD CULTURE POSITIVE FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"CNS are the most common contaminants isolated from blood cultures. When CNS\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"isolated from blood cultures represent true bacteremia, the blood is usually\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"obtained from a patient with plastic or metal in the body. The most common\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"source of coagulase negative staphylococcal bacteremia is an infected\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"intravascular catheter.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"When CNS are isolated from blood, the physician should carefully assess the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"patient to decide whether the isolation represents disease or colonization.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Colonization is more likely if a single bottle is positive or both bottles from\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"a single blood draw are positive. If multiple bottles are positive from separate\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"blood draws, it is more likely that the isolates reflect disease or colonization\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of an intravascular device. Isolates from contaminated bottles often take\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"several days to become positive. If the patient has risk factors for true\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"coagulase negative staphylococcal bacteremia, catheter-related blood stream\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"infection and/or the patient is severely ill, antimicrobials should be given. If\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"there is a plastic or metal prosthesis in the body, the physician should\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"evaluate the site for possible infection. If the isolates are likely to\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"represent contamination and the patient does not seem ill with CNS,\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"antimicrobial therapy would not be helpful and should not be given.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for treatment CNS bacteremia and infected\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"intravascular catheters treatment recommendations\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus epidermis and Other Coagulase-Negative\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Staphylococci\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mermel et al, Clin Infect Dis, 2009, 49\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 702,
    "fields": {
      "name": "ORZID3 GMENU ABX PROCED FOR INFECTED SKIN OUTPATIENT",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 2 gm PO 1 hour before procedure ($) [R]\", \"Text\": \"Cephalexin 2 gm PO 1 hour before procedure ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TRIMETH/SULFA 1 DS TAB PO ONCE PREOP\", \"Text\": \"Trimethoprim/Sulfamethoxazole 1 DS table PO 1 hour before incision\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO 1 hour before incision ($1.20/day)[DI] < OR >\", \"Text\": \"Minocycline 100 mg PO 1 hour before incision ($) [DI]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIMICROBIALS FOR PATIENTS UNDERGOING PROCEDURES THAT INVOLVE INFECTED SKIN,\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"SKIN STRUCTURES, OR INFECTED MUSCULOSKELETAL TISSUE TO PREVENT ENDOCARDITIS OR\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"PROSTHETIC JOINT INFECTION\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pathogen unknown or possibly MSSA or beta-hemolytic streptococcus\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Patients unable to take oral medications\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for parenteral prophylaxis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Suspected MRSA\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"($) [R,DI]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for parenteral prophylaxis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Rosengren et al, Curr Derm Rep (2012) 1, 55-63\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"infection in adults\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-to-Date article: Skin surgery: Prevention and treatment of complications\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Wright et al, J Am Acad Dermatol (2008) 59, 464-73\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Wilson et al., Circulation, 2021, 143(20)e963-e978\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 703,
    "fields": {
      "name": "ORZID3 GMENU ABX RABIES HIGH RISK GROUPS",
      "term": null,
      "displaytext": "Rabies High Risk Groups  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"RABIES HIGH RISK GROUPS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Occupational\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"1. Veterinarians and their staff (e.g. students and technicians)\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"2. Laboratory workers working with rabies virus or specimens that may contain\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"rabies virus\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"3. Other people with occupations or activities that bring them in to contact\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"with animal species at risk for rabies (e.g. animal control officers and cavers)\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Travel\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"1. Travelers who will be working with or around potentially rabid animals\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"2. People who will be in areas where dog-rabies is common and who won't be in an\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"area where safe and effective biologics are readily available within a few days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"after exposure\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"States, 2008: recommendations of the Advisory Committee on Immunization\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Practices. MMWR Recomm Rep 2008, 57:1.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"postexposure prophylaxis to prevent human rabies: recommendations of the\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"9\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 704,
    "fields": {
      "name": "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS",
      "term": null,
      "displaytext": "Rabies Post-exposure Prophylaxis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 3094, \"DisplayText\": \"MDH Health Guide on Animal Bites and Rabies Risk\", \"Text\": \"Minnesota Department of Health Guide on Animal Bites and Rabies Risk\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minneapolis Clinical On-Call Schedule\", \"Text\": \"Infectious Diseases On-Call Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Povidine-iodine solution wound cleanse\", \"Text\": \"Povidine-iodine irrigation solution\", \"Mnemonic\": \"8\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rabies immune globulin and vaccine series\", \"Text\": \"Rabies immune globulin STAT < AND > rabies vaccine STAT\", \"Mnemonic\": \"10\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rabies vaccine stat and 2nd dose\", \"Text\": \"Rabies vaccine STAT\", \"Mnemonic\": \"12\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tetanus/diptheria vaccine one dose stat\", \"Text\": \"Tetanus and Diphtheria (Td) vaccine booster dose STAT\", \"Mnemonic\": \"14\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 751, \"DisplayText\": \"Bite wounds (Outpatient)\", \"Text\": \"Bite wounds recommendations (outpatient)\", \"Mnemonic\": \"16\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"RABIES POST-EXPOSURE PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Patients are given post-exposure prophylaxis based upon their risk including\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"type of exposure, epidemiology of rabies in the area where contact occurred,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"circumstances of the exposure incident, species and the availability of animal\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"involved. The Minnesota Department of Health has staff available 24/7 to consult\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"health care providers on risk-status of individuals. They can be contacted by\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"phone at 651-201-5414. Refer to link below for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Discussion with Infectious Diseases inpatient attending by phone is highly\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"recommended. Use the link below to obtain the pager number for on-call staff.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Wound cleansing\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"All post-exposure prophylaxis should begin with immediate thorough cleansing of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"all wounds with soap and water. After cleansing, use povidine-iodine solution to\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"irrigate the wounds.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients without history of rabies vaccination\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"After wound cleansing, administer rabies immune globulin and first dose of\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"rabies vaccine series immediately.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Administer second, third and fourth doses of rabies vaccine series on days 3, 7,\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"and 14. An additional dose is given on day 28 for immunocompromised patients.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Patients with history of rabies vaccination\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Patients with a history of complete pre-exposure vaccination regimen and a\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"documented antibody response to the rabies virus, do not require rabies immune\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"globulin administration. If the patient does not meet these criteria, treat as a\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"patient without history of rabies vaccination above. If patient does meet these\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"criteria, after wound cleansing, administer first dose of rabies vaccine series.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Administer second dose of rabies vaccine series on day 3.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Tetanus Prophylaxis\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"In bite wounds that break the skin, tetanus vaccine is indicated if patient has\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"received <3 doses of tetanus vaccine or immunization history is unknown. Tetanus\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"immune globulin is also indicated in these patients if they have a tetanus prone\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"wound. For patients with 3 or more documented tetanus vaccine doses, tetanus\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"vaccine is indicated if >5 years since last booster in tetanus prone wounds and\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"indicated if >10 years since last booster in non-tetanus-prone wounds.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Treatment of infection\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"States, 2008: recommendations of the Advisory Committee on Immunization\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Practices. MMWR Recomm Rep 2008, 57:1.\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"postexposure prophylaxis to prevent human rabies: recommendations of the\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"9\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 705,
    "fields": {
      "name": "ORZID3 GMENU ABX RABIES POST-EXPOSURE VACCINATED PATIENTS",
      "term": null,
      "displaytext": "Rabies Post-exposure Vaccinated Patients",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rabies vaccine clinic order\", \"Text\": \"[CLICK HERE] to place clinic order for second dose\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 3095, \"DisplayText\": \"CBOC Information Link\", \"Text\": \"[CLICK HERE] for CBOC open hours and contact information\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RABIES VACCINE POST EXPOSURE DOSE CBOC 2 SERIES\", \"Text\": \"[CLICK HERE] to place clinic order and RTC order\", \"Mnemonic\": \"8\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"ORDER RABIES POST-EXPOSURE PROPHYLAXIS SUBSEQUENT VACCINE DOSES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"A second dose of the rabies vaccine is required on day 3 for patients with a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"history of documented rabies vaccination. To order the second dose of the rabies\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"vaccination, follow these two steps:\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"1) Select vaccine series below based on administration location\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"2) Click the [Next] button at the top right of this window when finished\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"If second dose will be administered at MVAMC ED\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If second dose will be administered at a CBOC\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Complete the following 4 steps:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"1) Complete rabies vaccination plan in the EMERGENCY DEPARTMENT STAFF NOTE and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"attach patient's primary care provider for follow up.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"2) Ensure the CBOC is open on day 3.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"3) Order vaccine dose and place return to clinic (RTC) order.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"States, 2008: recommendations of the Advisory Committee on Immunization\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Practices. MMWR Recomm Rep 2008, 57:1.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"postexposure prophylaxis to prevent human rabies: recommendations of the\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"9\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"4) Call inpatient pharmacy at ext 31-3128 to ensure vaccine dose is mailed over\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"night to the CBOC for administration.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 706,
    "fields": {
      "name": "ORZID3 GMENU ABX RABIES POST-EXPOSURE VACCINE NAIVE PATIENTS",
      "term": null,
      "displaytext": "Rabies Post-Exposure Vaccine Naive Patients",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rabies vaccine immunocompetent patients doses 2-4\", \"Text\": \"[CLICK HERE] for immunocompetent patients\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rabies vaccine immunocompromised patient dose 2-5\", \"Text\": \"[CLICK HERE] for immunocompromised patients\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 3096, \"DisplayText\": \"CBOC Information Link\", \"Text\": \"[CLICK HERE] for CBOC open hours and contact information\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RABIES POST EXPOSURE VACCINE 2-4 SERIES\", \"Text\": \"[CLICK HERE] for immunocompetent patients\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RABIES POST EXPOSURE VACCINE 2-5 SERIES\", \"Text\": \"[CLICK HERE] for immunocompromised patients\", \"Mnemonic\": \"12\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"ORDER RABIES POST-EXPOSURE PROPHYLAXIS SUBSEQUENT VACCINE DOSES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"In patients without documented rabies vaccination, subsequent doses of the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"rabies vaccine are required on days 3, 7, and 14. An additional dose is given on\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"day 28 for immunocompromised patients. To order subsequent rabies vaccinations,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"follow these two steps:\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"1) Select vaccine series below based on administration location and immune\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"status\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"2) Click the [Next] button at the top right of this window when finished\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"If all subsequent rabies vaccine doses will be administered at the MVAMC ED\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"If at least one subsequent rabies vaccine dose will be administered at a CBOC\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Complete the following 4 steps:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"1) Complete rabies vaccination plan in the EMERGENCY DEPARTMENT STAFF NOTE and\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"attach patient's primary care provider for follow up.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"2) Ensure CBOC is open on days when vaccine is scheduled to be given there. The\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"rabies vaccine is given on a 3, 7, 14-day schedule, an additional dose is given\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"on day 28 for immunocompromised patients\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"3) Order vaccine doses and return to clinic (RTC) order\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"States, 2008: recommendations of the Advisory Committee on Immunization\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Practices. MMWR Recomm Rep 2008, 57:1.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"postexposure prophylaxis to prevent human rabies: recommendations of the\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"9\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"4) Call inpatient pharmacy at ext 31-3128 to ensure vaccine dose is mailed over\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"night to the CBOC for administration.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 707,
    "fields": {
      "name": "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS",
      "term": null,
      "displaytext": "Rabies Pre-exposure Prophylaxis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 704, \"DisplayText\": \"Rabies Post-exposure Prophylaxis\", \"Text\": \"Rabies Post-Exposure Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 703, \"DisplayText\": \"Rabies High Risk Groups\", \"Text\": \"Rabies high risk groups\", \"Mnemonic\": \"6\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RABIES VACCINE 2 DOSE SERIES\", \"Text\": \"Rabies vaccine, 2 dose series\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 708, \"DisplayText\": \"Rabies Risk Categories\", \"Text\": \"Rabies risk categories\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rabies virus rapid fluorescent inhibition test\", \"Text\": \"Rabies virus rapid fluorescent focus inhibition test\", \"Mnemonic\": \"12\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RABIES BOOSTER VACCINE ONE DOSE\", \"Text\": \"Rabies booster vaccine\", \"Mnemonic\": \"14\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"RABIES PRE-EXPOSURE PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"For patients exposed to a rabid animal, refer to the Rabies-Post Exposure\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prophylaxis recommendations in the emergency department CDSS.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Rabies Vaccination\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"People who are in high-risk groups should be vaccinated against rabies.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Rabies Booster\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"People with continuous risk of rabies exposure should be tested for rabies virus\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"neutralizing antibody every six months. Those with frequent risk of rabies\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"exposure should be tested every two years.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"A booster vaccination should be administered if the serum titer falls to\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"maintain a value of at least complete virus neutralization at a 1:5 serum\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"dilution by the rapid fluorescent focus inhibition test.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"States, 2008: recommendations of the Advisory Committee on Immunization\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Practices. MMWR Recomm Rep 2008, 57:1.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"postexposure prophylaxis to prevent human rabies: recommendations of the\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"9\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Briggs et. al., MMWR Morb Mortal Wkly Rep, 2022, 71:619-627\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 708,
    "fields": {
      "name": "ORZID3 GMENU ABX RABIES RISK CATEGORIES",
      "term": null,
      "displaytext": "Rabies Risk Categories",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"RABIES RISK CATEGORIES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Continuous\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Rabies research laboratory workers, rabies biologics production workers\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Frequent\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Rabies diagnostic laboratory workers, cavers, veterinarians and staff and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"animal-control and wildlife workers in areas where rabies is enzootic. All\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"persons who frequently handle bats.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Infrequent\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Veterinarians and animal-control staff working with terrestrial animals in areas\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"where rabies is uncommon to rare. Veterinary students. Travelers visiting areas\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"where rabies is enzootic and immediate access to appropriate medical care\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"including biologics is limited.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Rare\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"U.S. population at large, including persons in areas where rabies is epizootic.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"States, 2008: recommendations of the Advisory Committee on Immunization\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Practices. MMWR Recomm Rep 2008, 57:1.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"postexposure prophylaxis to prevent human rabies: recommendations of the\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"9\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 709,
    "fields": {
      "name": "ORZID3 GMENU ABX RECALCITRANT ACNE AND ROSACEA",
      "term": null,
      "displaytext": "Acne and Rosacea Dermatology Orders  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 12 weeks\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500 mg PO BID for 7 days ($) [R] for 12 weeks\", \"Text\": \"Cephalexin 500 mg PO BID for 7 days ($) [R] for 12 weeks\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks\", \"Text\": \"Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 12 weeks\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg three times weekly ($) [O] for 12 weeks\", \"Text\": \"Azithromycin 500 mg three times weekly ($) [O] for 12 weeks\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 50 mg PO BID ($) [DI]\", \"Text\": \"Doxycycline 50 mg PO BID ($) [DI] prolonged therapy\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DERMATOLOGY SERVICE ORDER MENU FOR RECALCITRANT ACNE AND ROSACEA\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Recalcitrant Acne and Rosacea Treatment:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Refractory Severe Rosacea Treatment:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"**For dermatology use only, requires dermatology consult prior to treatment**\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 710,
    "fields": {
      "name": "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS",
      "term": "CDC Recommended Adult Immunizations",
      "displaytext": "CDC Recommended Adult Immunizations  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 3097, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"[Click Here] for vaccination history including link to Joint Legacy Viewer\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"[Click Here] for link to PDF of CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Chickenpox (Varivax, VAR)\", \"Mnemonic\": \"8\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 129, \"DisplayText\": \"TEsting\", \"Text\": \"COVID-19 *Inpatient orders only* (Comirnaty, Spikevax, Janssen)\", \"Mnemonic\": \"10\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Diphtheria (Tenivac, Td / Boostrix, Tdap)\", \"Mnemonic\": \"12\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Flu (seasonal influenza)\", \"Mnemonic\": \"14\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hiberix, Hib)\", \"Mnemonic\": \"16\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (Havrix, HepA)\", \"Mnemonic\": \"18\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (Engerix-B, HepB)\", \"Mnemonic\": \"20\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (Twinrix, HepA/B)\", \"Mnemonic\": \"22\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (Shingrix, RZV)\", \"Mnemonic\": \"24\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (Gardasil 9, HPV)\", \"Mnemonic\": \"26\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza (seasonal influenza)\", \"Mnemonic\": \"28\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles (M-M-R II, MMR)\", \"Mnemonic\": \"30\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (Menveo, MenACWY)\", \"Mnemonic\": \"32\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (Bexsero, MenB)\", \"Mnemonic\": \"34\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Mumps (M-M-R II, MMR)\", \"Mnemonic\": \"36\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Pertussis (Boostrix, Tdap)\", \"Mnemonic\": \"38\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcus (PCV20, Prevnar20 / PPSV23, Pneumovax 23)\", \"Mnemonic\": \"40\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Rabies (Imovax) - for post-exposure prophylaxis, refer to ED Antimicrobial CDSS\", \"Mnemonic\": \"42\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Rubella (M-M-R II, MMR)\", \"Mnemonic\": \"44\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Shingles (Shingrix, RZV)\", \"Mnemonic\": \"46\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus (Tenivac, Td / Boostrix, Tdap)\", \"Mnemonic\": \"48\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Whooping cough (Boostrix, Tdap)\", \"Mnemonic\": \"50\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Zoster (Shingrix, RZV)\", \"Mnemonic\": \"52\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 666, \"DisplayText\": \"Immunization of Patients Age 19-26 Years\", \"Text\": \"19-26 years\", \"Mnemonic\": \"54\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 667, \"DisplayText\": \"\", \"Text\": \"27-49 years\", \"Mnemonic\": \"56\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 668, \"DisplayText\": \"Immunization of Patients Age 50-64 Years\", \"Text\": \"50-64 years\", \"Mnemonic\": \"58\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 665, \"DisplayText\": \"Immunization of Patients Age 65 Years or Greater\", \"Text\": \">/= 65 years\", \"Mnemonic\": \"60\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"Bone Marrow Transplant, hematopoietic stem cell transplant (HSCT)\", \"Mnemonic\": \"62\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Chronic Liver Disease\", \"Mnemonic\": \"64\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 671, \"DisplayText\": \"Immunization of Patients with Diabetes\", \"Text\": \"Diabetes\", \"Mnemonic\": \"66\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"Functional or Anatomical Asplenia - Outpatient Orders\", \"Mnemonic\": \"68\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Functional or Anatomical Asplenia - Inpatient Orders\", \"Mnemonic\": \"70\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 672, \"DisplayText\": \"Immunization of Patients who are Health Care Personnel\", \"Text\": \"Health Care Personnel\", \"Mnemonic\": \"72\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 669, \"DisplayText\": \"Immunization of Patients with Heart/Lung Disease or Alcoholism\", \"Text\": \"Heart/Lung Disease or Alcoholism\", \"Mnemonic\": \"74\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 673, \"DisplayText\": \"Immunization of patients with HIV\", \"Text\": \"HIV\", \"Mnemonic\": \"76\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 676, \"DisplayText\": \"Immunization of Immunocompromised Patients\", \"Text\": \"Immunocompromised (not including HIV and HSCT)\", \"Mnemonic\": \"78\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Kidney Failure or on Hemodialysis\", \"Mnemonic\": \"80\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 675, \"DisplayText\": \"Immunization of Men who Have Sex with Men\", \"Text\": \"Men who Have Sex with Men\", \"Mnemonic\": \"82\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 989, \"DisplayText\": \"\", \"Text\": \"Pregnancy\", \"Mnemonic\": \"84\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patient Vaccine History:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Please note:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"*A vaccine series does not need to be restarted, regardless of the time that has\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"elapsed between doses.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"*For calculating intervals between doses, 4 weeks = 28 days. Intervals of 4\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"months or greater are determined by calendar months.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"*Any vaccine can be given with another unless otherwise noted on the specific\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"vaccine page.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"*Mild illness is not a contraindication to receiving any vaccine.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Vaccine information and orders - listed alphabetically below by organism name\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"*see below for immunization based on age or indication\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Cholera (Vaxchora) - refer to Travel Clinic\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Japanese encephalitis (Ixiaro) - refer to Travel Clinic\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Poliovirus (IPOL) - refer to Travel Clinic\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Tick-Borne Encephalitis (Ticovac) - refer to Travel Clinic\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Typhoid (Typhim Vi) - refer to Travel Clinic\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Varicella-zoster: refer to chickenpox for prevention of primary infection or\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"herpes zoster/shingles/zoster for prevention of viral reactivation\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Yellow fever (YF-VAX) - refer to Travel Clinic\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"By Age\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"By Indication\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nursing Vaccine Administration Text Order\", \"Text\": \"Monkeypox (Jynneos)\", \"Mnemonic\": \"35\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 711,
    "fields": {
      "name": "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY AGE",
      "term": null,
      "displaytext": "CDC Recommended Adult Immunizations by Age ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Item\": 666, \"DisplayText\": \"Immunization of Patients Age 19-26 Years\", \"Text\": \"19-26 years\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 667, \"DisplayText\": \"\", \"Text\": \"27-49 years\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 668, \"DisplayText\": \"Immunization of Patients Age 50-64 Years\", \"Text\": \"50-64 years\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 665, \"DisplayText\": \"Immunization of Patients Age 65 Years or Greater\", \"Text\": \">/= 65 years\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS BY AGE\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 712,
    "fields": {
      "name": "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY INDICATION",
      "term": null,
      "displaytext": "CDC Recommended Adult Immunizations by Indication",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS BY INDICATION\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": 638, \"DisplayText\": \"Bone Marrow Post-Transplant Vaccinations\", \"Text\": \"Bone Marrow Transplant, hematopoietic stem cell transplant (HSCT)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 670, \"DisplayText\": \"Immunization in Chronic Liver Disease\", \"Text\": \"Chronic Liver Disease\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 671, \"DisplayText\": \"Immunization of Patients with Diabetes\", \"Text\": \"Diabetes\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"Functional or Anatomical Asplenia - Outpatient Orders\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 274, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx INPATIENT\", \"Text\": \"Functional or Anatomical Asplenia - Inpatient Orders\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 672, \"DisplayText\": \"Immunization of Patients who are Health Care Personnel\", \"Text\": \"Health Care Personnel\", \"Mnemonic\": \"14\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 669, \"DisplayText\": \"Immunization of Patients with Heart/Lung Disease or Alcoholism\", \"Text\": \"Heart/Lung Disease or Alcoholism\", \"Mnemonic\": \"16\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 673, \"DisplayText\": \"Immunization of patients with HIV\", \"Text\": \"HIV\", \"Mnemonic\": \"18\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 676, \"DisplayText\": \"Immunization of Immunocompromised Patients\", \"Text\": \"Immunocompromised (not including HIV and HSCT)\", \"Mnemonic\": \"20\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 674, \"DisplayText\": \"Immunization of patient with renal failure on hemodialysis\", \"Text\": \"Kidney Failure or on Hemodialysis\", \"Mnemonic\": \"22\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 675, \"DisplayText\": \"Immunization of Men who Have Sex with Men\", \"Text\": \"Men who Have Sex with Men\", \"Mnemonic\": \"24\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 989, \"DisplayText\": \"\", \"Text\": \"Pregnancy\", \"Mnemonic\": \"26\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 713,
    "fields": {
      "name": "ORZID3 GMENU ABX RESPIRATORY PAPILLOMATOSIS",
      "term": null,
      "displaytext": "Respiratory papillomatosis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cidofovir 5 mg/ml for mucosal injection ($525/75mg Vial) [M]\", \"Text\": \"Cidofovir 5 mg/ml for mucosal injection ($525/75mg Vial) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RESPIRATORY PAPILLOMATOSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Respiratory papillomas are usually associated with human papillomavirus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infection. The papillomas are found in the pharynx, usually in the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"larynx.  They can be surgically removed, but they often recur.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Cidofovir is injected into the respiratory mucosa after papillomas are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"removed to prevent recurrences.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Elina Kiverniti o Nick Sevdalis oAnastasia Rachmanidou-Doran:  A\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"systematic review on recurrent respiratory papillomatosis:  clinical\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"effect and duration of benefit of different treatment modalities, Oncol\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Rev (2010) 4:35-42\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 714,
    "fields": {
      "name": "ORZID3 GMENU ABX ROSACEA",
      "term": null,
      "displaytext": "Rosacea",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% cream topically q24h ($) [DI]\", \"Text\": \"Metronidazole 0.75% cream topically q24h ($) [DI]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Doxycycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Minocycline 50 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 709, \"DisplayText\": \"Acne and Rosacea Dermatology Orders\", \"Text\": \"Recalcitrant Rosacea\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ROSACEA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Rosacea is an inflammatory skin condition resulting in erythema and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"telangiectasia of nose, cheeks, eyelids, and forehead. It typically occurs in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"mid-life and the etiology is unknown. Erythematous rosacea is the early stage of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"the disease and usually manifests with flushing reactions and persistently\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"erythematous skin. Late-stage disease is known as papulopustular rosace.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Symptoms include papular, pustular, cysts and nodules. Severe disease results in\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"tissue atrophy and rhinophyma (bulbus nose).\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"The goal of treatment is control of symptoms, not cure. General treatment\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"measures include avoiding triggers (e.g. spicy food, alcohol), skin care (e.g.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"moisturizing, gentle cleansing, avoiding topical irritants) and using sun\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"screen. Medical treatment includes topical agents as first line therapy and oral\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"treatment for refractory disease.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Papulopustular rosacea\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"**FOR DERMATOLOGY USE ONLY, REQUIRES DERMATOLOGY CONSULT PRIOR TO TREATMENT**\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"________________________________________________________________________________\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Acne Rosacea\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-to-Date Article: Rosacea: Pathogenesis, clinical features, and diagnosis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-Date Article: Management of rosacea\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"van Zuuren EJ et al., N Engl J Med, 2017, 377(18)1754-1764\"}, {\"Row\": 39, \"Column\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 715,
    "fields": {
      "name": "ORZID3 GMENU ABX RSV",
      "term": null,
      "displaytext": "Respiratory Syncytial Virus (RSV) (outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RESPIRATORY SYNCYTIAL VIRUS (RSV)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"No specific antimicrobial therapy is indicated. Contact Infectious Diseases for\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"more information on management of this disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Sanford keyword: Respiratory Syncytial Virus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 716,
    "fields": {
      "name": "ORZID3 GMENU ABX SA DECOLONIZATION",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid\", \"Text\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid\", \"Mnemonic\": \"4a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid\", \"Text\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid\", \"Mnemonic\": \"6a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STAPHYLOCOCCUS AUREUS DECOLONIZATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"From 10% to 40% of adults are colonized with Staphylococcus aureus, and the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"anterior nares is the most common site of colonization. The great majority of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"people never have disease with S. aureus, but a tiny fraction of people develop\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"clinical infections with the S. aureus that has colonized their skin or anterior\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"nares. Steps to decolonize the skin and anterior nares can transiently diminish\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"or eradicate S. aureus colonization and can prevent post-operative wound\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infection in certain high-risk circumstances. For people who have other forms\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"of recurrent S. aureus disease, not associated with an operation, results with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"decolonization have been disappointing, and decolonization is not routinely\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"recommended. Colonization typically reappears in most patients within a few\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"days or weeks after decolonization has been attempted. Clinicians occasionlly\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"wish to attempt decolonization for patients with frequent, troublesome\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"recurrences. The procedure here is one of several that have been studied, but\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"none have been particularly effective over the long run.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Consultation with Infectious Diseases is recommended.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Inpatient Decolonization Order Set:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"topically QDAY nursing text order ($) [M] for 5 days\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Outpatient Decolonization Order Set:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Order if patient is being discharged within 5 days\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"topically QDAY ($) [M] for 5 days\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Instructions\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"* Patient must wear clean clothes after bathing to prevent recontaminat\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"* Bedding and linens must be changed/cleaned daily until the end of the\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"decolonization protocol.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Bradley S Clin Infect Dis 2007, 44: 186\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Lonneke G NEJM 2010, 362: 9\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Schweizer et al, JAMA 2015, 313.212:162-2171\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"adults: Prevention and control\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 717,
    "fields": {
      "name": "ORZID3 GMENU ABX SOTROVIMAB EUA",
      "term": null,
      "displaytext": "Sotrovimab (EUA) Information",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Mnemonic\": \"02\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"If patient agreeable and meets criteria, please contact Minneapolis VA Emergency\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"infection control measures (wear mask, isolate, social distance, avoid\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"sharing personal items, clean and disinfect \\\"high touch\\\" surfaces, and\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"frequent handwashing) according to CDC guidelines.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Inclusion Criteria\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"ALL of the following criteria must be met for a patient to receive:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"2) Patient is not hospitalized due to COVID-19.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"3) Patient does NOT require oxygen therapy for COVID-19.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"For patients on chronic oxygen therapy: patient does NOT require an\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"increase in baseline oxygen flow rate due to COVID-19.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"4) Administration will begin within 7 days of symptom onset.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"5) Patient does not have known hypersensitivity to sotrovimab or components.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"The provider has communicated with the patient/caregiver regarding\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"information contained in the \\\"Fact Sheet for Patients\\\". The patient/\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"caregiver has been given the Fact sheet, informed that the drug is an\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"unapproved drug that is authorized for use under an EUA, given information\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"on alternatives and their risks and benefits, and the patient/caregiver\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"has the right to refuse or accept. (See top of page for Fact Sheet)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"7) Counseling is provided and documented in the electronic health record per EUA\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Printable Fact Sheets\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Note: See below for inclusion criteria. Does not require ID approval.\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"ID available to discuss if needed.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"including hospitalization or death.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"6) Patient has at least one risk factor for progression to severe disease\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"See link below for complete list:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"**Treatment:**\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Note: patient may be hospitalized for some other reason.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Sotrovimab (EUA) Information\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-Sotrovimab is available via FDA Emergency Use Authorization (EUA)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"for treating patients that meet specific criteria. Sotrovimab is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"not FDA approved drug.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"-Sotrovimab EUA does NOT include post-exposure prophylaxis.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"*Patients treated with this drug should continue to self-isolate and use\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 3098, \"DisplayText\": \"Sotrovimab EUA Patient Information\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Sotrovimab\", \"Mnemonic\": \"06\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sotrovimab EUA Provider Fact Sheet\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Sotrovimab\", \"Mnemonic\": \"08\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Sotrovimab EUA Provider Fact Sheet\", \"Text\": \"[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors\", \"Mnemonic\": \"12\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Exclusion Criteria\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Department charge nurse at 31-6736 to arrange for treatment if available.\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 718,
    "fields": {
      "name": "ORZID3 GMENU ABX STASIS DERMATITIS OP",
      "term": null,
      "displaytext": "Stasis Dermatitis (outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 68, \"Column\": 1, \"Item\": 783, \"DisplayText\": \"Cellulitis (Outpatient)\", \"Text\": \"Bacterial Cellulitis\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STASIS DERMATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Stasis dermatitis is a common condition that is often confused with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"bacterial cellulitis. Stasis dermatitis does not benefit from antimicrobial\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"therapy. It is important to distinguish between the two. The provider\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"should be mindful of the fact that bacterial cellulitis can occur on skin\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with underlying stasis dermatitis. (See link below for bacterial cellulitis)\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Common risk factors for venous stasis include advancing age, family\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"history of venous disease, increased body mass index, smoking, a history of\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"trauma, prior venous thrombosis and pregnancy. Chronic venous disease and\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"arterial vascular disease have some common risk factors (eg, smoking,\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"obesity) and pathophysiological processes. The most common symptoms reported\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"by patients with chronic venous disease are limb discomfort (tired, heavy\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"legs), pain, and limb swelling. Swelling is often worse with prolonged\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"standing and improves with leg elevation and walking. The skin of the\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"anterior surfaces of the lower legs often has brown or blue-grey\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"hyperpigmentation.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"People with venous stasis are prone to develop stasis dermatitis which\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"is one of the most common and earliest dermatologic signs of chronic venous\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"insufficiency. Stasis dermatitis is an inflammatory process that presents as\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"an eczematous rash characterized by itching, erythema, scaling, weeping,\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"erosions, and crusting. Longstanding cases may develop lipodermatosclerosis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"a fibrosing panniculitis of the subcutaneous tissue. Lipodermatosclerosis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"typically starts with a firm area of induration at the medial ankle. As the\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"process progresses, the entire leg lower leg can become involved with\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"extension up to the mid leg in more advanced cases. The skin overlying the\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"panniculitis is typically heavily pigmented and bound down to the\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"subcutaneous tissues. Brawny edema above the fibrotic area and on the foot\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"below is seen in advanced cases. Leukocytosis and fever are common in people\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"with stasis dermatitis.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Chronic venous disease is the most common cause of leg ulcers. They\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"are usually found low on the medial ankle over a perforating vein, or along\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"the course of the great or small saphenous veins. They occur more proximally\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"if precipitated by trauma. Venous ulcers are not found on the forefoot or\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"above the level of the knee. Venous ulcers can be multiple or single, and\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"can be exquisitely tender, shallow, exudative and have a granulation base.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"The ulcer borders are usually irregular but not undermined. They can extend\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"circumferentially around the leg if left untreated.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Arterial ulcers are typically painful, and punched out or stellate. The\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"surrounding skin is red and taut. Some arterial ulcers are pale - others have\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"a black or yellow eschar. They are often associated with trauma and commonly\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"occur on the foot over pressure points. There may be other signs of arterial\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"insufficiency on the lower limb including thin atrophic or hairless skin,\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"poor pedal pulses, diminished capillary refill, or hypertrophic deformed\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"nails.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Patients with stasis or lipodermatosclerosis are prone to bouts of\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"bacterial cellulitis, usually caused by Staphylococcus aureus or encapsulated\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"streptococci. Typically, stasis dermatitis develops slowly, over a week or\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"more. It is often bilateral. The onset of bacterial cellulitis is usually\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"abrupt, typically developing over 1 or 2 days. Bacterial cellulitis often\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"starts in one area and spreads to adjacent areas. Bacterial cellulitis is\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"unilateral. Both can present with fever and leukocytosis.\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"In a patient with stasis and cellulitis and the physician is uncertain\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"about whether bacterial cellulitis is present, the physician should consider\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"a trial of bed rest, leg elevation, and if there is fluid overload, diuresis\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"If the cellulitis improves in 24-48 hours, antibacterial therapy and the\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"attendant adverse reactions can be avoided. If it is clear that bacterial\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"cellulitis has occurred, antimicrobial therapy should be given.\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Stevens et al, Clin Infect Dis, 2014, 59(2): e10-52\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Up-to-Date article: Stasis dermatitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 719,
    "fields": {
      "name": "ORZID3 GMENU ABX SYPHILIS",
      "term": null,
      "displaytext": "Syphilis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 1026, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Mnemonic\": \"4\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Syphilis AB w/reflex to RPR w/titer\", \"Text\": \"Syphilis antibody test with reflex to rapid plasma reagin (RPR)\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine Penicillin 2.4 million units IM once (Cost $$$) [M]\", \"Text\": \"Benzathine Penicillin 2.4 million units IM once ($$$) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam Reaction Assessment\", \"Mnemonic\": \"12\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 14 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine Penicillin 2.4 million units IM qweek x3 ($$$)[M]\", \"Text\": \"Benzathine Penicillin 2.4 million units IM qweek ($$$) [M] x3 doses\", \"Mnemonic\": \"16\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Beta-lactam Reaction Assessment\", \"Mnemonic\": \"18\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 28 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 28 days\", \"Mnemonic\": \"20a\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 28 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SYPHILIS\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases. Evaluation and management are complex.\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Syphilis is a sexually transmitted disease caused by the spirochete Treponema\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"pallidum that can manifest as a variety of signs or symptoms. Primary syphilis\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"typically consists of painless ulcers or chancre at the site of infection with\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"regional adenopathy. Secondary syphilis often includes a skin rash (disseminated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"and/or including the palms and soles), fever, malaise, mucocutaneous lesions and\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"lymphadenopathy. Tertiary syphilis includes those with cardiovascular or\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"gummatous disease.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Latent syphilis is a period of disease when a patient does not have symptoms but\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"is found to be infected through serologic testing. Early latent syphilis refers\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"to latent syphilis acquired within the preceding year and late latent syphilis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"refers to all other cases of latent syphilis. Neurosyphilis, Ocular syphilis or\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Otosyphilis, can occur at any stage of syphilis with early manifestations (e.g.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"meningitis, stroke, vision or hearing loss) occurring within the first months to\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"years of infection and late manifestations (e.g. dementia, tabes dorsalis)\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"occurring after 10-30 years.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Diagnosis\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"A presumptive diagnosis is made through use of a nontreponemal or serologic test\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"(i.e. rapid plasma reagin [RPR]) and a treponemal test (i.e. fluorescent\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"treponemal antibody absorbed [FTA-ABS]). Direct methods through darkfield\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"microscopy and direct fluorescent antibody (DFA) must be used for definitive\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"diagnosis since T. pallidum cannot be cultured.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Management of sex partners\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Persons with sexual contact with a person with primary, secondary or early\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"latent syphilis within the last 90 days should be presumptively treated even if\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"serologic test is negative.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Primary, Secondary and Early Latent Syphilis\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Secondary treatment for patients who are not pregnant\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Tertiary and Late Latent Syphilis\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"*Outpatient treatment requires a follow up appointment on day 7 and day 14 to\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"administer 2nd and 3rd dose respectfully. Ensure these appointments are made\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"when ordering this treatment regimen.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Secondary treatment for patients who are not pregnant\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Neurosyphilis, Ocular syphilis or Otosyphilis\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Consult Infectious Disease for treatment\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines MMWR (2021) 70.4\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Mandell Chapter: Syphilis (Treponema pallidum)\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Sanford keyword: Syphilis\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Up-To-Date article: Syphilis: Screening and diagnostic testing\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Up-To-Date article: Syphilis: Treatment and monitoring\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 720,
    "fields": {
      "name": "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Td/Tdap 3 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TETANUS/DIPHTHERIA VACCINE ONE DOSE\", \"Text\": \"Td\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE\", \"Text\": \"Tdap\", \"Mnemonic\": \"6\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM (Td and Tdap)\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient orders:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"CPRS names:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"TETANUS/DIPHTERIA VACCINE\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"INJ (Td)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"DIPHTHERIA/TETANUS/\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"PERTUSSIS VACCINE INJ,SUSP\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(Tdap)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Tenivac (Td)\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Boostrix (Tdap)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Tetanus, diphtheria and\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"acellular pertussis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"(Td, Tdap)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*All people who lack\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"written documentation of a\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"primary series consisting\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"of at least 3 doses of\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"tetanus- and diphtheria-\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"toxoid-containing vaccine.\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"*A booster dose of Td or\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Tdap may be needed for\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"wound management, so\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"consult ACIP\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"recommendations.\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"*Adults who have not\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"received Td or Tdap in the\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"past 10 years or whose\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Tdap history is not known.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*For people who are\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"unvaccinated or behind,\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"complete a 3-dose series\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"with Tdap as the first\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"dose, followed by Td or\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"Tdap (observe intervals of\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"1-2m between dose  1 and\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"2, and an interval of 6-\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"12m between dose  2 and\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"3).\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"*Give Tdap to pregnant\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"women during each\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"pregnancy (preferred\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"during the early part of\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"gestational weeks 27\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"through 36), regardless of\"}, {\"Row\": 21, \"Column\": 3, \"Text\": \"the interval since prior\"}, {\"Row\": 22, \"Column\": 3, \"Text\": \"Td or Tdap.\"}, {\"Row\": 24, \"Column\": 3, \"Text\": \"*Give Td or Tdap booster\"}, {\"Row\": 25, \"Column\": 3, \"Text\": \"every 10yrs after the\"}, {\"Row\": 26, \"Column\": 3, \"Text\": \"primary series has been\"}, {\"Row\": 27, \"Column\": 3, \"Text\": \"completed.\"}, {\"Row\": 29, \"Column\": 3, \"Text\": \"*If Tdap is indicated,\"}, {\"Row\": 30, \"Column\": 3, \"Text\": \"Tdap should be given\"}, {\"Row\": 31, \"Column\": 3, \"Text\": \"regardless of interval\"}, {\"Row\": 32, \"Column\": 3, \"Text\": \"since previous Td.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"*History of severe\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"allergic reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or to a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"*For Tdap only, history of\"}, {\"Row\": 12, \"Column\": 4, \"Text\": \"encephalopathy not\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"attributable to an\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"identifiable cause, within\"}, {\"Row\": 15, \"Column\": 4, \"Text\": \"7d following DTP/DTaP, or\"}, {\"Row\": 16, \"Column\": 4, \"Text\": \"Tdap.\"}, {\"Row\": 18, \"Column\": 4, \"Text\": \"Precautions\", \"Header\": 1}, {\"Row\": 19, \"Column\": 4, \"Text\": \"*Moderate or severe acute\"}, {\"Row\": 20, \"Column\": 4, \"Text\": \"illness with or without\"}, {\"Row\": 21, \"Column\": 4, \"Text\": \"fever.\"}, {\"Row\": 24, \"Column\": 4, \"Text\": \"syndrome within 6wks\"}, {\"Row\": 25, \"Column\": 4, \"Text\": \"following previous dose of\"}, {\"Row\": 26, \"Column\": 4, \"Text\": \"tetanus-toxoid containing\"}, {\"Row\": 27, \"Column\": 4, \"Text\": \"vaccine.\"}, {\"Row\": 29, \"Column\": 4, \"Text\": \"*History of Arthus-type\"}, {\"Row\": 30, \"Column\": 4, \"Text\": \"reaction following a prior\"}, {\"Row\": 31, \"Column\": 4, \"Text\": \"dose of tetanus or\"}, {\"Row\": 32, \"Column\": 4, \"Text\": \"diphtheria-toxoid\"}, {\"Row\": 33, \"Column\": 4, \"Text\": \"containing vaccine\"}, {\"Row\": 34, \"Column\": 4, \"Text\": \"(including MenACWY): defer\"}, {\"Row\": 35, \"Column\": 4, \"Text\": \"vaccination until at least\"}, {\"Row\": 36, \"Column\": 4, \"Text\": \"10yrs have elapsed since\"}, {\"Row\": 37, \"Column\": 4, \"Text\": \"the last tetanus toxoid-\"}, {\"Row\": 38, \"Column\": 4, \"Text\": \"containing vaccine.\"}, {\"Row\": 40, \"Column\": 4, \"Text\": \"*For pertussis-containing\"}, {\"Row\": 41, \"Column\": 4, \"Text\": \"vaccines only, progressive\"}, {\"Row\": 42, \"Column\": 4, \"Text\": \"or unstable neurologic\"}, {\"Row\": 43, \"Column\": 4, \"Text\": \"disorder, uncontrolled\"}, {\"Row\": 44, \"Column\": 4, \"Text\": \"seizures, or progressive\"}, {\"Row\": 45, \"Column\": 4, \"Text\": \"encephalopathy until a\"}, {\"Row\": 46, \"Column\": 4, \"Text\": \"treatment regimen has been\"}, {\"Row\": 47, \"Column\": 4, \"Text\": \"established and the\"}, {\"Row\": 48, \"Column\": 4, \"Text\": \"condition has stabilized.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Booster doses\"}, {\"Row\": 23, \"Column\": 4, \"Text\": \"*History of Guillain-Barre\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 721,
    "fields": {
      "name": "ORZID3 GMENU ABX TPOXX MONKEYPOX TREATMENT",
      "term": null,
      "displaytext": "TPOXX Monkeypox Treatment",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TPOXX SharePoint Link\", \"Text\": \"[CLICK HERE] for link to required documents (Monkeypox Taskforce Teams group)\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INV-Tecovirimat 600 mg (3 capsules) orally q12h for 14 days\", \"Text\": \"INV-Tecovirimat 600 mg (3 capsules) orally q12h for 14 days\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INV-Tecovirimat 600 mg (3 capsules) orally q8h for 14 days\", \"Text\": \"INV-Tecovirimat 600 mg (3 capsules) orally q8h for 14 days\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CDC MONKEYPOX TREATMENT WITH TPOXX\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Eligibility:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"o Consent: Must have documented consent by patient or legally authorized\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"representative in paper or i-Med consent\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"o Primary/empiric treatment: Confirmed diagnosis or suspected infection based\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"on exposure and/or symptoms while testing is pending.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"o Secondary Treatment: Complications from replication competent vaccinia\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infection from vaccination, secondary transmission, or other exposure. TPOXX may\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"be used after VIGIV treatment or in conjunction with VIGIV and/or with other\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"therapies based on clinical judgement.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"o Post-exposure prophylaxis (PEP): May be considered on a case-by-case basis in\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"consultation with the CDC. Eligibility for PEP use depends on high risk exposure\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"confirmed or probable case and alternative or complement to PEP vaccination\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"is needed based on clinical judgment (e.g. vaccine allergy, immunocompromise).\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"o Dosage and duration: Weight based dosing for 14 days. But it may be longer\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"based on clinical progress but not to exceed 90 days. Oral tecovirimat capsule\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"should be taken by mouth with a full glass of water within 30 minutes after\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"eating a full meal of moderate or high fat (ideally about 600 calories and 25\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"grams of fat).\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"o CDC Case Reports Forms:  To be completed and returned to CDC by treating\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"physicians per IND protocol.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Exclusions:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"o Patient or legally authorized representative unwilling to sign an informed\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"consent and refuse tecovirimat treatment\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"o  Known allergy to tecovirimat and/or excipients of tecovirimat\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"o  Upon negative test results for orthopoxvirus whose treatment was initiated\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"based on clinical manifestations prior to laboratory results.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"o For IV tecovirimat only: patients with severe renal impairment (creatinine\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"clearance <30 mL/min)\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Oral Treatment:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Patients 40kg to < 120 kg\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Patients 120 kg and Above\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Intravenous Treatment:\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"See Inpatient Antimicroibal CDSS for IV treatment recommendations.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 722,
    "fields": {
      "name": "ORZID3 GMENU ABX UPPER RESPIRATORY INFECTIONS OP (URI)",
      "term": null,
      "displaytext": "Upper Respiratory Infections (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 15, \"Column\": 1, \"Item\": 777, \"DisplayText\": \"Bronchitis/COPD Exacerbation\", \"Text\": \"Bronchitis\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 726, \"DisplayText\": \"ACUTE SINUSITIS\", \"Text\": \"Sinusitis\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 984, \"DisplayText\": \"Pharyngitis (Outpatient)\", \"Text\": \"Pharyngitis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"UPPER RESPIRATORY INFECTION (URI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Upper respiratory infections include several common syndromes including\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the common cold, bronchitis (see below), pharyngitis (see below) and sinusitis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(see below). Most are caused by viruses and there is no benefit from\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antimicrobial therapy. If a patient presents with a URI, consider specific\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infections that do respond to antimicrobial therapy like herpes simplex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"stomatitis, pertussis or thrush. If no condition that benefits from\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobial therapy is present, antimicrobials will almost certainly not help\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"but will likely select for antimicrobial resistance and may lead to other\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"adverse effects.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Kogawa et al, General medicine, 2009, 10:7-15\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 723,
    "fields": {
      "name": "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Varicella Vaccine Information Page",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VARICELLA VACCINE 2 DOSE SERIES\", \"Text\": \"2 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: Subcutaneous\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient VAR orders:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"VARICELLA VIRUS VACCINE\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"INJ\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Varivax\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Varicella\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(Chickenpox, VAR)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*All adults without\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"evidence of immunity.\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \"NOTE: Evidence of immunity\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"is defined as written\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"documentation\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"of 2 doses of varicella\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"vaccine, a history of\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"varicella disease or\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"herpes zoster (shingles)\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"based on healthcare-\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"provider diagnosis,\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"laboratory evidence of\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"immunity or confirmation\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"of disease, and/or birth\"}, {\"Row\": 18, \"Column\": 2, \"Text\": \"in the U.S. before 1980,\"}, {\"Row\": 19, \"Column\": 2, \"Text\": \"with the exceptions that\"}, {\"Row\": 20, \"Column\": 2, \"Text\": \"follow:\"}, {\"Row\": 21, \"Column\": 2, \"Text\": \">>Healthcare personnel\"}, {\"Row\": 22, \"Column\": 2, \"Text\": \"(HCP) born in the U.S.\"}, {\"Row\": 23, \"Column\": 2, \"Text\": \"before 1980 who do not\"}, {\"Row\": 24, \"Column\": 2, \"Text\": \"meet any of the criteria\"}, {\"Row\": 25, \"Column\": 2, \"Text\": \"above should be tested or\"}, {\"Row\": 26, \"Column\": 2, \"Text\": \"given the 2-dose vaccine\"}, {\"Row\": 27, \"Column\": 2, \"Text\": \"series. If testing\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"indicates they are not\"}, {\"Row\": 29, \"Column\": 2, \"Text\": \"immune, give the 1st dose\"}, {\"Row\": 30, \"Column\": 2, \"Text\": \"of varicella vaccine\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"immediately. Give the 2nd\"}, {\"Row\": 32, \"Column\": 2, \"Text\": \"dose 4-8 wks later.\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \">>Pregnant women born in\"}, {\"Row\": 34, \"Column\": 2, \"Text\": \"the U.S. before 1980 who\"}, {\"Row\": 35, \"Column\": 2, \"Text\": \"do not meet any of the\"}, {\"Row\": 36, \"Column\": 2, \"Text\": \"criteria above should\"}, {\"Row\": 37, \"Column\": 2, \"Text\": \"either 1) be tested for\"}, {\"Row\": 38, \"Column\": 2, \"Text\": \"susceptibility during\"}, {\"Row\": 39, \"Column\": 2, \"Text\": \"pregnancy and if found\"}, {\"Row\": 40, \"Column\": 2, \"Text\": \"susceptible, given the 1st\"}, {\"Row\": 41, \"Column\": 2, \"Text\": \"dose of varicella vaccine\"}, {\"Row\": 42, \"Column\": 2, \"Text\": \"postpartum before hospital\"}, {\"Row\": 43, \"Column\": 2, \"Text\": \"discharge, or 2) not be\"}, {\"Row\": 44, \"Column\": 2, \"Text\": \"tested for susceptibility\"}, {\"Row\": 45, \"Column\": 2, \"Text\": \"and given the 1st dose of\"}, {\"Row\": 46, \"Column\": 2, \"Text\": \"varicella vaccine post-\"}, {\"Row\": 47, \"Column\": 2, \"Text\": \"partum before hospital\"}, {\"Row\": 48, \"Column\": 2, \"Text\": \"discharge. Give the 2nd\"}, {\"Row\": 49, \"Column\": 2, \"Text\": \"dose 4-8wks later.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 2 doses.\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"*Dose  2 is given 4-8wks\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"after dose  1.\"}, {\"Row\": 9, \"Column\": 3, \"Text\": \"*If dose  2 is delayed, do\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"not start over. Just give\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"dose  2.\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"*If 2 or more of the\"}, {\"Row\": 14, \"Column\": 3, \"Text\": \"following live virus\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"vaccines are to be given -\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"MMR, LAIV, Var, ZVL,\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"and/or yellow fever - they\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"should be given on the\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"same day. If they are not\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"given on the same day,\"}, {\"Row\": 21, \"Column\": 3, \"Text\": \"space them by at least 28d\"}, {\"Row\": 22, \"Column\": 3, \"Text\": \"(30d for yellow fever).\"}, {\"Row\": 24, \"Column\": 3, \"Text\": \"*May use as post exposure\"}, {\"Row\": 25, \"Column\": 3, \"Text\": \"prophylaxis if given\"}, {\"Row\": 26, \"Column\": 3, \"Text\": \"within 5d of exposure.\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"*History of severe\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"allergic reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or to a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"*Pregnancy or possibility\"}, {\"Row\": 12, \"Column\": 4, \"Text\": \"of pregnancy within 4wks.\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"*People on long-term\"}, {\"Row\": 15, \"Column\": 4, \"Text\": \"immunosuppressive therapy\"}, {\"Row\": 16, \"Column\": 4, \"Text\": \"or who are\"}, {\"Row\": 17, \"Column\": 4, \"Text\": \"immunocompromised\"}, {\"Row\": 18, \"Column\": 4, \"Text\": \"because of malignancy and\"}, {\"Row\": 19, \"Column\": 4, \"Text\": \"primary or acquired\"}, {\"Row\": 20, \"Column\": 4, \"Text\": \"immunodeficiency,\"}, {\"Row\": 21, \"Column\": 4, \"Text\": \"including HIV/AIDS\"}, {\"Row\": 22, \"Column\": 4, \"Text\": \"(although vaccination\"}, {\"Row\": 23, \"Column\": 4, \"Text\": \"may be considered if CD4+\"}, {\"Row\": 24, \"Column\": 4, \"Text\": \"T-lymphocyte counts are\"}, {\"Row\": 25, \"Column\": 4, \"Text\": \"greater than or equal to\"}, {\"Row\": 26, \"Column\": 4, \"Text\": \"200 cells/mm3)\"}, {\"Row\": 28, \"Column\": 4, \"Text\": \"*People with isolated B-\"}, {\"Row\": 29, \"Column\": 4, \"Text\": \"lymphocyte deficiency may\"}, {\"Row\": 30, \"Column\": 4, \"Text\": \"receive varicella vaccine.\"}, {\"Row\": 32, \"Column\": 4, \"Text\": \"Precautions:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 4, \"Text\": \"*Moderate or severe acute\"}, {\"Row\": 34, \"Column\": 4, \"Text\": \"illness with or without\"}, {\"Row\": 35, \"Column\": 4, \"Text\": \"fever.\"}, {\"Row\": 37, \"Column\": 4, \"Text\": \"*If blood, plasma, and/or\"}, {\"Row\": 38, \"Column\": 4, \"Text\": \"immune globulin (IG or\"}, {\"Row\": 39, \"Column\": 4, \"Text\": \"VZIG) were given in past\"}, {\"Row\": 40, \"Column\": 4, \"Text\": \"11m, see ACIP's Best\"}, {\"Row\": 41, \"Column\": 4, \"Text\": \"Practices Guidance\"}, {\"Row\": 42, \"Column\": 4, \"Text\": \"regarding time to wait\"}, {\"Row\": 43, \"Column\": 4, \"Text\": \"before vaccinating.\"}, {\"Row\": 45, \"Column\": 4, \"Text\": \"*Receipt of specific\"}, {\"Row\": 46, \"Column\": 4, \"Text\": \"antivirals (i.e.,\"}, {\"Row\": 47, \"Column\": 4, \"Text\": \"acyclovir, famciclovir, or\"}, {\"Row\": 48, \"Column\": 4, \"Text\": \"valacyclovir) 24hrs before\"}, {\"Row\": 49, \"Column\": 4, \"Text\": \"vaccination, if possible.\"}, {\"Row\": 50, \"Column\": 4, \"Text\": \"Delay resumption of these\"}, {\"Row\": 51, \"Column\": 4, \"Text\": \"antiviral drugs for 14d\"}, {\"Row\": 52, \"Column\": 4, \"Text\": \"after vaccination.\"}, {\"Row\": 54, \"Column\": 4, \"Text\": \"*Use of aspirin or\"}, {\"Row\": 55, \"Column\": 4, \"Text\": \"aspirin-containing\"}, {\"Row\": 56, \"Column\": 4, \"Text\": \"products.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 724,
    "fields": {
      "name": "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE",
      "term": null,
      "displaytext": "Zoster (shingles) Information Page",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"2 dose series\", \"Mnemonic\": \"2\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Vaccine route, orders, names\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Route: IM\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Outpatient RZV (Shingrix)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Orders:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"CPRS name:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"ZOSTER VACCINE INJ,LYPHL\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Stocked brand name:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Shingrix\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Other names:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Zoster, Shingles\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(RZV)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Immunization Action\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Coalition,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Summary of Adult\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Immunizations, 2021, P2011\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Freedman et al., Annals of\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"internal medicine, 2021,\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"174(3)374-384.\"}, {\"Row\": 1, \"Column\": 2, \"Text\": \"Recommended populations\", \"Header\": 1}, {\"Row\": 2, \"Column\": 2, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Text\": \"*People age 50yrs and\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"older\"}, {\"Row\": 6, \"Column\": 2, \"Text\": \">>NOTE: Do not test people\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"age 50yrs or older for\"}, {\"Row\": 8, \"Column\": 2, \"Text\": \"varicella immunity prior\"}, {\"Row\": 9, \"Column\": 2, \"Text\": \"to zoster vaccination.\"}, {\"Row\": 10, \"Column\": 2, \"Text\": \"Persons born in the U.S.\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"prior to 1980 can be\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"presumed to be immune to\"}, {\"Row\": 13, \"Column\": 2, \"Text\": \"varicella for the purpose\"}, {\"Row\": 14, \"Column\": 2, \"Text\": \"of zoster vaccination,\"}, {\"Row\": 15, \"Column\": 2, \"Text\": \"regardless of their\"}, {\"Row\": 16, \"Column\": 2, \"Text\": \"recollection of having had\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"chickenpox.\"}, {\"Row\": 1, \"Column\": 3, \"Text\": \"Administration Schedule\", \"Header\": 1}, {\"Row\": 2, \"Column\": 3, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 3, \"Text\": \"*Give 2 doses of RZV,\"}, {\"Row\": 5, \"Column\": 3, \"Text\": \"separated by 2-6m,\"}, {\"Row\": 6, \"Column\": 3, \"Text\": \"regardless of previous\"}, {\"Row\": 7, \"Column\": 3, \"Text\": \"history of herpes zoster\"}, {\"Row\": 8, \"Column\": 3, \"Text\": \"(shingles) or chickenpox.\"}, {\"Row\": 10, \"Column\": 3, \"Text\": \"*If previously vaccinated\"}, {\"Row\": 11, \"Column\": 3, \"Text\": \"with ZVL (Zostavax), give\"}, {\"Row\": 12, \"Column\": 3, \"Text\": \"2 doses of RZV at least 2m\"}, {\"Row\": 13, \"Column\": 3, \"Text\": \"after ZVL.\"}, {\"Row\": 15, \"Column\": 3, \"Text\": \"*A 1-time dose of ZVL may\"}, {\"Row\": 16, \"Column\": 3, \"Text\": \"be given to previously\"}, {\"Row\": 17, \"Column\": 3, \"Text\": \"unvaccinated\"}, {\"Row\": 18, \"Column\": 3, \"Text\": \"immunocompetent adults age\"}, {\"Row\": 19, \"Column\": 3, \"Text\": \"60y and older: however,\"}, {\"Row\": 20, \"Column\": 3, \"Text\": \"RZV is preferred.\"}, {\"Row\": 22, \"Column\": 3, \"Text\": \"*If 2 or more of the\"}, {\"Row\": 23, \"Column\": 3, \"Text\": \"following live virus\"}, {\"Row\": 24, \"Column\": 3, \"Text\": \"vaccines are to be given -\"}, {\"Row\": 25, \"Column\": 3, \"Text\": \"LAIV, MMR, Var, ZVL,\"}, {\"Row\": 26, \"Column\": 3, \"Text\": \"and/or yellow fever - they\"}, {\"Row\": 27, \"Column\": 3, \"Text\": \"should be given on the\"}, {\"Row\": 28, \"Column\": 3, \"Text\": \"same day. If they are not,\"}, {\"Row\": 29, \"Column\": 3, \"Text\": \"space them by at least 28d\"}, {\"Row\": 30, \"Column\": 3, \"Text\": \"(30d for yellow fever).\"}, {\"Row\": 1, \"Column\": 4, \"Text\": \"Contraindications/Precautions\", \"Header\": 1}, {\"Row\": 2, \"Column\": 4, \"Text\": \"__________________________\", \"Header\": 1}, {\"Row\": 4, \"Column\": 4, \"Text\": \"Contraindications\", \"Header\": 1}, {\"Row\": 5, \"Column\": 4, \"Text\": \"*History of severe\"}, {\"Row\": 6, \"Column\": 4, \"Text\": \"allergic reaction (e.g.,\"}, {\"Row\": 7, \"Column\": 4, \"Text\": \"anaphylaxis) to a previous\"}, {\"Row\": 8, \"Column\": 4, \"Text\": \"dose or to a vaccine\"}, {\"Row\": 9, \"Column\": 4, \"Text\": \"component.\"}, {\"Row\": 11, \"Column\": 4, \"Text\": \"Precautions\", \"Header\": 1}, {\"Row\": 12, \"Column\": 4, \"Text\": \"*Moderate or severe acute\"}, {\"Row\": 13, \"Column\": 4, \"Text\": \"illness with or without\"}, {\"Row\": 14, \"Column\": 4, \"Text\": \"fever.\"}, {\"Row\": 16, \"Column\": 4, \"Text\": \"*Consider delaying\"}, {\"Row\": 17, \"Column\": 4, \"Text\": \"vaccination in pregnant\"}, {\"Row\": 18, \"Column\": 4, \"Text\": \"or lactating women\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 725,
    "fields": {
      "name": "ORZID3 GMENU ACUTE BACT PROSTATITIS",
      "term": null,
      "displaytext": "Acute bacterial prostatitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"6a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) (Non-VA) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1gm IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"8a\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1gm IM x 1 ($) (Non-VA) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 14 days\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE BACTERIAL PROSTATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute bacterial prostatitis typically presents with fever, dysuria, chills,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"malaise, myalgia, pelvic or perianal pain. On exam, the prostate gland is tense,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"boggy, and extremely tender. The urinalysis reveals pyuria, and the urine\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"culture is positive. Men with dysuria and fever but without pyuria and/or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bacteriuria should be seen by a urologist. If there is any suspicion of abscess,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"especially in men older than 40 years, the patient should be seen by a urologist\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and transurethral prostate resection for drainage should be considered.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Most cases in men aged 35 and older, those with recent urinary tract\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with enteric Gram-negative rods. Most cases in men under age 35 and those who\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"are at high risk of sexually transmitted infections are associated with N.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"gonorrhoeae and C. trachomatis. Resistant organisms are more likely if the\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"patient has been in the hospital for more than 48 hours or received a course of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"antibiotics. There is increasing resistance in urinary pathogens to\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"ciprofloxacin.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"A urine Gram stain and culture should be performed in all patients to guide\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"antimicrobial therapy:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"There is limited data on duration of antimicrobial treatment for prostatitis. 14\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"days minimum is required. 4 to 6 weeks may be necessary to completely eradicate\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"bacteria in the prostate to ensure patient does not progress to chronic\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"bacterial prostatitis.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"_____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Hydration, bed rest and analgesics are recommended along with antimicrobials\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Age < 35 years and those at high risk of sexually transmitted infections\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Patient weighing less than 300 lbs:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"14 days\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Patients weighing 300 lbs or greater:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"14 days\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Age >/= 35 years\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Mandell chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Sanford keyword: Prostatitis\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute Bacterial Prostatitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 726,
    "fields": {
      "name": "ORZID3 GMENU ACUTE SINUSITIS (OPT)",
      "term": null,
      "displaytext": "ACUTE SINUSITIS ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 727, \"DisplayText\": \"Acute sinusitis--mild to moderate disease (Outpatient)\", \"Text\": \"[CLICK HERE] for treatment of mild to moderate bacterial sinusitis\", \"Mnemonic\": \"4\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 728, \"DisplayText\": \"Acute sinusitis--Severe disease (Outpatient)\", \"Text\": \"[CLICK HERE] for treatment of severe bacterial sinusitis\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"treated with decongestants, analgesics, and nasal saline. Diagnosis of acute\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sinusitis is based on the presence of at least 2 major or 1 major and at least 2\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"minor symptoms.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Major Symptoms\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"1. Purulent anterior nasal discharge\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"2. Purulent or discolored posterior nasal discharge\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"3. Nasal congestion or fullness\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"4. Facial pain or pressure\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"5. Hyposmia or anosmia\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"6. Fever\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Minor Symptoms\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"1. Headache\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"2. Ear pain, pressure or fullness\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"3. Halitosis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"4. Dental pain\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"5. Cough\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"6. Fatigue\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"If patient meets criteria above for acute sinusitis, treat with antimicrobials\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"according to the following criteria for mild to moderate or severe bacterial\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"sinusitis.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mild to moderate bacterial sinusitis\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1. Symptoms persisting beyond 10 days\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"2. Double-sickening - Symptoms typical of viral upper respiratory infection\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"initially improving for 5-6 days then worsening with new development of fever,\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"headache or increased nasal discharge.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Severe bacterial sinusitis\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"pain lasting for at least 3-4 consecutive days at the beginning of illness.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 727,
    "fields": {
      "name": "ORZID3 GMENU ACUTE SINUSITIS MILD TO MOD",
      "term": null,
      "displaytext": "Acute sinusitis--mild to moderate disease (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 738, \"DisplayText\": \"Acute Respiratory Infection (ARI) Symptomatic Therapy\", \"Text\": \"[CLICK HERE] to go to acute respiratory infection symptomatic treatment menu\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 5 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R,DI] for 7 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MILD TO MODERATE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Community-acquired bacterial sinusitis is most often due to Streptococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. Streptococci,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Staphylococcus aureus and anaerobes are isolated less frequently.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment for first 10 days of illness\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat with decongestants, analgesics, and nasal saline spray.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment of cases that have not improved in 10 days despite\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treatment with decongestants, analgesics, and nasal saline.\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment Failure\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"If symptoms worsen despite 72 hours or  fail to improve after 3-5 days of\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"initial empirical antimicrobial therapy, broaden coverage, switch to different\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"antimicrobial class and treat 7-10 days. If symptoms continue to worsen or there\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"is no improvement after 3-5 more days of treatment, obtain CT to investigate\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"non-infectious or suppurative causes. ENT consultation is recommended. If\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"sinuses are aspirated, specimens should be cultured.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"7\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 728,
    "fields": {
      "name": "ORZID3 GMENU ACUTE SINUSITIS SEVERE",
      "term": null,
      "displaytext": "Acute sinusitis--Severe disease (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"4a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID  ($) [DI] for 10 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEVERE SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Community-acquired bacterial sinusitis is most often due to Streptococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For patients who present with severe symptoms (high fever (>/= 102 degrees\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"consecutive days or facial pain lasting for at least 3-4 consecutive days at the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"to determine the extent of infection. If the CT shows extension of sinusitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"infection into surrounding structures (i.e. the cranium or orbit) consult ENT\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"immediately. Closely monitor all patients who present with severe signs and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"symptoms to ensure that signs and symptoms improve within 72 hours.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Outpatient Treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Treatment of hospitalized patient\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Treatment failure\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"If symptoms worsen or no improvement is seen after 3-5 days of treatment,\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"broaden coverage, switch to different antimicrobial class and treat 10 days. If\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"symptoms continue to worsen or there is no improvement after 3-5 more days of\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"treatment, obtain CT to investigate non-infectious or suppurative causes. ENT\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"consultation is recommended. If sinuses are aspirated, specimens should be\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"cultured.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Acute, Empiric Therapy\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Chronic\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Up-To-Date article: Microbiology and antibiotic management of chronic\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"rhinosinusitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 729,
    "fields": {
      "name": "ORZID3 GMENU ACUTE SPON BACT PERITONITIS",
      "term": null,
      "displaytext": "Spontaneous Bacterial Peritonitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO QDAY ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 ds tablet po qday for 90 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg po qday ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO QDAY ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg po qday ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SPONTANEOUS BACTERIAL PERITONITIS (SBP)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"SBP is infection of the peritoneal cavity in the absence of apparent trauma or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"other obvious cause. SBP occurs primarily in people with end-stage liver disease\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"are isolated.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Long-term SBP prophylaxis is indicated for patients who experience a first\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"episode of SBP. Short-term SBP prophylaxis is indicated for patients with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"variceal bleeding, or for patients who have low-protein refractory ascites (<1\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with low-protein refractory ascites. Consult Gastroenterology for more\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Acute SBP\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Prophylaxis in a patient with a previous SBP episode\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Prophylaxis in a patient with cirrhosis and variceal hemorrhage\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Prophylaxis for hospitalized patients with refractory low-protein ascites\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"(less than 1 gm/dL peritoneal fluid)\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Peritonitis and Intraperitoneal Abscesses\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"prophylaxis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 730,
    "fields": {
      "name": "ORZID3 GMENU ANTIVIRAL IMMUNOSUPPRESIVE MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 MG po bid ($0.40/day) [R]\", \"Text\": \"Acyclovir 800 MG PO BID ($0.40/day) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 MG po bid ($0.40/day) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 MG po bid ($0.40/day) [R]\", \"Text\": \"Acyclovir 800 MG PO BID ($0.40/day) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 MG po bid ($0.40/day) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Severly Immunosuppressive Chemo-immunotherapy\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Purine Analogues\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Chemotherapy with purine analogues such as fludarabine, cladribine, or\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pentostatin results in major cellular-immunodeficiency that may outlast the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"exposure by months and enhances the risk for viral infections.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Recommend antiviral prophylaxis for patients treated with purine analogues\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"if at least one of the following risk factors is present:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"a) Second-line chemotherapy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"b) Treatment with corticosteroids\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"c) CD4 cell count <50/ul\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"d) Age >65 years\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"e) Prolonged Mild or Moderate Neutropenia: Mild<1000 Neutrophils /\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"\\ufffdL (Grade III neutropenia) OR Moderate: <500 Neutrophils/\\ufffdL\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(Grade IV neutropenia)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Duration: Antiviral prophylaxis should be initiated in the first week of\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"therapy and continued until 2 months after completion of therapy.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alemtuzumab Therapy:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alemtuzumab is a potent reactivator of latent intracellular pathogens,\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"including CMV. Chemotherapy with alemtuzumab results in major cellular-\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"immunodeficiency that may outlast the exposure by months and enhances the\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"risk for viral infections. The risk of viral disease increases with the\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"intensity and duration of functional T-cell suppression experienced with\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"recipients of alemtuzumab.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Duration: Initiate antiviral prophylaxis with alemtuzumab therapy and\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"continue therapy for at least 2 months after last dose or until CD4 counts\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"are greater than or equal to 200 cells/ul, whichever is later.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date (accessed 6-10-12)\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 731,
    "fields": {
      "name": "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 730, \"DisplayText\": \"\", \"Text\": \"Select for recommendations for antiviral prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 912, \"DisplayText\": \"Influenza Seasonal 2021-2022\", \"Text\": \"Seasonal Influenza\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INFECTIOUS DISEASE (INPT)\", \"Text\": \"Consult Infectious Disease\", \"Mnemonic\": \"8\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"INFECTIOUS DISEASE (INPT)\", \"Text\": \"Consult Infectious Disease\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Prophylaxis for Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prophylaxis for Influenza and Other Respiratory Viruses\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Patients with active malignant disease are at higher risk for upper\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"respiratory infections due to influenza, parainfluenza or respiratory\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"syncytial virus (RSV). Although response to vaccination with the attenuate\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"influenza vaccine in patients on chemotherapy is variable, ranging\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"from 24-75%, immnunoprophylaxis with the influenza vaccine is recommended\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"patients with active malignant disease or chemotherapy, lymphoproliferative\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"disease, or multiple myeloma. In areas and seasons where influenza is\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"endemic, chemoprophylaxis can be considered in addition to vaccination in\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"exposed patients with a high risk of influenza complications.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Prophylaxis for Cytomegalovirus (CMV)\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Prophylaxis and monitoring for CMV reactivation is not recommended unless\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"patient has received an allogeneic HSCT. Usually the recommendations for\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"surveillance and prophylaxis of CMV infections from the institution\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"performing the HSCT will be followed.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Prophylaxis for Chronic Hepatitis B\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Reactivation of chronic hepatitis B in patients undergoing immunosuppressive\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"or antineoplastic treatment is a severe complication. Patients with positive\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"HBsAg, chronic hepatitis B infection, or a previous episode of HBV\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"reactivation who will receive immunosuppressive therapy should receive\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"prophylaxis.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Recommend routine testing for Hepatitis B prior to initiating Rituximab\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"therapy in patients.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Recommendations:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sandherr, M et al, Annals of Oncology 17: 1051-1059, 2006\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 732,
    "fields": {
      "name": "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 735, \"DisplayText\": \"\", \"Text\": \"Solid Tumors, Acute Leukemia, or Lymphoma\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 730, \"DisplayText\": \"\", \"Text\": \"Purine analogues or Alemtuzumab\", \"Mnemonic\": \"6\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 733, \"DisplayText\": \"\", \"Text\": \"Stem cell transplant recipients (autologous or allogeneic)\", \"Mnemonic\": \"8\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 305, \"DisplayText\": \"\", \"Text\": \"Rituximab Therapy\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 731, \"DisplayText\": \"\", \"Text\": \"Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)\", \"Mnemonic\": \"12\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 731, \"DisplayText\": \"\", \"Text\": \"Influenza and Other Respiratory Viruses\", \"Mnemonic\": \"14\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 731, \"DisplayText\": \"\", \"Text\": \"Cytomegalovirus (CMV)\", \"Mnemonic\": \"16\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 731, \"DisplayText\": \"\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"18\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Viral infections reactivate in a small percentage of people with malignancy\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Most viral infections in patients with hematologic malignancies or solid\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"tumors result from reactivation of asymptomatic latent infections,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"predominantly of herpes viruses, including herpes simplex virus (HSV),\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"varicella zoster virus (VZV) and cytomegalovirus (CMV). Exogenous\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"respiratory tract infections caused by influenza, parainfluenza\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"or respiratory syncytial virus (RSV) are less common.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"The main risk factor for clinically relevant reactivation is profound\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"disruption of cellular immune response, usually due to chemotherapy.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"The duration and severity of neutropenia are of lesser importance.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"The risk of viral disease increases with the intensity and duration\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"of functional T-cell suppression. Patients receiving conventionally\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"dosed chemotherapy regimens for solid tumors experience no major\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"T-cell suppression and do not have a higher incidence of\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"invasive viral infections.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"This section is organized mainly by type of malignancy.\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"There are separate sections for purine analogues (fludarabine,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"cladribine, pentostatin), alemtuzumab and rituximab.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Select below for recommended antiviral prophylaxis:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"This section is organized by virus.\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Select below for recommended antiviral prophylaxis:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 733,
    "fields": {
      "name": "ORZID3 GMENU ANTIVIRAL STEM CELL MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 731, \"DisplayText\": \"\", \"Text\": \"Select for Hepatitis B recommendations\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Stem cell transplant recipients (autologous or allogeneic)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Usually the standard prophylaxis and monitoring strategies recommended\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"by the institution performing the stem cell transplant will be\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"followed.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consult Hematology-Oncology or Infectious Disease for recommendations.\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Rituximab Therapy\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Recommend routine testing for Hepatitis B prior to initiating treatment\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with Rituximab.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Vega, J et al, J Clin Oncol 26: 2008 (May 20 suppl, abstract 8558)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 734,
    "fields": {
      "name": "ORZID3 GMENU ANTIVIRAL TREATMENT",
      "term": null,
      "displaytext": "ANTIVIRAL TREATMENT OUTPATIENT ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oseltamivir 75 mg po bid for 5 days ($12/day) [R]\", \"Text\": \"Oseltamivir 75 mg po bid for 5 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oseltamivir 75 mg po bid for 5 days ($12/day) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Antiviral Therapy Recommendations:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Who to Treat:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"The decision to treat should be based on clinical symptoms and/or presence of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"a high risk condition, and should NOT be delayed until laboratory test\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"results are available.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"It is important to use antiviral drugs early to treat influenza in people who\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"are very sick with influenza (for example hospitalized people) and people who\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"are sick with influenza and have a greater chance of getting severe\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"complications. If a patient is not in a high-risk group or is not hospitalized,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"healthcare providers should use clinical judgment to guide treatment decisions.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"People who have a greater chance of serious influenza complications include:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"*Persons who have chronic pulmonary (including asthma) or cardiovascular\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"(except isolated hypertension), renal, hepatic, hematologic, metabolic\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"disorders (including diabetes mellitus), neurologic and\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"*Persons who are immunocompromised due to any cause (including immunosuppresion\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"caused by medications or by HIV infection)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*Persons younger than 19 years of age who are receiving long-term aspirin-\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"or salicylate-containing medications and who might be at risk for experiencing\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Reye syndrome after influenza virus infection\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"*Residents of nursing homes and other long-term care facilities\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*Persons who are extremely obese (BMI greater than or equal to 40)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Antiviral Treatment:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"If indicated, antivirals should be started as soon as possible.  Maximal\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"benefit occurs when started within 48 hours of symptom onset.  However,\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"antivirals should not be withheld if symptoms began more than 48 hours prior\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"and the patient meets criteria for treatment and remains severely ill.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treatment Dosing:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Zanamivir is not recommended for patients with chronic respiratory disease such\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"as asthma or chronic obstructive pulmonary disease. These patients may have\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"bronchospasm with zanamivir. If zanamivir must be used, and patients are using\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"an inhaled bronchodilator, zanamivir should be taken just after the\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"bronchodilator.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Recommended:\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Requires Infectious Disease Approval\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Zanamivir 2 inhalations (2 x 5 mg) BID for 5 days ($) [O]\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"*Adults aged 65 years and older\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"neuro-developmental disorders\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"patients wt <80kg ($$$) [DI]\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Alternative for patients unable to tolerate or absorb oral oseltamvir:\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Peramivir 600 mg IV once ($$$$$) [R]\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Requires Infectious Disease Approval\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Extending the duration of treatment for oseltamivir or peramivir may be\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"needed for those patients with prolonged illness or who are immunosuppressed.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"*Pregnant women and women up to 2 weeks after the end of pregnancy\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"*Non-Hispanic Black persons, Hispanic or Latino persons, and American Indian\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"or Alaska Native persons\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Centers for Disease Control (CDC) (Accessed 9/20/22)\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"https://www.cdc.gov/flu/professionals/antivirals/summary-clinician\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"UpToDate Seasonal influenza in adults: Treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 735,
    "fields": {
      "name": "ORZID3 GMENU ANTIVIRAL TYPE OF MALIGNANCY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Solid Tumors\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"No Antiviral Prophylaxis Recommended\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Solid tumors do not significantly compromise the cellular immune system.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Therefore, patients are at low risk for opportunistic viral infections.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Documented invasive viral infections are very rare. Coincidental\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"mucocutaneous infections by herpes simplex are easily treated and do not\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"result in life-threatening invasive infections. Reactivation of\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) is rarely observed.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Acute Leukemia\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"No Antiviral Prophylaxis Recommended\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"In patients with acute leukemia, treatment is highly aggressive and consists\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of a combination of various cytotoxic agents administered in sequential\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"cycles as induction, consolidation and maintenance therapy. Persistent, i.e.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \">10 days and profound neutropenia (<500 neutrophils) regularly occurs and\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"correlates with the risk of developing fever and infections. Almost all viral\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infections during neutropenia constitute reactivations of herpes viruses.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"None of the available studies demonstrated an effect of antiviral prophylaxis\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"on the initiation of antibiotic treatment, number of febrile days, duration\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"of antibiotic treatment, and onset of opportunistic infections. Therefore,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"recommendation for antiviral prophylaxis in patients with acute leukemia can\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"be given.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Lymphoma\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"No Antiviral Prophylaxis Recommended\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Rituximab is a monoclonal anti-CD-20 antibody used for treatment of\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"lymphomas. It leads to a profound depletion of circulating B-cells. B-cell\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"recover usually within 3-6 months after treatment. Prolonged administration\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"of rituximab (e.g., maintenance treatment >12 months) may result in a\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"significant decrease of levels of immunoglobulin M. Parvovirus B19 and JC-\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"papovavirus infections have been reported with maintenance rituximab therapy\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"but drugs that would prevent these infections are not available. There is\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"substantial increase in risk of reactivation of herpes viruses (including\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"HSV, VZV, and CMV).\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Recommend routine testing for Hepatitis B prior to initiating Rituximab\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"therapy in patients.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Cancer Patients\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date (accessed 6-10-11)\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 736,
    "fields": {
      "name": "ORZID3 GMENU APPENDICITIS W/ PERFORATION",
      "term": null,
      "displaytext": "Appendicitis with perforation (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPENDICITIS WITH PERFORATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 737,
    "fields": {
      "name": "ORZID3 GMENU APPENDICITIS W/O PERFORATION",
      "term": null,
      "displaytext": "Appendicitis without perforation (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"APPENDICITIS WITHOUT PERFORATION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 738,
    "fields": {
      "name": "ORZID3 GMENU ARI SYMPTOMATIC THERAPY",
      "term": null,
      "displaytext": "Acute Respiratory Infection (ARI) Symptomatic Therapy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"Acute Respiratory Infection (ARI) Symptomatic Therapy\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Per CDC: Antibiotics Aren't Always the Answer. Be Antibiotics Aware.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibiotics do not work on viruses, such as colds and flu, or runny noses,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"even if the mucus is thick, yellow or green. Antibiotics also won't help\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"some common bacterial infections including most cases of bronchitis, many\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sinus infections, and some ear infections. When antibiotics aren't needed,\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Antitussive Therapy:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Guaifenesin Dextromethorphan 10 ML PO q4h prn\", \"Mnemonic\": \"14a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Guaifenesin with Codeine 10 ML PO q4h prn\", \"Mnemonic\": \"16a\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Wheezing:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albuterol Oral Inhaler 2 PUFFS q6h PRN 25DS\", \"Mnemonic\": \"24a\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Pain and/or Fever:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acetaminophen 650 MG PO q6h prn\", \"Mnemonic\": \"26a\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ibuprofen 400 MG PO q6h prn\", \"Mnemonic\": \"28a\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Throat Pain:\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Nasal Congestion:\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pseudoephedrine 60 MG PO q6h prn\", \"Mnemonic\": \"48a\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Rhinorrhea and Sneezing:\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ipratropium nasal spray (0.06%) 2 sprays each nostril\", \"Mnemonic\": \"50a\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Rhinorrhea:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oxymetazoline 0.5% Nasal Spray 2 sprays each nostril twice daily prn up to 3days\", \"Mnemonic\": \"46a\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Saline nasal spray 2 sprays each nostril q1h prn\", \"Mnemonic\": \"44a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Throat lozenge q1h PRN\", \"Mnemonic\": \"32a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"they won't help you, and the side effects could still hurt you. Reactions\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"ARI: Symptom-based therapy represents the mainstay of treatment.\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cetirizine 10 MG PO qday prn\", \"Mnemonic\": \"52a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzonatate 100 MG PO tid prn\", \"Mnemonic\": \"18a\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"from antibiotics cause 1 out of 5 medication-related visits to ED.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Please select only one item from each symptom category patient experencing.\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 3099, \"DisplayText\": \"CDC website Antibiotics aren't always the Answer\", \"Text\": \"<Link> CDC Print Pamphlet-Antibiotics aren't always the answer\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Select links below to print educational material for patient:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Relief RX for viral infections\", \"Text\": \"<Link> CDC Print Pamphlet-Symptomatic RX for Acute Respiratory Infections\"}, {\"Row\": 2, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Contact the CDSS Team\", \"Mnemonic\": \"02\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Guaifenesin Dextromethorphan 10 ML PO q4h prn\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Guaifenesin with Codeine 10 ML PO q4h prn\", \"Text\": \"Non-VA for above (*Controlled Substance: Requires written prescription*)\", \"Mnemonic\": \"16b\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzonatate 100 MG PO tid prn\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albuterol Oral Inhaler 2 PUFFS q6h PRN 25DS\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"24b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acetaminophen 650 MG PO q6h prn\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"26b\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ibuprofen 400 MG PO q6h prn\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"28b\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Throat lozenge q1h PRN\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"32b\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Saline nasal spray 2 sprays each nostril q1h prn\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"44b\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cetirizine 10 MG PO qday prn\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"52b\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pseudoephedrine 60 MG PO q6h prn\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"48b\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ipratropium nasal spray (0.06%) 2 sprays each nostril\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"50b\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oxymetazoline 0.5% Nasal Spray 2 sprays each nostril twice daily p\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"46b\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"___________________________________________________________________\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 739,
    "fields": {
      "name": "ORZID3 GMENU ASPIRATION PNEUMONIA",
      "term": null,
      "displaytext": "Aspiration pneumonia (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 798, \"DisplayText\": \"Community acquired pneumonia (Outpatient)\", \"Text\": \"Community acquired pneumonia (CAP)  < OR >\", \"Mnemonic\": \"4\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 925, \"DisplayText\": \"Lung abscess (Outpatient)\", \"Text\": \"Lung abscess\", \"Mnemonic\": \"6\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ASPIRATION PNEUMONIA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Aspiration of oropharyngeal or gastric contents induces inflammation and is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"often accompanied by fever and/or an infiltrate.  Bacterial pneumonia occurs in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"a minority of patients who aspirate, typically about 3 days later.  The patient\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"usually improves for the first 2 days and then worsens as bacterial pneumonia\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"develops with increased fever, new or progressive infiltrates, leukocytosis, and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"newly purulent sputum.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobials have no role for treatment of aspiration and their use entails\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"risk of side effects and selection of resistant organisms.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobials used for community-acquired pneumonia are appropriate for cases\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"that develop after an episode of aspiration.  For more information, consult\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pulmonary or Infectious Diseases.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment for patients with pneumonitis but WITHOUT LUNG ABSCESS or putrid\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"sputum\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Therapy directed towards anaerobic pathogens is usually unnecessary.  If\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"pneumonia is confirmed, treat as\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Refer to Nosocomial Pneumonia in the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treament for patients WITH LUNG ABSCESS\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Chastre J JAMA 2003, 290:2588\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Kalil AC et al Clin Infect Dis 2016, 63:1\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Luna CM  Crit Care Med 2003, 31: 676\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious Diseases\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell LA Clin Infect Dis 2003,37:1405\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Roig J  J Antimicrob Chemother 2003, 51: 1119\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 740,
    "fields": {
      "name": "ORZID3 GMENU ASYMP BACTERIURIA",
      "term": null,
      "displaytext": "Asymptomatic bacteriuria (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl >30 mL/min, for 5 days\", \"Mnemonic\": \"4a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"6\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO bid ($) [R]\", \"Text\": \"Cefadroxil 1000 mg q12h ($) [R] for 5 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 610, \"DisplayText\": \"Urological procedures\", \"Text\": \"Antimicrobial prophylaxis for urological procedures\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ASYMPTOMATIC BACTERIURIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Asymptomatic bacteriuria is common in women and elderly people, especially in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"those with chronic medical problems (e.g., diabetes, spinal cord injury,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"institutionalized patients, catheterized patients). Most patients have no\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"adverse outcomes and receive no benefit from treatment of asymptomatic\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bacteriuria.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Patients who have no symptoms of cystitis (i.e., no dysuria, pain, urgency)\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"should not be treated. The presence of pyuria (>7 wbc/hpf) or positive leukocyte\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"esterase, urine nitrate, or urine bacteria is not a sufficient indication for\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antibiotic treatment. Screening and treatment of asymptomatic bacteriuria is\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"indicated for pregnant women and patients who will have urological procedures\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"and may be indicated in patients < 1-month post-renal transplant. If an\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"indwelling catheter is in place and can be removed safely, it should be done as\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"the bacteriuria may clear.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Bacteriuria in pregnant women is associated with pyelonephritis, premature\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"delivery, and lower birth weight. Screening for bacteriuria is recommended at\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"least once early in pregnancy. If bacteriuria is not found upon initial testing,\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"further screening cultures are not needed. If bacteriuria (>10,000 CFU/mL) is\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"present, the patient should be treated. Testing should be repeated throughout\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"the pregnancy to detect recurrences.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Pregnant women, empirical treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Patients having urological procedures\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Renal transplant recipients < 1 month after transplant\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Screening and treatment of asymptomatic bacteriuria may be indicated. Consult\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"nephrology for recommendations.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary Tract Infections\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Nicolle et al., Clinical Infectious Diseases, 2019, 2.68(10)e83-e110\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Sanford keyword: Bacteriuria, Asymptomatic\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-To-Date article: Urinary tract infections and asymptomatic bacteriuria in\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"pregnancy\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Up-To-Date article: Approach to the adult with asymptomatic bacteriuria\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Up-To-Date article: Kidney transplantation in adults: Urinary tract infection in\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"kidney transplant recipients\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"US Preventive Services Task Force, JAMA, 2019, 322(12)1188-1194\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 741,
    "fields": {
      "name": "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 3100, \"DisplayText\": \"RESOURCE QTC PROLONGATION FOR DRUGS\", \"Text\": \"Please Click Here for Resource for Drugs that Cause QTc Prolongation\", \"Mnemonic\": \"4\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"COPD Orders...\", \"Text\": \"COPD OUTPATIENT GUIDELINES\", \"Mnemonic\": \"6\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 250 mg po daily COPD prophylaxis ($1/day) [M]\", \"Text\": \"Azithromycin 250 mg po daily for COPD prophylaxis ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 250 mg po daily COPD prophylaxis ($1/day) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Azithromycin for Prevention of Exacerbations in Advanced COPD\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Daily azithromycin prevents chronic obstructive pulmonary disease (COPD)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"exacerbations in people with advanced COPD (Albert et al, see below).\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Of note, in the study there was no benefit in the most severely ill\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"subgroup that was on the most pulmonary medications.  People\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with frequent exacerbations have more doctor visits and hospitalizations then\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"people with fewer or no exacerbations.  Frequent exacerbations are associated\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"with rapid decline in lung function and quality of life and increased risk\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"death.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"To receive daily azithromycin, patients must meet the following criteria and\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"receive approval from pulmonary service.  The evidence that benefits of daily\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"azithromycin outweigh risks is limited to people who meet the following\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"criteria.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Eligibility Criteria:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"*Age >40 years\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"*Clinical diagnosis of COPD (>= 10 pack-years cigarette smoking, a ratio of\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"postbronchodilator forced expiratory volume in 1 second [FEV1] to forced\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"vital capacity of <70%, and a postbronchodilator FEV1 of <80% of the\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"predicted value), *AND*\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"*Were either using continuous supplemental oxygen or had received systemic\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"glucocorticoids within the previous year, *OR*\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"*Had gone to an emergency room or had been hospitalized for an acute\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"exacerbation of COPD.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Exclusion criteria:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"*Asthma\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"*People with hearing impairments\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"*Congestive Heart Failure\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"*Resting heart rate > 100 beats per minute\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"*Use of medications that are associated with torsades de pointes (with the\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"exception of amiodarone)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"*Prolonged QTc interval (>450 msec)\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"*Use of medications that prolong the QTc interval\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"If, after trying all of the standard treatments, patients are still having\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"acute exacerbations of COPD, long-term antibiotic treatment with Azithromycin\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"may be considered.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Note: Guidelines for COPD can be found on the CPRS Tools Menu.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Select below for Outpatient COPD order sets for comprehensive management:\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"If the patient meets the criteria and is willing to have audiometric testing\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"and an electrocardiogram, please place a Pulmonary Consult for long-term\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Azithromycin therapy for the prevention of exacerbations of COPD.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Pulmonary is the only approved provider for ordering long-term\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Azithromycin therapy for COPD.\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Albert, RK, et al, Azithromycin for Prevention of Exacerbations of COPD.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"England Journal of Medicine 2011, 365:689-698\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Ray, WA, et al, Azithromycin and the Risk of Cardiovascular Death.  New\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"England Journal of Medicine 2012: 366:1881-1890\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 742,
    "fields": {
      "name": "ORZID3 GMENU BACTEREMIA",
      "term": null,
      "displaytext": "Bacteremia (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEREMIA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 743,
    "fields": {
      "name": "ORZID3 GMENU BACTERIAL VAGINOSIS",
      "term": null,
      "displaytext": "Bacterial vaginosis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days\", \"Text\": \"Metronidazole 500 mg PO q12h ($) [DI] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Metronidazole vaginal gel 0.75%, contents of 1 applicator intravaginally qhs ($)\", \"Mnemonic\": \"8a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po bid for 7 days\", \"Text\": \"Clindamycin 300 mg PO q12h ($) [H,O] for 7 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin phosphate vaginal cream 5 gram (contents of 1 applicator)\", \"Text\": \"Clindamycin phosphate vaginal cream 2%, contents of 1 applicator\", \"Mnemonic\": \"12a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin phosphate vaginal cream 5 gram (contents of 1 applic Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTERIAL VAGINOSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Vaginitis usually presents with discharge, itching, irritation, odor, or pain.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Bacterial vaginosis is the most common form of vaginitis. Normal hydrogen\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"peroxide and lactic acid producing vaginal flora, including Lactobacillus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"species, is reduced and high concentrations of anaerobic bacterial pathogens are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"present. Pathogenic bacteria commonly include Gardnerella vaginalis, Mycoplasma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"hominis, Nobiluncus, Prevotella and other Gram-negative anaerobes.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Vaginal pH should be measured, and the specimen should be examined under the\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"microscope for identification of clue cells (epithelial cell coated with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"bacteria). In bacterial vaginosis the vaginal pH is high (> 4.5), the discharge\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"is homogenous and gray-white, and the specimen has a positive amine or whiff\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"test characterized by a fishy odor before or after addition of 10% KOH.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Bacterial vaginosis nucleic acid amplification tests are available for common\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"pathogens to aide in identification of pathogen(s).\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Bacterial vaginosis may be transmitted sexually. Patients at risk of sexually\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"transmitted infections should be assessed for treatment.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"[DI] for 5 days\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"intravaginally qhs ($) [H,O] for 7 days\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and cervicitis\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Sanford keyword: Bacterial Vaginosis\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacterial vaginosis: Clinical manifestations and diagnosis\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacterial Vaginosis: Treatment\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 744,
    "fields": {
      "name": "ORZID3 GMENU BED BUGS (HEMIPTERA)",
      "term": null,
      "displaytext": "Bed Bugs (Hemiptera) - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Triamcinolone 0.1% cream topical bid prn for 10 days\", \"Text\": \"Triamcinolone 0.1% cream apply to affected area BID PRN for itching ($)[M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Triamcinolone 0.1% cream topical bid prn for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Hydroxyzine pamoate 25mg po tid then 25mg po tid prn\", \"Text\": \"Hydroxyzine pamoate 25 mg PO TID until symptoms resolve, then take 25 mg PO\", \"Mnemonic\": \"6a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Hydroxyzine pamoate 25mg po tid then 25mg po tid prn Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BED BUGS (HEMIPTERA)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Antimicrobial treatment is not indicated.  Treat itching with topical\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"corticosteroids or systemic antihistamines.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"TID PRN for itching ($) [H]\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 745,
    "fields": {
      "name": "ORZID3 GMENU BELL PALSY",
      "term": null,
      "displaytext": "Bell's palsy (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Lyme Disease\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PRED 60MG QID PO 7D VALACYCLOVIR 1000MG PO Q8H 7D\", \"Text\": \"Prednisone 60 mg q24h PO for 7 days <AND> valacyclovir 1000 mg PO q8h ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PRED 60MG QID PO 7D VALACYC 1000MG PO Q8H 7D NON-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PRED 60MG QID PO 7D ACYCL 400MG PO 5X/DAY 10D\", \"Text\": \"Prednisone 60 mg q24h PO for 7 days <AND> acyclovir 400 mg PO 5X/day ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PRED 60MG QID PO 7D ACYCL 400MG PO 5X/DAY 10D NON-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BELL'S PALSY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Herpes simplex and varicella-zoster are possible causes of Bell's palsy. Others\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"include Borrelia burgdorferi trauma. Some cases are idiopathic. Risk factors for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Bell's Palsy include pregnancy, diabetes, obesity, hypertension, and upper\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"respiratory infections. Neurology consult is encouraged.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If Lyme disease is suspected, refer to the Lyme disease treatment page:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment with prednisone and an antiviral within 72 hours of symptoms onset\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"improves the chances of a complete recovery.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"for 7 days\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"for 10 days\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Baugh et al., Otolaryngology-Head and Neck Surgery, 2013, 149(3S)S1-S27\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Eviston et al., J Neurol Neurosurg Psychiatry, 2015, 56.1356-1361\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Jalali et al., Laryngoscope, 2021, 131.1615-1625\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Antivirals against Herpes Viruses\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes Simplex, Bell's Palsy\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Schwartz et al., Otolaryngology-Head and Neck Surgery, 2014, 150(5)709-711\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-To-Date article: Bell's palsy: Treatment and prognosis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 746,
    "fields": {
      "name": "ORZID3 GMENU BITE WNDS EIKENELLA CORRODENS",
      "term": null,
      "displaytext": "Bite wounds with Eikenella corrodens (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH EIKENELLA CORRODENS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 747,
    "fields": {
      "name": "ORZID3 GMENU BITE WNDS METH RES S. AUREUS",
      "term": null,
      "displaytext": "Bite wounds with Methicillin-resistant S. aureus (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]  < OR >\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 10 days\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]  < OR >\", \"Mnemonic\": \"8a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 14 days\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 748,
    "fields": {
      "name": "ORZID3 GMENU BITE WNDS METH SUSC S. AUREUS",
      "term": null,
      "displaytext": "Bite wounds with Methicillin-susceptible Staphylococcus aureus (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]  < OR >\", \"Mnemonic\": \"10a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treat for 14-21 days.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID x10days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 749,
    "fields": {
      "name": "ORZID3 GMENU BITE WNDS P. MULTOCIDA",
      "term": null,
      "displaytext": "Bite wounds with Pasteurella multocida (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100mg PO BID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH PASTEURELLA MULTOCIDA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 750,
    "fields": {
      "name": "ORZID3 GMENU BITE WNDS STREPTOCOCCI",
      "term": null,
      "displaytext": "Bite wounds with Streptococci (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS WITH STREPTOCOCCI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection but no arthritis - 10 days joint involved - 14-21 days\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment for infection without joint involvement\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for infection with joint involvement\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"__________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID x10days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"12\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days (Non-VA)_\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID for 10 days ($) [DI,O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg po q12h for 10 days ($) [DI,O]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 751,
    "fields": {
      "name": "ORZID3 GMENU BITE WOUNDS",
      "term": null,
      "displaytext": "Bite wounds (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Mnemonic\": \"4\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]\", \"Text\": \"Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 749, \"DisplayText\": \"Bite wounds with Pasteurella multocida (Outpatient)\", \"Text\": \"Pasteurella multocida\", \"Mnemonic\": \"14\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 746, \"DisplayText\": \"Bite wounds with Eikenella corrodens (Outpatient)\", \"Text\": \"Eikenella corrodens\", \"Mnemonic\": \"16\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 748, \"DisplayText\": \"Bite wounds with Methicillin-susceptible Staphylococcus aureus (Outpatient)\", \"Text\": \"Methicillin-susceptible Staphylococcus aureus\", \"Mnemonic\": \"18\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 747, \"DisplayText\": \"Bite wounds with Methicillin-resistant S. aureus (Outpatient)\", \"Text\": \"Methicillin-resistant Staphylococcus aureus\", \"Mnemonic\": \"20\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 750, \"DisplayText\": \"Bite wounds with Streptococci (Outpatient)\", \"Text\": \"Streptococci\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BITE WOUNDS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bite wounds are prone to infection because of the pathogenic oral flora carried\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into tissues  by teeth.  Common pathogens include Eikenella corrodens, usually\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"from human bites, and Pasteurella multocida, often from dog or cat bites\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"streptococci and staphylococci.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Clean wounds with soap and water as soon as possible, add local antiseptic\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and debride non-viable tissue.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Consult Orthopedic surgery for all bite wounds involving the hand.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Antibiotic Prophylaxis Indications:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Severe injury less than 8 hours, Crush injury, Bone or joint penetration,\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Wound of the face or hands or genitals, Immunocompromised host, Asplenia,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Advanced liver disease\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"*Routine use of prophylactic antibiotics for non-immunocompromised patients\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"with superficial wounds with no puncture that do not involve the face/\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"genitals/hands is not recommended.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antimicrobial Treatment:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Empiric treatment for suspected or established infection following bite wound\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"In these cases, therapy should be directed against pathogen indentified\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"by Gram stain and culture whenever possible.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Rabies Prophylaxis:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Consider rabies post-exposure prophylaxis for all animal bite cases.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Contact Infectious diseases for assistance.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Consider tetanus immunization status:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"If immunization is up to date, nothing more needs to be done to prevent tetanus.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"If immunization is lacking, and:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"wound IS NOT tetanus prone, bring immunization up to date with Td\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"wound IS tetanus prone, bring immunization up to date with Td  < AND >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Select below for Tetanus vaccination information page:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treat deep wounds for the first 3-5 days after a bite to prevent infection.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"For wounds that later develop evidence of infection but without arthritis, treat\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"with antimicrobials for 7-14.  For wounds that develop infection of a joint,\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"treat 14 to 21 days.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Prophylaxis:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Duration 3 to 5 days:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Alternative for patients with penicillin allergy:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Empiric treatment for suspected or estabished infection:\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Duration 7 to 14 days:\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Alternative for patients with penicllin allergy:\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Pathogen-directed bite wound therapy\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Sanford keyword:  Bites\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"Mandell Chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Abrahamian FM New Engl Journ Med 1999, 340:85\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 752,
    "fields": {
      "name": "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)",
      "term": null,
      "displaytext": "Body Lice (Pediculosis Corporis) - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion for 10 min\", \"Text\": \"Permethrin 1% lotion Apply to affected area for 10 minutes then comb out\", \"Mnemonic\": \"4a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion for 10 min Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BODY LICE (PEDICULOSIS CORPORIS)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Lice are parasitic insects. Human lice survive by feeding on human blood.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Body lice proliferate in places where crowding of persons with poor hygiene\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"common, especially homeless persons.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Infested clothing and bed linen should be heat washed or discarded.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Itching is the most common symptom, but some patients present only with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"excoriations and inflammation on the neck and trunk.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"A repeat application may be used if live lice are seen 7-10 days after\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"nits ($) [M]\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: lice\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 753,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW 2-1-5 RULE",
      "term": null,
      "displaytext": "24 Month Order Set ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Seronegative ONLY and 2-1-5 Rule\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Not until 2 years post HCT and\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \">1 year off all immunosuppressive therapy (IST) and\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"at leat 5 months since last dose of IVIG/VZIG or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"or most recent plasma transfusion.\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine 0.5ml ONCE\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Varicella Vaccine ONCE\", \"Mnemonic\": \"20\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 754,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW 2-1-5 RULE 2020",
      "term": "CREATED 08/21/2020 BY SR",
      "displaytext": "24 Month Order Set ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Seronegative ONLY and 2-1-5 Rule\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Not until 2 years post HCT and\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \">1 year off all immunosuppressive therapy (IST) and\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"at leat 5 months since last dose of IVIG/VZIG or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"or most recent plasma transfusion.\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine 0.5ml ONCE\", \"Mnemonic\": \"10\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and not on active treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 755,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW 2-1-5 RULE SEATTLE ALLO 2020",
      "term": "CREATED 08/21/2020 BY SR",
      "displaytext": "24 Month Order Set ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Seronegative ONLY and 2-1-5 Rule\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Not until 2 years post HCT and\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \">1 year off all immunosuppressive therapy (IST) and\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"at leat 5 months since last dose of IVIG/VZIG or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"or most recent plasma transfusion.\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine 0.5ml ONCE\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If chronic GVHD only\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pneumococcal 23 Vaccine (PPSV23) ONCE\", \"Mnemonic\": \"20\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 756,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW 5-1-5 RULE",
      "term": null,
      "displaytext": "60 Month Order Set ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \">50yo ONLY and Seropositive ONLY and 5-1-5 Rule\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Not until 5 years post HCT and\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \">1 year off all immunosuppressive therapy (IST) and\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"at leat 5 months since last dose of IVIG/VZIG or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"or most recent plasma transfusion.\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Zoster Vaccine ONCE\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 757,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW INFLUENZA",
      "term": null,
      "displaytext": "Influenza ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Place order to be given ONLY ONCE per flu season\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Influenza ONCE\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 758,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW LABS",
      "term": "created for heme/onc 8/24/18 JB",
      "displaytext": "Bone Marrow Labs",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CBC & Diff\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Order PT/INR if on Warfarin (Coumadin)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PT/INR\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 759,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW MAIN",
      "term": null,
      "displaytext": "Bone Marrow Transplant Immunization  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Post Bone Marrow Transplant Immunizations\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": 773, \"DisplayText\": \"Seattle Autologous\", \"Mnemonic\": \"40\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 771, \"DisplayText\": \"Seattle Allogeneic\", \"Mnemonic\": \"30\"}, {\"Row\": 4, \"Column\": 1, \"Item\": 765, \"DisplayText\": \"Nashville\", \"Mnemonic\": \"10\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 770, \"DisplayText\": \"San Antonio\", \"Mnemonic\": \"20\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 775, \"DisplayText\": \"U of M\", \"Mnemonic\": \"50\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"***TESTING ONLY**\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Item\": 760, \"DisplayText\": \"Bone Marrow Transplant Immunization\", \"Text\": \"Bone Marrow Immunizations\", \"Mnemonic\": \"99\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 760,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW MAIN 2020",
      "term": null,
      "displaytext": "Bone Marrow Transplant Immunization  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Post Bone Marrow Transplant Immunizations\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": 774, \"DisplayText\": \"Seattle Autologous\", \"Mnemonic\": \"40\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 772, \"DisplayText\": \"Seattle Allogeneic\", \"Mnemonic\": \"30\"}, {\"Row\": 4, \"Column\": 1, \"Item\": 766, \"DisplayText\": \"Nashville\", \"Mnemonic\": \"10\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 770, \"DisplayText\": \"San Antonio\", \"Mnemonic\": \"20\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 776, \"DisplayText\": \"U of M\", \"Mnemonic\": \"50\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 761, \"DisplayText\": \"Mayo Bone Marrow Transplant Immunizations\", \"Mnemonic\": \"60\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 761,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW MAYO 2020",
      "term": "CREATED 08/2020 BY SR FOR CONNIE JAENICKE",
      "displaytext": "Mayo Bone Marrow Transplant Immunizations  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"Annual influenza shot (high-dose if >65yo)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"6 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Item\": 757, \"DisplayText\": \"Influenza\", \"Mnemonic\": \"10\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6 Months Immunizations\", \"Mnemonic\": \"20\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"8 months (or at least 2m after 6 month)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8 Month Immunization\", \"Mnemonic\": \"30\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"10 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"10 Month Immunizations\", \"Mnemonic\": \"40\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Immunizations\", \"Mnemonic\": \"50\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"24 Month Immunizations\", \"Mnemonic\": \"60\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"26 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"26 Month Immunizations\", \"Mnemonic\": \"70\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"27 months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meningococcal Conjugate Vaccine\", \"Text\": \"27 Month Immunization\", \"Mnemonic\": \"80\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"29 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meningococcal Conjugate Vaccine\", \"Text\": \"29 Month Immunizations\", \"Mnemonic\": \"90\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 762,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW MENINGOCOCCAL",
      "term": null,
      "displaytext": "Meningococcal",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meningococcal Conjugate Inj ...\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meningococcal Polysaccharide Inj (Age > 55)\", \"Mnemonic\": \"20\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"For splenectomized patients or per direction of transplant center\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Only for those 11-21 yo, those with >21 yo with functional asplenia, have been\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"splenectomized, living in a dorm setting, or military recruits\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 763,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW MENINGOCOCCAL 2020",
      "term": "CREATED 08/20/2020 BY SR",
      "displaytext": "Meningococcal",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"For splenectomized patients or per direction of transplant center\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Only for those 11-21 yo, those with >21 yo with functional asplenia, have been\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"splenectomized, living in a dorm setting, or military recruits\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Meningococcal Conjugate Vaccine\", \"Text\": \"Meningococcal Conjugate Vaccine\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 764,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW MMR",
      "term": null,
      "displaytext": "Measles/Mumps/Rubella ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"Do NOT give if still on Immunisuppression Treatment or if active GVHD\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine 0.5ml ONCE\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 765,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW NASHVILLE",
      "term": null,
      "displaytext": "Nashville ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Text\": \"6 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6 Month Order Set\", \"Text\": \"6 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"8 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6 Month Order Set\", \"Text\": \"8 Month Order Set\", \"Mnemonic\": \"12\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"10 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6 Month Order Set\", \"Text\": \"10 Month Order Set\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"16 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"16 Month Order Set\", \"Mnemonic\": \"35\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Minimal Time Interval Between Vaccinations:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Influenza: once annually\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 766,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW NASHVILLE 2020",
      "term": null,
      "displaytext": "Nashville ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Text\": \"6 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6 Month Order Set\", \"Text\": \"6 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"8 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8 Month Order Set\", \"Text\": \"8 Month Order Set\", \"Mnemonic\": \"12\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"10 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"10 Month Order Set\", \"Text\": \"10 Month Order Set\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"16 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"16 Month Order Set\", \"Mnemonic\": \"35\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Minimal Time Interval Between Vaccinations:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Influenza: once annually\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 767,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW PAPILLOMAVIRUS",
      "term": null,
      "displaytext": "Papillomavirus  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Text\": \"For Ages 9-26 years old\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Papillomavirous Human(Gardisil) Vaccine ONCE\", \"Mnemonic\": \"02\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"do not give with GVHD/on IST\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 768,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW PNEUMOCOCCAL",
      "term": null,
      "displaytext": "Pneumococcal ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pneumococcal 23 Vaccine (PPSV23) ONCE\", \"Mnemonic\": \"10\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"In patients with chronic GVHD who are unlikely to respond to\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pnemovax, it is preferable to administer a four\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Pneumococcal-conjugate Vaccine (Prevnar 13)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pneumococcal 13 Valent Vaccine (PCV13) ONCE\", \"Mnemonic\": \"20\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 769,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW PNEUMOCOCCAL 2020",
      "term": "CREATED 08/21/2020 BY SR",
      "displaytext": "Pneumococcal ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pneumococcal 23 Vaccine (PPSV23) ONCE\", \"Mnemonic\": \"10\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 770,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW SAN ANTONIO",
      "term": null,
      "displaytext": "San Antonio  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"15\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 771,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW SEATTLE ALLOGENEIC",
      "term": null,
      "displaytext": "Seattle Allogeneic ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"16 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"18 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"22 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"60 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"15\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"16 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"18 Month Order Set\", \"Mnemonic\": \"25\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 767, \"DisplayText\": \"Papillomavirus\", \"Text\": \"22 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 753, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 756, \"DisplayText\": \"60 Month Order Set\", \"Text\": \"60 Month Order Set\", \"Mnemonic\": \"50\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Minimal Time Interval Between Vaccinations:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Haemophilus influenza type B conjugated vaccine: 1 month\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Hepatitis A vaccine: 6 months\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hepatitis B vaccine: 2 months\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Papillomavirus human vaccine (Gardasil):\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"2 months after 1st dose, 4 months after 2nd dose\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"TDAP: 1-2 months\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"TD: 1-2 months\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 772,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW SEATTLE ALLOGENEIC 2020",
      "term": "CREATED 08/21/2020 BY SR",
      "displaytext": "Seattle Allogeneic ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 12, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"16 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"18 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"22 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"15\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"16 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"18 Month Order Set\", \"Mnemonic\": \"25\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 767, \"DisplayText\": \"Papillomavirus\", \"Text\": \"22 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 755, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Minimal Time Interval Between Vaccinations:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Haemophilus influenza type B conjugated vaccine: 1 month\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Hepatitis A vaccine: 6 months\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hepatitis B vaccine: 2 months\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Papillomavirus human vaccine (Gardasil):\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"2 months after 1st dose, 4 months after 2nd dose\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"TDAP: 1-2 months\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"TD: 1-2 months\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 773,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW SEATTLE AUTOLOGOUS",
      "term": null,
      "displaytext": "Seattle Autologous ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 21, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"16 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"18 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"60 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"50\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"16 Month Order Set\", \"Mnemonic\": \"60\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"18 Month Order Set\", \"Mnemonic\": \"70\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"6 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"8 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"10 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8 Month Order Set\", \"Text\": \"10 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 753, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"80\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 756, \"DisplayText\": \"60 Month Order Set\", \"Text\": \"60 Month Order Set\", \"Mnemonic\": \"90\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Minimal Time Interval Between Vaccinations:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Haemophilus influenza type B conjugated vaccine: 1 month\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Hepatitis A vaccine: 6 months\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hepatitis B vaccine: 2 months\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Papillomavirus human vaccine (Gardasil):\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"2 months after 1st dose, 4 months after 2nd dose\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"TDAP: 1-2 months\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"TD: 1-2 months\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 774,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW SEATTLE AUTOLOGOUS 2020",
      "term": "CREATED 08/20/2020 BY SR",
      "displaytext": "Seattle Autologous ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 21, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"16 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"18 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"60 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"50\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"16 Month Order Set\", \"Mnemonic\": \"60\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"18 Month Order Set\", \"Mnemonic\": \"70\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"6 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"8 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"10 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"6 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"8 Month Order Set\", \"Text\": \"10 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 754, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"80\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 756, \"DisplayText\": \"60 Month Order Set\", \"Text\": \"60 Month Order Set\", \"Mnemonic\": \"90\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Minimal Time Interval Between Vaccinations:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Haemophilus influenza type B conjugated vaccine: 1 month\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pneumococcal-conjugate vaccine (Prevnar 13): 1-2 months\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pneumococcal-polysaccharide vaccine (PPSV23): 2 months after Prevnar\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Hepatitis A vaccine: 6 months\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hepatitis B vaccine: 2 months\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Papillomavirus human vaccine (Gardasil):\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"2 months after 1st dose, 4 months after 2nd dose\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"TDAP: 1-2 months\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"TD: 1-2 months\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 775,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW U OF M",
      "term": null,
      "displaytext": "U of M ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"26 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"27 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"29 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"26 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"27 Month Order Set\", \"Mnemonic\": \"50\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"29 Month Order Set\", \"Mnemonic\": \"60\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 776,
    "fields": {
      "name": "ORZID3 GMENU BONE MARROW U OF M 2020",
      "term": "CREATED 08/25/2020 BY SR",
      "displaytext": "U of M ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"12 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"14 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"24 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"12 Month Order Set\", \"Mnemonic\": \"10\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"14 Month Order Set\", \"Mnemonic\": \"20\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"24 Month Order Set\", \"Mnemonic\": \"30\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Postvaccination antibody titers\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"are useful to monitor response and may be needed for additional\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"doses.  Titers should be drawn 1-3 months after the specific\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"vaccination series is completed.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"26 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"27 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"29 Months >/= Post Transplant\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"26 Month Order Set\", \"Mnemonic\": \"40\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"27 Month Order Set\", \"Mnemonic\": \"50\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"29 Month Order Set\", \"Mnemonic\": \"60\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 777,
    "fields": {
      "name": "ORZID3 GMENU BRONCHITIS NEW",
      "term": null,
      "displaytext": "Bronchitis/COPD Exacerbation",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 983, \"DisplayText\": \"Pertussis (Outpatient)\", \"Text\": \"Pertussis\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 95, \"DisplayText\": \"Bronchitis not benefited\", \"Text\": \"Bronchitis-antibiotics not a benefit in otherwise healthy patient\", \"Mnemonic\": \"6\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Doxcycline 100 mg PO BID for 5 days ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once on day one then 250 mg PO qday for 4 days ($) [M]\", \"Mnemonic\": \"12a\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO BID for 5 days ($) [R]\", \"Mnemonic\": \"14a\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 3101, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"16\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BRONCHITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Acute bronchitis should not be treated with antimicrobials except in specific\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"circumstances. If pneumonia is suspected, order a chest x-ray.  If an\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infiltrate is not present, the patient does not have bacterial pneumonia and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"need not be treated for it.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Acute bronchitis in an otherwise HEALTHY PATIENT\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antimicrobials provide no benefit.  If bronchitis persists beyond 2 weeks,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"additional diagnostic workup is needed to find a cause.  If a patient has\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"persistent cough with inspiratory whoop, consider a diagnosis of pertussis.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"For symptomatic treatment dextromethorphan and benzonatate combined with\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"guaifenesin has shown some benefit. Benzonatate and guaifenesin\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"alone did not show benefit. Also, allergy medicines and codeine\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"do not appear to help the symptoms.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Acute bronchitis in patients with COPD\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Symptoms of COPD exacerbation include dyspnea with increased sputum purulence\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"and volume, together with increased cough and wheeze. Co-morbidities are\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"common in COPD patients, thus exacerbations must be differentiated clinically\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"from other events such as acute coronary syndrome, worsening heart failure,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"pulmonary embolism and pneumonia.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Cornerstones of therapy include oxygen, bronchodilators, and in some cases\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"corticosteroids. Recommend antibiotics for moderately or severely ill patients\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"with COPD exacerbation who have increased sputum purulence and volume.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treatment for MILD DISEASE:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"No antibiotics recommended\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treatment for MODERATE DISEASE\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treat for 5 to 7 days.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Treatment for SEVERE DISEASE\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"NOTE: Fluoroquinolones are not listed as a choice because the risk of serious\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"side effects outweigh the benefits.\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Access: http://www.goldcopd.org\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Wenzel WP et al NEJM 2006, 355: 2125\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Mandell chapter: Bronchitis\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Sanford keyword: Bronchitis\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Murphy TF Chest 2000, 118: 204\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Masterton RG Int J Antimicrob Agents 2001, 18: 503\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 778,
    "fields": {
      "name": "ORZID3 GMENU CANDIDA VULVO-VAGINITIS",
      "term": null,
      "displaytext": "Candida vulvo-vaginitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg po once\", \"Text\": \"Fluconazole 150 mg PO once ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg po once Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole vaginal 1% cream 1 applicatorful qhs 7 days\", \"Text\": \"Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole vaginal 1% cream 1 applicatorful qhs 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% vaginal cream 1 applicatorful qhs 7days\", \"Text\": \"Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 7 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% vaginal cream 1 applicatorful qhs 7days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150 mg PO every 3 days for 7 days (3 doses) ($) [R,DI]\", \"Text\": \"Fluconazole 150 mg PO q72h for 7 days (3 doses) ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150 mg PO every 3 days for 7 days (3 doses) ($) [R,D Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole vaginal 1% cream 1 applicator full at bedtime for 10-14 days\", \"Text\": \"Clotrimazole vaginal 1% cream 1 applicator full qhs ($) [M] for 10 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole vaginal 1% cream 1 applicator full at bedtime for 1 Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% vaginal cream 1 applicator full at bedtime for 10-14 days\", \"Text\": \"Terconazole 0.4% vaginal cream 1 applicator full qhs ($) [M] for 10 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% vaginal cream 1 applicator full at bedtime for Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150 mg PO QWEEK for 6 months ($) [R,DI]\", \"Text\": \"Fluconazole 150 mg PO every 7 days ($) [R,DI] for 6 months\", \"Mnemonic\": \"16a\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150 mg PO QWEEK for 6 months ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA VULVOVAGINITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Candida vulvovaginitis typically presents with valvular irritation, burning or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pruritus. Vaginal pH should be measured, and the specimen should be examined\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"under the microscope for clue cells (epithelial cell coated with bacteria) to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"exclude bacterial vaginosis. In candida vulvovaginitis, the vaginal pH is\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"typically normal (4-4.5) and vaginal discharge is typically thick and curdy with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"white plaques on vaginal mucosa. Diagnosis is confirmed by identifying fungus or\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"yeast with KOH prep.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Most non-C. albicans species respond to fluconazole treatment except C. krusei\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"and C. glabrata. C. krusei can be treated with topical agents as for complicated\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"candida vulvovaginitis below. C. glabrata treatment is complicated and azole\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"therapy is frequently unsuccessful. Consult Infectious Diseases in patients with\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"C. glabrata vulvovaginitis.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Recurrent candida vulvovaginitis is treated as complicated candida\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"vulvovaginitis for induction treatment, followed by maintenance regimen for 6\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"months.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treatment of uncomplicated candida vulvovaginitis\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treatment of complicated candida vulvovaginitis (e.g. immunocompromised, severe\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"disease, pregnancy) or recurrent infection induction treatment\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Recurrent candida vulvovaginitis maintenance regimen following induction\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"treatment above\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Treatment of C. glabrate vulvovaginitis\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Failure of azole therapy is common, alternative topical treatments below require\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"compounding by a pharmacist. Please call pharmacy to order.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Topical flucytosine cream (17%) qhs for 14 days\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Topical boric acid capsule 600 mg intravaginal qhs for 14 days\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and cervicitis\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Vulvovaginitis\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Up-to-Date article: Candida vulvovaginitis: Treatment\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Up-to-Date article: Candida vulvovaginitis: Clinical manifestations and\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"diagnosis\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 779,
    "fields": {
      "name": "ORZID3 GMENU CAP TREATED IN OUTPT SETTING",
      "term": null,
      "displaytext": "CAP treated in an outpatient setting (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO TID for 5 days ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO TID for 5 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amox-clav 875/125mg po bid x5days <AND> Azithromycin 500 then 250\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>\", \"Mnemonic\": \"8a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA for above order\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300mg PO BID for 5 to 7 days ($) [R] <AND> Azithromycin\", \"Text\": \"Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Azithromycin\", \"Mnemonic\": \"10a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"NON-VA order for above\", \"Text\": \"NON-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amox-clav 875/125 mg po bid <AND> Doxycycline 100mg po bid x5days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>\", \"Mnemonic\": \"12a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300mg po bid <AND> Doxycycline 100mg po bid x5 days\", \"Text\": \"Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Doxycycline\", \"Mnemonic\": \"14a\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA for above\", \"Text\": \"Non-VA for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 3102, \"DisplayText\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Text\": \"[Link] Fluoroquinolones FDA Serious Adverse Reactions\", \"Mnemonic\": \"16\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]\", \"Text\": \"Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]\", \"Mnemonic\": \"18a\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN OUTPATIENT SETTING\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Preferred outpatient treatment for PREVIOUSLY HEALTHY PATIENT:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"conditions, or use of immunosuppressing drugs)\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Outpatient and UNcomplicated:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred outpatient treatment for PATIENTS WITH COMORBIDITIES:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"(WITH chronic obstructive pulmonary disease, diabetes, renal failure,\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"conditions, or use of immunosuppressing drugs)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Outpatient and comorbidity:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Azithromycin 500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"100 mg PO BID for 5 days ($) [DI]\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Alternative:\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Sanford: Community Acquired Pneumonia\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 780,
    "fields": {
      "name": "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT",
      "term": null,
      "displaytext": "Cardiovascular Outpatient Main Page  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CARDIOVASCULAR\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Section last reviewed  9/2020\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 781,
    "fields": {
      "name": "ORZID3 GMENU CAT-SCRATCH DISEASE",
      "term": null,
      "displaytext": "Cat-Scratch Disease (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1on day 1, then 250 mg PO QDAY for 4 days ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CAT-SCRATCH DISEASE\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cat-scratch disease occurs when a cat infected with Bartonella henselae\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"scratches or bites a person or licks a person's open wound.  A local pustule\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"develops followed by lymphadenopathy, typically on the same side of the body as\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"the scratch or bite.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Infections associated with other pathogens such as Francisella tularemia,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Coxiella burnetiid and other slow-growing bacteria may present with similar\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"symptoms.  Consult Infectious Diseases for more information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"About 10% of cases of cat-scratch disease present atypically with symptoms\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"involving the eye, nervous system, or lungs.  Consult Infectious Diseases in\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"these cases.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mandell chapter: Bartonella, including cat-scratch disease\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: cat-scratch disease\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Consult Infectious Diseases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 782,
    "fields": {
      "name": "ORZID3 GMENU CDIFFICILE COLITIS",
      "term": null,
      "displaytext": "Antibiotic Associated Colitis (C. Difficile Colitis)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 915, \"DisplayText\": \"Initial Episode of Antibiotic Associated Colitis...\", \"Text\": \"Initial Episode\", \"Mnemonic\": \"4\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 834, \"DisplayText\": \"\", \"Text\": \"First Recurrence\", \"Mnemonic\": \"6\"}, {\"Row\": 49, \"Column\": 1, \"Item\": 1014, \"DisplayText\": \"ORZID3 GMENU SECOND RECURRENCE ABX ASSOC COLITIS\", \"Text\": \"Second Recurrence\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Discontinue implicated antibiotic and avoid high risk antibiotic if antibiotic\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"therapy is still needed. Discontinue laxatives. Reassess need for tube feeds. C.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"difficile PCR testing should be completed to confirm diagnosis of C. difficile\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infection.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antibiotic risk (rank order):\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"High: clindamycin, fluoroquinolones, 2nd/3rd/4th generation cephalosporins,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medium: carbapenems, penicillins, 1st generation cephalosporins, macrolides,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"vancomycin, metronidazole\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Low: tetracyclines, aminoglycosides, trimethoprim/sulfamethoxazole, rifampi\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Very low: sulfonamides, nitrofurantoin, fosfomycin, methenamine\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Avoid antiperistaltic agents (narcotics, loperamide, etc.). Increasing evidence\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"suggests that antacid therapy, especially with PPIs and H2 blockers, increases\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"the risk for C. difficile disease and recurrences. Avoid antacid therapy\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"without clear indication, especially in patients at risk for primary recurrent C\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"difficile disease.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"The preferred route of antimicrobial therapy for C. difficile infection is by\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"mouth. Intravenous metronidazole should be used only when oral therapy cannot\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"be used to deliver drug to the colon. Intravenous vancomycin does not get into\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"colonic contents and is not effective.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"C. difficile infection usually responds to antimicrobial therapy, especially if\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"other antimicrobial therapy has been stopped. Relapse is usually due to failure\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"of normal colonic flora to re-establish itself, rather than antimicrobial\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"treatment failure. If symptoms do not respond to appropriate antimicrobial\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"therapy, re-consider the diagnosis. Relapse occurs in 6% to 25% of people after\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"their first episode of C. difficile infection.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Third Recurrence: Consult Gastroenterology and/or Infectious Disease\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Clinical\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"CDI: Patient with clinical symptom onset (e.g., 3 or more unformed stools in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"24 hours after discontinuation of laxatives) and laboratory confirmation of CDI.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"CDI Recurrence: Typically defined as a repeated symptomatic, laboratory\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"case of CDI within 12 weeks after a prior episode.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Severe/life-threatening disease (shock, ileus, megacolon)\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Fulminant CDI:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Clostridioides difficile Infection (CDI)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If diarrhea has improved or resolved prior to starting C. difficile\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"treatment, consider re-assessing the diagnosis before initiating therapy.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"The Infectious Disease service is always available to discuss CDI testing\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"and results.\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 97, \"DisplayText\": \"Clostridioides difficile Infection (CDI) 2-step testing\", \"Text\": \"<Click here> Information on C. difficile lab testing\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 783,
    "fields": {
      "name": "ORZID3 GMENU CELLULITIS",
      "term": null,
      "displaytext": "Cellulitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 936, \"DisplayText\": \"The approach to cellulitis\", \"Text\": \"More about cellulitis...\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"BACTERIAL CELLULITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cellulitis refers to inflammation of the skin and subcutaneous tissue and is\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"often associated with bacterial pathogens.  The most common pathogens are group\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"A streptococci and Staphylococcus aureus.  Group B streptococci are associated\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"with cellulitis in elderly people, in those with diabetes mellitus, and on feet\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and legs of patients with athlete's foot (tinea pedis).\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Mild cases can be treated with oral antimicrobials.  Moderate to severe cases\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"should be treated initially with intravenous antimicrobials.  Switch to oral\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"drugs after clinical improvement.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consider MRSA coverage for cellulitis associated with penetrating trauma,\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"history of MRSA infection, injection drug use, or infections not responding\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"to first line beta-lactams.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"if not improved in this time.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mild: Cellulitis without systemic signs of infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empirical treatment for MILD cellulitis\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for Penicillin Allergy or MRSA suspected\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"MRSA Suspected Mild Cellulitis\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Empirical treatment for MODERATE to SEVERE cellulitis\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO bid ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg q12h ($) [R] for 5 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 784,
    "fields": {
      "name": "ORZID3 GMENU CERVICITIS ASSOC STD",
      "term": null,
      "displaytext": "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Urine NAAT\", \"Text\": \"Chlamydia & GC PCR/LCR test\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 1009, \"DisplayText\": \"Recurrent or persistent urethritis (Outpatient)\", \"Text\": \"Treatment of recurrent or persistent cervicitis\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"The main diagnostic signs that characterize cervicitis are 1)women who present\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with purulent or mucopurulent exudate in the endocervical canal or on an\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"endocervical swab specimen and 2)sustained endocervical bleeding induced by\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"gentle passage of cotton swab through the cervical os. One or both signs may be\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"present.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Neisseria gonorrhoeae and Chlamydia trachomatis are the two most common sexually\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"transmitted cervicitis pathogens. Nucleic acid amplification tests for these\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"pathogens are more sensitive than culture and should be used for patients at\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"risk for sexually transmitted cervicitis.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For patients who have recently been treated for cervicitis\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"When diagnosed with sexually transmitted cervicitis, the patient's sexual\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"partner(s) during the previous 60 days should be evaluated for sexually\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"transmitted infection. If diagnostic tests for the cause of cervicitis are not\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"feasible, therapy for both N. gonorrhoeae and C. trachomatis should be given to\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"partners.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Initial treatment of patients and sex partners\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Patients and partners are often infected with both N. gonorrhoeae and C.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"trachomatis.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute cervicitis\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 1026, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 854, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Treatment for Gonococcal and Chlamydial trachomatis co-infections\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 785,
    "fields": {
      "name": "ORZID3 GMENU CHLAMYDIA URETHRITIS",
      "term": null,
      "displaytext": "Chlamydia urethritis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO BID for 7 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Text\": \"Azithromycin 1 gm PO x 1 dose ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHLAMYDIAL OR NON-GONOCOCCAL URETHRITIS OR CERVICITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment for chlamydial or non-gonococcal urethritis or cervicitis\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and Cervicitis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford keyword: Urethritis, cervicitis: chlamydial\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute cervicitis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-To-Date article: Urethritis in men\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 786,
    "fields": {
      "name": "ORZID3 GMENU CHOLANGITIS",
      "term": null,
      "displaytext": "Cholangitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po qday for 7days\", \"Text\": \"Moxifloxacin 400 mg PO qday ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po qday for 7days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg PO qday ($)[R,DI] <AND> metronidazole 1000mg PO bid ($) [DI]\", \"Text\": \"Levofloxacin 500mg PO qday ($)[R,DI] <AND> metronidazole 1000mg PO bid ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg PO qday ($)[R,DI] <AND> metronidazole 1000mg Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CHOLANGITIS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for initial IV treatment\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are due to common bile duct obstruction. Obstruction (if present)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"must be relieved with an endoscopical, transcutaneous, or surgical procedure.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Step down treatment for completion of antimicrobial course after initial\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"intravenous treatment in patients who can tolerate oral therapy. Base selection\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"on culture results.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Duration of treatment for total of 7 to 10 days.\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Cholangitis, Cholecystitis)\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Gallbladder Infections\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date article: Acute cholangitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 787,
    "fields": {
      "name": "ORZID3 GMENU CHOLECYSTITIS",
      "term": null,
      "displaytext": "Cholecystitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHOLECYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 788,
    "fields": {
      "name": "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN",
      "term": null,
      "displaytext": "Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ibuprofen 400mg PO TID 14 days\", \"Text\": \"Ibuprofen 400 mg PO q8h for 2 to 3 weeks\", \"Mnemonic\": \"4a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ibuprofen 400mg PO TID 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"This syndrome presents with intermittent perineal and/or low back pain,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"obstructive voiding symptoms, relatively normal examination, and negative urine\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cultures. Antimicrobial therapy is not indicated.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consult urology for non-antimicrobial therapy recommendations (e.g.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"alpha-adrenergic antagonists, anti-inflammatory medications) to reduce symptoms.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Anti-inflammatory treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-To-Date article: Chronic prostatitis/chronic pelvic pain syndrome\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 789,
    "fields": {
      "name": "ORZID3 GMENU CHRONIC BACT PROSTATITIS",
      "term": null,
      "displaytext": "Chronic bacterial prostatitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 296, \"DisplayText\": \"Urine Culture\", \"Text\": \"Urine culture\", \"Mnemonic\": \"4\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 788, \"DisplayText\": \"Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)\", \"Text\": \"Chronic prostate pain syndrome\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks\", \"Mnemonic\": \"8a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R,DI] for 4 weeks (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 4 weeks\", \"Mnemonic\": \"10a\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHRONIC BACTERIAL PROSTATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Chronic bacterial prostatitis usually presents as recurrent urinary tract\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infections with the same bacterial etiology. Pain, tenderness, and fever may\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"accompany intermittent episodes of cystitis, but men are usually asymptomatic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"between episodes and the prostate examination may be normal. Non-steroidal anti-\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"inflammatory drugs (NSAIDs) often relieve pain. If the diagnosis is uncertain or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"if the patient's symptoms do not respond to therapy, consult urology. The\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"presence of hematuria may be a sign of carcinoma, especially in older men, and a\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"urology consult should be requested.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"A urine culture should be performed in all patients to guide antimicrobial\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"therapy:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Chronic prostate pain syndrome should be considered in patients who have\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"symptoms of prostatitis but have negative urine cultures. Chronic prostate pain\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"syndrome is discussed elsewhere:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"4 weeks minimum and up to 6 weeks of treatment is required. Durations longer\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"than 6 weeks may be needed in treatment of resistant organisms. Treatment with\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"trimethoprim/sulfamethoxazole requires a treatment duration of 1 to 3 months.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Rees et al., BJU Int, 2015,116.509-525\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Lipsky et al., Clinical Infectious Diseases, 2010, 50(12)1641-1652\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Prostatitis\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-To-Date article: Chronic bacterial prostatitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 790,
    "fields": {
      "name": "ORZID3 GMENU CHRONIC SINUSITIS",
      "term": null,
      "displaytext": "Chronic sinusitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 728, \"DisplayText\": \"Acute sinusitis--Severe disease (Outpatient)\", \"Text\": \"Severe Sinusitis\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CHRONIC SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis of chronic sinusitis is based on presence of at least 2 of the 4\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cardinal signs/symptoms lasting >/= 12 weeks. In addition, diagnosis requires\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"objective evidence of mucosal inflammation using nasal endoscopy and/or CT\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"imaging. The initial therapy for chronic sinusitis is treatment with intranasal\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"corticosteroids and saline. For patients with severe nasal blockage by polyps,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"treat with a short course of oral glucocorticoids. Reassess patient after 1 to 3\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"months of intranasal therapy or after completion of glucocorticoid therapy. If\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"signs/symptoms have not improved, consult surgery, ENT and Infectious Diseases\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"as treatment is complex.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Acute exacerbations of chronic sinusitis can be caused by discontinuing medical\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"therapy, viral infections, allergens, noxious inhalants and bacterial or fungal\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"infections. Bacterial infections should be suspected when the patient has\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"increased signs/symptoms persisting for more than 10 days. Refer to Severe\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sinusitis recommendations for choice of antimicrobial therapy in these patients.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Repeated use of the same agent should be avoided to prevent promotion of drug\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"resistant bacteria or increased fungal colonization.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Cardinal Signs/Symptoms of Chronic Sinusitis\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"1. Anterior and/or posterior nasal mucopurulent drainage\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"2. Nasal obstruction/nasal blockage/congestion\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"3. Facial pain, pressure, and/or fullness\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"4. Reduction or loss of sense of smell\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Objective Evidence mucosal inflammation\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"1. Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"2. Polyps in the nasal cavity or the middle meatus\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"3. Radiographic imaging demonstrating mucosal thickening or partial or complete\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"opacification of the paranasal sinuses\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Rudmik et al., JAMA. 2015, 314(9) 926-939\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Chronic\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-To-Date article: Chronic rhinosinusitis: Clinical manifestations,\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"pathophysiology, and diagnosis\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-To-Date article: Microbiology and antibiotic management of chronic\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"rhinosinusitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 791,
    "fields": {
      "name": "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS",
      "term": null,
      "displaytext": "CMV colitis or esophagitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900mg po bid for 21 days\", \"Text\": \"Valganciclovir 900 mg PO BID ($$$) [R,O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900mg po bid for 21 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV COLITIS OR ESOPHAGITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection in immunocompetent patients is rare and usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"minimal or no symptoms. Patients in whom the risk for CMV disease is increased\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"include solid organ and bone marrow transplant recipients, persons receiving\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and requires Infectious Diseases consultation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for 3-6 weeks. Patients may be converted to oral therapy after initial\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"intravenous therapy and after clinical improvement of severe disease.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease or following clinical improvement of\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"severe disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 792,
    "fields": {
      "name": "ORZID3 GMENU CMV ENCEPHALITIS",
      "term": null,
      "displaytext": "CMV encephalitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV ENCEPHALITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 793,
    "fields": {
      "name": "ORZID3 GMENU CMV PNEUMONIA",
      "term": null,
      "displaytext": "CMV pneumonia (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV PNEUMONIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 794,
    "fields": {
      "name": "ORZID3 GMENU CMV POLYRADICULOPATHY",
      "term": null,
      "displaytext": "CMV polyradiculopathy (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900 mg PO BID ($$$) [R,O]\", \"Text\": \"Valganciclovir 900 mg PO BID ($$$) [R,O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900 mg PO BID ($$$) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV POLYRADICULOPATHY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection in immunocompetent patients is rare and usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"minimal or no symptoms. Patients in whom the risk for CMV disease is increased\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"include solid organ and bone marrow transplant recipients, persons receiving\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and requires Infectious Diseases consultation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration is likely to be prolonged and is individualized based on response.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Patients may be converted to oral therapy after initial intravenous therapy and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"after clinical improvement of severe disease.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease or following clinical improvement of\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"severe disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 795,
    "fields": {
      "name": "ORZID3 GMENU CMV RETINITIS",
      "term": null,
      "displaytext": "CMV retinitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900mg po bid for 14 days\", \"Text\": \"Valganciclovir 900 mg PO q12h ($$$) [R,O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900 mg PO QDay ($$$) [R,O]\", \"Text\": \"Valganciclovir 900 mg PO q24h ($$$) [R,O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valganciclovir 900 mg PO QDay ($$$) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CMV RETINITIS AND ACUTE RETINAL NECROSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infection in immunocompetent patients is rare and usually associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"minimal or no symptoms. Patients in whom the risk for CMV disease is increased\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"include solid organ and bone marrow transplant recipients, persons receiving\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and requires Infectious Diseases consultation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For sight threatening lesions (lesions within 1500 microns of the fovea)\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"intravitreal infections of ganciclovir or foscarnet are recommended in addition\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"to systemic treatment. Contact Infectious Diseases for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treat retinitis for 14 to 21 days. Patients may be converted to oral therapy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"after initial intravenous therapy and after clinical improvement of severe\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"disease. Treat acute retinal necrosis with IV therapy for at least 7 days and\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"until disease stabilizes then oral therapy for a minimum of 6 weeks. Maintenance\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"therapy after completion of treatment is indicated when CD4 count <100.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Discontinue maintenance therapy when CD4 count is >100 for 6 months.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment acute retinal necrosis or severe disease\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment of mild to moderate retinitis or after clinical improvement of severe\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"retinitis/acute retinal necrosis\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Maintenance therapy\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Cytomegalovirus\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Cytomegalovirus\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date article: Epidemiology, clinical manifestations, and treatment of\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"cytomegalovirus infection in immunocompetent adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 796,
    "fields": {
      "name": "ORZID3 GMENU CNS OUTPT",
      "term": null,
      "displaytext": "Central nervous system (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 745, \"DisplayText\": \"Bell's palsy (Outpatient)\", \"Text\": \"Bell's Palsy\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Lyme Disease\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 595, \"DisplayText\": \"Neurosurgery\", \"Text\": \"Neurosurgery prophylaxis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CENTRAL NERVOUS SYSTEM\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for Other Central Nervous System Infectio\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"(e.g. meningitis, brain abscess, HSV encephalitis, cranial/spinal epidural\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"abscess, subdural empyema, and suppurative intracranial thrombophilia).\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 797,
    "fields": {
      "name": "ORZID3 GMENU COM ACQ DIARRHEA/NO TRAVEL",
      "term": null,
      "displaytext": "Community acquired diarrhea (no recent travel) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 782, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Clostridium difficile\", \"Mnemonic\": \"4\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 3-5 days ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Text\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Mnemonic\": \"10a\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY ACQUIRED DIARRHEA (NO RECENT TRAVEL)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Acute diarrhea (< 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Empirical antimicrobials should be given only in cases of severe acute disease\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"or high-risk conditions: fever, >/= 6 stools in 24 hours, volume depletion\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"requiring hospitalization, severe abdominal pain, immune compromise, cardiac\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"disease, >/= 70 years old.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"If in the preceding two months the patient has taken a PPI or has been\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"hospitalized for three or more days, consider Clostridium difficile infection.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Bloody diarrhea\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"therapy and antimotility agents are not recommended in most patients with bloody\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"diarrhea due to an increased risk of hemolytic uremic syndrome when using these\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"agents. Obtain a stool sample for enteric pathogen PCR testing and reserve\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"antimicrobial and antimotility agent treatment until results are known. Enteric\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"pathogen PCR testing results are reported within 2 hours between 7am and 11pm.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"For more information on when an antimicrobial is indicated or if the patient has\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"severe/life threatening diarrhea or is immunocompromised, contact Infectious\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Empiric antimicrobial treatment for non-bloody severe acute diarrhea\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Subacute or chronic (>/= 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Primary treatment is hydration and electrolyte replacement. Empiric\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"antimicrobial therapy is not indicated. Investigate for the cause of diarrhea.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Gastroenterology and/or Infectious Diseases involvement is encouraged.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford guide keyword: Gastroenteritis, Diarrhea: Overview\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"settings\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 798,
    "fields": {
      "name": "ORZID3 GMENU COMM ACQ PNEUMONIA",
      "term": null,
      "displaytext": "Community acquired pneumonia (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 3103, \"DisplayText\": \"CAP Pneumonia Severity Index (PSI) Calculator\", \"Text\": \"CAP Pneumonia Severity Index (PSI) Calculator\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 779, \"DisplayText\": \"CAP treated in an outpatient setting (Outpatient)\", \"Text\": \"CAP treated in an outpatient setting\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMMUNITY-ACQUIRED PNEUMONIA (CAP)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Empirical regimens listed here cover the usual pathogens associated with CAP,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"including atypical pathogens.  Specific therapy should be guided by culture\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"results.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Diagnosis\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"CAP Pneumonia Severity Index (PSI) or PORT Score\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"The CAP pneumonia severity index is useful for estimation of mortality risk for\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"a patient with pneumonia.  Pre-estimated risk can then be used to determine how\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"aggressively to treat the patient's pneumonia and whether the patient can be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treated safely outside of the hospital.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"The Community-Acquired Pneumonia Severity Index (PSI) is a guide and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"should be used to augment clinical judgment. If social circumstances\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"or cognitive dysfunction would interfere with success of outpatient\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"treatment, the patient should be hospitalized.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"If a patient has taken an antimicrobial in the previous 3 months, it is prudent\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"to avoid giving the same or a similar drug for the current episode of pneumonia.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"(SEE INPATIENT CDSS for CAP treated in an Inpatient Setting)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Fine MJ, et al. N Engl J Med. (1997) 336: 243-250\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 799,
    "fields": {
      "name": "ORZID3 GMENU COMM INFECT PNEUMO",
      "term": null,
      "displaytext": "Pneumonia (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 739, \"DisplayText\": \"Aspiration pneumonia (Outpatient)\", \"Text\": \"Aspiration pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 798, \"DisplayText\": \"Community acquired pneumonia (Outpatient)\", \"Text\": \"Community-acquired pneumonia (CAP)\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Nosocomial pneumonia (including HAP or VAP) SEE INPATIENT CDSS\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  PNEUMONIA - OUTPATIENT  ++\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Note: Healthcare-associated pneumonia (HCAP), no longer used in the 2019\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and/or P. aeruginosa are use to guide whether to start\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"appropriate coverage empirically. (See CAP above)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 800,
    "fields": {
      "name": "ORZID3 GMENU COMM VIRAL GASTROENTERITIS",
      "term": null,
      "displaytext": "Viral Diarrhea  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"VIRAL GASTROENTERITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infectious diarrhea caused by viral pathogens such as Adenovirus, Astrovirus,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Norovirus, Rotavirus, and Sapovirus is usually self-limited. Treatment includes\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"supportive measures such as oral rehydration and unrestricted nutrition.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antiviral therapy is not recommended and for most viruses is unavailable.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antimotility agents may be used for one or two days in patients with mild to\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"moderate volume depletion. Antiemetic agents may be used for one or two days in\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"patients with vomiting.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford guide keyword: Gastroenteritis, Diarrhea: Overview\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute viral gastroenteritis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 801,
    "fields": {
      "name": "ORZID3 GMENU COMPLICATED CYSTITIS",
      "term": null,
      "displaytext": "Complicated Cystitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 1006, \"DisplayText\": \"Pyelonephritis (Outpatient)\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 296, \"DisplayText\": \"Urine Culture\", \"Text\": \"Urine culture\", \"Mnemonic\": \"6\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 725, \"DisplayText\": \"Acute bacterial prostatitis (Outpatient)\", \"Text\": \"Acute prostatitis\", \"Mnemonic\": \"8\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30mL/min, for 7 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"16a\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300mg PO BID ($) [R] for 7 days\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"18a\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID ($) [R] for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"20\"}, {\"Row\": 68, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"22a\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO bid x 7days ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"22b\"}, {\"Row\": 79, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"24a\"}, {\"Row\": 80, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"24b\"}, {\"Row\": 83, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"26\"}, {\"Row\": 84, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"28a\"}, {\"Row\": 86, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"28b\"}, {\"Row\": 95, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"30a\"}, {\"Row\": 96, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"30b\"}, {\"Row\": 100, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 7 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h ($) [R] for 7 days\", \"Mnemonic\": \"32a\"}, {\"Row\": 101, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"32b\"}, {\"Row\": 104, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"34\"}, {\"Row\": 105, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses\", \"Mnemonic\": \"36a\"}, {\"Row\": 106, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"36b\"}, {\"Row\": 108, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days\", \"Mnemonic\": \"38a\"}, {\"Row\": 110, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO q12h x 5 days ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"38b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMPLICATED CYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Complicated cystitis is defined as symptomatic bladder inflammation and symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"due to a bacterial infection in people with certain conditions (see below).\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Symptoms usually include dysuria, lower abdominal pain, and urgency. Complicated\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cystitis is commonly associated with Enterobacteriaceae, but more resistant\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"pathogens occur, including the Gram-positive pathogens staphylococci and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"enterococci.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Signs and symptoms that may indicate infection has extended beyond the bladder\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"include fever/other signs of systemic infection, flank pain, costovertebral\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"tenderness, and pelvic or perianal pain in men. Pyelonephritis should be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"considered in these patients:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Urine culture should be obtained before antimicrobials are given to guide\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"treatment of complicated cystitis:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Prostatitis should be considered in men with recurrence of urinary tract\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"infection:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"When patients who require paraenteral therapy are afebrile, clinically stable,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"and can take oral medication, convert to oral therapy based on the\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"identification and susceptibility of the isolate.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Complicating conditions\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Cystitis is considered complicated when one or more of the following is present:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"o Pregnant women\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"o Structural or neurogenic abnormalities (e.g. presence of obstruction, catheter\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"or nephrostomy tubes, neurogenic bladder, renal failure or transplantation)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"o Immunocompromise\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"o Persistent infection, relapse, recurrence, or treatment failure\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"o In some cases, men and patients admitted to health care settings may be\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"considered complicated\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Treat for 7 days. If patient is febrile, may extend duration up to 14 days total\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Mild to moderate disease\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Primary alternatives:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Secondary alternative:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Severe disease or if patient cannot take oral therapy\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Treatment for specific pathogens\", \"Header\": 1}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Enterobacteria including E. coli, klebsiella, and proteus\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 88, \"Column\": 1, \"Text\": \"Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 89, \"Column\": 1, \"Text\": \"S. aureus is an uncommon urinary tract pathogen and presence in the urine may be\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"due to hematogenous seeding from another site. Blood cultures are indicated to\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"rule out bacteremia in patients who have S. aureus isolated from the urine.\"}, {\"Row\": 92, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Pseudomonas\", \"Header\": 1}, {\"Row\": 98, \"Column\": 1, \"Text\": \"Enterococcus\", \"Header\": 1}, {\"Row\": 99, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"Alternatives:\"}, {\"Row\": 107, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 109, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 111, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 114, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 115, \"Column\": 1, \"Text\": \"Drekonja et al., JAMA, 2021, 326(4)324-331\"}, {\"Row\": 116, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 117, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 118, \"Column\": 1, \"Text\": \"Sanford keyword: Cystitis\"}, {\"Row\": 119, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 120, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 121, \"Column\": 1, \"Text\": \"Tamma et al., Clinical Infectious Diseases, 2021, 72(7)1109-16\"}, {\"Row\": 122, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute complicated urinary tract infection (including\"}, {\"Row\": 123, \"Column\": 1, \"Text\": \"pyelonephritis) in adults\"}, {\"Row\": 124, \"Column\": 1, \"Text\": \"Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary\"}, {\"Row\": 125, \"Column\": 1, \"Text\": \"tract, gastrointestinal tract, and central nervous system\"}, {\"Row\": 126, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}, {\"Row\": 127, \"Column\": 1, \"Text\": \"Walker et al., Clinical Infectious Diseases, 2016, 63(7)960-5\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 802,
    "fields": {
      "name": "ORZID3 GMENU CONJUNCTIVITIS",
      "term": null,
      "displaytext": "Conjunctivitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)\", \"Text\": \"Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)\", \"Mnemonic\": \"4a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/polymixin B ophthalmic solution 1 drop in affected Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ofloxacin 2 drops in affected eye every 2 hours while awake for 2 days then 2\", \"Text\": \"Ofloxacin 0.3% ophthalmic solution 2 drops in affected eye q2h while awake for 2\", \"Mnemonic\": \"6a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ofloxacin 2 drops in affected eye every 2 hours while awake for Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CONJUNCTIVITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Conjunctivitis is associated with viral or bacterial pathogens. Viral\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"conjunctivitis presents with watery discharge. Bacterial infections are more\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"likely to present with thick exudate and conjunctival injection. Allergic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"conjunctivitis typically presents with stringy mucus. If there is pus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"(hypopion), corneal involvement, possible bacterial conjunctivitis, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"keratitis, consult ophthalmology.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Viral conjunctivitis is most commonly caused by adenovirus. It is self-limited\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"and antivirals provide no benefit. Symptomatic treatment with ophthalmic\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antihistamine/decongestants and warm or cool compresses may relieve symptoms.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Bacterial conjunctivitis is most commonly associated with Staphylococcus aureus,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae, Haemophilus spp., Moraxella catarrhalis,\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Corynebacterium diphtheriae, Neisseria spp. or enteric gram-negative rods. It is\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"generally self-limited, but topical antimicrobials reduce duration of symptoms\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"and limit person-to-person spread of infection. If symptoms do not improve after\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"2 days of antimicrobial therapy, the patient should be seen by an\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"ophthalmologist.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment for acute bacterial conjunctivitis\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"q3h for 7 days ($) [M]\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment for severe cases of bacterial conjunctivitis involving suppuration or\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"contact lens wearers\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Consult ophthalmology and begin topical antimicrobials.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"days then 2 drops QID for 5 days ($) [M]\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Azari eta al, JAMA (2013) 1721-1730\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Microbial conjunctivitis\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-to-Date Article: Conjunctivitis\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Conjunctivitis, Bacterial\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 803,
    "fields": {
      "name": "ORZID3 GMENU CUTANEOUS ABSCESS",
      "term": null,
      "displaytext": "Cutaneous abscess (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 210, \"DisplayText\": \"[CLICK HERE] for list of MRSA risk factors\", \"Text\": \"[CLICK HERE] for list of MRSA risk factors\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO bid for 7 days ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 698, \"DisplayText\": \"Perianal/Anorectal Abscess\", \"Text\": \"Perianal/Anorectal Abscess\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CUTANEOUS ABSCESS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Incise and drain and cover the site with a dry dressing.  For small abscesses,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"systemic antimicrobial therapy is rarely necessary.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"If the patient is neutropenic, has multiple lesions, or has fever or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"leukocytosis, antimicrobial treatment may be necessary.  Contact Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases for assistance.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antimicrobial\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration: Treat for 5 to 7 days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mild to Moderate Cases:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Moderate or high suspicion of MRSA\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Low suspicion of MRSA\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"For SEVERE cases empiric coverage with MRSA agent\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"See Inpatient CDSS for intravenous therapy\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For Perirectal/Anorectal Abscess Select Below\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword:  Skin infections\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 500 mg PO BID for 7 days  ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 804,
    "fields": {
      "name": "ORZID3 GMENU CUTANEOUS CANDIDIASIS",
      "term": null,
      "displaytext": "Cutaneous Candidiasis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical bid for 28 days\", \"Text\": \"Clotrimazole 1% cream apply to affected area BID ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin Cream to affected area BID ($) [M]\", \"Text\": \"Nystatin Cream to affected area BID ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin Cream to affected area BID ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CUTANEOUS CANDIDIASIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cutaneous candidiasis is a superficial fungal infection of the epidermis.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Presents with red, erythematous patches, often in areas where skin contact\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"skin, including axillae, groin, and abdominal folds.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Keep affected areas dry and clean.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treat for 4 weeks.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Up-to-date\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford: Cutaneous Candidiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 805,
    "fields": {
      "name": "ORZID3 GMENU DECUBITIS ULCERS",
      "term": null,
      "displaytext": "Decubitis ulcers (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 698, \"DisplayText\": \"Perianal/Anorectal Abscess\", \"Text\": \"Perianal/Anorectal Abscess\", \"Mnemonic\": \"10\"}, {\"Row\": 40, \"Column\": 1, \"Item\": 783, \"DisplayText\": \"Cellulitis (Outpatient)\", \"Text\": \"Cellulitis\", \"Mnemonic\": \"12\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 952, \"DisplayText\": \"Osteomyelitis (Outpatient)\", \"Text\": \"Osteomyelitis\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DECUBITUS ULCERS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Relieve pressure and friction, provide good nutrition, and debride the ulcer.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Decubitus ulcers are colonized with bacteria.  Antimicrobial therapy is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"unnecessary unless the patient has infection of surrounding tissues signified by\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"erythema, warmth, local tenderness, or purulent discharge.  Rectal or groin\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"decubitus ulcers with surrounding infection need broad spectrum antimicrobials.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Ulcers located in other sites are usually treated with antimicrobials for\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"staphylococci and streptococci.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of therapy usually 7-14 days, but adjust to clinical response\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For deep abscesses away from the rectal area, obtain material for Gram stain and\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"culture and treat with:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treatment for Mild to Moderate Infections:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment for severe infection:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Refer to Inpatient CDSS\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"For PERIRECTAL ABSCESSES that need a systemic antimicrobial:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"If there are signs and/or symptoms of cellulitis or osteomyelitis, refer to the\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"advice page for the appropriate syndrome.  Contact the ET nurse, Infectious\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Diseases, Dietician, or Vascular surgery for more information.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Parish LC Dermatol Clin 2004, 22: 87\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"4a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID for 7 days ($) [DI,O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600mg po bid for 7days ($) [DI,O]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 806,
    "fields": {
      "name": "ORZID3 GMENU DEEP OROPHARYN INFECT",
      "term": null,
      "displaytext": "Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DEEP OROPHARYNGEAL INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Deep oropharyngeal infections may threaten life and must be treated immediately.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Assess the risk of airway compromise and monitor the airway if it is threatened.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"These infections are more common in people with diabetes mellitus and are caused\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"by mixed organisms including streptococcus sp., Staphylococcus aureus and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"anaerobes . Perform CT scan to diagnose abscess. ENT and Infectious Diseases\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"consults are essential.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"If the patient's condition worsens or does not improve during the first 48 hours\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"of antimicrobial therapy, surgical drainage is indicated. If surgical drainage\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"is done, antimicrobials are usually continued for 48 hours after the procedure.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"If surgical drainage is not done, 2 weeks of antimicrobial therapy until\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"clinical improvement is observed (e.g. resolution of fever and leukocytosis) is\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"appropriate.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Empiric Treatment\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Step-down treatment after initial intravenous therapy. Adjust duration based on\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"criteria above.\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Oral Cavity, Neck, and Head\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Ogle, Dent Clin N Am. 2017, 61(2)235-252\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Reynolds et al. Lung. 2009, 187(5)271-279\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-to-Date article: Submandibular space infections (Ludwig's angina)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 807,
    "fields": {
      "name": "ORZID3 GMENU DERMATOLOGY OUTPT MAIN",
      "term": null,
      "displaytext": "Dermatology Infections (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 910, \"DisplayText\": \"Impetigo (Outpatient)\", \"Text\": \"Impetigo\", \"Mnemonic\": \"5\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 835, \"DisplayText\": \"Folliculitis (Outpatient)\", \"Text\": \"Folliculitis\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 830, \"DisplayText\": \"Erysipelas (Outpatient)\", \"Text\": \"Erysipelas\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 849, \"DisplayText\": \"Furuncles and Carbuncles (Outpatient)\", \"Text\": \"Furuncles and carbuncles\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 783, \"DisplayText\": \"Cellulitis (Outpatient)\", \"Text\": \"Cellulitis\", \"Mnemonic\": \"12\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 939, \"DisplayText\": \"Necrotizing infections (Outpatient)\", \"Text\": \"Necrotizing infections\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 825, \"DisplayText\": \"Ecthyma Gangrenosum (Outpatient)\", \"Text\": \"Ecthyma gangrenosum\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 1035, \"DisplayText\": \"Staphylococcal Scalded Skin Syndrome (Ritter's Disease) - Outpatient\", \"Text\": \"Scalded Skin Syndrome\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 902, \"DisplayText\": \"Hidradenitis Suppurativa (Outpatient)\", \"Text\": \"Hidradenitis Suppurativa\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 1046, \"DisplayText\": \"Toxic Shock Syndrome (Outpatient)\", \"Text\": \"Toxic Shock Syndrome\", \"Mnemonic\": \"22\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 832, \"DisplayText\": \"Erythrasma (Outpatient)\", \"Text\": \"Erythrasma\", \"Mnemonic\": \"24\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 831, \"DisplayText\": \"Erysipeloid (Erysipeloithrix Rhusopathiae Infection) - Outpatient\", \"Text\": \"Erysipeloid\", \"Mnemonic\": \"26\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 781, \"DisplayText\": \"Cat-Scratch Disease (Outpatient)\", \"Text\": \"Cat-scratch disease\", \"Mnemonic\": \"28\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 922, \"DisplayText\": \"Leishmaniasis\", \"Text\": \"Leishmaniasis\", \"Mnemonic\": \"30\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 1012, \"DisplayText\": \"Rocky Mountain Spotted Fever (Outpatient)\", \"Text\": \"Rocky Mountain Spotted Fever\", \"Mnemonic\": \"32\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 138, \"DisplayText\": \"Dermatology Recommendations\", \"Text\": \"Dermatology Post-Op Infection\", \"Mnemonic\": \"34\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  DERMATOLOGICAL INFECTIONS - OUTPATIENT  ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 2, \"Item\": 804, \"DisplayText\": \"Cutaneous Candidiasis (Outpatient)\", \"Text\": \"Candidiasis\", \"Mnemonic\": \"40\"}, {\"Row\": 6, \"Column\": 2, \"Item\": 961, \"DisplayText\": \"Paronychia (Outpatient)\", \"Text\": \"Paronychia\", \"Mnemonic\": \"42\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 744, \"DisplayText\": \"Bed Bugs (Hemiptera) - Outpatient\", \"Text\": \"Bed bugs (hemiptera)\", \"Mnemonic\": \"44\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 899, \"DisplayText\": \"Head Lice (Pediculosis Capitis) - Outpatient\", \"Text\": \"Head lice (pediculosis capitis)\", \"Mnemonic\": \"46\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 752, \"DisplayText\": \"Body Lice (Pediculosis Corporis) - Outpatient\", \"Text\": \"Body lice (pediculosis corporis)\", \"Mnemonic\": \"48\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 1005, \"DisplayText\": \"Pubic Lice (Pediculosis Pubis) - Outpatient\", \"Text\": \"Pubic lice (pediculosis pubis)\", \"Mnemonic\": \"50\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 1013, \"DisplayText\": \"Scabies (Outpatient)\", \"Text\": \"Scabies\", \"Mnemonic\": \"52\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"54\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 842, \"DisplayText\": \"Blastomyces dermatitidis (Outpatient)\", \"Text\": \"Blastomycosis\", \"Mnemonic\": \"56\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 1034, \"DisplayText\": \"Sporotrichosis (Outpatient)\", \"Text\": \"Sporotrichosis\", \"Mnemonic\": \"58\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 851, \"DisplayText\": \"Genital herpes (Outpatient)\", \"Text\": \"Genital herpes (Outpatient)\", \"Mnemonic\": \"60\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 901, \"DisplayText\": \"Herpes whitlow (Digit or Hand Cellulitis) - Outpatient\", \"Text\": \"Herpes whitlow (Digit or Hand Cellulitis) - Outpatient\", \"Mnemonic\": \"62\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 946, \"DisplayText\": \"Orolabial herpes (Outpatient)\", \"Text\": \"Oral lesions: Mouth, Lips (Cold sores)\", \"Mnemonic\": \"64\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 1040, \"DisplayText\": \"Tinea Capitis (Ringworm) - Outpatient\", \"Text\": \"Tinea capitis (ringworm)\", \"Mnemonic\": \"66\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 1042, \"DisplayText\": \"Tinea Unguium (Onychomycosis)\", \"Text\": \"Tinea unguium (onychomycosis)\", \"Mnemonic\": \"68\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 1041, \"DisplayText\": \"Tinea Pedis (Athlete's Foot) - Outpatient\", \"Text\": \"Tinea pedis, Tinea corporis, Tinea cruris\", \"Mnemonic\": \"70\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 1043, \"DisplayText\": \"Tinea Versicolor (Outpatient)\", \"Text\": \"Tinea versicolor\", \"Mnemonic\": \"72\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 996, \"DisplayText\": \"Primary infection (Chickenpox) - Outpatient\", \"Text\": \"Varicella/Chickenpox (primary infection)\", \"Mnemonic\": \"74\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 1008, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\") - Outpatient\", \"Text\": \"Zoster/Shingles (reactivation)\", \"Mnemonic\": \"76\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Herpes simplex virus infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 2, \"Text\": \"Tinea fungal infections\", \"Header\": 1}, {\"Row\": 28, \"Column\": 2, \"Text\": \"Varicella-Zoster virus infections\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Item\": 634, \"DisplayText\": \"Acne\", \"Text\": \"Acne\", \"Mnemonic\": \"3\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 714, \"DisplayText\": \"Rosacea\", \"Text\": \"Rosacea\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 808,
    "fields": {
      "name": "ORZID3 GMENU DEVICE-RELATED INFECT",
      "term": null,
      "displaytext": "Device-related infections (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Intravascular catheter-related infection\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Prosthetic-valve endocarditis - Empirical Therapy\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Prosthetic valve endocarditis - Selected pathogens\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 780, \"DisplayText\": \"Cardiovascular Outpatient Main Page\", \"Text\": \"Infections involving cardiovascular devices (except valves)\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"++ DEVICE-RELATED INFECTIONS ++\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"If the desired syndrome is not listed below, return to the main menu and refer\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"to the pertinent organ-system.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Last reviewed 11/17\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 809,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA AEROMONAS",
      "term": null,
      "displaytext": "Diarrhea with Aeromonas (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH AEROMONAS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8(94)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Aeromonas sp.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-to-Date article: Aeromonas infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 810,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA C. CAYETANENSIS",
      "term": null,
      "displaytext": "Diarrhea with Cyclospora cayetanensis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID for 7 to 10 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CYCLOSPORA CAYETANENSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for patients with allergy to sulfonamides.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients without HIV/AIDS\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients with HIV/AIDS\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for patients with HIV/AIDS.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Cyclosporiasis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Up-to-Date article: Cyclospora infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 811,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA C. PARVUM",
      "term": null,
      "displaytext": "Diarrhea with Crytosporidium parvum (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]\", \"Text\": \"Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CRYPTOSPORIDIUM PARVUM\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibiotic therapy is usually used only for persons with severe disease or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"immunocompromised persons.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients without HIV/AIDS\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antimicrobial treatment for patients with HIV/AIDS\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for patients with HIV/AIDS.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Cryptosporidiosis\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of cryptosporidiosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 812,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA CAMPYLOBACTER",
      "term": null,
      "displaytext": "Diarrhea with Campylobacter (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Text\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CAMPYLOBACTER\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Fluoroquinolone resistance is increasing worldwide. Macrolide resistance is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"rare.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Campylobacter\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Campylobacter infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 813,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA E. HISTOLYTICA",
      "term": null,
      "displaytext": "Diarrhea with Entamoeba histolytica (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Text\": \"Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTAMOEBA HISTOLYTICA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary treatment for gastroenteritis\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment for gastroenteritis or extraintestinal disease\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases. Paromomycin is nonformulary and must\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"be order by Infectious Diseases.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"25-35 mg/kg/day PO TID for 7 days ($) [M]\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Sanford keyword: Amoebiasis, Entamoeba histolytica\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-to-Date article: Intestinal Entamoeba histolytica amoebiasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 814,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA ENTEROHEM E. COLI",
      "term": null,
      "displaytext": "Diarrhea with enterohemorrhagic E. Coli (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RIFAXAMIN 3DS 200MG TID\", \"Text\": \"Rifaximin 200 mg TID for 3 days ($$) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rifaximin 200 mg TID for 3 days ($$) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 819, \"DisplayText\": \"Diarrhea with Shigella (Outpatient)\", \"Text\": \"Link to Shigella/Enteroinvasive E. coli menu\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH ESCHERICHIA COLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Enteroaggretive E. coli (EAEC), Enteropathogenic E. coli (EPEC), and\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Enterotoxigenic E. coli (ETEC)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"EAEC infection can cause watery diarrhea with mucus that is occasionally bloody.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"It is more common in patients with HIV and those who have traveled to developing\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"regions. EPEC infection is associated with severe acute watery diarrhea that is\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"occasionally bloody. ETEC infection causes acute watery diarrhea that is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"occasionally severe. It is most common in travelers to tropical regions who are\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"exposed to contaminated food and water.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antibiotic therapy is not required for mild to moderate disease caused by these\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"organisms because diarrhea often resolves on its own. Do not use antimotility\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"agents in patients with bloody stool.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Primary treatment\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Antimicrobial treatment of severe diarrhea\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Antimicrobial treatment in patients with AIDS\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Enterohemorrhagic E. coli (EHEC) and Shiga Toxin-producing E. coli (STEC)\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"EHEC and STEC disease often presents as bloody diarrhea. It is more common in\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"people who have consumed undercooked meats or poultry, fruits or unpasteurized\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"fruit juices, vegetables, leafy greens or seed sprouts. Exposure risks include\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"swimming in or drinking untreated fresh water and visiting a farm, petting zoo,\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"healthcare facility, prison or childcare facility.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treatment includes supportive measures such as volume repletion and\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"administering appropriate nutrition. Do not use antimotility or antimicrobial\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"agents as they can increase shiga-toxin release and increase the risk of\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"hemolytic uremia syndrome (HUS).\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Enteroinvasive E. coli (EIEC)\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"EIEC disease typically presents as watery diarrhea, sometimes progressing to\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"bloody diarrhea. Refer to Shigella/Enteroinvasive E. coli menu for\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"recommendations.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Brunette, Gary W. CDC Yellow Book 2018: Oxford University Press, 2017\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Enterohemorrhagic E. coli / Shiga toxin-producing E. coli\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-to-Date article: Pathogenic Escherichia coli\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treatment is complex, consult Infectious Diseases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 815,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA G. LAMBLIA",
      "term": null,
      "displaytext": "Diarrhea with Giardia lamblia (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]\", \"Text\": \"Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]\", \"Mnemonic\": \"4\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 250 mg PO TID for 5 ($) [DI]\", \"Text\": \"Metronidazole 250 mg PO TID for 5 to 7 days ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 250 mg PO TID for 5 ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH GIARDIA DUODENALIS (ALSO KNOWN AS G. LAMBLIA AND G.INTESTINALIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Illness with Giardia is typically subacute but varies widely in its time course.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment is necessary when the patient has symptomatic disease. Diarrhea,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"abdominal pain, bloating, belching, flatus, nausea, and vomiting are present\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"acutely and after several days give way to flatus, loose stools, belching, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"weight loss.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Asymptomatic carriage of Giardia is common in household contacts of people who\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"are infected with Giardia. Treatment of asymptomatic patients can be considered\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"if they have contact with immunocompromised or pregnant people or live or work\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"in settings where there is risk of spreading infection to others (e.g., food\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"handlers, daycare, nursing home).\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Minetti et al, BMJ, 2016, 355.i5369\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Giardia duodenalis (G. intestinalis, G. lamblia)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date article: Giardiasis: Treatment and prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 816,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA ISOSPORA BELLI",
      "term": null,
      "displaytext": "Diarrhea with Isospora belli (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 tablet DS PO BID for 7 to 10 days ($)\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)\", \"Text\": \"Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg P Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 tablet DS QID for 10 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 tablet DS QID for 10 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 tablet DS QID for 10 days ($) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)\", \"Text\": \"Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)\", \"Mnemonic\": \"10a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg P Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 tablet DS PO 3X/week ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 tablet DS PO 3X/week ($) [R,DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 tablet DS PO 3X/week ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 25 mg PO QDAY ($$) [DI,O] <AND> leucovorin 10 mg PO QDAY ($)\", \"Text\": \"Pyrimethamine 25 mg PO QDAY ($$) [DI,O] <AND> leucovorin 10 mg PO QDAY ($)\", \"Mnemonic\": \"14a\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pyrimethamine 25 mg PO QDAY ($$) [DI,O] <AND> leucovorin 10 mg P Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CYSTOISOSPORA BELLI (FORMALLY ISOSPORA BELLI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"C. belli is associated with diarrhea in persons with HIV/AIDS and only rarely in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"immunocompetent persons.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons without HIV/AIDS\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"[R,DI]\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative for trimethoprim or sulfamethoxazole allergy\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"for 21-28 days\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons with HIV/AIDS\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Infectious Diseases involvement is essential. Initial treatment of acute\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"infection is followed by secondary prophylaxis until CD4 count is >200 for >6\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"months in response to ART without evidence of active C. belli.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Initial treatment\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Alternative for trimethoprim or sulfamethoxazole allergy\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"for 21 to 28 days\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Secondary prophylaxis\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Alternative for trimethoprim or sulfamethoxazole allergy\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford keyword: Cystoisospora belli\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-to-Date article: Management of Cystoisospora (Isospora) infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 817,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA MICROSPORIDIA",
      "term": null,
      "displaytext": "Diarrhea with Microsporidia (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albendazole 400 mg PO BID ($$) [O]\", \"Text\": \"Albendazole 400 mg PO BID for 7 to 14 days ($$) [O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albendazole 400 mg PO BID ($$) [O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albendazole 400 mg PO BID ($$) [O]\", \"Text\": \"Albendazole 400 mg PO BID ($$) [O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Albendazole 400 mg PO BID ($$) [O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH MICROSPORIDIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In patients without HIV/AIDs, symptoms may resolve without antimicrobial\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"therapy. In persons with AIDS, highly active anti-retroviral therapy (HAART) is\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"beneficial because recovery of host defenses helps to control microsporidial\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"disease. Infectious Diseases involvement is essential in patients with HIV/AIDS.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons without HIV/AIDS\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Antimicrobial treatment of persons with HIV/AIDS\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Continue treatment until CD4 count is >200 for >6 months after\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"initiation of ART.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Microsporidiosis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date article: Microsporidiosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 818,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA SALMONELLA",
      "term": null,
      "displaytext": "Diarrhea with Salmonella (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 651, \"DisplayText\": \"Enteric Fever\", \"Text\": \"Link to Enteric Fever Menu\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 7 days ($) [M]\", \"Text\": \"Azithromycin 500 mg PO QDAY for 7 days ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 7 days ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 14 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 14 days ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 14 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 14 days ($) [M]\", \"Text\": \"Azithromycin 500 mg PO QDAY for 14 days ($) [M]\", \"Mnemonic\": \"12a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 14 days ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH SALMONELLA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For systemic febrile illness or typhoidal Salmonella, refer to Enteric Fever\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Menu:\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment is not recommended for mild or moderately severe disease in otherwise\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"healthy individuals <50 years old, because the disease is self-limiting and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials can prolong the carrier state and increase the risk of relapse.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"By contrast, treatment should be considered for severe disease, and if the\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"patient is > 50 years old, is immunocompromised, or has another debilitating\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"underlying disease.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Antimicrobial treatment of immunocompetent patients\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"If infection acquired in Asia or patient is intolerant to fluoroquinolones\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Antimicrobial treatment of immunocompromised patients\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"If infection acquired in Asia or patient is intolerant to fluoroquinolones\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Salmonella: Non-typhi\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Up-to-Date article: Nontyphoidal Salmonella: Gastrointestinal infection and\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"carriage\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 819,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA SHIGELLA",
      "term": null,
      "displaytext": "Diarrhea with Shigella (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Text\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH SHIGELLA (BACILLARY DYSENTERY) OR ENTEROINVASIVE E. COLI (EIEC)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Shigellosis is generally a self-limited infection lasting 5-7 days.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Antimicrobial resistance is common and continues to rise for all recommended\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobials. Treatment should be reserved for patients who are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"immunocompromised, or who develop severe illness (e.g., requiring\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"hospitalization, invasive, or with complications) or live or work in settings\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"where there is risk of spreading infection to others (e.g., food handlers,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"daycare, nursing home).\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"CDC advisory: https://emergency.cdc.gov/han/han00401.asp\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Shigella\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date article: Shigella infection: Treatment and prevention in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 820,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA VIBRIO CHOLERA",
      "term": null,
      "displaytext": "Diarrhea with Vibrio cholera (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 300 mg PO once ($) [DI]\", \"Text\": \"Doxycycline 300 mg PO once ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 300 mg PO once ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 1000 mg PO once ($) [R,DI]\", \"Text\": \"Ciprofloxacin 1000 mg PO once ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 1000 mg PO once ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIARRHEA WITH CHOLERA (VIBRIO CHOLERAE)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Primary Treatment\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Aggressive hydration and electrolyte replacement are essential\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Tetracycline intolerant patient\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Vibrio cholerae\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date article: Cholera: Clinical features, diagnosis, treatment, and\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 821,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA VIBRIO NON CHOLERA",
      "term": null,
      "displaytext": "Diarrhea with non-cholera vibrio (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 3-5 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg BID for 3 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg BID for 3-5 days ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg BID for 3 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NON-CHOLERA VIBRIO\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Non-cholera vibrio is associated with gastroenteritis, septicemia, and wound\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infections. Vibrio vulnificans infections are acquired from contact with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"seawater or seafood, especially raw oysters. V. vulnificans cases are more\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"severe than cases with other species. V. parahaemolyticus causes\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"gastroenteritis and milder wound infections.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Antimicrobials do not shorten the course of disease in immunocompetent patients\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with mild gastroenteritis.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Primary treatment for gastroenteritis\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Antimicrobial treatment of minor wound infection, severe gastroenteritis or\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"immunocompromised patient with gastroenteritis\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for patient intolerant of fluoroquinolones\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"For intravenous treatment\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Antimicrobial treatment of severe wound infection or septicemia\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Vibrio parahaemolyticus\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Vibrio vulnificus: Cellulitis, Sepsis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date article: Vibrio parahaemolyticus infections\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date article: Vibrio vulnificus infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 822,
    "fields": {
      "name": "ORZID3 GMENU DIARRHEA Y. ENTEROCOLITICA",
      "term": null,
      "displaytext": "Diarrhea with Yersinia enterocolitica (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"YERSINIA ENTEROCOLITICA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobials are indicated only for patients with severe disease or immune\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"compromise. For patients with extra-intestinal disease, consult Infectious\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Diseases or Gastroenterology for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Primary treatment of gastroenteritis\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobial treatment of severe gastroenteritis or immunocompromised patient\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for fluoroquinolone intolerant patients\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Antimicrobial treatment of extra-intestinal infection\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Gastroenteritis, Yersinia enterocolitica\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of Yersinia enterocolitica and\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Yersinia pseudotuberculosis infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 823,
    "fields": {
      "name": "ORZID3 GMENU DISKITIS",
      "term": null,
      "displaytext": "Diskitis and vertebral osteomyelitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DISKITIS AND VERTEBRAL OSTEOMYELITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 824,
    "fields": {
      "name": "ORZID3 GMENU DIVERTICULITIS",
      "term": null,
      "displaytext": "Diverticulitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 to 10 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]  <AND>\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AN Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po qday for 7days\", \"Text\": \"Moxifloxacin 400 mg PO QDAY for 7 to 10 days ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 400mg po qday for 7days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO\", \"Mnemonic\": \"12a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DIVERTICULITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diverticulitis involves inflammation of an intestinal diverticulum, usually in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the colon, causing pain and disturbed bowel function.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Mild disease\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"metronidazole 1000 mg PO BID ($) [DI] for 7 to 10 days\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"BID ($) [DI] for 7 to 10 days\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Moderate to severe disease\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Diverticulitis and Typhlitis\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Diverticulitis\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date article: Acute colonic diverticulitis: Medical management\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 825,
    "fields": {
      "name": "ORZID3 GMENU ECTHYMA GANGRENOSUM",
      "term": null,
      "displaytext": "Ecthyma Gangrenosum (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ECTHYMA GANGRENOSUM\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Ecthyma gangrenosum lesions commonly begin as painless red macules which\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"rapidly evolve into areas of induration that develop into pustules and-or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"bullae. Ultimately, these become gangrenous ulcers. Ecthyma lesions\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"typically progress rapidly within 12 to 18 hours. They are often associate\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"with Pseudomonas aeruginosa bacteremia, especially in neutropenic patients.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Recommend blood cultures and culture of skin exudates.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Pseudomonas aeruginosa\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 826,
    "fields": {
      "name": "ORZID3 GMENU EMPYEMA",
      "term": null,
      "displaytext": "Empyema (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPYEMA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 827,
    "fields": {
      "name": "ORZID3 GMENU ENDOPHTHALMITIS",
      "term": null,
      "displaytext": "Endophthalmitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENDOPHTHALMITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Endophthalmitis is a medical emergency and presents with eye pain and visual\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"loss. It may be associated with gram positive or gram-negative bacteria,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"including Staphylococcus aureus and Pseudomonas aeruginosa, or with fungi.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consult ophthalmology immediately. The ophthalmologist will obtain an aqueous or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"vitreous fluid sample for gram stain and culture and begin intravitreal\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"antimicrobials.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment with intravitreal antimicrobials\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Fungal endophthalmitis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Fungal endophthalmitis is rarely diagnosed in temperate climates and treatment\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"is complicated. Ophthalmology and Infectious Diseases involvement is essential.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell chapter: Endophthalmitis\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Endophthalmitis, Hematogenous or Endogenous\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Tranos et al., Advances in therapy. 2016, 33(5)727-746\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacterial endophthalmitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 828,
    "fields": {
      "name": "ORZID3 GMENU EPIDIDYMITIS",
      "term": null,
      "displaytext": "Epididymitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO q24h\", \"Mnemonic\": \"6a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days\", \"Text\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO q24h ($) [R, DI] for 10 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 10 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Ceftriaxone 500 mg IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"14a\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]\", \"Text\": \"Ceftriaxone 1 gm IM once ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI] for\", \"Mnemonic\": \"18a\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid 10days ($)[DI]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"22\"}, {\"Row\": 71, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po q24h ($)[R,DI]\", \"Text\": \"Levofloxacin 500 mg PO q24h ($) [R, DI] for 10 days\", \"Mnemonic\": \"24a\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po q24h ($0.19/day)[R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"24b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EPIDIDYMITIS AND EPIDIDYMO-ORCHITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Epididymitis is inflammation of the epididymis and when testicles are involved\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"is referred to as epididymo-orchitis. Acute epididymitis is the most common\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cause of scrotal pain in adults. Other features include scrotal erythema and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"edema, pyuria, dysuria, thickened epididymis, swollen testis, and is usually\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"unilateral. It is primarily caused by infection but can also result from trauma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and autoimmune diseases. Testicular torsion should be ruled out before\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"treatment. Most cases in men aged 35 and older, those with recent urinary tract\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"instrumentation or surgery (e.g., prostate biopsy, vasectomy) are associated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"with enteric Gram-negative rods. Most cases in men under age 35 are associated\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"with N. gonorrhoeae and C. trachomatis. Resistant organisms are more likely if\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"the patient has been in the hospital for more than 48 hours or received a course\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of antibiotics. There is increasing resistance in urinary pathogens to\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"ciprofloxacin.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"A urine analysis, urine culture and urine nucleic acid amplification test (NAAT)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"should be performed in all cases of suspected epididymitis before starting\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"treatment to guide therapy:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients at risk of sexually transmitted infections should be assessed for\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"treatment. Refer to the Urogenital section of the Antimicrobial CDSS for more\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Patients with bacterial epididymitis treated with antibiotics should improve\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"within two or three days. If no improvement is noted, other causes of scrotal\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"pain and referral to a urologist should be considered.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Management should include bed rest, analgesics, and scrotal elevation. Older men\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"should have their residual urinary volume checked. If the residual volume is\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"elevated, the patient should be seen by a urologist as epididymitis is unlikely\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"to respond if the prostate is blocking the vas deferens.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Empirical treatment in men who practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"for 10 days ($) [R, DI]\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Empirical treatment in men who do not practice insertive anal intercourse\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Age >/= 35 years or\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Recent urinary tract instrumentation or urinary tract surgery (e.g., prostate\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"biopsy, vasectomy):\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Age < 35 years\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Patient weighing less than 300 lbs\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Patients weighing 300 lbs or greater\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"10 days\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Mandell Chapter: Prostatitis, Epididymitis and Orchitis\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Sanford keyword: Epididymo-orchitis\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Taylor, Stephanie, Clinical Infectious Diseases, 2015, 61(S8)S770-3\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Up-To-Date article: Evaluation of acute scrotal pain in adults\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Workowski et al., MMWR Recomm Rep, 2021, 70(4)1-187\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 829,
    "fields": {
      "name": "ORZID3 GMENU EPIGLOTTITIS",
      "term": null,
      "displaytext": "Epiglottitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EPIGLOTTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Maintaining the airway is the key to management. Call ENT service and ask them\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to see the patient immediately. Blood cultures and epiglottal cultures (in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"intubated patients) should be used to direct antimicrobial therapy. Empirical\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"therapy should be initiated prior to results of cultures as infection is life\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"threatening and cover for likely pathogens (Moraxella catarrhalis, penicillin\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"resistant S. pneumonia, beta-hemolytic streptococci and possibly Staph. aureus)\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empirical Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Epiglottitis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Rafei et al., Pediatric Clinics 2006, 53.2, 215-242\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Epiglottitis, Supraglottis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-to-date article: Epiglottis (supraglottis): Management\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 830,
    "fields": {
      "name": "ORZID3 GMENU ERYSIPELAS",
      "term": null,
      "displaytext": "Erysipelas (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 250mg po qid for 10 days\", \"Text\": \"Penicillin VK 250 - 500 mg PO QID for 10 days  ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 250mg po qid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 250mg po qid for 10 days\", \"Text\": \"Erythromycin 250-500 mg PO QID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 250mg po qid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ERYSIPELAS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"In contrast to cellulitis, erysipelas has sharply demarcated borders and a\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"characteristic raised, orange-peel appearance.  Most cases are associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"streptococcus.  In a minority of cases, especially those involving the face,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Staphylococcus aureus is also a potential pathogen.  In severe cases,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"methicillin-resistant Staphylococcus aureus (MRSA) coverage must be provided\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"until microbiology results are available.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treat for 5 to 10days, longer if patient is bacteremic.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Facial\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sudden onset of rapidly spreading red edematous tender plaque-like skin on\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"face in an otherwise healthy host.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"If erysipelas-like on the face treat as if MRSA is present:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Non-facial\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"_________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"MILD TO MODERATE disease\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"SEVERE disease\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Erysipelas\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 831,
    "fields": {
      "name": "ORZID3 GMENU ERYSIPELOID",
      "term": null,
      "displaytext": "Erysipeloid (Erysipeloithrix Rhusopathiae Infection) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin V 500mg po qid for 7 days\", \"Text\": \"Penicillin V 500 mg PO QID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin V 500mg po qid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500mg po qid for 7 days\", \"Text\": \"Erythromycin 500 mg PO QID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500mg po qid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ERYSIPELOID (ERYSIPELOTHRIX RHUSOPATHIAE INFECTION)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Erysipeloid is a localized cutaneous infection with Erysipelothrix rhusopathiae\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"It is a zoonotic infection of fisherman, fish handlers, and butchers acquired by\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"direct animal contact, most commonly with fish, but also with other animals\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(e.g., swine). It usually affects the hand or fingers and is characterized\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"throbbing pain and a red rash with a purple center and an elevated border.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Localized infections can be treated with oral antimicrobials.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Severe, diffuse cutaneous infections or systemic infections with E.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"rhusopathiae occur rarely after ingestion of undercooked pork or contaminated\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"seafood in immunosuppressed individuals.  These infections are treated\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"initially with intravenous antimicrobials.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment of localized infection (erysipeloid)\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"_____________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"___________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment of systemic or severe diffuse cutaneous infection with E.\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"rhusopathiae\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"___________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Erysipelothrix\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 832,
    "fields": {
      "name": "ORZID3 GMENU ERYTHRASMA",
      "term": null,
      "displaytext": "Erythrasma (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% topical solution bid for 14 days\", \"Text\": \"Clindamycin 1% topical solution apply twice daily ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% topical solution bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500 mg po bid ($) [DI]\", \"Text\": \"Clarithromycin 500 mg PO bid ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500 mg po bid ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ERYTHRASMA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Erythrasma presents as brownish-red, well circumscribed, irregularly shaped\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"patches in or near skin folds.  Patches in the groin often itch.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Most cases respond to topical therapy.  Systemic antibiotics are used for more\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"severe cases or those that do not respond to topical therapy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: erythrasma\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Holdiness MR Drugs 2002, 62:1131\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 833,
    "fields": {
      "name": "ORZID3 GMENU FEVER OF UNKNOWN ORIGIN",
      "term": null,
      "displaytext": "Fever of Unknown Origin (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 943, \"DisplayText\": \"Neutropenic fever (Outpatient)\", \"Text\": \"NEUTROPENIC FEVER\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FEVER OF UNKNOWN ORIGIN\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Fever of unknown origin (FUO) is the occurrence of several episodes of fever\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"greater than 101 degrees Fahrenheit over a time period of at least 3 weeks\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"despite 1 week of hospital evaluation. Cases with FUO are often classified in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"four categories: (1) classical, (2) neutropenic, (3) nosocomial, and (4) fever\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in persons with HIV/AIDS. Empirical antimicrobial therapy is rarely indicated\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"in patients with FUO.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Note that FUO in neutropenic patients refers to persistent fever that has\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"remained undiagnosed after extensive diagnostic work and empirical antimicrobial\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"therapy. New fever in patients with profound neutropenia is a different\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"syndrome and does require empirical antimicrobial therapy. Infectious Diseases\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"should be involved in any case where empirical treatment for fever of unknown\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"origin is being considered.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell Chapter: Fever of Unknown Origin\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 834,
    "fields": {
      "name": "ORZID3 GMENU FIRST RECURRENCE ABX ASSOCIATED COLITIS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin capsule taper and pulse\", \"Text\": \"Vancomycin Extended Pulse-Taper Regimen ($) [M]\", \"Mnemonic\": \"10a\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Discontinue implicated antibiotic and avoid high-risk antibiotic if\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"antibiotic therapy is still needed. Discontinue antacid therapy if possible.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"First Recurrence CDI: *The REGIMEN should be different from initial treatment*\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Severe/life-threatening disease (shock, ileus, megacolon)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Treatment and\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"prevention\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"CDI Recurrence: Typically defined as a repeated symptomatic, laboratory\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"confirmed case of CDI within 12 weeks after a prior episode.\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200mg Extended-pulse regimen ($$$$) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg po q12h x 10 days ($$$$) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg PO BID for 10 days ($$$$) [O]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125 mg PO QID for 10 days ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125 mg PO QID for 10 days ($$) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin capsule taper and pulse Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"125 mg po bid for 7 days, then 125mg po qday for 7 days, then\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"125mg every other day for 6 weeks)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Fulminant CDI:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FIRST RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 835,
    "fields": {
      "name": "ORZID3 GMENU FOLLICULITIS",
      "term": null,
      "displaytext": "Folliculitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topical to affected area TID for 7 days ($) [M]\", \"Text\": \"Mupirocin 2% ointment topical to affected area TID for 7 days ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% ointment topical to affected area TID for 7 days ($ Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clotrimazole cream to affected area TID for 7 days ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"FOLLICULITIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Folliculitis is an infection of the hair follicle with purulent exudate in the\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"epidermis. It is usually associated with Staphylococcus aureus.  In patients\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"exposed to swimming pools or hot tubs, folliculitis may be associated with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa. Candida albicans can cause folliculitis in patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"receiving antimicrobials and/or corticosteroids. For folliculitis in patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"with severe acne, consult Dermatology.  For extensive folliculitis or in\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"patients with HIV, consult Infectious Diseases.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Usually self-limiting. For most cases, treat with daily saline compresses until\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"symptoms resolve.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For moderate to severe cases associated with Staphylococcus aureus:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"For cases associated with Candida albicans\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Folliculitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 836,
    "fields": {
      "name": "ORZID3 GMENU FOOT ULCER IN PT W/ DM",
      "term": null,
      "displaytext": "Foot ulcer in patient with diabetes mellitus (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 838, \"DisplayText\": \"Foot ulcers WITHOUT infection of surrounding tissues (Outpatient)\", \"Text\": \"Foot ulcers WITHOUT infection of surrounding tissues\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 837, \"DisplayText\": \"Foot ulcers WITH infection of surrounding tissues (Outpatient)\", \"Text\": \"Foot ulcers WITH infection of surrounding tissues\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCER IN PATIENT WITH DIABETES MELLITUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Foot ulcers in patients with diabetes mellitus are colonized with bacteria.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Antimicrobials should not be used to treat colonization.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Cases with infection of surrounding tissues signified by erythema, warmth, local\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"tenderness, or purulent discharge should be treated with antimicrobials. Pain\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"may not be present in patients with neuropathy.  In patients with substantial\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"vascular disease, erythema and warmth may not be present and instead the tissues\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"will be dusky, mottled, or cool.  Capillary refill may be impaired.  Patients\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"with diabetes and ulcers are at risk for gangrenous infections.  If there is any\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"suggestion of gangrene, consult surgery immediately.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 837,
    "fields": {
      "name": "ORZID3 GMENU FOOT ULCERS W/ INFECT SURR TISSUES",
      "term": null,
      "displaytext": "Foot ulcers WITH infection of surrounding tissues (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO BID for 7 days ($) [DI]\", \"Mnemonic\": \"14a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of therapy:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antibiotics may be stopped 24-48 hours following curative amputation.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Otherwise, continue antibiotics until signs of infection have resolved.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"___________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Mild: ulcer with superficial inflammation\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Duration: treat until resolution of symptoms usually 1-2 weeks\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Oral therapy, no MRSA coverage:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Oral therapy, MRSA coverage:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"________________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Moderate: Ulcer with inflammation, extension into fascia\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Duration: treat to resolution of symptoms usually 1-3 weeks\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"For patients started on parenteral therapy, a switch to an oral regimen\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"is reasonable following clinical improvement.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Oral therapy with MRSA coverage:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Regimens for MODERATE intravenous therapy or SEVERE infections:\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND>\", \"Mnemonic\": \"18a\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875 mg po BID ($) [R] <AND> Doxycycline\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND> Doxycycline\", \"Mnemonic\": \"20a\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"100 mg PO BID for 14 days ($) [DI]\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 14 days ($) [R,DI]\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"therapy, de-escalate/modify regimen based on culture and susceptibility data.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125mg bid x14days + Doxycycline 100mg bid x14days\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clav 875/125 bid x14days +Trimeth-sulfa bid 14days\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 309, \"DisplayText\": \"Approach to foot ulcers with infection\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 838,
    "fields": {
      "name": "ORZID3 GMENU FOOT ULCERS W/O INFECT SURR TISS",
      "term": null,
      "displaytext": "Foot ulcers WITHOUT infection of surrounding tissues (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOOT ULCERS WITHOUT INFECTION OF SURROUNDING TISSUES\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Clinically uninfected wounds do not need antibiotic treatment.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Topical antimicrobials are not helpful, are associated with allergic reactions,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"and select for resistant organisms.  In general, local treatment should consist\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"of dressings with frequent changes, soaks, and debridement.Patients with\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"edema or impaired venous return should keep the limb elevated.  Wound care and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"improved control of diabetes can improve outcomes of infection and prevent\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"future complications.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59:147\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:e132\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 839,
    "fields": {
      "name": "ORZID3 GMENU FUNGAL SINUSITIS",
      "term": null,
      "displaytext": "Fungal Sinusitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FUNGAL SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Fungal sinusitis mainly affects immunocompromised patients, but occasionally it\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"occurs in immunocompetent hosts. Drainage is essential. Consult ENT and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Infectious Disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Sanford Keyword: Aspergillosis, Allergic Fungal Sinusitis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Up-to-Date article: Fungal rhinosinusitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 840,
    "fields": {
      "name": "ORZID3 GMENU FUNGI",
      "term": null,
      "displaytext": "Fungi (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 841, \"DisplayText\": \"Aspergillus spp. (Outpatient)\", \"Text\": \"Aspergillus and other moulds\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 842, \"DisplayText\": \"Blastomyces dermatitidis (Outpatient)\", \"Text\": \"Blastomyces dermatitidis\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 843, \"DisplayText\": \"Candida albicans (Outpatient)\", \"Text\": \"Candida albicans\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 844, \"DisplayText\": \"Candida glabrata (Outpatient)\", \"Text\": \"Candida glabrata\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 845, \"DisplayText\": \"Candida krusei (Outpatient)\", \"Text\": \"Candida krusei\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 846, \"DisplayText\": \"Coccidioidomyces (Outpatient)\", \"Text\": \"Coccidioidomyces\", \"Mnemonic\": \"14\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 847, \"DisplayText\": \"Cyptococcus Neoformans (outpatient)\", \"Text\": \"Cryptococcus neoformans\", \"Mnemonic\": \"16\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 848, \"DisplayText\": \"Histoplasma capsulatum (Outpatient)\", \"Text\": \"Histoplasma capsulatum\", \"Mnemonic\": \"18\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 985, \"DisplayText\": \"Pneumocyctis Jirovecii Disease (Outpatient)\", \"Text\": \"Pneumocystis (considered a fungus)\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ FUNGI ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome, site of infection, penetration of drug(s)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into site, and whether organism is pathogen, colonizer, or contaminant. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome section for more information.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Last reviewed 8/18\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 841,
    "fields": {
      "name": "ORZID3 GMENU FUNGI ASPERGILLUS SPP.",
      "term": null,
      "displaytext": "Aspergillus spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ASPERGILLUS SPECIES\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mild/moderate disease:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative treatment:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po bid 1 day then 200mg po bid\", \"Text\": \"Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Preferred treatment:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po bid 1 day then 200mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Consult Infectious Disease for alternative.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Patterson TF, et al. Clin Infect Dis. (2016) 63(4):433-442\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-Aspergillus species are ubiquitous, but invasive aspergillosis occurs primarily\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"in immunocompromised hosts. Neutropenia and glucocorticoid use are the most\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"common predisposing factors. Optimal management involves early diagnosis and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"early initiation of antifungal treatment.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"UpToDate: Treatment and prevention of invasive aspergillosis\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"-The most common clinical manifestation of invasive aspergillosis is pulmonary\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"disease, but other manifestations include central nervous system infection,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"rhinosinusitis, endocarditis, gastrointestinal disease, annd others.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of therapy should be a minimum of 6 to 12 weeks, although duration\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"is highly dependent on degree/duration of immunosuppression, disease site, and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"and evidence of disease improvement. Consult Infectious Disease.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Severe disease:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Refer to Inpatient CDSS for treatment.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 842,
    "fields": {
      "name": "ORZID3 GMENU FUNGI BLASTOMYCES DERM",
      "term": null,
      "displaytext": "Blastomyces dermatitidis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200 mg PO tid for 3 days, then 200 mg po BID for 6-12 months\", \"Text\": \"Itraconazole 200 mg PO TID for 3 days then BID ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200 mg PO tid for 3 days, then 200 mg po BID for 6- Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BLASTOMYCES DERMATITIDIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Contact Infectious Diseases in all cases. Lifelong suppressive therapy may be\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"required in immunosuppressed patients if immunosuppression cannot be reversed.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Disease outside of the central nervous system\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat for 6-12 months. It is recommended that immunocompromised patients be\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treated with at least 1-2 weeks of intravenous treatment and a total treatment\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"duration of 12 months.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Central nervous system infection\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Stanley et al. Clinical Infectious Diseases. 2008, (46)1801-12\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Blastomycosis\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of blastomycosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 843,
    "fields": {
      "name": "ORZID3 GMENU FUNGI C. ALBICANS",
      "term": null,
      "displaytext": "Candida albicans (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole troche 10 mg PO 5X/day ($) [M] for 7 days\", \"Text\": \"Clotrimazole troche 10 mg PO 5X/day for 7-14 days ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole troche 10 mg PO 5X/day ($) [M] for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200 mg PO QDay for 7-14 days ($) [R,DI]\", \"Text\": \"Fluconazole 200 mg PO QDay for 7-14 days ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200 mg PO QDay for 7-14 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI]\", \"Text\": \"Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg PO once then 400 mg PO QDay ($) [R,DI]\", \"Text\": \"Fluconazole 800 mg PO once then 400 mg PO QDay ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 800 mg PO once then 400 mg PO QDay ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA ALBICANS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Avoid using fluconazole empirically to treat candidal infections in patients who\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"have received an imidazole in the previous year.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment of thrush or oropharyngeal candidiasis\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Oropharyngeal candidal disease may present in different patterns, like white\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"plaques in the oropharyngeal area, erythematous macules (often in patients with\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"dentures), or as pseudomembranes.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Thrush infection often recurs, especially in patients with AIDS. Consult MRTC\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"clinic or Infectious Diseases (MRTC may also be consulted in the MVAHCS) for\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"more information on treatment of recurrent infection.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mild disease\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Moderate to severe disease\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Esophageal candidiasis\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Esophageal infection requires systemic therapy.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative for patient who cannot swallow tablets\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Systemic candidal infection\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Fluconazole is preferred empirical therapy in most cases. Amphotericin B should\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"be used empirically in patients who have received an azole antifungal drug\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"recently, or in patients who are critically ill.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location, severity of infection,\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Recent azole antifungal treatment\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Candidemia or Disseminated\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin swish and swallow QID ($) [M] for 7 days\", \"Text\": \"Nystatin swish and swallow QID for 7-14 days ($) [M]\", \"Mnemonic\": \"3a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"3b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 844,
    "fields": {
      "name": "ORZID3 GMENU FUNGI C. GLABRATA",
      "term": null,
      "displaytext": "Candida glabrata (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po bid 1 day then 200mg po bid\", \"Text\": \"Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po bid 1 day then 200mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA GLABRATA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"C. glabrata is often resistant to fluconazole and occasionally has some degree\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"of resistance to amphotericin. Higher doses of amphotericin are recommended due\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"to delayed killing effects against Candida glabrata.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for susceptible isolates\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Candidemia or Disseminated\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 845,
    "fields": {
      "name": "ORZID3 GMENU FUNGI C. KRUSEI",
      "term": null,
      "displaytext": "Candida krusei (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po bid 1 day then 200mg po bid\", \"Text\": \"Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Voriconazole 400mg po bid 1 day then 200mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CANDIDA KRUSEI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"C. krusei is resistant to fluconazole, and often has some degree of resistance\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to amphotericin. Higher doses of amphotericin are recommended for treatment of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"C. krusei due to decreased susceptibility.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Candida Species\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Candidiasis, Candidemia or Disseminated\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 846,
    "fields": {
      "name": "ORZID3 GMENU FUNGI COCCIDIOIDOMYCES",
      "term": null,
      "displaytext": "Coccidioidomyces (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po bid\", \"Text\": \"Itraconazole 200 mg PO BID ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po qday ($) [R,DI]\", \"Text\": \"Fluconazole 400 mg PO QDay ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po qday ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COCCIDIOIDOMYCES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pulmonary and Infectious Diseases consultations are essential for diagnosis and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mild to moderate disease\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Observation alone is indicated for some cases. Consult Infectious Diseases for\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"more information. If antifungal treatment is indicated:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Severe disease (diffuse pneumonia, rapid progression or central nervous system\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"infection)\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Galgiani et al. Clinical Infectious Diseases. 2016, 63(6) e112-46\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell Chapter: Coccidioidomycosis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford guide keyword: Coccidioidomycosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 847,
    "fields": {
      "name": "ORZID3 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS",
      "term": null,
      "displaytext": "Cyptococcus Neoformans (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po qday ($) [R,DI]\", \"Text\": \"Fluconazole 400 mg PO QDay ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po qday ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po bid\", \"Text\": \"Itraconazole 200 mg PO BID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CRYPTOCOCCUS NEOFORMANS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Duration of therapy is dependent upon location and severity of infection,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and response to therapy. Consult Infectious Diseases for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment of mild to moderate infection outside of the central nervous system\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"or step-down treatment once disease has stabilized\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment of central nervous system infection or severe infection outside\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"central nervous system\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Cryptococcosis (Cryptococcus neoformans and Cryptococcus\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"gattii)\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Perfect et al. Clinical Infectious Diseases 2010, (50) 291-322\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Cryptococcus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 848,
    "fields": {
      "name": "ORZID3 GMENU FUNGI H. CAPSULATUM",
      "term": null,
      "displaytext": "Histoplasma capsulatum (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HISTOPLASMA CAPSULATUM\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 849,
    "fields": {
      "name": "ORZID3 GMENU FURUNCLES AND CARBUNCLES",
      "term": null,
      "displaytext": "Furuncles and Carbuncles (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 716, \"DisplayText\": \"\", \"Text\": \"Select here for Staphylococcus aureus Decolonization\", \"Mnemonic\": \"4\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg po BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg po BID ($) [DI]\", \"Mnemonic\": \"16a\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 5 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"18a\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FURUNCLES AND CARBUNCLES\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Localized purulent infections include furuncles, carbuncles and cutaneous\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"inflamed nodule that usually develops as a complication of folliculitis. A\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"carbuncle is a more extensive lesion that extends further into the subcutaneous\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"tissue.  Contact a wound care nurse for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Incision and drainage is the mainstay of therapy for carbuncles, cutaneous\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"abscesses, and large furuncles.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"The decision to administer antibiotics directed against S. aureus as an adjunct\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"to incision and drainage should be made based on the presence of systemic\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"inflammatory response syndrome (SIRS) or in patients with markedly impaired\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"host defenses.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For recurrent skin abscesses in addition to culture and antibiotic therapy\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"recommended consider a decolonization regimen.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mild infection: Purulent infection without systemic signs of infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Recommend incision and drainage. No antibiotic indicated.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Moderate Infection: Purulent infection with signs of systemic infection.\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Recommend incision and drainage. Culture material and use results to guide\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"therapy.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treat for 5 days and extend/modify treatment if not improved in this time.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Alternatives\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Severe Infections:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Patients who have failed incision and drainage along with oral antibiotics\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"or those with SIRS or for infections in those with neutropenia or diminished\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"neutrophil function.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"See Inpatient Antimicrobial CDSS\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Sanford keyword: Furuncle, carbuncle\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO bid ($) [R]\", \"Mnemonic\": \"8A\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID for 5 days ($) [DI,O]\", \"Mnemonic\": \"20a\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO bid for 5 days ($) [DI,O]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 850,
    "fields": {
      "name": "ORZID3 GMENU GASTROINT OUTPT MAIN",
      "term": null,
      "displaytext": "Gastrointestinal (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 853, \"DisplayText\": \"\", \"Text\": \"Hepatic abscess\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 1015, \"DisplayText\": \"Secondary peritonitis (Outpatient)\", \"Text\": \"Intraabdominal abscess\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 1015, \"DisplayText\": \"Secondary peritonitis (Outpatient)\", \"Text\": \"Intraperitoneal abscess\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 698, \"DisplayText\": \"Perianal/Anorectal Abscess\", \"Text\": \"Perirectal/Anorectal abscess\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 737, \"DisplayText\": \"Appendicitis without perforation (Outpatient)\", \"Text\": \"Appendicitis without perforation\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 736, \"DisplayText\": \"Appendicitis with perforation (Outpatient)\", \"Text\": \"Appendicitis with perforation\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 787, \"DisplayText\": \"Cholecystitis (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"16\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 786, \"DisplayText\": \"Cholangitis (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"18\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 782, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Mild to moderate disease\", \"Mnemonic\": \"20\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 905, \"DisplayText\": \"Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)\", \"Text\": \"Severe/life-threatening disease\", \"Mnemonic\": \"22\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 911, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"24\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 824, \"DisplayText\": \"Diverticulitis (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"26\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GASTROINTESTINAL ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Abscess\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Appendicitis\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Cholecystitis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Cholangitis\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Clostridium difficile disease\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"(shock, ileus and megacolon)\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Diarrhea, infectious\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Diverticulitis\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 651, \"DisplayText\": \"Enteric Fever\", \"Text\": \"[click here]\", \"Mnemonic\": \"28\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 897, \"DisplayText\": \"Helicobacter pylori infection (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"32\"}, {\"Row\": 16, \"Column\": 2, \"Item\": 170, \"DisplayText\": \"Hepatitis A\", \"Text\": \"Hepatitis A\", \"Mnemonic\": \"34\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 171, \"DisplayText\": \"Hepatitis B\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"36\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 172, \"DisplayText\": \"Hepatitis C\", \"Text\": \"Hepatitis C\", \"Mnemonic\": \"38\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 1051, \"DisplayText\": \"Neutropenic enterocolitis (Typhlitis) - Outpatient\", \"Text\": \"[click here]\", \"Mnemonic\": \"40\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 957, \"DisplayText\": \"Pancreatitis (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"42\"}, {\"Row\": 28, \"Column\": 2, \"Item\": 729, \"DisplayText\": \"Spontaneous Bacterial Peritonitis (Outpatient)\", \"Text\": \"Acute Spontaneous Bacterial Peritonitis (SBP)\", \"Mnemonic\": \"44\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 980, \"DisplayText\": \"Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis...\", \"Text\": \"Peritonitis associated with\", \"Mnemonic\": \"46\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 1015, \"DisplayText\": \"Secondary peritonitis (Outpatient)\", \"Text\": \"Secondary peritonitis\", \"Mnemonic\": \"48\"}, {\"Row\": 34, \"Column\": 2, \"Item\": 843, \"DisplayText\": \"Candida albicans (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"50\"}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Helicobacter pylori infection\", \"Header\": 1}, {\"Row\": 15, \"Column\": 2, \"Text\": \"Hepatitis\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Neutropenic enterocolitis\", \"Header\": 1}, {\"Row\": 21, \"Column\": 2, \"Text\": \"(Typhlitis)\", \"Header\": 1}, {\"Row\": 24, \"Column\": 2, \"Text\": \"Pancreatitis\", \"Header\": 1}, {\"Row\": 27, \"Column\": 2, \"Text\": \"Peritonitis\", \"Header\": 1}, {\"Row\": 30, \"Column\": 2, \"Text\": \"peritoneal dialysis\"}, {\"Row\": 33, \"Column\": 2, \"Text\": \"Thrush\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"[click here]\", \"Mnemonic\": \"15\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Asplenia (Vaccines/Abx Prophylaxsis)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"Esophagitis\", \"Header\": 1}, {\"Row\": 10, \"Column\": 2, \"Item\": 652, \"DisplayText\": \"Esophagitis (outpatient)\", \"Text\": \"Other\", \"Mnemonic\": \"30\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 843, \"DisplayText\": \"Candida albicans (Outpatient)\", \"Text\": \"Candidal\", \"Mnemonic\": \"29\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Enteric fever\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 851,
    "fields": {
      "name": "ORZID3 GMENU GENITAL HERPES",
      "term": null,
      "displaytext": "Genital herpes (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO TID ($0.29/day) [R]\", \"Text\": \"Acyclovir 400 mg PO TID for 7-10 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO TID ($0.29/day) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO BID for 7-10 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po tid for 5 days\", \"Text\": \"Acyclovir 400 mg PO TID for 5 days ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po tid for 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po tid for 2 days\", \"Text\": \"Acyclovir 800 mg PO TID for 2 days ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po tid for 2 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500mg po bid for 3 days\", \"Text\": \"Valacyclovir 500 mg PO BID for 3 days ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500mg po bid for 3 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po tid for 10 days\", \"Text\": \"Acyclovir 400 mg PO TID ($) [R]\", \"Mnemonic\": \"14a\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po tid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po bid for 10 days\", \"Text\": \"Valacyclovir 1 gm PO BID ($) [R]\", \"Mnemonic\": \"16a\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po bid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 79, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po bid for 1 year\", \"Text\": \"Acyclovir 400 mg PO BID ($) [R]\", \"Mnemonic\": \"18a\"}, {\"Row\": 80, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po bid for 1 year Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 83, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO QDAY ($) [R] for 1 year\", \"Text\": \"Valacyclovir 500 mg PO QDay ($) [R]\", \"Mnemonic\": \"20a\"}, {\"Row\": 84, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO QDAY ($) [R] for 1 year Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 87, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po qday for 1 year\", \"Text\": \"Valacyclovir 1000 mg PO QDay ($) [R]\", \"Mnemonic\": \"22a\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po qday for 1 year Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"22b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GENITAL HERPES\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment of the initial episode decreases the duration of pain, lesions, and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"viral shedding by 1 to 2 days. Treatment of the initial episode does not\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"decrease likelihood of recurrent episodes.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Episodic therapy for relapses\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment of recurrent episodes must be started within 24 hours of symptom\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"onset. Treatment decreases the duration of pain and lesions, and viral shedding\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"by 1 to 2 days. Consider suppressive treatment for patients with more than 6\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"episodes per year.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Immunocompromised patients in whom genital herpes simplex disease is often\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"severe include: patients with HIV infection, organ transplants, malnourishment,\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"eczema or severe burns, and in patients receiving immunosuppressive\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"chemotherapy.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Treat mild to moderate disease for 10 days. In severe disease, treat with\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"intravenous acyclovir for 2 to 7 days based on clinical response, then treat\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"with an oral antiviral for a total duration of 10 days.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease or after clinical improvement of severe\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"disease\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Infectious Diseases consult encouraged.\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Chronic suppressive therapy\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Suppressive therapy is indicated in patients with more than 6 episodes per year.\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"Suppressive therapy is optional, and some patients may find episodic treatment\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"more convenient. The frequency of recurrences usually decreases after 1 to 5\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"years, and suppressive therapy should be stopped every few years to see if it is\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"still needed.\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"For a patient with more than 9 episodes per year\", \"Header\": 1}, {\"Row\": 91, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Center for Disease Control. MMWR 55(RR 11) 1-94\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes simplex\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 1026, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 852,
    "fields": {
      "name": "ORZID3 GMENU GENITOURINARY",
      "term": null,
      "displaytext": "Genitourinary (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 635, \"DisplayText\": \"APPROACH TO URINARY TRACT INFECTION (UTI)\", \"Text\": \"Approach to Urinary Tract Infection (UTI)\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 740, \"DisplayText\": \"Asymptomatic bacteriuria (Outpatient)\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 641, \"DisplayText\": \"Candida Urinary Tract Infections\", \"Text\": \"Candida Urinary Tract Infection\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 801, \"DisplayText\": \"Complicated Cystitis (Outpatient)\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 1006, \"DisplayText\": \"Pyelonephritis (Outpatient)\", \"Text\": \"Pyelonephritis\", \"Mnemonic\": \"12\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 1052, \"DisplayText\": \"Uncomplicated Cystitis (Outpatient)\", \"Text\": \"Uncomplicated cystitis\", \"Mnemonic\": \"14\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 725, \"DisplayText\": \"Acute bacterial prostatitis (Outpatient)\", \"Text\": \"Acute bacterial prostatitis\", \"Mnemonic\": \"16\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 636, \"DisplayText\": \"Balanitis and Balanoposthitis\", \"Text\": \"Balanitis and Balanoposthitis\", \"Mnemonic\": \"18\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 789, \"DisplayText\": \"Chronic bacterial prostatitis (Outpatient)\", \"Text\": \"Chronic bacterial prostatitis\", \"Mnemonic\": \"20\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 788, \"DisplayText\": \"Chronic prostatitis/Chronic pelvic pain syndrome (Outpatient)\", \"Text\": \"Chronic prostatitis/Chronic pelvic pain syndrome\", \"Mnemonic\": \"22\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 828, \"DisplayText\": \"Epididymitis (Outpatient)\", \"Text\": \"Epididymitis and Epididymo-Orchitis\", \"Mnemonic\": \"24\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Urethritis\", \"Mnemonic\": \"26\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 743, \"DisplayText\": \"Bacterial vaginosis (Outpatient)\", \"Text\": \"Bacterial vaginosis\", \"Mnemonic\": \"28\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 778, \"DisplayText\": \"Candida vulvo-vaginitis (Outpatient)\", \"Text\": \"Candida vulvovaginitis\", \"Mnemonic\": \"30\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Cervicitis\", \"Mnemonic\": \"32\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Pelvic Inflammatory Disease (PID)\", \"Mnemonic\": \"34\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Trichomonas vaginitis\", \"Mnemonic\": \"36\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GENITOURINARY ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Urinary tract infections\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Bacteremia/sepsis urinary tract source - refer to Inpt CDSS\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Male specific infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Female specific Infections\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Last updated July 2022\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Cervicitis\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Epididymitis\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Genital Herpes\", \"Mnemonic\": \"6\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Gonorrhea infection with/without Chlamydia\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Pelvic Inflammatory Disease (PID)\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Syphilis\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Trichomonas Vaginitis\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Urethritis\", \"Mnemonic\": \"18\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 939, \"DisplayText\": \"Necrotizing infections (Outpatient)\", \"Text\": \"Necrotizing infection\", \"Mnemonic\": \"20\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 1037, \"DisplayText\": \"Surgical site infection\", \"Text\": \"Surgical site infection\", \"Mnemonic\": \"22\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Sexually Transmitted Infections (STI)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Chlamydia (See Cervicitis or Urethritis)\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"Necrotizing Infection (including Fournier gangrene)\", \"Header\": 1}, {\"Row\": 20, \"Column\": 2, \"Text\": \"Surgical Site Infection\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 853,
    "fields": {
      "name": "ORZID3 GMENU GI LIVER ABSCESS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 680, \"DisplayText\": \"Amebic Liver Abscess\", \"Text\": \"Link to Amebic Liver Abscess menu\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LIVER ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Liver abscess should be suspected in all patients with fever, leukocytosis, and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"a space-occupying liver lesion. Liver abscesses fall broadly into two\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"categories: pyogenic and amebic. In the United States, pyogenic liver abscess is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"much more common. Amebic liver abscess occurs almost exclusively in travelers\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"and immigrants. If amebic liver abscess is suspected, select the link below.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment of pyogenic liver abscess\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Liver and Biliary System\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword: Hepatic Abscess\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Solomkin et al, Clin Infect Dis, 2010, 50:133-64\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-to-Date article: Pyogenic liver abscess\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 854,
    "fields": {
      "name": "ORZID3 GMENU GONOCOCCAL",
      "term": null,
      "displaytext": "Neisseria gonorrhoeae STI",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 162, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)\", \"Mnemonic\": \"2\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Uncomplicated gonococcal infections of the pharynx, cervix, urethra, or rectum:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"chlamydia.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients weighing less than 300lbs:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Patients weighing 300lbs or greater:\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"No reliable alternative treatments are available for pharyngeal gonorrhea.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"For persons with a history of a beta-lactam allergy, a thorough assessment\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"of the reaction is recommended. For persons with an anaphylactic or other\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"severe reaction to ceftriaxone, consult Infectious Disease for alternative\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"treatment recommendation.\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM x 1 ($) [M] <AND> Doxycycline 100 mg PO bid x7days ($)[DI]\", \"Text\": \"Ceftriaxone 1 GM IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]\", \"Mnemonic\": \"14a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"-If chlamydial infection has not been excluded, recommend to treat for\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500MG IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"-A test-of-cure is unnecessary for uncomplicated urogenital or rectal\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"gonorrhea for patients treated with the recommended or alternative regimen.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"For persons with a history of a beta-lactam allergy, a thorough assessment\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"of the reaction is recommended.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 240 MG IM Once ($) [R] <AND> Azithromycin 2000 mg PO Once ($) [DI]\", \"Mnemonic\": \"16\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Alternative treatment for beta-lactam allergy for pharynx:\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Alternative treatment for beta-lactam allergy for cervix, urethra, or rectum:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"-A test-of-cure is recommended for patients with pharyngeal gonorrhea.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Obtain nucleic acid amplification test (NAAT) 7 to 14 days after initial\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"treatment, regardless of regimen used for pharyngeal gonorrhea.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred treatment for patients and no chlamydial co-infection:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred treatment with chlamydial co-infection or chlamydial infection has\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"not been excluded:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Patients weighing less than 300lbs:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Patients weighing 300lbs or greater:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500 MG IM x1 dose ($) [M]\", \"Mnemonic\": \"08\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 GM IM x1 dose ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 785, \"DisplayText\": \"Chlamydia urethritis (Outpatient)\", \"Text\": \"[Click here] Chlamydial infection and no co-infection\", \"Mnemonic\": \"06\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Chlamydial infection and no co-infection:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Urine NAAT\", \"Text\": \"[Click here] Place order for gonorrhea/chlamydia lab NAAT test\", \"Mnemonic\": \"04\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Lab test:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"-When diagnosed with sexually transmitted disease, the patient's sexual\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"partner(s) during the previous 60 days should be evaluated for sexually\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"transmitted infection.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Gonococcal Infections:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for Doxycycline above\", \"Mnemonic\": \"12b\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for Doxycycline above\", \"Mnemonic\": \"14b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 855,
    "fields": {
      "name": "ORZID3 GMENU GRAM NEGATIVE BACTERIA",
      "term": null,
      "displaytext": "Gram negative bacteria (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 916, \"DisplayText\": \"Interim results:  Gram-negative bacilli (Outpatient)\", \"Text\": \"Gram-negative bacilli\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 917, \"DisplayText\": \"Iterim report of Gram-negative cocci (Outpatient)\", \"Text\": \"Gram-negative cocci\", \"Mnemonic\": \"6\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GRAM-NEGATIVE BACTERIA ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"site of infection, penetration of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"drug(s)into site, and whether\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"organism is pathogen, colonizer, or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"contaminant. See disease/syndrome\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"section for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Interim culture results\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"++ MULTIDRUG RESTANT ORGANISMS ++\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"ESBLS, Amp-C beta-lactamases, and\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Carbapenemases\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Consider whether patient is at risk\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"for or has evidence of infection with\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Gram-negative bacilli carrying\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"extended-spectrum beta-lactamases\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(ESBLs), AmpC beta-lactamases, or\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"carbapenemases.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"lactamases, and carbapenemases.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Last Reviewed December 2017\", \"Header\": 1}, {\"Row\": 16, \"Column\": 2, \"Item\": 857, \"DisplayText\": \"Acinetobacter baumanni (Outpatient)\", \"Text\": \"Acinetobacter baumanni\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 862, \"DisplayText\": \"Citrobacter spp. (Outpatient)\", \"Text\": \"Citrobacter spp.\", \"Mnemonic\": \"18\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 864, \"DisplayText\": \"Enterobacter spp. (Outpatient)\", \"Text\": \"Enterobacter spp.\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 863, \"DisplayText\": \"Escherichia coli (Outpatient)\", \"Text\": \"Escherichia coli\", \"Mnemonic\": \"22\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 866, \"DisplayText\": \"Klebsiella spp. (Outpatient)\", \"Text\": \"Klebsiella spp.\", \"Mnemonic\": \"28\"}, {\"Row\": 28, \"Column\": 2, \"Item\": 872, \"DisplayText\": \"Proteus spp. (Outpatient)\", \"Text\": \"Proteus spp.\", \"Mnemonic\": \"34\"}, {\"Row\": 31, \"Column\": 2, \"Item\": 875, \"DisplayText\": \"Serratia spp. (Outpatient)\", \"Text\": \"Serratia spp.\", \"Mnemonic\": \"40\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 859, \"DisplayText\": \"Bordetella spp. (Outpatient)\", \"Text\": \"Bordetella spp.\", \"Mnemonic\": \"12\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 860, \"DisplayText\": \"Brucella spp.\", \"Text\": \"Brucella spp.\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 861, \"DisplayText\": \"Campylobacter spp. (Outpatient)\", \"Text\": \"Campylobacter spp.\", \"Mnemonic\": \"16\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 865, \"DisplayText\": \"Haemophilus spp. (Outpatient)\", \"Text\": \"Haemophilus spp.\", \"Mnemonic\": \"24\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 897, \"DisplayText\": \"Helicobacter pylori infection (Outpatient)\", \"Text\": \"Helicobacter pylori\", \"Mnemonic\": \"26\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 867, \"DisplayText\": \"Legionella spp. (Outpatient)\", \"Text\": \"Legionella spp.\", \"Mnemonic\": \"30\"}, {\"Row\": 27, \"Column\": 2, \"Item\": 871, \"DisplayText\": \"Pasteurella multocida (Outpatient)\", \"Text\": \"Pasteurella multocida\", \"Mnemonic\": \"32\"}, {\"Row\": 29, \"Column\": 2, \"Item\": 873, \"DisplayText\": \"Pseudomonas spp. (Outpatient)\", \"Text\": \"Pseudomonas spp.\", \"Mnemonic\": \"36\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 874, \"DisplayText\": \"Salmonella spp. (Outpatient)\", \"Text\": \"Salmonella spp.\", \"Mnemonic\": \"38\"}, {\"Row\": 32, \"Column\": 2, \"Item\": 819, \"DisplayText\": \"Diarrhea with Shigella (Outpatient)\", \"Text\": \"Shigella spp (bacillary dysentery)\", \"Mnemonic\": \"42\"}, {\"Row\": 39, \"Column\": 2, \"Item\": 870, \"DisplayText\": \"Neisseria meningitidis (Outpatient)\", \"Text\": \"Neisseria meningitidis\", \"Mnemonic\": \"50\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 869, \"DisplayText\": \"Neisseria gonorrhoeae (Outpatient)\", \"Text\": \"Neisseria gonorrhoeae\", \"Mnemonic\": \"48\"}, {\"Row\": 37, \"Column\": 2, \"Item\": 868, \"DisplayText\": \"Moraxella catarrhalis (Outpatient)\", \"Text\": \"Moraxella catarrhalis\", \"Mnemonic\": \"46\"}, {\"Row\": 35, \"Column\": 2, \"Item\": 858, \"DisplayText\": \"Bacteroides spp. (Outpatient)\", \"Text\": \"Bacteroides, Porphyromonas,\", \"Mnemonic\": \"44\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Final culture results\", \"Header\": 1}, {\"Row\": 13, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 2, \"Text\": \">> Gram-negative bacilli <<\", \"Header\": 1}, {\"Row\": 34, \"Column\": 2, \"Text\": \">> Gram-negative cocci <<\", \"Header\": 1}, {\"Row\": 36, \"Column\": 2, \"Text\": \"Prevotella\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 856,
    "fields": {
      "name": "ORZID3 GMENU GRAM POSITIVE BACTERIA",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 919, \"DisplayText\": \"Interim report of Gram-positive cocci in pairs (Outpatient)\", \"Text\": \"Gram-positive cocci\", \"Mnemonic\": \"4\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 918, \"DisplayText\": \"Interim report of Gram-positive Bacilli (Outpatient)\", \"Text\": \"Gram-positive bacilli\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ GRAM-POSTITIVE BACTERIA ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"site of infection, penetration of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"drug(s) into site, and whether\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"organism is pathogen, colonizer, or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"contaminant. See disease/syndrome\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"section for more information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Interim culture results\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Last Reviewed December 2017\", \"Header\": 1}, {\"Row\": 17, \"Column\": 2, \"Item\": 893, \"DisplayText\": \"Staphylococci (Outpatient)\", \"Text\": \"Staphylococci\", \"Mnemonic\": \"10\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 891, \"DisplayText\": \"Group A (S. pyogenes) - Outpatient\", \"Text\": \"Group A (S. pyogenes)\", \"Mnemonic\": \"12\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 887, \"DisplayText\": \"Group B (S. agalactiae) - Outpatient\", \"Text\": \"Group B (S. agalactiae)\", \"Mnemonic\": \"14\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 884, \"DisplayText\": \"Streptococci Groups C, F, G (Outpatient)\", \"Text\": \"Groups C, F, G\", \"Mnemonic\": \"16\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 889, \"DisplayText\": \"Group D Streptococci (S. bovis) - Outpatient\", \"Text\": \"Group D (S. bovis)\", \"Mnemonic\": \"18\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 896, \"DisplayText\": \"Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient\", \"Text\": \"Viridans streptococci (including\", \"Mnemonic\": \"20\"}, {\"Row\": 26, \"Column\": 2, \"Item\": 890, \"DisplayText\": \"Streptococcus pneumoniae (Outpatient)\", \"Text\": \"Streptococcus pneumoniae\", \"Mnemonic\": \"22\"}, {\"Row\": 27, \"Column\": 2, \"Item\": 888, \"DisplayText\": \"Streptococcus anginosus (formerly S. milleri) - Outpatient\", \"Text\": \"Streptococcus anginosus (formerly\", \"Mnemonic\": \"24\"}, {\"Row\": 30, \"Column\": 2, \"Item\": 878, \"DisplayText\": \"Anaerobic Gram-positive cocci (Outpatient)\", \"Text\": \"Anaerobic Gram-positive cocci\", \"Mnemonic\": \"26\"}, {\"Row\": 33, \"Column\": 2, \"Item\": 883, \"DisplayText\": \"Enterococci (Outpatient)\", \"Text\": \"Enterococci\", \"Mnemonic\": \"28\"}, {\"Row\": 36, \"Column\": 2, \"Item\": 879, \"DisplayText\": \"Bacilli species (Outpatient)\", \"Text\": \"Bacillus spp.\", \"Mnemonic\": \"30\"}, {\"Row\": 37, \"Column\": 2, \"Item\": 880, \"DisplayText\": \"Clostridium spp. (Outpatient)\", \"Text\": \"Clostridium spp.\", \"Mnemonic\": \"32\"}, {\"Row\": 38, \"Column\": 2, \"Item\": 882, \"DisplayText\": \"Corynebacterium spp. (Outpatient)\", \"Text\": \"Corynebacteriium spp.\", \"Mnemonic\": \"34\"}, {\"Row\": 39, \"Column\": 2, \"Item\": 886, \"DisplayText\": \"Propionibacterium species (Outpatient)\", \"Text\": \"Cutibacterium (formerly\", \"Mnemonic\": \"36\"}, {\"Row\": 41, \"Column\": 2, \"Item\": 877, \"DisplayText\": \"Actinomyces spp. (Outpatient)\", \"Text\": \"Actinomyces spp.\", \"Mnemonic\": \"38\"}, {\"Row\": 42, \"Column\": 2, \"Item\": 885, \"DisplayText\": \"Listeria spp. (Outpatient)\", \"Text\": \"Listeria spp.\", \"Mnemonic\": \"40\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Final culture results\", \"Header\": 1}, {\"Row\": 13, \"Column\": 2, \"Text\": \"____________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 2, \"Text\": \">> Gram-positive cocci <<\", \"Header\": 1}, {\"Row\": 19, \"Column\": 2, \"Text\": \"Streptococci\", \"Header\": 1}, {\"Row\": 25, \"Column\": 2, \"Text\": \"S. mutans, S. mitis, S. sanguis)\"}, {\"Row\": 28, \"Column\": 2, \"Text\": \"S. milleri)\"}, {\"Row\": 31, \"Column\": 2, \"Text\": \"(including Peptostreptococcus)\"}, {\"Row\": 35, \"Column\": 2, \"Text\": \">> Gram-positive bacilli <<\", \"Header\": 1}, {\"Row\": 40, \"Column\": 2, \"Text\": \"Propionibacterium) spp.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 857,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG A. BAUMANNI",
      "term": null,
      "displaytext": "Acinetobacter baumanni (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases.\", \"Mnemonic\": \"4\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACINETOBACTER BAUMANNII\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Isolation of Acinetobacter baumannii from a culture often represents\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"contamination or colonization and not disease. For questions about whether a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patient should be treated, contact Infectious Diseases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Many isolates are resistant to multiple antimicrobials. If susceptibilities are\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"not known, start therapy with imipenem or amikacin.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"If susceptibities are known, use appropriate antimicrobial.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Acinetobacter carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Acinetobacter baumannii\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-To-Date article: Acinetobacter infection: Treatment and prevention\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 858,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.",
      "term": null,
      "displaytext": "Bacteroides spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 1000 mg PO BID ($) [DI]\", \"Text\": \"Metronidazole 1000 mg PO BID ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 1000 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACTEROIDES SPP. (INCLUDING PREVOTELLA, PORPHYROMONAS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"These bacteria are strict anaerobes and will only grow in anaerobic media.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Bacteriodes sp., Overview\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-To-Date article: Anaerobic bacterial infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 859,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG BORDETELLA SPP.",
      "term": null,
      "displaytext": "Bordetella spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BORDETELLA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Bordetella pertussis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 860,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.",
      "term": null,
      "displaytext": "Brucella spp.",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI] < AND > rifampin 600 mg PO QDAY ($)\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI] < AND > rifampin 600 mg PO QDAY ($)\", \"Mnemonic\": \"4a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI] < AND > rifampin 600 mg PO QD Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BRUCELLA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment for non-localizing disease only. Consult Infectious Diseases for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"specifc clinical syndrome since regimens vary (e.g. arthritis, neurobrucellosis,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"endocarditis, etc.)\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat with both drugs for 45 days.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"[DI,O]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword: Brucellosis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"brucellosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 861,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG CAMPYLOBACTER SPP.",
      "term": null,
      "displaytext": "Campylobacter spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY ($) [O]\", \"Text\": \"Azithromycin 500 mg PO QDAY ($) [O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY ($) [O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CAMPYLOBACTER SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal Optimal therapy depends on both the disease or syndrome and the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pathogen. See diagnosis/syndrome section for more information. Drugs\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"recommended below are best for most cases. If susceptibility results or other\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"factors make these inappropriate for this case, click need an alternative\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For information on gastroenteritis (usually involving C. jejuni), refer to the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Gastrointestinal and Intraabdominal infection section.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment of extraintestinal infectious not involving the central nervous\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"system infections\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment of central nervous system infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Campylobacter jejuni, Campylobacter coli\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Campylobacter infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 862,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG CITROBACTER SPP.",
      "term": null,
      "displaytext": "Citrobacter spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CITROBACTER SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sanford keyword: Citrobacter sp.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 863,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG E. COLI",
      "term": null,
      "displaytext": "Escherichia coli (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM SACHET PO X 1 DOSE\", \"Text\": \"Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose\", \"Mnemonic\": \"10\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Mnemonic\": \"12a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses\", \"Mnemonic\": \"14\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Mnemonic\": \"16a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES\", \"Text\": \"Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses\", \"Mnemonic\": \"18\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ESCHERICHIA COLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infections section.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"E. coli carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Mild to moderate infections including cystitis\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"E. coli carrying ESBL:\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"E. coli carrying carbapenemase:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Sanford keyword: Escherichia coli\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 864,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG ENTEROBACTER SPP.",
      "term": null,
      "displaytext": "Enterobacter spp. (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTEROBACTER SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Enterobacter sp.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 865,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG HAEMOPHILUS SPP.",
      "term": null,
      "displaytext": "Haemophilus spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HAEMOPHILUS SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Haemophilus influenzae\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-To-Date article:\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 866,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG KLEBSIELLA SPP.",
      "term": null,
      "displaytext": "Klebsiella spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO BID ($$) [R]\", \"Text\": \"Cefpodoxime 100 mg PO BID ($$) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO BID ($$) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM SACHET PO X 1 DOSE\", \"Text\": \"Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"KLEBSIELLA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"klebsiella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mild to moderate infections including cystitis\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Klebsiella sp.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 867,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG LEGIONELLA SPP.",
      "term": null,
      "displaytext": "Legionella spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY ($) [O]\", \"Text\": \"Azithromycin 500 mg PO QDAY ($) [O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY ($) [O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po q24h ($)[R,DI]\", \"Text\": \"Levofloxacin 500 mg PO QDAY ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po q24h ($0.19/day)[R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LEGIONELLA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Consider treating for up to 21 days in immunosuppressed patients who are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"severely ill upon presentation.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat for 10 days\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative for patients intolerant to macrolides\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treat for 10 days\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Legionella sp.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment and prevention of Legionella infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 868,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG M. CATARRHALIS",
      "term": null,
      "displaytext": "Moraxella catarrhalis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MORAXELLA CATARRHALIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For intravenous options, please refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Moraxella catarrhalis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-To-Date article: Moracella catarrhalis infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 869,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG N. GONORRHOEAE",
      "term": null,
      "displaytext": "Neisseria gonorrhoeae (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEISSERIA GONORRHOEAE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"See diagnosis/syndrome section for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Up-To-Date article: Disseminated gonococcal infection\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 854, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Mnemonic\": \"04\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"See Inpatient CDSS for disseminated gonococcal infection\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 870,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG N. MENINGITIDIS",
      "term": null,
      "displaytext": "Neisseria meningitidis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEISSERIA MENINGITIDIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Central nervous system infections require higher doses of antimicrobials.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseria meningitidis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment and prevention of meningococcal infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 871,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG P. MULTOCIDA",
      "term": null,
      "displaytext": "Pasteurella multocida (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PASTEURELLA MULTOCIDA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanford keyword: Pasteurella multocida\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-To-Date article: Pasteurella infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 872,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG PROTEUS SPP.",
      "term": null,
      "displaytext": "Proteus spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROTEUS SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"proteus carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mild to moderate infections including cystitis\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative for allergy to beta-lactam\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Proteus sp.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-To-Date article: Extended-spectrum beta-lactamases\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 873,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG PSEUDOMONAS SPP.",
      "term": null,
      "displaytext": "Pseudomonas spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PSEUDOMONAS SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"In severe cases, addition of an aminoglycoside to a beta\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"lactam may be beneficial. Aminoglycoside monotherapy is effective only in\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"treatment of UTI. Refer to genitourinary section for treatment of UTI due to\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pseudomonas. Consult Infectious Diseases for more information.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Oral treatment for mild infections\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative for severe infections\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Pseudomonas aeruginosa\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-To-Date article: Principles of antimicrobial therapy of Pseudomonas\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"aeruginosa infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 874,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG SALMONELLA SPP.",
      "term": null,
      "displaytext": "Salmonella spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 156, \"DisplayText\": \"\", \"Text\": \"More about ESBLs, Amp-C beta-lactamases, and carbapenemases\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SALMONELLA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For gastroenteritis antimicrobials are not usually indicated. Please refer to\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the Gastrointestinal and Intra-abdominal infections section for more\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consider whether patient is at risk for or has evidence of infection with\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"salmonella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"lactamase, or carbapenemase.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"For localized or systemic extraintestinal infections\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Salmonella sp.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 875,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG SERRATIA SPP.",
      "term": null,
      "displaytext": "Serratia spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO BID ($$) [R]\", \"Text\": \"Cefpodoxime 100 mg PO BID ($$) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 100 mg PO BID ($$) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SERRATIA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Sanford keyword: Serratia marcescens\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-To-Date article: Infections due to Serratia species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 876,
    "fields": {
      "name": "ORZID3 GMENU GRAM-NEG SHIGELLA SPP.",
      "term": null,
      "displaytext": "Shigella spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY ($) [O]\", \"Text\": \"Azithromycin 500 mg PO QDAY ($) [O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY ($) [O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SHIGELLA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information. Drugs recommended below are\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"best for most cases. If susceptibility results or other factors make these\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"inappropriate for this case, click need an alternative antimicrobial.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"infections section for more information. antibiotic resistance is increasing,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"especially among men who have sex with men. Drug selection should be based on\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antimicrobial susceptibility tests.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred treatment for systemic infections\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"MMWR (2015) 64.318\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Shigella Sp.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-To-Date article: Shigella infection: Treatment and prevention in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 877,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS ACTINOMYCES SPP.",
      "term": null,
      "displaytext": "Actinomyces spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACTINOMYCES SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternative for patients with beta-lactam allergy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Actinomycosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 878,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS ANAEROBIC GPC",
      "term": null,
      "displaytext": "Anaerobic Gram-positive cocci (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO QID ($) [H,O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID ($) [H,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANAEROBIC GRAM-POSITIVE COCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Anaerobic Gram-positive cocci, including peptostreptococci, are often involved\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"in mixed aerobic/anaerobic infections. Beta-lactams (like ampicillin and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"penicillin) and clindamycin are the drugs of choice against anaerobic gram-\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"positive cocci. Beta-lactam/beta-lactamase inhibitors are active against\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"peptostreptococci, so no additional anaerobic antimicrobials are needed\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"specifically to cover peptostreptococcus when drugs such as ampicillin-sulbactam\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"or piperacillin-tazobactam are used.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Anaerobic Cocci and Anaerobic Gram-Positive Nonsporulating\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Bacilli\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Peptostreptococcus sp.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 879,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS BACILLI SPP.",
      "term": null,
      "displaytext": "Bacilli species (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO QID ($) [H,O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID ($) [H,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BACILLUS SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"B. cereus\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome sections for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"For intravenous options, please refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If isolate is clindamycin-susceptable\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"B. anthracis\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Start combination therapy and contact Infectious Diseases immediately.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Hendricks et al., Emerg Infect Dis 2014, 20.2\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 880,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS CLOSTRIDIUM SPP.",
      "term": null,
      "displaytext": "Clostridium spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 782, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"Clostridium difficile disease\", \"Mnemonic\": \"4\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CLOSTRIDIUM SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For Clostridium difficile disease refer to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Mild to moderate infections may be treated with oral antimicrobials. For\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"neutropenic enterocolitis, gas gangrene, or other necrotizing infection,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"intravenous therapy is indicated. Combination therapy may be preferred. Refer\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to the appropriate section of the CDSS or contact Infectious Diseases for more\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"C. perfringens food poisoning is treated with supportive care. Diarrhea resolves\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"within 24 hours.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"For severe infection with Clostridium spp. other than perfringens, septicum or\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"sordellii, call Infectious Diseases.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred empirical treatment for mild to moderate infections\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"For intravenous options, please refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Alternative for beta-lactam allergic patients\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred empirical therapy for severe infections\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford Table 2: Recommended antimicrobial agents\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 881,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS COAG NEG STAPH",
      "term": null,
      "displaytext": "Treatment for Coagulase Negative Staphylococci (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 892, \"DisplayText\": \"Treatment for Staphylococcus lugdunensis\", \"Text\": \"Treatment for Staphylococcus lugdunensis\", \"Mnemonic\": \"4\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"14a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Mnemonic\": \"18a\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"warneri and S. xylosus\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to S. lugdunensis page for treatment.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Isolation of coagulase-negative staphylococci from a culture often represents\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"contamination or colonization and not disease. For questions about whether a\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"patient should be treated, contact Infectious Diseases.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"If susceptibility results are known, use them to select one of the following\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"drugs.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"If not, use vancomycin empirically until final culture and susceptibilities are\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"available.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred treatment for urinary tract infection associated with S. saprophyticu\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Alternative for resistant organisms\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Staphylococci\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus sp., Coagulase-negative\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus epidermidis\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Up-To-Date article: Infection due to coagulase-negative staphylococci: Treatment\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 882,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS CORYNEBACTERIUM SPP.",
      "term": null,
      "displaytext": "Corynebacterium spp. (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500 mg PO TID ($$) [DI]\", \"Text\": \"Erythromycin 500 mg PO TID ($$) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500 mg PO TID ($$) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 250 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 250 mg PO QID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 250 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CORYNEBACTERIUM SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Corynebacterium jeikeium\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome sections for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Corynebacterium diphtheriae\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Diphtheria is usually severe and often fatal. Antitoxin is the most important\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"treatment. Contact Infectious Diseases immediately.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"For intravenous options, please refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative for patients intolerant of erythromycin\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium diptheriae\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium jeikeium\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"diptheria\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 883,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS ENTEROCOCCI",
      "term": null,
      "displaytext": "Enterococci (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 894, \"DisplayText\": \"Treatment for Enterococcal infections (Outpatient)\", \"Text\": \"Treatment for enterococcal infections\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTEROCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The important human pathogens are Enterococcus faecium and Enterococcus\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"faecalis. The antimicrobial susceptibilities that are reported for enterococci\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"depend on the site of the sample. For all enterococci the microbiology\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"laboratory reports susceptibility for ampicillin and vancomycin. Additionally\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"the lab reports fluoroquinolone susceptibility for urinary isolates and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"susceptibility to gentamicin synergy for bloodstream isolates. For more\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"information on culture and susceptibilities, contact the microbiology laboratory\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Ampicillin is the drug of choice for enterococcal infections. Piperacillin is\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"also active against enterococcus. Cephalosporins are ineffective as single\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"agents for enterococcal infections. For patients who are allergic to penicillin\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"or infected with penicillin-resistant enterococcus, vancomycin is the preferred\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"drug. Nitrofurantoin is effective in urinary tract infections only. Linezolid\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"must be reserved for cases where no other drug can be used as it has many side\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"effects and drug interactions, is expensive, is bacteriostatic rather than\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"bactericidal, and its use promotes resistance.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Combination regimens include a primary anti-enterococcal agent (ampicillin or\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"vancomycin) plus gentamicin or streptomycin are synergistic in vitro and are\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"needed for severe infections like endocarditis or prosthetic joint infections.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"See relevant disease/syndrome sections for more information. Milder diseases\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"like cystitis or wound infection can usually be treated with a single drug. For\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"more information on treatment of enterococcal infections, contact Infectious\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Leuconostoc Species\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecalis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infection\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 884,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS GROUPS C, F, G",
      "term": null,
      "displaytext": "Streptococci Groups C, F, G (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCI GROUPS C, F, G\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Groups C and G Streptococci, and Other Related Organisms\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Strep\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-To-Date article: Group C and group G streptococcal infection\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 885,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS LISTERIA SPP.",
      "term": null,
      "displaytext": "Listeria spp. (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LISTERIA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"For meningitis, please refer to the meningitis section for treatment advice.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Listeria monocytogenes\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment, prognosis, and prevention of Listeria\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"monocytogenes infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 886,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS PROPIONIBACT SPP.",
      "term": null,
      "displaytext": "Propionibacterium species (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CUTIBACTERIUM (FORMERLY PROPIONIBACTERIUM) SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Isolation of Propionibacterium species from a culture often represents\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"contamination or colonization and not disease. For questions about whether a\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patient should be treated, contact Infectious Diseases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"disease/syndrome sections for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Sanford keyword: Propionibacterium acnes\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-To-Date article: Invasive Cutibacterium (formerly Propionibacterium)\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 887,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS S. AGALACTIAE",
      "term": null,
      "displaytext": "Group B (S. agalactiae) - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GROUP B STREPTOCOCCI (S. AGALACTIAE)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Group B streptococci (Streptococcus agalactiae) are associated most commonly\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"with bacteremia and meningitis in infants and bacteremia and urinary tract\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infections in elderly people and people with diabetes mellitus.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mild to moderate infections\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Severe infections\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell Chapter: Streptococcus agalactiae (Group B Streptococcus)\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus agalactiae, Group B Strep\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-To-Date article: Group B streptococcal infections in nonpregnant adults\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 888,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS S. ANGINOSUS",
      "term": null,
      "displaytext": "Streptococcus anginosus (formerly S. milleri) - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCUS ANGINOSUS (FORMERLY S. MILLERI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Ceftriaxone or penicillin are preferred for central nervous system infection.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Cefazolin or penicillin are preferred for infection outside of the central\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"nervous system.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Streptococcus anginosus group\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus anginosus group\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-To-Date article: Infections due to the Streptococcus anginosus (Streptococcus\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"milleri) group\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 889,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS S. BOVIS",
      "term": null,
      "displaytext": "Group D Streptococci (S. bovis) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GROUP D STREPTOCOCCI (S. BOVIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Bacteremia with Streptococcus bovis is associated with malignancy of the colon.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Resistance to penicillin is uncommon. Vancomycin should only be used in a\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"patient with beta-lactam allergy, or if beta-lactam resistance is strongly\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"suspected.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-To-Date article: Clinical manifestations, diagnosis, and treatment of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"infections due to group D streptococci (Streptococcus bovis/Streptococcus\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"equinus complex)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 890,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS S. PNEUMONIAE",
      "term": null,
      "displaytext": "Streptococcus pneumoniae (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO TID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO QDAY ($) [R,DI]\", \"Text\": \"Levofloxacin 750 mg PO QDAY ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750 mg PO QDAY ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCUS PNEUMONIAE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Refer to Central Nervous System section of the Inpatient Antimicrobial CDSS for\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"treatment of meningitis.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment for infections outside of the central nervous system\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative for patient with beta-lactam allergy, or when beta-lactam resistance\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"is suspected or proved\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Streptococcus pneumoniae\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus pneumoniae\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-To-Date article: Invasive pneumococcal (Streptococcus pneumoniae) infections\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"and bacteremia\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 891,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS S. PYOGENES",
      "term": null,
      "displaytext": "Group A (S. pyogenes) - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GROUP A STREPTOCOCCI (S. PYOGENES)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Group A streptococcus (Streptococcus pyogenes) is the most virulent\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"streptococcal species. Important syndromes include pharyngitis, cellulitis,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"streptococcal toxic shock syndrome, necrotizing fasciitis, erysipelas, rheumatic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"fever, and post-streptococcal glomerulonephritis. Optimal therapy depends on\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"both the disease or syndrome and the pathogen. See diagnosis/syndrome section\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Mild to moderate infections (non-necrotizing)\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"for 4 days\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Bacteremia, toxic shock syndrome and necrotizing infections\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Streptococcus pyogenes\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Strep\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-To-Date article: Group A streptococcal (Streptococcus pyogenes) bacteremia in\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"adults\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"12A\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 892,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS STAPH LUGDUNENSIS",
      "term": null,
      "displaytext": "Treatment for Staphylococcus lugdunensis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR STAPHYLOCOCCUS LUGDUNENSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Severity of S. lugdenensis infections vary from moderate to severe.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Approximately 25% of isolates are resistant to penicillin, but methicillin\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"resistance is uncommon, less than 5% of isolates.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"If susceptibility results are known, use them to select one of the following\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"drugs. If not, use vancomycin empirically until final culture and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"susceptibilities are available.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative for resistant organisms\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Staphylococci\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus lugdunensis\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-To-Date article: Staphylococcus lugdunensis\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 893,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS STAPHYLOCOCCI",
      "term": null,
      "displaytext": "Staphylococci (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 895, \"DisplayText\": \"Treatment for Staphylococcus aureus (Outpatient)\", \"Text\": \"for Staphylococcus aureus\", \"Mnemonic\": \"4\"}, {\"Row\": 44, \"Column\": 1, \"Item\": 881, \"DisplayText\": \"Treatment for Coagulase Negative Staphylococci (Outpatient)\", \"Text\": \"for coagulase-negative staphylococci\", \"Mnemonic\": \"6\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 716, \"DisplayText\": \"\", \"Text\": \"Click Here\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STAPHYLOCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Staphylococcus aureus is a virulent pathogen, and staphylococcal disease tends\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"to relapse. Optimal therapy often involves intravenous therapy for defined\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"durations. See sections on specific syndromes (e.g., bacteremia or\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"endocarditis) for more information.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Coagulase-negative staphylococci, including Staphylococcus epidermidis and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"several less common species, are less virulent than S. aureus and are most\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"commonly pathogenic when they colonize plastic or metal devices in a patient\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"(e.g., intravenous catheters, prosthetic joints or heart valves). S.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"lugdunensis is an uncommon but virulent coagulase-negative staphylococcus\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"species. S. saprophyticus is associated with urinary tract infections in women.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Beta-lactam antimicrobials are the most active drugs against beta-lactam\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"susceptible staphylococci. Penicillin is superior for penicillin-susceptible\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"staphylococci, but most strains are resistant. Nafcillin and oxacillin are\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"nearly as active as penicillin. Cefazolin or ceftriaxone (also beta-lactams are\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"next best. Vancomycin, a glycopeptide, is less active than the beta-lactams.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Trimethoprim-sulfamethoxazole, minocycline, and clindamycin are less effective\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"than beta-lactams for treatment of methicillin-susceptible staphylococcal\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"infections, but may be useful in patients with severe penicillin allergy. For\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"methicillin-resistant staphylococcal infections, trimethoprim-sulfamethoxazole,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"minocycline, and clindamycin are useful alternatives to to vancomycin, as they\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"are inexpensive and available in both intravenous and oral formulations. They\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"are preferred over linezolid in most circumstances because linezolid is\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"expensive, toxic with long-term use, and needed for treatment of highly\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"resistant bacteria like vancomycin-resistant enterococci.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Combination regimens include a primary anti-staphylococcal agent (beta-lactam or\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"vancomycin) plus one or more supplemental drugs (e.g. gentamicin and/or\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"rifampin) often synergistic against staphylococci in vitro, but there is no\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"evidence that combination therapy improves outcomes in staphylococcal infections\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"in humans. Combination therapy has become the community standard for treatment\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"of prosthetic-valve staphylococcal endocarditis based on experimental models and\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"limited clinical data that combination therapy is superior (see endocarditis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"section for details).\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Decolonization\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Baddour, et al. Circulation 2015, 132.15\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Mandell chapter: Endocarditis and Intravascular Infections\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus aureus\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 894,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS TREAT ENTEROCOCCI",
      "term": null,
      "displaytext": "Treatment for Enterococcal infections (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR ENTEROCOCCAL INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Isolation of enterococci in wounds often represents colonization rather than\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"infection. When colonization is suspected, enterococci need not be treated.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment for urinary tract infections\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment for systemic infections\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Alternative for patients unable to take vancomycin or vancomycin resistant\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"enterococci\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Linezolid has many drug interactions and adverse effects, is expensive, and\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"promotes bacterial resistance. It should only be used in cases where other\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"options are not feasible. Contact Infectious Diseases for assistance.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Leuconostoc Species\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecalis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Enterococcus faecium\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 895,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS TREAT S. AUREUS",
      "term": null,
      "displaytext": "Treatment for Staphylococcus aureus (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Mnemonic\": \"12a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TREATMENT FOR STAPHYLOCOCCUS AUREUS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If susceptibility results are known, use them to select one of the following\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"drugs.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"If not, use vancomycin empirically until final culture and susceptibilities are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"available.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for resistant organisms\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Staphylococcus aureus\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Staphylococcus aureus\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 896,
    "fields": {
      "name": "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO",
      "term": null,
      "displaytext": "Viridans streptococci (including S. mutans, S. mitis, ...) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"VIRIDANS STREPTOCOCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Viridans streptococci are a heterogeneous group defined by their production of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"green pigment on blood agar. Clinically important members of this group include\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"S. mutans, S. mitis, and S. sanguis. S. anginosus (formerly S. milleri) and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Streptococcus bovis are described separately. Viridans streptococci are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"important, common pathogens in endocarditis and can also be contaminants in\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"cultures of blood and other specimens. Consult Infectious Diseases for more\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to the Cardiovascular Section of the Inpatient Antimicrobialc CDSS for\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"diagnosis and treatment of endocarditis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment is penicillin or cefazolin. Vancomycin should be used only\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"in patients with beta-lactam allergy, or if beta-lactam resistance is strongly\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"suspected. For serious disease, consider addition of gentamicin for synergy.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Contact Infectious Diseases for more information.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Groups C and G Streptococci, and Other Related Organisms\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococci, viridans group\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 897,
    "fields": {
      "name": "ORZID3 GMENU H. PYLORI INFECT",
      "term": null,
      "displaytext": "Helicobacter pylori infection (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"BIS524MGQID TETRACY500MGQID METRO250MGQID OMEP20MG\", \"Text\": \"Bismuth subsalicylate 524 mg PO QID <AND> Tetracycline 500mg QID ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"BIS524MGQID TCN500MGQID METRO250MGBID OMEP20MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HELICOBACTER PYLORI INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"H. pylori infection is associated with peptic ulcers, gastritis, gastric\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"adenocarcinoma, and gastric lymphoma. Antimicrobials should be given to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patients with confirmed H. pylori infection. Antisecretory therapy should be\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"given concurrently. Contact Gastroenterology for more information or\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"First line treatment:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"<AND> metronidazole 250 mg PO QID ($) [H,DI] <AND> omeprazole 20 mg PO BID\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Take all for 14 days.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mandell chapter: Helicobacter pylori and Other Gastric Helicobacter Species\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Gastric/Duodenal Ulcer, Helicobacter pylori\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment regimens for Helicobacter pylori\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Chey et al, Am J Gastroenterol, 2017,112:212-239\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG\", \"Text\": \"Clarithromycin 500 mg PO BID ($)[R,DI] <AND> Amoxicillin 1000 mg PO BID\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"($)[R] <AND> metronidazole 500 mg PO BID ($) [H,DI] <AND> omeprazole 20 mg\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"PO BID. Take all for 14 days.\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Resistance to clarithromycin is increasing, do not use for patients with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"prior exposure to macrolides:\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"treatment failures to first line.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 898,
    "fields": {
      "name": "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN",
      "term": null,
      "displaytext": "Head and Neck / ENT (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 933, \"DisplayText\": \"Malignant otitis externa (Outpatient)\", \"Text\": \"Malignant Otitis Externa\", \"Mnemonic\": \"4\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 934, \"DisplayText\": \"Mastoiditis (Outpatient)\", \"Text\": \"Mastoiditis\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 954, \"DisplayText\": \"Otitis externa (Outpatient)\", \"Text\": \"Otitis Externa\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 955, \"DisplayText\": \"Otitis media (Outpatient)\", \"Text\": \"Otitis Media\", \"Mnemonic\": \"10\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 802, \"DisplayText\": \"Conjunctivitis (Outpatient)\", \"Text\": \"Conjunctivitis\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 827, \"DisplayText\": \"Endophthalmitis (Outpatient)\", \"Text\": \"Endophthalmitis\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 921, \"DisplayText\": \"Keratitis (Outpatient)\", \"Text\": \"Keratitis\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 981, \"DisplayText\": \"Periocular Infections\", \"Text\": \"Periocular Infections\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 997, \"DisplayText\": \"Prophylaxis for Ophthalmic Surgery\", \"Text\": \"Prophylaxis for Ophthalmic Surgery\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 1011, \"DisplayText\": \"Retinitis (Outpatient)\", \"Text\": \"Retinitis\", \"Mnemonic\": \"22\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 1055, \"DisplayText\": \"Uveitis\", \"Text\": \"Uveitis\", \"Mnemonic\": \"24\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 745, \"DisplayText\": \"Bell's palsy (Outpatient)\", \"Text\": \"Bell's Palsy\", \"Mnemonic\": \"26\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 990, \"DisplayText\": \"Preseptal cellulitis (Outpatient)\", \"Text\": \"Pre-septal Cellulitis\", \"Mnemonic\": \"28\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 987, \"DisplayText\": \"Postseptal cellulitis (Orbital cellulitis) - Outpatient\", \"Text\": \"Post-septal Cellulitis (Orbital Cellulitis)\", \"Mnemonic\": \"30\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  HEAD AND NECK++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Ear/Otologic\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Eye/Ophthalmologic\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Facial\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Section last reviewed June 2021\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 726, \"DisplayText\": \"ACUTE SINUSITIS\", \"Text\": \"Acute Sinusitis\", \"Mnemonic\": \"38\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 790, \"DisplayText\": \"Chronic sinusitis (Outpatient)\", \"Text\": \"Chronic Sinusitis\", \"Mnemonic\": \"40\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 839, \"DisplayText\": \"Fungal Sinusitis\", \"Text\": \"Fungal Sinusitis\", \"Mnemonic\": \"42\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 938, \"DisplayText\": \"Prevention of infection in patients with nasal packing (Outpatient)\", \"Text\": \"Nasal Packing (to prevent infection)\", \"Mnemonic\": \"44\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 944, \"DisplayText\": \"Nosocomial sinusitis (Outpatient)\", \"Text\": \"Nosocomial Sinusitis\", \"Mnemonic\": \"46\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 806, \"DisplayText\": \"Deep Oropharyngeal Infections (Lugwig's angina) - Outpatient\", \"Text\": \"Deep Oropharyngeal Infections\", \"Mnemonic\": \"48\"}, {\"Row\": 14, \"Column\": 2, \"Item\": 1036, \"DisplayText\": \"Suppurative odontogenic infections (Outpatient)\", \"Text\": \"Dental Infections\", \"Mnemonic\": \"50\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 829, \"DisplayText\": \"Epiglottitis (Outpatient)\", \"Text\": \"Epiglottitis\", \"Mnemonic\": \"52\"}, {\"Row\": 16, \"Column\": 2, \"Item\": 652, \"DisplayText\": \"Esophagitis (outpatient)\", \"Text\": \"Esophagitis\", \"Mnemonic\": \"54\"}, {\"Row\": 17, \"Column\": 2, \"Item\": 198, \"DisplayText\": \"Laryngitis and Croup\", \"Text\": \"Laryngitis\", \"Mnemonic\": \"56\"}, {\"Row\": 18, \"Column\": 2, \"Item\": 691, \"DisplayText\": \"Parotitis (outpatient)\", \"Text\": \"Parotitis\", \"Mnemonic\": \"58\"}, {\"Row\": 19, \"Column\": 2, \"Item\": 982, \"DisplayText\": \"Periodental disease (Outpatient)\", \"Text\": \"Periodontal Disease\", \"Mnemonic\": \"60\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 983, \"DisplayText\": \"Pertussis (Outpatient)\", \"Text\": \"Pertussis\", \"Mnemonic\": \"62\"}, {\"Row\": 21, \"Column\": 2, \"Item\": 984, \"DisplayText\": \"Pharyngitis (Outpatient)\", \"Text\": \"Pharyngitis\", \"Mnemonic\": \"64\"}, {\"Row\": 22, \"Column\": 2, \"Item\": 843, \"DisplayText\": \"Candida albicans (Outpatient)\", \"Text\": \"Thrush\", \"Mnemonic\": \"66\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 984, \"DisplayText\": \"Pharyngitis (Outpatient)\", \"Text\": \"Tonsillitis\", \"Mnemonic\": \"68\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Nasal/Sinus\", \"Header\": 1}, {\"Row\": 12, \"Column\": 2, \"Text\": \"Throat/Oropharyngeal\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 899,
    "fields": {
      "name": "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)",
      "term": null,
      "displaytext": "Head Lice (Pediculosis Capitis) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 3104, \"DisplayText\": \"Treating Head Lice URL\", \"Text\": \"http://www.cdc.gov/ncidod/dpd/parasites/lice/2004_PDF_Treating_head_lice.pdf\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion for 10 min\", \"Text\": \"Permethrin 1% lotion Apply to affected area for 10 minutes then comb out\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion for 10 min Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"HEAD LICE (PEDICULOSIS CAPITIS)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Lice are parasitic insects. Human lice survive by feeding on human blood.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"To make a diagnosis, use a nit comb, bright light, or lens to find a louse\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"living on the scalp.  Dead nits may remain for months after successful\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"treatment.  Dead nits are usually located more than 6 mm from the scalp.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Lice are often transmitted by infected clothing and bedclothes but not by\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"ordinary furniture that is not typically in contact with hair or scalp.  Refer\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to the following for advice on household cleaning for lice infestations:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Repeat if live lice are seen 7-10 days after treatment.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"nits ($) [M]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: lice\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 900,
    "fields": {
      "name": "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY",
      "term": null,
      "displaytext": "Hepatitis B Evaluation Anti-CD20 Antibody  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 3105, \"DisplayText\": \"Hepatitis B Oncology SharePoint\", \"Text\": \"Hepatitis B Oncology SharePoint\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Hepatitis B Serology Panel (Hep B)\", \"Text\": \"HEPATITIS B SEROLOGY PANEL\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"GI Liver\", \"Text\": \"GASTROENTEROLOGY LIVER OUTPATIENT CONSULT\", \"Mnemonic\": \"8\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HIV, Rapid\", \"Text\": \"HIV RAPID TEST (results in 1-2 hours)\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Consult Infectious Diseases (outpatient)\", \"Text\": \"CONSULT ID FOR HIV POSITIVE PATIENTS\", \"Mnemonic\": \"12\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"ORDER LABS: COMPREHENSIVE METABOLIC + PHOSPHORUS\", \"Mnemonic\": \"14\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Hepatitis B DNA level (viral load)\", \"Text\": \"HEPATITIS B DNA LEVEL (VIRAL LOAD)\", \"Mnemonic\": \"16\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"GI Liver\", \"Text\": \"GASTROENTEROLOGY LIVER OUTPATIENT CONSULT\", \"Mnemonic\": \"18\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Hepatitis B DNA level (viral load)\", \"Text\": \"Hepatitis B DNA level (viral load)\", \"Mnemonic\": \"20\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Entecavir 0.5 mg po daily (throughout anti-CD20 antibody therapy\", \"Text\": \"Entecavir 0.5 mg po daily (throughout anti-CD20 antibody therapy\", \"Mnemonic\": \"22\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Entecavir 1 mg po daily (througout anti-CD20 antibody therapy\", \"Text\": \"Entecavir 1 mg po daily (througout anti-CD20 antibody therapy\", \"Mnemonic\": \"24\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tenofovir 300 mg PO daily (throughout anti-CD20 antibody therapy\", \"Text\": \"Tenofovir 300 mg PO daily (throughout anti-CD20 antibody therapy\", \"Mnemonic\": \"26\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Hepatitis B evaluation for patients receiving Anti-CD20 Antibody Treatment\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NOTE: OUTPATIENT ORDERS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Before initiating anti-CD20 antibody treatment (rituximab, obinutuzumab,\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"ofatumumab) test all patients for Hepatitis B. Testing should be completed\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"within the last 6 months prior to the start of the initial infusion (same day\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"is acceptable, but not preferred). Annual Hepatitis B screening is not\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"necessary unless there are risk factors.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"More information at VHA Oncology SharePoint site for hepatitis B reactivation:\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Order Hepatitis B Serology Panel for all patients:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Includes hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"(total anti-HBcAb),and anti-hepatitis B surface antibody (anti-HBsAb).\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"IF HBsAg or anti-HBcAb is positive, Consult GI for all services except\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Oncology:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"(Includes Rheumatology, Renal, Neurology, and Dermatology)\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"IF HBsAg or anti-HBcAB is positive for an ONCOLOGY patient initial orders:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"a) Assess HIV status. To avoid potential HIV resistance-\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"refer HIV positive patients to ID for management.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"b) Obtain Labs: Comprehensive Metabolic AND Phosphorus\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"c) Obtain HBV DNA level (viral load) initially\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"d) Schedule GI Clinic Consult for co-management to order\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"liver imaging and follow-up as indicated.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"e) Start hepatitis B antiviral treatment (see below)\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Recommended Antiviral Treatment:\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Continue antivirals throughout anti-CD20 Ab therapy and for an additional\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"12 months to prevent hepatitis B reactivation, hepatitis, liver failure,\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"and death.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Obtain HBV DNA level (viral load) every 3 months\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"IF PATIENT IS CURRENTLY ON HEPATITIS B ANTIVIRAL THERAPY:\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"(lamivudine, adefovir, or telbivudine)\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Consult the provider who ordered the antiviral and inform the\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"provider the patient is being initiated on Anti-CD20 antibody therapy.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"IF PATIENT IS NOT ON HEPATITIS B ANTIVIRAL THERAPY:\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Lamivudine-naive patients:\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"and for an additional 12 months after therapy completed). (Cost $$) [R,O]\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Lamivudine-experienced patients:\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Preferred Treatment:\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"and for an additional 12 months after therapy completed). (Cost $$) [R,O]\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Alternative Treatment:\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"IF creatinine clearance equal to or greater than 50 ml per minute\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"and for an additional 12 months after therapy completed). (Cost $$) [R,O]\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Terrault NA, Hepatology 2016, 63:261\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Perrillo RP, Gastroenterology 2015, 148:221\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Hwang JP, Journal of Clinical Oncology 2015, 33:2212\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Up-to-Date\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 901,
    "fields": {
      "name": "ORZID3 GMENU HERPES WHITLOW",
      "term": null,
      "displaytext": "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po tid for 10 days\", \"Text\": \"Acyclovir 400 mg PO TID for 10 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po tid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po bid for 10 days\", \"Text\": \"Valacyclovir 1 gm PO BID for 10 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po bid for 10 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES WHITLOW (DIGIT OR HAND CELLULITIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Alternative for easier compliance schedule\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Sanford keyword: Whitlow, herpetic\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 902,
    "fields": {
      "name": "ORZID3 GMENU HIDRADENITIS SUPPURATIVA",
      "term": null,
      "displaytext": "Hidradenitis Suppurativa (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlorhexidine gluconate 4% liquid topically wash affected area q24h\", \"Text\": \"Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlorhexidine gluconate 4% liquid topically wash affected area q24h\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzoyl peroxide 10% wash topically daily q24h ($)[M]\", \"Text\": \"Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzoyl peroxide 10% wash topically daily q24h ($)[M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% cream topical bid prn\", \"Text\": \"Clindamycin 1% solution topically to affected areas q12h prn for flares ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 1% cream topical bid prn Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"10a\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI] for 12 weeks\", \"Text\": \"Minocycline 100 mg PO q12h ($) [DI] for 12 weeks\", \"Mnemonic\": \"12a\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO q12h ($) [DI] for 12 weeks Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]\", \"Mnemonic\": \"14a\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W\", \"Text\": \"Moxifloxacin 400 mg PO q24h ($)[R,DI] for 12 weeks <AND> metronidazole 500\", \"Mnemonic\": \"16a\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HIDRADENITIS SUPPURATIVA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A chronic inflammatory condition that typically involves occlusion, rupture,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"abscess formation and infection of hair follicles as well as secondary infection\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"of apocrine glands/surrounding tissues. Lesions most often occur in the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"intertriginous areas (axillae, inguinal and anogenital) in is associated with\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"smoking and obesity. There is a 40% genetic predisposition for hidradenitis\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"suppurativa (HS) and is often accompanied by pain, malodor, and drainage.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Cultures are negative 50% of the time and often are polymicrobial with S.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"epidermidis and S. aureus most isolated. The Hurley Staging System is often used\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"to determine severity of HS.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Therapy generally consists of treatment of comorbidities that can exacerbate HS,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"avoidance of triggers, pain management, wound care, and topical/oral\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"antimicrobials. Hormonal agents, steroids, retinoids, and surgery can also be\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"used to treat certain patients. Biologics may be considered in Stage II-III HS.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Consult Dermatology in all cases\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Hurley Staging System:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Stage I: recurrent nodules and abscesses with minimal scarring\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Stage II: limited number of sinuses and/or scarring within a body region\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Stage III: multiple or extensive sinuses and/or scarring\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Duration of Therapy:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Treatment is typically for 12 weeks but may require longer durations in certain\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"cases. Metronidazole should only be used for a maximum of 6 weeks to avoid\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"neurologic toxicity.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Interventions for All Patients:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Smoking cessation, weight loss, avoidance of triggers, and pain management\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"should be part of all treatment plans. Consult Dermatology for use of hormonal\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"agents, steroids, retinoids, and surgery.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Optional Topical Treatment, May be Used in Addition to Oral Therapies Below:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"< ADD ON THERAPY FOR FLARES - MUST USE IN ADDITION TO ONE OF THE AGENTS ABOVE>\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Stage I-II Initial Treatment:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Stage III Initial Treatment and Stage I-II Failure of Oral Doxycycline:\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Stage II-III Failure of Oral Clindamycin:\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"mg q8h ($) [DI] for 6 weeks <AND> rifampin 300 mg PO q12h ($) [DI,O] for 12\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"weeks\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Alikhan, Ali, et al. Journal of the American Academy of Dermatology 81.1 (2019):\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"76-90\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"John Hopkins ABX Guide Keyword: Hidradenitis Suppurativa\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Up-To-Date article: Hidradenitis suppurativa: Management\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Up-To-Date article: Hidradenitis suppurativa: Pathogenesis, clinical features,\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"and diagnosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 903,
    "fields": {
      "name": "ORZID3 GMENU HSV ENCEPHALITIS",
      "term": null,
      "displaytext": "HSV encephalitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"HERPES SIMPLEX VIRUS ENCEPHALITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 904,
    "fields": {
      "name": "ORZID3 GMENU IG DEFICIENCY HIS",
      "term": null,
      "displaytext": "Immunoglobulin deficiency (Humoral immune system) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"IMMUNOGLOBULIN DEFICIENCY (HUMORAL IMMUNE SYSTEM)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antibody deficiency typically leads to recurrent, severe respiratory tract\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infections associated with encapsulated bacteria, especially Streptococcus\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pneumoniae and Haemophilus influenzae, and to a lesser extent, Staphylococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"aureus. Recurrent otitis media, sinusitis, and pneumonia are common syndromes.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Gastrointestinal disease associated with Salmonella, Shigella, Campylobacter, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"rotavirus is also common in some patients.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Preferred empirical treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 905,
    "fields": {
      "name": "ORZID3 GMENU ILEUS/TOXI MEGACOLON",
      "term": null,
      "displaytext": "Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEVERE/LIFE-THREATENING CLOSTRIDIUM DIFFICILE INFECTION\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 906,
    "fields": {
      "name": "ORZID3 GMENU IMMUNOCOM COMP DEFICIENCY",
      "term": null,
      "displaytext": "Complement Deficiency (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"COMPLEMENT DEFICIENCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Complement deficiency can be inherited or acquired complement deficiency.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Acquired defects are usually a consequence of other diseases like systemic lupus\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"erythematosus.  Complement deficiency leads to increased rates of infections,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"usually of the upper respiratory tract, but also occasionally with bacteremia or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"meningitis.  Pathogens are usually Streptococcus pneumoniae, Neisseria\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"meningitidis, and Neisseria gonorrhea.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Patients presenting with fever or other symptoms suggesting systemic bacterial\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"infection should be treated immediately with antimicrobials active against these\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"pathogens.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred empirical treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Rich RR et al, eds.  Clinical Immunology\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Roitt I et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 907,
    "fields": {
      "name": "ORZID3 GMENU IMMUNOCOM MALIGNANCY",
      "term": null,
      "displaytext": "Malignancy (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 943, \"DisplayText\": \"Neutropenic fever (Outpatient)\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 991, \"DisplayText\": \"Prevention of infection in a patient with malignancy (Outpatient)\", \"Text\": \"Prevention of bacterial infections in a patient with malignancy\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 992, \"DisplayText\": \"Prevention of fungal infection in a patient with malignancy\", \"Text\": \"Prevention of fungal infections in a patient with malignancy\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 732, \"DisplayText\": \"\", \"Text\": \"Prevention of antiviral infections in a patient with malignancy\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MALIGNANCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Malignancies affect host defenses in many ways.  Hematogenous malignancies can\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diminish the effectiveness of neutrophils and other cells involved in host\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"defense.  Tumors often disrupt mucous membranes or blood vessels and allow\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"contaminating organisms into hollow cavities or the bloodstream.  Chemotherapy\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"used to treat these malignancies often impairs mucus membranes and suppresses\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"neutrophil production and function.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empirical antimicrobials are not indicated for patients with malignancy and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"fever unless they have neutropenia or a specific infectious disease, except in\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"specific circumstances.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 908,
    "fields": {
      "name": "ORZID3 GMENU IMMUNOCOM NEUROL DYSFUNCT",
      "term": null,
      "displaytext": "Neurologial Dysfunction (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 739, \"DisplayText\": \"Aspiration pneumonia (Outpatient)\", \"Text\": \"Aspiration pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUROLOGICAL DYSFUNCTION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Several types of neurological dysfunction predispose patients to infectious\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diseases.  Comatose patients are unable to keep weight off dependent tissues,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"predisposing them to decubitus ulcers and pressure necrosis.  Atelectasis is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"common in obtunded patients who cannot cough or breathe deeply.  When patients\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"require artificial ventilation, intubation compounds the risk of respiratory\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"infection.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Neurological dysfunction of the bladder can interfere with normal bladder\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"emptying and predisposes patients to bacteriuria.  The risk of bacteruria\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"increases if patients are catheterized.  Antimicrobial treatment is not\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"indicated for asymptomatic bacteriuria.  It provides no benefit and increases\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"risk of colonization with resistant organisms.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Neurological dysfunction of the gastrointestinal or pulmonary systems\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"predisposes patients to aspiration of oropharyngeal or gastric contents.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Aspiration causes fever, inflammation, and/or pulmonary infiltrate, but does not\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"require antimicrobial treatment. Bacterial pneumonia occurs in a minority of\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"patients who experience significant aspiration, typically about 3 days later.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"The patient usually improves for the first 2 days and then worsens as bacterial\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"pneumonia develops with increased fever, new or progressive infiltrates,\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"leukocytosis, and newly purulent sputum.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Rich RR, et al, eds.  Clinical Immunology\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Roitt I, et al, eds.  Immunology\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 909,
    "fields": {
      "name": "ORZID3 GMENU IMMUNOCOMPROMISED PT",
      "term": null,
      "displaytext": "Infections in Immunocompromised patients (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 446, \"DisplayText\": \"Basic concepts\", \"Text\": \"Basic concepts\", \"Mnemonic\": \"4\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 445, \"DisplayText\": \"Altered microbial flora\", \"Text\": \"Altered microbial flora\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 906, \"DisplayText\": \"Complement Deficiency (Outpatient)\", \"Text\": \"Complement deficiency\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 448, \"DisplayText\": \"Diabetes Mellitus\", \"Text\": \"Diabetes Mellitus\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 449, \"DisplayText\": \"Hypochlorhydria\", \"Text\": \"Hypochlorhydria\", \"Mnemonic\": \"12\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 907, \"DisplayText\": \"Malignancy (Outpatient)\", \"Text\": \"Malignancy\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 451, \"DisplayText\": \"Malnutrition\", \"Text\": \"Malnutrition\", \"Mnemonic\": \"16\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 908, \"DisplayText\": \"Neurologial Dysfunction (Outpatient)\", \"Text\": \"Neurological dysfunction\", \"Mnemonic\": \"18\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 454, \"DisplayText\": \"Neutropenia\", \"Text\": \"Neutropenia\", \"Mnemonic\": \"20\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 943, \"DisplayText\": \"Neutropenic fever (Outpatient)\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"22\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 1033, \"DisplayText\": \"Asplenia Recommendations Vaccines Empiric Abx\", \"Text\": \"Spleen absent or dysfunctional\", \"Mnemonic\": \"24\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 455, \"DisplayText\": \"Stress\", \"Text\": \"Stress\", \"Mnemonic\": \"26\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 456, \"DisplayText\": \"Tobacco smoke\", \"Text\": \"Tobacco smoke\", \"Mnemonic\": \"28\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 985, \"DisplayText\": \"Pneumocyctis Jirovecii Disease (Outpatient)\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"30\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ INFECTIONS IN IMMUNOCOMPROMISED PATIENTS - OUTPATIENT ++\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Innate defects\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Last reviewed February 2012\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Item\": 176, \"DisplayText\": \"HIV-AIDS\", \"Text\": \"HIV\", \"Mnemonic\": \"34\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 345, \"DisplayText\": \"Cell-mediated immunity (CMI) defects\", \"Text\": \"Cell-mediated immunity (CMI) defects\", \"Mnemonic\": \"36\"}, {\"Row\": 10, \"Column\": 2, \"Item\": 904, \"DisplayText\": \"Immunoglobulin deficiency (Humoral immune system) - Outpatient\", \"Text\": \"Immunoglobulin deficiency (humoral immune system)\", \"Mnemonic\": \"38\"}, {\"Row\": 11, \"Column\": 2, \"Item\": 626, \"DisplayText\": \"Transplantation\", \"Text\": \"Transplantation\", \"Mnemonic\": \"40\"}, {\"Row\": 7, \"Column\": 2, \"Text\": \"Immune defects\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 910,
    "fields": {
      "name": "ORZID3 GMENU IMPETIGO",
      "term": null,
      "displaytext": "Impetigo (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% Oint tid for 5 days ($$) [M]\", \"Text\": \"Mupirocin ointment to affected area TID for 5 days ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mupirocin 2% Oint tid for 5 days ($$) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100MG PO bid ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100MG PO bid ($) [DI]\", \"Mnemonic\": \"14a\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"16\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Impetigo and Ecthyma\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Impetigo is a superficial skin infection that rarely causes systemic\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"symptoms. Ecthyma is a skin infection characterized by crusted sores\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"beneath which ulcers form. It is a deep form of impetigo, as the same\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"bacteria causing the infection are involved. Ecthyma causes deeper\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"erosions of the skin into the dermis.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Gram stain and culture of the pus or exudates from skin lesions of\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"impetigo and ecthyma are recommended to help identify whether\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Staphylococcus aureus and/or beta-hemolytic Streptococcus is the cause.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Bullous and non-bullous impetigo can be treated with oral or topical\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"antimicrobials, but oral therapy is recommended for patients with\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"numerous lesions or in outbreaks affecting several people to help\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"decrease transmission of infection. Treatment for ecthyma should be an\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"oral antimicrobial.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment for impetigo with few lesions\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment for ecthyma and for impetigo with numerous lesions or\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"whose symptoms have not responded to topical treatment\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Treat orally for 7 days\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"IF MRSA confirmed or suspected:\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014 59: 147\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Montravers P Curr Opin Infect Dis 2016, 29:131\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 911,
    "fields": {
      "name": "ORZID3 GMENU INFECT DIARRHEA/GASTROENT",
      "term": null,
      "displaytext": "Infectious diarrhea/Gastroenteritis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 797, \"DisplayText\": \"Community acquired diarrhea (no recent travel) - Outpatient\", \"Text\": \"Community acquired diarrhea (no recent travel)\", \"Mnemonic\": \"4\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 1048, \"DisplayText\": \"Traveler's diarrhea\", \"Text\": \"Traveler's diarrhea\", \"Mnemonic\": \"6\"}, {\"Row\": 45, \"Column\": 1, \"Item\": 809, \"DisplayText\": \"Diarrhea with Aeromonas (Outpatient)\", \"Text\": \"Aeromonas\", \"Mnemonic\": \"8\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Adenovirus\", \"Mnemonic\": \"10\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Astrovirus\", \"Mnemonic\": \"12\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 812, \"DisplayText\": \"Diarrhea with Campylobacter (Outpatient)\", \"Text\": \"Campylobacter\", \"Mnemonic\": \"14\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 782, \"DisplayText\": \"Antibiotic Associated Colitis (C. Difficile Colitis)\", \"Text\": \"[CLICK HERE] for mild to moderate disease\", \"Mnemonic\": \"16\"}, {\"Row\": 52, \"Column\": 1, \"Item\": 905, \"DisplayText\": \"Severe C. Difficile disease - Ileus/Toxic megacolon (Outpatient)\", \"Text\": \"[CLICK HERE] for severe/life-threatening disease (shock, ileus and megacolon)\", \"Mnemonic\": \"18\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 816, \"DisplayText\": \"Diarrhea with Isospora belli (Outpatient)\", \"Text\": \"Cystoisospora belli\", \"Mnemonic\": \"20\"}, {\"Row\": 55, \"Column\": 1, \"Item\": 811, \"DisplayText\": \"Diarrhea with Crytosporidium parvum (Outpatient)\", \"Text\": \"Cryptosporidium parvum\", \"Mnemonic\": \"22\"}, {\"Row\": 56, \"Column\": 1, \"Item\": 810, \"DisplayText\": \"Diarrhea with Cyclospora cayetanensis (Outpatient)\", \"Text\": \"Cyclospora cayetanensis\", \"Mnemonic\": \"24\"}, {\"Row\": 57, \"Column\": 1, \"Item\": 813, \"DisplayText\": \"Diarrhea with Entamoeba histolytica (Outpatient)\", \"Text\": \"Entamoeba histolytica\", \"Mnemonic\": \"26\"}, {\"Row\": 59, \"Column\": 1, \"Item\": 814, \"DisplayText\": \"Diarrhea with enterohemorrhagic E. Coli (Outpatient)\", \"Text\": \"Escherichia coli [CLICK HERE], including varieties listed below:\", \"Mnemonic\": \"28\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 815, \"DisplayText\": \"Diarrhea with Giardia lamblia (Outpatient)\", \"Text\": \"Giardia duodenalis\", \"Mnemonic\": \"30\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 817, \"DisplayText\": \"Diarrhea with Microsporidia (Outpatient)\", \"Text\": \"Microsporidia\", \"Mnemonic\": \"32\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Norovirus\", \"Mnemonic\": \"34\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Rotavirus\", \"Mnemonic\": \"36\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 800, \"DisplayText\": \"Viral Diarrhea\", \"Text\": \"Sapovirus\", \"Mnemonic\": \"38\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 818, \"DisplayText\": \"Diarrhea with Salmonella (Outpatient)\", \"Text\": \"Salmonella\", \"Mnemonic\": \"40\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 819, \"DisplayText\": \"Diarrhea with Shigella (Outpatient)\", \"Text\": \"Shigella\", \"Mnemonic\": \"42\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 820, \"DisplayText\": \"Diarrhea with Vibrio cholera (Outpatient)\", \"Text\": \"Vibrio cholerae\", \"Mnemonic\": \"44\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 821, \"DisplayText\": \"Diarrhea with non-cholera vibrio (Outpatient)\", \"Text\": \"Vibrio non-cholerae\", \"Mnemonic\": \"46\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 822, \"DisplayText\": \"Diarrhea with Yersinia enterocolitica (Outpatient)\", \"Text\": \"Yersinia enterocolitica\", \"Mnemonic\": \"48\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INFECTIOUS DIARRHEA / GASTROENTERITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most episodes of acute diarrhea are self limited and do not need to be evaluated\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"or treated. In most mild to moderate cases, antimicrobial therapy does not\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"provide benefit and may prolong symptoms or shedding. Antimicrobial therapy is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"detrimental in cases involving enterohemorrhagic Escherichia coli.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"The decision for whether to test stool depends on illness severity and duration,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"the likelihood of specific infectious agents and the severity of any underlying\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"diseases. Send stool sample for enteric pathogen PCR testing if the patient has\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"volume depletion warranting hospitalization, bloody stool, >/= 6 stools in 24\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"hours, temperature >38.4?C, or severe abdominal pain or signs of sepsis, or is\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \">/= 70 years old or substantially immunocompromised. Replace fluid losses and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"correct electrolyte imbalances. Patients with diarrhea who were potentially\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"exposed during a community outbreak of infectious diarrhea should be tested for\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"the suspected bacterial, viral, and parasitic agents regardless of symptom\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"severity.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Obtain blood cultures if patients have signs of septicemia, suspected enteric\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"fever (e.g., fever plus recent travel to an endemic area or contact with someone\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"who has enteric fever), other systemic symptoms, immune compromise, or other\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"high-risk conditions.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Bloody diarrhea\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"therapy and antimotility agents are not recommended in most patients with bloody\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"diarrhea due to an increased risk of hemolytic uremic syndrome when using these\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"agents. Obtain a stool sample for enteric pathogen PCR testing and reserve\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"antimicrobial and antimotility agent treatment until results are known. Enteric\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"pathogen PCR testing results are reported within 2 hours between 7am and 11pm.\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"For more information on when an antimicrobial is indicated or if the patient has\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"severe/life threatening diarrhea or is immunocompromised, contact Infectious\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Empirical antimicrobial treatment of diarrhea\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Treatment of diarrhea caused by specific bacteria, parasites, and viruses\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Clostridium difficile:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Enteroaggretive E. coli (EAEC), Enterotoxigenic E. coli (ETEC),\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Enterohemorrhagic E. coli (EHEC), Shiga Toxin-producing E. coli (STEC),\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Enteropathogenic E. coli (EPEC), Enteroinvasive E. Coli (EIEC)\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Sanford guide keyword: Gastroenteritis, Diarrhea: Overview\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"settings\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 912,
    "fields": {
      "name": "ORZID3 GMENU INFLUENZA 2022-2023 OUTPATIENT",
      "term": null,
      "displaytext": "Influenza Seasonal 2021-2022",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza Vaccination Recommendations\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 734, \"DisplayText\": \"ANTIVIRAL TREATMENT OUTPATIENT\", \"Text\": \"Antiviral Treatment Recommendations\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 913, \"DisplayText\": \"Early treatment as alternative to chemoprophylaxis:\", \"Text\": \"Chemoprophylaxis Recommendations\", \"Mnemonic\": \"8\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nasopharyngeal Testing Menu\", \"Text\": \"Lab Influenza Testing Menu\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Seasonal Influenza\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Last reviewed September 2022\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 913,
    "fields": {
      "name": "ORZID3 GMENU INFLUENZA CHEMOPROPHYLAXIS",
      "term": null,
      "displaytext": "Early treatment as alternative to chemoprophylaxis: ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Early treatment as alternative to chemoprophylaxis:\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"In most cases, if a person is suspected of having been exposed to influenza,\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"early treatment should signs or symptoms develop is preferred rather than\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"chemoprophylaxis.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"The provider should explain the early signs and symptoms of influenza to the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"patient and advise the patient to immediately contact a health care provider\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"for evaluation and possible early treatment if these symptoms or signs\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"develop. Influenza-like symptoms or signs include fever, cough, sore throat,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"runny or stuffy nose, body aches, headache, chills, fatigue, vomiting, and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"diarrhea. Influenza can present without fever.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Health care providers should use clinical judgment regarding situations where\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"early recognition of illness and treatment might be an appropriate\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"alternative to chemoprophylaxis.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Early treatment alternative or chemoprophylaxis may be considered:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"*Persons who are part of a high-risk group and are household or close\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"contacts of someone with influenza-like illness\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Chemoprophylaxis recommended:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Chemoprophylaxis considered:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"*Atypical situations (such as case clusters). Contact state health department\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"for consultation.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Antiviral Prophylaxis Recommendations:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Zanamivir is not recommended for patients with chronic respiratory disease such\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"as asthma or chronic obstructive pulmonary disease. These patients may have\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"bronchospasm with zanamivir. If zanamivir must be used, and patients are using\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"an inhaled bronchodilator, zanamivir should be taken just after the\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"bronchodilator.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Zanamivir 2 inhalations (2 x 5 mg) daily for 14 days ($) [O] Duration based on\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Chemoprophylaxis duration: 7 days after last known exposure\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"*For control of outbreaks in institutional settings (long-term care\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"facilities and hospitals)\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Chemoprophylaxis duration: minimum of 2 weeks and continuing up to 1 week\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"after the last known case identified\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Note: Antiviral chemoprophylaxis is recommended for all residents, including\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"those who have received influenza vaccination.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Preferred treatment:\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oseltamivir 75 mg po daily for 14 days ($) [R] Duration based on last exposure\", \"Mnemonic\": \"4a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Oseltamivir 75 mg po daily for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative treatment:\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Requires Infectious Disease Approval\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"last exposure\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"patients wt <80kg ($$$) [O]\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"UpToDate Seasonal influenza in adults: Role of antiviral prophylaxis for\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"prevention\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Centers for Disease Control (Accessd 9/20/22)\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 914,
    "fields": {
      "name": "ORZID3 GMENU INFLUENZA VACCINATION",
      "term": null,
      "displaytext": "INFLUENZA VACCINATION RECOMMENDATIONS",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MVAHCS Vaccination Recommendations for Outpatients:\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Annual influenza vaccination is recommended for all persons aged 6\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"months and older without a specific contraindication.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"B viruses.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Minneapolis VAHCS Influenza Commitee 2022-2023\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Grohskopf LA, MMWR Recommendations and Reports 2022, 71(1):1-28\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Recommendation for adults aged >/= 65 years:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Recommendation for adults aged <65 years:\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Per available stock and ACIP 2022-2023 recommendations, the MVAHCS will provide:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Adjuvanted influenza vaccines - an ingredient is added to help create a\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"stronger immune response.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Quadrivalent influenza vaccine - made up of the four flu strains most likely\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"to cause the flu during the upcoming season (H1N1, H3N2, and two group\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"*Standard quadrivalent influenza vaccine\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"*Standing orders - no patient specific order needed\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Eggs and latex allergies are NOT considered contraindications to receiving\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"the vaccine, the only contraindication to the flu vaccination is severe\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"allergic reaction (i.e. Anaphylactic reactions).\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"*Adjuvanted influenza vaccine (Flu-Ad)\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 3106, \"DisplayText\": \"Influenza vaccine\", \"Text\": \"[Click here] Outpatient Influenza Vaccine Guidelines\", \"Mnemonic\": \"4\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 915,
    "fields": {
      "name": "ORZID3 GMENU INI EPISODE ABX ASSOC COLITIS",
      "term": null,
      "displaytext": "Initial Episode of Antibiotic Associated Colitis... ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125 mg PO QID for 10 days ($) [M]\", \"Text\": \"Vancomycin 125 mg PO QID for 10 days ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 125 mg PO QID for 10 days ($$) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Discontinue implicated antibiotic and avoid high-risk antibiotic if antibiotic\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"therapy is still needed. Discontinue antacid therapy if possible.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Initial Episode Preferred Treatment:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Clinical\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"manifestations and diagnosis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"(e.g., age >65 years old, concomitant antibiotic use during CDI treatment,\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"and/or immunosuppression)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Patient at increased risk of CDI recurrence:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg po q12h x 10 days ($$$$) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Patient not meeting criteria above for increased risk of CDI recurrence:\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Patient with clinical symptom onset (e.g., 3 or more unformed stools in 24 hours\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"after discontinuation of laxatives) and laboratory confirmation of CDI.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg PO BID for 10 days ($$$$) [O]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Fulminant CDI (hypotension or shock, ileus, megacolon)\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INITIAL EPISODE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Item\": 97, \"DisplayText\": \"Clostridioides difficile Infection (CDI) 2-step testing\", \"Text\": \"Information on C difficile lab testing\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 916,
    "fields": {
      "name": "ORZID3 GMENU INT RS GRAM-NEG BACILLI",
      "term": null,
      "displaytext": "Interim results:  Gram-negative bacilli (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM RESULTS: GRAM-NEGATIVE BACILLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pseudomonas, Bordetella, and Brucella spp. usually grow aerobically (but can\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"show up in an anaerobic bottle). Bacteroides, Fusobacterium, Porphyromonas, and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prevotella spp. usually grow anaerobically (but can show up in an aerobic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"bottle). Most other gram-negative bacilli are facultative, i.e. they can grow\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in aerobic or anaerobic culture conditions.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Some antimicrobial combinations are synergistic in vitro against some Gram-\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"negative bacilli. Combination therapy has not been shown to improve outcomes\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"in most circumstances. Single drug therapy is used in most cases. Contact\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Infectious Diseases for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Use susceptibility information to select an antimicrobial when a pathogen is\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"identified.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford Keyword: Antibacterial Activity Spectra\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford Keyword: Pseudomonas aeruginosa\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-Date Article: Principles of antimicrobial therapy of Pseudomonas\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"aeruginosa infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 917,
    "fields": {
      "name": "ORZID3 GMENU INT RS GRAM-NEG COCCI",
      "term": null,
      "displaytext": "Iterim report of Gram-negative cocci (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM RESULTS: GRAM-NEGATIVE COCCI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Gram-negative cocci may represent meningococci, gonococci, or Moraxella.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseria meningitidis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Sanford keyword: Neisseia gonorrhoeae\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Moraxella catarrhalis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 918,
    "fields": {
      "name": "ORZID3 GMENU INT RS GRAM-POS BACILLI",
      "term": null,
      "displaytext": "Interim report of Gram-positive Bacilli (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 923, \"DisplayText\": \"Large uniform bacilli in an aerobic bottle (Outpatient)\", \"Text\": \"LARGE UNIFORM BACILLI in an AEROBIC bottle\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 924, \"DisplayText\": \"Large uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"LARGE UNIFORM BACILLI in an ANAEROBIC bottle\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 1028, \"DisplayText\": \"Small uniform bacilli in an anaerobic bottle (Outpatient)\", \"Text\": \"SMALL PLEOMORPHIC BACILLI in ANAEROBIC bottle\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 1027, \"DisplayText\": \"Small uniform bacillin in an aerobic bottle (Outpatient)\", \"Text\": \"SMALL PLEOMORPHIC BACILLI in AEROBIC bottle\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-POSITIVE BACILLI\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"There are three typical morphologies (1)large and regular, (2)medium sized and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"variable, and (3)small and pleomorphic. The large, uniformly rod-shaped Gram-\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"positive bacilli are usually Bacillus spp. (aerobic) or Clostridium species\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"(anaerobic). Bacillus spp. include Bacillus subtilis (usually a contaminant),\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Bacillus cereus, and Bacillus anthracis. Medium-sized Gram-positive bacilli are\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"usually Lactobacilli (anaerobic). Small and pleomorphic bacilli are usually\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Listeria (aerobic), diphtheroids (aerobic), Propionibacteria (anaerobic), and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Corynebacteria (aerobic)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 919,
    "fields": {
      "name": "ORZID3 GMENU INT RS GRAM-POS COCCI PAIRS",
      "term": null,
      "displaytext": "Interim report of Gram-positive cocci in pairs (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"Help, additional information:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help page (instructions, restrictions, microbiology, etc.)\", \"Mnemonic\": \"02\"}, {\"Row\": 3, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Consult Infectious Diseases (outpatient)\", \"Text\": \"Consult Infectious Diseases\", \"Mnemonic\": \"04\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"A preliminary report of gram-positive cocci in pairs suggests staphylococci,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"streptococci, or enterococci.  If the patient is severely ill, is likely\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"colonized with resistant organisms, or if staphylococci or enterococci are\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"likely, treat with vancomycin until susceptibility results are known.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Cephalosporins are not active against enterococci or methicillin-resistant\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"staphylococcus aureus.  If encapsulated streptococci are likely, treat with\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"06\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA.  The Sanford Guide to\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Antimicrobial Therapy.  35th ed.  Hyde Park, VT: Antimicrobial Therapy Inc,\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"2005.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell GL, Bennett JE, Dolin R, eds.  Principles and Practice of Infectious\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Diseases.  6th ed.  Philadelphia, PA: Churchill-Livingston, 2005.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Medical Letter Treatment Guidelines 2007, 5:57\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"penicillin or cefazolin.  If pneumococci are likely, treat with\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"penicillin or ceftriaxone.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"For intravenous treatment options, please refer to Inpatient Antimicrobiala\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 920,
    "fields": {
      "name": "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT",
      "term": null,
      "displaytext": "Intravascular catheter-associated infection (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INTRAVASCULAR CATHETER-ASSOCIATED INFECTION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 921,
    "fields": {
      "name": "ORZID3 GMENU KERATITIS",
      "term": null,
      "displaytext": "Keratitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 660, \"DisplayText\": \"HERPES KERATITIS\", \"Text\": \"Herpes keratitis\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) every 1 hour\", \"Text\": \"Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) q1h ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops <AND> gentamicin 15 mg/ml\", \"Text\": \"Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops q1h <AND> gentamicin 15 mg/ml\", \"Mnemonic\": \"8a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin 50 Non-VA ophthalmic drops: 1-2 drops <AND> gentamicin 15 mg/ml\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"KERATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Keratitis is an emergency requiring prompt treatment to prevent vision loss.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Contact Ophthalmology immediately.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Keratitis is associated with viral or bacterial infection, trauma, foreign\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bodies, or allergies. About half of cases of infectious keratitis are caused by\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"bacterial pathogens, most commonly Staphylococcus spp., Streptococcus spp., and\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"gram-negative bacilli. Viruses are the second leading cause. Fungi and parasites\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"have also been associated with corneal infection. Obtain corneal scrapings for\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"gram stain and bacterial and viral cultures and start empirical therapy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"immediately.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Link to herpes keratitis page\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"If bacterial keratitis is likely, contact ophthalmology to obtain a corneal\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"scraping and give empirical antibacterial drops immediately. Modify therapy\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"based on Ophthalmology and/or Infectious Diseases recommendations. Ophthalmic\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"corticosteroids are contraindicated in patients with keratitis.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Duration of therapy\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment should be continued until ulcer and other signs of infectious\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"keratitis have resolved. A minimum of two weeks and in rare cases, up to a month\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"of therapy may be required.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mild to moderate bacterial keratitis empirical treatment\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Severe (vision-threatening) bacterial keratitis empirical treatment\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"ophthalmic drops: 1-2 drops q1h ($) [M] in affected eye(s)\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Suspected MRSA\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Patient may require vancomycin 50mg/mL eye drops q1h in addition to gentamicin\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"eye drops. Vancomycin eye drops must be specially compounded and managed by\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Ophthalmology.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Lin et al., Ophthalmology. 2019,126(1):1-55\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Microbial keratitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Sanford keyword: Keratitis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-to-Date article:  Complications of contact lenses\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 922,
    "fields": {
      "name": "ORZID3 GMENU LEISHMANIASIS",
      "term": null,
      "displaytext": "Leishmaniasis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LEISHMANIASIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis and treatment are complex.  Consult Infectious Diseases and/or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Dermatology in all cases.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 923,
    "fields": {
      "name": "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT",
      "term": null,
      "displaytext": "Large uniform bacilli in an aerobic bottle (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LARGE UNIFORM BACILLI IN AN AEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Large uniform bacilli in an aerobic bottle usually suggest Bacillus species.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Bacillus subtilis is usually a contaminant, Bacillus cereus is uncommon but\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"usually pathogenic. If Bacillus anthracis is suspected or isolated contact\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Infectious Diseases immediately.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical treatment of suspected non-anthracis Bacillus spp. associated with\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"disease\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for intravenous treatment options\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Empirical treatment of suspected Bacillus anthracis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for intravenous treatment options\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Hendricks et al., Emerg Infect Dis 2014, 20.2\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 924,
    "fields": {
      "name": "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT",
      "term": null,
      "displaytext": "Large uniform bacilli in an anaerobic bottle (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LARGE UNIFORM BACILLI IN AN ANAEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Large uniform bacilli in an anaerobic bottle usually suggest clostridium, a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"potentially severe pathogen. Combination therapy is recommended for necrotizing\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"infections as clindamycin has the theoretical benefit of inhibiting toxin\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"production.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical treatment of mild to moderate infection\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for intravenous treatment options\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Empirical treatment of severe or necrotizing infection\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for intravenous treatment options\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium perfingens\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Stevens et al., Clinical Infectious Diseases 2014 59.2\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 925,
    "fields": {
      "name": "ORZID3 GMENU LUNG ABSCESS",
      "term": null,
      "displaytext": "Lung abscess (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125 mg po bid for 6 weeks\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125 mg po bid for 6 weeks Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid for 6 weeks\", \"Text\": \"Clindamycin 300 mg po q6h ($) [H,O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid for 6 weeks Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LUNG ABSCESS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pulmonary and/or Infectious Diseases consultations are strongly encouraged for\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"all cases.  Obtain samples for gram stain and culture from fine needle\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"aspiration whenever possible.  Sputum culture is less helpful because it will be\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"contaminated with upper respiratory flora.  Classically, lung abscess is a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"complication of mixed anaerobic and aerobic pulmonary infection. The initial\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"infection may or may not be clinically apparent.  Malaise, weight loss, fever,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"chills, and malodorous sputum typically develop over a period of weeks.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cavitation and/or abscess can occur in cases of pneumonia from a single\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"pathogen, commonly Staphylococcus aureus or Pseudomonas aeruginosa.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Antimicrobial treatment should be directed against the specific pathogen.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treat for 6 to 8 weeks and adjust treatment based on clinical response.  Oral\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"medications should be used in patients who can take them.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Preferred oral treatment:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative for patient with severe penicillin allergy:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Bartlett JG Anaerobe 2012, 18:234\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell Chapter:  Principles and Practice of Infectious Diseases\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Harrison's chapter: Infections due to mixed organisms\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword lung abscess\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 926,
    "fields": {
      "name": "ORZID3 GMENU LUNGS AND MEDIASTINUM",
      "term": null,
      "displaytext": "Lungs and Mediastinum (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 738, \"DisplayText\": \"Acute Respiratory Infection (ARI) Symptomatic Therapy\", \"Text\": \"Acute Respiratory Infection (ARI) Symptomatic Therapy\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 777, \"DisplayText\": \"Bronchitis/COPD Exacerbation\", \"Text\": \"Bronchitis\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 826, \"DisplayText\": \"Empyema (Outpatient)\", \"Text\": \"Empyema\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 777, \"DisplayText\": \"Bronchitis/COPD Exacerbation\", \"Text\": \"Exacerbation of chronic obstructive pulmonary disease (COPD)\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 912, \"DisplayText\": \"Influenza Seasonal 2021-2022\", \"Text\": \"Influenza Seasonal\", \"Mnemonic\": \"12\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 925, \"DisplayText\": \"Lung abscess (Outpatient)\", \"Text\": \"Lung abscess\", \"Mnemonic\": \"14\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 935, \"DisplayText\": \"Mediastinitis (Outpatient)\", \"Text\": \"Mediastinitis\", \"Mnemonic\": \"16\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 983, \"DisplayText\": \"Pertussis (Outpatient)\", \"Text\": \"Pertussis\", \"Mnemonic\": \"18\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 1050, \"DisplayText\": \"Tuberculosis (Outpatient)\", \"Text\": \"Tuberculosis\", \"Mnemonic\": \"20\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 741, \"DisplayText\": \"\", \"Text\": \"Azithromycin for prevention of COPD exacerbations\", \"Mnemonic\": \"22\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  LUNGS AND MEDIASTINUM - OUTPATIENT  ++\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 739, \"DisplayText\": \"Aspiration pneumonia (Outpatient)\", \"Text\": \"Aspiration pneumonia\", \"Mnemonic\": \"26\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 798, \"DisplayText\": \"Community acquired pneumonia (Outpatient)\", \"Text\": \"Community-acquired pneumonia (CAP)\", \"Mnemonic\": \"28\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 945, \"DisplayText\": \"Nosocomial pneumonia (Outpatient)\", \"Text\": \"Nosocomial pneumonia (including HAP and VAP)\", \"Mnemonic\": \"30\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Pneumonia\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 927,
    "fields": {
      "name": "ORZID3 GMENU LYME ACUTE NEURO DISEASE",
      "term": null,
      "displaytext": "Acute neurological disease associated with Lyme disease (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"extensive neurological disease with intravenous antimicrobials.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment of isolated facial paresthesia (Bell palsy)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment of neurological disease other than Bell palsy\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Halperin et. al., Neurology (2007) 69.91-102\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 928,
    "fields": {
      "name": "ORZID3 GMENU LYME ARTHRITIS ASSOC",
      "term": null,
      "displaytext": "Arthritis associated with Lyme disease (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 28 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 28 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 28 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 28 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID for 28 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 28 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ARTHRITIS ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases respond to a 28 day course of oral antimicrobials. If symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"persist or recur, Consult Infectious Diseases or Rheumatology.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 929,
    "fields": {
      "name": "ORZID3 GMENU LYME CARDIAC DISEASE",
      "term": null,
      "displaytext": "Cardiac disease associated with Lyme disease (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat for 14 to 21 days. Cardiology consult recommended.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment of first degree or second degree heart block\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment of third degree heart block or other manifestation\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Refer to inpatient Antimicrobial CDSS\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 930,
    "fields": {
      "name": "ORZID3 GMENU LYME DISEASE",
      "term": null,
      "displaytext": "Lyme Disease (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 931, \"DisplayText\": \"Lyme Disease Prophylaxis\", \"Text\": \"Lyme Disease Prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 932, \"DisplayText\": \"Erythema migrans associated with Lyme disease (Outpatient)\", \"Text\": \"Erythema migrans associated with Lyme disease (outpatient)\", \"Mnemonic\": \"6\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 927, \"DisplayText\": \"Acute neurological disease associated with Lyme disease (Outpatient)\", \"Text\": \"Acute neurological disease associated with Lyme disease (outpatient)\", \"Mnemonic\": \"8\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 928, \"DisplayText\": \"Arthritis associated with Lyme disease (Outpatient)\", \"Text\": \"Arthritis associated with Lyme disease (outpatient)\", \"Mnemonic\": \"10\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 929, \"DisplayText\": \"Cardiac disease associated with Lyme disease (Outpatient)\", \"Text\": \"Cardiac disease associated with Lyme disease (outpatient)\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Lyme disease results from the transmission of Borrelia burgdorferi from an\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Ixodes spp. tick bite. Patients who display signs of illness or fever within 30\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"days of removing an attached tick should be evaluated for tick-borne illness.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"(deer tick) but who do not display signs or symptoms of infection should not\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"be treated with antimicrobials.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Prophylactic antimicrobial treatment may be beneficial in certain patients who\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"have been bitten while in endemic areas.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Except for erythema migrans, Lyme disease is a complicated, difficult disease to\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"diagnose and treat. Infectious Diseases consultation is strongly encouraged.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Wormser GP Clin Infect Dis (2006), 43: 1089\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 931,
    "fields": {
      "name": "ORZID3 GMENU LYME DISEASE PROPHYLAXIS",
      "term": null,
      "displaytext": "Lyme Disease Prophylaxis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 3107, \"DisplayText\": \"IXODES IDENTIFACTION LINK\", \"Text\": \"Ixodes scapularis identification\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TICKBORNE RISK MAP\", \"Text\": \"Tickborne Disease Risk in Minnesota\", \"Mnemonic\": \"6\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxyclycline PO 200mg once ($) [DI]\", \"Text\": \"Doxyclycline PO 200mg once ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxyclycline PO 200mg once ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"LYME DISEASE PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients who have been bitten while in endemic areas of New England, Mid-\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"tick infection rate with Borrelia burgdorferi is equal to or greater than 20%\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"may be treated with prophylactic antibiotics for prevention of Lyme disease.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Using a wait and see method by monitoring for signs and symptoms of Lyme disease\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"is also an acceptable approach in patients who have been bitten by an Ixodes\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"scapularis tick.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"All following criteria must be met to be considered for prophylactic treatment:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"2. Attached tick is reliably identified as an adult or nymphal Ixodes\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"scalpularis. Follow link below for identification guide:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"3. Tick is attached for greater than or equal to 36 hours based on degree of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"tick engorgement with blood or likely time of exposure to tick infested area.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"4. Prophylaxis must be started within 72 hours after time tick was removed.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"5. Patient was exposed to tick bite in endemic areas where rate of Ixodes\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"counties where there is high risk of tickborne disease are shown in the\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"following link:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Providers can call the Minnesota Department of Health (651-201-5414) or the\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services (608-266-1865) for specific rates of B.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"burdorferi infection of ixodes ticks in area where a patient was exposed.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"bite in New England or Mid-Atlantic States.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Prophylactic treatment if all above criteria are met\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Wormser GP Clin Infect Dis (2006), 43: 1089\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Minnesota Department of Health, Lyme Disease Basics (2017)\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"https://www.dhs.wisconsin.gov/publications/p01295.pdf\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 932,
    "fields": {
      "name": "ORZID3 GMENU LYME ERYTHEMA MIGRANS",
      "term": null,
      "displaytext": "Erythema migrans associated with Lyme disease (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ERYTHEMA MIGRANS ASSOCIATED WITH LYME DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Erythema migrans is the first manifestation of Lyme disease in 70-80% of cases.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"It is typically an erythematous circular rash, 5cm or larger in diameter, with\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"induration and central clearing (although other patterns occur). It usually\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"develops at the site of the bite and/or in one or more distant locations. The\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"rash occurs 3 to 30 days after the bite. Rashes with onset less than 3 days\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"after a tick bite are not from Lyme disease.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For pregnant patients or patients with doxycycline allergy\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanchez et al., JAMA (2016) 315.16\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Wormser et al., Clin Infect Dis (2006) 43.1089-134\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 933,
    "fields": {
      "name": "ORZID3 GMENU MALIGN OTITIS EXTERNA",
      "term": null,
      "displaytext": "Malignant otitis externa (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 28 days\", \"Text\": \"Ciprofloxacin 750 mg PO q12h for 6 weeks ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MALIGNANT OTITIS EXTERNA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Those who are elderly, diabetic, immunocompromised and debilitated are at\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"highest risk. Most cases are associated with Pseudomonas aeruginosa, but other\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pathogens can be involved. Obtain culture to identify etiologic agent and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"susceptibilities. Obtain a CT scan to determine whether osteomyelitis is\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"present. ENT and Infectious Disease consultations are recommended.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment of uncomplicated disease\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment of advanced disease, immunocompromised patients, or for coverage of\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"fluoroquinolone resistant Pseudomonas aeruginosa, in addition to above therapy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Treatment of early infection or step-down treatment after initial intravenous\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"antimicrobial therapy. Adjust for a total duration of 6 weeks of antimicrobial\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"therapy.\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Evans, Journal of Laryngology and Otology. 2011, 125(12)1212-1217Mandell\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mahdyoun et al., Otol Neurotol. 2013, 34(4)620-629\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Otitis Externa\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date article: Malignant (necrotizing) external otitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 934,
    "fields": {
      "name": "ORZID3 GMENU MASTOIDITIS",
      "term": null,
      "displaytext": "Mastoiditis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefuroxime 500 mg PO q12h for 7 days ($) [R]\", \"Text\": \"Cefuroxime 500 mg PO q12h for 7 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefuroxime 500 mg PO q12h for 7 days ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO q12h for 7 days ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)\", \"Text\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)\", \"Mnemonic\": \"10a\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cipro-Dex otic 4 drops in affected ear(s) BID for 4 weeks ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4\", \"Text\": \"Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4\", \"Mnemonic\": \"12a\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MASTOIDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute Mastoiditis\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Acute mastoiditis most commonly occurs as a suppurative complication of acute\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"otitis media. Diagnosis is supported by CT or MRI imaging and culture of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"drainage. Antibiotics and drainage of middle ear are sufficient treatment in\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"most cases. Mastoidectomy is necessary if abscess has formed in the mastoid\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"bone. If complication of first episode of acute otitis media, etiologies\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"typically include Streptococcus pneumonia (most common), Streptococcus pyogenes,\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"or Staphylococcus aureus. If secondary to chronic otitis media, etiologies\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"typically include Staphylococcus aureus or Pseudomonas aeruginosa. Patients\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"usually too ill for outpatient therapy. ENT consultation recommended. Obtain\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"cultures of auditory canal or middle ear fluid (preferred).\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Empirical treatment of uncomplicated disease\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Empirical Treatment of complicated disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Step down treatment after initial intravenous antibiotic treatment in patients\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"who can tolerate oral therapy. Base selection on culture results. Adjust for a\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"total duration of 3 weeks of antimicrobial therapy.\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Chronic Mastoiditis\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Chronic mastoiditis is usually the result of chronic otitis media with\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"perforation of the tympanic membrane. There is often associated formation of a\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"cholesteatoma (keratoma). Diagnosis is supported by CT or MRI imaging and\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"culture of drainage. Long term treatment with topical antimicrobials is first\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"line therapy. Infection is often polymicrobial, including Staphylococcus aureus,\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa and anaerobes. Treatment should be managed in\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"collaboration with otolaryngology and includes topical antimicrobials, care of\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"external auditory canal, and is some cases mastoidectomy. If possible, withhold\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"therapy until a pathogen is identified by culture of drainage to direct therapy.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Specific drug choice dictated by culture results.\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Empirical Treatment\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"weeks ($) [M]\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Loh et. al., The Journal of Laryngology & Otology. 2018, 132(2)96-104.\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Sanford keyword: Mastoiditis\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Up-to-Date article: Chronic otitis media, cholesteatoma, and mastoiditis in\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 935,
    "fields": {
      "name": "ORZID3 GMENU MEDIASTINITIS",
      "term": null,
      "displaytext": "Mediastinitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MEDIASTINITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 936,
    "fields": {
      "name": "ORZID3 GMENU MORE ABOUT CELLULITIS",
      "term": null,
      "displaytext": "The approach to cellulitis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 830, \"DisplayText\": \"Erysipelas (Outpatient)\", \"Text\": \"Erysipelas\", \"Mnemonic\": \"4\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 836, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus (Outpatient)\", \"Text\": \"Foot ulcer in patient with diabetes mellitus\", \"Mnemonic\": \"6\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"THE APPROACH TO CELLULITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In addition to antimicrobial therapy, several non-pharmacological treatments\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"improve the outcome of cellulitis.Elevation and immobilization of the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"affected limb reduces swelling.  Heat reduces discomfort.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Prevent tinea pedis infection by keeping feet clean and dry.  In patients with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"peripheral edema, good skin hygiene and support stockings reduce the incidence\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"of recurrent infection.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"In many cases of cellulitis, the affected area is usually not well-\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"differentiated from unaffected areas of the skin. Erysipelas is a special case\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"with typically a well-defined border and raised, orange-peel appearance.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Use broad-spectrum therapy for cellulitis arising in feet of patients with\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"advanced diabetes.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Schwartz MN New Eng J Med 2004, 350: 904\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Sanford keyword: Cellulitis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Cellulitis and subcutaneous tissue infections\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-to-Date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 937,
    "fields": {
      "name": "ORZID3 GMENU MORE ABOUT PHARYNGITIS",
      "term": null,
      "displaytext": "More About Pharyngitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MORE ABOUT PHARYNGITIS/ TONSILLITIS AND THE MODIFIED CENTOR SCORE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"As most cases are of viral origin, antimicrobials are not indicated in these\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"cases. Warm saltwater gargle rinses and throat lozenges provide temporary relief\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"of throat pain. Five to 10% of cases are caused by group A Streptococcus.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Antimicrobial treatment reduces symptoms by one day, prevents suppurative\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"complications and prevents acute rheumatic fever, an uncommon disease in US\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"adults.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Streptococcal pharyngitis or tonsillitis should be suspected when patients have\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"fever and exudate on the pharyngeal wall or tonsils without symptoms like cough,\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"nasal congestion, or runny nose that suggest viral infection or common cold. If\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"streptococcal pharyngitis is suspected in adults, perform PCR testing for group\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"A streptococci and treat only if positive.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Neisseria gonorrhoeae is a rare cause of pharyngitis. N. gonorrhoeae should be\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"considered for patients with risk factors for sexually transmitted diseases. N.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"gonorrhoeae infections must be reported to the state health department and this\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"will be done by Infection Control if the culture is positive.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"The Modified Centor score\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Used to estimate the likelihood that a patient with sore throat has\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"streptococcal pharyngitis and whether rapid PCR testing should be performed.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"1) Absence of cough = 1 point\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"2) Swollen and tender anterior cervical nodes = 1 point\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"3) Temperature greater than 100.4 degrees Fahrenheit (38 degrees Centigrade) = 1\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"point\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"4) Tonsillar exudates or swelling = 1 point\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"5) Age: 3-14 years = 1 point\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"15-44 years = 0 points\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"45 years and older = -1 point\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Patients with a score of 0 or 1 are at very low risk. PCR testing and antibiotic\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"treatment are not indicated. Patients with a score of 2 to 4 are at moderate to\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"high risk. PCR testing should be obtained in these patients to determine if GAS\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"is present. In patients with a score of 4 or greater, consider empiric\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"antibiotic treatment.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"CDC STD 2015 Guidelines MMWR. 2015, 64(3)1-7\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Choby, Am Fam Physician. 2009 79(5) 383-390\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Pharyngitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcal Pharyngitis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Stanford et al, Clinical Infectious Diseases. 2012, cis629\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-To-Date article:  Evaluation of acute pharyngitis in adults\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article:  Treatment and prevention of streptococcal pharyngitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 938,
    "fields": {
      "name": "ORZID3 GMENU NASAL PACKING",
      "term": null,
      "displaytext": "Prevention of infection in patients with nasal packing (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF INFECTION IN PATIENTS WITH NASAL PACKING\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis to prevent infection and toxic shock syndrome in\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients with nasal packing is not recommended. Antibiotics increase the risk of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"adverse events in patients with nasal packing with no proven effectiveness in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"preventing infection.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cohn, Annals of emergency medicine 2015, 1.65, 109-111\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Kucik et al, Am Fam Physician 2005, 71.2, 305-311\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Up-to-Date article: Approach to the adult with epistaxis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 939,
    "fields": {
      "name": "ORZID3 GMENU NECROTIZING INFECTIONS",
      "term": null,
      "displaytext": "Necrotizing infections (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NECROTIZING INFECTIONS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 940,
    "fields": {
      "name": "ORZID3 GMENU NEED AN ALT ABX MAIN",
      "term": null,
      "displaytext": "Need an alternative antimicrobial? (outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Allergic to recommended drug(s)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Decreased renal clearance\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Liver secretory or metabolic impairment\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Drug interaction\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Patient has multiple infections requiring antimicrobials\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Adjust therapy based on antimicrobial susceptibility\", \"Mnemonic\": \"12\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Other adverse drug effect\", \"Mnemonic\": \"14\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Other reason\", \"Mnemonic\": \"16\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 73, \"DisplayText\": \"Additional assistance...\", \"Text\": \"Please Click Here to contact the CDSS team\", \"Mnemonic\": \"18\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 144, \"DisplayText\": \"Drug allergies\", \"Text\": \"Information about drug allergies\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEED AN ALERNATIVE ANTIMICROBIAL?\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If you cannot use the recommended antimicrobials or you believe another one\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"would be better for your patient, you can order another drug. Please indicate\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"the reason you need an alternative drug below.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Note: Alternative antimicrobial selections will be reviewed and we may contact\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"prescribers to learn more about situations that need alternatives, improve the\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"CDSS, and in some cases offer suggestions.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Clarification/Comments:\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 941,
    "fields": {
      "name": "ORZID3 GMENU NEUT CAND ORAL THERAPY",
      "term": null,
      "displaytext": "Neutropenic fever--Patient IS a candidate for oral therapy (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 502, \"DisplayText\": \"Scoring tool to identify low risk febrile neutropenic patients\", \"Text\": \"Link to a scoring tool that identifies low risk patients for oral therapy\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> amoxicillin-clavulanate\", \"Mnemonic\": \"6a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg po bid ($) [R,DI] <AND> Clindamycin 300mg po qid ($) [H,O\", \"Text\": \"Ciprofloxacin 500mg po bid ($) [R,DI] <AND> Clindamycin 300mg po qid ($) [H,O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg po bid ($) [R,DI] <AND> Clindamycin 300mg po Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER--PATIENT IS A CANDIDATE FOR ORAL THERAPY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Can the patient be treated with oral therapy?\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"875/125 mg PO BID ($) [R]\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Freifeld AG Clinical Infectious Disease 2011, 52: 427-431\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Taplitz RA, J Clin Oncol 2018, 36: 1443-1453\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sanford: Neutropenia, Febrile, Low-Risk\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Related Infections. Version 1.2019. nccn.org\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 942,
    "fields": {
      "name": "ORZID3 GMENU NEUT NOT CAND ORAL THERAPY",
      "term": null,
      "displaytext": "Neutropenic fever--Patient is NOT a candidate for oral therapy (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 943,
    "fields": {
      "name": "ORZID3 GMENU NEUTROPENIC FEVER",
      "term": null,
      "displaytext": "Neutropenic fever (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 941, \"DisplayText\": \"Neutropenic fever--Patient IS a candidate for oral therapy (Outpatient)\", \"Text\": \"If patient IS a candidate for oral therapy\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 942, \"DisplayText\": \"Neutropenic fever--Patient is NOT a candidate for oral therapy (Outpatient)\", \"Text\": \"If patient is NOT a candidate for oral therapy\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 502, \"DisplayText\": \"Scoring tool to identify low risk febrile neutropenic patients\", \"Text\": \"Link to a scoring tool that identifies low risk patients for oral therapy\", \"Mnemonic\": \"8\"}, {\"Row\": 36, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC FEVER\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The risk of severe, rapidly progressive infections increases when the absolute\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"neutrophil count (ANC, segmented neutrophils plus bands) is less than 500\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cells/microliter.  The risk increases dramatically when the ANC is <100\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cells/microliter.  Because of these risks, patients with fever and neutropenia\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"to this degree should receive empirical antimicrobial therapy immediately.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical therapy should also be given to patients with fever and ANC 500-1000\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"cells/microliter when the concentration is expected to be <500 cells/microliter\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"within the next 48 hours.  For this purpose, fever is defined as a single\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"temperature greater than 38.3 degrees Celsius.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Initial therapy\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Since infection can be rapidly progressive and severe, broad-spectrum\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"antimicrobials are given urgently to patients with neutropenic fever as defined\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"above.  Vancomycin should only be given when there are clear indications for its\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"use.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Candidates for empirical treatment with oral antimicrobials include those who\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"are febrile but who have no evidence of focal infection or signs or symptoms of\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"severe disease, like hypotension.  Outpatient antimicrobials for neutropenic\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"fever must be ordered only in consultation with Hematology-Oncology or\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Modifcation to therapy\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Hughes WT Clin Infect Dis 2002, 34: 730\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Rolston KVI Clin Infect Dis 2004, 39: S44\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sipsas NV Cancer 2005, 103: 1103\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 944,
    "fields": {
      "name": "ORZID3 GMENU NOSO SINUSITIS",
      "term": null,
      "displaytext": "Nosocomial sinusitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NOSOCOMIAL SINUSITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Nasogastric tubes increase the risk of bacterial sinus infection associated with\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Staphylococcus aureus, streptococcus, and gram-negative bacilli, including\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pseudomonas aeruginosa. Aspirate sinuses for gram stain and culture to direct\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antimicrobial therapy. Adequate sinus drainage is vital to treatment.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Empirical antimicrobial treatment\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mandell chapter: Sinusitis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Sinusitis, Intubation Associated\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-To-Date article: Complications of the endotracheal tube following initial\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"placement: Prevention and management in adult intensive care unit patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 945,
    "fields": {
      "name": "ORZID3 GMENU NOSOCOMIAL PNEUMONIA",
      "term": null,
      "displaytext": "Nosocomial pneumonia (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NOSOCOMIAL PNEUMONIA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 946,
    "fields": {
      "name": "ORZID3 GMENU OROLABIAL HERPES",
      "term": null,
      "displaytext": "Orolabial herpes (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po tid for 5 days\", \"Text\": \"Acyclovir 400 mg PO TID for 5 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po 5x/d for 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 2gm po bid for 1 day\", \"Text\": \"Valacyclovir 2 gm BID for 1 day ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 2gm po bid for 1 day Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO TID ($0.29/day) [R]\", \"Text\": \"Acyclovir 400 mg PO TID for 7-14 days($) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO 5x/day for 7-14 days($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R]\", \"Text\": \"Valacyclovir 1 gm BID for 7-14 days ($) [R]\", \"Mnemonic\": \"14a\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po bid for 1 year\", \"Text\": \"Acyclovir 400 mg PO BID ($) [R]\", \"Mnemonic\": \"16a\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400mg po bid for 1 year Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO QDAY ($) [R] for 1 year\", \"Text\": \"Valacyclovir 500 mg PO QDay ($) [R]\", \"Mnemonic\": \"18a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 500 mg PO QDAY ($) [R] for 1 year Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OROLABIAL HERPES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Antiviral therapy is not beneficial after formation of vesicles. However, when\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"started as soon as prodromal symptoms of burning or tingling occur, antivirals\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"reduce duration of pain and lesions.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Immunocompromised patients in whom herpes simplex infections can be more severe\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"include: patients with HIV infection, organ transplant recipients, patients\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"undergoing chemotherapy, malnourished patients, and those with compromised skin\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"integrity.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Chronic suppressive therapy\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Indicated for patients with greater than 6 recurrences or severe recurrences,\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"immunocompromised patients or as adjunct to prevent transmission. Suppressive\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"therapy is optional, and some patients may find episodic treatment more\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"convenient. Patients should be reassessed every few years to evaluate if chronic\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"suppressive therapy is still necessary.\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Mandell chapter: Herpes simplex virus\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes simplex\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of herpes simplex virus type 1 infection in\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"immunocompetent patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 947,
    "fields": {
      "name": "ORZID3 GMENU OSTEOM EMP THERAPY",
      "term": null,
      "displaytext": "Empirical therapy for Osteomyelitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po qday ($0.19/day)[R (Var)\", \"Text\": \"Levofloxacin 500 mg PO qday ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po qday ($0.19/day)[R (Var) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EMPIRICAL THERAPY FOR OSTEOMYELITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Therapy should be modified when culture results and patient response to therapy\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"are known.  If cultures cannot be obtained, the oral regimens listed below can\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"be used for empirical therapy or to complete a treatment course after the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"patient's disease has improved. Consult Infectious Diseases for more\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Duration of treatment 4 to 6 weeks.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"ORAL treatment for MILD disease or for completion of treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"course\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"INTRAVENOUS treatment for MODERATE to SEVERE disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Berbari EF Clin Infect Dis 2015, 61:e26\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Calhoun JH Infect Dis Clin North AM 2005, 19:765\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Dis 2012, 54:393\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 948,
    "fields": {
      "name": "ORZID3 GMENU OSTEOM GNB",
      "term": null,
      "displaytext": "Osteomyelitis with Gram negative bacilli (other than Pseudomonas) - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125 mg po bid for 28 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < OR >\", \"Mnemonic\": \"4a\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125 mg po bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po qday ($0.19/day)[R (Var)\", \"Text\": \"Levofloxacin 500 mg PO qday ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po qday ($0.19/day)[R (Var) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Lew DP Lancet 2004, 364: 369\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Cunha BA Clin Infect Dis 2002, 35: 287\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 949,
    "fields": {
      "name": "ORZID3 GMENU OSTEOM PSEUDOMONAS AERUGINOSA",
      "term": null,
      "displaytext": "Osteomyelitis with Pseudomonas aeruginosa (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 28 days\", \"Text\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH PSEUDOMONAS AERUGINOSA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Lew DP Lancet 2004, 364: 369\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Cunha BA Clin Infect Dis 2002, 35: 287\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 950,
    "fields": {
      "name": "ORZID3 GMENU OSTEOM STAPHYLOCOCCUS AUREUS",
      "term": null,
      "displaytext": "Osteomyelitis with Staphylococcus aureus (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >\", \"Mnemonic\": \"10a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 28 days\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI] < OR >\", \"Mnemonic\": \"12a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH STAPHYLOCOCCUS AUREUS\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Methicillin-SUSCEPTIBLE S. aureus\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Methicillin-RESISTANT S. aureus\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"________________________________________________\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Spellberg B Clin Infect Dis 2012, 54:393\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Berbari EF Clin Infect Dis 2015, 61:e26\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Calhoun JH Infect Dis Clin North Am 2005, 19:765\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat for 4 weeks\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID [R] ($)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 951,
    "fields": {
      "name": "ORZID3 GMENU OSTEOM STREPTOCOCCI",
      "term": null,
      "displaytext": "Osteomyelitis with Streptococci (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >\", \"Mnemonic\": \"4a\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS WITH STREPTOCOCCI\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Osteomyelitis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Lew DP Lancet 2004, 364: 369\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Cunha BA Clin Infect Dis 2002, 35: 287\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat for 4 weeks.\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID [R] ($)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 952,
    "fields": {
      "name": "ORZID3 GMENU OSTEOMYELITIS",
      "term": null,
      "displaytext": "Osteomyelitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 947, \"DisplayText\": \"Empirical therapy for Osteomyelitis (Outpatient)\", \"Text\": \"Empirical therapy for osteomyelitis\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 950, \"DisplayText\": \"Osteomyelitis with Staphylococcus aureus (Outpatient)\", \"Text\": \"Osteomyelitis with Staphylococcus aureus\", \"Mnemonic\": \"6\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 951, \"DisplayText\": \"Osteomyelitis with Streptococci (Outpatient)\", \"Text\": \"Osteomyelitis with Streptococci\", \"Mnemonic\": \"8\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 948, \"DisplayText\": \"Osteomyelitis with Gram negative bacilli (other than Pseudomonas) - Outpatient\", \"Text\": \"Osteomyelitis with Gram negative bacilli (other than Pseudomonas)\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 949, \"DisplayText\": \"Osteomyelitis with Pseudomonas aeruginosa (Outpatient)\", \"Text\": \"Osteomyelitis with Pseudomonas aeruginosa\", \"Mnemonic\": \"12\"}, {\"Row\": 43, \"Column\": 1, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OSTEOMYELITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"In acute osteomyelitis, symptoms have been present for several days to weeks.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Chronic osteomyelitis is characterized by a longer duration of symptoms,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"sometimes months or years, and often dead, necrotic bone is present.  There is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"considerable overlap between the syndromes of acute and chronic osteomyelitis.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Symptom duration may be unreliable in a patient with neuropathy.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Obtain material for gram stain and culture before initiating antimicrobials.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Blood and bone cultures are ideal.  Sinus tracts are often colonized with\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"multiple species and usually only one or two are pathogens in bone.  If\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Staphylococcus aureus is present, it is likely to be a pathogen in bone.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Empirical antimicrobial therapy is the same for acute and chronic osteomyelitis,\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"but necrotic bone must often be removed for cure of chronic osteomyelitis.  If\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"complete debridement is not possible, long-term suppressive antimicrobials may\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"be needed.  Consult Infectious Diseases for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"The most important pathogens are S. aureus and streptococci.  Gram negative\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"bacilli are common pathogens in osteomyelitis associated with diabetic foot\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"infection.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Empirical treatment regimens\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Pathogen-directed treatment regimens\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Recommend Orthopedic, Neurosurgery (for spine or skull osteomyelitis), Podiatry\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"(for foot infections), and Infectious Diseases consults.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Treat for 4 to 6 weeks.  Do not place a long-term intravascular access device\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"(e.g. a PICC line) until it is clear the patient will need long-term intravenous\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"therapy.  Consult Infectious Diseases or Orthopedic Surgery for more\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \">>  For patients with infections associated with prosthetic materials see\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \">>  For patients with sternal infection associated with chest surgery, refer to\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"mediastinitis, under Lungs and Mediastinum, in the Inpatient Antimicrobial\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"CDSS.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Osteomyelitis\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Lipsky BA Clin Infect Disease 2012, 54:393\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 953,
    "fields": {
      "name": "ORZID3 GMENU OTHER PATHOGENS",
      "term": null,
      "displaytext": "Other Pathogens (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 964, \"DisplayText\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) - Outpatient\", \"Text\": \"Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)\", \"Mnemonic\": \"4\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 962, \"DisplayText\": \"Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis) - Outpatient\", \"Text\": \"Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 969, \"DisplayText\": \"Mycobacterium tuberculosis (Outpatient)\", \"Text\": \"Mycobacterium tuberculosis\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 965, \"DisplayText\": \"Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC) - Outpatient\", \"Text\": \"Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC)\", \"Mnemonic\": \"12\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 967, \"DisplayText\": \"Mycoplasma pneumonia (Outpatient)\", \"Text\": \"Mycoplasma pneumonia\", \"Mnemonic\": \"14\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 985, \"DisplayText\": \"Pneumocyctis Jirovecii Disease (Outpatient)\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ OTHER PATHOGENS ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome, site of infection, penetration of drug(s)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into site, and whether organism is pathogen, colonizer, or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"contaminant. See disease/syndrome section for more information.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Coxiella and Ehrlichia\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Lyme Disease\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mycobacteria\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Mycoplasma\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Pneumocystis infection\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Last reviewed 8/2018\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 954,
    "fields": {
      "name": "ORZID3 GMENU OTITIS EXTERNA",
      "term": null,
      "displaytext": "Otitis externa (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 849, \"DisplayText\": \"Furuncles and Carbuncles (Outpatient)\", \"Text\": \"Furuncles and Carbuncles\", \"Mnemonic\": \"4\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s) QID ($)\", \"Text\": \"Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID\", \"Mnemonic\": \"6a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Neomycin-polymixin-hydrocortisone otic 4 drops in affected ear(s Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID ($) [M]\", \"Text\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 7 days ($)\", \"Mnemonic\": \"8a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Text\": \"< ADD > ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OTITIS EXTERNA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Acute Localized Disease\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Often due to furunculosis and usually associated with Staphylococcus aureus.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treat mild cases with moist local heat. For cases with cellulitis or deep\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"invasion, incision and drainage as well as systemic antibiotics may be needed.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Refer to the Furuncles and Carbuncles page for antibiotic recommendations.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Acute diffuse and chronic otitis externa\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Most commonly associated with Pseudomonas aeruginosa, Staphylococcus aureus and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Staphylococcus epidermidis. Irrigate to remove cerumen, desquamated skin and\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"purulent material which can improve effectiveness of topical antibiotics. Avoid\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"products that contain neomycin if the tympanic membrane is perforated.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment if tympanic membrane is intact\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"for 7 days ($) [M]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Alternative if tympanic membrane is perforated or allergy to preferred treatmen\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Complicated Cases\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For cases resistant to topical therapy alone, patients with poorly controlled\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"diabetes mellitus, immunocompromised patients, cases where infection has spread\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"beyond ear canal and in those where topical therapy cannot be delivered\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"effectively. Culture secretions to guide therapy.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"In addition to topical therapy above\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Rosenfeld et al., Otolaryngology-Head and Neck Surgery. 2014, 150(2)161-168\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: Otitis Externa\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Up-To-Date article: External otitis: Treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 955,
    "fields": {
      "name": "ORZID3 GMENU OTITIS MEDIA",
      "term": null,
      "displaytext": "Otitis media (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO TID for 10 days ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO q8h for 10 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO TID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]\", \"Text\": \"Amoxicillin/clavulanate 875-125 mg PO q12h for 10 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID for 10 days ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h for 10 days ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID for 10 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 200 mg PO BID for 10 days ($$) [R]\", \"Text\": \"Cefpodoxime 200 mg PO BID for 10 days ($$) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 200 mg PO BID for 10 days ($$) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"OTITIS MEDIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the most common bacteria to cause otitis media.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Patient has NOT received antibiotics in the prior month\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Patient has received antibiotics in the prior month\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Alternatives\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Harmes et al, American Family Physician. 2013, 88(7)435-440\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Otitis media\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-Date Online: Acute otitis media in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 956,
    "fields": {
      "name": "ORZID3 GMENU OUTPATIENT GENRL ALT LIST",
      "term": null,
      "displaytext": "List of antimicrobials - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 2, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 500mg iv bid\", \"Text\": \"Acyclovir IV\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po tid\", \"Text\": \"Acyclovir PO\", \"Mnemonic\": \"4a\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po tid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amikacin 250mg iv qday\", \"Text\": \"Amikacin IV\", \"Mnemonic\": \"6\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500mg po tid\", \"Text\": \"Amoxicillin PO\", \"Mnemonic\": \"8a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500mg po tid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid\", \"Text\": \"Amoxicillin-clavulanate PO\", \"Mnemonic\": \"10a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amphotericin B Liposomal (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O]\", \"Text\": \"Amphotericin B IV\", \"Mnemonic\": \"14\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin 2gm iv q6h (alt 2)\", \"Text\": \"Ampicillin IV\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ampicillin-sulbactam 3gm iv q6h\", \"Text\": \"Ampicillin-sulbactam IV\", \"Mnemonic\": \"18\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone susp 750mg po bid (Var)\", \"Text\": \"Atovaquone PO\", \"Mnemonic\": \"20a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone susp 750mg po bid (Var) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg once then 250mg q24h for 4 days\", \"Text\": \"Azithromycin IV\", \"Mnemonic\": \"22\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg once then 250mg qday for 4 days\", \"Text\": \"Azithromycin PO\", \"Mnemonic\": \"24a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg once then 250mg qday for 4 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"24b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 2gm iv q8h\", \"Text\": \"Aztreonam IV\", \"Mnemonic\": \"26\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Benzathine penicillin IM\", \"Mnemonic\": \"28\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 500 mg PO BID ($) [R]\", \"Text\": \"Cefadroxil PO\", \"Mnemonic\": \"30a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 500 mg PO BID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"30b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefazolin IV\", \"Mnemonic\": \"32\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID Alt\", \"Text\": \"Cefdinir PO\", \"Mnemonic\": \"34a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID Alt Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"34b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 2gm iv q8h\", \"Text\": \"Cefepime IV\", \"Mnemonic\": \"36\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefotetan IV\", \"Mnemonic\": \"40\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Cefoxitin IV\", \"Mnemonic\": \"42\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 200 mg po BID\", \"Text\": \"Cefpodoxime PO\", \"Mnemonic\": \"44a\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodoxime 200 mg po BID Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"44b\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 2gm iv q8h\", \"Text\": \"Ceftazidime IV\", \"Mnemonic\": \"46\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg im once (ALT)\", \"Text\": \"Ceftriaxone IM\", \"Mnemonic\": \"48\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2gm iv qday\", \"Text\": \"Ceftriaxone IV\", \"Mnemonic\": \"50\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefuroxime 500mg po bid\", \"Text\": \"Cefuroxime PO\", \"Mnemonic\": \"52a\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefuroxime 500mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"52b\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500mg po q6h\", \"Text\": \"Cephalexin PO\", \"Mnemonic\": \"54a\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 500mg po q6h Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"54b\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 400mg iv q12h (ALT)\", \"Text\": \"Ciprofloxacin IV\", \"Mnemonic\": \"56\"}, {\"Row\": 64, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg po bid (Var)\", \"Text\": \"Ciprofloxacin PO\", \"Mnemonic\": \"58a\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500mg po bid (Var) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"58b\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500mg po bid (Var)\", \"Text\": \"Clarithromycin PO\", \"Mnemonic\": \"60a\"}, {\"Row\": 68, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500mg po bid (Var) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"60b\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 600mg iv q8h (ALT)\", \"Text\": \"Clindamycin IV\", \"Mnemonic\": \"62\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid\", \"Text\": \"Clindamycin PO\", \"Mnemonic\": \"64a\"}, {\"Row\": 73, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"64b\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin vaginal 1 applicatorful qhs for 30 days\", \"Text\": \"Clindamycin Vaginal\", \"Mnemonic\": \"66a\"}, {\"Row\": 76, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin vaginal 1 applicatorful qhs for 30 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"66b\"}, {\"Row\": 78, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical to affected area qid\", \"Text\": \"Clotrimazole Topical\", \"Mnemonic\": \"68a\"}, {\"Row\": 79, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical to affected area qid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"68b\"}, {\"Row\": 81, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream vaginal 1 applicatorful qhs for 30 days\", \"Text\": \"Clotrimazole Vaginal\", \"Mnemonic\": \"70a\"}, {\"Row\": 82, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream vaginal 1 applicatorful qhs for 30 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"70b\"}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg iv q12h (ALT)\", \"Text\": \"Doxycycline IV\", \"Mnemonic\": \"74\"}, {\"Row\": 87, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid\", \"Text\": \"Doxycycline PO\", \"Mnemonic\": \"76a\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"76b\"}, {\"Row\": 90, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ertapenem 1gm iv q24h (ALT)\", \"Text\": \"Ertapenem IV\", \"Mnemonic\": \"78\"}, {\"Row\": 92, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500mg iv q6h (ALT)\", \"Text\": \"Erythromycin IV\", \"Mnemonic\": \"80\"}, {\"Row\": 94, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 0.5% oint oph to affected eye qid\", \"Text\": \"Erythromycin OPTH\", \"Mnemonic\": \"82a\"}, {\"Row\": 95, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 0.5% oint oph to affected eye qid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"82b\"}, {\"Row\": 97, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500mg po fqid\", \"Text\": \"Erythromycin PO\", \"Mnemonic\": \"84a\"}, {\"Row\": 98, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Erythromycin 500mg po fqid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"84b\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"ALTERNATIVE ANTIMICROBIALS\", \"Header\": 1}, {\"Row\": 4, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg iv q24h (ALT)\", \"Text\": \"Fluconazole IV\", \"Mnemonic\": \"130\"}, {\"Row\": 6, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po qday (Var)\", \"Text\": \"Fluconazole PO\", \"Mnemonic\": \"132a\"}, {\"Row\": 7, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Fluconazole 400mg po qday (Var) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"132b\"}, {\"Row\": 9, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Ganciclovir 500mg iv q12h\", \"Text\": \"Gancicilovir IV\", \"Mnemonic\": \"134\"}, {\"Row\": 11, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Gentamicin 5 mg/kg iv q24h\", \"Text\": \"Gentamicin IV\", \"Mnemonic\": \"136\"}, {\"Row\": 13, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po qday\", \"Text\": \"Itraconazole PO\", \"Mnemonic\": \"138a\"}, {\"Row\": 14, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po qday Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"138b\"}, {\"Row\": 16, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Levofloxacin IV\", \"Text\": \"Levofloxacin IV\", \"Mnemonic\": \"140\"}, {\"Row\": 18, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Levofloxacin PO\", \"Text\": \"Levofloxacin PO\", \"Mnemonic\": \"142a\"}, {\"Row\": 19, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Levofloxacin PO Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"142b\"}, {\"Row\": 24, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Meropenem 1 gm IV q8h ($$) [R,O]\", \"Text\": \"Meropenem IV\", \"Mnemonic\": \"144\"}, {\"Row\": 26, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg iv q6h (ALT)\", \"Text\": \"Metronidazole IV\", \"Mnemonic\": \"146\"}, {\"Row\": 28, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po tid (alt 2)\", \"Text\": \"Metronidazole PO\", \"Mnemonic\": \"148a\"}, {\"Row\": 29, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po tid (alt 2) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"148b\"}, {\"Row\": 31, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% gel vaginal 1 applicatorful qhs\", \"Text\": \"Metronidazole Vaginal\", \"Mnemonic\": \"150a\"}, {\"Row\": 32, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Metronidazole 0.75% gel vaginal 1 applicatorful qhs Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"150b\"}, {\"Row\": 34, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid\", \"Text\": \"Minocycline PO\", \"Mnemonic\": \"152a\"}, {\"Row\": 35, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"152b\"}, {\"Row\": 37, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Moxifloxacin soln oph 1 drop tid for 7 days\", \"Text\": \"Moxifloxacin OPTH\", \"Mnemonic\": \"154a\"}, {\"Row\": 38, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Moxifloxacin soln oph 1 drop tid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"154b\"}, {\"Row\": 40, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Nafcillin 2gm iv q4h\", \"Text\": \"Nafcillin IV\", \"Mnemonic\": \"156\"}, {\"Row\": 42, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Neomycin 1000mg po tid\", \"Text\": \"Neomycin PO\", \"Mnemonic\": \"158a\"}, {\"Row\": 43, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Neomycin 1000mg po tid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"158b\"}, {\"Row\": 45, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Nitrofurantoin 100mg po bid\", \"Text\": \"Nitrofurantoin PO\", \"Mnemonic\": \"160a\"}, {\"Row\": 46, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Nitrofurantoin 100mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"160b\"}, {\"Row\": 50, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Penicillin 500mg po qid (Alt 2)\", \"Text\": \"Penicillin PO\", \"Mnemonic\": \"162a\"}, {\"Row\": 51, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Penicillin 500mg po qid (Alt 2) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"162b\"}, {\"Row\": 53, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Penicillin 4MU iv q4h\", \"Text\": \"Penicillin IV\", \"Mnemonic\": \"164\"}, {\"Row\": 55, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Piperacillin/tazobactam 3.375 GM IV Q6H (ALT)\", \"Text\": \"Piperacillin/tazobactam IV\", \"Mnemonic\": \"166\"}, {\"Row\": 57, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75mg po qday\", \"Text\": \"Pyrimethamine PO\", \"Mnemonic\": \"168a\"}, {\"Row\": 58, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Pyrimethamine 75mg po qday Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"168b\"}, {\"Row\": 60, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Rifampin 300mg iv q12h (ALT)\", \"Text\": \"Rifampin IV\", \"Mnemonic\": \"170\"}, {\"Row\": 62, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Rifampin 300mg po bid (Alt 2)\", \"Text\": \"Rifampin PO\", \"Mnemonic\": \"172a\"}, {\"Row\": 63, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Rifampin 300mg po bid (Alt 2) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"172b\"}, {\"Row\": 65, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Sulfacetamide 10% soln oph 1 drop qid for 7 days\", \"Text\": \"Sulfacetamide OPTH\", \"Mnemonic\": \"174a\"}, {\"Row\": 66, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Sulfacetamide 10% soln oph 1 drop qid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"174b\"}, {\"Row\": 68, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Sulfadiazine 1000mg po qid\", \"Text\": \"Sulfadiazine PO\", \"Mnemonic\": \"176a\"}, {\"Row\": 69, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Sulfadiazine 1000mg po qid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"176b\"}, {\"Row\": 71, \"Column\": 2, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Terbinabine PO\", \"Mnemonic\": \"178a\"}, {\"Row\": 72, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"178b\"}, {\"Row\": 74, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% cream vaginal 1 applicatorful qhs for 30 days\", \"Text\": \"Terconazole 0.4% Vaginal\", \"Mnemonic\": \"180a\"}, {\"Row\": 75, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Terconazole 0.4% cream vaginal 1 applicatorful qhs for 30 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"180b\"}, {\"Row\": 77, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Tobramycin 5 mg/kg iv q24h (ALT)\", \"Text\": \"Tobramycin IV\", \"Mnemonic\": \"184\"}, {\"Row\": 79, \"Column\": 2, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Trimethoprim PO\", \"Mnemonic\": \"186a\"}, {\"Row\": 80, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"186b\"}, {\"Row\": 82, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 5 mg/kg iv q12h\", \"Text\": \"Trimethoprim-sulfamethoxazole IV\", \"Mnemonic\": \"188\"}, {\"Row\": 84, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1ds tablet po bid\", \"Text\": \"Trimethoprim-sulfamethoxazole PO\", \"Mnemonic\": \"190a\"}, {\"Row\": 85, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1ds tablet po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"190b\"}, {\"Row\": 87, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po bid\", \"Text\": \"Valacyclovir PO\", \"Mnemonic\": \"192a\"}, {\"Row\": 88, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"192b\"}, {\"Row\": 90, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Vancomycin 1000mg iv q12h\", \"Text\": \"Vancomycin IV\", \"Mnemonic\": \"194\"}, {\"Row\": 48, \"Column\": 2, \"Text\": \"Oseltamivir PO (see Influenza Menu)\"}, {\"Row\": 21, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO bid for 5 days ($) [DI,O]\", \"Mnemonic\": \"143a\"}, {\"Row\": 22, \"Column\": 2, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO bid for 5 days ($) [DI,O]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"143b\"}, {\"Row\": 92, \"Column\": 2, \"Text\": \"Vancomycin PO (see C diff menu)\"}, {\"Row\": 2, \"Column\": 2, \"Text\": \"Fidaxomicin PO (see C diff menu)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 957,
    "fields": {
      "name": "ORZID3 GMENU PANCREATITIS",
      "term": null,
      "displaytext": "Pancreatitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PANCREATITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 958,
    "fields": {
      "name": "ORZID3 GMENU PARASITE BABESIA SPP.",
      "term": null,
      "displaytext": "Babesia spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 500 mg PO once ($) on day 1, then 250 mg PO QDay ($) [M] for 6\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"BABESIA SPECIES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treat for 7-10 days. If patient has persistent relapsing disease, treat for 6\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"weeks including 2 weeks after babesia are no longer detected in blood smear.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"days <AND> atovaquone 750 mg PO BID ($) [M] for 7 days\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"*Consult Infectious Diseases, requires NF consult for quinine.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Clindamycin 600 mg PO TID <AND> quinine 650mg PO TID\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Mandell chapter: Babesia Species\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Babesiosis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-Date article: Babesiosis: Treatment and prevention\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Vannier et al. N Engl J Med. 2012 (366)2397-407\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 959,
    "fields": {
      "name": "ORZID3 GMENU PARASITE TOXOPLASMA SPP.",
      "term": null,
      "displaytext": "Toxoplasma spp. (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 50 mg PO QDay ($$) [DI,O] <AND>\", \"Mnemonic\": \"4a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 75 mg PO QDay ($$) [DI,O] <AND>\", \"Mnemonic\": \"6a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIMETH 200 THEN 50 CLINDA 300 LEUCOV 10MG\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 50 mg PO QDay ($$) [DI,O] <AND>\", \"Mnemonic\": \"8a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIMETH 200 THEN 50 CLINDA 300 LEUCOV 10MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG\", \"Text\": \"Pyrimethamine 200 mg PO once ($$$), then 75 mg PO QDay ($$) [DI,O] <AND>\", \"Mnemonic\": \"10a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO bid\", \"Text\": \"Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO BID ($) [R,DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG\", \"Text\": \"Pyrimethamine 50 mg PO QDay ($$) [DI,O] <AND> sulfadiazine 0.5-1 gm PO QID\", \"Mnemonic\": \"14a\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 50MG CLINDA 600MG LEUCO 10MG\", \"Text\": \"Pyrimethamine 50 mg PO QDay ($$) [DI,O] <AND> clindamycin 600 mg PO TID ($)\", \"Mnemonic\": \"16a\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 50MG CLINDA 600MG LEUCO 10MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 66, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 25MG ATOVA 750MG LEUCO 10MG\", \"Text\": \"Pyrimethamine 25 mg PO QDay ($$) [DI,O] <AND> atovaquone 750-1500 mg PO\", \"Mnemonic\": \"18a\"}, {\"Row\": 68, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIM 25MG ATOVA 750MG LEUCO 10MG Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 70, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1DS tablet PO QDay ($) [R,DI]\", \"Text\": \"Trimethoprim sulfamethoxazole 1DS tablet PO QDay ($) [R,DI]\", \"Mnemonic\": \"20a\"}, {\"Row\": 71, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim sulfamethoxazole 1DS tablet PO QDay ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 73, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone susp 750mg po bid\", \"Text\": \"Atovaquone 750-1500 mg PO BID ($) [M]\", \"Mnemonic\": \"22a\"}, {\"Row\": 74, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone susp 750mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"22b\"}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY\", \"Text\": \"Pyrimethamine 50 mg BID for 2 days, then 50 mg PO QDay ($$) [DI,O] <AND>\", \"Mnemonic\": \"24a\"}, {\"Row\": 89, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"24b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TOXOPLASMA SPP.\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"If patient is immunocompetent and not pregnant, treatment is usually not needed\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"as disease is usually self-limited. Patients who are immunocompromised, pregnant\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"or have severe disease should be treated. Consult Infectious Diseases in all\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Non-pregnant patients\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat immunocompetent patients for 2-4 weeks. Treat immunocompromised patients\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"for 6 weeks or longer if radiologic disease is extensive or response is\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"incomplete at 6 weeks.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Patients weighing <60 kg\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"sulfadiazine 1 gm PO QID ($$) [DI,O] <AND> leucovorin 10-25 mg PO QDay($) [M]\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Patients weighing >60kg\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"sulfadiazine 1.5 gm PO QID ($$) [DI,O] <AND> leucovorin 10-25 mg PO QDay($) [M]\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Preferred alternative for sulfa allergy\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Patients weighing <60 kg\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"clindamycin 600 mg PO QID ($) [H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Patients weighing >60 kg\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"clindamycin 600 mg PO QID ($) [H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Secondary alternatives\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Chronic Maintenance therapy for immunocompromised patients\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Discontinue maintenance therapy if patient has remained asymptomatic and CD4 >\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"200 cells per microliter.\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Maintenance therapy\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"($$) <AND> leucovorin 10-25 mg PO QDay ($) [M]\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Preferred alternative for sulfa allergy\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"[H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Secondary alternatives\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"BID ($) [M] <AND> leucovorin 10-25 mg PO QDay ($) [M]\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Pregnant patients\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 80, \"Column\": 1, \"Text\": \"Patient diagnosed <16-18 weeks of gestation\", \"Header\": 1}, {\"Row\": 81, \"Column\": 1, \"Text\": \"*Contact Infectious Diseases, non-formulary consult is required for spiramycin\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"Spiramycin 1 gm po TID until week 18 of gestation\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Patient diagnosed >16-18 weeks of gestation\", \"Header\": 1}, {\"Row\": 86, \"Column\": 1, \"Text\": \"sulfadiazine 75mg/kg once, then 50mg/kg BID ($$) [DI,O] <AND> leucovorin 10-25\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"mg PO QDay ($) [M] for 4 weeks or duration of pregnancy if ultrasound evidence\"}, {\"Row\": 88, \"Column\": 1, \"Text\": \"of fetal distress\"}, {\"Row\": 91, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 94, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"Mandell chapter: Toxoplasma gondii\"}, {\"Row\": 96, \"Column\": 1, \"Text\": \"Sanford keyword: Toxoplasmosis\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Up-to-Date article: Toxoplasmosis in immunocompetent hosts\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 960,
    "fields": {
      "name": "ORZID3 GMENU PARASITES MAIN",
      "term": null,
      "displaytext": "Parasites (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 958, \"DisplayText\": \"Babesia spp. (Outpatient)\", \"Text\": \"Babesia spp.\", \"Mnemonic\": \"4\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 911, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis (Outpatient)\", \"Text\": \"Diarrhea, parasitic\", \"Mnemonic\": \"6\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 985, \"DisplayText\": \"Pneumocyctis Jirovecii Disease (Outpatient)\", \"Text\": \"Pneumocystis\", \"Mnemonic\": \"8\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 959, \"DisplayText\": \"Toxoplasma spp. (Outpatient)\", \"Text\": \"Toxoplasma\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ PARASITES ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Always consider disease or syndrome, site of infection, penetration of drug(s)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"into site, and whether organism is pathogen, colonizer, or contaminant. See\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"disease/syndrome section for more information.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Last reviewed 2/2018\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 961,
    "fields": {
      "name": "ORZID3 GMENU PARONYCHIA",
      "term": null,
      "displaytext": "Paronychia (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical qday for 14 days\", \"Text\": \"Clotrimazole 1% apply to affected area once daily ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical qday for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin Cream to affected area BID ($) [M]\", \"Text\": \"Nystatin Cream to affected area BID ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nystatin Cream to affected area BID ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($)for 10 days [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 901, \"DisplayText\": \"Herpes whitlow (Digit or Hand Cellulitis) - Outpatient\", \"Text\": \"Link to Herpes whitlow\", \"Mnemonic\": \"12\"}, {\"Row\": 42, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"14\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PARONYCHIA\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Cutaneous infection of the hand, cuticle or fingers usually occurring near\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"around the nail.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treatment depends on etiology.  Candida spp. are commonly involved when the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"patient has extensive exposure to water (e.g. dishwashers).  Staphylococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"aureus is more commonly after manicures or nail biting.  Herpes simplex\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"(whitlow) usually follows exposure to oral mucosa (e.g. wrestlers, dentists, or\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"anesthetists).\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment for paronychia associated with Candida\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treat for 14 days\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment for paronychia associated with Staphylococcus\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treat for 10 days.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Treatment for paronychia associated with Herpes whitlow\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Sanford keyword: paronychia\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 962,
    "fields": {
      "name": "ORZID3 GMENU PATH A. PHAGOCYTOPHILUM",
      "term": null,
      "displaytext": "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 10 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANAPLASMA PHAGOCYTOPHILUM (HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"MMWR RR. 2016, 65 (2) 1-44\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Sanford keyword: Ehrlichia sp., Anaplasma sp.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Up-to-Date article: Human ehrlichiosis and anaplasmosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 963,
    "fields": {
      "name": "ORZID3 GMENU PATH DISS M. AVIUM DISEASE",
      "term": null,
      "displaytext": "Disseminated Mycobacterium avium disease (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clarithromycin 500 mg PO BID ($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 250 mg PO QDay ($) [M] <AND> ethambutol 15 mg/kg PO QDay [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clarithromycin 500 mg PO BID($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay\", \"Mnemonic\": \"8a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 250 mg PO QDay ($) M <AND> ethambutol 15 mg/kg PO QDay [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DISSEMINATED MYCOBACTERIUM AVIUM DISEASE TREATMENT\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Many of these patients have HIV/AIDS. Management is complex. Consult\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Infectious Diseases.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Rifabutin is optional for disseminated disease. Rifabutin can improve cure\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"rates, but may decrease blood concentrations of many drugs. Consult Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases or Pharmacy for more information.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment is continued for 12 months and until CD4 count is >100 cells per\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"microliter for at least 6 months.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Two-drug treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"($$) [R]\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Three-drug treatment\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"($$) [R] <AND> rifabutin 300 mg PO QDay ($$) [R,DI]\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"<AND> rifabutin 300 mg QDay ($$) [R,DI]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Mycobacterium avium complex\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Mycobacterium avium-intracellulare\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 964,
    "fields": {
      "name": "ORZID3 GMENU PATH E. CHAFFEENSIS",
      "term": null,
      "displaytext": "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis) - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI] 5DS\", \"Text\": \"Doxycycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID ($) [DI] 5DS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"EHRLICHIA CHAFFEENSIS (HUMAN MONOCYTOTROPIC EHRLICHIOSIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Treat for at least 5 to 7 days, up to 10 days may be required for more severe or\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"complicated cases\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for IV options\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"MMWR RR. 2016, 65 (2) 1-44\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Ehrlichiosis: Human monocytic ehrlichiosis (HME)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Up-to-Date article: Human ehrlichiosis and anaplasmosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 965,
    "fields": {
      "name": "ORZID3 GMENU PATH M. AVIUM INTRACELL",
      "term": null,
      "displaytext": "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC) - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 966, \"DisplayText\": \"Mycobacterium avium pneumonia (Outpatient)\", \"Text\": \"Treatment for pneumonia\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 963, \"DisplayText\": \"Disseminated Mycobacterium avium disease (Outpatient)\", \"Text\": \"Treatment for disseminated disease\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 968, \"DisplayText\": \"Prophylaxis against Mycobacterium avium disease... (Outpatient)\", \"Text\": \"Prophylaxis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOBACTERIUM AVIUM INTRACELLULARE (MAI OR MAC)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"MAI colonization in patients with chronic lung disease is common. These\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients should not be treated with antimicrobials.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Occasionally, MAI causes pulmonary disease in patients who are not\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"immunosuppressed. Diagnosis and management are complex. Consult Infectious\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diseases and/or Pulmonary.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"MAI causes systemic disease commonly in patients with HIV/AIDS. Most of these\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"cases do not involve the lungs. After treatment, long-term prophylaxis is\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"usually given. Consult Infectious Diseases in all cases.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 966,
    "fields": {
      "name": "ORZID3 GMENU PATH M. AVIUM PNEUMONIA",
      "term": null,
      "displaytext": "Mycobacterium avium pneumonia (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clarithromycin 500 mg PO BID ($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Azithromycin 250 mg PO QDay ($) M <AND> ethambutol 15 mg/kg PO QDay [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOBACTERIUM AVIUM PNEUMONIA\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis and treatment are complex. Regimens containing 3 or 4 drugs are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually recommended, but two drug regimens may be sufficient in some cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Consult Infectious Diseases and/or Pulmonary in all cases.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Duration of antimicrobial therapy\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment is continued until sputum cultures are consecutively negative for 12\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"months.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Three-drug regimens\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Preferred treatment\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"($$) [R] <AND> rifabutin 300 mg PO QDay ($$) [R,DI]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"<AND> rifabutin 300 mg QDay ($$) [R,DI]\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Four-drug regimens may be recommended for advanced (severe) or previously\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"treated disease-Consult Infectious Diseases\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandell chapter: Mycobacterium avium Complex\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Mycobacterium avium-intracellulare\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment of Mycobacterium avium complex lung infection in\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 967,
    "fields": {
      "name": "ORZID3 GMENU PATH MYCOPLASMA PNEUMO",
      "term": null,
      "displaytext": "Mycoplasma pneumonia (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO BID for 7 to 14 days ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO x 1 ($) on day 1, then 250 mg PO QD ($) for 4 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO QD for 5 days ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg PO QDay for 5 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO QD for 5 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOPLASMA PNEUMONIAE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Optimal therapy depends on both the disease or syndrome and the pathogen. See\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"diagnosis/syndrome section for more information.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Preferred treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Intolerance to doxycycline and azithromycin\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell Chapter: Mycoplasma pneumoniae and Atypical Pneumonia\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Mycoplasma pneumoniae\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-to-Date article: Mycoplasma pneumoniae infection in adults\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 968,
    "fields": {
      "name": "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV",
      "term": null,
      "displaytext": "Prophylaxis against Mycobacterium avium disease... (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1200mg po q week\", \"Text\": \"Azithromycin 1200 mg PO q week ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1200mg po q week Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500mg po bid\", \"Text\": \"Clarithromycin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clarithromycin 500mg po bid Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROPHYLAXIS AGAINST MYCOBACTERIUM AVIUM DISEASE IN PERSONS WITH HIV/AIDS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Infectious Diseases should be involved in all cases. Patients with CD4 count <\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"50 cells per microliter, after ruling out disseminated MC disease, should\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"receive prophylaxis until CD4 count is >100 for at least 3 months in response to\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antiretroviral therapy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Preferred prophylaxis\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell chapter: Mycobacterium avium complex\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Sanford keyword: Mycobacterium avium-intracellulare\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 969,
    "fields": {
      "name": "ORZID3 GMENU PATHO M. TUBERCULOSIS",
      "term": null,
      "displaytext": "Mycobacterium tuberculosis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"MYCOBACTERIUM TUBERCULOSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Management of tuberculosis is complex. Contact Infectious Diseases and/or\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Pulmonary service for more information.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 970,
    "fields": {
      "name": "ORZID3 GMENU PBE DENTAL ORAL RESP PROC",
      "term": null,
      "displaytext": "Drugs for pt undergoing dental, oral, resp... (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 7, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 2gm po once\", \"Text\": \"Amoxicillin 2 gm PO 1 hour before procedure ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of beta-lactam reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500mg po once\", \"Text\": \"Azithromycin 500mg PO 1 hour before procedure ($) [M]\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ANTIMICROBIALS FOR PATIENTS UNDERGOING DENTAL OR ORAL MUCOSA TO PREVENT\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"BACTERIAL ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Preferred\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral prophylaxis\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Primary Alternative\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral prophylaxis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Secondary Alternative, after assessment of beta-lactam reaction above\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"endocarditis\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Wilson et al., Circulation, 2021, 143(20)e963-e978\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 2 gm PO 1 hour before procedure ($) [R]\", \"Mnemonic\": \"8\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 971,
    "fields": {
      "name": "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY AND SUPPLIES",
      "term": null,
      "displaytext": "Cefazolin PD 15 mg/kg once daily with supplies",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD CEFAZOLIN 1GM QDAY\", \"Text\": \"Cefazolin 1 gm PD once daily\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"OP PD CEFAZOLIN 2GM QDAY\", \"Text\": \"Cefazolin 2 gm PD once daily\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFAZOLIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Choose dose based on patient's actual body weight (ABW)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"ABW < 100 kg:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"ABW >/= 100  kg\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 972,
    "fields": {
      "name": "ORZID3 GMENU PD CEFAZOLIN 15MG/KG Q24H GENTAMICIN 0.6MG/KG Q24H",
      "term": null,
      "displaytext": "Cefazolin and gentamicin for PD associated peritonitis ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD CEFAZ 1GM QDAY GENT QDAY\", \"Text\": \"Cefazolin 1 gm PD once daily\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD CEFAZ 2GM QDAY GENT QDAY\", \"Text\": \"Cefazolin 2 gm PD once daily\", \"Mnemonic\": \"4\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"CEFAZOLIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Choose dose based on patient's actual body weight (ABW)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"ABW < 100 kg:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"ABW >/= 100  kg\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 973,
    "fields": {
      "name": "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY",
      "term": null,
      "displaytext": "Gentamicin 0.6 mg/kg once daily for outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 40mg daily\", \"Text\": \"Gentamicin 40 mg PD once daily\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 60mg PD daily\", \"Text\": \"Gentamicin 60 mg PD once daily\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Gentamicin 80 mg PD daily\", \"Text\": \"Gentamicin 80 mg PD once daily\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"GENTAMICIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Choose loading dose based on patient's adjusted body weight (AJBW)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(see below for AJBW calculation)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"AJBW < 80 kg:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"AJBW >/= 80  kg and <120 kg:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"AJBW >/= 120 kg:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Calculations:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"IBW:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 974,
    "fields": {
      "name": "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY WITH SUPPLIES",
      "term": null,
      "displaytext": "Gentamicin 0.6 mg/kg once daily with supplies ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD GENTAMICIN 40MG QDAY WITH SUPPLIES\", \"Text\": \"Gentamicin 40 mg PD once daily\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD GENTAMICIN 60MG QDAY WITH SUPPLIES\", \"Text\": \"Gentamicin 60 mg PD once daily\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD GENTAMICIN 80MG QDAY WITH SUPPLIES\", \"Text\": \"Gentamicin 80 mg PD once daily\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"GENTAMICIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Choose loading dose based on patient's adjusted body weight (AJBW)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(see below for AJBW calculation)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"AJBW < 80 kg:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"AJBW >/= 80  kg and <120 kg:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"AJBW >/= 120 kg:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Calculations:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"IBW:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 975,
    "fields": {
      "name": "ORZID3 GMENU PD VANCO 30MG/KG LD CEFEPIME 1GM Q24H",
      "term": null,
      "displaytext": "Vancomycin 30 mg/kg loading dose and cefepime 1 gm once daily",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"VANCO 1000MG LD REDOSE Q3-7D CEFEPIME QD\", \"Text\": \"Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCO 2000MG LD REDOSE Q3-7D CEFEPIME QD\", \"Text\": \"Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCO 3000MG LD REDOSE Q3-7D CEFEPIME QD\", \"Text\": \"Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"VANCOMYCIN\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Choose loading dose based on patient's adjusted body weight (AJBW)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(see below for AJBW calculation)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"AJBW < 50 kg:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"AJBW >/= 50  kg and <85 kg:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"AJBW >/= 85 kg:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Calculations:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"IBW:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 976,
    "fields": {
      "name": "ORZID3 GMENU PD VANCO 30MG/KG LD GENTAMICIN 0.6MG/KG Q24H",
      "term": null,
      "displaytext": "Vancomycin and gentamicin for PD associated peritonitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCO 1000MG LD REDOSE Q3-7D GENT QD\", \"Text\": \"Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCO 2000MG LD REDOSE Q3-7D GENT QD\", \"Text\": \"Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCO 3000MG LD REDOSE Q3-7D GENT QD\", \"Text\": \"Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"VANCOMYCIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Choose loading dose based on patient's adjusted body weight (AJBW)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(see below for AJBW calculation)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"AJBW < 50 kg:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"AJBW >/= 50  kg and <85 kg:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"AJBW >/= 85 kg:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Calculations:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"IBW:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 977,
    "fields": {
      "name": "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE AND SUPPLIES",
      "term": null,
      "displaytext": "Vancomycin 30 mg/kg loading dose with supplies",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCOMYCIN 1000MG LOADING DOSE REDOSE Q3-7D\", \"Text\": \"Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCOMYCIN 2000MG LOADING DOSE REDOSE Q3-7D\", \"Text\": \"Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PD VANCOMYCIN 3000MG LOADING DOSE REDOSE Q3-7D\", \"Text\": \"Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"VANCOMYCIN\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Choose loading dose based on patient's adjusted body weight (AJBW)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"(see below for AJBW calculation)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"AJBW < 50 kg:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"AJBW >/= 50  kg and <85 kg:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"AJBW >/= 85 kg:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pharmacy may be contacted at pager number 612-818-0841 for dosing information.\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Calculations:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"IBW:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 978,
    "fields": {
      "name": "ORZID3 GMENU PELVIC INFLAM DISEASE",
      "term": null,
      "displaytext": "Pelvic inflammatory disorder (PID) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > doxycycline 100 mg BID for 14\", \"Mnemonic\": \"4a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($)\", \"Text\": \"Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > doxycycline 100 mg PO BID for\", \"Mnemonic\": \"6a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500mg IM x 1 ($) <AND> doxycycline 100 mg PO BID ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500 mg IM x 1 dose ($) <AND> azithromycin 1 gm PO x 1 dose ($)\", \"Text\": \"Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > azithromycin 1 gm PO x 1 dose\", \"Mnemonic\": \"8a\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PELVIC INFLAMMATORY DISEASE (PID)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pelvic inflammatory disease (PID) refers to bacterial infection of the upper\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"female reproductive tract. Likely bacterial pathogens include Neisseria\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"gonorrhoeae, Chlamydia trachomatis, anaerobes, enteric Gram-negative rods, and\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Streptococcus agalactiae. PID should be considered in sexually active women\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"with pelvic tenderness and signs of lower genital tract inflammation. Signs and\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"symptoms may be mild or non-specific, and providers should have a low threshold\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"to initiate treatment. All women who are diagnosed with acute PID should be\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"tested for N. gonorrohoeae, C. trachomatis, and HIV. Male sex partners of\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"patients with PID should be examined and treated (see below) if they had sexual\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"contact within the 60 days before onset of the patient's symptoms.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Judge severity of infection based on clinical signs and symptoms, including\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"blood pressure, pulse, mental status, and degree of fever.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"days ($) [DI] < OPTIONAL > metronidazole 500 mg PO BID ($) [DI]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"For patients who cannot take ceftriaxone and doxycycline, call ID\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Treatment of sex partner who is a veteran\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Treat for both Chlamydia and Gonorrhea\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"7 days ($) [DI]\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"($) [M]\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Treatment for severe disease\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines: MMWR (2015) 64.3\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Neisseria gonorrheoeae (Gonorrhea)\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Sanford keyword: Pelvic inflammatory disease\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Up-To-Date article: Pelvic inflammatory disease: Treatment\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 1026, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 979,
    "fields": {
      "name": "ORZID3 GMENU PENTAMADINE MENU",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Prosthetic request for home nebulizer and clinic education visit\", \"Text\": \">>Click here to order this set\", \"Mnemonic\": \"4\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Pentamidine inhalation home orders (call 612-467-5193 for 3V LPN appt)\", \"Text\": \">>Click here to order this set\", \"Mnemonic\": \"6\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Pentamidine Home Administration\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pentamidine may be administered at home for patients who find it difficult\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"going to monthly clinic visits and are capable of performing home\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"administration. Patients who decide to take pentamidine at home require\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"a LPN clinic visit for education and a nebulizer with their first\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"prescription.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Initial Pentamidine Prescription orders (90 day supply)\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"3V LPN clinic visit\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Pentamidine Neb Air Compressor prosthetic consult\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \">>Equipment Requested: Pentamidine Neb Air Compressor\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Medical Condition: Pneumocystosis prevention\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Choose provisional diagnosis (e.g. lymphocytopenia)\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pentamidine 300mg Inhalation QMONTH (Cost $) [DI,O]\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Albuterol inhaler\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Syringes (10mL)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Needles (22 gauge, 1.5 inch)\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Sterile Water vials (10mL)\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Iso-Neb Filtered Nebulizer System\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Subsequent Pentamidine Prescription orders (90 day supply)\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Pentamidine 300mg Inhalation QMONTH (Cost $) [DI,O]\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Albuterol inhaler\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Syringes (10mL)\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Needles (22 gauge, 1.5 inch)\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sterile Water vials (10mL)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Iso-Neb Filtered Nebulizer System\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 980,
    "fields": {
      "name": "ORZID3 GMENU PERI ASSOC CAPD",
      "term": null,
      "displaytext": "Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis... ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200 mg PO every other day ($) [R,DI]\", \"Text\": \"Fluconazole 200 mg PO every other day ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 89, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 200 mg PO every other day ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 91, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 100 mg PO QDay ($) [R,DI]\", \"Text\": \"Fluconazole 100 mg PO QDay ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 92, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 100 mg PO QDay ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Heparin 1000 units PD qday\", \"Text\": \"Heparin 1000 units PD q24h\", \"Mnemonic\": \"8\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 1 gm PD Qday SNPW\", \"Text\": \"Cefepime 1 gm PD q24h ($$) [R]\", \"Mnemonic\": \"10\"}, {\"Row\": 51, \"Column\": 1, \"Item\": 972, \"DisplayText\": \"Cefazolin and gentamicin for PD associated peritonitis\", \"Text\": \"Cefazolin 15 mg/kg ($) [R] <AND> gentamicin 0.6 mg/kg ($) [R,O] PD q24h\", \"Mnemonic\": \"12\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin 15-30 mg/kg and cefepime 1 gm PD Qday SNPW\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>\", \"Mnemonic\": \"14\"}, {\"Row\": 58, \"Column\": 1, \"Item\": 976, \"DisplayText\": \"Vancomycin and gentamicin for PD associated peritonitis\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>\", \"Mnemonic\": \"16\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 971, \"DisplayText\": \"Cefazolin PD 15 mg/kg once daily with supplies\", \"Text\": \"Cefazolin 15 mg/kg PD q24h ($) [R]\", \"Mnemonic\": \"18\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 977, \"DisplayText\": \"Vancomycin 30 mg/kg loading dose with supplies\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]\", \"Mnemonic\": \"20\"}, {\"Row\": 67, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefepime 1 gm PD Qday SNPW\", \"Text\": \"Cefepime 1 gm PD q24h ($$) [R]\", \"Mnemonic\": \"22\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 974, \"DisplayText\": \"Gentamicin 0.6 mg/kg once daily with supplies\", \"Text\": \"Gentamicin 0.6 mg/kg PD q24h ($) [R,O]\", \"Mnemonic\": \"24\"}, {\"Row\": 73, \"Column\": 1, \"Item\": 971, \"DisplayText\": \"Cefazolin PD 15 mg/kg once daily with supplies\", \"Text\": \"Cefazolin 15 mg/kg PD q24h ($) [R]\", \"Mnemonic\": \"26\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftazidime 1 gm PD Qday SNPW\", \"Text\": \"Ceftazidime 1 gm PD q24h ($) [R]\", \"Mnemonic\": \"28\"}, {\"Row\": 77, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 gm PD Qday SNPW\", \"Text\": \"Ceftriaxone 1 gm PD q24h ($) [M]\", \"Mnemonic\": \"30\"}, {\"Row\": 79, \"Column\": 1, \"Item\": 974, \"DisplayText\": \"Gentamicin 0.6 mg/kg once daily with supplies\", \"Text\": \"Gentamicin 0.6 mg/kg PD q24h ($) [R,O]\", \"Mnemonic\": \"32\"}, {\"Row\": 81, \"Column\": 1, \"Item\": 977, \"DisplayText\": \"Vancomycin 30 mg/kg loading dose with supplies\", \"Text\": \"Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]\", \"Mnemonic\": \"34\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Peritonitis associated with peritoneal dialysis usually presents with abdominal\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pain, fever, nausea or vomiting, and cloudy effluent. The leukocyte\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"concentration is greater than 100 cells/microliter of dialysate, with more than\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"50% neutrophils.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Obtain Gram stain, culture, and cell count with differential of dialysate before\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials are given. Nephrology consultation is essential. If cultures\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"show Gram-negative or mixed bacterial infection, a gastrointestinal tract\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"infectious source is more likely. Gram-positive organisms like staphylococci\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"usually result from external contamination. Fungal peritonitis is rare and\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"requires immediate catheter removal.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"**Antimicrobial recommendations are for empirical therapy only. Regimens should\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"be tailored according to patient response and microbiology results in\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"consultation with Nephrology and/or Infectious Diseases for more information.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"To prevent catheter occlusion by turbid dialysate, add 1,000 units of heparin\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"per dialysis bag each day until one day after the dialysate is clear.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"If vancomycin is used, trough serum concentrations should be kept above 15\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"mcg/ml to ensure adequate intraperitoneal levels. Usually vancomycin must be\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"given every 3 to 7 days. Contact Nephrology and/or Pharmacy for more\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 85, \"Column\": 1, \"Text\": \"Antifungal prophylaxis may be used for the duration of antimicrobial therapy to\"}, {\"Row\": 86, \"Column\": 1, \"Text\": \"possibly reduce the risk of fungal peritonitis.\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"**Heparin add on therapy\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"If heparin PD therapy is needed in addition to antimicrobial therapy, click on\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"the heparin order below.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Antimicrobial therapy\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Duration of therapy depends on the pathogen identified. Treat staphylococcal and\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"streptococcal infections for 2 weeks and all other gram-positive infections for\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"3 weeks. In patients who have Staphylococcus isolated and had a previous\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"staphylococcal infection, treat for 3 weeks.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"All antimicrobials below are administered via peritoneal dialysate bag over 6\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"hours\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Empirical treatment while waiting for results of gram stain\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"MRSA risk factors\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"cefepime 1 gm PD q24h ($) [R]\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Alternative for severe penicillin or cephalosporin allergy\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"gentamicin 0.6 mg/kg PD q24h ($) [R,O]\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Gram positive organism\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Gram negative organism\", \"Header\": 1}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Alternative for severe penicillin allergy\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Alternative treatments for narrowing coverage based on isolate susceptibilities\", \"Header\": 1}, {\"Row\": 74, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 78, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 95, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"De Vin et al, Peritoneal Dialysis International, 2009, Vol. 39, pp. 5-15\"}, {\"Row\": 98, \"Column\": 1, \"Text\": \"Li et al, Peritoneal Dialysis International, 2016, Vol. 36, pp. 481-508\"}, {\"Row\": 99, \"Column\": 1, \"Text\": \"Mandell chapter: Peritonitis and Intraperitoneal Abscesses\"}, {\"Row\": 100, \"Column\": 1, \"Text\": \"Sanford keyword: Peritonitis, Dialysis (CAPD) Associated\"}, {\"Row\": 101, \"Column\": 1, \"Text\": \"Up-to-Date article: Microbiology and therapy of peritonitis in peritoneal\"}, {\"Row\": 102, \"Column\": 1, \"Text\": \"dialysis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Consult Nephrology in a all cases.\", \"Header\": 1}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Fungal prophylaxis:\", \"Header\": 1}, {\"Row\": 93, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 981,
    "fields": {
      "name": "ORZID3 GMENU PERIOCULAR INFECTIONS",
      "term": null,
      "displaytext": "Periocular Infections ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERIOCULAR INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Eyelid infections\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Patients with moderate or severe eyelid infections should be referred to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"ophthalmology.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Blepharitis\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Wash margins with baby shampoo daily and use warm compresses daily.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antimicrobials have no benefit.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Hordeolum (stye)\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For external disease (involving the gland of Zeis), daily hot pack massage\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"encourages drainage and relieves symptoms. For internal disease (involving\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Meibomian glands) ophthalmology consult is encouraged, as the infection seldom\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"drains without intervention.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Lacrimal infections\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Refer cases of lacrimal infection to ophthalmology, including infections of the\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"lacrimal gland (dacryoadenitis), lacrimal sac (dacrocystitis), or tear ducts\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(canaliculitis).\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Carlisle et al., American Family Physician. 2015, 92(2)106-112\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Mandell chapter: Periocular infections\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-To-Date article: Blepharitis\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-To-Date article: Eyelid lesions\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Blepharitis\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Sanford keyword: Hordeolum, Stye\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 982,
    "fields": {
      "name": "ORZID3 GMENU PERIODENTAL DISEASE",
      "term": null,
      "displaytext": "Periodental disease (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlorhexidine 0.12% PO rinse, swish for 30 seconds then spit, 15 ml BID for 7\", \"Text\": \"Chlorhexidine 0.12% oral rinse swish for 30 seconds, then spit 15 ml twice\", \"Mnemonic\": \"4a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlorhexidine 0.12% PO rinse, swish for 30 seconds then spit, 15 Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERIODONTAL DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Periodontal disease, including gingivitis and periodontitis, may progress into\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"more severe disease or cause hematogenous spreading of bacteria if left\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"untreated. All patients with periodontal disease should be referred to the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"dental service for assessment and direction of treatment. In the presence of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"gingivitis, the most commonly isolated subgingival flora includes Prevotella\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"intermedia, Capnocytophaga spp, Finegoldia magna and Peptostreptococcus. In the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"presence of periodontitis, flora increases in complexity to most commonly\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"include Porphyromonas gingivalis, P. intermedia, Aggregatibacter\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"actinomycetemcomitans, Tanneralla forsythensis and Treponema denticola.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Consult Dental Service\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Non-severe periodontitis or acute simple gingivitis treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"daily for 7 days ($) [M]\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Severe periodontitis or acute complicated gingivitis (ulceration, rapidly\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"advancing disease, severe pain, patients with immunocompromising conditions)\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"treatment\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Consult Dental Service\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Mandel Chapter: Infections of the Oral Cavity, Neck and Head\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-To-Date article: Complications, diagnosis, and treatment of odontogenic\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"infections\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-To-Date article: Overview of gingivitis and periodontitis in adults\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Vincent's Angina\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Slots et al., Periodontology. 2002, 28(1)106-176\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Tonetti et al., Journal of Periodontology, 2018, 89 S159-S172.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 983,
    "fields": {
      "name": "ORZID3 GMENU PERTUSSIS",
      "term": null,
      "displaytext": "Pertussis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 356, \"DisplayText\": \"Diagnosis of Pertussis\", \"Text\": \"Diagnosis of pertussis\", \"Mnemonic\": \"4\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 995, \"DisplayText\": \"Prevention of pertussis (Outpatient)\", \"Text\": \"Prevention of pertussis\", \"Mnemonic\": \"6\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500mg PO once on day one then 250mg PO QD for 4 days ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERTUSSIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Pertussis is associated with persistent cough in adolescents and adults.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Immunity conferred by pertussis vaccine wanes after about 10 years. The first 1\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"to 2 weeks of disease resembles viral upper respiratory infection. After this,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"the characteristic cough with whoop is present for 1 to 6 weeks, followed by a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"2 to 3 week period of gradual resolution.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative for macrolide intolerant or allergic patients\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Kline et al, Am Fam Physician (2013) 88.8, 507-514\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Langley et al, Pediatrics (2004), e96-e101\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Pertussis\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Bordetella pertussis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 984,
    "fields": {
      "name": "ORZID3 GMENU PHARYNGITIS",
      "term": null,
      "displaytext": "Pharyngitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 854, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Treatment of Gonorrheal Infections\", \"Mnemonic\": \"4\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 937, \"DisplayText\": \"More About Pharyngitis\", \"Text\": \"More About Pharyngitis/Tonsillitis and Modified Centor score\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Strep A PCR\", \"Text\": \"Rapid Strep A throat PCR testing lab order\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin V 500 mg PO BID ($) for 10 days [R]\", \"Text\": \"Penicillin V 500 mg PO BID for 10 days ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin V 500 mg PO BID ($) for 10 days [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine penicillin 1.2 million units IM once ($$$) [M]\", \"Text\": \"Benzathine penicillin 1.2 million units IM x 1 ($$$) [M]\", \"Mnemonic\": \"14a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Benzathine penicillin 1.2 million units IM once ($$$) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"[Click here] Assess Beta-lactam allergy prior to ordering alternative\", \"Mnemonic\": \"16\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($)\", \"Mnemonic\": \"20a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PHARYNGITIS AND TONSILLITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are viral, primarily due to adenovirus. Aside from streptococcal and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"pharyngitis, use link below for recommendations.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consider HIV screening for patients with pharyngitis\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Streptococcal Pharyngitis and Tonsillitis\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Diagnosis of group A streptococcal (GAS) infection is made through detection by\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"rapid PCR and should be reserved for patients who have a moderate to high risk\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"of GAS infection according to the Modified Centor Score. Use link below for\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Modified Centor score criteria and for more details.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Antimicrobials are not indicated\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"GAS Pharyngitis and Tonsillitis Treatment\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Preferred\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Primary alternative:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Secondary alternative, after assessment of beta-lactam reaction above:\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Choby, Am Fam Physician. 2009 79(5) 383-390\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Mandell chapter: Pharyngitis\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Sanford keyword: Streptococcal Pharyngitis\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"Stanford et al, Clinical Infectious Diseases. 2012, cis629\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Up-To-Date article:  Evaluation of acute pharyngitis in adults\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Up-To-Date article:  Treatment and prevention of streptococcal pharyngitis\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HIV AG/AB\", \"Text\": \"HIV AG/AB Lab\", \"Mnemonic\": \"6\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID x10days ($) [R]\", \"Mnemonic\": \"18a\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 985,
    "fields": {
      "name": "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE",
      "term": null,
      "displaytext": "Pneumocyctis Jirovecii Disease (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 986, \"DisplayText\": \"Pneumocystis Jirovecii Prophylaxis\", \"Text\": \"[CLICK HERE]\", \"Mnemonic\": \"4\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 2 ds tablets po q8h for 21 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 2 DS tablets PO TID for 21 days ($)[R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 2 ds tablets po q8h for 21 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Trimethoprim-sulfamethoxazole 5mg/kg PO TID ($)[R,DI] <AND> dapsone 100mg\", \"Mnemonic\": \"8a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"\", \"Text\": \"Clindamycin 450mg PO QID ($)[H,O] <AND> Primaquine 26.3 mg PO QDay ($)[DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone 750mg po bid for 21 days\", \"Text\": \"Atovaquone 750mg PO BID for 21 days ($)[M]\", \"Mnemonic\": \"12a\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone 750mg po bid for 21 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Prednisone 40mg bid 5days then 40mg qday 6days then 20mg qday 10days\", \"Text\": \"Prednisone 40mg PO twice daily for 5 days, then 40mg PO daily for 6 days,\", \"Mnemonic\": \"14a\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Prednisone 40mg bid 5days then 40mg qday 6days then 20mg qday 10 Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PNEUMOCYSTIS JIROVECII DISEASE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Diagnosis and treatment are complex, consult Infectious Diseases in all cases.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Pneumocystis jirovecii (formerly termed Pneumocystis carinii) in an ubiquitious\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"organism that causes disease in people with compromised cell-mediated immunity.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Disease is exceedingly rare in people with intact host defenses. Pneumonia is\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"the usual manifestation but P. jirovecii can infect extrapulmonary sites,\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"especially in patients who have been receiving prophylaxis with aerosolized\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"pentanmidine. P. jirovecii disease occurs most commonly in people with AIDS and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"fewer than 200 CD4 T lymphocytes/microliter.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"The abbreviation PCP is often used for Pneumocystis pneumonia. It was derived\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"from the old species name, Pneumocystis carinii.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Trimethoprim-sulfamethoxazole (TMP-SMZ) is the treatment of choice for P.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"jirovecii disease, including disease that occurs despite TMP-SMZ prophylaxis.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Corticosteriods should be prescribed for patients with AIDS and P. jirovecii\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"pneumonia and an arterial oxygen tension <70 torr or an alveolar-arterial oxygen\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"gradient of >35 torr.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Preferred treatment for mild to moderate disease or step-down treatment once\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"disease has stabilized\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"PO QDay ($)[DI] for 21 days\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"for 21 days\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Preferred treatment for severe disease\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Prednisone for patient WITH AIDS\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"then 20 mg daily for 10 days.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2015) 1-282\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Mandell chapter: Mandell Chapter Management of Opportunistic Infections\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Associated with Human Immunodeficiency Virus Infection\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Sanford keyword: pneumocystis pneumonia, Adult\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of Pneumocystis infection in HIV-\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"infected patients\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Prophylaxis for Pneumocystis jirovecii\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 986,
    "fields": {
      "name": "ORZID3 GMENU PNEUMOCYSTIS JIROVECII PROPHYLAXIS",
      "term": null,
      "displaytext": "Pneumocystis Jirovecii Prophylaxis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 ds tablet qday\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet q day ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 ds tablet qday Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 ss tablet qday\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 SS tablet q day ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 ss tablet qday Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dapsone 100mg po qday\", \"Text\": \"Dapsone 100mg PO q day ($) [O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Dapsone 100mg po qday Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ALBUTEROL AND PENTAMIDINE ORDERS\", \"Text\": \"Pentamidine 300mg Inhalation QMONTH ($) [DI,O] <AND> Albuterol 0.083%\", \"Mnemonic\": \"12\"}, {\"Row\": 54, \"Column\": 1, \"Item\": 979, \"DisplayText\": \"\", \"Text\": \"Pentamidine for home administration\", \"Mnemonic\": \"14\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PNEUMOCYSTIS JIROVECII PROPHYLAXIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Indications for primary prophylaxis of P. jirovecii include:\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"1) HIV/AIDS patients with CD4 count <200 cells/microliter\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"2) Hematopoietic or organ transplantation patients during immunosuppression\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"3) Patients receiving Alemtuzumab, temozolomide or fludarabine\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"4) Patients receiving >/= 20mg equivalent of prednisone per day for over 1 month\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"5) Patients with acute lymphocytic leukemia, rheumatologic disease receiving\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"immunosuppressive therapy and certain primary immunodeficiencies (e.g. severe\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-IgM syndrome)\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Dose and duration of prophylaxis varies with the indication. Please contact\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Infectious Diseases or Hematology/Oncology for more information.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Prophylaxis should be discontinued when host defenses are restored. In persons\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"with AIDS on highly active antiretroviral therapy, Prophylaxis should be\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"discontinued when the CD4 cell concentrations remain over 200 cells/microliter\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"for 3-6 months in patients, except that prophylaxis should be continued for\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"life in those who have had P. jirovecii disease.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative when trimethoprim/sulfa is poorly tolerated or contraindicated:\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"inhalation QMONTH ($) [M] clinic orders (call 612-467-5193 for 3V LPN\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"appointment)\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Sanford keyword: Pneumocystis pneumonia, Adult\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Up-to-Date article: Treatment and prevention of Pneumocystis pneumonia in HIV-\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Uninfected patients\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Recommended FIRST-LINE prophylaxis:\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"**Patient should be tested for glucose-6-phosphate dehydrogenase (G6-PD)\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"deficiency before starting dapsone. Individuals deficient in G6-PD\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"show about a 2-fold increase in sensitivity toward dapsone-induced hemolytic\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"anemia.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"G6-PD lab test are resulted the same day or next day. May be add on lab.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"G6-PD lab result should be \\\"normal\\\" to start dapsone therapy.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Alternative to the above regimens:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Due to efficacy and complicated logistics for administration, alternative\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"when above recommendations not appropriate for patient.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Alternative to the above preferred regimens:\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Atovaquone is alternative for patient for clinical reason:\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"(e.g. patients with SLE, hematologic concerns, G6PD deficiency)\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Maertens J, et al. J Antimicrob Chemother. 2016, 71(9): 2397-404\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Martin SI, et al. Am J Transplant. 2013, 13 Suppl 4:272-9\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Infected Adults and Adolescents. AIDSinfo (2018)\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone 1500mg qday for PCP prophylaxis ($$) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"G6-PD Screen\", \"Text\": \"[Click here] G6-PD Screen Lab Order\", \"Mnemonic\": \"7\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 987,
    "fields": {
      "name": "ORZID3 GMENU POSTSEPTAL CELLULITIS",
      "term": null,
      "displaytext": "Postseptal cellulitis (Orbital cellulitis) - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND >\", \"Mnemonic\": \"4a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa 2ds non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] < AND > trimethoprim-sulfamethoxazole 2 DS PO\", \"Mnemonic\": \"8a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS NON-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"POSTSEPTAL CELLULITIS (ORBITAL CELLULITIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Postseptal cellulitis (orbital cellulitis) is often preceded by sinusitis and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"requires immediate consultation with otolaryngology and ophthalmology. Urgent\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"surgical drainage may be necessary. The most common pathogenic organisms in\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"adults are streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"aureus.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Contact otolaryngology or ophthalmology immediately for urgent surgical\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"drainage. Broad-spectrum empirical antimicrobials should be used until a\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pathogen can be identified from the drainage fluid.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Duration of treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Orbital cellulitis should be treated until all signs of infection have resolved.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Uncomplicated orbital cellulitis should be treated for minimum of 2 weeks and\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"complicated orbital cellulitis (severe ethmoid sinusitis and bony destruction of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"sinus) should be treated for at least 4 weeks.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Empiric treatment\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Step-down treatment after initial intravenous therapy. Base selection on cultur\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"results.  Adjust duration based on criteria above.\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 7 days\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"q12h ($) [R,DI] for 7 days\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Carlisle et al., American Family Physician. 2015, 92(2)106-112\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Periocular infections\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-to-Date article: Orbital Cellulitis\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Sanford keyword: Orbital cellulitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 988,
    "fields": {
      "name": "ORZID3 GMENU PREGNANCY RISK INFO",
      "term": null,
      "displaytext": "List of Antimicrobials with Pregnancy Risk Category ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 13, \"Column\": 1, \"Item\": 3108, \"DisplayText\": \"Sanford Guide Pregnancy and Lactation Info Page\", \"Text\": \"Sanford Guide Pregnancy Risk & Lactation Safety Table\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RISK FACTORS FOR ANTIMICROBIALS DURING PREGNANCY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"The FDA amended its rules in 2015 concerning the Pregnancy, Labor and delivery,\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"and Nursing mothers subsections of the Use in Specific Populations section of\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"product labeling. Pregnancy categories A, B, C, D, and X have been removed.\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Drugs approved after June 30 will use the new format immediately, while drugs\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"approved after June 30, 2001 will be phased in gradually.\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"See Sanford Guide for comprehensive antimicrobial pregnancy risk and lactation\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"safety information\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Risk Factors (A,B,C,D,X) were assigned to all drugs, based on the\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"level of risk the drug poses to the fetus. Risk Factors were designed to\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"help the clinician quickly classify a drug for use during pregnancy. They\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"do not refer to breastfeeding risk. The definitions of the Risk Factors\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"are those used by the FDA.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Category Description\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"A Controlled studies show no risk\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Adequate, well-controlled studies in pregnant women\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"have failed to demonstrate risk to the fetus.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"B No evidence of risk in humans\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Either animal findings show risk (but human\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"findings do not) or, if no adequate human studies\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"have been done, animal findings are negative.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"C Risk cannot be ruled out\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Human studies are lacking and animal studies\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"are either positive for fetal risk or lacking\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"as well. However, potential benefits may\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"justify the potential risk.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"D Positive evidence of risk\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Investigational or postmarketing data show risk\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"to fetus. Nevertheless, potential benefits may\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"outweigh the risk.\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"X Contraindicated in pregnancy\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Studies in animals or humans, or investigational\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"or postmarketing reports have shown fetal risk\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"which clearly outweighs any possible benefit to\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"the patient.\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Up-to-Date website\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Sanford website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 989,
    "fields": {
      "name": "ORZID3 GMENU PREGNANCY VACCINE",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 3109, \"DisplayText\": \"Patient Specific Vaccine History and JLV Link\", \"Text\": \"Patient vaccine history\", \"Mnemonic\": \"4\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CDC Recommended Adult Immunization Schedule\", \"Text\": \"CDC Recommended Adult Immunization Schedule\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenza type b: indicated in asplenia, those undergoing\", \"Mnemonic\": \"8\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A: if at risk for infection or severe outcome from infection during\", \"Mnemonic\": \"10\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B: if at risk for infection or severe outcome from infection during\", \"Mnemonic\": \"12\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B: 3 dose series.\", \"Mnemonic\": \"14\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B high dose: 4 dose series, for those on hemodyalisis.\", \"Mnemonic\": \"16\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Zoster (shingles) Information Page\", \"Mnemonic\": \"18\"}, {\"Row\": 37, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza: one dose annually.\", \"Mnemonic\": \"20\"}, {\"Row\": 41, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency\", \"Mnemonic\": \"22\"}, {\"Row\": 46, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal B: Delay until after pregnancy unless at increased risk and\", \"Mnemonic\": \"24\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal: for those w/additional risk factor or another indication. Refer to\", \"Mnemonic\": \"26\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TD/Tdap vaccine 3 dose series\", \"Text\": \"Tetanus, diphtheria and pertussis: Tdap booster dose during each pregnancy.\", \"Mnemonic\": \"28\"}, {\"Row\": 60, \"Column\": 1, \"Item\": 662, \"DisplayText\": \"Haemophilus Influenza Type B Information Page\", \"Text\": \"Haemophilus influenzae type b (Hib)\", \"Mnemonic\": \"30\"}, {\"Row\": 61, \"Column\": 1, \"Item\": 654, \"DisplayText\": \"Hepatitis A Vaccine Information Page\", \"Text\": \"Hepatitis A (HepA)\", \"Mnemonic\": \"32\"}, {\"Row\": 62, \"Column\": 1, \"Item\": 659, \"DisplayText\": \"Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis B (HepB)\", \"Mnemonic\": \"34\"}, {\"Row\": 63, \"Column\": 1, \"Item\": 655, \"DisplayText\": \"Hepatitis A and Hepatitis B Vaccine Information Page\", \"Text\": \"Hepatitis A and Hepatitis B (HepA/B)\", \"Mnemonic\": \"36\"}, {\"Row\": 64, \"Column\": 1, \"Item\": 724, \"DisplayText\": \"Zoster (shingles) Information Page\", \"Text\": \"Herpes zoster (RZV)\", \"Mnemonic\": \"38\"}, {\"Row\": 65, \"Column\": 1, \"Item\": 664, \"DisplayText\": \"Human Papillomavirus Vaccine Information Page\", \"Text\": \"Human papillomavirus (HPV)\", \"Mnemonic\": \"40\"}, {\"Row\": 66, \"Column\": 1, \"Item\": 192, \"DisplayText\": \"INFLUENZA VACCINATION RECOMMENDATIONS\", \"Text\": \"Influenza\", \"Mnemonic\": \"42\"}, {\"Row\": 67, \"Column\": 1, \"Item\": 683, \"DisplayText\": \"Measles, Mumps, Rubella Vaccine Information Page\", \"Text\": \"Measles, mumps, and rubella vaccine (MMR)\", \"Mnemonic\": \"44\"}, {\"Row\": 68, \"Column\": 1, \"Item\": 681, \"DisplayText\": \"Meningococcal Conjugate Vaccine Information Page\", \"Text\": \"Meningococcal serogroups A, C, W and Y (MenACWY)\", \"Mnemonic\": \"46\"}, {\"Row\": 69, \"Column\": 1, \"Item\": 682, \"DisplayText\": \"Meningococcal Serogroup B Vaccine Information Page\", \"Text\": \"Meningococcal serogroup B (MenB)\", \"Mnemonic\": \"48\"}, {\"Row\": 70, \"Column\": 1, \"Item\": 700, \"DisplayText\": \"Pneumococcal Vaccine Information Page\", \"Text\": \"Pneumococcal 20-valent (PCV20)\", \"Mnemonic\": \"50\"}, {\"Row\": 71, \"Column\": 1, \"Item\": 720, \"DisplayText\": \"Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page\", \"Text\": \"Tetanus, diphtheria, pertussis (Td/Tdap)\", \"Mnemonic\": \"52\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 723, \"DisplayText\": \"Varicella Vaccine Information Page\", \"Text\": \"Varicella (VAR)\", \"Mnemonic\": \"54\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"IMMUNIZATION OF PREGNANT PATIENTS\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Pregnant women should receive the tetanus, diphtheria, and acellular pertussis\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"vaccine (Tdap) during pregnancy and the influenza vaccine during or before\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"pregnancy. Live vaccines are contraindicated (e.g. MMR and Varicella). See\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"immunization information pages located at the bottom of this page for other\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"indications, contraindications, and one-time dose orders to listed vaccines.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Specific vaccine orders for pregnant patients:\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"splenectomy and HSCT patients. Refer to specific immunization recommendations\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"for patients with these indications or refer to the Haemophilus influenza type b\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"vaccine information menu below.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"pregnancy.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"pregnancy.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Herpes zoster: delay until after pregnancy unless at increased risk and\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"information menu below.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Human papillomavirus: *CONTRAINDICATED*.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Measles, mumps, and rubella *CONTRAINDICATED*.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"or inhibitor use, travel to endemic countries, microbiologists, and college\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"students. Refer to specific immunization recommendations for asplenia and HIV or\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"refer to the Meningococcal A, C, W and Y vaccine information menu below.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"vaccination benefits outweigh potential risks. Refer to Meningococcal B vaccine\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"information menu below.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"specific immunization recommendations for patients with these indications or\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"refer to the Pneumococcal vaccine information menus below.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Varicella: *CONTRAINDICATED*.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Specific vaccine information pages:\", \"Header\": 1}, {\"Row\": 73, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 76, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Murthy et al. Annals internal medicine, 2022, 175(3)432-443\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 990,
    "fields": {
      "name": "ORZID3 GMENU PRESEPTAL CELLULITIS",
      "term": null,
      "displaytext": "Preseptal cellulitis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa 2DS\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND>\", \"Mnemonic\": \"4a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875mg po bid ($) [R] <AND> TMP/Sulfa 2 DS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"6\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] <AND> trimethoprim-sulfamethoxazole 1 DS PO\", \"Mnemonic\": \"8a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS NON-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PRESEPTAL CELLULITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Preseptal cellulitis involves soft tissues in front of the orbital septum and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"the eyelids and is often preceded by sinusitis. Infection does not involve the\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"orbital contents. The most common pathogenic organisms in adults are\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus aureus.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treat  under the guidance of ophthalmology and/or otolaryngology. Intravenous\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"antimicrobials are indicated initially for treatment of moderate to severe\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"disease. Switch to oral antimicrobials when the patient's symptoms improve and\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"the patient can tolerate oral medications.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment of mild to moderate disease\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS PO BID ($) [R,DI] for 5 days\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"BID ($) [R,DI] for 5 days\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment of severe disease\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Carlisle et al., American Family Physician. 2015, 92(2)106-112\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Periocular infections\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Johns Hopkins website\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Up-to-date article: Preseptal cellulitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 991,
    "fields": {
      "name": "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL",
      "term": null,
      "displaytext": "Prevention of infection in a patient with malignancy (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI]\", \"Text\": \"Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodofor ime 100 mg PO BID x7days ($$) [R]\", \"Text\": \"Cefpodofor ime 100 mg PO BID x7days ($$) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefpodofor ime 100 mg PO BID x7days ($$) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF BACTERIAL INFECTIONS IN A PATIENT WITH MALIGNANCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antimicrobial prophylaxis is often given to patients likely to have profound,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"prolonged neutropenia.  Profound neutropenia is less than 100 neutrophils and\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"bands per microliter, and such neutropenia is considered prolonged when it is\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"expected to last more than 7 days.  Most patients who should receive prophylaxis\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"have received stem cell transplants or are undergoing induction chemotherapy for\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"acute leukemia.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"If antibacterial prophylaxis is indicated\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of therapy: During period of expected neutropenia\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Taplitz RA Journal of Clinical Oncology, 2018, 36:3043\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Mandell chapter:  Prophylaxis and Empirical Therapy for Infection in Cancer-\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Patients\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Related Infections. Version 1.2019. nccn.org\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 992,
    "fields": {
      "name": "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL",
      "term": null,
      "displaytext": "Prevention of fungal infection in a patient with malignancy  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg po qday for 10 days ($) [R,DI]\", \"Text\": \"Fluconazole 400 mg po qday for 10 days ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 400 mg po qday for 10 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF FUNGAL INFECTIONS IN A PATIENT WITH MALIGNANCY\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Antifungal chemoprophylaxis is often given to patients undergoing induction\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"chemotherapy for acute leukemia expected to have profound neutropenia (less than\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"100 neutrophils and bands per milliliter) for more than 10 days and for patients\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"receiving allogeneic stem cell transplantation.  For most other patients the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"expected benefits do not outweigh the risks of adverse effects and selection of\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"resistant fungi.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Antifungal is usually given until the absolute neutrophil concentration\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"increases to more than 500 cells/microliter in patients undergoing induction\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"chemotherapy for leukemia.  Duration is 100 days for patients undergoing stem\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"cell transplantation.  Some physicians continue prevention after 100 days if\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"corticosteroids are part of the immunosuppressive regimen.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Recommend posaconazole prophylaxis for patients with Acute Myeloid Leukemia.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Contact Hematology Oncology or Infectious Disease for more information.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Patients who have had invasive fungal infection in the recent past and who are\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"about to become neutropenic may require chemoprophylaxis.  Contact Hematology-\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Oncology or Infectious Diseases for more information.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"If antifungal prophylaxis is indicated\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Duration of therapy: during period of expected neutropenia\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"For patients being treated for AML:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Requires Infectious Disease approval:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Posaconazole 300mg Tablets twice daily on day 1, then 300mg once daily on\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"day 2 and thereafter. Continue for 7 days after the neutrophil count\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"rises above 500/mm3. ($$$$) [DI]\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Taplitz RA Journal of Clinical Oncology, 2018, 36:3043\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Related Infections. Version 1.2019. nccn.org\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Mandell chapter: Prophylaxis and empirical therapy for infection in cancer\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 993,
    "fields": {
      "name": "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT",
      "term": null,
      "displaytext": "Prevention of bacterial endocarditis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 3110, \"DisplayText\": \"DENTAL ABX PPX SOP\", \"Text\": \"SOP for dental surgery antimicrobial prophylaxis\", \"Mnemonic\": \"4\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 970, \"DisplayText\": \"Drugs for pt undergoing dental, oral, resp... (Outpatient)\", \"Text\": \"Patients undergoing dental or oral mucosa procedures\", \"Mnemonic\": \"6\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 592, \"DisplayText\": \"Head and neck surgery\", \"Text\": \"Patients undergoing procedures on the respiratory tract that involve incision or\", \"Mnemonic\": \"8\"}, {\"Row\": 50, \"Column\": 1, \"Item\": 702, \"DisplayText\": \"\", \"Text\": \"Patients undergoing procedures for infected skin, skin structures, or infected\", \"Mnemonic\": \"10\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF BACTERIAL ENDOCARDITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Bacteremia occurs several times a day during daily activities like eating and\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"brushing teeth and rarely results in endocarditis, even in people with abnormal\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"valves.  While bacteremia might occur following dental or other procedures, most\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cases of endocarditis are from the millions more episodes of transient\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"bacteremia a person experiences per year from ordinary daily activities.  There\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"is no evidence that antimicrobial prophylaxis prevents endocarditis after\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"procedures.  The best available evidence suggests that prophylactic\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antimicrobials confer more risks than benefits in most situations.  A decision\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"about whether to administer antimicrobial prophylaxis should be based on both\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"the risk of endocarditis conferred by the patient's cardiac defect and the risk\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"of bacteremia from a planned dental or surgical procedure.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Minneapolis VAHCS SOP antimicrobial prophylaxis for dental surgery:\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Determine the need for prophylaxis through the 2-step process outlined\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"below.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Step 1.  Assess the risk of endocarditis for your patient\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Prophylaxis is recommended if a patient has any of the following conditions:\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"o  Prosthetic cardiac valve or material including: Presence of cardiac\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"prosthetic valve, transcatheter implantation of prosthetic valves (e.g. TAVR\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"cardiac valve repair with devices (e.g. annuloplasty, rings, or clips), left\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"ventricular assist devices or implantable heart\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"o  A history of infective endocarditis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"o  Certain specific congenital heart conditions - refer to the full SOP\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"(link above) or consult Cardiology for more detailed recommendations\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"o  Cardiac transplant that develops a problem in the heart valve\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Step 2.  Assess the risk of bacteremia from the planned procedure\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Prophylaxis is indicated for these procedures:\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"o  All dental procedures that involve manipulation of gingival tissue or the\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"periapical region of teeth or perforation of the oral mucosa.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"o  Procedures on the respiratory tract that involve incision or biopsy of the\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"respiratory mucosa, such as tonsillectomy and adenoidectomy. Prophylaxis is\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"recommended for bronchoscopy when it involves incision of the respiratory\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"tract mucosa.\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"o  Procedures that involve incision through infected skin, skin structures, or\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"musculoskeletal tissue.\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"o  Dermatologic procedures that breach the oral mucosa.\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Prophylactic Antimicrobials select below:\", \"Header\": 1}, {\"Row\": 49, \"Column\": 1, \"Text\": \"biopsy of the respiratory mucosa\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"musculoskeletal tissues\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"endocarditis\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Wilson et al., Circulation, 2021, 143(20)e963-e978\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 994,
    "fields": {
      "name": "ORZID3 GMENU PREVENTION OF INFECT",
      "term": null,
      "displaytext": "Prevention of Infection - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 993, \"DisplayText\": \"Prevention of bacterial endocarditis (Outpatient)\", \"Text\": \"Prevention of bacterial endocarditis\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 533, \"DisplayText\": \"Prevention of prosthetic joint infection before dental procedures\", \"Text\": \"Before dental procedures\", \"Mnemonic\": \"6\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 991, \"DisplayText\": \"Prevention of infection in a patient with malignancy (Outpatient)\", \"Text\": \"Antibacterial prophylaxis\", \"Mnemonic\": \"10\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 992, \"DisplayText\": \"Prevention of fungal infection in a patient with malignancy\", \"Text\": \"Antifungal prophylaxis\", \"Mnemonic\": \"12\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 732, \"DisplayText\": \"\", \"Text\": \"Antiviral prophylaxis\", \"Mnemonic\": \"14\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 729, \"DisplayText\": \"Spontaneous Bacterial Peritonitis (Outpatient)\", \"Text\": \"Spontaneous bacterial peritonitis\", \"Mnemonic\": \"16\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 986, \"DisplayText\": \"Pneumocystis Jirovecii Prophylaxis\", \"Text\": \"Pneumocystis jirovecii prophylaxis\", \"Mnemonic\": \"18\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 716, \"DisplayText\": \"\", \"Text\": \"Click Here\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  PREVENTION OF INFECTION - OUTPATIENT  ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Prevention of bacterial endocarditis\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Prevention of prosthetic joint infection\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Prevention of infection in patient with malignancy\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Prevention of infection in patients with liver disease\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Prevention of Pneumocystis infection\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Prevention of recurrent Staphylococcus aureus skin infection\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": 650, \"DisplayText\": \"ORAL MUCOSA OR INFECTED SKIN SURGICAL SITE ANTIBIOTIC PROPHYLAXIS\", \"Text\": \"Before procedures that involve infected skin, skin structures or musculoskeletal\", \"Mnemonic\": \"8\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"tissue\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 995,
    "fields": {
      "name": "ORZID3 GMENU PREVENTION PERTUSSIS",
      "term": null,
      "displaytext": "Prevention of pertussis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500mg PO once on day one then 250mg PO QD for 4 days ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PREVENTION OF PERTUSSIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Immunization\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Give a single dose of tetanus-diphtheria acellular pertussis vaccine (Tdap) in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"adults regardless of interval between most recent Td vaccine. One dose of Tdap\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"vaccine is given to pregnant women during each pregnancy.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Postexposure prophylaxis in adults\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Household contacts with symptomatic coughing should be treated as if they have\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"pertussis. Consult Infectious Diseases (outpatient) for all suspected cases of\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"pertussis and exposure to pertussis.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"CDC recommends postexposure prophylaxis in household contacts within 21 days\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"after exposure to pertussis regardless of immunization history. Non-household\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"contacts who are at high risk of severe illness or who have close contact with\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"high risk individuals should receive post exposure prophylaxis within 21 days of\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"exposure. Those at high risk of severe illness are infants less than one year of\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"age, women in third trimester of pregnancy and those with preexisting health\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"conditions that may be exacerbated by pertussis (e.g. immunosuppressed and\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"asthmatic individuals). A single dose of Tdap should be administered in those\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"who are not up to date.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Prophylaxis:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Alternative for macrolide intolerant or allergic patients\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"CDC:https://www.cdc.gov/pertussis/outbreaks/pep.html (Accessed 3-17-17)\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Kim et al, Annals of internal medicine (2016) 184-194\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Pertussis\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Bordetella species\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 996,
    "fields": {
      "name": "ORZID3 GMENU PRIM INFECT CHICKENPOX",
      "term": null,
      "displaytext": "Primary infection (Chickenpox) - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po 5x/d for 5 days\", \"Text\": \"Acyclovir 800 mg PO 5x/day for 5-7 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po 5x/d for 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po tid for 5 days\", \"Text\": \"Valacyclovir 1 gm PO TID for 5 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po tid for 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 mg PO 5x/day for 7 days ($) [R]\", \"Text\": \"Acyclovir 800 mg PO 5x/day for 7 days ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800 mg PO 5x/day for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po tid for 7 days\", \"Text\": \"Valacyclovir 1000 mg PO TID for 7 days ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po tid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PRIMARY INFECTION (CHICKENPOX)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Vaccinate all adults without evidence of immunity except for pregnant women.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Test antibody first in adults who have uncertain history of chickenpox or\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"vaccination.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Give Varicella vaccine x 2, 2nd dose 4-8 weeks after 1st dose\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Therapy must be started within 24 hrs onset of rash.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Therapy must be started within 24 hrs onset of rash.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Immunocompromised patients without prior immunity to varicella who are at risk\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"for disease include: patients with malignancy, current immunosuppressive\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"therapy, or HIV infection. Vaccination is not recommended while patients are\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"immunocompromised.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Contact Infectious Diseases for more information.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Treatment for severe disease, or if mild to moderate disease doesn't improve on\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"above therapy\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Kim et al. Annals Intern Med. 2018, 168(3):210-220\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Sanford keyword: Varicella-Zoster Virus\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 997,
    "fields": {
      "name": "ORZID3 GMENU PROPHYLAXIS OPTH SURG",
      "term": null,
      "displaytext": "Prophylaxis for Ophthalmic Surgery",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PROPHYLAXIS FOR OPHTHALMIC SURGERY\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"When indicated, ophthalmology will order antimicrobial prophylaxis before\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"procedures.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 998,
    "fields": {
      "name": "ORZID3 GMENU PROPHYLAXIS PROSTATE BIOPSY",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin Cefuroxime po MAIL\", \"Text\": \"Ciprofloxacin 500 mg po once ($) [R,DI] < AND >\", \"Mnemonic\": \"4\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin Cefuroxime po WINDOW\", \"Text\": \"Ciprofloxacin 500 mg po once ($) [R,DI] < AND >\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Antibiotic Prophylaxis Transrectal Ultrasound Prostate Biopsy Procedures (TRUSP)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"The recommendations for prophylaxis for TRUSP procedures have been updated based\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Outpatient Prescriptions for Mailing:\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Cefuroxime 1000 mg po once ($) [M], BOTH 2 to 3 hours before\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"scheduled prostate biopsy.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Outpatient Prescriptions for Window Pick-up:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Cefuroxime 1000 mg po once ($) [M], BOTH 2 to 3 hours before\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"scheduled prostate biopsy.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative for patients with anaphylactic or other serious beta-lactam allergy\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Administer in clinic on the day of procedure.\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Becopoulos T et al  J Chemother 1990 2:244-246\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Charalabopoolos et al Chemotherapy 2003 49:269-279\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Nam R et al J Urol 2010 183:963-969\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"based on emergence of resistant E-coli bacteria strains.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Alternative for patients who have not taken the oral medications:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 500 mg IM and Ciprofloxacin 500 mg po x1\", \"Text\": \"Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Ceftriaxone 500 mg\", \"Mnemonic\": \"8\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Administer in clinic on the day of procedure.\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Intramuscularly once ($) [M] BOTH given 1 hour before the procedure.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_________________________________________________________________\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Aztreonam 1 gm mg IM and Ciprofloxacin 500 mg po once\", \"Text\": \"Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Aztreonam 1 gm intramuscularly\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"once ($$$$) [R] BOTH given 1 hour before the procedure.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Patients weighing less than 300lbs:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Patients weighing 300lbs or greater:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 1 gram IM and Ciprofloxacin 500 mg po x1\", \"Text\": \"Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Ceftriaxone 1 gram\", \"Mnemonic\": \"10\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Intramuscularly once ($) [M] BOTH given 1 hour before the procedure.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 999,
    "fields": {
      "name": "ORZID3 GMENU PROS B/J ENTEROCOCCI",
      "term": null,
      "displaytext": "Enterococci infections in bone or joint prostheses (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Text\": \"Minocycline 100mg PO BID ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Text\": \"Linezolid 600 mg PO BID ($) [DI,O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO BID ($) [DI,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"ENTEROCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"followed by oral antibiotics. For severe infections, add an aminoglycoside for\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"synergy during the first weeks of therapy. Mild infections can be treated with\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"oral antibiotics only.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of Treatement\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"may follow treatment based on individual patient circumstances.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, Continuation of Therapy and Chronic\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Suppression\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Allergy to penicillin\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"For resistant isolates only\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1000,
    "fields": {
      "name": "ORZID3 GMENU PROS B/J GNB",
      "term": null,
      "displaytext": "Gram neg bacilli (other than pseudomonas) infections in bone or joint prostheses  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875-125 mg PO BID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS) INFECTIONS IN BONE OR JOINT\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"PROSTHESES\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"followed by oral antibiotics. Mild infections can be treated with oral\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"antibiotics only.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Duration of Treatment\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"may follow treatment based on individual patient circumstances.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, Continuation of Therapy and Chronic\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Suppression\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Alternative Oral Treatment for Intolerance to Above Oral Antibiotics\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"For treatment of mild infections and continuation of therapy\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"For Chronic Suppression\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1001,
    "fields": {
      "name": "ORZID3 GMENU PROS B/J P. AERUGINOSA",
      "term": null,
      "displaytext": "Pseudomonas aeringunosa infections in bone or joint prostheses (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PSEUDOMONAS AERUGINOSA INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"followed by oral antibiotics. Mild infections can be treated with oral\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antibiotics only.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Duration of Treatment\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"may follow treatment based on individual patient circumstances.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, For Continuation of Therapy\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Oral Treatment for Chronic Suppression\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1002,
    "fields": {
      "name": "ORZID3 GMENU PROS B/J S. AUREUS",
      "term": null,
      "displaytext": "Staphylococcus aureus infections in bone or joint prostheses (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 47, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Text\": \"Minocycline 100mg PO BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100 mg PO BID ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RIFAMPIN 600MG PO QDAY\", \"Text\": \"Rifampin 600 mg PO QDay ($) [DI,O]\", \"Mnemonic\": \"14a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rifampin 600mg po qday Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STAPHYLOCOCCUS AUREUS INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment Following Debridement and Retention of Prosthesis\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 to 6 months of\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"an oral antibiotic combined with rifampin (3 months in total hip, elbow,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"shoulder and ankle arthroplasty and 6 months in total knee arthroplasty).\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment Following 2-stage Exchange or Resection Arthroplasty Without Planned\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Staged Reimplantation of Prosthesis\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat with intravenous antibiotic for 6 weeks for all joint types.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment Following 1-Stage Exchange of Prosthesis\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 months of an\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"oral antibiotic combined with rifampin for all joint types.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Rifampin Synergy\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Rifampin is recommended for treatment with debridement and retention or one\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"stage exchange. When rifampin is combined with a beta-lactam or vancomycin in\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"vitro, bacterial killing is enhanced. Do not use rifampin alone, as bacterial\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"resistance develops rapidly. If patient does not tolerate rifampin it may be\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"omitted from treatment regimen. Contact Infectious Diseases for more\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"information.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Chronic Suppression\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Chronic suppression with oral antimicrobials may follow treatment based on\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"individual patient circumstances.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Oral Treatment for Continuation of Therapy or Chronic Suppression\", \"Header\": 1}, {\"Row\": 43, \"Column\": 1, \"Text\": \"MRSA or allergy to penicillin or cephalosporin\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Rifampin Synergy for Debridement and Retention or One Stage Exchange (Not For\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Chronic Suppression)\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"In addition to PO treatment above < ADD >\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1003,
    "fields": {
      "name": "ORZID3 GMENU PROS B/J STREPTOCOCCI",
      "term": null,
      "displaytext": "Streptococci infections in bone or joint prostheses (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Text\": \"Penicillin VK 500 mg PO QID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Penicillin VK 500 mg PO QID ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID ($) [H,O]\", \"Text\": \"Clindamycin 300 mg PO QID ($) [H,O]\", \"Mnemonic\": \"8a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300 mg PO QID ($) [H,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STREPTOCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"For acute, moderate or severe infections, treat with intravenous antibiotics\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"followed by oral antibiotics. Mild infections can be treated with oral\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antibiotics only.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for specific management advice.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Consult Infectious Diseases in all cases for specific management advice.\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Duration of Treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat for a total duration of 4-6 weeks. Chronic suppression with oral\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"antimicrobials may follow treatment based on individual patient circumstances.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Intravenous Treatment\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Oral Treatment For Mild Infections, Continuation of Therapy or Chronic\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Suppression\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Allergy to penicillin or cephalosporin\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1004,
    "fields": {
      "name": "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT",
      "term": null,
      "displaytext": "Infections in bone or joint prostheses (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 1002, \"DisplayText\": \"Staphylococcus aureus infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Staphylococcus aureus infections\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 1003, \"DisplayText\": \"Streptococci infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Streptococci infections\", \"Mnemonic\": \"6\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 999, \"DisplayText\": \"Enterococci infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Enterococci infections\", \"Mnemonic\": \"8\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 1000, \"DisplayText\": \"Gram neg bacilli (other than pseudomonas) infections in bone or joint prostheses\", \"Text\": \"Gram negative bacilli (other than Pseudomonas) infections\", \"Mnemonic\": \"10\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 1001, \"DisplayText\": \"Pseudomonas aeringunosa infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Pseudomonas aeruginosa infections\", \"Mnemonic\": \"12\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"INFECTIONS IN BONE OR JOINT PROSTHESES\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Common important pathogens include coagulase-negative staphylococci,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Staphylococcus aureus, streptococci, enterococci, and gram negative bacilli.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Obtain material for gram stain and culture and base antimicrobial therapy on\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"results of Gram stain. Blood, joint fluid, and affected tissue and/or bone are\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"ideal specimens to culture. Sinus tracts are often colonized and isolates from\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"drainage may not be pathogens. If Staphylococcus aureus is present,it is likely\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"to be a pathogen in the bone.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Pathogen-directed Treatment Regimens\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Acute infections can often be cured with debridement with joint retention\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"followed by antimicrobials. Infections with duration of symptoms greater then 3\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"weeks or infection within 4 weeks of implantation require one or two stage\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"remimplantation. Cases that are inoperable can be managed with long-term\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"suppressive antimicrobial therapy or joint removal without replacement depending\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"on patient's condition. Consult Infectious Diseases for more information.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Infectious Disease and Orthopedics consultations are essential.\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Empirical Therapy Before a Pathogen is Identified is Not Recommended.\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Text\": \"If patient has sepsis or is otherwise unstable, empiric treatment before culture\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"results are obtained may be justified.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for IV treatment options.\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Mandell chapter: Orthopedic Implant-Associated Infections\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Up-to-Date Article: Prosthetic Joint Infections: Treatment\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Prosthetic Joint Infection\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1005,
    "fields": {
      "name": "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)",
      "term": null,
      "displaytext": "Pubic Lice (Pediculosis Pubis) - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion for 10 min\", \"Text\": \"Permethrin 1% lotion. Apply to affected area for 10 minutes then comb out\", \"Mnemonic\": \"4a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 1% lotion for 10 min Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"PUBIC LICE (PEDICULOSIS PUBIS)\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Lice are parasitic insects. Human lice survive by feeding on human blood.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"To make a diagnosis, use a nit comb, bright light, or lens to find a louse\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"living in pubic hair.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"The presence of nits on a hair shaft, especially when they are located more\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"than 6 mm from the skin, does NOT indicate active infestation.  Nits may remain\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"present for months after successful treatment.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Household contacts and persons who may have come into contact with personal\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"belongings of an infested individual should be examined for evidence of lice\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"and discarded or cleaned if contaminated.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"A repeat application may be used if live lice are seen 7-10 days after\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"treatment.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"nits ($) [M]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: lice\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1006,
    "fields": {
      "name": "ORZID3 GMENU PYELONEPHRITIS",
      "term": null,
      "displaytext": "Pyelonephritis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 196, \"DisplayText\": \"Antimicrobial CDSS Lab Menu\", \"Text\": \"Lab menu\", \"Mnemonic\": \"4\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"6a\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ceftriaxone 2 gm IV once ($) [M]\", \"Text\": \"Ceftriaxone 2 gm IV once ($) [M] < THEN > one of the oral regimens below\", \"Mnemonic\": \"8\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 51, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R] for 14 days\", \"Mnemonic\": \"14a\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"14b\"}, {\"Row\": 56, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID for 14 days ($) [R]\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"16a\"}, {\"Row\": 57, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 60, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"18a\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 7 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 68, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Text\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"20a\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 72, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"22\"}, {\"Row\": 73, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"24a\"}, {\"Row\": 75, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"26\"}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 14 days\", \"Text\": \"Ciprofloxacin 750 mg PO q12h ($) [R,DI] for 14 days\", \"Mnemonic\": \"28a\"}, {\"Row\": 86, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"28b\"}, {\"Row\": 90, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO tid for 14 days ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO q8h ($) [R] for 14 days\", \"Mnemonic\": \"30a\"}, {\"Row\": 91, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO tid for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"30b\"}, {\"Row\": 94, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"32\"}, {\"Row\": 95, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days\", \"Text\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days\", \"Mnemonic\": \"34a\"}, {\"Row\": 96, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Linezolid 600 mg PO q12h ($) [DI,O] for 14 days (Non-VA)_\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"34b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PYELONEPHRITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Features of pyelonephritis include fever/other signs of systemic infection,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"flank pain, costovertebral tenderness, and pelvic or perianal pain in men. Most\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"cases are caused by Escherichia coli. Resistant organisms, such as Enterococcus\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and Pseudomonas, are more likely if the patient is elderly, has been in the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"hospital for more than 48 hours, or received a course of antibiotics.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Obtain a urine culture, urine Gram-stain, and blood culture immediately to guide\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"antimicrobial therapy:\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Drugs active against enterococci (ampicillin, piperacillin) or staphylococci\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"needn't be used if Gram-negative bacilli predominate on the smear. Broad\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"spectrum antimicrobials are needed if patient is at risk of having a multi-drug\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"resistant (MDR) organism.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Judge severity of infection based on clinical signs and symptoms, including\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"blood pressure, pulse, mental status, white blood count, and degree of fever.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Oral regimens are preferred over IV if severity is mild or moderate and patient\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"can tolerate oral antibiotics. In patients with severe or persistent disease,\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"new renal failure, or suspected urinary obstruction, obtain a renal ultrasound\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"to rule out obstruction or other complicating condition. Consult urology if\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"abnormalities are found.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"When patients who require paraenteral therapy are afebrile, clinically stable,\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"and can take oral medication, convert to oral therapy based on the\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"identification and susceptibility of the isolate.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Duration\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Treat for 7 to 14 days. In patients with a mild infection and a quick clinical\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"response, 7 days of treatment may be adequate. A longer duration may be required\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"in severe infection, resistant organisms, presence of obstruction, underlying\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"renal disease, immunosuppression, neurologic or structural abnormality, and men\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"in some cases. A 7-day course of ciprofloxacin has been shown to be as effective\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"as a 14-day course.\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Empirical treatment\", \"Header\": 1}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Oral treatment after single dose of ceftriaxone IV above:\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"History of Gram-negative MDR bacteria:\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Treatment for specific pathogens\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"Enterobacteria including E. coli, klebsiella, and proteus\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Alternative or isolate resistant to preferred antimicrobials:\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 78, \"Column\": 1, \"Text\": \"S. aureus is an uncommon urinary tract pathogen and presence in the urine may be\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"due to hematogenous seeding from another site. Blood cultures are indicated to\"}, {\"Row\": 80, \"Column\": 1, \"Text\": \"rule out bacteremia in patients who have S. aureus isolated from the urine.\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"Consult Infectious Diseases for more information.\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"Pseudomonas\", \"Header\": 1}, {\"Row\": 84, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 88, \"Column\": 1, \"Text\": \"Enterococcus\", \"Header\": 1}, {\"Row\": 89, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"Resistant isolate or alternative to preferred antimicrobials:\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 100, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 101, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 102, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"Sanford keyword: Pyelonephritis, Acute\"}, {\"Row\": 104, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute complicated cystitis and pyelonephritis\"}, {\"Row\": 105, \"Column\": 1, \"Text\": \"Up-To-Date article: Pseudomonas aeruginosa infections of the eye, ear, urinary\"}, {\"Row\": 106, \"Column\": 1, \"Text\": \"tract, gastrointestinal tract, and central nervous system\"}, {\"Row\": 107, \"Column\": 1, \"Text\": \"Up-To-Date article: Treatment of enterococcal infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1007,
    "fields": {
      "name": "ORZID3 GMENU PYOMYOSITIS",
      "term": null,
      "displaytext": "Pyomyositis  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PYOMYOSITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1008,
    "fields": {
      "name": "ORZID3 GMENU REACT PRIM INFECT ZOSTER",
      "term": null,
      "displaytext": "Reactivation of primary infection (Zoster or \"Shingles\") - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po tid for 7 days\", \"Text\": \"Valacyclovir 1000 mg PO TID for 7 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po tid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PREDNISONE TAPER FOR HERPES ZOSTER\", \"Text\": \"Prednisone 60 mg daily for 7 days then 30 mg daily for 7 days, then 15 mg\", \"Mnemonic\": \"6a\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PREDNISONE TAPER FOR HERPES ZOSTER Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po tid for 7 days\", \"Text\": \"Valacyclovir 1000 mg PO TID for 7 days ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1000mg po tid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"REACTIVATION OF PRIMARY INFECTION (ZOSTER OR SHINGLES)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Zoster represents reactivation of varicella-zoster virus. After primary\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"infection, virus remains latent in the sensory dorsal root ganglia.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Reactivation syndrome is characterized by painful, unilateral, vesicular,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"dermatomal rash.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Prevention\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Vaccinate all adults greater than or equal to 50 years of age with the\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"recombinant zoster vaccine regardless of past episode or receipt of the live\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"zoster vaccine.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Give recombinant zoster vaccine x2, 2nd dose 2-6 months after the first\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Immunocompetent patients\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment in persons <50 years\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment is not beneficial, none is recommended.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Treatment in persons >=50 years\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment with antivirals can shorten duration of pain and rash in patients over\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"50 years old. Treatment must be started within 72 hours of onset.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"There is evidence that addition of corticosteroids to antiviral\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"therapy decreases pain and duration of rash and improves quality of life\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"modestly during the acute shingles episode. Corticosteroids do not decrease the\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"incidence of post-herpetic neuralgia. Some authorities recommend addition of\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"corticosteroid therapy to antiviral therapy for patients over age 50 years.\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Corticosteroids are not recommended for patients at greater risk for steroid\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"toxicities (e.g., insulin-dependent diabetes mellitus, hypertension, peptic\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"ulcer disease) or for immunocompromised patients.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Optional Recommendation:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"daily for 7 days. ($)\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Immunocompromised patients\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"________________________________\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Immunocompromised patients at increased risk for complications of VZV disease\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"include: patients with malignancy, current immunosuppressive therapy, or HIV\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"infection. Treatment with antivirals shortens duration of symptoms and reduces\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"incidence of complications. In immunocompromised patients, treatment is\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"recommended to be started at any point during an active infection.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Treatment for mild to moderate disease\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Treatment for severe disease or progression from mild to moderate disease in\", \"Header\": 1}, {\"Row\": 62, \"Column\": 1, \"Text\": \"patients <=65 years\", \"Header\": 1}, {\"Row\": 63, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"Treatment for severe disease or progression from mild to moderate disease in\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"patients >65 years\", \"Header\": 1}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Kim et al. Annals Intern Med. 2018, 168(3):210-220\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Sanford keyword: Varicella-Zoster Virus\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1009,
    "fields": {
      "name": "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS",
      "term": null,
      "displaytext": "Recurrent or persistent urethritis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 2 gm PO x 1 dose ($) [DI] Azithromycin 1 gm PO x 1 dose ($)\", \"Text\": \"Metronidazole 2 gm PO x 1 dose ($) [DI] Azithromycin 1 gm PO x 1 dose ($)\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"PERSISTENT OR RECURRENT URETHRITIS OR CERVICITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Retreat with initial treatment regimen if patient was non-compliant with initial\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"treatment regimen or re-exposed to an untreated sex partner. If infection is not\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"due to non-compliance with treatment regimen or re-exposure to an untreated sex\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"partner, infection is most commonly caused by M. genitalium and less commonly T.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"vaginalis.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treatment for persistent or recurrent urethritis and failure of initial\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"doxycycline treatment\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"[M]\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Failure of above treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Consult Infectious Diseases (outpatient)\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines: MMWR (2015) 64.3\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and Cervicitis\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Urethritis, Recurrent/Persistent\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute cervicitis\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-To-Date article: Urethritis in men\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1010,
    "fields": {
      "name": "ORZID3 GMENU RELIEF RX INFORMATION",
      "term": null,
      "displaytext": "RELIEF RX Information -Antimicrobial Stewardship Team  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Text\": \"Acute Respiratory Tract Infections typically do not require an antimicrobial\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"prescription, however, patient's may be left unsatisfied. Relief Rx,\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"a symptom care pack including educational material, to ease veterans' symptoms\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"and help limit inappropriate antimicrobial prescriptions for viral infections.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Select clinics are participating in the Relief RX program with the Antimicrobial\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Stewardship Team. Please use link below to contact the team with questions\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"or to obtain more Relief RX packages for your site.\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 3111, \"DisplayText\": \"E-mail Antimicrobial CDSS Staff\", \"Text\": \"<Select Here> Contact ASP/CDSS Team\", \"Mnemonic\": \"10\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Note: The Relief RX package does not contain medications (other than throat\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"lozenges). Provider may order additional symptomatic medications.\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"RELIEF RX =  SYMPTOMATIC CARE PACK FOR VIRAL RESPIRATORY INFECTION\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1011,
    "fields": {
      "name": "ORZID3 GMENU RETINITIS",
      "term": null,
      "displaytext": "Retinitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 795, \"DisplayText\": \"CMV retinitis (Outpatient)\", \"Text\": \"Link to Treatment of CMV Retinitis and ARN\", \"Mnemonic\": \"4\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po 5x/d for 5 days\", \"Text\": \"Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 800mg po 5x/d for 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po tid for 5 days\", \"Text\": \"Valacyclovir 1 gm PO q8h for 5 days ($) [R]\", \"Mnemonic\": \"8a\"}, {\"Row\": 40, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1gm po tid for 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO TID ($0.29/day) [R]\", \"Text\": \"Acyclovir 400 mg PO q8h for 7-10 days ($) [R]\", \"Mnemonic\": \"10a\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Acyclovir 400 mg PO TID ($0.29/day) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R]\", \"Text\": \"Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]\", \"Mnemonic\": \"12a\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Valacyclovir 1 gm PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"RETINITIS AND ACUTE RETINAL NECROSIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Retinitis is a subset of uveitis, is rare in immunocompetent people: in these\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"individuals it is usually caused by varicella-zoster virus (VZV) or herpes\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"simplex virus (HSV). Retinitis is more common in immunocompromised patients and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"cytomegalovirus being the most common pathogen in these patients. Other\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"retinitis pathogens include Toxoplasma gondii, Bartonella henselae, Histoplasma\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"capsulatum, and Treponema pallidum. In most cases, patients have other\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"neurological symptoms or signs.  Patients with candidemia may present with 1-3\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"mm white punctate retinal lesions called cotton-wool spots. These may only be\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"visible on fundus examination. Treatment of candidal retinitis  is systemic\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"antifungal therapy. Consult Ophthalmology, Infectious Diseases, or Neurology for\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"help.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"VZV and HSV cause nearly all cases of acute retinal necrosis (ARN), with a small\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"number being caused by cytomegalovirus. ARN is a rapidly progressing retinitis\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"that occurs primarily in immunocompetent people and can cause vision loss.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Treatment with intravenous acyclovir or valacyclovir is essential to halt\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"progression of ARN.\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Ophthalmology and Infectious Diseases consultation is essential\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Treatment of Non-viral Retinitis or ARN\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Refer to specific pathogen treatment recommendations of the CDSS to treat\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"underlying infection\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Treatment of Retinitis or ARN due to CMV:\", \"Header\": 1}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Treatment of VZV Retinitis\", \"Header\": 1}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Treatment of HSV Retinitis\", \"Header\": 1}, {\"Row\": 45, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Treatment of VZV and HSV Acute Retinal Necrosis\", \"Header\": 1}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Ophthalmologist involvement is essential for treatment including\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"corticosteroids, vitrectomy, or laser therapy. Intravitreal foscarnet in\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"addition to a systemic antiviral may provide added therapeutic efficacy.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Duration\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Treat with intravenous therapy for a minimum of 7 days until disease has\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"stabilized then treat with or therapy for a minimum of 6 weeks\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"Treatment\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS for parenteral therapy\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 66, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Lau et al, Ophthalmology. 2007, 114(4)756-762\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious causes of uveitis\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Schoenbergeret al., Ophthalmology. 2017, 124(3)382-392\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Sanford keyword: Acute Retinal Necrosis\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Sanford keyword: Herpes Simplex\"}, {\"Row\": 72, \"Column\": 1, \"Text\": \"Sanford keyword: Retinitis\"}, {\"Row\": 73, \"Column\": 1, \"Text\": \"Sanford keyword: Varicella-zoster Virus (Chickenpox)\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1012,
    "fields": {
      "name": "ORZID3 GMENU ROCK MTN SPOTTED FEVER",
      "term": null,
      "displaytext": "Rocky Mountain Spotted Fever (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO q12h ($) [DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"ROCKY MOUNTAIN SPOTTED FEVER\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Rocky Mountain Spotted Fever is a tick-borne, potentially life-threatening\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"rickettsial disease. The highest incidence in the United States is in the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Southeastern and South-central states. Clinical diagnosis include fever in\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"endemic area, known or possible tick bite, with or without rash. Rash typically\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"spreads from the extremities to the trunk.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Diagnosis is difficult, consult Infectious Diseases for assistance.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Consider empirical therapy with doxycycline for a patient with an undiagnosed\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"febrile illness and relevant tick exposure.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treat for 7 days.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Rocky mountain spotted fever\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Masters EJ Arch Intern Med 2003, 163: 769\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1013,
    "fields": {
      "name": "ORZID3 GMENU SCABIES",
      "term": null,
      "displaytext": "Scabies (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 5% cream topical apply from head to feet\", \"Text\": \"Permethrin 5% cream apply from head to feet, leave on for 8-14 hours, then\", \"Mnemonic\": \"4a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Permethrin 5% cream topical apply from head to feet Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"SCABIES\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Scabies is an infestation of the skin by the mite Sarcoptes scabiei.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"It is transmitted by skin to skin contact. Outbreaks occur in nursing\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"homes, day care centers, and residential institutions.  Scabies is highly\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"contagious and meticulous infection control is needed.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment is a single application of permethrin cream.  Some experts recommend\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"a second application 7-10 days after the first application if the patient is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"still symptomatic or if live mites are found at that time.  Contact Dermatology\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"or Infectious Diseases for more information.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treat family members and other close contacts to prevent spread and recurrence.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Repeat application 7-10 days after the first application if patient is still\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"experiencing symptoms, or if lives mites are found.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"wash cream off with soap and water ($) [M]\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Scabies\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1014,
    "fields": {
      "name": "ORZID3 GMENU SECOND RECURRENCE CDIFF COLITIS",
      "term": null,
      "displaytext": "ORZID3 GMENU SECOND RECURRENCE ABX ASSOC COLITIS ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin capsule taper and pulse\", \"Text\": \"Vancomycin Extended Pulse-Taper Regimen ($) [M]\", \"Mnemonic\": \"8a\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Vancomycin capsule taper and pulse Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Patients with more than one recurrence of C. difficile infection are complex and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"difficult.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Discontinue any antibiotics if possible and avoid high-risk antibiotic if\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"antibiotic therapy is still needed. Discontinue antacid therapy if possible.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Second Recurrence:\", \"Header\": 1}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Severe/life-threatening disease (shock, ileus, megacolon)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Mandell chapter: Clostridium difficile infection\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"Sanford keyword: Clostridium difficile\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Up-to-Date article: Clostridium difficile infection in adults: Treatment and\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"prevention\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200mg Extended-pulse regimen ($$$$) [M]\", \"Text\": \"Fidaxomicin Extended-Pulse Regimen ($$) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Criteria for Use: Fidaxomicin VA-PBM (11/21)\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"*Infectious Disease or Gastroenterology consultation is recommended*\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Third or more recurrence: Consult Gastroenterology or Infectious Disease\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg po q12h x 10 days ($$$$) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fidaxomicin 200 mg PO BID for 10 days ($$$$) [O]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"< OR>\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"125 mg po BID for 7 days, then 125mg po qday for 7 days, then\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"125mg every other day for 6 weeks)\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Fulminant CDI:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"CDI Recurrence: Typically defined as a repeated symptomatic, laboratory\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"confirmed case of CDI within 12 weeks after a prior episode.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SECOND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1015,
    "fields": {
      "name": "ORZID3 GMENU SECONDARY PERITONITIS",
      "term": null,
      "displaytext": "Secondary peritonitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SECONDARY PERITONITIS, INTRAABDOMINAL ABSCESS, INTRAPERITONEAL ABSCESS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1016,
    "fields": {
      "name": "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK",
      "term": null,
      "displaytext": "Sepsis, severe sepsis, and septic shock (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPSIS, SEVERE SEPSIS, AND SEPTIC SHOCK\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1017,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC ARTH ENTEROCOCCI",
      "term": null,
      "displaytext": "Septic arthritis (Native Joint) with Enterococci - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO TID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH ENTEROCOCCI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Administer parenteral therapy initially then can be converted to appropriate\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"oral therapy.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Duration of treatment for 2-4 weeks, depending on response\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment, MILD-MODERATE infections\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Treatment, SEVERE infections\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Stevens DL Clin Inf Dis 2014, 59:e10-52\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1018,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC ARTH GNB",
      "term": null,
      "displaytext": "Septic arthritis (Native Joint ) with Gram negative Bacilli - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin/clavulanate 875/125mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po qday ($0.19/day)[R\", \"Text\": \"Levofloxacin 500mg PO qday ($) [R,DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg po qday ($0.19/day)[R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH GRAM NEGATIVE BACILLI (OTHER THAN\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"PSEUDOMONAS)\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Administer parenteral therapy initially for approximately 1-2 weeks\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"then can be converted to appropriate oral therapy.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Duration of treatment for 4 weeks depending on response\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Oral therapy to complete the course after intravenous therapy initially:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1019,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC ARTH N. GONORRHOEAE",
      "term": null,
      "displaytext": "Septic arthritis (Native Joint) with N. gonorrhoeae - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Mnemonic\": \"16a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days\", \"Text\": \"Doxycycline 100 mg PO BID for 7 days ($) [DI]\", \"Mnemonic\": \"18a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH NEISSERIA GONORRHOEAE\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Treat presumptively also for Chlamydia trachomatis infection\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"(asymptomatic urethritis) and test for HIV.  Infection control will\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"report cases with N. gonorrhea isolated to the state department of health.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Sexual partners within 60 days should be referred for evaluation and treatment.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Parenteral therapy recommended until clinical improvement, then switch to oral\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"therapy to complete 1-2 weeks of therapy.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Susceptibility results are required to guide potential switch to an oral medicat\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment for N. gonorrheae (Plus see below for Chlamydia treatment)\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for initial parenteral treatment\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"______________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Concomitant treatment for C. trachomatis\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Preferred treatment:\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Alternative treatment:\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Coakley G Lancet 2010, 375:846\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"MMWR Recommendations and Reports CDC 2015, 64:1-137\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1020,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC ARTH P. AERUGINOSA",
      "term": null,
      "displaytext": "Septic arthritis (Native Joint) with P. aeruginosa - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 14 days\", \"Text\": \"Ciprofloxacin 750 mg PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 750mg po bid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH PSEUDOMONAS AERUGINOSA\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Administer parenteral therapy initially then can be converted to appropriate\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"oral therapy.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treat for 4 weeks\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1021,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC ARTH S. AUREUS",
      "term": null,
      "displaytext": "Septic arthristis (Native Joint) with S. aureus - Outpatient ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1ds tablet bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 28 days\", \"Text\": \"Minocycline 100 mg PO BID ($) [DI]\", \"Mnemonic\": \"12a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Minocycline 100mg po bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH STAPHYLOCOCCUS AUREUS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Administer parenteral therapy initially for approximately two weeks\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"then can be converted to appropriate oral therapy.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Total duration of treatment 4-6 weeks depending on clinical response\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Methicillin-SUSCEPTIBLE Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Methicillin-RESISTANT Staphylococcus aureus\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"________________________________________________________\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Coakley G Rheumatology (Oxford) 2006, 45:1039\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID ($) [R]\", \"Mnemonic\": \"6a\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO BID [R] ($)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1022,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC ARTH STREPTOCOCCI",
      "term": null,
      "displaytext": "Septic arthritis (Native Joint) with Streptococci - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO tid for 14 days ($) [R]\", \"Text\": \"Amoxicillin 1000 mg PO tid for 14 days ($) [R]\", \"Mnemonic\": \"4a\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 1000 mg PO tid for 14 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid for 14 days\", \"Text\": \"Clindamycin 300mg PO qid for 14 days ($) [H]\", \"Mnemonic\": \"6a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clindamycin 300mg po qid for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT) WITH STREPTOCOCCI\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Administer parenteral therapy initially and then can be converted to\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"appropriate oral therapy.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Duration of therapy 2-4 weeks total\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-to-date online\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Mathews CJ Lancet 2010, 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1023,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)",
      "term": null,
      "displaytext": "Septic arthritis (Native Joint) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 751, \"DisplayText\": \"Bite wounds (Outpatient)\", \"Text\": \"Bite wounds\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"8\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 1021, \"DisplayText\": \"Septic arthristis (Native Joint) with S. aureus - Outpatient\", \"Text\": \"Staphylococcus aureus\", \"Mnemonic\": \"10\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 1022, \"DisplayText\": \"Septic arthritis (Native Joint) with Streptococci - Outpatient\", \"Text\": \"Streptococci\", \"Mnemonic\": \"12\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 1017, \"DisplayText\": \"Septic arthritis (Native Joint) with Enterococci - Outpatient\", \"Text\": \"Enterococci\", \"Mnemonic\": \"14\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 1018, \"DisplayText\": \"Septic arthritis (Native Joint ) with Gram negative Bacilli - Outpatient\", \"Text\": \"Gram negative bacilli (other than Pseudomonas)\", \"Mnemonic\": \"16\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 1020, \"DisplayText\": \"Septic arthritis (Native Joint) with P. aeruginosa - Outpatient\", \"Text\": \"Pseudomonas aeruginosa\", \"Mnemonic\": \"18\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 1019, \"DisplayText\": \"Septic arthritis (Native Joint) with N. gonorrhoeae - Outpatient\", \"Text\": \"Neisseria gonorrhoeae\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC ARTHRITIS (NATIVE JOINT)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \">>  For arthritis associated with a PROSTHETIC JOINT see\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \">>  For arthritis associated with a BITE WOUND see\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \">>  For arthritis associated with TICK EXPOSURE in an endemic area, consider\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Septic arthritis native joint:\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Aspirate the joint for gram stain and culture.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Use the gram stain of aspirated fluid to select initial therapy.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Use culture results to guide definitive therapy.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"In addition to antimicrobial treatment, successful managemet of acute\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"septic arthritis requires removal of intra-articular pus.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"See Inpatient CDSS for initial parenteral treatment\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Pathogen-specific septic arthritis treatment regimens\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Duration of therapy based on pathogen and clinical response. (See pathogen)\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"If the patient has an underlying rheumatoid arthritis, 6 to 12 weeks of\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"antimicrobials may be needed, depending on clinical response.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Consult Rheumatology for more information.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Sanford keyword: Septic arthritis\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Sharff KA Curr Rheumatol Rep 2013, 15:332\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Coakley G Lancet 2010, 375:846\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1024,
    "fields": {
      "name": "ORZID3 GMENU SEPTIC BURSITIS",
      "term": null,
      "displaytext": "Septic bursitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI]\", \"Text\": \"Doxycycline 100 mg PO BID  ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100 mg PO BID for 14 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($0.18/day) [R\", \"Text\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($0.18/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SEPTIC BURSITIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Aspiration for treatment and diagnostic confirmation should be performed\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"in all cases. Obtain synovial fluid for gram stain and culture to guide\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"therapy. Most cases are associated with Staphylococcus aureus.\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Intravenous therapy is recommended. Some clinicians treat mild cases in\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"otherwise healthy individuals with intravenous therapy for part of the\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"course and then switch to oral therapy. Other clinicians treat mild cases\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"with oral therapy for the entire course. Drug selection should be based on\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"microbiological results. Close clinical follow-up is needed for all cases.\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Moderate to severe cases\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Refer to Inpatient CDSS\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Mild cases\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Treat for 14 days.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Sanford keyword: Bursitis, Septic\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious arthritis of native joints\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Baumbach SF, Arch Orthop Trauma Surg 2014, 134:359\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days\", \"Mnemonic\": \"4a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefadroxil 1000 mg PO q12h ($) [R] for 14 days (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"< OR >\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1025,
    "fields": {
      "name": "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)",
      "term": null,
      "displaytext": "Sexually Transmitted Infections",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"14\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A diagnosis of a sexually transmitted infection can suggest sexual activity\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Sexually Transmitted Infections (STI)\", \"Header\": 1}, {\"Row\": 31, \"Column\": 1, \"Item\": 828, \"DisplayText\": \"Epididymitis (Outpatient)\", \"Text\": \"Epididymitis\", \"Mnemonic\": \"28\"}, {\"Row\": 33, \"Column\": 1, \"Item\": 978, \"DisplayText\": \"Pelvic inflammatory disorder (PID) - Outpatient\", \"Text\": \"Pelvic Inflammatory Disease (PID)\", \"Mnemonic\": \"32\"}, {\"Row\": 30, \"Column\": 1, \"Item\": 784, \"DisplayText\": \"CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Text\": \"Cervicitis\", \"Mnemonic\": \"26\"}, {\"Row\": 32, \"Column\": 1, \"Item\": 851, \"DisplayText\": \"Genital herpes (Outpatient)\", \"Text\": \"Genital herpes\", \"Mnemonic\": \"30\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 1053, \"DisplayText\": \"Urethritis associated with sexually transmitted disease (Outpatient)\", \"Text\": \"Urethritis\", \"Mnemonic\": \"34\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sexually Transmitted Infections (STIs)\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Item\": 663, \"DisplayText\": \"HIV-AIDS (outpatient)\", \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Mnemonic\": \"38\"}, {\"Row\": 39, \"Column\": 1, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"42\"}, {\"Row\": 38, \"Column\": 1, \"Item\": 693, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"40\"}, {\"Row\": 35, \"Column\": 1, \"Item\": 1049, \"DisplayText\": \"Trichomonas vaginitis (Outpatient)\", \"Text\": \"Trichomonas Vaginitis, Urethritis and Male Sex Partners\", \"Mnemonic\": \"36\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"that could result in HIV exposure. Recommendation is for the provider to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"HIV acquisition.  If the patient is interested, the provider should place a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"consult to MRTC clinic for further discussion and evaluation for PrEP.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Pre-exposure prophylaxis (or PrEP) is a way for people who do not have\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"HIV but who are at high risk of getting HIV to prevent HIV infection by\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"taking a pill every day. When someone is exposed to HIV through sex or\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"injection drug use, these medicines can work to keep the virus from\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"establishing a permanent infection.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"have shown that PrEP reduces the risk of getting HIV from sex by about\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"99% when taken daily. PrEP is much less effective if not taken consistently.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"As PrEP only protects against HIV, condoms are important for the protection\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"against other STIs. Condoms are also an important prevention strategy\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"if PrEP is not taken consistently.\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 785, \"DisplayText\": \"Chlamydia urethritis (Outpatient)\", \"Text\": \"Chlamydia\", \"Mnemonic\": \"20\"}, {\"Row\": 27, \"Column\": 1, \"Item\": 854, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Gonorrhea\", \"Mnemonic\": \"22\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 719, \"DisplayText\": \"Syphilis\", \"Text\": \"Syphilis\", \"Mnemonic\": \"24\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1026,
    "fields": {
      "name": "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU",
      "term": null,
      "displaytext": "Sexually Transmitted Infections (STI) HIV Exposure  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 663, \"DisplayText\": \"HIV-AIDS (outpatient)\", \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Mnemonic\": \"4\"}, {\"Row\": 25, \"Column\": 1, \"Item\": 693, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR NON-OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"6\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 697, \"DisplayText\": \"POST EXPOSURE BLOOD BODY FLUIDS PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE\", \"Text\": \"HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Sexually Transmitted Infections (STI)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"A diagnosis of a sexually transmitted infection can suggest sexual activity\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"that could result in HIV exposure. Recommendation is for the provider to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"HIV acquisition.  If the patient is interested, the provider should place a\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"consult to MRTC clinic for further discussion and evaluation for PrEP.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Pre-exposure prophylaxis (or PrEP) is a way for people who do not have\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"HIV but who are at high risk of getting HIV to prevent HIV infection by\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"taking a pill every day. When someone is exposed to HIV through sex or\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"injection drug use, these medicines can work to keep the virus from\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"establishing a permanent infection.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"have shown that PrEP reduces the risk of getting HIV from sex by about\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"99% when taken daily. PrEP is much less effective if not taken consistently.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"As PrEP only protects against HIV, condoms are important for the protection\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"against other STIs. Condoms are also an important prevention strategy\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"if PrEP is not taken consistently.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1027,
    "fields": {
      "name": "ORZID3 GMENU SM UNIF BAC AEROBIC BOT",
      "term": null,
      "displaytext": "Small uniform bacillin in an aerobic bottle (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SMALL PLEOMORPHIC BACILLI IN AEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Small pleomorphic bacilli in aerobic bottle are usually diphtheroids. These are\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually contaminants. Uncommonly such organisms prove to be Listeria\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"monocytogenes, which when present in a blood culture is likely a pathogen.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Listeria is more likely in patients with impaired cell-mediated immunity,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"pregnant women, elderly and patients on immunosuppressive therapy for\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"transplantation.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Empirical treatment if there is a strong suspicion of listeria\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for intravenous treatment options\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Empirical treatment if therapy is indicated and listeria is not suspected\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for intravenous treatment options\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Mandell chapter: Listeria Monocytogenes\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Mandell chapter: Other Coryneform Bacteria and Rhodococci\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Sanford keyword: Listeria monocytogenes\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Sanford keyword: Propionibacterium acnes\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1028,
    "fields": {
      "name": "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT",
      "term": null,
      "displaytext": "Small uniform bacilli in an anaerobic bottle (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SMALL PLEOMORPHIC BACILLI IN AN ANAEROBIC BOTTLE\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Small pleomorphic bacilli in anaerobic bottle usually suggest propionibacteria.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"These are often contaminants.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Treatment if therapy is indicated\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS for intravenous treatment options\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Mandell chapter: Other Coryneform Bacteria and Rhodococci\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Medical Letter Choice of Antimicrobials 2010, 8.94\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Sanford keyword: Propionibacterium acnes\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Sanford keyword: Corynebacterium\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1029,
    "fields": {
      "name": "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...",
      "term": null,
      "displaytext": "Soft Tissue, Muscle, Bone and Joint Infections (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 751, \"DisplayText\": \"Bite wounds (Outpatient)\", \"Text\": \"Bite wounds\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 1024, \"DisplayText\": \"Septic bursitis (Outpatient)\", \"Text\": \"Septic bursitis\", \"Mnemonic\": \"6\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 633, \"DisplayText\": \"Abscesses (Outpatient)\", \"Text\": \"Abscesses\", \"Mnemonic\": \"8\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 803, \"DisplayText\": \"Cutaneous abscess (Outpatient)\", \"Text\": \"Cutaneous abscess\", \"Mnemonic\": \"10\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 1007, \"DisplayText\": \"Pyomyositis\", \"Text\": \"Pyomyositis (Refer to Inpt)\", \"Mnemonic\": \"12\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 805, \"DisplayText\": \"Decubitis ulcers (Outpatient)\", \"Text\": \"Decubitis ulcers\", \"Mnemonic\": \"14\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 1037, \"DisplayText\": \"Surgical site infection\", \"Text\": \"Surgical wound infections\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++SOFT TISSUE, MUSCLE, BONE AND JOINT INFECTIONS - OUTPATIENT  ++\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Update/review in process Jan2019\"}, {\"Row\": 5, \"Column\": 2, \"Item\": 836, \"DisplayText\": \"Foot ulcer in patient with diabetes mellitus (Outpatient)\", \"Text\": \"Foot ulcer in patient with diabetes mellitus\", \"Mnemonic\": \"20\"}, {\"Row\": 7, \"Column\": 2, \"Item\": 952, \"DisplayText\": \"Osteomyelitis (Outpatient)\", \"Text\": \"Osteomyelitis\", \"Mnemonic\": \"22\"}, {\"Row\": 8, \"Column\": 2, \"Item\": 823, \"DisplayText\": \"Diskitis and vertebral osteomyelitis (Outpatient)\", \"Text\": \"Diskitis and vertebral osteomyelitis\", \"Mnemonic\": \"24\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Infections in bone or joint prostheses\", \"Mnemonic\": \"26\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 1023, \"DisplayText\": \"Septic arthritis (Native Joint) - Outpatient\", \"Text\": \"Native joint\", \"Mnemonic\": \"28\"}, {\"Row\": 13, \"Column\": 2, \"Item\": 1004, \"DisplayText\": \"Infections in bone or joint prostheses (Outpatient)\", \"Text\": \"Prosthetic joint\", \"Mnemonic\": \"30\"}, {\"Row\": 11, \"Column\": 2, \"Text\": \"Septic arthritis\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1030,
    "fields": {
      "name": "ORZID3 GMENU SPLENECTOMY DAILY ANTIBIOTIC",
      "term": null,
      "displaytext": "Asplenic Empiric Antibiotics",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Text\": \"HELP, additional information:\", \"Header\": 1}, {\"Row\": 2, \"Column\": 1, \"Item\": 169, \"DisplayText\": \"Help page (instructions, microbiology, drug properties, etc.)\", \"Text\": \"Help page (instructions, microbiology, etc.)\", \"Mnemonic\": \"02\"}, {\"Row\": 3, \"Column\": 1, \"Item\": 145, \"DisplayText\": \"Click for drug information. ([R]=renal excretion, [H]=hepatic excretion,\", \"Mnemonic\": \"04\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"[DI]=important drug interactions, [O]=other, [M]= minimal risk)\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 940, \"DisplayText\": \"Need an alternative antimicrobial? (outpatient)\", \"Mnemonic\": \"06\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Consult Infectious Diseases (outpatient)\", \"Text\": \"Consult Infectious Diseases (outpatient)\", \"Mnemonic\": \"08\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 124, \"DisplayText\": \"Cost(dollars/day)= $(<10) $$(10-50) $$$(51-100) $$$$(101-400) $$$$$(>400)\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-Date online\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Daily Antibiotic Prophylaxis for Asplenia\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"The need for daily antibiotic prophylaxis and its duration is typically\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"determined individually based on patient age, immune status, history of\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"infection, potential for adverse drug reactions and other factors.\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Daily antibiotic prophylaxis is in addition to the emergency supply.\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500MG PO bid for daily prophylaxis for asplenic patient ($) [R]\", \"Mnemonic\": \"14\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cephalexin 250MG PO bid for daily propylaxis for asplenic patient ($) [R]\", \"Mnemonic\": \"16\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Recommended:\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Alternative for penicillin and beta lactam allergy:\", \"Header\": 1}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 250MG PO qday for daily prophylaxis for asplenic patients ($)[DI]\", \"Mnemonic\": \"18\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Consider Prophylaxis:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"1) Approximately 1 year prophylaxis for all patients following splenectomy.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"2) Lifelong prophylaxis for patients with history of sepsis or other severe\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"infections caused by encapsulated organisms.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"3) Prophylaxis for as long as the patient is immunocompromised or for life\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"for patients with concurrent immunocompromising conditions (e.g. hematologic\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"malignancy, hypogammaglobulinemia, solid-organ transplant, advanced liver\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"disease, or HIV infection).\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1031,
    "fields": {
      "name": "ORZID3 GMENU SPLENECTOMY EMPIRIC ABX",
      "term": null,
      "displaytext": "Asplenic Empiric Antibiotics",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875MG PO BID for asplenia empiric antibiotic ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875MG PO BID for asplenia empiric antibiotic ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefuroxime 500MG PO BID for asplenia empiric antibiotic ($) [R]\", \"Text\": \"Cefuroxime 500MG PO BID for asplenia empiric antibiotic ($) [R]\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 750MG PO QDAY for asplenia empiric antibiotic ($) [R,DI]\", \"Text\": \"Levofloxacin 750MG PO QDAY for asplenia empiric antibiotic ($) [R,DI]\", \"Mnemonic\": \"8\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Self-medicate Empiric Antibiotics for Fever or Other Signs of Systemic Infectio\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Patients should keep an emergency supply of antibiotics on hand to be used\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"for the development of fever or other signs of systemic infection, and\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"seek medical care immediately if these symptoms develop.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Recommendations to self- medicate:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Alternative recommendation for penicillin/beta-lactam allergy:\", \"Header\": 1}, {\"Row\": 14, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Up-to-Date online\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Keenan RD, Br J Haematol 1999. 105:509\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1032,
    "fields": {
      "name": "ORZID3 GMENU SPLENECTOMY OPT CHART",
      "term": null,
      "displaytext": "Splenectomy Vaccines  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"02\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Functional or Anatomical Asplenia\", \"Header\": 1}, {\"Row\": 10, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Mnemonic\": \"08\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES\", \"Mnemonic\": \"10\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HAEMOPHILUS B VACCINE ONE DOSE\", \"Mnemonic\": \"04\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Repeat every 5 years:\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES\", \"Text\": \"MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) ONE DOSE\", \"Mnemonic\": \"12\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Note: Please select EACH recommended vaccine to place orders\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Revaccination (booster)required:\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Repeat 1 year after completing the primary series and every 2 to 3 years\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"thereafter:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE\", \"Mnemonic\": \"06\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE ONE DOSE\", \"Mnemonic\": \"12\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1033,
    "fields": {
      "name": "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY",
      "term": null,
      "displaytext": "Asplenia Recommendations Vaccines Empiric Abx ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 24, \"Column\": 1, \"Item\": 1032, \"DisplayText\": \"Splenectomy Vaccines\", \"Text\": \"[click here] Place order for specific vaccines for asplenia\", \"Mnemonic\": \"6\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 1030, \"DisplayText\": \"Asplenic Empiric Antibiotics\", \"Text\": \"Daily Antibiotic Prophylaxis\", \"Mnemonic\": \"8\"}, {\"Row\": 34, \"Column\": 1, \"Item\": 1031, \"DisplayText\": \"Asplenic Empiric Antibiotics\", \"Text\": \"Self-medicate Empiric Antibiotics\", \"Mnemonic\": \"10\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Functional or Anatomical Asplenia Vaccine & Antibiotic Prophylaxis Guideline\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Following a splenectomy there is considerably increased risk of developing\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"septicemia from invasive encapsulated organisms, namely Streptococcus pneumonia,\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Haemophilus inluenza type b and meningococcus. Key measures to prevent\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"such infections include education, vaccination, prophylactic antimicrobial\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"therapy in selected patients, and early empirical therapy for febrile\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"epsisodes. It is critically important to educate patients regarding the\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"lifelong risk of postsplenectomy sepsis, the importance of vaccinations,\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"and the need for urgent action in response to a febrile episode.\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Management of an Episode of Fever in an Asplenic Patient\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"*See Inpatient CDSS*\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Initiation of vaccine regimen:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Routine vaccines should be up to date.\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"See CDSS Immunization section to order, if needed.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Ideally splenectomy vaccinations should be given 10 to 12 weeks before\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"elective splenectomy.  Where this is not possible they can be given up to\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"two weeks before or at least two weeks post-splenectomy.\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Use of Antibiotic Prophylaxis for Asplenia:\", \"Header\": 1}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Use of antibiotic prophylaxis, in addition to vaccination, further reduces\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"the risk of infection and poor outcomes.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Daily Antibiotic Prophylaxis: (in addition to emergency supply)\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Emergency Supply Empiric Abx for Fever or Other Signs of Systemic Infection:\", \"Header\": 1}, {\"Row\": 36, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Clin Infect Dis 2014, 58:e44-100\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Up-to-Date: Prevention of infection in patients with impaired splenic function\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 3112, \"DisplayText\": \"Vaccinations for Adults without a Spleen\", \"Text\": \"[click here] Vaccinations for Adults without a Spleen\", \"Mnemonic\": \"4\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"MMWR Morb Mortal Wkly Rep 2022, 71(7):229\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1034,
    "fields": {
      "name": "ORZID3 GMENU SPOROTRICHOSIS",
      "term": null,
      "displaytext": "Sporotrichosis (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po qday for 90 days\", \"Text\": \"Itraconazole 200 mg PO q12h continue for 2-4 weeks after all lesions\", \"Mnemonic\": \"4a\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Itraconazole 200mg po qday for 90 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"SPOROTRICHOSIS\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Sporotrichosis occurs most often in people who have had significant outdoor\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"exposure to soil.  In immunocompetent people, disease is usually limited to the\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"skin.  In people with decreased host defenses (eg, HIV/AIDS, alcoholism,\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"diabetes mellitus, or chronic obstructive pulmonary disease) sporotrichosis\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"often disseminates to bones, joints, or lungs.  Consult Infectious Diseases or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Dermatology\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Cutaneous infection in a patient without HIV infection\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"resolved, usually for a total of 3-6 months ($) [DI]\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Consult Dermatology or Infectious Diseases.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Extracutaneous infection or any infection in a patient with HIV/AIDS\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"____________________________________________________________________________\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Consult Dermatology or Infectious Diseases.\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Kaufman CA Clin Infect Dis 2000, 30: 684\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Up-to-date website\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1035,
    "fields": {
      "name": "ORZID3 GMENU STAPH SCALDED SKIN SYNDROME",
      "term": null,
      "displaytext": "Staphylococcal Scalded Skin Syndrome (Ritter's Disease) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"STAPHYLOCOCCAL SCALDED SKIN SYNDROME (RITTER'S DISEASE)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Staphylococcal scalded skin syndrome (SSSS) presents with severe skin\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"blistering and exfoliation resulting from toxins produced by Staphylococcus\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"aureus.  SSSS is usually found in children and rarely in older adults.  Obtain\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"a skin biopsy to differentiate between SSSS and toxic epidermal necrolysis.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Initiate anti-staphylococcal therapy and obtain cultures and susceptibilities.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"If cultures reveal methicillin-susceptible Staphylococcus aureus (MSSA), change\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"to nafcillin or cefazolin for better antimicrobial activity.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Sanford keyword: Staph. Scalded skin syndrome\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Mandell chapter: The acutely ill patient with fever and rash\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Stevens DL Clin Infect Dis 2014, 59: 147\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Patel GK Am J Clin Dermatol 2003, 4:165\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1036,
    "fields": {
      "name": "ORZID3 GMENU SUPP ODONTOGENIC INFECT",
      "term": null,
      "displaytext": "Suppurative odontogenic infections (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 5 days ($) [R]\", \"Text\": \"Amoxicillin 500 mg PO q8h for 5 days ($) [R]\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin 500 mg PO TID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h for 5 days ($) [R]\", \"Mnemonic\": \"8\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10\"}, {\"Row\": 21, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"12\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days\", \"Text\": \"Cefdinir 300 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"14\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cefdinir 300 mg PO BID 5 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS ($) [O]\", \"Text\": \"Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($) [M]\", \"Mnemonic\": \"18\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO once on day 1, then 250 mg PO QDAY X4DAYS Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DENTAL INFECTIONS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Surgical drainage, scaling and antimicrobial treatment are essential. All\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"patients should be referred to the dental service for assessment and direction\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"of treatment. Empirical coverage for likely pathogens (streptococci,\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Peptostreptococcus, Finegoldia, Bacteriodes and other oral anaerobes) is\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"required.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Consult Dental Service\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Preferred:\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Primary alternative:\", \"Header\": 1}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Secondary alternative, after assessment of beta-lactam reaction above:\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Lockhart et al. JADA. 2019, 150(11)906-921\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Mandell chapter: Infections of the Oral Cavity, Neck, and Head\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Ogle, Dent Clin N Am. 2017, 61(2)235-252\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Reynolds et al. Lung. 2009, 187(5)271-279\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Up-to-date article: Complications, diagnosis and treatment of odontogenic\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Infections\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1037,
    "fields": {
      "name": "ORZID3 GMENU SURG SITE INFECT",
      "term": null,
      "displaytext": "Surgical site infection  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"SURGICAL SITE INFECTION\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1038,
    "fields": {
      "name": "ORZID3 GMENU SYSTEMIC INFECT DIS",
      "term": null,
      "displaytext": "Systemic Infectious Diseases (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 742, \"DisplayText\": \"Bacteremia (Outpatient)\", \"Text\": \"Bacteremia\", \"Mnemonic\": \"4\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 920, \"DisplayText\": \"Intravascular catheter-associated infection (Outpatient)\", \"Text\": \"Intravascular catheter-associated infection\", \"Mnemonic\": \"6\"}, {\"Row\": 7, \"Column\": 1, \"Item\": 1016, \"DisplayText\": \"Sepsis, severe sepsis, and septic shock (Outpatient)\", \"Text\": \"Sepsis and septic shock\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": 478, \"DisplayText\": \"Leukocytosis\", \"Text\": \"Leukocytosis\", \"Mnemonic\": \"10\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 833, \"DisplayText\": \"Fever of Unknown Origin (Outpatient)\", \"Text\": \"Fever of unknown origin\", \"Mnemonic\": \"12\"}, {\"Row\": 10, \"Column\": 1, \"Item\": 943, \"DisplayText\": \"Neutropenic fever (Outpatient)\", \"Text\": \"Neutropenic fever\", \"Mnemonic\": \"14\"}, {\"Row\": 11, \"Column\": 1, \"Item\": 930, \"DisplayText\": \"Lyme Disease (Outpatient)\", \"Text\": \"Lyme disease\", \"Mnemonic\": \"16\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++  SYSTEMIC INFECTIOUS DISEASES - OUTPATIENT  ++\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Last reviewed July 2017\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1039,
    "fields": {
      "name": "ORZID3 GMENU TACE IR CHEMOEMBOLIZATION",
      "term": null,
      "displaytext": "Antibiotic Prophylaxis for IR Chemoembolization  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 4, \"Column\": 1, \"Text\": \"-Antibiotic prophylaxis in patients undergoing transarterial therapy for\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"hepatocellular carcinoma may not be routinely necessary.\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"-However, patients with an incompetent sphincter of Oddi from previous\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"surgery, sphincterotomy, biliary drainage, or prior biliary instrumentation\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"are at increased risk of infection following embolization.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"If no antimicrobial prophylaxis recommended, select below:\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Antimicrobial Pre-Procedure Prophylaxis Transarterial Chemoembolization (TACE)\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Gaba RC, et al. J Vasc Interv Radiol 2017, 28:1210-1223\"}, {\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"02\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Levofloxacin 500mg IVPB once 60 minutes prior to TACE procedure\", \"Text\": \"Levofloxacin 500 mg IVPB once 60 minutes prior to TACE procedure\", \"Mnemonic\": \"12\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Piperacillin-tazobactam 3.375 gm IVPB once 60 minutes prior to TACE procedure\", \"Mnemonic\": \"10\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative for penicillin allergy:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Minneapolis VAHCS Interventional Radiology\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Recommended prophylaxis:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"*No antimicrobial prophylaxis recommended for TACE procedure\", \"Text\": \"*No antimicrobial prophylaxis recommended for TACE procedure\", \"Mnemonic\": \"08\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1040,
    "fields": {
      "name": "ORZID3 GMENU TINEA CAPITIS (RINGWORM)",
      "term": null,
      "displaytext": "Tinea Capitis (Ringworm) - Outpatient",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250mg po qday for 28 days\", \"Text\": \"Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250mg po qday for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 16, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TINEA CAPITIS (RINGWORM)\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Tinea capitis is a common fungal infection of the scalp and hair. It is\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"characterized by itchy, red, raised, scaly patches often sharply defined.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"redder margins than centers create impression of ring. Tinea capitis primarily\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"affects prepubescent children, but can affect people of any age.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Treatment:\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treat for 4 weeks.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1041,
    "fields": {
      "name": "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)",
      "term": null,
      "displaytext": "Tinea Pedis (Athlete's Foot) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical bid for 28 days\", \"Text\": \"Clotrimazole 1% cream apply to affected area BID ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Clotrimazole 1% cream topical bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 1% cream topical bid for 28 days\", \"Text\": \"Terbinafine 1% cream apply to affected area BID ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 1% cream topical bid for 28 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg q week x 2-4 weeks\", \"Text\": \"Fluconazole 150mg q week x 2-6 weeks ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 150mg q week x 2-4 weeks Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250 mg PO QDAY x 2 weeks\", \"Text\": \"Terbinafine 250 mg PO QDAY x 2 weeks ($) [R,H,DI,O]\", \"Mnemonic\": \"10a\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250 mg PO QDAY x 2 weeks Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Dermatophyte (tinea) Infections\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TINEA PEDIS (ATHLETE'S FOOT), TINEA CORPORIS, TINEA MANUUM, OR TINEA CRURIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Dermatophyte fungal infections are common worldwide. Dermatophytes\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"metabolize and subsist upon keratin in the skin, hair, and nails.\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Most tinea infections can often be cured with topical therapy alone.  Systemic\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"therapy is reserved for severe or refractory infection, recurrent infection, or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in immunocompromised patients.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Treat for 4 weeks\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Treatment\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Alternative\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Systemic treatment\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Up-to-date website\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1042,
    "fields": {
      "name": "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)",
      "term": null,
      "displaytext": "Tinea Unguium (Onychomycosis)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250mg po qday for 42 days\", \"Text\": \"Terbinafine 250 mg PO qday for 6 weeks ($) [R,H,DI,O]\", \"Mnemonic\": \"6a\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250mg po qday for 42 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TINEA UNGUIUM (ONYCHOMYCOSIS)\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}, {\"Row\": 48, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 300 mg PO q week for total of 6 months ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Alternative oral therapy:\", \"Header\": 1}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Toenail infections treat for at least 6 months\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Fingernail infections treat for 3 months\"}, {\"Row\": 52, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 300 mg PO q week for 3 months ($) [R,DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"Topical Treatment:\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciclopirox 8% nail lacquer: Apply once daily to affected nail(s)\", \"Mnemonic\": \"12a\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"Remove with rubbing alcohol every 7 days. ($) [M]\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"See accompanying medication pamphlet for specific instructions.\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Treatment is continued until nail clearance or up to 48 weeks.\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"Gupta AK, et al. Br J Dermatol 2020 182(2): 287-299\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"Up-to-date website: Onychomycosis Management\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"Preferred Terbinafine first-line oral:\", \"Header\": 1}, {\"Row\": 56, \"Column\": 1, \"Text\": \"Ciclopirox is a topical first-line treatment for both fingernails and toenails.\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Complete resolution occurs in approximately 7 percent of patients treated\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"daily for 48 weeks.  Ciclopirox is a well-tolerated treatment. Potential side\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"effects include temporary nail changes and local skin irritation.\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Fingernail infections treat for 6 weeks\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"Toenail infections treat for 12 weeks\"}, {\"Row\": 39, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 250 mg PO qday for 12 weeks (R,H,DI,O]\", \"Mnemonic\": \"4a\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Onychomycosis is a fungal infection of the nail that presents with yellow,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"thick, or crumbling nails. Obtain a fungal stain of nail sample prior to\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"initiating treatment. Using large nail clippers, remove as much of the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"unattached dystrophic nail as possible. Place the piece of clipped nail plate\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"in formalin jar and send to pathology for fungal stain (PAS). Treatment should\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"only be initiated if stain is positive for fungal elements. Fungal culture is\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"NOT recommended.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cure is unlikely if the entire nail is involved, or if a portion of the lunula\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"is involved. Sometimes after treatment the fungus is cured, but the nail\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"still does not appear normal because once nail dystrophy occurs, that\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"is not reversible.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"Systemic therapy is most likely to achieve a cure, especially with more nail\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"involvement. If <25% involvement topical therapy may be considered. If\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \">50-75% involvement systemic therapy should be considered.\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Terbinafine works about 70% of the time to cure the fungus, and reinfection\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"is common, so many patients will need to do more than one course\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"of treatment.  Fluconazole pulse dosing response rate is approximately 50%.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"May consider retreatment with oral therapy after one year.\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Recommend Dermatology Consult for retreatment after failure of 2 courses of\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"terbinafine or fluconazole.\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"Oral Treatment:\", \"Header\": 1}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Toenails take 12-18 months to grow out completely, so improvement should not\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"be expected to be observed for at least 6-9 months.  Continued improvement can\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"be experienced following treatment completion.\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1043,
    "fields": {
      "name": "ORZID3 GMENU TINEA VERSICOLOR",
      "term": null,
      "displaytext": "Tinea Versicolor (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ketoconazole 2% cream top qday for 14 days\", \"Text\": \"Ketoconazole 2% cream to affected area QDAY for 14 days ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ketoconazole 2% cream top qday for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 1% cream topical qday for 14 days\", \"Text\": \"Terbinafine 1% cream apply to affected area QDAY for 7 days ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Terbinafine 1% cream topical qday for 14 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Selenium lotion 2.5% leave on for 10min then rinse qday for 7 days\", \"Text\": \"Selenium sulfide lotion 2.5% apply to affected area, leave on for 10\", \"Mnemonic\": \"8a\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Selenium lotion 2.5% leave on for 10min then rinse qday for 7 da Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 28, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 300 MG PO weekly for 2 weeks ($2.20/day) [R\", \"Text\": \"Fluconazole 300 MG PO weekly for 2 weeks ($2.20/day) [R\", \"Mnemonic\": \"10a\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fluconazole 300 MG PO weekly for 2 weeks ($2.20/day) [R Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 31, \"Column\": 1, \"Item\": 258, \"DisplayText\": \"References\", \"Text\": \"References\", \"Mnemonic\": \"12\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"TINEA VERSICOLOR\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Pityriasis or tinea versicolor is a common superficial fungal infection.\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Patients often present with erythematous, hypo- or hyperpigmented patches,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"usually on the trunk or extremities.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Topical antifungals can be used for limited disease.  For disease that involves\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"nails or does not respond to topical therapy, use oral antifungals.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Oily skin products or exposure to hot environments often lead to recurrences.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Return of normal skin color often takes several weeks after the treatment\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"course is finished.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment limited disease:\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"minutes, then rinse/shower thoroughly QDAY for 7 days ($) [M]\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Treatment extensive disease:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Up-to-date\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"Sanford keyword: Tinea\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"AK Gupta AK, J Cutan Med Surg. 2014, 18:79\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1044,
    "fields": {
      "name": "ORZID3 GMENU TIX-CIL EUA",
      "term": null,
      "displaytext": "Tix-cil",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"Tix-Cil (Tixagevimab plus cilgavimab)\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"On December 8, 2021 the FDA issued an EUA for AstraZeneca's Evusheld\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"(tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"(prevention) of COVID-19 in certain adult and pediatric patients.\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"The product is only authorized for those individuals who are not currently\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"infected with SARS-CoV-2 virus and who have not recently been exposed to an\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"individual infected with SARS-CoV-2. The authorization also requires that\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"individuals either have:\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"-moderate to severely compromised immune systems due to a medical condition or\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"or due to taking immunosuppressive medications or treatments and may not\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"mount an adequate immune response to COVID-19 vaccination (examples of such\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"medical conditions or treatments can be found in the fact sheet for health\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"care providers) [see link top of page]\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"[ OR ]\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"-a history of severe adverse reactions to a COVID-19 vaccine and/or component(s)\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"of those vaccines, therefore vaccination with an available COVID-19 vaccine,\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"according to the approved or authorized schedule, is not recommended.\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"-One dose of Evusheld, administered as two separate consecutive intramuscular\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"injections (one injection per monoclonal antibody, given in immediate\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"succession), reduces the risk of developing COVID-19 for six months.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"-Evusheld is NOT authorized for the treatment of COVID-19 or for post-exposure\"}, {\"Row\": 50, \"Column\": 1, \"Text\": \"prevention of COVID-19.\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"-Pre-exposure prevention with Evusheld is not a substitute for vaccination in\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"in individuals for whom COVID-19 vaccination is recommended.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Monoclonal antibodies are laboratory-made proteins that mimic the immune\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"system's ability to fight off harmful pathogens such as viruses. Tixagevimab and\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"cilgavimab are long-acting monoclonal antibodies that are specifically directed\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"against the spike protein of SARS-CoV-2, designed to block the virus' attachment\"}, {\"Row\": 26, \"Column\": 1, \"Text\": \"and entry into human cells. Tigagevimab and cilgavimab bind to different,\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"non-overlapping sites on the spike protein of the virus.\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"Emergency Use Authorization (EUA): Tixagevimab plus Cilgavimab (EVUSHELD)\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"Tixagevimab plus Cilgavimab combination is available via FDA Emergency Use\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Authorization (EUA) for pre-exposure prophylaxis for COVID-19 for patients\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"that meet specific criteria. They are not FDA approved drugs.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"There are no adequate, approved and available alternatives to Evusheld\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"for the pre-exposure prevention of COVID-19 in the authorized population.\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"-In patients with prior COVID-19 vaccination, at least 2 weeks are required\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"between the vaccination and the administration of Evusheld.\"}, {\"Row\": 56, \"Column\": 1, \"Text\": \"**PBM EUA Criteria to be completed on web link:\", \"Header\": 1}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Answer to ALL of the following statements should be YES for administration:\", \"Header\": 1}, {\"Row\": 60, \"Column\": 1, \"Text\": \"2)Patient has no known recent exposure to an individual infected with SARS-CoV-2\"}, {\"Row\": 58, \"Column\": 1, \"Text\": \"1)Patient has no symptoms consistent with COVID-19, or if any symptoms, has a\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"a documented negative SARS-CoV-2 test within 72 hours prior to administration\"}, {\"Row\": 61, \"Column\": 1, \"Text\": \"3)Patient has moderate to severe immunocompromise per the EUA definition or\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"a documented medical contraindication to vaccination. (Note: refusal to\"}, {\"Row\": 63, \"Column\": 1, \"Text\": \"be vaccinated does not constitute a contraindication for the purpose of\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"eligibility for this drug.)\"}, {\"Row\": 65, \"Column\": 1, \"Text\": \"4)In patients with prior COVID-19 vaccination (e.g. immunosuppressed) at least,\"}, {\"Row\": 66, \"Column\": 1, \"Text\": \"2 weeks have passed since the last dose was given (if no prior vaccination\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"answer YES)\"}, {\"Row\": 68, \"Column\": 1, \"Text\": \"5)The Fact Sheet for patients/caregivers has been made available to the patient/\"}, {\"Row\": 69, \"Column\": 1, \"Text\": \"caregiver prior to administration of this drug\"}, {\"Row\": 71, \"Column\": 1, \"Text\": \"Note: Our staff is identifying the highest risk patients from our database\", \"Header\": 1}, {\"Row\": 72, \"Column\": 1, \"Text\": \"for this medication. We will contact patients who are currently eligible\", \"Header\": 1}, {\"Row\": 73, \"Column\": 1, \"Text\": \"for the limited doses currently allocated.\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Patient Criteria for Use:\", \"Header\": 1}, {\"Row\": 44, \"Column\": 1, \"Text\": \"Important information:\", \"Header\": 1}, {\"Row\": 80, \"Column\": 1, \"Text\": \"1)Providers approved to order: Dr. Klein (oncology) and ID Staff only\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"2)Second dose is not being scheduled/addressed at this time. We will pull\"}, {\"Row\": 82, \"Column\": 1, \"Text\": \"list of patients and assess the overall situation close to 6 month timeframe.\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"NOTES:\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Link to complete EUA documentation:\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Item\": 3113, \"DisplayText\": \"LINK EUA PROVIDER TO FILL OUT\", \"Text\": \"[Click here] Pharmacist to complete EUA prior to dispensing medication\", \"Mnemonic\": \"04\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Printable Fact Sheets for EUA:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Evusheld\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Tix-Cil\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Minneapolis VAHCS is using the Minnesota Health Department's framework\"}, {\"Row\": 75, \"Column\": 1, \"Text\": \"for allocation of the medication. Our ID physicians shared in the development\"}, {\"Row\": 76, \"Column\": 1, \"Text\": \"of the plan and provides for consistency in the community.\"}, {\"Row\": 83, \"Column\": 1, \"Text\": \"3)Administration in separate area from where COVID positive patients being seen\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"4)Pharmacy dispense in original kit to clinic (decrease waste/short expiration)\"}, {\"Row\": 85, \"Column\": 1, \"Text\": \"5)Separate clinic created for patient appointments (23537 MSP 3V INJECTION)\"}, {\"Row\": 77, \"Column\": 1, \"Text\": \"[Click here] Minnesota Dept of Health-Prioritization of patients\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1045,
    "fields": {
      "name": "ORZID3 GMENU TIX-CIL Provider Andrea S. Clinics",
      "term": null,
      "displaytext": "Tix-Cil Provider Orders  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Emergency Use Authorization (EUA): Tixagevimab plus Cilgavimab (EVUSHELD)\", \"Header\": 1}, {\"Row\": 9, \"Column\": 1, \"Text\": \"Tixagevimab plus Cilgavimab combination is available via FDA Emergency Use\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Authorization (EUA) for pre-exposure prophylaxis for COVID-19 for patients\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"that meet specific criteria. They are not FDA approved drugs.\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Printable Fact Sheets for Evusheld EUA:\", \"Header\": 1}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Minneapolis VAHCS is following the Minnesota Health Department's framework\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"for allocation of Evusheld. Our ID physicians shared in the development\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Nursing pre-screening questions prior to Evusheld administration:\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"(Note: COVID-19 vaccination is not required to receive Evusheld)\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"-No current symptoms consistent with COVID-19 or recent exposure (last 10 days)\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"-No hypersensitivity to any COVID-19 vaccines, polysorbate 80, or polyethylene\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"glycol (PEG)\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"-At least 2 weeks have passed since last dose of COVID-19 vaccine\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"to patient/caregiver prior to administration\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"-Nursing will provide hardcopy of Evusheld Patient/Caregiver Fact Sheet\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"ii) If provider would like to provide patient with Evusheld fact sheet:\", \"Header\": 1}, {\"Row\": 61, \"Column\": 1, \"Text\": \"iii) Place medication order, nurse text order and RTC order:\", \"Header\": 1}, {\"Row\": 52, \"Column\": 1, \"Text\": \"*** IF patient meets criteria for Evusheld:\", \"Header\": 1}, {\"Row\": 54, \"Column\": 1, \"Text\": \"i) Provider to document discussed Evusheld with patient in CPRS\", \"Header\": 1}, {\"Row\": 55, \"Column\": 1, \"Text\": \"(e.g. progress note, patient contact note, addendum)\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"of the document and allows for consistency with our local healthcare community.\"}, {\"Row\": 62, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Evusheld medication orders + RTC Appt\", \"Text\": \"[Click here] Evusheld medication order + Nurse Text Order + RTC Appointment\", \"Mnemonic\": \"12\"}, {\"Row\": 59, \"Column\": 1, \"Text\": \"-or- patient may access information on the internet at Evusheld.com\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Evusheld_Allocation\", \"Text\": \"[Click here] Fact Sheet for Patients/Caregivers EUA Evusheld\", \"Mnemonic\": \"4\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Evusheld_Provider\", \"Text\": \"[Click here] Fact Sheet for Health Care Providers EUA Evusheld *NEW 10/22\", \"Mnemonic\": \"6\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Evusheld_Allocation\", \"Text\": \"[Click here] Prioritization of patients (See pages 7-8)\", \"Mnemonic\": \"8\"}, {\"Row\": 58, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Evusheld_Allocation\", \"Text\": \"[Click here to print] Fact Sheet for Patients/Caregivers EUA Evusheld\", \"Mnemonic\": \"10\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Prioritization/eligibility of patients:\", \"Header\": 1}, {\"Row\": 50, \"Column\": 1, \"Text\": \"__________________________________________________________________\", \"Header\": 1}, {\"Row\": 3, \"Column\": 1, \"Text\": \"This menu for ordering Evusheld may be used by providers in these clinics:\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cardiology, Endocrine, GI, Hem/Onc, Infectious Disease, MRTC, Pulmonary,\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Renal, Rheumatology and Neurology.\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"(...because of Evusheld administration clinic assignment.)\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Evusheld is NOT authorized for the treatment of COVID-19 or for post-exposure\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"prevention of COVID-19.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Link to complete EUA documentation:\", \"Header\": 1}, {\"Row\": 26, \"Column\": 1, \"Item\": 3114, \"DisplayText\": \"LINK EUA PROVIDER TO FILL OUT\", \"Text\": \"[Click here] Pharmacist to complete EUA prior to dispensing medication\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Patients who have received a COVID-19 vaccine, Evusheld should be administered\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"at least two weeks after vaccination, per Evusheld EUA.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Note: COVID-19 vaccine not required to receive Evusheld.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Evusheld and COVID-19 vaccine:\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"Per CDC: Patients who previously received antibody products as part of COVID-19\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"vaccinated at any time.\"}, {\"Row\": 47, \"Column\": 1, \"Text\": \"Evusheld administration notes:\", \"Header\": 1}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Evusheld administered as 2 IM injections at one clinic visit, patient to\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"remain in clinic for 1 hour after administration, current redosing q6months\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"Evusheld REPEAT dose q6 months orders\", \"Header\": 1}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tix-Cil med + nursing instructions + RTC order\", \"Text\": \"[Click here] Orders for Evusheld REPEAT dose q6months\", \"Mnemonic\": \"14\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"New Patients (See below for REPEAT q6month dose orders)\", \"Header\": 1}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1046,
    "fields": {
      "name": "ORZID3 GMENU TOXIC SHOCK SYNDROME",
      "term": null,
      "displaytext": "Toxic Shock Syndrome (Outpatient) ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TOXIC SHOCK SYNDROME\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to Inpatient Antimicrobial CDSS.\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1047,
    "fields": {
      "name": "ORZID3 GMENU TRAVEL MEDICINE",
      "term": null,
      "displaytext": "Travel Medications ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 3, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin PO 500mg BID PRN 3ds\", \"Text\": \"Ciprofloxacin PO 500mg BID PRN\", \"Mnemonic\": \"2\"}, {\"Row\": 4, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin PO 500mg QDAY PRN 3DS\", \"Text\": \"Azithromycin PO 500mg QDAY PRN\", \"Mnemonic\": \"4\"}, {\"Row\": 5, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Loperamide 2-4mg QID PRN\", \"Text\": \"Loperamide 2-4mg QID PRN\", \"Mnemonic\": \"6\"}, {\"Row\": 6, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bismuth Subsalicylate 524mg QID PRN\", \"Text\": \"Bismuth Subsalicylate 524mg QID PRN\", \"Mnemonic\": \"8\"}, {\"Row\": 8, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Bismuth Subsalicylate 524mg QID\", \"Text\": \"Bismuth Subsalicylate 524mg QID\", \"Mnemonic\": \"10\"}, {\"Row\": 11, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Cholera vaccine po 100ML one dose\", \"Text\": \"Cholera Vaccine ONCE\", \"Mnemonic\": \"12\"}, {\"Row\": 12, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A VACCINE 2 DOSE SERIES\", \"Text\": \"Hepatitis A 2 Dose Series\", \"Mnemonic\": \"14\"}, {\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis B 3 Dose Series\", \"Mnemonic\": \"16\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE\", \"Text\": \"Hepatitis B 4 Dose High Dose Series (for immunocompromised patients)\", \"Mnemonic\": \"18\"}, {\"Row\": 15, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE 3 DOSE SERIES\", \"Text\": \"Hepatitis A/B (Twinrix) 3 Dose Series\", \"Mnemonic\": \"20\"}, {\"Row\": 16, \"Column\": 1, \"Item\": null, \"DisplayText\": \"HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES\", \"Text\": \"Hepatitis A/B (Twinrix) Accelerated 4 Dose Series\", \"Mnemonic\": \"22\"}, {\"Row\": 17, \"Column\": 1, \"Item\": null, \"DisplayText\": \"ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES\", \"Text\": \"Herpes zoster (Shingrix) 2 dose series\", \"Mnemonic\": \"24\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"JAPANESE ENCEPHALITIS VIRUS VACC 2 DOSE SERIES\", \"Text\": \"Japanese Encephalitis Virus Vaccine 2 Dose Series\", \"Mnemonic\": \"28\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE\", \"Text\": \"Measles, Mumps, Rubella Vaccine ONCE\", \"Mnemonic\": \"30\"}, {\"Row\": 21, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES\", \"Text\": \"Measles, Mumps, Rubella Vaccine 2 Dose Series\", \"Mnemonic\": \"32\"}, {\"Row\": 22, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL B VACCINE 2 DOSE SERIES\", \"Text\": \"Meningococcal B Vaccine 2 Dose Series\", \"Mnemonic\": \"34\"}, {\"Row\": 23, \"Column\": 1, \"Item\": null, \"DisplayText\": \"MENINGOCOCCAL OLIGOSACCHARIDE CONJ (MenACWY) 2 DOSE SERIES\", \"Text\": \"Meningococcal Conjugate (MenACWY) Vaccine Booster\", \"Mnemonic\": \"36\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE\", \"Text\": \"Pneumococcal 23-valent vaccine ONCE\", \"Mnemonic\": \"40\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"POLIOVIRUS VACCINE ONCE\", \"Text\": \"Poliovirus Vaccine ONCE\", \"Mnemonic\": \"42\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"POLIOVIRUS VACCINE 3 DOSE SERIES\", \"Text\": \"Poliovirus Vaccine 3 Dose Series\", \"Mnemonic\": \"44\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RABIES VACCINE 2 DOSE SERIES\", \"Text\": \"Rabies Pre-exposure Vaccine 2 Dose Series\", \"Mnemonic\": \"47\"}, {\"Row\": 31, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RABIES BOOSTER VACCINE ONE DOSE\", \"Text\": \"Rabies Pre-exposure Vaccine Booster dose\", \"Mnemonic\": \"48\"}, {\"Row\": 32, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TETANUS/DIPHTHERIA VACCINE ONE DOSE\", \"Text\": \"Tetanus Diphtheria Vaccine booster dose\", \"Mnemonic\": \"50\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE\", \"Text\": \"Tetanus/Diphtheria/Pertussis (TDAP) Vaccine booster dose\", \"Mnemonic\": \"51\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"TYPHOID VACCINE INJ ONCE\", \"Text\": \"Typhoid Vaccine Inj ONCE\", \"Mnemonic\": \"54\"}, {\"Row\": 38, \"Column\": 1, \"Item\": null, \"DisplayText\": \"YELLOW FEVER VACCINE ONE DOSE\", \"Text\": \"Yellow Fever Vaccine ONCE\", \"Mnemonic\": \"58\"}, {\"Row\": 41, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Atovaquone/Proguanil 1Tab PO QDAY 24DS\", \"Text\": \"Atovaquone/Proguanil 1Tab PO QDAY 24DS\", \"Mnemonic\": \"60\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chloroquine 500mg QWEEK\", \"Text\": \"Chloroquine 500mg PO QWEEK 56DS\", \"Mnemonic\": \"62\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Doxycycline 100mg QDAY 30DS\", \"Text\": \"Doxycycline 100mg PO QDAY 30DS\", \"Mnemonic\": \"64\"}, {\"Row\": 44, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Mefloquine 250mg QWEEK 56DS\", \"Text\": \"Mefloquine 250mg PO QWEEK 56DS\", \"Mnemonic\": \"66\"}, {\"Row\": 48, \"Column\": 1, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Pre-exposure prophylaxis recommendations\", \"Mnemonic\": \"70\"}, {\"Row\": 47, \"Column\": 1, \"Item\": 704, \"DisplayText\": \"Rabies Post-exposure Prophylaxis\", \"Text\": \"Post-exposure prophylaxis recommendations\", \"Mnemonic\": \"68\"}, {\"Row\": 1, \"Column\": 1, \"Text\": \"Travelers Diarrhea\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Prevention:\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Vaccines - Administered in Clinic\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Malaria Prevention\", \"Header\": 1}, {\"Row\": 46, \"Column\": 1, \"Text\": \"Rabies\", \"Header\": 1}, {\"Row\": 29, \"Column\": 1, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Rabies Pre-exposure Prophylaxis Recommendations\", \"Mnemonic\": \"46\"}, {\"Row\": 28, \"Column\": 1, \"Item\": 704, \"DisplayText\": \"Rabies Post-exposure Prophylaxis\", \"Text\": \"Rabies Post-exposure Prophylaxis Recommendations\", \"Mnemonic\": \"45\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Treatment:\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tick-Borne Encephalitis Vaccine Once\", \"Text\": \"Tick-Borne Encephalitis Vaccine ONCE\", \"Mnemonic\": \"52\"}, {\"Row\": 35, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Tick-Borne Encephalitis Vaccine 3 Dose Series\", \"Text\": \"Tick-Borne Encephalitis Vaccine 3 Dose Series\", \"Mnemonic\": \"53\"}, {\"Row\": 18, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Japanese Encephalitis Virus Vaccine 0.5ml ONCE\", \"Text\": \"Japanese Encephalitis Virus Vaccine Booster\", \"Mnemonic\": \"27\"}, {\"Row\": 24, \"Column\": 1, \"Item\": null, \"DisplayText\": \"PNEUMOCOCCAL 20-VALENT VACCINE ONE DOSE\", \"Text\": \"Pneumococcal 20-valent (PCV20) vaccine ONCE\", \"Mnemonic\": \"38\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Typhoid Vaccine 1 CAP PO Every Other Day for 4 doses\", \"Text\": \"Typhoid Vaccine PO every other day for 4 doses (Opt Med)\", \"Mnemonic\": \"56\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1048,
    "fields": {
      "name": "ORZID3 GMENU TRAVELER DIARRHEA",
      "term": null,
      "displaytext": "Traveler's diarrhea",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Text\": \"Azithromycin 1000 mg PO once ($) [M]\", \"Mnemonic\": \"4a\"}, {\"Row\": 27, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 1000 mg PO once ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"4b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Text\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M]\", \"Mnemonic\": \"6a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Azithromycin 500 mg PO QDAY for 3 days ($) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 33, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 34, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 36, \"Column\": 1, \"Item\": null, \"DisplayText\": \"RIFAXAMIN 3DS 200MG TID\", \"Text\": \"Rifaximin 200 mg TID for 3 days ($$) [M]\", \"Mnemonic\": \"10a\"}, {\"Row\": 37, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Rifaximin 200 mg TID for 3 days ($$) [M] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TRAVELER'S DIARRHEA\", \"Header\": 1}, {\"Row\": 4, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Acute non-bloody diarrhea (< 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Most cases are mild and self-limited. Reserve antimicrobial therapy for\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"patients who have severe traveler's diarrhea: pus, or mucus in stool, fever, or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"diarrhea that is incapacitating.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Bloody diarrhea\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"therapy and antimotility agents are not recommended in most patients with bloody\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"diarrhea due to an increased risk of hemolytic uremic syndrome when using these\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"agents. Obtain a stool sample for enteric pathogen PCR testing and reserve\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"antimicrobial and antimotility agent treatment until results are known. Enteric\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"pathogen PCR testing results are reported within 2 hours between 7am and 11pm.\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"For more information on when an antimicrobial is indicated or if the patient has\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"severe/life threatening diarrhea or is immunocompromised, contact Infectious\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Primary treatment\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Hydration and electrolyte replacement\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Empiric antimicrobial treatment for non-bloody severe acute diarrhea\", \"Header\": 1}, {\"Row\": 28, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"Alternative\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Subacute diarrhea (>/= 14 days of symptoms)\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Primary treatment is hydration and electrolyte replacement. Empirical\"}, {\"Row\": 42, \"Column\": 1, \"Text\": \"antimicrobial therapy is not indicated. Attempt to make a diagnosis with, for\"}, {\"Row\": 43, \"Column\": 1, \"Text\": \"example, enteric pathogen PCR testing, Clostridium difficile testing in those\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"who used a PPI or were treated with antimicrobials in the last 8-12 weeks, and\"}, {\"Row\": 45, \"Column\": 1, \"Text\": \"endoscopy. If bloody diarrhea, fever, or abdominal pain/tenderness is present\"}, {\"Row\": 46, \"Column\": 1, \"Text\": \"the case should be evaluated by Gastroenterology and/or Infectious Diseases.\"}, {\"Row\": 49, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 51, \"Column\": 1, \"Text\": \"Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Sanford keyword: Travelers Diarrhea\"}, {\"Row\": 53, \"Column\": 1, \"Text\": \"Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80\"}, {\"Row\": 54, \"Column\": 1, \"Text\": \"Up-to-Date article: Travelers' diarrhea: Clinical manifestations, diagnosis, and\"}, {\"Row\": 55, \"Column\": 1, \"Text\": \"treatment\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1049,
    "fields": {
      "name": "ORZID3 GMENU TRICHOMONAS VAGINITIS",
      "term": null,
      "displaytext": "Trichomonas vaginitis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 1026, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"4\"}, {\"Row\": 19, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days\", \"Text\": \"Metronidazole 500 mg PO q12h for 7 days ($) [DI]\", \"Mnemonic\": \"6a\"}, {\"Row\": 20, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"6b\"}, {\"Row\": 25, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days\", \"Text\": \"Metronidazole 500 mg PO q12h for 7 days ($) [DI]\", \"Mnemonic\": \"8a\"}, {\"Row\": 26, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 500mg po bid for 7 days Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 29, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 2 gm PO qday for 7 days ($) [DI]\", \"Text\": \"Metronidazole 2 gm PO q24h for 7 days ($) [DI]\", \"Mnemonic\": \"10a\"}, {\"Row\": 30, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Metronidazole 2 gm PO qday for 7 days ($) [DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TRICHOMONAS VAGINITIS AND URETHRITIS\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"Male sexual partners of women with trichomonas vaginitis will not have symptoms\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"but should be treated to prevent recurrent vaginitis in the female sexual\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"partner.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Diagnosis\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"The discharge is purulent, malodorous, and thin. The vaginal pH is greater\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"than 4.5. Nucleic Acid amplification test (NAAT) for trichomonas has improved\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"sensitivities and specifities compared to wet mount.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Treatment of Initial Episode in Men and Woman\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Pregnant women with trichomonas infection may be treated with metronidazole\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"during any trimester.\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"Treatment of Veteran Male Sex Partners (Non-Veteran Sex Partners Should Be\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"Referred to Non-VA Care)\", \"Header\": 1}, {\"Row\": 24, \"Column\": 1, \"Text\": \"1st failure\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"2nd failure\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"3rd failure\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Consult Infectious Disease\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"________________________________________________________________________\", \"Header\": 1}, {\"Row\": 37, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Sanford keyword: Trichomoniasis\"}, {\"Row\": 39, \"Column\": 1, \"Text\": \"Mandell chapter: Vulvovaginitis and cervicitis\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"CDC STD Treatment Guidelines: MMWR (2021) 70.4\"}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Up-To-Date article: Trichomoniasis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1050,
    "fields": {
      "name": "ORZID3 GMENU TUBERCULOSIS",
      "term": null,
      "displaytext": "Tuberculosis (Outpatient)",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"TUBERCULOSIS\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Evaluation and management are complex.  Consult Pulmonary and/or Infectious\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"Diseases.\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Patients with suspected or proven pulmonary tuberculosis must be in respiratory\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"isolation.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"References:\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"Centers for Disease Control (CDC). Tuberculosis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1051,
    "fields": {
      "name": "ORZID3 GMENU TYPHLITIS",
      "term": null,
      "displaytext": "Neutropenic enterocolitis (Typhlitis) - Outpatient  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"NEUTROPENIC ENTEROCOLITIS (TYPHLITIS)\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Refer to the Inpatient Antimicrobial CDSS\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1052,
    "fields": {
      "name": "ORZID3 GMENU UNCOMPLICATED CYSTITIS",
      "term": null,
      "displaytext": "Uncomplicated Cystitis (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 801, \"DisplayText\": \"Complicated Cystitis (Outpatient)\", \"Text\": \"Complicated cystitis\", \"Mnemonic\": \"4\"}, {\"Row\": 26, \"Column\": 1, \"Item\": 740, \"DisplayText\": \"Asymptomatic bacteriuria (Outpatient)\", \"Text\": \"Asymptomatic bacteriuria\", \"Mnemonic\": \"6\"}, {\"Row\": 42, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 7DS 100 MG PO BID\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 7 days\", \"Mnemonic\": \"8a\"}, {\"Row\": 43, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 7DS 100 MG PO BID Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"8b\"}, {\"Row\": 45, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days\", \"Mnemonic\": \"10a\"}, {\"Row\": 46, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"10b\"}, {\"Row\": 49, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days\", \"Mnemonic\": \"12a\"}, {\"Row\": 50, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"12b\"}, {\"Row\": 53, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"14\"}, {\"Row\": 54, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 5 days\", \"Mnemonic\": \"16a\"}, {\"Row\": 55, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"16b\"}, {\"Row\": 59, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O]\", \"Text\": \"Nitrofurantoin SA 100 mg PO q12h ($) [R,O], CrCl =/>30 mL/min, for 5 days\", \"Mnemonic\": \"18a\"}, {\"Row\": 61, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO BID for 5 days ($) [R,O] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"18b\"}, {\"Row\": 63, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 3 days\", \"Mnemonic\": \"20a\"}, {\"Row\": 65, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R, Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"20b\"}, {\"Row\": 68, \"Column\": 1, \"Item\": null, \"DisplayText\": \"FOSFOMYCIN 3GM SACHET PO X 1 DOSE\", \"Text\": \"Fosfomycin 3GM sachet PO ($$)[M] once\", \"Mnemonic\": \"22a\"}, {\"Row\": 69, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"22b\"}, {\"Row\": 71, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]\", \"Text\": \"Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 5 days\", \"Mnemonic\": \"24a\"}, {\"Row\": 72, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"24b\"}, {\"Row\": 75, \"Column\": 1, \"Item\": 92, \"DisplayText\": \"Beta-lactam Allergy Assessment\", \"Text\": \"Assessment of Beta-lactam Reaction\", \"Mnemonic\": \"26\"}, {\"Row\": 76, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]\", \"Text\": \"Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 3 days\", \"Mnemonic\": \"28a\"}, {\"Row\": 77, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI] Non-VA\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"28b\"}, {\"Row\": 82, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]\", \"Mnemonic\": \"30a\"}, {\"Row\": 83, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1/2 SS tablet PO q24h ($) [R,DI]\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"30b\"}, {\"Row\": 85, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]\", \"Text\": \"Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus ($) [R,DI]\", \"Mnemonic\": \"32a\"}, {\"Row\": 86, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Trimethoprim/sulfamethoxazole 1 SS tablet PO once post-coitus (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"32b\"}, {\"Row\": 88, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min\", \"Text\": \"Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min\", \"Mnemonic\": \"34a\"}, {\"Row\": 89, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO qhs ($) [R,O], CrCl =/>30 mL/min (NOon-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"34b\"}, {\"Row\": 91, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O], CrCl =/>30 mL/min\", \"Text\": \"Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O], CrCl =/>30 mL/min\", \"Mnemonic\": \"36a\"}, {\"Row\": 92, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O] (Non-VA)\", \"Text\": \"Non-VA order for above\", \"Mnemonic\": \"36b\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"UNCOMPLICATED CYSTITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Uncomplicated cystitis is defined as symptomatic bladder inflammation caused by\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"bacterial infections in people with structurally and neurogenically normal\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"urinary tract. Symptoms usually include dysuria, lower abdominal pain, and\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"urgency. Most cases of uncomplicated cystitis occur in pre-menopausal,\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"non-pregnant, sexually active young women and is commonly associated with\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Enterobacteriaceae (e.g. E. coli and Klebsiella sp.) and occasionally S.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"saprophyticus.\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cystitis is considered complicated when it occurs in pregnant women, people\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"with abnormalities of the urinary tract, immunocompromised individuals and those\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"who have persistent, recurrent, or relapsed infections, or treatment failure are\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"considered complicated. Diagnosis and treatment of complicated cystitis is\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"discussed elsewhere.\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"The presence of pyuria (>7 wbc/hpf) or positive leukocyte esterase, urine\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"nitrate, or urine bacteria is not a sufficient indication for antibiotic\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"treatment. Asymptomatic bacteriuria occurs in patients who have bacteria in the\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"urine with no symptoms of cystitis, and with few exceptions, should not be\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"treated. Diagnosis and treatment of asymptomatic bacteriuria is further\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"discussed elsewhere:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"The prevalence of antimicrobial resistance among bacteria associated with\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"uncomplicated cystitis has increased. A urine culture should be considered in a\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"patient who has had substantial involvement with healthcare or exposure to\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"antimicrobials. If a patient fails to respond to therapy, a urine culture should\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"be done.\"}, {\"Row\": 34, \"Column\": 1, \"Text\": \"For women with recurrent uncomplicated cystitis (2 episodes in 6 months or 3 or\"}, {\"Row\": 35, \"Column\": 1, \"Text\": \"more episodes in 12 months), suppressive therapy is indicated after infection is\"}, {\"Row\": 36, \"Column\": 1, \"Text\": \"eradicated and non-antimicrobial prevention methods, such as increased fluid\"}, {\"Row\": 37, \"Column\": 1, \"Text\": \"intake and avoiding spermicide, are considered. Consider consulting Women's\"}, {\"Row\": 38, \"Column\": 1, \"Text\": \"Clinic for treatment recommendations.\"}, {\"Row\": 40, \"Column\": 1, \"Text\": \"Men, empirical treatment\", \"Header\": 1}, {\"Row\": 41, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 44, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 48, \"Column\": 1, \"Text\": \"Primary alternative:\"}, {\"Row\": 52, \"Column\": 1, \"Text\": \"Secondary alternative:\"}, {\"Row\": 57, \"Column\": 1, \"Text\": \"Women, empirical treatment\", \"Header\": 1}, {\"Row\": 58, \"Column\": 1, \"Text\": \"Preferred:\"}, {\"Row\": 60, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 62, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 64, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 67, \"Column\": 1, \"Text\": \"Primary alternatives:\"}, {\"Row\": 70, \"Column\": 1, \"Text\": \"<OR>\"}, {\"Row\": 74, \"Column\": 1, \"Text\": \"Secondary alternative:\"}, {\"Row\": 79, \"Column\": 1, \"Text\": \"Women, suppression\", \"Header\": 1}, {\"Row\": 80, \"Column\": 1, \"Text\": \"*Avoid trimethoprim/sulfamethoxazole in the first and third trimesters\"}, {\"Row\": 81, \"Column\": 1, \"Text\": \"*Avoid nitrofurantoin in the third trimester\"}, {\"Row\": 84, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 87, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 90, \"Column\": 1, \"Text\": \"< OR >\"}, {\"Row\": 93, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 96, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 97, \"Column\": 1, \"Text\": \"Drekonja et al., JAMA, 2021, 326(4)324-331\"}, {\"Row\": 98, \"Column\": 1, \"Text\": \"Gupta et al., Clinical Infectious Diseases, 2011, 52(5)e103-20\"}, {\"Row\": 99, \"Column\": 1, \"Text\": \"Mandell chapter: Urinary tract infections\"}, {\"Row\": 100, \"Column\": 1, \"Text\": \"Sanford keyword: UTI, Acute, Uncomplicated, Adult, Female\"}, {\"Row\": 101, \"Column\": 1, \"Text\": \"Sanford keyword: UTI, Adult, Male\"}, {\"Row\": 102, \"Column\": 1, \"Text\": \"Sanford keyword: Prevention of Recurrent UTI, Female\"}, {\"Row\": 103, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute simple cystitis in men\"}, {\"Row\": 104, \"Column\": 1, \"Text\": \"Up-To-Date article: Acute simple cystitis in women\"}, {\"Row\": 105, \"Column\": 1, \"Text\": \"Up-To-Date article: Recurrent simple cystitis in women\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1053,
    "fields": {
      "name": "ORZID3 GMENU URETHRITIS ASSOC STD",
      "term": null,
      "displaytext": "Urethritis associated with sexually transmitted disease (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Chlamydia/GC Urine NAAT\", \"Text\": \"Chlamydia & GC PCR/LCR test\", \"Mnemonic\": \"4\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 1009, \"DisplayText\": \"Recurrent or persistent urethritis (Outpatient)\", \"Text\": \"Treatment of recurrent or persistent urethritis\", \"Mnemonic\": \"6\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 785, \"DisplayText\": \"Chlamydia urethritis (Outpatient)\", \"Text\": \"Treatment for chlamydial or non-gonococcal urethritis\", \"Mnemonic\": \"8\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"URETHRITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES\", \"Header\": 1}, {\"Row\": 7, \"Column\": 1, \"Text\": \"The main differential in a person who presents with dysuria is between cystitis\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"and urethritis. Bacterial urethritis is more likely in people with mild\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"dysuria, onset over a few days, or recent sexual contact.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"The two most common sexually transmitted urethritis pathogens are Neisseria\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"gonorrhoeae and Chlamydia trachomatis. Nucleic acid amplification tests for\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"these pathogens are more sensitive than culture and should be used for patients\"}, {\"Row\": 13, \"Column\": 1, \"Text\": \"at risk for sexually transmitted urethritis.\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"For patients who have recently been treated for urethritis\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Initial treatment of patients and sex partners\", \"Header\": 1}, {\"Row\": 20, \"Column\": 1, \"Text\": \"Patients and partners are often infected with both N. gonorrhoeae and C.\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"trachomatis.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 28, \"Column\": 1, \"Text\": \"Mandell chapter: Urethritis\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis\"}, {\"Row\": 30, \"Column\": 1, \"Text\": \"Up-To-Date article: Urethritis in men\"}, {\"Row\": 5, \"Column\": 1, \"Item\": 1026, \"DisplayText\": \"Sexually Transmitted Infections (STI) HIV Exposure\", \"Text\": \"Sexually Transmitted Infections and HIV Exposure [CLICK HERE]\", \"Mnemonic\": \"3\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 854, \"DisplayText\": \"Neisseria gonorrhoeae STI\", \"Text\": \"Treatment for gonococcal infections\", \"Mnemonic\": \"10\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1054,
    "fields": {
      "name": "ORZID3 GMENU UROLOGY CIPRO IN CLINIC",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 13, \"Column\": 1, \"Item\": null, \"DisplayText\": \"Urology Order: ciprofloxacin 500mg give in clinic and nurse text order\", \"Text\": \"Ciprofloxacin 500 mg x1 orally ($0.10/day) [R,DI] give in clinic and nurse text\", \"Mnemonic\": \"10\"}, {\"Row\": 4, \"Column\": 1, \"Text\": \"In cases where prolonged catheterization follows a procedure, antimicrobial\"}, {\"Row\": 5, \"Column\": 1, \"Text\": \"therapy at the time of catheter removal may be considered, since\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"colonization has likely occurred. The recommendation to treat empirically\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"depends on host factors, the duration of catheterization, and the\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"potential of morbidity or mortality.\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"Single dose of fluoroquinolone may significantly lower incidence\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"of bacteriuria for patients undergoing ureteroscopy for stone removal.\"}, {\"Row\": 2, \"Column\": 1, \"Text\": \"Urologic Clinic Procedures\", \"Header\": 1}, {\"Row\": 15, \"Column\": 1, \"Text\": \"References\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"(2008) (Reviewed and validity confirmed 2011, updated February 2012)\"}, {\"Row\": 18, \"Column\": 1, \"Text\": \"www.aua.org\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1055,
    "fields": {
      "name": "ORZID3 GMENU UVEITIS",
      "term": null,
      "displaytext": "Uveitis",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Text\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 1011, \"DisplayText\": \"Retinitis (Outpatient)\", \"Text\": \"VZV or HSV retinitis and ARN\", \"Mnemonic\": \"4\"}, {\"Row\": 15, \"Column\": 1, \"Item\": 795, \"DisplayText\": \"CMV retinitis (Outpatient)\", \"Text\": \"CMV retinitis and ARN\", \"Mnemonic\": \"6\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"UVEITIS\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Most cases are non-infectious. Most infectious cases are associated with a\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"pathogen causing systemic or central nervous system infection. Diagnosis of\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"uveitis usually must be made presumptively due to the technical difficulty of\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"sampling the uvea. Cases have been associated with fungi, bacteria, viruses, and\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"protozoa like Toxoplasma gondii.\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"For treatment of posterior uveitis (retinitis) or acute retinal necrosis (ARN)\", \"Header\": 1}, {\"Row\": 12, \"Column\": 1, \"Text\": \"due to Varicella-zoster virus (VZV) or herpes simplex virus (HSV) or\", \"Header\": 1}, {\"Row\": 13, \"Column\": 1, \"Text\": \"Cytomegalovirus (CMV)\", \"Header\": 1}, {\"Row\": 17, \"Column\": 1, \"Text\": \"Treatment of uveitis involves treating the underlying infection and is usually\", \"Header\": 1}, {\"Row\": 18, \"Column\": 1, \"Text\": \"systemic. Refer to specific pathogen recommendations for treatment of underlyin\", \"Header\": 1}, {\"Row\": 19, \"Column\": 1, \"Text\": \"infection. Contact Ophthalmology and/or Infectious Diseases for assistance.\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"_______________________________________________________________________________\", \"Header\": 1}, {\"Row\": 23, \"Column\": 1, \"Text\": \"References:\"}, {\"Row\": 24, \"Column\": 1, \"Text\": \"Mandell chapter: Infectious causes of uveitis\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1056,
    "fields": {
      "name": "ORZID3 GMENU VIRUSES OUTPT MAIN",
      "term": null,
      "displaytext": "Viruses (Outpatient)  ",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 1, \"Column\": 1, \"Item\": 653, \"DisplayText\": \"Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)\", \"Mnemonic\": \"2\"}, {\"Row\": 6, \"Column\": 1, \"Item\": 643, \"DisplayText\": \"Cytomegalovirus (CMV) Main Page (outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"4\"}, {\"Row\": 9, \"Column\": 1, \"Item\": 911, \"DisplayText\": \"Infectious diarrhea/Gastroenteritis (Outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"6\"}, {\"Row\": 12, \"Column\": 1, \"Item\": 656, \"DisplayText\": \"Hepatitis A (outpatient)\", \"Text\": \"Hepatitis A\", \"Mnemonic\": \"8\"}, {\"Row\": 13, \"Column\": 1, \"Item\": 657, \"DisplayText\": \"Hepatitis B (outpatient)\", \"Text\": \"Hepatitis B\", \"Mnemonic\": \"10\"}, {\"Row\": 14, \"Column\": 1, \"Item\": 658, \"DisplayText\": \"Hepatitis C (outpatient)\", \"Text\": \"Hepatitis C\", \"Mnemonic\": \"12\"}, {\"Row\": 17, \"Column\": 1, \"Item\": 745, \"DisplayText\": \"Bell's palsy (Outpatient)\", \"Text\": \"Bell's palsy\", \"Mnemonic\": \"14\"}, {\"Row\": 18, \"Column\": 1, \"Item\": 903, \"DisplayText\": \"HSV encephalitis (Outpatient)\", \"Text\": \"Encephalitis\", \"Mnemonic\": \"16\"}, {\"Row\": 19, \"Column\": 1, \"Item\": 1025, \"DisplayText\": \"Sexually Transmitted Infections\", \"Text\": \"Genital herpes\", \"Mnemonic\": \"18\"}, {\"Row\": 20, \"Column\": 1, \"Item\": 901, \"DisplayText\": \"Herpes whitlow (Digit or Hand Cellulitis) - Outpatient\", \"Text\": \"Herpes Whitlow (digit or hand\", \"Mnemonic\": \"20\"}, {\"Row\": 22, \"Column\": 1, \"Item\": 660, \"DisplayText\": \"HERPES KERATITIS\", \"Text\": \"Keratitis\", \"Mnemonic\": \"22\"}, {\"Row\": 23, \"Column\": 1, \"Item\": 946, \"DisplayText\": \"Orolabial herpes (Outpatient)\", \"Text\": \"Oral lesions: Mouth, Lips (Cold sores)\", \"Mnemonic\": \"24\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"++ VIRUSES ++\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Cytomegalovirus (CMV)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 1, \"Text\": \"Diarrhea, viral\", \"Header\": 1}, {\"Row\": 11, \"Column\": 1, \"Text\": \"Hepatitis\", \"Header\": 1}, {\"Row\": 16, \"Column\": 1, \"Text\": \"Herpes Simplex\", \"Header\": 1}, {\"Row\": 21, \"Column\": 1, \"Text\": \"cellulitis)\"}, {\"Row\": 27, \"Column\": 1, \"Text\": \"Last reviewed 8/2018\", \"Header\": 1}, {\"Row\": 6, \"Column\": 2, \"Item\": 663, \"DisplayText\": \"HIV-AIDS (outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"28\"}, {\"Row\": 9, \"Column\": 2, \"Item\": 912, \"DisplayText\": \"Influenza Seasonal 2021-2022\", \"Text\": \"[click here]\", \"Mnemonic\": \"30\"}, {\"Row\": 12, \"Column\": 2, \"Item\": 690, \"DisplayText\": \"Parainfluenza (outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"32\"}, {\"Row\": 20, \"Column\": 2, \"Item\": 715, \"DisplayText\": \"Respiratory Syncytial Virus (RSV) (outpatient)\", \"Text\": \"[click here]\", \"Mnemonic\": \"34\"}, {\"Row\": 23, \"Column\": 2, \"Item\": 745, \"DisplayText\": \"Bell's palsy (Outpatient)\", \"Text\": \"Bell's palsy\", \"Mnemonic\": \"36\"}, {\"Row\": 24, \"Column\": 2, \"Item\": 996, \"DisplayText\": \"Primary infection (Chickenpox) - Outpatient\", \"Text\": \"Varicella/Chickenpox (primary infection)\", \"Mnemonic\": \"38\"}, {\"Row\": 25, \"Column\": 2, \"Item\": 1008, \"DisplayText\": \"Reactivation of primary infection (Zoster or \\\"Shingles\\\") - Outpatient\", \"Text\": \"Zoster/Shingles (reactivation)\", \"Mnemonic\": \"40\"}, {\"Row\": 5, \"Column\": 2, \"Text\": \"Human Immunodeficiency Virus (HIV)\", \"Header\": 1}, {\"Row\": 8, \"Column\": 2, \"Text\": \"Influenza, Seasonal\", \"Header\": 1}, {\"Row\": 11, \"Column\": 2, \"Text\": \"Parainfluenza\", \"Header\": 1}, {\"Row\": 19, \"Column\": 2, \"Text\": \"Respiratory Syncytial Virus (RSV)\", \"Header\": 1}, {\"Row\": 22, \"Column\": 2, \"Text\": \"Varicella-zoster\", \"Header\": 1}, {\"Row\": 14, \"Column\": 2, \"Text\": \"Rabies\", \"Header\": 1}, {\"Row\": 16, \"Column\": 2, \"Text\": \"Post-Exposure Prophylaxis\"}, {\"Row\": 17, \"Column\": 2, \"Text\": \"is available in ED CDSS only\"}, {\"Row\": 15, \"Column\": 2, \"Item\": 707, \"DisplayText\": \"Rabies Pre-exposure Prophylaxis\", \"Text\": \"Pre-Exposure Prophylaxis\", \"Mnemonic\": \"33\"}]"
    }
  },
  {
    "model": "pages.page",
    "pk": 1057,
    "fields": {
      "name": "ORZID3 GMENU WARFARIN DRUG INTERACTIONS",
      "term": null,
      "displaytext": "",
      "version": "Minneapolis",
      "contents": "[{\"Row\": 26, \"Column\": 1, \"Item\": 3115, \"DisplayText\": \"Lexicomp Drug interactions\", \"Text\": \"Lexicomp Drug Interactions\", \"Mnemonic\": \"4\"}, {\"Row\": 3, \"Column\": 1, \"Text\": \"DRUG-DRUG INTERACTIONS BETWEEN ANTIMICROBIALS AND WARFARIN\", \"Header\": 1}, {\"Row\": 5, \"Column\": 1, \"Text\": \"Several antimicrobials will affect metabolism or the effect of\"}, {\"Row\": 6, \"Column\": 1, \"Text\": \"warfarin on a patient's clotting function. If possible, avoid using an\"}, {\"Row\": 7, \"Column\": 1, \"Text\": \"antimicrobial with a significant interaction with warfarin. If you\"}, {\"Row\": 8, \"Column\": 1, \"Text\": \"decide that an antimicrobial that interacts with warfarin is needed or\"}, {\"Row\": 9, \"Column\": 1, \"Text\": \"you stop an antimicrobial that could interact with warfarin, you\"}, {\"Row\": 10, \"Column\": 1, \"Text\": \"should determine the INR more frequently than usual and adjust dosage\"}, {\"Row\": 11, \"Column\": 1, \"Text\": \"accordingly. Instruct patients to inform their primary warfarin\"}, {\"Row\": 12, \"Column\": 1, \"Text\": \"provider whenever an antimicrobial is prescribed for them.\"}, {\"Row\": 14, \"Column\": 1, \"Text\": \"Antimicrobials can alter warfarin's anticoagulant effect by decreasing\"}, {\"Row\": 15, \"Column\": 1, \"Text\": \"intestinal synthesis or absorption of vitamin K or by affecting\"}, {\"Row\": 16, \"Column\": 1, \"Text\": \"distribution or metabolism of the vitamin. Some antimicrobials increase\"}, {\"Row\": 17, \"Column\": 1, \"Text\": \"synthesis of coagulation factors.\"}, {\"Row\": 19, \"Column\": 1, \"Text\": \"Antimicrobials can decrease the rate of warfarin absorption, compete\"}, {\"Row\": 20, \"Column\": 1, \"Text\": \"with warfarin at sites of warfarin metabolism, induce warfarin\"}, {\"Row\": 21, \"Column\": 1, \"Text\": \"metabolic enzymes, or inhibit the function or synthesis warfarin\"}, {\"Row\": 22, \"Column\": 1, \"Text\": \"metabolic enzymes. Some antimicrobials displace warfarin from protein\"}, {\"Row\": 23, \"Column\": 1, \"Text\": \"binding sites.\"}, {\"Row\": 25, \"Column\": 1, \"Text\": \"Check for warfarin-antimicrobial interactions on Lexicomp:\"}, {\"Row\": 29, \"Column\": 1, \"Text\": \"References\"}, {\"Row\": 31, \"Column\": 1, \"Text\": \"Holbrook, Anne M., et al. Archives of internal medicine 165.10 (2005): 1095-\"}, {\"Row\": 32, \"Column\": 1, \"Text\": \"1106\"}, {\"Row\": 33, \"Column\": 1, \"Text\": \"Lexicomp website\"}]"
    }
  }
]
